<SEC-DOCUMENT>0000950170-23-007681.txt : 20230314
<SEC-HEADER>0000950170-23-007681.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314060414
ACCESSION NUMBER:		0000950170-23-007681
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40287
		FILM NUMBER:		23729089

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ikna-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-14T06:00:37.2225+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:ikna="http://www.ikenaoncology.com/20221231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_73fc101d-7745-47d5-b271-65058a5425c1" name="ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" contextRef="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496">P5Y</ix:nonNumeric><ix:nonFraction id="F_6405c329-beba-47dc-a7ce-628745e34612" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2bfa3cd5-7671-450c-9646-fc3da919b9cd" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd">http://fasb.org/us-gaap/2022#InProcessResearchAndDevelopmentMember</ix:nonNumeric><ix:nonNumeric id="F_ea7b51ae-9485-4d01-9e50-58f15f5b438a" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0">http://fasb.org/us-gaap/2022#InProcessResearchAndDevelopmentMember</ix:nonNumeric><ix:nonNumeric id="F_1c0b9497-2641-40d2-943a-f38d1b6ede6c" name="dei:AmendmentFlag" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_11ef3329-dcf3-4ec2-8622-e99fe0bb4b61" name="us-gaap:PreferredStockValue" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_03b4de73-343f-4ac2-8c26-c4a271fedc1c" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric id="F_178f4674-c445-42ef-af4b-4fce1a943cc3" name="dei:DocumentFiscalPeriodFocus" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0">FY</ix:nonNumeric><ix:nonFraction id="F_839b234b-d83d-4063-a99d-0257ea516d6b" name="us-gaap:PreferredStockValue" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_158d126e-6bca-4219-b170-503c05bf52e5" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_f7ac34a0-df59-4770-a2ef-cea6de0ce0ef" name="dei:EntityCentralIndexKey" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0">0001835579</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ikna-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_5380a635-35e8-4659-a29b-6c6c312f0478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_686297fa-085a-4a4a-a878-5b20c1fcf30f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a0f4009-cad0-4026-8941-85d87debcc2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d9274dc-5a91-43f3-a6de-fddb2971143b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f720352-5344-47c4-bf64-7ee0c53bfc69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_201175b1-5ec1-482c-82bd-42e11405e926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6011e744-0468-4b9d-a6aa-2ad82bb602fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_527c0073-0dca-4b32-809c-4a7e62aec6ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_094353c9-0180-4db6-835f-7fd1043e467d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d13cc7f8-a86c-42e2-8850-115bf15cdd7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7197b178-a4ef-4f27-bbbb-2a2195a83543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f708ee60-4251-4c02-b611-2b02ced0c594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32847360-0e0a-4bc8-8675-0ec3449433c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7496043-4245-45bf-886a-e65de0a22afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51a2a164-bf0e-4c35-b339-4d0fabaee032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1178e06-1abe-41ec-b7dd-8ac5bb40a35b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94b787e9-7a65-4675-ae1c-15ef31484f3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbbd90fc-7f8c-4e81-9033-43797f48a0e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_622ece3c-9861-4130-adc3-64fee0afb1e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82efe98b-6310-4367-b03b-b818789abe68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7251b328-1b51-45ee-a489-0591be444c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c06f1a61-16c4-4100-89a4-3b2b77f6fab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a1ea8b-e577-4c5b-9f0d-b1c3d8bddc84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:NotSubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-31</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2d96cc4-4b37-4a61-9a19-85166d8d9462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_243e768c-5a7d-4e4d-92c7-d1c089eaaf89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4de011a1-1fee-47df-a29f-9beca448f979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f2e0b59-0865-42b0-91fa-b28782511684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aaa08537-cb74-4d4d-a39a-8997e07e77df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a216833a-bcc3-4948-b7e6-e2ffb74f7b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_172039bc-db4e-4260-9a5f-1630d4a4a0ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-31</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01480c2c-876c-40b4-a15a-bc9c124601af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84324036-af2c-40fe-9fa2-a3dbfb992c04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5422dba2-f132-4a6c-8c0d-9f0758d86563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25c317f9-19e2-409c-9f55-9c90713949a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56a2b03d-825c-40b9-ae08-f05fa29edc0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-21</xbrli:startDate><xbrli:endDate>2020-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b8449eb-5f80-4e42-a3a7-9af92acd3f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0328cea2-41fd-451c-a98a-8066850c22de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72b4e02a-df1a-4585-b5ad-11bbc8dc7393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac9d39c1-132d-4ba8-be7b-fc7b585405ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af45af9b-bf8b-48ad-9b86-a379550ecc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_629dc6f2-dce8-43e8-9319-86cbd98602c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2ab031b-2c82-4ab6-b6af-8f43dbaf9ec4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f069e2a6-5458-4e6d-b129-855b9f38dccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e250053-4619-45f1-9e2b-a7efc1571f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01fa273c-adc6-48a9-9be3-a48fc56e1ffa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac826982-7dbc-4cee-848b-c0246e9b311d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1bdd79a-55db-4f3d-b9dc-b5eea09238fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55096704-6551-4982-b2dd-3b2dd0624c46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2afa1f5-af40-4100-93ce-80c9cdaa0874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32986907-9238-453d-9ab9-8a0f5484f461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72e7b2cf-5188-421c-b31a-cb8c26070efc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f3e63dc-8be1-44b1-bd62-8504096da2d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f74818aa-b473-442b-83e4-0dd0c0bedd47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_006dc649-dc41-474f-8ec9-76fa6ad1fab7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a06410af-63e3-4326-a071-99bd20e03747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25d90a8b-c846-4756-bd61-dd59c2bafa2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbac1559-abd3-46e6-b271-d81b0a7eaae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14d9fef1-667e-4963-8142-cdd235c7f806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aede6e61-a0c9-4e55-bbf8-f41b83685d83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f72bf92b-b49c-4e3d-b668-ab6a03cec96d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30df2e55-bbb5-427e-82b4-f114563688e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db24a009-c7dc-477b-81ab-fa7a1a7149cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79681f83-bcfa-43cd-b9a8-9202b8e8dd42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b5743c1-f77e-4a80-9bb0-c3531c20806d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f11f597d-a8dd-465c-abcf-5256cc5c240e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb286aec-68e2-4e6f-b537-31fc48bc69b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfe38f01-f9ca-4eaf-a331-878b48fafd55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_039e47d5-8439-4779-9f97-da794a71c14e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_846b01fb-e362-4321-8448-6f496f45b801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_addbb181-d517-444c-af21-20959683d0dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9ce082a-af1a-4ce0-b0b5-24c0aa1bc3a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b633a850-2bce-4c3c-abbd-d9eeb2480f83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33bcb973-7966-4f4c-bc9c-e3aa82ff7119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5743e53-9eec-4995-bd5a-136752b9e092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1c560c7-417e-4680-8016-5472ee398972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-20</xbrli:startDate><xbrli:endDate>2021-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84d516bd-f241-4424-bbd6-e29e016466cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73e45bb4-192d-4764-86f0-84eb2db89c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e02eba-c186-44f9-b40a-69c6eda8c2f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b851c3a-24e1-41dc-a872-7efb1cd60872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81be7afb-a84c-4259-b0db-774799b8967e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35a41072-255d-4437-a4a9-cad64e6da60a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffa36058-10c5-475b-85fe-d2a62ed6bfd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a48902d-ac69-43f6-b35e-bc502c7e3265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9117ee30-cb2e-437f-bbc2-c141841cb4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23fc5900-4ca2-478b-99d4-086caa8e243f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68d0106c-cdc4-4aae-a92c-8c34b9586d82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9e73fef-5f12-49d2-b304-fdc0a8211ca9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49f118e2-3aad-42e9-9966-9b49f9d34542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3be42be-7b3d-40ba-ad4b-e05df3584a06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesA1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:StockPurchaseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e1254ff-dea8-4f2d-8b51-985639cee2f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8d5e815-4402-469f-92c1-05e99f28eae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30eb871a-b095-47c3-a919-45cc40650449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b4cb83-83c9-4fda-8ec2-4663fab1916f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_998a15cc-e896-4027-85f6-00d38c4c670f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f09330b3-63fd-4523-8016-448dd3b3e3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b6fbf11-0f77-40b2-8c0f-e122abf4d570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>ikna:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Position"><xbrli:measure>ikna:Position</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4308152c-2ede-4e02-ac55-8254dbed51f3" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0032ec5b-9a77-407b-9d3f-82fccf01f445" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d611cddb-3307-4b2a-8d09-933885144442" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d72db59b-5e4d-4a9e-9b19-23e844d6cdb5" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0f337402-6974-4b3a-9887-c6afe294e678" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_12b79b0e-fbe8-4f73-b3bf-b7675d1d5923" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b8a1603-cece-4205-b09a-5f61b48419d2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40287</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:21.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd503cab-f71d-4cd6-b820-76b9be962440" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:21.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c75d021d-bdef-4dbc-9359-af4bffd1e2bb" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_308a2150-54a2-42b8-95d6-c3ab6e216c73" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81-1697316</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ce0fa41-69e6-44ab-b7ab-55406c2de232" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">645 Summer Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb0b89d9-a651-4879-83e5-ab464ff37003" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 101</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_147c458e-4299-4967-94b8-1b38ecfa4581" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d11bde9-ccd3-4440-9b07-ca69c10576fa" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8ce0bdcc-dcac-43e6-b98a-8bc606dfd3b2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6ebf18cf-472f-474a-8be0-137a91c578a9" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ee8e4baf-fad1-4e37-8cb4-ee914eeba2cc" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273-8343</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e35c4446-120e-49b9-8da6-d273036b60d9" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1788f8c6-3a9a-4ac0-9be2-19572c5b7afd" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKNA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fbba9783-823d-4cf5-b97e-eb2ed28201b4" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4be225d-fd8b-4994-8538-bd737f5392e4" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b262263e-1088-42e4-968d-05c031914194" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a6702a0-6d90-4907-ab66-cb497e5c4a0c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9cc279de-012f-4806-9c34-4bb3c6a885aa" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0dc3c24c-30b2-47f4-96c6-2940d4ea23cb" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f802e109-b619-43bd-b8ad-f63409bf0ee2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1ccbaa2e-e5c5-4625-b7a2-88c5426faec6" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d8f1ffc-6a0e-4eb3-bd65-7b8e6f7c6dc2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f23f4b1c-b009-4f74-8676-f840f72a1623" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_178f4674-c445-42ef-af4b-4fce1a943cc3;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mark</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ea148d2-cf21-4987-9063-4425f19ce2f7" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1c0b9497-2641-40d2-943a-f38d1b6ede6c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the closing price of the shares of common stock on June 30, 2022 was $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59544cca-f1e9-4e04-9fdb-b7dbe2e47f50" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">58.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 10, 2023 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40af6117-b814-4e49-aca7-cdf2f1b642e5" contextRef="C_30df2e55-bbb5-427e-82b4-f114563688e7" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,257,493</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_60295a05-483f-4d69-a025-0b7ad68040cb" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#x2019;s proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.0%;"></td>
    <td style="width:82.0%;"></td>
    <td style="width:7.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#legal_proceeding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a targeted oncology company with a limited operating history. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no products approved for commercial sale and have not generated any revenue from product sales. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never successfully completed any clinical trials for our oncology programs, and we may be unable to do so for any product candidates we develop. Certain of our oncology programs are still in preclinical development and may never advance to clinical development. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to conduct our Phase 1 clinical trials of IK-930 and IK-175 and expect to rely on third parties to conduct clinical trials for our other targeted oncology programs, including IK-595, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The material and other risks summarized above should be read together with the text of the full risk factors below and with the other information set forth in this Annual Report, including our consolidated financial statements and the related notes, as well as with other documents that we file with the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above, or described in full below, are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains express or implied forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). These statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to efficiently discover and develop product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability and the potential to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials, and on a larger scale, for commercial use, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to commercialize our products, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the implementation of our business model, and strategic plans for our business and product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates of our future expenses, revenue, capital requirements, and our needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future agreements with third parties in connection with the commercialization of product candidates and any other approved product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate and degree of market acceptance of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments in the United States and relevant foreign countries;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain key scientific or management personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of laws and regulations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our use of proceeds from our initial public offering; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments relating to our competitors and our industry; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of the ongoing COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, bank failures, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those under the caption &#x201c;Risk Factors.&#x201d; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#x201c;Risk Factors&#x201d; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or into which we may enter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 1. BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach, we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signaling pathways in the tumor-microenvironment (&#x201c;TME&#x201d;). Our approach in each of our programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. Our most advanced targeted oncology program, IK-930, is a paralog-selective inhibitor of the transcriptional enhanced associate domain (&#x201c;TEAD&#x201d;). The TEAD transcription factors execute the ultimate step in the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted and chemo therapies. Our first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, we are developing IK-175, an aryl hydrocarbon receptor (&#x201c;AHR&#x201d;) antagonist in collaboration with Bristol Myers Squibb. Our focus on patient-driven development allows us to research both known and novel targets, with a shared guiding principle of aiming to address the unmet needs of biomarker-defined patient populations. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust discovery engine and a portfolio of early stage targeted oncology programs. Across the entirety of our pipeline, shown below, we aim to utilize our depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_0.jpg" alt="img40748725_0.jpg" style="width:619px;height:276px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced targeted oncology product candidate, IK-930, is an oral, paralog-selective, small molecule inhibitor of TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. In our ongoing first-in-human Phase 1 clinical trial, we are focusing on indications that provide the potential to achieve rapid proof-of-concept, such as NF2 deficient mesothelioma and solid tumors with YAP1 or TAZ gene fusions, including epithelioid hemangioendothelioma (&#x201c;EHE&#x201d;). Approximately 40% of mesothelioma patients are genetically deficient for the tumor suppressor NF2 and 100% of EHE patients have oncogenic YAP1 or TAZ gene fusions. In October 2021, our Investigational New Drug Application (&#x201c;IND&#x201d;) for IK-930 was cleared by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) and we subsequently initiated a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of IK-930 as a monotherapy in patients with advanced solid tumors with or without gene alterations in the Hippo pathway. The first patient was dosed in January 2022. IK-930 received orphan drug designation for the treatment of mesothelioma from the FDA in March 2022. In June 2022, IK-930 was granted fast track designation from the FDA for the treatment of unresectable NF2-deficient mesothelioma.  In addition to the monotherapy approach, we plan to assess IK-930 in combination with other targeted therapies across several indications with multiple targeted therapies. Based on the role that the Hippo pathway plays in resistance to other targeted therapies, we believe that IK-930 may expand the patient populations that could benefit from therapies like EGFR inhibitors, KRAS inhibitors, and MEK inhibitors, among others. We have an established clinical collaboration with AstraZeneca for the evaluation of osimertinib</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in combination with IK-930 for patients with EGFR-mutant lung cancers as a cohort in the clinical program. Initial data from the monotherapy IK-930 clinical program is expected in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We nominated a development candidate in our RAS pathway program in November 2022. The RAS pathway is implicated in at least half a million new cancer diagnoses each year in the United States alone. We aim to target the pathway on multiple levels, including preventing known resistance mechanisms to achieve deep and sustained responses. Our first program in the space, IK-595, is designed to achieve novel inhibition of MEK-RAF by trapping MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors.  IK-595&#x2019;s potential ability to complex CRAF, in particular, prevents a well-recognized signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. In addition, trapping CRAF in an inactive complex prevents the kinase independent anti-apoptotic function in RAS and RAF mutant cancers, a mechanism that cannot be addressed with first generation MEK inhibitors or pan-RAF inhibitors. We are developing IK-595 as an oral therapy, with a half-life designed to enable a pharmacokinetic profile that we believe can be potentially superior to other pathway inhibitors, with the goal of optimizing the therapeutic window for patients. We plan to submit an IND to the FDA for IK-595 in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These two programs, IK-930 and IK-595, stemmed from our internal discovery engine, which continues its focus on discovering and developing novel targeted oncology programs. Our early research follows our philosophy of designing treatments for selected patient populations identified through the genetic make-up of their tumors and with the potential to expand the patient population that can benefit from targeted oncology through tackling mechanisms of therapeutic resistance. Our pipeline also includes our immune-signaling program targeting AHR with our novel inhibitor, IK-175. The ongoing Phase 1a/1b clinical trial is evaluating IK-175 as a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas, for which current standard-of-care therapy is no longer effective or is intolerable. Initial clinical data from the program was presented in November 2022 at the Society for Immunotherapy of Cancer Annual Meeting. These initial data included a 40% disease control rate and 20% overall response rate in urothelial carcinoma patients who received IK-175 in combination with nivolumab, with the majority of combination patients experiencing reduction in their target lesions. The study is ongoing, and we plan to share updates from the program in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dedicated to bringing next generation targeted oncology therapies to cancer patients. In order to achieve this goal, we will continue to rely on our deep understanding of complex biologic pathways, multi-modality drug discovery, structure-guided and computer-aided drug design, experience and skills in drugging novel and previously intractable targets, and robust biomarker-driven translational research informing clinical development. Our current pipeline consists of programs based entirely on internally discovered compounds from our robust research efforts. The key components of our current strategy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to advance IK-930 through clinical development as both a monotherapy and in combination with other targeted agents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing IK-930, an oral, paralog-selective small molecule inhibitor of TEAD, to evaluate its potential to bring therapeutic benefit to patients. We plan to continue advancing the ongoing monotherapy Phase 1 clinical trial of IK-930 in tumors harboring genetic mutations in the Hippo signaling pathway. Our clinical development strategy is designed to achieve clinical proof-of-concept in genetically defined subsets of solid tumors where significant unmet medical need exists and to leverage the potential for fast-to-market opportunities in orphan indications. In addition, we plan to evaluate the combination of IK-930 with other targeted therapies to address therapeutic resistance, including EGFR inhibitors and inhibitors in the RAS pathway. The first of these planned combinations is supported by our clinical supply collaboration with AstraZeneca evaluating IK-930 impact on osimertinib resistance in EGFR mutated cancers.  </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance IK-595 to IND and the clinic. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most recent development candidate, IK-595, is a dual MEK-RAF complex inhibitor designed to trap MEK and RAF in an inactive complex, thereby more completely inhibiting RAS signals than existing inhibitors. We plan to advance IK-595 rapidly towards the clinic to evaluate its potential best-in-class capabilities and differentiation for patients. IK-595 is being developed as an oral therapy, with a half-life designed to enable pharmacokinetic profile that we believe has the potential to lead to an optimal therapeutic window for patients relative to other agents in this class.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to progress our research in both the Hippo pathway and RAS pathway towards identification of additional potential development candidates and furthering our leadership in the space. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a robust discovery effort ongoing towards identifying opportunities for targeted oncology pipeline growth, including additional work within the Hippo and RAS pathways. This work, which resulted in IK-595&#x2019;s selection as a development candidate, currently includes targeting multiple nodes in the RAS pathway. Our research team is also dedicated to generating additional data to further our knowledge in the both the RAS and Hippo spaces as our current programs continue to evolve and novel approaches to targeting the pathways emerge.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue advancing IK-175 by generating additional clinical data in urothelial carcinoma. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-175 is being evaluated in a Phase 1 clinical trial as a monotherapy and in combination with nivolumab in urothelial carcinoma. In November 2022, we presented initial clinical data at the Society for Immunotherapy and Cancer Conference and showed encouraging anti-tumor activity. The study is ongoing and we plan to provide clinical updates in 2023. If Bristol Myers Squibb exercises their option to exclusively license IK-175, we would receive $50 million in opt-in fees, which would provide a meaningful source of non-dilutive capital. Additionally, we would be eligible to receive up to $450 million in clinical, regulatory, and commercial milestone payments and royalties on worldwide net sales.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximize the value of our pipeline through continued discovery efforts and growth; generate a pipeline of programs supported by robust translational research and designed for biomarker-defined patient populations. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal discovery engine has resulted in the three candidates we are currently advancing in clinical trials. As we seek to expand our targeted oncology pipeline and advance it through proof-of-concept clinical trials, we plan to continue building a fully integrated biotechnology company. As we grow, we plan to advance programs that fit with our philosophy of patient-focused development by identifying biomarker-defined populations with significant unmet need that can benefit from targeted therapeutics. We hold worldwide development and commercial rights to our targeted oncology programs, and we intend to continue to develop our capabilities in late-stage clinical development and commercialization to maximize the potential value of these programs. As we continue to build the Company, we remain open to partnering opportunities in which we can leverage our expertise in drug discovery and development that add value to the Company and our stakeholders.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeted Oncology Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our targeted oncology discovery efforts include programs that target the Hippo and RAS pathways, emphasizing our philosophy of designing treatments tailored for specific patient populations identified through the genetic makeup of their tumors. Our pipeline is built on the Hippo and RAS oncosignaling network, where nodes are often connected through orthogonal mechanisms and compensatory pathways.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of working within these interconnected signaling networks, our targeted oncology programs are designed to address multiple patient populations. First, they are designed to serve patient populations with genetically defined tumors by targeting mutations in the oncogenic pathways that drive their cancers. Second, they aim to address patient populations in which the target is involved in therapeutic resistance to other targeted therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_1.jpg" alt="img40748725_1.jpg" style="width:624px;height:481px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-930, a TEAD inhibitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 is an internally discovered, oral, paralog-selective, small molecule inhibitor of a TEAD transcription factor. TEAD functions as the ultimate step in the Hippo signal transduction pathway by driving expression of genes involved in cell proliferation and survival. TEAD consists of a family of four paralogs and IK-930 is designed to selectively inhibit one of these isoforms that we believe has the potential to achieve efficacy and balance potential kidney toxicity associated with TEAD inhibition. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all human cancers. Such genetic alterations are often associated with poor clinical outcomes. The involvement of the Hippo pathway in mechanisms of resistance to other targeted therapies has been well established; the pathway is implicated in resistance to EGFR inhibitors, MEK inhibitors, and others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 is a novel inhibitor of TEAD that exploits a recently discovered and promising binding pocket on TEAD to enable the inhibitory effect upon the Hippo pathway. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 blocks palmitate from binding TEAD, thereby disrupting TEAD-dependent gene transcription. The mechanism of action of IK-930 is differentiated from historically unsuccessful attempts using either small molecules or cyclic peptides. Using structural biology-guided chemistry, we were able to generate novel TEAD inhibitor compounds across several chemical series directed to this binding pocket in TEAD and profile them using various </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assays assessing potency, selectivity, tolerability, and antitumor activity. In addition, considering the potential on-target kidney toxicities associated with the Hippo pathway, it was important to design IK-930 to be paralog-selective in order to drive optimal antitumor activity, while significantly reducing the dose-limiting effects of kidney toxicity. By selecting IK-930 based upon these characteristics, we believe IK-930 has the potential to bring differentiated therapeutic benefit to patients with tumors harboring genetic mutations and alterations in the Hippo signaling pathway. Moreover, activation of the Hippo pathway confers resistance to certain targeted therapies, such as EGFR inhibitors and MEK inhibitors, which supports the potential for IK-930 to be combined with these therapies to overcome therapeutic resistance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently evaluating IK-930 in a first-in-human Phase 1 clinical trial as a monotherapy. The study aims to evaluate the safety and preliminary antitumor activity of IK-930 in Hippo-mutated cancers in orphan indications such as NF2-deficient malignant pleural mesothelioma and EHE, a rare type of vascular sarcoma. The FDA granted IK-930 both orphan and fast-track designation for the treatment mesothelioma in the first half of 2022. In addition, we plan to evaluate IK-930 in combination with multiple other targeted agents, with the aim of potentially addressing therapeutic resistance in more prevalent tumor indications characterized by genetic alterations. The first planned combination is IK-930 with osimertinib for patients with EGFR mutant non-small cell lung cancer (&#x201c;NSCLC&#x201d;). The Phase 1 clinical trial is currently advancing in monotherapy dose escalation as expected, with multiple dose cohorts cleared.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Role of the Hippo pathway and TEAD in oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hippo pathway is a highly conserved developmental signaling pathway that modulates the regulation of multiple biological processes, including cell proliferation, survival, differentiation, organ size, and tissue homeostasis. Dysregulation of the Hippo pathway is associated with the induction of hyperproliferation, cellular invasion, metastasis, cancer cell maintenance, and therapeutic resistance, and has been linked to other pro-tumorigenic activities, such as activation of regulatory T cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hippo signaling cascade begins with NF2, a gene that encodes the scaffold protein merlin, which links multiple extracellular cues to an intracellular signaling cascade. Merlin activates the kinases MST1 and MST2 (&#x201c;MST1/2&#x201d;) which subsequently phosphorylate and activate the kinases LATS1 and LATS2 (&#x201c;LATS1/2&#x201d;). LATS1/2 phosphorylates two key transcriptional coactivators of TEAD: YAP1 and TAZ. When phosphorylated, YAP1 and TAZ are sequestered to the cytoplasm where they are targeted for proteasome-mediated degradation. When the upstream portion of the signaling cascade is inactivated through normal regulation or through inactivating mutations, YAP1 and TAZ are not phosphorylated and can shuttle into the nucleus. Once inside the nucleus, YAP1 and TAZ bind TEAD to enable the transcription of TEAD target genes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hippo Pathway</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_2.jpg" alt="img40748725_2.jpg" style="width:337px;height:301px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nuclear YAP1 was observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription. Data suggest that the addition of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. In addition to resistance to EGFR targeting, there are emerging data indicating the Hippo pathway is involved in resistance to other targeted therapies as well, including MEK inhibition inhibitors in BRAF and RAS mutated cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two Clinical Strategies for IK-930 to Address Multiple Cancer Patient Populations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_3.jpg" alt="img40748725_3.jpg" style="width:624px;height:314px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The monotherapy and combination approaches represent two distinct therapeutic strategies. Genetic alterations in the Hippo pathway that drive primary cancers provide a potential opportunity for IK-930 as a monotherapy. Separately, the role of the pathway in therapeutic resistance could open a wide range of patient populations that could benefit from IK-930, including EGFR mutant and KRAS mutant cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Epidemiology of Hippo pathway driven cancers; monotherapy strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Published literature suggests that approximately 10% of all solid tumors present with dysregulated Hippo pathway and subsequent activation of TEAD, representing the populations that could potentially benefit from a monotherapy approach with IK-930. Dysregulation can occur at multiple nodes within the pathway. For example, the tumor suppressor gene NF2 can undergo inactivating mutations or YAP1 and TAZ can undergo gene fusion or amplification. These genetic alterations lead to tumor formation in mouse models and therefore are believed to be genetic drivers of cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on available epidemiological data, we estimate that approximately 125,000 newly diagnosed cancer patients annually within the United States have tumors which harbor genetic alterations in the Hippo pathway, based on the incidence of cancers with YAP1 and TAZ gene amplification or fusion, as well as NF2 loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figure below illustrates the incidence of individuals with newly diagnosed cancers that harbor Hippo pathway genetic alterations in the United States on an annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incidence of Hippo Pathway Genetic Alterations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_4.jpg" alt="img40748725_4.jpg" style="width:624px;height:340px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genetic alterations in the Hippo pathway are present in diverse cancer types but there are certain cancers, including more prevalent indications, such as lung squamous cell carcinoma, and rarer indications, such as mesothelioma and sarcoma, which are reported to have a particularly high incidence of genetic alterations in the Hippo pathway, where alterations are considered to drive tumor formation and growth, and are associated with a poor patient prognosis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of function mutations in NF2 are found in approximately 40% of cases of malignant mesothelioma and are associated with poor prognosis, including a significantly shorter progression free survival and overall survival. IK-930 has orphan designation for the treatment of mesothelioma. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All cases of EHE a form of soft tissue sarcomas have YAP1 and TAZ gene fusions, where 90% of patients have TAZ-CAMTA1 fusions and the remaining 10% have YAP1-TFE3 fusions, which are directly linked to the etiology of these cancers. The disease is defined by the presence of one of these alterations. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Meningiomas also exhibit a high frequency of NF2 deficiency accounting for approximately one-third of primary central nervous system (&#x201c;CNS&#x201d;) tumors.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other solid tumors have exhibited Hippo pathways alteration, including in squamous lung cancer, where YAP1 and TAZ amplifications are found in approximately 6% and 29%, respectively, based on internal analysis of The Cancer Genome Atlas (&#x201c;TCGA&#x201d;) using the Genome Data Commons and cBioportal tools. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our translational strategy, we have conducted bioinformatics analyses of the genomic and transcription profiles of cancer patients, broadening our understanding of the pathway's role in certain cancers, and supporting our indication selection and clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Genetic Analysis of Indications with Hippo Alterations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_5.jpg" alt="img40748725_5.jpg" style="width:415px;height:160px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted genetic (top image) and transcriptional analysis (bottom image) of Hippo pathway dependency that identified a common subset of cancers. The data show the results from the genetic analysis of Hippo pathway alterations and the transcription analysis of YAP/TAZ activation. The overlapping cancer types present as indications with high potential for impact through Hippo pathway inhibition. For example, mesothelioma, head and neck squamous cell carcinoma, cholangiocarcinoma, and non-small cell lung cancers demonstrate high frequencies of Hippo pathway alterations as well as high YAP/TAZ activity scores.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Transcriptional Analysis of YAP/TAZ Activity Scores</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_6.jpg" alt="img40748725_6.jpg" style="width:456px;height:177px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hippo-implicated mechanisms of therapeutic resistance; combination strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beyond the role of certain Hippo pathway alterations in driving cancer, several pathway components are known to drive resistance to targeted therapies such as EGFR inhibitors, including osimertinib. Approximately 30% of patients with NSCLC will have EGFR mutations. Osimertinib (Tagrisso&#153;) is an EGFR inhibitor approved for the first-line treatment of patients with NSCLC whose tumors have certain EGFR mutations. Despite the robust clinical activity exerted by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available to date. A 2019 publication (Leonetti, et al., Br J Cancer, 2019) on EGFR resistance, reported a lack of actionable mutations for 40-50% of first-line osimertinib resistance patients. This is a population in which the Hippo pathway may be conferring resistance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Resistance Mechanisms to First Line Osimertinib</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_7.jpg" alt="img40748725_7.jpg" style="width:452px;height:314px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leonetti, et al., Br J Cancer, 2019</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe this population represents a substantial opportunity for TEAD inhibitors. Published data (Lee, et al., BBRC, 2016) from patient tumor samples shows that, upon acquired resistance to EGFR inhibitors, there is an increase in nuclear YAP1 in tumors as compared to tumors collected prior to EGFR inhibitor treatment. In EGFR mutant lung cancer cell lines </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the increase in nuclear YAP1 was observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_8.jpg" alt="img40748725_8.jpg" style="width:524px;height:251px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lee, et al., BBRC, 2016</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In EGFR mutant lung cancer cell lines </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, osimertinib leads to increased nuclear YAP1 and activation of TEAD dependent gene expression which can be inhibited by IK-930. In addition, IK-930 combined with osimertinib significantly increased the incidence of apoptosis </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and anti-tumor activity in mouse xenograft studies in EGFR mutant lung cancer cells. These data suggest that the addition of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. In addition to EGFR resistance, additional information is emerging from newly marketed and later stage clinical development targeted oncology programs, including suggested resistance to MEK inhibitors. We have generated preclinical data supporting our belief of the clinical opportunity to treat patients with multiple types of genetically-defined tumors and tumors with resistance to other targeted therapies with IK-930.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The epidemiology findings in mesothelioma, EHE, soft tissue sarcomas, as well as other solid tumors, including meningioma, point to the critical role of the Hippo pathway in tumor formation. In addition to the strong biological rationale for pursuing development of IK-930 in these cancers, we believe that these are areas of high unmet medical need in which IK-930 has the potential to provide meaningful clinical benefit to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Monotherapy Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Malignant mesothelioma is a rare cancer in the tissue lining the lungs and is a very aggressive cancer with a poor prognosis. After initial diagnosis, patients are reported to have a median life expectancy of 15 months. Approximately 3,000 people in the United States are diagnosed with mesothelioma each year. On average, about 2,500 mesothelioma-related deaths occur in the United States each year. There are few effective treatment options for advanced unresectable malignant mesothelioma and to date only two treatments have been approved by the FDA for the treatment of this condition. The combination of cisplatin and pemetrexed was the first systemic treatment approved by the FDA in 2004, followed only by the May 2020 FDA approval of nivolumab in combination with ipilimumab. Even with this newly approved treatment, the median overall survival of these patients is 18 months, with most of the patients eventually progressing and dying from their disease. IK-930 has orphan designation for the treatment of mesothelioma. Approximately 40% of malignant mesothelioma patients are associated with NF2 deficiency and this genetic alteration has been described to contribute to asbestos-induced mesotheliomagenesis in animal models, showing that NF2 drives the malignant behavior of this subset of mesothelioma cases. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to mesothelioma, meningioma also has high frequency of NF2 deficiency. Meningioma is the most common CNS tumor, accounting for approximately one-third of primary CNS tumors. Surgery and/or radiation therapy (&#x201c;RT&#x201d;) constitute the initial therapeutic approach for meningiomas. Furthermore, surgery and/or RT can control disease in some patients with recurrence. Unfortunately, despite the appropriate use of surgery and RT for initial disease management and management of recurrent disease, there is a subset of patients in whom disease cannot be controlled with local approaches. Experience with systemic treatments is limited and although several agents have been studied, none have an established role in prolonging progression-free survival or overall survival. The outcome of this subset of patients with persistent or recurrent meningiomas continue to be poor, underscoring the substantial need for new therapies. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soft tissue sarcomas (&#x201c;STS&#x201d;) represent a rare and heterogeneous group of solid tumors derived from mesenchymal progenitor cells and characterized by a variety of genetic alterations. Recent molecular and genetic studies in large cohorts of STS cases have demonstrated an essential role of YAP1/TAZ in sarcomagenesis, implying that a YAP1/TAZ directed therapeutic approach could represent a rational strategy in a selected subgroup of these tumors. STS account for 1% of all adult malignancies. While the clinical outcome of these diseases has improved in the last decade with the use of anthracycline-based chemotherapy and the introduction of novel therapies targeting different cell pathways and the use of immune checkpoints, the prognosis for a significant subgroup of patients with STS is still poor and there is an unmet medical need for these patients. For these reasons, the identification of novel molecular targets is important in these rare malignancies. Recent studies in a large cohort of STS tumors showed that myxoid liposarcomas, synovial sarcomas and angiosarcomas, in addition to EHE, expressed the highest levels of YAP1/TAZ gene expression, potentially driving tumorigenesis in these subsets of STS.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EHE is a rare STS that grows from the cells that make up the lining of blood vessels with an incidence of one case per million people in which 100% of the cases harbor genetic alterations of Hippo pathway with approximately 90% of the cases harboring a genetic fusion between TAZ and CAMTA1(&#x201c;TAZ-CAMTA1&#x201d;) and the other 10% of cases harboring a genetic fusion between YAP1 and TFE3 (&#x201c;YAP1-TFE3&#x201d;). This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone. It usually occurs in people between 30 and 50 years of age but can occur in young children and older people. Surgery and radiotherapy have been used as treatment for localized disease and several interventions have been used with palliative intent in the recurrent or metastatic cases, including steroids, interferon, and others, but there is currently no specific targeted therapy approved for the treatment of advanced EHE. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Combination Therapy Opportunities</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the successful expansion of personalized oncology using targeted therapies to selectively treat patients with specific mutations in key oncogenic drivers, intrinsic and acquired resistance to targeted agents is a growing clinical problem. Activation of YAP1/TAZ has been associated with the development of resistance to various targeted agents, including in EGFR mutant NSCLC, and in KRAS mutant tumors such as pancreatic carcinoma, CRC, and NSCLC. In EGFR mutant NSCLC, the successful early use of 3rd generation anti-EGFR inhibitors has improved the clinical outcome for these patients in not only in first line metastatic disease, but also early disease, and has become a new therapeutic paradigm for this patient population. However, the most efficient approach to managing emerging resistance to early use of 3rd generation EGFR inhibitors remains to be determined. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution, IK-930</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 is an oral, paralog-selective, small molecule inhibitor of TEAD that binds to a recently discovered lipid binding pocket on TEAD itself. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket. IK-930 blocks palmitate from binding TEAD, thereby disrupting TEAD-dependent gene transcription. The mechanism of action of IK-930 is differentiated from historically unsuccessful attempts in targeting the pathway. We believe that targeting the lipid binding pocket of TEAD has the potential to yield more potent and selective molecules as compared to these historical attempts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting a Phase 1 clinical trial of IK-930 in multiple tumor types, including cancers with high frequencies of Hippo pathway alterations. In addition to primary cancers linked to the pathway we plan to evaluate combinations with IK-930 in patients with the potential for acquired resistance to other targeted therapies, the first of which will explore IK-930 in combination with osimertinib. We expect to share initial clinical data from the monotherapy program in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have generated a robust preclinical dataset supporting IK-930 as a potential monotherapy solution for Hippo altered cancers and in combination to combat therapeutic resistance. In addition, our in-depth translational work coupled with our clinical development strategy positions us to select patients most likely to benefit from TEAD inhibition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our preclinical studies, we believe IK-930 is a potent, well tolerated, and selective TEAD inhibitor with favorable pharmacologic properties. The pharmacological properties we have observed have aided in determining our dose-escalation strategy in our clinical program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a TEAD reporter cell line, IK-930 inhibited TEAD-dependent transcription with an EC50 of 25 nM, and inhibited proliferation of H226 cells, an NF2 mutant mesothelioma cell line, with an EC50 of 21 nM, demonstrating that IK-930 has high potency in inhibiting activated Hippo signaling in cultured cancer cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figure below illustrates the inhibition of TEAD by IK-930.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inhibition of TEAD by IK-930 blocks TEAD-Dependent Transcription and Proliferation in H226 Cells Containing an NF2 Mutation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_9.jpg" alt="img40748725_9.jpg" style="width:360px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of IK-930 to selectively inhibit proliferation in Hippo pathway mutated cells was demonstrated in the H28 mesothelioma cell line, which does not have any Hippo pathway mutations. This cell line is insensitive to IK-930. However, knockdown of NF2 using CAS9-CRISPR converts H28 into an IK-930 sensitive tumor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figure below illustrates IK-930 blocking the proliferation of cells with NF2 loss but not in cells with normal NF2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 Blocks Proliferation in Cells with NF2 Loss but Not in Cells with Normal NF2</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_10.jpg" alt="img40748725_10.jpg" style="width:353px;height:264px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of IK-930 to specifically inhibit TEAD mediated transcription was also demonstrated in the NF2 mutant (TEAD active) H226 mesothelioma cell line. Cells were treated in triplicates with IK-930 or DMSO control for 24 hours, then, RNA was extracted and sequenced. The expression levels of six TEAD target genes were compared between DMSO and IK-930 as represented in the heatmap below. IK-930 resulted in lower level of TEAD-target gene expression (green) compared to DMSO (red) consistent with inhibition of TEAD activity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We developed the six gene TEAD signature shown on the heatmap below through a combination of literature curation and experimental characterization using proprietary datasets from RNA sequencing experiments in mesothelioma, NSCLC, and HNSCC cell lines and mouse xenografts mesothelioma treated with DMSO control or IK-930.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robust Inhibition of TEAD Target Gene Expression</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_11.jpg" alt="img40748725_11.jpg" style="width:272px;height:253px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted multiple studies evaluating IK-930 in preclinical animal models. We observed IK-930 exhibited antitumor activity in three </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> xenografts models with different genetic alterations leading to constitutively active TEAD transcription status: NCI-H226 (NF2 deficient mesothelioma), MSTO2H11(LATS1/LATS2 mutant mesothelioma) and Detroit 562 (YAP1 amplified head and neck cancer). These studies were conducted utilizing 6-8 animals per group and in all models IK-930 dosed animals experienced increased</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tumor growth inhibition compared to vehicle. These studies demonstrated IK-930 antitumor activity in tumors driven by Hippo pathway signaling (constitutive TEAD activity).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Antitumor Activity of IK-930 in Hippo Mutant Xenograft Models</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_12.jpg" alt="img40748725_12.jpg" style="width:624px;height:178px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to potential for single agent activity in tumors with genetic alterations in the Hippo pathway, we believe there is an opportunity for IK-930 to be beneficial in combination with other targeted therapies in the therapeutic resistance setting. Alterations in the Hippo pathway have been connected to post-targeted treatment tumor growth or recurrence. For example, YAP1 activation (nuclear localization) has been shown to drive resistance to EGFR targeted therapies. NSCLC patients who develop resistance to EGFR inhibitors have higher levels of nuclear YAP expression in their tumors compared to baseline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also conducted studies to evaluate the mechanism by which IK-930 can prevent the expansion of EGFR inhibition tolerant persister cells. These data demonstrate the potential for the combination of IK-930 with osimertinib to delay emergence of resistance to EGFR inhibition, and may further impact the residual disease state prolonging the duration of osimertinib clinical benefit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon high dose osimertinib treatment, most EGFR mutant PC9 cells experienced apoptosis; however, a small subset of drug-tolerant cells, called persisters, were able to survive and continue to proliferate in the chronic presence of osimertinib. The addition of IK-930, concurrently with osimertinib, or after the emergence of the osimertinib-tolerant persister population, led to a clear reduction in the number of persister cells. These data demonstrate IK-930 treatment effectively prevented the survival and expansion of osimertinib-tolerant persister cells. This highlights IK-930&#x2019;s potential as a combination agent in preventing and reversing therapeutic resistance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persister Cell Emergence Mechanism</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_13.jpg" alt="img40748725_13.jpg" style="width:330px;height:252px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 + Osi Combined Prevented Emergence of Persisters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_14.jpg" alt="img40748725_14.jpg" style="width:561px;height:237px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 Addition after Persister Emergence Attenuated Expansion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_15.jpg" alt="img40748725_15.jpg" style="width:520px;height:241px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to these data that highlight the clinical opportunity to treat EGFR resistant patients with IK-930, we observed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that inhibitors of EGFR promote YAP1 nuclear localization in EGFR mutant NSCLC cells, which led to an induction of TEAD-dependent gene expression. We observed that IK-930 was able to suppress osimertinib-induced TEAD-dependent gene expression and to significantly enhance apoptosis when combined with osimertinib in EGFR mutant tumors grown </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition, we observed significantly enhanced antitumor activity when IK-930 was combined with osimertinib in multiple EGFR mutant tumors grown </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For example, in the H1975 EGFR mutant lung cancer xenograft mouse model, there was meaningful tumor growth inhibition in the group treated with IK-930 in combination with osimertinib, as well as complete regressions in the group treated with IK-930 in combination with osimertinib and trametinib, a MEK inhibitor, supporting that shutting down the mitogen-activated protein kinase (&#x201c;MAPK&#x201d;) survival pathway further leads to antitumor activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figure below illustrates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> apoptosis (left) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> antitumor activity (right) in EGFR mutant lung cancer models treated with osimertinib, IK-930, or the combination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 in EGFR Mutant Lung Cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_16.jpg" alt="img40748725_16.jpg" style="width:624px;height:196px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A clinical supply collaboration with AstraZeneca is in place for osimertinib for evaluation in combination with IK-930 for patients with EGFR mutant NSCLC in our ongoing Phase 1 clinical trial, assessing IK-930&#x2019;s impact on EGFR resistance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also conducted studies in several tumor models of KRAS-mutant cancers assessing the combination of IK-930 with trametinib. RAS-mutant cancer patients with resistance to MEK inhibitors could represent additional patient populations that could benefit from IK-930 combination therapy. There are multiple MEK inhibitors available and in development, including our own dual MEK-RAF inhibitor, IK-595. These studies were conducted with one of the most widely used approved MEK inhibitors, trametinib. In two models of KRAS G13D mutant cancers, HCT116 and LoVo, IK-930 combined with trametinib demonstrated more robust anti-tumor activity than either single agent alone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 Combination with Trametinib in two KRAS G13D CRC Models</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img40748725_17.jpg" alt="img40748725_17.jpg" style="width:624px;height:215px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a mouse model of KRAS G12S mutant cancers, A549, a combination of IK-930 with trametinib, showed significant impact on tumor inhibition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930 Combination with Trametinib in KRAS G12S NSCLC Model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_18.jpg" alt="img40748725_18.jpg" style="width:425px;height:251px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Importantly, in all three of these models, IK-930 added activity only when treatment with trametinib was present, suggesting the resistance of the tumor is linked to the Hippo pathway and could benefit from TEAD inhibition. These data support studying IK-930 in combination with targeted therapies in multiple tumor types, including EGFR and KRAS mutant tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-930 clinical development strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the broad role of the Hippo signaling pathway on tumor biology and cancer progression, our development plan for IK-930 monotherapy is focused on biomarker selected patient populations based on NF2 loss, and/or YAP1 and TAZ gene fusion in patients with solid tumors. We plan to utilize a comprehensive clinical development strategy focused on genetically defined patient populations targeting orphan disease indications of high unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing Phase 1 clinical trial of IK-930 is exploring IK-930 as a monotherapy and is currently in dose escalation. The initial monotherapy arm of the trial is evaluating the safety and activity of IK-930 in rare and orphan tumors associated with specific genetic alterations such as NF2 loss. The clinical trial is designed to determine the maximum tolerated dose and the recommended Phase 2 dose as illustrated in the figure below. Currently, we are enrolling the monotherapy dose escalation cohorts with patients with tumors known to have high incidence of Hippo pathway alterations and are advancing as expected, with multiple dose cohorts cleared.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The monotherapy dose expansion is planned to include multiple cohorts and select patients prospectively based on specific Hippo genetic alterations, such as NF2 loss and/or YAP1 and TAZ gene fusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 Clinical Trial of IK-930; Monotherapy Clinical Trial Design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_19.jpg" alt="img40748725_19.jpg" style="width:365px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combination cohorts of other targeted therapies with IK-930 present additional development opportunities, including the cohort in combination with osimertinib for patients with EGFR mutant NSCLC to assess IK-930&#x2019;s impact on therapeutic resistance to EGFR inhibition. This strategy is based on a distinct non-genetic mechanism from the monotherapy approach in genetically altered cancers. In addition to EGFR mutant cancers, there are multiple potential therapeutic combinations, including MEK inhibitors in patients with RAS mutant cancers, that we are considering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 Clinical Trial of IK-930; Combination Therapy Clinical Trial Design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_20.jpg" alt="img40748725_20.jpg" style="width:381px;height:288px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial clinical data from the monotherapy dose escalation cohorts is expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-595, a dual MEK-RAF inhibitor</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Targeting in the RAS pathway and MEK inhibition in cancer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The RAS pathway is implicated in at least half a million new cancer diagnoses each year in the United States alone. Ten of the twenty most common cancers worldwide are associated with RAS pathway mutations, representing a major unmet need for new and innovative approaches in the pathway.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 of the 20 Most Common Cancers Worldwide are Associated with RAS Pathway Mutations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_21.jpg" alt="img40748725_21.jpg" style="width:503px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cox. Nature Reviews Drug Discovery (2014); World Cancer Research Fund International</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We aim to target the RAS pathway on multiple levels, including preventing known resistance mechanisms, to achieve deep and sustained responses. Our most recent development candidate and first in the RAS pathway, IK-595, is a dual MEK-RAF inhibitor that is designed to trap MEK and RAF in an inactive complex. The RAS-RAF-MEK-ERK cascade MAPK pathway regulates cell proliferation, differentiation, and survival. Activating mutations in this pathway are known to drive tumorigenesis in a large number of patient populations. Targeting MEK and RAF has the potential to impact patients across a plethora of indications, including RAS and RAF-altered cancers, both in targeting genetic mutations and in targeting escape mechanisms from other targeted therapies, potentially prolonging duration of response for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_22.jpg" alt="img40748725_22.jpg" style="width:333px;height:336px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Existing drugs targeting MEK, classified as kinase inhibitors, are limited by insufficient pathway inhibition and narrow therapeutic window, and are only currently addressing BRAF type I mutant cancer patients and NF1 mutant neurofibroma patients. One of the well-known mechanisms of resistance to existing MEK inhibitors in RAS mutant populations is through CRAF bypass, the reactivation of CRAF through ERK mediated negative feedback control. More recently, CRAF function independent of its kinase activity has also been reported to drive tumor growth, a function that is not addressable through kinase inhibitors, including selective or pan-RAF inhibitors. We believe these two important CRAF roles in tumorigenesis and therapeutic resistance are significant factors in why existing MEK inhibitors, including the four FDA approved therapies, are insufficient for serving the large patient populations with RAS or RAF gene alterations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_23.jpg" alt="img40748725_23.jpg" style="width:624px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the approved MEK inhibitors, there are several in development. In many of our preclinical studies, we compared IK-595 to both approved MEK inhibitors and other experimental MEK inhibitors, including avutometinib (&#x201c;VS-6766&#x201d;), Verastem&#x2019;s clinical-stage MEK-RAF inhibitor, as a representative of the class of competitor molecules in development. We believe IK-595 has advantages over the class of MEK inhibitors as it could provide broader, more durable antitumor activity and a better therapeutic window for patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution, IK-595</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 is a potent, oral, small molecule MEK-RAF complex inhibitor that is designed to more comprehensively inhibit MAPK signaling than existing treatments, while achieving a broader therapeutic window for patients. Through its ability to stabilize MEK-RAF interaction, including CRAF, IK-595 aims to prevent both CRAF bypass and kinase-independent CRAF activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_24.jpg" alt="img40748725_24.jpg" style="width:253px;height:370px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 is being developed as an oral therapy, with mechanistic differentiation and a pharmacokinetic profile potentially superior to available inhibitors and those in development, with the potential for an improved therapeutic window for patients. We plan to submit an IND for IK-595 to the FDA in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have generated a robust preclinical dataset supporting IK-595 as a potentially durable therapeutic solution for multiple cancer types linked to the RAS pathway, expanding the potential populations that could benefit from existing MEK inhibitors. These studies demonstrate and include:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potent inhibition capabilities of IK-595 through multiple biochemical and cellular potency assays</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 ability to stabilize MEK and RAF, including CRAF, which we believe is key to differentiation in the class; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 inhibition of phosphorylation, and thus subsequent activation, of MEK and ERK (pMEK and pERK)</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Durability of the inhibition of pERK, and downstream target gene expression</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 preclinical efficacy in RAS and RAF altered cancer cell lines </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential synergy of IK-595 in combination with other targeted therapies </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including in combination with KRAS G12C inhibitors, EGFR, PI3K, SHP2, and SOS1 inhibitors</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Projected pharmacokinetics and pharmacodynamics of IK-595, which has been designed to have shorter half life in humans to allow for potentially differentiated dosing strategies </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 demonstrated high potency in a variety of biochemical and cellular assays. IK-595 biochemically inhibits unphosphorylated MEK (uMEK). Additionally, in AsPC-1 cells, IK-595 potently blocks cell proliferation and the phosphorylation of ERK and MEK.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_25.jpg" alt="img40748725_25.jpg" style="width:624px;height:81px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measured IK-595&#x2019;s effect on the MEK-CRAF interaction in KRAS mutant cancer cells (HCT-116). Western blot quantification of the MEK immunoprecipitates from HCT116 cells illustrates that IK-595 strongly increased the association of endogenous MEK and CRAF proteins, whereas trametinib decreased the MEK-CRAF interaction, and trametiglue had no effect. VS-6766 also increased MEK-CRAF association, but to a significantly less extent. These data indicate that IK-595 is differentiated from other MEK inhibitors in its potential to stabilize the MEK-CRAF complex.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A similar data trend was seen with MEK-BRAF association. These data indicate that IK-595 is differentiated from other MEK inhibitors in its ability to stabilize the MEK-CRAF in a completely inactive complex.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_26.jpg" alt="img40748725_26.jpg" style="width:564px;height:249px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effect of IK-595 on MEK phosphorylation was measured in KRAS mutant AsPC1 cells, using a Mesoscale Discovery (&#x201c;MSD&#x201d;) kit detecting total and phosphorylated MEK. In AsPC-1 cells after 4 hours of treatment, IK-595 potently inhibited MEK phosphorylation with an IC50 of 0.6 nM, while VS-6766 was more than 10 fold less potent with an IC50 of 7 nM. Trametinib had little effect on MEK phosphorylation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_27.jpg" alt="img40748725_27.jpg" style="width:286px;height:219px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assessed levels of phosphorylated and total MEK following 4- and 48-hours of treatment of HCT-116 cells with IK-595 compared to seven other MEK inhibitors, displayed below by Western blot analysis. IK-595 was observed to completely block phosphorylation of MEK at both 4 and 48 hours. VS-6766 and trametiglue were also observed to block the phosphorylation of MEK at both 4 and 48 hours. Trametinib had minimal or no effect on MEK phosphorylation at either timepoint, whereas 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> generation MEK inhibitors, namely mirdametinib, binimetinib, selumetinib, and cobimetinib, significantly increased MEK phosphorylation at both 4 and 48 hours. This suggests that IK-595 not only inhibits MEK protein, but also induces an inactive conformation of MEK-RAF protein complex to block RAF mediated MEK phosphorylation and activation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_28.jpg" alt="img40748725_28.jpg" style="width:459px;height:238px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measured the ability of IK-595 to inhibit ERK phosphorylation as compared to trametinib and VS-6766 through multiple studies. Levels of phosphorylated and total ERK following the treatment of KRAS mutant AsPC-1 and NCI-H2122 cells as well as CRAF amplified 5637 cells for up to 72 hours with IK-595, trametinib, or VS-6766 were determined by Western blot analysis. IK-595 inhibited ERK phosphorylation for up to 48-72 hours, whereas a rebound in ERK phosphorylation was observed in trametinib and VS-6766 at as early as 12 hours. These data support our belief that IK-595 can achieve more durable inhibition than existing and competitor MEK inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_29.jpg" alt="img40748725_29.jpg" style="width:603px;height:439px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The antitumor activity of IK-595 was evaluated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in multiple xenografts models, four of which are shown below having different RAS/MAPK alterations: AsPC-1 (KRAS G12D pancreatic); NCI-H2122 (KRAS G12C non-small cell lung cancer), 5637 (CRAF amplified bladder cancer) and OCI-AML-3 (NRAS Q61L acute myeloid leukemia model that is resistant to standard of care, venetolax). These studies were conducted utilizing 8-10 animals per group. Animals were dosed daily and tumors were measured twice weekly. These studies demonstrated IK-595&#x2019;s robust antitumor activity in tumors driven by alterations in the RAS/MAPK pathway. Similar activity was demonstrated in the AsPC-1 model when IK-595 was dosed intermittently at 6 mg/kg every other day (QOD). In addition, in all models, body weight of the mice was maintained similarly to that of the vehicle group.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_30.jpg" alt="img40748725_30.jpg" style="width:624px;height:447px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measured the synergy of IK-595 with multiple potential combination agents. For each agent, we assessed the synergy of IK-595 in combination with the given agent in multiple cell lines, measure cell viability and calculated Loewe sum of synergy scores. IK-595 demonstrated significantly higher synergy score with AMG510 (sotorasib), a KRAS-G12C inhibitor, over trametinib and VS-6766. Additionally, IK-595 showed significant synergy with other KRAS-G12C inhibitors (adagrasib), as well as P13K, EGFR, SOS1, and SHP2 inhibitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 Synergy with KRAS-G12C Inhibitors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_31.jpg" alt="img40748725_31.jpg" style="width:293px;height:211px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 Synergy with Multiple Potential Combination Agents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_32.jpg" alt="img40748725_32.jpg" style="width:468px;height:457px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key consideration for next generation MEK inhibitors is to broaden the therapeutic window that allows for deep inhibition and anti-proliferation effect in cancer cells but give normal cells sufficient breaks in pathway inhibition to minimize toxic side-effects. In order to optimize for tolerability, trametinib and VS-6766&#x2019;s clinical dosing regimens are designed to accommodate their very long half-lives in humans (trametinib 72-120 hours and VS-6766 60-100 hours). Because of this, clinical doses of trametinib and VS-6766 cannot reach concentrations above IC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for pERK inhibition as assessed in KRAS mutant cancer cells, or below IC50 through the entire treatment duration, leading to insufficient antitumor efficacy and poor tolerability.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the predicted shorter human half life of IK-595 will allow for flexibility in dosing schedules and enable transient concentrations above IC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and recovery in normal tissues during periods of low exposure, providing an advantageous therapeutic window for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trametinib and VS-6766 Pharmacokinetics Based on Actual Clinical Dosing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_33.jpg" alt="img40748725_33.jpg" style="width:461px;height:225px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 Projected Dosing and Pharmacokinetics (Model Only)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_34.jpg" alt="img40748725_34.jpg" style="width:276px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These data combine to support our efforts to advance IK-595 for the treatment of multiple types of RAS and RAF altered cancers. We believe they also demonstrate IK-595&#x2019;s competitive advantages over existing MEK inhibitors and others in development, including ability to trap CRAF in an inactive complex with MEK to avoid CRAF bypass and kinase-independent activity resulting in durable inhibition of the targets, as well as an improved therapeutic window.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-595 translational and clinical development strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In planning for clinical development, we have assessed the sensitivity profile of IK-595 in a large number of cancer cell lines harboring different RAS and RAF gene alterations. We plan to initially conduct our clinical program in indications with high prevalence of mutations that demonstrate higher sensitivity to IK-595 and have potential reliance on CRAF function. The ability of IK-595 to inhibit cell proliferation was evaluated by a 5-day cell titer glo (&#x201c;CTG&#x201d;) assay in ~250 cell lines with genetic alterations that included KRAS, NRAS, BRAF, CRAF alterations, EGFR, PIK3CA, and PTEN mutations. Area under the curve (&#x201c;AUC&#x201d;) of percent inhibition dose response curves were graphed. IK-595 demonstrated increased sensitivity in NRAS and KRAS mutant as well as CRAF altered cell lines compared to RAS wild-type cell lines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_35.jpg" alt="img40748725_35.jpg" style="width:297px;height:335px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical development plan includes the identification and selection of novel indications that show unique sensitivity to IK-595 and may be less explored by other inhibitors in the RAS pathway. In addition to our assessment of IK-595 as a monotherapy in RAS and RAF altered cancers, we are developing a combination strategy that leverages our own pipeline and expertise, as well as partnerships with therapeutics in RAS-MAPK and other compensatory pathways in which MEK-RAF may be a mechanisms of resistance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595 is currently in IND-enabling studies and we plan to submit an IND for IK-595 to the FDA in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immune Signaling Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to our programs targeting the RAS and Hippo pathways, we are also advancing programs that target immune-signaling pathways that modulate the TME. These programs, like our targeted oncology pipeline, are supported by robust biomarker research that allow us to prospectively select patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two of our immune signaling programs, IK-175 and IK-412, are partnered with Bristol Myers Squibb. Through our strategic partnership, Bristol Myers Squibb has the exclusive right to license each of IK-175 and IK-412 through completion of Phase 1b clinical trials. IK-175 is an inhibitor of AHR and urothelial carcinoma patients are currently being evaluated in the expansion cohorts of the Phase 1 clinical trial, an indication that show high expression of AHR. IK-412 is an enzyme therapy designed to lower levels of immunosuppressive kynurenine in the TME. The IK-412 program experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the partnership, we have made the strategic decision to pause IK-412 development for the remainder of the term of the Bristol Myers Squibb Collaboration Agreement (defined below) after the completion of on-going chemistry, manufacturing, and controls (&#x201c;CMC&#x201d;) activities, which concluded in 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our third candidate in immune signaling was IK-007, an oral selective antagonist of the EP4 receptor. IK-007 was evaluated in combination with pembrolizumab in a Phase 1b clinical trial in patients with microsatellite stable colorectal cancer (&#x201c;MSS CRC&#x201d;). In November 2022, we made the strategic decision to prioritize our targeted oncology pipeline and discontinued development of IK-007 in MSS CRC. In December 2022, we shared a clinical update on the program in which data concluded that IK-007 in combination</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with pembrolizumab had a tolerable and predictable safety profile in MSS CRC. However, due to small sample sizes, correlation of clinical benefit with levels of PGEM, a metabolite in the EP4 pathway we identified as a biomarker, was inconclusive. The combination of IK-007 and pembrolizumab produced limited, but durable, antitumor activity that compares favorably with standard of care and checkpoint inhibitors alone. However, the trial did not reach predefined levels of antitumor activity to support further development in this indication. Investigator initiated programs with IK-007 continue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-175, an AHR antagonist</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-175 is a potent, selective oral antagonist of AHR. We observed evidence of antitumor activity of IK-175 as a monotherapy and in combination with an anti-PD-1 antibody both in our preclinical models and more recently in initial clinical data presented from our ongoing Phase 1b clinical trial. Pursuant to our master collaboration agreement with Celgene Corporation (now Bristol Myers Squibb) we are responsible for development of IK-175 through the completion of a Phase 1b clinical trial, through the completion of which Bristol Myers Squibb has an exclusive right to exclusively license IK-175 worldwide. See &#x201c;&#x2014;License and Collaboration Agreements&#x2014;Master Collaboration Agreement with Bristol-Myers Squibb&#x201d; for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dual role of AHR in cancer progression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR is a ligand-dependent transcription factor that drives tumor progression through direct cancer cell and immunosuppressive effect in the TME. In some tumors, such as bladder cancer, high levels of AHR lead to constitutive, always-on activation and direct stimulation of tumor cell growth. AHR is also a critical component of a dominant immunosuppressive pathway in cancer, a pathway that modulates the function of cells in both the innate and adaptive components of the immune system. AHR is, in its inactive form, found in the cytosol, outside the nucleus. Upon binding of a signaling molecule or ligand, AHR migrates to the nucleus and functions as a transcription factor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR is overexpressed and constitutively activated in a number of tumors, including, but not limited to, bladder cancer. Constitutive activation of AHR also has been reported in head and neck squamous cell carcinoma, as well as castration-resistant prostate cancer. In melanoma, constitutive activation of AHR is believed to represent a significant mechanism of resistance to approved inhibitors of BRAF kinase. Inhibition of constitutively active AHR in patient-derived acute myeloid leukemia cells has been shown to sensitize these cells to killing by natural killer cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bladder cancer overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We prioritized patients with bladder cancer as a lead indication for the development of IK-175 based on the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Poor prognosis of patients with bladder cancer is associated with a high AHR transcript profiling score; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High levels of AHR mRNA and protein as measured by immunohistochemistry and RNAscope are found in bladder cancers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nuclear localization of AHR is high in bladder cancers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bladder cancer is the most common malignancy involving the urinary system and there were an estimated 81,400 new cases of bladder cancer and 17,980 deaths in the United States in 2020. The five-year survival for patients with early-stage disease is 88%; however, for patients with metastatic disease or cancer that has spread to other parts of the body, the five-year survival drops to 5%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most common treatment for patients diagnosed with advanced or metastatic bladder cancer is chemotherapy with platinum-based drugs, such as carboplatin or cisplatin, in combination with gemcitabine. Patients with metastatic disease that progresses during or after platinum-based chemotherapy are increasingly being treated with checkpoint immunotherapy. A number of PD-1 and PD-L1 checkpoint inhibitors have been approved by the FDA for the treatment of patients with refractory bladder cancer. Objective response rates in clinical trials with checkpoint inhibitors have generally been between 13% and 29%. The median overall survival of patients with advanced or metastatic bladder cancer from the start of initial therapy is 12.7 months. Other drugs have been recently approved for use in patients with metastatic bladder cancer after failure on platinum based regimens and checkpoint inhibitors, including Enfortumab vedotin and Sacituzumab govitecan (antibody directed conjugates &#x201c;ADCs&#x201d;). However, no approved treatment is available for bladder cancer patients who are resistant or refractory to checkpoint inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our solution, IK-175</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-175 is an internally discovered small molecule AHR antagonist that we are developing in collaboration with Bristol Myers Squibb for the treatment of advanced or metastatic solid tumors, including urothelial carcinoma, the most common type of bladder cancer,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">where AHR-activation is known to lead to poor prognoses. We observed that IK-175 is potent and selective for AHR in multiple </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assays and species.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have an ongoing, open-label Phase 1 clinical trial evaluating IK-175 as a monotherapy and in combination with nivolumab. The dose-escalation cohorts enrolled locally advanced or metastatic solid tumor patients. In November 2022, we presented initial clinical data from the dose-escalation cohorts and the first stage of the expansion cohorts in urothelial carcinoma. The study is currently ongoing. Clinical pharmacokinetic and pharmacodynamic data supports once-daily clinical dosing in patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-175 indication and patient selection strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our IK-175 clinical development strategy includes enrolling patients with cancers with a high expression of AHR, leading to our selection of bladder cancer and urothelial carcinoma. As part of our robust translational strategy, we have explored three tumor profiling technologies centered on AHR to help guide indication selection and/or candidate patients:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR gene amplification: Increases in the number of copies of the AHR gene as assessed by Fluorescent In Situ Hybridization (&#x201c;FISH&#x201d;) are observed in over 5% of multiple cancers such as esophageal, bladder and lung cancers. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nuclear AHR positivity: Constitutive activation of AHR leads to its localization to the nucleus, which can be directly measured by a proprietary immunohistochemical staining assay that we developed. In the monotherapy expansion cohort, we are prospectively enriching for patients with tumors that exhibit activated AHR using this assay. With the proprietary assay we developed, we assessed multiple tumor samples and found bladder cancer has the highest percentage of nuclear AHR positivity of those sample test. Head and neck cancer, melanoma, and ovarian cancer also resulted in higher-than-average scores, as displayed in the image below. The assay also is being used in our ongoing clinical trial to select patients with high nuclear-AHR positivity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunohistochemistry Tumor Microarray Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_36.jpg" alt="img40748725_36.jpg" style="width:434px;height:259px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR-dependent gene transcription: Activation of AHR leads to changes in transcription of many genes, which can be quantified by standard mRNA transcription profiling technologies. We discovered this gene transcription expression signature. We generated a profile of the transcriptional changes induced by AHR activation across a panel of cell lines. We then used this profile to score tumors based on available transcript profiling data in public databases. We found that bladder cancer patients with transcriptional profiles that scored highest using our activated AHR profile had poorer prognoses compared to those with low scores, as illustrated in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR-activated Gene Transcription Signature is Associated with</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Poor Overall Survival in Bladder Cancer Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_37.jpg" alt="img40748725_37.jpg" style="width:310px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing Phase 1 clinical trial and initial clinical data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently evaluating IK-175 as a monotherapy and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma, which accounts for over 90% of all bladder cancers, in an open-label Phase 1 clinical trial. Enrollment in the dose escalation completed and we advanced to the two-stage dose expansion, enrolling unresectable locally recurrent or metastatic urothelial carcinoma (dose expansion) who have exhausted prior standard of care therapies. Dose escalation ranged from 200-1200 mg QD and 800 mg BID (monotherapy) and 800 mg and 1200 mg QD (combination with nivolumab 480 mg q4w). Expansion cohorts used a Simon 2-stage design requiring at least 1 responder in stage 1 urothelial carcinoma patients to proceed to the second stage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary endpoints of the trial include safety, tolerability, maximum tolerated dose, and recommended phase 2 dose. Secondary endpoints include pharmacokinetics, overall response rate (&#x201c;ORR&#x201d;), duration of response (&#x201c;DoR&#x201d;) and additional, immune pharmacodynamic endpoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, at the Society for Immunotherapy of Cancer Congress, we presented initial data on 43 patients from the dose escalation and stage 1 of the dose expansion. IK-175 was well tolerated with a predictable and manageable safety profile. Encouraging anti-tumor activity and duration of response was observed in the IK-175 nivolumab combination expansion cohort.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data set included:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43 total patients; 40 evaluable for anti-tumor activity</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 dose escalation patients (15 monotherapy, 5 combination)</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 dose expansion urothelial carcinoma patients (10 monotherapy, 10 combination)</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patients in the trial were all heavily pretreated, with all of the urothelial carcinoma patients having advanced on checkpoint inhibitors within 12 weeks of their last dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior Lines of Therapy for Urothelial Carcinoma Patients in Stage One of Expansion Cohort</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39.037%;"></td>
    <td style="width:26.278%;"></td>
    <td style="width:5.343%;"></td>
    <td style="width:29.343%;"></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monotherapy (n=10)</span></p></td>
    <td style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combination (n=10)</span></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td colspan="4" style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior lines of anti-cancer therapy</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;1-3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;4-10</span></p></td>
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
    <td colspan="2" style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:1pt solid rgba(118,113,113,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADC experienced</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:1pt solid rgba(118,113,113,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:1pt solid rgba(118,113,113,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the initial clinical data is described in the table below. The combination cohort demonstrated a 20% overall response rate and a 40% disease control rate (&#x201c;DCR&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Initial Clinical Data from Stage 1 of Urothelial Carcinoma Expansion Cohorts</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.546%;"></td>
    <td style="width:31.657%;"></td>
    <td style="width:30.796%;"></td>
   </tr>
   <tr style="height:20.9pt;">
    <td style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monotherapy (n=10)</span></p></td>
    <td style="border-top:1pt solid rgba(165,165,165,1);background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:1pt solid rgba(165,165,165,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combination (n=10)</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td colspan="3" style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Best overall response</span></p></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Confirmed partial response</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;text-indent:54.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><div style="margin-left:0.5in;text-indent:0.0pt;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.349748743718593%;">1</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(10%)</span></div></div></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2     (20%)</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Stable Disease</span></p></td>
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;text-indent:54.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><div style="margin-left:0.5in;text-indent:0.0pt;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.349748743718593%;">1</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(10%)</span></div></div></td>
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2     (20%)</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Progressive disease</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;text-indent:54.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><div style="margin-left:0.5in;text-indent:0.0pt;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.349748743718593%;">6</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60%)</span></div></div></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6     (60%)</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ORR, n(%)</span></p></td>
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;text-indent:54.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;"><div style="margin-left:0.5in;text-indent:0.0pt;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.349748743718593%;">1</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(10%)</span></div></div></td>
    <td style="background-color:rgba(240,240,240,1);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2     (20%)</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid;padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DCR, n(%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2     (20%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid;padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4     (40%)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the encouraging statistical data, these initial data showed encouraging antitumor activity in both the monotherapy and nivolumab combination cohorts in patients that are refractory or resistant to check point inhibitors. These observations in both cohorts contribute to our confidence in IK-175 in combination with nivolumab as a potential therapy for urothelial carcinoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the monotherapy dose expansion cohort, 20% of patients achieved disease control with one patient achieving a confirmed partial response with a duration of response at the time of the data cut-off of nearly 15 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent &#x394; in Sum of Diameters Over Time (Urothelial Carcinoma; IK-175 Monotherapy Dose Expansion)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_38.jpg" alt="img40748725_38.jpg" style="width:498px;height:219px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The observed rate of progression of non-responders in this group suggests that patients in this population have rapidly advancing disease when a treatment does not have impact. In addition to the 40% DCR and 20% ORR in the combination expansion in urothelial carcinoma, we observed reduction in target lesion in the majority of the patients and duration of lesion reduction ranging from 4 to 8 months at the time of data presentation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent &#x394; in Sum of Diameters Over Time (Urothelial Carcinoma; IK-175 Nivolumab Combination Dose Expansion)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_39.jpg" alt="img40748725_39.jpg" style="width:477px;height:302px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These initial results demonstrate encouraging, durable, anti-tumor activity in stage 1 of both the monotherapy and combination arms in urothelial carcinoma patients. We believe these data are encouraging and the study is currently ongoing; we plan to provide a clinical update on the program in 2023. In addition to the program in urothelial carcinoma, we had initiated a Phase 1 program in head and neck cancer evaluating IK-175 in combination with nivolumab. Recently we made a decision to stop the head and neck study prior to enrolling any participants in order to direct resources towards completing the data package for the Bristol Myers Squibb partnership, which is eligible for opt-in until early 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficient Early-Stage Research to Expand Targeted Oncology Portfolio</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our discovery efforts have produced all three ongoing development programs in our pipeline. We believe we have a proven track record in discovery and development of novel therapeutic candidates, with a highly efficient process that has led to an average of less than three years from concept to IND, nearly half the industry average. Our discovery engine is built on early incorporation of translational and clinical input to ensure the work we do has specific patient needs in mind and real-life potential in the clinic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Discovery Engine Utilizes Multiple Strategies in Parallel, Including Early Inclusion of Translational Medicine to Ensure Efficient Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_40.jpg" alt="img40748725_40.jpg" style="width:616px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Across our early-stage program, we are conducting additional work in both the Hippo and RAS pathways in the effort to develop therapies for cancers that target key nodes and feedback connections. This work, coupled with the progress we have made with IK-930 and IK-595, and encouraging data from our partnered immune-oncology program, form our well-balanced pipeline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline of Wholly-Owned Targeted Oncology Assets and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advanced Partnered Immune Signaling Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img40748725_41.jpg" alt="img40748725_41.jpg" style="width:628px;height:280px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition, and strong defense of intellectual property. While we believe that our pipeline and our knowledge, experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We compete in the segments of the pharmaceutical, biotechnology, and there are other companies focusing on structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and other diseases. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted oncology therapeutics. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety, and convenience of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe principal competitive factors to our business include, among other things, our ability to identify promising biomarkers, our ability to successfully transition research programs into clinical development, our ability to raise capital, and the scalability of our pipeline and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-930</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other companies that have publicly disclosed that they are developing TEAD inhibitors are: Vivace Therapeutics, Inc., Novartis International AG (Novartis), Inventiva S.A., Kyowa Hakko Kirin Co., Ltd., SpringWorks Therapeutics, Inc., Cedilla Therapeutics, Inc., BridGene Biosceiences, Betta Pharmaceuticals, Beactica Therapeutics, Sporos Biodiscovery, Light Horse Therapeutics, Tasca Therapeutics, Orion Corporation, Merck, Sanofi, and Roche/Genentech. Vivace Therapeutics, Inc. and Novartis are both in Phase 1 clinical trials with their programs. All other programs are preclinical.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-175</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of one other AHR antagonist in clinical development under development by Bayer AG, or Bayer. Bayer is currently enrolling patients with advanced solid tumors in a Phase 1 trial for BAY-2416964 in advanced solid tumors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-595</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to approved MEK1/2 inhibitors (Mekinist, Mektovi, Cotellic, Koselugo), we are aware of the following clinical-stage MEK1/2 inhibitors: SpringWorks&#x2019; mirdametinib, DayOne Biopharma&#x2019;s pimasertib, KeChow Pharma&#x2019;s tunlametinib (HL-085), Sino Biopharmaceutical&#x2019;s TQB-3234, Fosun Pharma&#x2019;s FCN-159, Recursion&#x2019;s REC-4881, and Lupin&#x2019;s LNP3794. Additional MEK/RAF-targeted agents include Verastem&#x2019;s avutometinib (VS-6766), Immuneering&#x2019;s IMM-1-104, and IMM-6-415. Pan-RAF inhibitors include DayOne Biopharma&#x2019;s tovorafenib (DAY-101), Erasca&#x2019;s naporafenibum (LXH-254), BeiGene&#x2019;s lifirafenib (BGB-283), Genentech&#x2019;s belvarafenib, Kinnate Biopharma&#x2019;s exarafenib (KIN-2787), Jazz Pharma&#x2019;s JZP-815, and Deciphera&#x2019;s DCC-3084.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Master Collaboration Agreement with Bristol Myers Squibb</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, we entered into the Bristol Myers Squibb Collaboration Agreement with Celgene Corporation (which was acquired by Bristol Myers Squibb in November 2019) under which Bristol Myers Squibb may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine and AHR, excluding AHR agonists except for inverse agonists, or the Collaboration Candidates, which we are developing as IK-175 and IK-412. The Bristol Myers Squibb Collaboration Agreement triggered an upfront payment of $95.0 million, which consisted of approximately $80.5 million in cash and an equity investment of approximately $14.5 million for which we issued 14,545,450 shares of our Series A-1 Preferred Stock pursuant to a separate stock purchase agreement. The series A-1 shares automatically converted into common stock upon the completion of our initial public offering (&#x201c;IPO&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a program-by-program basis, through the completion of a Phase 1b clinical trial for each of IK-175 and IK-412, Bristol Myers Squibb has the exclusive right with respect to such Collaboration Candidate to a worldwide exclusive license with us to develop, commercialize and manufacture the compound (and products and diagnostic products containing such compounds) underlying such Collaboration Candidate. Additionally, if we do not complete a Phase 1b clinical trial by the end of the research term (as defined below), we may elect to provide a data package to Bristol Myers Squibb upon which Bristol Myers Squibb may exercise the foregoing option for an additional $0.25 million fee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As previously disclosed in 2021, the IK-412 program experienced manufacturing delays as a key component required in the manufacturing of IK-412 is similarly essential to the manufacturing of COVID-19 vaccines and therapies. Considering these delays and the timeline of the Bristol Myers Squibb partnership, we made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb contract term after the completion of on-going CMC activities, which concluded in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If and when Bristol Myers Squibb exercises its rights for a Collaboration Candidate, and as a result of the timing of our submission of INDs with respect to each Collaboration Candidate, Bristol Myers Squibb is required to pay us $50.0 million, in the case of an exercise of its option with respect to IK-175, and $40.0 million, in the case of an exercise of its option with respect to IK-412. The option exercise fees are payable within fifteen (15) days after the execution of each license agreement. Upon the execution of each license agreement, we will become eligible to receive up to $265.0 million under such license agreement in regulatory milestones and $185.0 million in commercial milestones as well as a tiered royalties at rates ranging from the high single to low teen percentages based on worldwide annual net sales by Bristol Myers Squibb, subject to specified reductions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb will continue to pay royalties on a Collaboration Candidate-by-Collaboration Candidate and country-by-country basis, until the latest of (i) there being no valid claim under the licensed patents covering the Collaboration Candidate, (ii) expiration of all regulatory exclusivity for the Collaboration Candidate in such country, and (iii) twelve (12) years after the first commercial sale of the Collaboration Candidate in the applicable country (the Royalty Term), after which the applicable license granted to Bristol Myers Squibb in such country will become non-exclusive, fully paid-up, perpetual, irrevocable and royalty-free.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research term under the Bristol Myers Squibb Collaboration Agreement continues for a period of five (5) years from its effective date. The term of any license agreement described above would continue on a Collaboration Candidate-by-Collaboration Candidate and country-by-country basis until the expiration of all Royalty Terms under such agreement, unless earlier terminated as described below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bristol Myers Squibb Collaboration Agreement may be terminated (i) by either party on a program-by-program basis if the other party remains in material breach of the Bristol Myers Squibb Collaboration Agreement following a cure period to remedy the material breach, (ii) by Bristol Myers Squibb at will on a program-by-program basis or in its entirety, (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party, or (iv) automatically, on a program-by-program basis if Bristol Myers Squibb fails to timely deliver an opt-in notice to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each license agreement may be terminated (i) by either party if the other party remains in material breach of the license agreement following a cure period to remedy the material breach, (ii) by Bristol Myers Squibb at will, (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party, or (iv) by us, in its entirety, if Bristol Myers Squibb challenges a patent licensed by us to Bristol Myers Squibb under the license agreement or any jointly-owned collaboration patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon our termination of a license agreement for Bristol Myers Squibb&#x2019;s breach, bankruptcy or insolvency or patent challenge, we would receive (i) upon our timely request, a nonexclusive worldwide license under Bristol Myers Squibb&#x2019;s know-how and patents covering the applicable licensed compound to the extent that such compound (or product or diagnostic product containing such compound) has been or is in active development or commercialization as of termination; and (ii) subject to determination of an applicable license payment in accordance with the license agreement, an exclusive license for the foregoing. If Bristol Myers Squibb terminates a license agreement for our breach or bankruptcy or insolvency, Bristol Myers Squibb&#x2019;s license will survive for six (6)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">months. Additionally, in the event of our material breach, Bristol Myers Squibb may elect to have the license agreement continue, with all future payments under that license agreement reduced by 50%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent License Agreement with the University of Texas at Austin</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2015, we entered into an exclusive patent license agreement (the &#x201c;License Agreement&#x201d;) with the University of Texas at Austin, or the University, pursuant to which the University granted us a worldwide license to certain technology and IP rights relating to IK-412, a kynurenine-degrading enzyme.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the License Agreement, and we pay a license fee of approximately $40,000 per year. We will also be obligated to make milestone payments to the University of up to an aggregate of $0.7 million upon meeting certain development milestones and up to an aggregate of $4.0 million upon meeting certain regulatory milestones, as well as low single digit royalties based on worldwide annual net sales on any licensed product, subject to specified reductions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will be obligated to continue to pay royalties on a licensed product-by-licensed product and country-by-country basis, as long as there is an existing valid claim under the licensed patents in such country. Please see &#x201c;Business&#x2014;Intellectual Property&#x2014;IK-412,&#x201d; for additional information concerning the intellectual property related to the License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the License Agreement expires on licensed product-by-licensed product and country-by-country basis until the expiration of all royalty terms, unless earlier terminated as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The License Agreement may be terminated (i) by either party if the other party remains in breach of the license agreement following a cure period to remedy the breach, (ii) by us at will, (iii) by the University, in its entirety, upon our bankruptcy or insolvency, or (iv) by the University, in its entirety, if we challenge a patent licensed by the University to us under the license agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with AskAt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection of our acquisition of Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), in December 2018, we acquired in-process research and development assets related to AskAt Inc.&#x2019;s, (&#x201c;AskAt&#x201d;) selective EP4 antagonists based on the intellectual property associated with a License Agreement, or the AskAt Agreement, between Arrys and AskAt, dated December 14, 2017. Pursuant to the AskAt Agreement, AskAt granted Arrys an exclusive license worldwide, other than China and Taiwan, to the research and development of the licensed compounds in human diseases. AskAt controls the prosecution and maintenance of all intellectual property rights pertaining the licensed technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the AskAt Agreement, we are obligated to make milestone payments to AskAt, including up to $4.0 million upon the achievement of certain clinical development milestones, as well as milestone payments of up to an aggregate of $600 million upon the achievement of certain worldwide annual net sales milestones. We are also obligated to pay low single-digit royalties on annual worldwide net sales on a licensed-product-by-licensed product and country-by-country basis, for the period beginning upon the first commercial sale in such country and ending upon the later of (i) 10 years from the first commercial sale in such country, or (ii) the expiration of valid claims in such country. Please see &#x201c;Business&#x2014;Intellectual Property&#x2014;EP4 Antagonists Patent Families,&#x201d; for additional information concerning the intellectual property related to the AskAt Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the AskAt Agreement expires on licensed product-by-licensed product and country-by-country basis upon the expiration of the royalty term for such licensed product, unless earlier terminated as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The License Agreement may be terminated (i) by either party if the other party remains in material breach of the license agreement following a cure period to remedy the breach, (ii) by us for convenience upon 180 days&#x2019; notice or (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and future products, and methods of using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Our commercial success depends, in part, on our ability to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions and improvements we consider important to our business, and to defend any patents we may own or in-license in the future, prevent others from infringing any patents we may own or in-license in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, future products, and proprietary technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to practice our technology or commercialize our product candidates. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in-license in the future. Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented, or have the scope of their claims narrowed. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#x2019;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The term extension period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. The term extension period cannot be longer than five years, and the term extension period may not extend the patent term beyond 14 years from the date of FDA approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that our pending patent applications, and any patent applications that we may in the future file or license from third parties, will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or in-license in the future. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, our overall patent portfolio includes over fifty (50) patent families comprising issued patents, pending U.S. and PCT International patent applications, and pending patent applications in foreign jurisdictions. The patents and patent applications have claims relating to our current product candidates, methods of use and manufacturing processes, as well as claims directed to potential future products and developments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TEAD Inhibitor Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we solely own ten patent families related to TEAD inhibitors and degraders, compositions thereof, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2040 to 2043, not including any patent term adjustment, patent term extension, or supplementary protection certificate (&#x201c;SPC&#x201d;). These patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to a first collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2023, this TEAD patent family contains one issued U.S. patent and one pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, Australia, Canada, India, South Korea, Mexico, Argentina, and Taiwan. The issued U.S. patent includes composition of matter claims encompassing IK-930. Our issued U.S. patent and any U.S. or foreign patents that issue in the future from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to a second collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2023, this TEAD patent family contains one issued U.S. patent and a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, Australia, Canada, India, South </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Korea, Mexico, Argentina, and Taiwan. Our issued U.S. patent and any U.S. or foreign patents that issue in the future from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to a third collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to a fourth collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to a collection of TEAD degrader compounds, compositions thereof, and methods of their use. As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to combinatorial methods of using TEAD inhibitors. As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2042, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to translational methods of selecting patients for treatment with TEAD inhibitors. As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2042, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to certain TEAD inhibitor formulations, and methods of their use.  As of March 1, 2023, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2042, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to crystal and salt forms of certain TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2023, this patent family contains one patent application that will serve as a priority application for an international patent application and/or any direct national stage patent applications to be filed in the future within the one-year period following the filing date of this priority application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2043, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one TEAD patent family directed to certain TEAD inhibitor combination therapy technologies.  As of March 1, 2023, this patent family contains one U.S. provisional patent application.  Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2043, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current lead TEAD inhibitor, IK-930, is covered by our solely owned U.S. patent with composition of matter claims that is expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. Our current lead TEAD inhibitor, IK-930, compositions thereof, and methods of the use, are also covered by our solely owned pending U.S. and foreign patent applications, whereby any U.S. or foreign patents that, if granted and all appropriate maintenance fees paid, are expected to expire from 2040 to 2043, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MEK Inhibitor Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we solely own five patent families related to MEK inhibitors, compositions thereof, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2042 to 2044, not including any patent term adjustment, patent term extension, or SPC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, our patent family directed to a first collection of MEK inhibitors, compositions thereof, and methods of their use contains, as of March 1, 2023, one pending PCT application, whereby any U.S. or foreign patents that issue from this patent family, if</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">granted and all appropriate maintenance fees paid, are expected to expire in 2042, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RAS Signaling Pathway Program Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we exclusively own eleven patent families related to inhibitors and other molecules targeting the RAS signaling pathway, compositions thereof, and methods of their use, including seven pending PCT applications and at least four pending U.S. provisional patent applications. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2041 to 2043, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AHR Antagonists Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we solely own eight patent families related to AHR antagonists, compositions thereof, and methods of their use. U.S. patents that have issued in these patent families and any further U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2038 to 2043, not including any patent term adjustment, patent term extension, or SPC. The published patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family one is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2023, this AHR antagonists patent family contains three U.S. patents, patents in foreign jurisdictions such as Singapore, Taiwan, Eurasia, and Chile, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, Australia, Canada, India, South Korea, and Mexico. These U.S. and foreign patents and any further U.S. or foreign patents that may issue from AHR antagonists patent family one, if granted and all appropriate maintenance fees paid, are expected to expire in 2038, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family two is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2023, this AHR antagonists patent family contains two U.S. patents, patents in foreign jurisdictions such as Israel, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, Australia, Canada, India, South Korea, and Mexico. This U.S. patent and any further U.S. or foreign patents that may issue from AHR antagonists patent family two, if granted and all appropriate maintenance fees paid, are expected to expire in 2038, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family three is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2023, this AHR antagonists patent family contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, and Canada. Any U.S. or foreign patents that issue from AHR antagonists patent family three, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family four is directed to crystal forms of certain AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2023, this AHR antagonists patent family contains one issued U.S. patent, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, and Canada.  Any U.S. or foreign patents that issue from AHR antagonists patent family four, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family five is directed to certain AHR antagonist formulations, and methods of their use. As of March 1, 2023, this AHR antagonists patent family contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, and Canada. Any U.S. or foreign patents that issue from AHR antagonists patent family five, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family six is directed to methods of selecting patients for AHR antagonist treatment. As of March 1, 2023, this AHR antagonists patent family contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, and Canada. Any U.S. or foreign patents that issue from AHR antagonists patent family six, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AHR antagonists patent family seven is directed to methods of using AHR antagonists. As of March 1, 2023, this AHR antagonists patent family contains a pending PCT application. Any U.S. or foreign patents that issue from AHR antagonists patent family seven, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, our solely owned patents and patent applications covering current lead AHR antagonist IK-175, salts and crystal forms thereof, compositions thereof, and methods of the use include four issued U.S. patents, multiple pending U.S. and PCT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">international patent applications, patents in foreign jurisdictions such as Singapore, Taiwan, Eurasia, and Chile, and pending patent applications in Europe, Japan, Australia, Canada, China, and other foreign jurisdictions, all of which are described above where, if granted and all appropriate maintenance fees paid, are expected to expire from 2038 to 2043, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IK-412</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own and exclusively license patents and patent applications related to our IK-412 program. Our in-licensed patent portfolio related to this program includes three patent families that include patents and patent applications covering our IK-412 biologic drug product as a composition of matter and methods of using the same, alone or in combination with other therapeutic agents. The three exclusively licensed patent families are licensed from the University of Texas at Austin.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, the first in-licensed patent family includes three issued patents in the U.S., which are projected to expire in 2034 and 2035, excluding any patent term extensions, if applicable. The first in-licensed patent family also includes issued patents in Europe, Hong Kong, Australia, Canada, China, Israel, India, Japan, Korea, New Zealand, and South Africa, and such patents are expected to expire in 2034, excluding any patent term extensions, if applicable. Within this first in-licensed patent family, pending patent applications include those in the U.S., Brazil, Canada, China, Europe, Japan, and South Africa.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, the second in-licensed patent family includes two issued patents in the U.S., which are projected to expire in 2035, excluding any patent term extensions, if applicable. This second in-licensed patent family also includes issued patents in Israel and Japan, and such patents are expected to expire in 2034, excluding any patent term extensions, if applicable. Within this second in-licensed patent family, patent applications are pending in the U.S., Canada, Europe, and Japan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, the third in-licensed patent family includes patent applications in the U.S., Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Eurasian Patent Organization, Hong Kong, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, Thailand, Taiwan, and South Africa. Patents that issue from these applications are projected to expire in 2039, excluding any patent term adjustments or extensions, if applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we also solely own patent applications related to our IK-412 program. The company-owned patent portfolio related to this program consists of one patent family that currently includes one U.S. patent application and pending patent applications in foreign jurisdictions, such as Australia, Europe, Japan, China, and Canada covering our IK-412 biologic drug product as a composition of matter and methods of using the same, alone or in combination with other therapeutic agents. Patents issuing from the company-owned patent family are projected to expire in 2040, excluding any patent term adjustments or extensions, if applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EP4 Antagonists Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we have an exclusive license to six patent families directed to EP4 antagonists, crystal forms thereof, compositions thereof, and methods of their use. The U.S. and foreign patents that have issued in these patent families and any further U.S. or foreign patents that may issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2024 to 2037, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we and AskAt Inc. jointly own three patent families directed to EP4 antagonist compositions, methods of making certain EP4 antagonists and their formulations, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we solely own one  patent family directed to EP4 antagonist salts and crystal forms, and methods of using the same. Any U.S. or foreign patents that issue from this patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trade Secret Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patents, we rely on unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. In particular, we anticipate that with respect to the building of our compound library, our trade secrets and know-how will over time be disseminated within the industry through independent development and public presentations describing the methodology. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. These agreements may also be breached, and we may not have an adequate remedy for any such breach. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademark Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have filed for and obtained Notices of Allowance for trademark protection with the U.S. Patent and Trademark Office for the IKENA and IKENA ONCOLOGY word marks for goods and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacture if our product candidates receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If necessary, we expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governmental Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations, or CROs, clinical investigators and contract manufacturing organizations, or CMOs will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, where we are initially focusing our drug development, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, as amended, and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#x2019;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a New Drug Application, or NDA. The process generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually and when certain changes are made; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an institutional review board (&#x201c;IRB&#x201d;) or independent ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation and submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug product&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payment of user fees for FDA review of the NDA; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical studies and clinical trials for drugs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes the results of animal and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#x2019;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Phase 1 clinical trials involve initial introduction of the investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#x2019;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, the FDA released a draft guidance entitled &#x201c;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#x201d; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of NDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#x2019;s initial receipt of the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. marketing approval for drugs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA package requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#x2019;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug to the satisfaction of the FDA. FDA must approve an NDA before a drug may be marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews all submitted NDAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards designed, including cGMP requirements, designed to assure and preserve the product&#x2019;s continued identity, strength, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan drug designation and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#x2019;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited development and review programs for drugs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review and accelerated approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A new drug is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a new drug may be eligible for breakthrough therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug alone or in combination with one or more other drugs may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with fast track or breakthrough therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including priority review designation and accelerated approval. A product is eligible for priority review, once an NDA is submitted, if the product that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#x2019;s goal date to take action on the marketing application is six months compared to ten months for a standard review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products are eligible for accelerated approval if they are designed to treat a serious or life-threatening disease or condition and can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Accelerated approval is usually contingent on a sponsor&#x2019;s agreement to conduct, in a diligent manner, adequate and well-controlled additional post-approval confirmatory trials to verify and describe the product&#x2019;s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after accelerated approval is granted. Additionally, under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or an indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the Agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric information and pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and certain NDA supplements must contain data that can be used to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a product candidate that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. Unless otherwise required by regulation, PREA does not apply to a drug for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA for a new active ingredient that is orphan-designated if the drug is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A drug can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. post-approval requirements for drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educational activities. Although physicians may prescribe approved products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including not only by company employees but also by agents of the company or those speaking on the company&#x2019;s behalf, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products are obtain reimbursement under federal health care programs. Promotional materials for approved drugs must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third party manufacturers that a sponsor may use. Manufacturers and manufacturers&#x2019; facilities are also required to comply with applicable product tracking and tracing requirements. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program user fee for any marketed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or withdrawal of product approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulation of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May 28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#x2019;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#x2019;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In Vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Companion Diagnostic Devices.&#x201d; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#x2019;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for co-development of an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#x2019;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#x2019;s facilities for compliance with its authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other regulatory matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following product approval, where applicable, the manufacturing, sales, promotion and other activities around product candidates and/or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA. Regulatory agencies with authority over product candidates may include, and are not limited to, the Centers for Medicare &amp; Medicaid Services (&#x201c;CMS&#x201d;) other divisions of the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;), the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other healthcare laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians, and third-party payors, both governmental and commercial, will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including, but not limited to, those described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute (&#x201c;AKS&#x201d;) prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have actual knowledge of the federal AKS or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus treble damages, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal AKS constitutes a false or fraudulent claim for purposes of the civil False Claims Act (&#x201c;FCA&#x201d;). </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity, and potentially individuals associated with the entity, from participation in Medicare, Medicaid and other federal healthcare programs. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Health Insurance Portability and Accountability Act of 1996 (&#x201c;HIPAA&#x201d;) imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#x201c;HITECH&#x201d;) and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#x201c;ACA&#x201d;) imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, for certain payments and &#x201c;transfers of value&#x201d; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made in the previous year to certain non-physician providers such as physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback and false claims laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These myriad data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to scrutinize interactions between healthcare companies and healthcare providers and increase investigations, prosecutions, convictions and significant settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#x2019;s attention from its business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Insurance Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the U.S. and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the U.S. such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the U.S., the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (&#x201c;CMS&#x201d;) an agency within the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Factors payors consider in determining reimbursement are based on whether the product is, among other considerations:<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#x2019;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current and future healthcare reform legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. The ACA includes provisions of importance to our potential product candidates that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanded manufacturers&#x2019; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#x201c;average manufacturer price,&#x201d; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanded the types of entities eligible for the 340B drug discount program; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part D; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. Due to the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) as well as subsequent legislation, these reductions had been suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Then, a one percent (1%) payment reduction occurred beginning April 1, 2022 through June 30, 2022, and the two percent (2%) payment reduction resumed on July 1, 2022. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three (3) to five (5) years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#x2019;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#x2019;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#x201c;best price&#x201d; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation (&#x201c;MFN&#x201d;) Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, on December 29, 2021, CMS rescinded the Most Favored Nations rule. Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The Inflation Reduction Act of 2022 (&#x201c;the IRA&#x201d;) further delayed implementation of this rule to January 1, 2032. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug sponsor to make its drug products available to eligible patients as a result of the Right to Try Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union Member States may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced Member States, can further</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compliance with other federal and state laws or requirements; changing legal requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling or packaging; (iii) the recall or discontinuation of our products; or (iv) additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other U.S. environmental, health and safety laws and regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain workers&#x2019; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government regulation of drugs outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the EU, medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Centralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EU, and in the additional Member States of the European Economic Area (&#x201c;EEA&#x201d;) (Iceland, Lichtenstein and Norway). Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tissue engineered products) and products with a new active substance indicated for the treatment of certain diseases, which includes products for the treatment of cancer. For medicines that do not fall within one of the mandatory categories, an applicant still has the option of submitting an application for a centralized marketing authorization to the European Medicines Agency (&#x201c;EMA&#x201d;) as long as the medicine concerned contains a new active substance not yet authorized in the EU, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EU. If pursuing a marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, the EMA&#x2019;s Committee for Medicinal Products for Human Use (&#x201c;CHMP&#x201d;) is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit/risk ratio. Under the centralized procedure the maximum timeframe for the evaluation of a marketing authorization application (&#x201c;MAA&#x201d;) by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#x2019;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">National authorization procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Decentralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU Member State for a medicinal product that has not yet been authorized in any EU Member State and that does not fall within the mandatory scope of the centralized procedure. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mutual recognition procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;In the mutual recognition procedure, a medicine is first authorized in one EU </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EU Member States in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In both cases, as with the centralized procedure, the competent authorities of the EU Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain is no longer covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations continue to be recognized in Northern Ireland). All medicinal products with a centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of three years from January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (&#x201c;MHRA&#x201d;), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. On January 24, 2023, the MHRA announced that a new international recognition framework will be put in place from January 1, 2024. Under this new framework, the MHRA will have regard to decisions on the approval of a marketing authorization made by the EMA and certain other regulators when considering whether to grant a UK marketing authorization. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States through decentralized or mutual recognition procedures with a view to more quickly granting a marketing authorization in the UK or Great Britain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, new products for therapeutic indications that are authorized for marketing (i.e., innovator products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic applicants from referencing the preclinical and clinical trial data contained in the dossier of the innovator product when applying for a generic marketing authorization in the EU during a period of eight years from the date on which the innovator product was first authorized in the EU. The additional two-year period of market exclusivity period prevents a successful generic applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EMA to be a new chemical entity, and products may not qualify for data exclusivity. Even if a product is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, in the EU a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition;  (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product will be of a significant benefit to those affected by that condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no MAA shall be accepted, and no marketing authorization shall be granted for a similar medicinal product.  A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Market exclusivity may also be revoked in very select cases, such as if (i) it is established that a similar medicinal product is safer, more effective or otherwise clinically superior than the authorized product; (ii) the marketing authorization holder of the authorized product consents to such revocation; or (iii) the marketing authorization holder of the authorized product cannot supply enough orphan medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining a marketing authorization in the EU, applicants must demonstrate compliance with all measures included in an EMA-approved pediatric investigation plan (&#x201c;PIP&#x201d;) covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA (&#x201c;PDCO&#x201d;) may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. If an applicant obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate or SPC, provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to 2 years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2017, the EU adopted the Regulation (EU) 2017/746 on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> diagnostic medical devices (&#x201c;IVDR&#x201d;) which became applicable on 26 May 2022 and repealed Directive 98/79/EC on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diagnostic medical devices. Devices that comply with the requirements of the IVDR are entitled to bear the CE conformity marking, indicating that the device conforms to the general safety and performance requirements of the IVDR, and, accordingly, can be commercially distributed throughout the EU (in-vitro diagnostic medical devices cannot be marketed in the EU without a CE Mark). The method of assessing conformity varies depending on the class of the product, but normally involves a third-party assessment by a &#x201c;Notified Body&#x201d;. This third-party assessment may consist of an audit of the manufacturer&#x2019;s quality system and specific testing of the manufacturer&#x2019;s product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted which replaced the Clinical Trials Directive 2001/20/EC. The Clinical Trials Regulation was entered in to application on January 31, 2022 and is directly applicable in all the EU Member States (meaning no national implementing legislation in each Member State is required). The transitory provisions of the new Clinical Trials Regulation provide that, by January 31, 2025, all ongoing clinical trials must have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transitioned to the new EU Clinical Trials Regulation. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, through the Clinical Trials Information System, (&#x201d;CTIS&#x201d;); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA, which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government regulation of data collection outside of the United States</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internationally, numerous jurisdictions have their own data security and privacy legal frameworks with which we will be required to comply if we conduct clinical trials in those jurisdictions or otherwise conduct business in those jurisdictions. In the event we conduct clinical trials in the EEA or otherwise collect personal data from data subjects in the EEA, we will be subject to additional privacy restrictions. The collection and use of personal health data in the EEA is governed by the General Data Protection Regulation (the &#x201c;GDPR&#x201d;) which became effective on May 25, 2018. The GDPR applies to the processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, enhanced requirements for securing personal data, requirements to conduct privacy impact assessments for &#x201c;high risk&#x201d; processing, limitations on retention of personal data, mandatory data breach notification and &#x201c;privacy by design&#x201d; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#x2019;s global revenue for the preceding financial year, or &#x20ac;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There continues to be a level of uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, further to the UK&#x2019;s exit from the EU on January 31, 2020 (&#x201c;Brexit&#x201d;), the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#x2019;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#x2019;s data protection regime, which is independent from but largely aligned to the EU&#x2019;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the UK is regarded as a third country under the EU&#x2019;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significantly, to enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with EEA and UK data protection laws. On June 4, 2021, the European Commission issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the European Commission&#x2019;s new standard contractual clauses but has issued a new version of a UK-specific transfer mechanism (i.e. the UK International Data Transfer Agreement or the UK International Transfer Addendum to accompany the European Commission&#x2019;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">standard contractual clauses for UK Transfers), to enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be further divergence between the EEA and the UK. The United Kingdom has announced plans to reform the country&#x2019;s data protection legal framework in its Data Reform Bill, which will introduce significant changes from the EU GDPR. This may lead to additional compliance costs and could increase our overall risk exposure as we may no longer be able to take a unified approach across the EEA and the UK, and we will need to amend our processes and procedures to align with the new framework.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data protection authority activity differs across the EEA and the UK, with certain authorities applying their own agenda which shows there is uncertainty in the manner in which data protection authorities will seek to enforce compliance with GDPR. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, many jurisdictions outside of Europe are also considering and/or have enacted comprehensive data protection legislation. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. In addition, should we utilize third party distributors outside of the United States, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UK formally left the EU on January 31, 2020, and, the EU and the UK have concluded a trade and cooperation agreement (&#x201c;TCA&#x201d;) which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore aligns in many ways with current EU regulations, however it is likely that these regimes will diverge significantly in the future now that Great Britain&#x2019;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 10, 2023, we had 80 full-time employees, of which 38 have M.D. or Ph.D. degrees. Within our workforce, 58 employees are engaged in research and development and 22 are engaged in business development, finance, legal, human resources, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our website address is https://www.ikenaoncology.com/. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our code of conduct, corporate governance guidelines and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through the &#x201c;Corporate Governance&#x201d; portion of our website.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="legal_proceeding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 1A. RISK FACTORS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. In evaluating the Company and our business, careful consideration should be given the risks described below, as well as the other information in this Annual Report on Form 10-K and in other documents that we file with the SEC. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a targeted oncology company with a limited operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We commenced operations in 2016 and are a targeted oncology company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. We have no products approved for commercial sale and therefore, have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our net losses were $68.8 million and $34.1 million for the twelve months ended December 31, 2022 and 2021, respectively. We had an accumulated deficit of $214.2 million as of December 31, 2022. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to increase significantly in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant sales, marketing and manufacturing expenses. As a public company, we will continue to incur additional costs that we did not incur as a private company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract, hire and retain qualified personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully open clinical trial sites and recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our product candidates and products, should they receive regulatory approval, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; expenditures that we will or may incur to develop additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for our products should they receive regulatory approval, which may vary significantly; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have no products approved for commercial sale and have not generated any revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have generated minimal collaborative revenue from our product candidates and have not generated revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless and until we obtain regulatory approval of, and begin to sell, one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successfully complete our ongoing and planned preclinical and clinical studies for our programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timely file and the acceptance of IND, for our programs in order to commence future clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successfully enroll subjects in, and complete, our ongoing and planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain and maintain acceptance of the products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">position our products to effectively compete with other therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain and maintain healthcare coverage and adequate reimbursement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enforce and defend intellectual property rights and claims; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement measures to help minimize the risk of the COVID-19 pandemic to our employees as well as patients and subjects enrolled in our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain a continued acceptable safety profile of our products following approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of pharmaceutical products is capital-intensive. We are currently advancing multiple targeted oncology programs through preclinical development toward identification of potential therapeutic candidates and subsequent planned IND filings. Additionally, we are conducting Phase 1 clinical trials of two of our candidates, IK-930 and IK-175 and we plan to submit an IND to the FDA for our MEK-RAF complex inhibitor, IK-595, in the second half of 2023 and initiate a Phase 1 clinical trial shortly thereafter. Consequently, we expect our expenses to significantly increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek regulatory approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. We also continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 30, 2021, we completed our IPO of our common stock and expect that the net proceeds from the IPO, together with our existing cash, cash equivalents and marketable securities are sufficient to fund our operations into 2025. However, our future capital requirements will depend on and could increase significantly as a result of many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of product discovery, preclinical and clinical development, laboratory testing and clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, prioritization and number of our research and development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs, timing and outcomes of regulatory reviews of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under our existing collaboration agreements or any additional collaboration agreements we may establish; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of securing manufacturing arrangements for clinical and commercial production; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to the development of any companion diagnostics we may use in the future;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential additional expenses attributable to adjusting our development plans (including any supply related matters) to the COVID-19 pandemic. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets in general and the recent volatility in the capital markets may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product that has received regulatory approval or be unable to expand our operations or otherwise capitalize on our business opportunities as desired, which could materially affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of common stock or securities convertible or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that may materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, acquiring, selling or licensing intellectual property rights, and making capital expenditures, declaring dividends or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which could have a material adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also could be required to seek funds through arrangements with additional collaborators or otherwise at an earlier stage than otherwise would be desirable. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves, any of which may have a material adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have never successfully completed any clinical trials for our oncology programs, and we may be unable to do so for any product candidates we develop. Certain of our oncology programs are still in preclinical development and may never advance to clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not yet demonstrated our ability to successfully complete clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. IK-930 is in clinical development, currently in a Phase 1 clinical trial. However, our other targeted oncology programs, including IK-595, are still in preclinical development and IND enabling studies, and may never advance to clinical development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently advancing additional early-stage targeted oncology programs through preclinical development toward potential therapeutic candidates and subsequent IND.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their positions, including, but not limited to, regarding the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or result in the composition of stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a NDA to the FDA, MAA, to the European Medicines Agency (&#x201c;EMA&#x201d;) or other marketing applications to regulatory authorities in other jurisdictions, for each product candidate and, consequently, the regulatory approval of each product candidate. IK-175 is also currently in clinical development. We are conducting a Phase 1 trial with IK-175 in patients with bladder cancer with activated AHR. However, we do not know whether these or any of our future clinical trials will begin on time or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to conduct additional preclinical studies or clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive, or are only modestly positive, or, if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not obtain regulatory approval at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining regulatory approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to be subject to post-marketing testing requirements; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience having the product removed from the market after obtaining regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discovery and development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preliminary and limited. Although we believe, based on our preclinical work, that the genetic alterations targeted by our programs drive the formation and spread of cancer, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients with specific target alterations, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type, commercialize our product candidates and achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical studies and future and ongoing clinical trials may not be successful. Currently, we have two programs in early clinical development and our other targeted oncology programs are in preclinical development. It is impossible to predict when, or if, any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and outcomes are uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. Our preclinical studies and future and ongoing clinical trials may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or otherwise obtain access to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our products that receive regulatory approval. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain regulatory approval, and we may not realize the full commercial potential of any of these therapeutic products that obtain regulatory approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received all of the necessary data or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary top-line data we previously published. As a result, preliminary, interim and top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the price of our common stock to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, regulatory agencies and others may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular program, the likelihood of obtaining regulatory approval of the particular product candidate, commercialization of any approved product and the business prospects of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the preliminary, interim or top-line data that we report differ from actual results, or if regulatory authorities or others, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience delays in initiating or completing our preclinical studies or clinical trials, including as a result of delays in obtaining, or failure to obtain, the FDA&#x2019;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will not be delayed, require redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our preclinical studies or clinical trials or to delay or terminate a clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators or IRBs or ethics committees may delay or may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective clinical research organizations (&#x201c;CROs&#x201d;) the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically significant results across tumor types or indications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, be unable to provide us with sufficient product supply to conduct or complete preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we currently anticipate. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could encounter delays if a clinical trial is suspended or terminated by us, including upon the recommendation of the Safety Monitoring Committee (&#x201c;SMC&#x201d;) if applicable for such trial, by the IRBs of the institutions at which such trials are being conducted, or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including, but not limited to, failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with, among other considerations, our clinical trial design or our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, principal investigators for our current and future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. Such an outcome could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the COVID-19 pandemic and related variants, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In particular, because we are focused on patients with specific genetic mutations for the development of our targeted oncology programs, and on patients with specific biomarkers for the development of our TME programs, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience difficulties with identifying specific patient populations for any biomarker-defined trial cohorts. The patient eligibility criteria defined in our trial protocols, including biomarker-driven identification may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria. We will also rely on the willingness and ability of clinicians to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the competitive trial environment, the eligibility criteria of our ongoing and planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit or enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, limiting our ability to identify patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#x2019;s expedited review and development programs, including breakthrough therapy designation and fast track designation, or otherwise seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reporting of the preliminary results of any of our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">factors we may not be able to control, including the impacts of the COVID-19 pandemic, that may limit patients, principal investigators or staff or clinical site availability. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We anticipate that certain of our current product candidates and future product candidates will be used in combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our current product candidates and any future product candidates have the potential to be administered in combination with checkpoint inhibitor immunotherapies or other standards of care like chemotherapies, targeted therapies, or radiotherapy. For example, through our clinical supply collaboration with AstraZeneca, we plan to explore IK-930 in combination with AstraZeneca&#x2019;s epidermal growth factor receptor (&#x201c;EGFR&#x201d;) inhibitor, osimertinib, and we are currently evaluating IK-175 in combination with nivolumab, which is marketed by Bristol Myers Squibb. Our ability to develop and ultimately commercialize our current programs and product candidates and any future programs or product candidates used in combination with osimertinib, nivolumab, or other checkpoint inhibitor immunotherapies or other targeted therapies, will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing targeted therapies checkpoint inhibitor immunotherapies or other comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA, other U.S. regulatory agencies and/or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates and any future product candidates. Moreover, following product approval, the FDA, other U.S. regulatory agencies and/or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive regulatory approval. Such developments may include changes to the other product&#x2019;s safety or efficacy profile, changes to the availability of the other product, quality, manufacturing and supply issues with respect to the other product, and changes to the standard of care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that Bristol Myers Squibb, AstraZeneca, or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing targeted therapies, checkpoint inhibitor immunotherapies or other combination agents. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Results from early preclinical studies and clinical trials of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies and clinical trials of our programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any results from our early preclinical studies and clinical trials of our targeted oncology and TME programs or our product candidates may not necessarily be predictive of the results from later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies and clinical trials of our product candidates according to our current development timeline, the results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to file INDs, or similar applications for our programs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to nominate multiple development candidates stemming from our RAS-pathway and additional Hippo pathway research programs. We plan to progress candidates to IND or similar application, however, we may not be able to file such INDs or similar applications on the timelines we expect. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or similar applications to a new IND or similar application. Any failure to file INDs or similar applications on the timelines we expect or to obtain regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. Because our targeted oncology programs and our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented from, or delayed in, obtaining regulatory approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Although we are currently conducting Phase 1 clinical trials of two of our candidates, IK-930 and IK-175, it is likely, as is the case with many oncology therapies, that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, our product candidates could cause undesirable side effects that we have not yet observed. Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. Most product candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development or regulatory approval of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to develop certain of our product candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates, in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our product candidates modulate pathway for which there are currently no approved or effective therapies, which may result in uncertainty. We select programs for cancer driver targets based on compelling biological rationale. We explore new programs based on extensive preclinical data analysis which sometimes cannot predict efficacy or safety in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our product candidates utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. We utilize structural biology in tight integration with our medicinal chemistry and biology capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our ability to expand our pipeline of product candidates, and we cannot predict whether we will continue to have access to these capabilities in the future to support our pipeline development. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of product candidates will not arise in the future, which may cause significant delays or we raise problems we may not be able to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#x2019; lack of experience with them. The novelty of the mechanism of action of any of our product candidates may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. If our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, operating results and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA. the EMA, the MHRA and comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future conduct additional clinical trials outside the United States, including in Europe, the United Kingdom, Australia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practices, (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. The EMA, the MHRA and many other comparable foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, the EMA, the MHRA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States, the European Union, the United Kingdom or the applicable jurisdiction. If the FDA, the EMA, or the MHRA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving regulatory approval or clearance for commercialization in the applicable jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Although we intend to explore other therapeutic opportunities in addition to the programs and product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our product candidates, we must obtain regulatory approval. Currently, all of our product candidates are in discovery, preclinical or clinical development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval may be delayed, if obtained at all. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidate involved. Changes in regulatory approval policies during the development period, changes in or enactment of additional statutes or regulations, or changes in regulatory review policies for each submitted NDA PMA or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to enroll a sufficient number of patients in our clinical studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we were to obtain regulatory approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays in obtaining, or if we fail to obtain, approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The extent to which COVID-19 continues to impact our operations or those of our third party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, the emergence of variants or continued action to contain the coronavirus or treat its impact, among others. COVID-19 or similar pandemics could adversely impact our preclinical or clinical trial operations in the U.S., including our ability to recruit and retain patients and principal investigators and site staff. For example, similar to other biopharmaceutical companies, we may experience delays in initiating IND-enabling studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in activating new trial sites. Any negative impact COVID-19 has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to monitor the impact of COVID-19 related supply chain issues relating to the rest of our business. Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites the rest of which could be adversely affected by global health matters, such as pandemics. We are currently and plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the ongoing COVID-19 pandemic. Some factors from the COVID-19 pandemic that have delayed and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may continue to delay, or have otherwise adversely affected enrollment in the clinical trials of our product candidates, as well as our business generally, include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations on travel that could interrupt key trial and business activities which could delay or adversely impact the conduct or progress of our prospective clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential negative affect on the operations of our third-party manufacturers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business disruptions caused by potential workplace, laboratory and office closures</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of components required in our manufacturing process for certain of our programs due to COVID-19 related vaccination and treatment efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in federal, state and local regulations as part of a response to the ongoing COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other factors arising from COVID-19 and any variants could worsen in countries that are already afflicted with COVID-19 or could continue to spread to additional countries. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to reformulate our product candidates which could require additional nonclinical studies or clinical trials and delay the development or regulatory approval of such product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New risks and side effects associated with our product candidates may be discovered during clinical testing. Our product candidates also may experience stability issues. For these or other reasons, we may need to reformulate our product candidates. Such reformulation may require us to conduct additional nonclinical studies or clinical trials to bridge or demonstrate the comparability of our modified product candidate to earlier versions, which could delay our clinical development plan or marketing approval for our product candidate. Reformulating a product candidate may also result in a delay in continuing a clinical trial. There can be no assurance that we will not experience delays in the completion of a clinical trial or in the commencement and completion of our future trials due to the need to reformulate our product candidates and subsequently discuss with or receive authorization from regulatory authorities to implement these changes in clinical trials. Additionally, reformulating a product candidate may cause us to experience a shortage in supply or cause the cost to manufacture our product candidate to increase. Any reformulation of our product candidates could substantially increase the costs and expenses of developing our product candidates and delay such development and marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and genetic diseases. There are other companies focusing on targeted oncology to develop therapies in the fields of cancer and other diseases. We also compete more broadly across the market for cost-effective and reimbursable cancer treatments. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, our ability to identify biomarkers, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the companies that we compete against or which we may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The incidence and prevalence for target patient populations of our programs and product candidates have not been established with precision. Our most advanced targeted oncology product candidate, IK-930, is an oral, paralog-selective, small molecule inhibitor of TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of all cancers and these genetic alterations are generally associated with poor clinical outcomes. The Hippo pathways is also associated with mechanisms of resistance to targeted therapeutics and could represent a larger population of patients. We are conducting additional research in the Hippo pathway to identify potential next generation programs. Additionally, we are currently evaluating IK-175 in a Phase 1 clinical trial in patients with solid tumors and patients with urothelial carcinoma, including those with activated AHR. AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients. We are also conducting IND-enabling studies on IK-595, our oral, small molecule MEK-RAF complex inhibitor, for which an IND submission to the FDA is planned for the second half of 2023. We have additional early-stage programs evaluating multiple nodes in the RAS pathways. KRAS mutations in the RAS signaling pathway occur in approximately 26% of all cancers. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our programs and product candidates, are based on our estimates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, the indications for which our product candidates are approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with the cancers and solid tumors for which our product candidates may be approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our current product candidates or any future product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never commercialized a product candidate for any indication. Even if our current product candidates and any future product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant revenue and may not become profitable or may be significantly delayed in achieving profitability. Market acceptance of our current product candidates and any future product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch, from existing therapies even when new and potentially more effective or safer treatments enter the market. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our or our competitors&#x2019; products, our products may not be accepted by the general public or the medical community. Future adverse events in targeted oncology, immune-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to educate the medical community and third-party payors on the benefits of our current product candidates and any future product candidates may require significant resources and may not be successful. If our current product candidates or any future product candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our current product candidates and any future product candidates will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy of our current product candidates and any future product candidates as single agents and in combination with marketed checkpoint inhibitor immunotherapies, targeted agents, and other combination agents; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commercial success of the checkpoint inhibitor immunotherapy drugs, targeted agents, and other combination agents with which our products may be co-administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of adverse events associated with our current product candidates and any future product candidates or those products with which they may be co-administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which our product candidates are approved and the approved claims that we may make for the products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the product&#x2019;s FDA-approved labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our current product candidates and any future product candidates that may be more restrictive than other competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the standard of care for the targeted indications for our current product candidates and any future product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the relative convenience and ease of administration of our current product candidates and any future product candidates and any products with which they are co-administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of adequate coverage or reimbursement by third party payors, including government healthcare programs such as Medicare and Medicaid and other healthcare payors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the price concessions required by third-party payors to obtain coverage; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of adequate coverage and reimbursement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent and strength of our marketing and distribution of our current product candidates and any future product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our current product candidates and any future product candidates or to which we agree as part of a REMS or voluntary risk management plan; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of our current product candidates and any future product candidates, as well as competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to offer our current product candidates and any future product candidates for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent and strength of our third-party manufacturer and supplier support; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the actions of companies that market any products with which our current product candidates and any future product candidates may be co-administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval of other new products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse publicity about our current product candidates and any future product candidates or any products with which they are co-administered, or favorable publicity about competitive products; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product liability claims. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement by government authorities for new products are typically made by CMS, since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. However, one payer&#x2019;s determination to provide coverage for a product does not assure that other payers will also provide coverage for the drug product. Further, a payer&#x2019;s decision to provide coverage for a drug product does not imply that the payor will provide adequate reimbursement. Reimbursement agencies in the European Union may be more conservative than CMS. Factors payors consider in determining reimbursement are based on whether the product is:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (&#x201c;ASP&#x201d;) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our Phase 1 clinical trials of IK-930 and IK-175 and expect to rely on third parties to conduct clinical trials for our other targeted oncology programs, including IK-595, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our current Phase 1 clinical trials of IK-930 and IK-175, as well as any other current product candidates, including IK-595, or future product candidates that may emerge from our targeted oncology programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely and expect to continue to rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, our principal investigators and our CROs are required to comply with regulations, including GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced cGMP regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, significantly increase our expenditures and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we designed our current ongoing clinical trials of IK-930 and IK-175 and intend to design the future clinical trials for our product candidates, including IK-595, these trials are conducted by CROs and we expect CROs will conduct all of our future clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development program may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research, development, commercialization and/or strategic collaborations, including the existing collaboration that we have with Celgene Corporation (now part of Bristol Myers Squibb), are subject to numerous risks, which include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may have significant control or discretion in determining the efforts and resources that they will apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may have limited influence or control over the approaches to research, development and/or commercialization of product candidates in the territories in which our collaboration partners lead research, development and/or commercialization; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators might not pursue research, development and/or commercialization of collaboration product candidates or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus, availability of funding or other factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development for collaboration product candidates or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators might not properly maintain or defend our intellectual property rights or might use our intellectual property improperly or in a way that jeopardizes our intellectual property or exposes us to potential liability; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaboration activities might result in the collaborator having intellectual property covering our activities or product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which could impact the collaboration and us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes might arise between a collaborator and us that could cause a delay or termination of the collaboration or result in costly litigation that diverts management attention and resources; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration. For example, although Bristol Myers Squibb provided us with an $80.5 million upfront payment and a $14.5 million equity investment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon entering into that certain master collaboration agreement with Celgene Corporation (now Bristol Myers Squibb), we might need additional funding to advance product candidates prior to the completion of a Phase 1b clinical trial, the clinical milestone when Bristol Myers Squibb must decide whether to exercise its exclusive license rights to IK-175 or IK-412. On November 20, 2019, Bristol Myers Squibb acquired Celgene Corporation and Bristol Myers Squibb may take a different approach to our collaboration or determine not to continue the collaboration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to exercise a license or other option under the collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to either secure other funding to advance research, development and/or commercialization of the relevant product candidate or abandon that program, the development of the relevant product candidate could be significantly delayed, and our cash expenditures could increase significantly if we are to continue research, development and/or commercialization of the relevant product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any one or more of these risks, if realized, could reduce or eliminate revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates for preclinical development and clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of our product candidates receive regulatory approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any CMO with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to establish any additional agreements with third-party manufacturers or do so on acceptable terms. Reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The active pharmaceutical ingredients (&#x201c;API&#x201d;) used in all of our product candidates are supplied to us from single-source suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also unable to predict how changing global economic conditions or potential global health concerns such as the COVID-19 pandemic will further affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Establishing additional or replacement suppliers for the API used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s own evaluation of a potential collaboration. Such factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the U.S. and other countries for our current or future product candidates, as well as for their respective compositions, formulations, methods used to manufacture them, and methods of treatment, in addition to successfully defending these patents against third-party challenges. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the U.S. and abroad related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our current or future product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our current or future product candidates. In addition, if the breadth or strength of protection provided by our patent applications or any patents we may own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, in jurisdictions outside the U.S., a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported co-owner of our patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such co-ownership. Furthermore, patents have a limited lifespan. In the U.S., and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a jurisdiction-by-jurisdiction basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or in-license may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including generic versions of such drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds, methods, formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until at least 18 months after the earliest priority date of patent filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in patents we may own or in-license patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent applications covering our current or future product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may be significantly narrowed by the time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we acquire patent protection that we expect should enable us to establish and/or maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may become involved in post-grant proceedings such as opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others from whom we may in the future obtain licenses to such rights, in the USPTO, the European Patent Office (&#x201c;EPO&#x201d;), or in other countries. In addition, we may be subject to a third-party submission to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from our pending patent applications. Competitors may allege that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed under our patents or patent applications. Competitors may also contest our patents by claiming to an administrative patent authority or judge that the invention was not patent-eligible, was not original, was not novel, was obvious, and/or lacked inventive step, and/or that the patent application filing failed to meet relevant requirements relating to description, basis, enablement, and/or support; in litigation, a competitor could claim that our patents, if issued, are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent patents we may own or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in-license by developing similar or alternative technologies or drugs in a non-infringing manner. For example, a third-party may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to obtain, maintain, or enforce such patent claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for patent protection on these inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially adverse consequences to building our product brand recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the protection afforded by patents we may own or in-license, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that may not be patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that may not be covered by patents. Although we require all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe any patents we may own or in-license. In addition, any patents we may own or in-license also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or in-license is not valid or is unenforceable or that the other party&#x2019;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that any patents we may own or in-license do not cover the technology in question or that such third-party&#x2019;s activities do not infringe our patent applications or any patents we may own or in-license. An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or in-license at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-grant proceedings provoked by third-parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may own or in-license. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO post-grant proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent offices may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to detect infringement against any patents we may own or in-license. Even if we detect infringement by a third-party of any patents we may own or in-license, we may choose not to pursue litigation against or settlement with the third-party. If we later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third-party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources to such disputes, such disputes could adversely impact our business reputation and/or protection of our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intellectual property landscape relevant to our product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. For example, many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our current or future product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While certain activities related to development and clinical testing of our current or future product candidates may be subject to safe harbor of patent infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that such product candidates infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">applications, which are owned by third parties, exist in the fields in which we are developing our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current or future product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#x2019;s attention from our core business and may impact our reputation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#x2019;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a court prohibiting us from developing, manufacturing, marketing or selling our current product candidates, including IK-930, IK-595, and IK-175, or future product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or violate third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose to challenge the patentability of claims in a third-party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#x2019;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our current or future product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#x201c;clear and convincing,&#x201d; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications can take many years to issue. In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued and patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or future product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending third-party patent applications which may later result in issued patents that our current or future product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates or other technologies, could be found to be infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our current or future product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our current or future product candidates, which could harm our business significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to obtain patent or other intellectual property protection for our current or future product candidates or our future products, if any, in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to pursue patent coverage of our current or future product candidates in all countries. Filing, prosecuting and defending patents on current or future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our current or future product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Much of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of any patents we may own or in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our patent applications or any patents we may own or in-license in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we may own or in-license at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may from time to time be party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or future product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our current or future product candidates, and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the priority of invention of any patented technology; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any granted patents we may own or in-license covering our current or future product candidates or other valuable technology could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">including the USPTO and the EPO. A patent asserted in a judicial court could be found invalid or unenforceable during the enforcement proceeding. Administrative or judicial proceedings challenging the validity of our patents or individual patent claims could take months or years to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our licensors or strategic partners initiate legal proceedings against a third-party to enforce a patent covering one of our current or future product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, in the process of obtaining the patent during patent prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or in-license in such a way that they no longer cover our current or future product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we may own or in-license, allow third parties to commercialize our current or future product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our future licensors&#x2019; priority of invention or other features of patentability with respect to our patent applications and any patents we may own or in-license. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current or future product candidates and other technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the current or future product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation in the U.S. and other countries could increase those uncertainties and costs. For example, the Leahy-Smith Act, signed into law in 2011, introduced provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#x201c;first inventor to file&#x201d; system. The Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the U.S. and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. As mentioned above, patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or future product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future product candidates or the use of our current or future product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our current or future product candidates that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent applications that we own or may in-license may not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents, should they issue, that we may own or in-license, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license, should any patents issue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such trade secrets or know-how; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop or in-license additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable regulatory approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review designation for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business strategy, we may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of more than 200,000 in the United States where there is no</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, in EU, the European Commission, upon the recommendation of the EMA&#x2019;s Committee for Orphan Medicinal Products, grants an orphan designation in respect of a product if its sponsor can show that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (i) such condition affects not more than 5 in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized for marketing in the EU when the application is made, or (ii) the product would be a significant benefit to those affected by the condition. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that, without the benefits derived from orphan status, sales of the product in the EU would generate sufficient return in the EU to justify the necessary investment in its development; (3) there must be no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or, if such a method exists, the product would be of a significant benefit to those affected by that condition. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have received orphan drug designation from the FDA for IK-930 for the treatment of mesothelioma. Generally, if a product with an orphan designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in EU. The EU market exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. <br />Even if we obtain orphan drug exclusivity for any product candidates in addition to IK-930, that exclusivity may not effectively protect IK-930 or our other product candidate from competition because different products can be approved for the same condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A breakthrough therapy designation and fast track designation by the FDA, even if granted, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have received fast track designation from the FDA for IK-930 for the treatment of unresectable NF2-deficient mesothelioma. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. We may seek fast track designation for some of our other product candidates. The FDA has broad discretion whether or not to grant this designation, so even if we believe another particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, as we have for IK-930, we may not experience a faster development process,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek accelerated approval of our current or future product candidates using the FDA&#x2019;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#x201c;IMM&#x201d;) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA generally requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post approval confirmatory clinical trials, which must be completed with due diligence. FDORA gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such trials in a timely manner or if such post-approval trials fail to verify the drug&#x2019;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory trial or submit timely reports to the agency on their progress. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA, the EMA, the MHRA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA, the EMA, the MHRA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#x2019; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Additionally, regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of impactful legislative and regulatory changes to the health care system and legal framework that could impact our ability to sell our products profitably. In particular, in 2010 the ACA was enacted. The ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since enactment of the ACA, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how future additional healthcare reform measures of the Biden Administrations or other efforts by third parties, if any, to challenge repeal or replace the ACA, will impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 2, 2011, the U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension that lasted from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the suspension, a 1% payment reduction began April 1, 2022, lasting through June 30, 2022. The 2% payment reduction resumed on July 1, 2022. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 became law, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws and future laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gave individual states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On&#x202f;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (&#x201c;H.R. 1865&#x201d;), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the IRA was signed into law. The IRA includes several provisions that may eventually impact our business, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business and the healthcare industry in general is not yet known.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such heightened scrutiny resulted in several U.S. Congressional inquiries as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the Administration&#x2019;s policy to: (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, imposing inflation caps, and, supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs the U.S. Department of HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#x2019;s implementing regulations. FDA released such implementing regulations on September 24, 2020, they went into effect on November 30, 2020, and provide guidance for states to build and submit importation plans for drugs from Canada. Furthermore, on September 25, 2020, CMS stated that drugs imported by states under the Act would not be eligible for federal rebates under Section 1927 of the Social Security Act and, accordingly, manufacturers would not report these drugs for &#x201c;best price&#x201d; or Average Manufacturer Price purposes. As these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the MFN Model under which Medicare Part B reimbursement rates would have been be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development (&#x201c;OECD&#x201d;) countries with a similar gross domestic product per capita. However, on December 29, 2021, CMS rescinded the MFN rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. This deadline was pushed back to January 1, 2027 by the Bipartisan Safer Communities Act. The IRA further delayed implementation of this rule to January 1, 2032. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden Administration may reverse or otherwise change these measures, both the Biden Administration and the U.S. Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as through local state Medicaid programs could have a significant impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. Such reductions could potentially lower the price that we receive for our products. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our products. It is not clear how other future potential changes to the ACA, or other similar measures, will change the reimbursement model and market outlook for our current and future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not currently have any products on the market, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business once we begin commercializing our product candidates. Healthcare entities, physicians and other providers, and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain regulatory approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, or AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, arrangement, or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, which is also known as treble damages, imprisonment of up to ten years, and exclusion from government healthcare programs such as Medicare and Medicaid. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. In addition, the government may assert that a claim including items or services resulting from a violation of the federal AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA, or federal civil money penalties. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal civil and criminal false claims and civil monetary penalties laws, including the FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent and/or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal AKS constitutes a false of fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery which are known as qui tam suits and also referenced above;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare benefits, items or services relating to healthcare matters. Similar to the federal AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Physician Payments Sunshine Act, or the Sunshine Act, and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, or CHIP, with specific exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians, nurse practitioners, certified nurse anesthetists, physician assistants, clinical nurse specialists, and certified nurse midwives as well as teaching hospitals. Manufacturers are also required to disclose ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the creation, maintenance, receipt, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and to seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of personal health information, other personal information, and privacy generally, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal price reporting laws, which would require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal AKS and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#x2019;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, or GDPR, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement has led to an increasing number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with all applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions would likely be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against, settling and/or otherwise resolving any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and individual imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </span><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA, and comparable foreign </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a REMS which may include distribution or use restrictions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial holds; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or other regulatory enforcement action; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. Most notably, in the European Union and the UK, the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, is subject to the GDPR and the UK GDPR, respectively, as well as applicable national data protection requirements. The GDPR and UK GDPR are wide-ranging in scope and impose numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. Compliance with the GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European and UK-based activities. Similar comprehensive data protection requirements exist in many other jurisdictions around the world and will have any impact on any plans for expansion outside of the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Relating to Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on many of our key employees and members of our executive management team as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recruiting and retaining qualified scientific, clinical, manufacturing and general and administrative personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, we have experienced a very competitive hiring environment in Boston, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Cyberattacks could include industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, including ransomware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial, or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. If we were to experience an attempted or successful cybersecurity attack of our information systems or data, the costs associated with the investigation, remediation and potential notification of the attack to counterparties, data subjects, regulators or others, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants, could be material. In addition, following any such attack, our remediation efforts may not be successful. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#x2019; personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g., the GDPR or UK GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies, and potentially disrupt our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in the losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California Consumer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Privacy Act, or CCPA, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA, which entered into force on January 1, 2023, creates additional obligations with respect to processing and storing personal information. Additionally, some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (the &#x201c;CDPA&#x201d;) and, on July 8, 2021, Colorado&#x2019;s governor signed the Colorado Privacy Act (&#x201c;CPA&#x201d;), into law. The CDPA became effective January 1, 2023, and the Colorado Data Privacy Act will become effective July 1, 2023. Moreover, on March 24, 2022, Utah&#x2019;s governor signed the Utah Consumer Privacy Act, or UCPA, into law. The UCPA will take effect on December 31, 2023. Most recently, on April 28, the Connecticut state legislature passed &#x201c;An Act Concerning Personal Data Privacy and Online Monitoring,&#34; which will take effect on July 1, 2023. While these new state laws incorporate many similar concepts, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. At the federal level, there is a bipartisan bill being debated. This proposed legislation, the American Data Privacy and Protection Act, if passed, would help to streamline certain of our privacy obligations, but would also introduce new stringent privacy and data security obligations that would apply to personal data collected from throughout the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with U.S. and foreign and/or privacy data protection laws and regulations, it could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to successfully integrate acquisitions, which may adversely impact our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have in the past and in the future may continue to acquire complementary businesses or technologies. Acquired technologies, products or businesses may not perform as we expect, and we may fail to realize anticipated synergies or results. In addition, our acquisition strategy may divert management&#x2019;s attention away from our existing business, and expose us to unanticipated problems or legal liabilities, including responsibility as a successor for undisclosed or contingent liabilities of acquired businesses or assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have successfully integrated our past acquisitions of Arrys Therapeutics or Amplify Medicines, however, if we are unsuccessful in integrating any future acquisitions, it could impede us from realizing all of the benefits of those acquisitions and could weaken our business operations or future prospectus. The integration process may disrupt our business and, if new technologies, products or businesses are not implemented effectively, may preclude the realization of the full benefits expected by us and could harm our results of operations. In addition, the overall integration of new technologies, products or businesses may result in unanticipated problems, expenses, liabilities and competitive responses. The difficulties of integrating an acquisition include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issues in integrating the target company&#x2019;s technologies, product candidates or capabilities with ours; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining employee morale and retaining key employees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">integrating the culture of the target company with ours; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preserving important strategic relationships and collaborations; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consolidating corporate and administrative infrastructures and eliminating duplicative operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if the operations of an acquisition are integrated successfully, we may not realize the full benefits of the acquisition, including the synergies, pipeline expansion or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 10, 2023 we had 80 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any of our product candidates receives regulatory approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dual class structure of our common stock may also limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation entities affiliated with or managed by certain of our stockholders will hold an aggregate of 5,586,311 shares of our non-voting common stock. Upon written notice, these entities could convert a portion of these shares of non-voting common stock into up to an aggregate of 9.99% of our shares of common stock. Upon 61 days&#x2019; prior written notice, these entities could convert all of their respective shares of non-voting common stock into shares of common stock. Consequently, the holders of our non-voting common stock who have exercised their option to make this conversion, will have the effect of increasing the relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as one or more shareholders or groups of shareholders who own at least 5 percent of the corporation&#x2019;s equity increasing their equity ownership in the aggregate by a greater than 50 percentage point change (by value) over a three-year period), the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future or subsequent shifts in our stock ownership, some of which are outside our control. As of December 31, 2022, we had federal and state net operating loss carryforwards of approximately $108.9 million and $105.9 million respectively, and our ability to utilize those net operating loss carryforwards could be limited by an &#x201c;ownership change&#x201d; as described above, which could result in increased tax liability to us. Furthermore, our ability to utilize our net operating losses or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in our consolidated financial statements could be limited and may expire unutilized. Under the current law, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December 31, 2020. State net operating loss carryforwards and other tax attributes may be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similarly limited. Any such limitations may result in increased tax liabilities that could adversely affect our business, results of operations, financial position and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have commenced an at-the-market (&#x201c;ATM&#x201d;) offering program to raise capital. Increased volatility and decreases in market prices of equity securities generally and of our common shares in particular may have an adverse impact on our willingness and/or ability to continue to sell our common shares through our ATM offering. Decreases in these sales would/could affect the cost or availability of equity capital, which could in turn have an adverse effect on our business, including current operations, future growth, revenues, net income and the market prices of our common shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we commenced an at-the-market, or ATM, program to raise capital. Under our ATM program, we have entered into a sales agreement to sell common shares, up to a maximum aggregate market value of $100.0 million, through one or more at-the-market offerings. Given the decrease in the market price of our common shares and volatility in the capital markets, we may not be willing or able to continue to raise equity capital through our ATM program. We may, therefore, need to turn to other sources of funding that may have terms that are not favorable to us, or reduce our business operations given capital constraints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alternative financing arrangements, if we pursue any, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock, or other securities. These securities could be issued at or below the then prevailing market price for our common shares. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest, and any premium or make-whole has been paid. In addition, if we borrow funds and/or issue debt securities through a subsidiary, the lenders and/or holders of those debt securities would have a right to payment that would be effectively senior to the Company&#x2019;s equity ownership in the subsidiary, which would adversely affect the rights of holders of both the Company&#x2019;s equity securities and its debt and debt securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest in any newly-issued debt securities and/or newly-incurred borrowings would increase our operating costs and increase our net loss, and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common shares could be materially and adversely affected. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could result in a material adverse effect on our business, operating results, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in tax legislation could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#x2019; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our fifth amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv) any action asserting a claim that is governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws will further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses in our amended and restated bylaws may limit our stockholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets. See &#x201c;Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates&#x2014;The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.&#x201d; Inflation rates, particularly in the United States, have increased recently to levels not seen in years. Increased inflation may result in increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks, which may impact our ability to raise additional capital in the future. The March 2023 failure of Silicon Valley Bank and its potential near- and long-term effects on the biotechnology industry and its participants such as our vendors, suppliers, and investors, may also adversely affect our operations and stock price. In addition, U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions. Various of Russia&#x2019;s actions have led to sanctions and other penalties being levied by the United States, Australia, the European Union, and other countries, as well as other public and private actors and companies, against Russia and certain other geographic areas, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system and restrictions on imports of Russian oil, liquified natural gas and coal. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could disrupt or otherwise adversely impact our operations and the operations of third parties upon which we rely, as well as the global economy and financial markets, and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Related sanctions, export controls or other actions that may be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. A severe or prolonged economic downturn, inflationary environment, rising interest rates, or political unrest could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. The extent and duration of the military action, sanctions, and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report on Form 10-K and the documents incorporated by reference herein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act and a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) December 31, 2026; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the available exemptions available to us so long as we qualify as an &#x201c;emerging growth company.&#x201d; We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#x201c;emerging growth company,&#x201d; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an &#x201c;emerging growth company,&#x201d; we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will continue to incur costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, and particularly after we are no longer an &#x201c;emerging growth company&#x201d; or a &#x201c;smaller reporting company,&#x201d; we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company or a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In additional, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns, which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 1B. UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 2. PROPERTIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters is located in Boston, Massachusetts where we lease and occupy 20,752 square feet of office, laboratory and animal care space. The lease, or the Boston lease, commenced on February 19, 2021, and the term is expected to expire on May 31, 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 3. LEGAL PROCEEDINGS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 4. MINE SAFETY DISCLOSURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 5. MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock trades under the symbol &#x201c;IKNA&#x201d; on The Nasdaq Global Market and has been publicly traded since March 26, 2021. Prior to this time, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 10, 2023, there were approximately 78 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#x201c;nominee&#x201d; or &#x201c;street&#x201d; name.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings, if any, to support our business strategy and do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the sole discretion of our board of directors after taking into account various factors, including our financial condition, operating results, capital requirements and any plans for expansion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from Initial Public Offering</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 30, 2021, we closed our initial public offering (&#x201c;IPO&#x201d;) in which we issued and sold 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares of common stock issued and sold in our initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No. 333-253919), which was declared effective by the SEC on March 25, 2021. The offering terminated upon the closing of the IPO. Jefferies LLC, Cowen and Company, LLC, Credit Suisse Securities (USA) LLC and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. The aggregate gross proceeds to us from our initial public offering, inclusive of the over-allotment exercise, were $143.8 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate net proceeds to us from the IPO, inclusive of the over-allotment exercise, was approximately $131.3 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the planned use of IPO proceeds from that described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on March 26, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 6. RESERVED</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 7. MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below. Please also see the section entitled &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d; We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach, we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signaling pathways in the TME. Our approach in each of our programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. Our most advanced targeted oncology program, IK-930, is a paralog-selective inhibitor of TEAD. The TEAD transcription factors execute the ultimate step in the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted and chemo therapies. Our first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, we are developing IK-175, an AHR antagonist in collaboration with Bristol Myers Squibb. Our focus on patient-driven development allows us to research both known and novel targets, with a shared guiding principle of aiming to address the unmet needs of biomarker-defined patient populations. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust discovery engine and a portfolio of early stage targeted oncology programs. Across the entirety of our pipeline, we aim to utilize our depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced targeted oncology product candidate, IK-930, is an oral, paralog-selective, small molecule inhibitor of TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. In our ongoing first-in-human Phase 1 clinical trial, we are focusing on indications that provide the potential to achieve rapid proof-of-concept, such as NF2 deficient mesothelioma and solid tumors with YAP1 or TAZ gene fusions, including EHE. Approximately 40% of mesothelioma patients are genetically deficient for the tumor suppressor NF2 and 100% of EHE patients have oncogenic YAP1 or TAZ gene fusions. In October 2021, our IND for IK-930 was cleared by the FDA and we subsequently initiated a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of IK-930 as a monotherapy in patients with advanced solid tumors with or without gene alterations in the Hippo pathway. The first patient was dosed in January 2022. IK-930 received orphan drug designation for the treatment of mesothelioma from the FDA in March 2022. In June 2022, IK-930 was granted fast track designation from the FDA for the treatment of unresectable NF2-deficient mesothelioma.  In addition to the monotherapy approach, we plan to assess IK-930 in combination with other targeted therapies across several indications with multiple targeted therapies. Based on the role that the Hippo pathway plays in resistance to other targeted therapies, we believe that IK-930 may expand the patient populations that could benefit from therapies like EGFR inhibitors, KRAS inhibitors, and MEK inhibitors among others. We have an established clinical collaboration with AstraZeneca for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers as a cohort in the clinical program. Initial data from the monotherapy IK-930 clinical program is expected in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We nominated a development candidate in our RAS pathway program in November 2022. The RAS pathway is implicated in at least half a million new cancer diagnoses each year in the United States alone. We aim to target the pathway on multiple levels, including preventing known resistance mechanisms to achieve deep and sustained responses. Our first program in the space, IK-595, is designed to achieve novel inhibition of MEK-RAF by trapping MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors.  IK-595&#x2019;s potential ability to complex CRAF, in particular, prevents a well-recognized signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. In addition, trapping CRAF in an inactive complex prevents the kinase independent anti-apoptotic function in RAS and RAF mutant cancers, a mechanism that cannot be addressed with first generation MEK inhibitors or pan-RAF inhibitors. We are developing IK-595 as an oral therapy, with a half-life designed to enable a pharmacokinetic profile that we believe can be potentially superior to other pathway inhibitors, with the goal of optimizing the therapeutic window for patients. We plan to submit an IND to the FDA for IK-595 in the second half of 2023.<br />These two programs, IK-930 and IK-595, stemmed from our internal discovery engine, which continues its focus on discovering and developing novel targeted oncology programs. Our early research follows our philosophy of designing treatments for selected patient</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">populations identified through the genetic make-up of their tumors and with the potential to expand the patient population that can benefit from targeted oncology through tackling mechanisms of therapeutic resistance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline also includes our immune-signaling program targeting AHR with our novel inhibitor, IK-175. The ongoing Phase 1a/1b clinical trial is evaluating IK-175 as a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas, for which current standard-of-care therapy is no longer effective or is intolerable. Initial clinical data from the program was presented in November 2022 at the Society for Immunotherapy of Cancer Annual Meeting. These initial data included a 40% disease control rate and 20% overall response rate in urothelial carcinoma patients who received IK-175 in combination with nivolumab, with the majority of combination patients experiencing reduction in their target lesions. The study is ongoing, and we plan to share updates from the program in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated as a Delaware corporation on March 2, 2016, and our headquarters is located in Boston, Massachusetts. Since our inception, we devoted all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. On March 30, 2021, we completed an IPO, in which we issued and sold 8,984,375 shares of our common stock at a public offering price of $16.00 per share, including 1,171,875 shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock, for aggregate gross proceeds of $143.8 million (or $131.3 million after deducting our discounts, commissions and offering expenses).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not had any products approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses in every year since our inception and expect to continue to incur significant expenses and increasing net losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $68.8 million and $34.1 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $214.2 million. We expect to continue to incur significant expenses and operating losses for at least the next several years as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance the development of our product candidate pipeline; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and continue research and preclinical and clinical development of potential new product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license additional product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand our infrastructure and facilities to accommodate our growing employee base and ongoing development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish agreements with CROs and CMOs in connection with our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our continued operations as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity instruments, debt financings, or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain marketing approval for our product candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would materially adversely affect the development efforts of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our product candidates and our business overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings, when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of $156.9 million. We believe the existing cash and cash equivalents on hand as of December 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements into 2025. To date, we have primarily financed our operations through proceeds from private placements of preferred stock, payments from a collaboration agreement, related party revenue and completion of the IPO. We expect to incur substantial operating losses and negative cash flows from operations for the foreseeable future as we continue to invest significantly in research and development of our programs. Our belief with respect to our ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from our estimates, we may need to seek additional funding sooner that would otherwise be expected. There can be no assurance that we will be able to obtain additional funding on acceptable terms, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the onset of the global pandemic in 2020, we have been closely monitoring the spread of COVID-19 and its variants, and plan to continue taking steps to identify and mitigate the adverse impacts on, and risks to, our business posed by its spread and actions taken by governmental and health authorities to address the COVID-19 pandemic. In 2021, we adopted a permanent hybrid work model for those employees who are able to conduct their roles remotely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ultimate extent of the impact of the COVID-19 pandemic on our business, financial condition and results of operations is highly uncertain and will depend on future developments that cannot be predicted, including new information that may emerge concerning the severity of the COVID-19 pandemic, existing and emerging variants and the level of acceptance of vaccines, and actions taken by government authorities and businesses to help contain or prevent the further spread of COVID-19. If we, or any of the third parties with whom we engage, were to experience any shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially negatively affected, which could have a material adverse impact on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, we cannot predict the extent to which our business, financial condition and results of operations will be affected. We remain focused on maintaining a strong balance sheet, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to COVID-19 and variants thereof. We will continue to work diligently with our partners and stakeholders to advance our clinical studies to the extent safe to do so for patients, caregivers and healthcare practitioners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See &#x201c;Risk Factors&#x201d; for a discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our revenue has been derived from research and development revenue under our Bristol Myers Squibb Collaboration Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, we entered into the Bristol Myers Squibb Collaboration Agreement with Celgene Corporation (which was acquired by Bristol Myers Squibb in November 2019), pursuant to which Bristol Myers Squibb may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine and AHR excluding AHR agonists for inverse agonists, which we are developing as IK-412 and IK-175, respectively. On a program-by-program basis, through the completion of a Phase 1b clinical trial for each of IK-175 and IK-412, Bristol Myers Squibb has the exclusive option to exclusively license to develop, commercialize and manufacture the relevant product candidate worldwide. Concurrent with execution of the Bristol Myers Squibb Collaboration Agreement, we entered into a stock purchase agreement with Celgene Corporation (now Bristol Myers Squibb) in November 2019 (&#x201c;the Stock Purchase Agreement&#x201d;) pursuant to which we issued Celgene Corporation 14,545,450 shares of Series A-1 preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb paid a total of $95.0 million in aggregate upfront consideration related to the Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement. We are eligible to receive $50.0 million, in case of an exercise of its option with respect to IK-175, and $40.0 million, in case of an exercise of its option with respect to IK-412. If we do not complete a Phase 1b clinical trial by the end of the research term, we may elect to provide a data package to Bristol Myers Squibb upon which Bristol Myers Squibb may exercise the foregoing option for an additional $0.25 million fee. Upon the delivery of each license, we become eligible to receive up to $265.0 million in regulatory milestones and $185.0 million in commercial milestones as well as a tiered royalties at rates ranging from the high single to low teen digits percentages based on worldwide annual net sales by Bristol Myers Squibb, subject to specified gross sale reductions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research and development activities. These efforts and costs include external research costs, personnel costs, consultants, supplies, license fees and facility-related expenses. We expense research and development costs as incurred. These expenses include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with CROs which are primarily engaged to support our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with CMOs, which are primarily engaged to provide drug substance and product for our preclinical research and development programs, nonclinical and clinical studies and other scientific development services; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of acquiring and manufacturing preclinical study materials, including manufacturing registration and validation batches; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquisition of in-process research and development assets that have no alternative future use; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to compliance with quality and regulatory requirements; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments made under third-party licensing agreements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete the clinical development of, or obtain regulatory approval for, any of our current or future product candidates. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to add and retain key research and development personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our successful enrollment in and completion of clinical trials, including our ability to generate positive data from any such trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and cost of any future clinical trials for existing or future product candidates in our pipeline; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with the development of any additional programs we identify in-house or acquire through collaborations and other arrangements and the success of such collaborations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms and timing of any additional collaborations, license or other arrangement, including the timing of any payments thereunder; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain agreements and operate with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to manufacturing of our product candidates or to account for any future changes in our manufacturing plans; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patents, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates, both in the United States and internationally; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement for our product candidates, if and when approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectively competing with other products if our product candidates are approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from the ongoing COVID-19 pandemic or similar public health crisis; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain a continued acceptable safety profile for our therapies following approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, auditing, tax services and insurance costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our general and administrative expenses will increase as our organization and headcount needed in the future to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys and accountants, among other expenses. Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.047%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.124%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.124%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.877%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.987%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.224%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development revenue under<br />&#160;&#160;&#160;collaboration agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,618</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,985</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,367</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(50</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,321</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,108</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,213</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,201</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,015</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,186</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,522</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,123</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,399</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(70,904</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34,138</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(36,766</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,139</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,116</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9200</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(68,765</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34,115</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34,650</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development revenue under collaboration agreement is related to the Bristol Myers Squibb Collaboration Agreement for the IK-175 and IK-412 programs which was executed in January 2019. The decrease in revenue during the year ended December 31, 2022, as compared to the same period in the prior year, was primarily due to change in estimate of the total services to be performed on the IK-412 program during the remainder of the Bristol Myers Squibb Collaboration Agreement term. In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays. Considering these delays and the timeline of the Bristol Myers Squibb partnership, the Company made the strategic decision to pause IK-412 development activities, outside of the committed manufacturing efforts, for the remainder of the Bristol Myers Squibb research term. As a result of the decision to pause, the Company recorded a change in estimate during the year ended December 31, 2021 and recognized $16.5 million of research and development revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.66%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.018%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.018%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.98%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.65%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct research and development expenses by program:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-930</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,377</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,351</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,026</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-175</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,829</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,844</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">985</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-412</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,960</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,984</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">976</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-007</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,732</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,632</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(900</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IK-595</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,499</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,793</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,706</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other discovery stage programs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,192</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,915</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(723</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development personnel and overhead<br />&#160;&#160;&#160;expenses and unallocated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,732</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,589</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,143</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,321</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,108</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,213</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in research and development expense of $17.2 million was primarily attributable to employee-related expenses due to an increase in headcount, research activities and consulting services for the Company&#x2019;s development candidate IK-595, and increased clinical trial costs for IK-930.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our general and administrative expenses:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.84%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.029%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.029%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.014%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.603%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,201</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,015</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,186</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in general and administrative expense of $4.2 million was primarily attributable to an increase in compensation and benefit related expenses due to an increase in headcount.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. To date, we have financed our operations primarily through private placements of preferred stock, from upfront payments from the Bristol Myers Squibb Collaboration Agreement, from cash obtained from acquisitions, and most recently, from common stock in our IPO. In March 2021, we completed our IPO in which we received net proceeds, inclusive of the exercise by the underwriters of their option of purchase additional shares, of approximately $131.3 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of $156.9 million. Based upon our current operating plans, we expect that our existing cash and cash equivalents balances will enable us to meet our planned operating expenses and capital expenditure requirements into 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our sources and uses of cash for the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(74,109</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60,252</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(99,284</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,760</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,095</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131,738</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(172,298</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,726</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support the business. We have historically experienced negative cash flows from operating activities as we invested in developing our platform, drug discovery efforts and related infrastructure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in cash used in operating activities of $13.9 million was attributable to the increase in our net loss incurred in the year ended December 31, 2022 of $34.7 million, primarily a result of increased spending on research and development activities as we advance our preclinical and clinical programs. This was partially offset by a decrease in the realization of revenue previously deferred of $15.4 million as a result of the Bristol Myers Squibb collaboration agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in cash used investing activities of $97.5 million was primarily attributable the purchases of marketable securities of $216.3 million in connection with the Company investing its excess cash, offset by $118.5 of marketable security maturities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The decrease in cash provided by financing activities of $130.6 million primarily reflects cash proceeds received in connection with the IPO in March of 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur additional costs associated with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our existing cash, cash equivalents, and marketable securities as of December 31, 2022, will enable us to fund our operating expenses and capital expenditure requirements into 2025. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the in-licensing or acquisition of assets in line with our strategy; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 27, 2022, we filed a shelf registration statement on Form S-3 (&#x201c;Shelf&#x201d;), with the SEC, which covers the offering, issuance and sale by us of up to an aggregate of $300.0 million of our common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. We simultaneously entered into a sales agreement with Jefferies LLC, as sales agent, to provide for the issuance and sale by us of up to $100.0 million of our common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf, which we refer to as the ATM Program. The Shelf was declared effective by the SEC on May 5, 2022. As of the date hereof, no sales have been made pursuant to the ATM Program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a non-cancelable operating lease agreement for our office, lab and animal care facility space in our Boston, Massachusetts corporate headquarters. We expect lease payments under this commitment to total $1.8 million in 2023 and increase annually through the lease expiration in 2026. Our total future minimum lease payments for each of the next five years and in total are included in Note 14.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts typically, do not contain any minimum purchase commitments and are cancelable by us, typically upon prior notice of 30 days. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or that we may be required to make royalty payments under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property such as our patent license agreement with the University of Texas at Austin and our license agreement with AskAt, Inc. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are more fully described in the Notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To determine revenue recognition we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, then assess whether each promised good or service is distinct. When we offer options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, we evaluate whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, we then recognize as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, we recognize revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At each reporting date, we calculate the measure of progress for the performance obligations transferred over time. The calculation generally uses an input measure based on costs incurred to-date relative to estimated total costs to complete the transfer of the performance obligation. The measurement of progress is then used to calculate the total revenue earned, including any cumulative catch-up adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors, including research laboratories, in connection with preclinical development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CROs and investigative sites in connection with preclinical studies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMOs in connection with drug substance and drug product formulation of preclinical studies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage nonclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for stock-based compensation awards in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation&#x2014;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC 718). ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the consolidated statement of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to ASC 718, we measure stock-based awards at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Due to the lack of a public market for our common stock and a lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the weighted-average expected option term is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of our stock options. We utilize this method due to lack of historical exercise data and the &#x201c;plain-vanilla&#x201d; nature of our stock-based awards. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. For options granted to non-employees, we utilize the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and have no current plans to pay any cash dividends on our common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock contractual obligation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, the fair value of the shares of common stock underlying the stock options was determined by the Company&#x2019;s board of directors. Because there was no public market for the Company&#x2019;s common stock prior to the Company&#x2019;s IPO, the board of directors determined fair value of common stock at the time of grant of the option by considering a number of objective and subjective factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including independent third-party valuations of the Company&#x2019;s common stock, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and the general and industry specific economic outlook, among other factors. Following the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock has been determined based on the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2012, the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;), can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, (the &#x201c;Securities Act&#x201d;) for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (2) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide this information required under this item.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear beginning on page F-1 of this Annual Report for the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Our Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#x2019;s principal executive and principal financial officers and effected by the company&#x2019;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#x2014;Integrated Framework (2013 framework) (COSO). Based on its assessment, management believes that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EM 9B. OTHER INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 11. EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our independent public accounting firm is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f65e68ad-980d-4f3f-8d83-a33d8a0443cc" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d416e17-80fd-4977-b3d2-b8c551bec17e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, PCAOB Auditor ID: 42.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="margin-left:4.44%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See the Index to Consolidated Financial Statements in the Financial Statements Section beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:4.44%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All financial statement schedules have been omitted as they are not required, not applicable, or the required information is included in the financial statements or notes to the financial statements.</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.12%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.861%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex21.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger by and among the Registrant, Arrys Merger Sub, Inc., Arrys Therapeutics, Inc. and OrbiMed Private Investments VI, LP, as stockholder representative, dated December 18, 2018 (Incorporated by reference to Exhibit 2.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger by and among the Registrant, AMI Merger Sub, Inc., Amplify Medicines, Inc. and Atlas Venture Fund XI, L.P. as stockholder representative, dated October 1, 2020 (Incorporated by reference to Exhibit 2.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex33.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex35.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amended and Restated Investors&#x2019; Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000095017022003998/ikna-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of the Registrant&#x2019;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Incorporated by reference to Exhibit 4.3 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2016 Stock Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended &amp; Restated Non-Employee Director Compensation Policy</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Amended and Restated Employment Agreement (Incorporated by reference to Exhibit 10.6 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.12%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.861%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and between the Registrant and AskAt, Inc., dated December 14, 2017, as amended on December 18, 2018 (Incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Collaboration Agreement by and between the Registrant and Celgene Corporation (now Bristol Myers Squibb), dated January 14, 2019 (Incorporated by reference to Exhibit 10.8 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent License Agreement by and between the Registrant and The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, dated March 29, 2015, as amended on May 18, 2016, December 15, 2016, October 24, 2017, April 25, 2018 and January 9, 2019 (Incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement between the Registrant and OPG MP Parcel Owner (DE) LLC, dated July 31, 2020 (Incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiaries of the Registrant (Incorporated by reference to Exhibit 21.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">em 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.917%;"></td>
    <td style="width:2.037%;"></td>
    <td style="width:5.102%;"></td>
    <td style="width:46.944%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Manfredi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Manfredi, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.009%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:46.556%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:21.417%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Manfredi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Manfredi, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jotin Marango</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chief Financial Officer and Head of Corporate Development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jotin Marango</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer and Principal Accounting Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Owen Hughes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Owen Hughes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Bonita</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Bonita, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Iain D. Dukes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Iain D. Dukes, D.Phil.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jean-Fran&#xe7;ois Formela</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jean-Fran&#xe7;ois Formela, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Maria Koehler</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Koehler, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Otello Stampacchia</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Otello Stampacchia, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Richard Wooster</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Wooster, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /><br />INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.618%;"></td>
    <td style="width:7.382%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ff6c7dc-a384-4888-8eea-f6623c70ee93" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Shareholders and the Board of Ikena Oncology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Ikena Oncology, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting.  Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_170b3a3d-f27c-41bb-9b40-1add33c6fcd3" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9dd7689a-f511-4f8d-8137-0a7cec907b68" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6906936c-1987-4587-8944-770049dde6d7" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdeb5616-ab12-4dec-8dd8-325f99b1daaa" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dc49f8e-4c84-4229-8919-b34109975cbd" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_505ecfd7-c469-41a3-a33b-6b6a0d1a9814" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2e55227-365b-4ce9-8ca5-ea89781da7af" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9f1b7e8-8bf9-4159-bdac-1c72c56e7cac" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,010</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e11e1fa6-83a2-4b40-a460-16d090fd5d94" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ab66a8d-8c62-40a8-9148-0be0759827c1" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,205</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cb77f24-a743-467a-9cd3-985334c59316" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3355153a-547d-4ed2-8fb0-61c64a00aecf" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27727eab-40aa-47c1-9663-ebbab41406a4" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_762d0f28-bf69-4679-88cb-df7060d97be1" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eb79fb5-fcb7-48ef-ad82-09a943a723ea" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e04d8d54-011e-402a-a1ab-f390fd9f9726" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">172,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2503982b-d851-42d6-9207-848089446bfb" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffe4e1fc-1669-43ec-9eea-960153aefa88" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,093</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e3d8e2e-6089-4ec6-87f4-6fdf5d4750ac" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea6b7d1b-39ae-4a88-9232-79f0a7abe232" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a700a5c7-896e-45a6-ab0c-ec3e68577d97" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c51ad5c-7aa8-42cf-b76e-f0c7ff2c6aee" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,907</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94511d2a-95d8-4aec-9ee8-7b3dac5382ff" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd2442f1-25cc-4b5b-b153-1db8346e8830" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e4fb984-aeb0-44f5-b4a8-e56781810264" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed7780b5-31ec-4cac-bfd4-0d882ef50ca6" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffcaf436-3c8f-4455-ad7d-80431ede34dd" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of operating lease liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0965abe3-2d9f-466a-af41-75296f9fd461" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fe9443c-ddde-4bb4-9b28-7c5b4e85db84" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2826f143-17e0-4dce-b4e2-fad153d1b713" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d9c36b0-2b72-4381-be2c-c633ce3322a5" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b626f817-f96c-4193-a04b-26913e995196" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_158d126e-6bca-4219-b170-503c05bf52e5;"><span style="-sec-ix-hidden:F_6405c329-beba-47dc-a7ce-628745e34612;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 15)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63ba0316-9ac2-4b24-85ea-9e625f777f9c" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_4f9e7571-3061-4b65-a3fd-2dca1186364a" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7b6080c-eb1b-4dad-9bc1-1ce60f1e7be8" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8382c052-3888-40d5-94ee-ae80584bfda9" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as of December 31,<br />&#160;&#160;&#160;2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb546de8-7d6e-41da-a590-399308ef1787" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b5b934f3-62f6-4b05-9301-be6d14916088" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cba1f416-89ea-404e-a248-4695448a6d2a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_81b5787e-5e44-44ee-938f-8d5eebb35a8f" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2022 or December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_11ef3329-dcf3-4ec2-8622-e99fe0bb4b61;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_839b234b-d83d-4063-a99d-0257ea516d6b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dfc1e60-36ff-41d9-a392-5bd947fc5c26" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_7f7c21a5-4d50-4330-b85b-b06f9eb20465" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f979d14a-12f6-41d5-a8ee-8e49855dba85" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d2286ff-ddc2-40ac-93fd-b5689b320a23" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_afd7c150-0120-4cc6-ac92-310df9e9d7ff" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,257,493</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />&#160;&#160;&#160;issued and outstanding as of December 31, 2022; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d3a6919-7b83-4d4c-b25f-ab8267816086" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized,<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae2cfe2d-b366-4784-846a-1b0923c25052" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6a380edf-4450-4487-9d16-8d82d58ab93c" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;issued and outstanding as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8330eb24-5a82-4eb2-bd6f-39c0cec753fd" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2c7f283-f252-4d21-b5d2-9fd098280842" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_798ac250-01c8-43f9-93bd-3dfdd41fd521" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2bb159a-2430-4cca-a65a-d1e3da0d5e80" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_538bfb45-7cc3-4f9b-92f3-67612809e5f9" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3403b16b-73cd-4cf7-9427-ddd9dc4b2023" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214,219</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c7d4f89-8cb6-4aac-903e-6995dfc627b6" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">145,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1090bb7-d9b5-45e1-86d1-b74169881396" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39cc023d-66be-4622-835a-be667a2b1719" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0807440d-8bab-4ccc-a36c-9015cf4727a1" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">172,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ee20b53-a17f-4870-b353-e680f8fc7cd6" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.599%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development revenue under collaboration </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_ea7b51ae-9485-4d01-9e50-58f15f5b438a;"><span style="-sec-ix-hidden:F_2bfa3cd5-7671-450c-9646-fc3da919b9cd;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">agreement</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d51b80c-09e1-4a0b-aae5-8764fbd3fa66" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,618</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b45d859f-9186-4604-9fea-903bc4721429" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74e2475a-8a1c-41dc-a2cb-2bc2097121c7" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,321</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8ee5a4f-5d5d-452a-b8d9-e36e87547e57" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,108</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa457c4a-fe1d-4003-baa0-63ad682290fe" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fb4475b-3daf-4e5d-b109-e69226641e62" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,015</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73e01067-2d38-4f76-9e60-3cc3d6dcf1e1" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdc5ce4c-dd8a-4970-8554-5f7571e279a5" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5afd65f7-42b3-4de2-afd3-60042a71b2a6" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9a1aa4b-e7d1-4555-9976-f32c9a8d02a9" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,138</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92965262-1f3d-4a3f-9e09-913a705c5190" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b242fbe-338f-4c72-9bbc-147d7ad3cc7b" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcedffd0-eeda-4306-8a50-9189a50026c5" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_293611bc-abc3-4c07-9f7d-489ae035583a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,139</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc768058-2bca-4cb3-8593-76215c21a31e" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd331fa3-5a3e-4280-90d7-7c7e7bffa59e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9261545-f4f6-48ad-8e34-eddacaf2ed86" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9aef705a-1379-40bd-9dfb-002ebfc52239" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf9e4441-d1f4-4eba-b4af-f84b73dc3c42" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a63838c9-6aa1-46a0-965a-f4436c411609" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders basic and<br />&#160;&#160;&#160;diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97bb4655-567b-4003-a7ea-edcbbb3396fb" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_de35bffb-33b4-4a5c-8b2a-7a9fc9c69815" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.90</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c10c767-c823-4a33-a235-355bb7df1b5b" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_95079362-398b-41d3-90ed-e85b498b47c3" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.22</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a148df8b-b39e-4152-a8c9-77c7191485d5" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_ce714607-da36-41f6-a69c-91f6dddd8065" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">36,188,420</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1b0a880-ed3a-4978-9539-1340b262990c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_cdf04b2b-26e7-4798-b351-b8dc48d3bff7" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,983,359</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#x2019; EQUITY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(DEFICIT)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.64%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.939%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.8549999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.775%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.8549999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.8549999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.8549999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.8549999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.801%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.965999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable<br />Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-in<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other Comprehensive<br />Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;<br />Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4f40769-238b-414a-81a4-703f4f73f4d4" contextRef="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a3ef001-21c1-401a-bdb6-76e1b7d94064" contextRef="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63f038b1-a484-41b4-9f06-189eb6a83874" contextRef="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,096,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b99a5668-2a99-4f10-b948-21f3bf598914" contextRef="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_144ba852-fc42-4e9e-807c-6c98fe718d2c" contextRef="C_243e768c-5a7d-4e4d-92c7-d1c089eaaf89" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f7acc27-5903-4c8f-aaa9-611e4b78f692" contextRef="C_a06410af-63e3-4326-a071-99bd20e03747" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">111,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bfbf4b9-bf3f-4f1e-9bb7-b774cff231a4" contextRef="C_c5743e53-9eec-4995-bd5a-136752b9e092" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">101,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial public offering, net of issuance costs <br />&#160;&#160;&#160;of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b57c3536-0a10-4797-bf23-8071358dbbf9" contextRef="C_9117ee30-cb2e-437f-bbc2-c141841cb4a7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;million</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d9204f2-3ace-416a-ab87-52c24d0ca62e" contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,984,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f8021ac-4c59-4d5c-90b2-5e7379ae5e40" contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cff30641-a34d-4504-8664-0905669edde8" contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b9ee2af-c4a4-4609-b256-b5d14103c069" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible preferred<br />&#160;&#160;&#160;stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93edb919-0dae-45ac-a30a-1434d0a45e54" contextRef="C_81be7afb-a84c-4259-b0db-774799b8967e" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db02fd6d-6cd9-492c-94f6-b5e693e276d3" contextRef="C_81be7afb-a84c-4259-b0db-774799b8967e" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d52fe46-076f-4f60-8747-80f1aea469bb" contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,678,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4e1a0d5-3d9c-4010-b98d-15a3b37b87ec" contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a78d74c3-3d70-43f6-a6d3-1ddf7e8e6b6e" contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_192049fb-6dcb-483f-8b10-64ba9156c82a" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_646288b1-dfe9-49ec-9141-a4705a9ce0ff" contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">215,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_913ae434-f558-4513-8fb1-4f380782de01" contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_292f65c3-fed3-4a07-998d-c3c138bb098c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b907d153-a7e4-4a14-adcd-0c780cc2f550" contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5026b851-cfeb-43f6-a3a4-c7076cfdd25c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99f7ab2c-666a-429c-98ee-295d11e79998" contextRef="C_72b4e02a-df1a-4585-b5ad-11bbc8dc7393" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_762b688d-1a27-4ecf-83ee-6ecd9b976b81" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bdb3e3e-830c-46ad-b44e-e29d24d5bc1a" contextRef="C_629dc6f2-dce8-43e8-9319-86cbd98602c8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09478e82-9c50-4030-9cbe-d03303306c00" contextRef="C_629dc6f2-dce8-43e8-9319-86cbd98602c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad3b26a8-5cce-45aa-a2e9-a5018ec05d3f" contextRef="C_f11f597d-a8dd-465c-abcf-5256cc5c240e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b3b310e-7c65-43c5-a04b-e24764366c64" contextRef="C_7251b328-1b51-45ee-a489-0591be444c4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">145,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_832c28ea-ce05-42e2-be5b-ead0d358c343" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f55f5716-b306-48d1-9df4-96da43c7ff6a" contextRef="C_f708ee60-4251-4c02-b611-2b02ced0c594" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">282,459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_983abdf0-9fbf-4e38-b701-f6d7539bf3fd" contextRef="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41591396-776a-4c5a-8fbf-7085898720c2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_154b1b83-7870-42c8-a1d4-064e5e1ed8f8" contextRef="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faef7fa9-22c6-4a4e-b8be-bda05550f4ba" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed4fe579-a5e7-46db-a5f4-82d2d38d2cc2" contextRef="C_82efe98b-6310-4367-b03b-b818789abe68" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8087d33c-422a-43ac-a69a-8a7d2b6ecaae" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4fb24b5-ca70-4c39-806d-31263dbd9079" contextRef="C_23fc5900-4ca2-478b-99d4-086caa8e243f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2897b050-4cd3-42f6-a766-898f95b751ef" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d1276b5-6dc1-4346-84e2-46b896426225" contextRef="C_51a2a164-bf0e-4c35-b339-4d0fabaee032" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,257,493</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55cd04c6-3182-45d8-9a76-759f7b4aca73" contextRef="C_51a2a164-bf0e-4c35-b339-4d0fabaee032" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d82c01ad-5ec8-4543-a8c9-847fbce5f981" contextRef="C_32847360-0e0a-4bc8-8675-0ec3449433c4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b918c4f-2e34-43c2-ab41-0f673ffc2953" contextRef="C_d9ce082a-af1a-4ce0-b0b5-24c0aa1bc3a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c915d94a-1fc0-40ef-98d0-4e2b2c5202a6" contextRef="C_5b851c3a-24e1-41dc-a872-7efb1cd60872" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214,219</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4efb2f3-18b7-40be-9730-396cb7965c23" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NSOLIDATED STATEMENT OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_966e34e9-4de1-419b-a98d-64f3fee7e1e2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa6b480f-7c99-40a8-8c5d-ba355d96006c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in provided by<br />&#160;&#160;&#160;operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90a81e2e-1c54-4c0e-8d88-71a03d9c7586" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_354dab70-a1cc-4eff-864a-c9428863de75" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05967816-18ee-4067-b1a6-011d79eaae0c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:AmortizationOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ad4b036-ae3c-4894-ba81-9c05034475c1" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6694228-7916-4a5c-bc2c-2f8f6a0875bf" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c7e8dc3-b63b-4ea2-8020-992cf8e84a0a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3b856b2-6c8c-44e4-b11d-60787e1793fe" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_313f0f4b-c8a6-4077-b77b-5fe1b6ff579a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:GainLossOnSaleOfProperties" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">173</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net realized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb3b7463-040a-4d00-b1f8-7bb179bee35c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ebce16-f8d9-4f95-92ea-d19cd7aeafe8" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1ad4b54-e800-4e7b-b8e5-190f1e55d1e9" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44270916-16bd-4bc2-b06f-65c2a44ed9b3" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">291</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f928e8cc-a70b-4579-bd3f-adf2616a5ce2" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1a657d5-7ccd-407a-b320-cc607248d4e7" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44dec041-6744-43ac-abd0-e72c6b8ab3d4" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3c4a89a-0d6a-49b5-a722-05303b5e42fe" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInLeasingReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,292</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b194d1e-a41d-475c-9032-42a86b73ea56" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInLeasingReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba9fff82-edb9-46fb-a0b8-a512162f6c3a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,618</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5e4e90e-428e-49f5-a3d8-c25f720a19bb" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits and other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b07ce2cb-1678-40e6-9feb-6230cf93a473" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bed47e8-8e15-412b-aa7b-12c4037a3b8c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,514</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_858c39c2-12e7-4256-ba91-15185f0c5c9e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f040d17-4937-422d-9e35-4fe27656786d" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b3d0c2d-127c-4b4a-b567-be43c2b618eb" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0cb7eac-b06d-4012-b389-9c09777234e5" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14cd1890-ecde-4043-826c-b91db803c63e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales and maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0399dc49-01d7-4778-9ff9-236059b6190c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cb14d9d-aea3-41a2-b388-e90d2d25f51a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">99,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c1b410f-89b7-477c-ac9a-05f1a598ba2a" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from initial public offering, net of offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416ae11c-b04c-45ec-9939-d8058b3e6829" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_905d117d-f480-40d0-8857-e54af698162c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23ef1675-a9dd-4e1f-80ff-9fb644e80cf2" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of preferred stock, net of offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_622807e6-e9a7-4937-a27c-697b9a1d4271" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f04819b5-b508-46dc-80b1-60bf182c009b" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c55cc71-d18a-47b8-a798-f1872b922b51" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5065572b-3e32-4028-b367-982e89a25a19" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">172,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c51744b0-27a4-4eff-8a04-01b62dc3f0c0" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_461e1578-fb61-4e8d-a8ee-f1f2d019cfde" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d8a3d2-c68f-4260-bc24-2250d5085c9a" contextRef="C_c5743e53-9eec-4995-bd5a-136752b9e092" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_881ed603-9b03-442a-a0e9-965a7ea05beb" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc48dc2b-5bfb-4bb9-a88a-6b60aa9dfea2" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcb76cba-0c3a-402b-b866-448e89dcc7b3" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acaa84d7-f477-4f15-a74b-7f113cec9ec8" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash included in other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a669014-ae2d-4fec-b785-2b45670b803d" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3d3b2ac-c7db-4eff-a5f4-1b3008cd136c" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5548c22-c97c-409a-887e-89dc1f033c2a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07091b86-42c6-4073-a381-87fc55d915ad" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of non-cash activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment in accounts payable and accrued<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c70d6a-1b26-4867-bccc-7eee67f0f378" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49f2cbac-e34b-4178-a18d-c05b4d15f6a1" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets and lease liabilities recognized upon lease inception</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5d4d06d-530e-47bb-a694-1d70e94184ff" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_75cb478e-4246-4865-8eb9-8f415df0c6b5" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. NATURE OF BUSINESS AND ORGANIZATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ikena Oncology Inc. is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With a robust biomarker and translational approach, the Company aims to develop targeted treatments and define patient populations who are most likely to respond to treatment. Ikena&#x2019;s current programs are across the Hippo pathway, RAS pathway, and key immune signaling pathways in the tumor-microenvironment (TME). The Company&#x2019;s approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. Since the Company commenced operations in 2016, it has  advanced multiple product candidates into clinical development. In addition, the Company has a robust pipeline of discovery-stage targeted oncology programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 30, 2021 the Company completed an initial public offering (&#34;IPO&#34;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b65d532-b23f-4c5d-a75c-656ad72cf4d9" contextRef="C_ffa36058-10c5-475b-85fe-d2a62ed6bfd4" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,984,375</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including full exercise of the underwriters&#x2019; over-allotment option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cab69bfc-14c3-4585-a7d4-e63aca8d6022" contextRef="C_14d9fef1-667e-4963-8142-cdd235c7f806" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,171,875</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f926a8b4-fb52-470c-a906-6719b9f7fac9" contextRef="C_01480c2c-876c-40b4-a15a-bc9c124601af" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3a53b39-b9eb-42bc-8d95-f59d40c4344f" contextRef="C_35a41072-255d-4437-a4a9-cad64e6da60a" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">131.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_afaff87a-7fb8-422e-93d4-317f2df572cf" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_886f55de-9a08-4232-a685-d4107951029d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c84eeae-0c35-48a4-b4ce-79d94b196c54" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses research and development revenue under a collaboration agreement.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2174d29e-9ecc-465f-b7a6-eaef58a0dfdd" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of preferred stock, payments from a collaboration arrangement and related party revenue. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, the Company&#x2019;s revenue has primarily been from a collaboration agreement. The Company has devoted substantially all of its financial resources and efforts to identifying potential product candidates and conducting preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company&#x2019;s cash, cash equivalents, marketable securities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_451969b1-9677-44e5-a017-29e7d56adbcb" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">156.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company believes the cash, cash equivalents, marketable securities as of December 31, 2022 will enable it to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements, though it may realize additional cash resources upon the achievement of certain collaboration agreement option exercises, or it may pursue additional cash resources through public or private equity or by establishing collaborations with other companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s expectations with respect to its ability to fund current and long term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any collaboration exercise options will be achieved or that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations. As of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3206be85-93bf-4366-a49e-731ebb57191b" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">214.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c029763-5428-46c9-8982-f4fea7c478fe" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23db9a92-053e-49ec-8bb2-cf5c5b528fcf" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96c26712-9a08-4b85-a184-d68e1c39ce2c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of December 31, 2022, the Company has not experienced any credit related losses on accounts that hold the Company&#x2019;s cash, cash equivalents and marketable securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers and CROs to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company&#x2019;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c0600f1-7dfb-4fa9-a6a8-1c3ec942e411" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial instruments consist mainly of cash equivalents, restricted cash, accounts payable, and marketable securities. The carrying amounts of cash equivalents, restricted cash, and accounts payable approximate their estimated fair value due to their short-term maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in the Company&#x2019;s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c21b7658-6cf3-4473-9ff9-9efa8305b59d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. The Company&#x2019;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash equivalents are generally composed of commercial paper, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2255814b-e102-4341-91a8-af300e5e4d72" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company invests its excess cash balances in marketable securities and classifies its investments as available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its investments in marketable securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. The Company reports available-for-sale securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the marketable securities, the Company considers all available evidence to evaluate if an impairment loss exists, and if so, adjusts the investment to market value through a charge to its consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2fb8bf7-94ae-432e-a057-a84d8bfe4dd4" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5213e007-9f53-4878-8c18-f41412febbd9" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d84616f0-7fb1-4276-a20f-bd852a0c1e40" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a91d44af-71fa-4321-baeb-e313253f58fa" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d241210-3de6-46f3-88b6-068ec462c80a" contextRef="C_94b787e9-7a65-4675-ae1c-15ef31484f3e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e88bdc8-e0c4-4936-b782-a8ed23c6f269" contextRef="C_f9e73fef-5f12-49d2-b304-fdc0a8211ca9" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6201a87f-10c1-43ab-9353-77a4327e304d" contextRef="C_e2ab031b-2c82-4ab6-b6af-8f43dbaf9ec4" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of their useful life or lease term.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3fe9ced6-616e-4aee-9904-4149004740dc" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_163146a6-6a57-44fb-bbe7-bef3d1d260e9" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b75d043f-244e-4808-836b-7afd22a862fc" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c9ddc28-e61a-463f-ac73-5048b604abd7" contextRef="C_72e7b2cf-5188-421c-b31a-cb8c26070efc" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52ef560c-fa32-4f8f-9aec-c451f602eece" contextRef="C_c2afa1f5-af40-4100-93ce-80c9cdaa0874" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had one collaborative agreement with Bristol-Myers Squibb, which the Company entered into in January 2019  For a complete discussion of the accounting related to Bristol Myers Squibb Collaboration Agreement, see Note 8, Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec93bd26-6654-42c6-9997-ddcddcdffb49" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14a2851c-a6b8-4120-8025-18ef500b48e9" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d38467be-27f0-4784-8720-a63024177fd7" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3dbc20b8-0179-440d-bacf-888e894b32f1" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:LeasesPolicyPolicyTextBlock" escape="true" continuedAt="F_3dbc20b8-0179-440d-bacf-888e894b32f1_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_03b4de73-343f-4ac2-8c26-c4a271fedc1c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC) 842 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dfcf4282-f7d8-46a6-82a4-0701b95c3c82" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df6c8dbf-1a5f-446d-a7df-488a6e95fa13" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_3dbc20b8-0179-440d-bacf-888e894b32f1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9aee768-3fbd-490f-ba97-3fcf74f7a59b" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b8f402ca-7793-4ef6-b76d-ebf1777b0936" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i) all components of net loss and (ii) all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_af6a1034-8dfd-4227-be8d-2f92298f819d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a973f224-34c3-453b-a0b3-25f27e95719b" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_380cc449-cc31-4c7d-a214-cc4d057d7c6c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c04ead81-bded-4415-9018-060028e07d0c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#x2019;s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.432%;"></td>
        <td style="width:1.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.588000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.384%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.384%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.384%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae669dc4-8c70-454e-b9d8-a436494dddc9" contextRef="C_aede6e61-a0c9-4e55-bbf8-f41b83685d83" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebfe8a74-70e0-45d0-81b7-b747f0d3cbf4" contextRef="C_006dc649-dc41-474f-8ec9-76fa6ad1fab7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76db2d08-4fc5-4541-9986-fc01eb1c838c" contextRef="C_dfe38f01-f9ca-4eaf-a331-878b48fafd55" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,606</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce69b128-98f6-4af7-9201-5e9d0947d622" contextRef="C_846b01fb-e362-4321-8448-6f496f45b801" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,606</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22987c04-23b2-4600-b79f-221ffab59cf6" contextRef="C_aaa08537-cb74-4d4d-a39a-8997e07e77df" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8874886e-3036-4be5-be03-06e8e4454b7d" contextRef="C_55096704-6551-4982-b2dd-3b2dd0624c46" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d958f067-3138-41aa-a717-d05f4b19cb3c" contextRef="C_56a2b03d-825c-40b9-ae08-f05fa29edc0d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5765ebcb-00a6-4cef-a7f4-6db14276fbcb" contextRef="C_998a15cc-e896-4027-85f6-00d38c4c670f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a3f743e-8bff-4112-a61b-566e136d81ef" contextRef="C_49f118e2-3aad-42e9-9966-9b49f9d34542" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.534%;"></td>
        <td style="width:1.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.418000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.204%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.407%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b2e45c3-d6db-45fd-ae9a-1c25a181871c" contextRef="C_094353c9-0180-4db6-835f-7fd1043e467d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a555cffc-04c5-4399-9495-ac0b9b39fbe5" contextRef="C_25d90a8b-c846-4756-bd61-dd59c2bafa2c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe5e7537-2340-429d-a8ae-d42c729ce48b" contextRef="C_73e45bb4-192d-4764-86f0-84eb2db89c0e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bde9137-114c-4197-9210-d7e50de15afc" contextRef="C_3d9274dc-5a91-43f3-a6de-fddb2971143b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60b2954a-70ef-4abe-85e4-2d42e83e4860" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:FairValueLevel3TransfersOutAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f7caed54-b7a3-4827-b98f-33a3951a262b" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:FairValueLevel3TransfersOutAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers into or out of Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09907a05-91cd-4b82-b5f1-a4c3e2f67da0" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. MARKETABLE SECURITIES</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_de19ee7c-dd2d-48a6-afdb-3e26c16416d4" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#x2019;s marketable securities (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.064%;"></td>
        <td style="width:1.211%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.211%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.142000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.442%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25a7719d-3d42-4458-ba63-44a404e36147" contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1500d7d7-a1f3-4ca6-a76e-05fcac56fbf6" contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5c08f63-b01e-4920-b448-d3e19de3c123" contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,606</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3d561d2-c8b1-4d39-94ba-2a13a5e9d072" contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89ed79b0-ecde-4717-905b-42a51a05176d" contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f62fd8b2-5cb6-4d9b-aed9-b229f02182f8" contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b41b1a1b-ec31-4a7a-b5f5-3af3bb5952f1" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45d54a49-a755-4d56-9e1a-d9a5c14de86d" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_987cfceb-345a-4de1-8f40-9686f5a06749" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did not hold any marketable securities as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99cc0846-d302-447b-a480-b06d76d91875" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Position" decimals="INF" format="ixt:numdotdecimal">43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> marketable securities in an unrealized loss position. These investments were in loss for less than 12 months and the Company considers the loss to be temporary in nature. The Company considered the decline in market value for these investments to be primarily attributable to economic and market conditions. In accordance with the Company&#x2019;s investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b22c0f8-fca2-4254-9a28-518d5580275a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cb7ed4ca-cb74-450c-9945-a2da4f942391" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any impairment charges related to its available-for-sale securities during years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d653cdea-c4de-41a6-81dd-89b37968771a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_012209b5-1788-4bd7-945f-f332242e345a" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any credit-related allowance to available-for-sale securities as of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The Company does not intend to sell its marketable securities and it is not more likely than not that the Company will be required to sell the investments before the recovery of their amortized cost bases, which may be maturity.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4532111c-ef43-487b-8db8-3e84b128cee6" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities fair value by contractual maturity were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.057%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.002%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_538e24e4-fd41-4207-bca3-d73a7a909b0c" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_924a9dde-711b-4dae-8ad3-811755af0091" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bfc3a39-610a-4b34-a139-aee2821db47c" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c0e6120-b6d9-4d55-b924-2926e5adc5c8" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_789dd700-37e2-498c-9392-234be7550095" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.986%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.227%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d9b7bcd-8ce7-467c-90a3-348a63c6e98f" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:ClinicalManufacturingAndScientificDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab7137cd-db26-451d-a748-af467c8927fe" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:ClinicalManufacturingAndScientificDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3486ee17-684f-4669-a3cd-8c3b2de60e7a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">727</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5099475-2b92-480e-9830-68ceb8f398e0" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ed7ee72-179f-43d6-ba2c-e778742ca8c5" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">964</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0854250c-2368-4208-b914-ed41fc1dab00" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd38ec81-a312-48cc-b0fa-35daafe2fe6d" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,063</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e53ef7d7-3880-4f86-b04e-847d49bc2a83" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_376e0b13-99f6-41e3-bb18-6bc1f22a5304" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. PROPERTY AND EQUIPMENT, NET</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c894ecd-a61f-418f-b60a-b0e613e6755a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.200000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.189%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a09767a2-f9c6-46da-940b-602e6d5fe228" contextRef="C_201175b1-5ec1-482c-82bd-42e11405e926" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdc14f18-4697-4cd2-80f1-34aea49e1442" contextRef="C_f09330b3-63fd-4523-8016-448dd3b3e3e7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d355764b-841a-4e53-8076-48e0ecac3bb8" contextRef="C_5422dba2-f132-4a6c-8c0d-9f0758d86563" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f8f80e0-0226-43a1-b2d9-e6e055679dca" contextRef="C_5a48902d-ac69-43f6-b35e-bc502c7e3265" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cf4cd28-0a5a-427b-8c89-e742d67e9788" contextRef="C_8f3e63dc-8be1-44b1-bd62-8504096da2d5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44e0fc5c-6a3b-4a3f-bdda-756bd53e2b32" contextRef="C_d7496043-4245-45bf-886a-e65de0a22afc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_462b3c43-9560-41ce-815f-40376c02030d" contextRef="C_527c0073-0dca-4b32-809c-4a7e62aec6ae" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">475</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb5867d3-e501-49af-bc65-b6cf37be6269" contextRef="C_b1bdd79a-55db-4f3d-b9dc-b5eea09238fe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_222b9062-af93-4c34-8990-2c2e3c1c78aa" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39f04601-389d-4126-98f2-0d8fa6c41558" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2322e57f-21f0-4533-9c87-b8504b5bfcb5" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7592c94e-d5e2-4333-a946-31a9b7b7905d" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c27ac342-d3e3-42e1-bd67-69696d0d6b3e" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5766bab7-6d70-4c20-8fbf-5171025834d1" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e97927f-bcf9-4136-93c6-609e2afc147e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0cc2288-da61-40c7-946e-c59ca6822aa2" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99ba23a3-5f0e-4987-8e51-b96e4b73c098" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6b20ed8c-eb2a-4631-924e-77b7a7eab586" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6e7880b-0d8c-49c8-aa7e-65c3c9b595ab" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b01192c-c885-4dfa-8645-b2508661809e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.986%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.227%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d7c2c63-f9b9-487d-a75f-93aec31b16f2" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38a6f76a-a054-402a-ab13-1e59225cdad8" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3bfa276-7415-42c7-b1c8-2e875acc35f3" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f9da631-f7a6-4c24-82b6-79c5444e003a" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43f429b4-ba2e-4e05-a8c9-860a4ec5edab" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4543d311-e774-4804-8666-647710118a2c" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e509454f-49df-4632-866d-e52c2d0dbff3" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa9fbce8-7e0b-40a1-81d0-a76839260c02" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ebb440f-a310-422e-9300-d92c72c6258a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d387648-83bf-4ca5-a07d-626f1655c661" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span><ix:nonNumeric id="F_faea375e-fed5-4887-9f21-56eb969ee6bc" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_faea375e-fed5-4887-9f21-56eb969ee6bc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BRISTOL MYERS SQUIBB</span></ix:nonNumeric></span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_faea375e-fed5-4887-9f21-56eb969ee6bc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, the Company entered into the Bristol Myers Squibb Collaboration Agreement with Celgene Corporation, which was acquired by Bristol Myers Squibb in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the Bristol Myers Squibb Collaboration Agreement, the Company entered into a stock purchase agreement with Bristol Myers Squibb, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fb0e564-b160-4c9f-9ea9-685e6a834e4b" contextRef="C_c3be42be-7b3d-40ba-ad4b-e05df3584a06" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,545,450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A-1 Preferred Stock (the &#x201c;Stock Purchase Agreement&#x201d;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#x2019;s IPO, the series A-1 preferred stock converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement Structure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Bristol Myers Squibb Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#x201c;AHR&#x201d;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program (&#34;the research term&#34;). Bristol Myers Squibb has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, Bristol Myers Squibb is responsible for the worldwide development, manufacturing and commercialization of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb paid the Company a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ebc268a-1f49-4344-a8d2-6c8ba6998a9f" contextRef="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285" name="ikna:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">95.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate upfront consideration related to the Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75b84419-33fd-4ff9-a88d-078ea4258545" contextRef="C_25c317f9-19e2-409c-9f55-9c90713949a5" name="ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in case of an exercise of its option with respect to IK-175, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e34c73b9-5e9c-4e03-baec-c4dc62db7b46" contextRef="C_4de011a1-1fee-47df-a29f-9beca448f979" name="ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to Bristol Myers Squibb to support the decision to exercise the option for an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d42ddda7-6cab-44e2-a586-d8f073b57a5d" contextRef="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285" name="ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" unitRef="U_USD" scale="6" decimals="-4" format="ixt:numdotdecimal">0.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ade6f97a-126d-4aaa-931a-caf7a5f747f6" contextRef="C_bb286aec-68e2-4e6f-b537-31fc48bc69b9" name="ikna:MilestonePaymentsEligibleToReceive" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Considerations of the Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bristol Myers Squibb Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09477ecc-c670-4657-b9d3-ec93862b64f9" contextRef="C_172039bc-db4e-4260-9a5f-1630d4a4a0ab" name="ikna:UpfrontAmountAllocatedToEquityArrangements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the upfront from the Bristol Myers Squibb Collaboration Agreement was allocated to the equity arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the Bristol Myers Squibb Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ed3697a-f2a0-4e6e-8784-5db8eb8a039d" contextRef="C_5380a635-35e8-4659-a29b-6c6c312f0478" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">78.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the distinct performance obligations identified above, the Company allocated the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae6a45b2-7639-4cfd-a7ef-290b5e3dca5f" contextRef="C_5380a635-35e8-4659-a29b-6c6c312f0478" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">78.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06a8214c-99cc-41de-894c-6af44d885590" contextRef="C_0b6fbf11-0f77-40b2-8c0f-e122abf4d570" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for research and development services for IK-175; and </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c34231a0-6e68-4051-a4bd-ac21dfc64514" contextRef="C_61e02eba-c186-44f9-b40a-69c6eda8c2f4" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for research and development services for IK-412. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the Bristol Myers Squibb partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb research term outside of the committed manufacturing efforts, which were completed in 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company recognized revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2edbcdd3-768a-48bc-beea-e4ddd80eb19b" contextRef="C_79681f83-bcfa-43cd-b9a8-9202b8e8dd42" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5">15.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7c4aca1-8656-4410-a408-1d66b4014422" contextRef="C_f069e2a6-5458-4e6d-b129-855b9f38dccf" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, from the Bristol Myers Squibb Collaboration Agreement. The consolidated balance sheet as of December 31, 2022 includes current deferred revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56d4efc7-0203-40ff-83e7-5588c8787d32" contextRef="C_6011e744-0468-4b9d-a6aa-2ad82bb602fe" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5">9.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to this agreement. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for the partnered programs.</span></p></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb603fe4-4d44-48e2-89ab-c07d05f92802" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. COMMON STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f6b318f-6132-4fcd-92bd-39f4e2efc5f6" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e511544c-9404-4ca0-8244-8937366a692a" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock authorized, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91bf82a9-7aa7-40c6-b2fe-936f8bffa663" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_33ee195b-b6b6-4266-9473-7f9f7b16bd73" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,257,493</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eba61a5f-8ba9-40f4-90d7-eff4489dd5de" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_09a8954a-9f25-4039-bebb-ce47c47fb092" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ab02681a-178b-4788-822a-a76f6bf226c9" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_37870834-f7f4-478f-8748-ba04109effc4" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2016, the Company&#x2019;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#x201c;2016 Plan&#x201d;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company&#x2019;s stockholders approved the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32c29d49-4ef0-4cd5-b211-76aaba9cebb4" contextRef="C_a1c560c7-417e-4680-8016-5472ee398972" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The shares of the Company&#x2019;s common stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares initially reserved under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_352b5f5d-3c92-486b-90af-ae3c6f5f4b5d" contextRef="C_d8d5e815-4402-469f-92c1-05e99f28eae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,263,664</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock. The 2021 Plan contains an &#x201c;evergreen&#x201d; provision, which allows for an annual increase in the number of shares of common stock availab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">le for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1bcf823-27dd-4b56-b2c3-da8990aadd32" contextRef="C_f74818aa-b473-442b-83e4-0dd0c0bedd47" name="ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan. On January 1, 2022, the number of shares of common stock available for issuance under the 2021 Plan increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66387948-6a2c-4adf-98e1-8f3586df5c59" contextRef="C_ac826982-7dbc-4cee-848b-c0246e9b311d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,439,001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares as a result of the automatic increase provision of the 2021 Plan. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3587a7db-063d-4492-b591-1aec1b234f73" contextRef="C_d13cc7f8-a86c-42e2-8850-115bf15cdd7b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,639,915</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock remain available for future issuance under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vesting periods for equity awards, which generally is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a73056e-01aa-4bf6-bc81-ffd32c57ef46" contextRef="C_32986907-9238-453d-9ab9-8a0f5484f461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are determined by the Board of Directors. The contractual term for stock option awards is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13751916-16ff-4146-a7f7-f79fb5f8484e" contextRef="C_32986907-9238-453d-9ab9-8a0f5484f461" name="ikna:StockOptionContractualTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47d976b9-3bb0-4d85-8456-45cae7a49599" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.571%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.983%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.61%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.225%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc955cd0-6e07-4d9d-a94d-da4f2a2141fa" contextRef="C_db24a009-c7dc-477b-81ab-fa7a1a7149cd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d3dcf6d-34fe-4494-adc4-02fcb577a4ca" contextRef="C_9f720352-5344-47c4-bf64-7ee0c53bfc69" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cf72d2f-c44a-4b74-856a-91a0e5d0ff06" contextRef="C_0328cea2-41fd-451c-a98a-8066850c22de" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,551</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a55370a9-bfe1-4532-8b13-12b37b75a3ce" contextRef="C_0b5743c1-f77e-4a80-9bb0-c3531c20806d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17944a17-6608-42dc-a676-e0fa61c58a4f" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c81d2247-17fa-4a5c-9d4b-9785e0275125" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average fair value of the stock options granted during the year ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71dfbd72-e298-4809-bc7e-dd873d0ba54e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.52</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d14b83d1-c20d-47ec-8e1b-f79c14541fcf" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. As of December 31, 2022, the total unrecognized stock-based compensation balance for unvested options was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de1b62c4-0e68-4b69-a201-256a6ff7dfcf" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which is expected to be recognized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d37131c9-42b5-4e3c-85fa-446223832994" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0cd825b4-2cbc-41d3-9c62-ac287a9fa75c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_0cd825b4-2cbc-41d3-9c62-ac287a9fa75c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022: </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_0cd825b4-2cbc-41d3-9c62-ac287a9fa75c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.133%;"></td>
        <td style="width:0.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.190999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.88%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.056%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.17%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ef16a02-07e5-4469-9b7b-ba0dc7316684" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed9d2f8c-712c-4484-8541-a420b4a2ac09" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ae16d8a-4fae-4381-b9b5-b080759f10d6" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_973651d4-7c45-4c27-94c4-c00df15ff551" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b52a9c1-9918-44d4-b395-ba1d26ccab2b" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,927,649</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87e249b4-ca09-4536-b030-bc3224e028a6" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_120bfeb3-c378-4055-bf17-f77b2787a009" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">282,459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf59e4d6-f547-48c1-8ca7-26f1fa9ca696" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bff3ad8f-8bc9-4066-996d-c2cd4a1899b2" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,084</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca2d43d0-573a-4959-b21b-3baf293a9d52" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c5e3b7d-b2f2-4953-a44f-d39a2b08c4a7" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,589,479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_033782ab-02f2-45f3-856e-e43b343c4306" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a66f0ee7-4d93-41f3-b8cd-94576db9e80f" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5874241b-7300-40d7-a340-a8db8dcd376a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">362,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb41aa6a-8b27-4e19-99ea-38a95ea23619" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,589,479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2c69e6c-d0e2-4eee-aea8-83fbbae5630e" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a07bfe6-4734-41aa-ba12-80db4e6e118d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22535096-3c34-4a5a-b542-7a84b7f09de7" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">362,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf655db0-a0f7-4db4-aa8c-4a254786bfaf" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,009,095</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac8ab3c5-eb88-484d-a1f2-cd0ec18a22a7" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4df8d6f5-3d80-40f9-997c-ed856e7405c0" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eccb3115-b870-41aa-b4d3-db75a74c8f4b" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">358,798</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intrinsic value of options exercised for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9769da9b-fd94-43eb-a6a3-544f2dcd908a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f4c6026-9939-42f6-9918-9ff50a329128" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5997ee8a-0998-46b5-a708-3957fccef2a8" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is estimated on the date of grant using the Black-Scholes option pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.725%;"></td>
        <td style="width:1.158%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.6%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.169%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.347999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7867a0a9-84c8-45a1-92a5-8140b6e9155c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.67</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49bbf2a8-1c18-4e4e-b59b-ec1ed55ddabf" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.59</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f98bc386-8aa6-42d3-827c-298ce83f7b03" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.68</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac470747-528c-45e7-a678-e4810e0ec0f3" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d98b09c3-dee2-4841-9dd2-b6ba1e62642f" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06e72b35-a124-4d7d-8f4e-374d9f867c08" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2656b1f-1d44-47d7-9d75-c4f35e79488a" contextRef="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.15 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b527a175-58bd-41e3-ba41-b87bac0e441e" contextRef="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2aa4becd-7326-459f-97d5-eb6fca558d8b" contextRef="C_af45af9b-bf8b-48ad-9b86-a379550ecc14" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_345aa1f2-2b07-4bdd-a99b-11a9366157eb" contextRef="C_30eb871a-b095-47c3-a919-45cc40650449" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788e9515-6bec-45bf-8b1b-826cc41bf226" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">83.60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6970675-5fd8-4fbd-ae46-6f058da7646d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">86.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bee4b7a6-d6e4-41c4-99f5-9a07a68566af" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">68.58</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49261f67-4bd7-41e8-b631-cded3cc64b3a" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">73.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0283e1dd-61fb-4920-9d5d-16cc42fe1d9e" contextRef="C_686297fa-085a-4a4a-a878-5b20c1fcf30f" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f74b417e-48ad-40d3-8ed3-f1d0a4fba5ec" contextRef="C_cbbd90fc-7f8c-4e81-9033-43797f48a0e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">346,613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26956665-623d-4b1c-8f89-92f249f2ff53" contextRef="C_d2d96cc4-4b37-4a61-9a19-85166d8d9462" name="ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22406af0-9576-46f3-ac3f-7133f002b9c5" contextRef="C_b1178e06-1abe-41ec-b7dd-8ac5bb40a35b" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been purchased by employees under the ESPP.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bc5d1289-e084-4f5d-87f8-e0b09640fcbd" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. EMPLOYEE BENEFIT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). Contributions to the plan by the Company totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff82a124-6530-47cf-bfc8-95d0cd0dc921" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1e9570d-2987-4d7c-97ab-4c849d88949c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t make any employer contributions for the year ended December 31, 2021. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2022 and 2021, were immaterial.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2b8585f-986b-4117-88f8-4507e9ae1a02" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. INCOME TAXES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66912e43-5cc2-438e-9d75-6966d3f6822e" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.7%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.073%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.062%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64cf790a-7164-4942-ac41-97c903ac760d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_273fa240-692e-482a-9737-9d05ce3dd40c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ef42c9f-5d6f-49be-97dd-e79f305bea7c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_add49d61-d6f4-43a4-9828-efa1c3d92957" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e6ae90a-e2ff-4dff-b01e-91c305d7a06a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e735e373-77b2-4d03-82a3-cd9f824633e9" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b4c3017-2eb2-4643-9c82-385537364f51" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d7f27ff-a135-478d-9a16-91977d72442c" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eba934c-88b7-45ee-9372-356069ccb285" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c493b5a-fea5-4e56-a0a6-bcc8578b11d4" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee263551-cabe-4466-9a48-b617a55d5604" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">32.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acac9ec9-9701-4203-b3c3-936cd1fc6cd1" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ba6e7ec-843b-4ee7-b887-5baf516ccc13" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.200000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.189%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c584b7e-2601-4cef-86d2-933e9daa5466" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,875</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a0f060a-a179-483e-bc14-11a182697a5b" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04254c7b-e3a6-48e0-ad45-f09e0e162cb4" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d19add1c-3e2e-41bf-ab93-87fe8d4627e3" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07a04a24-0101-47c2-8d50-55e1b2ed7f57" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36c157fa-32ec-4dc8-9436-7ebb5357013f" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73e9422f-2eb9-4ae8-be03-a7f1a378c24f" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">219</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1509a84-921b-4a67-b141-a94dc96a3c13" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be0fbf35-09ee-4b72-b610-162b2ffb8797" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff9cacd6-a64c-4cb0-ae37-0d1d70483a5a" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e47563f-e84a-47ea-9b58-e4df170659fb" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51767fe8-f8f4-447c-9f69-d75e13136203" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_831bf862-416c-4d36-98bb-24442557e621" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b33df7dd-9c8c-430b-87a1-f7d5f675b2fb" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,026</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9254a752-34ec-46dd-972b-c61d786e66b7" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8ee59f5-ac9b-47a5-9616-94a1188e24ae" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="ikna:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;E</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e19e5f3-a42d-4e81-84cf-20edc1d397d1" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="ikna:DeferredTaxAssetsCapitalizedResearchAndExperimental" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0054a55-af50-4550-b053-aa684ca480ad" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40c9feb6-86e7-427d-85d1-058a363af00d" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72dc9a5f-2ede-453c-b8d9-da05f07042ea" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acb61428-2851-46db-9c76-782c320f504b" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba8eb8a7-f74a-4cbe-8ce1-bf3979e590ed" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_622a5bf7-f1b5-4c84-9b1b-58897ee144de" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f820e76f-2f27-444e-9bab-c1311e38d52a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_909b91f9-32ba-4294-b0db-1912cdeb23c0" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset and liability before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_655265dd-b658-4b02-ba2e-17f4fd1399f2" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1b3ad92-d8b3-452c-8dd7-4b3b459cf219" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,027</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86dd508b-9bff-4e30-bbff-548f82f8ef60" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de6a32d1-e5b8-4bba-8837-2c455955cb62" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,027</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11a2e086-c508-4134-b6a4-7b423dcfac63" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2022, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cde55db-f574-4241-b9ec-29ec30d98422" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million primarily due to the increase in the Company&#x2019;s book loss reported in the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) amended Section 174 and now requires U.S.-based and non-U.S-based research and experimental (&#x201c;R&amp;E&#x201d;) expenditures to be capitalized and amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_73fc101d-7745-47d5-b271-65058a5425c1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five </span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ed879b2-085c-4385-81f8-de3088e3ce96" contextRef="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9" name="ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;E expenditures in the year paid or incurred. The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e6d80b8-a2c5-4a8d-8de0-13961a606f0f" contextRef="C_18a1ea8b-e577-4c5b-9f0d-b1c3d8bddc84" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">108.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_149b57d8-65c7-4b1e-b04d-17c1011d4388" contextRef="C_0f2e0b59-0865-42b0-91fa-b28782511684" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of Federal &amp; State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_568c2e47-627b-4fde-b40e-643464deedcd" contextRef="C_039e47d5-8439-4779-9f97-da794a71c14e" name="ikna:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06ff01a2-5a08-440e-94f9-f102149282a9" contextRef="C_1b8449eb-5f80-4e42-a3a7-9af92acd3f91" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c199fe2-8d0a-4fc3-982f-3aaa331ac9f3" contextRef="C_ac9d39c1-132d-4ba8-be7b-fc7b585405ba" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, to offset future income taxes, which will begin to expire beginning in</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bf1f778a-8543-4a3e-828d-2cc9e1cfbf0c" contextRef="C_84d516bd-f241-4424-bbd6-e29e016466cc" name="ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96e1cfbd-e7ff-46c8-9e39-dbeddf34dc99" contextRef="C_7197b178-a4ef-4f27-bbbb-2a2195a83543" name="ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2031</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows the provisions of ASC 740-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; and specifies how reserves for uncertain tax positions should be classified on the balance sheet; among other provisions. As of December 31, 2022, and 2021, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91de8126-fd05-4882-8084-66a3ced1e90a" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_620e9e6e-b8f1-43b9-a72d-2e426acb4d45" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recorded tax reserves associated with any unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c89f67d1-5777-47ad-92eb-3ca5212d4424" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incurred interest and penalties related to uncertain tax positions.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s federal and Massachusetts income tax returns for the years ended December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa54746f-7ef1-4436-8a32-0ca7aa001308" contextRef="C_3a0f4009-cad0-4026-8941-85d87debcc2e" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce43b1bf-0a5d-4b6a-aeb2-9f7b006ee794" contextRef="C_a216833a-bcc3-4948-b7e6-e2ffb74f7b17" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7c56653-c5ac-4cbc-aba7-1ecc9ebb4f85" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. RESEARCH LICENSE AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2015, the Company entered into an exclusive patent license agreement (the &#x201c;UT Austin License&#x201d;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#x201c;University&#x201d;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86b66387-6854-4784-bea2-c996f5f7556f" contextRef="C_84324036-af2c-40fe-9fa2-a3dbfb992c04" name="ikna:LicenseMaintenanceFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1d90754-f033-4a32-a704-6bf51dc93a9b" contextRef="C_33bcb973-7966-4f4c-bc9c-e3aa82ff7119" name="ikna:PotentialDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon meeting certain development milestones during the term of the UT Austin License. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ae565a9-80bc-4dac-be79-92378c45ae52" contextRef="C_f72bf92b-b49c-4e3d-b668-ab6a03cec96d" name="ikna:RoyaltiesTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company acquired IPR&amp;D on an Arrys&#x2019; immune-oncology candidate based on the intellectual property associated with Arrys&#x2019; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8d5d490-2aea-46d0-87aa-24c8d8666270" contextRef="C_76b4cb83-83c9-4fda-8ec2-4663fab1916f" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c5652e7-2414-4b30-a8b8-4d20dd6756ef" contextRef="C_4e1254ff-dea8-4f2d-8b51-985639cee2f0" name="ikna:PotentialDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, as well as certain sales event milestones ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30dc8754-773c-447d-b6df-ba4ff05bca0b" contextRef="C_5e250053-4619-45f1-9e2b-a7efc1571f50" name="ikna:PotentialSalesEventMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43f534b9-6c9c-4248-b59c-5a39cbae03b8" contextRef="C_bbac1559-abd3-46e6-b271-d81b0a7eaae4" name="ikna:PotentialSalesEventMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">250</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million contingent on sales in a calendar year, during the term of the AskAt License.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd2119dc-b238-45f4-8652-dd1cea4a4711" contextRef="C_addbb181-d517-444c-af21-20959683d0dd" name="ikna:RoyaltiesTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a123a5b5-363a-4382-b128-aff0832de03d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. LEASE OBLIGATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 21, 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_374dda2e-30ec-425f-ac23-2b63e522a359" contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6" name="ikna:AreaOfLeasedProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">20,752</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#x2019;s corporate headquarters. The commencement date of the lease was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bc31fe7d-2f87-4266-af2d-74dffe3cb100" contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee" name="ikna:LeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 19, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the lease term is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b50b1196-7ae8-47bf-8082-f8bb2cb89a6d" contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The base rent at commencement is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_215ff3c7-11ce-4101-9d37-cd56bed2320e" contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee" name="ikna:OperatingLeaseMonthlyBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per month and escalates by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44a124a6-e3d2-4972-80d5-d701cd6b3af3" contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee" name="ikna:PercentageEscalationInAnnualBaseRent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% annually for total lease payments during the term of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed847182-e939-42b6-9266-f1d31823e010" contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4adca1fb-fc92-4fd7-8bd9-d27cd2722817" contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6" name="ikna:LetterOfCreditToSecureLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26e86c24-879f-483b-bf16-636dd323877b" contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an operating lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac13c0b7-4bc2-4f72-a3ab-509cfc1d33f8" contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the commencement of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d9ad33f8-0954-4972-b8aa-c7a6953679a3" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f17c2f0e-2fdc-4ebd-a50d-58290d71a01d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50dc3210-c324-4538-82e3-e7405be104e1" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d02d9ae8-663b-440b-861a-19fbfefd108b" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d383baa2-0fea-429b-bd13-08aa4e9df356" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_611fd979-109d-4119-a054-72c58214fa19" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bced8ae7-4dee-4652-bcc3-0ba08cc1ac1d" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with the Company's operating leases.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ad8a936-20d5-4b05-b88d-b53329a1144c" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of<br />&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d9f405c-1b63-418e-95ff-8346ea25e9db" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,774</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0ed6f04-2788-4c50-8521-5474d102c1d0" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
       <hr style="page-break-after:always;" /></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d4f5334-f50f-47fb-b3ac-a53d609b8bd5" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining lease terms and discount rates related to the Company's leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.88%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.88%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_babddb6e-a2c5-49ed-ac8f-f65a9ab748bc" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f8152b3-ea8b-4df1-b7ce-44b743948c64" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_295f648e-6336-463c-81e1-8f07349a8d13" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2336bc72-a4a6-4345-834b-2cc7ebb0bd92" contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_269f4e50-40ea-4c98-a5ef-c8f76f8ed04a" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future minimum lease payments for the Company&#x2019;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"></td>
        <td style="width:1.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.994%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br />Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_282a9a65-b272-45d7-8e84-1432f9a4769d" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39f8f05d-101a-424b-8040-28bf1d35aa56" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,882</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91a8e2a1-0d7f-434b-8c1d-5309e5683184" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d68da348-dc28-46d7-8dfa-ef90d4612538" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df8486a-6982-4d70-a6ed-a5f4cc513889" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f507fb81-5e11-46e1-bc23-19f5f5f50c03" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eeb961c-14d2-4aa4-b763-739b447ad445" contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_90dc5dfd-56c2-424b-a3d4-4016e6d1928d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_90dc5dfd-56c2-424b-a3d4-4016e6d1928d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. COMMITMENTS AND CONTINGENCIES</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_90dc5dfd-56c2-424b-a3d4-4016e6d1928d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2022 or royalties on future sales of specified products that have not yet occurred as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6ab52a0f-4cd4-4ec3-8b6b-20a2cd9cc730" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into several agreements with a director and an entity affiliated with a director:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 11 above, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31b2df6d-e368-4f15-9624-926fc7535016" contextRef="C_b633a850-2bce-4c3c-abbd-d9eeb2480f83" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dc52d62-89d2-4bd9-b994-832a19c0d6e5" contextRef="C_c06f1a61-16c4-4100-89a4-3b2b77f6fab2" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Certain entities affiliated with directors purchased shares in the IPO.</span></div></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1f938dd-2613-46a0-a163-482acba4b75d" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a8508d5c-99be-4d8a-9312-e3da46e3ac79" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.467%;"></td>
        <td style="width:1.178%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.972%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.166%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.216999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_335ad33e-20fc-4973-be86-1ed8dbb1f39b" contextRef="C_01fa273c-adc6-48a9-9be3-a48fc56e1ffa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,589,479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e0303dd-8604-48d0-b574-64c211b05545" contextRef="C_68d0106c-cdc4-4aae-a92c-8c34b9586d82" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9862c6f-c9c0-433e-88d5-92e23a699725" contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,589,479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f8bccbb-dd8f-466c-8d50-0f3745e556b7" contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ikna-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IKENA ONCOLOGY, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the &#x201c;Policy&#x201d;) of Ikena Oncology, Inc. (the &#x201c;Company&#x201d;) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#x201c;Outside Directors&#x201d;). This Policy will become effective as of December 15, 2022 (the &#x201c;Effective Date&#x201d;). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Retainers</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Retainer for Board Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: $35,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:82.843%;"></td>
    <td style="width:4.336%;"></td>
    <td style="width:1.703%;"></td>
    <td style="width:9.74%;"></td>
    <td style="width:1.378%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Annual Retainer for Non-Executive Chair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Annual Retainers for Committee Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit Committee Chair:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation Committee Chair:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nominating and Corporate Governance Committee Chair:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nominating and Corporate Governance Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair and committee member retainers are in addition to retainers for members of the Board of Directors. No additional compensation will be paid for attending individual committee meetings of the Board of Directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Retainers</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: An initial, one-time stock option award (the &#x201c;Initial Award&#x201d;) to purchase 35,040 shares will be granted to each new Outside Director upon his or her election to the Board of Directors, which shall vest in equal annual installments over three years from the date of grant, provided, however, that all vesting shall cease if the director ceases to have a Service Relationship (as defined in the Company&#x2019;s 2021 Stock Option and Incentive Plan).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#x2019;s 2021 Stock Option and Incentive Plan) of the Company&#x2019;s common stock on the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: On each date of each Annual Meeting of Stockholders of the Company following the Effective Date (the &#x201c;Annual Meeting&#x201d;), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the &#x201c;Annual Award&#x201d;) to purchase 17,520 shares, which shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director ceases to have a Service Relationship, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value of the Company&#x2019;s common stock on the date of grant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale Event Acceleration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: All outstanding Initial Awards and Annual Awards held by an Outside Director shall become fully vested and exercisable upon a Sale Event (as defined in the Company&#x2019;s 2021 Stock Option and Incentive Plan).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board of Directors or any committee thereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximum Annual Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in a calendar year for services as an Outside Director period shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of Directors; (or such other limits as may be set forth in Section 3(b) of the Company&#x2019;s 2021 Stock Option and Incentive Plan or any similar provision of a successor plan). For this purpose, the &#x201c;amount&#x201d; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Originally adopted on March 19, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Policy approved on December 15, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>ikna-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-254858) pertaining to the 2016 Stock Incentive Plan, 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan of Ikena Oncology, Inc.,</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263640), pertaining to the 2021 Employee Stock Purchase Plan of Ikena Oncology, Inc.,</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-264517), of Ikena Oncology, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 14, 2023, with respect to the consolidated financial statements of Ikena Oncology, Inc., included in this Annual Report (Form 10-K) of Ikena Oncology, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACTIVE/115337866.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>ikna-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Mark Manfredi, certify that:</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Ikena Oncology, Inc.;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.395%;"></td>
    <td style="width:4.957%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.4%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>ikna-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Jotin Marango, certify that:</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Ikena Oncology, Inc.;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.0%;"></td>
    <td style="width:6.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:60.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jotin Marango</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jotin Marango</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Head of Corporate Development</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal FInancial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ikna-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with this Annual Report on Form 10-K for the period ending December 31, 2022 of Ikena Oncology, Inc. (the &#x201c;Company&#x201d;) as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.395%;"></td>
    <td style="width:4.957%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.4%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Manfredi, Ph.D.</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jotin Marango</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jotin Marango</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Head of Corporate Development</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img40748725_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *8!<X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#FO%KNBVNUV7);H<>E;FGDG3K8DY)B7G\*P
M?%_W;3ZM_2M[3O\ D&VO_7)?Y"@"S1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]3\JXU&ZEAGE,:D%02!QC&1VK0;6?%-LWBG1;*Z?4;S3_)DMYVC7S-C\L,
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MS[:W:V0!N-K#!S[UK7%Q%:VTEQ,VR*-2[L>P'4U%I^H6NJV$-]92B6VF&Y'
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M-IZC:015G0M"M]"MYDADDEDGD,LTLAY=CU/'2M6BJYG:PN57N%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH *1E5U*L 5/!!'!I:* $5510JJ%4<  8 I
MGD0["GE1["<E=HP34E% $;6\+L&>*-F P"5!(%(UO VW=#&=GW<J./I4M% #
M)(8IE"RQHX'0,H-.5550J@ #H .E+10!"]G;2,6>WA9CU)0$FI0 JA5  '
M[4M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YSX8T+3-9O\ Q.+^
MSBF87[JLC+\R D]#U%>C5R</A"\M+C46L];E@BOYFEE585)&>P)Z=:TA*R>M
MB)*[6AS6G>,+O1O"_D&199EU%[*">X)(5!SN;UQFM&/Q=JLEIK$-M/:7MQ9P
M+<17,4+*CKGYE*D\$#/>MN?P7I[:):Z=;/);M:2^?#.IRPD_O'/7-:-CI=U"
MLPO]0:\$J;-OE*B@?0=ZMSAO8E1EL80\73W6IZ7':>6;5[!KZ[;&2%QP!Z<U
MC6WQ OI!:7QGLI(;BX$;6$<;>;&A. V[H3[8[UT/AOP3:^'FO#]H>Y%RGEX<
M8V)S\H_.I-.\+W6F".VM]9F6PC?<D'E*6 SG;OZXHO306F<VFMGP_J'B^^2(
M2R_:XHXU)P"S# S[5L1ZYK.FZ[::;JKVMP+VW>6*2&,IY;JN2I&3D>]6I_!=
MI=?VP+B=V74I5EX&#$R]"#3H/#$D5X-1OM0EO[F"W:&WW(%" C!.!U)]:'*#
M_KR!*2.>3QAX@CT"SUZ=;,V;W(@DA53O8;B-P.>.G2K-UXD\02WOB%;)K-(-
M+PZ^9&2SC;G;U^O-0>'/!ES>:#91:G=745O'<M.]BZ  L&..>H'?%=&/"L:R
MZXXN6_XFHPPV_P"K^7''K3DX)B2DT9%IXGUH:AH3WJ6GV75P<11*=T7&0=Q/
M/Y5FS_$&\?[;>6]Q9)#;3F-+%XV:690<$[NQ]L5U!\*1EM"/VIO^)3]WY1^\
MXQSZ5'#X4FL9[@:;JTMK:SRF5H?*5]K'KM)Z4E*F.TRE/KVM7OB&XT_36M88
MDL4N@\\98@GM@'O^E<]KFM:GK>B>&[^.=+9I;X1.BJ2/,#$;NO*\=*[N/0$3
MQ!<ZK]H8M/:K;%".@'?-99\#0_\ "/V>F+?2+):7)N89P@X;<3R._6B,H*P.
M,F=1;+,EM&MQ(LDP4!W5=H8^H'.*EJ.W22.WC2:7S9%4!I-H&X^N!TJ2L#4*
M*** "BBB@ HHHH **** "BBB@ HHHH **1G5%W.P4>I.*3S$_O+W[^E #J*;
MYB?WE[=_7I09$'5U[]_3K0 ZBF[U_O#\Z/,0#.]<8)Z^G6@!U%)O7.-PSG'7
MO2>9'C.]>F>O:@!U%-WKG&X9SCKWH\Q,9WKC&>M #J*;O7^\.N.M D0C(=<<
M'KZT .HIOF(/XE[]_3K1O0]&7MW]>E #J*;YB#^->_?TZTC2QH"6=0!U)- #
MZ*;YB8SO7&,]>U&]<XW#.<=>] #J*;YB$9WKC&>O:EWKG&X9SCKWH 6BFB2,
MC(=<8!Z]C1O7.-PSTZT .HIOF(1G>O;OZ]*-Z#^(=^_IUH =13=Z?WE[=_7I
M1YB?WU[]_2@!U%-WKG&X=<=:/-C_ +Z],]: '44F]<XW#.<=>])YL>,[UQC/
M7M0 ZBF[USC<.N.M)YT6X#S$RPR!N'(H ?13?,3^\O?O1YB?WE[=_7I0 ZBF
M^8G]]>_?TZT;T_O#\Z '44WS$'\:]">OIUI=ZYQN&<XZT +13?-CQG>N,9ZT
M;USC<,YQU[T .HIOF)C.]>F>O:C>F<;AUQUH =13?,3&=Z]N_K09$'5U[]_3
MK0 ZBF[T_O#MW]:/,3^^O?OZ=: '44W>N<;AZ=:/,3^^O3/7M0 ZBF[USC<,
MYQU[T>8F,[UQC/7M0 ZBF[USC<,YQU[T"1",AUQC.<T .HIN]/[PZXZT"1",
MAU['KZ]* '44WS$_OKW[^G6CS$_O+V[^O2@!U%-\Q/[Z]^_I1O7^\.N.M #J
M*;YB$9WKC&>M!=!U9>N.M #J*8LT;*&612I&00>"/6EWKG&X9SCKWH =13?,
M0C.]<8!SGUZ4;TSC</SH =13?,3^^O;OZ]*/,3^^O?OZ=: '44W>G]X=N_K1
MYB?WU[]_3K0 ZBF[U_O#KCK1YL>,[UZ9ZT .HI-ZYQN&<XZTGF(1G>N,9ZT
M.HIN],XW#.<=:/,3&=Z]CUH =13?,3.-ZYY[^G6C>G]Y>W?UH YKQ?\ =M/J
MW]*WM._Y!MK_ -<E_D*P/%[KMM/F'5^_IC-;NGNHTVU&X?ZI._L* +=%-\Q,
M9WKC!/7TZT;USC<,YQU[T .HIOF)C.]>F>O:C>F<;AG..O>@!U%-\Q,9WKC&
M>M'F)G&Y<YQUH =13?,3&=R]CU]:/,3^^O?OZ=: '44W>G]X=N_K1YB?WU[]
M_3K0 ZBF[TSC<.N.M'F)C.]<8SUH =13=ZYQN&<XZ]Z/,0C.]<8SG/:@!U%-
MWIG&X9SCKWH\Q,9WKC /7M0 ZBF[TSC<,].M'F)C.]>W?UZ4 .HIOF)_?7OW
M].M&]/[P[=_7I0 ZBF^8G]]>_?THWKG&X=<=: '44T2(1D.N,9Z]J-ZYQN&<
MXZ]Z '44WS$QG>N,9SGM1O3.-PSG'6@!U%-\Q,9WKC /7UH\Q/[Z]QU].M #
MJ*;O3^\O;OZ]*/,3^^O?OZ=: '44W>G]X?G1YB8SO7N>OIUH =13=ZYQN&<X
MZT>8F,[UQC/6@!U%-WIG&X9SCK1YB8SO7IGKVH =13?,3.-RYSCK1YB8SN7'
M!ZT .HIOF)G[Z]^_IUHWI_>';O0 ZBF^8G]]>_?TZT;TSC<,].M #J*;YB8S
MO7IGK1O3.-PSG'7O0 ZBF^8F,[UQC/6C>F<;AG.,9[XS0 ZBF^8F,[UQC/6C
MS$SC>O7'6@!U%-\Q/[R]CU]>E'F)_?7OW].M #J*;O3^\O;OZ]*/,3^^O?O0
M ZBF[TSC<,YQUH\Q",[UQC/6@!U%-WIG&X9SCKWH\Q,9WKC&>O:@!U%-WIG&
MY<YQU[T>8F,[UQ@'KZT .HIN]/[P_.CS$_O+V[^O2@!U%-\Q/[Z]^_IUHWI_
M>';OZ]* '44WS$_OKW/7TZT;TSC<,YQUH =13?,3&=ZXQGKVHWKG&X9SCK0
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MQM'2@Q1DY*+G.>G?I3Z* &"*,# C7& .GITH\J/_ )YIW_A]>M/HH ;Y4?\
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M\J/&/+7MV].E'E1_\\U[]O7K3Z* &>5'_P \U[=O3I0(HP,"-,<CIZ]:?10
MSRH\YV+G(.<=QTH\J/&/+3&,8VCI3Z* &^5'G.Q<YSG'?UI/*CQCRTQC&-HZ
M>E/HH ;Y:9SL7.<YQWI/*CQCRTQ@#&T=!TI]% #/*C_N+U)Z>O6CRH_^>:]N
MWITI]% #/*C_ .>:]^WKU_.G!%4DJH!/7 I:* "BBB@ HHHH Q/%O_(NS_[\
M7_HQ:VZQ/%O_ "+L_P#OQ?\ HQ:VZ?0A?&_E^H4444BPHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQ/%O_(NS_P"_%_Z,6MNL3Q;_ ,B[/_OQ?^C%K;I]"%\;^7ZA1112+"BBB@ H
MHHH **** "BBB@ HHHH *Q?%W_(I:G_UP:MJL7Q=_P BEJ?_ %P:FMR*GP,V
M(_\ 5K]!3J;'_JU^@IU(L**** .0^)__ "3O5O\ <7_T(5POBO4+_2]=\-WN
MFP>==Q:&Q0?W?DY;'?'7%>K>(=$A\1:'<Z5/*\44X 9TQD8.>_TJA_PB%J=<
MTK5#<2E].M3:I&0-KKC&36U.<8K7S,Y1;9C^$;S0_#O@:VU4W,LXO&$ES<B)
MY)))FZ[@H)XY%4?$+R:GXCT+Q##I=WJ^A)#(A@C@)=9"2 QC;!_$CM75^'O"
M]MX:FOOL,\OV6ZE\U;9L;(6[[>^#Z>U2ZUHUWJDD3VNM7NG%%*L+?:0X/J&!
MY%'.N:X[.UCB/!2?:+#Q/!_8C3VT&H[[;3IBHVG&=O)VC%8]M>-IVM^,9VM7
MT;4#IQ:'3UP5V@?ZP,ORD_3UKT6#PA:V6A#3=/O;RT<2^<;J.3,KR=V8GALY
MZ&HM-\$6-K>7=]?W-QJ=[=Q&"2>Y(_U9ZJ   *KVD;MBY7H<%/8VVG>"_ VJ
M6<"QW[7D&Z9.'?>"6!/?.*]DKC].^'MG8W=DTFHWUW:6#E[.TF8%(6/0\#)Q
MVS785%22EL.*:"BBBLBPK U#_D=]#_Z];O\ ]I5OU@:A_P COH?_ %ZW?_M*
MG$B>WS7YF_6=IVDKI]]J5T)2YOIA*5(QLPH7'OTK1JBNL:>VL-I(ND-^L?FF
M#G.WU]*%?H49">$8TTG[!]K8C^T/MV_9W\S?M_IFLUO#^K7?BC7[BUU.ZTR.
M<Q(&$2NDR[,$C=T8'N*ZEM8T]=8323=)]O>,R" 9)VCOZ"KU5SR0K)G W_A.
MXMM<\-6>CRW5I;V-I<*+M$#[&.S&_/!W<\5JCP7$^E7,%Q?SR7]Q<K=O>A0K
M"5?NE5Z #ICTKJ:*'4D'*CG],\-S0:H=4U;4GU*]6(P1,T2QI&A.3A1W.!D^
MU6M8T&'6%LXI65;:"X6>2$(")L X4^V3G\*EN-<L+>QGO#,7B@E\A]BDD/N"
M[??DUHTFY7N.RV,&[\*6$NH:??64<5E/9RELPQ >8I&"IQ53_A#O+\,:?I-O
MJ,D,]A*)H+H1@D,">JG@CYB*ZFBCGD'*CFYO#=\FH?VA8:T]M=S1)'=L8%=)
MBO1MI^Z>3TJS'H##6]/U2:^DGFM+62W)= #)O*DL<8 ^[T K;HHYF%D<_>>'
MKO\ MB?4M*U9["2Y55N(S"LJ.5X5@#T..*CO?#%U->6E_9ZU/;:C#";>2X,2
M/YR$Y^9<8SGH1TK8U/5+;2+,W-T7V[@BK&A9G8]%4#J33-*U>VUB&62W65&A
MD,4L<R%'1AV(IWE:XK(K^'M!3P_:3VZW4MSYT[3M)+RQ+=<GOS5.]\,W/]KS
MZGH^KRZ;/<@"Y01+*DA' ;:W1O>M676-/@U:'2Y;I%O9T+QPG.64=3Z47.L:
M?::E;:?/=(EW=9\F+DEL=>G3\:+RO<=D84O@Z<7D%[;:S.MXD!@EFN(DF,BE
MMV1D84Y]./:I-/\ !T=A9Z-;B]DD_LRY>X#LHS(6#<'T^]^E=/6=#KEA-TFV
MYNFM%W*?GD7.0/7H>?:CFDT*R*%[X4MM0?6/M$\FS4EC!"<&(IT(/KGFFQ^&
M[NZTZ[LM:UF;48IXO* \I(M@_O?*.6]ZVH;M9[FX@6.93 5#,Z$*V1GY3WIN
MHZA!I=FUU<EA&I5?E&222 ,#ZFCFEL.R,RQT;581Y=[KTEW (VC5/LZ(3D8!
M8CDD?A3[#0I=-\*VVC6FH2126\2QI<J@SD=]IR/PK:HI<S"R,;0]";29KVZN
M+LW5Y>,K2R",1K\HP %'2MFBBDW?5C2L%%%%( J"]_X\+G_KDW\C4]07O_'A
M<_\ 7)OY&@3V,OP=_P B;H__ %Z1_P#H(K;K$\'?\B;H_P#UZ1_^@BMNG+<F
MG\""BBBD6%5C=&99/L@25HW*.&)7!';I3;VX\A[4;F'F3!/E YX/7/;BJ>FS
M1VZ:E+,X1%NY"6)^E-PO$R=5*?*0F>]^VAO+_P!+SM$.?E*8ZYK8@:=DS/&B
M-Z*V:QO[3N'AMF6*..[NV?RFD& D0Y#-^&./>I8KR\L[N"*\G@N8IVV"2-=I
M1L9&1GIQ65+#2IMMRN+ZS![+^F;-%<_97.M:FDLL<MO;QQRNBYC+%\$CUXJ?
M^V)S9JHB3[>9S;[,_*''4_3'-;N#V)6(BU>SM^9LT5@W=QK.F)')++;W,;RJ
MC8C*%,G&>O(K>I.-M32%12;5K-!1114F@4444 <QXO\ NVGU;^E;VG?\@VU_
MZY+_ "%8/B_[MI]6_I22^++71XK:TELM0E80(V^&W++R/6A(&[(ZBBN3_P"$
M_L?^@9JW_@(:/^$_L?\ H&:M_P" AIV9/,CK**Y+_A/['_H&:M_X"FD_X6!8
M#KIFJ_\ @*:+,.9'745R/_"P;#_H&ZK_ . IH/Q"L ,_V;JO_@*:.5AS(ZZB
MN/\ ^%B6'_0-U3_P&-'_  L33_\ H&ZI_P" QHLPYD=A17''XBZ>.FFZH?\
MMW-)_P +&L/^@9JG_@/1RL.9'945QG_"R-/_ .@9J?\ WXI/^%D6/_0+U/\
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M_P"%OK_T!I/^_O\ ]:CE8>TCW/3Z*\P_X6^/^@,__?W_ .M1_P +>_Z@S_\
M?W_ZU'(P]I'N>GT5Y?\ \+>/_0%?_O[_ /6H_P"%O-_T!6_[^_\ UJ.1A[2/
M<]0HKRX_%Y^VBG_O[_\ 6II^+LW;1?SE_P#K4<C#VD>YZG17E1^+MSVT9?\
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M]<J"[M(;ZUDMYT#QN,$&KC5:W,I8>+V.0\'^)))Y3IM[)N(4M%(QZXZ@_A7
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M7/\ UR;^1J>H+W_CPN?^N3?R- GL9?@[_D3='_Z](_\ T$5MUB>#O^1-T?\
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MEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<&K:K%\7?\BEJ?\ UP:FMR*GP,V(_P#5K]!3J;'_ *M?H*=2+"BBB@ HHHH
M**** "BBB@ HHHH **** "L#4/\ D=]#_P"O6[_]I5OU@:A_R.^A_P#7K=_^
MTJ<2)[?-?F;]%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS_$<FE^S19^Z?X3U/;I4M% 61 +2$+M"G&&'WCT)R?UIWV:(MNVG.X-U/4#
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MBBB@ HKF?%WBI/#9TU?E+7-RJN#VC_B/ZBNE!#*"#D'D46%?H+1110,****
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M2+"BN;\,^([C6_[:\^"*/[!>26Z;,_,J]"<]ZI^'/'-O?^&H-5UJ2VL3-</
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"[:?5OZ5(VA7%_!;3Q:W?VBF!!Y4+ +TZ\BH_%_P!VT^K?TK>T[_D&VO\
MUR7^0H!JZ,/_ (16\_Z&;5?^^U_PI#X4O?\ H9]5_P"^E_PKIJ*=V+E1RY\)
M7I_YFC5?^^E_PIC>#[\_\S5JH_X$*ZNBB[%RHXYO!-^W_,V:K^8J-O E^?\
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MH **** "BBB@ J"]_P"/"Y_ZY-_(U/4%[_QX7/\ UR;^1H$]C+\'?\B;H_\
MUZ1_^@BMNL3P=_R)NC_]>D?_ *"*VZ<MR:?P(****184444 (RJXPR@CT(HV
MJ>JC\J6B@!@BC&,1J,# XZ#TH6*-""L: CIA<8I]% K(:J(HPJJ!G/ IU%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM._Y!MK_ -<E_D* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<CC/O7IOARXO[KP]93ZG;K;7CQYDA5<!/08[<8K>JK+:QG!Z[D'BW_D79_\
M?B_]&+6W6)XM_P"1=G_WXO\ T8M;=8]!KXW\OU"BBBD6%%%% !1110 4444
M%%%% !1110 5B^+O^12U/_K@U;58OB[_ )%+4_\ K@U-;D5/@9L1_P"K7Z"G
M4V/_ %:_04ZD6%%%% !1110 4444 %%%% !1110 4444 %8&H?\ ([Z'_P!>
MMW_[2K?K U#_ )'?0_\ KUN__:5.)$]OFOS-^N;O?&VF6%]=6LUO?L+5@L\\
M=L6CCR >6'L:Z2O,=4CUHOXPET^XB%JLZ_:(/)W2.GEKNV-G .WV-53BF]1R
M;6QZ!=:M96>COJLDP-FD7F[UYW+C(QZYJ"#Q#IL_A\:YYQCL=A<M(N"N#@@C
MUSQBN3U[4+)-(\-:/I5K<7EI<>7.(K==[FWB /3/<[1^=1Z.;+4AXB\.ZC#<
MZ=;W$GVJ!+@"-U60\D<D<./UJN16N+FU.NTCQ%::S*\4,%Y!(J[PMS;M'N7U
M&>HK7KD=%U34[+Q,OAW4;J'45:U,\-Y&H5P%(&V0#C//4=:K^+GLK[5TTYK&
M_P!0NH[8S&&*\^SQ1+G&\DLN6].O2ER>]8=]#MJ*\KLGN=;\/^"8;R]NLSS3
M1S21S%7=0K#!8=>!C-6;II=!TKQ-IMA=7$5I;W%NL;M*6:!),;R&8D^I]J?L
M^E_ZO87,=O<ZW%;>(K'1FA=I;N*259 1M4)C(/YT:WKUKH,,$ES%<2F>7RHX
M[>/>S-@GI] :XVWTC3=&^)NBV^FSRO&;*X9HY+EI=ARO(W$XS_2MGQNER\_A
M];.6.*X.I#8\B;U4^6_49&:.5707=F;.CZ]9:VLWV;SHY8&"S03QF.2,GD9!
M]:;:>(].O=>N]%AE8WEJH:0%?E[9P>Y&1GZUSFAWK:3<>*+S695DU2VVO.Z+
MM1X@I,90=AU'.>:YJQO+C3ET+6;K2=2M[I;IWOKF6'$12<\\YS@'9CCM3]FF
MV',=[=^,+.UU.XL%L=3N9;<JLC6UJ7521D<CV-= IW*#@C(SS7$V,.LR^+O$
M3:;>VD$(N(?,6: R%CY8Z$,,<5TGB'5/[&T"]O\ &YXHR8U_O.>%'YD5$HJZ
M2&GU8W3/$.G:OJ%_8VDC--8N$FRN!GD<'N,@BF6_B.REMKRXFW6\5K=M:,S\
MY8,%R,=B2*X#1I9=!U3PW-)IFI6F8FLK^:YA"K(\AW Y!.3OS^=2ZI8VUYX6
MUPW*%A%KSD'<5QF50>GL36GLU<GF=CU*BO.-;L9)?$NG^';)8/[,CLWG2">\
MDC25]V"=RY9B,]/>F7.DZA';>'M)O]1)234Y$!M;EV*P^6Q$9<X8XZ9ZU'LU
MW*YCTJBO.-9TV:7Q/9^'+98CIMM8F6*WNKV6,2-NP3N7+,5'8GC-,ELKY&T#
MP]K.H![&XGN#(]O<O\P49CB,APQQD_7%'LUW#F.YL=7COM4U&P2)U>Q9%=CC
M#;EW<5HUQ7@FUMK+7_$UM:7$D\$<\*JTDID*_)]W<>3CI7:U,TD[(:=T%%%%
M2,**** "H+W_ (\+G_KDW\C4]07O_'A<_P#7)OY&@3V,OP=_R)NC_P#7I'_Z
M"*VZQ/!W_(FZ/_UZ1_\ H(K;IRW)I_ @HHHI%A1110 4444 %%%% !1110 4
M444 %%%% ',>+_NVGU;^E;VG?\@VU_ZY+_(5@^+_ +MI]6_I6]IW_(-M?^N2
M_P A0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_Y%V?\ WXO_ $8M;=8="E\;^7ZA1112+"BBB@ HHHH **** "BBB@ HHHH
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M/H*H6E[HMD[?9(=C%<Y5.6! (]^]5>ZT1@Z:C*TFNG5K;RVZ?(G\. ?V8Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MG/&VM3Z!H<5_ SC;=0K($0,S(6&X 'N171U1U72H=7@AAG9U6*>.==AZLC9
M^G%5%I/43VT/+-3\1>$M3T]K-M*\0VZFY:Y62"$JZ.WWMIR< ^E>D^%?L/\
MPC%@--@FALQ'B-)UPX /\7O6OM7^Z/RI<8Z54IIJR$HV=S$\6_\ (NS_ ._%
M_P"C%K;K$\6_\B[/_OQ?^C%K;J.@E\;^7ZA1112+"BBB@ HHHH **** "BBB
M@ HHHH *Q?%W_(I:G_UP:MJL7Q=_R*6I_P#7!J:W(J? S8C_ -6OT%.IL?\
MJU^@IU(L*S+O1UN]>L-4>9A]B214BQP6? W9]@/UK3HIIV YNP\&VFF_VU);
M3R"XU1G)E8 F$-D[5'IDDU7G\%R+_8ITW5Y+)M*MS;Q'R$DW @ DAN_%=913
MYY"Y48<F@3W<6FC4-2>Z>RN?M!<PJGFD A00.!C-3Z=HD>FZEJ-S#,Q@OG$K
M6Y7Y4DQAF'UXR/:M6BES,+(S-1T:/4;O3IGD*)93F<1A1AVVD#/IC)JA?>%5
MO)]7D2_F@&J1Q1S*BC@)D'!]P2*Z*BFI-!9&#J?A'2[[238P6\-H1L\N:*)=
MR%2",?E5W3M)33[_ %&[\TR27THD;(QM 4 +_GUK1HI<SM8+(****0PK U#_
M )'?0_\ KUN__:5;]8&H?\COH?\ UZW?_M*G$B>WS7YF_7$7^I>++7Q1I^D)
M>Z41?1S2*YM'^0)MX/S\YW5V]<MJUI<2?$/P]<I!*UO%;72R2JI*H3LP">V<
M&JAOJ.1H6FO6JZ-=7=W=(QL"T=XZ1,@#I]["G)^G6JUWXXT*Q=XY[B;S8PK/
M$MN[.JLNX$@#(&.I[5SNNVDZ^-/[#BCS::XT=U*<\+Y1_>9_W@$%2?VN^D^+
M?$I&CWE\LOD(K6L7F$-Y9PK#J ?7I5J"W%S,ZF\\3:396-M>/<F6*Z&;<0(T
MK2C&<JJ@DC%1OXMT=-*CU'[0[0R/Y2(D3-(7[KL W9'<8XK@QX7O]*M_#MQJ
M,&HR06UI+!.FFNWFP.[AAPO++C@X]!6K-ING0:!'+#IOB&(-=-.ERBE[J*3&
M-Y4Y;!'&"/J*.2(<S.YL+Z'4;*.[@$@BD&0)(RC?BI (JS6/X8FU2?08)-80
MK=DM]Y0K%<_*64<!B,9%;%9-6=BEL%%%%(84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4%[_QX7/\ UR;^1J>H+W_CPN?^N3?R- GL9?@[_D3=
M'_Z](_\ T$5MUB>#O^1-T?\ Z](__016W3EN33^!!1112+"BBB@"*XM8;N,)
M/&'4'(SV-0MIEDS;C;1Y *YQV( Q^@_*K=%.[)<(O=%/^R[(D$P*<+MY)/%"
MZ79*RMY"DJ,#))_GUJY11S/N+V<.R*T-A:P!?+A5=K;A['&,_E5FBBE>Y226
MB"BBB@84444 <QXO^[:?5OZ5O:=_R#;7_KDO\A6#XO\ NVGU;^E;VG?\@VU_
MZY+_ "% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X@2YMI()!E)%*D>QJ2B@#P_
M2+%[CQ.-)F!S'<&-@?8\_P J]O50B*BC"J, #L*XRST/ROB??7P7$1MQ,/3>
MWRG^1-=I5SE>QE2ARW"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,3Q;_ ,B[/_OQ?^C%K;K$\6_\B[/_
M +\7_HQ:VZ?0A?&_E^H4444BPHHHH Q_%>HMI/A34[Z-BLD5NQ0CJ&(P,?B:
MXWPY,SZ]I,6C:]J.J 1$ZH9I3)"HV\<D<,6Z 'I78^)M*GUG38;*$J$:YB>;
M<<?NU8,<>O2J-QHVI6GB:\U724MPEQI_DF)VV@S*V48@#I@D9K6+2C8AIW,7
MQ?K.HR7[2:==/;Z?HTT37CH?]<[,N8_H%))]R*N>,;V6+6]+M;R_N].T29'\
MVZMFVYER-JL^#M&,_6H)_AQ!)X7N;4W5U)J4\;/)(;IUCDG/)8KG&,^U:%];
M>*;O37TQK/2GBF@$33R2L2A*X8E,?-SG'(JKQTL+7J=!I=J;/3H8#>S7@4?+
M/,P9F';)'7CO5RJ.CZ<ND:-9Z<LC2BVA6(.W5L#&:O5B]S1!1112 *Q?%W_(
MI:G_ -<&K:K%\7?\BEJ?_7!J:W(J? S8C_U:_04ZFQ_ZM?H*=2+"BBB@ HHH
MH **** "BBB@ HHHH **** "L#4/^1WT/_KUN_\ VE6_6!J'_([Z'_UZW?\
M[2IQ(GM\U^9OT444BRI_9MG_ &K_ &F80;SRO)$I).$SG &<#FG06%M;7=S=
M0Q!9KDJ9GR?F*C _2K-%.[ ****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5!>_\ 'A<_]<F_D:GJ"]_X\+G_ *Y-_(T">QE^
M#O\ D3='_P"O2/\ ]!%;=8G@[_D3='_Z](__ $$5MTY;DT_@04444BPHHHH
M**** "BBB@ HHHH **** "BBB@#F/%_W;3ZM_2M[3O\ D&VO_7)?Y"L'Q?\
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M\_!_[Y%'E3?\_!_[Y%344 0^5-C_ (^#_P!\BCRI<_Z\_P#?(J:B@"'RIO\
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M_I!_[Y%'E2_\]S_WR*FHH A\J;_GX/\ WR*/*E_Y^#_WR*FHH A\J7_GN?\
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M )^#_P!\BIJ* (?*E_Y^#_WR*/*E_P"?@_\ ?(J:B@"'RI?^?@_]\BCRI?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8GBW_ )%V?_?B
M_P#1BUMUB>+?^1=G_P!^+_T8M;=/H0OC?R_4****184444 %%%% !1110 44
M44 %%%% !6+XN_Y%+4_^N#5M5B^+O^12U/\ ZX-36Y%3X&;$?^K7Z"G4V/\
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MK_UR7^0K!\7_ ';3ZM_2M[3O^0;:_P#7)?Y"@"S1110 4444 %%%% !1110
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MGH3STYKN+72["R1DM;*"%60(RQQ@ J.@/MR:K_\ ".:+]A^P_P!E6GV7?O\
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M* .8\7_=M/JW]*DGT_7+NULGTS64LHA H:-K</DXZY-1^+_NVGU;^E;VG?\
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M, GN<4^BBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZY-_(U/4%[_QX7/_ %R;^1H$]C+\'?\ (FZ/_P!>D?\ Z"*VZQ/!W_(FZ/\
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MT?3^Z?\ &G8F_O)_WR?\:='_ *M?H*=2*(\3?WT_[Y/^-&)O[R?]\G_&I**
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M?WT_[Y/^-244 1XF_O)_WR?\:,3?WX_^^3_C4E% $>)O[R?]\G_&C$W]]/\
MOD_XU)4<5Q#/%YL,T<D?/SHP(X]Q0 8F_O)_WR?\:,3?WD_[Y/\ C2"Y@-O]
MH$T9@QN\P,-N/7/2F3ZA96JHUQ=V\(<90R2!=WTR>:+ 28F_O)_WR?\ &C$W
M]Y/^^3_C2QRQS1K)$ZR(PRK*<@_C3Z (\3?WD_[Y/^-&)O[T?_?)_P :DHH
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M3_OD_P"-&)O[Z?\ ?)_QJ2B@"/$W]Y/^^3_C1B;^\G_?)_QJ2B@"/$W]Y/\
MOD_XT8F_OI_WR?\ &I** (\3?WD_[Y/^-&)O[Z?]\G_&I** (\3?WT_[Y/\
MC1B;^\G_ 'R?\:DHH CQ-_>3_OD_XT8F_O1_]\G_ !J2B@"/$W]Y/^^3_C1B
M;^^G_?)_QJ2B@"/$W]Y/^^3_ (T8F_OI_P!\G_&I** (\3?WD_[Y/^-&)O[Z
M?]\G_&I** (\3?WT_P"^3_C1B;^\G_?)_P :DHH CQ-_?3_OD_XT8F_O1_\
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M/^^3_C1B;^\G_?)_QJ2B@"/$W]]/^^3_ (T8F_OQ_P#?)_QJ2B@"/$W]Y/\
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MP:MJL7Q=_P BEJ?_ %P:FMR*GP,V(_\ 5K]!3J;'_JU^@IU(L**** "BBB@
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ME\ %ODB<]4F^0C\ZPJT90?D1*#3-RBF1S13+NBD1P>ZL#3ZQ("BBB@ HHHH
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M778\T_X3#QK_ -"^/^_3TG_"9>-/^A?'_?EZ],HHYX]@NNQYE_PF7C3_ *
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M&VO_ %R7^0K!\7_=M/JW]*WM._Y!MK_UR7^0H LT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !31&BNSA5#M@%L<FG44 %%%% !1110
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ME+ON-W^J3&X\[^V.#TJ:B@"'?<8_U29PO\??OV[4;[C/^J3&6_C_ .^>W?\
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M23[-O*QRNN!*!_$OJOH:'%I7!,T**Y$7.M^(]4U&/3=373+*PG^SAU@65YI
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M;K3/"FG6=ZB)<0PA71,87VX]J\MN;WPXVKZDOB+Q/K"7Z7<BE;20^4$S\H&
M>@KU7PNUB_ANR;3;F>YLRG[N6X)+L,GJ36]5-17_  3.&Y'XM_Y%V?\ WXO_
M $8M;=8GBW_D79_]^+_T8M;=8]!KXW\OU"BBBD6%%%% !1110 4444 %%%%
M!1110 5B^+O^12U/_K@U;58OB[_D4M3_ .N#4UN14^!FQ'_JU^@IU-C_ -6O
MT%.I%A1110 4444 %%%% !1110 4444 %%%% !6!J'_([Z'_ ->MW_[2K?K
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M/D9)+W3I)X_W[(P(\O&0IXP>1FO3P01D'(HI1FXJP.-RG="6[T:=1"R32V[
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M9%1M8/&F??/.?PKK9M(TZX.9K*!^2?F0'D]:<-,L1=B[%I#]H'(DV#/3'\J
M+$,,=O"L42[448 ]*?110!S'B_[MI]6_I6]IW_(-M?\ KDO\A6#XO^[:?5OZ
M5O:=_P @VU_ZY+_(4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH;B[MK2,R7
M%Q%"@ZM(X4?K7!^*?B98VMK+:Z*XNKMQM$J_<3W]S5*+>PTKG*?$G6!J_B@6
M,+[H+(;..A<_>_P_"NX^'%ZS:,=/D;+0'<@/]T__ %Z\[\'>'IM>U<^;NVX:
M260_Y[FNBMIY]"U'*?++"Q5E/<=P:[%34HN"W->6ZL>KT5@Z=XOTF^"I)<+;
M3'JDQV\^QZ5N(Z2*&1E8'H0<UQ.+B[,R::W'4444A!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'F$-OXGT6YO;>UT/0I+:2YDFC^T
MW \P!CGD\9KT#17NI-(MWO(+>"X*_/';MNC4Y[&O'C)X5;4M3&J:'JNLW(O9
M0;R!'=&&[@#!&,=,>U>L^&/L7_".67]GVDUI:;/W<$RD.@R>"#S6]5:?U_F9
MPW(_%O\ R+L_^_%_Z,6MNL3Q;_R+L_\ OQ?^C%K;K'H-?&_E^H4444BPHHHH
M **** "BBB@ HHHH **** "L7Q=_R*6I_P#7!JVJQ?%W_(I:G_UP:FMR*GP,
MV(_]6OT%.IL?^K7Z"G4BPHHHH **** "BBB@ HHHH **** "BBB@ K U#_D=
M]#_Z];O_ -I5OU@:A_R.^A_]>MW_ .TJ<2)[?-?F;]>;2?9[OQ;K45];Z]<[
M;E$C:R:7RHU*+P=I ')S7I-<F-/\2:;K.J7&FPZ;-;WLRRCSY75EPH7' ]JJ
M#M<<B6[\0ZE#K5UH^EZ.+N2U@CE,DESY:X;/!."<\<=?PJ!_&LDUAH<]AIC3
MRZJ718GE"&-E&2"<'C(/-:EEI5S#XCU'4Y6CV75O#&%4G(9-V?P^:LC3/"=[
M91^'5DEA)TV:=Y=I/S!P<8X]ZI<G]>@M2==52W\3.VHVIM[F+2?M$[)<L\:
M/RH7 !_WNM3:3K>K:O EU+HZVVG7$)DBE-P#( 1E=R8XR/0FG7OAU[_Q%=WD
MKJ+2XTPV1 /S ELY^F*CT+3_ !)86\&FWL^GR65M#Y2S1JWFR@#"Y!X7WZT/
MEL&MSG?!WB'4=/\ "FA_:-*_XELC+;_:C/\ /N9B VS'W<\=<UJ:MX_BL+^^
MAACLWCL3MF\Z\6*1V R0B$<X_#FI;?PM>Q>"M)T9I8?M%G-%)(P)VD*^XXX]
M*27PYJ5EJ]_/I]MI-U;WTOGG[:AWPN1@XP#N'&<<53<&VQ>\D6#XJNKZ\2#0
M]+%ZHMX[F9Y)A%M5QE5'!RQ';CZU'\-Y&E\%VSN&#-+,2K')'[QN#2SZ+KME
MK,E_H\UA_I=O'%<K.C (Z<!T [8)^4^U:'A/1I] T"+3[B599$DD8R+_ !;F
M)!_6IER\MD-7OJ;=%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 5
M!>_\>%S_ -<F_D:GJ"]_X\+G_KDW\C0)[&7X._Y$W1_^O2/_ -!%;=8G@[_D
M3='_ .O2/_T$5MTY;DT_@04444BPHHHH **** "BBB@ HHHH **** "BBB@#
MF/%_W;3ZM_2G2:UJ5C#;0VN@7-[%Y"'SHY% )QTP:;XO^[:?5OZ5O:=_R#;7
M_KDO\A0MQF!_PDNM?]"G>_\ ?U*/^$EUK_H4[W_OZE=115778+G+_P#"2ZW_
M -"G>_\ ?Y*:?$VM@_\ (I7O_?U*ZJBBZ[!<Y7_A)];_ .A2OO\ OZM!\3ZV
M!_R*5]_W]6NJHHNNP71R?_"4ZW_T*-__ -_%H_X2G6_^A1OO^_BUUE%%UV"Z
M.1/BK7.WA"^_[^+1_P )7KO_ $*%]_W\%==11==@N<A_PEFN_P#0H7__ 'V/
M\*3_ (2S7O\ H3[[_OX/\*["BCF78+HX_P#X2S7O^A0O?^^Q_A2'Q;K_ &\'
MWO\ WW_]:NQHHYEV"Z.-_P"$MU__ *$^]_[[_P#K4A\7>(!T\'WO_??_ -:N
MSHHYEV"Z.+_X2_Q!_P!"=>_]]_\ UJ3_ (3#Q!_T)U[_ -]'_P")KM:*?,NP
M71Q)\8^(!U\'7O\ WT?_ (FD_P"$R\0?]"=>_P#?1_\ B:[>BCF78+KL<-_P
MFNO?]"?>_P#?1_\ B:0^-M?'_,GWG_?3?_$UW5%'-'L%UV.%_P"$WU[_ *$^
M\_[Z;_XFF_\ "<Z]_P!"A>?FW_Q-=Y11S1[!==C@CXYU_P#Z%"[_ #;_ .)I
MO_"=>(?^A1NOS;_XFN_HHYH]@NNQY^?'?B'''A&Y_$M_\33?^$\\0_\ 0IS_
M )O_ /$UZ%11S1[#NNQYT?'_ (BS_P BK+_X_P#_ !--/Q!\0CC_ (1:0'WW
M_P#Q->CT4^:/8+KL>;'XA>(1U\,/_P"/_P#Q-)_PL/Q#_P!"RW_C_P#A7I5%
M'-'L%UV/-#\1/$/_ $+1_P#'_P#"F_\ "Q?$/_0M_P#H?^%>FT4<T>P778\Q
M_P"%C>(?^A<'Y/\ X4?\+&\0_P#0O+^3UZ=11SQ_E"Z['EY^(_B+MH$8'N'I
MA^)'B+'_ " HA^#UZG11SQ_E"Z['E9^)7B(#_D"P#ZJ_^--/Q*\18_Y ]M_W
MR_\ C7JN!Z"C:O\ ='Y4^>'\H778\H_X67XC_P"@3:_]\/\ XT?\+*\2?] J
MT_[X?_XJO5MB_P!T?E1Y:?W%_*CGA_*%UV/*#\2O$O\ T#+3_OA__BJ:?B5X
MDQ_R#K3_ +X?_P"*KUGRX_[B_E2>3$?^6:?]\BCGA_*%UV/)3\2O$N/^/"S'
M_;-O_BJ:?B5XF/2TLQ_VS;_XJO6_(A/_ "RC_P"^12?9H/\ GA'_ -\"GSP_
ME"Z['D1^)'B@](+,?]LC_P#%4G_"QO%1_P"65I_WY/\ C7KWV6W_ .>$7_?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWM._Y!MK_P!<E_D*P?%_W;3ZM_2M[3O^0;:_]<E_D* +-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3)8DGB>*10R.,,#W%/HH \>U:V?2-=N+!R=H.Z-O53T_PK
M;\%^'H9]0?4)HPR0_<!Z%O\ ZU7/B-I+S6UMJD"9D@81R8[J3P?S_G74:#8?
MV=H]O 1^\VAG_P!XUURK7I>9JY^Z:5%%%<AD%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!B>+?^1=G_ -^+_P!&+6W6
M)XM_Y%V?_?B_]&+6W3Z$+XW\OU"BBBD6%%%% !1110 4444 %%%% !1110 5
MB^+O^12U/_K@U;58OB[_ )%+4_\ K@U-;D5/@9L1_P"K7Z"G4V/_ %:_04ZD
M6%%%% !1110 4444 %%%% !1110 4444 %8&H?\ ([Z'_P!>MW_[2K?K U#_
M )'?0_\ KUN__:5.)$]OFOS-^J;Z58264UD]I$UM.S-+&1PY8Y)/U-7**5RR
MO'8VL5PL\<"+*L0A5P.0@YVCVJ%-&TV.PEL4LH!:S%FDBV#:Q/))%7J*=V%C
M/AT/2[>S:TBL85@=@[(%X9AR"?7H*2ZT#2;V\-W<V$$MP0%,C+DD#I6C11=B
MLBK)IME,MRLEM&PN<>?D?ZS P,TXV%HT\DS6\9DDC\EV*\LG]WZ<U8HHNQF7
M:^'-'LE<6VG6\6^,Q-M7JAZK]*EL=$TO3)GELK&"WD<8+1I@X]/85?HHYF*R
M,W4- TC5;B.XO]/M[B:,85Y$R0/3Z4MQH&DW5U'<SZ?;O-& JL4Z =!^%:-%
M%V%D59-.LYOM/F6\;?:E"SY'^L & #^=$FFV4LC2/;1L[0^0Q(Y,?]WZ5:HH
MNQF=:Z#I-D9C:Z?;PF92C[$QE3V]A[5-%IEC RM%:QH5A%NI48Q&/X1[5;HH
MNPL9LOA[2)H+6"33K=HK48@4IQ&/0>U/;1-,>UMK9K&$PVK!H$V\1D>GI5^B
MB[%9%&;1M.N+66VFLXGAED,KH5X9R<[OK[T0:/IUJMN(+.&,6Y9HMJ_<+<$C
MW/K5ZBB['8AM[6"T5U@B6,.[2-M'5B<D_4U-112 **** "BBB@ J"]_X\+G_
M *Y-_(U/4%[_ ,>%S_UR;^1H$]C+\'?\B;H__7I'_P"@BMNL3P=_R)NC_P#7
MI'_Z"*VZ<MR:?P(****184444 %%%% !1110 4444 %%%% !1110!S'B_P"[
M:?5OZ5O:=_R#;7_KDO\ (5@^+_NVGU;^E;VG?\@VU_ZY+_(4 6:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!KQI*A210RGJ",BG444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9FOV4VH:
M/+;6X!D9D(!..C G]!6G110*VMPHHHH&%%%% !1110 4444 %%%% !1110 5
MF^(+.;4- OK2W ,LT15 3@9HHH$U=6-%!A%!Z@4M%% PHHHH **** "BBB@
MHHHH **** "BBB@ K)N[">;Q-IE\@'D6\$Z2'/(+[,?^@FBBA,35S6HHHH&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %17*-+:31K]YD91]2*** */AVRFT[PYIUE< ":"W2-P#D @<UIT44,25E
M8****!A1110 4444 %%%% !1110 4444 %%%% &)XATVYU%;<6Z@["<Y./2M
M6SC:&R@B?[R1JI^H%%% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img40748725_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +Y ]P# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNFU'91N0D#C.2.?:JB:9K'Q&\8W7B*PUB72+#2)&L],D^RK+YK8(ED ?@9.
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MCH<=*:(8UD,@C0.>K!1D_C5?3-0AU;2[74;<2""ZB66,2+M;:PR,CM5N@ I
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M&.G:@*%&   >>!2T4 (%"C"@ >@IJQ1HNU8T50<X"@#/K3Z* "BBB@ HHHH
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M-S: K'+$X)!PQ)!&*Y2R\>^.]9\"W7BFSL])M+*S264M<HY:Z56)PB@_* H
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M?2Q9?Z#'YCP.'W?=]"!4WC677O%/PSNK:#0;NSNM0N8[=;9V#2I"7&7<#A>
M>,G&: ,W3-2O?!'PH\'VNGQQ-J.I7,$(692W,S%W. 1S@FNN\5^([W2=>\,:
M58+"9=5O3'+YBDXA1=SD8(P>G-87CZPOK'5/!NH6FEW6HZ;H]PS3P6B;Y%^0
M*C!>^#5?2K?Q%XB^+-GKVK:--IVEV>G2?8XYB"RL[;3OQP'(R<#H * -*]\2
M^(]=\4:AHOA%=/BATO:MY?7RLZF4C(C15(Z=S6!X,U34)-;\=^*M<@MX;O3X
MELWCA<M&#"A9]I]"<'\:/#<_B/PC?^)=(C\,7U]?7VJ2W=I>* +9D?&"\A/
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MPZI\0/%>C7MQH]WI>@Z/*;H"^4)-=3XPN$YPJ]<GK0!Z11110 4444 %%%%
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M&V[<_6G7'BF&+PM;ZU' 9#<;%CAW8)=CC;GVY_*N<>UDC\52>'1$QM)]034
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MYF.[(HX?+4+YDC8.<LV33$M-D@?SYS@YVE\BK%%',PNRM=0.T0,<[HZG@EL
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M,^M&!G.!GUI:* $*JV,@''J*,=<8R:6B@#)T'1VTF&Y:>83W-U.TTL@&,D]
M/85K444VVW=DPBH+E04444B@HHHH **** (YW5(69R HQDD9[U)4-W$)K9D+
M;02.<9[BIJ>EA]"&VD\Q'.W;B1U_(D9J:HX555;8% +L3M.><\U)1+<&%%%%
M(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 48SUHHH *,9HHH 3 SG SZTM%% !CG-%%% "8
M["E(!&",BBB@ P*,<YHHH ,<Y[T8YS110 A /4 TM%% &5HNCMI9O99I_/N;
MN<S22;<<=E^@K5HHIMMN[)C%15D%%%%(H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MO4OL?VA?M'V3?L&/.SG&3^E:E<_KNEM>WR2"XACQ&%Q(<'J?\:WPZ3GJ[%T[
M7U-FSD,MC;R$!2\:M@=!D5/4<&TV\6S;LV#;MZ8QV]JDK&6[)>X4444A!111
M0 4444 %%%% !112,RH,L<"@!:*K/>(#P,_6H_MQ_N#\Z +M%4OMQ_N#\Z/M
MQ_N#\Z +M%4OMQ_N#\Z/MQ_N#\Z +M%4OMQ_N#\Z/MQ_N#\Z +M%4OMQ_N#\
MZ!?'^X/SH NT572[1NO%3*ZL.#0 ZBBB@ HHHH **** "BBB@ HHHH KWSNE
MH[1DA@1@CZBK%17$JPP,[%@!C[O7K4M5]D?0@M8S$D@)',KMP?5B:GJ"UD,J
M2$@#$KKP/1B*GHE>[N#W"BBBI$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !115:^U"STRV:YOKF*WA7J\C8'_UZ ;MJRS17
MF.M?&"T@=HM'LC<D<":8[5_!>I_2N)O_ (D>)[YC_P 3 P*?X8$"@?CU_6MH
MT),XYXVE'1:GT)29'J*^7I=9U2=BTVHW;D\_-,Q_K4 O+I6W"XE!]0YJ_J[[
MF/\ :*_E_$^J:*^8+?7]8M'#0:I>1D=,3-C\LUT6G?$_Q+8L/-N8[M!U6= <
M_B,&D\/+HRXYA!_$K'OM%>>:'\6=*OW6'4H6L)3_ !YWQ_GU%=]!<PW,*RP2
MI)&XRKHV0?QK&47'<ZZ=6%17B[DM%%%2:!1110 4444 %%%% !1110 4444
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M2I%$DA+/(P51\IZDU<MF84TG-)]S8N/#.AW=AX@?31?VUQH[$,UQ(KQS $C
M( P>*/!_@[3=;TEKK4[B:&6YG:WL0C!0SA223QR,UIW6N)XFTOQ-H]]J,*R6
M\[7%A*TBQK(H8X3(P&]NO6HM0U[0] 30-.%J^HOID:SB>UO B+*QRW !W'\:
MRO*UCJY:=^9VM_P3"\,>%8]3GU8Z@+@KI<9,EO; >;*V2,#/3I6)JO\ 9GVA
M/[,AO($VXEANR&9'ST! &1^%=OK%O+_PF-UJ_AK7]/M7GC2<!KI4W%OO Y^7
M@C)!]:S?B#J-G?RZ8!+:7&JQP$7\]H/W;/Q@9'![U2DVS.=-1@UV_$XRMK0/
M%>J^&YQ)93EH<Y>W<Y1QWX['W%8M%:-)JS.>,G%WBSZ4\->)K+Q+I<=[:MC/
M#QM]Z-NX-;E?./P[UV72/$ZV^\_9[H[&7/&[^$_T_&OH>TG$\*L.XK@J1Y78
M]W#5O:PYGN3T5AZWXC72[RWTZTLY;_5+D%HK:-@N%'5G8\*OO52U\57<.K6N
MFZ]H[:;+>$K;2I.)HI&'\)8 8;V(K)SBG8[XX:K*/,EY[J]O3<Z>BN5N/$^L
M2:_J&F:5H,=X+'R_,EDO1%G>N1@%3[T_5/$NJ6$ND6<6B1SZCJ"N3 ;P*L90
M D;]O/'L*7M(E+"5;I::Z[K:U]==-.YT]%9VD76J74$C:IID=A(&PB)<B;<,
M=<@#%:-4G?4PE%Q=G_G^04444R0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K#UG2X[Z\25YWC(C"X$9;N?\ &MRN;\07-]#?QK:R3*AB
M!(0'&<FNC#*3J>Z[,TIWYM#H+=UDMHG4Y5D!!QC(QZ5)45K&(;2&($D)&J@D
M8)P*EK"5KNQ#W"BBBD(**** "BBB@ HHHH 9*N^)E]164PPU;%9UXC1DN%W
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M&!^J#\JB.EVY_@%7J* *0TRW'\ J9+2).B"IZ* $"JO04M%% !1110 4444
M%49/]"OA*/\ 47!"R#^Z_0-^/0_A5ZHKB!;FWDA?HXQGT]ZB<6UIN@):*KV,
MS3VB,_\ K!E''^T#@_J*L546I)- %%%%, HHHH **** "BBB@ HHHH ****
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MN@^A!:1O&D@<8)E=A]"Q(J>H;:3S$<[0N)'7CV)&:FHE>[N#W"BBBI$%%%%
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M8_G5A+S&-_YU3HX.0>AX-(LUU8.,@TZL?2[L^;);N<LC$5L4 %%%% !1110
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M_74M3$ HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ>I)Q4U06CNZ2%R21*X&?0,<5/1*]W<'N%%%%2(**** "BBB@ HHHH ****
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MO&PZ4G&::/JNTG$\*L*L5C:',)K;Y"5]B :UMLG]\?\ ?->>?1CZ0#%-VO\
MWQ_WS1M?^^/^^: 'T4S:_P#?'_?-&U_[X_[YH ?13-K_ -\?]\T9=64%@03Z
M4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_$$]_%?
MQK:O.$\H$^7G&<G_ .M725CZKJD-C=+%(;C)0-^[( ZG_"M\-?VFBN73^+:Y
MIVL8AM(8@20D:J"1@G ]*EJ"R+FPMC)G>8EW;NN<#.:GK*7Q,E[A1114B"BB
MB@ HHHH **** "BBB@ HHHH **** "BBF9_?;?\ 9S0 ^BBB@ HHHH ****
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MZ18I-3LK62R+G D5 RLJD]2">@H\;31:GX]\&:39N)+VVOFOIU3DPPJAR6]
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MT /HIG[S_9H_>?[- #@P;.#R*6H7SD9V[NV.M21[]G[S&[VH =1110 4444
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M!;('<?-5G3]$AM0"5&:UU4*,"N:4G)W9ZM*E&E'EB*.!1114F@4444 %%%%
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ME2,$4M%,#A%T#2CX_>Q-C%]F%AYGE\XW;L9_*I=-U0:=K^OQ_8KZX#3KC[-
M9 N >OI72#1XQXA.L>:_F&W\CR\#&,YS2V.DQV-Y?W*2LS7CAV!'"XST_.NA
MU4UKKH>7'!RC)."2]YOIM9V//3B7P;I(:)I0^J',1."_)^7\:U]?M+>U\*_)
MI#6(>\CWP ABX_ GZ5L-X0B_LFVL4O94-O<&X24*"=W/;IWJQ<>'YKZP^RWV
MJ37&)EE5S&JD8[<"K=6-T[]?,YXX*JH.+CJXI=.WW_H8_AOR/^$DOY=/ADL=
M/AA"RVTWRMYG7=M)XXK-LKKR=9L_$;3#%_>2021[ONQGY4X]MN:ZR^\/1W>H
M7%Y%=26\EQ;FWE" 88>OUJ&?P;I$NEBS2WCBD55 N$0>9D8YSZG'ZTE4A>[Z
MERPE=)1BE[K;736^EETTT^9S.M?V>WB?6TO87EG-N@M1&C,PDV\8QTYQUIUS
M;3R:GH4&HZ>^H3BQ.^ N <Y/4D]0*[&RT9;/5;G4#</)+<1HC!@/X1C/XU%J
M>AO?:G!J$%_+:3PQF,%$5N#UZT*LM%Y?H$L#-J4K:M[:;<U];Z-]KF)<0);^
M)O#$45K]D0),?(R#L)&2..*FFMH;WX@W-M<1B2%].7<C=#\^:U+K03>VUKY]
M_,;VV8O%>*JJX)]@,8QQ4NFZ*EA=S7LUS+=WDP"O-+@?*.@ ' %1SJU[ZV_4
MV6&FY<KC[K:?3;EM:W](YOP]H^G#4M=<6D8>UN2(#_<&#TK-TUY+C0O#FE&1
MTMKR>7SBK8+*K?=SZ'-=Q9:/'8S:A(DKL;V0R,"!\I.>GYU13PE:)HMMI_VB
M8/:N9(;A3AT8G.:OVJOJ^WY?YF7U*HHI126]_/WD[?-*QI6&D6.EM(;* 0B0
M#<JL=IQWQZU>JCI]C<6AD:YU&>\9L >8JJ% ] !5ZN>6^]SU*22BDH\OEI^@
M4UD5AR*=14FA5DL().J"JCZ';.?N"M6B@#&_X1ZVS]T4]-"ME/W!6M10!4CT
MZ"/H@JRL:KT IU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &+;?\C?>_P#7LG\ZVJQ;;_D;[W_KV3^=;5<V%^&7
M^*7YC84445TB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110!%<1+- R,&(./N]>M2U7OD=[1UC!+$C 'U%6*K[(^A'"RLK%"" [
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M;/!_.MW1FM;"Y6=!12 @C(/!I:R)"BBB@ HHHH **** "BBB@ HHHH ****
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M'<_X5T85R53W%=FE*_-H;5O&L5M%&H(5$"@$Y( %25!9(\=A;QR##K$H8>X
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M?!<@.8T;']TNH/Z$UTM4=9TY-7T:[T]SM$\13=Z'L?P.*NFU&:;'%V:9P4F
M0HZ#@?2D%4[&>5XVM[I=E[;-Y-PAZAAW^AZBKHKH::=F2U9V9(M2H*B6IDI
M<1=S);^(O$$LFE_;D$2YX7]WQUYY_*KDDQTOX?00?:D=[H"))-WRJ'//)[ 9
MK>@T:&+4[Z],C.;U0CQD#  &.*K6?A2"V-BKW4LT-F[O'$ZC:2WK]*ZO:P=K
M]+?@CHYXNWR_(H^%9K.QUZ_TFRN8IK22-9H3&X8!@,,*;X*ELQ9I%)I4TLYN
MI,7(M R+SQE^V*Z.;08)]4LM0B;[/+;;AB) !(#U!JWH6CQZ)IYM(IGE4R-)
MN< '+'IQ4RJQ:?=V!S33--4J0)3D2I0M<QF0&(^E0R0^U:(C.*R]>U&+1=*E
MNY!N?[L,8ZR2'H!32;=D%KZ&'X-F^S7%[;(?W4=[*J#VSG^9->C*<J#7G'@Z
MQDA6-7.Z0DO(WJQ.37HR#" 5C5:<VT*3NV.HHHK,D**** "BBB@ HHHH ***
M* "BBB@ KP'XJ63V/CJ:=P?*O8DD1L<9 VD?^._K7OU<EX_\)IXIT/RX\+>V
M^7MW/KW4^Q_PK2E+EE<YL52=2G9;GSY1394GL;F2TO(FBFC;:RN,$'WIW6NY
M.YX1Z);II9^%^C/JUS<P01ZB[C[/$'9B,\=1CZU=TO7U\2:OXMU%(3#$=),<
M:-][:N>3[UYW)JU]+I$.E//FRAD,J1;1PQZG.,]Z-/U:^TM+I;*?RA=1&&;Y
M0=R'MST_"L^3<Z572:[?\"QTOP_ET2#Q!IHNK?4/[5=R('!!A!(^4E>&/YXK
MIM%CAL$\:IKS"YACNXC=-%P&!;/3TYY%<'9^,=?L+2.UMM0*1QKLC)C1G1?1
M6(R!^-4HM:U&&SOK1+IO)OR#<A@&,A!SDD\T.#;"%:,4EZ_D=!\2(+Y/%!N+
MF59K2>-6LG08018X4?3_ .O7(5?N-:U"[TJVTRXN3)9VQS"C*,I]#C./;-9S
M.J#+'%7%65F8U)*4G)=16(523T%5[>%[R]CA0$M*X4?C3))3(<#@=A7;^#?#
M<HF6]N(R)&'[I".0#W-14FDKE4*3JS44>M^% RP@=@ *ZJLG1++[-:KD<XK6
MKA/H0HHHH **** "BBB@ HHHH **** "BBB@ K,U&UM)KA6N(H&<( #)+M.,
MGM6G7.Z_I<]]?)+$T041!?G?!SD_XUOATG/5V+I[[V-RTD\VR@DVA=\:MM';
M(Z5-4< 5;>)4"A @"A3D8QV-25C+=DO<****0@HHHH **** "BBB@ K.NI2\
MA'85HUDRC$ASZT ,J&:[M[>:&&:4)).VV,$'YCZ5-65XCMEN-$N'SMDMQY\3
MCJK+R*J*3=F9UI2A!RCNBZE];227$:3*6MO]<.?DXSR:;;:C9WEHUW;W"20+
MG<XS@8ZUS<N^U\'00P9EO=489(P&=GY;].*9;226-YJEE-9M9QW5J988F=6Y
M5<-@CBM?9*S.'Z[)2BFMUKOHW=I7V[7]=#HK/6],U";RK6\CDDQD+@@D>V1S
M4UOJ-G=SRP6URDLD6-X0YQ^/2L#P_I=Q<6^D7]U<1-%;0?N(XTP>1CYB>OX4
M[2[^P?Q??K!<P%98HTB"$88C.0/I2E3CKR]"J>*J6@ZEES/\+7[OKH:UYK-K
M87J6TY89C,KN!D1J#CGOR:+37=,O[@6]K=K+*<X4*PZ?455T+-Y?ZAJQ^[+)
MY,/_ %S3C]3FJ6EWJZ?I&N7;$?NKR8CW;L/SHY%9KJ-8BI=2;7*[O;HOGUW-
MZVU"TN[B:"WN$DE@.)%&<J:K1^(-)EN5MTO5,S-L5=C#+>G2N:T_[5I&H:5<
M75B]NDJFWGF:12)&<[@<#ISZU>M-4L-4\0M=7%["B6S&&S@=\%F[OCWZ"J=)
M*_5&<,;.2BG92OLT]M^K73UNSJ:/J,CN***YSTQ=/NRES);.<E3P?45L5R33
MX\1;5[*H/UQ75IR@H =1110 4444 %%%% !1110!7O9'BM'=#A@1@_B*L5%<
M2+%"SL<*,<XSWJ6J^R/H06L;1I('&"978?0L2*GJ"UD\Q)#M"XD=>/8D9J>B
M5[NX/<****D04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNB@"I_9T']P?E1_9T']P?E5NB@"J-/@!^X/RJ9(4C^ZH%244 %%%% !1110
M4444 %%%% !1110!%<RB&W:1MV!C[O7K4M17$2S0,C!B#CA>O6I:>EA]""UD
M:5)"V.)748'8,14]1PNKJQ4@@.P.!CD'FI*);@]PHHHI""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ-;2?>7W'JOO64Z5E=:H3CU1O44 YHK(D**** "BBB@ HHHH **** "BBB@
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M&%%%% !1110 4444 %%%% !1110 4444 %<WX@-^+^/[*;CR_*&?+SC.3_\
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M4I/XI'G(A=ND$I_X":B\J3[<L?D29,6[;M.>O6O0]1>ZCL)9+,*TZ#<JL/O
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MD>@^%HBL&<8':NHJCIMH+6W5<<XJ]7$>\%%%% !1110 4444 %%%% !1110
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M .$RTP#$,5[.WI';MC\S6M;>&T:\OAG[LJC_ ,<6KJ^&8QUJ8UX-74?Q_P"
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MGN?J:[O3M*BLT&%&:T$B2,84 4^L6[[G:DHJR#I1110,**** "BBB@ HHHH
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M><V^KR0Y^5\,!]:Z$'(!H 6BBB@ HHHH K7%C#/\V-K_ -Y:HO;26YPXRO\
M>'2M>@C(P::DT1*FF4;>5D &<KZ5=5@PR*@:V .Z/CVI\76AA&ZT8V\C\VU=
M-P7)')^HJ>J][(\5H[QG# C!_$58IN_*C3H1PHJ*P48!=B><\DU)4%K&T22!
MAR978<]BQ(J>E+<'N%%%%(04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>\N&M
M427:#$&Q*>ZJ>_X'K[58I&574JP!5A@@]Q4R3:T S!<?9IM1=5WNTR+&O]YC
M&N!6FN[8-^-V.<=,UDZ=I<UM?323R!XE;_1QW V@9/O@8K7K*AS6;DK;Z?,;
M"BBBMQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[%/N"N6\.::R?O9!R>>:ZL<"@ HHHH **** "BBB@ HP,YHHH BN)%B@9V)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YS7].O;
MR_22WC+((@I(;'.3_C71U@:YJ8LKU(S;1RYC#;F)]3Q^E=&%<U4]S<TI7YM#
M;MT6.VBC4854  SG  ]:DJG;2QVFGVR3RQQLL:H=S#J  15A)XI%#)*C*<X(
M8$'%8RB[MD-$E%0I=VTKA([B)V/97!-#W5O%CS)XTW#(W,!D4N5[6"S)J*C\
M^(IO\U-F-V[<,8]::EW;RDB.>)R!D[7!P*.5]@LR:BH9+NVB;;)<1(W7#. :
M<T\2(7:1 H ));CGI1ROL%F245%'=02@F.:-P.NU@<4C7ELDA1KB(.#@J7&:
M.5]@LR:BBBD(**** &O&LBX89K)NM(R2\#%&/IWK8HI-*2LP//=3\'V5XQ-W
MH]C.?[_DA6_-<5BOX!\/!@3X=3/?%Q*!^6ZO6RBGJ*C,$9ZJ*E4TM(MKT;7Y
M,+)[H\NM?"6F6K[K7P_9*W9I(S(1]-Q-;<>C7URJI(VV(=$4!5'T XKMA;QC
M^$4\(HZ"CV<;W>K\]?S#;8P=/\/1089ADUNQQ+$N%&*?15@%%%% !1110 44
MR6:*!0TLB(#P"QQ21SPRJ&CE1P3@%6!YIV=KA8DHJ%;RV=PBW$3.3@*'&:62
MZMX@#)/&@/3<P&:.5]AV9+14:S1.@=9$*D$@AN..M-CN[:5ML=Q$[=<*X-'*
M^P69-14+W=O$0))XD)&0&<#(IQGB";S(FW&[=NXQZT<K[!9A.R+"Q<J%XSN&
M1UJ2J<\L%Y;O%%<1L>"2K9QR/2KE-JRU!D-M()4<A<8D9>N>AQ4U0P^5&&52
MH)=B1NSR34I=5ZL!]31+?0&+12!E(R"#]#2"1"<!U)],U-A#J*:74=6 ^II=
MRXSD8^M "T4T.AZ,I^AH+H#@LH^IHL ZBDW*!G(Q]:0.IZ,#]#0 ZBFF1 <%
MU!],TI90,D@?4T6 6BD#*W1@?H:3S$SC>N?3-%@'44A=5ZL!]30&4C((/T-
M"T4T.A. ZD^QH+H.K ?4T6 =12;EQG(Q]:0.AZ,I^AH =132Z X+*#[FE+*!
MDD8^M "T4T.IZ,#]#09$!P74'TS18!U%(64#)8#ZF@,IZ,#]#0 M%-\Q,XWK
MGTS2EU7JP'U-%@%HI RD9!!'UI Z$X#J3[&@!U%-+H.K ?4TNY<9R,=<YH 6
MBFAT/1E/T-!= <%E!]S18!U%(64#)(Q]: RM]U@?H: %HHHH **** "BBB@
MHHHH **** "BBB@ HIKND:%W8*HZDG %1I=6\N?+GC?;R=K XIV;U"Q-14+W
MEM&Y1[B)6'52X!ISSQ1J6DE10#@EF Q1ROL.S)**BCN()1F.:-QG&58'FD^V
M6WF>7]HBWYQMWC.:.5]@LR:BHI+B"(9DFC09QEF YI4GBD4-'*C*3@%6!S19
M[BL245"EY;2.$2XB9CT4.":'NK>+'F3QINY&Y@,T<KVL.S)J*C$T13>)$*X)
MSNXQZTU+NVE8K'/$Q R0K@\4<K[!9DU%0O=VT3;9+B)6(SAG IYFB5"YD0*
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MP0PY\J)$SUVJ!FI**+O85PHHHI %%%% !1110 4444 %%%% !1110 48HHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJ6N^+_"%U)I\UO96:S7ER'93Y4I3:B-@]1D]/2LW23XA\*Z]XAA'AB[U/\
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M2+Y\$PYR-Q+<J1DXZU8U/3]$OOBWHEE<65BL%AH[S&.>-.=S"-%.>N &P.U
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M2KIK>_@O#>W+7$CVL:QP*WW2L:*2%4;<=>N: .IHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH @M)/-MP^T+\S# ]B14]0FW'EE$=XP3GY
M#C'THC@,8(,\KYQRQ!Q^E4[.[&[%?5=&TS7+3[)JMA;WEON#".>,. 1WY[TV
MTT'2;'S/LFFVL DA$#B*(+F,9PO';D_G5AK4M(7^TSCG.T,,?RI\D)D7'G2)
MSG*D#\*++N!3;0=)?1DT=M/MSIJ *MJ8QY8 .0,?7FDU;P]HVO)$FK:9:7JP
MG=&)X@^T^V:NQPF-0#+(_.<L>?I3%M2L@?[3.><[2PQ_*BR[@-L],L=.,QLK
M2&W,S!I/*0+N(  )Q[ #\*6XTZSN[JUNKBVBEGM&+02.N3$2,$J>V1Q3Y+<R
M  3RIC/*D#/Z4Y(BJ!?-D; /)/)S2LNX$-UIUE>W%K/=6L4TMJ_F0.ZY,;8Q
ME?0XK*U_03/H6O)HL%M!JNIV[1M.PV[VV[ 6(!/ K8CMC&^[[1._LS C^5$E
ML9"#]HF3 Q\K 9_2G97W"R,+1/!&@:1'I\ZZ/8?VC:V\<7VI8%WDJH&<XSGC
MKUJE)X*AU;QEK.J:]9V-[87%O!;VD,J[RH3+,2".#N;MZ5UZ+L0+N+8'4]33
MJD15L]-L=/L%L;.T@@M$7:L$<85 /3 XJCIGA3P_HMW)=:9HUC:7$GWI88%5
MC^(%;%% #71)(V1U#(P(96&00>QK'LO"'AS3MOV+0["WVS"=3' JD2#HW3J*
MVJ* ,C5O"V@:]/'/JVCV5[+&,(\\*L0/3)[5)J7AS1=8LH;/4=*L[JV@(,44
ML*E8\#'RCMQ6G10!4CTNPBOQ?1V<*72P"W$RH PB!R$!],]J1-)TZ/5I-52R
M@&H21B)[D(/,9!T4GKBKE1S3QVZ;Y6VKD#H3R?I0E?1 9^I^'-$UFY@N=3TJ
MSO)K?_523PJY3G/&1ZU8ATK3[>UGM8;*!+>X9GEB$8VN6^\2.^:L>?&(]^6V
M[=WW3T^E,CNX9=VPO\HR<QL/YBGROL.S*5CX;T33--FTVRTJS@LIB3+ D(".
M2,'([\ 4S2/"N@:!*\NDZ/964D@PSP0A6(],^E:$EY#$^QR^?:-C_(4]YXXT
M+,6P,9PI/6CE?8+,RI?"/AV:_N+^71+![NY4I-,8%+.",')QW%:T44<$*0Q(
MJ1QJ%1%& H'  ID=S%*I*%L @<H1_,4UKR%9/+)?=G'^K;'YXI\LMK!9C;33
MK*PDN9+2UBA>ZE,T[(N#(YX+'U/ K.U'P?X;U;4!?ZAH=A=78P/.E@5F..F3
MCFM:2XCB7<Y;&<<(3S^ I8YXY5#(6P3CE2/YBERNU[!9F7JOA3P_KC0MJFC6
M5XT"[(C-"K;%]![>U6VT?36ELI#8V^^QS]E(C \G(P=OIQQQ4J7D+R"-2^XG
M',; ?GBI1*A95&<MG'RGM0XM;H+,R/\ A$/#G]L'5_[#L/[1+[_M/D+OW?WL
MXZ^]3ZAX=T;5;VVO=0TNTNKJV(,,LL09HR#D8)]QFM.BD(R[WPUHFI:E#J-]
MI-G<WD/$<\L*LR^G)IYT#2#8PV1TZV^RPS">.'RQM60,6W >N23GUK1HH JR
MZ=93:A!?RVL3WENK)#,RY9 WW@#VSBJ%WX1\.W^J#4[O1+">^!!\^2!6;(Z'
M.*V:* ,C5_"^@Z_)')J^D6=[)$,(\\(8J/3)[5I6UK!96T=M:PQPP1KM2.-0
MJJ/0 =*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI9V(5DO)&&V<;=S%0.<+TYJK=>*K+_A!KGQ/92;[5;)[J)G4KN 4D9!YY(H
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M9[E(7\EE A0YS(Q/88[5I9 ZF@ HHHS0 45GZUJ%SI>DSWEIIT^HSQXV6L!
M>0D@<$\<9S^%7D8M&K,NQB 2I/2@!U%%&<=: "BBC(H **,CUHZ4 %%%&01D
M4 %%&1ZT9!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG"A(SE4)/W=[\"O2=8\#^'=>OH+W4-.$EQ#'Y2NDCQ[H_P"XVTC<OL<BG?\
M"%^'QH5SHJ:>L>G7,WGRP([*&?<&['@94<#CC% 'F.H^#(- \->#2);F;Q+-
M?VD,=VTK;HA]YT49P$"@C&.>IZUTJZ=:^/O'/B"#7-T^DZ*T5M;V)D*QM(R[
MGE< C)Z 9Z5W-[HMAJ%YI]W=0;YM/D,ML=Q 1BNW. <'@]ZR-5\ >&M:U1]2
MO=/8W4H"RO%/)$)0.!O", W''.: .+UZQNG\1V'@C0[%;O1K*Q-Y/97&H/")
MP[D*I?#,R+_=Z=/2DN]&O/ _PX\6W+26]N;]!';:?9R.\-JSCR\*6Y+$MD\
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M=+B"ZU"6[=3S';PNS*#Z;W*J/8&NL\/W?_"::[X==)-VG:!I\5S<N#P]Y)&
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M.% Y/ K:N/AWX8N=2GOGT]UDN)/-FCCN94BE;N6C5@I)[Y'- ')ZWH5W)=^
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M4QZG*\UXLA+B5F&&SGMCC'2J&B>!/#OAV]%WIMD\<RJ5C+W$D@C!ZA%9B%_
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MH]MI=J(4D;?(Q9G>1O5F8EF/U- &G1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4%S'Y@B&X+ME5N>^#TJ>J]W(\:P
M[#C=*JGZ$\U4;WT&MRQ115/5-4M-&TZ;4+Z1H[:$ NRQLY&3C[J@D]>PJ1%R
MBN+_ .%K^#O^@A=?^"VY_P#C==59:A;:AIL6H6[L;:6/S$=T9#M]2& (_$4
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M;1^+I?"\FG:/<7TMJMW%<0M(L-JA8J?-SRQXXQC/MVGTWX@W=IX6U[4/$%M
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ML[70$@X?=PH]=N.F.?2#4Y];U#XS7*:%;6TDVG:2L)N+MF\FW:1MY)5>68@
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M4DBE* 2MM D <!G^4D'H!6DNNV47C?Q/J5[96BP:!I\4;WXC/G'<#(R9SC'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %132+&$W$C<X48&>34M0W$7FHG7*
M.' '?%.-KZC1-15>2:X60A+4NO\ >W@4^1Y50E(2Y&,#<!FGRL+$M<_XYU/^
MQO NMWX.'BM)-G^\1M7]2*VHI)G4EX"AR.-X-074?VU&M;K38[BV8C<LI5E.
M#D$J?IFCE86/.M.\%^*[WPGIOA74[S2HM CBB$TELKBXGC&&\H@_*N>A8$YQ
MTYK<U+PWKVG^+Y?$'AHZ9(;FS2TFM;\N@0(259&0'UP0178222HH\N#?SC 8
M#CUI8WE907A*'/(W XI6=KA8XZW\$7B^'/$45QJ22:YKRO\ :+P1D(A*;415
MZ[%''K5>7P?KFK_#;_A'-4ETVTN[<0K:/:;Y(L1;2N\, 3DKR /SKMDFN&D"
MM:E5[MO!Q2R2SJ%V6Q?/7YP,4^5WL%C"\/P^*4NLZO;Z%:6P0Y33C(S2/V.6
M"A0.>.:H:3X6U73_  AX@LVGMCJ^JSW<XE5FV!I<A<G&>!CM77J\A0$Q8;!.
MW<.OI3(I9W?$EL8U_O;P:7*PL</JG@C5%\'>%]-TB6R^U:'-!.8[DL(9VC7!
MR0"1\Q)Z5J7?A_5-5\3>&=4OWM!'I<<TD\<3-@SN@4%,CE1\W)YKJZ*0CSP>
M$_%VGZCX@AT?4M-AT_6+A[K[5*KFY@=E *JOW3TX)/'H:6V\ WT'A?PAHAGM
MFBTJ\CN[XY;]Z5W-A>.?G/?%>A44 <]XWT.]\2>$+[1K">*"6["QM)(3A4W#
M=T'7;GBL-/"WB76KW2X?$MQI2Z5I<RSQPV"OFZD080N&X0#KM&>>]=[10!P)
M\,>)-'\3:O?:+'HEY:ZI.MR?[0WK)!)M"D JIW+QGM6KK'A[4]7U/PM-<7%L
MT6F7!NKS *^9((RJ[%YXRQ/)].M=310!S!\-7,_Q NM>N9(C:'3!8VZ*QWJ2
MY9R1C SP.O:L3PUX<\6>%[2VTF'_ (1]M.M6(6_<2?:#%N)Y3 &[!QG=CO7H
M5(RJZ%'4,K#!!&010!P5A=0>(OB_->V<R7-EH^EB#SHF#IYTK[B PXSM49K4
MTCPU>VFL>*M1N;B+SM7E46[QDL8XDCV)G('.<G KH;'3K+3+?[/86=O:09+>
M7;Q+&N3U. ,59H Y/X?Z)KGASP_'HVKG3FAM!LMI+1G+2#))9]P&"<]!GO69
M=7=OXA^+>CPV4\=U;Z-9SW,[Q,'1)9"(U4D<!L!CCK7?U5LM-L--21;"RMK5
M9&WN((E0,WJ<#DT 8VFZ!=V_CK6]?NI(6BNH(+:U522R(@);=D<98]LUE3>'
MO$^C^*=7U7P[)I4T.KF-YDU R*T+HNW*E =PQS@X^M=Q10!Y]=?#V[/A :/'
M?1W%W>ZG'?:K=3 IY^'#OM SC[J@#T'6MW5/#]WJ/CC0M6,D/V#3(ISY9)WF
M5P%! QC  /?O7244 <WI'A^ZM/&GB#7;N2%UOE@AM50DM''&IR#D<98YXI=5
MT"[U+QOH6K&2'[!ID<[&,D[S*ZA00,8P!GO71T4 <WI7A^[M/&FOZ]=20NMZ
MD$-JJDEDCC4Y!R.,L<\9KG5^'FH2> SI<EY;)K U-M4$V"\32^:74-D D8P#
M]*]&HH XN#P[X@UO7=.U/Q3-IT<.F.9;:RT\NZO,1@2.S@'@$X '?K5C0_#F
MHZ78^)9)9;=M1U6\GN(W5CM4%0L8)QG@ 9P*ZRB@#SL^ -2M/"GA2WTZYLQJ
MWA]A*HGW&"=RI#@D#<,DD@X_"M;2?#FKW7B:+Q'XEGLS=6T#06=G9;C% &/S
MON8 LQ  Z  5UU% '%>%?#_B/P_<ZU;S2Z9-97=S/>03H7$S22$8#C&T 8QD
M$]*JKX'U.'X0MX3@N;==1GB*3S[FV;GDW2$'&3P2.E=_10!Q&N^$]43Q!IFM
M: NFS/:61L'M-0#",QY!#*R@D,,>E3:YH7B+7_ -]H]S+IL.H7F(R+?>L,41
M9=R@D9)VAN<#KVKL:* .9\8^%Y/$7@Z31K*X2VF0Q/ SKE-T;!@& ['&*QAX
M6\5:SXKT'6O$%[IJ0::\DAL;+>4#%"JMN898Y/?& .,YKOZ* /)?#2^+M0U+
MQ-KGAV;2#;:EJ<D(:^5P\8B_=JZ[00PP/NG'3KS6X_P]EAT/P]H]O=)-#::F
MFH:C-,2'N7!+D@ 'DN1P>PKN+:TMK*$0VEO%!$"2$B0*N2<DX'J:FH X74?#
M.OV?C&_UW0X]'NX]1BB6:'4BZF)XP0&1E5N"#R..E;%^GBQ=*M%LUT2ZNR&%
MY'<>9'$P/380&/'3D<^U=%10!R_@CPO-X:L;\W+6PN+^[:ZD@LU*P0$@#9&#
MVXZ\9)Z52UKP[XBC\;KXC\/3Z<S360LIX;_> BA]P=-HY/L<?6NUHH \WM_
M6NV_A'Q;8R:I;W6KZ[,[?:G!1=C*J\@ XXW8 SCCFMO7O"<^IV7AG3[=X%LM
M,O8)[A7)&](E(55 'K@\XZ5UM% '"W'AKQ18>+M7U+0;S3%M=86+SGO%=I;9
MD4KE%'#<'."1S6IX"\-7/A3PPNGWMRMS=O<33S3*2=[.Y.3D#G&,UTU% '%:
MUX>\0P>-?^$F\.OIDLDUD+.>WU N@ #;@RL@)SVQBC6_#?B&_DT#68+G36U[
M2FE+1R*ZVTHD&U@",LN!C!YKM:* ./TSPYK3ZS=>(]:N;-]7-HUK96]MN\BU
M4\GYF&6+$#)P.!C%9[^!M27X1Q>$8;BV6]=%6YFW,$.9-\A!QDYY XKT"B@#
MF=<\-W&IZ_X9GB:%-.TF=YY8F)W,WEE8]HQC@G/-84?AWQMI>OZ]J.DW.B.-
M7N=^+H2;H$50J,"!\QQ_"<#/?FO0Z* . ?X>2PZ#H&CV]TDT5KJB:AJ4TQ(:
MY8$NQ  /)<C@]A6Y8:!=P^/-8\07,D+0W%K!:VJJ261%RS;N.,L>V:Z.B@#S
MF7X>:A=>"=<TR6\MX]3U'4Y-1$R[FCSY@9%;(!QA0#_6IO\ A%_%>L^*M UG
MQ!>Z:D&FR22&QLMY3<4(5MS#+')]L =\UZ!10!QUKH&OZ?\ $74M9@DTZ;2]
M26%9C*7$\(C4C:@ VD$G.21UJH/ 5Q>^'_%UAJ%U&EQKUW),LL66$:841@Y
MZ!1D>_6N\HH X!O"_BCQ!%I^G>);C2H=)LI(Y9(M/WLUX8^5#;@ BY ) S]:
MV](T"ZM/&6OZY=/"RWRP0VJH3N2.-3D-QP2S$\9KI** .;\$>'KGPYHD]O?2
M127ES>3W<SQ$E27<D<D \+M'X52U#0-?3XBP^(M-DTZ2TDLULIH[HN'B02;F
M9-HP2?0XZ5V-% '-:+X?N['Q;XBURZDA<Z@84ME1B2D4:8PV1P2Q)XS7/?\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img40748725_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Q CT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\011Z!_:LT#1J<A(RV2QS@5E.M"#M)VTO\ ) ;%%<UI/B>>[O8;:^L&MOM
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MD0/*)DCZG_ZU=;!_J5^E<\]S6.Q)1114C"BBB@ HHHH **** "BBB@ HHHH
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M ^@J7470:BQVCQ2ZCJ3WDH^\<CV%=LHVJ!52PL4LX@JCFKE8F@4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\'[T:Y_45TR'*@UQJ2B]\1LT?*1X0$=\?_7S79(,(!7/+<U6PZBBBI&%%%%
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M*_X4?9];_P"?EO\ OE?\*/:(.1FK165]GUO_ )^6_P"^5_PH^SZW_P _+?\
M?*_X4>T0<C-4 GI6/JFL+&K6MFWF3MP77D)_]>A]*U2Z^6>YD9?3.!^E:.G>
M'8K<AG&34RJ7V&H]R+P[I9@02N/F-=+3418U 48%.K,L**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R56>%T1RC,I
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MRLV/4YK4L="@M<':":V**0"*H48 I:** "BBB@ HHHH **** "BBB@ HHHH
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M4C8.<!CP3W'I6BH2>YS2QM-;:G>R7EM%C?<1+DD#+CG'6J<FOZ9& 3<@C!/
M/'UKB/*SG))['W%*(@#D@'GO6BPZZLPEF#Z(ZU_%5@O193QS\N,'L*@;Q?;C
M[MM(>.[#K_A[US(15].,TN%'?H,?A5>PB9/'5#H6\7KSMM#T[MW]>G2H7\5[
MKF.3[+C:A !;N<<GCI6(=O.?3!J*1E^UQJ>Z-G]*SK4XQBGYK\T$,75D]SIO
M^$O7G-F1TQE^GUX_*I!XNMSG-M(/3D?CGTKFSCG/XTAV\Y]<FM/81%]>JG6+
MXJT]LY$H]/EZCU]JMQZ[ILIP+E1DX&X$9]_I[UQ!5<\X^]D\4WRD]N^??VI.
M@BUCY]4>B1W=O,/W<\;_ #;>&'7TJ:O-A$000[ ^H/(],>E3P7M_;8\FX90O
M(7/R@]^.]0Z#Z,VCCXO='H5%<;!XFOH<"5%E4#OP2/4D>GTK4MO%-K)@3H\3
M8Y(Y!/H.]9NE)'1#$TI=3>HJ"WO;:Z_U$R.< D \@'VJ>LS=.^P4444#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIW]:C=P@ZX[CWKHC!1//J5I38W:!QVSD"HV< >@/IU%6;>QNKU\0Q$)D_,W
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M9HYTW1L"._M6$HM'H0J*:)****DL**** "BBB@ HHHH **** "BBB@ HHHH
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MS4T5L9FW-D)_.KX 48  'H*;EV)C3OJQ(XTB7:BA1Z"G445!L%%%% !1110
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M444 %%%% !1110 4444 %!Z44'I0! ],2'S#EONC]:EV;VYZ5*!@8%.Y-@
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MT8<$>]:/L]B$NJW)M;NG6%+*!]EQ=97?_P \XQ]]_P !^I%989+VTDTF,".
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M3[X+=?RK3O\ 0M.BTZYD2WVND3,"';@@?6F:G_R,FF_0_P!:U-3_ .05=_\
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MVN)9$#<D@ UH6=DM].;=B!:1L!</G'F-U\L>WK^51I;R[+9(CLFNY?*C?^X
M"6;Z@ X]_I6W?6^GZ?HRV[VRRQ+A(H3R7<]/Q)[_ %J).[LBHJRNS5 "@
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MO4_^1DTWZ'^M:FI_\@J[_P"N+_R-94=\3Z_^VH.Q4\-_\@*W^K?^A&JFN?\
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M#B_WG_\ 0C7;&5.6+ING\/([6]4+H0:]_P A?2/^NO\ [,M;]8&O?\A?2/\
MKK_[,M;]:8;_ 'BOZK_TE SG_#G_ !^ZM_U\'_T)J7Q+_K=-_P"NX_I2>'/^
M/W5O^O@_^A-2^)?];IO_ %W']*X/^96_7_V\?4WZP-$_Y#NK_P"^/_0FK?K
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M]*1M'A8#<C\&0\\[1D"L7%(T4F=91114%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5') DHPR@U)10!CW.@P2G(&#5&3P]+GY9
MG ^M=-5'4M33341GAEDWDX"#I6=6=.G%SJ;(#B['PZ9O$VHI)*[!1D98G^[6
MS?>'[>WTB[8J"?+_ *BJUKJ5S'K-W=P:=/*)QA5P1CIZ ^E7ICKVJPM";:*U
MA<8;<><?Y]J\6CC(RP\Z<4W)N5K)]6[:[%6+>DM:6&@VLDSI$H3J?J:R;J6Y
MUW5HI=,5XUA7;Y[< =?\?K5^S\+01A&O)GN&7HN<*/;UK>CC2) D:*B#HJC
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M\-_\@*W^K?\ H1IFJV4]SJFF31)N2&0ESGH,J?Z&JD6LWAC6*PT618QPNX$
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MX(KF%H9D#QL.0:DHKTFDU9[".;:TU#0)#)9;KFR)RT)Y*_3_ !%:FGZU9Z@
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MKKR;B.'RG;?_ !#M5BDU8$TRO<27*21B"(.I^\3VJW$GF2JF>IQ4;,$4LQP
M,DTVWG29!+$Q*YQZ4^@=3:CL!?WUQ;1R-!:6I$;-'Q)*Y )^;L!D=*M2>%]+
M>(J(6$G59F<NP/\ P+/Y57T^Y\G5U<G]UJ"<^TR#G\UP?PJ^]YJ@=@NE*R@\
M'[2HR/RK#WKFVEB*"]DTUEMM11$0G$=S&N(V]B/X3^E:X.1D=*R9+K49(VCF
MT4.C#!7[0I!'OD4W2;>^M_.4Q>1;9'DQ22;RG7(!';I@4.-U<2E9V-BBBBLS
M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ()+*UF<O+;0NQZLR FF-96D<;%+. D
M#( C'-6J*=V*R.,M)(7L-B0W4M[-(9+B.&V( ;LN3@  <5<@TC49<?NK>T3U
MD/FO^0PO\ZZ>BJYV+E1@#2+07:6EQ=WLT[QF16\THH (' 7 '6L^Z\U))[6>
M0RO:N%25OO.C#*Y/<CD9K<F'_%2VK?\ 3M(/_'EK*UE-FM2GM+;*WXJQ!_\
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M<+B,H>%WYW+[<@G'O2G9ZHJ.FC-VBBBLRPHHHH **** "BBB@ HHHH ****
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MHQN@TO\ JQ]FD^?OQQS0X3D]@^L48I-R6OF2WT$MA<G4K1"P/_'S"O\ &O\
M>'^T/UIMS/%/J6C7$+AXY#(%8=\IG^E6[75;2\NC;1,_G")92CH5(4].O\JI
M:9;Z;=W4E[922E89G3RSD(LG1B 1_P#6H5TO>6P^>,FN5K7]-S:IJ1HA8HBJ
M6.20,9IU%9&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:<;YGT5%6(!>">YST'O5?5UW_JR,WF$[:1_/NUMOTVW.VFU73K>3RY[^UB?
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M]R8P,!W'[OD'Z=*ZBL:D.25CMH5?:PYUW?X-H****@V"BBB@ HHHH YO7?\
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MC%6BK(****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img40748725_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,_!;8# 2(  A$! Q$!_\0
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M*+("Q]ON_P#GYE_[[-'VZ[_Y^9?^^S5>BBR L?;KO_GYE_[[-'V^[_Y^9O\
MOLU7HHLA%C[?=_\ /S-_WV:/MUW_ ,_,O_?9JO119 6/MUW_ ,_,O_?9H^WW
M?_/S-_WV:KT4[("Q]ON_^?F;_OLTGV^[_P"?F7_OLU7ZT460KEC[?=_\_,W_
M 'V:/MUW_P _,W_?9JO119 3_;+K_GYF_P"_AI/MMU_S\S?]_#4)HZ4607)_
MMMT/^7F;_OX:!>77_/S-_P!_#4'6BBR G^VW7_/S-_W\-'VVZ_Y^9O\ OX:A
MI.M%D*Y/]LNO^?F;_OX:/MMU_P _,W_?PU#24607)_MEU_S\S?\ ?PT&]NO^
M?F;_ +^&H": *+(+DXO+K_GYF_[^&@WMU_S\S?\ ?PU 32@8IV0KD_VRZ _X
M^9O^_AI/MEU_S\S?]_#4'6EZ4K(+D_VRZ'_+S-_W\-)]MNO^?F;_ +^&H*7I
M19!<G^V77_/S-_W\-)]MNO\ GYF_[^&H*7I3LA7)_MET!_Q\S?\ ?PTGVVZ_
MY^9O^_AJ#K2@4607)Q>77_/S-_W\-!O;K_GYF_[[-0$T 4607)Q>77_/S-_W
M\-!O;K_GYF_[[-0TWJ:+(5R?[9='_EYF_P"_AIWVRZ'_ "\S?]]FH>@IO+'V
MHM<+D_VVZ)XN9O\ OLTX7ET/^7F;_OX:@ Q2$T6079.;VZ_Y^9O^^S2"\NC_
M ,O,W_?PU"!2T:!>Q-]LNO\ GYF_[[-(;RY(P;B4_P# S4-*!320KDHN;C_G
MO+_WV:/M,X_Y;R?]]FHNE)FD&I*;JX_Y[R?]]FE%Q<=YY?\ OLU&JX^M.Q3L
MA7)/M$__ #VD_P"^C2_:)_\ GM)_WT:CI:5@N2?:)_\ GM)_WT:7[1/_ ,]I
M/^^C45.Q185V2?:)_P#GM)_WT:7SYO\ GM)_WT:CHHL%R3[1-_SVD_[Z-+Y\
MW_/:3_OHU'2XHL*[)//F_P">TG_?1I?/F_YZR?\ ?1J/%+BBR"Y)Y\W_ #UD
M_P"^C2^?-_SUD_[Z-1TM*P7)//F_YZO_ -]&CSYO^>K_ /?1IF*6BPKL?YTW
M_/5_^^C2^=+_ ,]7_P"^C3**+!=DGG2_\]7_ .^C1YTO_/5_^^C3,4N* NQ_
MG2_\]7_[Z-+YTO\ SU?_ +Z-,Q2XI6%=C_.E_P">C_\ ?1I?.E_YZ/\ ]]&F
M4M 78[SI?^>C_P#?1I?-E_YZ/_WT:92XHL%V/\V7_GH__?1I?-D_YZ/_ -]&
MF4M KL=YLO\ ST?_ +Z-!D<]78_C3:7% 78N]_[[?G2[W_O-^=)BEQ0%Q=[_
M -YOSI=[_P!YOSI,4N*!7%WO_>;\Z-[?WC^=)2XH"[%WM_>/YT;F_O'\Z3%+
MB@5Q=S?WC^=+N;^\?SI,4N*078NYO[Q_.C<W]X_G1BB@+L7<W]X_G1N;^\?S
MI*0MZ4!<=O;^\?SI#(W]X_G3,T4!=CO,;^\?SI/,?^\WYTVB@!WF/_>;\Z-[
M_P!YOSIM&*!W';W_ +S?G1O?^\WYTE% 7%WM_>;\Z7>W]X_G3:* N2QR#>/,
MW%>^":T1:1$ AGP?]JLFM*PFW1F,]5Z?2HG?=&U%INS)?LD7^W_WT:/LD7^U
M_P!]&IZ*RYF=/)'L0?9(O]K_ +Z-+]EB]&_[Z-34478<D>Q#]EB]&_[Z-'V6
M'^Z?^^C4U%%V')'L0_98O[I_,T?98O[I_,U-11=ARQ[$/V6+^[^II?LT7]S]
M:EHHNPY8]B+[-%_<_6C[-%_<_6I:*+L.6/8B^SQ?W*/L\7]RI:*+L.5=B/[/
M%_<%'D1?W!4E%%V/E78C\B+^X*7R8_[@I]%%V'*NPSR8_P"X*/)C_N"GT478
M<J[#/*C_ +@H\J/^X*?12N%D,\J/^X/RI?*3^XOY4ZBBX60WRD_N+^5'EI_<
M7\J=10%D-V)_<7\J-B?W%_*G44!9#=BC^$?E2[5_NC\J6B@+(3:O]T?E1M'H
M*6B@=A,#T%&!Z"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** . /4_6FTK?>/UI*ZR HHHH$%%%% !1110 4444 %(:":*
M8@HHHI %!HI!S3 44=:#Z4=*!!110?2@ ZTM'2DI %!-!H I@ %!-*32 =Z!
M !WH)H)I10 4AH)I0*  #%%%% @Z4E%*!0( *":#Q0!0  4O2CI3>III +U-
M.Z"D P*3J>*6X!U..U. Q0!@4A.:8@)S0!0!2TF&P4E%*!32L  4=*#Q3>M&
MXO47J:<JXH5<4[% !BEHI:!!2T8I<4 %+112$%+13L4 )BG8HQ2T %%+10(*
M7%&*6@ I:*7% A*7%+BEQ2 3%+BEQ2T"$Q2T4M !2XHQ2T %%+10 4N*,4N*
M0@Q1BEQ2XH 3%+BEHH$%&*7%+B@!,4N*7%+B@!,4N*,4M(08HHI"U "TA:FY
MS10 9HI**!A112XH 2EQ110 4444 %%%+MH'82EP:7 %%(=@VU-;2>5.I['@
MU#10-:.YN45'"_F0JWJ*DKG.Y.ZN%%%% PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMDR-Z&MBL6M>)MT2MZBHFC>B]T/HHHK,W"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@'_UC?6FT
MY_OM]33:ZS,**** "DI:* "DZT'FBF(****0!2=32FCH*8 :!Q0**!!0:7I2
M"@!>E)UHI:0!TI *.M+TIB FD [T#FE- "&EZ4"D)H *7I0!10(2EZ4=*2@
MIU(!03VIB \TH%(!032 ": .YH [TI.*; "<4*,<T*.YI2<4" FFBBG=*& 4
ME% %"0"@4=*.E)U-&XA*>!BA5Q3J  "EHI:!!2T 4M !2T4M(04N*,4M !BE
MI:* "EHI:!!BEHI: "EQ1BEQ2$&*7%&*6@ Q2T4M @I<48I: "BEHH *7%&*
M7%(08I<4N*6@!,4M%+0(*,4N*7% "8I<4N*6D(3%+12$T +G%-)I,TE Q:2B
MB@ HI<44 %%%% !112@>M ["4[%%%(=@HHHH&%%%+0 E+110 4444AA112T
M)2XHHI@%%%% !6E9MNMP/0D5FU>L&^5U]#FHGL:4G:1<HHHK(Z@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH X!_]8P]S3:?+_K7_ -XTRNLS"BBDH 6D)I:2F(.E HHI %!HI.M,
M!11U-!]*.@H$%**2@^E !U-*:*2D M(>3032@4Q!TI.IH-+T% !TI!12]*
MT@'>CK2T""@4G6@FF &E H I>E A#0!0*7I2 ":0#)HZFG=!3>@"$X%(!DY-
M ^8T[H*0@)P*;1UI1Q3 7I2444)!YA2]*.E(30(#3E7%(HI]  !2T4M @I:
M*6@ I:*6D(,4M %+0 4ZBB@ I:*6@0"EHI: "EQ0!2TA!BEI:6@0444M !2X
MHQ2T %+12XH$&*7%&*7%( Q2XHQ2T %%+10(*7%+BEQ0 F*7%+12$%'2D)Q3
M<T *324E% PHHI: $I:** "BB@#- !2@9I0,44BK!P****!A112T )2T44 %
M%%%(8448I: $Q2T44P"BBB@ HHHH ****!7"K-BV)R/456J:V.+A/KBD]BH.
MTD:E%%%8':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% ' 2?ZU_\ >--ITO\ K7_WC3:ZS,***0TQ
M >3110*0!110:  T=*!1U-,0#UHHI: #I0*3KS10 4O2BDZF@ %*31TI!R:!
M !WHI2:!0 =*3K0:4#% @Z4E%+TH .E(**=0(*3J:.M** #I2=:":4#%/8
MP*3[Q]J"<\"G 8I"#H*0G-!- %,  HI:2DD 4M %(338MP)I5'>D SS4@%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@L)BEHHH&%%%+B@8E><?%+7M5T:72TTZ]DMA*)&?9CYB-N/YFO2<5Y+\9O\
MCYT?_<E_FE5#<PQ#:IMHV_ OQ"CUL)IVJLD>H]$DX59_\&]N_:N_KR[QW\/6
MD9M9T*,B8?/-;1\9/]Y/?V_*L;1OBMJNFVPM=1MEO3'P)&;8_P!#QS_.FX\V
ML2(U73?+4^\WK+Q;KFF_$=]!U>Z2XM9)?+C_ ':KMW<H00!Z@<YZUZ97@%EJ
M%[XN^(]C>F,)+)=1/M3I&B$?R KW^E-6*P\G)/M<*TD.8U/L*SL5H0_ZE?I6
M4CMI;CZ***@W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ-NLT,1LR4RPSM+;_P ,XK;\4^7XMT_4H;<A-1T2ZF)@4X$L.XY8#IGCGO\
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M#''?.>]>D:)H&G^';-[738FCB=_,8,Y;YL =_H*N6BL8TTW*[25C3HHHK,Z
MJS:=6_"JV*L6OWF^E)[%T_B+5%%%0=(4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"5!-0YM[&]/#):SU,?0?#RPHG[L(BCA0.E=A%&(T"@4J1J@P!4E9G6%%%%,
MHHHH **H:KK%CHMFUS?3K&@Z#JS'T [UYOK/Q0O9W,>E0+;1?\])!N<_AT'Z
MU2BWL93JQAN>KYQ5=KVU5MK7,*D=BX%> 7VN:IJ1/VR_N)@?X6<[?RZ51R?4
MU?LO,P>*[(^D([FWE.(YXW/HK U+7S4&93D,0?8ULV'BS7=.P(-1G*#^"1MZ
M_D>E#I/H"Q2ZH]\H KSG0_B?%*4AUB#RF)QY\7*_B.H_6O0K>Y@NH5E@E22-
MAE64Y!K)Q:W.F%2,UH34444BPHI0*6D%@ HHHH&%%%.Q0 @%+112 ****!A2
MT44 %%%% !112T )BEHHI %<;XYT/0-7DLGUO5S8&,.(AYJKOSC/WAVP*[*N
M#\9Z;!JWC7PQ:7<!EMI!.)%Y ^Z".1[BJCN95?AV.;_X0SP%_P!#9_Y,1?X5
MWG@O2])TK1Y(='U$WULTQ<R;U;#8 Q\OT%<O;^ ]+;Q[>6LFDR?V4MJK1D[]
MF_C.&[GKQFM?X:6WV32M4A$;1HFHRJBD'[H  ZU<G=;F5*/++9+<[7%+1161
MU!4]M_K#]*@J:V_UOX4/8N'Q(MT445F=(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P=WQ>3_ /71OYU$
M.*EN^;V?_KHW\ZB-=?0Q$H-+2=33 !0>32GBD'K0(4],4@HI>U "$THXI!UI
M:!'/^)+^>W\JW3P^VK0R EAU52/4;36)+XON]+LMLGA)[2V'&#)L7G_@%:'C
M#Q3/X?$$%K"C33J2)'/" >W>N5LY-$OIQ>^(]:DNYR<^2JML7VSC]!@5O&.F
MJ.F$/=NUI\SM?!^HVVIZ,TEIIZV,4<I3RE;<"< YS@>M= >E9VB7^F7]D3I1
M3[/$VS")M . >GXUH]364MSGG\3 4&EZ4G4TD2"CO2L>U+T%(HR<TMQ"@8%(
M3DU=ATZ:49;$:GUZ_E5@:0G>5OP%2ZD44H-F4**UO[)C_P">K_D*/[(C_P">
MK_D*2J1'[.1DBE/ K5_LF/\ YZO^0H.D1G_EJ_Y"AU8B]G(R0,FI!6F-)C'_
M "U?\A2_V7'_ ,]7_(4>UB'LY&92UI?V7'_ST?\ 2E_LR/\ YZ-^E'M8A[.1
MFBG5>;3./DEY]Q5.:*2W/[Q< ]&'2FII[$N$EN-IPI!@TX51 "G"D%+0 M**
M2G4""EHI10(!3A2"G"D "EHI:!!2B@4M !2T4HI"%%**!2B@!1112T" 4X4@
MIPH !2T4A.*0@)IM%)0,***6@ HHHH *<!2 4M(I(0J&ZBHFMHVZJ*FHH&5_
ML4.?NBG+:Q+T45/10 U8U7H*=12TAA1113 **** "L'Q3XGM_#>G^8P$EU("
M(8O4^I]A6U--';P232L%CC4LS'L!R:\!\0:S+KVLSWTA8*QQ&A/W$'05<(W9
MA7J\BTW*^I:I>:O>/=7LS2RMZ]%'H!V%4Z**W/.;OJPHHHI@%%%% !6WX>\4
M7_AZX!A<R6Y/SP,>#]/0UB44FK[CC)Q=T?0NB:W::YI\=W:ON1QT/4'N#[UJ
M 5X5X%UZ32->%H[XMKD]#V?L?QZ?E7N-O*)HE8=ZY91Y78].E/VD;DM%%%2;
M!2@4 4M @HHHI %%%&Y?44 +12;@>XI:!A1110 4M%%( HHHH **,4M "8KF
M_%)\4K+:GPY':LN&\XS8R#QC&?QKI:Y3Q>GB2[N+/3] NX+5)E<SRNP#@#'3
MJ>_8?E51W(J?#_D<M;:_\0KO5[O3(5T\W5H%,J[5P,].<UU?@36M0UO2;J34
MQ%]I@NG@/EK@< ?U)KG7^'VO:*R7GA[7";^5"EV]QQYF3G(R&_7GWKJ_!WAZ
M3PWH8M;B<37,DC33.N<%SZ9Z].M5)JVAC24U+6YT%%%+BLSJ$J6WXE%1U)!_
MKEH>PX[HN4445F=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!PEW_ ,?D_P#UT;^=05-=_P#'Y/\ ]=&_
MG45=:,1#2BDZFE-,0AY-*?2D'K10 "@TO04@ZT +VI*6@4".=\5ZM8Z7# LU
MBE[=RDK!"4!)_3Z?6N<;4M4MT-Q<>#;86ZC+8BY _P ^U:?BR0Z;XBTC69HV
M>SAW1R%1G83T/Z_I6G+XT\/QVQE&H(_&0BJ=Q]L8_G6JT2LKF\=(JRN7-!O;
M#4-*2YTZ)(HI"=R*H!5NX..]:8KE/ ,4G]D75RT1BBN;IY8D[!<#I^6/PKK.
M@J)+WK&516DTA":512=32G@4F0(>3BM;3K,!!,XR3]T'M[UEQJ68#NQQ72JH
M50HZ 8K*K*RL735W<6BBBN<V"BJNHWJZ=IT]XR%Q$N[:#C-9Z>(X6T-M1\B0
M,'\OR,C=OSC%4H2:NC&=>G"7+)ZVO\C:HK!7Q,)HK+[-8RS7%TC2+$'5< '!
MY-.O==N[.2!3I$I6=E2,F9 2Q&<8[=_RJO92O8CZY1MS7T]'U^1N45DW&M26
MDEE'/82HURZH3N4JC'/&1U/':I=7U"2Q@A6W17N)Y5BC5AD<]2<>@S4\CNO,
MMXBG9N^VYHT5CW>NO8WL45QI\ZP2RB%9]RX+'_9SG%;%#BUN5"K&;:CN@IKH
MLB%'4,IZ@TZBI-#G9U-C>^0Q)C8;HV/IZ5..1FCQ.F-.2Y'#0R _@>/ZBH;2
M3S(5;U%=,)71RU(V98I:*459F I:*6@ IPI!3A2$ IPI!2T""G"DIPH *6B@
M4 **44"E%(0HI:**!"THH%+0 HI:**0@/%,)I2<TV@84444 +1110 4H&: ,
MTM(:04444%!2T44 %%%%(8M%%%, HHHH ****!'+?$+4/L'A&X )#W#+ I'O
MR?T!KQ*O7?BK$[^%(I%!*PW:._L,,O\ -A7D5;T]C@Q+]\*Z;P_HVF77AS5]
M6U%;J3["T06."54W;B0<DJ:YFNY\%:DEKX<UNUBU>WTV_G:(P2S2%!P3GD ]
MO;O3G>VA%%)RU\QY\%Z8?%NC:>LUT+34;<3LCE1+%\I."<8[>E5;SPYI$V@Z
MO?V O;=]-G\HBXD5TEYQP0JX/MS6ZFO:6OBOPY+=:E;W-W:Q2+?:@@VHY(^4
M9P,XZ9]ZHW6NV_B70-6T_4]307%O=^;8R2O@,A)&WW '\ZSO+0Z'&G9V\_R*
M^A^";/4?#(N+B>9-5NHY9;*%2 K*F!R,9))S^%9NAZ-I<_A?5=9U%+J0V<D:
M+%!*L>[<<<DJ?6NDF\8:'IOB/3(;>P2ZATU$MXK];AE 4C#L%'!ZGK4<VKZ;
MH^E^*HM-O;.1Y[N*2U0JLBNI()PK @XR>W:G>0N6FMK:7_+_ #//[QK5[EFL
MHI8H.-J2R!V'U( _E4%37=U+>W+W$WE^8_7RXU1?P50 *AK4XWN5Y)&BN8Y$
M)#H0RD=B#7T'X9O?M5A&Q_B4&OGB9MTIQ]*]V\&AELX5/9 /TK"J=F#^T=A2
M@4H%%9':%%%<GXS\91>'+;[/;[9=1E'R(>D8_O-_04)-NR%*2BKLV-:\0Z;H
M%OYU_.$)^Y&O+O\ 05YMJWQ3U&X+)IEO':)VD<;W_P !^M<1>WUUJ-T]S>3O
M-,W5W.35>NB-)+<\^IB92^'1&E=^(-8OF+7.I73Y[>80/R%4#-(3DR.3_O&F
M45I8P;;W+$.H7EL08+N>,C^Y(170:9\0/$&G, UW]JB'\%P-WZ]?UKEZ*&D]
MQQG*.S/9] ^)&FZHRP7H^Q7!.!O.4;Z-V_&NU1U<94YKYCKL?"OCNZT61+:^
M=IK'(&X\M$/4>H]JQG2ZHZZ6)Z3/;:*K6=Y%>0)-"X=' 96!X(JSBL#M"C%+
M12 **** "N5\<>&K+6M,>^F>>*YL89'ADB?&.,X/Y5U5<=XXM-3OVM;2UUVT
MTNSE1Q<>?(%:3IP/7C/<=:J.Y%2W*[JYR.F:EXHT/PU9:PFNV5S;3H6^QW[X
M?@D?*3R>GK^%=[X+\3MXKT>2]>V%N\<IB95;<"0 <C\ZY71_ O@RQ*R7^L6^
MH2@<"2Y18Q] #G\S7H&EQZ;%9!-*%L+8'C[-MVY_#O52:,J,9IZO3MN7:***
MS.D*?#_K5^M,I\7^M7ZT#6Y=HHHK,Z@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@[O\ X_9_^NC?SJ$U
M/>#%]<?]=&_G4'4UUK8Q%%)U-*:0>M,0II!12]J $)I>E(.M+0(2E- I* ,#
MQ'KT.E>7;7&FRWL<Z'<JJ"N/0YKD1JOAY91(/"4^X=B,C\NE=!XGUQM%\2:4
MTL\B611C,B<[O3BG_P#"PM S]^?_ +]&MDFEHCHBFHII7-;P_JZ:S8M,EG+:
MK&_EA)!CH >/;FM4FL_1]:LM<M7N+)G*(^P[EVG. ?ZUH#DUF]&<\M'M84#
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M"M+X*_\ (C2_]?LG_H*4I>[&2[">B8WP9XKO7'BVZU>[DGM].N',:D#*H"W
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M#CKO-LVW]<4 =%'\2_"\NIK91WLKAIA +I;:0VYD)QM\W&W.>,YQ[UUU<#X
M\0^&[;X::"C7]G ([>*WEB=P&%QP&7;UW%\GISG-=]0 4444 %%%% '"7O\
MQ_7'_71OYU .E3WO-_<?]=6_G4)KK6QBQ#R:4T@]:*8@%!I>@I!UH 7I24M
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MJ::U8ZQIT,<L*":*ZG$;Q,HP?E/)_#-+=VEOK'@G0+.#5]+CEM&G\T3W:QD
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M4C"M*0, L1RV!P,U8HH&8Z>%/#L>J'5$T+3EORV[[0+9 ^[USC.??K6Q110
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MY:<X!.%0?* <CGTKD];O=?\ '3:9X??PKJ&F+'?13ZC=7.WR42,[B(V!^?)
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MH7:%@&&UPXP2".JCM4/B#Q+;>'I=*CN899#J5ZEG'Y>/E9@2"<]N*M?VE/\
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M4M=+L["XBTJXDGB6<B1I.H<  CH/:MRN9\$65[9:7=_;K9K>6:Z:4(WH0O\
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MXBWFJF2TTPM:V1^4N.))!]>P]JX8DDY)R31172HI;'F3G*;NPHHHJB0HHHH
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MC[3-YO\ J]NWVZG-*51/F\[%TJ$X>SOTO?YG&V#ZXGC;Q#_8D5M(YE_>>><
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M[;TSCC-:7BCPQ_PDD^BR?:_L_P#9FH)>X\O?YFT$;>HQUZ\_2I/^$=_XKO\
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M@S[XH Z6HY[>"ZB,5Q#'-&>J2*&!_ UBV_C3PU=:V=&@UJTDU#<5\E7Y+#J
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M:,5I%$/E4"I<VS:%"G#5*[,32] 2 !G'-= B!%  P!3@,45!L%+110 4444
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M'>F IX%"CC-(W4"G=!20CG_$>O7.DR0PP:--J"2J2Q0G"^QPIKF%UU4E\U?
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M7@E>%G^YYJ;1C)P.#Q2ZAX\U1?&&I^&=&\-OJ%[9I$XD-P(X@KIN)=B/EQD
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M2EB[GG=@ CH/05T J);Z&52W,[#A2TE+4F8HIPI!2T" 4X4@IPI **6D%**
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M D*N_5@J@9/Y5;HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)YR?6J::CJ9PE"51<JMOT.NHHHK,Z@J:'[I^M0U/$/DI,J&X^BBBI-0HHHH
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M"J  /2EK!U7T-U174SOL4W^S^=+]CE_V?SK0HI>TD/V42A]DE_V?SI?LDO\
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+K/PDU5]!C\NS@FCCV"+RPK>8C' _P"!9K$UG08O#/A[PWXPT:V\N:&.%KL
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MI12&+1110 4ZD%+2&@H%%** %HHHI %+110,***!0 M%%%( I:04M !1110
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MFM&@ HHK(\,^(+;Q3X?MM9M(I8H+C=M24#<-K%3G!/<4 :Y (P1D&D50JA5
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MHHI:!!2T44B@HHI0*  "EHHH&)112T %%%% !112T#"BBB@ I:2EI#"BBB@
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M?RUNO,5D1@2V[:,$\\?K6;XU.L+\8?#LFA+;/>QZ;.PBN20DJ[N5R/NDCH:
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M7!@C*E<(0I;+9/3C% &U144ES!% 9Y)HTA SYC, OYTZ*:*>)989$DC;D.C
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MNRF0"4L6P0N.-QQQ^=5KOP!H]YX;TS1GDNT&EA?L=W'*%GA91@,& QG\,>U
M'-ZIHNG>#_B/X3F\/6J6/]IRS6MY;0?*DT80L&*],J><U5\#^$-(UK7_ !7J
MNJV_VV6#Q!<I;1S'*0%7#%E'9B2,G_9%=AHG@BUTK5QJ]WJ6HZOJ21F**XOY
M0WDJ>H15  SW/6M+0_#]IH!U(VLDS_VA>R7TOFL#MD?&0N /EXXSD^] &M7D
MGPI\*:3?6U]K=];"ZO8=7N!;-*<BWVR9&P=B222:];K'\.>&[/PO83V=E)/)
M'-<R7+&9@2&<Y(& .* /)=-6^\2:[XGO+WP./$I74I+1)9KZ*,6\:  1JKG(
MZYR.N?6IKVWUZP\&^$O"^O>=:Q7^L_9;A#<!W-KN)2-G4\\8'!Z+7?7_ (!M
MYM8NM4TO6=5T:XO"&NEL95$<S 8W%64@-[C%6[_P7IVJ>%X]"U"YOKI(G$L=
MY+/FX20$D2!\<,,G'&,<8Q0!7F\'Z!H6F:K=Z/I<-E-)82Q-Y&55UVDC*@X)
M]\9KD](8?\,S2'(_Y EP/QPXKM-"\(KI%S)<W6M:MJTSQF$&_G#*B'J J@#G
M R3DUA?\*CT8V5SIKZGK#:/+O,>FFY'DPLV?F4;<G!.0&) (S@T <]XBTF'7
M+_X7:;<R2K;3VLHF$;%3(@@B)0D=FQ@^Q-:7Q$\-:=9^'_#.B:5&=,M9_$-N
MF;3Y&3>L@9E]#S78/X2L'O?#UV9KGS-"C>.U 9<.&0(=_'/"CICFK6MZ!:Z\
M=--U),G]GWT=]%Y3 9D3. V0?E^8YQ@^] '"^/\ 2[7P=X!^P^&=.%JNHW]O
M;3+;2>6SJQP?G)X) "[C_>K-@\.:Y'XBT&[T7P$OAW[)<J+J>/487$MN1AD=
M5.6['N:]1UO1;'Q#I%QI>I0^;:SC#*#@C!R"#V((!S6)I?@J;3KVWGE\5^(+
MZ*W.8[>YN$V'_?*H"WXF@#DM \+:3XC^(_C>36+87D5O=Q".WE.8@S1\MM[M
M@ 9[5A2ZA>:%\)?$6FV%U-%%:^(9=*AE#_-#;^<!@'MP2/QKUW2O#EGH^L:O
MJ=O).TVJRI+.LC JI5=HVX (&/4FJ<?@?1ET?6=*G66YM-7NY;RY29@</(P8
M[2 , $ CJ1CK0 W3/ WAK0IK>^TO2H;>ZMHBJ31$AG!&#NY^;/7G/->3>'[#
M4/%/AF\O[KP&VMW>HS3DZH^I0QR(0[*H0,=R;,# ]L]#7JFA^!UT:^@N9?$&
MMZBMLI6WAO+D-'&",=%4;CCC)S59_AU!!=W,NCZ_K6CP74AEFM;*9/*+GJRA
ME;:3[4 ;/@^#5K;PAI=OKO\ R$XK=4N,N'.X<<D<$XQ7(7-C:>+/C!J.F:Y;
MK=6.E:=$]K:R\QEY#EI"O<@?+STKT.SM1964-JLLLHB0())GWNV.['N:P/$/
M@JUU[4[?58M1U#2]4@C,*W=A($9HR<[&!!#+GGZT 9?B;3_"/ACPO;Z;<Z1+
M<V<]ZOV73+=F/G3MT4*6 V]3@G;[9Q7,>&89-/\ C';11>&CX<@NM)D9[59X
MW68JXPY"$@$9Q79W?P\TV]\/PZ9/?ZG)-!<B[BU![C=<+-_?W$8_#&/:I-*\
M"6>F^((=>FU/4[_4XX'@,UW,K;T8@XP% &,<8QU.<T <;X-\':+XBUKQG=:S
M:_;MNN74,44S$QQ#.2RKT#'/)Z\#I70?"&XFE\!I!-*\HM+RXMHF<Y(1)"%&
M?8<5TNA^'+/P_+J<EI).YU&]DO9O-8':[]0N ,#ZY/O2>&_#=GX6TQ["QDGD
MB>>2X)G8%MSMDC@#B@#A_&VD6>N?%WPI87^YK5[.Y,D8<J)0,':<=0>X[TB6
M5MX-^*DEMX?M4@M;S0Y;J>RBXC$D;?+)M[$_=XKJO$G@73/$^JV>I7=S?07=
MG$T=O):S",QEB#O!P3N&..W)R#3O#G@NT\/W]UJ3W]_J>IW2"*2[OI [B,<A
M%P  N><8ZT >1:#I>J>)/ YO'\!MJFI:@KR_VVVI0I*923M=<G<FT@8''2O;
M?#*:G%X8TR/6L?VFELBW7S!LR  $Y'!/TKGU^'$%I+,ND>(M<TJRFD,C65I.
M@B4DY.S<A* G/0]^,5V%M +6UAMU>1UB14#2,69@!C))Y)]Z ):*** "BBB@
M HHHH XC5/\ D)7'^^:K#I5G4_\ D*7'^^:KG@5UK9'.]QH^\:<U(O2@U1(#
MK10.E%);AU 4IH%(U-B%7UIXIJ]*>*!"BE%)3))HX5R[ >U FR44CR)&NYV"
MCU)K,FU)VX@7:/[S=:HR%G.Z1RQ]S343">(C';4U)=7A0D1*TA]>@JC+J5W+
MG#B-?11_6H(TDF;;#&6/L./SJ[#H\SX,T@0>B\FJM%&#E6J;&:_S'+N6/J30
M@+G$<;/_ +JYKH8=)M(CDQ[SZN<U=554850!["ES]@6%;^)G.1Z9?2CB((/]
MLXJRF@SG_67"CZ#-;HI:7.S18:FC*30(!]^:1OIQ4ZZ'9#JC-]6K0%**GF9H
MJ4%T*0T>Q _U _,U5N=.M$U&Q180%<ON'K@<5KR1K+$\;9VL"IQZ&L"6]-K=
MVL=SDR6Q<>[@K\I'UZ5P8ZNJ<4IZ*\=?22_37Y&M*E%O1=_R-;^R+ _\NZ_F
M::=$L&_Y8D?1C4NGP20VY:8DS2MODYZ$]OPJY793G*45)JUS.5.%[6,MM M#
MG:TJ_1J@?PX?^65T?HRUN"G"KYF9NC3?0YE]#OH^4,<@'H<54EM+F'_6V[CU
M.,BNR%+34V92PL'L<.-N[C*M[<5>@U&]@P$G+*/X7YKI)K&UN!^]A1CZXP:S
MYO#T1YMY6C/HW(I\R>YG["<?A86_B!< 7$)4_P!Y.16I#=P7"YAE5O;O7-SZ
M;>6PR\6]1_$G/Z56!&<J2K#TXI<J>PU6G%VFCL:2N?M]5N82!(?-3WZUKV]_
M!<\*VUO[K<&H::.F%2,MBT****184X=*:.M.I%(***!0,6BBBD,!2T44P"BB
MB@ HHH[T""BBBD #K3J04M PI124X=*0(****"AC6\,G+Q(Q]2*A;3;8]$*_
M0U;HK.5*$MT@394^Q.O^JNI5]F.10([Y.DL;_P"\,5;I:GV,>EU\Q\S*GG7:
M#Y[8-[HW]*7[<H^_%*GU6K5%'));2"Z[$*7EN_24 ^_%2JZM]U@?H:1HHW^\
MBGZBHC8P'HF/H:/WB[/^OF&A8I1546A7_5SR+[9R*79=KTE1OJ,4^>2WB%D6
M:*K^9<K]Z%6_W6H^U@??BD7ZBCVD>H6+ I:A6ZA;^/'UXJ0.K=&!^AJE)/9A
M8=1113 *6BB@84E*:2@3%%+110,*2E-)0(!3J2EI,H**** %%+110,0T44M
M!1110 4M)2T#"BBB@ I:**0PHHHH **** "BBEH&%%%% !2@9(%)3D^^*!HF
MHHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0,K9V
ML#@X.#T-+7F?A>:*/P_\1);JXN88(]8U%I);=L2QH%R2A[,!T]Z /3**Y27Q
M;HOACPAH=_?7=R;"ZCABBN)_GD.8]P:0]22%YZDDT:-\0-+UC6TT@VFI6%W-
M$9K9;^U:'[0@ZE,]: .J#*Q(5@2IP0#TI:\P\+:W9:#J7Q#U/4[CRK6WU;))
MY/W!@ =R>@%=3?>-].T_3--NI[6_^T:E_P >M@EN6N).,_<'3 Y.>E '34$@
M#). *Y_0?&&FZ]+>VZ)<V5[8@&YM;V(Q21J1D-@\$<'D&N)\6_$[1=2\%:[%
M:P:FMK/:7%O;ZBUFZV\LNQ@%5_<\#- 'JW49%%97ADD^%-').2;&#G_@ KB8
M?B3=CXB:EI$FBZU)8Q0Q+''%IS%T<L0TC8_@/&&Z<4 >ET5S.N>.-/T751I4
M=IJ&I:B(_.>VTZV,S1IV+XX7/O5WPWXHTWQ38RW.G/*&AD,,\$\9CEA<=593
MR#0!LT5P?Q"O]2\-7VC>*;6XN#IMK,+?4[4.?+:&0@"0KTW*3U]_2G6>I7WB
M7XGRK9W<R:'H4.R412$)<W,@^ZV.&"+CCL: .ZHKQN_\5:JGCA_%,>HW \+V
MFJ)HTMMO/E,"N'F(Z<2$#/H*ZWXHWE[:^'=.2QOKBS>ZU6VMGFMI-C[';! /
M:@#MZAN+JWLXQ)<SQ0HS! TCA06)P!SW)KS>\_M;P1XV\-V=OK^H:I8:Q.]O
M/:ZA()63 R'1L9&.XZ5H>*$_X2/XC>'O#ZD-;:<#J]Z.V1E(A]2Q)QZ"@#OJ
M*\@\:Z%J'A^Z\.QV?B[Q(5U'5(K2;S+\G"-UQQP:T/'MI?\ @_X<WSV/B'6)
M9Y;J "XN+HM)&"X!"MQ@$4 >GT5R.A^&8;/48+M/%FM7[("3;W&H>9&V1CE<
M<]:POB=>:]J6HV/A?PQ>W%IJ!MYM1FEMY"C[8UPB9'9G./RH ]+HKF="\0G7
MOAW!KD3XFEL6=B/X9%4AOR8&N,\&>'-:\0>!--UJ/QIK\&J7$)D#27'FPALD
M<HPY'% 'K-%<IX!\17WB#1;J/5HXTU;3;R2QO!']UI$Q\R^Q!'ZUJ:_X@M_#
M]M#)+:WMW)/)Y<4%E;M+([8ST'08'4T :]%<[X>\96'B&_N].6VO;'4;15>6
MTO83%($/1@.X]QZBLR[^)VC6]W=QP66K7MM92&*ZO;2R:2"%AU!8=<=\9H [
M6BO--7^)-UI_Q%@TN+2=7N-.%F[O'!I[.\SY7:\>.60 X)'>NB%_9MX^"BXU
M3[<=%$_V$MB#R_,^]L_YZYX^G% '4T5AZ/XKTO6O"W_"16KNM@$=V,B[64)G
M<"/7@U0D\>V']CZ5J%MINJW9U2-I;:WMK0O(4&,LP'"CD'D]Z .KHKE].\<V
M&JZ5J=U;66I?:=,(6YT]K4_:48C('E]3GMCK@UB?#3QY>>*K 0ZAI^I"Y,DQ
M^UFR*6^U7(5=_3<!@8]0: /0Z*Y#PWKVBZ;\-[?66U.^ETJ))'^U:BY>9AYC
M#YCU)SP!Z8%167Q+TFYU"SM+O3]7TT7S!+2>_LVBCF8] &]3[T =I17):M\1
M-'TG7KC0V@O[K5(E1EMK2V,KR!AGY0/0#DGI6GX:\3Z?XJT^6[L!,AAE:">"
MXC,<D,@ZJRGH>10!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!Q.I?\A2X_WS55NE6]2_Y"ES_OFJ;=0*ZULCF>XX=*:>M.[4VJ$.[4E+
M24(!132:=VI,<B@70>.E*S*BY8X%123"/@<M5.1FD.7/X4[&<IJ)+->L?EA&
M/]HU2;DEF8D^IJ54>4[8US[]A5R"P1"&D^=OT%/1&#4ZAGQ6\UQ_JTPO]X]*
MT(=+B4AI29&]^!^570 !@<"E%)R9I&C&((JH,*H ] *>*04ZI-112BDI10(4
M4HI\<,D@RHX]34PLV[N/RJ7)+<I0D]D0"G"I_LA_YZ#\J7[*?[X_*IYXA[*?
M8@JO/80W%W#<N/GBZ>]7_LI_OC\J7[,?[X_*HG[.:M+5#5.:V(J6I?LY_OC\
MJ/(/][]*OGB+V4^PP4HI_DG^\/RI?*/]X?E1SQ%[*?8;2BE,;#H0:9NVMAA@
MTU)/8B4)1W0\4X4@IPH("J=U86UUGS(QN_O+P:N4R@&D]S!GTB:$Y@;S%]#P
M15+&&VL"K#UXKJJAGM8;E<2(">Q[BJ4NYE*BG\)EVVH30X5_WB>_6M:&XCG7
M*-]0>HK+FTV6 [H\R)Z=Q44)PV5.#[4-)["C*4=)&^O6EJG;WF?EEZ_WJN=:
M@Z(M-:!2TE+04%%%%(8M%%%, HHHH$PH%%% !110.M(8X=**** "G4@I:0T%
M**2E'2@!:***0"BBBB@84"BEH ****0 *6BB@ HHI:!C3&C=54_45&;6$G.S
M!]CBIJ*3BGNAW(/LVW[LCK^-+LG'20-]14U**GD70+D.^=>L:M]#2^?C[T;K
M^%2T&GRON.Y&)D/\6/K3U93T(/XTA4'J!2>2A_A_*CWA:$E%1^2!T9A^-&UQ
MT?/U%%WV ?0*9EQV!^E.#^JFGS(:0^BFAU]:4$'H:5P%I124ZF 4E+24#"EH
MHH ***!0,6BBB@ I124M( HHHH&%%%% !1110,6BBB@ HHHH *?&/FIE21#@
MFDREN24444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !\HX7[;;''N81FNX6W@2X>=88Q,X >0*-S = 3U-$<$,4DDD<4:22D&1E4
MN1P,GO0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%:G
M_P A.Y_WS5/JU7=3_P"0G<?[YJDO)KKCL<SW''I2#K2M2"J>P@- HI10MA=
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MW%R\KT+*D,,BG5%%4M)FB"E%)2TAA1113 ****!!WHHHH *44E.'2D,****
M%'2EHHI#"G4@ZTM !110*0Q:*** "EI!2T@"@44"@!:*** "EI!2T#"BBB@
MI:04M PI*6DH$P%.I!2T#04E+24""G"DI:3*08!ZBF[%/:G44@&B/T)%+M<=
M&_.GT460QF7] ?I1N/=33J6BP#=XI<@]Z7%)M'I1J,6EIH4=B12X/K0 M%)\
MWH*,GN*+@.HI,BES0,**** "BBB@84M%% !1110 4444#"IHQ\E0U.HPHI,<
M1:***184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@#BM4_P"0M<?[]53TJUJG_(6N?]^JAKLCLCF>X#K0:!UHHZB
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MBB@!12T@I:0T%*.E)3J "BBBD M%%% PI:2EI %%49-7M([S[,SMNW!"^T[
MQZ*3TS5X4!86BLJ]OYW\]+ IB!2TLS#*@@9VCU/\JOVLIGM(96&&= Q ]Q3:
ML%R:EI*6D,**** "EI!2T#"DI:2@3%%+2#I2T#"DI324"%I:04M(H***!UH
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M*\^O15'][#;JOU7Z_P"97QZ/<]O'-.%4[&Y%Q"K"KHI&(4RGGI3*!"4"BE%
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M*****0PI124X=* "DI:2@8HHHHH *!12T#"BBB@ %+112&%%%% !1110 4M
MHH&%%%% !1110,*6DI: "G(/FIM21C@FDP6X^BBBD:!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <9JO_(4N/\ ?JD>M7M5_P"0I<?[]4*[([',]QW:DI:2FA"BD-.%,[B@
M70D%.I!2T"%IPIM.% "THI*44A#A3A313J %I124X4"%I124HI"'"O-?C%<L
MFFZ7:@G;++)(??: !_Z%7I0KS?XP6C2Z1IUV!E89FC;VW $?^@UG+^)"^U_T
M=OQL5'J>05H:/'I4MYLU9[Q(6&$-HJLV[(Z[B!CK6?4D#!9XV)P P)/XUZ,U
M>+5["6YWTW@KP^/&,7AJ&]U,W6X>;(Z1[-ICW_*0<YZ=1ZUR^L6FBQSI;:,V
MIRW'FF-Q=1H ><#;M)SS77-K^EGXQ_VM]MC^P87]_P [?]2!_/BH(;B(^+;+
M4-:\46=_9VTCS(JS2.4QRJX91C)Q^5>-2JUX.,IMOW$[>>MUM^&ANXQ>W<S/
M%OA"W\/Z?;7-I>-<GS3;W60,1S!0=HQ^-7+GPIX;M+O3M.N=3U&&]OK:*9)/
M)1H5+] >0W7VJ9=?T+6-!\064BSV<MRWVV-KJ<2 S ]%P@QD<=^*FU3^P]5U
M?1M4FU^RBM;2S@2:(;VF+)DD!0N.^.M)5<0DH5')-7U2WT36R:[H=H[HX75=
M,GT?5;G3[G;YT#E&*G(/N/8TNCWCZ?K-E>1DAH9T<8]B*L>)=777?$=[J2(4
MCGDRBMU"@8&?? J+0;%]3U^PLD&3+.JGV7/)_ 9->HF_87K;VU^[4Q^U[I]#
MZ3+LO;B#/"2,!^== .E<AX?NH[W4+F>)@RM*Q_,UUXZ5PT)<U*+3OH145I,0
M]*;3F.!6+>:T/,$%F \C'&\] ?;UK/%8NEAH\U5^BZOT0H0E-V1IRS10)OED
M5%]2:SWUN,MLM8))W]A@4D.C[W$M]*9I/[N>!3=(54O]050 H<  =N37G5<1
MC9U*<+*FIMKO+1-^B_$V4::3>]ON&3WNK)"TIMXXD49.>3_.EA.LW$*2I-"%
M<9&0/\*NZM_R"Y_]W^HJ33?^0=;?]<Q4_5IO%^QE5FURWWMK>W2P^=<G,HK<
MS!>:N+Q[7]U)(B[B,<8X^GK4QU6\MN;NQ8)W=.U+%_R,\_\ UR'_ ++6G<?\
M>TO^X?Y5.&HUY0J2C6DG&4EK9JR]5^I4I1NDXHKVNJ6EV0J2X<_POP:NU@:;
MIEM>Z6K2*1)N.'7@TLDUYHA42.+BV8X&3R*NCF-:%&-;$Q]UI/FCTOW6_P U
M<4J47)Q@]3>I:KVEY#>1;X7SZCN/K5BO7ISC4BIP=TS%IIV84"@G R:R+C5G
MEE^SZ<GFR]W_ (5K+$8JGATG-[[+J_1%1BY;&G-/%;IOED5%]6.*S9-=B9ME
MI!+</[# _P :2'1?,<37\S3R?W<_**LV-S#)-<V\,(C$#;>._7_"N&57%591
MBVJ2EMUD]+^BT]2TH)=[?<51/K4OW+:*(?[1_P#KT>5KI_Y;VZ_A_P#6JYJC
MM'ID[HQ5@O!'UJ2P=GT^W=R2QC!)/?BI^K7K^QE5FW:][VZVZ)#YO=YDD4/^
M)Y'S^XD]O\XH_M:\MN;RP8)W=.W^?K3XII6\1SPESY:Q#"YX'3_&M21MD;.1
MD*"<4J-&<U*5*M)<K:UM):>J_4)22LFD5+75;.[(6.4!S_"_!JZ.M8\5K::S
M9B=H!"Y)&Y#SQ_.H\ZCH^2<W5J._\2BJIXVM""J5H\T'KS1OMYQW7RN#IQ;L
MM^QO457M+V"]B\R%\CN.X^M6*].$XU(J4'=,S::T8HI:3H,FL2^UX>:+:P D
ME8[=Y^Z#[>M88G%TL-'FJ/T[OT'&#D[(V)KB&W3?-(J+ZL<5ER^((G8Q6=O+
M<OZ 8'^-9MMIEU?7<S7-S$\L+[6CD#'Z'@CBGZ2+V&]U!8%M?E?#!RRJ.3TP
M#Q7#4JXR=2$-*:E\Y;7]/S-$H)-[V(8_-C$L)M?):( B,G^]DBBT>X=6,Z!"
M#QBI7FFO]2:8I#L@A*/)"Y96)88&<=1R:=7H0@Z<>1N[[LN+YM25;@C!:.)V
M'1G0$C\:8[M(Y9CECU-0SK(\#+$VUR.#1"LBPHLK!G Y([U?0?4#;Q&<3E/W
M@& U63)%+;B"YA$J*<J0Q5E/L1TJ*JUO>+<3R1!&4IW-&K$[;$KPVRGS&1I-
MHSF>0R8_ \?I2PW"7$>Z-LJ#CTQ3R 001D&DCCBMK=Y2FV"/E@@Y)[ >Y- ]
MB0;X_+$:;[F4X@0],]V/L*WK&R2QM_+#%W8[I)&ZNQZDU3LM.(MY9[MF2XG7
M#%&QY*]E4]L5)H\DLMM(SR/+$)"(9'^\R>I_'-4EI<QE*[-&BB@4$BT444#$
MI124X=*!(***0T PI:2E%#&A:***0P%.I!2T#$-%% H 6BBB@84M(*6@ HHH
M%(!:***!A1110 444"@8M%%% !1110 4444#%HHHH *F4845"!DXJ>DRHA11
M12*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH XS5?\ D*7'^]5&KVJ_\A.Y_P!ZJ0ZUV1^$
MYGN+24II!30A>U(/O4IZ4B_>H%T)!2BD%.% @%.%(*44 +3A313A2$**=2"E
MH 6G"FTX4"%I124HI"'"L[7M*AUK1[G3KCA)TP&_N,.5;\#6B*4KN7!J)QYX
MV&G9W/F+4]-NM(U&:QO(C'/$V&![^X]0:J5[YXM\*6?B"U"W'[JXC&(;I5R5
M']UAW7^5>.:YX7U30)F6[MRT&?DN(_FC<>Q_H>:WHXE2]RII+\_3_+=%./5;
M&-111762%%%20037,RQ01/+(W 1%))_ 4F[:L".N[\(::^DV)UR=2L]SF"R0
MCG!^])],<#ZFGZ#X'2T:*\U\9;[R:>I^8^GF'^$>W6NPN+.>\DMYYQ_RT"JH
M& H'0 =A7B9GB^;#R]D]%N^^NR_5_P!+:G&TE<U=+T::VC%Y9_+*.2G9JZ>P
MU&.\A)(V2)]]#V]_I4T$2P1 <  5CW 2XN);O3<^;"?W@QQ(/;UKCQ"^IU%4
MH[2WCW[N*[KJNOJ1%^T5I??_ )CIIYM8G,%L2EJOWY/[U,OK6*TFL(XEP/,Y
M/<].M:.G7-O<6P\A%CV_>C'&TU4UC_C[L/\ KI_45R5Z$)81XF4N>4G'7HES
M+1=E^/<N,GS\B5DK_D:U9.E?\A+4?^NG]36M63I7_(2U'_KI_4UZ.+_WG#^K
M_P#2690^"7]=2UJW_(+G_P!W^HJ33?\ D'6__7,5'JW_ ""Y_P#=_J*ETS_D
M'6__ %S%'_,P?^#_ -N8U_"^92B_Y&>?_KD/_9:T[C_CVE_W#_*LR'_D9[C_
M *Y#_P!EK3N/^/:7_</\JSP7\.M_BG^953>/HBCH/_(+3_>;^=1:_P#ZJV_Z
MZBI=!_Y!:?[S?SJ+7_\ 5VW_ %U%<D_^1/'_  Q_0T7\?YBWFFO!+]LT_P"2
M5?O1CHU6[#48[V%B?DD3[Z'M_P#6JYD 9/05@7 2XN);S3<^;"?W@QQ(/;UK
M>O'ZE4]I1VEO'OW<5W75=?4F/[Q6E]X^6>?69S!;$QVBG#R?WJGF8:2]G;VR
M*%E?#DCD]/\ &K.F75O<VH\A%CV_>C'&TU4UC_C]T_\ ZZ_U%83AR89XM3YI
MRM[W9-K1=E^/<I.\N2UD;%8VD_\ (2U/_KK_ %:MFL;2?^0GJ?\ UU_JU=V+
M_P!YH>K_ /2690^"7]=2WJ__ "";C_='\Q4FF_\ (-MO^N:_RIFK_P#(*N/]
MT?S%/TW_ )!MM_US7^5'_,P?^!?^E,?_ "[^92@_Y&FX_P"N(_\ 9:U;C_CV
ME_W#_*LJ#_D:;G_KB/\ V6M6X_X]I?\ </\ *HP7\*M_BG^8Y[KT1G^'_P#D
M$I_O-_.I-6O);-(#$1\\H5LC.1Z5'X?_ .02G^\W\ZC\0?ZNT_Z["N;GE3RF
M,H.SY8_H59.LTQ;W2Y+>7[;IWR2K]Z,=&_SZ5;T_4H[Z%F/R2)_K$/;_ .M5
MXD $DX KG;C9<7,M[IF?-A/[P;?ED'MZUI7C]2J>TH[2WCW[N*[KJNOJ$??5
MI?>5]6UB2[=(+=7^SL_E[E(&\^F3P*;<6]W$UJL5K!;^4VX[GWL>G+8P#^!K
M<L7L=2T_RQ!'Y?\ '"5&%/TK*U;3_L=Q9I93/&'?:(W8L@Z=NU9JC1='ZS6E
MSN5M?FK)=E?_ ()<9>]RI6&.EQ-=?:);V42;=O[A5CX],\FH5L;9'=Y 96D;
M.9FW<_C5R>*YM3_I%JP7O+!\Z_E]X?K5)X[;4C\DA?RFR=G^?:O5DHN2YOD"
MM;W2YN(C$8P$'10, ?A55;U&O&M@C;A_%VJS15+S';L%5#=R2R,MM#Y@4X+L
MV%SZ#UJS(&:)PIPQ4@'WJMIS(;&-%&&0;67N".M(8L=TXF$5Q$8G;[ISE6_&
MIY)4A0O(VU?6JNI$-$D*\RNZ[ .HP<D_E5J2))D*2*&4]C0@?D.5@ZAE.5(R
M#5@$2Z?);JZI,'66-G^Z64@@'\JKJH50JC  P *9<2F&%I A8CL*:WT$]M2W
M=ZP+M(K:XCDLHG/^D22#Y<#^%6''/KZ5NVTMO+"OV:2-HU&!Y9! %<S!,[1+
M(-T989(SS0EI%).&6 "0G[T64;\UQ3YNAG[/JCK*45A-+-IU_;11WS7:32!&
M@DPSJ#_$".P]ZW:9%@H-%(: 84ZFCK3J!(*2EI* "G"D%+292"BBB@!12T44
M#$I:2EH ****!BT444 %+24M(84444 %%%% !2TE+0,**** "BBB@84HI*6@
M HHHH =&/FJ6F1CC-/J66M@HHHH&%%%% !1110 4444 %%%% !1110 4444
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M)9V_' "&0_B2<?I3;6TAFD^R:C-="X'_ "R:7;&_NNT $?K6Q)J5C#*T4MW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '&:O\ \A2?_>_I5(5=U?\ Y"D_^]5):ZU\*.9[L*44E**K
MH3T T+TI&ZTY>E"!CA3J04M A13A313J0"BE%(*<*!"BE%(*<*!"BE%(*<*
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MHQZVW\K]OD=?0***S.P****0QU%%% "BEI!2TAH*<.E-IPZ4 %%%%(8M%%%
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M+!;M'9/ BHQ<MEL\]2370UC.U]#LH.;B^?>[_,6BBBI-Q*4=:2E'6@0M%%%
M,2E%)2B@:%HHHI#"G4T=:=0,#24&B@!:***!A2T@I: "@44HI %%%% PHHHH
M *44E+0,**** "BBB@84M)2T %%%.09;Z4 2 8 %+114F@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <9K'_ "%KC_>_I5/M5S6/^0K<?[W]!5/M76MD<TNH
ME**2G"J9+&FGBF&GB@&.I:04M API:04M(0HIPIHIPH <*6D%+0(<*6D%+0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img40748725_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (3 \\# 2(  A$! Q$!_\0
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MG>P3N%W%8W!('K67XY_Y$Z_^B?\ H:U5--5%?N9UY*5";3Z/\CQ.BBBO7/E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.C^W9_RO[_\ @!]6H_R+[D>H?\(-X<_Z!H_[^O\ _%4?\(-X<_Z!H_[^O_\
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M_.C^W9_RO[_^ 'U:C_(ON1ZA_P (-X<_Z!H_[^O_ /%4?\(-X<_Z!H_[^O\
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M'/\ H&C_ +^O_P#%5T-%'M9]V'U>C_(ON1SW_"#>'/\ H&C_ +^O_P#%4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV_[^O_C1_P (;H7_ #YM_P!_7_QK'^R:_=?C_D,\IHKU;_A#="_Y\V_[^O\
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M_A6-12LB[LV?^$KUO_G_ '_(?X4?\)7K?_/^_P"0_P *QJ*+(+LV?^$KUO\
MY_W_ "'^%'_"5ZW_ ,_[_D/\*QJ*+(+L]CT2>6ZT6UGF<O(Z99CW-7ZS/#O_
M "+UC_USK2)P"<9]A6#W-5L+16&GBS36TR[OW\^-+2X-M)&\9W^;P-@4=220
M.*LZ?K<%_>S61M[FVNXD61H;B/:2AX# @D$9&.M%AW-.BJ6K:M9Z)IDVH7\H
MCMXAR>Y/8 =R:I)XHT]YM.CVW &HP&>W<Q_*RA=Q!]"!V]Z5@N;5%8^F^(HM
M5BMYK:POS;W #),T0"X/?KG%;% !1110 4444 %%%% !1110 4444 <A)K]W
M'J4R+J,!E6^^SI8M& 73(&=W4'!)S[5O'68/[2FLA%.SP8,L@3Y(P5R"3FLN
MXT+49X[ZSWV8M+NY,QD.XR("0>!C&>.N:TTTPFXU0RN#%>A5 '4 )M.:VER'
M)!54_P"O/_@"6^N6UQ(B^3<1B6-I(6>/ E4<G;CGIS@@&F#Q!:JMR;B&YMC!
M%YS+-'@LG3(P3WX]:H6?AVYMXFB(LHG2!HHKN%6\T$C ;!X'OBEL]!N[>>:;
M;8JSVOD;/G=6.<DMGD@\_P#UZ5H#4ZVFA9U#79[6VM9H].N<RW"1,CJN<'TP
MV,GM[ULH^^-7*LFX [6ZCV-<]'H-['IYC66!)5NDN(806,487'R@GG!Y/MFM
MN:TCO;00WL4<@(!=.JY]J4N7H73<]6R+5K_^S-*N+P*&,:_*"< L3@9/IDBJ
MNB7ANVFW:M#?,H&Y(X@GEG\\D?X5/?Z5'=Z-)IT.V!=H$9 R$(((X],@50>U
MU2%KK4Y! ]_]F%O!%;J2N<YRV>3R?P -"Y7&W4)N:FGT_P"'N/N[K4;K4;RV
ML+B*W%G$K$O'O\QV!(!YX&!]>:JZCXAN3X<ANK%46[FMC<D,,B-%&6/Y\#ZU
M:GTW4TO)[FRGM@UW"D<_FJ?E901N7'7@]#Z"H+OPHDFFR06UY<QRFT%L/GPC
M  @;A@\9)SCUJER:7,Y*JT^6_7_@6^0NIZTT,]K:_;8;+?!Y\L[IN/8!57WY
M^@%;=F_F64+_ &A;C<@/G(  _N *RFTF^M9[:YL9XI)H[?[/)]J).X9R#D=P
M<_@:T-*L/[,TR"TW[S&#EL8R223@=ADU,N6VAI3Y^=\Q<HHHK,W"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML#QO_P B/K/_ %Z/_*M^HKFVAO+:2WN8DEAD7:\;C(8>A%" Y75M1:SM/"K1
M7?E0O>0Q3E7PI4QGY6]B<5FZ]K-RMSXP%I?OMM-.A:/RY/\ 5.=V2,=#TKK(
M?#6AP6D]I%I-FEO/CS8A$-KXZ9'M3H/#FBVUO-;P:7:1PSH(Y42( .HS@'UZ
MFJNA69S<*7VB:[H.W5+Z]34HI%N(KF3>"RQ[PRC'RG/&!7/7E[>-X!F\2'Q+
M>1ZI,V&@68"-#OQY0C[$#OUX]*]0>QM9);>5[>-I+;/D,5YCR,';Z<<5Q&H>
M#-1U*>XMY[/10MQ)F75(XBLYCW XVXQN(&-V>E--":-CQ??W5II&GQP7;6:7
M=W%;SWBXS#&V<L"> 3@#)Z9KG+Z^O/#_ (BO+;3M8N]02#19KE()Y?-*2 C!
M)ZGCG!_E7HEQ:6]W:/:W,*30.NUHY%W*P]P:IV/A_1]-D62RTRUMW52@:.(
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M"32]'GO(D5WCVX#=.6 _K45>7D?/M;4#G/\ A7MK_P _TG_?'_UZ/^%>VO\
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M_BJ.7$]_R#GR_M^9OI\.[9$5?MTAP,?ZO_Z]._X5];?\_P!)_P!\?_7KGO\
MA:&I_P#/E:?DW_Q5:'_"P;__ )];;\F_QK&=.I'<]"A7HU5:'0T?^%?6W_/]
M)_WQ_P#7H_X5];?\_P!)_P!\?_7K._X6#?\ _/K;?DW^-'_"P;__ )];;\F_
MQJ+3-[Q-'_A7UM_S_2?]\?\ UZ/^%?6W_/\ 2?\ ?'_UZSO^%@W_ /SZVWY-
M_C77>'M4EUC2Q=3(B-O*X3..,>M)\R&N5F%_PKZV_P"?Z3_OC_Z]'_"OK;_G
M^D_[X_\ KUV5%3SL?*BM86BV%C#:JQ<1+M#$8S5FBBI*"BBB@ HHHH ****
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M@] "<TRR\0:OXD_L.R@NTTU[NP:\N)XXPS-M8+M0-P.>3UXI<H7.]K$\7?\
M(KWG_ /_ $-:I>%-0U*YU'7;/4;Q+HV5RL4<B1A!C8#T'?U]ZN^+O^17O/\
M@'_H:UABE:C/T?Y#1X[??Z@?[W]*SZT+[_4#_>_I6?71D7^YKU9\[F?^\/T0
M4445[)YX4444 %%%% !1110 #K6V.E8@ZUMCI7-B.AZN6?:^7ZA1117,>L%>
MG>!_^1='_75OY"O,:].\#_\ (NC_ *ZM_(5$]BH;G255CU*QF>X2.\@9K?\
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M_B:]3VU/N<7U2O\ R,XVBNR_X5IKG_/6S_[^-_\ $T?\*TUS_GK9_P#?QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@((R#D'N*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH YK7;N^NO$%AH%E=M9">&2XGN4 +[%(&U,\
MDGKV%9E[?:OX4U$6<5U+JT5S:336\=T09%DB 8KN &00>_>NBUG0TU5[>YBN
M9;._M23!=1 $KD8((/#*>X-0Z9X>>VU$ZEJ6H2ZE?^68DDD146-#R0J+P,XY
M/>JNA%.Y\90QR63P1B2UDT]]2N7SS%" -N/4DG'X&J<GBK7[6#3;N\T>UCM-
M1N8HH]MP6>%7/&\8P3CTZ5?TCP78Z7#J4#RO<PWJF+9(,>5#\V(U]AN-5/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -XIG:3[XK<HHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[QS_P B=?\
MT3_T-:Z&H+RRM]0M'M;J(2POC<A)&<'(Z>XJH/EDF9U8.=.45U3/GFBO;_\
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M.[@=2I<,L@(VCJ?I4AGB'EYE0>9PGS#YN,\>M $E%0/>VD4QADNH4E5=Y1I
M&"^N/2FRZA90_P"MN[>/I]^0#KT[]Z +-%0_:K?[0+?[1%Y[+N$>\;B/7'7%
M$MW;02QQ37$4<DG"([@%OH#UH FHI@EC,K1!U,B@$J#R >^*C>]M8K?[1)<P
MI!G'FM( OIUZ4 3T4BLKH'1@RL,@@Y!%117EM--)#%<PR2Q_?1'!9?J.U $U
M%0_;+4W7V7[3#]H SY6\;\>N.M8<WB^UACO'-M,1:Z@E@V,<NVW##V^:BP'1
M44R::*WB:6:1(XU&6=V  ^I-(EQ#) )XYHVA(W"16!7'KGI0!)15>._LYD#Q
M7<#J5+ K(""!U/T%+]LM?*>7[3#Y<8!=_,&%!YY/:@">BL^^U5;?3DO+2,7J
M.ZJOE2J 03C().#BK$E_9POLENX$;<$VM( =QZ#ZT 6**BGN8+6(RW$T<,8Z
MO(P4?F:'NK>-$=YXE5^58N &XSQZ\4 2T56_M&Q$"3_;+?R9#M23S5VL?0'.
M#4D]S!:Q&6XFCAC'5Y&"C\S0!+63XFN)K3P_<SP2-'*NS#*>1\P%:4<\4Q81
M2HY7&[:P.,],UD>+O^18O/\ @'_H:UCB&U1FUV?Y >4R^*]=69P-3N  QQ\Y
MI]KXJUQ[A0VIW!'/!<UAS?Z^3_>/\ZDL_P#CY3\?Y5[,8Q]DG;I^A\Q3JS]N
MES/?OYG4_P#"2:Q_S_S_ /?1I5\2:QN'^GS=?[QK)I5^\/K7)9'T%V>TV+M)
MI]L[L69HE))[G JQ5;3O^07:?]<4_P#015FN<W"BN='C&S/E3&SO5L);C[,E
MXT8$;.3M'&=VTGC=C&:T=6UF'2!:"6&>9[N<6\20@$ER">Y  P#3L*YHT5G_
M -JK%97-Y>VT]E!;H7=I]GW0,DC:QJI9^)(KBY@AGL+RS%S$TL$DZ#:Z@9.<
M$[3CG!Q189MT5SUIXPL[I[)C:7D-K?R&*UNI8P$D;G'?(S@XR!FNAI6 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@N@!/W1@'%>J44<P['$> (H$O_$36=I+:V;W:- DD93Y=G4 ]!Z#TK<\7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M4U.P35-/ELY'9$DQDKUX(/\ 2K=9VNW\NF:-<7< 0R1[<!QD<L!_6LZKBH2<
M]K:@<P_PQTUW9C>W62<_P_X4L7PSTV*0.+VY)'KM_P *SO\ A/M6_P">5I_W
MPW_Q5=7X6UFYUJPFGN5C5DDV#RP0,8![D^M=*J5.1:Z'+'"T.:ZCJ9W_  K^
MP_Y^KC]*!\/[ $'[5<?I7745',SHY41P1"WMXH5)(C0(">^!BI***DH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'U!_I6IXN_Y%B\_X!_Z&M<>,CRTIKR?Y'71J>TCS'E%>B_#_ /Y!%S_UW_\
M917G5>B_#_\ Y!%S_P!=_P#V45NOX:]$*/Q'6U5_M*S_ +1_L_[3']LV[_))
M^8KZ_K5JN6U!@OQ)TDD@ :?<$D]OF2I1HSIY)$AB>61U2- 69F.  .I-4$U[
M2I!:%+^!A>';;D-Q*<XPI[G(K"\223ZM>6^F_9;M]%*>==3VR;Q<?W8@0>G<
MGTXKE](F$GA/P2H21 FKA?F7 /\ K>GJ*:6@-GH:^(M'>^^Q+J,!N#)Y00-U
M?^[GIN]NM:=<-<VMGJ=Q9>'=#B5;#3[Q;F\N5.5C96+^6K'JY8\^@_*NYI-
M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY%B\_P" ?^AK6W6?KEA)J>CSV<3*KR;<%^G# _TK+$)RI22W:8T>.UZ+\/\
M_D$7/_7?_P!E%9'_  K_ %'_ )^;7_OIO_B:ZGPSHL^B6,L$\D;L\F\%"2.@
M'<#TKH37(D9Q3N;=9^J:1;:K;31RKY<LD#P"X11YB(WW@I(XS6A14&A#:VL-
ME9PVL"!(84$:*.R@8 J)=*T](+>%;*W6*W?S(4$8Q&W/*CL>3^=6Z* ,U/#^
MCQX\O3+1,'(VQ <^M:5%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A=0P4L QZ#/)H
M 6BD9U4@,P&3@9/6EH **** "BD) ZD"HTN())WA29&ECQO0,"5STR.U 7):
M**AFN[:V95GGCC9@2H=@"<<G% FTMR:BHK>YANX%GMY4EB;[KH<@]JEH&G?5
M!1110 53U34%TO3I;QXRZQXRH."<D#^M7*Q/%W_(KWG_  #_ -#6LJ\G&E*2
MW28&3_PL*T_Y\Y?^^Q_A71:/JB:O8"[CC:-2Q7!.>E>-5ZCX(_Y%Q/\ KHW]
M*\K 8RM6J\LWI8#HZ***]H HI,@$ D9/2@D#J0* %HI"0!DD >II: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP2.V1Q6G:6IM8RAN)Y\G.Z9@2/;H*&QI%BBBBI&%%%% !1110 4444 %%%%
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MUP>AQ[46 OT5#)=0Q7,-N\@$L^[RU_O8&3^E34 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UW2-2SL%4=2Q
MP*=6)XN_Y%>\_P" ?^AK459\D'/L@-E'210T;*RGNIR*=6!X,.?#%N3_ 'G_
M /0C6_2HS]I3C/N@"BBBM "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***PO%FM7&@Z-]LMDC>3S0F
M) 2,$'T(]*<8N3LB*DU3BY2V1NT5Y/\ \+.UG_GVLO\ OAO_ (JMCPQXYU+6
MM?M[&X@M5BD#9,:L#PI/<GTK9X::5V<D,PHSDHJ]V>@4445@=P4444 %%%%
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M_P#A5K3O&?AW5KZ.RL-4BGN9,[(U5@3@$GJ/0&G9BNC>HHHI#"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "D*AAA@"/0T44 "J%&%  ] *6BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img40748725_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X H(# 2(  A$! Q$!_\0
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MCG%A:BUEC;;/ 8@CH>VX#^=%OZL%_P"KFO1110 4444 %%%% !1110 4444
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M-0_\%Z?XT?V7XC_Z&H?^"]/\: -VBL+^R_$?_0U#_P %Z?XT?V7XC_Z&H?\
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MU^\WX?SJ/='_ ,\O_'JFMV4L=J8Z=_>@"W1110 4444 %%%% !1110 4444
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MFLZ^'K1IMRJ-KMK_ )G3@<SPU7$0IPH*+?733\#V"G/]\UGG7-'_ .@O8?\
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M"C@'&0>O-%I=P7ULES;2"2%\[7'0X./Z5-3U3)]V<>Z9GRZ)833V4[PDRV8
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M\H:[*&=4*,.13C]Z/&QW#SQE;VLN9?(XG^U-/_Y_8?\ OJL%[RV/C9+@3IY
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M *!%A_X#K_A1_8>C_P#0(L/_  '7_"K]% %#^P]'_P"@18?^ Z_X4?V'H_\
MT"+#_P !U_PJ_10!0_L/1_\ H$6'_@.O^%']AZ/_ - BP_\  =?\*OT4 5H-
M"T<AS_9%AG&/^/=?\*B.AZ/D_P#$HL/_  '7_"M6#[DG^?6H3U/UH S_ .P]
M'_Z!%A_X#K_A3XM)TRWE66'3;.*5#E72!0RGV(%7** '^:_K1YK^M,HH ?YK
M^M'FOZTRB@"0R-L7GUI/-?UI#]Q?QIM #_-?UH\U_6F44 /\U_6CS7]:910
M_P U_6@2OD<]Z92C[P^M $DDC"5@#WIOFOZT2_ZU_K3* '^:_K1YK^M,HH ?
MYK^M'FOZTRB@!_FOZU-;NS,V3Z?SJM4]K]YOP_G0!=HHHH **** "BBB@ JG
MJRW#Z/>K:Y^T&!Q'CKNP<8JY133L[DRCS1:.%BNM%_X0M[: 0B_2R<.FS$BN
M%._/&1SGFF)<:CI<'EV=U<3M)HPN%21MVQP0,J.V 3Q[5W?EIDG8N3UXZTH5
M000HR!CIVK7VJ['#]2EI[UFE;16_4\ZO;MI-.U*&TU&XO[$Z>))7F??LEW#
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MG^%;M% &%_:GB/\ Z%9?_!@G^%*NJ>)-PQX67_P8)_A6Y3D^^* ,#^U/$?\
MT*R_^#!/\*Y#Q+<7]SXKLFU#318NMBX11.)=PW]<BO3*X_Q9X?UC5-<LK_3(
M[65(;5H'6>7802V<CBN3'4I5<-.$%=M&V'FH58REL<S15_\ X1;Q5_SXZ;_X
M%G_"C_A%O%7_ #XZ;_X%G_"ODO['QO\ )^*_S/8^NT/YOP90HJ__ ,(MXJ_Y
M\=-_\"S_ (4?\(MXJ_Y\=-_\"S_A1_8^-_D_%?YA]=H?S?@RA7+/_P E'C_Z
MX?\ LM=Q_P (MXJ_Y\=-_P# L_X5F'X=^*V\0C6?)T[Y4V>5]H/IC.<5V8/+
M,53]IS1WBTM5N_F8UL52ERV>S3)**O\ _"+>*O\ GQTW_P "S_A1_P (MXJ_
MY\=-_P# L_X5Q_V/C?Y/Q7^9M]=H?S?@RA15_P#X1?Q5_P ^6F_^!9_PI/\
MA%_%7_/EIO\ X%G_  H_L?&_R?BO\P^NT/YOP91IMO+<P^)M"DM+474XGDVP
MF0)N^0_Q'I6A_P (OXJ_Y\M-_P# L_X5;T?PMKT?B/3;Z_BLH;>S=Y#Y4Y=F
M)4@ #'O79@,LQ5+$PJ3C9+S7^9CB,52G2<8O4Z#^U/$?_0K+_P"#!/\ "E;5
M/$98_P#%++_X,$_PK<IS_?-?6'CF!_:GB/\ Z%9?_!@G^%']J>(_^A67_P &
M"?X5NT4 87]J>(_^A67_ ,&"?X5/97^MS7D4=WX?6V@8X>87BOL'T YK6HH
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M[ @01E7"L#G<2<C(P.326VBWMIH&AJ+,-)8W7GSVRE<MG>,CG!8%@W7M0!T
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M62-#"ZG]N_M'4"2^[R#/^ZY[;<=* 'X/I1@^E3?:%_YY_K_]:C[0O_//]?\
MZU #'!*1\'[OI3-K?W3^59VJZ''J5RMRVI:I;$H!Y=M<[$&.^,=:H_\ "*1?
M]!O7?_ T_P"% &_M;^Z?RHVM_=/Y5@?\(I%_T&]=_P# T_X4?\(I%_T&]=_\
M#3_A0!O[6_NG\J-K?W3^58'_  BD7_0;UW_P-/\ A1_PBD7_ $&]=_\  T_X
M4 ;^UO[I_*G(K;Q\I_*N>_X12+_H-Z[_ .!I_P *5?"<18#^W-=_\#3_ (4
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M /\ L:/L?@C_ *'2\_[_ /\ ]C6;M7^XO_?(HVK_ '%_[Y%8?ZP?]._Q_P"
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MY/!5M+I<\#W<_P!MEG-T;D.P FW;@WE[MO& /H*Z=<A1N.3CDBEHH *:P'7
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M.FT4 .\Q_P"^WYT!WW#YVZ^M-I1]X?6@!\CN)7P[=?6F^8_]]OSI9?\ 6O\
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MX;M'$45N_P#"!^)_^>^D_F]'_"!^)_\ GOI/YO7J?7*/<^._L''?RK[T>?\
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MQ_N+^5'G'^XOY4 (8WV+\C=^U-\M_P"XWY5(9OE7Y%[]J3SC_<7\J &>6_\
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M0$ES("4C:-EW8ZXR*VZ\?TV]CL/%FBW4RRO'')+D11EVY3L!7H/_  F&F_\
M/IJW_@ ]>9B:*HU'!.Y]!E^+>+H*LU:]S?HK _X3'3?^?75O_ !Z/^$QTW_G
MUU;_ , 'KG.TWZ<_WS7/?\)CIO\ SZZM_P" #TK>,=-+$_9=6_\  !Z -ZBL
MO3=?LM5O!:P0W\;E2V9[1HUX]SQ6QY+>J_\ ?5 $=%2>4WJO_?5'E-ZK_P!]
M4 1T5)Y3>J_]]4>4WJO_ 'U0 ^#[DG^?6H3U/UJQ#&0K@D<^A^M1&)LGE?\
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M7E4JS:D[?EZ&!]I_Z=;[_P !7_PH^T_].M]_X"O_ (5O?\+!\4_W=+_[X?\
MQH_X6#XI_NZ7_P!\/_C3_P!9Z7\R^YG)_8^7?\_)?U\C!^T_].M]_P" K_X4
M?:?^G6^_\!7_ ,*WO^%@^*?[NE_]\/\ XT?\+!\4_P!W2_\ OA_\:/\ 6>E_
M,ON8?V/EW_/R7]?(X;RKG_A+_MWV"^^S>7MW_9GZX],5M_:?^G6^_P# 5_\
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M:2OI3US"^Q>*O^@]IW_@ ?\ &C[%XJ_Z#VG?^ !_QK=HH POL7BK_H/:=_X
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MYDOJ?RH\R7U/Y4 1TH^\/K3_ #)?4_E2B27<.3U]* &R_P"N?ZTRII))?-8
MG /'%-\R7U/Y4 1T5)YDOJ?RH\R7U/Y4 1T5)YDOJ?RH\R7U/Y4 1U/:_>;\
M/YTSS)?4_E4UN[L3N)[=O>@"U1110 4444 %%%% !1110 4UXTDV[T5MK!EW
M#.#ZCWHHH 1X8Y&#/&C, 0"5!(!ZC\:B2QLXX_+2U@5",;5C &,YQCZ\T44
M.GM+:ZV_:+>*;:<KYB!L'VS3F@A;S-T49\P8?*CYA[^M%% #7M+:2:.9[>)I
M8_N.R LOT/:AK6W>X6X>WB:=!A9"@+ >QZT44 "6EM',\T=O$LLGWW5 &;ZG
MO2M:V[V_V=X(F@QCRR@*_ETHHH &M;=HW1H(BDG#J4&&[<^M,.GV3)&AM("D
M7^K4QC"?3CBBB@"5(8HVW)&BD*%R% ^4=!]*CDL[6:=9Y+:%YD^[(R L/H:*
M* 'B"$0>0(H_)QCR]HVX],5(    , = *** "CK110 WRT_NBCRT_NBBB@ V
M+_=%'EI_=%%% !Y:?W11Y:?W1110 >6G]T4>6G]T444 9M]X;T74[G[1?:7:
MW$VT+YDD8)P.V:K?\(7X9_Z =C_WY%%% !_PA?AG_H!V/_?D4?\ "%^&<Y_L
M*PSZ^2*** #_ (0OPS_T ['_ +\BC_A"_#/_ $ ['_OR*** #_A"_#/_ $ [
M'_OR*/\ A"_#/_0#L?\ OR*** #_ (0OPS_T ['_ +\BK=AX>T?2IFFL--MK
M:1EVL\484D>F:** -#RT_NBCRT_NBBB@ \M/[HH\M/[HHHH /+3^Z*/+3^Z*
M** #RT_NBCRT_NBBB@ \M/[HH\M/[HHHH /+3^Z*/+3^Z*** #RT_NBCRT_N
MBBB@ "*.@H\M/[HHHH /+3^Z*/+3^Z*** #RT_NBCRT_NBBB@ \M/[HH\M/[
MHHHH /+3^Z*/+3^Z*** #RT_NBCRT_NBBB@ \M/[HH\M/[HHHH /+3^Z*/+3
M^Z*** #RU)SM%'EI_=%%% !Y:?W11Y:?W1110 >6G]T4>6G]T444 'EI_=%
,11T%%% #J*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img40748725_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ J\# 2(  A$! Q$!_\0
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M;(JQ4-H\4EG"\ VPL@*#&,#''%353W)6P4444AA1110 4444 %%%% !1110
M4444 %%%% '/:GJ>K66J)(L5N--5TB*,?WLI;J5^GIWKH:X_Q)>P7-]'8/:7
M(U2&57L9(U)!SC+9Z# R#FNO&<#/7O0M@ZBT444 %%%% !1110 4444 %%%%
M !1110 4444 %8M[KC0^(K'2X8MZREO/D[)\N57ZGK6U7$RZ/K=IXDL)?[0@
MEMI+V29AY/S!2O0GZ<4=0Z';4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137;
M8N30 ZBJ_P!J3U/Y4?:D]3^5 %BBJ_VI/4_E1]J3U/Y4 6**K_:D]3^5+]I3
M!.3Q[4 3T57^U)ZG\J/M2>I_*@"Q15?[4GJ?RH^U)ZG\J +%%5_M2>I_*C[4
MGJ?RH L457^U)ZG\J47*$@9/Y4 3TTHK'+*#]1437"J<'.?I2?:D]3^5 %@#
M P.E%5_M2>I_*C[4GJ?RH L457^U)ZG\J/M2>I_*@"Q15?[4GJ?RH^U)ZG\J
M +%%0?:4QG)Z^E)]J3U/Y4 6**K_ &I/4_E1]J3U/Y4 6**K_:D]3^5'VI/4
M_E0!8HJO]J3U/Y4?:D]3^5 %BBHDG5R0N>!GD4TW2 X)/Y4 38&<X&1WI:K_
M &I/4_E1]J3U/Y4 6**K_:D]3^5'VI/4_E0!8HJO]J3U/Y4?:D]3^5 %BBJ_
MVI/4_E2_:4P#D\^U $]%5_M2>I_*C[4GJ?RH L457^U)ZG\J1KZ"/'F2HF>F
M\@9_.@"S153^TK3_ )^H?^^U_P :/[2M/^?J'_OM?\: +=%5/[2M/^?J'_OM
M?\:5=0M6Z7,/_?P?XT 6J,54.HV@./M,/_?:_P"-']HVG_/S#_WVO^- %NBJ
MG]I6G_/U#_WVO^-']I6G_/U#_P!]K_C0!;HJI_:5I_S]0_\ ?:_XTHU"V8X6
M>-F/0*P)_G0!:HJO]J3U/Y4?:D]3^5 %BBH#<H,<GGVI/M2>I_*@"Q15?[4G
MJ?RJ:-PZAAT- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "J&K:F-+@
MA?[.\[S3I B(0,LW3D\8J_6)XFLKB^M]/CMA*&6_A=GBQN103EN>./I0!-::
M];3+=BZ!LI;-PDZ3L,+D94[@<$$&K1U73Q;1W)OK802$A)/-7:Q&<@'//0_E
M6/>V,^C6AETV&2ZN;BZ5[JXE7S90,8WA1@' P !C K%L=(U%_L37-G(VW79+
MIM\:KB,H</MR0.3^= '9C4K$V7VT7<'V7_GMY@V=<=>G7BF-K&F)#'*VH6HC
MD!*,95PV#@XYYY(%<Q+IM]#>277V*22"'6C=&)0"70Q!=ZCOACGUX-:7V9KW
MQ/I>H"PDC@C@N/FE0*4=BN"1V) /O0!LC4;(WILQ=P&Z'_+'S!OZ9Z=>E-75
M=/>>2!;VW::)2SH) 64#J2/05RNF:-,EV+;4!J;21:B]VC1A/(;+%E8MC/0X
M()SVZ4EM'K5YXBTB>ZLG@2VEG$J)"%2(%6 P^<N#@'@8H V;+Q-;:II\%W8&
M%]]P(726=4* L5SWR3C('>M3^T;+[;]B^UP?:O\ GCY@W],]/I7*6MA>KH>G
M6+V4XFM-5623*_*4\UFW ]Q@@UHZ"DU@\]A=:?,TS7LTPN @,;!F+!]WK@A<
M=>/2@#HZCFYC8#DX-25A6/A?3-'OI-0M4F$[!L[I68<\G@T 6]C_ -T_E1L?
M^Z?RJ;[5_L?K1]J_V/UH AV/_=/Y5S'B+QWHGA;4H+#49)?/E0NPC7/E+V+?
M7M76_:O]C]:\H^('PXU/Q)XI75=+DA$=Q&%N!*V/**C (]0: .X\,^)=/\6:
M8U]II?:CE)(I!AXS[CWK:"-M;Y3T]*XKX9>$[OP?IEVVHE3>W<@+1(V5C5>!
MSW)S7=BYR"=O3WH @V/_ '3^5&Q_[I_*IOM7^Q^M'VK_ &/UH AV/_=/Y4;'
M_NG\JF^U?['ZT?:O]C]: (=C_P!T_E1L?^Z?RJ;[5_L?K1]J_P!C]: (=C_W
M3^5*B/O'RGKZ5+]J_P!C]:5;G+ ;?UH CE1B^0I/X4S8_P#=/Y58>XV-C;G\
M:;]J_P!C]: (=C_W3^5&Q_[I_*IOM7^Q^M'VK_8_6@"'RW_NM^5<+JWQ7\.Z
M1JMQI[I=7$D#;'D@4%-W< ^U>@?:O]C]:\&UOX1^(6UN\DTQ8)[*24R1.\H5
ML,<X(]B: /0Y_B3X>M_#$&O&25X9Y/*6W4#S0PZ@CVZUU%C=0ZE807MFXFMI
MT#QNO0@UY!<?"+5?^$/M4AEB;64N&EE@+XC"L ,!O48!KU3PII8\,^&+'2 _
MG-;QX=^F6)R<>V30!H3R):VDEQ<,(H8@7=VX"J!R36%X7\7Z5XOBN7TQI UN
M^UXY1AL=F ]#6OKMFFN:!>Z7(QB6ZB:+>.=N1UKB/ACX(O\ PC<7][JC1_:)
M@(8XXVR-@.=Q/J?2@#L-<U>T\/:1/J>HL4MX1T ^9SV5?4FL/PY\0M#\4:F=
M/L3/'<>7YBK,N-_J![BK/Q \/R^+O"\EA;,([J.19H=Q^5V'\)],YKB? ?PT
MU?0_%4&JZL84BM4+1K$^XNY&,'T S0!ZSL?^Z?RHV/\ W3^53?:O]C]:/M7^
MQ^M $.QNZD?6DVGV_.F:E!!JNG36-RC^3,-K['*MCV(Z5S'_  KSP]_<O_\
MP-?_ !H ["W!#MG'3UJ-E.X]/SKF(/AUX>,F=M]P,\WCG^M1M\._#H/W;_\
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M:1_SYC_OMO\ &M7:?0T;3Z&OE?K-;^=_>SZ;ZO1_D7W(RO\ A'-(_P"?,?\
M?;?XTH\.Z0/^7,?]]M_C6IM/H:-I]#1]9K?SO[V'U>C_ "+[D97_  CFD?\
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M1:G'X;\/7FJW*%TMUW!%ZL3P!^>*XGPA\5+'6(KA-?>VTRYC(:,@G9(I_J*
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M_P#JF^AJ#I*7F-[4>8WM3** '^8WM1YC>U,HH ?YC>U*)&VMTZ5'3A]UOI0
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M?\*LT4 5O[.T_P#Z!]G_ -^%_P */[.T_P#Z!]G_ -^%_P *LT4 5O[.T_\
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M8=P?,S8_L[3_ /H'V?\ WX7_  H_L[3_ /H'V?\ WX7_  JS178:%;^SM/\
M^@?9_P#?A?\ "C^SM/\ ^@?9_P#?A?\ "K-% $:6EI Z20V=M$X'WDB"G\Q4
M_F-[4C=%^E-H ?YC>U7+<YA!JA5^V_U"_P">] $M%%% !1110 4444 %%%%
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M'_34O_ %_P#"NKWMZ_I1O;U_2@#E/^%A^'_34O\ P!?_  H_X6'X?]-2_P#
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M'DM(8&3*$[@(_85Q9A%RP[45=Z?F=6#DHUDVS7W'U-&X^IK#_P"$OT'_ *"
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M 'U0$AP<;<=^: *E%6_+@]4_[ZH\N#U3_OJ@"I15ORX/5/\ OJCRX/5/^^J
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MW+7.0^P>)?\ H5;W_OXO^-'V#Q+_ -"K>_\ ?Q?\:V?[5\:_]!O3_P#P$/\
MC1_:OC7_ *#>G_\ @(?\:Y?88;^KB_LK^[^)C?8/$O\ T*M[_P!_%_QH^P>)
M?^A5O?\ OXO^-;/]J^-?^@WI_P#X"'_&C^U?&O\ T&]/_P# 0_XT>PPW]7#^
MRO[OXF%<:9XFGM9H1X7O 9$*@F1>,CZU5T3P]XITW2X[-_#5T[(6)82*!SSZ
MUI:_XR\9Z#:P3OJ=A.)91$%%MC&>_6M==7\:K_S&M/Y'_/H?\:OV5!1MT8UE
MV\%'\3$^P>)?^A5O?^_B_P"-'V#Q+_T*M[_W\7_&MK^UO&I_YC>G_P#@(?\
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M:4!4Y'TQ6=5^V_U"_P">] $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_E1M;T/Y5-YZ?\ /+]://3_ )Y?K0!#M;T/Y5EWOB+2-.U>TTF\O4BOKO\
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M^59>BZ*^BSR2R:QJ.HB1 H2[<$)SU&.];7GI_P \OUH AVMZ'\JO6XQ"N?\
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MHV-Z4J(V\<=Z %F^_4>:EF4E^!7,ZWXUT7P_K=EI-_*PN+K'*C*P@G +^@-
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M]&_Y\5_[[;_&I_M2/G_7S-?[*K?S+\3H?^$"E_Z'63_OB.C_ (0*7_H=9/\
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M;HOTIM/9&PO';M2;&]* &U?MO]0O^>]4MC>E7;<$0KG_ #S0!+1110 4444
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M=R[RYVGU'RU)Y/P\_P"ADUK_ +[?_P")K66!DX1CS;7_ !,H9G"-24^5ZV_
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M%N&^]@]_2@#M?LS_ -Y:/LS_ -Y:9YTG][]*/.D_O?I0!)]F?9C*]:3[,_\
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M_OHT?\)OX5_Z#]G_ -]&M7^SM/\ ^@?9_P#?A?\ "C^SM/\ ^@?9_P#?A?\
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MKTI/LS_WEI&F?"_-V]*;YTG][]* '_9G_O+5J%2D84]1Z52\Z3^]^E7(&+1
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MJ77_ )\7_P *;_PL3P_Z:E_X O0!U-%<M_PL3P_Z:E_X O1_PL3P_P"FI?\
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M^WYTVB@!WF/_ 'V_.G"1]K?,WYU'3A]UOI0 >8_]]OSH\Q_[[?G3:4*6Z#-
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M("0.Y (P.YK6MM,NI=:&K:@T(EBA,$$,)+*@8@LQ8@9)P.PP!WH V*PM/O\
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M"_Y[T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img40748725_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '7 J8# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@W
MG[SQCI@_YY0RG\P!_2MT#BL)#YGC:<'_ )8V:$?\"8_X5O4 (144SK! \TK
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M;S'Q_=3D@^QH AM=!U66TBDFU^\$CJ&8(0 "?3BIO^$>U#_H8;_\Q_A70 8
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M%LL6ES7T]S:705%VQ0 @[F( '/N:=<>(M3TQ+T7ZVCSQ6[3*(GY4@9VD?UH
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M&\S<S[LA2I"J?;''%=-K6MKI&C3ZA&!.(1T#<$D]R.E4;37=5NHIC%IEO*Z
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MDT\[RR2PR,A;GY1D<\# I+WPK$=$N+&RDE#3/&VZ>5I,;6![_2NB'&./I3J
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M/9&WMS(P9BS/(V68GN36C0 !THH **** "BBB@ HHHH **** "BBB@ HHHH
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M\*R1D%6&:ES7UT6FDSQ7H["T4450!1110 4444 %%%% !1110 4444 %%%%
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MB=I_W]%(?$&CKUU2S'_;9?\ &I%T?30/^/"W_P"_8I1I&G#_ )<;;_OTM,"
M^(M&Q_R%;/\ [_+4-UKMFNEWEW87-O<O;QE]J29 ^N*O_P!EZ>!_QXVO_?E?
M\*@N](MI].N;6&&*#ST*,40#/Y4 <W>^.8H;73FLVMKB:Y5VE0,3LVQEOYC%
M+8>*-1N-.DO);C2) MN9O*@9MRGWSVJW?^$[>[M+"&/RX6M0Z[TC +[D*?US
M3;/PWJ4=B]C/<Z<;<P^3F&U*/CW.: ,ZQ\9ZA-/;1M_9M\US TBQ6+L7C(&1
MNSV/3ZUH67BF>.>]@U."-I+=4<_9 S<MGY#_ +0Q3KOPDI@LO[/EBLKJVA:+
MSDC&3E<#..OK51?"&HG2A8O>V:A)%D_=0LN\CKO.<G/UH OMXWTA+2&X+3LD
M@8[5C+%=OWLT@\;Z/Q@S[BRHJ&)LL6!(P/PJEIW@A[2#RVO4;B4?*A'^LR3^
M1-5]6\*W\5[IESITZM/%+&K,R9"A5(W$>G- '2PZW9SZ3-J,;'R8@=X=2I7'
M8CM6>_B&\BFT2"2P^74F*O(&XB.TD#'X5,GAYD\/W]E--YMS>[FED P&8^@[
M#@4Z+2YK^TT66X;R9[)O,=,9!.TKC]: -&>^BAAD>-DEE ^6,-RQ]*Y<^+-3
M@:XM9[.W:Y1%D!A)9(@S8VOWW#KQVK:N?#5B\4KVL*P73 E)<D[6]<9J#P_H
M5]I%M+!-<6<L;+D&.$AF;^\Q).: )])UE]312\2PD1@N7./FST'T_J**R-3\
M%W%Y(LEM?HCD#S/-4G)&>1@CU_044 =I1110 R10R,O8C%<S#X0DMX_+AU:Y
MCC!)51SC)S748I:F4(S^)7&FUL<[;^&&AOH+F;4KB?R6W*K],UNR0Q3)MD0,
MI.<&I<4F*(PC'X4#;>Y!/8VMR&$\"2;EVG<,Y'I5&^\/Z9>::]@UI$(6C9%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX2U?2W>&WD^V6<A@ED4':6\LX9?Q4"F:OIUQ#8WM\-%86IM;A4MP_,;'D/\
MI^%=ISH]&^U0^67\U2 <$Y[XZ5#%J%O+%&QE1#(,JK-@FO/XM-U=]-2WAM9'
M%R\%RLN_A5$8!'YT^/PIJSV<WR%+K[&(HW+\AL\CVR.] ST!;^U:W\Y;J$Q
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MCC(Z;:?5;3I/,TVUDS]^)3^8JS0 4444 %%%% !1110 4444 %%%% !1110
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MTM)KB0X2)"Y/L!FO.-'BNYO$%@QTR^B1')9Y8"JCCUKO=9TXZMI<MCYQB67
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M,=!WH S+[QXEMJ4*0VQGM9HX'1U!S^\8J?RQ6D?&VD":9/-;;&KG?M.&V#+
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M0 ^BF!^3D8%.W?2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZFNR7[M5EM(4OY;L+^^= C$^@Z?SJR.E "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "'^=0W%M#=1-%<1)*C#!5QD&IZ* .8F\)BW._1KZ6Q).
M3%]^,_13P/PJO)=:YIY_T[2_M*=Y;-L\>K!L?I77XHH Y.#Q%IDQ -QY+#@K
M.IC_ /0L"M&.2.9-\3I(OJC9%:-W86E\NVZM89QZ2(&Q^=9,WA#1Y&+)#+"W
M;RIF4#\ <4 6/;M15 ^%[M#B#7[V->R%%(_,C-']AZW&?DU=)/\ KK'_ (4
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M 4444 %%%% !1110 FT"EHHH **** "DQ2T4 %%%% "8%+110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )C-&!2T4 %&*** #%
M%%% !@4F!2T4 &*1NE+10P.)?X9>'YM:N-3NHFG>9]YC<_(#]*M:1;0^&]8;
M3%B6.TN<R6K 8P1]Y,_K75$''&*RM:TQM2T]D5MMQ&PD@<?PN.1222U-9UZL
M_BE=&J/6JNHV,.HV$UI.,QR+CZ'L:@T75%U/3EE8;)T)2:,]4<<$5HXSS3,C
M%\/7\LD,EA=Y^VVA\N0G^-?X7^A%;6<CVKGM?ADTZY@URW',(\NY4?Q1'O\
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M#>I+;>=OB4#RV_NG% '744#@"B@ HHHH **** "BBB@ HHHH **** "BBB@
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M#)JYO'S$5(F+[SM.?3&/PH [4C2Y+:12+1[<2_O =I7?GO\ [6:HF7PRFH@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMI'D2%N'/KD\9]Z&N-8T_7M3U&^TVZCF>T),D3JVU<X4+[8_K0!ZB0IR H)
M[BFQQHI(6-5 ]%KS'3M2U>ZDDL1?3"(7<821!N_=F/+?-WY[U!>ZCKFE:.ET
MVHW3>9#)O=D'R8D4+^."?K0!Z9?6-OJ-C-9SH&@E!5E'!Q5B*%(8Q%&H50
M *Y[PO/+)>7\*74EW9(5\N9QCYB/F _&NGV]J %'3BBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>VT]BHBCFZ[\#) [?XUU- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 8'I1110 4444 %%%% !1110 4444 %%%% !1
M110 5!=VT-W;M!/&LD3$;D8<'!S4]! /6@!BD'H<BGTF!Z4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img40748725_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &: S(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBL76/%FA>'[B.WU348[::1
M-ZH59B5SC/ /H: -JBF0S1W$$<T3!XY%#HPZ$$9!I] !1110 4444 %%0W<_
MV6SGN/+>3RHV?8@RS8&<#WKF? WC7_A,[:\E.FO9FV<+R^]6SGH<#D8Y'N/6
M@+G64444 %%%% !17.:+XUTO7M<O-(M$N1<VF[S#(@"_*VTX()[UT= !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %> ZM8W'Q!
M\6^)+V!V,.G6[>1MZ-L.%7_@6&->Q^+KN[L_"NH26%O/<7C1&.%((R[[FXS@
M#MG/X5Y?X3^%^MSZ*MX=>O=$EN"=]JL+JV 2 6^=??@CO5(F6NAV'PJUU=3\
M%1PRR9FT\F%\]0@Y4_3''_ :Y2WU_P :?$'6;X>'K^/3["T.4W'9D$G;E@I)
M8@$XZ<?G/X$T/5_"7CK4-(N+.\GTRZ0QF\6W<1,0-RMNY X+#KU-4--MO%?P
MSUK48++0YM4LKK'EO'&[@X)VG*@X/)!!ZT"Z':>%];\3V&C:C)XPL706433)
M<_(#(H'*D+QGT/?-<CHNK?$3QM-=:KI.H6]I;6[E4A; 0G&=@&T[CC'+>O6N
MK\-V?BOQ%H&IIXKD\B&]@:&"W\E4=-P.6( R.V ??/:N.\.W'CCP(;O0X/#L
ME\LDI:*01.T8<@#<''!7@9!QCVH N^"/%OB/4M8U^#5+URUM932+#M4"*16
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MNQ\%/:ZA9SVTC7,A,<\;1MM(7G!P:X*+P]J?@G6+ZWN/!Z>(+.8_Z/*8#)M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5;4?\ D%W?_7%__035FB@#
MYM\%^)/#VA6]XFMZ%'J3RLIB+PQOL !R/FZ9R.E='\/-$U#68O$Q@MGL=)U&
MUDCA5L[-['Y I/4*"03[U[?157)43PGP9XUNO L-WX?U#1;F:Y,Y>.-.'WD
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MP6>N^)GU#1+>\^UI#)#^_?T1G!QM'/;/-0Q?"5TNH;%]55_#<&HG48[(P_O
MY'W"^?N#KTS2 ZG4?B#X2TF_FL+_ %ZSM[J$XDB=^5.,X/YUK:1K6FZ]8B]T
MJ]AN[8L5$D39&1U%4=9\-Z)>6U[<W.DV4MP\3%I7@4L?E]<9KC?@( /AE!C'
M_'Q+_P"A4P/3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN$\<_%;0? MS'9W2S7=ZZ[S!!C*+V+$\"@#N
MZ*Y;P5X^T7QU8R3Z8[I+$<2V\HPZ>A]"/<5U- !1110 4444 %%%% !1110
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M"2L='HW_ !YG_>-:-9VC?\>9_P!ZM&D0%%%% !1110 4444 -=BD;,%+$ G
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M')R><<5T]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S/B9B+F/&<^7V^IKIJY/Q3<I'J,,;.%)BSSZ9- T<WJ:3/9(HY)(R
M!UK)MK:.]?[.X,C?I[YKHFVM&K 9S]T@U2G;[%"9;>/]\YPJ+[]S34K:%)A>
MW4NGQ06MNO8 E!DCTJ"[NO)B5KIV>2%"TA7LW92*9=W3PRQ,S@2,O[Q@O' J
MA]AN+I&GA#><6'G%GRK*>OXU?+=78C=TC48M0MHY[<$$N58-UXK0:6.6-_,
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M<4Q=P)'WF'W2.Y]*IBY>!3.;:38QX)/)(/(I7MN%KEZRN$*7+*9B5?YE9.A
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MIM&BU>T?458J;<2#=N R1]?:D3Q;X?DULZ*FKVC:D&V?9Q)\V[&=OU]J^?\
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ML=)LTL]/M(;6V3[L42!5'X"K5%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!B^)_$MMX5TV/4+R*62!IEB;RL;ER#S@]>E+9ZAX?\ &&FGR7M-1MC@
MO%(H;:?]I6&0?J*=XE;0ET64^(OLWV#^+SQD9P<;>^[KC'/I7@%V+63Q2G_"
MOTU8/_#M)R.?X<<[/]X_6FE<ENQ[38_#C0-+\1VVM:='-:S0%CY*R;HVW*0>
M#DCKV./:NMKS/PK'\3%\26AU\M_9?S>=EK<_PG'W?F^]CI7IE#&@KD?'CI':
M6;R-M'FD9[<UUU<OXRGBCAM(I I+LQ (SP!DU+*1Y]=:Q!IU]';F,GSHV=7
MX7;SDU3O_%VFVFF6T]S!<3/<KOAA@CS+M'5B,\ 5P?C":V;Q'J#Q^(I4V6^8
MHMIQN)QY0]L<YKJ+:UE@\.Z;JFD*=:NXH#!&^\1[E).>OH>,=\4#-.S-IJ.B
M/<:<?)@F/F&4>N>1CL:V[:X1XUVN&51M93_.L'P5;)/X4$4;Y_>R"<.N"DN<
MLF/8]ZZ"#3=BX=@#QNVC[PIZ")H+>.1/,D0$DY7(Z"G364,L@F" 3JNU6]O2
MK*@   <#I2TK"N9D\4D6',189'(YQ4$EQ(A0)&'#MA@3U'M[UM @C(((]JC>
MWB>0R[!YFW:&/:@=^YGAH1M8,H ;"D\<^E-C6_EUB-TN56R13YD6.68_TJLI
MO;6\C2X6/[*R[2VS+"3M^%6K*69+MO/\O8WR@@\CGJ:GU&)X@0BPC8%N)URJ
M_P 0YXJ.T8R6^2@4]ZMZTIDT>Z$4FR:-#)&0,_,.16="MY'I:%PK7#J&^7C!
M-4MPZ%EH(A'(B1J/,!W8[TAAC^SB 1KM7U%31JDMLJRD0S@?-M.>:@#RI=-$
MZ QD I(#U]011>^X!:_Z%:RQ*[,&8LK,<E2>P]J9]EF1A+MB,#+G.X[\TZ9"
M0RJ<;ABIYI2T$61M*#+>G%#5@*TL4X*O#(4 Y;(SFK;_ &?RD8'9(X#+CK@?
MTJG=W4T MA'#YD4TF)2/X5QD'\Z8\L,<PO$+RAML8V#=CGK]*0&BD@D3RI@&
MW<9]:[?P?"+?1/+#$@2-@MUQ7%P+%(?.3.[.&],_2NW\*R))I3;&#!96!(]:
M:$>;ZA?7>G>*;YP\C1R2G?'DD >M6%U;3[R2-!<NC/T^8@?G4>N7,@UZX,2E
M@)65AL'/XFL^33@T3SDY)ZQ#  %9JZT-+)FO/:R/$-]R"V, HY -5/L\\:*F
M]\#D@,1FJ^CW$VUT1 K;3M#<A3VJS%?I=2K9ZD DH.!,K8!/H:M2%9D$4]U"
MJB038W ;BQ]:);B[C82*[%4;<P#GY03@9K1.F+;KGS9,9#[@<JQ]*KB#=#<'
MSER>2SKSCTQWI@1VUR\<O^L=$SN=MY)/M4ADEEG9HYY3&J_<\S P>]5V\K>J
M[9$0J""#C/U]*E58Y2SEUD>,8P>.3TIV$,GEN"GSR8"M\S*Q^6I/[1EEBDA7
MS T1'&3RO<U7OV\^U%O'"#<[5\W:?E_.K:2O"R6V49_+)Z<Y]36;W*Z%22_N
M7L2MM+<;YV,:DGD8Y_(5-:+*D\KM=$.75BBMAFP.1]2:2SMQ:O) %=G!\QF8
M\$GT]*9YTS 7$-NK/')M&XC '=LT)ZW M27$YN]J.Q382P9SN!ZXJ%M4U".R
M,T5NP4DDJ['<1[5/)"9%A= 6D(+/D8&?K3UE\VP;)C5\$9#9'X4["$N3.$T]
MVGFE8!G8,V=H(&!C^5,MO-2:1'\PL1O$I;@Y[ U LJR122JX?<%7(]N#4H9V
M@@FB8%=_?C*$=/:J6JN!%<RW5F(V,D\P=PK$M]T>IHM?.C$CP:A(_FG?&C'@
M\\_A3FD^SV?F2,1&.64C.?>JUI<_;B(=F8U.%8+M_$>@I*S8:V+'G74>I&-0
M^#&7WASS[5--)++$JEWVMP6!.1Z4Y_+2:/S8RKKR"/Y'VJI/=PR3K;[V60CC
M@@.*-@W.@\$)*/%$KR<'[.=W)^8Y'->D5Y_X),G]M.KC(6 @,3R>17H%-*Q,
MMPHHHIDA4-U!]JM)K?S98?-1D\R%MKID8RI[$=C4U5[^.YETZYCLY5BNGB98
M9&&0CD':3UZ'% ' ZYHFD^'8%DU'QSXIC=^(X5U+=)(?]E0N3_*J?AWPWXEO
M]8MM2;5M?L=)BD600:C?-+-< '.&08" ]"#G\:=H_@[QEHUV]\J>&;O47.6O
M;Q[B68_CT''' %=+:?\ "P/MD/VS_A&?LOF+YWD^?OV9YVYXSC.,U1)U=%%%
M24%%%% %;4/^0;=?]<7_ )&O.O@+_P DR@_Z^)?_ $*O1=0_Y!MU_P!<7_D:
M\Z^ O_),H/\ KXE_]"H ].HHHH **** "BBB@ I" 00>AI:0C*D9QD=: /D#
MXF^'= T?QQ=0:;K<<B33,\T0C9OLK$Y*DC@XST'->G^%/&&B>"_#-KX<\'QW
M7BG5Y@9G^SQE4#L/XB?N@8Z=?6O-/&?PN\6Z?XJO!#I5U?07%P\D-Q;H7#!F
M)&3V//.:]\^$'@^\\'^#1;ZG#''?SRF:0+@LH(&%)]1B@#(B\ ^*?&TJW?CW
M5V@LB0RZ/I[;4 ]';O\ K]:]&T?0M+\/V2V>DV,-I O\,2XS[D]2?K6C10 5
MY%XIN)OB=XT7P=ITKKH6FL)=6N4.!*P/$2GO@_U]*W_B9XON=&LK?0M#4S>(
M=6/DVT:=8U/60_3FK?A_1])^%G@21KJ=0L"F>]N3UFD/4_4\ "@"3QKXKLO
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MQ^]NYOGED/J6/3J>!73  # &!10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!C>)O#=KXITV.PO9)4@6996\H@%L9
MXR>G6K.CZ%IF@V@MM+LHK:/^+8/F?W9CRQ^M:%% !1110 5RWC96>SMU4#!8
MACWQCI74URWC2*62"U96 C4L67NQQQ0"/)-3\*17=Y>2O#:@2^4%.WE44\_B
M:EUG1M2>:TN-!GMK=XXFB-K(G[K;G.X ="*UIWO3/;K&J>3UF;KQZ5?0"U"(
M<EY6[=0*6Y1S%MH^IZ'HMM]AOLW1N6N+Q\?ZS=]X 5U.CR^?9>>TI>64[G]
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M6SMXX((QA(XE"JH]@*GHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDG X-9QFNG"RW"@.#UB.0!V-#&D+IEH+9YB\+1K(Q;:YR0U#VH6Z3S(4:0Y
MFQRH_P#KU,);>Y:&0NXD==NY""IJ+4X;YHE2&5 X<%68?PYY_2I;TT'UU)+6
MX-L1%-*[B1R$8_P<="?2G2B%4:9 ZN3\H!QD^M5Y[2#4M/=;@RK%DJP8[<CZ
MU62Y:.^,-R!MV 1R]$"C@*/4TQ6-.*8RP%9.6[^],E\^&63R8\L1E9&&0*$O
M(XE&V,LN,;B<$U1N]3O+F^BM-/C!.\>=G^!?4GU]J+A8NR36TT$<5ZR&0C)
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MT58),*HZ],FJ\MO>0HRM)$.>'XQBK4<8>V4J2I ^8#K^%) R)OMB(S,Z[RI
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MO<W4T3;9FMT!6,]P22,D>U<[XM^/EE;6HB\*6CZA/( !<2H5C1CT&.K-STH
MN_&3QY'IL,?A6QO4MKR^'^E7+' MX3UZ=SR,5P5W\0=2L='TWPMX TRXLK.?
M$4%W+&!<7;=&=5[9ZYKH;+P3I/AW0Y_'WQ%9[_5I_P!\;67&T2-]U-O=O;H/
MPKJ?AQX8O;Z_E\<>)80NJ7BXL[8CY;.#^$*#]TXX^GUH TO /PTT[PI:)>7L
M:7VO2_/<7LIWMN/4*3T^O6N\HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  CS,$'O73US'C-U2TMMS!1O/7Z4F-'$Q274OG&=5PKGR@G9??WJ0%I5SO7
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M^% '>45P?_"Y? ?_ $'4_P"_3_X4?\+E\!_]!U/^_3_X4 =Y17!_\+E\!_\
M0=3_ +]/_A1_PN7P'_T'4_[]/_A0!WE%<'_PN7P'_P!!U/\ OT_^%'_"YO ?
M_0=3_OT_^% '>45P?_"Y? ?_ $'4_P"_3_X4?\+E\!_]!U/^_3_X4 =Y17!_
M\+F\!_\ 0=3_ +]/_A1_PN7P'_T'4_[]/_A0!WE%<'_PN7P'_P!!U/\ OT_^
M%'_"Y? ?_0=3_OT_^% '>45P?_"Y? ?_ $'4_P"_3_X4A^,W@,#/]N*?I$_^
M% '>T5P?_"YO ?\ T'4_[]/_ (4?\+F\!_\ 0<3_ +]/_A0!WE%<'_PN7P'_
M -!U/^_3_P"%'_"Y? ?_ $'4_P"_3_X4 =Y17!_\+E\!Y_Y#J?\ ?I_\*/\
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M>QATG5=.66X,.IRRRS,67<ID&&V\<#TSFMNB@+&-/X:LKBRTBU>6<1Z7+%+
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M/6])FOC8Q:G9/> D&W6X0R CJ-N<URND^%]:A\0W=_<)I.GP7-DUO)'IC/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img40748725_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA=&AE=R!/
M)T1O;FYE;&P    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M,@  DI(  @    ,T,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,CHP,SHQ-2 Q,#HT.#HQ,  R,#(R
M.C S.C$U(#$P.C0X.C$P    30!A '0 : !E '< ( !/ "< 1 !O &X ;@!E
M &P ;    /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(R+3 S+3$U
M5#$P.C0X.C$P+C0Q-3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y-871H97<@3R=$;VYN96QL/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( >$"2 ,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** #%&*\IDUW48_A<U^U_,)UU=XS-N^8()V&/I@8KI?#]W?>*=:_MY+F2'18
M0T=E;HW_ !\'H97]O04["N=CBC%<]XVU:ZT?P9J-_IW-Q#%E&QG9SC=CVKE6
MF'AO5/#]U8>(;C4UU"X6"ZBGN!()=Z\. .A!Q0%STO%%>;>.S;::MW=#Q-?P
M:N<-8VL<VU%)X50N,$'!ZFKNJ7>IZEJOA[P[-=26,EW:_:=0DMFVN=J<HI[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBN-\5:KKVD^)?#@MKNS73=1U1+*6'[,3,089')\PM@#,?0+GD<\<
M@'945Y[JNK^(+N;Q7J&DZH;*'PV?*@M/)C>.\D6W2=_-+*7 /F!1L*XP3SG
MC?7];\2MKE_H.J-IEOH]M"]M#Y$<B74KVZW!\TLI;9MDC7"%#]XY/& #T:BO
M./%'QGT#P?X>\.ZMK%GJ$T?B"U^TVZV:(^P;(V(;>Z_\]1CZ'I5/P?\ 'WPM
MXV\5V?A_2[#5X;N\W^6]S#$L8V(SG)60GHI[=: /4Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B7BC_D\CP;
M_P!@63_T"\KVVO$O%'_)Y'@W_L"R?^@7E 'MM%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)>*/\ D\CP
M;_V!9/\ T"\KVVO$O%'_ ">1X-_[ LG_ *!>4 >VT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=&&593D$>H-2=A5U*DJDKR,<)A*>$AR4]GKJ.HHHK([0HHHH **** "BBB@
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M!9/_ $"\H ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJUNOM$+,=^$#[F&X 9(]&% '8T444 8^H^)]%T>[2UU/5+:VG90VR60 JI.
MS?W03QDX&:;J?BG1-%O!;:IJ,5O+L61PV2(D8E0[D#"*2" S8'!YXK@+^/44
MNOB7>K=6 6W=6FM;ZU\Q;BW6RC8([;AB(YD' X)<\\BK>D7%M=VOCZXO+?[/
M'-:V[F&?_EG;G3HR%.>P;S1]=U 'IW7I7B7BC_D\CP;_ -@63_T"\K:U+P1X
ME\9^ _!_V'QGJ/A>[M-,C^V?9!)FX=XHOO;9$^Z5;KG[QZ=_/-(\+:IX0_:F
M\*6&M^)KOQ+<2:?-,MW>!MZ*8KE1&-SN< J3U_B/% 'TM1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP&37.^&K.XDMY+R0@7"JZIO!*^<[;YF[$@.0G;B/WJ7QC-+-#9Z1:X^T:A.
M#_=1,,S?3(4'V)K?L[:.SM(K:$8CB0*OX5?PQ]3G?OSY>B_,R+;3M8AU":Y-
MU8GS@@8"W?@+GI\_O6]B@4M2W<TA!05D%%%%(T"BBB@ HHHH **** "BBB@
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M:LK7^?\ P#<HHHK$[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KQ+Q1_R>1X-_[ LG_H%Y7MM>)>*/\ D\CP
M;_V!9/\ T"\H ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!#TKD?&EA8+!:W3V,4US+?0H!@!I23C;GW Q]*ZJ:9((FEE<)&@+,S'  '
M4FN4UI_,6SU6])AMX[^'R4D^7RT#<R,#T) []%QT)-7"Z=SGK*,ER-7_ $\R
M0Z8EM;VV@Q(@>_=I[TQKA?*4@N,>C96,#KM)/4&NKSQ6/H<;SK-JMTA2:](*
M(XP8H1_JT/OR6([,[#L*V,4I-MZFE."A%*.PM%%%2:!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <5XIU7Q/I-IK6L1
M2:98Z9I,!EA2[C:5KW:@=RS*X\H9RBC#'(W<Y"U7NO$>OZG-KLV@R6UG%H=O
M$_D74!<W,S0B=D9LC8NQT7(!.23VP8-:T[7]9\8N^LZ%<7^A6,B/865O<P+'
M/(.3-.&<%L-]U.@QDY.,2:A8>(K&]\1OI6C/??\ "11QR1DW$2+9S^0L+"7+
M E $0Y3>3\PP."0"[JWQ3\*>'M#T;5/$&I?V?#K-L+BT'DR2[UVHQ_U:G&!(
MO7&<UY2OC#0_&W[6'A+4O#%]]NM8M,E@>7R7CPXCNF(PZ@]&7G&.:]YT+2X]
M$\.Z=I,+;H["UBMD8]PB!0?TKR+Q1_R>1X-_[ LG_H%Y0![;1110 4444 %%
M%% !1110 4444 %%%% !1110!3OKFYM8%>UL9+URV"D;HI ]<L0*H:-K<^KJ
M)3I-Q:V[;@)9)8R,JQ!&%8GJ#VIOB?7_ /A'-)^W&.*4;@NR24H22#PN%;)X
MZ<=^:YSX?>*SJA.F>1'"8@\F6F)=@SEN%V8XW8^]^%:QIR<'-+0XYXNC"LJ,
MI>\^AZ!FFDC'-([JBEF(  R23P*R=S:WPNY=/SR2,&Y^GI'[_P 7T^]FE<Z9
M2MHMP"_VS.K\BPB;<H_Y^&'0_P"X#R/[QYZ#GPKXD^(-6'C74[ :E="UBG4I
M!YIV+A1C"]*]YU2]>W$5G8!6OKD$0*?NH!UD;'\*\?4D#O7'>(OASX>:2UNY
M[>:6ZNKV%;B9YFS+N;#$@' )]L>U;T9QC*\C*=-M:/7J6_A)J5[JW@C[1J5W
M-=S"YD7S)G+-@ <9/UKNZRM"T'3_  WIHL-)A,,&\OM+%OF/4Y/TK5K&;3DV
MC:*:BDPHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KQ+Q1_R>1X-_P"P+)_Z!>5[;7B7BC_D\CP;_P!@
M63_T"\H ]MHHHH **** "BBJ]S.UO:O*EO+<%>D4(&YN>V2!^M %BBL&P\2&
M^O9;9-(U&-H)1#,SI&%C8JK\X<G[KJ>,]:WJ+-;B3N%!Z44'H:!GF6M?$6ZT
MS7I+*WN+>:&*0I+(+)B4YZ#]Z-V.A/%>@:=<_;-.M[@2I.)8P_FQH45LCJ%)
M)'T)KQWQ!X1U&3Q3(+.PN1%>3.R!RFXX.6Q\W(QR,XKUS0;1;'0;.W6*2$11
M*OERD%A]<<9^E==:--0BX[GAY?4Q4J]15E[O3_@&G24=J@NKJWLX3-=3QPQK
MU>1@H'XFN0]IM)79S?C[19]>\/K;VD$DLZ2AT$90 '!'S;F''/;)Z<5QW@'1
MY-'U-=6U:&6)&5XK<HRMO;)!&T-N)X( "GUS3?C-JDESX>L#:Q7$<'VDXF<&
M/>=IZ*><>Y 'IFN2^#\LA^(UJ&=B##*",_[)-=T.94&NAY%;"TJN*C77Q*WH
M>ZI:7&I,)-30Q0 _+:!@=WO(1P?]T<>N[C$NH:@ED$AB3[1>S ^3;!L%\=S_
M '5'=NWN2 :\FKR7DC6^A*MRZG;)=/GR(OQ'WV_V5_$KQ5FPTQ+'S)=[SW,V
M#-/(<O(1T]@!DX48 R?4UQL]6,4MOO%T[3VM2\]U)Y]Y/@S2XP..BJ.RCL/<
MDY))JKXE_P!3IW_81M__ $.MFL;Q+_J=._["-O\ ^ATD[LI[&U1112*"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KQ+Q1_R>1X-_P"P+)_Z!>5[;7B7BC_D\CP;_P!@63_T"\H ]MHH
MJ"ZN8K.TFN;A]D4*-)(V"<*!DGCV% $U%<9-\5?"D0&R]FFS_<M9!C\U%;8U
MJ5P&BTF_=2.#L0?S8&K<)+=&"KTY?"[^FIL9HS62-5U!AQH-ZI_VI8/Z2&E^
MW:P?NZ1&O_72[ _DIJ>4?MH]G]S(M#S_ &QXC_["2?\ I);ULD^]<;INHZC#
MJVO;H=/M\WZ-(TUX?E/V: <#9R,8.<CG(]ZLS:\T1)N?$^@6@'57^8C\3*O\
MJKE8E571-_A^9U0-!Q7(?VS8R\_\);)/[64<;@_3:C']>:43Z-+UBUZ_8_WK
M>[V'\P$HY0]I)[1^]K]+F/JOQ*\,+XEL&-\^+)YTF/D/\I*[1VYY%=5:>*+;
M5+..YT:TN[Z.5=R.L)B7_OJ3:/RS7SMJ7A+7VU>41:'?H)YI#"AMV!8 YX&.
MPKW#P?;>)K3P=IMF;2QLO*@"YN7D>3_@485=I]MQK>K"$8IHB,JDVUM\C>V:
MS><2R0:<A_YX_O9/^^F 4'_@+4&QTS2E-]?2IO7K=7DN2OT+<+]!@4PZ1J5Q
M_P ?VNW)!ZQVD20*?QPSC_OJIK;PYI=I,)X[027 Z3W#M-(/^!N2WZUA==S1
M4U>[U?F9NI7%AXBA6"WT3^VHU;<DEQ'Y=NIZ9#N.1[H&K$\(^"-.EL8;^]@@
MW[I5$-O$(TQO889A\S],8)"X_AKT$UC>%/\ D6X/^NDW_HUZ:FU&R*Y4Y:FM
M'&D,:QQ(J(HPJJ, #T J2BBLS0*Q?$G^IT[_ +"-O_Z'6U7->(KF\DFMX+;2
M+^X$%Y#,TL8CVLJD$XRX/Z4UN3+8Z6BJME=/=VPE>UGM221Y<X4,/?Y21^M6
MJ104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#MIK&G6R6E_%8^2I=O,@F=FRS%NA0#OZURO_";?$[_HD?\ Y<MM_P#$T?\
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M?<\ 9P!C=HH **** "BBB@ HHHH KWW-A<8_YY-_(UY9X?E31/"WPTU?5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP$%NVQ0@4[ ^&!R?O&O7USM&[&['./6@!U%%% !1110 4444 %%%% !1110
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M:UJ[-WK'AW2M0N2H4S7=E'*^!T&YE)Q6A:V%I9LS6EK# 65$8Q1A<JHPHX[
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M4]%T^\M;?_4V]Q:I)''QCY5((''I5E-/LXWMS':0(;52EOMC4>2I&"%X^4$
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M'Q/'& BG4(W( Q\S6\1)_&NDHHH **** "BBB@ HHHH **** "BBB@ HHHH
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img40748725_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA=&AE=R!/
M)T1O;FYE;&P    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M-0  DI(  @    ,R-0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$TFB-+;Z]X>U>:[U?[6AMK4N720LX#+LQQ\I)SVQ7J%O;06D(AM8(X(QT2-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7FW[/G_)"O#W_;S_Z4RUZ37FW[/G_)"O#W_;S_ .E,M 'I-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWG_TIEKTFO-OV?/^2%>'O^WG_P!*9: /2:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *2@U#<W,=I;O-,VV.-=S'T% FTE=E75;J6*-+>S(^UW!*19&0OJ
MY]E'/N<#O5+2[:.R\0WEO$242SMP"QR3\TW)/<FK6GV\DDS:A=KMGF4!(S_R
MQCZA/KW)]>.@%-M?^1KU#_KTM_\ T*:KV31S-.4XR??3TLS6HHHJ#J"BBB@
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M<R:1.D4\4,63+&=NUGR2 W^V/RKH:3GZ4TQRAS-.]K#J***DT"BBB@ HHHH
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MU9M](TZT %I86T('3RXE7'Y"LO=.N]1]$OG?]$5O^$ETIAF"Z^U?]>L;3?\
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MP_Y&+5?^V7_H)K6K)L/^1BU7_ME_Z":<>IC4^*/K^C-:BBBD;!1110 4444
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M*!ENEK+TK7;/6D+Z?]I:/:&$DMG+$K _W6=0&_#-:E%K;BO?8****!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <?XGM]:A\5Z7JVC:%%K(MK6>$I)>+!Y3.T9
MW#<#GA2/QK,\+R^,-*N;BVG\&6UI8W=^TX,>K1D6R/C=A0G/S;FP.I:O0Z*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;]GS_DA7A[_ +>?
M_2F6O2:\V_9\_P"2%>'O^WG_ -*9: /2:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@""ZM8;VUDMKF,20RJ5=3W%>5_%;4M6
MT;P[9V8O+F.47.8KJ)RIGC"GAR/XQQGL>".X'K=9VK:/9ZU8M:ZC DT9.5+*
M"4;LRYZ$5=.:C)-D3BY*R/)/@AJ=[=:Y?6UU>3S01V@*1/(65?G X!Z=:]K%
M<;X!6SM=&L[?[%;VE\]JK^;'$J_:8_[P(')!(R.Q/H03V555ES3;%35HV%HH
MHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\V_9\_Y(
M5X>_[>?_ $IEKTFO-OV?/^2%>'O^WG_TIEH ])HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBJE_!=3P!;*\^R.#DOY0DR
M/3!H Q- L8M0\$Z6DF]'2!'BE3AXG X93_D$$@Y!(K1L=0D^U'3]14)>(NY6
M PEPH_C3],KU4GN""6:!I%UHUC':3:C]KABC"1@P!"N/<'FK=[81:C"$N P*
MMOC=&VO&PZ,I['^A(.02*IM79*3L7:*R+:_EM[I+#5BHE8X@N ,)<>W^R^.J
M]^HXR!KU+5AWN%%0RR"*)Y&#$*I8A5+'CT Y)]A65:>*=.O+P6L":AYV0K*^
MFW*!,]-Q:,!1[G%%FPND;=%%% PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KS;]GS_DA7A[_ +>?_2F6O2:\V_9\_P"2%>'O^WG_ -*9: /2:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *UU:PWEN]O=1K)$XPRL/\\]\]JS/M%WHF%O#+=Z=VN<%I8!Z2 <LO\ MCD?
MQ#JU;E%"8K$,$T=Q"DT$BRQ. RNC JP]01UK+TS_ )&G6_\ MW_] -5=;MWT
M'3-0UC1W6 V\,EQ-:LN8I]JEC\H(VL<?>'7N#7FOAKXM7M[XRCBDTV!1JMS!
M Y61OW?\&1Z]<UI&FY)M&<IJ+29[=11169J%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME^0AMQ38?]8G )Z^QK>G4C%-25S*=-MKE=CZ&HKS;_A-OB=_T2/_ ,N6V_\
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M;2E?39KB.V-TUT!(7?@%(@IW*#U)92.2 0*Z"@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *P_%^E:?J_A:^AU2S@NXHX9)4CGC#J'"-AL'N,FMRHY8
MHYHGBE4.C@JRL,@@]10!Y]8!7F^&JSA6B%@[H&Z><+5-I'^UL,N/;-6?!^E0
M:IH.L6,S3PV*:]>FV^PW<ML0HE;(#Q,IQO+\ X]N*ZF[T'3+[3HK&[L8);6W
MV^3$R<1%1A2O]T@<9':K5C8VFF645GI]O';6T2[8X8E"JH]@* ,>TT+4%\1_
MVGJFJ1WD=NLT=G&EF(Y(TE96*R2!CO VJ!A4X&6W'D=#110 4444 %%%% !5
M/4=-L=7L)+/5+2&\M9,;X9XPZ-]0>#5RB@#R?2XT'@3X<VY1?L9U:,2IM^3"
MQ7#1Y'3 E6,C_:"UO:!8IJ6N^.K"0RQZ>=6A*FSN9+=ED^R6[R8>-E9?FP3@
MC)+9ZFNGGT+2Y]'&E36%NVGC&+8QC8N#N! [$$ @CH1FI--TNRT>S%IIEK%:
MP!F;9$N 6)R6/J23DD\DT 8]AH&L67BA]0DU:TNK$KY44$UE(UQ#$% "+.9R
M.6 9F*$MW/"XZ>BB@ HHHH **** "JU[8VNI64EI?P1W%O*,212+E6'7D59H
MH \CL+:W@^%NDV8ACBT]?%CQ21*NV,1C59 JD#C;N"#'3H*Z;2[1;OQ]XTLS
MOCLIH[(N;69X7\XQOO.]"&5M@AY!!QCVKICHVFMI<NFMI]NUC,SM);&,&-R[
M%V)7IDL23[G-+IFD6&CV[0:9:1VT;N9'$8^^QZL3U)X')]* *RZ$D6J:9=0W
M$OEZ?;2VZI,[2O('\ODR.Q8D>7U.2<]:V*** "BBB@ HHHH **** ."T_3+3
M2_BIXA71[.&U:;0[29A!&%\R4S70W''5N ,GT'I6+X>54T;X32V2H;AXSY[C
M[S*UC(TVX]>90I.?XMN>:].6SMUU"2\6"-;J2)87E"_,R*6*J3Z NQ _VC5&
MR\-Z/IFI2:A8:9:P7<F_=*D8!^=@SX]-S $XZGDY- &?I7A>?3M;:X;4!)8Q
MSW-S:V@@*M'+.Y>0O)N.\;F?:-JX#'KQCIZ** "BBB@ HHHH **** .*MM*L
M-.^,+36%E!;RW>D2RW$D485IG\]/F8CJ>3UKFM,0#PEX#G@2+^T6UYC(Q^^9
M&^T?:>>N<;\_3GI7J1L[<WPO#"AN1&8A+M^8(2"5SZ9 .*HP>'=&M=8?5+?3
M+:.^<LQG6,!LM]XCT+8Y(Y/>@!9M(,WBFQUDS[?LEG<VGD[/O^<\#[MV>,>1
MC&.=W;'.K110 4444 %%%% !1110!Q6IZ5I]K\5] U"VLX(KNZM[P3W"1@22
MA5CP&;J0/2N7NE(\":I<1HG]J_\ ":*49QAS(-31(_?_ %.U1_L>U>JR6=O+
M>0W,L*// &$4A7+(&QNP>V<#\JHMX:T9]8&K-I=L=0WB3[1Y8W;PNT/_ +VW
MY=W7'&<4 4I]%UF3QBFJC5;%K&,*L=G-I[O)"N,.4D$P4,W/S%"0..F<]'11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E-[JU21$2ZN+4B0 '?#,\+'@G@M&2/;'3I0!HT444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img40748725_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '> @$# 2(  A$! Q$!_\0
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M (70W_0*'_?7_P!>C_A=#?\ 0*'_ 'U_]>O*,48I?7:W<T_U9R[^7\6>K_\
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MH_X6!<?\^2_]]5QU%>/_ &MBNY\__;>,_F_ ['_A8%Q_SY+_ -]4?\+ N/\
MGR7_ +ZKCJ*/[6Q7\P?VWC/YOP.Q_P"%@7'_ #Y+_P!]4G_"P+C_ )\E_P"^
MJX^BC^UL5W'_ &WC/YOP.R_X3VX8'%G&/Q-+_P )Y/\ \^:?]]5QZ4ZE4S?%
M1:M(RK9[C8M6E^!UW_">7'_/FG_?5'_">7'_ #YI_P!]5R-%1_;.+_F,?[?Q
MW\WX'7?\)Y<?\^:?]]4?\)Y<?\^:?]]5R-%']LXO^8/[?QW\WX'7?\)Y<?\
M/FG_ 'U534_B9-IEG]H;3U<;L8#<USE8GBK_ ) O_;05TX/-,35K*$GH=N7Y
MSBZV(C"<M'Y'2?\ "[6_Z!/_ (]1_P +M;_H$C_OK_Z]>245[GMYGU'MZG<]
M;_X7:W_0)_\ 'O\ Z]'_  NUO^@3_P"/?_7KR2BCV\P]O,];_P"%VM_T"?\
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M>H_ZV'_KD*J5WK9'X/F?^^5?\3"BBBF<(4444 %=MX9_Y :?[YKB:[;PS_R
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M;&7'WH_^^J?(Q.O3MN1:C_K8?^N0JGBM6_L)GDA(,?\ J@.6%5?[-G_O1_\
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M1X5MY)&R=HRJJ"67.>0.E7?!<V= BM7M[N&:%G+K<6LD7WG8C!=0#QZ9QWH
MZ*BBB@#S+XT?\@73/^OAO_0:PO@S_P C)?\ _7I_[.M;OQH_Y NF?]?#?^@U
MA?!G_D9+_P#Z]/\ V=:\N?\ OB_KH?=8;_DG)_/_ -*/:J***]0^%"BBB@#"
M\._\?&K_ /7Z];<O^J?_ '36)X=_X^-7_P"OUZVY?]4_^Z: ,KPO_P BY:?\
M#_\ 0VK7K(\+_P#(N6G_  /_ -#:M>@ JO??\@^Y_P"N3?RJQ4%]_P >%Q_U
MS;^5#&E=V/BR^M;G^TKLBWE.9F_A/K5?[+<_\^TO_?!KN;FXF%Y/B0_ZQOYU
M']IF_P">AKRY8R*>Q]G#AFI**ESG%?9;G_GVF_[X-'V6Y_Y]IO\ O@UVOVF;
M_GH:/M,W_/0TOKD>Q?\ JO4_G.*^RW/_ #[2_P#?!H^RW/\ S[2_]\&NU^TS
M?\]#1]IF_P">AH^N1[!_JO4_G1Q?V2YW+_HTO4?P&NWG@F\Q?W3_ '%[>U,%
MQ-N4>8<9J>]N9UNV E8# XS[5E6KQJ1V/1RO*JF!K-J2=T5O(F_YY/\ E1Y$
MW_/)_P J4W,__/9_SH^TS_\ /9_SKE]T^AM6\A/(F_YY/^5'D3?\\G_*E^TS
M_P#/9_SH^TS_ //9_P Z/=#]]Y">1-_SR?\ *@P38/[I_P J7[3/_P ]G_.C
M[3/@_OG_ #H]T&JUNA8O(9=T/[M_]6.@JOY,O_/)_P#OFK5Y<3!H<2L/W0[U
M7^TS_P#/9_SJY6N>5#VFNPWR9O\ GD__ 'S1Y,W_ #R?_OFG?:9_^>S_ )T?
M:9_^>S_G2]TO]YY#?)F_YY/_ -\T>3-_SR?_ +YIWVF?_GL_YT?:9_\ GL_Y
MT>Z'[SR&^1-_SR?_ +YK$\56\[+IX6"1B$;.%/%;OVF?_GL_YUU>@.TFD(TF
M';<>6&:J.(CA[SM<^7XLQ<L+@/:25U='BOV6Z_Y]IO\ O@T?9+K_ )]IO^^#
M7ON%_N)_WR*3 _N)_P!\BI_MN'\I^7_ZSQ_D/ _LEU_S[3?]\&C[)=?\^TW_
M 'P:]\P/[B?]\BC _N)_WR*/[;A_*'^L\?Y#P/[)=?\ /M-_WP:7[+=?\^TW
M_?!KWS"_W$_[Y%&%_N)_WR*/[;A_*'^LT?Y#C?AE%)%I5Z)(V0F48##%=O52
MY.(UVX7GL,56WO\ WC^=>=B^3$U/:O2YX>/C#&5?;[7-2BLO>_\ >/YT;W_O
M'\ZY?J\#B^HP[FI167O?^\?SHWO_ 'C^='U: _J,.YJ<UF:\K-IN "3O' I-
M[_WC^=6+5BV[)S]:VH4X4JBGV-\+0A0JJI>]CD/*D_YYO^5'E2_\\V_*NV_
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M6JM=J^%'I1^"/H%%%% PHHHH *L6G5ZKU8M.KTT'<L4445PGEA1112 ****
M')]XU[97B:=37ME?2Y%M/Y?J?6<.?#4^7ZA1117OGTH4444 %%%% !1110 4
M444 >4?'5]F@:7_U\M_Z#7._ N3?XGU$?].1_P#0UK:_: ?9X>T@YZW3?^@U
MS7P DW^+-3&?^7$_^AK7.X_O;GH0K6PKA_6Y]"4445T'GA1110!A>'?^/C5_
M^OUZVY?]4_\ NFL3P[_Q\:O_ -?KUM2_ZI_]TT 9?A?_ )%RT_X'_P"AM6O6
M/X7_ .1<M/\ @?\ Z&U;% !6)KFL&S<6,5G+<RS0NQV$ (H[G-;=<YJG_(RI
M_P!>$E)[%0^)'SI<'-W.>G[QN/QJ.I;G_C\G_P"NC?SJ*OG);L_8J/\ #CZ!
M1112-0HHHH&A1]Y?J*GOO^/Q_H/Y5 /O+]14]]_Q^/\ 0?RJOLF:_BHK&B@T
M5!U!1110,*.QHH[&@3V+5Y]Z#_KD*KU8O/O0?]<A5>KEN>1'J%%%%(L****
M"NO\._\ (&3_ 'S7(5U_AW_D#)_OFL,3_"9\1Q]_R*7ZHU****\8_"0HHHH
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M4 <S'8:_I][?-8BR>&XF,J^:Q!&>W%2R/XI\IP8=.^Z?XVKH:;+_ *I_]TT
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M(MF*I>GY'S]7%\N9JCZ?D>A4445[9] %%%% !39?]4_^Z:=39?\ 5/\ [IH
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MHKQC\)"BBB@ HHHIC(;G_5K]:JU:N?\ 5K]:JUVKX4>E'X(^@4444#"BBB@
MJQ:=7JO5BTZO30=RQ1117">6%%%%( HHHH 4=_I7MM>)#O\ 2O;:^FR+X9_+
M]3ZWAWX9_+]0HHHKWCZ0R_$.F2:OHLUI"ZI/E)(F?[N]&#+GVRH!I;#4-1NI
MD2YT6:S4+F226>-EW>B;&);ZD+Q^5:=% '/6NB2SZ;K]C>*8H]0N9RC*03L=
M0 W'X\&LC4M)OM4T:+3K[P['-J42)#'J0,+1+@CYP682*,#D!>O3/6NXHH Y
MT^';6]\4:A?:EI=I<PO% MO)/$DA!7=NQG)'45T5%% !1110!R7CW_CPM/\
MKJ?Y5G> _P#D*W/_ %P_]F%:/CW_ (\+3_KJ?Y5G> _^0K<_]</_ &85\S6_
MY&\?E^1\=B/^1]'Y?D=]1117TQ]B%%%% !39?]4_^Z:=39?]4_\ NF@#*\+_
M /(N6G_ _P#T-JUZR/"__(N6G_ __0VK7H HZS_R!;W_ *XO_*J$=E:W7AF!
MKBWCE:.W)0NH)7CM5_6?^0+>_P#7%_Y57L_^173_ *]C_*DRH?$CYHN1B\G
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M !1110 4444 %%%% !1110!2UC_D"WW_ %[O_P"@FN:\"?\ )+M/_P"O5_\
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M%%X=@O#L/0$&O:Z\2'?Z5[;7T>26Y9V\OU/J>'^7EGR^7ZA1117NGT84444
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MS'D_,V.,#UZUVL,2P01PH,)&H5?H!BGT4 %%%% !1110 4444 8L7S>-[O\
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M59L+'5]6\4P:WJMBNG0V4#Q6UL9UE=G?&YV*\ 8& .?6NJHH **** "BBB@
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M]7_\$]W_ /&J/^$IT_\ Y]]7_P#!/=__ !JERR[!=&U16+_PE.G_ //OJ_\
MX)[O_P"-4?\ "4Z?_P ^^K_^">[_ /C5'++L%T;5%8O_  E.G_\ /OJ__@GN
M_P#XU1_PE.G_ //OJ_\ X)[O_P"-4<LNP71M45B_\)3I_P#S[ZO_ .">[_\
MC5'_  E.G_\ /OJ__@GN_P#XU1RR[!=&U16+_P )3I__ #[ZO_X)[O\ ^-4?
M\)3I_P#S[ZO_ .">[_\ C5'++L%T;5%8O_"4Z?\ \^^K_P#@GN__ (U1_P )
M3I__ #[ZO_X)[O\ ^-4<LNP71M45B_\ "4Z?_P ^^K_^">[_ /C5'_"4Z?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Q?B:S\4V5KJ>K6?BSR;:"-YH[3^
MSHFP%&=N\\]NN*[2L;Q=_P B;K/_ %Y2_P#H)H Y_P +6OBO4]/TS5[KQ;O@
MG5)I+3^S8AN7NN\8/XXJ"&;Q1KWBO7[.Q\2_V;;:?,B1Q_8(ILAESU.#V]^M
M=!X&_P"1&T7_ *]4_E7(Z;INM7_CGQ8=)U_^R@EQ%Y@^QI/YF5./O'C'/YT
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MB\ ?\B'HW_7N/YFN=\'?\DNU?_>O/Y&NB\ ?\B'HW_7N/YF@#.^)O_(!T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img40748725_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (E![P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5R\'B345F\1)J%E;6_\ 9=NL\8BF:7<I5VRQVKS\O0#\
M3745@'1KK^U/$-SMMGCU"VBBA2;+*2JN"' _A^8=#TS0!23Q%?VWAZ^U2XNM
M)OW@B&VWLB4Q,<!4=B[8R2!TJ&X\2ZQI4MSIE]'8W&ID6OV26!&BB?SY#%AE
M9F/R%2QP>1C&#56?P?J.J-=3R6FF:1*--^QV\5HYE1G#K(CO\B?*C( HQG#/
MTSBI;[P_KFL7-UJ\T-I:WT0M/L5MYWF*3!*97WOMX#[BG .  W4X !HP>([C
M3M/U]];6*271(S/*]E&5$\7E^8&5&8[3PRX+$97.>>.%_P"&CO!__0-US_OQ
M#_\ ':]!TK29YIM8N]9M;?\ XF;+&;3B55@5-H5R1ALDN2.F&QS6%XT\%^%;
M7P+XAN+?PUHT,\6F7+QR1V$2LC")B""%R"#SF@#I/"WB2S\7>'+37+".>.UN
MM^Q)U <;79#D D=5/>MBO/\ X)?\DAT+_MX_]*)*] H **** "BBH7NK>*98
M9)XUD;HC, 3^%*4E'5NP$U%%%, HJM>7]M8"$W,GEB:984.TD%VX4''3)XR>
M*)[^VM[RUM)9-L]T6$*!22VT9;IT '<^H]: +-%0W5U#96DUU</L@A0R2-@G
M"@9)P.>E$MU%#9O=-O,2(9#LC9V*XSPH!)/L!F@":BFJX:,.,[2,\@@_E45G
M>0:A9PW=K)YD$R!XWP1D'H<'F@">BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FJ07ESI5
MU!I]VMI>21,D-PT>_P IB,!MO?'7%<QIO@NX@\-WOA^]N+.2RO;>2.XFAA<7
M$LCC!E=V=MS=3DCT[#%=E10!Q]QX/OM:%RVNZA \S::^GPR6D)39O*L\IW,?
MF)2,@=!M/)S3KKPC>ZR;V;6+^#[7+9"TMWM(2JPX<2>9AF))+JAVYP N.Y-=
M=10!AZ5H]]'K5QK&JW%O+=R6Z6L:6T95$126)Y))+,WT  'J3N444 ?/_P#S
M=Y_G_GPKZ KY_P#^;O/\_P#/A7T!0 4444 %%0S7"P$ QRMG^Y&6_E5>?5(X
M8))?L]R=BEL&%AT]\<5E.O3A?F>P[-EZBL'2?$9OWE26V<%>08E+<>]:@OT)
MQY-S_P!^&_PK*CC:%:"G"6C&XM:,M444R56>)U20QNRD*X )4^N#Q742/HKG
M_P"U[J3PU&Z%5U.5_L8X'RSABC-CN!AGQZ"KEWK2V9E M+JZCMA_I$\03;%@
M G(+ DX.<*#^?% &I17.IKCV^H:MMM;V]@B='+0[2L2&)#QN89[G"Y/MR,W9
M]7MK6XED>:=HQ!$ZQJ@*MO9E7;@;BQ(Q@\=/>@#5HK%FO[J:?3M]G=V.Z\",
MLSQ_O%\J0_P.PQD#KW%2RZ[%%)DVERUH)!$UX-GE*V[;TW;L!N,A<?ADT :M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9=3NGU+58;M=0N4BDCOY=L85R%Q$6,9  Z%2*W/#M_-J?A^SN[G;Y[QXE*#
M+ D$@=@2": -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8,K#((.012T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/^._^2>>)?\
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MBH ]@HHHH **9*SI$S1IYC@9"9QD^F:H_;-2_P"@3_Y,+32N1*:CO^3-&BO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB2O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM=_:'_MOP]J>D_\ "+>3]NM);;S?[0W;-Z%=V/+&<9SC(KK_ -G'_DGFH?\
M85D_]%15Z!X[_P"2>>)?^P5=?^BFKS_]G'_DGFH?]A63_P!%14 >P4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5KAVDD%
MM$Q#$9D<?P+_ (GM^)[5,Y<JN W_ (_)\_\ +O$W_?;C^@_G]*+C_D(6?_ _
MY591%C1410JJ, #L*K7'_(0L_P#@?\JQG&T+O=M?FAHMT445T""BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\9Z9 -RBBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U>?\ [./_ "3S4/\
ML*R?^BHJ] \=_P#)//$O_8*NO_135Y_^SC_R3S4/^PK)_P"BHJ /8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:[K'&SNP55&2
M3VH;MJP&7$WDH-J[I&.U%]3_ (46\/DQD%MTC'<[_P!XU';HTCFYE4AV&$4_
MP+_B>_Y=JLUE!<SYW\OZ\_ZZC"LRYO[-=0MLW< V%PV9!\IQW]*TZ**L)35H
MNVW2^SOW0)B(ZR(KHP96&0P.012T45JA!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&:O?>(
M+V66TG^']OJ5G'*3$T^H0%7QD!]K*<''Y9KLZP/%E[<6MA:0V]T;/[9>1VTE
MT,;HD;.2N> 3@*#VW9H Q-)&J6FIP/%\-;#3@SA'NH;RW#1H3AC\J@GCG ZU
MW5<1-IMQX1N].N8/$&K7PNKR.UDM=0N!,'5SC*< AA][([ YKMZ (Y[B&U@>
M>XFCAAC&YY)&"JH]23P*SX?$V@7,R0P:WILLLC!41+N-F8GH  >37->(;CP+
MI6O&3Q'()[^2/>BW<<MPB(3T5<%%&5/09_.J/_"2_"D\?9]*_P#!2W_QN@#T
M>BLO1=!L-!@>'31-';-@K TSNB<DDJ&)VYSSCBM2@ HHHH *\_\ BAX)\.ZW
MX>UC7]1T_P [4['2IOL\_G2+LV([K\H8*<,2>0:] KR_XM:=XYN-.U*YT/6;
M&U\/1Z5+]NM)D!DEP',FT^6W5, ?,.1VZT :'P2_Y)#H7_;Q_P"E$E>@5Y_\
M$O\ DD.A?]O'_I1)7H% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5>^NA964URREA&N<#O5BJDW^F%[=?\
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M/3'7FKE !1110 4444 ?/_\ S=Y_G_GPKZ KY_\ ^;O/\_\ /A7T!0 4444
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MZ_\ 135Y_P#LX_\ )/-0_P"PK)_Z*BH ]@HHHH **** "BBB@ HHHH ****
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M#H7_ &\?^E$E>@5Y_P#!+_DD.A?]O'_I1)7H% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1151=0B>;R1'/OX)!A88!. >G3@U$
MJD86YG:X6+=%%%6 4457FE<OY$)_>$99NR#U^OH*F4E%78"2R-+(;>%B"/\
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M#T/0KZ74] TZ_F5%EN;:.5P@(4%E!.,]N:T*K:?#:V^FVL-B +1(E6'#%AL
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MC2KNV_X2*#2'L[F9;=9=/:0-$[<*6#]03@<=,UUM '):J_B#3?%4]]I7A_\
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M$E>@5Y_\$O\ DD.A?]O'_I1)7H% !1110 4444 %%%% !1110 4444 %%%%
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M>._^2>>)?^P5=?\ HIJ\_P#V<?\ DGFH?]A63_T5%0![!1110 4444 %%%%
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M !?/N,\=ZU*** "BBB@ HHHH ^?_ /F[S_/_ #X5] 5\_P#_ #=Y_G_GPKZ
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M#H7_ &\?^E$E>@5Y_P#!+_DD.A?]O'_I1)7H% !1110 4444 %%%% !1110
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M6[LO+_/_ "^\-"JMDC,'N&:=QR-_W1]%Z?UJU115QA&.R%<J7'_']9_[S_\
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MX[_Y)YXE_P"P5=?^BFKS_P#9Q_Y)YJ'_ &%9/_145 'L%%%% !1110 4444
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MBBHS/"I(,J CJ"PH$W8DHH!! (.0>AHH&%%%% !1110 4444 %%%% !1110
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M_/\ SX5] 5\__P#-WG^?^?"OH"@ HHHH **** "BBB@ HHHH **** "BBB@
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MMKK,:_@OWC^('UJ:VTVTM9#+'%NF(P9I&+R'_@1R<>W2K=%TA6G+=V]/\_\
M@&=_937'.H74ER/^>2_NXO\ OD<D?[Q-7HHHX(UCAC2.-1@*B@ ?@*?12;;*
MC",=4@HHHI%D-S,\$6^.VEN&SC9$5!^OS$#]:SM&>[BC:WN-,N8=T\\OF.\1
M4!Y&<#Y7)SAAVZUKT52>EC-T[S4K[>G^04445)H%%%% !1110 4444 %%%%
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MQJ<TFK;>G^9)1114F@4444 %8=]IE@VM:?FQMCYAE+YB7YCMSSQS6Y6=>?\
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M] 5\T>%O$EGXN_:9M-<L(YX[6ZW[$G4!QMLV0Y )'53WKZ7H **** "BBB@
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M]*$4N5GE9=C,35G-58?A;\V;E%9V[6H_^6-A/])7B_\ 96H^WZ@G^MTB5O\
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M[>/_ $HDKT"O/_@E_P DAT+_ +>/_2B2O0* "BBB@ HHHH KW=T;2,R&"61
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M2N22><UN44 ?/%C86>F?M8QV=A:06EK'G9#!&(T7-B2<*.!DDG\:^AZ^?_\
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MDWL;2G&/Q.QHT5G?VK))_P >^F7TONR+$/\ Q\@_I1YNL2_=M;. >LDS.?\
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MI#Y:CW=O3_-_Y&?LU6?[\UM:KZ1*96_[Z.!_XZ:/['MY/^/J6>[/<3R$J?\
M@ POZ5H44![&+^+7U_RV,K5=#L=1TK[!(S6EMN#'[.53IVZ8Q6'X3\*Z=IMP
M;ZWN[EIDFN(]C2J5*B1E&0 "> #]:ZV:"&YC\N>*.5,YVNH89^AJ*'3[*WD$
MD%G;Q..C)$JG\P*=WL9RPZ=53Y5I_7X%FBBBD=(4444 %%%% !1110 4444
M%%%% &5KNMZ1I%LD>K2KLNR84@\LRM,2.5" $GKCICD>M<Q#KNL-+9:7X?\
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M2"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-XIB\2OJ\I:34AX
M>\H8&B%!=!P1RV[YCSGA,\ >]=S10!Y]X(7PM%XEUA-*$"S"11"L^X7'W/W@
M'F?O/O9S7H-4KS2-.U":&:\LH)IH&#Q2N@+QD$$;6ZCD#I5V@ HHHH ****
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M1R..CS#S&'XMDTFVQWGTC][_ ,K_ )@VM:<&*K=QRN.JP9E;\ER:3^TY)/\
MCWTV\D_VF41C_P ?(/Z5?5510JJ%4= !@4M(?+4>\ON7^=S"U74M6L=,FNUM
M+=-@^50[2N2>!P !^IKC_!D]Y)J<ME=27L<-RS.2F5S(.3EL9&1GH1VKTF>(
MS0F-9I(B?XX\9'Y@U3L]*^Q2EUOKMPSL[(Y4JQ/7.%%*QPU\'4GB(5.9V7I\
M^Q)!I5C;R"1+9#+_ ,]9/G?_ +Z;)_6KE%%,]&,8Q5HJP4444%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %! ((/0T44 >""XE'[0W_  AH;_BG\8^QX'_/IYGW_O\
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M;_@F?Y^JO]RPMD'K)='/Y!#_ #HV:P__ "WL8O\ MD\G_LRUH44%^SOO)O\
M#\K&?]BOW_UFJR+_ -<8$7_T(-1_96[_ %M_?2?]MMG_ * !6A10'L8==?FV
M9_\ 8E@?]9$\O_7:9Y/_ $(FI8M*TZ YAL+6,^JPJ/Z5;HH&J--:J*^X0 *
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **PM3\3I8ZG+IUKIE[J5S!;BYN5M0G[F,
MDA<[V7+-M;"C)^4].,W$U[2FT*'6WO[>'3)8DE6ZGD$:!7QM)+8QG('/<XH
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M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\
M]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@Q
MA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&
M'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H*
M*Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3O
MP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H
M?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\
MBJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'
M_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_
M .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ
M@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__
M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\
M]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@Q
MA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&
M'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H*
M*Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3O
MP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H
M?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\
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M;]W/^JZ;1][VY ./_P"%0>,/^BLZY^4W_P ?H_X5!XP_Z*SKGY3?_'Z]@HH
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M7_T4M 'G_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%%
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M^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\
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M_0F:'_W^7_Y(KV"B@#Q__A(?CG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\
MY(KV"B@#P?PW\2OBUXNTZ2_T/PSH=W:QRF%GR8\. "1AYP>C#\ZV/^$A^.?_
M $)FA_\ ?Y?_ )(H_9Q_Y)YJ'_85D_\ 145>P4 >/_\ "0_'/_H3-#_[_+_\
MD4?\)#\<_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"
M0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0
M_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O
M_P D5[!10!X__P )#\<_^A,T/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)%>P44
M >%CXJ?$/2O'6B>'/$FAZ-9/J-Q K+&&=O*DEV;@5E8 \-U].E>Z5\__ !3_
M .3A?!7_ &X_^E;U] 4 %%%% !1110 4444 %%%% !1110 4444 %%%% '&V
M=[;:/X]\4R:E/';12VMK=1R3,%4Q(KJY!/\ =(Y]-P]:I:)X3@\1_!NP\/ZK
M]IMH+N!)&6(A)(U\P2HO((& %&,>U=O=6%G?>7]KM(+CRFW1^;&'V'U&>AJQ
M0!X7XE^ 7A71O"NKZI;ZAK+3V5E-<1K)-$5+(A8 XC!QD>HKF/A-\)M!\>>%
M;K5-4N]2AGBO7MU6UD15*A$;)W(QSESW]*^A_$NFS:SX5U?2[=HUGO;*:WC:
M0D*&="H)P"<9/H:Y?X3>"M2\!^%;K2]4GM)IY;U[A6M79E"E$7!W*ISE#V]*
M .;_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __ !JO8** /'_^
M&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\
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MKU"@#Q__ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J]@HH \?\
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M$M<_[_P__&J]@HH \?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\
MP_\ QJO8** /'_\ AG'P?_T$M<_[_P /_P :H_X9Q\'_ /02US_O_#_\:KV"
MB@#Q_P#X9Q\'_P#02US_ +_P_P#QJN$\"?";0?%'BKQCI=[=ZE'!HMZ+>V:&
M1 SKOE7+Y0@G$8Z =37TW7!^!/!6I>%_%7C'5+V>TD@UJ]%Q;+"[%D7?*V'R
MH .)!T)Z&@#F_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :
MKV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_
M .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __ !JO8** /'_^&<?!
M_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US
M_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH ^9/BS\)M!\!^%;75-+N]2
MFGEO4MV6ZD1E"E';(VHISE!W]:][\"?\D\\-?]@JU_\ 12UA_%GP5J7CSPK:
MZ7I<]I#/%>I<,UT[*I4(ZX&U6.<N.WK74>&M-FT;PKI&EW#1M/964-O(T9)4
MLB!21D XR/04 :E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !63KVJ3:;;VL=I'%)>7MR
MEK;K*Q"!B"Q8XY("*[8'7&,CJ-:L7Q)IUS>1:?=642376G7B7<<3/L$@VLC
M'H#LD;&>,XSCJ !^@ZK<:BM];WL<4=[I]T;:?RB=C'8KJRYY *2*<<X.1DXR
M=>L/PYI]W;/JM_?1+#<ZE>?:#"'#^4HC2)%)'!.V,$XX!8C)QD[E !1110 4
M444 %%%% !1110 5S_A[5]1UA([J5M.%M(F\1PNQE53]PL#TR.:Z"N*TKPU=
M1:UI%Q_8NF:1'IWG&62REW&YWJ1L'R@["3O.XYW*O7K0!VM%%% !1110 444
M4 %%%% !2$D*2!DXX'K2T4 <G%XNNDL?$<][IB0S:1,L26\<^\REHHW0%L
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MCCK0!UE%<]X&O+F_\$Z5/=R223F'8TDARS[25#$]R0 <^]=#0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/3Y47I]:U** ,K2_#]GI5S)=1R75Q<O&L)GNIVE<1KR%!8\#))]SR<UJT44
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M J^ %    '  I:* "BBB@ HHHH **** "BBB@ JO#8VELDZ0VT4:W$C23!5
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M !1110 4444 8_B'_5Z=_P!A"#_T*H_$3I<1VNEQ.#=SW$,BH.JHDBLSG'0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXANM&COK,W4"H0BW*EW8[LKMZY7;S]>U&K>)M,T74K"RO;VS@>Z9A^^N%C*
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MRVLBQM.TJ3[E*.&QP #NR/<#\:JW>G7,PU("$,)[VWE0%A\RKY6X]>VUORH
MLC6[2XM+MX)G@DMX3*WVFUD0HN"0VQ@K,O!Z>A&<U!_PD$4DVHVP$L+VD6\W
M$EI*8_NDD] "!Z!N>QINKZ?=W5W>/#&6233)8%^8#,A/ Y/Z]*CN[.]/]KVZ
M6<CB\L]L<JN@4.(RNTY8'.<=L<]: -*[U:UL/+6X,[,Z;OW%K)+@>IV*=H^M
M4[OQ';PW<EJAD7_1#<+=?9I)(@.Q.T8(QSPP]*KZK:ZA/<-";:]GM6MT$(M+
MO[.(Y,G<9&#JQ'W>FX8!XSUIKI>I6^BVMK]ADEE;1OL;[)$Q%(%_B+,,C/&1
MF@#H+K5[2R:..9Y9)G3?LM[>25MO]XJ@8@<'D_2F2Z_IL4=LYN&<7(8PK%$\
MC/M(# *H)R,\C&1SZ&JS)>Z;JDUU'8S7L5Q#$FV!XP\3)NZAV4;3GL>N>.]1
MZ=I=U!J%M=31*I8W4L@#AA$9'1E7WX!SCC.: -BSO(+^V6XMW+1DD?,A1E(.
M""I ((/8C-3UG:3;3VSZAYZE1+>/)'\P.4(7!]N0:T: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 5K*PM]/C=+=7&]R[M)(TC,WJ68DG@ <G@ #H*LT44 1"WB6Z>Y"
M_OG18V;)Y4$D#'U8_G4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4457O[ZVTRPFO;R416T"EY'()P/H.30!8HJ*UN8KRTANH&+0S()$8J5
M)4C(.#R/QJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHJ"VO;6]$AM;F&<1.8Y#%(&V..JG'0CTH GHHHH **** "BBB@ HHHH **
M*@NKRULHUDN[F&W1F"*TKA 6/0 GO[4 3T444 %%%06MY:WT/G6ES#<1;BN^
M%PXR.HR.] $]%%% !1110 4444 %%%% !1110 4444 %%%1SSPVT#SSRI%#&
MI9Y)&"JH'<D]!0!)13(9HKB%)H9$DBD4,CHP*L#T((ZBGT %%007EK=231V]
MS#,\+;)5C<,8V]& Z'V-3T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-"XRDD;!E8>H(X- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*L9/C3>RO:Q,Z:>EPI*_=DR%W?7'>@#K-$\2Z/XCBDDTF^2Y$9PX"E67TRK
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M.0 ,>]=%>Z!XNUC6]'OK_P#L* :?<B7S+5Y3(4_B4;EQ@B@"?P/_ ,A[Q?\
M]A,_RKM:XKP/_P A[Q?_ -A,_P J[6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?VIO;"XM5GE@:6,H)8F*NA
M(X8$="*L44 <)X8\5R67A?5(M=D9M1T(M'<EVRTH&=C9/7=TSWZ]ZT? Z:B/
M#S:KK5W,]S?L;HI)(2L$9Y55!X48YX]?:N<\:Z';7'Q$T%69UAU0[+R)3A9A
M$0R[AW[#Z"NA^(FI36'A22UL^;W476SMT!&6+G!Q^&?S% '+Z7KFJQ>(=/\
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MJV4-TYDGM+6[,<,C'J2,9Y[X(KJZ* ,CP]X<L?#-E-9Z>9?)DG:;;(P.TG'
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M:IK.FZE<R3%]/9GAB##RRQ&,L,9)'&.16M10 5RH\ :2NA7.C+/>+9SW?VO
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M+.WO(WOM2O);N%H9)[NY,CA#V7/RCKZ5HZ/I<&BZ1;:;;/(\-NFQ&D(+$>^
M!^E7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img40748725_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (% JD# 2(  A$! Q$!_\0
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #UHH/6B@ HHHH
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M^E<]K.F:S<ZO<I'ILYW7L4\<T!18C&I7)8GYBXP>..*[^BH4VG<T=%-6./\
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M4XIKJ)+I[VWN+J"[\R=D5E=6&\850,8 /3K523P[KEQXFLKN>(O';:B9S/\
M;V$9B(8*%@'R[AN&2>?0FN[HHYV'L8F7:V$W]N7VHW"@,R+;VW.=L8Y)]LL?
M_'16,VBZCJ>I68O;*WLXK-Y"UU:S;7F# @!-N&3KDY(]LUUM%',QNFF<O/H]
M]I5^EQI4#WZ/:&U9;N]8NAW$AB[Y)'//4\=#7/IX(U"&.REE@GN'.G16D\-M
MJDEJ(W3/4H0'0[CZD8Z'->D44<[%[)7N<C>Z=/I^F:M%'"I-Y;P6EK$KEMS!
M"N,GG SU/89KJ+2#[+906^[=Y4:IGUP *E(!() R.GM2T.5QQ@HL****DT"B
MBB@ HHHH **** "BBB@ HHHH **** ,S7]/FU/2)+>W9!.&62,2$A696# -C
ML<8K$UG1]5\1Z>[7%I'92QSQ2Q10W9224)U#2IC;UXQ77452DT9RIJ3N<=IW
MAJXMYK:=+26 _:))91<7[W4A!CV LS$\^P)%7%\/W4OP^CT.1DCNA:+$3G*[
MQC@D=LC!]JZ6BCG8E22OYG$:EH.L^(OMS75I%8>99I%$J79)+JX8@L@!4''!
M'/TZ4U?#NJ0V,\EI:7$4[R1^8D^KR3S2QC.561B?+Z\$'/TKN:*?.Q>Q7<X"
MS\*ZO;6$+&!?.@UK[>L#WK3,T94K@R/R6^;//I6Q)HEXUD8PB;SK O/O#_5^
M:&S]<5T]%+G8_9(****DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S=7LIKT6(A _<W<<KY.,*,YK2HH3L[DRBI*S.#TKPA=V%_&KP3R_9Y9
M)(KN75IGB&[)4B D@-S@C 'OVJ"W\):U=71>]1HF-G-;R3/J+RJ[MC!6+[J(
M<=  ?:O0Z*OVC,_8Q[G%W6DZ[JIE-Q86UKC3)+1 MR'+2$CGH,+QQW]0*N:C
MH5[=:3KUO&D?FWNSR<L.<(@Y].5-=145S<1VEI-<S$B*%#(Y R0 ,GBCG8>Q
MCU9Y_JTLVGRZKIL"VEP+S48I0WV@"168)E"F,DX7(QQCTQ75^(;"[N[C2KFS
MC25K.]$SQL^S*X(.">XSTJ(>(='G%M?K:SR32(3"19L9C'@$L!C=MY'/2IG\
M4Z6IC"R32[XQ*3#"S[$)QEL#Y>>.:;YM+(A*"O=F,=!U5X(M&,,2V4=^MW]N
M$WS%5D\P+MZ[B1@]L9Y[5LZO8W<^L:/>VT:R);22+,I?:0KIC</7!QQ2RZ_:
M6;W)N)RX2=(8XXX6+EF0,% _B.,GBJLWBZV2_P!+MHK.]D%].T)8V[KY1523
MN!'7(Y]N:/>;O8:]FE:_](K?\(Y=R:9HEJP1#:R2F=E894.KC(]3\PK)TSP9
M=VED]L]M<-/#:26\=Q-JTLR.2, I&Q(7(ZYQCMFNL7Q#8&\6V/VA6=F1)'@8
M([*"2%8C!/!_*HK/Q5I=\4\MYXTDB:9))H61&5?O8)&#BB\NPN6GW,7Q)H6M
M7^(;:+S;5K'R%CCOWM#'+@Y+E.77D<9QP>.:AMH=9M;N]L;6PM[F;^S+6!S)
M<;0C[7&3P<KUZ<^U=%%XFTV579FFA58_-#30L@=,XRN>O)'3U%6-/U2SU&:=
M8$ECGC"^8DT)C?:<[3@\D=<'ZT7:6P^6$GHSCKCP/<1797R[F_@FMX8CLU26
MU12BX.]%.&4]>A/;%7I](UQ1+IUO96[VC7Z70N6N<8CR"5VXR6&/H?6NSHI<
M[*]A$Y:31M1>YE0PIY(U9;U)!(/F3G/'4$5+HUAJFG+;:9)96K6EM*[B\,FX
MNI)*X7&0_/)/'7&<UTE%+G=K J,4[H****DV"BBB@ HHHH #UHH/6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR9(V.U5\LH%4XY/3DX[THJ.[*FYMM(Z,9P,]>]+114&P4444#"BBB@ HHHH
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MZAMC$9&>W%>*VTQD!5N2.]>J^%II)O#MKYD>S8/+3_:4< U2V(DK/0V:***
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M>01]*ZN!_-MXY-P;<H.X# -,3T=B2BBB@ HHHH **** "BBB@ HHHH ****
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M=<D*GS#\#_6ERIZHI3:LI+4XV"W=&+$9.. .M>H>&-+DTG3?.N;EQYR[VB8
M+'_7..M1Z9X/@TV]M[D7;RM$<X9 -WI7*^(M3NKV^FM9YTF@BE.U57Y?;ZFA
M))";<G:QVL?BO1G16>^BAR2,2$#&#CGTJV&TS6[<J&MKR%6&<$. <<?H:\FS
MVJQ9WMS8SK-;3O&XZ[6X/L1T-+F17([:LT]:\.7&E//.D?\ H(D"QLS@L<@=
M?QR/7IQ6*ED]RQ"6SNP&2 AS]:],\/:K)KFGR274, *L%V*=WXD$<<UH:CJ,
M6F63W4^\QJ0#M&3S3:38E)V//M"\./>ZCY-W%+! J[SE,;^1QSZUVWB"SNKS
M19;2RCB9WPI#]E]O?TKB=8\3WNI3KY3?9X(I-\07[V>Q)Z?ABJZ>(M7CX2_D
M&3DYPV?S%%TMA6F]69LD;Q2O%(I5U)5@>HJ@]M(&.T C/&#7627>G:W%,;I8
M[+4796^T.Q*/@ 8]N*THO 1;'F:E\F 0R1\G\#2<>Q2J='N<796LC3+"HS+*
MP55'<UZWI&GOIE@EJ]RTX7[I*@;1Z#VJEHWAF'1KM[B.=I69-GS*!CUQ6Y3V
M%?F=PHHHH&%%%% !1110 'K10>M% !1110 5DZU<R0B)(Y=N\$,HZ_6M:N>U
MTYOXQR,1\>^30*UW8S  O0?6CKW_ "-0W3%8N#C)JD"5.0<&H-3JM*U"X:X2
MVD=60YPS=>G2FZZY-Y$@Z!,GGOFLZP,KSVYC(60L,'^=:&N+-]I\UHML*@*'
M!'.?6KW1EM(QYY#'&2!R>*J"YE!SNS[5;GC,D6!U'(%4_L\N<;#4&IHVLY#Q
M3(I+*P8+ZFN@UIV_LT<8W.N2>U8FGVDLTJ11.$=1G?C.WWQ]:Z&^LI+RW2,S
M$%>2 .&-4EH92W.78X4D=0*S223DG)K4==DC1/PZD@CZ54:SYX?CW%2:IW%M
M&)5@3\H]:[#2=_\ 9L6]MW7'L/2N9LK%Y9/)AY8\DGL/6NNM[>*UC\N)<+G/
M6J6QG)ZDM%%%, IDLL<$+S2N$CC4LS'H .II]9^NV<M_H-_:0@&66%E0'H3Z
M4+<3=E=%>T\26=W<01>3=0"X_P"/>6:+:DW&?E.?3FM=VV1L^UFVC.%&2?I7
M)-??VT-%LK:TNDGMIXYK@20L@@"*01N(P22<#%96GPM'/<)#;7$DKVUQYDKQ
M21S(<<"7DHY)X!'X5IR)G/[9K?4]!C;S(D?:R[@#M88(]C[TZN _L47MIJ;W
M-I,\L>E6H@)W B0(^=O^T#CWJ'4].U*TD9='AGB:?2%>;8&.Z02+NSR,MMSW
M!/-'(NX_;/L>BU6DOH(Y9H0QDN(HA*T,8R^TYQ@>Y!'X5P3Z;]ITZ18B9+>:
MZM0\%O:S0J/G^8G<2<XZXJSJFBVUAKNL26E@8VET79;O%&QRP+[@".^"O%'(
M@]JVKV.\4[E#8(R,X/6JDVI16]PD,L<RF280HQ3AF(SQ[5R%_H_VBUU^[>WF
M>ZCBA:U/S95EC'*^^?2EU*W,E[(UY;W$EN=1@=]L;M\OE\G [9ZT*"[DRK2M
MHCNJ*YWPI&4743!'+%IC7)^Q1R*RD+@;L!N0N[.*Z*H:L['1&7,KA112,RHI
M9B HZD]J0SE=0CDCOY6DA,?F-N'H?\XK.N8F<JRC)'!KL;B&WU"%=SYC1]Q*
MGT[5B#2Y99&$$MNPS\JESDKG@]*'%O4(S2T9AI;R%QE<#/>NCT2"9Y3/&ZB)
M3M;C.ZG_ -@2=?M*?38?YYJK?W,H9K)2JPQ$+B,8SQ22MJ-MRT1N?;;69,"=
M!DX^8X-+'%&X8B17[94]*Y3 _&I8+F>V??"Y4GJ.Q^M-2$Z;.I:%6 7'3C-1
M);-GDXP>.*33[UKV%G:,)M;& V<_X5A>,=3O+%+>.UN!&LH8.H'S?7/852DR
M&EN:UUK^FV5TT%Q<JA5-Q;JOT^M36VKZ?=B/R+R)S)]P!N3^%>2].M+D[MP)
M##&&!P1^-3=&G)+N>S45Q'AGQ'?3WL&G7#1R(Q/[R3.['IGU^M=O0+R"BBB@
M85@7FLZHU_<P:3IT-U%9X^T-+-L+-C.Q/?'<\5OUSDRZQI6I7QL=,%]#?.)%
M<3+'Y#XP=X/5> >,GVJHV,ZC>EBXOB;25L[2YN+M+872!T24\@=.?09XR>*?
M+KEI:37?VVYMH((7C17,G.7&0&]">WK7,:IX>U.WL+:WL;-YKK[+Y!N8)D50
MV2<2I)PT>3VR>O%3W&@:C-?O(]K&Z-J%E.=I&TK&@#D GH".E7RQ[F7/4TNC
M>C\4:'*8PFJ6Y+OY8&[!#=,'^Z?KBK+:QIRZB-/:\B%V3CRL\YQG'IG';K7.
M:MX>N;G2?$T5O9H9[Z57@P5!?"J,Y[8(/6JUMX8NH=<F2YMKVYADOOMB7*WH
M6%?0,F=VX>P(/J*7+'N/VE1=#:O/&OA^RA:5]0655E6%O)4R%6)Q@X'%6?[?
MLX6N6O+JVABCG$4;;SDDH'PPQPW)X],5C?V+?0>#(K:*Q5KV*Z6X: ,H,F)=
MQ&[.,D>IIIT._EUS[4]F/);6$NR&93B,6P3.,]FXHY8ASU-[&Z=;MYX;6XL9
MK>>"9V7<7(.54D@#'7CH<5%HGB73M:BA6*YA^UR1[V@5LD>N/7'?TK.?1KW[
M>9$MP(_[1EG&&4?(T.T'K_>JOI&F:H6T6VN=+%DFFY=[@2HPDR"-J@<]\G./
MQH:C82G4YMCLJY?Q3K]YID@M;>-5$L61-GY@<XX'TKJ*\U\73^=XCF4'*1(J
M?0XR?YBL^ANU=I&++(]Q,TLTC22-U9SDFI[/4;RPF6:VN) ZYP'8NOY$]*S[
MF4QJ .I/6JRW,JMDMN'H:F[-7%,]!T:32_$-](+K3,WCKYDT@/R9'&<=B:Z1
M-!TI!@6$'3&2N:\^\,W;P:]9M&H8RMY94YR01SCZ8S^!KU*KN]S'D2;3/.O&
M31KJ\-K%&D:6\( V]PV>.O;'ZUS<D@B7<:V_%3H_B*Y,<F\#:"?[IQR/\^M<
M[> X4]JB6YK#X1RW49;!!7/<UT7A*ZAM=?B,I15E!0,W9CTY]^GXUR%=%H 5
M-5M#);37"(P++$I8^QP.P.*<=Q5/A/5Y&V1.V,X4G%>.2',LC$8W.S8/;))K
MV&X61[>1(7"2E2%<C(!]<5Y5JVE7.CWGDW15M_S+(O1\\G\<YH>PH_$8ER[&
M4KG@4V"1ED"C)!/(J>:V,C[E8#ZT06K+(I/)[*HS4FAV_@1KIKJZ&X&U"+N!
MZANV/PS6IXVN7AT18T8#SI K#U7O2>%-!_L^V6]G$J74@(*,<!5[ CU[_E5;
MQX=UK:((I&8.6W@?*HQSG]*T,=_O.&8A5+'H!FJ?VQ\\*,>]6I!OB8#N*SBI
M!P00:S-C1MY]Q61>&4@X]Q7K=KJ5O+I4-[+*(HV49:4@<]#7D%I#(P")&6DD
M;:JXY)Z"NZ\3"6#PG9VUW;PK+O"G8<JN!U'UJUM<RE\20FH>-]MX@L(BT,9.
M\N,"3L,=P*;!X[E 43V:$[N61B./IZUQQ(5<G@ 5!]KCSR&I<S*]FNY['I^I
MV>J0F6TF#@'##H5/N*MUY'I4T46J6L[[2BR G<3@C\/S_"O6PP8!E((/(([T
M]U<G9V8M%%% PHHHH #UHH/6B@ HHI'=40N[!5'))[4"%K$UBPF=WNUDWJ !
ML(^Z/459.N6@9P=Y .%*KNW#U&*LQ7MK=DQHZOD<J1UH%?JCD9$$L>W/7H:@
M%GSR_'TKKY](MKBX,SEU)&-J$ 4BZ/8QQ@-&6VC[S-S^.*5B^8S-*TP7&)9D
M;R /EY(W$'\ZZ"6)9H7B;.UA@UG)JEE:9MTW&.,<,OS9/I5F'4[2=E5)AN;H
M",4_0B]]S-FT)Q<8MRHAVYR[<YI$T&8J-\\:MZ*"1_2MZL[6+B6VMHS#)L9G
MQ[D8- ]1D$EOI$:032+N=B2X'\ZLQZG92X"W"9)P%)P?R-<OW)[GJ:3@^F*5
MQJ#L=3=Z?#=QA&RA#;MR  ^_YU FAV:N682/D8 9^!],8K/T[4+A)T@9P\;M
MCY^2OMFMZXD$-M+*3M"(6SZ8%-:D[71S4MVBNXLXC C+L8L<EOUXJ&.YN(,&
M.XD7:, ;L@#TQTJ/.>>Y.3526Z97*H!@>M2Y,N,58Z"SUIX\)=?.I/WP.1^'
M>MJ">.YA66)MR-T.,5Q,%QYAVL,&NHT6<R61C)):(XS[=1^E-.XFK,TJ***8
M!114;1;O^6D@^AH$R2BJK6H<E?M5P#Z!QQ^E1-IP8G%_> CKB5?\*=D3=]B_
M16/<:9#!!)-/K%_%$BEV<SJ H')/W>E1)HD5Q%'+%KFIM'(-R,MPF&!Z8^6G
M9=Q<TNWXFW)(D,3RR,%1 69CT %1VMW;WULES:3QSPN,K)&V01]:YN_\'//8
MW,<>O:V[O&P5&ND"DD=#\G2L7X=_#>[\('[3=ZQ,\CCYK2!L0@^ISU/Y4K(:
M<KZH]$HHHI%A6=J%VJ[H2IPI!+=>>W'>M&L*XG^TW/S*H,>0"O7KZUK2C=W,
M:TK*P\KD GAFZC)Q26X6SG$@!([KGH/456FF<, K$ "I(V\^+YA\P.,BM[.V
MNQS*2OIN;L<J2QB2-@RD9!%<C*_F32/GJ[?SK<LO-200HX4$,3N_B/8_RK(N
MK2XMI )]K,W.Y>A/>N6I'ET.RG.^K,NYD;S-H) 'H:;!*XD"DD@GN:FGMS(^
MY2.G0TD-LR2*S$?05D;G0: TGFSJ!^[V@D_[7;],US7C=R^MQKC 2$#ZY.:Z
M[2+ VZ>>Y=9'&"G;';/O7-^,-'U"2YDU+>LMLBA0@R#&/?U^M7:Z,KZWZ'%7
M3E(QM."3UJD'8'(8Y^M:$L?FQX!&>HJL+-\_>7'K4&IIZ1)<'4+-[; N#(-A
M/3/2O8.W/6O-/"^@MJ=QOE\Z.UB'^L0E2S=@IKTI1M4+DG QD]35]#)ZR8M%
M%% PHHHH *3</4?G5,7EK/JLVG;2T\,2RO\ +\H#$@<^O!XJ4V=I(,F&-AZT
M[=R+M[$^]?[P_.D\Q/[Z_G5-M)TQP6:TA(]:B;P]HKCG3K<CZ4>Z*\_+^OD:
M'FQ_\]$_[Z%'G1?\]4_[Z%8</A[PM?P>?#I]C-%DC>HR,C@\_A4<O@/PE,P,
MN@V+'H,I_P#7HL@3D^P]_&N@P^(9=#N+^."^0*0LIPK[AQM;IGVZUT ((R#D
M5P!^$GA>3Q!+J,L"_9MJB.QC^6)<#DGN<UW<$,5O;QPP(J1(H5%7H .@%#L.
M+?4DKS7Q7;W::Q-<SVPBCE;;&R]'P,9/OC%>E54U+3H-4LFM+C=Y3,K':<'@
M@]?PI%=;GCMS$9%!49(-5A;RL<;<>YKO;CP1=/>3F"6)8-V8M[9)!['CL<T#
MP%<%/FU"-&_V4S^%+E&JB[&=X4TN[N]26XMYQ EM@LQ3=NSQMZ_6N]GU:PM;
MAX)[J.*1$$C;S@ $XZ]/PKG-=NKOP]I=C96;PIN0K(ZK\Q('4>GUKB7)D;=(
M2[==SG)_,TW9:$Q3D[['H.NZ-9:Q9>?IZP-=L<HR,H$GKD]ZX2]LIK.ZGMIX
M\M$V&P,CZ_2F0326TZ31'9(ARK#@YKMO"_B*YO[H6=S'"9=I8S@A6<#U'>A-
M2W#6!Q<>E7+ /'8S,I&X,L9(Q79:/'8>&=*6_NY"+NZC'R$<\9.T#ZGK]*Z]
MGV*68\*,FO'KJ5IKJ21I'D.X@/(<L5R2,G\>E&B6@]9.USN(O'%B1%YT$R%E
MR[* P0^G7)_*K\<VC>)HG&V.5PA0+*HW*#W /^>*\Q9U7AF ^M.BE9'66"5D
MD4Y5T."#[4E+4;AH=PO@*V&-U_.?7" ?EZ?CFKEOX+TRUFBECDN2T;AQOD!Z
M'/I5CPM>S7VBK-<322R[V#,Z@8YZ#':IM?U.72-+-W%$DA#JI#M@#)QGW[<5
M7D0M4:$EQ#%)'')(JO(2$!."WTH<0W,31OLDC<;6'4'VKR:\U"ZO[AI[J9I'
M(( _A4'J .W05!%)) H6"1X@""!&VT CITJ;HOE9T.J>$;RT,1M0USYC$%(T
MP$YXY)]*IQ>%M9F8XLBN.\C!?RS6YH7BVZGF2TNH#<2.P59(\*<=\@_TKLZ;
ML]24VM#DO#/AF2QO)+G4+=?-CQY!#Y ]3_*H?'LB%;*/SP) 6/E=R/6MB[\5
M:;9WPMGDW@(6:2/Y@I'\/UJG<ZIX;UZ!8YIHQ-)\D9==LBG/'7IS3MT"_7<\
M[N,F!JSZZ/4-&O=,ECCN8@?-!*;.<^W'>JBZ9/)\Z64KXX^6,_RJ>5EJ<>Y!
M81E_*3:[;W'RKR3ST%>S6^W[-%L1D38 %<8(&.AKDO!^A"-CJ%RKI-&Q1(F7
M ''6NQIVL3?F=UL%%%% PHHHH #UHH/6B@ KG-9E=[UHA,S1 #,?8'^M='7*
M:AG^TKDMG)?H?3&!^E'0%N5B0.2>*0%6Z,,CNIYJM>$[E7MUJNC%7!4\YJ#0
MZ_1[R6XDDBEE+;%& 5_7-1:Y,XE2))B%*_.@^M5M&!.HJ0X7Y3D?WO:C6,G4
MY"V1A5 ^G^2:KH967-8H< >U)\K<9!J"[8A !T)YJH"5.0<$5)J=1I-[-]JC
MM6DS&0< C/X9J37W;?;I@A<,<^IXK*L=[W%MM;8Y8?-G&*W-6T^:Z(ECDX1<
M>61U]>_6K6J,FDF<W.Q6$E3@],U0R<YR<_6M%E$L9&>HZBJ_V,Y^_P ?2H-2
M>V>1EC921)N 5AZYQFNNO<_V?*"AD)3!5>IK!TK3?M+J64^0F0QSU/I73*H1
M%5<X48&35+0REJSC.02#]Y>"/0U0FB<2,=I(SG-==J6E&X:6XB)\W8-L8P Q
M'J?>L]=&O6R"B*>Q+\?C2:[%J7<QK6)E<LPQQQFNNTB&:&TQ+MVM\RCN,^M4
M[7198[F-[@Q.@Y*@D\]JW*:5B6[A1113 *KWUP]I87%Q' \[Q1LZQ)]YR!G
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MI*NTE3S7FFMZ.^D:C) I:2(()%8*3A2<#=CH<TWL3%VEJ<W.2TS$^M.MB1,
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ME7;'$5$6<E1Q@^O/]*UUUW1=#<V,3$0HI?<AW?,3]WZU5U&X\/:_'\DX2]E
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M9K*70'Q\UPH.>RYX_/K6Y10(QUT",$$W#GG^Z,5L444 %%%% PHHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M>M%!ZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<:1>:O>6LMQ=WUNPN+*X-S";\RLS!3C;$4 CV]#@_GUKJO#W_(5O?^O.T_\
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M6Q44%O#:Q"*")(T'\*C%2U;,HJRL%%%%!04444 %%%% !1110 4444 %%%%
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M(XXI;F',;O%&GG$8W;1DCO\ I69)K>V4^1&IBV\!N#GU^E/AUY&*B6!DYPS
MY J>;6Z-.7W;,0VYMHHV;>I9R.3VQWIT5N;SS%$C*H('M@_UK41HKB(,I62,
M]^HK/U2[DL8TCMD1?,!PV.A^E7[5V\S-4E?R+D7DVRBW$@RHSACSBBXMH+M,
M2HK<?*W<>XKDW)E<M(2['J6.:?%-)!(KQNRE3D<\?E63EJ;<CM8ENK*>S(\Q
M/E8G:0<]^^.^*K"U#_,L!;'7:N:W].U1KN58)(<R %BXQ@>AQ6KDTK(:D]C
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M(KA3N&X9P?6LQM!A9W;SG4,V54 87VK6HH%8SO[$L]N"),XZ[JT$4(BH.B@
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M>KZ&;=V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'K10>M
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !56:$F0E4Z]ZM44T[$M7*@LUW9<9!'3-1F$Q !
M<[,^M7Z3 (P0*KG9+IKH06T10$E2"?4U7U+3X[B&21$/GXR"O5L=JT**EN[N
M4HV5CC9X7A<PSQ[6&,@\]>E0K!&SX5,GV'%=L8HV;<T:%L8R5!.*<H"J%4
M=AP*FR*YF9&C6(C07;-EG4A5QPHS_P#6K3G@CN8'AE!,;C# '&14E%,7J8LV
M@[IG,,JQQGE5()(]J%\/CJ]R<^BI_P#7K:HH"Q#:P"VMHX0<[!C.,9J:BB@
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >M%!ZT4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 !ZTCNL:%W8*H&23VI3UKG
MM;D)OE19'PJ E.P/;ZT!Y%QM>MEF= DCJOW649#59M]4M;F01QNP8C/SJ5_G
M7+D@#)/%(&1^ RM2N/DTT9VM%8FBW4SS&"29G54RH(SW]:I>-[IH-/MTCGDC
M=Y.B-C<,=S3(NRS?^+M-L;Q8-QF7!WM#\VP]AQ2VWC#2+B2.(R2Q2.0-KQG
MSZMT_6O-^E,\Q"<;E.>U+F+Y/,]H!!&001ZBEKSKPKJEY%J5O9?:#]E=_N$9
M.3_(5VFK:LNE-8!HC)]KNDMA@XVEN]5:^Q#E:]S1HJO<70MIHE?RQ&P8L[N%
MV@#KCO\ TI[W5NC;7GC4[#)RP'RC^+Z>]*S#F1+14-O=6]VA>VGCE4'!*-G!
MK&?Q',4FNK?3))M/AE,3SJXW'!PQ5>I --1;$YQ2N;]%5S?V:W26S74*SN,K
M&7 8_A698>(H[^ZMH%MW0SM<KDD<>2X4_GFBS!SBM+FW1112+"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img40748725_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 \@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/%VJVVO:M;VVF06=H\#.N"TDF_=C R<[0<=JY;Q!#%;6WQ=A@C2*(16S!$7
MR;=23@>IYJS+KOAOP]\3-2O/$2+&ATJSCANWMVD2(D.60D [2P QZ[2* /4[
M#4+/5;&*]L+F*YM91NCEB8,K#V(JS7#?"V'&AZK>0VTEMIM]JT]UIT3H4Q;M
MMVD*?N@D,0/0BNYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1G=E%._[V1U^M!BC;.Z-#G .5'..E/HH **** "BBB@ HHHH **** "BBB@
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MI/(M;W49%'V3R(V7<Z2?Q%E3[N/XO:@#V$<C-% X&** "BBB@ HHHH ****
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MQ[/."_\ +1/53V- &I1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:TK^2H5PJ@99L!]H R> .:J^-/%FG7/@7Q# EMK(>33+E%,FBWB*"8F'+-$
MH]R0!WKI_#^B)H.G-;BXDN9YII+BXN)  TLKMEFP. .P Z  54\=_P#)//$O
M_8*NO_134 =!1110 4444 %%%% !1110 5D^([FWM]*VW!;]]*D4849.XG.?
MH &8_P"RIK6KEI_^)YXR$'WK32UPWH96 +?DI11_OR#M71AH)SYGM'5_UZD5
M/AMW&6OANY>9&F9%AX)()R1]/\:ZRBBHJUI57[PJ=.,-@HHHK(T"L/4/^)+J
M@U9>+.Y*Q7P[(>B3?A]UO8@GA*W*S?$4S6WAK5)U5',=I*P610RG"G@@]1[5
MM0?OJ/?3[Q/8TJ;(BR1LCJ&5A@J1D$5\QQ?&OQA#"D4<UF$10J@VX. /J:]]
M\#ZO=Z]X-TW4[YD:YN(RSE%VC.2.!7I9CDF)R^"J56K-VT9$*D9Z(Q)=1NWE
MW^?*F/NJ'.%'I78:5<R7>FPS2_?(()]<'&:KSZ!8SSF4JZDG+*K8!JQ;-]FD
M^QN H&3"0,!E]/J/UZ^N..O5A4@E!:HRI0G"5Y,N4445QG2%%%% &/J>O)87
M'D)%YK@9;+8 JWIFI1ZE 752CJ<,I.<5B:YICO?O/$Z'<GF.K,!M X)YXQ6G
MHFF/I\#F4CS)",@'@ =/YUUSA25%-;G-&51U6GL:M%%%<ATA1110 4444 %%
M%% !1110 4444 %9'BK_ )%#6O\ KPG_ /19K7JCK5E)J6A:A8PLBRW-M)"A
M<X4%E(&<=N: //\ X=MX\_X1?PX/+\-_V-]FAY\R?[1Y.!VV[=^/?&:?KD.L
MZU\7&T.UU^^TW36T9)[A;60ASB4CY,\(QXRP&<#'>I=!TSXFZ%HNGZ3&GA&2
MWLX4A#M-<[RJC&?N8S70)X=O%^)<GB0R0?8VTI;+8&/F;Q)OSC&-N/?/M0!P
MVB:-X@U'Q3XA\'S^,]972-)>&5)XY@+V3S5W*IG()VK@]!SGTXJUI/BS5?#W
MP_\ %\E[=OJ5UX>O)K2VN+@Y>4#;Y9<]R"PR>]==HOAR\T[QUXFUR:2!K;5%
MM1 B,2Z^4A5MP(P.3Q@G\*SK/P&\NF>,--U66%K;7;Z6>,PDEHT95 )R!\P(
MSW'O0!Y_+JFN6NDP:KI<GQ"N_$ V2O'<V$K64Y)!=?+QM5,9QMY'%=5K$>M:
M]\5AHD&N7VEZ=)HB7%REM*5D!\PC$9/",3@%L9P,=ZT]-T[XCV-I!I;ZAX=>
MV@41+J#1S-.R#@$Q<+OQ_M8K53P[>+\2Y/$AD@^QMI0L@FX^9O$F_.,8VX]\
M^U ',>)GEL?$'AKPK>>)M0T[1Y+25Y-0:Z\NXNI4P%1IL#!P<GIG\JJ>!9FL
M-6\9Z@-?U?6]*TKY+6:YOWGC<>7O=1DE2RD ;AV;WJ+QV5N_BG:6B+H*2+I)
MWGQ" ]M*IER%C3(RX*DD@].W%;'@W7'U#4]2\'75IH4MI;V8<S:%D6RJY*F)
ME.0K=3@$\4 </:ZWJ^L^'CKANO'W]O3QM/!]@LI#8*W.Q%C *NG0$G)/)S73
MZSJ'B;5]9\!6L6H7.AW>IV<[7R*I&PB-&;]VW&X?,!N!VYSVK3T;P_X]\+Z>
MFAZ5?:#=Z7;Y6UN;Y9A/&A)(5D7Y6QG ^85L7WAK4KSQ?X6UA[JWD72H9TNF
M(*-*TB!0R* 0!D$X)X]Z ,/0H=0\*?$M/#K:[J>K:;?Z:]VO]IS>=+%*C@'#
MX'RD'IZU1\.Z5JOQ#M;OQ'>^*M<TU)+N6.QM=-N1#'%&C[1O7!WL2ISG_P#5
MU]WX=NY_B/I_B)9(!9VVGRVKH6/F%F8$$#&,<>M<]8>$_&OA2>\L?#&HZ))H
MMS</<1KJ4<IEM2YRRJ$X8=<9(_Q *WCSQ!?VFNZ'X6^U:RT4MJUS?W&C6Y:[
MF"X4!=H^0%LEB/8#%.\"ZAJ\?C&?3HXO%$V@269F677[:17AG#8VK(PRP(.<
M'ICBMKQ#X3UFZO\ 1]?T;4K5?$&FPF!VNHB(+M& W!PO*\_,,9QFM;0D\6-=
M23>()=(2'9MCM]/61OFR/F:1\=AC 7OUH L^(PQT.?&M#14&TR7Q"?NTR-V"
M_P JDC(R>F<UY?HWB*PL/B-H.G>'/&=_KMG?^=#?6][=-<["J;D=&(XR0<X.
M#7?>//"\_BSP\EE:SP17$%S'=1"XCWQ2,AR$<#JI[UB?\(SXRU7Q;X>UG6KG
M1(K;2I)3]DL?,.0T97<&8<G..,  =S0!G1:?K7BGXB>+M,;Q/JNG:3:26Q$5
MC-LEW-$" KG.Q>"2%'S$\]*9IWBK5?#G@7QF+J]DU&Z\/74EM:W5S\SR*0OE
M^8?XB"W)[UV&A>';O2_&/B;5YY(&M]5>W:!48EU\N/:=P( '/3!-9MOX$EFM
M/&=EJ4T/V;7[IY8FA)9HU*!06! ^8$9P,CWH XCQOX2UBP^%-_JT_B_6+VZF
MMHY+VWNI%DMY S*2L:$?N\$Y!'ICOQ[)I?\ R"++_K@G_H(KS74_!7Q!UWPA
M-X:U+6M%6TCA$<4T"2"6Z*_<$I8$(. 3M!)QCUKTZRA:VL;>!R"T<2H2.F0,
M4 >0ZIXCGU_QCKEK=2^,$T_3)Q:6T7AR&3&X#YWED09)ST4\ >N:O:<OB[Q!
M\/M3C%UK%CJFEWS2:9<WT;6LMU$F&43+P&!!*G/!P">AK<F\,>)M#\3ZGJOA
M2YTJ2UU5UENK+4O,0)*!C>C(#][N"*GUG0_%VN>%&TFZU+38Y[Z<)>RVR/&(
MK4\.D6=Q9B,C+8^\?:@#(\"^)+WXC:X/$"33V>CZ;"+=;-)<">Z=09&< _,J
M@@+GUS6?X:T76O&4GB$WWB[6K.RM-8NH+:*PN3'("&_BD.25 ( 08 Q[UT]A
MX+E\/>-H=3\/_9;;1[BT%OJ%D25^9!B.2, $%L<')''N:X[PA:>-!+XHN?"]
M_I1BDUV[CDM=31]L; _ZQ&3G)R,J1CB@#<\*ZQJ6K> =3MM5\1_V?=Z3J$MA
M<ZLRH"4C8?-E_E5BIQN.<=>36'HWB*PL/B-H.G>'/&=_KMG?^=#?6][=-<["
MJ;D=&(XR0<X.#6Y/\+IA\/TT2'4HIM3%^-3FN+J+,5Q/NW$.HYV'I^%3_P#"
M,^,M5\6^'M9UJYT2*VTJ24_9+'S#D-&5W!F')SCC  '<T 9T6GZUXI^(GB[3
M&\3ZKIVDVDEL1%8S;)=S1 @*YSL7@DA1\Q//2GZ)J7B>/P;XQTJSO)M2UC1;
MJ6VL;F8!I9%VAEW9^\X!/)ZG%=5H7AV[TOQCXFU>>2!K?57MV@5&)=?+CVG<
M" !STP35+3/#&MZ6_BJ>TOK2"ZU2_P#M=G(4,JJ %&V12!UVD'!X!R#F@#+^
M'5QHM]=M+9^*/$%WJ<4.R\TS5[IB\3\98Q,."#QE?EYQ5+3?%FH:/X$\<:U+
M-->3V&K7<=L)Y"X0;E5%Y/"@GH.U;6F>%_$5]XTLO$GB631XI=/@DA@BTM9#
MYA<8)=W .!SA??K2Z;X"9O#/B?1-7EB:'6=0N+E&MV)*)(05)R!\P(SCD>YH
M PM4\*^(M)\(S^)H_&VN2:[:VIO9(Y)P;-R%W,@AQ@+@$#\Z76]7UOQ%K7@$
M:5JLVD#6;*::X\H[@JF-'.%/RE@"0"0<9S5F7PK\0]1T0>&=1UK0TTAHQ;RW
MUO%*;N6$ #!4_(&(X)SWK>NO"$B^*O"=]8&"+3M$MYX#$S'?M:,(@7C!QCG)
M'XT 8^A0ZAX4^)<?AUM=U/5M-O\ 37NE_M.;SI8I4<*</@?*0>GK7HU<S=>'
M;N?XCZ=XB62 6=MI\MJZ%CYA=F!! QC''K734 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !12$A022 !R2:X.3XI6;:=875CHNJWDNHSS)96T<8
M$D\40R\P!/">G<T =[15#1=7M-?T6SU:Q9FM;N(2Q[A@@'L1ZCH?I5^@ HHK
M@X/'.HO::?K#VEI_9=]J?]GI;H[&YCS(T8<GH3E<E,<#/)(H [RBN4N/$.KW
M>H:U%HEK9R0Z.1')]I=@;B78)"BD<( &4;CGDGCC-1Q>+YM<NM*M- C@$M]I
MHU-Y;L$B")B H*J02Q)8=0!M/6@#KZY_QW_R3SQ+_P!@JZ_]%-4_AK6WUS3Y
MGG@6WN[6YDM+F)'W*LB'!*G RI&"..AJ#QW_ ,D\\2_]@JZ_]%-0!T%%%% !
M1110 4444 %%%8/BKQ(WAJTM)8],N=1ENKD6Z06Y&[)5FSSV 4Y]*TI4I59J
M$%JQ-VU9HZOJ*:3I-S?.N_RD^1,X+N>%4>Y8@?C5'PMIKZ?HZ-.V^ZN"9II,
M8W,Q+$^V22V.VXBN3UGQ'=ZA)IB:CX?NK>S%[$)/+N89@S,VP!]A.%&[.3QG
M&#GBO1ZZJU*5"BH/>3ULT]MEI?O<A-2E?L%%%%<)H%%%% !5'6K*34="O[&$
MJ);BW>)"YP 64@9]N:O4549.,E)= /G$_ +Q4 3_ &AHW_?Z7_XW7M7@"P;3
M/ VDVC3PSF.'_60[MK9)/&X CKT(!!KI*PX/^)-K[6IXL=29I8/2.XZNG_ A
MEQ[A_45[&,S;$YC2]G6:TU5E;U_#4SC3C!W1N5%<6ZW$6PDJP.Y''56'0BI:
M*\9-IW1;5]#)DUV"U(AN<F=>'\L94'U_KBM*">.YA66%@R-T-<;J6G745_+^
MYD<.Y9652<Y.?SKHM @>WTW:Y&XN25SG;['WKKK4:<::E%ZG/2J3<W&2-2BB
MJ>HNQ@6VC)$EPWE CJ!_$?P /XXKDBN9V.ANRN5#']KTW4;D\_:8G6/_ *Y@
M$+^>2W_ JT[=_-MHI/[R!OS%+Y:"'RE4!-NT =A5;26+:/9$]?(3/UP,UI)\
MT6_/^OR(BK2M_7]:ERBBBLC0**** "BBB@ HHHH **** "BBB@ HJKJ&IZ?I
M-M]IU*^MK.#./-N95C7/IEB!4<>M:5-I;ZG%J=D^GH"6NEN%,2@=27SC]: +
MU%>9^ ?%=]XOUJXOI/%=BL*W,R1:%%'$6,*\+)NSYG7!ST_.NW\2>(++POH%
MWK&H,1;VR;BJ_>=CPJCW)('XT :M%>?1ZG\4;RS74[?1_#EO!(OF)IUS-,;G
M;C.TN,(&_# [XKH?!WBJ#Q?X=CU2.![257:&YMI#EH)5.&4G]<\<$<#I0!T%
M%9MAXBT/5;E[;3M9T^\G09>*WNDD91TY"DD51T+4[HVFK76LZKHTL-M=RJLM
ME+\EO$O\,K$X#C^+TH T]2T?3-8A6+5-.M+Z-3E4NH%E /J P-/L-,L-*M_L
M^G6-M9P9SY=O$L:Y^B@"JX\0Z(;Z&Q&L:>;R=0\5O]I3S)%(R"JYR01SQ4D6
MMZ3/JDFEQ:G92:A&"7M$N$,JCW3.1U':@"]1534=5T[2+<7&IW]K90%MHDN9
MEC7/IEB!FB/5=.FTTZE%?VKV 0N;I9E,04=3OSC ]<T 6Z*S'\2:%'(\;ZUI
MRND N'5KI 5B.")",\+R/FZ<UA^$/B!IGB_3W:"YL+?4-\RK9_;%D<JC$!\#
M!VD 'IT/6@#KZ*Y_0-7D7PI;ZCK^KZ-*[$A[RRF M6RY50K,?H/K6C%KFD3Z
MH^EQ:I92:@@)>T2X0RKCKE,Y'Y4 7Z*PQ=ZB?&K6?V_2O[.%D)/L88_;-^[&
M\CIY>.,^M8'A3QG&;/6Y_$FM6=ND&M7-G;/=21P 1H1M0'C)&?<T =W13(I8
MYXDEBD62-U#*Z'(8'H0>XJ*>_L[6XAM[B[@BFF#&*.20*T@498J#R<#DXZ4
M6**I:=K&F:NDCZ9J-I>K$VV1K:=9 C>AVDX-1W_B#1=*N([?4=7L+.>7_5QW
M%RD;/VX#$$T :-%07-[:6?D_:KJ&#SI!%%YL@7S'/15SU)P>!S4%MK>E7EM<
M7-KJ=E/;VS%9Y8KA66(CDAB#A2/>@"]5>UL;2Q$HM+6"W$TAED$,83>YZL<=
M2>YZU%IVL:9K$+3:7J-I?1(=K/:SK*H/H2I-9OAW4KR?2;S4=5U+1[BU-Q*]
MO<:?+NA6W!P-SGC<,-D]* -^BLVV\0Z+>6$]_:ZQI\]G "9KB*Y1HXP.3N8'
M _&L/PC\0=)\675_;P7%E%-!=R06\0O$>2YC3'[T(,$*><=>!G- '745G2^(
M-%@U--,FU>PCU!R MJ]R@E8GIA"<G\JL7.HV-E+'%=7MO!)*KM&DLJJ7"C+$
M GD <GTH LT56L=0LM4M%N]/O+>[MG)"S6\JR(V#@X8$CK5:3Q%HD6IKIDFL
MZ>FH,0HM6ND$I)Z#9G.?PH TJ*J:CJNG:1;BXU._M;* MM$ES,L:Y],L0,UD
M^(M<5/ FK:SHM]#*8K*6:WN8&65-RJ2"#R#S0!T-%>>ZGXEU>W\.^ [J*[VS
MZI>V<5XWEH?-62,EQC&%R?3'M79ZGKFD:*(SJNJV-@),A#=7"1;L=<;B,T 7
MZ*C@GBN8$G@E26&10R21L&5@>A!'45)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!6OKNSM+=C>3Q11LI'[QPNX8Y KRGPKX:6VLH=4MO&MI((]*-KH;
M30HK6L4A#AY%S\S@87MTYKTO7M"T?7]/^SZU8PW=M$?-"RKG:0",CWP37C.A
M>$+O7=%MM1TCP#X4339D_P!&_M&>1IWC' 9RO&XXS^- 'JOP^32X_ 6C1Z--
M+/IZP;8I94VL^"<L1VRV>*Z6LSP[:W-EX?LK6[M+*TGBCV-!99\F/!X"YYQC
M%:= #7W;&V8#X^7/3->066E&/2=-$.DZBGCI-0CDNKQ[>0#>9!Y\C2X\MHC'
MN  )'*@#(X]AHH X);J7PMJ'BJ"XT_4+D:A<_;K(VMH\HG+PI&8]R@JK!D_B
M(X(.<9Q1T#2;CP->Z'/J$%Q);G08]/N)+:!YQ#/&Y< A 3M;S' .,94=,C/I
M=% '(>"M,NDT?6KJ5;K3Y=9U*XO8E=5$T". B$JP(#;4#;6!P3@CJ*I>--"U
M&'P+XAE?Q9K,Z)IERS121685P(F^4[8 <'IP0?0BN\KG_'?_ "3SQ+_V"KK_
M -%-0!T%%%% !1110 4444 %8_B17.F@H"<."V.P_P XK8JAK=VUCH5]=)CS
M(X',8/=\?*/Q.!6M%OVD;=R*BO%HY'3E=M1@" GYQD>W?]*[VJ>FVH@L8"\:
M"X,2^:RH%+-CGI[U<J\36]I+3H10I\D?4****YS8**** "BBB@ JCJ]@FHZ;
M+ TAA88>.8=8G4Y5Q]" ?TJ]4-U_QYS_ /7-OY54&XR36X,P+#QQX>EL(7O=
M?T6"Z*CS8UU&%@&[X(;D=Q[=<5NV5_9ZE:K=6-U!=6[$A98) Z'!P<$<=:^)
M:^I/@S_R3#3?^NDW_HQJ^HSO(:6 H*O";=W:WK=_H84JKF['?53N%:UF-Y&"
M4/\ KT ZC^\/<?J/H*N45\M%V9LU<165U#*0RD9!'0BJ<'^DZC-<=4A'DQ_7
MJY_/ _X":P;W5YK.ZDMK,A(D<\$9Y[@>@SVK7T*[%U8?<5&1B&"]R><_CFNB
M5&5.'/W,8U8SER]C4JEI/&G(O]QW3_OER/Z5=JEIG$=PG]VYE_5BW]:Q7P/Y
M?J:/XD7:***@L**** "BBB@ HHHH **** "BBB@#S5=/L?$GQHU>#6X(;R/2
MM/@^PVMP@>-=^2\FT\$YP,_3T%,TG2=/T?XS:GHVF6L,6E7NBK=7=DD8\D2B
M7:#MZ#*D\=\UT_B/P/IWB/4+?4C=ZCINIP)Y:7NFW'DRF/.=A.""N>Q%3^&?
M"&F^%EN7M9+JZO+HAKF]O9C+/.1TW,?3T  H Y7X,V-HGA:ZN4M8%N/[2ND\
MT1@-MW],]<>U2_&C<G@2.Y(8V]MJ-M-<8&?W8?!S[9(KJ_#7AJS\*Z9)86,L
M\D3W$EP3.P+;G.2. .*TKVRMM1LIK.\@CGMID*212#*LIZ@B@"6.1)HDEC=7
MC=0RLIR"#T(KR3PGHS^*O"GC^*PN/LUOK&JW*VDPR58<#<,=5)R#CWK=_P"%
M2:4(#91Z_P")8]*/']F)J1^S[/[F,;MOMNKJ7\,:2?#0\/PVYM=.5 D:6SF-
MH\'<&5@<A@P!SUSR<T <AX1OXM)UZS\/:WX3L=&UIK=DM+RR1&AND0#=L8#<
MO3.UO0<]*QM+_P"2:?$K_L(:G_Z#7;Z+X%L=(UA=6GU+5=6OXXS%#/J5SYIA
M0]0@  &<<G&?>I;?P5IMOH>N:0D]V;?69IYKABZ[E:48;8=N !VR#^- 'F/B
M;PGHFF_ 2#5;6PCCU2.WM+M;_'^D>:S1Y;S/O?Q'C.!QCI6SXS\*Z)X:L/"E
MYH^G06EY!K5I&+F-!YLBL2&WOU?/?.:[C5/!^GZMX*'A6>:Z6Q$,4'F1LHEV
MQE2.2I&?E&>*L:]X<L_$-K96]W).B6=W%=QF)@"7C.0#D'CU_G0!YUK,&LZW
M\9-1@M+'1;[^SM.B^SPZPSB-%<Y9XU56RQ/!..@ S2MX5UOP_P"%O'UWJ,>D
M6EIJ&GM)%9:6\ABCD6)@[895P6XZ>E=QXA\$Z=X@U&WU/[5?Z=JD">6E]IT_
ME2F/.2AR"&7/8BD@\%6<>B:GID^I:K>?VE"8;BYN[HR2[2"/ER-JXW'HO>@"
MAX"\)Z%9^#M)N%TNUENKFQ1Y[F:)7EEWJ"P9R,D'CCI@ =JROA-I]DG@JXND
ML[=;@7EXGG",!]OF,,9QG%=_IEA%I6E6FGP,[0VL*0HSD%BJ@ 9QCGBN?TCP
M%I^A:Y=ZE8:CJT<-TTDCZ<;K-J'?[SA,=?J3_*@#S20;OV7K90S*2Z#*G!'^
ME]JW_''A30O#&C^'K[1M,M[.\M=8M%2YB3$KAGPP=_O/G/.2:ZH_#[23X#C\
M'_:+W^ST((DWIYO$GF==N.OMTK5\0>';/Q)8V]I>23QQP7,5TIA8 EHSD Y!
MX]: .9B_Y+Q/_P!B\O\ Z/-8GP[\*^']7N_%E]J6FVM_=?VY=0?Z4@E$:9SA
M5;(7.3DCDUZ"OAVT7Q:_B023_;&LA9%-P\O8'WYQC.<^^/:O/?&7@#3M$TZY
MU32]3UBPO;Z_W7,UK=^495E8DHP4 %1DXR,C/4U4(.<E%=29S4(N3V1K?!YO
M+\-ZM8Q,6L;'6+JWLSNR/)# @ ^F2:J>(]&MO&/QBT_2[Y3)IVDZ6UU-"&($
MKR/M"-CJOR@X[X]*[S0="T[PUH\&E:7 (;2 ':N<DDG)))ZDGFO/K/P,WB?Q
MIXIUZ^FUK1[@7B6MC<VDK6TIBC10Q7(PR,<<X(.*DH@MO[/T#XI^*;[1;.WM
MK#2?#ZF[AMHPD9FR74$+P#L6LGPSX;\0:UX0E>;PKHTU]KD1N)M;U*\$KN)!
MD$1B,E=JD84, ,5ZGH7A'2/#^CW&FVL+S1W3,]W+<N9)+EF&&:1CU)K*TOX<
MVND20I:>(O$:V,#AHK#^T/W* '(487=M]MU '+>)?#*3WGP_\ O=S36L"O-<
MRABCND,84<CH&W$=> >M=#XR\#B\\+0Z?X;T_38%@O8KN6P:,107@3K&^T=\
M+R?[H!KHSX=M&\7+XD:2<WBV7V)8RP\M4+[R0,9W9[YZ=JK:]X477+V&[37-
M:TR:.,QYTZZ$:NN<_,K*P/UQF@#E=-\1:2O@SQ3KEGX?AT35M/BEM[ZW5$!$
ML:$J-R8##+<'_P"M5=_!>H7OP=\-Z5IRV\LUK]GO9K.[)$5W_&T3GT+-GGC@
M9KIY/A[HK^#KKPRCW<=I=R>;=3B;=/.^X,S.[ Y+%1GCIP,59USPDFLW4%S%
MK>LZ7+#'Y0_LZZ$:NO7#*RL#]<9H P/#VL:!=^&_$.J#PY;:1>V*O;ZI:M'&
M1NB4M@E1AUYX./Z5@:2L?@SX!CQ!;VT*:N]B9UNA$N\/._RG..@WKQTXKT+3
M_!VCZ;X;N]"BBE>UO!)]J>64O+<,XP[NYY+'UJCI7P^TO3O#5WX?N+[5-4TZ
MYC$)CU"Z\SRHP,!8\ !0.V!G@>@H X2W^'FL:IX13P]+X7T;2_-VM=ZO/=_:
M[J1LAGD7" [R<]6P,XK6US0[?Q5\7=+TB]W3Z=HNE&XEC9C^^=W"A7]0=H)'
M?'/%=1HW@A=&NX)O^$D\17L<'^KM[N^W1CC !"J"P'HQ/05I6'AVTT_Q%JVM
MQR3O=ZF(EE$C J@C4JH0  @<Y.2>: #48XM!\*Z@=)M8+46UM-+#%!$$16VE
MN%&!R>:XWX>>#/#&H_#O2;JZTFROKF\A%Q<7<T2O,\I)+'?]X$$D=>*](90R
ME6 *D8(/0UPT'PJT:TN&%IJFNVVFM)YATJ'4&2TR3DC:!G!/4;L4 <YK,&LZ
MW\9-1@M+'1;[^SM.B^SPZPSB-%<Y9XU56RQ/!..@ S2MX5UOP_X6\?7>HQZ1
M:6FH:>TD5EI;R&*.18F#MAE7!;CIZ5W'B'P3IWB#4;?4_M5_IVJ0)Y:7VG3^
M5*8\Y*'((9<]B*2#P59QZ)J>F3ZEJMY_:4)AN+F[NC)+M((^7(VKC<>B]Z .
M,UK_ )%+X7_]A'3_ /T4:T/%6A:GI_C&?Q3#H%GXDL)K1+>:SE*^?;JA)+1;
MP58$$DKP2<5T]UX.T^[T[0;*2:Z$6B30SVQ5ER[1+M7?\O(QUQC\*KZUX&M=
M9U&:\36=;TXW*A;F*PO/+CGP ,LI!P< #*X.* -/PQJ>F:SX:L+_ $:,1:?+
M$/)B$8C\L#C;M' P01@<<5K53TK2K+1-*MM,T^$0VEL@CBC!)P/J>2?>KE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #)F*P2,&VD*3G&<<>E?/&F>+K
MCPYI@M+7XB&"QC9C&DGAJ3;$&;.U2>BY/ [=!7T0[;$9@I; S@=37 W'Q"U&
M:VEB'P[\2RET*^7+;H$;(Z,=QX/?@T =/X3OI=2\+V%Y-??;I)4):Y^S&#S/
MF(SY9Y7TK9KGO NGZEI7@;1K'5V)OX+54E!8$KZ*2.N!@?A70T (2%4L3@ 9
M)K#/C3PRN-VNV R0HS,!DG@"MVN,N1_PD?Q*2QD&[3O#\"73IV>[ESY>1WV(
M"P]W!["@#H;_ ,0:-I5S';:AJME:3R %(YYU1B"<9P3TSQGUJ74=8TW1X4EU
M*_MK2.1MJ-/*$WG&<#/4XYXKE-$MX;^\\?&^B65I+XVTB2+D&!;:/:O/\/SL
M<>Y]:Q/A[-<7^M>'IK\N\D'A.!H"^3R\I#MD]RL<63UY]Z /3K:Y@O+:.YM9
MXY[>50\<L3AE=3T((X(K$\=_\D\\2_\ 8*NO_135C>"[BXL--\3K!I\US%:Z
M]=):VML45BA*L0N]E4 ,[G&1T./2F>--=U&;P+XAB?PGK,"/IERK2R2V95 8
MF^8[9R<#KP"?0&@#O**** "BBB@ HHHH *P?%.)[6PTXJ6%[>Q1L!V53YA/T
M^0#\:WJP+G%WXWL8<G%E9R3L.Q,C!%_$;&_.M\-I/F[)O[MOQL14^&W<WZ**
M*P+"BBB@ HHHH **** "D90ZE6&01@BEHH Y7_A6O@S_ *%ZR_[Y/^-6_"L-
MOIEI/H<5M%;/82'Y(EVJ\;DLD@'OR#_M*W:M^L778WLY(-<MT9I+,$7"*,F2
MW/WQCN5P''?Y2!]XUV+$5:Z]E5FW?:[;UZ??L39+5&U138Y$EC62-E=' 964
MY!!Z$4ZN,HP]0\/"[NFGBF$9?EE*YY]16CIU@FG6ODJQ8D[F8]S5NBM95IRC
MRMZ$*G%2YDM0JE8_+=ZBGI< CZ&-/ZYJ[5*W^75KU?5(G_/</_9:F.TO3]4.
M6Z_KH7:***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3[0MM&?[HC4!A_WT6K<FF2W@DFE;;'&I=B>P R:QO"$,D?AJVEG4+<7.ZXF
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MJD7^%']O>+/^A+_\JD7^%=511[6'\B_\F_S#V,_^?C_\E_R.5_M[Q9_T)?\
MY5(O\*/[>\6?]"7_ .52+_"NJHH]K#^1?^3?YA[&?_/Q_P#DO^1RO]O>+/\
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M** "BBB@ HHHH **** /COQO_P CWKW_ %_S?^AFO8/V? /[#UAL#(N4 /\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_CIK%HHYV'U>)M?;[;_ )Z_^.FC[?;?\]?_ !TUBT4<[#ZO$Z"*9)E+1MD
MXZ5F>*;<W7A+6(%^^]E,%/HVPX/YXJSI?_'LW^^?Y"K<B++&T;C*L"I'J#6U
M*?)*,^VIRU(V;B9UE<+<:A'<+]VYLHW'TR3_ .S5IUR_A5V.D^'MYRXTTPN?
M5T\L']0U=16N)AR5''M^CM^AE#J%%%%8%A1110 4444 %%%% !1110 4444
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MAI(+E)9;CS%0Y"A,9/OS6]6F)G3;7LR*$9I/G"BBBN8W"BBB@ HHHH ****
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MAC6Y=;T^X-S#'#>V=U+9W21-N3S$.,J3S@@JPSR,XJ'QW_R3SQ+_ -@JZ_\
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MB,AH^KD#!!SUQ1T+1KOP-=Z)<7=K<W-N-"CT^[>S@>X,,T;[Q\B L5;S)!D
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MM[4/$&BZ3.L&I:O86<K+N"7-RD;$>H#$<<&O!?@E9ZA_PD>I"!S:3&S^66:
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M )(H Z"BN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**Y_\
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MA,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#H**Y_P#X2'5/^A,US_O]9?\
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MW [T%K!&3QT^9&'/IZ8K8K#TWQ$UUK4FC7VGS6%^MN+I$=U=)8MP4E64]0Q
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M+XA35[W4=/EM9;._TYT6X@D96X==R.I4D%2,^AR#Q0!LT444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7G%E\6O[0TZ/4K7P5XHGL7!
M99H;5'# '!(P_/0UZ/7$_"+_ ))5H'_7%O\ T-J .ET+7-/\1Z-;ZKI<XGM)
MURC8P0>A!'8@\$5HUXPVI+!H?B5=.N]1@AU/Q.]O9C24'GW#;%\P1,<! 65R
M9.@P3WIW@E=;LOB%-H6H)K5G87NE2R_9=1U9;N0D.JB1=O\ J^K#KSCV& #V
M6BO*=-U34M0TWP_X/FO9O[5M]3>WU*97(=H+4A]Q.<_O 8!G/.\USNKS>(-$
MU^\U37I?%D2)>M+#J>F3BXL$@#?*'@&-J!>""<YR>>A />**9%(DT22QL&1U
M#*P[@]#3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img40748725_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &: W,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9 8#H<<\T 3T444 %%%% !14"WMJUZ]DMS";M$$C0"0>8J$X#%>H!(//M4]
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MY4V%D7^(C X[UIZ?J<?C+3]2LKC0]5L;%XO)+:C;^09@X(8*A.[ &.2!UXH
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M1RH4LJ ' Z#/I4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBJFH6":C L4D]S" V[=;SM$WTRI!QSTIQ2;UV
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M9P>1D^U=+J_Q-T'1M:OM(EAU*XO[+898K6T:4[60/NR.  &&<X_&N*N(;_\
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MX;@3@EUY&VH?%/AWPQX@\:>!+H6,5U::FDP9V+?OH5M]T><G/'!YY]:[#6O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&7_ " [;_L*Z;_Z6PU?T#6(?$&@V>JP1O''<QA_+?[R'H5/N""/PJAXR_Y
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M7<>QGC.&7G((^A KC[KX=Z[JHTQ-7\:2W<6G74-S#$FGI$K^6<_/ALL2.,Y
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M1169KGB#2O#=B+S5[U+6 L$4L"S.QZ*J@$L?8 U!H7BW0O$L5P^DZ@EP;?\
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M2://<2L%CBBOHF9R>P ;)-;=<9I:_P#"2>/M2U.8;[+0F^P6*GIYY4-/)CU
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MT?\ "?Z3_P ^VI_^ ;T?5JO\K#ZS1_F1U5%<K_PG^D_\^VI_^ ;T?\)_I/\
MS[:G_P" ;T?5JO\ *P^LT?YD=517*_\ "?Z3_P ^VI_^ ;T?\)_I/_/MJ?\
MX!O1]6J_RL/K-'^9'545RO\ PG^D_P#/MJ?_ (!O1_PG^D_\^VI_^ ;T?5JO
M\K#ZS1_F1U5%<K_PG^D_\^VI_P#@&]'_  G^D_\ /MJ?_@&]'U:K_*P^LT?Y
MD=517*_\)_I/_/MJ?_@&]'_"?Z3_ ,^VI_\ @&]'U:K_ "L/K-'^9'545RO_
M  G^D_\ /MJ?_@&]'_"?Z3_S[:G_ . ;4?5JO\K#ZS1_F1SLMTW_  NE)O\
ME@FVT+?[30E@/SKTRO-O[(U*7PQ)KXM)!J9U,:HEN5._8#@)C_=R<5OCX@:2
M0";74Q[?8VKHQ%-U.7D5^56?R.;#U%3YO:.W,[KYG545RO\ PG^D_P#/MJ?_
M (!O1_PG^D_\^VI_^ ;US_5JO\K.GZS1_F1U5%<K_P )_I/_ #[:G_X!O1_P
MG^D_\^VI_P#@&]'U:K_*P^LT?YD=517*_P#"?Z3_ ,^VI_\ @&]'_"?Z3_S[
M:G_X!O1]6J_RL/K-'^9'545RO_"?Z3_S[:G_ . ;T?\ "?Z3_P ^VI_^ ;T?
M5JO\K#ZS1_F1U5%<K_PG^D_\^VI_^ ;T?\)_I/\ S[:G_P" ;T?5JO\ *P^L
MT?YD=517*_\ "?Z3_P ^VI_^ ;T?\)_I/_/MJ?\ X!O1]6J_RL/K-'^9'545
MRO\ PG^D_P#/MJ?_ (!O1_PG^D_\^VI_^ ;T?5JO\K#ZS1_F1U5%<K_PG^D_
M\^VI_P#@&]'_  G^D_\ /MJ?_@&]'U:K_*P^LT?YD=517*_\)_I/_/MJ?_@&
M]'_"?Z3_ ,^VI_\ @&]'U:K_ "L/K-'^9'545RO_  G^D_\ /MJ?_@&]'_"?
MZ3_S[:G_ . ;T?5JO\K#ZS1_F1U5%<K_ ,)_I/\ S[:G_P" ;T?\)_I/_/MJ
M?_@&]'U:K_*P^LT?YD=517*_\)_I/_/MJ?\ X!O1_P )_I/_ #[:G_X!O1]6
MJ_RL/K-'^9'545RO_"?Z3_S[:G_X!O1_PG^D_P#/MJ?_ (!O1]6J_P K#ZS1
M_F1U5%<K_P )_I/_ #[:G_X!O5S2_%^E:M?K8Q-/%<LI9([B%HRX'7&>N*3H
M54KN+&L12;LI(WJ***Q-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH X+QI!9W/CSP?!K*12:2[7.U)QF)KH*OEAL\9QYFT'OGOBN
ME\3V&AZAX>O(O$,-N^F+&S2M/@", ?>!_A([$<CM5G6-%TWQ!ILFG:M9Q7=I
M)]Z.0=^Q!Z@^XYKEK?X2>$8IXI)[2ZO4A;=%!>W<DT2'_<8X/'KF@"]\-9KV
MX^&_A^6_9FN&LT)9SDLO\!)[Y7;754@ 4    < "EH SM?U>+0/#^H:O.I>.
MSMWF* X+;1D*/<]/QKF]'U[4[C6;"V?6M(O9)@_VVRA78T. <F)MQ\P*V%8=
M><\=*W?%>C-XB\)ZKH\<BQR7EL\2.W16(X)]LXKFFL]2UN;PI;C1;C2CI%RM
MQ<R.4V($B>/RHRI.X,6'3C:.<' H BE\6ZW_ ,(O=>,8Y+4:7;W,A%BT!WR6
MJ2&-F\S=PY +CC'08/WJUY-4UC6?$FJZ;H]W;6<&F11!II;<S>=/(I<+]X80
M+M)QR=W48YYV?1=9'@6\\#+I=P[S7$MO%?;D\@6SREQ(3G.51L;<9+#T.:W!
M#?>&?%&M7EOI-W?V>IQPRQ?9BA*31Q^68VW,, JJ$-TZY([@&SX5US_A)/#%
MCJQC6)YT/F1JVX(ZDJX![@,I%5_&7_(#MO\ L*Z;_P"EL-5/#GA%;+P/INBZ
MC)<1RP[II?L5Y+!B1V9V&^-E8KESQG!P#C@52\2>&K#3]/L[J&XU5Y$U73L"
M?5KJ9#F\A'*/(5/7N..O6@#N*\__ .;A?^Y4_P#;NO0*\_\ ^;A?^Y4_]NZ
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M*#TP16K0 44A(4$D@ <DFL72/%5AK@MGL8=0:"Y3?%.]E*D;+C(.YE P1TH
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MCG7L^3S%R/VG/Y6)****S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUO\ 2M*@M3JNG;Y(-3DE=?\ 3(<84P*#SC^(>O/2NUBBC@A2&&-8XHU"HB#
M4#@  =!6%XR_Y =M_P!A73?_ $MAH Z"O/\ _FX7_N5/_;NO0*\__P";A?\
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M=2N6L]/FG0991Q]2<5S5IX@O5ND\Z021L<%2H&/IBNB%B9@6O)FF+ C8N50
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MR$G"@Y. "?PH [BO/_\ FX7_ +E3_P!NZ] KS_\ YN%_[E3_ -NZ /0****
M"BBB@##\2XN8+/2_E)O[E8W4GK&OSO\ ^.J?SK<K#0_;?&,ASF/3K8* 1QYD
MISD'V5<?\"K<K>K[L8P\K_?_ ,"Q$=6V%%%%8%A1110 4444 %%%% !1110
M456GO[6W)6290P_A')_(5#_:L1Z0W)'J(C2NBU3FU=(I>$T\G0A;GK#<SH?^
M_K$?H16Y7.Z#=16\FII/*L?F7SRQ!CCY&"G\.<\5T(((!!R#W%;5Y*564D[W
MU^\SC"4(I25A:***R&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9&H:_%97!@6(RNOWN<
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ML161 QP&8#'\ZEOM(@DLYUM;>**:0?>10N[D'G'KBN;@T:^EN!&T#H ?F8]
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B>VMY)TGD@B:9%*K(R
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MG(?$S1-0\0> [W3-*M_/NY&B*1[U7(#J3RQ Z ]Z\$_X4]X\_P"@%_Y-P?\
MQ=?55%>KEV?8G+Z3I4HQ:;OJGY=FNQ$Z2F[L\\^)>G36WP_UN<ZG>21/$O\
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MM/N+07$]N9HVC\Z!@LD>1C<I(.".QQ7!0Z;I-A\0M(TWPM:QP7%DKR:S-;C
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M*;%;@/GG<&WC@@BFR(-VU,J[OM=U_P 7:GHNDZJND6^E1Q&69;=)I)GD4L
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M17*SR.5#AN">.17:445Y.)KRQ%:5:>\G<T2LK!1116(PHHHH **** "BBB@
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M/GXY,;_E[BK'VZ]_Z$_Q!_W_ +'_ .2*.5A[>!:HJK]NO?\ H3_$'_?^Q_\
MDBC[=>_]"?X@_P"_]C_\D4<K#V\"U157[=>_]"?X@_[_ -C_ /)%'VZ]_P"A
M/\0?]_['_P"2*.5A[>!TEA_QY1_C_,U9KG(==U*&(1KX-UT@>LUC_P#)%/\
M^$AU3_H3-<_[_67_ ,D5:V.23O)LZ"BN7N/%]W:3VD,_A'7$DNY3# /,LSO<
M(TA'%QQ\J,>?3UQ5C_A(=4_Z$S7/^_UE_P#)%,DZ"BN?_P"$AU3_ *$S7/\
MO]9?_)%'_"0ZI_T)FN?]_K+_ .2* .@HKG_^$AU3_H3-<_[_ %E_\D4?\)#J
MG_0F:Y_W^LO_ )(H Z"BN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO
M_DB@#H**Y>_\7W>F:=<W]YX1UR.UM8FFF?S+,[44$L<"XR< 'I5C_A(=4_Z$
MS7/^_P!9?_)% '045S__  D.J?\ 0F:Y_P!_K+_Y(H_X2'5/^A,US_O]9?\
MR10!T%%<_P#\)#JG_0F:Y_W^LO\ Y(H_X2'5/^A,US_O]9?_ "10!T%%<_\
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MX%QDX /2@#J**Y__ (2+5/\ H3=<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(H
MZ"BN?_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#H**Y_P#X2'5/
M^A,US_O]9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_Z$S7/^_UE_\
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M_)% '045S_\ PD.J?]"9KG_?ZR_^2*/^$AU3_H3-<_[_ %E_\D4 =!17/_\
M"0ZI_P!"9KG_ '^LO_DBC_A(=4_Z$S7/^_UE_P#)% '045R]QXON[2>TAG\(
MZXDEW*88!YEF=[A&?'%QQ\J,>?3UQ5C_ (2'5/\ H3-<_P"_UE_\D4 =!17/
M_P#"0ZI_T)FN?]_K+_Y(H_X2'5/^A,US_O\ 67_R10!T%%<__P )#JG_ $)F
MN?\ ?ZR_^2*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Q-3\,6FI7TEZMS>V=S-"+>>2SF\LS1@DA6^FYL,,,,G!%;=% %>
MQL;;3+"WL;*%8;6WC$<4:]%4# %9?BR":YT>W2"*25QJ=@Y5%+$*MW"S'CL%
M!)/8 FMRL/4?$JV>JMIEGIMYJ5Y% +F:.U,8\I"2%R791N8JV%'/!Z"@#<HJ
MGI6J6NM:7;ZC9.7M[A-R%A@CL01V(.01V(-7* "BBB@ HHHH ***R]8UI=):
MUA2SN;V[NY#'!;VX7<V!EB2Q"JH Y)/H!DD"@"OX+@FM? OAZWN(I(9XM,MD
MDCD4JR,(E!!!Y!!XQ6Y63HNO0ZP]Y;FVGM+VRD$=S:W&W>A(W*<J2I4@Y!!_
M(@BM:@ HHHH **** "BBB@##M8)E\=:M<-%(('TRR1)"IVLRRW18 ]"0&4D=
MMP]:W*P_^$KTYO&0\+QEY+\6K7,A4#9& 5 5C_>.X''I@]Q6Y0 4444 %%%%
M !1110!AZ[!--K'AAXHI'2'4W>5E4D(OV2X7+>@W,HR>Y [UN5S5[XQBMI;\
MVVDZC?6NG-LO+FV5-L; 98 ,P9RH()V@^@R<BNBBE2>%)HFW1R*&5O4'D&@!
M]%%% !1110 4444 8?C.":Z\"^(;>WBDFGETRY2..-2S.QB8  #DDGC%;E9&
MLZ_'I-U9626EQ>W]\7$%M!M!*H 78EB%"KD9R>X R33M UZV\0V4T]O'-!);
MSO;7%O. )(94^\K8)'<'()!!!H U:*** "BBB@ HHHH *P]"@FAUCQ.\L4B)
M-J2/$S*0'7[);KE?4;E89'<$=J35/%VDZ5KFG:++<"34;^41QP1D%D!!.Y_[
MHX.,]>V<'$FJ>(4L-3ATNVL+G4-0DA:X,%N4'EQ XW,790,G@#.2<]@2 #9H
MJAHVKVNN:9'?VF\1LS(R2+M>-U8JR,.S @@_2K] !1110 4444 %8=U!,WCK
M2;A8I# FFWJ/(%.U6:6U*@GH"0K8'?:?2K&O^(=,\,:5)J.JW200H/E!/S2-
MV5!U9CZ"HKCQ';6_A^TU?[/<RB\6+R+:)0TLC28VJ.0 >>22 ,$DXH V:*Q=
M+\0I?ZI/I=S8W.GZA#$L_D7!1M\9) =61F!&00><@]N1G:H **** "BBB@ K
M#\9P377@7Q!;V\4DT\NFW*1QQJ69V,3   <DD\8K:DD2*-I)'5$499F. !ZD
MUC>'?%>F>*3J#:5(TT%E<_9S-CY)6VJV4/=?FQGOC(R,&@#;'2BL*_\ %FFV
M'BO2_#;EY-0U$.RJ@!$2JC-E^>,[& ]<'TK=H **** "BBB@ HHK"3Q=I,WB
MX>&;>?S[\0//+Y6"D(4J-K'^\=V<=0.N,C( OA.":VTBX2>*2)SJ=^X5U*DJ
MUW*RGGL5((/<$&MRL"_\4BWU&[L;#2K[5)[)%>[%KY8$6X95<NR[G*\[1GC&
M<9&=;3K^#5--MK^U9C!<1K+&64J<$9Y!Y!]J +-%%% !1110 445A>)_%VD>
M$[))]2N ))6"0VZ$&24YQ\J^@[GH* %M8)E\=:K<-%(('TRR1)"IVLRRW18
M]"0&4D=MP]:W*RM:UV'1A9Q_9Y[J[O9?)MK: +OD;:6/+$  *I))/0>O%)H>
MOP:XMXBV\]K=64YM[FVG"[XWP&'*D@@@@@@]#]10!K4444 %%%% !1169K.M
M)HZ6RBTN;RZNI?*M[:V"[G;!8\L0J@ $DDC\\"@"MKT$TVK^&7BBD=(=3=Y6
M520B_9+A<MZ#+*,GN0.];E8-EXKLIX]5^VQ3:=-I2A[R*ZVYCC*E@X*D@J0#
M@@]B#@C%1:=XNBO+^QM;G2[_ $_^T(VDLI+H1[9L#<5^5B5;;\VU@#C/<$
MZ.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM-+FQT^UM2^ Y@A5-V.F<#FI+?3[*TEEEMK2WADE.9'CC"ES[D#F@"Q1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK&%QW!/M4UI\.;G^T-.DUCQ7J>KV6FSI<6EK<(@Q(GW&=P-SD=><9/6N[HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img40748725_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &C!3$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\:O^10T[_L,6O\
M,UZ/7G'QJ_Y%#3O^PQ:_S->CT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\:O\ D4-.
M_P"PQ:_S->CUYQ\:O^10T[_L,6O\S7H] !1110 4444 %%%% !1110 4444
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MXV#IYUS*\BL#D,)2V_(['=D=* .#L+*>Z^*_B"TUNUT]UN]!BDGMH4+Q'$A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH *1E5U*L RD8((R"*6B@!%544*H"J!@ #
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M*JGHVR15;;[XQ6O7$>(+5;SXF^$I[(@W-LER]TT9Z6Y3 W>Q<C&>^<=*[>@
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M>9P"D1$H"LWT' [9(S4D'4/8VDER+E[6%IP-OFF,%L>F>M2&WA90K0QE0NP
MJ.%]/IP./:JKW#0(;.$3RW*Q'9))$Q5FQQEP-O6L.VN[EYWM6;57WVIEE#($
MD60,HPF0.#D]...#0!T7V"S\^2;[)!YL@VN_EC+#T)[TOV*U^UBZ^S0_: ,>
M;L&['UZUA64]UJ'V6SDN[B+Y9FD88$HV.H5&.,9 ;G'6M;1KJ6\TBWGF(:1E
M(9@,!B"1G\<9H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!'+-%#L\V1$WL$3>P&YCT ]37G\WBWQ#-:.B+8V5U9Q2R7#2%76XE!.R*)
M=^2"!RQ/''X>@2P13[/-B238P=-Z@[6'0CT/O7D=S<O,)K6ZNM)M[JT65?M,
M$,3+>7)8[ [F,I&@X!!())]N0#UNUDDFM(99HQ'*\:LZ YVDCD9[U+4-H)19
MP"<()O+7>(_N[L<X]LU-0 4444 %%%% 'G'QJ_Y%#3O^PQ:_S->CUYQ\:O\
MD4-._P"PQ:_S->CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<J9(:X4Q(X']UFP#6BHU&FU%Z>0KH[.BLZWU_1KN=(+;5K&:9SA8X[A&9OH
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M(>JGG!]CZ4N@>(+/Q':7%U8B3R8;E[?<XQO*_P 2_P"R<\&@#5HHHH ****
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M27M[(@EVY=R<+$O7 )Z =S7.:G+J?C+3[BRT646.FRH4?494),P/41+Q\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK&L?]@>T_P#1L]=97)V7_)6-8_[ ]I_Z-GKK* "BBB@ HHHH **** "BBB@
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MM0K,OR?W3@\CV/%6XHDAB2*-0L:*%51V Z"GT4 %%%% !1110 4444 %%%%
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M3GA>_'M7I]5M/L(-,L(;.W7;%$N![^I/N:LU=6ISO39&&#POL$VW>4M7_P
M*S]5U V<*QPC?=3';"GOZ_05:N[J*RMGN)FPB#\_:L_2K66:9M3O!^_E&(T/
M_+-.P^M9'82:=HUO9(DDB++=\L\S#)W'KBM*BB@ HK,N?$FAV<L\5SK%A#)
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MM";>2W*KS'+('8'.3EAP23SQZU?K/T,1KHMJ(H8X8PGRQQS^<J\]G_B^M:%
M!1110 4444 %%%% ')V7_)6-8_[ ]I_Z-GKK*Y.R_P"2L:Q_V![3_P!&SUUE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLV>=YP#GI@=/UKWBBE0Q"I24N5,&KG'Z3-X]?1[-KRUT07)A4RB2:4-NQSN
M4@'UQ73:>;XV:'4EMUNN=PMV9DZ\8+ &K5%8SGS=$@L!Y&*Y)H1IMWK5Q9 ^
M? T*PB:5V1=RKG@GWKK:B:V@8R%H8R9""^5'S8Z9]<5 S#O=2O+*XB59S<"*
M6*&X_<*JY=@.6+#G# X4'WZUT-5I-.LIKD7,EI"\XQB1D!/'3GVJS0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^L7.DP68769
M+1+:1MH%T5VL>N/FXS7&SP>"%NX[_3?$T.F74 9(Y+>_4HFXC</+<E,' X '
M2O0'1'&'56 ]1FO)8)R^BZCH5HUN=&2UFN5O9[ F5X-Y#L@W8=@2<,0,\'%
M'K49S$AW[_E'S?WO>G56T_RO[-M?(E:6+R4V2,<EUP,$_459H **** "BBB@
M#SCXU?\ (H:=_P!ABU_F:]'KSCXU?\BAIW_88M?YFO1Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***"0!D\"@"IJ6H0:5I\UY<-B.-<X[L>P'UK*\-:?.!-J^H#_3[WYB#_ ,LH
M_P"%!Z5R+1Z_XB\1^;$WVG38;OY6/$.%/H>O%>G5O./LXVOJSS\/5^M5'4::
MC':_5]_\@I&940N[!549)/0"EK#G=]=NS:PL5L(F_?2#_EH?[H]JP/0,:*VU
M75]46YW-)9B?<K2'";0>R_3VKM::B+'&J(H5%& !T IU !6+XH\36'A31WO[
MYF8D[(((^9)Y#T11W)_2I?$'B+3O#.DS:CJ,X2.,<(.7D8]%4=R:Y;PQX?U#
M7-83QAXIBVW>/^);I[<K91GH2/\ GH>Y[?RWITU;GG\/Y^2_7L)OHCBO"GP2
MN9]8MO$/B&X2,/*;I]-*>8P);<$=CP>V>*]Q1$B14C5411@*HP *=117Q-2N
M[S>P))!1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N UWQ#IMY?AK>;1W54V,;[2IY7SD]" .
M/_KUW]<KXBFF34U%S<:Q;V(B4Q-ID1<M)D[@^U6/3;CMUH U?#<,-OX<L8K>
M830K'A9!&8P>>RGD#T%:M4=&DO)='M7U!"MTR R!@ <^X' .,9'K7#ZJ^FC6
M);._\,W5Y*)#Y=Q?7BJLN<#Y"[ 8Z<#\J /1J*Q] TZ.SM1-':7%AYBX-F]S
MYJ)C@$8)4<#MZUL4 %%%% !1110!R=E_R5C6/^P/:?\ HV>NLKD[+_DK&L?]
M@>T_]&SUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*^)=92YCNM'
MLWYV%;NX#[5A!'W >\C#C Z Y..*GU34-0U29M,T([!G;<W_ &B'=4]7]^@]
MSTNZ;HEMHUAY=M#YTB*2H8_>/4\GN3U)Y/>LISYDXPW[]O\ -^7W^>L4H:RW
M//\ 2;%8[^W*R6MJ+=P8)"%4(@()7GJ#W]:]5W+MW9&W&<]L5R.EZWNU:_,]
MK;1Q!@T[?:5/D@+CCCYN1V[FM<13ZWAKA'@T[^& \/-[OZ+_ +/?OZ5AEV$]
MA3:DWN]U;[D]==_5]#2K>3][05KF?6&,5B[0V0.)+H=9/41__%?E6E;6L-G;
MK!;QB.->@'^>34BJJ*%50J@8  P *6N^4KZ+8P<KZ+8*Q];\00Z08K:*%[S4
M[G/V:RA(WR>K$]%0=V/ ]SQ5;5O$$YOCHVA1)=ZM@&5GSY-FIZ-*1W]$')]A
MS5K1/#\&C^;.\KW>HW&#<WLV/,E/I_LJ.RC@?K5**BN:?W?UT(*VD>'YEOO[
M9UR9+S5R"$VC]U:*>J1 ]/=CRWL.*WW=8T9W8*JC)8G  I:;)&DL;1R(KHX*
MLK#((/4$5$I.3NQG)^&-0LI?$WB9(KRV=Y+V,HJ2J2P$"= #S775GVV@Z/9S
MI/:Z38P3)]V2*W167Z$#BM"JJ24G="04445F,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'+B*W@\/WNMZ
MEH%U"CV\YB6TN)FM7^=CY<L0.4#, 2,;3GK7J.LV-U?16_V2>"&2&82AID=Q
MD9QPKK^N1[5YA=7NGF2XD:^>90C3/)#I]\R&/<5+@B?!7((R.* /6-/D\W3;
M638L>^%&V*,!<@<#VJS45L5-K"4(*[%P1Z8J6@ HHHH **** /./C5_R*&G?
M]ABU_F:]'KSCXU?\BAIW_88M?YFO1Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YK6[N?5K_ /X1
M_3I"A(S>SK_RR3^[]34.N>,[2UDET^P<2ZB6$2DC"(Q.,D^U;&AZ1'H]CY6[
MS+B0[YYCUD<]36JCR+FE\CBG46(DZ--Z+XFOR]7U[(N6=I!8VD5K;H$BC7:H
M%3T5F:G?R)(EA9_->3#K_P \U_O&LMSL225D8>H>(+F[OGTR*)H4:7RF91E\
M9P<5U5M;16END$*A8T& *@L--@T^!410S]6D(^9B>IS5R@85E>(O$6G>&-)D
MU#4IMD8^5$49>5CT51W)K(U_XC>'-!-Q;M?)=ZE$0BV%L=\KR'@( .AS^54/
M#GA74-4U5/%/C (^I#FRT\',5@I]/63U-;PHV7/4T7XOT_S%?L>?>&OA=XKU
M/QC9^*=8N%MX#<_:_+N7\R<#=E5*XP#C\OTKWRBBC$8B==IRZ E8****P&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<=<P3S:C.V@6.IVTYD;S+EYO*MV;/+;'W;_P7G!YK
ML:YG7M6U'1]465+S1X[.:(*D6H79@/F G)7"G/!'Y4 ;U@MVEA M_)%)=A!Y
MKQ*54M[ UR>L)XHU.\NK=;6VETG<45(+I$>0#LY9&P>.@QUKK;*2>6SBDN5A
M69ERPA<NGX$@9'X5QFIVLMK+->P>(_+AAOW,<$>G"9Q.X(*#G+G#'@?TH Z7
MPY;)9Z%;VT=HEHL6Y/)2X\\)@G^/N?Y5J%@" 2 3T&>M9'AB-$T.-DNS=>;)
M)*\IB\HEF<E@4_A()(Q[5@:QIYA^)WAF^:^NY?/:Z5;=W'E1 0?PJ!U..2<T
M =KO0.$W+O(R%SSBC>F_9N7>1G;GG%>1W-O9-;:MK<A3_A)(?$BP03%L3*!.
MB)$.^PQGIT()/O2S6UB8=0UMRG_"21^)A!#,6Q* )U1(AWV&(_=Z$$GWH ];
MWIOV;EWXSMSSCUIU>1"WLA;IK:E#XE/B?R#+O_>X^T;##Z[/*_AZ8Y]Z[_5/
M#^HZA?-<6_BC5=/C( %O;I 4&!U&^-CS]: *-E_R5C6/^P/:?^C9ZZRN$\-Z
M?<:;\3-9@NM5N]2D.E6C":Z6,,!YL_R_(JC'&>F>:[N@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***J7=_':Y7[\NW=L!Q@>K'HH]S4SG&"O($KEB66.&,R2.$1>2
M2<"L*#4I?$DCII^Z/3%)62[Z&4]UC]O5JS4M[CQE,'FD9=%4_>3*_:O9.XC]
M6ZMVP.O7QQQ6T"QQ(D44:X55&%4#^0J'"4_CT7;K\_\ )?/L:M*&^_Y"0016
MT*PPQJD:C 4"L;Q3-.=,-I8W!2\FX6-%R[KW QT^M3MJ%QJ+F+2@!&#A[QQE
M!_N#^(^_3ZTKBST"SDN7$LLK#YI"-\DK8SC/\AP*ZJ</9M:;;((KEDF]^QYC
MH6DZG<ZVD5LACF@<%W=>(\'N#_*O8E!"@,<MCDXQFN#T/QU:76OZC$^D:G;!
MY4\R66)=L?[L8W;6)Y]@>M=Q-<P6]J]S/*D4"+O>1SM55ZY)/2NC&SG.2YHV
M-,35=1IM6):Y6YU>]\1W,NG>'9?*M8V,=WJV,JA'5(<\._JWW5]SQ46Z]\;'
M"&:Q\-GJXRD]^/;ND1]?O,/0=>JMK:"RM8[:UA2&")0J1QKM50.P K"RI[ZO
M\CEW*VDZ19:)8K9V,6R,$LS,=SR,>K.QY9CW)J]1163;;NQA1112 **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH #TKR8?8=5L]OFZ'I*1>?;&TEU.2*9(V<EXI,8X)&=O0=C7K
M)Z5Y;X?DM(]+:*VU_P /1QI-*/*O[-1/$=YRLG[SD^YZB@#TVUC2*TACC5%C
M1%50GW0 .,>U2TR+_5)RK?*.5Z'Z>U0ZA8P:E926MQYAB?[PCD9"?Q4@T 2M
M<0K 9VFC$(&3(6&T?C2-=6ZV_P!H:>(08SYA<;<?7I7E]A:&V\#>"#J5K*=+
MM;AC?1/$6"?+((V=<9VABO7V-0P011W-I>W5H_\ PBPUNZEC1X#Y2HT0$;E,
M<)YF_'& 2#WH ]6DNK>* 3R3Q)"<8D9P%.>G-2 A@"""#R"*\DTZ""UU'3[S
M5;1AX8^U7[6:36[&.(.R^62A'R@@2;<CC/;-=%X?\/3ZMX"MK&>]U32XQ<RS
M6YM93#,L&]_+0Y!(&TCCZ>E %+XU?\BAIW_87M?YFO1Z\2^)O@Y="T'3KP>(
M->O_ /B:6Z>3?7GFQ\D\XVCGBO;: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+UK68](MUPAFNYCL@MU^
M](W^'O4&J^*M,TLRPF<37BX"V\>2Q8]!GH*;HNCSK<-JVJD2:E,.%_A@7^ZO
M]3_DZ*%ES2V_,Y*E9SE[*B]>K[?\'LC.TWP1:M.-2U;,M_)(9I$0[8U8G.,#
MKBNNHJ*YN8K2V>>9MJ(,FIE.4WJ:T</3HJT%;OY^IGZCKMM:;H8G$MWG8D0_
MO'U-2Z7IYLT>:=O,NYCNED_H/85CZ?X>CO)_[3N0T9DD,B0CL,Y&:ZBI-@K$
M\4^*+'PGI!O;S=)([>7;VT?,D\AZ(H_SBCQ%XKTCPSI\]S?W<>^,#;;HP,LC
M'HJKUR:Y[PMX<O\ 5M7'C#Q5'C467%A8'E+",^W_ #T/<]OY;TZ:M[2IM^?E
M_FQ-]$<KX:^"_P!HU:#Q-KUR]O=R7)O&TZ#[L9+;E4N3DX[_ ,Z]FHHI5J\Z
MSO-[ DD%%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCO$=V=.USS[1X9;J6W5)
M8);&:XV(&;# Q@E<DG@]<>U=C7&^(OM">(O,5=<CA-JH$FDP*VYMS9#D@YQQ
MCCC)]: -_P /0I;^'[**-Y'18^&DB,1Z_P!P\J/0=ABL]]+L_M7]MZ:S7LAE
M#I$L^Z%68A7D4#C=M)Y^M:^DDMI5N6:[8[>3>*%E/^\  ,US7B.;PUHUY"TT
MR:??3NH,EM-Y#A2<%R!PP&.X/2@#J+"QBTZV\B$N5+O(6<Y)9F+$G\2:=+9V
MT]S;W,L"//;EC#(PR4W#!P>V1Q531A.UMYS:FNH6LJAH)?*"MCGJ1PW&.<"M
M*@#.?0-(DUA=7?3+5M1486Y,0\P<8Z^N.,T-H&D/K"ZNVF6IU%1@7)B'F#C'
M7UQQGTK1HH SAH&D#6#JXTRT&HD8-UY0\SICKZXXSZ5HT44 <G9?\E8UC_L#
MVG_HV>NLKD[+_DK&L?\ 8'M/_1L]=90 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A(4$D@
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MBCHH_P G-=L*<*,;+^OZ[]39V@O/^MO\_NT*_P!GO-6^:]#6MF>ELK?/(/\
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M.??((C4_5R*N#PQJVJL)-2MOM1SD'6+OS$'TMX0(_P R?K5^PJ/XY*/IJ_\
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MQ1)&OHB@"GT52BELBE&,=D%%%%,H**** "BBB@ HHHH **** "BBB@ HHHH
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M:DOX;NS.-:,[I:G00PZ78/';QBVBD5<JI(WX]?7\:Q]0\=Z1;7)LK#SM6O\
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M[O[(M];-<;BGEB4%MPZKCUX/'6JVB^(;#78KQ[1V!L[A[>=)!M*LIZ_0]0:
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MA?6:765O73\SLZ*\\7Q_K"W!N)=%C-@3Q&DG[X#L3VS[5(WQ(N6_U/AV<_\
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M5 9DD< GUZU-_8UF,;1,N/2=_P#&K]%0ZU1N]V4J4%T*']DPC[MQ>+]+E_\
M&C^RESD7M\/^VY/\ZOT4>UGW#V<>Q0_LQATU&]'_ &T!_F*/[.G XU2[_$(?
M_9:OT4>UE_20>SB4/L5X,[=4F_&)#_2N;UR+7VU"$6WG3I;D.D@B !;\.O\
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MQ+I]PI,CF CL_?\ *KUMJ-I>.4MYUD8#) ]*6VT^ULU(@A5=W4]2?SJP%4=
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MD?S%8_\ ;WC'_H28_P#P;Q__ !-']O>,?^A)C_\ !O'_ /$T7CV_K[@Y:O\
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M>];D<#1VRQ><[R*FWSF +'W/&,U4CTMXDE9;Z?[5+MW7!5,X'0!<;0.3V[T
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M,JV]G;M,XC'5R!T'/?\ "M#3=2M-7TV#4+&836LZ;XW (R/H>0>V* +5%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR*\3;2GV@N&!Z,,8/'3O5C6K6ZA\2Q:DL][% UKY DM+99S&P8L<J58@'(Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :Z[XV4,
MRD@C<O4>XJMIVG0Z9:^1"7;<Q>221MSR.>K,>YJW10 56EL(9=1M[YMWG0(\
M:8/&'VYR/^ BK-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img40748725_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G!!,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;&3S+:==R,00?0@@]"#D$>HKS&POCHNK0^+[ZTOETB]NKTH?LSL\*R>7Y;%
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M5B8XD3[5<':H&=W_ -:K:C"@9)QW-=<)2?Q*PADUQ#;^7YTBIYCB--QQN8]
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M'B*S963N2922#VVC@8Z4 =51110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'BO_D3];_Z\)_\
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M:W%T9CES&AX#'U+;0?H:BO-,U7_A(-2N5@:2WE?%KCCR9O*"B8^HSQG^'K]
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M*** "BBB@ HHHH **** "BBB@ HHJM?WL6GVC7$N2!@*BC+.QZ*!W)--*^B
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M%#L9%CF+NF[!.>0 2,C.VF^)K3Q OA76#+K%@\8LIBZKIS*2-AR ?-./K@T
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M>:YN[EF?#%A@9!R?E[G&*S#XPNU6]464$\D:1R6YB=UCD5Y GWF0 ]0<KD4
M:>E^'FL]3-]<36KR!65%M;00+EB"S/R=S' YX'7BMVN6_P"$AU>&XN$NM/LQ
M%:7$4$[QW#$OYFW!0%>VX9!QWQ6_J=RUEI5Y=(,O#"\B@CN 30!:HKF=(^TV
MFL6T+7UQ=1WED;B03ONVR KRO]T'<>!QQ3+87EEXJD?41>>3=3LEI(MX6AQM
MR%,7\)P&YYYH ZFBLC5M1O[:_L;+3[:"66Z61B\\I14" 'L"3G.*S+3Q7=&U
MCO=0L(H+:>TEN8Q'-O=?+QD-P!SGC!^M '545BV&J:E)JR65_:6T0EMVN$>&
M8M@!E&T@@<_-U'%8NKZPT-I+K,]Q*FGQZC%'&$)P8T8AFXZ[FS^ % ':45SD
MFN:JXD6WL;0S6\ N9TDN#@*VXHH(!RQ"\GI]:V["Y-YIUM=%-AFB60KG.,@'
M&?QH L4444 %%%% !1110 4444 -DD2*-I)&"(@+,S'  '4UDV,;ZK=KJMPA
M6%,_8HF&, ]9"/[Q[>@]R:;+_P 3V]: <Z;;/B8]IY!_![JIZ^IX[&MKI5_"
MO,!"0H))P!R2:KH#<N)7!$0.8U/?_:/]*!_I;9_Y8*>/]L_X?SJS7/\ Q'?I
M^?\ P![!5:Q_U#?]='_]"-3NQ1"P1G(_A7J:K6)D",DD$D?S,V6QCDY[&E)_
MO8^C_0.A;HHHK804444 %%%% !1110 4444 %%%% !1110!ROB:]V:K:V5UK
M3Z-8O"TGVE&5#)("!LWL"!P<X[_A5GPI?O=PWL(OSJ-K;3"."]."95V@D$CA
MB"2,BH=;CU2R$]Q->Z5>:>6+_9M218@@ X D''7NRFKGAC6[;6M.D>ULGM(X
M)##LVC82.Z$<,ON* *?C*ZTBP@M;G67OVMS)Y:P6S,%=CS\P4C/I@G%8%M;^
M$)9HE@\(ZM \I"I.MA+'LSQNW@\=>M=;XEUW2M"TU9=7 :"9Q&L90-O/7&#Q
MVSS7%:5?6\VK6DNEZUINA6;. UBM^EPT^< +Y>=B'M\I[T >BV%FMA:);)-/
M*B?=:=][ >F3R<>]27%O!=P-!<PQS0M]Z.10RGOR#4M% 'E%DFF1?#"V_MFU
MO_[/BU:X:26R9T>U GEQ(=F&VCV]<U7L+]+!=.UUI=2N?"^GZK*+:ZNT>218
M7@V^9R-YC$A8 D9P:]?HH \CT_4[?1M9@\7:BMQ%H=Y=WQAG:W?]T)/+V.5
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M@)HS2ZA9QQ6=Y!;VUP)B)[@-%'C.!&H)SG/X"NLHJ*YF-O TJPRS$?\ +.(
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M *W/4Y[^AX]*EO(+O;:WL]U9P7MNSA<D^4ZL.0<\YX!S[5L%$+ARHW@8#8Y
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KWMY#86CW,Y(1>P&2Q/
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MZ/Y4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_[H_E3Z9#_J(_\ ='\J?0 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-.%JSSSR>?>RC][,1C_@*CLH]/SR:O445Q-MZLH****0!1110 4444 %%%%
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MW +8)^M '3456L;>:UM%BN+N2[FZO,ZA=Q]@. /:K- !1110 4444 8NN?\
M(6\._P#80;_TGFK:K%US_D+>'?\ L(-_Z3S5M4 %%%% !1110 4444 %%%%
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MKHPR&'I3P   . *6N2/B6[_X29K:2:PM[!9)8"LA/FAD3=O)R %.>!CIWYH
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M,D&99) S.K [G) X/H:UZ*+Z6"VH4444AA1110 4444 %%%% !1110 4444
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MKJEA!?6,Z3VLZ!XY$Z,#0!FZY_R%O#O_ &$&_P#2>:MJL77/^0MX=_["#?\
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MQGOUQ7>'5-2ON-,TUDC/_+S?9C7ZA/O'\=M?-D_PVUV;Q=)$TVF,[SF8XO$
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M0O\ \(5%HW[LC[2LL+$\CY<(<\_TKK:YR+PU?R';J7B74;N'(/EQA( ?4$H
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M#\T5S?R,;YUQ<7LLR_\ 'O-_"S$9]ZZNL77/^0MX=_["#?\ I/-6U0 4444
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M ^8'E1QC)ZU[_P"$-.?2?!^D6$AB,D%JB.82"A..2".OUKT,13HPHPE'5O\
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MHXX(8G=XXD1I#ERJ@%C[^M244 %%%% !1110 4444 %%%% &+KG_ "%O#O\
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M&:J7/B/43<-:6&F13W8X,8N-WE_[Y VK^>?:N%^"EM>:SX#87FIW)LX[R1!
MC%2W"D@OUV\G@8KUFUM+>RMU@M8(X8EZ)&N *BM3C1J.#UL-7:.>ET/7-6"G
M5M7BAB[V=E$?+/LS,=S?H/:M*+0HXXEB:]O&B48$:2")0/8(!6K163FV.R/.
M?$OPO.O:L;N*^AMX@@14:(R-QU)8MDFNLLO#.G6]C!%+:6_G)&JN\*&,$@<D
M 'BMJBAU)-)-B4(IW,W^P; ?=%PG^Y=2K_)J/[%C'W+R_3Z7+'^>:TJ*GF8[
M(S/[(E!RNKZ@/8NA'ZK7F[+XO7Q[_:4=KJ/V96^S"1X@Q\G/7' /]ZO6Z*N-
M3EZ$RA<S!:ZP@XU.&0_[=MC^34;=<4_ZS3G'^XZ_U-:=%1<JQF^=K*=;*SD_
MW;EE_FAJ*YOK]+:4SZ8Z1A"6>&Y3*C')!.*UZBN;:&\MI;:XC$D,JE'0]&!Z
MBG==@L>;^"_%=UK6LW\$)FE=6,ENES=$ 1=,$8.2.#^-=U]EU:?_ %VH10+W
M6VAY_P"^FS_*HK#PKH6EW:W=CIL,$Z@A73.1D8/>MBJG)-WBB8Q:6IF?V%:/
M_P ?33W9_P"GB4L/^^?N_I5Z&V@MEVP0QQ#T10/Y5+147;*L@HHHI#"BLV[U
M_2K&X:WNKZ**5<91CR*OPRQSPI-$P>-U#*PZ$'H:;BTKM$1J0DW&+3:'T4$@
M=3BJ\E_9Q'$EW A_VI *5KE.26[+%%4&UG3U.!<JW^X"W\A7'6NO^([GQ8-)
M65/*W[BY@Q^ZZ[L'GI^IK2-*4K^1RUL93I.*WN[::GH%%%%9G6%%%% !1110
M 4444 %%%% !1110 5Q/B+1KC4+RXF2RT[24CS_Q-Y)RLQRN-P";>G3YVKL;
ME)I+65+>40S,A$<A7<$;'!QWQZ5YS>:%>6DEK/KFF7.KRPSH\MXDQN$*#.[$
M)QMXQP <XH [[2&5M(M2EZ;Y?+'^DG'[W_:XJ[4%G<075G%/;',#J"GRE>/H
M>E3T %%%% !1110 5D>*_P#D3];_ .O"?_T6U:]<GX[N]033$T^R6V$=^DL-
MQ+,"3&A7&5 (R?F[U%2I"G%SF[)=02OL=3#_ *B/_='\JAO=0M-.A\Z[G2)"
M<#/5CZ =2?85PUKXOUMC<6MU#:1A=IBN+:)W)3'(\LD_-D=SCZU;L]0ABF-S
M':R2W3#!N;V9/-^@R0$'L.*=.I"I!3@^9/:W^>R_/R)E.,7:3L;OG:MJPQ;Q
MG3;4_P#+:909W'^RG1?JV3[5-:V>F:2[,IWW+_ZR:1C)*_U/7\.E99U*68?/
M+8_]M;T_^@HN/UJ:.[8+@:SI%L/2*,9_\>;^E4_;-6245]_Y?YD^UI]S9^TR
MR?ZFV<_[4AV#_']*Y[QC<FSTA)[V8)%Y@'R+\H)!^\:M;[>08G\4;O\ KG+%
M'_(5E^([/2+G0;M#?Q77[LEC/?,<<<$!<@G.,<5C5P:KP=.HVT_E_7S!XB,5
MS)K3S'^#;K3;S39[GS(W19-N]R-N<=L]ZZ!M<TJ+Y1?6YQ_#&P<C\!FN8\'P
MZ':>';030Z>T@C'S(GF2$_Q;OER#GM73)J5J@_T>UN''_3.V8?S JJ&#IX6"
MI4UHA+$1FN;F6HG]NVS#,$%Y/_USMG_J!1_:5X_^IT>Y(]9'1/ZY_2I/M]RW
M^JTRX/\ OLB?S-'G:H_W;2VC'_32<D_D%_K6]@]HO/[F,\W69/NVME"/5YV<
M_D%'\Z3[-K$@^?4+>+_KC;9_]"8U)Y>JOUN+6,?[$3,?S+?TH^PWC?ZS4YB/
M1(T7^E <S_E?X?YD?]E7$G^NU:]8_P#3,K&/T%!T*Q/,QGF/K+<.0?PSC]*D
M_LF,_P"MNKR4>C3D?RQ2C1M/'WK59/\ KJ2__H1-%_,/?[?C_P  @%MH%D<^
M5I\3>I" _K4@U;38_ECE!]HHRW\A5N.SM8?]5;0I_NH!4P  P!BE=#M/R10_
MM56/[NSO']"(2!^N*R/$NJM;:)--<Z=,B#&PFX"$N>!]QLUTU17$'VB+9YLL
M7.=T;8-.,DGL14A4E!I2U]$<5X#OI9]):.TMHFEAPDAENGR1S@A2"!Z<>E=9
MOU4_\L;,?]M6/_LM/L-/CTZ+RHI9GC  59'W;0/2K=.I-.3:1&'HU(4HQJ2;
M:*'_ !-C_P ^0]_G-&W5S_RUL5_[9.?_ &85?HJ>8V]GYO[RAY>JGK=6@^D#
M?_%4?9]3/6^B'T@_^O5^BCF#V:[O[V9_V34#_P Q/'T@6@65]WU60_2%!_2M
M"BCF8>RCY_>_\S"U>UU6/2YC9WTLMR1M0'8@&>_2L3P3IM[_ &>\.H-+]G!W
M0^7<X').1A3GKS7:RQ1SH4EC21#_  NN13(;2VMB3!;Q1$\'RT"Y_*K52T'$
MYY812KQJW=DK6N0II-A&VX6D3-_><;C^9YJTJ*@PJA1Z 8IU%9MM[G5&,8[(
M****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >::[B7Q3J)-Y<.\3H%C%PP$'[L<J
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MO\W/T_&KIJ&MV<^(GB%R^SBGKK_6AV=%4/[-?_H(WO\ WVO^%']F,>NHWO\
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M-Y9SI/;3H'CE0Y5E/0BN3\3ZA9:+XUT#4]6F2WL!;W,*SR'"1RML(R>@)56
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M2'Q<1>K9GP_K/VAHS*$\J/E00"<^9CJ1^=;=A9QZ=IUK8PEC%;1)"A<Y)50
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M,T^'2M,M[" N8K=!&A<Y) ]:);"*74[:_8OYMO')$@!X(<J3G_O@?K0!F?\
M"1S_ /0N:U_W[B_^.5%:^+&O;2&ZM_#^M/!,@DC?RHQN4C(/,GI71$9!%5M.
ML8M,TVUL("QBMHEB0N<DA1@9]^* ,5O%I6\2T/A_61/)&TBIY4?*J5!/^LQP
M67\ZF_X2.X_Z%S6O^_<7_P <K6:S@:_CO2G^D1Q-$K9/"L5)&/JB_E4] '-V
MGB[[=;+<6V@:S)$Q(#"*,9()!ZR>H-$OB[R;J"VDT#65FGW>4OE1_-M&3_RT
M]*V=,TZ'2K!+. N8T+$%SD_,Q8_J31<:=#<ZA9WKEQ+:;_+ /!W#!S0!F_\
M"1W'_0N:U_W[B_\ CE06GB[[?:QW5MH&LR0R#*L(HQG\Y*Z2JFF:?#I6G0V-
MN7:*$84N<GKGG\Z ,>3Q<8KN&U?P_K(GF5FC3RH_F"XW?\M.V1^=3?\ "1W'
M_0N:U_W[B_\ CE:4VGPSZE:W[%_-MDD1 #P0^W.?^^15N@#G+;Q8UW$9(/#^
MM.@=XR?*C'S*Q5AS)V((_"B7Q:8)H(I?#^LK)<.4B'E1_,P4L1_K/12?PJ_X
M?M)[/3I8KB/8[7ES(!D'Y7F=E/'J"#5JYL(KJZLKB0N'M)6EC"G@DHR'/X,:
M ,S_ (2.X_Z%S6O^_<7_ ,<J&U\6F]@\ZW\/ZR\>YDW>5&.58J1S)V((KHZJ
MZ=81:99BU@+F,2229<Y.7<N?U8T 8TOBXP7$$$GA_65EN"5B7RH_F(!8_P#+
M3T!J;_A([C_H7-:_[]Q?_'*TKG3X;J^LKN0N)+1F:, \$LI4Y_ U;H YNT\7
M?;K9;BVT#69(F) 811C."0>LGJ#2S^+C:M LWA_64,\GE1CRHSN;!./]9Z _
ME6QINGPZ581V<!<QH6(+G)^9BQ_4T7NGPWTEH\I<&UG$Z;3C+!67GVPQH S?
M^$CN/^A<UK_OW%_\<J&V\6F[1W@\/ZRZI(\3'RHQAE8JPYD[$$5T=5;"PBTZ
M*6.$N5EGDG;<<_,[%C^&2: ,:;Q8;>2".7P_K2M/)Y<0\J/YFVEL?ZST5C^%
M3?\ "1W'_0N:U_W[B_\ CE:=W8Q7DUG+(7#6DWG1[3P6V,G/MAS^E6J .<MO
M%C7<1E@\/ZTZ!WC)\J,?,K%6',G8@C\*)?%I@FMX9?#^LK)<.4B'E1_,P4L1
M_K/12?PK9L+&+3K9H(2Y1I9)3O.3EW9S^&6-%S8175W97,A</:2-)&%/!)1D
M.?P8T 9G_"1W'_0N:U_W[B_^.5>TC5HM8MI98X)X&BE:&2*=0KJRXR."1W'>
MK]8OAZWF@;5_.B>/S-1ED3<,;E(7!'M0!M4444 %%%% !1110 4444 %%%%
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MU[<7$+P&]OY[I(I!AD1V^7<.Q(&<>]=!0 4444 %%%% !1110 4444 %%%%
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MYK2O&%M>Z1%>W=M=6KRSM D;6[@NP+8"C')(7\^*M1>*]+FEBC5K@;Y!$S-
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MZ(6@O);N+9&1*#(C*03G'!;(..U #X/%$TFN'2I;.U6XDCD:%8[Y9&RF/ED
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-MJ+7<<@<DNC,[<C;\K MCJ>G:NEHH XVY\'L^L7LAMXKJSO9Q/)YE_/$4.
M"#&OR./E&.GOFFCPKJ3ZO:7,ZV+M;7YN3>.[M-)'\V$ (PF 0, D'':NTHH
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img40748725_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L K(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_%E]<:9X-UR_LY/+NK73[B:%]H.UUC8J<'@X('6
MMBN?\=_\D\\2_P#8*NO_ $4U '04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>;0/!NCZ5<$&>UM(XY=IR-^/FP>XSFHO'?\ R3SQ+_V"KK_T4U=!7/\ CO\
MY)YXE_[!5U_Z*:@#H**** "BJM_J%OIMM]HN3((\A?W<+R')]E!-<WKWCK3[
M+P[J=U9/=?:X;262#S-/G"[PA*Y)0#&0.I%7"G.?PH5SKJ*^7H/CKXT-Q&'F
MLBA<;A]F'(S[&OH/_A,=&_OWO_@NN/\ XBNBO@JU&W,KW["4DS>HJ*UN8[RV
MCN(=_ER#<N]"AQ[A@"/Q%2UR;%&7K&@6.MRV,EX'+6<XGCVD#<1_"W'*D@$C
MU4>E,U#0A>7XO[;4KW3KKR_)DDM3&?,0$D!ED1UX))! !Y/..*S]1\336&J7
M$,GV9+:&ZMXFDDR-J.C,Q)SCC%:FCWM[J0EO)8!;V4A'V6-T(E*C.7?G@-P0
MN,@=>3@ $EOI4-OJ'VX2S/-]F2V)D;.54ELGC.[+'-5[3P[9V<ED\<DS&T\_
M8'((/G-N;/'KT_K4FNZG)I6FB>&-9)I)HX(@YPH>1P@+>P)SQ6?;:AK2:A=:
M-=3Z;+J/V=;FWGC@>./:6*G=&78_*1GAOFSCY: )(O"T<-I-8)JNHC39(7@6
MR+1E(E9=ORL4W\9.,L0/H!4MUX<66XBN;/4[_3[A(%MVEMC&?-C7.T,)$9>"
M200 >3SCBLT>(-4LH]2MKP65Y>6TD$,,ULC0Q/)*<*K*6<J5R"?F/!!XSBK^
MF7^IQZW+I&KO:32FW%S!/:PO$K+NVLI1F?!!V\[N=W08H VH8O)@CBWN^Q0N
M]VRS>Y/K3ZYC7Y_$U@'FL=2TG;+*L5K;2Z9([LS' !<3@>I)V\ $XXJO>>(+
MX>*CHJ:]H5A,D,++#=VS/)<N^[/ECSTX^7I@]: .OHHK)U'Q)I>E7HL[J68W
M1B\\0P6TLS^7DC=A%)QD<^G'J* -:BL6R\6:+J-Q!#:7C2_:,B&402"&4@9*
MK*5V,V,\ YX/'!I#XMT47*0FYE'F3"".4VLOE22$X"I)MV,<^A/0^AH VZ*R
MM?O9[:SAM[)]E[>3+;P-@'83RSX/'RJ&;GC@5F1:U]AU[6(9FN+IVN8(K6UC
M(9F)A4MM!( ')8G( H ZBBN>OO%T%E%=W(TS4;FQM2RRW<"1F,,IPR@%PYP>
M"0N!Z\''0 Y /K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!1U#[1''YL5R\?SHNT*I'+ 'J/>K4*
M/&F))6E.?O, /Y5!J/\ QZ#_ *ZQ?^AK5NL(QM6EJ]EU?F/H%%%%;B"BBB@
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MFW-M!W#K]WC!]"480 ^E4!H.CC5/[4&DV U#.?M8MD\W/3[^,_K6A0 4444
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MB&)P?F/&3CID]3RFIWCV>D6/B62VFGEO-46[6&-<OY0BD$:@=?N $]\D\=J
M/1:*Y**[U*]N-.TY=; >]MY+][RTCC8! 4"QQ;E*E?G^\P8D#MGC0\-W-[*^
MK6][>F\:TO3#'*8U0[/+1@"% !/S')X^@'  -VBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHJK<LTL@M8R06&9&'\*_XGI^9J9R
MY5<!$_TNX\T_ZF(XC_VF[M]!T'XGTJW2*JH@50 JC  ["EI0CRK7=@PHJ*2Y
M@A;;+/&C=<,X!I\<L<J[HW5U]5.15V =1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !115>_NFL;&:Y6UN+HQ+N\FW ,C#_ &02,GVS].:
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M(K0U+3X=4L6M)V=8V=')0@'*L&'4'NHJW10!4&GPKJ[ZD&?SG@6W*Y&W:&+
M],YRQ[USNI:5I^C6>E*DNM0R6:-%#>:?;&XD"G!9'58W!#8'5.W4&NMHH X[
M1M!N+O0-5AE>ZMDU.\,I-T,S/"0BMN'&TN%;CC:&' Q@=3/8VUS]F\V(-]FD
M$L."1M8 @'CV)JQ10!S&KZ'96T47V70;V\7SWG'V"]\B6!VQDH6E3:K<Y56
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)++87[ $6>H1F"7DX  ;AB<?PDUOUE:9>P>(;%+F?2;NV$<V4BU&W".K+T<
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M@.XP3QG(_ U;C)13(4ES6-:BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M_+QST]% %73-.MM(TJTTVS0I;6D*0Q*3DA5  R>YXZUD^._^2>>)?^P5=?\
MHIJZ"N?\=_\ )//$O_8*NO\ T4U '04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJU_<)XFM_P!WJ9B70YXU:652RJ-K$[AD'(P,?K5I;F]&I-KJ:U=.?[:_LYK
MR@P>5YGEX"8X?'SYZX_.@#T*O,_%(\*+XNNQXSG,L;11M8H)9"(EQAP5C.02
MW.2,$=#P:],KBKMO$>D^+=4O-,\+KJ-M=I%^^-['$VY5P<9YV^V.N3WH E\#
M?\(9F^_X1+K\GVG_ %W^UM_UG_ NE=A6/H6HZU?F?^U]!_LK9M\O_3$G\S.<
M_='&,#\ZV* "BBB@ HHHH **** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\ CO\
MY)YXE_[!5U_Z*:@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7^I6]K$C6T<++R% )+, JJ".23Z8R2 >GMM'EN+F.^UF5+FY0[H8$SY%N?\
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M4445B:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'454^V-+Q;0/+_MM\B?F>3^ -'V>XF_U]P57^Y!\O_CW7\L5G[5/X%?\OO\
M\KCL2S74%N0)) &/11RQ^@')K@+G4=0;4VF:65)U8A5&1MYZ8_I7H$-M#;@B
M*-4SU(')^I[U1DM+E[]+O[/9ED5E!+')R1@YV]L'\Z\O,\)6Q,8VE:SZ)O\
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M3<2R-<7C##3R=<?W5'15]A^.3S5VBBDW<84444 %%%% !1110 4444 %%%%
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MQ1:CHB6ESX@,$MZR7FW6KU@(OL\S#<?-^4>8L?/'.!WP0#M**Y__ (0W2_\
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M?$!@EO62[VZU>L!%]GF8;CYORCS%CYXYP.^#J?\ "&Z7_P _6N?^#V]_^/4
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M+ARH+#H<<B@"*Q@:VL+:W=MS11*A;U( &:GHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KS7Q!XBM/%FL7WA9-5L]/T:UD\G5;J6Y1)+@_Q
M6\0)R!V9OJ!7I50FUMV8LUO$23DDH.: .+M]3TSPSXUU^34;J"SM;RTM;BTD
MD8*DJ1JR,J'^(KA>!SAU]:UO %G<V/@32(;N)H9S#YCQ-UCWDMM/N-V/PKHC
M&C!0R*0IRN1T/M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .8\2:MH4KW.A:SJ4VE9M_.$YN?LPD0Y#;),C)7N.V1QS7)>&KJ33;WP
MIJVM!+&T?2;G3TEE00(,31M#N' 0O&FX#CG(QVKU)D1\;U5L'(R,X-*R*ZE7
M4,IZ@C(H Y3P(//@UO4XR3:ZEJLUQ;-V>(*D88>H8QE@>X(-=91THH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JU_J-CI5HUWJ-Y;V=LI ::X
ME6- 3P,LQ JS7.>,O^0?IO\ V%;3_P!&K0!J:;KFD:R'.EZK8WPC^^;6X27;
M]=I.*OURGC>UC@LK76K>)5U.SNX!#,HP[*\JHT9/=6#$8/'0]0*I^(/%]UH]
MU<S07UA<6]HZB:SAL)YI .,[IT8I&V"3ADP.,GG- ';T5SC^));)->^WQ1A]
M.Q+ (\CSXG7]WU_B+!D^H]\53O=>U>WU'3]+GNM+TRYFMDD:XN[=WBN)B2##
M%^\4!AC/+,2".* .OHK)\1ZG<Z-X<N]0@B2:X@0%8R#ASD#'4>M9T^JZWH]_
M8OJK:?-8WLWD;;:%TDMF*LRY8N1(/E()"IV.* .GHKCEUSQ%<:"?$L"Z<-.\
MDW*6$D3^>\(&<^=OVJQ7G&P@=,]ZDC\27=_XD%A;7FGV$6(WAAO+=VEOHV4,
M6B;>H&,D<!\$<XH ZVBN.\)1ZP/$/B-KN_LI;=;_  T<5FZ,6\F+!#&5@!CC
M&#D\Y'2C4X]8;XE:9]EO[**W^P3'RY;-W;:'BW#(E49/8XX]&H [&BN1T[Q)
MJ?\ PCUUXCU5;6+3H(9G^SPPMYK>6Q&[<7P 0I^7'H<]AF6'Q 5KZP6?7?#5
MXE\Q3[+8W ,MH=I8;FWMYB\8)"IC.: /0:*XC3_%=]/KEI8&_L;V*_2003V^
MFSQ1Q.JEA^\9RDHX/W2I[_2GH5_K>B^!]3U*:XLKPQ75QY,4=J\9W?:&#9)D
M;(.>!@8]30!Z'17+3ZCXD@UB#2S_ &:TE]')+!.(7VVP3;N#KOS+]X8(*9YX
M%4KWQK/I&F/'J4FG0Z@-0_L\7,K&&USLW^:VYB5&T_=W9)XSSF@#MJ*X"/Q[
M(+/5XX-0T;6;JR@CN(Y]-;]U(&?:49 [E6&/[QSD&MH:CKMGK=K8W\NG.FH1
MR_9V@@<&"5%W;7RY\Q<9Y&SITYX .EJ&.ZMY;F:VCN(GGAVF6)7!://(W#J,
M]LURWP^35%T>X:_O+2>(WER$6&U:-@PG?<2QD;()Z# QZGK3]4U^^L=4NH+*
MTM7E^UVMNI=2"PD4Y+$'MCTX&: .JEECAB>65UCC12SNYP% ZDGL*2&:*XA2
M:&1)8I%#(Z,&5@>A!'45S/\ :^JV=YJ6FZJ;"ZD2P:]MY8(&C1E&0R.C.W0X
MY!Y!Z#%9N[6;OQKH,]M>:?!#+I3R>2UD[;5W0[U!$H&3G@XX[AJ .UMKJWO;
M=9[2XBGA;(62)PRG!P<$<=014U<E_;\R>&+"Y2[TS3I[AW51);/,&PS<)$C*
MS'C)P>.:PM4UK5M>\+Q/#<6MO<6NM06TS26$R"4B6,HPC=U9!\P)4DYZ ]Z
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img40748725_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .) ^X# 2(  A$! Q$!_\0
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MH;EBL1(]*=;G=;1-ZH#^E $E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "9&2*6JB2$WLJ]@1_(5;H **** "
MBBB@ HHHH KWG^H;Z4^U_P"/.'_KFO\ *F7G^H;Z4^U_X\X?^N:_RH EHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH HQ_\A&?ZC_T$5>JC'_R$9_J/_015Z@ HHHH **** "BBB@"O>?ZAOI3
M[7_CSA_ZYK_*F7G^H;Z4^U_X\X?^N:_RH EHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HQ_\A&?ZC_T$5>JC
M'_R$9_J/_015Z@ HHHH **** "BBB@"O>?ZAOI3[7_CSA_ZYK_*F7G^H;Z4^
MU_X\X?\ KFO\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO+_%_Q?@T?4)=.T:U
M2]N(F*232$B-6'4 #EN?<?C5PA*;M$:BY;'J%%>%'XN>,K3;<W>CVJVS]-]M
M*BGZ,6_QKT7P1\0;#QE&\(B-KJ$2[GMV;<&7^\I[C^57.A.*NRG!I7.PHHHK
M$@**** "BBB@ HHHH **XWXD:GXBTK08)O#D<K3M.%E>* 2LJ8/\)!XSCG'\
MZO>!;[6M1\*6USK\;I?,S9WQ>6S+G@E<#'Y"KY'R\P^72YTE%%%0(**** "B
MBB@ HKR'Q!\6]8T_Q5>Z1IVDVTX@F,*!@[.Y'!X4^M5(_C3K-C=JFK^'XT0]
M57?$X]?O9S6ZP]1JY?LY'M-%<U<^)+?5OA]J6N:/.R@6,\D;8P\;JC<$=B"*
MX[X-:]JVLR:RNIZA<78B$)C\YRVW._.,_05"I/E<NPN5V;/5J***S)"BBB@
MHHHH **** "BBB@ HKB?&7Q*TKPKYEI%_IFI@?\ 'NA^6,]M[=OIU^G6LWX;
M_$'5?&&J7MKJ%M9Q)#")$-NC*<[L<Y8UI[*?+SVT*Y':YZ1116#XQUJ]\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M//%=O8? ]WNUDU?7#+$#RD$9W,/3<QX_(UU3Y$XRD[61J[)IMD7P^CF7X/\
MBMW!$+QW)CSW/D8)'Z?E7&>!O$&NZ2U]8>';/S]0OP@5PN\QA-V2 >/XNIX%
M>[ZYIMII'PYU:PL8A%;0:9<*B#L/+;\SWS7G7P(53<ZXVT;@D(!QR 2_^ J8
MU$X3G82E=-F9:_$3QEX5\1I:>)6>6+<#-!-&@(4_Q*RC\NH[5[#XHU6^TKPQ
M=:AI-F;V[15\F)5+;MS 9P.3@'.!Z5Y%\<@/^$HTXXY-D.?^!M7IWB#Q1%X2
M\%P:G)$9I#''%#'G&YRN1D^G!/X5%2*DH22U9,E>S2.",/Q@OH6O?-:# W+
M#"A(] O_ ,56M\,?B#J7B'4)]&UK;)<I&9(YP@0G!PRL!QGD8P!T-9VD:O\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1C_P"0C/\ 4?\
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M3S,H**78;>4.>5)_&N-^#X\GXB31(3M^S2I]0&7_  %2?'#_ )'2S_[!R?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *,?_(1G^H_]!%7JHQ_\
MA&?ZC_T$5>H **** "BBB@ HHHH KWG^H;Z4^U_X\X?^N:_RIEY_J&^E/M?^
M/.'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"C'_P A&?ZC_P!!%7JHQ_\ (1G^H_\ 015Z@ HH
MHH **** "BBB@"O>?ZAOI3[7_CSA_P"N:_RIEY_J&^E/M?\ CSA_ZYK_ "H
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MATSDGY369_PM;_J3O$G_ ("?_7H ]$HI$;>BM@KD9PPP1]:6@ HHHH ****
M"BLKQ/J<VC>%]3U*V5&GM;9Y4$@)4D#(SC'%5O!6M7/B'P?IVJWBQK<7"$N(
M@0N0Q' )/I0!O4444 %%4!K>F'6CHXO8O[1$?F&WS\VWUI-<U,Z-HEYJ0MI+
MDV\9D$,?WGQV% &A163X:UIO$/AZTU5K.2S-PI/D2'++AB.N!UQD<=#6M0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>9>,/
M%?BF+XAV7A;PX]E&]Q;>:&N4R"V'8Y/883TH ]-HKR^\USXH^'8#>:AI&E:G
M9Q#,PM"P<+W/7/Y*:['PCXNT[QCI'VZP+(R'9- _WHF]#ZCT/?\ ,4 ;]%%%
M !1110 4444 %%%1SR>3;R28SL4MCUP* )**\9\+^)?B9XQTZ;4=+N-'2!)V
MA*RQE2& 5N.#QAA7<>%8_'2:C*?$\VF26?DGRQ:@[Q)D8[#C&[]* .NHHHH
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MWE[X*O8;G3I7,SZ5<KW]%/?CCJIP .<4 =]H-[JEQHB7&O645A>H6$T:2!D
M!/S Y/!'/6N*MO&?B_Q=-<S>#]+L(M*AD\M;O42V9F'7:%/ Z>OUSP+"^+_^
M$R^$>NZE;P&WN8[2XAGBSD*PCR<'TVG/Z=JYWX>:;XTN? ^GRZ+XBL+6Q/F!
M()+0.R'S&SDX]<GZ$4 ==X1\;7NI:Y=^'/$5A'8:Y;+OVQ-F.9..5R3Z@]3Q
M]#7;UYWH_@7Q"GCRU\3ZWK=K=RP0M$5@@V;P58 'MQNS^%>B4 >/^-+VUT[X
M[^'+N]N([>WCL07ED;:J\SCD_C7HEKXS\,WMU%;6VO:?+/*P2.-9U)9CT YZ
MUYUXVT^TU3XZ^'+*^@2>VEL0'C?HPW3'^8KOK3P%X5L;N&[M=#M(IX7#QNJG
M*L.01S0 WQSXM3P;X>.H?9_M,\DJP00[L!G()Y/H "?T[UC6E]\38;JUGO\
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MM;\ ?$C2M&GUN[U31]6!5!=N6:-NG&<X()'3 (/2O7:\N^(G_)3? G_7R?\
MT-*]1H \DT55UC]H769[@;QI]J1 &_@($:<?]].?QKUNO&M3O5\#_'1]5O\
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M'7^IO<PM;M;/Y3!P1*S*=H7UR:YWX,V,UG\.[=YD9?M,\DR _P!TD '\=N:
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M .V1GG)QFN^KQ;Q#I-S\*-2TR^\.:K<O97ET(I-+G?>&[G:/TSU!(YYKVF@
MHHHH **** "BBB@ HHHH **** *,?_(1G^H_]!%7JHQ_\A&?ZC_T$5>H ***
M* "BBB@ HHHH KWG^H;Z4^U_X\X?^N:_RIEY_J&^E/M?^/.'_KFO\J ):***
M "BBB@ HHHH **** "BBB@ K!\::!+XH\(W^C03)#+<!-KN"5!5U;G'^[BMZ
MB@#RRP\&_$FRTZ#38?&%C!9P1B.-8[<%E4< 9V _K6UX5^&MKH>K-K>IW\VL
M:RQ)^TSC 0GC*C)YQQDGZ8KN:* .<\9^#[/QGHPL;B5H)HG\R"X09,;XQT[C
MU'%<J/"_Q.>S_LV3Q=8BT*[#<+$3/MZ==HY]]V?>O3:* .>\-^$++POX:?1]
M/EE4R!C)<]':1AC?[8XQZ8%<P- ^*$$!L8?%&ERVV"BW4T3"<#U^Z1GW))]Z
M](HH YSP?X/M/"7AK^QTD^U"1FDN)'7 E9@ ?EYP, #'M7*6_@'Q7X5N;A?!
MNO6L>G3OYGV/4$)"-[$*?SXZ#.>M>G44 <GX;T?Q=!JC7_B37X+E/**)96D.
MV)22#NS@$D8[CO76444 >>>-/ VNZSXQT_Q'H.J6ME<VEN(5,Z;L$%SD#:0>
M'(Y%0?V!\6/^AQTW_P !4_\ C5>E44 <YXFTC7]1L;)]$UL:?J%LVYBR9BGR
M,$,.>.XX-<K<^!?%WBN>TB\8ZU8-IEO*)C;6$9_>D<<DJ,<$COU]Z]-HH YG
MQMX-M?&>C+9S2M;W$+^9;W"C)C;&.1W![CCH/2N7'A+XE7< TV^\8VJ:?@(T
M\$9-PR_7:#GWW9]:].HH XCQ?X!EUVRT=],U)K35-'Q]EN)1NW8V_>]\J#GG
MOQS61JO@CQKXJTN:T\0^(;)(PA,5O8H5220?=,C%02!UQBO3J* .7_X1BY_X
M5K_PC/GQ?:?[/^R>;SLW;<9]<4NA>$_L7P^B\+ZC(LH-O)!*\.<$.6Y7([;J
MZ>B@#S#2?!GC_0+#^Q=,\2Z:NEJ6\J:2 F:,$Y.%P1W)Y)K6\#^ [CPAK>LW
M4E_]LAO1'L>0DRDC)9G.,9))]:[FB@#@/%_@?6+_ ,4VGB?PUJ=O9:G#%Y+B
MX4E''(ST/8D8QZ5KMH>NZAX"O=(UC4;>XU6Z@EC,Z)MC7=G:, #@#'.,UU%%
M &#X3T!]!\'66B7C13M#&T<A4$HX+$XY[8-<;;_#[Q7X5NKA?!OB&WBTZ=]_
MV2_0L$/L0I_,8SQG.*]0HH X7PWX#O+7Q$?$OB75?[4U@+LA*KMBA7&/E'XG
ML!R>,G-6KCPC=S?%&T\5+<0BUAM# T1SO+889'&,?,.]=A10!S_C?0)_%'A"
M_P!&MIHX9KCR]KR9VC;(K<XY_AJ]X>TZ31_#FFZ;*ZO):6T<+,G0E5 )'MQ6
ME10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*>)?AUX?\5ZD
MFH:G#.;A8A%NCE*@J"2,C\375T4 <'9?![P99SB8Z?+<%>0L\[,N?H,9_&NY
MAABMX4A@C2**-0J(BA54#H !T%/HH Y;Q/\ #[P_XLG2YU"V=+M1@7%N^QR.
MV3T./<<5!X?^&?AOP[?+?P0375Z@^6XO)/,93Z@8 !]\9KL** ,+Q/X0TCQ=
M;0PZI%(3 Q:&6*0H\9.,X/X#KGI61HWPN\/Z/J<.HLU[J%U!@PO?3^9Y9'0@
M  <=L]/K7:44 4M6TC3]=TZ2PU.U2YMI.J/V/J#U!]Q7$#X,^&P=@N]7%L>M
ML+K]V?PVY_6O1** *6DZ39:'I<&FZ= (+2 $1Q@DXR23R>3DDG\:N,JNA5AE
M6&"/44M% 'GA^"G@XDGR+P>WV@UL>&OAWH'A/4GO]+CN%G>(PDR3%AM)!Z?\
M!%=710!@:'X0TO0=5U'5+;SY;V_?=--.^]NN=HXX&?Y#TI-5\&Z5JWB*PUZ7
MSXM0LB-DD$FW> <@-QR.H^A(KH** /'M2TFQUOX]76GZE;)<6LNG -&W^X,$
M'J#[BNDTWX/^%=.U".\:.ZO&C(,<=W*'1,=!@ 9'L<UV']D:=_:O]J_8H/[0
MV;/M.P>9M],]:NT 5-2TVSU?3IM/O[=9[69=LD;="/PZ'W%<;9?"'PO9W$<C
M_;KN")M\=K<W&Z%3_N@#/XYKO:* ,;PWX9T_PK97%IIHE$,]PUPPD;.&8 $#
M@8&%%,\.>%--\++>KIWG8O)C-)YK[L'T''2MRB@#$U?PKIVM:UI>JW?G?:=,
M<O!L?"DD@_,,<]!53Q1X#T7Q9/#<WZW$5W"NR.XMI2CJN2<=QU)[5TU% ')^
M'?AWH7AO4#J, N;N_P ;1=7DOF.HQ@XX ''?&:T-2\*:;JOB/3M=N?.^V:>"
M(=KX4]>HQSUK<HH HZOH^GZ[ITEAJ=JEQ;2=4<=#Z@]0?<5Q,7P6\)QR@N=0
MFA!R+=[G]V#^ !_6O1** (;2TMK"TBM;2"."WB7:D<:A54>P%9/ASPIIOA9;
MU=.\[%Y,9I/-?=@^@XZ5N44 8FK^%=.UK6M+U6[\[[3ICEX-CX4DD'YACGH*
MVZ** ,S7/#^E^)-/-EJUHES!G<H.05/JI'(/TKB!\#O"@FW&?5#'G/DFX79_
MZ#G]:]*HH SM%T'3/#M@MCI5G';0 Y(7DL?5B>2?<UYM\0+6"^^+OA.UNH4F
M@EB*21N,A@6;((KUJJ5QI&G7>H6]_<64$MW;?ZF9T!>/Z'M0!Q<?P9\))?"X
M:.]DB5MR6KW&8EYS@<;L?4UWT44<$*0PQK'%&H5$08"@= !V%/HH X35/A)X
M8U75YM2=;R"2=R\T5O-M20GDY&">3Z$5O>(?">F>)C8&_$W^@S":'RGV\\<'
MCD<"MVB@""\L[;4+.6TO((Y[>5=LD<BY5A[BN"/P5\)F=F4ZBD+')MUN?W9_
M3/ZUZ)10!2TG2+#0]/CL--M8[:VCZ(@ZGU)ZD^YYJAI?A33=(\0:EK5KYWVO
M42#-O?*CG/ QQ6Y10!B>)?"NG>*[6VM]2\[9;SB=/*?:=P!'/!XYIOB?PAI'
MBZVAAU2*0F!BT,L4A1XR<9P?P'7/2MVB@#B]&^%WA_1]3AU%FO=0NH,&%[Z?
MS/+(Z$  #CMGI]:[2BB@ HHHH **** "BBB@ HHHH **** *,?\ R$9_J/\
MT$5>JC'_ ,A&?ZC_ -!%7J "BBB@ HHHH **** *]Y_J&^E/M?\ CSA_ZYK_
M "IEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ HJKJ-A%J>G3V4S.L4R[6*$ @
M>V<URO\ PK'1?^?K4/\ OXG_ ,15Q4&O>=OD<]:I6B[4X<R];?HSM**XO_A6
M.B_\_6H?]_$_^(H_X5CHO_/UJ'_?Q/\ XBKY:?\ -^'_  3'VV+_ .?2_P#
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MG_-^'_!#VV+_ .?2_P# O^ =I17%_P#"L=%_Y^M0_P"_B?\ Q%'_  K'1?\
MGZU#_OXG_P 11RT_YOP_X(>VQ?\ SZ7_ (%_P#M**XO_ (5CHO\ S]:A_P!_
M$_\ B*/^%8Z+_P _6H?]_$_^(HY:?\WX?\$/;8O_ )]+_P "_P" =I17%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^H;Z4^U_P"/.'_KFO\ *F7G^H;Z4^U_X\X?^N:_RH EHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJK+J=A!J,&G
M2WUM'?7"EH;9Y5$D@ ))5<Y( !Z>AJU0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!1C_ .0C/]1_Z"*O51C_ .0C/]1_
MZ"*O4 %%%% !1110 4444 5[S_4-]*?:_P#'G#_US7^5,O/]0WTI]K_QYP_]
M<U_E0!+1110 4444 %%%% !1110 4444 %8/C+Q3:>#?"]WK5VN\1 +%$#@R
MR'A5']?0 GM6]7D'QM/VS6_ FC3_ /'E>ZL//!Z<-&O/X2-0 FC?#_7/'=BF
MN>.-?U.(W:B2#3+&7R8X$/*AA@\X(]_4DUU/A_PX?AW#J]Y=^)KV[\/QPB9(
MKTF1K;;DN0PY(QC@#\,]>WKSOXWZD=/^%VH1(2);V2*U3'?+!B/^^5:@#N-*
MU2SUO2[?4M/F,UI<IOBD*,NY?7# $?B*JZ%XETCQ+8SWND7@N;:"9H))/+9
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MAJ<>W4/$-R;@ _P0 G8![<D_3;7H=_>1Z?IUU>S<16\3RO\ 102?Y4 <Q?\
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MN0)(XW>5$IP$7/09R/HJ^E4_"FF:9<_M#^)+S3+6*&VTZU$;^4,*;A]H8XZ
M\.#[@T >JW>NZ58:G::;=ZA;PWMYG[/ [@-)CT%:%8E]X2T74O$UCXBN[3S-
M3L4V6\ID;"CD_=S@GYCSC^E;= !1110 4444 %%%% !1110 4444 %%%% &!
MXTN)[7PE?36\TD,J^7M>-BK#,BC@CVK!T_PKK5_IMK>?\)=J">?"DNSYSMW
M'&?,YZUM>//^1+U#_MG_ .C%K2\/_P#(M:5_UYP_^@"NB,W&E==SS*M&%;&.
M,[V45U:ZOLSG/^$+UK_H<=0_)_\ XY1_PA>M?]#CJ'Y/_P#'*[2BI]O/^DC7
M^SL/V?\ X%+_ #.+_P"$+UK_ *''4/R?_P".4?\ "%ZU_P!#CJ'Y/_\ '*[2
MBCV\_P"D@_L[#]G_ .!2_P SB_\ A"]:_P"AQU#\G_\ CE'_  A>M?\ 0XZA
M^3__ !RNTHH]O/\ I(/[.P_9_P#@4O\ ,XO_ (0O6O\ H<=0_)__ (Y1_P (
M7K7_ $..H?D__P <KM**/;S_ *2#^SL/V?\ X%+_ #.+_P"$+UK_ *''4/R?
M_P".4?\ "%ZU_P!#CJ'Y/_\ '*[2BCV\_P"D@_L[#]G_ .!2_P SB_\ A"]:
M_P"AQU#\G_\ CE'_  A>M?\ 0XZA^3__ !RNTHH]O/\ I(/[.P_9_P#@4O\
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M9K-\)^$],\&Z&FE:8KF,,7DEE(,DKGJS$ 9/0?0"@#9BBC@B2*)%2-%"JJC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH HQ_\ (1G^H_\ 015ZJ,?_ "$9_J/_ $$5>H **** "BBB
M@ HHHH KWG^H;Z4^U_X\X?\ KFO\J9>?ZAOI3[7_ (\X?^N:_P J ):*** "
MBBB@ HHHH **** "BBB@ HHHH *\@^']K#XT^(OBCQ=J2+<BQNC8::D@W+"B
MY^8 ]#C!^K-ZUZ_7D6E^$?'_ (,U;6;3PO\ V+/I6I79N(YKUG#6^[KE1UP,
M#OG /J* *^K:7I>H?M):+%96L*2V5FUW?-&N-SX;9N]QE#GT(JQ;P1>./CQJ
M7]H()]-\,VZI;P/RGGMC+%3P3G=_WROI6CX"^'FJ>&O'6N:[JMZM\]W D:7+
M']Y*S;6E8KT4;E  ] *JW?A+QGX;^(6L>(/",>EW=MK"*9HKZ1E\IQCGC&1G
M)X/<C'0T 9_Q6TO2]3^(_@?3(K2'^T)[OS+B1%PQMU93AO4'#XSTP:T?B(O]
MG?%?X>ZNO'F7,ED[?[^%4?\ D1J30OAUXA@^*=IXLU[4(+Z1+1S+*AVJLS;D
M$<:8X14/4\DY/>MKXJ>%-7\4:+IAT$PKJFGZA'=1-*VT  -_7:?PH Q-:'_"
M>?&;3M(C'F:3X8'VN\8?=:X."B>^,+^3BH(+:+QS\=]2&HJ)],\-0(EO;R#*
M&9L98J>.N[_OE?2NU\!>#T\':!]FEF^TZE=.;B_NB<F:9NO)YP.@_/J37*7?
MA/QGX;\?ZQK_ (132KNVUA5,T-\[*8G'?C&1G)Z_Q8QQF@#.^*FE:5J?Q(\#
MZ9%:0C4)[KS+AT7#&W5E.#Z@X?&>F#4OQ<LW\4^.O!GA&*9XEFDENKAHSAE0
M <CT.%DQ[U;T'X=>(+?XI6WBS7=0@OY$LW,LJ?*%F;<@2-,<(J'J>22?6MR/
MPKJ4WQEF\4W8B_LZ#31:6>'R^\G))'8<O^8H Y;XTZ-IFF_#K2]#TO3[>!IM
M1AM[2.- -I(;)]>< $]3FK/Q1:76O$GA'P$LTBVFH3>??%3@R11\[<_17/U"
MGM70>,O"FI>)/&?A&ZC$7]EZ5<O=7)9\,7&TI@=^5_6JOQ!\&ZYJFOZ)XH\,
M3VRZMI19?)N20DJ'MD?5A]&ZC% '8R>'M&FTR+39-+LVL8MIC@,*[$*XP0,<
M$8%>,ZSJ.I^(OC1?S1>&YO$.G^'56&&S69(TCF89\Q@W!.0_;^%?2O1?#J>/
M[S64N_$KZ58:?"C 65B"[3.1@%V;. .N ?K6%=^%/%WAGQYJOB+PFNG7UIK&
MTW5G>2&-D=1U##W)_P"^B,=Z &_\(WXG\:^,]"U[7](M-!LM&D,L4"7 GN)F
MR" S*-H7*@X^OKQ4MX(O''QXU+^T$$^F^&;=4MX'Y3SVQEBIX)SN_P"^5]*[
MGPP_C">>YG\3PZ5:PD 6]M9,[L#GDNQX],8KC;OPEXS\-_$+6/$'A&/2[NVU
MA%,T5](R^4XQSQC(SD\'N1CH: ,_XK:7I>I_$?P/ID5I#_:$]WYEQ(BX8VZL
MIPWJ#A\9Z8->S5Y3H7PZ\0P?%.T\6:]J$%](EHYEE0[569MR".-,<(J'J>2<
MGO7JU 'D_P 9(TU75O!?AW8I;4-55Y#CGRTP&_#$A/X5V/CJ\AT'X?Z_>PQI
M"RV4BJ44+\[#:OZL*Y_X@>%/$E]XN\/^)_#0LI[G3 Z-;7;%5(;N/P)'48XZ
MU)XW\/\ BSQ=\,H](=-/CU>ZFC-VL,C+"B!RWRDY)QA,^ISB@"I\'O!6G^'O
M UIJUW;QOJ%]!]HEFE4$QQ,,J@ST&TY/J2<]JH?!.2/3OAWKFN.GE6DM_<7:
M(. L:HO_ ,21^%>A:[IMTW@F_P!*T=4^TM8/;6P=MH!*;5Y[8KEX/!NK:9\$
M&\*6(@.JO9/"P\S"%I&)D^;'HS4 <W\#?!]K/H4OBW58$N;[49I3"95#")-Q
M#$ ]"S Y/H![YL6=E;^./C;JB:A$DVD^&((X;6T9<Q^:W\17IP0W_?*^E>B^
M$=%;P[X0TG2'V^;:6J1RE>A?'S$>V[-<3>^$?%WAOQYJGB3P@-.O+;5@IN[.
M]<H5<=U(_$]?XCP>M %'XY6T#1>$Q:1(NKOJ\4=JZ !PN#D#VW&.K/Q"_P")
MQ\6O 6@CE89I-0E7L0GS+G_OVP_&K^B^"==U;Q=;^*_&]U:275FI&GZ=9Y,-
MN3U8D]6_KCG@ 1^-/"GB@_$+2_&7A9;&XN+>T-I+;7CE5(RYR"/]_P!1R!UR
M: *_QVO2?!UEH,+_ .E:Q?Q6Z)ZJ"&)_!MGYU5^*$?\ :&J^#OA];.\5C?3!
MKH(<$P18POY!C]5%-E^'GBS6O'/ASQ)XCO;.XDM9S-/!;DK#:HF&C2,'EB6R
M23[=<5M_$+P?KFJ>(-"\3^&7M3JFE,P,-T2$E0]LCZL.W7KQ0!4^,=EH.E?"
M:[A;3K5%B\N&Q18POEN6 &S'3"AC[@&LSQNI\+?LZVVF ;9YK6VM<#N[$,X_
M'#USGQ"TGQ1KVL^%K+Q3=6?VK4+]8X-+T_<8H(01YDCD\LW(YZ  XZUZ7\1/
M"FI>++GPU;6HA_LZUU)+J^WO@[%Q@ =^"X_*@"A8>$=*\!_"345FM(I+H:7(
M]],ZAFE?RR=N3_"#\H'3@5;^#-E)8_"C1$ESND62;![!I&(_0@_C6E\2-%U7
MQ%X$U#2-'$1N[K8F9'V@+O4MS] 1^-;FB:<NCZ#I^F)C;:6T< ([[5"_TH O
MT444 %%%% !1110 4444 %%%% !1110 4444 <YX\_Y$O4/^V?\ Z,6M+P__
M ,BUI7_7G#_Z *S?'G_(EZA_VS_]&+6EX?\ ^1:TK_KSA_\ 0!6K_A+U_0X5
M_OK_ ,*_-FC11161W!17 _&76-0T/X<7EYIEW+:7/G1()8FPP!<9P>U9WPE\
M6ZG??VAX6\23M)K>F$.LDA^:>!L$-[XR.?1E]Z /3Z*\U_MG4O\ AH+^R/MT
M_P#9W]D>;]EWGR]^?O8]?>LGQ,VN:_\ &M?#5IXEU+2;(:8)P+-\?,">W?.>
MOM0![!17&^'/!6J:'JZWMUXSUG5(@C*;:Z8%"3W_  K-U7P-XN\0ZM>7-YXY
MO-,L_-;[':Z4#'LCS\I=@06;'4<\]Z /1**\N^&VN:_;>,/$'@GQ!J!U.73%
M6:"]88=D;!PWKPZGDDCD9/%>HT %-:1$959U4L<*"<9^E4-8U_2/#]NMQJ^I
M6MC$Q(0SRA=Y'4*#R3]*\Q\?:KI^L^-?AI>:9>V]Y;-J<@$L$@=<YBR,CO[4
M >OT56O]1LM*LWN]0O(+2V3[TL\@11^)XJAH_BSP_P"()7BTC6;*]E0$M'#,
M"P&<9V]<>] &NSJBEG8*HY))P!3(9X;F,202QRQDXW(P8?F*\:^,?B+1]1US
MPUX8N-6A%@^H9U>-)POEHNS D(^Z,,WY9[5LW^@>#XO 3KX9\4)X<TN>^65K
M^SO&*M(!M*;B_&<#C/50: /4**9E88<R2?*B_,[G' '))K!LO'?A34=173[/
MQ#IL]VQVI&EPI+GT4]&/TH Z&BN2U6RAE^(^B7+>*IK29() FBK+A;L8;+;<
M\XZG@_<'3%=)?ZC9:59O=ZA>06ELGWI9Y BC\3Q0!9HK'T?Q9X?\02O%I&LV
M5[*@):.&8%@,XSMZX]ZMSZOIMKJ,6GW%];Q7DL;2I"\@#,B]6 ]!@_E0!=HK
M#TWQEX:UC4#8:=KNGW5V,XBAN%8MCD[<'YOPS7+_ !-^(Z>#8+&'3KO3WU)[
MV)+BVG.YD@96)?:"".B\GUH ]$HK,T?Q%HWB!9FTC4[6^$) D-O*'V9SC..F
M<'\JTZ "BLF;Q1H-NEZ\^LV,2V+B.Y+SJHA<]%;)X)P<"C3?%&@ZQI\U_I^K
MV5Q:P#,TJ3#$0Z_-_=X]: -:BL;1O%OA[Q#-)#I&LV=[+&,M'#*"P&<9QUQ[
M]*T+_4;+2K-[O4+R"TMD^]+/($4?B>* +-%8^C^+/#_B"5XM(UFRO94!+1PS
M L!G&=O7'O4VL^(='\/0+/K&I6ME&Y(0SR!=Q'8#J?PH TJ*SM'U[2?$%H;K
M2-0MKV$':S02!MI]#Z'ZU7UCQ;X>\/RK%JVM6-G*P!$4LP#D'OMZX]Z -FBJ
M-EK.EZEIQU&QU"UN;)02T\4JLBXY.2#@8[^E>>Z;\7=,G^(6M:9>:OI,>@V\
M,365WYF/-<JI8;BV#@EAP.U 'ISR1QE0[JI8X4$XR?:G5Y/\4YXKKQ#\-KBW
MD66&76X7CD0Y5E+QD$'N"*[M/&GAB75_[*CU_3FORVP0"X4L6Z;>OWL]NM &
M[12,RHI9F"J!DDG  KG[;QWX3O-06PMO$>F2W3$*L:7*G<3T"G."?84 ;\DD
M<2[I'5%Z98X%.KRO]H+_ ))D?^OV+_V:NH^(EI!>>&5CN/%$OAN,7"-]MCE\
MLG&?D)W#KUZ]0* .LHIHQ%$-SY"KRS'T[FN>3X@>#Y+X6:>)M*:<D *+I,$^
M@.<9]LT ='15>^O[33;*6]OKB*WM8ANDEE8*JCU)K)O_ !MX7TN2".^U_3H'
MG57C5[A<E6&5;KPI'0GB@#>HK(U7Q3H.AVT%QJ>KV=K#<8,+22C]X/5?4<CD
M<<U?L;^SU2RCO+"ZANK:492:%PZM]"* +%%<YJ'C[PEI5\;*]\0Z=#<J<-&9
MP2A]&Q]T_6MVUN[>^M8[JTGBGMY1NCEB<,K#U!'!H FHHHH **** "BBB@"C
M'_R$9_J/_015ZJ,?_(1G^H_]!%7J "BBB@ HHHH **** *]Y_J&^E/M?^/.'
M_KFO\J9>?ZAOI3[7_CSA_P"N:_RH EHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BJMAJ=AJL4DNG7UM>1QR&)WMY5D"N,9
M4E2<$9''O5J@ HHHH ***JW>IV&GRV\5[?6UM)<R"*!)I50RN>BJ"?F/(X'K
M0!:HHHH **** "BJM[J5AIJQ-?WMM:B:011&>54WN>BKD\D^@JU0 4444 %%
M%% !7)^*? 5GXHU&#4O[5U?3-0@B,*7&G71B.W).#P>Y/3%=910!Q_ASX<:/
MX>U8ZP]UJ.JZL4V"]U.X\Z1%Q@A> !_/!(SS78444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!SGCS_D2]0_[9_\ HQ:TO#__ "+6E?\ 7G#_
M .@"LWQY_P B7J'_ &S_ /1BUI>'_P#D6M*_Z\X?_0!6K_A+U_0X5_OK_P *
M_-FC11161W'F?QZ_Y)7>?]?$/_H8K(^(%A<^'!X;^(VDQLT^G110:A&H_P!;
M;L,<_3)&?]H'^&NI^+V@ZGXD^'MUIVD6INKMIHF6)6520&!/4@5U*Z9%>>'%
MTO4(0\4MJ()XR<Y!7:PH \PL+ZWU/]HJVO[2026USH"RQ./XE;D']:H>)4\0
MO^T)CPS)I\>H_P!D+\U_O\O9DY^Z"<]*/AQ\-O$WA/XF2W-]%YNC6UM-;VEV
M9D.Y"V5&T'<#R2>,9S[5UG_".:M_PO?_ (2#[&?[*_LKR/M&]<;\_=QG/Z4
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M]*?:_P#'G#_US7^5,O/]0WTI]K_QYP_]<U_E0!+1110 4444 %%%% !1110
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MQ?@O_D9?%?\ U^?^SRUVE:U_C^[\CBR]WPZ]9?\ I3"BBBLCM"BBB@ HHHH
MYSQY_P B7J'_ &S_ /1BUI>'_P#D6M*_Z\X?_0!6;X\_Y$O4/^V?_HQ:TO#_
M /R+6E?]></_ * *U?\ "7K^APK_ 'U_X5^;-&BBBLCN"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *,?_ "$9_J/_ $$5>JC'_P A&?ZC_P!!%7J "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_9Y:[2M:_Q_=^1PY=_NZ]9?^E,****R.X**** "BBB@#G/'G_(EZA_VS_\
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M)7M0XWJAQR1^(_,5H4 %%%9\^N:7:ZQ;:1/?P1ZC=*7AMF<!Y%&<D#\#^1H
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.?"/_ "4G7?\
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M'LM?^*O@G2M1C,EI<K,DJ*Q4D=>HY'2NFL? ?BFUO[>XF^(VIW$44JN\+VR
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MBBB@ HHHH **** *]Y_J&^E/M?\ CSA_ZYK_ "IEY_J&^E/M?^/.'_KFO\J
M):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2GVO_'G#_P!<U_E0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><^$?\ DI.N
M_P#;Q_Z.6O1J\Y\(_P#)2==_[>/_ $<M;TO@GZ'FX[^-0_Q?H>C4445@>D%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.>//^1+U
M#_MG_P"C%K2\/_\ (M:5_P!></\ Z *S?'G_ ")>H?\ ;/\ ]&+6EX?_ .1:
MTK_KSA_] %:O^$O7]#A7^^O_  K\V:-%%%9'<%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 48_^0C/]1_Z"*O51C_Y",_U'_H(J]0 4444 %%%% !1110!7O/]0WTI]K_Q
MYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+1110 4444 %%%% !1110 4444
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M=I11SP_E_%A]7Q'_ #^?W1_R.+_X336O^A.U#\W_ /C='_"::U_T)VH?F_\
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MM*_Z\X?_ $ 5J_X2]?T.%?[Z_P#"OS9HT445D=P4444 %%%% !1110 4444
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M!K^DZ.-#FF6.:TMG=I[=6Z;F)P6[9&1GTS5SXM_\C5\.O^P[%_Z''5SXZ_\
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M^20Z%_V\?^CY*M^+? ^C^,=22Z@U.;3O$&GJ%2\L9@)8@>0'4'IR2.AYZX-
M&MX7/BI8;F'Q2NFM-&X\B>P+!95(YRK<@@_A5/POXDUK6?$/B"PU+0)M/M=/
MG\NUN7# 7*Y89!(P> IXS]ZL+X:>(]=N];\1>%]>O(=2GT61%34(E"^8K9X8
M#C(Q]>H.<9KNK/6=,U"^N[*SO[>>ZLV"W$,<@9HB<\,!TZ'\J +U%%% !111
M0 4444 %%%% %&/_ )",_P!1_P"@BKU48_\ D(S_ %'_ *"*O4 %%%% !111
M0 4444 5[S_4-]*?:_\ 'G#_ -<U_E3+S_4-]*?:_P#'G#_US7^5 $M%%% !
M1110 4444 %%<-\3/&VH>$-.TV+1;2"\UC4KH06T$P)4CN< @GDJ.H^]5GX:
M>,W\<>$(M3N$ABODE>&ZBA!"HX/& 23RI4]>] '845XSHWCKQ)=^"_B!J$^I
M;[K2;B5+*3R(QY0&<# 7#=.^:]"\ :I>ZWX#T;4M1F\Z\N+</+)M"[CD\X4
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M["&QFP8KF2Y18WSTVL3@_A5NTO+74+6.ZLKF&YMY!E)87#HP]B.#0!R.F_\
M)6-8_P"O-?Y15VE<7IO_ "5C6/\ KS7^45=I6M;=>B.' _#/_%+\PHHHK([@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .<\>?\B7J'_;/_ -&+6EX?_P"1:TK_
M *\X?_0!6;X\_P"1+U#_ +9_^C%K2\/_ /(M:5_UYP_^@"M7_"7K^APK_?7_
M (5^;-&BBBLCN,KQ%X=TSQ5H\FE:M"TUI(RLRJY0Y4Y'(YK2AB2"".&,82-0
MJC.< # I]% '.:?X$\.:5XHN?$=EIXAU.Y#"619&VG<06(7. 21Z5;_X1?2?
M^$K_ .$F^SM_:OV?[-YOF-C9Z;<X_&MBB@ KS^^^"O@?4+^XO;C3)FGN)6ED
M(NI "S')XSZFO0** .,\._"SPEX6UB/5=)L)8KR-657:X=P PP>"<=*[.BB@
M#F?%/@#PWXR:*36+#S+B$;8[B)VCD4=<9!Y'L<XYJO8?#+PGIJZ=]ETS9)87
M'VJ*7S&WM+_>=LY;Z'CTKKJ* ,;Q'X5T3Q;8K9ZWI\=W$AW(22K(?56!!'X'
MGO7/Z5\(O!^DZE!J$=C//<6\@D@-S<O((F!R" 3CC ZYZ5W-% &/J_A?2=<U
M32M2O[=I+K2I3+:.)&78QVDY .#]U>OI2^)/#.E>+-)_LS6(&FM?,638LC(=
MPZ<@@]ZUZ* *NI:;9:QI\UAJ-K%<VDR[9(I5R&'^>_:N+T_X,^!].U&.]BTI
MY#$VZ**>X>2-#ZA2>?QS7?44 9%WX9TJ]\36'B&>!FU*PC>.WD$C *K @_+G
M!X8]:;XC\*Z)XML5L];T^.[B0[D))5D/JK @C\#SWK9HH X;2OA%X/TG4H-0
MCL9Y[BWD$D!N;EY!$P.00"<<8'7/2NBN_#.E7OB:P\0SP,VI6$;QV\@D8!58
M$'Y<X/#'K6O10!D>(O#.E>*K"*RU>!IH(IUG15D9,.N0#D'W-3:[H.F^)-)F
MTO5K5;FTEQN0D@Y'(((Y!'J*T:* .=\*>"-$\%Q7,>C0RI]I*F5I9FD)"Y"C
MGH!DUT5%% 'G]S\%_!-S>R7!T^>-)7+R6\5U(L3$]?E!X^@Q7:VNEV%GI::9
M;VD,=BD?E+;A!LV8P1CN#W]:MT4 >?2_!/P)+=O-_9,J([;F@2ZE6,GZ!N/H
M.*[2/2-/AT8Z1!:QP6!B,(@B&Q0A&"!CIU-7:* ,C2_#.E:-X97P]90,FFK'
M)&(S(S':Y8M\Q.>2QJ70=!T_PWHEOH^F0F*R@W>6C.7(W,6/)Y/+&M*B@#@Y
M_@WX'GU4WYTC86?S)((YG6%VSGE,XQGL,#VKI-&\,:1X?N]0N=,M1;R7[K).
M%8[25! PO11R>!6Q10 5Q>M?"KPCK^N-K%[I[_:Y"#,8IW19<8^\ <=ATQG%
M=I10!B>)O".B>,+!+/6[);F.-M\;!BKH?4,,$?R-85O\(_!=MIC6,>D_*\B2
MO,TSF5V7IE\Y ]A@>U=Q10!D:SX9TK7[S3+K48&DFTRX%S:D2,NR0$$$@'GD
M#@T_Q#X>TWQ1HTNDZM"TUG*59D5RA)4@CD<]16I10!4N--M;K29=+EC+6DL!
MMW3<1E"NTC/7IWJOI'A_3-#T"+0[*V TZ)&00R$R JQ)8'=G()8]?6M.B@#S
MZ7X)^!);MYO[)E1';<T"74JQD_0-Q]!Q7:1Z1I\.C'2(+6."P,1A$$0V*$(P
M0,=.IJ[10!FZ#H6G^&M%M](TN)HK*WW>6C.6(W,6/)YZL:PO$GPS\,>*=3_M
M._M9DOBH1Y[>=HV=1T!P<'\LUU]% &%HGAO1?!6CSPZ+IQBB ,LBQ[I)9F ]
M3DL?0?E7._#'PS>Z:FK^(]8@-OJVO7)N9;8_\N\>6*(??YB3^ ZBN_HH ***
M* "BBB@ HHHH **** *,?_(1G^H_]!%7JHQ_\A&?ZC_T$5>H **** "BBB@
MHHHH KWG^H;Z4^U_X\X?^N:_RIEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ H
MHHH \,\1^)%N?CO%.=(U?5[/P[;;!#I=KY[+.XR6(R,#G'U2F_"K61IWQ6\1
M:,VGW^F6NK;KVUM=0@\F5&!)QM[9!;\%%>H^%?!.F>$;G5;FRFNI[C4Y_/N)
M;EU9B<DX&%'&6/YTS5_ NF:QXOTOQ/)/=P:CIPVQF!U"R+DG#@J21R1P1P30
M!X]X=_Y)U\5?^ON;^M>L?"O_ ))=X>_Z]!_,TRR^&>C6.B^(-*BN;\P:[(TE
MRS2)N0MG.P[,#KW!KH?#^B6WAS0;/1[-Y7M[2/RXVF(+D>Y  _2@#RG['9^*
MOVC-3L=?BBO+;3=/!L[2==T>2$))4\'[['GV]*K_ !5T?3]*O/"'AFQM18Z#
MJFK>9>P0L4C<EHUQZ*,$G P.^.*]"\3_  ZT;Q1JMOJTD^H:=JMNNQ+[3;CR
M9=O/&<'U/.,\U'<_##PY?>%SH-\MY=Q&=KG[5/<%[CS2,%]_KC QC''2@#@O
MB!HVG>$_B3X#N_#=C;Z?=7-V8)8[5!&LD>Y%Y5<=G8$]^_2D\.>'=)U_X[^,
M_P"UK&&]CMPK1PSJ'CW$*,E3P2!G&>F:[S0OAEH^BZY'K4]]JNL:C"GEP3ZK
M=>>T*^B<#'4_3)Q6EI/@S3M'\6:OXCMYKIKS5 HG21E,:XQ]T!01T[DT >.?
M#+P=H6I:;XX^W:?'="TGFM[83#>(%PW* _=;A?F'/ K*&KZC:_LQ1);S2!9=
M2:UD8,05B)+%?H2,8]S7N?A[P+IGAJ#68K*>\D75IFFG\YU)5F!!VX48'/?-
M0Z3\.= TOP7+X3>.:^TN5V=UNV!?).<@J%Q@@8(Y% 'DVH^$?%%[INA_\([\
M-+;1+W3Y8YHM2AU6W=Y !_'C:6R<'))[^M:7C#P]9>*?VA=-TG5/,:SETM7F
MCC<IY@4R,%)'.,@?E7;:?\)M*L7MT?7?$=Y86Y4Q:?<ZB3;+M.5&Q0.!CIG%
M;<W@O3IO'D'B]IKH:A!;&V6,.OE%?FY(VYS\Q[T >?>./AS?V6KZ!JGAK0[+
M5]*TBV:W.BW;EEP2Q+#><,3N[Y.5'#=NM^%VN:+KGA>671='.CK%=.EQ8XXB
MEP"VWH,<CL/H*N^)/ =GXCU)=1&KZUI=WY0A>32[PPF1 20K#!!P6/YUH>%_
M"NE>#]'&F:1"R0[S([.VYY'.,LQ[G@?E0!BZ;_R5C6/^O-?Y15VE<7IO_)6-
M8_Z\U_E%7:5K6W7HCAP/PS_Q2_,****R.X**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#G/'G_(EZA_VS_\ 1BUI>'_^1:TK_KSA_P#0!6;X\_Y$O4/^V?\ Z,6M
M+P__ ,BUI7_7G#_Z *U?\)>OZ'"O]]?^%?FS1HHHK([@HK%\3W>O6>E*?#FF
MP7VH22B,+<2[(XE()+MW(& ,#GFO/M=\6?$/P%#;:QXEBT+4-(DG6*X2P$BR
M0[NZENHX[YYXXZT >MT5R?CWQBWA+0;:YL[07NH7UREI90%L*\CYP3[<?J!Q
MG-<-XM\3_%+PA:V%Y?S>&3;W=PMNTD44I6!VZ;LG.W@\C/3Z4 >RT5P'CKQ9
MKW@GX>V>JW"V$NJB>&*Z\M&:$YSNV D'MQFL/5/%OQ.BT6;Q5;:'I%KHT*&?
M[!=,YNC".2[8( ..<<$>AH ];HKE3X\TR/X<IXSF5TLVM1/Y6?FWGCRQZG=\
MN?QKE;76?BWK6EIKNGZ=X=M;65/-M]/N6D,TB'E<G(&2,=UZ\@4 >J45P>@?
M$RUU?X?ZEXDFLI(+G2UD%[9 Y99$&< GL>.3TY]*S="U?XGZWIUCX@A3PV=/
MNPLJV'[P2"(G^_TWXYY./Y4 >B7VIV&EQ1RZA?6UI')((D>XE6,,YSA021DG
M!X]J=?WD>G:==7LJNT=O$\SK&NYB%!) '<\5XU\>D\2>1I;+)IO]B_VE +=<
M/YXN-DG+\;=F-W3GI7?Z7<>,],T'6+SQ1)HLT\$#2VG]GB3;\JL2'W8[A>GO
M0!K>%O$=IXM\.VNM64-Q#;W&[:EP@5QM8J> 2.H[&MBN-\$^,9-8^&%KXKUP
MPP'RIY;AH5(15CD=<@$D]$_.N:TKQ/\ $[Q?8'7= TW0++279C:P:@TAFG4'
M&25XY(/]W\>M 'J]%9^A7=_?:):7.J6/V&^=/W]MOW>6V<$ ]QQG\:J^)[O7
MK/2E/AS38+[4))1&%N)=D<2D$EV[D# &!SS0!M45Y)KOBSXA^ H;;6/$L6A:
MAI$DZQ7"6 D62'=W4MU''?//''6NG^)?B^[\'>$HM8L%AD)NHHV\Q"P,;9)P
M 1S@4 =I17E.H>(_BFVER^)++1='MM,CC,RZ;=%VNVB SN;& &QSMR".F":V
M+OXA->?""X\9Z1%&DZV^\0S?.(Y ^UE.,9P<XZ9X- '?45Y3:>)OB=XITB'6
MO#VDZ19V/E!XX]0+^=>''+* <*I/3)'&#G!K<\)^/W\4^ =0UH6J6VI:>DJ7
M%NV2JRHF[Z[3QQ]1GC- '=45XUX9\<_$;QQIEI>Z%IFEPV\'R7EQ=AE6XDSR
M(QG@!<<^O?M75^-?'&H:1KFG>&?#>GPW_B#4%,B+.Q$4$8S\[X(..&XR.A]@
M0#NJ*\GU+QCX]\!RVE[XPM-'OM#FE$4UQIGF![<MT)#=1U[<XZ@GGL_$]_XH
M$%E'X1L+"ZDN=S27=Y*1# N!@X7YFSGC'I0!TM%>6/XO\:^$/$VBV'BZ+2+S
M3M7N!;1W.GAU:&0D  ANH^8=N@SG(P>A\?\ C:;PI!I]EIEDM_KFJS>18VS-
MA<\99O8$CN.O48)H [*N3M/&3W/Q/O\ P>;)52UT\7@N?,R6)*#;MQQ]_KGM
M69I5W\3K/6+(:[8:%>Z;<R!)FTYY%DM@?XCOZ@=\9^M<;J^K:MI7[0FJ_P!A
MZ7_:.I76DQV\,;-MCC),;&20]D 4_4D#O0![C17EVG^,_&.@>.-+\/>-;72W
M@U?<+2[T[?A9!_"=W7J!T'W@<FO4: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH HQ_\A&?ZC_T$5>JC'_R$9_J/_015Z@
MHHHH **** "BBB@"O>?ZAOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?^N:_RH EH
MHHH **** "N+U+Q)XA_X2F\T?1[&SN/(17_>9#;2JDDDN!U:NTKB]-_Y*QK'
M_7FO\HJUI6U;5[(X<<Y6IQC)J\DM/1A_:7C_ /Z >G_]]C_X[1_:7C__ * >
MG_\ ?8_^.UVE%/VJ_E7]?,/J4O\ G[+[U_D<7_:7C_\ Z >G_P#?8_\ CM']
MI>/_ /H!Z?\ ]]C_ ..UVE%'M5_*OZ^8?4I?\_9?>O\ (XO^TO'_ /T ]/\
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M14GSN]C;#8?V$'&][MO7S"BBBH.@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G
M/'G_ ")>H?\ ;/\ ]&+6EX?_ .1:TK_KSA_] %9OCS_D2]0_[9_^C%K2\/\
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MI+G2Y3-:L)&78QQR0#S]T=?2M>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *,?_(1G^H_]!%7JHQ_\A&?ZC_T$5>H ***
M* "BBB@ HHHH KWG^H;Z4^U_X\X?^N:_RIEY_J&^E/M?^/.'_KFO\J ):***
M "BBB@ KB]-_Y*QK'_7FO\HJ[2N+TW_DK&L?]>:_RBK6EM+T_P CAQOQ4O\
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MB_/R&Q@'MF@#Z HKS*/Q[XIT?Q]I6A>*M)TR"TUD'[(]C*[O"W]UR>&(. <
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M[K8(R/8T >]T5X[X@N?$&I?'4>';#7[S3["XTU6F$4A.Q02S&-3E5D. -V.
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M&+6EX?\ ^1:TK_KSA_\ 0!6K_A+U_0X5_OK_ ,*_-FC11161W!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %&/_D(S_4?^@BKU48_^0C/]1_Z"*O4 %%%% !1110 4444
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M/$F".<XZ^A'K7H6B?#>UTCQC;Z_=>(]6U34XK=XHUO9E8^6>#VR0-Q_$U?\
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MKLJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD@?\"')K8\:^.;O1-7T[PYH&G)J7B'4 7BBD?;'#&.KN>N.&].A]@<#XK_\
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M^0= *R;SQOXH\0>*=2T/P-8::\6EMY=YJ&I,_E^9_<4)SD$$=^AZ<9J_#/\
MY*;\2_\ K]@_]K5!\%9DL[[Q?HMVX758M6DFD1^&=#P& [C(/_?0]10!W'A+
M4O$M[#=P>*-)@L;RVD"K+:N6AN%(SN3.2,="":W+Z>6VL+F>"W:YFBB9XX%(
M!E8 D*">A)X_&D@O[.YNKBU@NH99[8J)XT<%HRW0,.V<&L_Q7K9\-^%-3UE8
M?.>SMVD6,]&;L#[9QGVH XB^U?XN6VFW&LG2O#4-O!&TK:>TDLD^T<D;@=I;
M&>A_"NFT3QBGB#X=?\)3:6XB8VDLODR'<%DCW J2,9&Y3SQD>E<39V/B+7O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'CC/7'&>E>N>'_#FD^%M*33='LTMK926*@DEF/5F)Y)]S6DB)&@1%55'0*,
M4Z@#P3X9> /#_C+PQJTVJ6T@NK?7+A8KJWD,<JC9'QN'49.<'..?4UZ[X6\&
MZ'X-LI+;1;(0"5MTLC,7>0CIN8\_AT&3ZUN)&D8(1%4$Y(48R:=0!BZ1X6TS
M0]8U?5+))%NM6D66Z+.6!9=V,#M]XUH:EIMEJ^GS6&HVT=S:3KMDBD7*L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<\>?\
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M0_[9_P#HQ:TO#_\ R+6E?]></_H K5_PEZ_H<*_WU_X5^;-&BBBLCN"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *,?_(1G^H_]!%7JHQ_\A&?ZC_T$5>H **** "BBB@
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M\?\ _0#T_P#[['_QVC^TO'__ $ ]/_[['_QVCV+[K[P^O1_DE_X"SM**XO\
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MYK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"C'_R$9_J/_015ZJ,?_(1G^H_]!%7J "BBB@ HHHH ***
M* *]Y_J&^E/M?^/.'_KFO\J9>?ZAOI3[7_CSA_ZYK_*@"6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C'_R$
M9_J/_015ZJ,?_(1G^H_]!%7J "BBB@ HHHH **** *]Y_J&^E/M?^/.'_KFO
M\J9>?ZAOI3[7_CSA_P"N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\
MOTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\
MG[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\
M/V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M
M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/
M_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y_
M_;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MO
MQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y
M_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/
M[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%
M%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D
M_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^
M% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_
M 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^
M_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^
M?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?
M^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B
M'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S
M]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#V
MWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0
M_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_
M -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P *
M/[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H
M%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3
M_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X
M4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]
M^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?
MX4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[
M/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_O
MTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_
MY^S_ -^D_P */[;\0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/
MV?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^
M(?\ G[/_ 'Z3_"C^V_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\
M0_\ /V?^_2?X4 >@45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?
M_P!M^(?^?L_]^D_PH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"C^
MV_$/_/V?^_2?X4 >@45Y_P#VWXA_Y^S_ -^D_P */[;\0_\ /V?^_2?X4 >@
M45Y__;?B'_G[/_?I/\*/[;\0_P#/V?\ OTG^% 'H%%>?_P!M^(?^?L_]^D_P
MH_MOQ#_S]G_OTG^% 'H%%>?_ -M^(?\ G[/_ 'Z3_"GQZUKY<!KHX_ZY)_A0
M!U\?_(1G^H_]!%7JR=*::4&6<[I&ZG&*UJ "BBB@ HHHH **** $90PP:J2:
M?%(<E15RB@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP_P!T
M4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V7#_=
M%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']EP_W
M11_9</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H?V7#
M_=%']EP_W15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP
M_P!T4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V
M7#_=%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']
MEP_W11_9</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H
M?V7#_=%']EP_W15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *
M']EP_P!T4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH
M H?V7#_=%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z*
M *']EP_W11_9</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?
MHH H?V7#_=%']EP_W15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7
MZ* *']EP_P!T4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T
M5?HH H?V7#_=%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=
M%7Z* *']EP_W11_9</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</
M]T5?HH H?V7#_=%']EP_W15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#
M_=%7Z* *']EP_P!T4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP
M_P!T5?HH H?V7#_=%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V
M7#_=%7Z* *']EP_W11_9</\ =%7Z* *']EP_W10-,A!^Z*OT4 110K$, 5+1
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img40748725_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .) [P# 2(  A$! Q$!_\0
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MH;EBL1(]*=;G=;1-ZH#^E $E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "9&<4M59)"+X)VV _J:M#I0!7O/]
M0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2E_Y"8_ZY
MC^9JZ.E4I?\ D)C_ *YC^9JZ.E %>\_U#?2GVO\ QYP_]<U_E3+S_4-]*?:_
M\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAV!_$<834BS[P HXW';]WCI6-\6?^2<:E_O0_P#HU:[6N*^+/_).-2_WH?\
MT:M<]-WJ)^9G'XD8?P-_Y%C4?^OS_P!D6O//':VUQ\4+E-&*;GN(E!B V^=A
M0<8[[NOOFI/!'@?6/%6G7$]AJR6=M'-Y<B%GRQV@YP.#U%>G^#OA3I_AF_CU
M*ZNFOKV,DQ'9LCC[9 R<GWS^%=4I0ISE*^O8U;49-W.0^.G_ "&M)_Z]W_\
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MYK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?B&]2RAEGMKF0XCCNHPN\^@()&?;-/V4[7L/E=KV.SHHHK,D**** "BBB@
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M8%O4[>M6+7_DWMO^O)__ $8:Q4$Z<7W9%ERHB?XW6(T$7:Z6W]H-,T8M//R
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MR/7;M(_#/XUR&M6$&J?&B:QNE+07&I+'( <$J2,C->C?%30=+M_AY-);6%O
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MT_X08R;%W_:HQNQSCYN]7R1A5CIN/E49(XSX=_$>'0M/LO#[Z9),TMUCSEE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD:.!TW*#3E4*H50 !P .U4J\8ZQCJ-32U2*>CZ<FD:+9:=&VY;6!(MV,;MH
MS^/6KM%%<S=]3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** *4O\ R$Q_US'\S5T=*I2_\A,?]<Q_,U='2@"O
M>?ZAOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?\ KFO\J ):*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *4O_ "$Q
M_P!<Q_,U='2J4O\ R$Q_US'\S5T=* *]Y_J&^E/M?^/.'_KFO\J9>?ZAOI3[
M7_CSA_ZYK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"E+_R$Q_US'\S5T=*I2_\ (3'_ %S'\S5T=* *
M]Y_J&^E/M?\ CSA_ZYK_ "IEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7OC/2+#QE8^%9WF&IWL)FA CRF/FZMV/R-^5 '04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445@>*?&>A^#+6"XU
MR[:!+ARD6V)G+$#)X4&@#?HK@+/XT^ ;V98EUT0NQP//MY$'_?17 _$UWD,T
M5Q"DT$B2Q2*&1T8,K ]"".HH ?1110 4444 %%%% !116!XI\9Z'X,M8+C7+
MMH$N'*1;8F<L0,GA0: -^BO-_P#A>O@'_H*3_P#@))_\37HD$\=S;Q3Q-NCE
M0.AQC((R* )**** "BBB@ HHHH **** "BBJFJZE;:-I-WJ=XS+;6D+32E5R
M=JC)P._2@"W165X;\0V'BK0;;6=,:0VEQNV>8NU@58J01]0:U: "BBB@ HHH
MH ***X?7_B[X+\.WLEE=ZKYUU&=LD5K&TNP]P2/ES[9R* .XHKF/#?Q"\*^+
M9S;Z-J\4]R%W&!U:.3'?"L!G'MFNGH ***.@R: "BHK>Y@NXA+;31S1DX#QL
M&'YBL2Z\9Z19^-+/PG*\PU2[A,T0$?R;0&."WKA&_*@#H**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** *4O_(3'_7,?S-71TJE+_R$
MQ_US'\S5T=* *]Y_J&^E/M?^/.'_ *YK_*F7G^H;Z4^U_P"/.'_KFO\ *@"6
MBBB@ HHHH **** "BBB@ HHHH S]>_Y%[4_^O27_ - ->=_ VPL[OX56HN;2
M"8-/,&$D8;/S^]>B:]_R+VI_]>DO_H!K@_@+_P DKL_^OB;_ -#- ',_%70K
M?X>ZII'COPQ"EC*MV(+RW@&V.8$$_=' !"L#ZY!Z\UZGXI\7Z7X1\-OKFH.S
M6_RB)(\%IF;[JKGOW^@)KSWX]7@U#2]&\)6/[[5=1OD=($Y.P!ER?3+,/R/I
M3?C-%#9WG@&*?;_9<.IHLX;IM!C S_P$/0!?D\?_ !"ATXZS)\/ -+">:8_M
MR^>(^N2N,].VW/M75V/C[1;_ ,!R>+XGD%A%$TDB$#S$9>"A&?O9P/Q!Z&NG
M=E5&9R @!+%N@'O7BWP;T:T\0?#_ ,5:;.K?V3?:E-'&$X(4HG*_3Y<?2@#<
ML_'7C_4-/@UNT\"0RZ3.HECC6_7[0T1Y# >XYQC/\Z[+Q=XKT_P9X?EU?4=[
M1JP2.*/&^5ST5<]^I^@->97,OC?X-Z4DCW%KX@\)VSK'AQY=Q;H3@#/ID@#[
MWT I?C5=/J-OX%O+.X6"UN+])%GE0,L98(49E/! !8D4 :]U\0/'>E:8=<U3
MP&D6D*!)*D=\&N(8^[%<=AVP,=\5Z)HVK6>O:-::K82>9:W40EC)X.#V/H1T
M(]17#WGA/XBWUE/9W'CFQ>">-HI%_LA!E6&".OH:Z+P'X7D\&^#[/0I;T7C6
MYD/FA-@^9RV ,GUH U->_P"1>U/_ *])?_0#7EOP5U7P]:_#:TBU&_TN&Y$\
MQ*7$T:OC=QPQS7J6O?\ (O:G_P!>DO\ Z :\B^#G@3POKWP[M;_5=$M;NZ::
M56ED!R0&P.] 'K]O>Z8--DOK2>U:R56=IK=E9,+U.5X.,5YW8?$+QIXDLVUC
MPUX,@N-&WLL+7%\L<LX4D$@=!R"._/K7H%AH&E:7H[:18V,5O8,&4P1C"D-G
M=^>:\KFT#QG\)-.N[OPW?6^K^&;<M<2:?>#;+ G5BK#K@9).??:>: /3+WQ)
M;:1X0_X2'68I+&)+9)YH'P7C9@/W?;+9.WZUPEM\0_'NHZ>NMZ?\/S-HSCS(
MP;Q1/+'SA@O7D8XVG/;(YK*^+NO#Q/\  ZPUJQC:.WN[F&21&.2@^<$9[X<
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M&M_:=N&6,1@]W\Q<8]__ *] %KX@^.E\$Z!IVKQP174%U?16[,7.%C968N,
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M ,(H]N3I7D" 1[OF '(.?[V1G/K7"6_PG\2V=H-(M/B)J,6A ;1;K !*J?W
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M[@Y_G[$=:]1HH ;%&D,211J%C10JJ.@ Z"G444 %%%% !1110 4444 %%%%
M!1110 4444 4I?\ D)C_ *YC^9JZ.E4I?^0F/^N8_F:NCI0!7O/]0WTI]K_Q
MYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+1110 4444 %%,F,BP2&)0TH4E
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M ,=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_\ ] /3_P#OL?\ QVC^TO'_ /T ]/\
M^^Q_\=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_P#] /3_ /OL?_':/[2\?_\ 0#T_
M_OL?_':/8ONOO#Z]'^27_@+.THKB_P"TO'__ $ ]/_[['_QVC^TO'_\ T ]/
M_P"^Q_\ ':/8ONOO#Z]'^27_ ("SM**XO^TO'_\ T ]/_P"^Q_\ ':/[2\?_
M /0#T_\ [['_ ,=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_\ ] /3_P#OL?\ QVC^
MTO'_ /T ]/\ ^^Q_\=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_P#] /3_ /OL?_':
M/[2\?_\ 0#T__OL?_':/8ONOO#Z]'^27_@+.THKB_P"TO'__ $ ]/_[['_QV
MC^TO'_\ T ]/_P"^Q_\ ':/8ONOO#Z]'^27_ ("SM**XO^TO'_\ T ]/_P"^
MQ_\ ':/[2\?_ /0#T_\ [['_ ,=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_\ ] /3
M_P#OL?\ QVC^TO'_ /T ]/\ ^^Q_\=H]B^Z^\/KT?Y)?^ L[2BN+_M+Q_P#]
M /3_ /OL?_':/[2\?_\ 0#T__OL?_':/8ONOO#Z]'^27_@+.THKB_P"TO'__
M $ ]/_[['_QVC^TO'_\ T ]/_P"^Q_\ ':/8ONOO#Z]'^27_ ("SM*HZO?3:
M;IDUW!9O=R1@'R4."1GGL>G7I7,_VEX__P"@'I__ 'V/_CM']I>/_P#H!Z?_
M -]C_P".T*E9ZM?>*6-3BTH33_PLV-#\5Z9KJA(9?*N>]O+PWX>OX5N5X]XJ
M36-Z7>J:586-P6R);>4"1_? <Y^N/QKJO VJ>([Z-5O8/.L0/ENICM?\/[_^
M>:NI02CSQ>AS87,I2J^PJQ=^]FOO73\CMZ***YCV HHHH ***S]:FU2#3B^D
M6T5Q=[@ DIP,=^X_G32N[$SERQ<K7MV-"BN+_M+Q_P#] /3_ /OL?_':/[2\
M?_\ 0#T__OL?_':U]B^Z^\X_KT?Y)?\ @+.THKB_[2\?_P#0#T__ +['_P =
MH_M+Q_\ ] /3_P#OL?\ QVCV+[K[P^O1_DE_X"SM**XO^TO'_P#T ]/_ .^Q
M_P#':/[2\?\ _0#T_P#[['_QVCV+[K[P^O1_DE_X"SM**XO^TO'_ /T ]/\
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M_P#OL?\ QVCV+[K[P^O1_DE_X"SM**XO^TO'_P#T ]/_ .^Q_P#':/[2\?\
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MF/YFKHZ4 5[S_4-]*?:_\></_7-?Y4R\_P!0WTI]K_QYP_\ 7-?Y4 2T444
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MS5T=*I2_\A,?]<Q_,U='2@"O>?ZAOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?\
MKFO\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX ]._6@#5\8>,+#P9HD>JWT,\\$DZ0*+<*3ELG/) Q@&NAKRK]H A/AW;L>
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M?]<Q_,U='2@"O>?ZAOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?^N:_RH EHHHH
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MTV]\<6,EK=1-%*HTE!E6&#R#Q7.?%70CX<^">BZ))<_:C:7D$1E*;=_#]LG
M[5TL/PJO8($LD\?>)ETY %$"7 #!<8VA\<#VQBMWQ/X#L?$WA.R\.RW=S#;6
M;PM'("'<B-=HW%NI(/)]: .ICC2*-(XT5(T 5548  Z "O+/";*O[0'CB,G#
MFVMV /4C9'S^H_.O5:X/Q+\,;?6_$_\ PD6GZWJ6BZF\0AGEL7V^:H  SWZ
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M/.'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!Q>F_\ )6-8_P"O-?Y15VE<7IO_ "5C6/\ KS7^45=I6M;=>B.' _#/
M_%+\PHHHK([@HHHH **** ,[Q!_R+6J_]><W_H!K-\!_\B7I_P#VT_\ 1C5I
M>(/^1:U7_KSF_P#0#6;X#_Y$O3_^VG_HQJV7\)^OZ'"_]]7^%_FCHZ***Q.X
MS]>_Y%[4_P#KTE_] ->2_"#_ (0S_A7%C_;/]@?;?,FW_;/)\S&\XSNYZ5ZU
MKW_(O:G_ ->DO_H!KR7X0> _"VN_#BQO]4T2UNKMY)@TL@.2 Y [^E 'I%_J
M6D^&/!6HZSI%O9?8[>WDN46T"K'*X''*\<D 9KA/AAX(L=9T<>,_%4,6K:OJ
MC-.&NU\Q(8\_*%5N!TS[# &,5U_BOPK!+\,=5\.Z+9K$GV1Q;6\7 W [P!]6
M_G6)\*-4T[Q9\*X-&G8/);6[:?>VQ;:X7!7MR 5(Y]<^E &_=>#/!FIWUI<C
M3-.2]MIDGAEM0L4@=6W#E,$C(Z'-<=\;DCDNO!23*C1-K*!U< J5RN0<]JYS
MQOX \/>"O%/@B?0[62WDN-8B20M,[Y =".IXZUT'QTM(;]_!]G<*6@N-66*1
M0<95L C/T- 'H,.A>%!,A@TK1A*&!0I;Q;@1TQ@=:\]^($-K<?&[P1%>Q0RV
MS0S;TG4,A&&Z@\=:Z#3_ (,>"-+U*UU"UTV9;BUE6:)C=2$!U((.,\\BN8^)
MFCV&O_&/P9I>IP>?97$$RRQ[V7< &(Y4@CD#H: ,[XS:;X<MDT4^&(;.#Q2;
MZ-;:/3@JR%<'EE7_ &MF"?P[UZ;XZ\9#P-X>M]5N+,70>YCMY%$OEA=P)+9V
MG.,=,5YKX@\.6'P<\8:-XHT6';HEU-]COX91YI@#?Q(S98< GK_#C.#BM_X_
M%7^'=J00RMJ4.".01M>@ U+XN:M96@UR+P5?2>%@X']HR3!'="<!Q$1D*<C!
M/!R.1FIKOXKZA?17%]X2\)7>MZ1:*3<7K2B!20,L(U();&><#\.]=%\344?#
M#Q"NT;19/@8X&.E'PP15^&/AT!0 ;)"0!Z]: -+PGXGLO&'ANUUJP#I%."&C
M?&Z-@<,I_$?B,&MNO*_@!Q\/)U'1=2F 'H,)7JE 'D=C\9=1U^)H/#O@^XU#
M4HI'^T0K<XCAC!PK%RH&YN<+[=379>)/'%OX7T+3[N]L+A]2U I';:9"0TKS
M, 2GX$X)^G'(%<G\ HHU\'ZM*J*)'U>8,P') 5, GVR?SJA\48=1E^+?@E;*
M^BL)9$F2VN9H1(B2_P"Z>"3E0/<B@#<F^)6MZ!<VC^,/!TFD:9=2B);V*^2X
M6%CT$@4<?7\@<5N>+_&Q\.7NF:5I^ER:MK.ILPM;2.41@JHRS,YR !].QZ8K
MF?$'P]\<>*-'ETG5O&ME+9S%2ZKI2J<J01@AL]16SXJ^'DFNVVC76GZQ-I^N
MZ,@6UOU3<&X (9<]#C]3P0<4 :?AC7O$>HWUS9^(/"[Z2\2"2.=+E9XI03C
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MBYDM#*)3$<GC<  >,'\:\^^/W_)+Y_\ K[A_F:]0KR_X_?\ )+Y_^ON'^9H
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MCAP/PS_Q2_,****R.X**** "BBB@#.\0?\BUJO\ UYS?^@&LWP'_ ,B7I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_"0:+_T&-/_ / E/\:/^$@T7_H,:?\ ^!*?XUF_\('X:_Z!O_D>3_XJC_A
M_#7_ $#?_(\G_P 51:EW?X!?&]H_>_\ (TO^$@T7_H,:?_X$I_C1_P )!HO_
M $&-/_\  E/\:S?^$#\-?] W_P CR?\ Q5'_  @?AK_H&_\ D>3_ .*HM2[O
M\ OC>T?O?^1DZ+<077Q2U::WFCFB:S&UXV#*<"(<$>]=S63I?AK2-&N6N+"T
M\F5D*%O,=LJ2#CDGN!6M4U9*37*:82C.E!JI:[;>GFPHHHK,Z@HHHH ****
M,[Q!_P BUJO_ %YS?^@&LWP'_P B7I__ &T_]&-6EX@_Y%K5?^O.;_T UF^
M_P#D2]/_ .VG_HQJV7\)^OZ'"_\ ?5_A?YHZ.BBBL3N"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *4O\ R$Q_US'\S5T=*I2_\A,?]<Q_,U='2@"O>?ZAOI3[7_CSA_ZY
MK_*F7G^H;Z4^U_X\X?\ KFO\J ):*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
MG_FL_P#G_GWKT:O.?^:S_P"?^?>MZ'VO1GFYE_RY_P <?U/1J***P/2"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.\0?\BUJO\
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M_6]5AM]'\00Z+I"PYFEBA\RXDER?E&> H 7D$')/6O,O$VH>)M:^*/@&36=
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MSU'4&;3M.:,PI(0$@7#9.>PP.:Z?PI;>++:.Z'BK4-.NW8K]G-E$R;1SNW9
MSVQ^->">)[/6[OQ)\2?[)9FM8KF"348(N))H!NW!6[ =3QT^A! /3O#>OZ]\
M0/&[ZKIMW-8^#M-<Q1X4 ZA(.IY&=O\ 3'<G'2V=I<+\2-1NCXK6>!K10-"#
M+FW/RCS"-V0#@\X'W^O'-OP3?Z)J/@[39_#R)%IGDA8H5ZQ$=5;_ &@<Y]3S
MSG-<5HG_ "<EXD_[ \7_ +1H ]4KE=1M+B3XB:3<IXK6UA2V<-H>Y<W7WOG
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M2!J:=3[RU1\.V,?@;XZ7'AO2]T>C:MI_VQ;7<66*0$\C/3[C?@0.PJ[\+O\
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MCVR3D\"MOXE>%-8OM3T3Q7X:ACGUC1I"?L[L%^T1$\KDD#CYN..&/?%>BT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@#.\0?\ (M:K_P!><W_H!K-\!_\
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M/.'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HK@?%!U63Q_IUMI5V+>X>TRA<_(#^\SD8(Z ]JM?V;X_\ ^@YI_P#W
MP/\ XU6WL=$^9:G!]>?/**IR=G;2W^:.THKB_P"S?'__ $'-/_[X'_QJC^S?
M'_\ T'-/_P"^!_\ &J/9+^9?U\A_79?\^I?<O\SM**XO^S?'_P#T'-/_ .^!
M_P#&J/[-\?\ _0<T_P#[X'_QJCV2_F7]?(/KLO\ GU+[E_F=I17%_P!F^/\
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M/IUM831S7 ^ZC%9, _\ ?0_.F?%G0=4US_A&/[,LI+G[+JT<TVS'R(.K'VH
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M@&90P)7)!P#C!]JT+2TM["SAM+6)8;>!!'%&@P%4#  _"IJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#@=7^'NHKXKN_$OA;Q&^CWUZJK=Q26RSQ3
M;1@'!(P>/?OTR:2R^'FI7OB&PUKQ=XD?69M.?S+.VBMEMX8G_O$ G<<@'MR!
MU%=_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!2E_Y"8_ZYC^9JZ.E4I?\ D)C_ *YC^9JZ.E %>\_U#?2GVO\
MQYP_]<U_E3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <7J7_)6-'_Z\V_E+7:5Q>I?\E8T?_KS;^4M
M=I6U7:/I_F<."^*K_B?Y(****Q.X**** "BBB@ HHHH **** "BBB@ HHHH
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M%?)927ENEVZ&1(&E42,@ZL%SD@>M5K'Q!HNIW3VNGZQI]W<1C+Q6]RDCJ/<
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M\YO_ $ UF^ _^1+T_P#[:?\ HQJTO$'_ "+6J_\ 7G-_Z :S? ?_ ")>G_\
M;3_T8U;+^$_7]#A?^^K_  O\T='1116)W",H="IZ$8->._#,>+/ Y_X1"^\*
MW5S;&^9DU..4"%8FQECQVQG&<G.,#%>QT4 >4>)M,\1^%OBF?&FBZ-)K-E>V
M0M;RW@8"5",<@=_N(<\]QQQ6=J&G^./%/C[PGX@U+0_L&FVEX?+LU<226Z?*
M6DE88^]@8';;^)]HHH \[UK0]3N/CEX;UF*SD?3K:PFCFN!]U&*R8!_[Z'YT
MSXLZ#JFN?\(Q_9EE)<_9=6CFFV8^1!U8^U>CT4 <?\4]+OM:^&NL:?IUL]S=
MS+&(XDZMB5"<?@#6'XL\#ZIX@^'/AZ+3R(-=T:.WN($D. 9$0!D)['(X[9 [
M<UZ910!Y5=>,_B!JVDRZ5:> ;JRU::/R6NYIU%O$2,%P>^.2!DXXZ]Y-2\!W
M6B? >[\*Z=&;W4#""XB_Y:RF16;;GL.0/85ZC10!D>%;::R\(:):W,9CG@L(
M(Y$;JK+&H(/T(KE=5\9>);"_U#3;SX?WVHVYD=+::T=9(IXB?EW@@[>.N<_2
MO0:* . ^$?A74O"_AF[&J0):7%_>O=BSC8%;92  O'&>.W;%=_110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %*7_ )"8_P"N8_F:NCI5
M*7_D)C_KF/YFKHZ4 5[S_4-]*?:_\></_7-?Y4R\_P!0WTI]K_QYP_\ 7-?Y
M4 2T444 %%%% !1110!Y]\8/$%[HO@^.STF>2'5=5NH[.V>%BKJ2<D@CD<#&
M1TW"LKX1:SJUOJWB+P=XAU"XOM1TRX\R.XN)6=I(C@<%B3C[I'/\=9'C";6?
M%OQKL=.\.#3Y9?#=N;AO[0W^0)6(SG9R2,QX]P:S;Y_$W@_XSZ%XB\3C24&K
M_P"A3-I9D\LC 7YM_.1E#]%H U_#?_)6_B5_UZ?^RBMCX _\DO@_Z^YOYBL?
MPW_R5OXE?]>G_LHK8^ /_)+X/^ON;^8H ZWQ9XWT?P;%;?VB;B:YNWV6UG:Q
M>9-,W PJ\>HZD=:J67Q&T2XT34=4OXK_ $>/3BHNH=3MC#*F[[OR\YW=@,FN
M'\=W,.A?'CPKK>L?NM(-JT"7$A_=QR?O!SZ8WH2?0Y[4SXUZQ8^*/A],= OX
M-1BTV^ADO3:MYBHK*X'S#@\D=#QWH ZBP^,7A^[O[&VN[#6=+COR!9W6H6?E
MPSY(QM8,<@Y'/3GFKVN_$W0_#WB=O#]Y!J#WWD+-&MO;^;YQ8X$: '<7/IC'
MO7GGQ:\1:+XQ\)^'=(\-7D%_J5U>Q/!;VQ#21+L8?,!RA^8<''0^AK5\K'[3
M%HLF'>/1A\Q&3G:1G^= &[:?&?PY>13QPV.MMJ<,AC;2A8EKHD9S\@)&!@YR
M1CO70>&O'6A>*?#LVMV5RT-K;[A<BY 1H"HR=_) XYR"17"^!(T'QW\=L$7<
M$3!QR,[<_G7(Z!97=[\.?BA:Z<CF<W[%4B7)95;+* /501B@#T9/C3X:9DG:
MRUJ/2GE\E=7>Q(M"W^_G/8]JV?%7Q%T'P=>:?!JS3A+Z.26.>) T8" 'GG/.
M0!@'.:\;TV.#7?AE;:?J'Q:TVRTO[.JR:7)IL EBV$';]X2-@CJ!S[YK>\::
M7;1>+_A3I<K_ &ZVC58B\T>/.4>4 64^N,X- '9K\8?#+^&+36Q%J)6\N&MK
M:S6W#7$TBXR%4,0>H[]P.O%='X9\4VWB>WN'BL-2T^:W<)+;:C;&&5<C(.,G
M@_6N8^*&D^'-7;2(=4\2#P]JL#O/IUZS[%4C;NR20O\ =_B!XX[U6^$OBS6]
M?GUW3=5OK?58M+F6*#5($VK.#N]  > #D>O?@T ;.I?\E8T?_KS;^4M=I7%Z
ME_R5C1_^O-OY2UVE;5=H^G^9PX+XJO\ B?Y(****Q.X**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#.\0?\ (M:K_P!><W_H!K-\!_\ (EZ?_P!M/_1C5I>(/^1:
MU7_KSF_] -9O@/\ Y$O3_P#MI_Z,:ME_"?K^APO_ 'U?X7^:.CHHHK$[@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"E+_ ,A,?]<Q_,U='2J4O_(3'_7,?S-71TH KWG^
MH;Z4^U_X\X?^N:_RIEY_J&^E/M?^/.'_ *YK_*@"6BBB@ HHHH ***X3Q,-0
MOO'5AI5IJMU8QSVNXF)VP"/,.=H(R?E JX0YW:YSXFO[&*E:[;2MZG7VVE:=
M9WMQ>VNGVL%U<G,\\4*J\O\ O,!EOQI-1T?3-7CC34].M+U(FWQK<P+($;U&
MX'!KF/\ A"]:_P"AQU#\G_\ CE'_  A>M?\ 0XZA^3__ !RKY(?S?@S'ZQB/
M^?+^^/\ F=/%H^EP7=S=Q:;9QW-T-MQ,D"AYAZ.V,L/K3]/TVPTFU%KIME;6
M=N"6$5M$L: GJ<* *Y7_ (0O6O\ H<=0_)__ (Y1_P (7K7_ $..H?D__P <
MHY(?S?@P^L8C_GR_OC_F=7?:?9:I:M;:A9V]W;L<F*XB61#^!!%-LM*T[3;0
MVEA86MK;'),,$*HASP?E Q7+?\(7K7_0XZA^3_\ QRC_ (0O6O\ H<=0_)__
M (Y1R0_F_!A]8Q'_ #Y?WQ_S.AL/#>A:5<M<Z=HNG6<[##2V]JD;$>Y4 U8.
ME:<=4&J&PM?[0">6+OR5\W;_ '=^,X]LURW_  A>M?\ 0XZA^3__ !RC_A"]
M:_Z''4/R?_XY1R0_F_!A]8Q'_/E_?'_,ZF#2M.M;^XO[>PM8;RXQY]Q'"JR2
MX_O,!D_C18Z5IVF&8Z?86MH9W\R8V\*Q^8W]YL 9/N:Y;_A"]:_Z''4/R?\
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M0?\ (M:K_P!><W_H!K-\!_\ (EZ?_P!M/_1C5I>(/^1:U7_KSF_] -9O@/\
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M[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF: 30,AE4AL%<CYA]* *47Q5\9ZMX'E\5Z5X?TN&PL>+O[5,[-,0?F\I5Q@
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MLMQ_:%ZEFOED#86S\QSVXJQK'BW2-"UG2=*OYW2[U60QVJK&6!((')'3E@*
M-RBHY9X8-GG2QQ[VVIO8#<?09ZFH-3U*VT?2KK4KUREK:Q--*P&2%49/ ZT
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M )"8_P"N8_F:NCI0!7O/]0WTI]K_ ,></_7-?Y4R\_U#?2GVO_'G#_US7^5
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MSG;N .,]^M %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH SO$'_ "+6J_\ 7G-_Z :S? ?_ ")>G_\ ;3_T8U:7B#_D6M5_
MZ\YO_0#6;X#_ .1+T_\ [:?^C&K9?PGZ_H<+_P!]7^%_FCHZ***Q.X*\/UW0
MO^%I^/O%B??M=$T\V%F<\?:SEL_@P93[8KUCQ5KD?AKPKJ>LRXQ:0,Z@]&?H
MJ_BQ _&O*?AOIWQ&T?PG'/IFG:#+'J;F_::]FE$TAD (+;1CH!^= '9?![Q"
MWB#X=6'G,3=V&;*<-U!3&W/_  $K^.:@\0_$'5AXN?PKX0T6/5=3MXO-NY9Y
M=D, ., GN>1W'7'/..4^'DNJ^$OB[J_A_78;6V?7HS?PQVKEHO,!8X3/.,>9
M_P!\BM7X:R);_%?XB6=UA;Z2Z2:,-PS19<C'MAT_,4 8&H>(M3UKXQ^";36]
M$DTG5+*682Q%Q)'(K+\KHXZ@[3],5WWC/Q]=:)KMCX;T#2?[6U^\4R"$R!$B
MCY^9S^!XXX'7IGGO'-Y;3?'#P):1SQO<0&8S1J<E R_+GTS@TZPD2U_:9U1;
MS"M=Z.HLRW\6/+) _P"^)/R- '+?$/Q+KU]=^&-'\3:!_9E_'J\$\<T$HD@G
M3.T[3V()''/6O3?&'B9=%\8^$--.F6MT=4N98Q/*/GM]NSE..IW_ *5S/QMO
M+83>$+$SQ_:SK$,PAS\VP'!;'ID@5/\ $S_DIOPT_P"OV?\ ]HT 8?QJO/$0
MU_P_$FE6QL(M4A>PG,XW3S8'R,/X1G(S7?1:YXE@\%Z]J?B;0K*UFL[6::*V
MCG$J3*L98ANN 2,5SGQJ=8F\&S.=L::Y"68] .O]*[7QW_R3SQ+_ -@JZ_\
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M))P *\T^ O\ R2NS_P"OB;_T,UVWBB&>X\):S!:@FXDL9TB"C)+F-@,#ZXH
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M8)6N4C'W?DX0D#L2?<FK?C3P%K&K:YH?B70-2M(]=TI/+)O4(BG7WV D=6X
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M?.#CGIU->L>'[;QT^I"X\37^B1VJ(0+72X9")">C,\G(QZ#K7/V7@?Q-X?\
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MT]E98[=NL1#$%>_&<UG:_P##/3=?U*[O3K&O6 O0!=V]C?&.&XPH7YT(.?E
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M=K/PKT?5/$$VN6NHZQH]]<<7+:7=^2)_][@_IC\Z .2\$07EK\?O$4%_J_\
M:UU'I2B2Z\E(B3NBX*IP".E>S5R7AOX<Z#X4UR35M+%REQ):_99%DEWJ_P P
M8NQ(W%R1R<X]A76T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;B#RKE4#9ZARPPB@#[Q)R2!CFI_#GQ$_M[0-7O&T*^BU+29C!=:9"1-+O!P
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M_G7J= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!G>(/^1:U7_KSF_\ 0#6;X#_Y$O3_ /MI_P"C&K2\0?\
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M_MI_Z,:ME_"?K^APO_?5_A?YHZ.BBBL3N"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 4I?\ D)C_ *YC^9JZ.E4I?^0F
M/^N8_F:NCI0!7O/]0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!2E_Y"8_ZYC^9JZ.E4I?\ D)C_ *YC^9JZ.E %>\_U#?2GVO\ QYP_
M]<U_E3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4I?^0F/^N8_F:NCI5*7_D)C
M_KF/YFKHZ4 5[S_4-]*?:_\ 'G#_ -<U_E3+S_4-]*?:_P#'G#_US7^5 $M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %*7_D)C_KF/YFKHZ52E_Y"8_ZYC^9JZ.E %>\_P!0WTI]K_QYP_\
M7-?Y4R\_U#?2GVO_ !YP_P#7-?Y4 2T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4I?\ D)C_ *YC^9JZ.E4I
M?^0F/^N8_F:NCI0!7O/]0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!2E_Y"8_ZYC^9JZ.E4I?\ D)C_ *YC^9JZ.E %>\_U#?2GVO\
MQYP_]<U_E3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 4I?^0F/^N8_F:NCI5*7
M_D)C_KF/YFKHZ4 5[S_4-]*?:_\ 'G#_ -<U_E3;H$PL!Z5R5[J>L6[^7;W!
M5%& /+4\?B* .THKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\
M[;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^
M(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HK
MS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^
M%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#
MT"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[]
M)_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_P
MH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[
M])_A1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I
M/\* /0**\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S
M]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\
MWZ3_  H ] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0
M_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\
MG[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HKS_\
MMOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^%']M
M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO
M/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[])_A1
M_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ]
MHKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A
M1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\*
M/0**\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_O
MTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_
M  H ] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/
MV?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_
M 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#
M_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^%']M^(?^
M?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;
M\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[])_A1_;?B
M'_G[/_?I/\* /0**\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_
M /MOQ#_S]G_OTG^%']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?
MB'_G[/\ WZ3_  H ] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**
M\_\ [;\0_P#/V?\ OTG^%']M^(?^?L_]^D_PH ] HKS_ /MOQ#_S]G_OTG^%
M']M^(?\ G[/_ 'Z3_"@#T"BO/_[;\0_\_9_[])_A1_;?B'_G[/\ WZ3_  H
M] HKS_\ MOQ#_P _9_[])_A1_;?B'_G[/_?I/\* /0**\_\ [;\0_P#/V?\
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M_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP_P!T4?V7#_=%7Z*
M*']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V7#_=%']EP_W15^B@
M"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']EP_W11_9</\ =%7Z
M* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H?V7#_=%']EP_W15^
MB@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP_P!T4?V7#_=%
M7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V7#_=%']EP_W1
M5^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']EP_W11_9</\
M=%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H?V7#_=%']EP_
MW15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP_P!T4?V7
M#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V7#_=%']E
MP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']EP_W11_9
M</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H?V7#_=%'
M]EP_W15^B@"A_9</]T4?V7#_ '15^B@"A_9</]T4?V7#_=%7Z* *']EP_P!T
M4?V7#_=%7Z* *']EP_W11_9</]T5?HH H?V7#_=%']EP_P!T5?HH H?V7#_=
M%']EP_W15^B@"A_9</\ =%']EP_W15^B@"A_9</]T4?V7#_=%7Z* *']EP_W
M11_9</\ =%7Z* *']EP_W11_9</]T5?HH H?V7#_ '11_9</]T5?HH H?V7#
G_=%']EP_W15^B@"A_9</]T4#3(1_"*OT4 0PVZQ#"C%3444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img40748725_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )=! <# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A:W@K_H-?\ DK-_\11_PM;P5_T&O_)6;_XBOF>BCV40^M3[(^F/^%K>"O\
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M_0:_\E9O_B*/^%K>"O\ H-?^2LW_ ,17S/11[*(?6I]D?3'_  M;P5_T&O\
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M *%W5O\ P"D_^)H_X1#Q-_T+NK?^ 4G_ ,31=!RR[&-16S_PB'B;_H7=6_\
M *3_ .)H_P"$0\3?]"[JW_@%)_\ $T70<LNQC45L_P#"(>)O^A=U;_P"D_\
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MR?FZ^]=+;:?965NUO:VD$$+$EHXHPJDGKD 8IEKI>GV,<D=G8VUNDGWUAA5
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MG3O_  *3_&OGRBCZI'N']K3_ )4?0?\ PD>A_P#09T[_ ,"D_P :/^$CT/\
MZ#.G?^!2?XU\^44?5(]P_M:?\J/H/_A(]#_Z#.G?^!2?XT?\)'H?_09T[_P*
M3_&OGRBCZI'N']K3_E1]!_\ "1Z'_P!!G3O_  *3_&F1>(M$$8!UG3Q_V])_
MC7S_ $4?5(]P_M:?\J/H/_A(]#_Z#.G?^!2?XU>M[F"[@6>VFCFA;.V2-@RG
M!P<$>]?-U>X_#_\ Y$C3O^VO_HQJRK4%3C=,Z\'CI8B;@U;0Z6BBBN8](***
M* "BBB@ HHHH **** "BBB@ ID?\?^\:?3(_X_\ >- #Z*** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "F?\M_^ _UI],_Y;_\  ?ZT /HHHH ****
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MER1^8@;9(NUER,X([&@"2BBB@ HHHH **** *VH?\>,GX?S%<M_Q;3_J4O\
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M3CQ?0****V.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "KND_\ (3A_X%_Z":I5=TG_ )"</_ O_0351^)$5/@?H>R?"[_D*7/_
M  '_ -!>O6:\F^%W_(4N?^ _^@O7K-98KXSKRO\ @?,****YCT0HHHH *9#_
M *H4^F0_ZH4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9'_'_ +QI
M],C_ (_]XT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8O^MD_"GTQ
M?];)^% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "F?\M_^ _UI],_Y
M;_\  ?ZT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO
M->1075O;.?WEP6"#_=&35=]=TJ-V1]0MU93@J7 (-<9XAU^-O%%E<6TJR06F
MT[D.0<G+?I@5PXO'4Z$.9-/5?GK^!2C<]#HK-_X2#2/^@E;?]_!3KC6]/MQ#
MNF>1IU+1I!"\S,HZMM0$X]^E=<:L)Z1:9-C0HK/;6+42:>B;W%^S+$RKP"%+
M'=G!'0CIG-6)KOR;NVM_L\[^?N_>(F4CP,_,>V>@JP+%%%% !167_P )#IGG
M&,3R,JOY9F6"0PALXP90NP<\=>O'6M2@ HJ,3PM.T"RH9D4,T88;E!S@D>AP
M?RJ2@ HHHH **** "BBB@ HJAJFLZ?HT<,FH7(@2:01(Q4D%CVX''U/%6+R\
MM["SEN[J41P1*7=SS@?A0!/15>QO;?4K**\M)/,MYEW(^TC(^AYJ/5-2ATC3
M9KZX61HHL;A& 6Y('&2/6@"Y10.1FB@ HHHH **** "BBB@"MJ'_ !XR?A_,
M5G_\(AX9_P"A=TG_ , H_P#XFM#4/^/&3\/YBOEC0/\ EX_X#_6M:5/G=KV.
M7%5U1CS-7/I?_A$/#/\ T+ND_P#@%'_\31_PB'AG_H7=)_\  */_ .)KP*BN
MCZJ_YCSO[5C_ ,^_Q_X![[_PB'AG_H7=)_\  */_ .)H_P"$0\,_]"[I/_@%
M'_\ $UX%11]5?\P?VK'_ )]_C_P#WW_A$/#/_0NZ3_X!1_\ Q-'_  B'AG_H
M7=)_\ H__B:\"HH^JO\ F#^U8_\ /O\ '_@'OO\ PB'AG_H7=)_\ H__ (FC
M_A$/#/\ T+ND_P#@%'_\37@5%'U5_P P?VK'_GW^/_ /??\ A$/#/_0NZ3_X
M!1__ !-'_"(>&?\ H7=)_P# */\ ^)KP*BCZJ_Y@_M6/_/O\?^ >^_\ "(>&
M?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q->!44?57_,']JQ_Y]_C_ , ]
M]_X1#PS_ -"[I/\ X!1__$T?\(AX9_Z%W2?_  "C_P#B:\"HH^JO^8/[5C_S
M[_'_ (![V_A'PT$;_BG=)Z?\^4?_ ,30GA'PT47_ (IW2>G_ #Y1_P#Q->"4
M4?57_,']JQ_Y]_C_ , ]]_X1#PS_ -"[I/\ X!1__$T?\(AX9_Z%W2?_  "C
M_P#B:\"HH^JO^8/[5C_S[_'_ (![[_PB'AG_ *%W2?\ P"C_ /B:/^$0\,_]
M"[I/_@%'_P#$UX%11]5?\P?VK'_GW^/_  #WW_A$/#/_ $+ND_\ @%'_ /$T
M?\(AX9_Z%W2?_ */_P")KP*MCPM_R,=I_P #_P#0&H>%?\PUFD6[>S_'_@'L
MO_"(>&?^A=TG_P  H_\ XFE3PGX<C8,GA_2E8="MG&#_ "JKH'_'\_\ UR/\
MQ715S33@[7/2H3C5AS6L5+72M.L7+VEA:V['J8850G\A[FK=%%0VWN;J*6B"
MBBBD,**** "F0_ZH4^F0_P"J% #Z*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F1_Q_[QI],C_C_WC0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IB_ZV3\*?3%_P!;)^% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "F
M?\M_^ _UI],_Y;_\!_K0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?\1>&K75HFN%*P72+GS>S =F_QKRZO7O$#3C19XK9&>XG'E1JO
M4EN#^F36'8^!+5=.=+UV:[D'WT/$9]O7\:^>S++Y8BNO8QUM=OIY?,TC*RU*
M'A#PU;7L*ZE=LLJAB$A[ CNWK]*Z+5-(OCJ::OI%Q#'>I!Y#17*$Q2IG(!QR
MI!R<C/TJKX6L+O1I[S3;D9C)$L,B_=<=#]#]WBM>[T>SO9_/E$Z2E=C/!<20
ME@.@;8PW8R<9Z9/K7HY;1C2PZ2C9]?4F3NSD]3UV[OK?0]3L].W7L=S<+]E:
M3/SI&ZD!@/FZ''KTXJU9W#_;_#;P:I<7<=Z9Y9I&D(60[,XV9PH!Z+VQZY-=
M(FDV$8LQ';(BV1)MU0D!"05/ Z\$]?6HXM"TV"\6[BMMDR2/*I#MM5W&&(7.
M!GZ>_6O0).45KM/"DFM'4;UKN"[?9F=MFP3E=A7.UAC/)!//7  KKM9,ZZ'J
M!MMWGBVD\O;UW;3C'OFD_L;3SICZ=]G_ -$=B[1[VY);>><Y^]S5^@#-\/>0
M/#FF_9L>3]FCVX.?X16&MY=#1O%\C7,P>"><0L7.8P(E(VGMR<C%;2^'=,24
MND,B*7WF%9Y!"6ZY\H-LZ\].O-%WX=TJ^GFFN;8N9P!,GFN$DP, L@.TD#H2
M,C ]!0!A:)8QR^*IIWENFD%A:S9-U+@L2^<C=@CCH>/;FH==U%EBN[_3O[5D
MDM;E4-R+@"W4AE#)Y>\;AR1G8>>YQ74?V-8_:X+I8W2:!!&C1S.F4'16 .&'
MLV:@G\,Z1<O,TMLS"9_,>/SG$9?^]L#;0W'4#- %!K>34O%6J6LU[>);16T#
M)%!.T8#-O^;*D'MTS@]P<#&5%JM_>Z?X?M9!>W'VB.5YS:RK%++Y9"CYBRX'
M.3@YX^M=G'96\5[->)'B>=521]Q^8+G''3N:JMH.FM8PV?V<K# Q>$I(ZO&2
M225<'<.IZ'OB@#G6FU>WLH;"X^V6L-UJ0@BEFF5YU@9=V"ZEN<@J#G.,=^:L
MW)FTK5KBPM;BZ>";3I9]LL[RM$ZD %68EAG/3/4<5MG1=/:P>R> O"[;V+R,
MSENS;R=VX8&#G(P,=*=9:39V#RR01N990 \LTKRNP'0;G)./;.* .?2]N?[!
M\(R&YE\RXFMQ*WF',@,3$[CWR>>:5I+G3M;:75Q?B.6\"VUW!<$P!6X6-XLX
M']W.T\G.X=:UH?#.D6\L,D=J=T#[X=TSL(CS]P$D*.>@P#QQP*D&@Z<+M;CR
M9"RR>:L;3N8E?^\(R=@.23D#J<]: ,SQ9:17]UHMG,,Q3W,D;?0PR"LRWO)=
M8@T[0IV+7%H[-J SDX@("Y_WFV-],UV-Q96]U-;S31[I+9S)$=Q&UL%<\=>"
M>M1PZ996][=7D5NJ7%V%$[@G+[1@?Y% '$Z;=7/]A>&-/BBO)(9X)))4LY5B
MD?9C"[BRX&6R<'/'IFK.JKJ$?@?6(KZ*XCC68?9OM,JR2^660X9E9LX.X<G.
M,5TQT'33I]O8BW*P6QS!LE=7C/JK@[A^=.;1=/?3I;!X6>WE.Z0/*S,YR.6<
MG<3P.2>P% &#X@NA+_:(M/[6ENK.#<7M;@1Q6S;2PR-Z[^Q((;C\J>)+C5=:
MTB*:[N(X9]+:>:."4QAVRG=>1UZ@@]NA(.Q=^'],O9Y9I[=F:90LJK,ZI* ,
M#>H(5L>I!_2K$6F6<-Q!/'#MD@@^SQMN)VQ\<=>?NCGKQ0!RJ7MZ-/33OMD^
MUM8>P-R7)E6+E@-W7=_#NZ_C5NZ:72=5N+&VN+I[>;399\2SO*T3I@!@S$D9
MSTSVK;?1=/DMKBW>V!BN)3-("QSYA_B!SE3P,$8QVI+?1;"V6X"1.S7"[)9)
M9GD=EQC&]B6QUXSWH Y6"*[&G>&+I=6U#S[\QQW+-.6#JT18@*?E4_*!N #=
M\YYJ_'>+I;>(+:YO;L6=LT)B;S#)*OF*/E5FR3D],],]16\NDV2P64(@Q'8D
M&W&]OD(4J._/!(YS23Z-I]S]L\ZW#_; HGRQ^;:/E[\$>HQ0!B:+/<0^*)[(
MPZA!;-9K,(;ZX$S!P^,JV]R 0>F>W2NIK/L]%L+&[:Z@B?[2R>6TTLSR.RYS
M@EB2?Z5H4 5M0_X\9/P_F*^6- _Y>/\ @/\ 6OJ?4/\ CQD_#^8KY8T#_EX_
MX#_6NG"_$>9FG\/^O(VJ***] ^?"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "MCPM_P C':?\#_\ 0&K'K8\+?\C':?\  _\ T!J3V*C\
M2/7- _X_G_ZY'^8KHJYW0/\ C^?_ *Y'^8KHJ\VO\9]+@?X(4445B=@4444
M%%%% !3(?]4*?3(?]4* 'T444 %%%% !1110 4444 %%%% !1110 4444 %,
MC_C_ -XT^F1_Q_[QH ?1110 4444 %%%% !1110 4444 %%%% !1110 4Q?]
M;)^%/IB_ZV3\* 'T444 %%%% !1110 4444 %%%% !1110 4444 %,_Y;_\
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MH[?>VT9.\1J#EMHZ 8SVQ6IH-]>3WM[;3->3VT81X+FZM# S9R&0@HH.",Y
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M1ZI]KU*7PM<RS75A--+EX51,Q.87).'4G/4<\8[9YK>N-%62^DO+:]N[*68
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MKX#T<K_C&K1117GGT 4444 %%%% !1110 4444 %,A_U0I],A_U0H ?1110
M4444 %%%% !1110 4444 %%%% !1110 4R/^/_>-/ID?\?\ O&@!]%%% !11
M10 4444 %%%% !1110 4444 %%%% !3%_P!;)^%/IB_ZV3\* 'T444 %%%%
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M7@'_  E_B;_H8M6_\#9/_BJ/^$O\3?\ 0Q:M_P"!LG_Q57R2[F'MZ7\I[_\
M\*I\%?\ 0%_\FIO_ (NC_A5/@K_H"_\ DU-_\77@'_"7^)O^ABU;_P #9/\
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M_A(]<_Z#.H_^!3_XU<:$Y*_,85<=1INSA^1ZC_PJGP5_T!?_ ":F_P#BZ/\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IB_ZV3\*?3%_ULGX4 /HHHH
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M0 4444 %%%% !1110 4R'_5"GTR'_5"@!]%%% !1110 4444 %%%% !1110
M4444 %%%% !3(_X_]XT^F1_Q_P"\: 'T444 %%%% !1110 4444 %%%% !11
M10 4444 %,7_ %LGX4^F+_K9/PH ?1110 4444 %%%% !1110 4444 %%%%
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M7.GHHHK804A4,02 2#D9'0TM% !2;1N#8&X# ..<4M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!6U#_CQD_#^8KRJT^!OV6Z2
M;_A(MVW/'V+';'_/2O5=0_X\9/P_F*\*_P"%X^)O^?'2?^_4G_QRM*?-]DYZ
M_LFK5$=G_P *D_ZC?_DI_P#9T?\ "I/^HW_Y*?\ V=<9_P +Q\3?\^.D_P#?
MJ3_XY6IIOQ?\07ELTDEGI@(<K\L4GH/]OWK=2KMV3."=/ P5W'\_\S?_ .%2
M?]1O_P E/_LZ/^%2?]1O_P E/_LZS/\ A:FN?\^NG?\ ?M__ (NC_A:FN?\
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MHHH **** "F?\M_^ _UI],_Y;_\  ?ZT /HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I&&Y2,D9&,BEHH X;Q _B31G,T6H2S69/$FQ<I
M[-Q^M<<;VY-]]M,K?:=_F>9WW9SFO3_%EY]C\.7)!PTH$2_\"Z_IFN#'A;53
MI7V\6YV]?*_CV_WL?Y-?)YGAZBK\M)RE97MJ[&L6K:F[X?D\2:S()7U"6&S!
M^:38N6]EX_6M[Q#+*8;+2K:XEBGOIA'YL;[72-1N=@1WP,?\"IO@^\^U^'(
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M/%:J53:O49"C<WO@>G;) +LVKW<NI7%EIEE%<O:JIG>:X\I59AD*,*Q)QR>
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M(K7?ALOJ]U?#2])O_M85G6]'S0L%"_*VQMRD#IQS]>+T&C2P:_:7J_9DMX+
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M ('_ .@-7H]><>%O^1CM/^!_^@-7H]9SW.FC\)V%E_QXV_\ UR7^53U!9?\
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M_P"%2?\ 4;_\E/\ [.C_ (5)_P!1O_R4_P#LZZG^W[K_ )YP_D?\:/[?NO\
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M /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-:M-1N+;?IEXT$Z#A,
MJ_MR.#[UIT5%2"J1<7^&@'D.JZGJUR39ZE-(3$^3&Z@8;\![U-H^I:YF/3],
MGDP22J*H('J<D<"K^K6=WXD\6745HN4B(C+G[J <')^N:G\+17.B>*FL;R,H
MTT90>C8Y!![]#7R$*55XF[E+E;Y>;_@FUU8W]2?4M%\'W]T]^TM_'"7$I1<(
M?88Q^=5]*U=YM?M[.UUH:M;R6KRW!/E'R&! 7!C51R21@Y/%:WB:SN-0\-:A
M:6L?F3S0E43(&3]3Q5 VU]J6JZ3.VG2V*6&YI)9GC+."FW8H1FX)Y.<=!UK[
M"$5"*BC$7PUJ$_\ PB5K<S+=7D[/(H"_.['S& Y8X' ZD@59'B:T$%P9;>YB
MN8)5@:T95,I=AE -K%3D'KG'7.,&LNVTS6+3PE86<<4JRQW):ZA@F5)'B+L2
M$?< #RI^\.,\U430=26\N+^*QF7R[NWN88)[SS9)%565E+,QPWS< G'O5 :E
MIJ[S>++P3K=6D,&GJ\D%P0 AWMEN"5/&.03Z=L5#?Z])=W.B""WO[6*XO4*2
M. JSQ[6_NL2 >#A@"?3@X=)INH:MJ>I37%H;.WNM-^R1[Y59P=S?>"D@=<\$
M\=\\!IM]8O%T."32S MA<1O/(TZ$-M1ER@!)(YSS@\C@\X -&Y\2VUM+/_HU
MU);6T@CN+M%7RHFXR#E@QQD9(! _ U+?Z[#8:E;Z>+6YN;JXC:2)(%4[@I&>
M68 =<\X''7. <+_A'I(I+ZTN--O;R&YGDD22+46B@*N2=LB>8,8SSA6R/RK8
MET^X_P"$MLKQ(O\ 18K*2%GW#ABRD#'7H#0 >(K^YL=-M9K9C#))=P1L"%)V
MLX##N.AQQ3M<OKFSNM'2"38MQ?+%*-H.Y"K''/3D#I3_ !#ITVIZ7Y5L4^T1
MS1SQB0D*61@V"1TSC%5)H;[6M0TUYM.EL8+.;[0YGDC8NVT@*NQFXY))..@_
M  M6^OQ7>JW-A;V=W(]K+Y<\@50D? (.2PR#GL">.0.,Q'Q/;!#<"TO#IXD\
MLWVU?*SG&<;M^W/&[;COTYI=&T^XMKW6WN(]B75WYD1W [EV*,\=.0>M9 TS
M51X7/AG^SVY4V_VWS(_*\LG[V,[]V.VWKWQS0!J0ZY>2>*+K3#ILQMXHXV$J
MF/C<6&X_/]WCC SUR.E9VB>(S;Z2KWL-]+&+R6&2\(#(A,S!0<MN(Y49 ('3
M/!QHQVEU9>*9+E+62>UN+6*#S$=!Y11FY8$@D8;MGITJ@=&U ^![C3OL_P#I
M;SR.L>]>09RXYSC[O- &M?:]%9W,T$=G=W;6\8DN#;JI$2GIG<PR2 3A<GVZ
M54AOS<^,8?(N7>SETOSD56.QLR##8]<=ZJW>C31:WJ%RUE?WD%X5=?L=^8-A
M"A2'7S$!!QG(R>HJU8Z/+9^(;66*U6&SATP6P"R[PC;P=H)^8\=R* )-*U.,
M:#:S6D.IWXD9PHD*M*<,<[F)"@#MD],53U/6OMMEID]G)/ 3JL=O/&3M92&(
M9&P<'\R#56UTK6+31M)MI+>Z:")YC=6]I<K%*26)0APZ\<\@,.HZTVWT'4DL
M(8S:LK#6UNRK7'F$1>I8G+']: .AUS49M/M8%ME5KJZG2WAWC*JS?Q$<<  G
M\*?;6EY9OYLVJW%W$$.])8(\Y]5\M5(^AW9J/7M.GU"UMWM&075I<)<PAR0K
M%>JDCH""136O-6O+6:.#3);&<PMLENI(RHDQ\N C-GGKG'X]* 'V^MI+J$5E
M/975I+,C/!YX3$H7&<;6)!&0<'!J/3_$=OJ0FDAM;I+:!I%EN)0JHC(2"/O9
M/3.0".>H.0,?3=*U#^VM)NY;*^C%O'(MS)=WWG$NR8RJ[V &?3'TQ5S3M$NC
MX1OM+N0()KAKD DAL!V8J>/8@T 63K:7FG7$K66I6UJUN\J7.U064#JN&)4X
MY&X"F0:];P0Z;:0PW]W-<V@FA&%9W4 ??8D -SDDD#WR0"Q#JMSH4FG2Z2\,
MHLWB:1IH]COMVC9@DX)_O!<"FZ7I=Y;ZEI$TL.U+?2C;RG<#MDS'QUY^Z>1Q
MQ0!<7Q'9MI7V[RYP?--O]G*?O3*#CR\ XSGWQWSBG1:[$7N8KBTN;2X@A,YA
MF"%GC'\2E6*GD8ZY_.L=M%U!8Y+A( TT&L/>Q1%U'FQD8P#T!()QG'(YQ5B>
MQOM5U"XOY+)[18[&6VABE="\C/@DG:2 . !SZ]* )$\7VCI9RM8Z@D%Z +:5
MH1B5B,A0 2P/7D@+QG..:O6NMPW4=W_HUS'<6C!9K9D#2 D KC:2#D'J#]<5
MF1:3>KI?A>$P8DL7C-P-Z_(!$RGOSR0.,TE[IVKB;Q!-8#RY;D0>0X< N%&'
M /\ "<9 )QS^= &M8ZPEW?2V,MK<6EW'&)?*GV$LA)&X%&88R,=<UHUS&CZ9
M<P^)9+XV=W;VK6?E#[7>>?)NWY[NV!CT./I73T 5M0_X\9/P_F*^/J^P=0_X
M\9/P_F*^/JVH]3CQ?0*Z#0O^/%_^NA_D*Y^N@T+_ (\7_P"NA_D*ZJ7Q'E8G
M^&>B>!O^7_\ [9_^S5U]<AX&_P"7_P#[9_\ LU=?6DMSGI_"@HHHI&@5U.C_
M /(+A_X%_P"A&N6KJ='_ .07#_P+_P!"-88CX3NR_P#BOT_R+U%%%<9ZX444
M4 %%%% #7^XWT-"?<7Z"A_N-]#0GW%^@H =1110 4444 %%%% !1110 4444
M %%%% !1110 4R'_ %0I],A_U0H ?1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !3(_X_P#>-/ID?\?^\: 'T444 %%%% !1110 4444 %%%% !1110
M4444 %,7_6R?A3Z8O^MD_"@!]%%% !1110 4444 %%%% !1110 4444 %%%%
M !3/^6__  '^M/IG_+?_ (#_ %H ?1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!B:]::N\1GTF]=)%',!"X;Z$C@UYQJ6J:E?,(M0
MF=S$QPKJ 5/?M7L5>7R:?>>*/$%[-:J/*\PCS7X4 <#\< 5\_G%"3<?9MWE]
MF[L_D:0?<AT?4M>D,6G:;<28&=J!00HSDDDC@<UV,T^J:?\ 8-+6\6?4KYF+
M3RIE(4498A1C)Y &>I/IQ6)X06XTCQ)+IUW&8WFC( /<CD$'N,9KJ-9T^ZEO
M+#4[ (]U9,_[IVVB5&&&7/8\ C/&16V3TG[/GG)MK2S;LK>0IO4CL;B)=5%L
MOB=;V5=RR6DI@+@CT$:J01CG.?PZU,=>CCO(()[*\@CN)?*AN)54([X) QNW
M#.#C*BJC0W^I^(]-OFT^:SALDF#&X>,ERX &T(S>G.<5DQZ1K$\NFO=VMX]W
M!>K-<W$E]F%E#'F.,.1C!'\*D#UKVB#HEUU9;B6.WL+RXBBE:%IXU39Y@ZK@
ML&Z\9QCWQDUG:?XIE?1+W4M1TZ>&*U:7+)L(8(Y7:!O)W8'/09!P:CGTV\;6
M4N-/T^XT^X:Z#W%PEROV>:,9SNCW99BOJ@(/?C)ADTO4SX7UK1A8.99&G>"4
M2)LEWN6 'S9!Y[@#CK0!H7>K0W-M83R1:G:12WD2P,A1#-NSC<-Q.P]P0#[5
M<_MQ'O)8+>RO+B.&0137$2J41^,CE@QQD9V@X_.J^M:?=7=MI*01;VM[V&64
M;@-JKU/)Y_"H=-BU+1YKRT73GN8IKMYXKA)45 KMDA\G<".>BG/% &SJ%[%I
MVG7%[-_JX(VD;'? SBL;PS?ZB\MS8:S*)+U$CN%(0+^[=>G _A8,,_2I_$NG
MW6K6MMIT 9;>:=3=3*5S'&OS< ]22 .A]ZJRZ)?6GB*PU.&ZN;_*M;7/G&)"
MD1Y!&U5SAOJ>>* *VO\ B,S:-(]E#?1Q-<1QQWJ !'(E4, 0VX#[PR0 ?7D9
MV+[7HK.YF@CL[N[:WC$EP;=5(B4],[F&20"<+D^W2L!],UE?"Z:!'II8P2)_
MI)G0))&L@8%1G=NQV( X//0&U=Z--%K>H7+65_>07A5U^QWY@V$*%(=?,0$'
M&<C)ZB@#4F\0VJ7%K;V\-Q>2W<!N(!;J"'08[L0!P<\D#\< B^([-M*^W>7.
M#YIM_LY3]Z90<>7@'&<^^.^<57M-)EM-=TZ2*V6*SM].>WPLF\(Q9"%!/S'@
M'G':J+:+J"QR7"0!IH-8>]BB+J/-C(Q@'H"03C..1SB@#:M];ADGF@NK>>QF
MAB\YDN=G,?=@49@0._.118ZR+X"0:??16[QF2*:2-2LBCT"L6&1R P!/UK*O
M-)O-?N[J>>V>PC^P2VD2S,C.S28RQV$@*,#OGKTJU:S:T^E?8UT[[)=1VQ07
M$LJ-'Y@7"E0I)()YY P/RH M6^MI+J$5E/975I+,C/!YX3$H7&<;6)!&0<'!
MJ/3_ !';ZD)I(;6Z2V@:19;B4*J(R$@C[V3TSD CGJ#D#'TW2M0_MK2;N6RO
MHQ;QR+<R7=]YQ+LF,JN]@!GTQ],5<T[1+H^$;[2[D"":X:Y )(; =F*GCV(-
M %DZVEYIUQ*UEJ5M:M;O*ESM4%E ZKAB5..1N ID&O6\$.FVD,-_=S7-H)H1
MA6=U 'WV) #<Y)) ]\D L0ZK<Z%)ITNDO#*+-XFD::/8[[=HV8)."?[P7 IN
MEZ7>6^I:1-+#M2WTHV\IW [9,Q\=>?NGD<<4 7%\1V;:5]N\N<'S3;_9RG[T
MR@X\O .,Y]\=\XIT6NQ%[F*XM+FTN((3.89@A9XQ_$I5BIY&.N?SK';1=06.
M2X2 --!K#WL41=1YL9&, ] 2"<9QR.<58GL;[5=0N+^2R>T6.QEMH8I70O(S
MX))VD@#@ <^O2@"1/%]HZ6<K6.H)!>@"VE:$8E8C(4 $L#UY("\9SCFKUKK<
M-U'=_P"C7,=Q:,%FMF0-("0"N-I(.0>H/UQ69%I-ZNE^%X3!B2Q>,W WK\@$
M3*>_/) XS27NG:N)O$$U@/+EN1!Y#AP"X48< _PG&0"<<_G0!K6.L)=WTMC+
M:W%I=QQB7RI]A+(21N!1F&,C'7-:-<QH^F7,/B62^-G=V]JUGY0^UWGGR;M^
M>[M@8]#CZ5T] %;4/^/&3\/YBOCZOL'4/^/&3\/YBOCZMJ/4X\7T"BBBMCB"
MBBB@ HHHH **** /4_AG_P C5HW_ %S;_P!$M7N]>$?#/_D:M&_ZYM_Z):O=
MZC$_$O0Z,L_A2]7^@4445S'HA1110 U_N-]#0GW%^@H?[C?0T)]Q?H* '444
M4 %%%% !1110 4444 %%%% !1110 4444 %,A_U0I],A_P!4* 'T444 %%%%
M !1110 4444 %%%% !1110 4444 %,C_ (_]XT^F1_Q_[QH ?1110 4444 %
M%%% !1110 4444 %%%% !1110 4Q?];)^%/IB_ZV3\* 'T444 %%%% !1110
M 4444 %%%% !1110 4444 %,_P"6_P#P'^M/IG_+?_@/]: 'T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -D3S(V0D@,",CJ*CM;6
M"RMTM[:)8XD& JUG:QJXTZ^TR'( N)]K_P"[C'\V!_"M>LHSA.;2WCI]^HRO
M<65O=2PRRH#)"^^-QP5/U]#Z58HHK112;:ZB"BBBF 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4/^/&3\/YBOG#_ (53
MXU_Z O\ Y-0__%U]'ZA_QXR?A_,5Y'_POK_J6O\ R>_^UUI3<OLG/75-VYW8
MXS_A5/C7_H"_^34/_P 71_PJGQK_ - 7_P FH?\ XNNS_P"%]?\ 4M?^3W_V
MNC_A?7_4M?\ D]_]KK2]3L<_+0_F?]?(XS_A5/C7_H"_^34/_P 71_PJGQK_
M - 7_P FH?\ XNNS_P"%]?\ 4M?^3W_VNC_A?7_4M?\ D]_]KHO4[!RT/YG_
M %\CC/\ A5/C7_H"_P#DU#_\71_PJGQK_P! 7_R:A_\ BZ[/_A?7_4M?^3W_
M -KKIO _Q,_X3/6IM._LC['Y=NT_F?:?,SAE7&-@_O=?:DY36MBHTZ$G9-_U
M\CR;_A5/C7_H"_\ DU#_ /%T?\*I\:_] 7_R:A_^+KZ8HJ?:R-?JL.[/)O W
M@S7]'U_3;J_L/)AA1A(WG1M@F-EZ!B>I%>LT45-2HYN[*H4(T(N,>KN%%%%0
M;A1110 U_N-]#0GW%^@H?[C?0T)]Q?H* '4444 %%%% !1110 4444 %%%%
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MZ&N8TK2Y?L-CI5_/K7G6TR,8$MD$.Y6W!A+Y>"O?[^[J.O%;F@6TL&IZ])+
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M-S%%'!*AGL63(:2(.5);)Z\*>.S"KOB)[I=!GBLHI'NK@""/8I.PN=NXXZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4R'_5"GTR'_5"@!]%%% !1110
M4444 %%%% !1110 4444 %%%% !3(_X_]XT^F1_Q_P"\: 'T444 %%%% !11
M10 4444 %%%% !1110 4444 %,7_ %LGX4^F+_K9/PH ?1110 4444 %%%%
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M10 4444 %%%% !1110!6U#_CQD_#^8KYP_X53XU_Z O_ )-0_P#Q=?1^H?\
M'C)^'\Q7.Z#\0-)\0P/-:6]ZBIC(E1 >21V8^AK2GS:\J.?$*GI[1V/$O^%4
M^-?^@+_Y-0__ !='_"J?&O\ T!?_ ":A_P#BZ^@_[?M?^><WY#_&C^W[7_GG
M-^0_QK2]3L<]L-_,?/G_  JGQK_T!?\ R:A_^+H_X53XU_Z O_DU#_\ %U]!
M_P!OVO\ SSF_(?XU=L[R.]B,D88 -M^8?Y]:3E-*[14*=";M&1\W_P#"J?&O
M_0%_\FH?_BZ[GX5>"?$/AOQ1<WFK:?\ 9[=[)HE?SHWRQ="!A6)Z*:]?HJ'4
M;5C:.'C%W04445F= 4444 %%%% !1110 U_N-]#0GW%^@H?[C?0T)]Q?H* '
M4444 %%%% !1110 4444 %%%% !1110 4444 %,A_P!4*?3(?]4* 'T444 %
M%%% !1110 4444 %%%% !1110 4444 %,C_C_P!XT^F1_P ?^\: 'T444 %%
M%% !1110 4444 %%%% !1110 4444 %,7_6R?A3Z8O\ K9/PH ?1110 4444
M %%%% !1110 4444 %%%% !1110 4S_EO_P'^M/IG_+?_@/]: 'T444 %%%%
M '(^(-7\0:+*75;>6T8_++Y9X]FYX/\ .N*N=6NKK5AJ4A47 96&T8 *XQQ^
M%>J:W/';:)>2RJK*L3?*PR"3P!^>*\IBTJ^FT^2^CMG:VC.&<#]?<5\MF\*L
M:JC&3:WMVL:PM8ZW1O$'B+6KGRX([98U_P!9*T9VJ/SY/M740:B9-:N-,:/F
MW@CE,N[[VXL,8QQ]WU[UG^#)XYO#<*HJJT;,C[1C)SG/Y$57-A#?>-]1$SW*
M[+*#'D7,D/\ %)UV,,_C7MY?&7L5.4W)RUU(EN;-GJ8N[W4;<Q",64JQERV=
MV4#9Z<=:EL]2L=15VL;VVN@A 8P2J^WZX/%<7=64J:?XJM;/SI +J#<'9YF9
M-D9<')W-\N>,YQP*O6TT<]Y/JL6HV.JF"P=&M=/M2HD7@JK'>XSP0%//)XZU
MW$G2VNIZ??2R16E];7$D?WTBF5ROU /%9^M^(;?3[6=;6ZM)+Z)XPUNT@+*&
M=5)*@Y'#?RK L=0;4?$F@S+>V$_[B8;+*%E$.4!V,V\@XP., \9Q5*>XL/\
MA"(=.GV-JT-TC2P[,RQR><-SL.J@@GYCP=PYYH ]&=UC1G=@JJ,EB< #UJM:
MZG87T3RVE];7$<?WWAE5POU(/%5?$-Y]@T*ZN?LJ7.P#]VXRHY'S,/0=3["N
M<M+HW?B34)?M]I>AM*(,UG$4C.&/&2[!B,GD'C.* .LBU73I[D6T-_:R7!4.
M(DF4L5(R#@'.,$'-5=9UNUTRTNPMW:B_CMWFBMY)!N;"DCY<Y(X[5SL$$4'A
M?P<T42(1<6Q!48Y=#N_/)S4%Y<6,.B>)[#4/+;4)IIY%@9,R2C&8V5>I  '(
MX&T],4 =I%=EM*2\D4;C )65>!]W/%8>F>,$U'PS>ZL;(PSVD9D>U,F3C;N4
M[L=&&.<>M:D7_(L)_P!>8_\ 0*X2^@EL/ EEJ]N"8YM*%I>(!U5E^1_JK''T
M;VH []M6LK>PM[N]N8+1)E4J9I0HR1G )QFIIKZTMK07<]U!%;$ B9Y J8/3
MYCQS7'RRRV>L:?=37ME96[:9''#/>PEX]V<NH.]0K$!>IY XZ&B&*'2)/#\U
MS=I+I<3W!%P8C%%&[',?#$X7!8*<XY&#R* .AN=9 O='2SD@GMKZ5T:53N&%
M1FRI!QU7WK2AN(+@R"&:.0Q.4D",#L8=0<=#[5R/B'&JR:/_ &)>)!)-<S^7
M<Q*-I?RGR0<8()XW#\#FMKPS<6LNC1P6]L+22V/E3VN>8I!UR>^>N[OG/>@!
M(-:N[ZZN186$<UK:SFWDD>XV2%EQNVIM(.,]V&:T;G4;*SFBBNKRW@EF.(TE
ME52YZ< GGJ.E<CKLNFP2W-]HFI-:Z[OP;.)N;F0' #P'DY&<-@<'=DBK2W5I
M9Z]K*ZT8E>[BA$,<BY\Z/9@QH/X_F)^49/(XYH Z9;VT?R=MU"WGDB'$@/F8
MY.WUQCM227UG"L[2W4"+;X\XM( (\C(W>G'K7#Z<\=KHO@V_G=8;2!I%EE<X
M6/<C!<GL,\9-2-K,<6HZO>0)"T,U_;(EU<QDQ0CR@/-/3*\8!R <CG!H [*/
M4[":S:\BO;9[5>#,LJE!_P "SBF#6-,/VC&HV9^S?Z_$Z_NN<?-S\O/K7!WL
MQGT;QE(;F&Y5TA;S8(C'&_RXRH+-GH.02#BNCN;*U7QCH(6WB BLYQ& @ 3&
MP# [8R?SH WUO+5[/[8MS";7;O\ .$@V;?7=TQ[TRVU.PO8))K6^MIXH_OO%
M*K*O&>2#QQ7&,@CLYFD7.GP>('DN5QE5CZY(_NAB">W>M"62+6/$%S-I,L=Q
M#_9LD$\T+!D9R1L7<."1\QZ\9]Z .G^V6ICAD^TP^7.0(6WC$A(R-I[Y'/%1
MG4K 7PL3>VPO#R+<RKYAXS]W.>G-<9;:C:7&E>$K*&827%O<0+.B DPE8V4A
M_P"Z<]CC.#CI5G[7'IVK^187EK?I=:@'ETZ6/_2(6)^9U/4!2 WS+T'#=* .
MHU/48=+LS<3*SY98TC3&Z1V.%49[DFH[2YU1YE6]TZ"&-ER'@NO-VGT8%5_3
M-4O$\,IMK"[CB:9;*]CN)$12S%!D$@#J1NS^%)?:Q::II%[;Z-?Q75X]M(8Q
M;.'*G:<9Q]WGIG'- &I;ZG87<\EO;7UM--%GS(XY59DP<'(!R.:P=,\27EZ=
M"\R* ?;VN%EVJ>/+SC;S[<YS5+1EBO+G1A'J]@SV*$"UM;-DE1=A5DDS(VP9
MQG('('>J>@]?"/\ UTO?_9J .UU/48=+LS<3*SY98TC3&Z1V.%49[DFH[2YU
M1YE6]TZ"&-ER'@NO-VGT8%5_3-4O$\,IMK"[CB:9;*]CN)$12S%!D$@#J1NS
M^%2R>(=,N;*X-C-#J3K \GV>W82%@!G:<9QGISUH NVNIZ??2R16E];7$D?W
MTBF5ROU /%$>J:?+.(([^U>4J6$:S*6(!()QGH""#]#7(:?J!U#Q+H$PO;"<
M>1,"EE"RB$% =C-O8$C XP#QG%0VUJW_  K[43;0,S2WLKSK&,M(@GP_U^0$
M?2@#J[C6;>XTRXN-*U+3)'BVYDDG!B0D_P 14\=\5<N+^SLP3=7=O!A=Y,L@
M7"Y SR>F2!GW%<QXFU'2M0\*Z@=.GM[ADBC!>##!5WC"EAP/]WK[5?N(HY/'
MFG,Z*S1Z?,R$C.T[T&1^!(_&@#:6\M7L_MBW,)M=N_SA(-FWUW=,>]10ZOIM
MQ;27,.H6DL$9Q)*DRLJ'W(.!7',BQV4I=/\ B7VVON]PH7*K'UR1C[H8@GTJ
M#Q;<P:DNIW>FS1SVR::8KF:%@R,_F*47<."0-QZ\9]Z .W&L:8?M&-1LS]F_
MU^)U_=<X^;GY>?6I?M]G]B^V_:X/LFW=Y_F#9CUW=,5@W-E:KXQT$+;Q 16<
MXC 0 )C8!@=L9/YUG17PTO3[TK' $.N2()KA=T5KDY\PC(P,D]QRW44 =C:W
MEK?0":TN8;B(G&^%PZY^HJ:N5\*S&?6M>E^TPW(=X6\VWB,<;_(1E06;/0<@
MD'%=50!6U#_CQD_#^8KQ7X7_ /(,N?\ @/\ Z$]>U:A_QXR?A_,5XK\+_P#D
M&7/_  '_ -">NG#=3S,RVAZ_H=Y11174>:%=%H'_ !XO_P!=3_(5SM=%H'_'
MB_\ UU/\A6-?X#KP/\8U:***XCV@HHHH **** "BBB@ HHHH :_W&^AH3[B_
M04/]QOH:$^XOT% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "F0_P"J
M%/ID/^J% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "F1_Q_P"\:?3(
M_P"/_>- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "F+_K9/PI],7_6
MR?A0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IG_+?_@/]:?3/^6__
M  '^M #Z*** "BBB@"IJ.GQ:G;K;SEO)WAG4<;P.<?3./RJRD:11+'&BJBC
M4#  ]*=14J$5)RMJP*5CI=OIT]P]J-D<Y#&(?=5NY'IGCCVJ[111"$8+EBK(
M HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "@\BBB@"IIFGQ:5IL%C SM
M%"NU2Y!8CWP!5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *VH?\>,GX?S%>1_#G1-6L=.N%N],O;=CMP);=T)Y?U'N
M*]<U#_CQD_#^8KEO^%K>"O\ H-?^2LW_ ,16M*;C>R.7$T85;<SM8=]BNO\
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M%%% !3%_ULGX4^D"@,3ZT +1110 4444 %%%% !1110 4444 %%%% !1110
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MM(+=I;6X^TW+;8K1=AD8]2/O;1@<D[L>] &C15#3M5BU%[B(0S6]Q;L%F@F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW'H*L>(=7>TDTP+=FSL+IR)K]54^7\N4&6!4;CW([?C0!T-%5K!76T3?>_;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXU"[,S*\&EEM.M6!SE0VYC]<;%_X#795'#;PVT?EP0QQ)DMMC4*,DY)P/4T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)*QH"Q [D# [TNEZU8:PLOV.23?"0LL,T+PRQY&1NC<!AD<@D<]J -"BBB@
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MD9QNWXR,9VX_#F@#5HHHH **K:AJ%KI5C)>WLOE6\>-[[2V,D < $]2*P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %5KZPMM2M6MKJ,21MZ]0?4'L:LTR9VCAD=4+LJDA1U)QTJ9J+
MBU)70'CFIVL=CJ=S:Q2&1(I"@8C!.*W_  5H]GJ5Q-/=?O#;E2L)'!SGD^O3
MI6_HGA*&W#W6J(EQ=S9+*PRJ9Z_4^_Y4_3?#[Z'X@,UH2]C<(493UB/4?4<8
MS[U\UA\LJ0JPK3C[K>W;L:N6ECI>E%%%?3F05Q^B:@-)\(:_J3(9!:7VI3E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img40748725_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +& L # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]W+GRX(VE?:,G"C)Q^5<LOQ$TYH!<?V7JZVYY\XVPV >N0U;GB/_ )%C5O\
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M%1%"J!V Z4ZBBN8](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ*YD2*UFDD9E1$9F*]0 .WO4M5[Z%[C3[F&/&^2)D7/J0151MS*XUN,TLEM)
MLB223 A)/?Y15NF1?ZE/N?='W/N_A[4^B3O)L'N%%%%2(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK)U7Q-HNB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U0E=)O2"01
MY!';Y35NF2_ZE_N?=/W_ +OX^U5%VDF-;C+.-(;*WBC8LB1JJL1C( ZU-5>Q
MF>XT^VFDQODB5VQZD U8HE?F=P>X4445(@HHHH **** "BBB@ HHHH ****
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M)459HDFI.X/<****D04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5M1C>73+N.-2SO"ZJ!W)4U9J*YD2*UFDD9E1$9F*]0 .WO50;4E8:W%@01P
M1H$$850 @.=O'2I*J:62VDV1)))@0DGO\HJW1)6DT#W"BBBI$%%%% !1110
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M]*W945?QR3_A4]10#/F/_><G\N/Z5+W0$M%%%4 4444 %%%% !1110 4444
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MK<SL#W"BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(;*WBC8LB1JJL1C( ZU-1*W,[ ]PHHHJ1!1110 4444 %%%% !1110 4444
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MI'ETRTDD8L[PHS$]R5%6:C@01P1H$$850 @.=O'2I*).\FT#W"BBBI$%%%%
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M444 %%%% !1110 4444 %%%% !1110 4444 5B9"^)0N,\ GBIOWO]U/S/\
MA3R 1@C(IJIM/!.WT- "9E]$_,_X49E]$_,_X4^B@!F9?1/S/^%&9?1/S/\
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M[VO\+_-#Z&O11178(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M]],]OI]S-'C?'$SKGU )JQ45S&DMK-'(K,CHRL%ZD$=O>JC;F5QK<98PO;Z?
M;0R8WQQ*C8]0 *L5#9R)-96\L:E4>-652<X!'2IJ)7YG<'N%%%%2(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?L]UJ?B
M/58?[3O+>*W\G8D+X'S)D_RJU_PCT_\ T'=3_P"_@_PHTO\ Y&K7_P#MW_\
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M=6MND$.N7:1H,*JJN!70T4OJ5&][:^K_ ,PYF8?]AW__ $'[W_OE:/[#O_\
MH/WO_?*UN44_JE+S^]_YA=F'_8=__P!!^]_[Y6C^P[__ *#][_WRM;E%'U2E
MY_>_\PNS#_L._P#^@_>_]\K1_8=__P!!^]_[Y6MRBCZI2\_O?^879A_V'?\
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MOS.X/<****D04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD U8HE?F=P>X4445(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 56U&-Y=,NXXU+.\+JH'<E35FHKF1(K6:21F5$1F8KU
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M1110!Y]X[L)-/U&#Q';QEHE3R+U5'.S/#_@?Z50C=)462-@R,,JP.017I5S
MEQ"\;J&5@05(R"/2O+=5T6\\)W#S6D<ESH[$LT*\O;^I7U7_ #[UU4Y*:Y7N
MOQ*MS*W4NBI!52TN[>]@$UM*LD9[J>GU]*M"FTUN02K4@ (P1D&HUJ1:0Q+>
MTM[5-EO!%"A.2L:!1G\*8FDZ>H&+"U #[Q^Y7AO7IU]ZLK4JT[L=V.5 P(8
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M( !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!S^K_Z!:ZE'TM[NWE9/19=A)'_ AS]0?6KMM_I]
M]]H/-O;9CB]&?HS?A]T?\"JUJ%C#J5C+:3CY)!C(Z@]B*EMX([:WC@B7;'&H
M51[5RJC)56_L_P##_AU'?0DHHHKJ$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5'.@D@D0H) RD%"<;N.E254U0E=)O2"0
M1 Y!';Y3515Y)#6Y)92^?86\VT)YD2MM'09 .*GJ&SC2&RMXHV+(D:JK$8R
M.M342MS.P/<****D04444 %%%% !1110 4444 %%%% !1110 4444 %%%(S*
MBEF(50,DDX % "TA( ))  ZDUQ>I^/5DG>S\.6HU&=3A[ACMMXS_ +W\7T'Y
MU@7.GWNKG?X@U2:['7[-$?+A'X#K]36\:#WF[?F5RV^+0[34?&WAW3&,<VI1
M23=/*M\RL3Z87.#]:R'\?W4__(.\-7TH/1KEU@!]^<UF6MG96"[;2UBA]T4
MGZGJ:L>836BC372_K_P O%;(5_$?C"YYBMM)LU])&>1OTXJ,ZEXQD/.JZ?%G
M_GG:YQ],FI 2:<,T[I;17W!S^10M!XGL8V2VUNT1"Y<K]B7!)ZU;&J>,T'%]
MI4O^_ P_D:F&:> :2Y4K**MZ(?.QB>*_%-M_Q\Z)978[FUN3'^C@U9C^(MK
M<:KI>HZ>.\KQ;XQ_P)?\*C%+SBAJ#WB',NJ.ETWQ!I.KJ#87]O.<9VHXW#ZK
MU%:((->;7GAS2;X[Y;-$EZB6+Y&!]<C^M$$_B70B#97G]K6@ZV]XV)0/]F3O
M^-2Z,7\+^_\ S#E3V9Z517-Z#XQT_6G-O\]K?)_K+2<;77Z>H^E=&K!AQ6$H
MN+M)$M-:,6BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%17-S!9V[W%S-'#"@RTDC!5 ]R: ):*\S\0_%RSM=T&AP?:Y1QY\H*Q
MCZ#JWZ5YSJWC/Q!K6Y;O4IA$?^641\M,>A Z_CFMHT)/?0XZF-IPT6I] 7OB
M#1].R+S5+2%A_"\RAORSFL&?XG>%8&*B_>4C_GG Y_4@5\_T5JL/'JSDEF$W
MLD>ZO\6_#2M@"]8>HA']33H_BQX9?&Y[N/G'S0_X$UX113]A GZ_5\CZ(M/B
M'X6O&"IJL<;>DRM'^K "M^UU"SO4WVMU#.G]Z*0,/TKY8J2&>:VE66"5XI%Z
M/&Q4C\14O#KHS2.8R^TCZLR**\!TCXF>(=,95GG6^A'5)Q\V/]X<Y^N:]-\/
M?$71M<*0M+]DNVX\F8XR?]ENA_G[5C*E*)V4L73J:7LSL:*:KAAP:=69TA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]2_W/NG[_W?
MQ]J?535 6TF] !),#@ =_E-5%7DD-;C[&9[C3[::3&^2)7;'J0#5BHK:-(K6
M&.-65$154-U  [^]2T2MS.P/<****D04444 %%%% !1110 4444 %%%% !11
M10 4444 1W%Q#:6\EQ<2+'#&I9W8X"@=Z\SU'5+SQG*26EM= !^2(':]U_M-
MZ+[5H>-KUM6UJ#PY&Q%K$HN;['\7/R1_U/X>E5W<* J@!0, #M753CR)2ZO\
M"K\J\PC6*VA6&"-8XU&%51@"C<2:8.:<*"!P%/ I *D44 <_I/BE-1U5K)[0
MPY+K')YFX,5ZC&!CCFGZQXI32=12T6T,Y^7S'$FT)NZ#H<GO7,P1O#H\NJ1#
M,EEJ3/\ 53M!'\J6]5[C1?[6E&'OM05ESU"*&"C^==WL8<U[:;?,ZO9QYO(Z
MN\UZ[BUI],LM+^URI$)"?M CX_$>X[U+<:[<V2Z<+O3O*FO)_),?GAO+YP#D
M#!^E85_';R^.+A;G4I;!/LJD2QSB(D\<9/\ +VJ7Q!'%-#H$-M?O.ANQ&+D2
MAVSD<[NA(K-4X^ZK;^O82A'30Z&SUG[?K-S96UN7M[88DN=_&_\ N@8Y_/M6
MN%]JYCPA.+07&@W")'>6CEOE_P"6JGG=^H_#%=:JUC5BHRLC.:L[(BV>U(4J
MP$H*5F28NJ:-;:HBF0-'/&<Q7$1VO&?4'^E3^'O$UY9WZZ+KC W&/]'NAPMP
MO]&]O\G1:.LC6])75+!H<[)D.^&4=4<="*I6DN66WY#3Z,] BE$B@@U)7&>#
MM?DU'3D^T?+<QL8IE]'7@_X_C79*VY<URRBXMQ9+5G9BT445(@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***1F"J68@*!DD]J ,KQ#XAL?#6EO?7K\
M?=CC7[TC>@_SQ7@?B;Q;J?BB[,EW(4MU.8K9#\B?XGW-2^-?$TGB;7Y9P[?8
MX28[9.P7U^IZ_D.U<Y7;2I**N]SQ<5B74?+'8****V.,**** "BBB@ HHHH
M**** .U\)_$6]T.XCMM2E>YTYCM+-\SP^X/<>WY>A]QLKZ&]MTFAD62-U#*R
MG((/<5\KR#=&P]J]!^%?BF2"5M%N'S'@R0$GI_>7^OYURUJ:^)'HX/$N_LY_
M(]QHJ*"42Q@BI:YCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO]5O]3 .RZN#Y9(ZHO"FO4]-!%NN?2HQ'\1_+\@G\1>HHHK$@**** "BBB@
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MO-@ )K<KE?#>?+%=4.E<!]&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M["XAW!/,B9=QZ#((S51MS*XUN1Z6"NDV0(((@0$'M\HJW4<#B2"-PXD#*"'
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M6=1DB<%71[IR&!Z@@GFGRRT\B%."4DEN=9:_\4Y\*KFX;Y;O6Y?*3'41#/\
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M** *U[:17EK)!-&LD<BE61AD,#U!%>"^,_AW=Z%<27FEH\UCRQ0<O#_BOO\
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M%%6:)*TFD#W"BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#>1
MI-97$4C%4>-E9@,X!'6IJKWTSV^GW,T>-\<3.N?4 FJC?F5AK<?;2)+:PR1L
MS(Z*RENI!'?WJ6J]C"]OI]M#)C?'$J-CU  JQ1*W,[ ]PHHHJ1!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCMI$5P+@$IN XQZ\UE2>,-/CD:,PW.5)!PJ]O^!4444J492::",4V:_VV/\
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MD/*\RAU&0HQ[GGG\***JG1@ZZ@UH.,$YV&Z;X@:_@EN&M!'#$0&Q+N;)Z8&
M/UIFJ^)5TN<6[6IDFQEL/A0#TP<9/Y445T?5J7UCDMH:>SC[2UBQI^LO?6BW
M+6RQI(_EH!+N.[WX&!^=4M0\6)8W;6RV;2/'PY,FT9]N#D?E111##4G7<&M
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( ((<JY;G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img40748725_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G!-D# 2(  A$! Q$!_\0
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MH;EBL1(]*=;G=;1-ZH#^E $E%%% !1110 4444 %%%% !1110 4444 %%%%
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MII;O3;""*[C,3+Y;;=N,D8/*GH36;\>RH^&%P&LWGS<Q8D4X$!R?G/J/X?\
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MG=)E<D\]B!CM6GXB^&VC>)O%VF>);VXODO=/$0B2&1!&WER&1=P*D]2>A'%
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MWX7"@CG Y)XKY[\+?\(-JFJ:U=?$6YNK'49+@NL4,#HBDDEQM120<]B!^)H
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MTEO;I&TASGYB ">2>M3WUA9ZG:/:7]I!=VSXWPW$8D1L'(RI&#S5BB@#.N-
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M#XR."1UJ_10!2M='TNQO;B]M--L[>[N3F>>*!4>7G/S,!EN?6KM%% !1110
M4444 %%%% !1110!1TW_ (]E^E7JHZ;_ ,>R_2KU %>\_P!0WTI]K_QYP_\
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M\1]SDT >M0_$[P7<:Z-%A\06SWS/Y:J VQF]!)C83VX/7BM_5M8T[0M/DO\
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M?:)J,=W;K=*"R9!1O.3@J<%3]0*['Q'I.AW'QRT*]N?%,UMJL<2&'2UMG;S
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MQFMWN[)6X5F +1*OU#,OU6@#VW2O%VA:WK-_I&G7XGOM/)6YB$;CRR#@_,0
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MU/QO\1["Y7=!<R20R#U5I9 ?YT >TZ)KVF>(](CU72;M;FRDW;90I7H<'(8
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M26,W<UZDD"9^;"JVYA[<XS[BN7^(]M<6G[.O@^&Z!69;BW)5A@@&&4@'\"*
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MLOTJ]0!7O/\ 4-]*?:_\></_ %S7^5,O/]0WTI]K_P ></\ US7^5 $M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QW@?X;:-X DOWTFXOI3>A
M!(+J1&V[-V-NU5_O'KFNQHH Y#3_ (<:/IWCRZ\80W%\VH7._?&\B&(;@ <#
M;GMZT:W\.-'U[QIIOBJZN+Y+[3_+\J.*1!$VQRXW J3U/8BNOHH Y;QG\/\
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M!%.MPK6K*K;@K*!\RD8PQ[5TE% %+1]+@T31;'2K9I&@LX$@C:0@L54  D@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H NCI10.E% !5&3_D(P?4_P#H)J]5&3_D
M(P?4_P#H)H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 4=-_P"/9?I5ZJ.F_P#'LOTJ]0!7O/\
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MHHH **BC5VC5C*V2 >@_PIVQO^>K_D/\* 'T4S8W_/5_R'^%&QO^>K_D/\*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !WJ6Q$UE:27UY%;1#+2-CZ#N:]S\,60B$4:#"1J%7Z#BN*\)^'6LU\^=?\
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MWI:LS]'T7;AG6NKAB$:  4L<2QK@"I*R.P**** "BBB@!D7^J6GTR+_5+3Z
M"BBB@ HIJN&)'0CL:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5*7_D)C_KF/YFKM4I?^0F/^N8
M_F: +HZ44#I10 51D_Y",'U/_H)J]5&3_D(P?4_^@F@"]1110 4444 %%%%
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MFQ_WQ1YL?]\4^B@!GFQ_WQ1YL?\ ?%/HH 9#_J8_]T?RI]%% !1110 4444
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MU2E_Y"8_ZYC^9H NCI10.E% !5&3_D(P?4_^@FKU49/^0C!]3_Z": +U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M8;Z.:_N;/:R30!6(8?>5APP]LAA]5-9^B3Q6NB75Q.X2**\O7=VZ*!<2DFI-
M:AD@,.K6R%I[/.]%ZRPG[Z^YX##W4#O6'HLL>NQ+9P.)+&.]N;JY=>0^;F0Q
MI^/WC[ =FK913A?I_P .6EI<ZVUG-S:0SF*2+S$#^7(,,N1G!]ZEHHK$@***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
MCIO_ ![+]*O51TW_ (]E^E7J *]Y_J&^E/M?^/.'_KFO\J9>?ZAOI3[7_CSA
M_P"N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"O?V-OJ=A/97<8D@F0HZGN/\:EBBC@A2&) D<:A451PH'
MI]%.[M8 HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB]D@']<U'_PM#Q7_ ,_T?_@.G^%5]7D9?7Z7F>_T5X+#\5?%$?WYK:7_ 'X
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MVCB1<?B!FM%0D<TL?26UV?0]%?-;>,O$C$DZW?<^DQ%)_P )AXC_ .@W?_\
M?YJKZN^Y']H0[,^E:*^=8?B%XJ@(*ZO*WLZ(W\Q6S9_%W7X"!<PV=RO?*%&_
M,''Z4G0D5''TGO='N-%>;:7\8-+N"$U&SGLR?XT/FI^. #^AKM],\0:5K";K
M"^@GXR51_F'U'4?C64H2CNCIA6IU/A9I44@(-+4FH4444 %%%% !1110 444
M4 %%%% !1110 4444 %4I?\ D)C_ *YC^9J[5*7_ )"8_P"N8_F: +HZ44#I
M10 51D_Y",'U/_H)J]5&3_D(P?4_^@F@"]1110 4444 %%%% !1110 4444
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M_P#A8?B#_G[D_P"_C?XURE%:?V?A^J;]7)_J8O&5W]K\CJQ\0]?# _:Y./\
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M;_Q[+]*O4 5[S_4-]*?:_P#'G#_US7^5,O/]0WTI]K_QYP_]<U_E0!+1110
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MU+,Q]@.M/N[&[T^;R;VUGMI<;MDT91L>N#79?#6WCM[S4O$%PO[C3+9F!/\
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M:RRLP0>@!/'0=*EP<K7+C55-/DOJ>E^)/"9U3XA:7<0%YK'4MLSLS%@%7!8
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M\WDX$C1/PP1?D&!UVY!/XFM&N>UW1;F>.SU#37!U:QQY;.<><O\ $C'T//\
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M>\_U#?2GVO\ QYP_]<U_E3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1110
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MJ]0!7O/]0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+1110 4444
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M HHHH *R?#O_ "#)O^O^\_\ 2F2GB[FM=>-K<ONM[M=UJQ&-KJ/FC_$#</\
M@7H*S[*^.G^'YWC027$FH7<5O$3C?(US+@?3N3V )[5HHOEMWM^I5M#HZ*BM
M8Y8;2&.>8S2J@#RD ;VQR<#I4M9DA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #9(TEC:.10R,"K*>A![5#!):QR&R@,:M"HS$O&Q3TXJQ
M61+:3)XJM[R*,F&2V:*9AT&#E<UE5DXM22OJE\F-&O1116H@HHHH **** "B
MBB@ I",J0?2EI&SM..N.* ([6-(;2&.-65$C555NH '&?>I:AM%F2R@6X.Z8
M1J)#G.6QS^M35,/A0!1115 %%%% !1110 4444 %%%% !1110 4444 4=-_X
M]E^E7JHZ;_Q[+]*O4 5[S_4-]*?:_P#'G#_US7^5,O/]0WTI]K_QYP_]<U_E
M0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &+XIT5]<T.>WMY!%=['$,AZ992I4^Q!(/USVJ]IEC_ &?8K$S^9,Q,
MDTN/]9(W+-^?0=A@=JN457.^7EZ#N[6"BBBI$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !5>]>TAMS<WGEB* ^9OD&0A'<>AYJQ574[07^E7=H1_KX7
MC_,$4UN3*]G8L1NLL:R(P9& 92.X-.K+\.)=1>'-/BO8FBN(X5C=&ZC;P/T
MK4H:L[!!\T4PHHHI%!1110 C %&!Z$57TZ&.WTRT@B<O''"B(Y&"P"@ U8;(
M4XZXXJ"P>>33K5[I=MPT2&5<8P^!D?GFGT)^T6****104444 %%%% !1110
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MF;^"Y&T9_P![I^M92I2CT.JGBJ4]F=C13$D1U#*P(/((I]9G0%%%% !1110
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M VS&-3(,8PV.?UJ:IA;E5@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH
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MM'^ W9^1Z/16-I&M1:A&01LF3B2,GE3_ (>]; ((R*YFFG9D"T444@"BBB@
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M_P"^:Y'7?%KZS::-#':FVDTR,(L@EW;R N#C Q]WWJQXP\<S>++>S@:S%K'
M2S 2[][$ 9Z#&.?SK!0>AW2KP:;ZK;[K,[/Q'_R/G@W_ '(__0JQO'G_  BG
M_"2ZE]L_MK^T]H_U/E>3NV#;U^;'3/XUD:EXY.H:]HVIC3O+_LT*/+\[=YF#
MGKM&/UJ;4O&'AW5[^6^OO!_FW,N-[_VG(N<# X"@=!0HM6%.K"2DDUOUOV.C
M\$OI\?PSNGU52UB+]?-';&Z/K[9QGVS6+\5K?45\0Q7-Q)YMA+&/LA0?*H'5
M?KGG/?(_#$M?%0MO!5[X=%ED7,OF>?YOW>5.-N.?N^O>IF\9-<^#?^$>U"Q%
MUY>/LUR9=K18Z<8.<<CJ..*:BU+F)E5A*GR7Z?CV.6HHHK8Y HHHH ?HFK3:
M%K4-["3^[;#J#]Y.X_S[5]*:+J27EM&Z.&5E!4CN#7RU(<R,?>O;?AQ?O)H-
MD'8DA2GX!B!^@KDKKJ>CEU1W</F>HT4R-MR T^N<]4**** "BBB@ HHHH **
M** .:_YJ=_W!O_:U=+59+^U?4)+!90;J.,2-'@\*> <]*LU4G>QG3BE>SOJ%
M%%%2:!1110 A.%)SCWJ.UD66TAD642JZ*PD P'!'7\:D8 J0>A%0V44<%A;P
MQ*Z1QQ*J*_W@   #[T^@M;D]%%%(84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 52E_P"0F/\ KF/YFKM4I?\ D)C_ *YC^9H NCI10.E%
M !5&3_D(P?4_^@FKU49/^0C!]3_Z": +U%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Y?J%_P#\);KKW3'=H]A(4M8_X9I!UD/J/3_]==AXVU"7
M3O"5]);G%Q*H@BQUW.=O'T!)_"N0M;9-/T^"TC^[$@7ZGN?Q-=-%<L7/KM_F
M4GRQN3O)DTT4T4\4S,<*>!30*D44#//=:LVNO$&LO'GS;>)9D([8VY_3-;FK
MZP;SPI:_9S_I&HE80H]2<-_A^-265G,?&FIRRV\GV:6 *'9#M;A> >A[UF>'
M]"OHO$BQ744WV*Q:1X6=2%8DX&#W['\*[KQ:5_LI/\#JNFE?H6?#-JEGK>N6
MT?W(D5!^&:SO"]_X<MM+9-62V-P921YEL9#MP,<[3[UOZ/9W,?B37I'MY4CE
M_P!6[(0'Z]#WJCX6O[C0]+>UNM$U=W,I?,5J2,$#U(]*&[J7RZ^0V[W^0_Q>
MT-IJGAYU4)!%)N"HO104Z >W:IO#L)\2ZM+K]X5,<+^7:P;L^7CN1Z\_GSZ5
M+XA@N=0U7PY=065R8Q*'D!B.8@60_/CIW_*D33KSPSXJ$UC:S3:7?'$J0H6\
MH^N!T )S]"14IKV:2WL_S$O@MU.PVTNVI0E.V5QG.5RM,*5;V4QHZ ,N[2:V
M=;^T'[^+[RC_ ):+W7_#W_&NKTG4H[VVCE1MRNH8'U!K%,>5Z5G:%.;'4;JR
MS\J2;T'HK<_SW5-17C?L/H>@57O+VVL(#/=3)%&.['K[#UJ2%]\8-9.N>&[7
M6U#N[Q7"C"2 Y ]B.G\JXJ[J1@W25Y>8E;J0?:M5UWBR5M/L3_R\2#][(/\
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M@YW8'6IZ@LI#-86\K1B,O$K% ,;<CI4]3"W*K %%%%4 4444 %%%% !1110
M4444 %%%% !1110!1TW_ (]E^E7JHZ;_ ,>R_2KU %>\_P!0WTI]K_QYP_\
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M^/9?I5Z@"O>?ZAOI3[7_ (\X?^N:_P J9>?ZAOI3[7_CSA_ZYK_*@"6BBB@
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M_7,?S-7:I2_\A,?]<Q_,T 71THH'2B@ JC)_R$8/J?\ T$U>JC)_R$8/J?\
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M-9ZY=@+=:W>L/2#$.?\ OD5-X+>7YA9=SN;S5+#3(Q)?7D-NIZ>8X!/T'?\
M"N>N?']NX*Z187-\W:5QY47YMS^E9-KX3A64R_9]\I.3)*2[$_4UT%KX=9L%
MA4.K!;*_K_7ZAS16QR]TNK>('!U:ZWQ9R+2 %(A]>[?C6[IF@D[0$"J.  ,
M5T]IH4<6"5%:\5LD0P *RG4E/<ER;W*5AIB6ZCY>:TP !@4O2BH)"BBB@ HH
MHH **** "BBB@ HHHH K7]A#J5HUM/N"$@@HV"".A%5M*BU.V:2VOI$N(4 \
MFXSAV'HP]1ZUI45FZ47-5.OY^H[A16'I\]WI^J-I=Z\D\<NZ2UN&Y)'4JWN*
MW**515%>UFMUV!H****T$%%%% !1110 4444 %!Z&BD894@^E #8?]1']S[H
M^Y]WIV]J?4%E&D-A;Q1L71(E56(QD <&IZF/PH HHHJ@"BBB@ HHHH ****
M"BBB@ HHHH **** *.F_\>R_2KU4=-_X]E^E7J *]Y_J&^E/M?\ CSA_ZYK_
M "IEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I,"EHH R/%*C_A$=:X_Y<)__ $6U:NQ?2L77
M;N&^\#:K=6[[XI-/G*G&/^6;<$'D'L1VK6NKN&SC5YWVAW6-< DEF.  ![FK
M:?*EYO\ 0JVA+M'I1@4M%02%%%% !1110 4444 %%%% !1110 4444 %%%%
M$<\R6\$D\K;8XU+L?0 9-5]*U!-5TNWOXXI(DG7<J2 !@/PJ'7].GU;1;BPM
MYU@><!2Y&?ER,C\1D5>@@CMK>*")=L<2!$'H ,"JTMYD7ES^5B2BBBI+"BBB
M@ HHHH 0C*D8S[5':QK%:0QK$(E1%41@Y" #I^%2,,HPSC(ZU7TZ%K?3+2%I
M1*T<*(9 <AR% S^-/H+J6:***0PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JE+_R$Q_US'\S5VJ4O_(3'_7,?S- %T=**!THH *HR?\
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M2",C@\U+4"*R6<2=%%3+&J]!3Z* "BBB@ HHHH **** "BBB@ HHHH ****
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M9!'Z'\J=9S1SP,\4CR*)9$+..05=E(^@(('L*L4]"5=J]R$7,3JI1U8O&9$
M/WEXY^G(_.H]-G-SI=I.8Q&984<HO1<J#@?2K5% [.]PHHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J4O_(3'_7,?S-7:I2_\A,?
M]<Q_,T 71THH'2B@ JC)_P A&#ZG_P!!-7JHR?\ (1@^I_\ 030!>HHHH IR
M:1ILVH)?RZ=:/>IC;<-"ID7'3#8R*IV*^&[G5[BXT\:5+J:$B>2W\MIE['<1
M\PZ8YK8KP[0MV@:HGBF,$0'6;BPOB/\ GFY!4GV!S^E95)<C6AZ&$H/$0G[S
M32LO/?3\#V.VT72K-YGM=,LX'G!$S10*ID!ZAL#G\:I:=;^%YX;S3],AT>2+
M.+JVMEB*YZ?.J_0]?2H?&NLR:+X8N)K;)O9\6UHJ]3*_"X]QR?PKE/A]HZ:!
MXWU[3$(/D6EJ';^\Y3+'\231*24U%(*5&4Z$ZTI.ZV\[-+\+JQU-S/X+LH'T
M>ZET""%'W/92M"JJW7)0\ _A5B&'PMK6G+%!%H]]8VGW418I8X>.P&0O%<3I
MO_",_P#"=^+?^$A_LC=]HB\G^T/+SC:<[=_X9Q7:VT.AIH%[+H,>G+;21ON:
MP5 C,%/4IP32C+F[%5Z?LK).5W9WZ7:3_4L"PT+6HK:\%IIU]'&,6\PC24*
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MK&].FG!R:OJ<MI/@[7M<M&NM.L/.A5S&6\U%^8=1\S#UJOK'AK6- \LZG8O
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MJ[,8Y K ]%.U3@>V"#^)J:ICM]X!1115 %%%% !1110 4444 %%%% !1110
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M?4_^@FKU49/^0C!]3_Z": +U%%% !1110 4444 %%%% !1110 4444 %%%%
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M?:_\></_ %S7^5,O/]0WTI]K_P ></\ US7^5 $M%%% !1110 4444 %%%%
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M$GE/_=DX_7I6F"" 0<@]"*S::W.J,E)73"BBBD4%%%% !1110 4444 %%%%
M!1110 4444 06\J23W2HK!HY0KDG@G8IX]L$?K4],C&'E.U!ELY7J>!R??\
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MG)HNIP];5F]T.?Y5WE%-59&<L%2>QYPXDB;$L3I[,M(&1NN#WKT9T212KJK
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MN9FY6%/[S?X5+H-[-J&D17%P5,I+*648#88C/Z57*[7)YE>QI4445)04444
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MU2E_Y"8_ZYC^9H NCI10.E% !5&3_D(P?4_^@FKU49/^0C!]3_Z": +U%%%
M!1110 4444 %%%% !1110 5%/<1VZ;I&P/3N:BNKU8/E3#/Z=A6-*SROOD;<
M?>J4;F52JH[#KS4)KK*J3''Z#J:SR /K4SL!QWJW:Z/)<8>X)C3^Z.IK72*.
M-J=5F6D<MP_EP1EV]!6Q:>'D!#WC[V_N*>/SK8A@BMX_+B0(OH*DK-S;V.FG
MAHQU>HR.*.%-D:*B^BC%/HHJ#H"BBB@ HHHH **** *.J7S:;;)=&,-;I(/M
M#9YCC/!?\#@GVS5>XY\6Z<1_SX77_HRWK4=%DC9'4,C AE(R"#VKAIKB]TWQ
M'9Z+"':Z6TN(;*9AD>6[PE68^J!'SZ[!_>K6G'FVWU_(N*N=;9W[7M[>)&@^
MS6["(2Y^_(/O@>PX&?7([5>J"RLXK"RBM8 ?+B7:"3DGU)/<D\D^IJ>LY6OH
M2_(****0@HHHH **** "BBB@ I&564JP!!Z@BEHH R+W0+><F2 ^3)R>.A/]
M/PK#N+2XL7VS)\O0..AKLZ:Z+(A1U#*PP0>]7&;1SU,/">JT9Q@ :M*RU.:U
MPCYDB]#U%6+S0P-TEH<'J8ST/TK,PR.8Y%*L#@@UI=21S<LZ3.I@N(KA-\;
MCT[BI:YF%WA??$Q!]N];5I?). KX63T]?I64HV.NG54M]RY1114FP4444 %%
M%% !1110!G6&EFSN99&F,D8^6W0C_4H<$J/Q_0"M&BBHA",%:(!1115@%1SS
M);P232'"1J78^P&34E,EB6:%XG&4=2K#U!H PK;Q5"YB-[:3V4,X!AFEY1@>
MF2.E6]=O9K;3D-I(%EGE2)),9V[CUKFX+JX@ADT>XVR+:$Q%)%!#IG*DCZ8_
M*HWMIUBB73I&>"*99OL,C9(*G/[MC_(_K35KZDRO;0WUO[S1KI8-5E$]I*<1
MW@7;M/\ =<#I]?\ (W<@C.1CUK-L]1T_7K22( -QMFMY1AT]B/ZUCZIOT723
MI-O=M++=.4@##YH8OXLGN ,\^_M3=F"NO0KQ:HMUKTNJ;!)#'F"V!_NC[SCW
M)Z5-;:G#H-WJEJP++(ZW%I&O63S/X1^-9ZK%;PJBX2-!@9/05:=HX[S1M3=0
MWDRFTD)YP&SL/MC)I+S!WZ&[H^FRP-)?WQ#ZA<<N>T:]D%1^&OFL[R;_ )[7
MDK_KC^E;).%)QG Z5BZ$R:9X;MVOW6W/S,_FG;@EB>_M57NF*UFD;=%<]/XI
M20$:9:277;SF_=Q#_@1Z_05FWEQ>3:=->ZAJSHBG:EM8J4WN>B[CR?>H*N=G
M15'1H;J#1[6.]D9[D)\Y8Y.>N"?;I^%7J!A1110 4444 4=-_P"/9?I5ZJ.F
M_P#'LOTJ]0!7O/\ 4-]*?:_\></_ %S7^5,O/]0WTI]K_P ></\ US7^5 $M
M%%% !1110 4444 %%%% !4%Q<K",#E_2DFG(&U.OK5!_4]:I(SG.VQ#.[S/N
MD.?0>E5G/. ,D] *M+%).^R,9]3V%:5M8Q6_S$;I/[Q_I5W2,%3<W=F=:Z2\
MV'N"43KM'4UKPPQP($B0*H]!4E%9MMG1"$8[!1112+"BL;Q1J>HZ1HDEWIFG
MF^N%8#R@"<+W; Y./:N ;XH>([50;SPV$!/4I(F1^.:WIX>=17B7&G*2NCUB
MBO,+7XS6;,!>Z//%ZF&4/^A"UU6F>/\ PUJK*D6I)#*W_+.X!C/YG@_@:)X:
MK#>(.E-;HZ6BD!# $$$'D$=Z6L" HHHH 9+%'/"\,R+)&ZE71AD,#U!%/  &
M!P*** "BJ&I:WIFCQ[]0OX+88R!(X#'Z#J?PKC]0^+F@6V5M(;J\;L538I_%
MN?TK2%&I/X45&$I;([^BO([CXS7!.;?1(T7/62<MG\E%2?\ "QO&!Y'ACC_K
MVF_QK;ZG5ZJWS+]C,]8HKR*/XQWT4K+<Z'$=APRK,R%3TYR#6S8_&#19V"WE
MG=VN?X@!(H^N,']*4L'67V0=&:Z'HE%9>E>)-&UL?\2[48)VZ[ V'_[Y.#^E
M:E<[BXNS1FTUN%%%%(04444 %%%8&J^-?#VCDK=:G"91_P LH?WC9]"%SC\<
M548RD[15QI-[&S<6D-TNV5 WH>X_&L2YTN:U.Z/,L?ZBN5O/C+IL;$66EW,X
M'>5UCS^6ZJ2_%+Q!> FQ\-AQ[+))C\@*Z8X6OO8)X5SW1V"8:M"UO)(/E;+Q
M^_45YG/XW\3%C+)X8,:@?,5@E4?K1!\4'B;9>:05/<I+@_D1_6K>%J-;'/\
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M:RH3N+*+:S?\"/3\*J0I!;.7MX%60\F9SOD)]=QZ?ABBJ]G:-;M)^]:0R-D
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M_* .,_6D,TDD2091U8?[)S5=+")+PW(+;SDXSQS5>[LDMHVNK0>5+&-Q"]&
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MQ;XZT^'2+VR0CS)X'B 8_-\RD?='UZFO,_#=EXDUNS?1]($BV;R[YY,E8P2
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MZ_Y*)XB_[:_^C17=>,U9_!FKA5+'[*YP![5=?_>(_(J?\1?(P_A-_P B4/\
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M\H#S5M)%GQW5N%!_'FJ%( K/N1)9WIO$C:2)U"RJHY&.AJ>*U,5W+.968/\
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M?:_\></_ %S7^5,O/]0WTI]K_P ></\ US7^5 $M%%% !1110 4444 %%%%
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M.E% Z44 %49/^0C!]3_Z":O51D_Y",'U/_H)H O4444 %%%% !1110 4444
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M=HXX&7:P88)+>@Y'-:4GAW0YCF71M.<^K6J'^E,E\-:5(L:Q6RVHC!"BU_=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(P?4_P#H)J]5&3_D(P?4_P#H)H O4444 %%%% !1110 4444 %%%% !1110
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MY#D'Y?H>W_ZZV]$1X]#LDD4JXA7((Y'%7Z*IRNB%&SN%%%%26%%%% !1110
M4444 4=-_P"/9?I5ZJ.F_P#'LOTJ]0!7O/\ 4-]*?:_\></_ %S7^5,O/]0W
MTI]K_P ></\ US7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H
M NCI10.E% !5&3_D(P?4_P#H)J]5&3_D(P?4_P#H)H O4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 4=-_P"/9?I5ZJ.F_P#'LOTJ]0!7O/\ 4-]*?:_\></_ %S7^5,O/]0WTI]K
M_P ></\ US7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H NCI
M10.E% !5&3_D(P?4_P#H)J]5&3_D(P?4_P#H)H O4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYK_8,W]TT?V#-_=- 'I5%>:_V#-_=-']@S?W30!Z517FO]@S?W31_8,W]TT
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M_=%%% !]GC_NBC[/'_=%%% !]GC_ +HH^SQ_W1110 ?9X_[HH^SQ_P!T444
M'V>/^Z*/L\?]T444 'V>/^Z*/L\?]T444 'V>/\ NBGJ@7H*** '4444 %-9
M0W6BB@!GV>/^Z*/L\?\ =%%% !]GC_NBC[/'_=%%% !]GC_NBC[/'_=%%% !
M]GC_ +HH^SQ_W1110 ?9X_[HH^SQ_P!T444 'V>/^Z*/L\?]T444 'V>/^Z*
M/L\?]T444 'V>/\ NBC[/'_=%%% !]GC_NBC[/'_ '1110 ?9X_[HH^SQ_W1
M110 ?9X_[HH^SQ_W1110 ?9X_P"Z*/L\?]T444 'V>/^Z*/L\?\ =%%% !]G
MC_NBC[/'_=%%% !]GC_NBC[/'_=%%% !]GC_ +HH^SQ_W1110 ?9X_[HH^SQ
M_P!T444 'V>/^Z*/L\?]T444 'V>/^Z*/L\?]T444 'V>/\ NBC[/'_=%%%
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)@ '2EHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img40748725_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -^ F0# 2(  A$! Q$!_\0
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MH;EBL1(]*=;G=;1-ZH#^E $E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)D9Q2U5DD(O@G;8#^IH M44#
MI10!7O/]0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0!+1110 4444
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M:3RXV\IY-S8SC" GH* -JBD5@ZAE.5(R".XI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BLO4?$N@Z/.(-3UO3;*9AN$=S=)&Q'KAB
M*T+>XANH$GMYHYH9!E)(V#*P]01P: )**** "BBB@ HHHH ***;)(D4;22,%
M1 69CT '>@!U%8OASQ=H7BV"XFT+4$O([>3RY2$9"K8R.& ./?I6U0 4444
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M,LH!XR5R/T5JB^,GC7PKJ_PTAL=,U2TNKBXDB>&&!@S1JO)W ?<XXP<'GZT
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MTKBWN+EPJ ,59?F/ !4?IBCQ/J>G^+_CWX57P[/%?&RV-<W-N=R85RY^8<$
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MH+;2#P"V,8Z_7.AX1TY/ _[15UX>TF20:9<PMNA+[MJF+S #GKM(P#UP?<T
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MRR1;VP)>;Y2H#L44D<YR2W3\:SM<^%_BVW^(E[XI\':_96!OQB<7"DL@.W<
M"C!@2N><8_6O8** /-]7^'VK:A\7M%\71W=F;*R@6.9'9A*S /D@!2/XAW'>
MH/BS\--2\<SZ7>Z+=VEK>V@>.1[AW3<C8(P54G@Y[?Q&O3Z* .1\ >"T\(^!
MH=!NC#/*^]KMH\E)&?J!D D8P.G:N$MOA;X]\(75U#X%\66EOI=Q(9/(O4R4
M/XQN"<8&X8S@<5[310!S/@G0]>T33+A?$>NMJ]]<3F4R8(6(8 V*#VXSP!UZ
M5+XU\)VOC7PO<Z+=2-#YF'BF49,4@Y5L=_0CN">G6NAHH \?\/> OB?I<FGZ
M;<^,[1=!LY4(2 %IFC4Y"9* @$#&-Y 'J.*M^*OA?KA\92>+?!.N0Z9JEP,3
MQW"YC8X )SM;K@':5/(SFO5:* /+/"?PPUI/%Z>+?&VN1ZKJL*[;>. 'RX^P
M/1>F3\H4#)SS5VR^'^J6WQIO?&;W-F=.GAV)$K-YN?+5>1MQCY3WKT:B@#SR
M?P%J<GQJM_&:W%G_ &=';^4T1=O-W>6R\#;C&2.]1ZW\/]4U+XQ:1XOAN;-=
M/LX522)W;S20'Z +C^(=Q7H]% 'SCK&CZEK?[1VJV^D:J^EZA'$LT%RJ[@&6
M%.".X/(/7Z'I79^%OA9X@;QRGBWQQK=MJ5];@?9X[8';D# )RJA0.2%"]3G/
MKZ!%X0T*'Q5+XFCL NL3)Y;W/FORN OW<[1P!SBMN@#SG2_A_JEC\9M3\8R7
M-FVG74)1(E9O-!*H.1MQCY3W]*Q+[X5^*M"\37^K_#_Q';Z='J#EY[:[3*J2
M<\?(X(R3C*@@'&:]AHH X'PWX>\>:9I^L76K^);;4]8NH EI&P9;:W< X;A1
MUR,X0=*Y2U^!\S?#O5=-U&ZM9_$E]<_:OMN]F174G:"Q7<007R<=6[X%>TT4
M <]X(TS6=%\(V&F:[/;7%[:IY7FV[LRL@^YDL <@8'3M7%^._AIXAU7QQ:>+
MO">KVECJ440C;[4#@$!AN'RL#E3C!&*]5HH \U\9?#&]\7Z'HLTNL"'Q-ID:
MXOU3"2OP3D#!7YAD$=.>.:P)/A7XY\67EI'X\\5VUUI=JX<6]DN#(>X.$0 X
MXW'<1D^M>TT4 ,BBC@A2&)0D<:A54= !P!7SIK&CZEK?[1VJV^D:J^EZA'$L
MT%RJ[@&6%.".X/(/7Z'I7T=6)%X0T*'Q5+XFCL NL3)Y;W/FORN OW<[1P!S
MB@#S_P +?"SQ WCE/%OCC6[;4KZW ^SQVP.W(& 3E5"@<D*%ZG.?74TKX?ZI
M8_&;4_&,MS9G3[J$HD2NWF@E4'(VX_A/>O1Z* .#^)'PY_X39;&]L=0.G:SI
MS;K:X .#R#@XY&" 01TYX.:Q=-\)?%>XU*S.O>-[,6$$R2NEE'AY0I!*DB-#
M@@8.2>O0UZM10!P?Q5\!W7CO0+2WTV>WM]0M+D312SEE7;@AAE02.QZ=J3X5
M> ;GP'H5W#J,\%QJ5Y/YLTL#,R[0,*,L 3W/3O7>T4 >/7WPK\5:%XFO]7^'
M_B.WTZ/4'+SVUVF54DYX^1P1DG&5! .,UUG@OP[XMTW^T+GQ7XD75+F[142&
M)2L4.,Y*\*.<CHHZ5VM% 'G?PE\!:GX"TS4[?5+BSFDNK@2H;5F8!0,<[E'-
M'P]\!:IX2\4>*-3OKBSE@U6X\V!8'8LHWNWS J .&'0FO1** /'=(^%WB_PO
MXYN]0\/^(;*WT2^NUFNHG0F5HPY;9@H1D D;@P/->H>(-"LO$N@WFCZ@A:VN
MH]C;>JGJ&'N#@CZ5I44 >)Z=\,_B9X2233_"OC*Q32F;<JW47S*3UPIC<#\"
M,UI^)_AIXI\0_#BWT*ZU^WU#5AJ'VR6ZNRR(%VL-BX4G SQP!UZ5ZS10!P?C
M+X?OXH^&EMX=$L"ZA:10_9YWR$$B*%/(!."-PZ=ZYC6OA?XM\2>'?"6AZIJ.
MF?9=*)%ZR2R%I5!"KMRG)$8QR1R37L=% '.2_#_P?-;O"?"^C*'4KN2PB##(
MQD';D'WKA_!?PQ\0^'/!_BGPY>7^GRV^IQ.+-HG<['9&0EP5&,C9TST->MT4
M <5\+?!]_P""/!_]DZE/;37!N7F+6S,R88  98 ]O2NUHHH \J\>?"W5?%_C
M^QURUU:+3K>VM1&LL;-Y\<JEV5E &",E?X@>#6;;?";Q;K_BRPU3QYXBM-1M
M=/(,,-NIS)@YP1L55R<9/).,>A'L]% 'F'Q[TZTO/AI-<SR)'-9W$<D!;JS$
M[2H^H8G\*3X#>'_['^'D=[(FV?5)6N#D<[!\J#Z8!;_@5=QXC\+:-XMT]+#7
M+,W5LD@E6/S7CPP! .4(/0FM*TM(+"S@L[6)8K>"-8XHUZ*H& !^ H ^:_"^
MA>(-7^*7C*;PSK@TK4[2YF9&=-T<H:5@5<8/'0]#TZ5Z5\/OAAJ6A>);WQ3X
MHU2+4M<N0R@PY*)NZMD@<XX    X^G:Z1X0T+0M7U#5=-L!!>Z@Q:ZE\UVWD
ML6/!) Y)Z 5MT >(VWPC\;^']0U&S\+^++6QT/4)-TNY3YZ+ST^4\@'&0ZY]
MJU_!_P ,?$/ACP-KVB1ZW!:ZA>W FM+VT9R4 VXW9 (SMP<9X/>O5Z* /%;K
MX6>//%MW9P>-_%=E<Z7:R^8J6D0\QNQ'$:8)'<EL>E='XJ\-?$>3Q#/?>$O%
M=K:64ZH/LEXNY8BJ@';F-QSC/&.M>CT4 <)\-?A[)X'MM0GO=0^W:GJ4BR7,
MBKM0$9.!Z\LQSQUZ"F_%'X?7'CK3K!]/ODL]3T^5I+=Y<[#G&02.1RJG.#TZ
M<UWM% 'AU[\*?B!KNL:1J_B'Q/I]]<V5TC&'YDC2-6#$IMC W''/RCH.3VZO
MQ%\/]4U?XMZ'XL@N;-+"PC198W9O-)!<_* N/XAU(KT:B@#SOX@^ M4\5^*O
M"^JV-Q9QPZ5/YDZSNP9AO1OEPI!.%/7%5?B%\,M4U[Q+9>*?"^JQ:=K=LH0F
M;(1P,X;(!.<$@@@@C X[^G44 >)7/PB\8:IX@T/Q!K7B6UU#4K6ZCDN5?*1I
M$C*0L05,$\-GA0<CW->VT44 %4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H NCI10.
ME% %>\_U#?2GVO\ QYP_]<U_E3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1
M110 4444 %%%% #9&V1L^,[03BN-^''C_P#X6!IE]>_V9]@^RW'D[//\W=\H
M.<[5QUZ5V%Q_Q[2_[A_E7S'\/?'7_"&?#O5TLH_M&MW^H^386ZKN)8HHW%>X
M&1QW) ]: /??'/BL>"_"ESKAL7O?)9%\E7V9W,!DM@X'/H:N>%]<_P"$E\,:
M=K7V22T^V0B7R'.2F?? R.X.!D8KS[7]7\;^$O@Q<:MJNL!_$321/O%O%BW5
MG4>7@+M8@9R2#R3CH#6?XP\>^)-)^#?AGQ!9Z@(]3O7B%Q-Y$9W@HQ/RE<#)
M Z 4 >T45X)XC\6?%O1]%@\932:;:Z1*R$::J*[(C?=,A*[N<C[K9YZ"O0->
MU_Q+J?@+2M8\*+8V\]\D<UQ-?.JI:Q,A);+''!P.A^E '=T5\^V/Q(\8^'/%
M^D6.L^)] \26.H3+#)_9TD;^3E@N<HBD'D'D$'!_#>^('C[Q*GQ!C\(>']3T
MS1"(5D:^U#:%=B,[065@!T XR3WH ]DHKA-'UCQ1X9\%ZQJ/CEK6ZFT\-+#<
M6A4"YCV@CH!@[N/NCZ5Y?'\1?'NL6,OB&W\7>%-,MQN>/1YKB$3,J]L,I;)Q
MW8$^V10!]%UF>(=8'A_P[J&KM;O<"S@:8Q(<%]HSC/;ZUS/@KXCZ=K_@:UU[
M6;NQTN1I6MIO.G$<?FKSA2Y[C!QDX]\9J[XA\763^"-?U/PYK-C=W-C9R2+)
M:S1SB)]I*D@$CMW]* )? /B__A./"T>M?V?)8;Y7C\IGW@[3C*M@9'X=01VK
MIZ\6M_'OB5_V?9_%#:CG64FV+<^1'P/."_=V[>AQTK*F\4_%S4/!,?C"TN+"
MRTRV@#O%Y:-+<JN \I!0@ D,< KQT!X) /?JR?$VMCPYX9U'63;_ &C[' TW
ME;]F_';.#CZX-<0?BH\/P8A\9RVL1OY%\E8.0C3[BF>N=O!;&<XXSWK@M6O_
M (KWWPTO==U6>PN]$U&U)>U\M4F@B;I(-JCCH>68X/(] #VCP-XJ'C3PG::X
M+,V?GLZF'S/,V[6*_>P,],]*Z*O%?!'BR/P5^SS;ZTT(GDCDE2&(G =VE8 $
M^G<_2N<D^(GQ M=*'B1O&'A.>(@2G14GA:95)^[M W9'IO+?C0!]&T5X_P"/
M?B5JL'PKT'Q3X?G%E/?SHLJ[%DQ\K[D^93_$N,X!XK'\1>*/BYIFA1>,W?3;
M32&*.=-2-9'2-C\ID)7/.5!VL#ST'. #WBBO+?$GQ;_LSX8:3XELK2)K_50(
MX896^2-P#O)Z9 ((ZC.1TKA[GXC^.O"T=OJU_P"+/"VOVSR*)=-L[F%Y4!Y/
MW%4\=,@L ?44 ?15%>0?%'XB:SX>F\(WGAZ;=:ZEF62W,:G[0O[LJN2"5R&(
MXQUK"\1^,/BIX#O-.UGQ%/ILVF7DH5[&WC4B+N4+;0P; .#N8<=Z /?*XKXD
M?$$?#W2[*]_LS[>;F?R=GG^5M^4G.=K9Z=*P_BM\0]4\._V1HWAJ-'UC5B/*
MD=0QC4D*N%/&YF/4\#!_#R[XM)\0+/1=,LO&4]C?0-<&6"]M0 0VW!C8!5'0
MY^[^)[ 'T_%()84D P'4, ?>GUY?\2?B'>>$;'1=)T<6JZIJ2 +<7;A8K=.!
MN)) ZGJ>!@YS7'VWQ,\6>$]=TU=>\3^'/$FFWDPBF_LV:-WMQD#=\BJ1USR"
M#@CB@#Z HKQSXA>//%F@_%'2]$\/^7=1W=HNRRD1-LDK%U#%\;@!A3U XJ@O
MC#XB^"_'^C:7XPO+&_L-6E5%^SQJ!'N8+\I"JV5++G.<C\Z /96UC2TU5=+;
M4K-=19=RVAG42D8SD)G..#VJ[7R[JNG>.3\=XK5-9L1XC=6:VNR@\I(_+8@$
M>7C.S(^Z>>_>OH87>H:'X):\UF:.ZU"RL&ENI(QA9)$0EB, <$CT'TH @\0^
M//"_A241:UK,%K,0#Y(#228/0E$!('OBI=+\:^'-:T:ZU;3M6@N+.U0R7#KD
M-$H!)+(1N' /4<XKQWX)>%-.\7C6/%?B2VCU6\DNS$HNU$B [0S,5/!/S #/
M3'%>AZ[X*T'P_P"'_%>JZ18I92W6D3Q2Q0 +$0$8@A1P#],#VH :OQK^'C,%
M'B$9)QS9S@?GLKMK#4+/5;&*]T^ZANK64926%PRM]"*^9/ ^O?#BP^&M]:>)
M;.UN=89Y3&OV$O.5*C;MEVX7G/\ $,5Z;\ -(U/2O EP^HPRP)=79FMXY05.
MS:HW8/0$C],]Z .Q\2?$#POX1O(;37-5%I<31^8B>3)(2N<9^13CD'KZ5T4$
MT5S!'/"ZR12J'1U.0RD9!'X5\Y7FB2?%3Q)X^UI=TD6GVYM].[@NAR-OU"-_
MW\KTGX(>(QKWPYM+>1LW.F,;23/]T<H?IM('_ 30!HZA\7O FEZC<6%YKHCN
M;>0Q2H+69MK X(RJ$'GT-;WAOQ7HGBZREO-"O?M=O%)Y3OY3QX; .,. >A%?
M//AK5?!^E?%CQ?+XQCLWM'N)UA%U9FX7?YW8!6P<9YKWSP7?^%-3T>2Y\(16
MD=@9BK_9;0VZF0 9RI5<G!'.* +/BOQ-9>$/#EUK5^':& #")C<[$X"C/J36
M#\/?'U]XW2XDNO#%YI$"(DEO/*S/'<*V>58HH.,=L]:Y']H.VU]_#*7%M?6Z
M:"A1;JV91YDDI?Y6!V]!_O#Z&J-EJ/CGPG\#[G6+G6K5Q]ELSI/DQ(S6\1*@
MJP,8!.TJ.=W3K0![I17 Q^(]6;X'GQ$;O_B;?V0;G[1Y:?ZS:3NVXV]>V,5S
M$?CKQ&W[/;^*#J/_ !.1)M%SY$?3S]GW=NW[O'2@#V6BO 9O%/Q<U#P3'XPM
M+BPLM,MH [Q>6C2W*K@/*04( )#' *\= >">P/Q5:#X-0>,IK2-KZ4>0L R$
M:?<5SZ[>"V,].,T >G52;6-+355TMM2LUU%EW+:&=1*1C.0F<XX/:O*?#DOQ
MDOFTS7KF]TR33+N2.233C&BR) Y&3]T=%.<;R?8GBN U73O')^.\5JFLV(\1
MNK-;790>4D?EL0"/+QG9D?=//?O0![1X[^(X\$ZQHNG_ -CSWYU.39OCDV[/
MF5>!M.YOFZ<?6NZKQSQWXM\7^%-1\"Z8=5B^TWA6/4GCA1EG8-&I(W)P/F;H
M%ZU?^('CWQ##XPL_!/@V& ZM<QAY;F8!A"#D\ \#"C<20>",#- 'JE%>'3>-
M/B'\.O$FF6WC>YL=5TO4'V?:+= OE\@'!5$Y&0<%3D=#Z7OB%X\\6:#\4=+T
M3P_Y=U'=VB[+*1$VR2L74,7QN &%/4#B@#V.BO#5\8?$7P7X_P!&TOQA>6-_
M8:M*J+]GC4"/<P7Y2%5LJ67.<Y'YU[E0 4444 %%%% !1110 4444 %4I?\
MD)C_ *YC^9J[5*7_ )"8_P"N8_F: +HZ44#I10!7O/\ 4-]*?:_\></_ %S7
M^5,O/]0WTI]K_P ></\ US7^5 $M%%% !1110 4444 %%%% !1110!'<?\>\
MO^X?Y5\I>$O LOBCX<ZQJ>F*RZYI6H>;;M'P\BA%)0$<YXRON/>OK&B@#P+Q
M%XV/CG]GF_NIE(U&TF@@O%"X!<2+AQ[,.?8Y%4/B$#_PSOX-X_CA_P#13U]&
M44 >4_%A2/@/@@Y$-GD>GS)7$_$*SU*X^#7@6:&.YETF"WC:_2#/'R+M8\'
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MY\.-#T[5_C)XUAU;2[6]BCEF94N[=9 K&?J P.#C->\:=I6G:/;&VTRPM;*
ML7,5M"L:ECWPH SP*MT4 >9_'K_DE=Y_U\0_^AU!K>C7NM_LZ6MA8PM+=?V5
M:R+$!\S; C$ >N <#N>*]3HH ^;;#XD3W_PFD\%V'A^_N-6ALGMKB38!##$,
MY=CG((4=" ,]^U6X@?\ ADZ3C_EJ?_2FOH>B@#RFR4_\,S,,'/\ 8DG'X-7&
M6OAJ_P#$W[,UC#IL33W5I=R72PH,M(%DD# #N<,3COC%?1-% 'BW@[XU6L]E
MHWAQ?#VJ2ZR@BM)(XU'EKMPK/G.X8 R05X]>]9'Q"U!O!7QYTWQ7J-E<RZ7]
MG #P+G<?+=" 3@;AG.,]*^@** / ?BSJ"ZQXB^&^IQ030QW<@E6.9<.H:2(@
M$>O-6_'Z:EX'^,%GX\_LZ>]T=X!'<- N3'\A1@?3C!&< \C->YT4 ?._B+7Y
M_C=XBT/3/#VDWT.EV4_FW5Y<H!LSC.=I(& #@9R2>G%:_C53_P -(^$@ 3^X
MB_1I*]QHH \2^- /_"Q/A^>WVO\ ]JQ5[;110 4444 %%%% !1110 4444 %
M4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H NCI10.E% %>\_U#?2GVO_'G#_US7^5,
MO/\ 4-]*?:_\></_ %S7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JE+_R$Q_US'\S5VJ4O_(3'_7,?S- %T=**!THH
M KWG^H;Z4^U_X\X?^N:_RIEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ HHHH
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M^U_X\X?^N:_RIEY_J&^E/M?^/.'_ *YK_*@"6BBB@ HHHH *1F"*68X I:*
M(/.#_P 81?U/^%/5XE& P'XT;"O,9Q_LGI_]:GJQ8<J0?0T -\V/^^*/-C_O
MBGT4 ,\V/^^*/-C_ +XI]% #(?\ 4Q_[H_E3Z** "BBB@ HHHH **** (G@1
M^H%4I]*AE!^45I44 <S/X=1LX%8]SX,M9F+26D#D]2T8-=]@4TJ#VH$TGN>3
MZ[X,L[;0=1GCL+9&CM97#+"H((4G(.*N?\(199_Y!UK_ -^5_P *[;Q1&O\
MPB6M''_+C/\ ^BVK5\I/2K;?*OZ[![.-MCSR#PC#"P,5K%&?58P*T(O#1SR*
M[,1*.U*$ [5 ));'-P>'47&16I!I4,0'RBM+ HH&1) B= *EHHH **** "BB
MB@ HHHH B3S$4+LSCWIVY_\ GG_X]3Z* &;G_P">?_CU&Y_^>?\ X]3Z* (F
MW,.8NG?=TI(I'9B",J/XO\]:?L+'YSD?W1T_^O3Z "BBB@ HHH)P,F@ HKGM
M3\;^']+<Q27Z37&<"&V'FN3Z?+T/UQ6++XXUF[_Y!OATQ1G[LM],$/XH.?UK
M6-&;UM]^A7(SNZ*\YDU/QC=??U6PLO\ KVM?,Q_WV:KM;:W,<S^*=0/_ %R"
MQ_RJ_8=Y+\0Y5W/3J*\P_L[4O^AGUC_O_P#_ %J5;+5XCF'Q1J8;_IH5D'Y$
M4>P7\WYA:/<].HKSA+OQ=;?ZO7;:Z Z+<V@7]5JS'XO\26G_ !_:%;W:CJ]E
M/C\E;DTO82Z-/^O.P^3LSOJ*Y73_ (@:%>2"&>=["X[PWJ>41^)X_6NGCFCE
M0.CJRD9!!R#64H2A\2L2XM;CZ***D04444 %%%% !1110 4444 %%%% !111
M0 52E_Y"8_ZYC^9J[5*7_D)C_KF/YF@"Z.E% Z44 5[S_4-]*?:_\></_7-?
MY4R\_P!0WTI]K_QYP_\ 7-?Y4 2T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!@:S?1ZCX%U>YB5E!L;A61QAD8(P93
M[@@BM6]OH[)8=ZL[S2K%&B?>9C_0 %C[ US7BW_B4Z;K$PXL]1LYDD]$G\LA
M6_X$!M/N%]:UM/\ ^)IJ<FJMS;Q;H+,=B,_/)_P(C ]ES_%6[BN5/IK^A;6E
MS9HHHK @**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@/$'B6
MZUF\FT?0YS#;1$I>7Z=<]TC/KZG_ ";ITW-Z#2N:^N>-K33KEM/T^%M2U/O!
M"?EC_P!]NB_3K]*Y6ZM]5USY]?U)VB//V&U)CB'L3U;\:FL[.UTNW\BTB"+_
M !'^)CZD]S4A8DUTKEA\'W]?^ /GM\(VUM+.P3;:6T4([E% )^IZFIS(348I
MP%)MO5DWN.!)IP!H IX%(! *<!2@4\+0 T TN#3PM.VT 5;BUM[N+R[F".9/
M[LBAA^M9D>BW&EN9M U":P?J8"=\+GW4]/K6[LI"E4IM:%*30FE^.6AN$L?$
M-L+"X;A)P<P2GV;^$^QKM(Y5D4$$$&N%NK2&[MW@N8EEB<8*L,BLJRU*]\&3
MI'-))<Z$QVAF^9[4]L^J_P"?K,J2GK#1]O\ (=E+;<]2HJK:7D=U"LD;JRL
M00<@BK5<I 4444 %%%% !1110 4444 %%%% !5*7_D)C_KF/YFKM4I?^0F/^
MN8_F: +HZ44#I10!7O/]0WTI]K_QYP_]<U_E3+S_ %#?2GVO_'G#_P!<U_E0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 445@:IXTT#26,<^H1R3]!
M#!^\<GTPO0_7%5&,I.T5<:3>QOT5PDOCG6+LG^R_#S1QG[LU]*$_-!S^M4WU
M/QC=??U:PLO^O:U\S'_?9K58>75I?UY#Y>[/1Z*\Q:VUN8YG\4Z@?^N06/\
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MN58GOL8[6'X\5W&B77F1 $U%=7M/O^94];2-VB@=**P("BBB@ HHHH ****
M"BBB@ JE+_R$Q_US'\S5VJ4O_(3'_7,?S- %T=**!THH KWG^H;Z4^U_X\X?
M^N:_RIEY_J&^E/M?^/.'_KFO\J ):*** "BBB@ HHHH **** "BBB@ HHHH
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M^@J'&*6ITJ3;T&:'J=UJ*3VUZHCO+1A',$Z-Z,/K7+/$\-UJ&I1#+V=Z"?\
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M#H*6BB@ HHHH **** "J4O\ R$Q_US'\S5VJ4O\ R$Q_US'\S0!='2B@=**
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MU2E_Y"8_ZYC^9H NCI10.E% %>\_U#?2GVO_ !YP_P#7-?Y4R\_U#?2GVO\
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4I?^0F/^N8_
MF:NU2E_Y"8_ZYC^9H NCI10.E% %>\_U#?2GVO\ QYP_]<U_E3+S_4-]*?:_
M\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6+XG\3Z?X4TA[^_?_ &8H5/SRM_='^/:F^*?%6G>$M*:]OWR[
M96&!3\\K>@]O4]J^:O$7B+4/%&KOJ.HR98\1Q+]R)>RJ/\YK&M65->9Z>79;
M/&3[16[%\2>([_Q5K+ZGJ!4.1LBB3[L2=E'YGFLC(/'^37:> ? %UXPO1<7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "J4O_(3'_7,?S-7:I2_\A,?]<Q_,T 71THH'2B@"O>?Z
MAOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?^N:_RH EHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE+_R$Q_U
MS'\S5VJ4O_(3'_7,?S- %T=**!THH KWG^H;Z4^U_P"/.'_KFO\ *F7G^H;Z
M4^U_X\X?^N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JE+_ ,A,?]<Q_,U=JE+_ ,A,?]<Q_,T
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M>>QJV#FI+3N%%%% !1110 4444 %%%% !0:*#0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*7_D)
MC_KF/YFKM4I?^0F/^N8_F: +HZ44#I10!7O/]0WTI]K_ ,></_7-?Y4R\_U#
M?2GVO_'G#_US7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M$X%1&GMTIE @---.---,0E)2TE "JP5LFABAR?FS2&FT .9P8@O.10SAHU!!
MW"F&DH$/>7]X&7/ [TR1E9LJ",]<TAI.U,!*2EI*!#310:* &9*L".HK1B?<
MH/K6<:MVQ^04F.);HH'2BD6%%%% !1110 4444 %!HH- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4I?^0F/^N8_F:NU2E_Y"8_ZYC^9H NCI10.E% %>\_U#?2GVO\ QYP_]<U_
ME3+S_4-]*?:_\></_7-?Y4 2T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ",/EJ.I:C(P:!"&FFEI#3$)24M)0 &G>6NTG=DCTIIIZ?ZMZ (33W
M6)0<9/.::B[G I9FW.?0<4"%6.-SM#-FH2-I(/:IT B3>W4]!4!.22>] "4E
M+24Q#32'I2FFF@!#5N 84"J\:;F]A5V-:3*BB4=*6BBD4%%%% !1110 4444
M %!HH- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %4I?\ D)C_ *YC^9J[5*7_ )"8_P"N8_F: +HZ
M44#I10!7O/\ 4-]*?:_\></_ %S7^5,O/]0WTI]K_P ></\ US7^5 $M%%%
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M2A: LBN(AZ9^M2".I=HI<4#(PE/ Q2T4 %%%% !1110 4444 %%%% !1110
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M=Z+!S$U%1"7U%.$BGVI#NA]%("#T-+0,**** "BBB@ HHHH *#10: "BBB@
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MOI3[7_CSA_ZYK_*F7G^H;Z4^U_X\X?\ KFO\J ):*** "BBB@ HHHH ****
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MI!J%NB# ^7^=:]4Y**T'>VQC6$*F^E1AP@./SK1ND5+*8* /D-4[#_D)W'_
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M>/RHOI8.MSJZ*RK'7[2]N1:LDUM=$9$-PFTGZ=C6K2*"BBB@ JE+_P A,?\
M7,?S-7:I2_\ (3'_ %S'\S0!='2B@=** *]Y_J&^E/M?^/.'_KFO\J9>?ZAO
MI3[7_CSA_P"N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG#S1$?YYH2:8[:FA5"'_ )"4GXU?JA#_ ,A*3\:2ZB1/>_\ 'I)^'\Q19?\
M'G'^/\S1>_\ 'I)^'\Q19?\ 'G'^/\S1]D.A7U/[T7X_TK0K.U/[T7X_TJU)
M=1QC.?SIV;2#H5$_Y##?C_*K5S=I;K_>?LM9C2/)=L\0)9NF!5RVT_:1)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"0F/\ KF/YFKM4I?\ D)C_ *YC^9H NCI10.E% %>\_P!0WTI]K_QYP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*/\ A')/2N]\M?2CRU]* ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\
MA')/2N]\M?2CRU]* ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/
M2N]\M?2CRU]* ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/2N]\
MM?2CRU]* ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/2N]\M?2C
MRU]* ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/2N]\M?2CRU]*
M ."_X1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/2N]\M?2CRU]* ."_
MX1R3TH_X1R3TKO?+7TH\M?2@#@O^$<D]*/\ A')/2N]\M?2CRU]* .#7P[(&
9'%=-I%B;9 "*UO+7TIP4#I0 M%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img40748725_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "+!"P# 2(  A$! Q$!_\0
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M?^?[7/\ P924?\*?\._\_P!KG_@RDKT"B@#S_P#X4_X=_P"?[7/_  924?\
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M/_\ A3_AW_G^US_P924?\*?\._\ /]KG_@RDKT"B@#S_ /X4_P"'?^?[7/\
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MS_P924?\*?\ #O\ S_:Y_P"#*2O0** //_\ A3_AW_G^US_P924?\*?\._\
M/]KG_@RDKT"B@#S_ /X4_P"'?^?[7/\ P924?\*?\._\_P!KG_@RDKT"B@#S
M_P#X4_X=_P"?[7/_  924?\ "G_#O_/]KG_@RDKT"B@#S_\ X4_X=_Y_M<_\
M&4E'_"G_  [_ ,_VN?\ @RDKT"B@#S__ (4_X=_Y_M<_\&4E'_"G_#O_ #_:
MY_X,I*] HH \_P#^%/\ AW_G^US_ ,&4E'_"G_#O_/\ :Y_X,I*[6_U73M+$
M1U"_M;,3/Y<1N)ECWM_=7)&3["@ZKIPU0:6;^U_M IY@M/.7S=O][9G./?%
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M?6NN^(%GH.H_'_3+7Q/) NDMIH\TW%P84!_>E<N&&.<=Z=X\T%?#/ASX::.
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M*C;DM8@2NT#L>,8Z@>Y-1^(=#O-5^/?A^^DTBZFTAM,>*XE>V8Q+N28%';&
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MDC')'KGOTZ7X7:S?ZUX)BDU2X-S>6UQ-:O.PP9-CD GWQB@#LZ*** "BBB@
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MY/.\GR\[CTV[C_.E\2>.](\,V>E7=P)[NWU298;:2SV.IW#(;)8#;CN,UT]
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M(\0:9JTL=E<I<,IMDC90J* V.A/YT ?0U%5=-G>ZTNTN)1B26!'8>A*@FK5
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MBC_T*^A_^![?X4 >@45YW/KOQ/MX6ED\,:'M7KB_;_"J?_"8?$;_ *%G1?\
MP-;_  H ]0HKR_\ X3#XC?\ 0LZ+_P"!K?X4?\)A\1O^A9T7_P #6_PH ]0H
MKR__ (3#XC?]"SHO_@:W^%'_  F'Q&_Z%G1?_ UO\* /4**\O_X3#XC?]"SH
MO_@:W^%'_"8?$;_H6=%_\#6_PH ]0HKR_P#X3#XC?]"SHO\ X&M_A1_PF'Q&
M_P"A9T7_ ,#6_P * /4**\O_ .$P^(W_ $+.B_\ @:W^%'_"8?$;_H6=%_\
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M;OJEX9_LZL,$(,#&1QSFN?\ ^$P^(W_0LZ+_ .!K?X4?\)A\1O\ H6=%_P#
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M?]"SHO\ X&M_A1_PF'Q&_P"A9T7_ ,#6_P * /4**\O_ .$P^(W_ $+.B_\
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M=8U327GURRMK.[$Q01V\ID4K@$')[\F@#<HHHH **** "BBB@ HHHH ****
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M/V6[TQI-@?\ NL'.2<X'&.HZUG76@:O\4O 7A/Q);W<-EXAL3]HB>9"(I&#
M$G R 2@88!],<US_ (KM_%=_\4O MGXBNM(DO5NO/2VTN.3;'&KJQ=B_)R$/
ML-IH Z^Z\7>.=2^(FM^&O#D/AU8=-2.3?J*SAF#*IZHW)R3V%=QX=_X2+^SF
M_P"$F_LO[=YAV_V9YGE;,#&=_.<Y]NE<QK/PLM-3\0ZCKUIXCU_2M0O54.;"
MZ$2?*H R N2.,XS69\%O%&LZ]IVL6&L7;7SZ9="&*\8<R*<\$]\;<Y//S<T
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MR3&VM8E)9-D0^9U4=2S9Z>E1Z+XMU75/&9TNZTG^S[)[ W<"S_\ 'P1O"@L
M<+GGY<9'K70>'])30O#]CID9!%O$$9A_$W5C^)R:Y]O^2RI_V C_ .CZ .RK
M/GU[1[:(RSZM8Q1B0PEY+A% <=5R3]X=QUK0KSGP9X:T?5)O$5YJ.GP7DQU:
MYA!N$$@10V<*#PO)/(YH ZKQ9K<VB>$KW5[$0RRPQJ\?F99&RP'8C(P?6HO!
MWB&?Q!I$KWL44.HVL[V]U%%G:'!X(SS@@@UPJLP^!.IPEB4@DEACW')"K/P/
MPK;FO(?"'C5;^Y<QZ;K-CF5B>%GA3.?Q3CW- $GBSQS?Z-XEL],TVWMIH0\*
MWLDP8E/-?"JN",' )YSVKO*\@OK69O!VGZW>(5O=8UVWNY >JH6(C7Z!<?G7
MK] !1110 4444 %%%% !1110 4444 %%%% !1110 5'/,EO!),^[9&I=MJDG
M &> .34E% '&Z+XMU75/&9TNZTG^S[)[ W<"S_\ 'P1O"@L <+GGY<9'K795
MQK?\EE3_ + 1_P#1]=E0!S6JS^,VO)QH]GH\=K%PC7LKL\_ )("<*.HY/;WJ
MUX2\0?\ "3>';?4VMS;RN622+.=KJ2#@^G%1>(M*\0ZB'&C^((]-C,6W8;,2
M,6YYWEOE[#@<5G_#>\BE\,O8)9):R:9<R6<RQN75W4Y9PQY.2<\T =3->VMO
M-'#-<PQRR*S(CR ,P498@'J .OI4=CJFGZHCOI]]:W:(=K-;S+(%/H<$XKCO
M&.FVNK^//"EE>QF2V=;HO'D@/A5(!QU&0..].ATZRT7XK6D6F6L-I%=:7(9H
MH$"(Q5Q@[1QGWH 9I/CF_N/'=UHM_;VJ6!N9K6TFC5@YDC ;#9)'*GVY%='X
MJUM] T&6[@C26[=EAM8GSAY7.%!QV[_05P,NGS7>E^+KRT!^W:9KK7UOCKNC
M521^*[A6U::E!XW\8:9+;?/INEVJWK^GVB0813[JN3]: -SP1KMYXC\-1ZA?
MQP1W)EDC=8 0GRL1QDD]O6NBKB_A;_R):_\ 7W<?^C#7:4 %%%% !1110 44
M44 %=!H?_'D__70_R%<_70:'_P >3_\ 70_R% &G1110 4444 %%%% !1110
M 5S6H>"-,U+QOIWBR::[%_I\1ABC1U$1'S<L-N<_.>A':NEHH YJR\$:;8>.
MK_Q=%/=G4+V$021LZ^4%^3H-N<_(.Y[U#I7P_P!(T3QE>^)M.EN[>XO5(N+5
M)%^SN2<EMNW.<\]>I/K75T4 0W=K#?6<]I<)O@GC:.1<D;E(P1D<]#7!S_![
M1+QEBOM9\1WFG(P*:;<:DSVZ@= !C=@?[V:]"HH Y[7/"%EK6EV>GQ7FH:3'
M9$?9WTJ?R'C 7:%! (QCMBJOAOX?:-X:U*75$EOM1U65=C7^I7!GFV^@. !T
M[#-=710!Q.K?#'3=4O;FXBUOQ#IL=T[27-M8:BR0S,WWBR$'K[8K?\-^&=)\
M)Z0FF:-:BWM@Q=N2S.QZLQ/)/ _(#H*UZ* "BBB@ HHHH **** "BBB@"EJW
M_(,F_P" _P#H0KF:Z;5O^09-_P !_P#0A7,T %%%% !1110 4444 %17%O#=
MVTMM<1K)#*A1T89#*1@@U+10!Q]M\.-*@E@62_U:ZL;=P\.GW%V7MT(^[\N,
MD#L"2*VM2\/VFJZMI>I3R3K-IKL\*QN K%A@[ACGIVQ6M10!R_B+P3!XEDF^
MUZUK,5O,%#6D%PJP\8Q\I4]QGZUJZ)HQT6VD@.IZC?[VW![Z82,O&, @#BM.
MB@#-N]$MKW7-.U:1Y1/8"01*I&T[Q@[AC/;C!%$NB6TWB*WUMGE%S!;M;J@(
MV%6())&,YX]:TJ* ,S2]"M=)DU%X6E?^T+EKF82D$!F ! P!QQWS5?PSX5TW
MPG9SVNFK)LGF,S&1@3D\ 9 ' QQ6W10!F:!H5KX=TP6%I),\0D>3,Q!;+')Z
M >M:=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.N>'[;7
MH8EFN+RUFA):*XLYS%)&2,'!''Y@UK44 <[HW@VPTC4FU-[J_P!1U#9Y:W.H
M3^:\:GJJ\  ?A6QJ5A%JNEW6GSLZQ7,31.4(# ,,'&0>:M44 9%WX=M+SPL?
M#TDDXM#;K;[U8>9M4  YQC/'I3KGP_:75]I-V\DPDTLL8 K##97:=W'/'IBM
M6B@##O/">EWWBJR\13)(;ZTC,: $;&'."1CJ-QQS5B30K67Q+!KK23?:H;9K
M94!&PJ3DDC&<_C6I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !69KN@V/B+3_L=\C[5<21R1MM>)QT96[$5IT4 <[HW@ZRTC4?[1DOM1U*]5
M/+CGU&X\UHE/4+P ,^N,_F:N6GA^TL_$5_K<<DYN;Y$25&<% %&!M&,C\ZUJ
M* ..E^&VD233B.^U:WL;B0R3:=!=E;=R>N5QG!] :L:CH5Q=^(_#\$-JD6B:
M6K3\, #*!MC0+UX&3GI74T4 1SQ>?;RPB22/>A7?&<,N1C(/8UQW_"MX#J O
M_P#A)_$GVL1^3YWVQ-VS.=N=G3/.*[6B@!J+LC5=S-M &YNI]S6?H^B6VB)>
M+;/*XN[J2Z?S"#AWZ@8 XXK2HH YW_A#-._X16Z\/>==?9+EW=WW+Y@+/O.#
MMQU]JF\1^%--\4:3#IVH>;Y4,BR(T; ,"!CJ0>H)!K<HH RM9\/6>MV5K:3M
M+%%:SQSQB$A>4^Z.0>*U:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ J.>+S[>6$221[T*[XSAER,9![&I** .*_X5O =0%__ ,)/XD^UB/R?.^V)
MNV9SMSLZ9YQ6]?\ AVTU+4])OYYKGSM,9FAVN ') !WC'/3MBM>B@#E]0\$6
MUY?3W4&LZWIYN&+S165Z4C=CU."#@_3%;&BZ+8>'],CT_3H/*@0D]<EF/5B3
MU)K0HH S;O1+:]US3M6D>43V D$2J1M.\8.X8SVXP11+HEM-XBM];9Y1<P6[
M6ZH"-A5B"21C.>/6M*B@#,TO0K729-1>%I7_ +0N6N9A*00&8 $# '''?-5_
M#/A73?"=G/:Z:LFR>8S,9&!.3P!D <#'%;=% &9H&A6OAW3!86DDSQ"1Y,S$
M%LL<GH!ZUIT44 %%%% !1110 4444 %=!H?_ !Y/_P!=#_(5S]=!H?\ QY/_
M -=#_(4 :=%>0ZEX"\.7.J7<\ME,9))G=B+R<9)8D\!\"JO_  KSPS_SXS_^
M!T__ ,70![117B__  KSPS_SXS_^!T__ ,71_P *\\,_\^,__@=/_P#%T >T
M45XO_P *\\,_\^,__@=/_P#%T?\ "O/#/_/C/_X'3_\ Q= 'M%%>+_\ "O/#
M/_/C/_X'3_\ Q='_  KSPS_SXS_^!T__ ,70![117B__  KSPS_SXS_^!T__
M ,71_P *\\,_\^,__@=/_P#%T >T45XO_P *\\,_\^,__@=/_P#%T?\ "O/#
M/_/C/_X'3_\ Q= 'M%%>+_\ "O/#/_/C/_X'3_\ Q='_  KSPS_SXS_^!T__
M ,70![117B__  KSPS_SXS_^!T__ ,71_P *\\,_\^,__@=/_P#%T >T45XO
M_P *\\,_\^,__@=/_P#%T?\ "O/#/_/C/_X'3_\ Q= 'M%%>+_\ "O/#/_/C
M/_X'3_\ Q='_  KSPS_SXS_^!T__ ,70![117B__  KSPS_SXS_^!T__ ,71
M_P *\\,_\^,__@=/_P#%T >T45XO_P *\\,_\^,__@=/_P#%T?\ "O/#/_/C
M/_X'3_\ Q= 'M%%>+_\ "O/#/_/C/_X'3_\ Q='_  KSPS_SXS_^!T__ ,70
M!ZWJW_(,F_X#_P"A"N9KBC\._#!&#8SG_M^G_P#BZ3_A7/A;_H'S?^!L_P#\
M70!VU%<3_P *Y\+?] ^;_P #9_\ XNC_ (5SX6_Z!\W_ (&S_P#Q= ';45Q/
M_"N?"W_0/F_\#9__ (NC_A7/A;_H'S?^!L__ ,70!VU%<3_PKGPM_P! ^;_P
M-G_^+H_X5SX6_P"@?-_X&S__ != ';45Q/\ PKGPM_T#YO\ P-G_ /BZ/^%<
M^%O^@?-_X&S_ /Q= ';45Q/_  KGPM_T#YO_  -G_P#BZ/\ A7/A;_H'S?\
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M#YO_  -G_P#BZ/\ A7/A;_H'S?\ @;/_ /%T =M17$_\*Y\+?] ^;_P-G_\
MBZ/^%<^%O^@?-_X&S_\ Q= ';45Q/_"N?"W_ $#YO_ V?_XNC_A7/A;_ *!\
MW_@;/_\ %T =M17$_P#"N?"W_0/F_P# V?\ ^+H_X5SX6_Z!\W_@;/\ _%T
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MKGPM_P! ^;_P-G_^+H_X5SX6_P"@?-_X&S__ != ';45Q/\ PKGPM_T#YO\
MP-G_ /BZ/^%<^%O^@?-_X&S_ /Q= ';45Q/_  KGPM_T#YO_  -G_P#BZ/\
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:#Z/8Z'H+6FGPM%"9V<JTC.<D#NQ)["@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img40748725_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_26.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *'!1$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBT[4;:ZDMFV3+#(&,9]#CITHTK7=*UR.232M1MKU(FV.T$@<*?0XKQSX&?\
M(R^-/^O@_P#H;T?LWNL>@:Z[L%1;A2S$X &R@#W.BN%;XP^!5U+[#_;B&7=M
MW")RF?\ ?QC]:[E65T#J0589!'<4 +1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 5YK^SMY/+GNX(GQG:\@4_D:C_M;3
M?^@A:_\ ?Y?\:YOQ'\+_  IXKU9M4U>PDFNV18RZW#H,#IP"!61_PHOP!_T"
M9O\ P+E_^*H [O\ M;3?^@A:_P#?Y?\ &C^UM-_Z"%K_ -_E_P :X3_A1?@#
M_H$S?^!<O_Q5'_"B_ '_ $"9O_ N7_XJ@#N_[6TW_H(6O_?Y?\:/[6TW_H(6
MO_?Y?\:X3_A1?@#_ *!,W_@7+_\ %4?\*+\ ?] F;_P+E_\ BJ .[_M;3?\
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MHOP!_P! F;_P+E_^*H [O^UM-_Z"%K_W^7_&C^UM-_Z"%K_W^7_&N$_X47X
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M[_M;3?\ H(6O_?Y?\:/[6TW_ *"%K_W^7_&N$_X47X _Z!,W_@7+_P#%4?\
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M?_BJ /1D=9$#HP92,@@Y!I:K:?86^EZ?;V-HA2WMXQ'&I).%'3DU9H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *SO$'_(MZI_UYR_^@&M&J]\+=M/N5NR!;&)A*3_ ','/Z9H
M \_^"EQ"GPGT59)HU(,_!8#_ );R5WSWEL<#SX3_ ,#%?/C6WP,C9E77-00
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M;J%[@+^\8. "?6M6.ZM\Y-Q%D?[8KP;R?@;_ -![4_RN?_B*/)^!O_0>U/\
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MI/7^R[+_ ,!T_P *MVNB:01SI5C_ . Z?X5 TO&*T;%MRB@!?["T?_H$V/\
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M"$ F0#'O0!VVFZ3I,JC.F61_[=T_PK5&A:./^858_P#@.G^%8'A34X[Z ,C
MUUN>,T 8UYH^D)$Q&EV0Q_T[I_A7)R6^EK.P.GV?7_G@O^%==K-PMO9R.QP
M*\=N/%]BVH21"8;@W- '<"WTLC TZS_[\+_A31;:7_T#K/\ [\+_ (5S,/B.
MV9<B4?G2MXBM@>)1R/6@#I_LFEX_Y!]G_P!^%_PJ":WTQ4/_ !+[/_OPO^%<
M\/$=N00)A^=4K_Q9:0PL6D' ]: -RS33I=0"?8+3&>GDK_A7:3:1I3:-<L-,
ML@1 YSY"_P!T^U?/]EXZ"ZX@QB-GQNKWZSN1<>&II <[K=C_ ..F@"K\#/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:[X[O/&&I6,FGVJVPL]/MIAB4IG+.P[9)/%>@4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !115;41=G3;H6!07GE-Y!D^[OQQGVS0!YU\8-(U23_A'
MO$VE637TNA7;326JC)=&VDG Y."@_.N)\4>/M1^*&E)X4TSPK>PS7,\?FS2C
M(A"L"3TXZ=379ZE%\6SX:T=;*XTX:L&F^WMA-I&5\K&1CINSBL46_P =0<BY
MTO\ [YB_^)H ]ELX#;65O 3DQ1JA/K@8J:HK;SOLL/VC'G;%\S'3=CG]:EH
M***KB^M#-Y(NH/-Z;/,&?RH L4444 %%%0_:K?S_ "/M$7G?\\]XW?EUH FH
MHHH \HT/_DY;Q-_V!X__ &A7J]>4:'_R<MXF_P"P/'_[0KU>@ HHHH ****
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M.6ZLL?:(E/S1Y&1FJOA?Q##XHT*+58('@CD9E".02-I([?2@#9HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#3_ *#%G_X"2?\ Q%'_  M7X:?]!BS_ / 23_XBM#_A#/#2<_\ "-:0Q/\
MTXQX_P#0:!X*\+[3_P 4]I.3_P!.4?'_ ([0!G_\+5^&G_08L_\ P$D_^(H_
MX6K\-/\ H,6?_@))_P#$5;7P7X8'!\/Z23_UY1_X4/X.\-$;E\.:1D<8^Q1\
M_P#CM %3_A:OPT_Z#%G_ . DG_Q%'_"U?AI_T&+/_P !)/\ XBM*T\%>&%B
MD\.Z06ZG-C$?_9:M-X,\*$9'AG1__ "+_P")H P_^%J_#3_H,6?_ ("2?_$4
M?\+5^&G_ $&+/_P$D_\ B*MW_@?PS);LL?AW2U;J2MG&#_*N<B\!:/!.\\NC
MZ<8B?E3[,A(_2@#8_P"%J_#3_H,6?_@))_\ $4?\+5^&G_08L_\ P$D_^(J@
M/#'AX$*N@:46]#9QY_E5P>#O#S*,>']+W'[W^A1\?I0 _P#X6K\-/^@Q9_\
M@))_\11_PM7X:?\ 08L__ 23_P"(H;P5X;$)4:!INX]S9Q_X5FR^#/#Y9$&C
M::5SU%I&#_*@#2_X6K\-/^@Q9_\ @))_\11_PM7X:?\ 08L__ 23_P"(K3LO
M!/A<0A6\.:2QQU:QC/\ [+5H^"_"O3_A&M&!_P"O"+_XF@"_X>\1:-XETXWF
MAWD=U:HYB+1J5VL #C! (X(_.M:O*O@7&D6C^)(XT5$76I555& !M3@"O5:
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M><^"@/&WB,WFM/Y?]@K'%9Z._6,E1BX<?Q$]L<"O2?$'_(MZI_UYR_\ H!H
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M0U+=<9)Z4 >=? __ )!?B?\ [#DW_H*5ZG7E?P/_ .07XG_[#<W_ *"E>J4
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M6ZZ16-F9)(^,_.I(V^GUK$M_BE9RZQ8:9<^&O$UA-?2^5 U[8B)2?J7[>P-
M'=T5@>(/%^G>'9X+26*\O+^X!:&RL8#+,ZCJ<= /<D58T#7UUZVEF_LS4].>
M)]C0ZC;^2_U')!'N#0!KT5QES\2=-6[GAT[2=<UB.W<QS7&FV1EB1@<%=Q(W
M$?[.:["&59X(YE#!9%# .I4@$9Y!Z'VH ?1110 4444 %%%% !1110 4444
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M!X__ &A7J]>4:'_R<MXF_P"P/'_[0KU>@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH) &2
M<"H_M$/_ #VC_P"^A0!)35^\WUIOVB'_ )[1_P#?0IJW$.YOWL?7^\*+ 345
M']HA_P">T?\ WT*59HG.%D0GT#"BP#Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2\0
M:+J%]X\\+ZG;P;[2Q,YN)-ZC9N0@<$Y//IFNMHH \MU_X>ZEJ7Q(AN8"!X;O
M9([K4X]RC=+%G:",Y.[C.!VKH[W1-0E^*NE:U';YTZ#398))=ZC:[,"!MSGI
M[8KKZ* /-)(O%_A[Q[K^IZ9X3_M>SU%8=D@U&&#;L4@\-D]_05I:[%XC\6?#
MC5[.Y\/?V=J<Z&.&T-['-O&0<[QA1WX/I7<T4 >?:_X2U2$:1XD\.PJ/$6GP
MQPS0%U5;N+ #1L2<9'8D]JZS67DD\)Z@\L1AD:QE+1D@E#L.1D<&M6L[Q!_R
M+>J?]><O_H!H X7X,H&^$NB$G',__H^2N]Y#85NG-<#\&,_\*FT4^AG_ /1\
ME=\N022/F- "@EN/S%1X5WV8I^X;<#KWIA88)QB@!' &<C [4PQ*_+*,U( 7
M&2,^M'WFV \T 1/'O&>@'ZTH5% +=<<5*X4$ =J,?+F@!F%;&> :D&6X[#M4
M/*@J?F]*F&0!GKZ4 17$*SQX(!QVQ5!=-C+[I8P>V>]:FWKQ[FHP&'W3D9Z&
M@"L;%"H0=A@9%,.GPQIY8A4@]<#%7P1N([>M&5;. 210!073K<Q-&J+@]<C-
M,CTV)-Q,:DXQP.U:: *<L,4;@7^3I0!3M+>.)=J@8SGI5X%57'KTQ3 N&(+<
MFE$963.* *M]9I.F"BMCU&:YZ3PU9?:MZVR!G^]@5U<GS'Y3@]Q4:JO3.6H
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M)O\ L#Q_^T*]7KRC0_\ DY;Q-_V!X_\ VA7J] !1110 4444 %%%% !1110
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M/_H8O$W_ (&I_P#&Z7_A1VB?]#%XF_\  U/_ (W0 I^*'B0G(^&^L#_MI_\
M84UOB=XD8_\ )-]7'_;3_P"PH_X4?HG_ $,/B;_P-3_XW0?@?HG_ $,/B;_P
M-3_XW0 ?\+-\28_Y)SK'_?S_ .PI1\3O$@4@?#C6,GOYG_V%)_PH_1/^AB\3
M?^!J?_&Z/^%(:)_T,7B;_P #4_\ C=  GQ.\2JN&^'.L.?4R?_84G_"S/$8S
MCX<:P,_]-/\ ["E_X4AH?_0Q>)O_  -3_P"-T?\ "C]$_P"AB\3?^!J?_&Z
M!?B;XC'_ #3?6#_VT_\ L*<WQ/\ $; ?\6WU@'U\W_["C_A1VB?]##XF_P#
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M;F>X2UU:6&)IGW,%"IWKU.@ HHJ"]O;?3K&>]NI!%;P(9)'/0 #)H GHKBO
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M&88/S$#I7CX\>^(<<7/Y+0!]9C5(<_ZQ?IF@:M!G[XKY-_X3_P 1 Y^U$?\
M :>/B'XAR,W''IB@#ZQ_M6 #AQ^=-?5X%4L7'3UKY2'Q%\1#GSQ^*T]/'OB"
M]FCA\PMN;&%'6@#ZEL-92\E*H0<5I/=*A"L<'M7%^!+">/2HIKD'S7&3FH/B
M+K-QH&GK?Q*2(SR!0!W@N%]11YZ=S7SH_P ;KC:H6T;W^:HC\;K_ "?]%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "F32K!!),P)6-2QQZ 9I]174OD6DTVW=L1FQZX&:
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M_P#(%OO^N#_R-?(\G^L?ZFO9RG:7R/4R[:0VBBBO8/3"NW^$W_)0+3_KF_\
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M_P!$>\.?]_8?_BZ3[+XI)Q_PI[P[_P!_8?\ XN@#OO\ A:_@7_H8K7_OE_\
MXFJUQ\3O DPY\0VI_P" O_\ $UQ?V/Q5_P!$>\.?]_8?_BZ7[%XJ_P"B/>'/
M^_T/_P 70!U:_$;P&/\ F8;4?\!?_P")IW_"R/ ?4^(+4G_=?_XFN1^R>*1_
MS1[PY_W]A_\ BZ/L?BG_ *(]X<_[_0__ != '7_\+*\!_P#0P6O_ 'R__P 3
M3O\ A9?@3_H8;7_OE_\ XFN.^Q^*O^B/>'/^_P!#_P#%T"S\5'_FCWAS_O\
M0_\ Q= '8_\ "R_ A/\ R,-J/^ O_P#$U8C^*?@5!@>([7_OE_\ XFN'^Q>*
MO^B/>'/^_P!#_P#%TGV/Q5_T1[PY_P!_H?\ XN@#OO\ A;'@7'_(QVO_ 'R_
M_P 34$OQ1\"R?\S%:_\ ?+__ !-<2++Q4>GP>\.?]_H?_BZ7[!XK_P"B.^'?
M^_T/_P 70!V"_$WP(O\ S,-I_P!\O_\ $T[_ (6=X%_Z&*U_[Y?_ .)KC/L7
MBL?\T=\.?]_H?_BZ7[#XK/\ S1WPY_W^A_\ BZ .Q_X6=X%_Z&&U_P"^7_\
MB:7_ (6?X%[>(;7_ +Y?_P")KC?L'BO_ *([X<_[_0__ !='V'Q7C/\ PIWP
MY_W^A_\ BZ .Q/Q.\"$_\C#:_P#?+_\ Q-.C^*'@1#D>(K7_ +Y?_P")KB_L
M/BO_ *([X<_[_0__ !='V+Q5_P!$>\.?]_H?_BZ .['Q7\"_]#':_P#?+_\
MQ-1S?%/P+(A7_A(K;G_9?_XFN(%GXJ/3X/>'/^_T/_Q=+]@\5_\ 1'?#G_?Z
M'_XN@#I%^(/@,2;CX@M>O]U_\*L?\+)\"8_Y&&U_[Y?_ .)KD?L?BK_HCWAS
M_O\ 0_\ Q=*++Q6>GP>\.?\ ?Z'_ .+H ZT?$GP'G/\ PD-K_P!\O_\ $T[_
M (67X%S_ ,C!:_\ ?+__ !-<C]A\5_\ 1'?#G_?Z'_XNC[!XK_Z([X<_[_0_
M_%T =:?B7X%/_,PVO_?+_P#Q-0-\0O ;2!O^$@M>/]E_\*Y@V/BL=?@[X<_[
M_0__ !=(;/Q2#C_A3WAS_O\ 0_\ Q= '<Q?%3P+&@7_A(K7C_9?_ .)J7_A;
M'@7_ *&.V_[Y?_XFN#%AXK89'P=\.'_MM#_\72_V=XM_Z(YX<_[_ $/_ ,70
M!T'P(FCN=$\1SPL'BDUJ5D8=""B$&O5ZX'X3:_'KOAR]V:'9Z.]I?/;R6]H
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M=:KICZ8JHHA,QX"D%>=F>"!7&07GB*#4I++Q/XOUO0+@,1ON+>1XSSZJV?\
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M17;_  F_Y*!:?]<W_E6&)_@R]&8XC^%+T/I"BBBOE3YX**** "BBB@ HHHH
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M7J]>4:'_ ,G+>)O^P/'_ .T*]7H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "FO_JV^AIU-?_5M]#0!Y:>II*4]325^5RW.X****0&AH?\ R&;;_?KT
M6O.M#_Y#-M_OUZ+7V?#?^[2]?T1SUMPHHHKZ(Q"BD.<<'%,;>HSN'Y4 244W
M#_WA^5.H **** *6L_\ (%OO^N#_ ,C7R/)_K'^IKZXUG_D"WW_7!_Y&OD>3
M_6/]37LY3M+Y'J9=M(;1117L'IA7;_";_DH%I_US?^5<17;_  F_Y*!:?]<W
M_E6&)_@R]&8XC^%+T/I"BBBOE3YX**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O(?#[>,!XF\9CPW%HC1G4CO;4))58-L'0(I!'U
M->O5P'_"">)++6]6OM$\9)I\.I7'VAX&TI)BIP!]XO[>@H S/ <T<'@KQ+I%
MQ#+#K-FUPVHAV#!Y74MO4@#Y3V':N0BO?&-M\)-+BO!IL/A6YB6"YN[-7DNH
M8'.TEE8A><XR,XS7K&B>"H-&TK5(#?3W=_JFXW=[.!N=BNW.T< #L*FT[PC!
M:> H_"EU/]J@%J;9Y=FS<#GG;DXZ^M &3XPU.U\'?"Q_[/D)3[.EI9L#DL7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I&944LQ 4#))["EJMJ/_ "#+O_KB_P#Z": ([/5].O\
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M7IEY%=6^XIYD39&1U'ZU=H ***KR7UI%=1VLEU EQ)]R)I ';Z#J: +%%%%
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M)%>2-68="14T=M$BX"C [5PO_"K_ !Q_T4F[_P"_!_\ BJ/^%7^./^BDW?\
MWX/_ ,50!WODI]/:@1+^-<%_PJ_QQ_T4F[_[\'_XJC_A5_CC_HI-W_WX/_Q5
M 'H'E*.W%->!'!X%<#_PK#QQC'_"R;O_ +\'_P"*H_X5?XX_Z*3=_P#?@_\
MQ5 '>P6\<).% SZ59 XX&:\Y_P"%8>.!_P U)N_^_!_^*I?^%9>.?^BE7?\
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MY#X>>"7\#Z-=V<VI-J$]U=-<R3&/9R0HQC)_NYS[UU] !1110 4444 %%%%
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MR8"<* !UKV"@ I-R^H_.AONGZ5X9>SS"^N )7 $C?Q'UH ]R,B X+"D\V/\
MOBO!_M$W_/:3_OHT?:)O^>TG_?1H ]Y$B$X#"EW#U'YUX+]HF_Y[2?\ ?1K1
MT&:5O$&GAI7(-PG!8_WA0![51110 4444 %%%% !1110 4U_]6WT-.IK_P"K
M;Z&@#RT]324IZFDK\KEN=P4444@-#0_^0S;?[]>BUYUH?_(9MO\ ?KT6OL^&
M_P#=I>OZ(YZVX5Y3\7_'VN>"KC3%TAX MPKF02Q;^A&,5ZM7@7[1G_'WH?\
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MU-O*5&TD^U6&E;/- '%MX)\5J<?\+*UW_OM__CE(W@OQ6I'_ !<K7<'OO?\
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MK_DF.F?5_P#T(UWM?&XK^//U9T1V*6L_\@6^_P"N#_R-?(\G^L?ZFOKC6?\
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M [^2,<_=QCJ>*M>&?&,?B&\O=/GTZZTS4[+:9K2YP6"MT8$<$?2L?_FN)_[
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MD5I6[2!,@#;VS0!%J\+/;(VUMR'-,TR?S[;)X(."*M3>86W, 485 L9ARB(
M",Y H DNX6DB(B<*:K0+MN40N&)ZXJ5UD$><'WJM"LB7@8K@$\>M '7Q ,B@
M=0.*<Z,1R/FIEHW[D9Z]JE(RI))R* .*U]W2<XS4%HZNJ-(>!4_B9&\PE<\5
MGV-I*\:MDX/:@#>4JX&W/--NML@ 9@,5'%!)&1P?:BZM)05..#U- %8S#:8@
M<C'>L>]E7**.&S^=;1L&+=#M]A6/J-FRR[E4G% '4:%(7M@5.!T-;ZY,>.U<
M[X;!2#:X]Q71J<H0./K0!Q_BT^7$2.IZUBZ0Y.U^J]*Z7Q+;^;;G/(K T*SP
M&4MWX!H UG=2-V> .E06[MSA2"#TJ[+;]F&![4Z"TR0#F@"N\HQNQQCFN;UV
M5C'F/  [>M=9):M\P &/>N;UNU<*-HX'6@!GA R,3E<BN]N\'2;GG@0O_(UQ
M?A>$A^#CU KM+EE.DW0QTA?_ -!- $/P,_Y);8_]=Y__ $8U>CUYQ\#/^26V
M/_7>?_T8U>CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5'<2^1;2S$9\M"V/7 S4E(RAU*L,J1@B
M@#@_A1K^J^*?#EUK>IW0E%Q=R"WB"!1#&IP!QU-+\6-?U7PMX8M]:TN[$)M[
MN,3Q,@831L<%>>A_^O7'3^#_ (B> =4O9/ [P:AI%U,9OL<K*&B)Z\,0/Q!_
M"JY\(?$KXAZE9KXS\C3=&MIA*UNC(3)CT"D\]1DD=: /;[6<7-G!< 8$L:OC
MTR,U-38XUBB2-!A4 4#T IU !1110 4444 %%%% !1110!Y1H?\ R<MXF_[
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M+(@P'8#D@=LFK%% !1110!SW@OPW)X4\.1Z7+<K<,LLDGF*NT?,Q.,5T-%%
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M$;7/_ =?_CM']O\ P?\ ^A'US_P'7_X[7T*QYQ@@^U-PW3(YH ^?/[?^#_\
MT(^N?^ Z_P#QVC^W_@__ -"-KG_@.O\ \=KZ"526.>:52RX]10!\^?V_\'_^
MA&US_P !U_\ CM']O_!__H1M<_\  =?_ ([7T&NX"E7(Z\&@#Y[_ +?^#_\
MT(VN?^ Z_P#QVC^W_@__ -"-KG_@.O\ \=KZ(.",G&:#G''4=?>@#YW_ +?^
M#_\ T(VN?^ Z_P#QVC^W_@__ -"-KG_@.O\ \=KZ% /3<.:=T&!0!\\?V_\
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M^09XG_[#DW_H*5ZG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\AFV_P!^O1:^SX;_ -VEZ_HCGK;A7@7[1G_'WH?^Y)_,5[[7@7[1G_'WH?\
MN2?S%?89;_O,?G^1SSV/#****^K, HHHH ^L_@U_R3'3/J__ *$:[VN"^#7_
M "3'3/J__H1KO:^-Q7\>?JSHCL4M9_Y M]_UP?\ D:^1Y/\ 6/\ 4U]<:S_R
M!;[_ *X/_(U\CR?ZQ_J:]+*=I?(]7+MI#:***]@],*[?X3?\E M/^N;_ ,JX
MBNW^$W_)0+3_ *YO_*L,3_!EZ,QQ'\*7H?2%%%%?*GSP4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(>%/TI:1ONGZ4 >-_#GQ9K
M0\5M:ZYJ,UU9:M)<)9&4\12Q.<H#[K_(5UWQ'UN_M+*QT319VAU;5IC&DJ'Y
MH(D!>20?0#'X^U<-9:3<7WPEN-2T_(U/1]7GU"U(ZDI(2R_BN>/7%;_A"^_X
M3?5-8\:-&RVJ6?V&P1QC:-NZ5A]6P/P- #8-?U9O@!)K!U"<ZD+1B+K=\^=V
M,Y]:VM$\&WQAL-0E\:>))B429H9+B,HV0"01LSC\:Y.W /[,TH/3[&W_ *'7
M0^%?#'@O3O[,U"UO_P#3EB1E5M5=QN*\C87([],4 -U#Q<="^)^L+J5_(FDV
MNC1SK!G(\PR8^4=V/2M?P4FOZA]I\0Z[/+!]NP;32\_):P_PEAW<]3Z5Q?B?
MPPOBKXM:Q9+*8;N+18)[2;_GG*LI*DCN*[?P-XK;Q#8366HH+?7M.;R+^V/&
M&'\:C^ZW44 2_$+69="\#:I>6YQ<F+RH?]]SM'\ZP/%44_@KX/1V^D3O;36D
M<*"6,X8L6&\_4DDGZU8^,(9? PF&=D%[;RR?[H<9S2_%PAOAC>,.A:$C_OL4
M =#J_BW1/#TEM#JU\MM)/&TD>]3A@N,\@8SR..],\/\ C30?$\\UOI=XSSPC
M<\,L3Q.!Z[7 ./>N:\36T%U\4O!J7$*2JL-PX#KD A1@U)J*+'\<-&= %:32
MIPY'\0#+C- &K>?$CPM8-,DVHL9(9F@DBCMY)'5EZ_*JDX]^E7SXPT+_ (1A
M_$:WZ2:4@!:>-2V.0.@&<Y(XQ7#_  ^U;0;#7_&,5W=6EO?'5)G8S$(S1Y]3
MU%<\D?VKX2>.[JPB8Z=<7[S6@5>#&'4LP'IP30![#JOB'3=$T8:M?SF*R)0"
M0(S??("\ 9Y)%<EXE^)MOX?\<Z5HC1LUK*LIO'^RRNZ$+E/+VC#9/7 ./:L/
MXC^(]'O/A;96MKJ$$\]P]H8XXWW-A70DD#H!CO6KXPN(;+XK> [FZE2& )>(
M9)#M4$Q@ $F@"QX_NX_[!T7Q?8A]^GWD4RLR%&,,AV.I!&0""#@^E=;KKB3P
MOJ3K]UK*4CZ%#7-?%2XAE^&.I/&Z2).(TC96R&+.H&#]:WK]&C\$72/]Y=.<
M'Z^6: .2^"@!^$NB^H,__H^2N\X!.TXS7 _!4@?";1O<S_\ H^2NZ=M@[8/>
M@ :0 D=2*:TF%R>!Z5E7FN6%B6,\\<>.NYJIQ^+]*DPHNHN>AW<'Z4 ="')'
M3 %+N9L'C-8$GBK3$RK7D2GJ/FZTT>+-,5%:6Z1#VYZT ="&) /2G9X!([]:
MYB?QIH\.&:_B0-P 34]GXNTF[E$4-U&[]>&XH Z7CK37! XZ5''+YB@C&T\@
MU4U35+;3;=I[J0+&@R23C% %P-R0/PH#,#CMZUY\?BOX7,[1+J2H0<<CBGR?
M%?PVA5!J,9]30!W[,P(Z4%F"YP<UP'_"UO#9BWB]7.<8IDOQ:\.(HS>=.P%
M'H1<E>>/:E#Y( _'->8W/QG\.6RY,DK$\X"=*O\ AGXH:1XHU VUH'7T,@Q0
M!Z(/F!&>:C<LPQGIVIBL" >3]*YCQIXRM/"6G_:KB.5\]!&N?SH Z,.0S;B,
MCI2>8<<C _G7A,_Q]@.[RM/ESG@L:C_X7]S_ ,@]MOIGK0![T&8KSVZ&E$K
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M".0O$R8;&>];]1Q010 B*)(P>2$4#-24 %%%% !1110 4444 %%%% !1110
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MGC5[.0J/X]I 7ZU]$3^%='E?Y]-@;/<H*O6.D6MD<PV\<?N!0!;B7Y<D\@<
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M*W/C/P;<Z+:7$5O-+)&XDE!*C:P/;Z5TUM$8+2&$D$QHJDCO@8J6B@ HHHH
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M_P!=F_\ BJ]6HH \F.H?%XC_ )%W0_\ O\W_ ,52C4?B^/\ F7M$_P"_S?\
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M_&6\\2>%++[)X?M+<P2S1Q^7%<3$<[5XQP0<8[9[T >VT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !61XE\-:;XKT6;2M4@$D$@X8?>C;LRGL16O10!
MQOPY\+:SX0T>XTK4]56_MHYC]BX.8XO0D_R[5V5%% !1110 4444 %%%% !1
M110 4444 <KX\?Q2=%CM/"D"&\NI/)>Y9P/LR'JXSW_E7E>CG4?@?XF:+6D%
M]H6JLN_4DC^=).^X]?7@GWKWZJ.LZ-8:_I5QIFIVR7%I.NUT;]"#V(Z@]J .
M+\=^!+'Q[IEMK.C7:6^L0*)K&_A;&_'(!(_0]0:ZKPM_;?\ PC=D/$7D_P!J
MA,3F'H3Z^F?7%9/@'P7+X'TVZT[^U9KVU><O;1R#_4IZ?7U[5UU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img40748725_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_27.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 59!OP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9M-,?]J7LXC@#KN 5>7;'?L/^!5Z'7@VI#_A8/Q;UN\/[S2/"]C+''W5IPK
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M_%/<0*VMW48:ZF89,>>?+7T [^I_# !P6F^"OC5J,:W-UXI;3R>?+GO6+?\
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M9:M$,S6,K?-QU*'^(?J.XKN*^9?C;H$_@WQW9>*=%=[3[<QE#Q<>7<+]X_\
M @0<=_FKV?X:>/(/'GAE;LA(]1MR(KR%>BOV8?[+=1^([4 =G1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5\X?M$^+/M>KV?A>VDS%9@7%T >LK#Y0?HIS_P.O?M>UFV
M\/:!?:O>'$%I"TK#/+8Z*/<G 'N:^'=6U.YUK5[S4[Q]]S=3--(?<G.![=J
M+WA+P]/XJ\5:=HL&0;F4*[C^!!R[?@H)K[?L[2"PLH+.VC$=O!&L4:#HJJ,
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MY#'B#_KWB_\ 0FH ^BZX3XR_\DEU[_<B_P#1R5W=<)\9?^22Z]_N1?\ HY*
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MMYM1LO"UO)B*!1=70!ZN<A%/T7)_X$/2G_LU:6KW^O:LR_-%%%;1G_>)9O\
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M*1/_ -@Z7_T..O5OCY=3VWPOG2$D+/=112X_N9+?S5: .(E^,/C+QOXJ71?
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M7D7C?Q/#KGQ5\*>#;&02+::@E[>E3D;XP75/P )/U'I7KM 'A?[2W_('\/\
M_7Q-_P"@K7SI7T7^TM_R!_#_ /U\3?\ H*U\Z4 ?6VF>#]/\;?!+0])O@%8Z
M?$\$X&6AD"\,/Y$=P37RWK^@W_AK6[K2-3A,5U;OM;T8=F4]P1R#7V+\-_\
MDFOAS_L'P_\ H(K!^+7PWC\<:)]JLD5=;LT)MVZ><O4QD_R]#[$T ?-_@'QO
M>^!/$D>HV^Z2V?"7=OGB6/\ ^*'4'^A-?9.D:O9:[I-MJFG3K-:7*!XW'IZ'
MT(/!'8BOA"6*2"5XI4:.1&*NC#!4C@@CL:]-^#OQ+;P=JW]EZG*?[#O'&XD_
M\>TAXWCV[-^?;D ^KZ*1'61%=&#*PR&!R"/6EH **** ,[7_ /D6]4_Z])?_
M $ U\(U]W>(/^1;U3_KTE_\ 0#7PC0!]"?LS_P#'KXE_W[;^4E>]UX)^S/\
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M<1L?8U\!5][:C*(-,NYB<".%V/X FO@F@#Z3_9LF=O"^LPG/EI>JZ_4H ?\
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M(?\ (]Z9_P!@Q?\ T;)7+?!O_DK.@_\ 723_ -%/74_M(?\ (]Z9_P!@Q?\
MT;)7+?!O_DK.@_\ 723_ -%/0!]BU\B?''_DK>K_ .Y!_P"B4KZ[KY$^./\
MR5O5_P#<@_\ 1*4 :W[._P#R4B?_ +!TO_H<=?1GBSPY;>+/#%]HEV2L=S'A
M9 ,F-P<JP^A -?.?[.__ "4B?_L'2_\ H<=?0GC7Q./!_AF;6WM_/B@EB61-
MV"$:15)'N <XH ^.O$_A;5O".LR:9J]L8I5Y1QRDJ]F0]Q_^HX-4])UC4-"U
M*+4-+NY;6[B.5DC.#]#ZCU!X-?:VO>'="\;:&MMJ5O%>6DJB2&53\RY'#HPZ
M<?GWR*^7?B3\*]1\!3BZCD-YHTS[8KG&&0]E<=C[C@^W2@#W;X5?%&'QY9/9
M7J);ZW;)NEC7[LR=-Z^G.,CMD>O'I%?&WPBN9[;XIZ"UN3EYC&X'=&1@V?PY
M_"OLF@#"\:X/@/Q$#T_LRY_]%-7P[7VY\0)A!\.O$CG_ *!EPH^IC('\Z^(Z
M /LKX1LS?"KP^6Z^0P_ .P%=K7.> -/;2_A]H%FZ[9$L8BZ^C,H8C\R:Z.@
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M)+$8).T# ]:]THH ^ *]5^$OQ7L_ 5E>Z;J=C<7%G<2B='MMI='P%((8@$$
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M"\7:1JLP8PVEW%-(%&3L# MCWQFOM70O$&E^)M,74='O$NK1F*^8H(P1U!!
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M+'$@51] .* &6%E!ING6UA:ILM[:)88E]%4  ?D*^1_C7_R5W7?K!_Z(CK[
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M<\U[)10!\ 5]:?"CX@>']8\+Z'H4=ZL>KV]JMNUHZD,QC3DJ<8(PN>M>ET4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M['I=E#9VVXOY4*!5R>IQ0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &6'\2^W;MWSVM% 'D_@OQ'XB\&SV7A'QKI\[1F1+73M6@4R0R9(5$=ATZ@
MG!Z9'>O6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *XKQOXUO-$F31?#^DW&J^(;F+S(84
MC)CA0DJ))&Z 94\9[<D5VM% 'E'@#X1OIFK-XH\6W"ZCX@ED,P7.Y('/.[/\
M3?H.W8UZO110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !115/5M2@T;1[W4[DX@M('G?'4A03@>_% '/>-?B-H'@6!/[3
MF>2[D7=%9P -(P]3SA1[G\,US%U\8-1T>V@U#7_ FJZ?I,S +="99",]-R8&
MT^Q(KP/2=1N?&7Q7TN\U5O.DO]5@,JGD!#(OR#V"\#V%?47Q1LX[[X8^(8I%
M!"V;3#/JGSC]5H W-"U_3/$NE1:GI%VES:R<!EX*GNK \@CT-:5?)GP1\73>
M'O'5MITDI_L_56%O*A/ D/\ JV'ON^7Z,:^LZ "BBB@ K"\8>*[#P9X<N-8U
M Y6/Y8H@<--(?NH/K^@!/:MFXGAM;>6XN)%BAB0O)(YP%4#))/IBOD+XK>.K
MKQMXB25%EBT>$,+"-P1YBY*F7ZL5/TQCL: /HSX;_$ ?$+2KR^&F&P^S3B'8
M9_-W?*#G.U<=:[6O%/V;/^14UG_K^'_H KVN@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_\ X7;\//\ H8?_ "2N/_C==1X;\4Z-XNTZ2_T.\^UVL<IA9_*>/#@ D8<
M]&'YU\8>)/"VL^$=1CL-<L_LEU)$)E3S4DRA) .4)'53^5?0_P"SC_R3S4/^
MPK)_Z*BH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#Y@_:._Y*'I__ &"H_P#T;+7?_LX_\D\U#_L*R?\ HJ*N _:._P"2
MAZ?_ -@J/_T;+7?_ +./_)/-0_["LG_HJ*@#V"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /F#]H[_ )*'I_\ V"H__1LM=_\ LX_\
MD\U#_L*R?^BHJX#]H[_DH>G_ /8*C_\ 1LM=_P#LX_\ )/-0_P"PK)_Z*BH
M]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +"LG_HJ*@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YKQKXE_P"$=T?]
MPV+^YRMOE-P&,;F/;@'CKR1P1FJC%R=D14J1IP<Y;(MZQXKT;0V:.\O%\\*3
MY$8+OD '! ^Z3D8W8S6#_P +4T/_ )]=1_[]I_\ %UY')))-*\LKL\CL69V.
M2Q/4D]S3:[HX6"6IX4\TK-^ZDD?0>E>(=)UO<-.OHYF7.4Y5P!CG:P!QR.<8
MK3KYNM[F>TG6>VFDAF7.V2-BK#(P<$>U>W>"O$)\0Z$LD[J;V!O+G  &3V;
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MW%]=P6L(X,D\@11^)XH L453L-6TW58VDT[4+6\1>K6\RR ?BI-7* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@_:._Y*
M'I__ &"H_P#T;+7?_LX_\D\U#_L*R?\ HJ*N _:._P"2AZ?_ -@J/_T;+7?_
M +./_)/-0_["LG_HJ*@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT;?\3+6B4WKCJD2\GCH>E '!_L[^+-1DU>\\,W5P\UE]F-Q;K(V?*964%5]
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MKT?X$>+;SQ)X/GL]0F:>ZTR41"5SEFB893)[D88?0"M_XN 'X5>(,C_E@O\
MZ&M>;?LRGY/% [9M?_:M 'KGCCQ;:^"?"MUK-ROF.F(X(<X\V4_=7^9/L#7$
M>$? (\8V$'BKQZ\FJ7U\@FM[-W98+6)N5"H#U(P>?7UR:YC]I:_DSX?TY6(C
M/G3N/4_*J_E\WYUVND>#/%,^BV$L'Q%U".%[>-HT6QA(52H( _"@#D/BW\)-
M'TOP]-XD\-0&PGLBKSP1N=CID#<N3\K#(/'& >]:GP+^(U[XCAN/#NLSM/>V
MD7FV]PYRTD0(!#'N02.>I!]LUOZA\./$FJZ?/87WQ#U":UN$,<L;6,0#*>HX
MJGX(^"UMX)\3PZU!KD]RT:.AB: *&##'4'\?PH YSXV> -#T[PO?>)HA=R:I
M)<Q@RSW+R<,W( )X'H.U87P:^&WAOQIX8OK[6;>:6>&\,*&.9D&W8IZ#W)KT
M;X]_\DLNO^OF'_T*L?\ 9O\ ^1(U3_L)-_Z+CH [VU\'#0O"RZ%X5U!](02E
M_/:(7# '.X#<<9SCDYQZ5\L_$.QU72OB%>:;JVK7&J3V\B;;F=B2RLJL."3C
MAL8''%?9U?)?QN&/C!?>ZV__ *+6@#ZLOHKF:QFBL[E;:Y9"(YFC\P(WKMR,
M_3-?+'QLTG7=%\1VL.K>(KK6(;F'SHC*/+6-@2" @.T=CP!UKZOKYS_:5'_$
MZT _].\O_H0H W_#VC^)_B!X%T73(KR70/#=O910R2*N;B_8* V!D;8\Y SU
MZX(Z<3\3O@W'X'T2+6M+U&>ZM5E6.=)E >,GHP(X(SQT[BO??AU_R3?PW_V#
MH?\ T 5C?&Q0WPBUS(Z>01_W_CH J?!'Q7=^*/ NS4)6FO-/F-LTKG+2)@%2
M3W.#C_@.:Z+QAH'B#7K9X='\3RZ.GE$;8;<%W?G!,F<J.@^7!]^U>:?LTD_V
M+KX[?:(O_06KW.@#Y(^"TLT_QCTN6YD>29A<%WD8LQ/DOU)ZU];U\E_!P8^-
M5@!V:Z_]%25]:4 ?(%U?2:9\>;V]AM);R6'79GCMX1EY6\UL*/J<"O2]2^#G
MBSQY.VK^*_$L5I=N,Q64,!FCMU/1!\P QWQG/7)K@;+_ ).1;_L8I?\ T:U?
M65 'QKK_ (=\4_"7Q/!(+EH)N7M;VV8[)E'4<_AE3Z]P17T]\.O&4?CGPC;Z
MKM6.Z4F&ZB7HLH SCV(((^OM6)\<M(AU/X7W\[H#-8O'<1-W!W!6_P#'6/Z5
MPW[-%U)_Q4=H23&/L\JCT/S@_P A^5 'T!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!\P?M'?\E#T_\ [!4?_HV6N_\ V<?^
M2>:A_P!A63_T5%7 ?M'?\E#T_P#[!4?_ *-EKO\ ]G'_ ))YJ'_85D_]%14
M>P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXC%K>,DB31:9,_ELN0<C;G!!'3T]Z]^TZ^CU*PBNXH;F%),X2Y@:&08)'*,
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MT?D(7:,ERVUX^I'.,KGCTKN-*^/FCRP+#K.C:K9:D!AX(X/,#-_L\@_@1^-
M&W\;-0CL/A5JRNP#W)C@C&?O,7!(_P"^0Q_"N6_9RT*6R\,ZGK,R%1J$ZQQ9
M_B2//S#VW,P_X#46I:#XF^,NN6DVIV-SH/A.T;='%<#;<3D]6V]B1P"> "<;
MN:]FT^PM=+T^WL+*%8+6WC$<4:]%4=!0!9HHHH **** "BBB@ HHHH ****
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M_P#V<?\ DGFH?]A63_T5%7 ?M'?\E#T__L%1_P#HV6N__9Q_Y)YJ'_85D_\
M145 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROQ*O);#X;
M>()X"1(+-T!'4;OE)_(UU59^NZ3%KN@:AI,YVQ7EN\#,!RNX$9_#K0!Y]\-_
MA?X1M_!^E:C<:9:ZG>7EM'<23W2"4990VU5/R@#..F>.:[<>$/#*C \.Z0!Z
M"RC_ /B:^5(O%?COX9:A<>'X]2GM/LTA!MY$62/KG<@<'"GKD8SFM6/X^^.D
M&&N;)_=K4?TQ0!])2^"/"<PQ)X8T9OK8Q?\ Q->3?%WP%X?\*Z;8>*=!MDTV
M_MKZ$"*%B$E.<C"]F!7/&.,UPTOQ]\=2*0MQ8QGU6U&?US3O"3^*OB[X[TY=
M:OI[RQL)5N+@E0L42 YP%4!0S8V],_E0!]74444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?,'[1W_)0]/_ .P5'_Z-EKO_ -G'_DGF
MH?\ 85D_]%15P'[1W_)0]/\ ^P5'_P"C9:[_ /9Q_P"2>:A_V%9/_145 'L%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI_:FG_\
M/];?]_E_QJW7/_\ "(:?_P ]KG_OI?\ XFN3%3Q,;>PBGWN[%1MU-7^U-/\
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M** "BBB@ HHHH **** "BBB@#A_BI_R+%M_U^K_Z ]=+X<_Y%C2?^O*'_P!
M%<U\5/\ D6+;_K]7_P! >NE\.?\ (L:3_P!>4/\ Z *VE_"7J<4/][GZ(TZ*
M**Q.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2D6>H]?F*@]M] 'TE\'_  R?#?P^L_/4B]O_ /3+@M][+@;0?HNW\<UWM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ\K5/%RI<7/#)IX.Z./_ *Z'^(^PX^M>VO);V<48=XH(]RQ(&(49)PJCW)P
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M2G_V=>ET4_K%3N1_9^&_E_%_YGFG_"I/^HW_ .2G_P!G1_PJ3_J-_P#DI_\
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M=25OL\+2E"A1G _A7> "QZ 9YKYGU#4+O5M0FO[^=Y[J=MTDC]2?Z #@ <
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M 4444 %%9EWXCT.PN7MKS6=.M[A,;HIKI$9<C(R"<C@@U#_PEWAK_H8=)_\
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MN'IGU7'UKZ:^'OQ#TWQ_I+3VZ_9[^  75HQR4)_B4]U/K^= '8T444 %%%%
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M+L:M%9D7B#2YIDBCNLN[!5'EMR3T[5IUM2K4JJO3DGZ.XFFMPHHHK404444
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ME?\ :%_Y*4G_ %X1?^A/0!2\4_#/4(/ ^C>+]/>:\M)K"%KN-B6>W.P#</\
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M-@B"0SLWR[3TP>^>V.O:OF/XF?&6^\6&72M%,EEHO*N<XEN1_M>B_P"S^?H
M#L_B=\<H[3SM%\(S+)/RDVHKRJ>HB]3_ +70=L]1XQX)EDG^)'AR65VDD?5[
M9G=SDL3,N23W-8=K:W%[=16MK!)/<2L$CBC4LS$]@!UKU;2/A+XC\*ZMX5\0
M:I]F1&UFS22V1RTD6Z5<%N-O7C@GJ* /J.BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTK5;2\5AG$,H9A]1U'XUIUD6'A7P[I5VMWIV@Z79W*@@36]G'&X!Z\J :UZ
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M-X$N)S,_AJT#DYQ&71?^^5('Z4 9>I?&;P[M%IX;%QK^K2\06EI X!/JS$#
M]<9JS\/O!-[I-Y?^)_$DB3^)=4.9BG*V\?&(U_(9[?* .F3U>C^'M&\/PF+2
M-+M+)6^]Y$04M]2.3^-:= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%K>VUZDC6TR2K'*\+
ME3G:ZG#*?<$8JOK6C6/B#1[G2M2@$UI<IL=#^A![$'D'L17SVGQAU#P'XP\4
MZ6=-BU"R;6+F6-6E,;1L9#G!P>.,XQUS6E_PTRW_ $*0_P#!C_\ :J ///B5
MI7B7PM>VWAG5=0N;K2+0%M-+'Y&C)/./[PS@@].@XQ7.^&?"VK^+M733='M6
MFF/+N>$B7^\[=A_D9->@>./C)8^.O#[Z9?>$Q%(IWV]RM_EH7]0/+Y'8CO\
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MW9_Y=+@!)>_09PW"D_*3@=<5TM<4X2@^62LR91E%VDK!1114DA1110 4444
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M_P ('XP_Z%37/_!?+_\ $U]O44 ? UU:7-E</;W=O+;SH<-',A1E/N#R*W?
M\,L?Q \+N\;JK:K:[2RD _O5Z5]@>)O".B>+]/:SUFQCG&"$E Q)$?5&ZC^1
M[YKY@'@^Z\#_ !LT'1[A_-C&J6DEO-C'FQ&9<-CUX(/N#0!]=T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,'[1W_)0]/_[!4?\
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M="N'NH[;6()99S$R+DRH H# $]#GCTH ]]HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^8/VCO^2AZ?\ ]@J/_P!&RUW_ .SC_P D
M\U#_ +"LG_HJ*N _:._Y*'I__8*C_P#1LM=_^SC_ ,D\U#_L*R?^BHJ /8**
M** "BBB@ HHHH **** "BBB@ HHHH **** .0\=^!+3QCIX92D&J0+BWN2."
M.NQ\=5)_%2<CN#X?JOPZ\5Z3/Y<FC7%PI9E22T7SE8 ]?ER5!SQN /MP:^GZ
M*[</CJE%<JU1U4<7.DN7='RO:>!_%-[<I;Q:!J*N^<&:!HEX&>6?"CIW->S_
M  Y^',7AB!=3U-$EUF1>!PRVRD<JI[L1U;\!QDMZ#13KX^I5CR[(=;&3J1Y=
MD%%%%<)R!1110 4444 %%%% !1110 4444 %>#>/?#5]X5\9KJ_A:POH($A%
MVTUO"S10/E@X! P%VC)4\88C[O%>\T5OAZ[HRNE=/H;4:SI2ON>$VGQD\77]
MREM9Z3IUQ</G;%#;2NS8&3@!\G@$T^+XO>,Y]0.GQ:+8R7H9D-NEK,9 RYW#
M;OSD8.?3!J'XHV>B>'O$UC>>'YK>TU2!DDFM(4^6-A@QN%V[ >.5)YRIV\DG
MF?#?BJ+3_B"GB;4HG96FGFF2V4$[I%<?*&/3+=STKV84:4Z?M(T^GXGIQI4Y
MPYXPZ?B=Y_PL'XE?]"A_Y3;G_P"*KL? ?B'Q+KO]H?\ "1:/_9WD^7Y'^C20
M^9G=N^^3G&%Z>M;.A^*]"\2;QI.I0W#IG='RC@#&3L8!L?,.<8SQ6S7E5JL;
M.'LU%GGU:BLX\EF%%%%<AS!1110!YK_9>H?\^-S_ -^6_P *:VG7R(SO97"J
MHR28F  _*E_X3'QQ_P!"W_Y(S?\ Q5(WBOQC<H8+K0/*MY!LED^QS+M4\$Y)
MP,#N:^<J\+0A!S]ILO(RCF<&TK/[AL-G=7"%X+::50<$HA89_"I/[+U#_GQN
M?^_+?X5%#K_B/2D,&D:3]LMV.]I/LTDF&Z$94@= ./>I/^$Q\<?]"W_Y(S?_
M !58X+AN.)P\*SG;F7D55S&%.;@T]/([CP_%)#HEO'+&T;C=E6&"/F/:M.JV
MG33W.EVD]U'Y5Q)"CRQ[2NUBH)&#R,'L:LU]+1I*C3C27V4E]Q?-S>]W"BBB
MM (KFXBM+6:YG;9#"AD=L$X4#).![5X+XB\17GB343<W)V1+D0P*<K&O]2>Y
M[_0 #USQY))%X*U)HW9&*HI*G!P74$?0@D?C7AE=N%@K.1XF:U9<RIK;<***
M*[#QSO\ X>>*KB'4TT>^N6DM9EVP&1L^6X'"@D\*0, <\XQC)KU>OFZVN);2
MZAN8&V30N)$; .&!R#@^]>J:)\28IKH6.N6OV*YW^691D1JV3PP;E,<#OSG.
M!7%B*+;YHH]K+\9%1]G4?H=E?Z=:ZE"([F/=MSM8'!4GT/\ D5S$+WWA>]9)
MD:6Q=N6 X/N/1N.GM]#795'/!%<P/#,@>-QAE/>O#Q> 562K4GRU%L^_D^Z/
M<C*VCV([*]@U"V6XMVW(>H/53Z'WJQ7&W-CJ'AJ9KJSEWVK, <C/'8./TR/T
MS6S!XHTR2!'EF,4A'S(48[3]0.:RP^9QNZ6*]R:WOHGYIC<.L=4;-<5IW_([
M/_UWF_DU=!_PDFD_\_?_ )#?_"N7LKZWB\4->/)BW,LC;]IZ$-CCKW%<6:8J
MA.K0<)IVFF[-:;%0BTGH=[165_PDFD_\_?\ Y#?_  JQ9ZO8W\QBMI_,<+N(
MV,./Q'O7LPQF'G)1C4BV_-&7*UT+M%%%=(@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M . DG^% 'NG_  TO8_\ 0LW'_@6O_P 31_PTO8_]"S<?^!:__$UX7_PC&O\
M_0#U/_P$D_PH_P"$8U__ * >I_\ @))_A0![I_PTO8_]"S<?^!:__$UDWOQE
MF\=>*/"VCVVE_8+7^VK269FF\QI,2K@=  ,\]^@Z=_(?^$8U_P#Z >I_^ DG
M^%:7@^QN[#XC^&8[RUGMW.JVI"S1E"?WJ]C0!]L4444 %%%% !1110 4444
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MX6=K1117Z*<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^E>Q:+XBT?Q':?:M'U*WO8NYB?)7V8=5/L0* -.BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Y@_:._Y*'I__ &"H_P#T;+7?_LX_
M\D\U#_L*R?\ HJ*N _:._P"2AZ?_ -@J/_T;+7?_ +./_)/-0_["LG_HJ*@#
MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N0\5?$72/"&J1:?J%M?2RR0B8&W1&7:69>[#G*
MFNOK/OM"TC4YUFU#2K&[E5=@>XMTD8+DG&2#QDG\ZTI."E^\5T73<$_?5T<)
M_P +O\-?\^.K?]^H_P#XY7F6C^*K'3_B=)XFEBN&LFNKF8(BJ9-L@<+QG&?F
M&>?6O?\ _A$?#7_0O:3_ . 4?_Q-'_"(^&O^A>TG_P  H_\ XFNVGB</3348
MO56W.N%>C!-*+U\SC?\ A=_AK_GQU;_OU'_\<KIO"7CC3/&7VS^SH+N+[)LW
M_:$5<[MV,;6/]TU<_P"$1\-?]"]I/_@%'_\ $U=L-(TS2O,_L[3K2S\S&_[/
M L>[&<9V@9QD_G7/4EAW%J$6GZF$Y47'W4[GE'Q-T.Y\,^([+QIH=OY860-=
M>6I"B7/WGP<XD!VG& <<G+UZ;X;U^T\3:%;:G:.A$B@2QJVXPR8&Y#P.03Z#
M(P>A%7=0T^TU;3YK"_@2>UG7;)&_0C^A!Y!'((!%>*^!M0N_ GQ%N?"M_.[6
M5Q-Y(!^[YC8,4@4;L%AM!&1]X9/RUM'_ &BC;[4/Q7_ -5^_I6^U'\4>YT44
M5P'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XU\3()(O%I=Y
MVD6:W1T4](QRNT<],J6[?>->RUROCGPO+XCTZ)[63%W:[FCC8@+(#C*Y['Y1
M@]/7KD;4)J,[LX\=1E5HM1W6IXG74WO_ "*R_P#7*+^:US$D<D,KQ2HR2(Q5
MD88*D=01V-=/>_\ (K+_ -<HOYK7GY[_ !\)_P!?%^:/-R[^'6_PLP-/O6L;
MQ9A]W[KC&<KWKTSP9;6Z^)9KY9@&FM=BH!D/RIR#GT4< >IKS"SL[C4+R*TM
M(6EGE;:B+U)_H/?M7HB^'-2\+PVSM,MQ&N&$D4?$,F<D'/5<]&(]0<< O.J<
MJ$XXZC\45:2[Q_X&_P#PQME4G-.G-7C>Z?9_\'^MSTNBN:T;QA:W]XUA>B.S
MO/E,0:3Y9P>!M)QAL\;>OH3SCI:WISC4@IQV>J/74D[VZ!1115#.'_X6IH?_
M #ZZC_W[3_XNC_A:FA_\^NH_]^T_^+KI?^$<T/\ Z VG?^ J?X5GZ]H.C0^'
M=3EBTFP21+25E=;9 5(0X(..#6Z=)NUF<,HXJ*;YE]QE?\+4T/\ Y]=1_P"_
M:?\ Q='_  M30_\ GUU'_OVG_P 75/X;:3IM_P"';B6\T^UN)!=LH>:%7(&Q
M.,D=.378_P#".:'_ - ;3O\ P%3_  IS]E&35F12>*J04U):^1<LKJ._L+>\
MB#".>)95##D!@",^_-3TV...&)(HD5(T4*J*,!0.@ ["G5SL]!7MJ%%%% PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &<?^2>:A_V%9/\ T5%0![!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y+\<[ZQ&EZ9IY5&U S&92
MI:.(*5.>X#,5QV.P^E>,7%Y<W?E?:;B:;R8Q%%YCEMB#HHST [ <5=\0ZU/X
MAU^]U:X&U[F3<$R#L4<*N0!G"@#..<9K,KZG"T?8TE%[GT.'I>SIJ+W)K2\N
M;"Y2YL[B:WN$SMEA<HRY&#@CD<$BO;?AS\4&U>=='\03(+]VQ;76T(LQ)^XP
M& &],<'IUQN\,HHQ&'A7C:6_<*U"-6-I'V/16'X.UEM?\(:9J4A=I980LK.H
M4M(I*N<#C!921[$<#I6Y7S$HN,G%]#Y^47%M/H%%%%2(**** "BBB@ HHHH
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MD\U#_L*R?^BHJX#]H[_DH>G_ /8*C_\ 1LM=_P#LX_\ )/-0_P"PK)_Z*BH
M]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA5S345\)ZE"=62;FDNUG<****S-PHHHH **** "BBB@ HHHH **** "BBB@
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M/9?J%%%%<AZP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZE7G8CG<KR5CZ++U2C!QIN[ZA1117.>@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!R_@[Q1_PD,^OVLTD?VK2]5GM"BC!$88^
M62/< C/JIKJ*^3'\5:KX+^,7B/7+&&6:TCU2>.\C .QXS*WRD] >X/J/J*^H
M]$UJP\1:-:ZKILPFM+E-Z-W'J".Q!X(]10!)IVDV&D131Z?:QV\<\S3R+&,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-Y:07]E/9W*;[>XC:
M*5,D;E88(R.1P>U>,>"Y&\#?%B_\,O,C65VWE*SN!SMWPDDJ,MAMF!@%G[X%
M>VUY%\8='U"TU'3?%]C+_P >?EPD"/<8F5V=)#P1C)QSWV]<\=N#DI-T9;27
MX]#JPKNW3>TOSZ'KM%9GA[6H/$.@66K6XVI<Q[BF2=C#AER0,X8$9QSC-:=<
M<HN+:>YS--.S"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#/UC3$U2R:+Y1,O,3L/NG_ ]/_U5E>&-3<[M,N=PECSY
M>\X( ZICKD?RSTQ72UR_B;3WAF35[;AT93(2>A& K '\ORXZUY&84Y4)K&TE
MK'XEWC_P/ZV-(.ZY6=116?IVJP7FF+=NZQA?EE+?*%;C/7MR,?6I?[4T_P#Y
M_K;_ +_+_C7H1Q-&45)25GKN19ENBJG]J:?_ ,_UM_W^7_&C^U-/_P"?ZV_[
M_+_C5>WI?S+[T%F6Z*K+J-B[JB7MNS,< "522?SJS5QG&?PNXK!1115 %%%%
M !1110 4444 %%%% !1110 5F>(_^18U;_KRF_\ 0#7#_P#"8^./^A;_ /)&
M;_XJH+WQ/XUO["XLY?#K".>)HF*V4V0&!!QSUYK=49)WT.">-IN+23^XVOA7
M_P BQ<_]?K?^@)7<5X_H&I>+O#E@]G9^'YGC>4RDS6<I.2 .Q'' K5_X3'QQ
M_P!"W_Y(S?\ Q554I.4VU8SPV+A3I1A).Z\CTNBLSP_>7VH:';W6I6WV:[?=
MYD6QDVX8@<-R. #^-:=<[5G8]&,E**DNH4444BB*XMH+N!H+F&.:%L;HY%#*
M<'(R#[U1_P"$<T/_ * VG?\ @*G^%:=%--K8EPC+5HS/^$<T/_H#:=_X"I_A
M1_PCFA_] ;3O_ 5/\*TZ*?-+N+V<.R,S_A'-#_Z VG?^ J?X5IT44FV]QJ,8
M[(****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &!H/AF'2K/5[>Y6"X34M0N;N52F5996R%8'KA<"O-=LWP4\89'F/X'UB;G
MJWV&8_T_F!W*\^Q6M[;7J2-;3)*L<KPN5.=KJ<,I]P1BJ^M:-8^(-'N=*U*
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MJX#]H[_DH>G_ /8*C_\ 1LM=_P#LX_\ )/-0_P"PK)_Z*BH ]@HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[XYT!O$OA"^T^)$:
MZVB6WW*"?,4Y !)&TL,KG/ 8UR?P7\117OAV30Y"BW%@Q>,# +Q.Q;/7)(8D
M'@  IW->G5XEXL27X>?%*V\0VP?^S]19I)D4D[LD"9<;N3DAQG"[B/[M=V&_
M>TY4'ONO4ZZ'[R#H_->I[;1117"<@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!S_B_P#Y!,7_ %W'_H+5Q5=KXO\
M^03%_P!=Q_Z"U<57PG$'^^OT1U4OA"BBBO%-"WI?_(6LO^NZ?^A"O2J\UTO_
M )"UE_UW3_T(5Z57V'#7\*IZK\CGK;H****^E,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^2AZ?\ ]@J/_P!&RUW_ .SC_P D\U#_ +"LG_HJ*@#V"BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO\OZ2E'JMC0HHHKTR HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\QBMI_,<+N(V,./Q'O50QF'G)1C4BV_-"Y6NA=HHHKI$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\4>-K6XO?B9XC@M8)9YFU.YQ'$A9C^\;L
M*S/^$8U__H!ZG_X"2?X5];>*/A7X5\53/=7%B;34&;=]MLF\J3=_>/9C[D$U
MS0TGXH>!^=+U&'Q9I:?\NUX=ERJ^S$\_]]'_ ': /F[_ (1C7_\ H!ZG_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU V5FW'V6RS&I'HQSN;\3CVKA: /HKPM^T99S[+?Q/IK6S]#=6>73ZE#\P_
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MBBB@#Y@_:._Y*'I__8*C_P#1LM=_^SC_ ,D\U#_L*R?^BHJX#]H[_DH>G_\
M8*C_ /1LM=_^SC_R3S4/^PK)_P"BHJ /8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YWQYI4NM>!]6LH=_FM#
MYB*B%V=D(<* .I8KC\>_2OEJOL>O)?'WPF:_GGUCP]O>]GF,D]I)( KECRR,
M<8.<D@G')QC !]3+L5&G>G/1,]#!8B-.\);,\2HJ:[L[FPN7MKRWFM[A,;HI
MD*,N1D9!Y'!!K0T#PWJOB;4$M-,M7E)8+)*0?+A!SR[=A@'W., $\5[;E%+F
M;T/6<DE=O09X=TQ-9\1Z=ILC[([FX2-V\Q4(4GYL%N,XS@<Y.  2<5]:5XQJ
MOP96T\&>;:W+S:Y;JTTH4%DF&,F-% SD8^4XRQ)R!D;>I^%?C#_A(M %C?77
MF:K995_,?+RQ?POT&<9VGJ<@$GYA7BXZ2Q$?:4W=1T?^9Y6+DJT>>#NE_5SO
MJ***\H\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O/_$G_ "'[K_@'_H KT"O/_$G_ "'[K_@'_H KY_B3
M_=8_XE^3-:/Q&51117Q1TA70>$/^0M+_ -<#_P"A+7/U;T^XN[2Y^T688O&I
M9P%)&WON]JZL#65'$PJ-729,E=6/2J*R]*URVU1-O$4^<>4S9)]QZ\?E6I7Z
M-1KTZ\%4INZ9R--.S"BBBM1!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\9_$_7=5U3QWK=K?:A<3VUK?S100NYV1JKD *O0<#K7(00374Z06\4DTSG"
M1QJ69CZ #K7H.J^$-:\3?$WQ/)INB76I6T&JW F$4BQ#/F-QO;@']:]+\.#Q
MEX4@\O1?A+96S$8:47Z-(_U<L6/TSB@#@_"OP%\4:YLGU39HUHW/[\;IB/:,
M=/\ @1%>W>%?@_X1\+;)DL?M]ZO/VF]Q(0?]E?NK^6?>LK_A,?BG_P!$YA_\
M&"?XT?\ "8_%/_HG,/\ X,$_QH ]2K.UC6;;1(+66Y61A<W<-F@0#.^5PBGD
MC@$Y/L*\^_X3'XI_]$YA_P#!@G^-<+XB\5^-M6^(G@_3O$FC'1[-=7M98H$!
M*RN)5&2^2&P#T'3- 'T91110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\P?M'?\E#T__L%1_P#HV6N__9Q_Y)YJ'_85D_\ 145<!^T=
M_P E#T__ +!4?_HV6N__ &<?^2>:A_V%9/\ T5%0![!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5=5LM$TV
M;4=1F\FTAQODVLV,D*.%!/4BN9_X6KX*_P"@U_Y*S?\ Q%=-JNE66MZ;-IVH
MP^=:38WQ[F7."&'*D'J!7,_\*J\%?] 7_P FIO\ XNNBE["W[V]_*QM3]C;]
MY>_E8X?XI^-?#WB3PQ;6>DZA]HN$O%E9/)D3"A'!.64#JPKIO#GQ*\(V'AC2
M;.YU;9<6]G#%*GV:4[65 ",A<'D=JTO^%5>"O^@+_P"34W_Q='_"JO!7_0%_
M\FIO_BZZ75PKIJG[UEZ&[J8=P4/>LO0FL_B5X1O[V"SMM6WW%Q(L42?9I1N9
MC@#)7 Y/>O/O'_A67P3KMGXM\.0O';K-OFB0$1P/D<<$$1OD@CH.1G# #T&S
M^&OA&PO8+RVTG9<6\BRQ/]IE.UE.0<%L'D=ZZ/4-/M-6T^:POX$GM9UVR1OT
M(_H0>01R" 16<*].C-.E>SW3L1&K"G-.G>W6Y2\-Z_:>)M"MM3M'0B10)8U;
M<89,#<AX'()]!D8/0BM:O!G2[^#_ (\C99;BYT2[7<RJ,&6/D8.1M,B$@\8R
M".5#D5[AI^H6FK:?#?V$Z3VLZ[HY$Z$?T(/!!Y!!!K/$T%3:E#6+V_R(KT>2
MTHZQ>Q9K USQKX>\-WJ6>K:A]GN'C$JIY,CY4D@'*J1U4UOUR'BKX=:1XOU2
M+4-0N;Z*6.$0@6[HJ[0S-W4\Y8UG15-R_>MV\B*2@Y?O-AG_  M7P5_T&O\
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ME>P:A;+<6[;D/4'JI]#[UT83'PQ#<&N6:WB]_P#@HF4&M>A8HHHKO)"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,7PWH9T*'459HW>\U&XO24&/\ 6.2 ?<#
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M-EKO_P!G'_DGFH?]A63_ -%14 >P4444 %%%% !1110 4444 %%%% !1110
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M<=D3@[<8Z98'KP<1]\<>=F-%3I<_5'%CJ2E3YNJ/:J***^?/%"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".
M>"*Y@>&9 \;C#*>]<G=Z1>:#<B^TYFDA1<ONP2!W##N._'3VQFNPHKBQF!IX
ME)O22V:W149.)YK_ &IJ'_/]<_\ ?YO\:/[4U#_G^N?^_P W^-5**_//;U?Y
MG][.NR+?]J:A_P _US_W^;_&C^U-0_Y_KG_O\W^-5**/;U?YG]["R/0O#\LD
MVB6\DLC2.=V68Y)^8]ZTZRO#?_( M?\ @?\ Z&:U:_1L"V\+3;_E7Y')+XF%
M%%%=1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M< +(PYX*G[PX;^?/6L.O.QG$%2G44:,>FJDG=/MOZ%QI)K4] _X232?^?O\
M\AO_ (4?\))I/_/W_P"0W_PKS^BN3_63%?RQ^Y_YE>QB>@?\))I/_/W_ .0W
M_P *U:\JKU6O:R?,JN-Y_:)+EMM?K?S?8RJ04;6"BBBO;,PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@_:._P"2
MAZ?_ -@J/_T;+7?_ +./_)/-0_["LG_HJ*N _:._Y*'I_P#V"H__ $;+7?\
M[./_ "3S4/\ L*R?^BHJ /8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQT $F>?XAP>W+C)2C1E*+LT<^*DXTG*+LSHO^%(>&O\ G^U;_O['_P#&Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?,'[1W_)0]/_ .P5'_Z-EKO_ -G'_DGFH?\
M85D_]%15P'[1W_)0]/\ ^P5'_P"C9:[_ /9Q_P"2>:A_V%9/_145 'L%%%%
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M/Y%*36S/*J***_,SL"BBB@#J-(\26=AI<-M+'.73=DJHQRQ/K[UL?\))I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@_:._P"2AZ?_ -@J
M/_T;+7?_ +./_)/-0_["LG_HJ*N _:._Y*'I_P#V"H__ $;+7?\ [./_ "3S
M4/\ L*R?^BHJ /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S_ /X1O5O^?3_R(G^-'_"-ZM_SZ?\
MD1/\:] HKY__ %;PO\TOO7^1K[:1Y_\ \(WJW_/I_P"1$_QH_P"$;U;_ )]/
M_(B?XUZ!11_JWA?YI?>O\@]M(S]$MIK/1X()TV2KNRN0<98GM6A117N4::I4
MXTX[))?<9MW=PHHHK01E>)/^0!=?\ _]#%>?UZ%X@BDFT2XCBC:1SMPJC)/S
M#M7$?V7J'_/C<_\ ?EO\*^-XAI3GBHN*;]U?FSHHM<I4HJW_ &7J'_/C<_\
M?EO\*/[+U#_GQN?^_+?X5X/L*O\ *_N9K=%2O5:\U_LO4/\ GQN?^_+?X5Z5
M7U'#=.</:\RM\/ZF-9[!1117U!@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\P?M'?\E#T_P#[!4?_ *-EKO\ ]G'_ ))YJ'_8
M5D_]%15P'[1W_)0]/_[!4?\ Z-EKO_V<?^2>:A_V%9/_ $5%0![!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!^T=_R4/3_^P5'_
M .C9:[_]G'_DGFH?]A63_P!%15P'[1W_ "4/3_\ L%1_^C9:[_\ 9Q_Y)YJ'
M_85D_P#145 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\
MXW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3M
MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_
M .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_
MPNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\
M'* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>
M_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX
M>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /
M?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)
MVW_^.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
M0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /?_\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^
M.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^
M25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\*2^(?_0O?^3MO_\ '* /?_\ A=OP
M\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KP#_A27Q#_ .A>_P#)VW_^.4?\
M*2^(?_0O?^3MO_\ '* /?_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_
M\;KY8\2>%M9\(ZC'8:Y9_9+J2(3*GFI)E"2 <H2.JG\JT/#?P[\5>+M.DO\
M0]*^UVL<IA9_M$4>' !(P[ ]&'YT ?2__"[?AY_T,/\ Y)7'_P ;H_X7;\//
M^AA_\DKC_P"-UX!_PI+XA_\ 0O?^3MO_ /'*/^%)?$/_ *%[_P G;?\ ^.4
M>_\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-UX!_PI+XA_\ 0O?^
M3MO_ /'*/^%)?$/_ *%[_P G;?\ ^.4 >_\ _"[?AY_T,/\ Y)7'_P ;H_X7
M;\//^AA_\DKC_P"-UX!_PI+XA_\ 0O?^3MO_ /'*/^%)?$/_ *%[_P G;?\
M^.4 >_\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-UX!_PI+XA_\
M0O?^3MO_ /'*/^%)?$/_ *%[_P G;?\ ^.4 >_\ _"[?AY_T,/\ Y)7'_P ;
MH_X7;\//^AA_\DKC_P"-UX!_PI+XA_\ 0O?^3MO_ /'*/^%)?$/_ *%[_P G
M;?\ ^.4 >_\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-UX!_PI+X
MA_\ 0O?^3MO_ /'*/^%)?$/_ *%[_P G;?\ ^.4 >_\ _"[?AY_T,/\ Y)7'
M_P ;H_X7;\//^AA_\DKC_P"-UX!_PI+XA_\ 0O?^3MO_ /'*/^%)?$/_ *%[
M_P G;?\ ^.4 >_\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-UX!_
MPI+XA_\ 0O?^3MO_ /'*/^%)?$/_ *%[_P G;?\ ^.4 >_\ _"[?AY_T,/\
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MP_\ DE<?_&Z\ _X4E\0_^A>_\G;?_P".4?\ "DOB'_T+W_D[;_\ QR@#W_\
MX7;\//\ H8?_ "2N/_C='_"[?AY_T,/_ ))7'_QNO /^%)?$/_H7O_)VW_\
MCE'_  I+XA_]"]_Y.V__ ,<H ]__ .%V_#S_ *&'_P DKC_XW1_PNWX>?]##
M_P"25Q_\;KP#_A27Q#_Z%[_R=M__ (Y1_P *2^(?_0O?^3MO_P#'* /?_P#A
M=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z^6/$GA;6?".HQV&N6?V2Z
MDB$RIYJ290D@'*$CJI_*M#PW\._%7B[3I+_0]*^UVL<IA9_M$4>' !(P[ ]&
M'YT ?2__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C=> ?\*2^(?\
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M_P#H7O\ R=M__CE 'O\ _P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
MXW7@'_"DOB'_ -"]_P"3MO\ _'*/^%)?$/\ Z%[_ ,G;?_XY0![_ /\ "[?A
MY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-UX!_PI+XA_P#0O?\ D[;_ /QR
MC_A27Q#_ .A>_P#)VW_^.4 >_P#_  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?
M_)*X_P#C=> ?\*2^(?\ T+W_ ).V_P#\<H_X4E\0_P#H7O\ R=M__CE 'O\
M_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW7@'_"DOB'_ -"]_P"3
MMO\ _'*/^%)?$/\ Z%[_ ,G;?_XY0![_ /\ "[?AY_T,/_DE<?\ QNC_ (7;
M\//^AA_\DKC_ .-UX!_PI+XA_P#0O?\ D[;_ /QRC_A27Q#_ .A>_P#)VW_^
M.4 >_P#_  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C=> ?\*2^(?\
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M7;\//^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !NO /\ A27Q#_Z%[_R=M_\
MXY1_PI+XA_\ 0O?^3MO_ /'* /?_ /A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_
M .25Q_\ &Z\ _P"%)?$/_H7O_)VW_P#CE'_"DOB'_P!"]_Y.V_\ \<H ]_\
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M]##_ .25Q_\ &Z\ _P"%)?$/_H7O_)VW_P#CE'_"DOB'_P!"]_Y.V_\ \<H
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M'?\ )0]/_P"P5'_Z-EKO_P!G'_DGFH?]A63_ -%14 >P4444 %%%% !1110
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M?M'?\E#T_P#[!4?_ *-EKO\ ]G'_ ))YJ'_85D_]%15P'[1W_)0]/_[!4?\
MZ-EKO_V<?^2>:A_V%9/_ $5%0![!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'S!^T=_R4/3_^P5'_ .C9:[_]G'_D
MGFH?]A63_P!%15P'[1W_ "4/3_\ L%1_^C9:[_\ 9Q_Y)YJ'_85D_P#145 '
ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M33RWKW"M:NS*%*(N#N53G*'MZ4 =Y1110 4444 %%%% !1110 4444 %%%%
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M[E4YRA[>E '>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\P?M'?\ )0]/_P"P5'_Z-EKO_P!G'_DGFH?]A63_ -%1
M5'\6?A-KWCSQ5:ZII=WIL,$5DENRW4CJQ8.[9&U&&,.._K74?";P5J7@/PK=
M:7JD]I-/+>O<*UJ[,H4HBX.Y5.<H>WI0!WE%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !17-^,_&^C^!M(%]JDC%Y"5@MX^9)F'8#T'<G@?B!7#Z;X[^)
M'B+1&\0Z-X7TE=+.YHH)YW,\RJ3DK@@=B.0,]LT >N45Y]\//BSI'CPFS,1L
M-61=QM9'W"0#J4;C..XP"/?K7H- !1110 45S?C/QOH_@;2!?:I(Q>0E8+>/
MF29AV ]!W)X'X@5P^F^._B1XBT1O$.C>%])72SN:*">=S/,JDY*X('8CD#/;
M- 'KE%>??#SXLZ1X\)LS$;#5D7<;61]PD ZE&XSCN, CWZUZ#0 456O]0LM+
MLWN[^[AM;9.6EF<(H_$UY!XL_:&T;3M]MX;M6U.X''VB7,< /L/O-^GUH ]H
MHJCHM[)J6A:??2JJR7-M',X3H"R@G'MS5Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **R?$GB72_">BRZKJ]QY-M'P !EI&/15'<G_P"OTKSG1?B)
MX[\;PW.H>%/#>F1:9!(8U?49VWRL!G"[2 #R/89ZT >N45YEX'^,5EXCUA]
MUJR.D:VDC1")GW1R.IP5![-D'@_@37IM !1110 44C,J*69@J@9))P *\U\6
M?&_PIX;WP6DQU>^7CRK1AY8/^U)T_+<?:@#TNBN,^&7C&[\<^%I-7O+:"W?[
M5)"L<.<!0%(R2>3SUX^E=G0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444C,J*69@J@9))P * %HKS3Q9\;_"GAO?!:3'5[Y>/*M&'E
M@_[4G3\MQ]JV/AEXQN_'/A:35[RV@MW^U20K'#G 4!2,DGD\]>/I0!V=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P?BS
MXO>$_">^&2]^WWR\?9;/#D'T9ONK^)S[5#\+?B)=_$)=8N)[&&SAM)8UACC8
MLV&#$[F/!/'8"@#T*BBJ>J:I9:+IEQJ.HW"6]I;KODE?H!_4]@.YH N45Y#I
M?Q2\4>.=2O(? ^@67V*TQONM4E8!LYP-JD8)P>,GWQ4^@_&41^)Y/#'C/34T
M?4XY!%YT<FZ L<$9SRH((P<D<]J /5Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHI&944LS!5 R23@ 4 +17FGBSXW^%/#>^"TF.KWR\>5:,/
M+!_VI.GY;C[5L?#+QC=^.?"TFKWEM!;O]JDA6.'. H"D9)/)YZ\?2@#LZ**R
M?$GB72_">BRZKJ]QY-M'P !EI&/15'<G_P"OTH UJ*\CT7XB>._&\-SJ'A3P
MWID6F02&-7U&=M\K 9PNT@ \CV&>M7_ _P 8K+Q'K#Z!K5D=(UM)&B$3/NCD
M=3@J#V;(/!_ F@#TVBBLGQ)XETOPGHLNJZO<>3;1\  9:1CT51W)_P#K]* -
M:BO(]%^(GCOQO#<ZAX4\-Z9%ID$AC5]1G;?*P&<+M( /(]AGK5_P/\8K+Q'K
M#Z!K5D=(UM)&B$3/NCD=3@J#V;(/!_ F@#TVBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HKD?%?Q+\+>#PZ:CJ*R7:_\N=M^\ESZ$#A?^!$5SOPX^*]Q
M\0/%6HV2:;%9V%O;>;'ER\K'<!R>!C!Z ?C0!ZA115/5-4LM%TRXU'4;A+>T
MMUWR2OT _J>P'<T 7**\ATOXI>*/'.I7D/@?0++[%:8WW6J2L V<X&U2,$X/
M&3[XJ?0?C*(_$\GACQGIJ:/J<<@B\Z.3= 6.",YY4$$8.2.>U 'J]%%4]4U2
MRT73+C4=1N$M[2W7?)*_0#^I[ =S0!<HKR'2_BEXH\<ZE>0^!] LOL5IC?=:
MI*P#9S@;5(P3@\9/OBI]!^,HC\3R>&/&>FIH^IQR"+SHY-T!8X(SGE001@Y(
MY[4 >KT453U35++1=,N-1U&X2WM+==\DK] /ZGL!W- %RBO(=+^*7BCQSJ5Y
M#X'T"R^Q6F-]UJDK -G.!M4C!.#QD^^*GT'XRB/Q/)X8\9Z:FCZG'((O.CDW
M0%C@C.>5!!&#DCGM0!ZO1110 4444 %%%% !1110 444C,J*69@J@9))P *
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MV^5@,X7:0 >1[#/6K_@?XQ67B/6'T#6K(Z1K:2-$(F?='(ZG!4'LV0>#^!-
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M\E5\0?\ 7=?_ $!:]T_9Z_Y)H_\ U_R_^@I0!ZM1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5@^(O"EOXG"17VHZE'9!"KVEK<>5
M'+GNY4;C],X]JWJ* /C3XI^$K+P9XWGTO3GD-HT231B4Y90W49[\@UZK^S1_
MR"_$/_7:'_T%ZXO]H/\ Y*9_VXQ?S:NT_9H_Y!?B'_KM#_Z"] 'NU?.W[1OB
M>634=/\ #$$A$$4?VNY /WG)(0'Z $_\"%?1-?&_Q>O&OOBIKTC'.R981[!$
M5?Z4 >T_LYP+'\/KV; WR:D^3["./ _G^=>:?M"6Z0_$P2*,&>QBD;W.67^2
MBO4_V>ACX:R'UU"4_P#CJ5YG^T7_ ,E&M/\ L&1?^C)* /8/@OXGE\3?#RV-
MU(9+NP<VDK,>6"@%"?\ @) SW(->AU\^_LT7C>;XBLB24(@E4>A^<'^GY5]!
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^)/ MAXLF?^U[_ %.2
MT*A1917/E0@COA0"Q_WB?:NHHH ^'O&NA1>&?&>JZ-;R/)#:SE(V?[Q4@$9]
M\&OHO]GK_DFC_P#7_+_Z"E>%_%S_ )*KX@_Z[K_Z M>Z?L]?\DT?_K_E_P#0
M4H ]6KY6^/GB>76/'1TB.0_8]*01A0>#*P#.WUY"_P# 3ZU]4U\+^*KQM0\7
M:S>.<F>^FD_-R: /JGX*0+!\)=$V@ R><['U)F?^F*^=_BQ&=/\ BUKIMV,;
MK<I,K*<$,R*^0?7)S7TA\'QCX4: /^F+G_R(U?.?QH_Y*WKW^]#_ .B8Z /I
M[X?^(SXK\#:5J\A!GEBVSX_YZ*2K'';)!/XU\]_'SQ/+K'CHZ1'(?L>E((PH
M/!E8!G;Z\A?^ GUKT?\ 9RO&F\"W]JQ)\C4&*^P9$./S!_.OGGQ5>-J'B[6;
MQSDSWTTGYN30!]4_!2!8/A+HFT &3SG8^I,S_P!,5\[_ !8C.G_%K73;L8W6
MY2964X(9D5\@^N3FOI#X/C'PHT ?],7/_D1J^<_C1_R5O7O]Z'_T3'0!]/?#
M_P 1GQ7X&TK5Y"#/+%MGQ_ST4E6..V2"?QKI:\=_9RO&F\"W]JQ)\C4&*^P9
M$./S!_.O8J "BBB@ HHHH **** "BBB@ HHHH *R=>T(:_;1VTFI:A9P DR+
M93"(RC'W6;&X#Z$>]:U% 'R9\9_ NF>"=>L1I)F%M>PLYCE?>593@X)YP<CK
M[UN_LV_\C?J__7A_[46K?[2W_(7\/_\ 7";_ -"6JG[-O_(WZO\ ]>'_ +46
M@#Z6KYV_:-\3RR:CI_AB"0B"*/[7<@'[SDD(#] "?^!"OHFOC?XO7C7WQ4UZ
M1CG9,L(]@B*O]* /:?V<X%C^'U[-@;Y-2?)]A''@?S_.O-/VA+=(?B8)%&#/
M8Q2-[G++_)17J?[/0Q\-9#ZZA*?_ !U*\S_:+_Y*-:?]@R+_ -&24 >P?!?Q
M/+XF^'EL;J0R7=@YM)68\L% *$_\!(&>Y!KSG]HWQ/+)J.G^&()"((H_M=R
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MU9[?X7ZXQ.?L-S+*N>P\I6Q^8/YU\VLS.Q9B2Q.23W- 'V_X&@6V\ >'8D
M73;?./4QJ2?SS7R!J=W<>&OB%?W.FOY,UAJ<IA([;9#@?3C&/2OL?PH-O@[1
M!Z:? /\ R&M?&?C7_D?/$7_83N?_ $:U 'VKHNJ0ZWH=AJL'$5Y;I.HSTW*#
MC\,XJ]7GOP1O&N_A1I(<DM"98LGT$C8_0@5Z%0 4444 %%%% !1110 4444
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MPD_]!-?!= 'W3X5_Y%#1?^O"#_T6M:U9'A7_ )%#1/\ KP@_]%K6O0 4444
M%%%% !1110 4444 %%%% !1110 4444 ?!^MP-;:_J,#C#Q74J,/<,17UU\(
M?^24Z!_UP;_T8U?.OQFT!]"^)>IG81!?M]LB;'WM_P![_P ?W5]"_!F43?"7
M0F!Z)*I_"5Q_2@#YW^,YS\6]>_WXO_1*5ZW^S= R^#M6G(^62_V#_@,:G_V:
MO(?C$P;XL:^0<_O8Q^425]&_"#07\/\ PTTJ"9"EQ<J;J4'J"YRN??;M'X4
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MB@ HHHH **** /E7]H/_ )*9_P!N,7\VKM/V:/\ D%^(?^NT/_H+UQ7[0?\
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MOA+H3 ]$E4_A*X_I7SI\8F#?%C7R#G][&/RB2@#U[]FZ!E\':M.1\LE_L'_
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M6A#>H_G0688-MDSG?(1QD'D =^?:O<:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/U?4Y-*M5GCTR^U
M L^TQ62(SKP3DAF48XQU[BO/=1^//AO2+Z2RU'2-?M;J,X>*:T16'X&2@#U*
MBO)$_:(\(2.$2PUMF/0+;QDG_P B5*O[07@X2!)K;6+<_P#36U7C\G- 'JU%
M<AH7Q0\&^(I4@L-<@%P_"PW ,+$^@W@9/TS77T %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?-?[2?_ "-6C?\ 7D?_ $,U]*5\U_M)_P#(U:-_
MUY'_ -#- '#?"?\ Y*GX?_Z^?_937V;7QE\)_P#DJ?A__KY_]E-?9M '-_$(
M _#GQ(&Z?V;<'\?+-?$E?8_Q?U)-,^%NMNS -/$+=!ZEV"G]"3^%?'% 'T]^
MS@7_ .$!U$'[G]IOM_[]19KR/XS^)YO$7Q#OH?,)L]-<VD"9X!4X<_4L#SZ
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M5)%?4/\ PI#X>_\ 0!/_ (&S_P#Q='_"D?A[_P! $_\ @;/_ /%T >@T4 8
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MOVB?"OV'7K/Q+;QXAOU\FX('25!\I/U7_P! -><> ?$S^$?&NFZON(@CDV7
M'\43</\ 7 .1[@5]9_$'PPOB_P $ZCI(4&X:/S+8GM*O*_3/0^Q-?%#JR.R.
MI5E."",$&@#ZP^+^I37^DZ3X1TJ4&\\17*Q;E.=L (+-QV^[]1NKNQI]OI/A
M@Z=:)LM[6S,,:^BJF!_*O&/@7:ZAXFU3_A)M7<RQZ/9II6GDCIQDGZA2!G_;
MKW'4O^07=_\ 7%__ $$T ?!-?5'[//\ R363_L(2_P#H*5\KU]4?L\_\DUD_
M["$O_H*4 >KUP'QKA$WPDUOCE/)<>V)D_IFN_KA?C&0/A-KQ/_/.,?\ D5*
M/F/X:ZBVE?$GP]<JVW-['"Q_V9#L;]&-?:U?#'A-&E\9:'&GWFU"W4?4R+7W
M/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img40748725_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_28.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %T LT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BLSQ'J8T7PSJFJ'_ETM)9@/4JI('YBO(?#G
MBS4? OPX\%P16+:GJ6NW4CF%G)=T+<;23P<-'R>!F@#W&BN#\(>-=9U;QGK?
MAG7-+M;6[TZ*.;?:RM(F'"D*20,G##GCH:NWWB^XLOBEIOA5[>$6E]8/<).3
M\_F*7RH&>FU<].] '5SSPVL#SW$L<4*#+22,%51ZDGI3HY$EC62-U=& 964Y
M!!Z$&O$O$_C^7Q1X,U5)-'M+S2[S6XM)TU#+(GVG#%_,9E(.,JF,=\@YJW)J
M?C(?%Z+PWH":?#IFC60*V9FD$)@.%4O@?? 92%Z<4 >R45YGIWQ#U[6O$6N6
MNGZ39+I.C7QBN]0N9615A0X<J!G<^ S=@ !G.X5FWGQ6\3?\(U<>,+#PW:?\
M(Q#,$0W-R5N)TWA-X !"C<<=_P >M 'KU%48[Q+_ $);Z'<L=Q;"9,\$!ER/
MQYKP3X.:E>Z#JVA27=U/-I_B:&>$>:Y81W,,C8ZGNN![EO:@#Z)HKYP\4ZG?
M:[\0[#Q'%>7"::GB&#2;*-'(1UC(,C^X+'@_6K.K'2+CXR>+(M?T_7=1MT$/
MD1Z9YK&,^6N20C# H ^AJ*\1^(VH6_A74_AK<6B7\>G6IFE-OEFE* 0G:P)R
M6P2.?>ND^%]E<:\]S\0-5N_.O=5W);6\<Q:*S@!P$ Z;OEY_Q+4 >E4R::*W
MA>::1(XD4L[NP"J!U))Z"O(OCE-;QWW@U+^XD@TZ34B+QDD9/W.4WY*\_=ST
MYKDK.X,A\?Q>&KO4+GP9'HLH1KEW>,3[5XC+\_W_ ,.O\- 'T5#-%<0I-!(D
ML3@,CHP96![@CJ*?7B'A7QQXB\+^#O![WVA6@T"[>*P29;DM.2V</MQ@ @$X
MY/'45V&K>-M<NO&EYX6\)Z59W5UI\"S7ES?3,D:%@"$ 49)P1S]?2@#OZ*\F
MF^,EQ%X,EU"314M]8@U0:5<6\T_[F"7!)=G ^[P1]0><<G1U;Q[K^A_#B_\
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M#QE+_9?QC\!ZFH\N2_2>QG']Y<#:I^C29_"@#U*BBB@ HHHH **** "BBB@
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M<7'F.1)+(-I5L 8)+!B>GWJFTWPIXDTGXJZSX@B?3)]*U41^897<3QA$PJJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML,3E@=DA7=D\Y.,UUE<QX!T^'3?"Z00Z3?:6IFD<V]]*))<DY+%@3G/6NGH
M**** "BBB@ HHHH \_\ BG_S)7_8UV/_ +/7H%>?_%/_ )DK_L:['_V>O0*
M"BBB@"IJE[_9ND7M_P"7YGV:!YMF[&[:I.,]NE<S:^*/%%[:0W5OX+WP3QK)
M&W]J1#<K#(.",]#6WXH_Y%'6O^O"?_T6U'A?_D4=%_Z\(/\ T6M;1Y5#F:OK
MY_HRU91O8R?[?\7?]"3_ .56+_"C^W_%W_0D_P#E5B_PKK**7M(_R+\?\PYE
MV_/_ #.3_M_Q=_T)/_E5B_PH_M_Q=_T)/_E5B_PKK**/:1_D7X_YAS+M^?\
MF<G_ &_XN_Z$G_RJQ?X5-H_B;4;WQ$^C:GH?]FSBT-TI^UK-N7>%_A&.I/?M
M735R?_-6_P#N!?\ M>JBXR37*EIY_P"8TT[Z'64445@9A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@ZM]:
M6D'5OK0 M%%% !1110 44A8 X)I: "BBB@ HHHH **** "O/-?\ ^0[=_P"\
M/Y"O0ZY'5?#U_>:I/<1+'Y;MD9?':O#SZA5K8>,:46W?IZ,UI-)ZG,45M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,RPQF1SR!PHY/6O%O!,CZQH/CSPZEG?P7NM7%[<V9GMGCC*NF%W,1@<XXH
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MV:Y/_FK?_<"_]KUUE<G_ ,U;_P"X%_[7K"E]KT(CU.LHHHK(@**** "BBB@
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M[R>Y@E)-R\0/EA4(^4$X8Y/&, GK7:JRNN58,/4'-+0 4444 %%%% !1110
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MUN<>-P:Q=-0;M9W/G[^Q]3_Z!UY_WX;_  H_L?4_^@=>?]^&_P *^@:*\_\
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MR?F/U'JWB37/%6F:C'#H?@[^VK5H@[7']IQ6VU\D%-KC)P #GW]J ,?XI_\
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MJ#T(Z$$@\&N@TKPSHK_%#Q%9-IT!L([.UF6RV_Z.)'WJS^5]S=A%&<9Z^IH
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MI&^Z?I2TC?=/TKZ ^I%'2O!?CM_R,VF?]>?_ +.U>]#I7@OQV_Y&;3/^O/\
M]G:L,1_#/5R;_>UZ/\B?X#?\AC6/^O=/_0C7N=>&? ;_ )#&L?\ 7NG_ *$:
M]SHP_P##1.<?[Y+Y?D</\7?^2=7W_72+_P!#%> >'/\ D:-)_P"OV'_T,5[_
M /%W_DG5]_UTB_\ 0Q7@'AS_ )&C2?\ K]A_]#%<V)_BH^8Q?\9?(]_^+O\
MR3J^_P"ND7_H8KP+PO\ \C;HW_7]!_Z,6O??B[_R3J^_ZZ1?^ABO O"__(VZ
M-_U_0?\ HQ:>)_BH,7_&7R_,^M:***[SU#Y8U3_D+7O_ %W?_P!"-?0'P\_Y
M$/2?^N;?^AM7S_JG_(6O?^N[_P#H1KZ ^'G_ "(>D_\ 7-O_ $-JWJ_"CZ_/
M_P#=*?JOR9\_ZI_R%KW_ *[O_P"A&OH/P!_R(FD_]<C_ .A&OGS5/^0M>_\
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MZ9;T_P 2>"_^$CU&.\_X2;Q'I>R(1>3IE_Y$;8).XKM.6YQGT ]* ,?XI_\
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MM=M#=PNQAF8#>RE6&Y21G;QSGGF@#EM:N]0U_4/AWJ:ROITEW*S&W>$,89#
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MW/W<1DKQTZUNUA>$8YHM C6?PU;>'9-[?\2^WDC=%Y^]F,!>>O2MV@ HHHH
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MW_(S:9_UY_\ L[5+\!_^0YJW_7LO_H51?';_ )&;3/\ KS_]G:L/^8<]1?\
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MUX9\!O\ D,:Q_P!>Z?\ H1KW.M\/_#1Y.<?[Y+Y?D</\7?\ DG5]_P!=(O\
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M %Q;^8JUXX_X^K3_ '&_F*J^#?\ D-M_UQ;^8JUXX_X^K3_<;^8I]0.?M?\
MD&:Y_P!@JY_] KOO"_\ R*.B_P#7A!_Z+6N!M?\ D&:Y_P!@JY_] KOO"_\
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M5X%X7_Y&W1O^OZ#_ -&+3Q/\5!B_XR^7YGUK1117>>H?+&J?\A:]_P"N[_\
MH1KZ ^'G_(AZ3_US;_T-J^?]4_Y"U[_UW?\ ]"-?0'P\_P"1#TG_ *YM_P"A
MM6]7X4?7Y_\ [I3]5^3/G_5/^0M>_P#7=_\ T(U]!^ /^1$TG_KD?_0C7SYJ
MG_(6O?\ KN__ *$:^@_ '_(B:3_UR/\ Z$:*OPH6?_[I3]5^3.DHHHK ^1"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "LGQ3-<VWA'6I[/BZBL)WAP<?.
M(V*_KBM:D(#*58 @C!![T ?/DVG:5;?"+X>WUG##'J!U>V,<T2#S'D+OO!.,
MGD?FH%>D>-=5^)%CK,,7@_P_INH:>;=6DENI K"7<V5&94XVA3T[GGTLZ;\+
M/"6E:Q!J5K82B2VD,UM"]P[10.>K(A. >_L<8Z"NSH \'U]?C/XC_LO[9X1T
MI/[-U"+4(?)N(QNDCSM#9G.5Y.0,'WIGB34OC#+8RZEJGA32(+:QA>61XYE.
MU%&YCCSR3@#M7O=8?C2":Z\"^(;>WBDFGETRY2..-2S.QB8  #DDGC% 'BGA
M'6OBO?64.O:%X9TJZM+A76.1Y%4, Q4\&8$<J1S5SQ)J7QADLI=2U/PII$%M
M90/+*\<RG:BC<QQYY)P!VKT/X06%YIGPMT:SO[2>TNH_/WPSQF-US/(1E3R,
M@@_C6YXT@FNO OB&WMXI)IY=,N4CCC4LSL8F   Y))XQ0!XE87'Q1DT1]3/A
MO3?[(O;$M)<"5<BV=,EPOG9SMY P3[=JW]-UWXRPZ59Q:7X3T:?3T@1;6625
M0SQ!1L8_OQR5P>@^@KN+2":U^"\%O<120SQ>'E22.12K(PM\$$'D$'C%;GA?
M_D4=%_Z\(/\ T6M:_P#+KYE_8/-?^$A^.?\ T)FA_P#?Y?\ Y(JI;>/OBW?Z
MKJ6DV?A'1VU#3?*^U1M,,1^8NY.3, <@'H3CO7M=</X8L+RW^*7CV\FM)X[6
MZ_L_[/,\9"2[8&#;6/#8/!QTK(@Y?_A(?CG_ -"9H?\ W^7_ .2*J6WC[XMW
M^JZEI-GX1T=K_3?*^U1M,,1^8NY.?. .0#T)QWKVNN'\,6%Y;_%+Q[>36D\=
MK=?V?]GF>,A)=L#!MK'AL'@XZ4 <O_PD/QS_ .A,T/\ [_+_ /)%9G]L_%;_
M (2G[3_PC.E?\)#]B\O[)YB^7]EWYWY\[[V_C[W3MWKW.N3_ .:M_P#<"_\
M:]:TOM>A<>IXOKWB#XF:1K%A;:KX>TNWO-8N#':1APPDD+*,9$Q"\NO4CK]:
MZNPU/XW:=:BWA\':,R DY>=">?I<5J_%/2=2U#QU\.[BRT^[N8+34R]S)#"S
MK"OFP'+D#"C"DY/H?2O5*X:6#H4INI3BDWU$Y-JS/FO7M?\ B7H^KZ?:ZKX>
MTNWN]7G,=I&'#"1RRC&5F(7EUZD=?K75V&I_&[3K46\/@[1F0$G+SH3S]+BM
M7XIZ3J6H>.OAW<66GW=S!::F7N9(86=85\V Y<@8484G)]#Z5ZI12P="C-U*
M<4FP<FU9GC__  D/QS_Z$S0_^_R__)%<QXP_X6WJ5J^J:QX6TRWM["!Y)'AG
M3"HHW,2/.). .U?0]8?C.":Z\"^(;>WBDFGETRY2..-2S.QB8  #DDGC%=49
M.+NC*<(SCRR5T>(^$(_BUIT46LZ/X7TVXAO;96B>:=,-&V&!QYP(XQUI_C#_
M (6WJ5J^J:QX6TRWM["!Y)'AG3"HHW,2/.). .U>U^"X)K7P+X>M[B*2&>+3
M+9)(Y%*LC")000>00>,4>,X)KKP+XAM[>*2:>73+E(XXU+,[&)@  .22>,57
M/*_-?4GV%/D]G;3L>(^$(_BUIT46LZ/X7TVXAO;96B>:=,-&V&!QYP(XQUKJ
MO^$A^.?_ $)FA_\ ?Y?_ )(KT3P7!-:^!?#UO<120SQ:9;))'(I5D81*""#R
M"#QBMRIE)R=V5"G&FN6*LCPCQ./C/XL\/7.BW_A'28[:XV;V@N(PXVL&&"9R
M.JCM7EGAGP?XQO\ Q#=IH^D1W-]H=T@N8GGC41R*YP"2XW#,;#Y3VZ]*^RJ\
MK^%FDZEI_COXB7%[I]W;07>I![>2:%D69?-G.4)&&&&!R/4>M:T\15IQY82L
MBFDS \0R_&GQ+H-WH]YX0TB.WNE"NT,Z!P 0>"9R.WI7D_AOP;XPU'7KR+2-
M(CN+W1+I5NHVGC41R!FP"2X##*,/E)Z?2OLNO*_A9I.I:?X[^(EQ>Z?=VT%W
MJ0>WDFA9%F7S9SE"1AAA@<CU'K13Q%6FN6$K(&DRG_PD/QS_ .A,T/\ [_+_
M /)%'_"0_'/_ *$S0_\ O\O_ ,D5[!16(SY>U*R^),&OV6GW?AZQCU#56F:V
MB$R$2%!O?D2D# /<CVS7:Z5?_&W2-,AL+?P?HS10@A3).A8Y)/.+@>M=IXHL
M+RX^*7@*\AM)Y+6U_M#[1,D9*1;H%"[F'"Y/ SUKN*QIX>E3ES0C9G/2PM&E
M)RIQLV?+VI67Q)@U^RT^[\/6,>H:JTS6T0F0B0H-[\B4@8![D>V:[72K_P"-
MND:9#86_@_1FBA!"F2="QR2><7 ]:[3Q187EQ\4O 5Y#:3R6MK_:'VB9(R4B
MW0*%W,.%R>!GK7<44\/2IRYH1LPI86C2DY4XV;/'_P#A(?CG_P!"9H?_ '^7
M_P"2*X+XD0?$N_MO^$A\3>';"RM;&)8FDMYD( 9\#*^:Q)W,!Q7T[7#_ !?L
M+S4_A;K-G86D]W=2>1LA@C,CMB>,G"CDX )_"M914E9G92JSI2YX.S/(_ >F
M_%70(1K&A>&;"Y@U&V1T>XGCPT9PRD#SE(R".M5OB1;_ !+O[;_A(?$WAVPL
MK6QB6)I+>9" &? ROFL2=S <5] ^"X)K7P+X>M[B*2&>+3+9)(Y%*LC")000
M>00>,5A_%^PO-3^%NLV=A:3W=U)Y&R&",R.V)HR<*.3@ G\*GDC;EMH:?6JW
MM/:\WO=SR3P'IWQ5\/V_]K:%X9T^Y@U*WC='N)X\&,C<I \Y2,@]Z[/_ (2'
MXY_]"9H?_?Y?_DBO1/!<$UKX$\/6]Q%)#/%IMLDD<BE61A$H((/((/:MRJC%
M15D9U:LZLN>;NSPKQ&WQH\3Z++I5[X0TF."5E9FAGC#?*01@F<CMZ5YQX:T/
MQQJ'B"[CT?1;>YOM$NE%U$TR*(Y%=L DR#<,HP^4GIUZ5]>5Y7\+-)U+3_'?
MQ$N+W3[NV@N]2#V\LT+(LR^;.<H2,,,,#D>H]:F5.,G=HYY4H2=Y+4Y[Q&WQ
MH\3Z++I5[X0TF."5E9FAGC#?*01@F<CMZ5YSX9T3QQ?>(KI='T6WN;[0[M!<
MQ/,BB.17. 29!N&8V'RGMUZ5]=UY7\+-)U+3_'?Q$N+W3[NV@N]2#V\LT+(L
MR^;.<H2,,,,#D>H]:)4XR=V@E2A)WDM2G_PD/QS_ .A,T/\ [_+_ /)%'_"0
M_'/_ *$S0_\ O\O_ ,D5[!15FA\DZAIGCI/&$.@W.B6J:SJ"-<Q6PF0AE^<D
M[O,VC[C\$YX^E>D:->?&S0](M]-MO!^CO# "JM+.A8Y)/.+@#OZ5M:]I.I3?
MM&>&-4BT^[?3X=-=);M86,2-MN.&?& ?F7@GN/6O5*;DWN=-;&5ZT5"I)M(^
M2=0TSQTGC"'0;G1+5-9U!&N8K83(0R_.2=WF;1]Q^"<\?2O2='O?C9HNDV^F
MVW@_1WA@7:K23H6(SGG%P!W]*V=>TG4IOVC/#&J1:?=OI\.FNDMVL+&)&VW'
M#/C /S+P3W'K7JE#DWN%;%UZT5&I)M(IZ3)?3:-8RZI#'!J#V\;7449RJ2E1
MO4<G@-D=3]35RBBD<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6-XF\3Z=X3TAM2U(RF(-M5(5W.YP6.!WPJLQ]E-;-<%\1/"NLZ];WES
MIT\$H32Y[:"RDB)8R2<,RMN #%0%&1QEO6@#N;>=+FVBN(\[)4#KGK@C(K&U
M+Q;I>E^(M.T*<RM>WQ 01IE4SNV[SGC=L?'KM/I5_18;FWT.QAO-GVF.!%DV
M# !  Z9/\ZX+5_!_B(>+;#5()[6\637!>2N82K00K$R(I^?!55..!G<Q/J*
M-#Q!XYTBZT?5K"-;H"6.[LHKEH<123QQN70'KD;3R1@XX)KI?"__ "*.B_\
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M'4?)^W1VT:W'D+A/,"@-M Z#.<5A?\U;_P"X%_[7K6E]KT+CU+X\6Z6WB_\
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MG.*LMG:=I ;'&>F: ,*#Q=I=SXNF\-0M,]]#$9'8)^[&-A*[O[P$B$CWK>)
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M+;>Q/*]A0!Z.OB317U7^RUU.U-[O,?DB09W@9*?[V.=O7':EC\1:/*+4QZC
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MN#_U+'_DQ1_Q<'_J6/\ R8H]E_>7WAR>9UE<G_S5O_N!?^UZ/^+@_P#4L?\
MDQ1H^C^(?^$N?6];?3/^/ VBI9&3_GH'!(8?7OZ<548J*;;6PTK7U.LHHHK
MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img40748725_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_29.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,=!$<# 2(  A$! Q$!_\0
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M*9STYZ5<N+B&U@>>XFCAAC&YY)&"JH]23P* )**S]-U[1]:+C2M6L;[R_O\
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M&OUNS9R>5. C+L;G^\!D<'D9'% &U113)IHK>%YII$CBC4L[NP"J!R22>@H
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M76^%_#.O6?P^\>0QZ;JMMI5Y!(-(TR[!:X&0^?D'()RHQW]^I[/X3^$K'3?
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MKY>W@9& !TJSX1\7>(-"\ :&FI>#M>NG@1[6X$%N?/CV8$9\IL%@5/4'@J:
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M"9SN/0 XR: ,'1?#>G^%?VC+#3=-$QB_LYY'>>0R/(Y1\LQ/<^V!7L.K>&-
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M<Y) P=PP1F@"YHUJG@'X]IX>TAGCT;6K0SFSW$I$X5CD9]XS^#8["NC^.O\
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MS/&-A!(3J3\YX]5YQFKOQ U#6/&WPNUE+7PIK-H1-;BWAN8/](G^<%CY2Y(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1\==K XI]>:?"^\TZUU?7O#L?A5/#VIV1B>YABN?/256&58-VX(X]_P&G?\
MB?QW;ZC<PV?PZ^UVL<KI#<?VW!'YJ D*^TC*Y&#@],T =Q17'^#?&6H^(]8U
MO2=6T#^QK[2?(\R+[8MQN\U68<JH X /!/7MBNPH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 456OK^TTRU:YO9TAA7JSG]!ZGV%5
M=*\0Z5K>\:=>),R<LN"K >N& ./>GRNU[$N<5+E;U-.BBBD4%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4XGXG-)?06IM"\T%JSBX,8)1&. ,D<9X/T_&N?\ AY9WDWBN">!7$,(8S/V
M((P?J?\ /%>S1PQ0PK#'&B1*-H15 4#TQ2QQQQ+MC147T48%;JO:'(D<4\#S
MUU6<OZ0ZBBBN<] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"OB_>>'I?B
M7I.G^+I[Q-%@TMKA4MB<F9Y&49 &>B9S[#WS[K7":GKT:_%NW\/ZA'I_]FMH
MQN]]Q&N[S?-*X#-VP.E 'B_@O4_AXUQ!/XJOM4U*\@F$&GP3J[100J0(L!<<
MX )'3V[GZCKR*Y\;V<WPU'B&RT_1[?4_MJP+!L1_E^T>62!P>5YKUV@ HHHH
M *K:A8VVJ:=<V%Y&)+:YB:&5,XW*PP1^1JS10!PWA[X7:7H&KV6H-J>K:BVG
MQM%817UP'CM5;@[  .W'TQZ#%^P^'VA6VF36%_$VL0R7DEXO]I[9C&[@ A<C
M@<?J:ZJB@#E_#7@#0O"FLZGJ>F6RQS7Q VA%"PIQE$P 0I(!(]0*ZBBB@#S_
M ,)?\E>^(O\ W#/_ $G:O0*\_P#"7_)7OB+_ -PS_P!)VKT"@ HHHH ****
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M6MM8U 644-RT:6S(Y.\ 'ELXZ]@*S;G1KE/A!;^/GUS59O$D,$-U'<R73;5
M=5\O8#C;MZYY)))ZD4 >]5!?7<6GV%S>S;O*MXFE?:,G:H)./RKR7Q]<:EK'
MQ&&@_P!DZCJNGVVG+<+8V6H"T\QF<@R.<@L!@  =#]:;IFB7][X#\7:1K]A?
M6NFVRFXT^WN;]9I8L1%BA=&R5##(#=FQSS0!Z5)KDL_A2'7-'TV;46N((KBW
MM ZQ/(K[2.6. 0&R?I6PI)4%EVDCD>E>+3Z#I^@_L\7>HZ89X[G4-)LYKAS<
M._S_ "GY03A>6;@8_2NB\7:,WB'XH:-IDFHWMI:-I=Q)<+:RF-IE$D?R%AR
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M5MYIK;;&C98[U../8U\UB*V/^OVIJ7L[KII;2_0V2ARZ[G94445].8A1110
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M)7']H1JGFYS]W!/3'/U% &[1110 4444 %%%% !1110 4444 %%%% !1110
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M ;K[#BOH"@ HHHH **** "BBB@ HHHH \_\ "7_)7OB+_P!PS_TG:O0*\_\
M"7_)7OB+_P!PS_TG:O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH J:G</;:=-)'DRD;(P!D[VX7]
M2*DL[9+*RAMD^[$@7IU]ZJ7>+G6+.UQE80;F3([CY4_4D_A6E64?>FY=M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/!'IC!Q7H%% '*>#_#.O>'%-OJ7B>/5+%(1%;VL>F16JPX[@H>>.,5U=%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/RK4HE%Q=FK TT[,****0@HHHH **** "BN5\<^-;?P9IL4K0?:+NX8K!#G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\ PNWX>?\
M0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C= 'H%%>?_ /"[?AY_T,/_ ))7'_QN
MC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8
M?_)*X_\ C= 'H%8?B_0#XF\,7FE)*(I95!C=N@92",^QQC\:YO\ X7;\//\
MH8?_ "2N/_C='_"[?AY_T,/_ ))7'_QNJC)QDI+=#C)Q::Z'F^E_"/Q-<ZNE
MO>VRVMJK_O+@RJPVY_A ))..GZXKZ'50B*J]%&!7 ?\ "[?AY_T,/_DE<?\
MQNC_ (7;\//^AA_\DKC_ .-UMB,5.NUS=#:MB)UK<W0] HKS_P#X7;\//^AA
M_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !NN<P/0**\__P"%V_#S_H8?_)*X_P#C
M='_"[?AY_P!##_Y)7'_QN@#T"BO/_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0
MP_\ DE<?_&Z /0**\_\ ^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;
MH ] HKS_ /X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\ QN@#T"BO/_\
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M$94\'! /X4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\_\ C;_R2'7?^W?_ -'QUZ!5>^L+/4[.2SO[2"[M9,;X9XQ(C8((RIX." ?P
MJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ?&W_DD.N_\
M;O\ ^CXZ[^J]]86>IV<EG?VD%W:R8WPSQB1&P01E3P<$ _A0!8[4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<%\4?%?B+PAX?DU/1K&R>"$(9KBZ<G!9PH54'4\Y))  ]37
M>UYY\6M'\2^)O#C:#H>E07,-SM>6XDNEC,15PP 4]<X]: ._@D,MO%(V,N@8
MX]Q4E9?AZ74YM$MVUBPCL;T J\$<PE  . =PZY&#6I0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44PS1+,L+
M2H)6!*H6&X@=P*?0 4444 %%%% !113$FBD=TCE1GC.'56!*GW]* 'T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4I-)T^;5H=5DM(FOX(S%'<%?G5#U7/I5VBB@ HHHH **** "J5II&
MGV-]>7MK9Q175ZRM<S*OS2E1@;CWQDU=HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKRW\K;N SC?G//K2:S\4/&?AT:-JNI^'-._LC5B%AM89G-TA(!&YC\H)!R
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M^^H^&+(K*T$6H16YN7QSN+'(Q]WITS@\\>R44 <IX2U'Q#.38ZGX+3P_8V\
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MV]<]L50\"Z7\0O!7@ZXTN+0[6[>UORT$<]VB^?;L#G8RL=K;@#\PZ,:]>HH
M\COO#7BWQ_XRT#4]>T*V\/V&C2^=L^V)<RSG<K8!08 RH'.,9)YKUBXMXKNV
MEMIT#PRH4=#T92,$?E4E% 'DF@:%XZ^&?VG3-&TJW\2Z%),TMLAO5MIK?/9B
MXQCZ9YYXSBK?PW\(^(M-\7^(O$^O6EO8MJQW):).)6C)8M@L./09S^5>H44
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M TWR#<>:GW\'C;G=^.,52TOP-J<WC[QW<:E:F'2=;MO(@G$J$N" "=H.1CW
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M=P*]%HH **** "BBB@ HHHH **** "BBB@ HHHH \VUWQUK,FEWVD?\ "O\
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MM.BB@#RKX*Z1J6DKXH&HZ?=69FU(O%]HA:/S%YY7(Y'N*Y[PY;^)_!-UXO\
M#\/A34;^?4YWDL;R-1]E(;< 9)#@+@$''7/&!UKW:B@#YW7PUKJ_LXRZ4=%U
M'^T?[1WBT^ROYI7>.=F,X]\5U7Q-T;5+_P -^"(K/3;RYDMKN!ITA@9S$ @R
M6 'R@>]>O44 >7^.M*U&[^+O@>]MK"ZFM+9G\^>.%F2+D?>8#"_C61IL6L_#
M/X@^)KN3PWJVKZ3K4OVB"?3(?/=6RS;64$8'SL,GT&,U[/10!XCHWA'7D\%_
M$'7-0TV6#4?$,<TD&G("\J#YR 0.<DOC'7CWQ7?_  ML[K3_ (::':7MM-;7
M,<+!X9HRCJ=['E3R*Z^B@#!\;6\UWX%UZWMH9)IY;"9(XXU+,[%#@ #DFO)K
M[P=J][^SYHJ0Z?>Q:[I,OVF&W\EEG!\U@0%QNSA@W3^$5[O10!X?H_A/6;;X
M%>));VQNY-?UII+F: P'SV.\  H!G/!;&/XJ9K/A#Q!)X#^'^L:?I<]QJ/A\
M1RSZ<X*2$ JQ&T\Y!0#'7GI7N=% 'C6IPZQ\3_'/AF=/#FJZ/I6BRFYN)]4@
M\EW;<IV*N>?N 9]STQRS2X=>^'?Q(\421^&-4U:QUN03VDMC&&4/EF"NQ.$&
M7()/IG!%>T44 >$^$_!&OZGX&\>Z+J=@]EJ%_>>9%YJ,D3N#N^1C]Y=PQD9%
M9&B^%- @TN#3M7^$OB2YU^-?+DEB>5;:9QQN\WS J@]>!@=LU]&T4 >2>)O#
M]ZGQ'^';6&CW*6&GQ^7)Y*-+';   *SXQQC&3UQ7K=%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !115/5]3@T71KW5+K=Y%I \\FT9)
M502<>_% %RBO(['XN^(%FL+[6O!-Q8>'[Z5$2^$I;RU<X5V&T9!R/3KQG@'U
MR@ HHHH **** "BFK(C,RJZEE^\ >1]:'=(UW.RJH[L<"@!U%,CFCESY<B/C
MKM8'%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCXCUC6])U;0/[&OM)\CS(OMBW&[S59ARJ@#@ \$]>V*["O/_  E_R5[XB_\
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M% !1110 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\ 134
M'@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+704 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGAK_ +!5K_Z*6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,O&WAWQP_P 0
M;7Q)X2;3R(]-^QL+M^A,C,Q"^XV\^U>FUQOB#XE:-X5\5P:)K:7%I%<P++#?
MLA,))8@J2.1C YY SSB@#A?#/AWXM^&HVM;2/05MIKIKB<DY9B[98Y_E7ME>
M?ZU\8/#.G:C!IFFR2:WJ,T@18=.'F*,^KCC\!D^U>@4 %%%% !1110 4444
M%%%% 'G_ (2_Y*]\1?\ N&?^D[5Z!7G_ (2_Y*]\1?\ N&?^D[5Z!0 4444
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MI&8LV/3)Z"NN-:*IN%CDGA*LL0JO-H:]%%%<QZ04444 %%%% !1110 4444
M%%%% #9-YC;RR ^#M)Z9KY]U_P"'/Q#\5ZE&^K3^%;F^@(;( 60@= ^U 67G
MH>*^A*^/1K'AU](&MC5=5M?&=Q?/)//&21'%(Q5L$ <["3P0<G\* />OAT/$
M^G:Q<Z)K^I^'WBMK8-%8:8%5X?F R555VC%>D5Y3\))_A[]KN[;PC]KFU$0A
M[JZNU;S)%W#J3QU(X %>K4 %%%% !7FOCV-]=^(7A3PK<W<\&E74=S<7,4$Q
MC-P47*J2,' P3@>I] 1Z57->*_!=EXKDL+F2\OK"_P!/=GM;RQEV21[@ PR0
M00<#_).0# ^%;W-J_BC0Y+N:YM-*U:2"T,[EF2+&0F3U _QKEOBUKZ:Y/K&C
M0:HMI:Z#:?:)U$_EO<W3C]W&HR"P498XSS@5VR_##28_"4F@0W^IQ">Z%Y<7
MJW'^D32YR69\<YQZ>_6KOB+X=>&/$D%[]JTJUCN[M</>QP)YRG^\&(ZT 0IX
MAN-,^%ECK6EZ?+KMQ'96^RVM7+/,3L5L%0QR,DG@_=->=^)?BGXJU'PKJ]E<
M?#'6;."XLIHI+F0R[859""YS"!@ YZCIU%>RZ+I%GH&C6FE6$2QVUM&$154#
M/<DXXR223[DUG>._^2>>)?\ L%77_HIJ #P)_P D\\-?]@JU_P#12UT%<_X$
M_P"2>>&O^P5:_P#HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\S^)>C>,
M]9N/LVF7.@#09(E5X=3523+D\C*''&,8.>*],KPKXOWGAZ7XEZ3I_BZ>\318
M-+:X5+8G)F>1E&0!GHF<^P]\@%+1/"/CKX=0QR)J/A/3;:215DGE(\R4$_=W
MLFX^PS7T%7RYX+U/X>-<03^*K[5-2O()A!I\$ZNT4$*D"+ 7'. "1T]NY^HZ
M "BBB@ KG_'6IW.C>!-<U&S8I<P6<C1..J-C ;\,Y_"N@JMJ%C;:IIUS87D8
MDMKF)H94SC<K#!'Y&@#QO2M+;PMKOP[U'3]4O9I-=C*ZD9KEI4N2T2N&P3@8
M)./P]\^@_$+Q2?"_AP-;21)J5_,ME8F5MJ+*_ =B> JC+$GCCWJEX>^%VEZ!
MJ]EJ#:GJVHMI\;16$5]<!X[56X.P #MQ],>@Q?L/A]H5MIDUA?Q-K$,EY)>+
M_:>V8QNX (7(X''ZF@#C_@Z+>PUSQ;I$6K_V@+>>$I(T_F-*-GSR#D\%C^N*
MFU;XI^*M.UF^LK?X8ZS>06]Q)%'<QF7;,JL0'&(2,$#/4]>IKK/#7@#0O"FL
MZGJ>F6RQS7Q VA%"PIQE$P 0I(!(]0*ZB@#R?X4ZQ>:]X[\=ZG?Z3/I-U-_9
M^^RGSOBQ$ZC.54\@ ]!UKUBO/_"7_)7OB+_W#/\ TG:O0* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "N4\:>+V\-0PPVT227DX+#?\ =11W/K[5TUQ<PVD)FGD"(.Y[GL!Z
MGVKD/%'A:Z\6QQW*>79RP@K"DP.YU/\ ?(^[[  ^_7 TI*/->6QSXEU/9M4O
MB*/A7XA7&I79L=0M/,G<$PFV3ER!D@@G'3)SD#BNO\S6+K_5P6]DA_BF;S7_
M .^5(4?]]&N8\'> Y-#O_P"T=0FBDN$!$21$D+D8))..<$C%=R2%4LQ  &23
MVJJK@I>X9X6-9T_WSU,J72X?+,FHW5S> ?P.^U#[;%P#^.:M6-E':IN6&.(D
M8$<:@+&/[H _7U_*G1 W,HN'!$:_ZI3_ .A'W/;T'UJU7*FZCYGMT_S_ ,CK
M48QV"BBBM!A52'_1[N2W/W),RQ_^S#\SG\?:K=5[R)GB#QC,L1WI[D=OQ&1^
M-954[<RW7]/^N]AHL44R*59HDE0Y5P"*?6B::NA!1113 **** "BBB@ HHHH
M **** "BBB@ KQS0_'EK-\/]$UO4=/T:;4;_ %-;2>,1I'L1I67?CD\  \U[
M'7R_K%O\)-)\:RZ/+8:A]BMO-BNIUFD+1SHY78J]QQUH ]KTG687^)U[HMA'
M8?8(]*CN0]M&NXR&0J06';&.*[6O%_A"_A!_&FKIX/L+L6D=DF^[GD;)8O\
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M* "BBB@ HHHH \_\)?\ )7OB+_W#/_2=J] KS_PE_P E>^(O_<,_])VKT"@
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M %%%% !1110 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\
M134 '@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+704 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC'>NJ\'_ /'C<?\ 73^E?.X#.*^)Q?L9)6UVOT^9M.FE&YT=%%%?1F(4444
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MQBO3:\N^&VB>)'\2WOB?7O$>C:X)[-;..?390X&'W8.U%7N??FO4: "BBB@
MHHHH **** "N?\=_\D\\2_\ 8*NO_135T%<_X[_Y)YXE_P"P5=?^BFH / G_
M "3SPU_V"K7_ -%+705S_@3_ ))YX:_[!5K_ .BEKH* "BBB@ HHHH ****
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M5,F(77YER<9QD>Q%>H5Y_P"$O^2O?$7_ +AG_I.U>@4 %%%% !1110 4444
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MBB@ HHHH ***ANYC!:O(HR^,(/5CP!^9%3*2BG)] (K;]]=3W'8'RD^B]?\
MQ[(_ 57L?]-U&XOSS''FWM_H#\[?BPQ]$'K1>E[/3(K.V<BYF(@B;N"1\S_@
M S?A5^W@CM;:*WA7;'&H11Z 44HN,-=W_3(E[TK=B2BBBJ+"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-\;>!M)
MUW2]5OH]$LKK77M'6WEF0$F0(0G)XZXQGBNRK(\57=[8>$=8O-.4M>P64TD
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ME>^(O_<,_P#2=J] H **** "BBH;FZALX?-G?:N<# R6/8 #DGV% -VU9,2
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M*?1@>0?8U/5.ZTZ*YD$Z,\%THPL\1PV/0]F'L<BH/M\]C\NIHHC[7<0/E_\
M QU3Z\CW'2G:^PN9KXC3HI%974,I#*1D$'((I:DL**** "BBB@ HHHH *@GE
M;>((<>:PR3V0>I_H/_KTL\QCVI& TS_=7^I]A2P0B%",EG8Y=SU8UE)N3Y8_
M/^NXQT42PQA$S@=SU)[D^]9^G_OM5U.Y[!TMU/J$7)_\>=A^%<G\0_%5]I,\
M&FZ?(8'DC\V24#YL$D #TZ']*I?#CQ->7-_)I-VYF1P\R2$98-G+9/?.2>:Z
MXT&J?,MCAEC*?MU2Z_J>F4445B=H4444 %%%% !1110 4444 %0W=W#8VLES
M</MC09)QDGT '4DG@ =2:E=UC1G=@J*,LQ. !ZUDVB-J]U'J,ZD6D9S9Q,,;
MO^FK#U(^Z.P.>IP*BNKV*2ZLDT^UFDG;4KY-MU(NV.+.1;Q]=O\ O' +'U '
M0"M.BBDW=B;N%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %>+_'
MN334G\-)K=_?KI3R3BXL[!@)9 %4AP&^0[3@?-_>X[U[17F/Q0@\0CQ-X6U#
MPQIMC>:I:-.T?VJYC3(90"H1W4MD<Y4Y&/>@#GO@C_PA'_"0:G_PBW_"0_:?
MLH\W^U/)V;-X^[Y?.<XZU[?7$>"-3^(=]J%RGC+0M.TZT6+,+VL@8L^>AQ*_
M&,]A7;T %%%% !1110 4444 %<_X[_Y)YXE_[!5U_P"BFKH*Y_QW_P D\\2_
M]@JZ_P#134 '@3_DGGAK_L%6O_HI:WC(@."Z@_6L'P)_R3SPU_V"K7_T4M<K
MJAW:M>9'_+=__0C7F9GF'U&$9<M[OO8N$.8](\Q-I;>NT=3G@5BWGB2W2<VM
MF&N;G&=D*%V]CM'0>[%5]ZP?#VEIJIN$GN+E+>/83%%)L$A.>I'/&.Q'6NRL
M[&UT^ 06=O%!%G.V-0H)]3ZGWK?!5WBZ$:ST3Z+UMO\ UZH;48NSU,>*PU>]
M?S;B8:>I[H1+<$>FXC9']%#?[U:5CI%CIS-);P?OG&'GD8O*_P#O.V2?IFKU
M%=J]U<L=%_7W_,ES;T"BBBD2%%%% %6]TZQU&,1WMG!<H.@FC#8^F>E4/[ ^
MS\Z;J=]9XZ1F7SH_IMDW8'LI%;-%4IR6B92DUH8WF^(+/_66UGJ,8_B@<P2?
M]\-N4_\ ?8H'B:QB.-02XTUN_P!LB*(/^V@RGY-6S01D8/2GS)[H.9/=#(IH
MKB)989$DC;D.C @_B*BNK"SO5"W5K#.!T\V,-C\ZHR^&]*DE::*U^RSMR9K-
MV@<GW*$;OQS3/L&M6G_'IJRW*#_EG?P@GZ!TVX^I#46CT8.,9:7^\F_L2"/F
MTN;RT/;RIR5'_ 6ROZ4>1K$'^KO;:Y7^[/"48_\  E./_':A_MB_M>-0T6X4
M#K+9,+A/R&'_ /'*LV6N:9J$IBMKV)IQUA8[9%^J'##\13:GOO\ B0Z-M5^!
MYQX\\4:U%J0TT,;%8D#.+>8GS">^[ .,=L>M7? /B^ZE:>RU2:>XC1-\<Q1Y
M67G!!(!..>IK3^($7A58K>?7KTV=P?EB:(;G<>A4 Y'OQ]:N^!8?#BZ2\WAZ
MZ^U([8EE?[^1V((&/;C\ZZ&U[&_+_7J<"PF*5?VM_=[_ *&O_P )#I ^_J$$
M7_75O+_]"Q5F+4["?_4WUM)_N2J?Y&K55I=/LI_]=9V\G^_$#_,5R^Z=OO\
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MKMP^.G1BXK4ZJ.+G2BX[D%C;FTL+:V:0R&&)8RYZM@ 9J>BBN)N^IRA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %97B;3YM6\+ZKIUO'!)-=6L
MD*)<%A&Q92 &*\@<]1S6K6/XLMKV]\'ZS:Z:6%]-93)!M.#O*$#!['/>@#R'
MPNGQ)L#9^'M/\7>%+A+(",VJ7*23)&IY! 3=P.*]VKY5TY/#5RVAZ3X:\+ZY
M9^-K>XMS-<2NVU&5AYC,-QPO?[BX_G]54 %%%% !1110 4444 %%%% 'G_A+
M_DKWQ%_[AG_I.U7_ (AV6M3Z3#=Z'"EQ<6S,7@*EBZ'&2H!Y(P..^:H>$O\
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M5Q_\;KT"B@#S_P#X7;\//^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !NO0**
M//\ _A=OP\_Z&'_R2N/_ (W1_P +M^'G_0P_^25Q_P#&Z] HH \__P"%V_#S
M_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_QNO0*\_\ ^;A?^Y4_]NZ #_A=OP\_
MZ&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z] HH \_P#^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;KT"B@#S__ (7;\//^AA_\DKC_ .-T?\+M^'G_
M $,/_DE<?_&Z] HH \__ .%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\
M;KT"B@#S_P#X7;\//^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !NO0** //\
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M[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-UZ!10!Y_\ \+M^'G_0P_\
MDE<?_&Z/^%V_#S_H8?\ R2N/_C=>@44 >?\ _"[?AY_T,/\ Y)7'_P ;H_X7
M;\//^AA_\DKC_P"-UZ!10!Y__P +M^'G_0P_^25Q_P#&ZV/#?Q$\*^+M1DL-
M#U7[7=1Q&9D^SRQX0$ G+J!U8?G745Y__P W"C_L5?\ VZH ] HHHH ****
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M<WAK5-;LM*&B>(KI;:WBM?,\^W,G^K+$G#9')Q^G2@#UFBBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YY\6M'\2^)O#C:#H>E07,-SM>6XDNEC,15PP 4]<X]:]#HH
MR_#TNIS:);MK%A'8WH!5X(YA*  < [AUR,&M2BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *K:A+=P:=<2V-LMS=I&3#"TFP2-CA2W;/K5FB@#R3P
MAX6\5))XMT_7-&M[2P\1R7,\D\=XLC0F4$; HZ_>//'2HM)\&>-;W_A$M&UR
MVTZVTOPW=)<F\@N"[W)B_P!6%7' Z YQGKQT/L%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >6>-]*\::IX\T35-,\/VL]GH<LCP.]^J&Y\Q
M4SD$?+@J?7-6]6T7Q?I?C:X\3^'=/L;PZEI\=O<VUQ<^7Y,R]'SCYE XP.O-
M>D44 >/V7PY\1>$[#PA?:*+34-3T9+A+NVDE\M)A,22$8CC:2>3UX/M77_#_
M ,.:IHL&KW^MF!=2U>^>\EAMVW)"#P$![D>M=C10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !113)HEG@DA8D*ZE25.#@C'!H ?17A]UX+L8OC+9>&EU'6?[-
MET@W;I_:,N[S/,=<[LYQA1Q73V$]AHOQ4O[".ZU>5[+P\KB&:</!Y:%!D \F
M3@<GU;UH ])HKRU?C?I@TZRU6;P_K4>DW,@A-\85,:R'.5'.6Q@Y(]"!G%=!
MX>^(5OK?B&?0[K1]2TB]2V^V1I?HJ[X<XW<$X//0^_I0!V5%>9K\:]#:9)SI
MVH+HSS^0-38((\YQNV[MVS/?'X=J[/Q;JCZ)X/UC4XB!+:V<LL>?[X4[?UQ0
M!K1313J6AE2102I*," 1U'%/KY\\0+-X8^ 7@V2TGN('GU""YF>%RK2"1)9"
M#CKU'Y"MKQAX^MM=\1^"K72O[6M3_;EOYWG6\ENLB%U&W)QNZ]* /::*X75_
MB7!9:YJ&DZ5H.JZU/IJ![Y[*-2D.1D+DGEL \ =CZ'#A\4='GTOPWJ-I!<S6
M^NWJV460%:&0MM.\9['TS[9H [BBN:'C.U/BS5_#_P!EF\[3;(7DDN1M=2 <
M#OGFL/2/BS8ZKHEYKC:)JMMI%I:M.]Y)&NQW4J#$G/S'+8SP,@^E '?R2)#&
MTDKJB*,LS'  ]S2JRN@=&#*PR"#D$5QFDZ_'\0M$U#3KG0=2T^WO++,;W:#9
M-%(" 592>1U(ZC(JI\&-3EU+X8:8MP3YUF7M&!&" C$*,>R[1^% '?T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%>5_&G08(?!^J^)X+S4(-1@2!(_)NW2, RHI
M^0'&<,:H^*M#TGPG\+GOSJ/B!%NFM'F>"^+2Y&>%+G 'S'/T'I0![%17$ZY\
M1HM(\4S>'+?0]3U/44MUN$CLT#;E.<DDGY0,#D]R .M8B?&_2I=(35X_#^MG
M3$D6*\NC"H2V<G&TG=\QZ'C^\O<XH ]1HKC?$_Q%L/#VJ6VDP6-UJ6I3P?:!
M!;E%"19P&9F( R>@_P#K9UO"?BO3_&.BC4]/$J*LK0S0S* \4BXRK8)&>0?H
M10!LF:)9EA:5!*P)5"PW$#N!3Z\TT _VU\=O$]])\RZ-8P6,'<+YGSL?KD,/
MI7%_#7XC6^G_  XO;34VUBZOFDG*SI;RS 948^?G'/Y4 >_T5Y'X(\<V_AKX
M,^'+[5#>ZA>WLTMO;P1?O9[B0SR *,GTQW]!Z"NFT?XCVVHZK?:1?Z/J.DZK
M:VIN_LUVJ_O8QW1@2#_GK@X .VHKA&^*&GKX TWQ=_9]S]FO[D6Z0;EWJ=[)
MD]L90G\:DUSXCQ:1XJD\-V^A:GJ>HB!9UCLU4Y4YR3DC &.I[D"@#MZ8DT4C
MND<J,\9PZJP)4^_I7%2_$NV_X2B\T6RT/5;];":."\NK:-62%G. <9W$#G)
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img40748725_30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_30.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -%!(X# 2(  A$! Q$!_\0
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MVI:_HVC,BZKJ]A8EQE!=7*1;OIN(S2W.NZ/96$5_=:K8P64I"QW$MPBQN3R
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MI-I7</7# $?B*N4 %%9%AXGT?4]=O]$L[SS-1L #<P^4X\O/3YB,'KV)K7H
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MC_6F,;LJ.WJ>*X3X9WD?@^&2XOO!GC6[U_4'S>7SZ42HR<X#%L[<\DGDGD]
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M#1-0FOM*TFTL9YHQ%(;:,1JR@Y'RKA?QQFO-;C2=?^'?Q.U3Q+IVBW>LZ%K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!DL4<\+Q2HKQNI5E89# \$&O.
MQ\%]!CBEM+;6/$5KI<K%I--@U BV?/4%=I)!^O:O1Z* *.CZ/8:!I-OI>F6Z
MV]G;KMCC4DXYR>3R22223ZU>HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%=#M[&#;YDN_?MW,%'"SDGD@<"O7/#6I3:SX5TC5+A8UGO;*&XD6,$*&= Q
MR2<9/J: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 87B3P=H?BQ;?^V+,S/;$F&6.5XWCSP<,I!P<=.E1V7@;PSI_ANX\/6V
MD0+I=QGSH"2WF'CEF)W$\#!SD8&,8KH:* .9\.?#_P ,>%)IYM)TQ8YIX_*D
MEED:5BG'R9<G"\#@=<#T%0:1\,O".A:PFJZ?I"QW498Q%I7=8BW4HK$A?P''
M:NMHH Y'5/ACX0UG6GU:^TA9;J1U>7$KJDK+T+H&VM^(Y[YKK0 JA5   P .
MU+10!Y_\;?\ DD.N_P#;O_Z41UT'@3_DGGAK_L%6O_HI:Y_XV_\ )(==_P"W
M?_THCKH/ G_)//#7_8*M?_12T =!115:ZAN9MGV>[^SXSN_=A\_G30F[+8+_
M %"UTRT>ZO)EBA7JQ_D!W-9VD>*M(UN<P6EP?. R(Y%*EA[>M<S\0-*U632H
M)S<M=0P.3(BQ!=N1][CJ!S],UQ_A/3[Z^\0VIL]\9BD#O*!D(H]?KTQWKKIX
M>$J3FV>17S"M3Q*I*&FGJSW"BJ$=IJ"R*SZGO4$$KY"C(],U?KD:L>M%M[JQ
MD^)->@\,:%<:Q=03S6UN5,HA4%E4L 6P3R!G)]A3]<UVST#P]>:W=,6M;6$S
M'9@EQV"YXR3@#ZU:U&P@U33+K3[I-]O=0M#(OJK @_SKRC2;V?Q!8^&O ]VV
M^ZTZ]D75@>\5FPV9![.Q@.>_-(H]:BN UK%-,I@+J&*2$ H2.A[9K)\1^(&T
M&3146V$W]I:G%8$E]OEAU=MW0YQLZ<=:Y*[MKO6_BAK5K<:=IFH0V-E;&T@U
M)V"(LF_>Z+L8$DC:6P"  .YK,UWPY=:=H'A31M3N%>)O%:>4EM,_[F!EF*Q!
MSAOE!*YXXQ0!ZTKJX)5@V#@X.<&J>D7-[=Z<DVH6D5K<EG#113"50 Q .X =
M0 ?;.*Y"PLK71OC&;'3+>*SM+G0#--!;H$1Y$G55<J.,A6(SZ?2N1TEO-^&W
M@K3IY"NG7^OS6]XN<+*GGW#"-O\ 99E4$=^G>@#TWQ9XC'AOPO<:S#"EWY4D
M2!/,V@[Y5CZ@'INS^%;CND:[G954=V.!7GOQ*T;2])^'6L-IUC;VAFFLC*L$
M80-BYC )4<9QQGV'H*9J<%WK'Q4O;*6QTZ_AL],AEM;;49&$:[V</(JA6#-P
M%W$<#@=30!Z/17.>#-$OM TFYL;R6W,?VN22UAMV9DMH6P5B!8 X4EL<< @5
MT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !16)?1:C;S6@35IL3W'ED&&/@;6/'R^U:EK#-#&5FN7N&)R&=54@>
MGR@53C97N9QJ<S:L_P /\R>BBBI- HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***CFGAMXS)/*D2#^)V"C\S0!)14,%W;72EK>X
MBF ZF-PV/RJ:@ HHHH **** "BBB@ HHHH *\_\ "7_)7OB+_P!PS_TG:O0*
M\_\ "7_)7OB+_P!PS_TG:@#T"BBB@ HHHH **** "BN7\2_$#0?"MRMK?32R
M7) 8PVZ;F4'H3D@#\\UKZ)KNG>(M.6_TRX$T!.T\8*L.H(/0UHZ4U%3:T+=.
M2CS-:&C11169 45D:EK\.FZ_HND/"[R:J\R1NI&$\N,N<_4#%4&\;Z9!:Z]=
M7@>WAT:Y^S2,V"97VJP" =2=X '4F@#IJ*JZ;=37VFV]U<6<EG+*@=K>4@O'
MGLV.,UC3>)[AO$U[H=CI+W4UG!%-+(9UC7$F[ &?]TT ='16%JGB0:4=,M9+
M&:;5=28K!90NI.57<Y+$@!5'4^XP"34%MXPADCUN.YL9[6_T>+SKBUD9270H
M65T8$AE.".Q!!R!0!TE%8.@Z]?:Y9V%\-':WL;V!9TE:Y5BJLFY<J._('XUK
M7US):6<D\5I-=R+@+!"5#N20.-Q '7)R>@- %BBN?T_Q/]H\1OH-_IT]A?\
MV;[5$'97CFC#!2593U!(R#CKD9%;SR)'MWNJ[B%7<<9)Z#ZT .HJ%;RU>.21
M;F%DB)$C!P0A'7)[4\2QM%YJR(8\;MX/&/7- #Z*K0:A974GEV]Y;S/C.V.5
M6./H#7*^(/%E[IVMZK%91Q2VNBZ++J-X&'+2D$PQY[9".3^% '9T50TO4DOM
M)TZ[F,<4M[ DJQ[N[*&(&>N,U++J5A#*8I;VVCD'!1I5!_+- %JBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML#0!JT5GZ7K5EK#WZV;LQL+M[.?<I&)%"D@>HPPYK0H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH SM5_X^-,_P"OP?\ HMZT:\=U[QKJ
M=[JI:UF,%O;RYA55&<C(W'/<@FO0O!^NRZ_HGVBX4">*0Q2%1@,0 <X[<&NB
MI0G""DSSL-CJ5:M*G$Z"BBBN<]$**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .=\2>-M&\*W5K;ZD\_F3J9#Y,+2"*,$ R28^Z@)
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MIC6\;6)@^SF CY3'MV[<>F.* /+O C@:J[^)&QK$&EQOI#D?N4LO*7)B'7S
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M;I^E6^G>2Q5[5LOYF1@??/&-W:N[H **** "BBB@ HHHH \_^-O_ "2'7?\
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M3:7I:1%AO9-1D8@=R 8!D^V1]:UJ**\YM/96.)N_0Y_QW_R3SQ+_ -@JZ_\
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MDQ"Z_,N3C.,CV(H ]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &Y?GQO/3IT[UZI7D7PRTJ\LO%$DL_PYA\/(;5U^V)<,Y)W+\F"3UZ_A7KM
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M?D7_ *%6C69K3HD=EO95S>1=3C^*JA\2,ZOP,TZ***DT"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\C^*=OK%[X\\+VVFZG;Z)^ZG:/59?E._
MO%N[Y !VGKD^E>I:G<W%GI=U<VEFUY<11,\=LKA#*P&0H)Z9KQ3Q)XI^%OC3
M4(I/&$6KZ5J-HGDFWN8949.<X(0-Z]\4 =EX'T?Q-8ZZ\VK^.K?7+8P,HM8P
MN0V5PW'IR/QKT.O!/#FO?"_PIKGVCP79ZSK&KS1&".&WCD.X$@_\M ,<@<X.
M*]RT^>XN=-M9[NU-I<RPH\UN7#^2Y +)N'!P<C/?% %FBL+Q);^);I+>'P]?
MV%@"'-Q<W,)E9<8VA%X'/S9)/&!P<UYMI7Q7US_A56J:W>0V=UJMK?\ ]GVL
MD0*Q7#G;AO?&XGC&<#IUH ]FHKRP>,/$W@WQ++IGBRZM-3MI-)FU&*>V@\DH
M\0+-'UP1A3SUY'TJA9^-/&MA#X6\0ZQ<:?/I/B"\CMC90VY5K82YV$/G).!D
MY^GN #V*BO'-0\;>--1L_%'B/0;K3H-(T"[>V2TFMS(UT(\%V9\\<'(QCCCW
MKTFW\4:7_P (UINN:A>VNG6M_!%*C7<ZQKETWA<L0"<9_(T <S\;?^20Z[_V
M[_\ I1'70>!/^2>>&O\ L%6O_HI:X?XO^+/#>I_"W6;.P\0:5=W4GD;(8+V.
M1VQ/&3A0<G !/X5W'@3_ ))YX:_[!5K_ .BEH Z"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBD(R",D9]* %HK!N+"2/5+*!=1O]DJR%OWWH!CM[UI-+%IELB/)-,Y.$5CO
MDD/H/\X ZU3CV,HU&[W5K%F6:.")I975(U&69C@ 50\N;5.9E>&R[1'AYO\
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M)8W+J/H2!G\JZ*]>52*3.# X*%"I*46_*ZZ$E%%%<IZ@4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>6_%:;P\FHZ=;W/A&7Q-KUQ$PMK:)G!2('EF*YP,GT['D5ZE
M7D_QA?3],OM)UN/Q6WA_7(DDB@986E$\1P2K*H. #@Y((YZ$XP 1_"V;PY_P
MDEU9CP5+X8\1PVQ<Q2L[>; 6 )4MCN!V^A/./7*\5^$VI:;K'C"ZO[[Q;+K_
M (A:S,<8^RO%'! &!;&X 9+%>P[^M>U4 %%%% !1110 4444 %%%% !7G_A+
M_DKWQ%_[AG_I.U>@5Y_X2_Y*]\1?^X9_Z3M0!Z!1110 4444 %%%% !1110
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MVWKQUJUJ?PV\'ZQK?]LZAH5O/?$AF=BP5R.[(#M;\0:ZH  8 P!0!X?\4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^?TK8HJZN)JU9<TF74KU*DN9LQO^$3\/]M'LQ["("C_ (131?\ GR_\BO\
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M>[NI/(V0P1F1VQ-&3A1R< $_A0!Q]AXO^-6IZ=;7]GX1T.2UNHEFA?S -R,
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M=)U:W^SWT'G>9%O5]NZ9V'*D@\$'@UV% !1110 4444 %%%% !1110 4444
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MXK'C.#3_ .U2;6[LYV%FD61M#+GIG/0=.E 'O%%(K!U#*05(R".]+0 4444
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M^W_9KN(QN4(#+Z$9[@X(^E<QX<^'/]CZ[::QJ>OWVLW-A;&UL!<JJK;H1@D
M=6QQN[@G.>,=S10 4444 %%%% !1110 4UUWHRDD;AC(/(IU% '!6_PUDDUS
M3;_6O%&J:Q#I<OG6-M<*BA''1G*C+D8!SQR/<BN]HHH **** "BBB@ HHHH
MP/%_AZ[\3Z))IEKK,NF1S!DN&CA63S8V4JR'=T!SU'/%<[#\+@_@9O"VHZ_>
M74$4D<EE.D2Q/:%/N[<9SWZ\\GFO0:* .2\+^!_[!UF]US4-8NM8UB[B6!KJ
MX54$<2\[$5> "0"?4@>^>MHHH **** "BBB@ K.UNQO=2TJ6UT_5)-,N6*E;
MJ.)9&3!!/RMQR./QK1HH X/PC\.;CPIH5[HR>)KV:RN(V6(1Q)$]N[=71ADY
M^OI4^B_#Y[/Q1!XBUKQ!?:UJ%K$T-H9T2-(5;@D*HY;!(SZ'Z8[6B@ HHHH
M**** "BBB@#.U[3)=9T*]TV"^FL9+F,QBYA'SQYZD?AQ^-<GX3^'FH>%TM[+
M_A*9KK1HD=&TXV44:2!E(Y8?-U.<YR<5WM% 'G.E?"6#3[O3$N/$&HWNCZ5<
M&ZL=-E"A(Y,D@LP&6P22.GY9!]&HHH **** "BBB@ IDJ-)"Z(YC9E(#@9*G
MUI]% 'FWAKX8:MX7N2]EXUNS%+<BYND:RB+7)SEM[G+'//.>YJWK7PTE\07,
MT&I>*M6GT.:Y-R^F-LQDN7V>9C=L!/"]@!@\ UWU% "*H10J@!0, #M2T44
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MUZ%110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;*(UR&X^]TS755'!;PVR;((8XD)SMC4*,^O%24 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUY!^SK_R(NI?]A23_P!%QUG_ !"\=*?B2/#-_P");SP]H=I LES<6*N)YI6
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M63"+O4L'^3@X4'C/)->R44 >7>.OA?>^*O &@Z1;3V<>JZ4D:"65F$9 C"N
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M I!)4GKCG/KQT&H^!-2O/C+I?C%+BT&GVEJ87B9F\TMMD' VXQ\X[]J] HH
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M:+/%PR?>65_G)^H8_I67HOASXGZ%I<&@VNL^&VTZW7RH;V6"5KE(Q]WY.$)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M( RQX&20/QJ2">&ZMXKBWECF@E0/')&P974C(((X((YS7!_&W_DD.N_]N_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\ )//$O_8*NO\
MT4U<_P#!+_DD.A?]O'_I1)70>._^2>>)?^P5=?\ HIJY_P""7_)(="_[>/\
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M^[;UXZT 4_C;_P DAUW_ +=__2B.N@\"?\D\\-?]@JU_]%+7E_Q2_P"%C_\
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M>[>88U0MZD#DU;IJ.)$5P& 89&Y2#^1Y%.KF;N[L]6,5%**V04444B@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C
M/BCH]WK?@>XM;2\TZR994F:ZOY6B2$*<[@ZC*L#C!KSG1-?\</KFG0W/Q2\)
M75NUS$LD$4L9DE3< 57]R"6(X'(Y/6NS^-Z6C?#:X>\G*1Q7,,@BR1]H(;_5
MY'3(SSVQFN \/Z]\,Y=;TM+/X>ZI!=/<Q"&9E++&Y8;6)+\@'!S0!]"T444
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M.TNBWGN(F&"^P;3M9^!@\<&NEDTZRFU"#4)+6%KR!62*<H-Z*W4 ]<'THO\
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M.(2")1*RM(!\S(NT$^PR<?F:?5;3[EKO3[>X9=K2(&(]ZLU)H%%%% !1110
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MH **** //_C;_P DAUW_ +=__2B.N@\"?\D\\-?]@JU_]%+7/_&W_DD.N_\
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M-,?:I\G_ %N_.5V?[61WXZYXS7A/@K4OAS:^,]-E#>*K^Y:]4VJ7D</E+.[
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M35^BM:N(E524CGPN I8:3E"^O<****P.T**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQ'4_$^J^'?C%XE_X13PW<:T9X+;^TD56'ERJORE6 .
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M\?T]ZD@M4@)?)>5OO2/RQ_P'L.*R.PB\B6[YNODB[0*>O^\>_P!!Q]:M@!0
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MH/ G_)//#7_8*M?_ $4M '04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4R26.( R2*@)P"QQ4=S>VMD@>YN(H5/ +
ML!GZ>M>+^+=3N=1\0W33._EQN5A1@0 G8@'ID8/XUO0H.J[;'#C<;'"QO:[/
M;BP"[B0%QG/:L\ZD]T2FF0B<=#.QVPCZ'JW_  'CW%<;\.UDU2QN8K\RSVEL
MR"".1B8\G.1CH<8'!SC->A@ # & *FI!4Y.+U-*%9XBFJBT3^\H1Z8KR+-?2
MF[F4Y7<,1H?]E.@^IR?>K]%%9MM[G1&*CL%%%%(H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O-?$OACX37_B&[N?$-QI*ZM(RF
MX$^KM"X.T 902#'&.U=CXJ\1P^%/#\^KW%K<W4<+(IBME#.=S!> 2/6O"]9\
M5?#3Q!JUQJFJ> ?$$][<$&67>Z[B  .%E ' '04 =7\,K/PMIGQ0\2V7A;RK
MBR%G"\=S%,TJQY(W1ALD,,X.>3U&:]BKR[X3ZUX2N+F]TWPQX7OM'Q&)I9+I
M.9<' &\LS'&XX!.!S7J- !1110 4444 %%%% '/^._\ DGGB7_L%77_HIJY_
MX)?\DAT+_MX_]*)*Z#QW_P D\\2_]@JZ_P#135S_ ,$O^20Z%_V\?^E$E 'H
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %0W,D\40:"W\]\XV[PO'KDU-5/4]3MM(T^6]NV*Q1CH.2Q[ #UII7=D3
M-J,6V[+N5(M5OY;B>%=).Z$@-_I"]QD5JH6**67:Q'*YS@UYWIOQ$M1K%P]S
M9O#;W+K\ZON*8&,D8Y]>/UKM%2YU10\I:WLV&1$C?/(/]IA]T>PY]^U:U*3@
M_>5CBPN+A63]G+F?]6Z(?+?O-*UO8(LLJG#RM_JXS[GN?]D?CBI+:P2"0SR.
MT]RPP9GZ@>BCHH]A^.35B**.&)8HD5(U&%51@ >PI]9WZ(ZU"[O+5A139)$A
MC,DCJB#JS' %5?-N+OB &"+_ )ZNOS'_ '5/3ZG\JDT.>\;S2*EI"&Q&VYF4
M'J1C&?S-<QIF\ZG;+&NXM( 5[,">0?:O27TRSDMWAEA$BORY<Y9CZYZU1T32
M;*U1YXH )1+*@<DD@!V48].!3 V      !T I:**0!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '"_%O2;W5O SK8V37[6UU#<RV29S<1HV608YZ<\<\<<
MUYRVJ:?XW\1>&K+PQX%GTFZL-2AN+B\:T6$01(<LN5[>QQTQC)KU3XB:;H^I
M^%6CUK6GT>WBF25+R.41LL@SM )Z]3P.:\C\-^//$ECXNT_1- \13>,-,DG2
M.>2?3Y T$9< MO\ O="3N)(XH ^B**** "BBB@ HHHH \_\ C;_R2'7?^W?_
M -*(ZZ#P)_R3SPU_V"K7_P!%+7/_ !M_Y)#KO_;O_P"E$==!X$_Y)YX:_P"P
M5:_^BEH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S-4\0Z
M5HK(E_=K$[\J@4LV/7 !P*MV5]:ZC:I<V<R30MT9?\\'VJN625[:$*I!RY$U
M?L6**H2ZQ8QR&)9O/F'!BMU,C#ZA<X_'%,^TZI<_ZBRCMD/\=T^6_P"^$_JP
MHY6)U([+7T-*JESJ=E9N(YKA!*>D2_,Y^BCD_E4']ER3\WU_<3^L<;>2GY+R
M?Q)JW;65K9H4MK>*%3U"*!GZ^M%HH+S>RMZ_U^I4^WWMQ_QZ:<X4])+IO*'_
M 'SRWY@4?8+VX_X^]1<*>L=JOE#_ +ZY;\B*TJ*.;L'L[_$[E2VTRRLW,D%N
MBRGK*?F<_5CR?SJEJWA?2=:F6:\MLRJ,;T8J2/0XZUL44*<D[IZA*E3E'E<5
M8K6&GVNF6BVMG"L4*]%7N?4GN:LT44FV]66DHJRV"BBBD,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR'7G\4^/?B+K'A
MG2/$<GA_3=&BB,DML&\V9W4,#P5..H^\.@ZYX]>KY^^(\^CK\1[F2ZO=;\'Z
MEM6)-:M8G>&\CVKR=I5LC[ORDCY1GI@ ';?#O5-?L/%FN>"O$&I_VM)IT4=Q
M;WQ7#E& ^5N^>0>23UY(Q7I=<)\,_"^AZ)I]WJ.EZX=>N]08-=:DTPD+E<X7
M@G&,G.23D\G@ =W0 4444 %%%% !1110!S_CO_DGGB7_ +!5U_Z*:N?^"7_)
M(="_[>/_ $HDKH/'?_)//$O_ &"KK_T4U<_\$O\ DD.A?]O'_I1)0!Z!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7+^-K)]8TG^SK,-+>(ZS")/0 CYCT'4XSU(XK8:ZEO7:*P8+&#A[HC('J$'\
M1]^@]SQ2310:=98C>ZB#/EI((3-([>K?*Q/UQZ5I!N$D^IS5HQK4W!_"]W_D
M>,67A_5+Z^^QQ64PE! ?>A4)[L3TKW&RM_L=A;VNXOY,2Q[CWP,9_2N7LM10
MZMJ7^FZK@M&5*V#%FPH!R/*XP>.@KIFNXH8XP2\DCJ"J;?G;_@/&/?. /:M<
M15E4M=6./+,'2PZDX2NW^299JJ]X7<QVB><X.&;.$3ZGU]AS]*;Y$]US<MY<
M?_/&-NO^\W?Z#CZU:1%C0(BA5 P% P!7,>J01V8\P37#^=,.02,*G^Z.WUZ^
M]6:** (9[?SRO[Z:/'_/-L9J"'34@QLN;G&XM@R<$DY/ZDU=HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH$WS2)&H_B=@!^M43KNFDXBN/M!]+9&F_P#0 :?%HNF0OYB6,!D_YZ,@9O\
MOH\U>  &!P*GW2?WC[+\?\C-_M.YD_X]]*NV']Z4I&OZG=^E&=:EZ+8VH]R\
MQ_+Y/YUI44<RZ(.1O>3,W^SKR3_7ZM<8_NP(D8_D3^M8'BGP4-6M8Y+*>3[9
M%G'VB9W#@]LL3CVQQ78T54:LHNZ(JX:G5@X35[GGOA'P->:=JJ:CJ11##DQQ
M(VXEL8R3TQ7H5%%%2I*H[R##X:GAX<D HHHK,W"BBB@ HHHH **** "BBB@
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MY!$*\?I6F+5!5/W>WD7B514_<V(/^$BT/_H,Z=_X%)_C4)\6^&@<'Q#I.?\
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M_P"H/JW_ (#?_7H]G+L')(V:*QO^$@)X71M6)[#[.!^I8"C^W;C_ * &K?\
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M63.A*R"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!Q?B35M5UQ]3\/>"]5@L?$.FR0/<R7468UCD4L "4
M8$D8[5R<'@#XDZUK>D2^,/%6G7.FZ=>1WJQ6D8#F1#D=(D]QDDXSTK.N]"\3
M:W\9_&B^'/$7]C-$ED9F\O=YH,"X_+!_.N@T[P1\1[;5+2>[^('VBVCF1YH?
M(QYB!@67\1D4 >HT444 %%%% !1110!Y_P#&W_DD.N_]N_\ Z41UT'@3_DGG
MAK_L%6O_ **6N?\ C;_R2'7?^W?_ -*(ZZ#P)_R3SPU_V"K7_P!%+0!T%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ,6&))7E6-%DDQO<* 6QTR>]/HHH
M**** "BBB@ HHHH \_\ C;_R2'7?^W?_ -*(ZZ#P)_R3SPU_V"K7_P!%+7/_
M !M_Y)#KO_;O_P"E$==!X$_Y)YX:_P"P5:_^BEH Z"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\^^-=S<6?PMU*:VGD@E62'#Q.58?O5[BL*#XWE+>-3X*\0,0@&X0]>.O2O0/
M&/A:W\9>&;C1+FXDMXIV1C)$ 6&U@W?Z5MQ1B*%(P<A%"Y^E '&^"_B%_P )
MCJ%Q:?\ "/ZGIODQ>;YEXFU6Y P/?FNUHHH **** "BBB@ HHHH Y_QW_P D
M\\2_]@JZ_P#135S_ ,$O^20Z%_V\?^E$E=!X[_Y)YXE_[!5U_P"BFKG_ ()?
M\DAT+_MX_P#2B2@#T"BBB@ HHHH ***9+-%"NZ61(U]68 4 W8?12!@RAE((
M/0BJ,^JQ([Q6R&YF3AQ&0%C_ -]CPOTZ^QII-DRG&.Y?JA)JB/(T-C$UW,IP
MVPX1#_M/T'T&3[51_>ZA_KV>Z4_\L+;Y8!_O.<%_PX_V:OQVD[1K&\J6\*C
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MB@ HHK-?Q!I$=Y]D?4K9;C.TH9!P?3Z^U-)O8#2HHHI %%%% !1110 4444
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MF\[SHR_W?.&W&,=3GVKZ KE]#\-WFF>._%>N320-:ZO]C^SHC$NOE1%&W C
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MRX[>M=Y0!X__ ,*@\8?]%9US\IO_ (_1_P *@\8?]%9US\IO_C]>P44 >/\
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M7/\ OQ#_ /':FX'JC:3IKG+:?:,?4PJ?Z5"?#NBD'_B4V()[K;J#^8%>8_\
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M#@?^1:7_ (:.\'_] W7/^_$/_P =KFE--MV)N>G?;=3_ .@1_P"3*T?VA?\
M_0%N/^_T7_Q5>8_\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\ X[2Y
MEV$>G?VG=_\ 0"U#_ONW_P#CM8/C#Q)>V&@2-;V5W:RRN(A-(%&S.<X(8\\5
MQ_\ PT=X/_Z!NN?]^(?_ ([574?C]X'U6PELKO2M<>&08(\F($>A'[WK50G%
M23:&F8EEJM]I]^+VVN9$GSDMN^]['U%>VVGB*UGLX)I8;R)I(U9@;.;:"1G
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M_P"%]^&1]VZ\6 >GV:S/\^:++N![E17AO_"_?#H^[<^*#_OV=F?Y$4?\+_T
M<B?Q$3_M6-J1^CBCE7<#W*BO#?\ AH+0_P#GKKG_ (+[?_X[1_PT+HW][5/_
M  6Q?_)%'*NX'N+NL:,[L%51DL3@ >M8,7C7P_->_9$U%/,+;0Q5@I/^\1C\
M>E>1ZA\;=/\ $-FVD027<;7)"!I;%8N^<%A.V,XQ]WG.*R<XYS77A\-&I%ML
MN,;GTC17BVG_ +07A?3M/@LKJUUBXGMT$3RQ11E7(XR"9 2/<U9_X:.\'_\
M0-US_OQ#_P#':XVK.Q![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&Z
MY_WXA_\ CM(#V"BO'_\ AH[P?_T#=<_[\0__ !VC_AH[P?\ ] W7/^_$/_QV
M@#V"BN;\%>-=-\>:--JFEP7<,$5PUNRW2*K%@JMD;688PX[^M=)0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &/KWBO0O"\<3ZWJEO9"8D1B1OF?'7"CDXR.?>KVFZG8ZQI\5_IUW#
M=6DHRDT+!E;G!Y]CD$=B*\[D2.Z_:+,5^D<D<?A[=:I(,C<91D@'OC?^%/\
M@H(U\.:\EL<V*:]=+:8^[Y6$QM]NOZT >ET444 1SSQ6MO)<7$J10Q*7DD=@
MJJH&223T K#T;QQX8\0W[V.DZU:7=T@),2-R0.I&?O#Z9K8OHK2:PN([](7L
MVC83K. 4*8YW9XQCKFO*O#=FGC?XKQ>-=-LQ:>'])MWM+2?RPAOI,.I8#'W
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M?6M2@LDD.V/S#RY[X Y/6N ^*=A9V_B?P/=PVL,=S<^(K8S3*@#R8*@;CU.
M .?2I]12.Y_:(TZ&^2.2*/07>T209'F&1@Q /\6T'\!0!Z%I>JV&M:?%?Z9=
MPW=I+]R6)MRG'!_'VJY7FGP<6)+?Q=':$?8D\172V^W[H7Y<8]L8KTN@"&[N
M[:PM9+J\N(K>WB7=)+*X55'J2>!5'2?$>CZ[I<FIZ;J$,]C&S*\X)55*C+9)
MQP!WJY>6-IJ$'D7MM#<P[E?RYD#KE3D'!]" :\U^#$-M/\/-4@NXXGM7U&Z2
M5)0"C(0 0P/&,9S0!V.D>.O"VO:DVG:7KEI=78!/E(_+ ==N?O?AFNAKR+1;
M*+QS\5;/Q5I%I';>'M#B:V@NEB"&]DPRG9_L+NZ^WOQZ[0 5CWOBK0M.UFUT
M>ZU2WCU*Z8+%;;LNQ/3('3/OBMBO+/B+8VEMX^\!W$%K#%/<ZN6FD1 &D("
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M)/)K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "O'_ -G'_DGFH?\
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M?7M1U[5)H'OKR..!8K<'RX(H]Q"ACRQ)8DD@=ACCGH* "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI6H&24[7+,PB=AT)ZDMU^6NUU+X4:??ZUJM['K.JV=MJ^#J%E;2A8YR/4XR
M<G(SSDCH:YOQ[HT'A[X40>!K>TU+6+N7BQ>*VW$,)0V6*C P&(]Q^)H BTI_
M$?BK3/'_ (G\/W<OVJ[G^QZ0/.(411$!FCR< LN,'LPZ]ZR_ &K0Z9XPTFPU
M1_%>C:M,AAFM]1D,UM?28Z_-@J2>00,=L^OJ&B>"K:S^&]EX4N6DC5;94FDM
MI"CB4G<S*PZ'>2:HZ;\-(K?6=.U'5?$.K:R=,R;&*\==L1( W' !8\#DGM0!
M;^)_B"\\,?#O5=4T\[;M%2.*3&?++NJ;OPW9'OBO/M7L;[X=:=X3\26.NZM?
M75[=P6VH0W5RTJ70D0LQ"D\$8('ID?C['J^DV6NZ1=:7J,(FM+F,QR(3C(]C
MV(Z@]B*XS2?A38V%]IDM]K>JZK:Z20=/L[R13' 1]TX &XC QZ8H YCPIX8L
M8_CUXJQ->?Z MO/%FX8[F>-20W]X98X!Z<>E>Q7%K;W:!+F"*90<@2(& /XU
MAZ=X2M].\::SXF2YE>?5(XHY(6 VIY:A1@]><5T- 'D?P>L+.74/&ADM(',>
MN2A"T8.T G ''%<]\+K>=/ASJ7C>[U34[N_TL7<EM!+=OY/R0YPRYYR3G/L/
M2O6?"G@^V\*3:Q+;W4LYU.\:\D$@ V,Q/ QVYJ/P;X(LO!WAB708IY+RVED=
MW,ZC+!P 5('; H \7T>3QG<:1I?B+1[#Q1=ZS),+B>YEO%:TNHR3N3R\\+C@
M<<8^F-;Q]=W6LZ[XHDTG^WK]](@/FS)?BTM=/*QLQ*J.96R#D=21UQBNXTSX
M3V>ESV\,/B#6SH]M<&X@TO[0!$K$D[20-Q7)/&>_.<G+]2^%&GW^M:K>QZSJ
MMG;:O@ZA96TH6.<CU.,@')R,\Y(Z&@#S#Q'"_B/P=\,]4U.[NIKR[O([2:3S
MB"R^81N_W_\ :ZUT$?A\ZE\;-2\,'6-7M]+M=%C/EP7C*T@'E* S=>K9)ZG'
M/!-=?<?"NRN?!FC^'FU6\1M(N/M%I>QJ@D5LL0",8(&[VZ#WSI:-X$ATGQC+
MXF?5+J\O9=/2QD\X+\X79\Y('WCL'MS0!XG!#K+_  ;U3Q-<^)M8>_T>^%O8
M;+ME5$$J*2PZDDR-U)P%4#CBNF\5>(-7U[Q9H&C-!JMW9-HL6H3VFDSB"2:5
M^I9LCY1QQZUVZ_"^P7X?ZEX1_M"Y^S7]S]H>?:N]3O1\ =,90#\:L:O\.+/4
M3H]U:ZG>Z;JNE6RVL-_:D!VC QM8$$$=3CW- 'F>L7/BW3?@UXEAU<:K:BWO
MH3ITUY,#<"!I%^1G4\XQU]_3 &E=Z5?>%_$_@&[@U_5;F36'^SZ@MQ<LR2@J
MO1>B@;C@=L+W&3VUW\,K*\\#WGAJ;5M2F^V3B>>]N)/-F9PP;OP!QT _7FM+
M5O!EMJUWX;N)+N9&T*42Q!0,2D!1AO\ OGM0!YS\'?#MG!XW\9W"2W9?3=4D
MMX0T[$,NZ1<N/XFP.IYKVRN1T?P%;Z%XQU'7[#5+V./49&FN;#*^2\AS\W3/
M5B?J:ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img40748725_31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_31.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %* <H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 -DD2*,O(ZHB\EF. *565QE6##U!S7D_QJM;B:&QDNK:^NM$2WN
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M\5?#>A67PQURXM=&L()DA4I)';(K+\Z]"!0!Z0CK(BNC!E89!!X(IU4=%_Y
M6G_]>T?_ *"*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<;XE\<3:-XBM='L=(>^<F!KN8RA$MTEE\M#ZL2<\>U=E7C'Q+N?"TGC^
M.S\2RW]BBV,<D5[II<2$^8QV28!! P"IQD'- 'IWAC7U\2:,+[[*]K*DLD$T
M#D$QR(Q5AD=>16S7-^!9- D\)VH\-%VTQ"RHTBL'9L_,6W#)).3FNDH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#SKX@WCZ1XL\,ZQJ$=\^@6AE:8VBLPCGP-C.J\E>HI?AM,][K7
MB;4;".^C\/W=Q'+9B\#*6D*DRL@;D*217*ZCXQ\0WEKJB6VKB.]U371HMA:1
M(NZTC1B'D]22/7IGBNM^'EUJ%KXA\2^&KK6)]8MM*> P7<Y#2#>F61F'7!%
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MMFQZ/\*OOZE]$_K7I5>:_"K[^I?1/ZUZ57C8K^*S*6X4445SDA1110 4444
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M/A5KY"*#Y*=!_P!-%H ZK1?^0%I__7M'_P"@BN5^)_\ R ;?_KM_0UU6B_\
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MI5>:_"K[^I?1/ZUZ57C8K^*S*6X4445SDA1110 4444 %%%% !1110 4444
M%%%% !7F7C.7Q)I7CF*^TTZ++97EK';+:ZK>;!),'8@HG][Y@,CKFO3:\B^)
MVDWL/BJSUNVMM*OLQP+''>W20O;M%-YA9-QQAQ\IQS0!Z+X8O=3U'0H;K5XK
M*.Z<MQ93>;$5SP0W>MBN3^'.GG3?!\433VDC23S3%+.3?##O<MY:'T7.*ZR@
M HHHH @O?^/&X_ZY-_*N5^%?_),]$_ZY-_Z&U=5>_P#'C<?]<F_E7*_"O_DF
M>B?]<F_]#:@#L:*I:MJ*Z5IDUZT9D6( E0<9YQ7*?\+)M?\ H'R?]_!_A0!W
M%%</_P +)M?^@?)_W\'^%3V7Q M[V^@M5L9%,KA 3(.,G'I0!V-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$^/GU.R%MJ5G?^'X
MK>%6$MOK* +*>HVOU4]:P_!OQ6T;4KN*SN-$?2Y;B86\=U!%NM9I.<*L@ Z]
MLCO6=XG\4:=JAU#6;GPG;7_]G7RZ5I$EV^X7%R6(<%.@48SG'-=/X8OY?$EQ
M?^'O%&C6,&HZ'<03JELQ,)R-T;IZ$4 =Y1110 5Q/Q>_Y)3K_P#UQ3_T8M=M
M7$_%[_DE.O\ _7%/_1BT =1HO_("T_\ Z]H__017*_$__D V_P#UV_H:ZK1?
M^0%I_P#U[1_^@BN5^)__ " ;?_KM_0UMA_XL1QW/)J***]LV/1_A5]_4OHG]
M:]*KS7X5??U+Z)_6O2J\;%?Q692W"BBBN<D**** "BBB@ HHHH **** "BBB
M@ HHHH *\C\;60G^);3/X-'B:/\ LV-#&T\8\D[V.51CGGN<>GO7KE>8_$30
MYM?UR*WTSPE+<ZHD"E-;-T;5+<9.!O7YF(Y.!ZT ==X,B2'PY$B>'O[ 7S'_
M -!RIV\_>^7CGK705P'@VP\;^']5M],U_4TUG3Y;5G-T(R&MY5( 0L>6!!/)
MYXKOZ "BBB@""]_X\;C_ *Y-_*N5^%?_ "3/1/\ KDW_ *&U=5>_\>-Q_P!<
MF_E7*_"O_DF>B?\ 7)O_ $-J -7QA_R*U]_NC^8KQRO8_&'_ "*U]_NC^8KQ
MR@ K1T#_ )&"P_Z[I_.LZM'0/^1@L/\ KNG\Z /;JX7XGW,]MI5DT$SQL92"
M48CM7=5P'Q5_Y!%C_P!=C_*M:'\1'+CG;#R/-/[6U'_G^N/^_AH_M;4?^?ZX
M_P"_AJG17IV1\QSR[G=?#B^N[GQ1LGN99$\ASM9R1GBO7*\;^&7_ "-G_;N_
M]*]DKS\3\9]#EC;H:]RE=ZM96,WE7$VQ\9QM)XJO_P )'I?_ #\_^.'_  KF
M_&'_ "%D_P"N0_F:YZOCL;GE>AB)4HQ5D_/_ #/54$U<]%_X2/2_^?G_ ,</
M^%7+/4+:_5FMI-X7&>"*\NKLO!?_ ![77^\O]:TR[.:^*Q$:4XI)WVOV]12@
MDKG44445]*9A1110 4444 %%%% !1110!Y_%\++=/%2:FVL73Z9%?-J,6EE!
MY:7+=7W=2,\XK9\)>$Y?#]SJFHW^I/J.J:G,)+BX9 @"J,(B@= !7GVLW'Q#
M\'^(C/)JVEG1&EN)8[C4)W6(!VRJ2'&=PZ*!QUKN_ VL:[KEG->:I<:%<6K8
M%O+I,SR GG<&W#CM0!I^+/$EKX4\.76KW6"(AMCCSCS)#PJY[9/?L,FO#K/Q
M/JUCX8^(#OKL5QJTEU;@36\X8('.',7/W1NVY%?0=[86>I6YM[ZU@NH20?+F
MC#KD=\&N6A^&7AF)-=C^Q*8M9P)XU55$8'01X VC.#]0* ,7PIGPKXU\2:%;
M27USI=K807L<$DC32*Y!#!<\DMCIZUD?$GQW%JOP[UFR7P_X@MC-$H$US8-'
M&OSJ?F;/%>@^&?!]CX8DNYX;B\O+R[VB:ZO)?,D95&%7/H!65\7O^24Z_P#]
M<4_]&+0!U&B_\@+3_P#KVC_]!%<K\3_^0#;_ /7;^AKJM%_Y 6G_ /7M'_Z"
M*Y7XG_\ (!M_^NW]#6V'_BQ''<\FHHHKVS8]'^%7W]2^B?UKTJO-?A5]_4OH
MG]:]*KQL5_%9E+<****YR0HHHH **** "BBB@ HHHH **** "BBB@ KY\MM0
MD\1W2Z/K6JZFJQW=WJ'B/<SQBUBCRL4:D#A2,' KZ#KSW3_BUX+U*6>VO;J"
MQ?R_WRWFT!CN92A]3\N<>A% %[X5W%W<^ ;.2YEGEC\R5;66X_UCP!R(RW_
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MFWNXO-MIXIH\XWQN&&?J*X[XO?\ )*=?_P"N*?\ HQ: .HT7_D!:?_U[1_\
MH(KE?B?_ ,@&W_Z[?T-=5HO_ " M/_Z]H_\ T$5ROQ/_ .0#;_\ 7;^AK;#_
M ,6(X[GDU%%%>V;'H_PJ^_J7T3^M>E5YK\*OOZE]$_K7I5>-BOXK,I;GC?Q,
M_P"1K/\ UQ7^5<;79?$S_D:S_P!<5_E7&UVTO@1\GB_X\_4*]U\$?\BC8_[I
M_F:\*KW7P1_R*-C_ +I_F:QQ?P([,I_BR]#H:***X#W@HHHH **** "BBB@
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M /7%/_1BT =1HO\ R M/_P"O:/\ ]!%<K\3_ /D V_\ UV_H:ZK1?^0%I_\
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MM?&XK^//U9T1V"BBBL!A1110!YK\2YX9O$/A[2-9U.?3/#MV)C<S12^4)95
MV1L_8=3[T_X8W,:ZKXCTK2]4GU/P_8RPBRN)9?,VLR$O&K_Q ''TKM=1CT;5
M+9[/4A97,!/S13E6&1['O7,>$KP1^.O$NAV7V>/2+"*U:U@MXU5$+IENG7)H
M [FN$^,0F/PPU7RMVW]V9=O_ #S\Q=WX8KNZ9+%'-$\4J+)&X*LC#(8'J"*
M/-/#,D3_ !*\5R>'!9R6XTRU""(@0&;#;02OMUQSBD\3Z5\2/%/AN]T2YL?#
M<$5V@1I([N8LN&!XRGM7H6F:/INBV[6^F6-O9PLQ9D@C" GU.*NT <#:/\3;
M2S@METSPPRPQK&";N;) &/[E9WB#2OB/XBLTMKBQ\-PJC[PT=U,3T]TKT^BG
M&3B[H#P>Y^'WCFUM9KB2/0RD2,[8N),X S_=JMHO@OQIKNBV6JVL6BK;W<*S
M1B2>0,%89&<+UKWJ^M_MFGW-L&VF:)H]V,XR",_K5'PSHY\/^&--TAIA,;.W
M2$R!<;MHQG':MOK-7^8KF9Y]X<\/_$7PT;@V]GX=F\[&?,NI1C'T3WK>^U_$
M_P#Z!7A?_P #)O\ XBNXHK*4G)WEN3N>/:_X0^(/B'4OML]MX?A?:%VI<RD<
M?5*Y+Q!X7\7>'%T\WD6D,+Z\CLXO+G<X=S@$Y4<5]'5S?B[PNWB=-(5;H6_V
M#48;TY3=O"'.WKQGUJU6FE9,YI8.A.3E*.K/+O\ A6?CO^[H7_@1)_\ $UV&
MDV_Q*T?3(;&+3O#,B1 @,UW,"><_W*]%HJ95)25I,JEAZ5)W@K'#FZ^)Q!']
ME>%^?^GR;_XBN.E\">/I97D,.@ L<X%S+_\ $U[314&YX!'X>\9R>)IM!%OH
MOVN*U6Z9C/)LV%BHYVYSD>E:\'@;Q_!.DJPZ 2C!@#<R\X_X#7I<7AYHO'%S
MXB^T@K-8I:>1MZ;7+;L_CTK=H X?[5\3_P#H%>%__ N;_P"(J_HUQXZDU.-=
M:L-"BL<'>]I<2O(#CC 90.M=310 4444 %%%% !7G/BW3-4LO&Z^(+?PPGB.
MUFL!9_9RZ![=PQ;< _&&! ..>*]&K@9/'OB-)71?AWK3JK$!A+'@CUZT :7P
MXTN?2/!T%K<F!93--(T$$@=+;<Y;R@1_=SBNLKC?AE97]EX5E&I6,MC<3W]S
M<>1+C<JO(6&<>QKLJ "O(M7\+>()?$NI:7!I;2Z?J>LVVI_VB)5"1(F"ZL.N
M[*X'KFO7:* .4UGP%9:WJ4U[-K&NP-* &BM=1>.,<8X4<"LVV^$VCV=NEO:Z
MUXD@@082.+5'55^@'2N]HH X27X5:7-&8YM=\2R1GJCZK(0?PJM_PICPW_S_
M &N?^#!O\*]$HH \7\,_#31]5UGQ+:W-_K'EZ=J MX-M\P.SRT;GU.6-=*GP
M;\/1N'34==1U.0RZBP(-=U:Z?9V4UU-;6\<4EU)YL[*,&1\ 9/O@ 59H X?_
M (5?I_\ T,/BC_P;R5#<?"31;Q0MUK'B*=5.0)=3=@/SKOJ*!-)Z,\TN?@OX
M9BM99%N]9RB%A_IS=A]*P_ WPLT+Q!X+TS5;V\U<W-Q&6DV7K 9W$<#\*]F9
M5="K %6&"#W%06-A:Z9916=C;QV]M$,)%&,*HZ\"GS/N3[.'9'"V_P '= M)
M/,MM2UZ"3&-\6HNIQ]15K_A5^G_]##XH_P#!O)7<44F[E)):(X*3X3:-,VZ;
M6/$4C=,OJ;DUR_Q ^'FF^&_ VIZO8:IK8NK=4,9DOW9>9%4Y'T)KV6JVH:?9
MZK8RV-_;QW-K*!YD4@RK8.1D?4"LW2IMW<5]P[G#_P#"H-!Q_P A/7__  8O
M4L7PHTF $0ZWXDB!ZA-4=<_E7>44XTH1=TD%SA_^%7Z?_P!##XH_\&\E94_P
M)\(74[SW$FJS32'<\DEX69CZDD<UZ;16BDX[,#PGQ'\'O"NE^(O#-C;B^\G4
M;N2&?=<9.T1EACCCD5TO_"@O!/IJ7_@5_P#6KT>XT^SO+FVN+BWCEFM'+P.P
MR8V(P2/0XJU5>TGW8K' VOPDT:QMUM[/6/$5O OW8H=3=%'T XJ=?AAIZL#_
M ,)!XGX.>=6DKMZ*ANXPHHHH **** .*NOA+X(O;N:ZN-#1YIY&DD;SI!N9C
MDG[WJ:U_#O@S0/"9N#HFGK:&XQYI#LV[&<?>)]36]10 4444 %%%% !12.ZQ
MHSNP5%&69C@ >IKRSQGXOBU*+1[NPUR_L/"\TT\-YJNG(=R2K@("Q!PA.[D#
MF@"[J7Q.CT_QM=V%R8K/2-, CN6E1GN+F9QE!%&N3M !);&*[C1M:T[Q!I<.
MI:7=)<VDPRDB?J"#R"/0UY%X3NM6U/67:>SM9O%D%BTFD:K?(R+=V9DV;I%7
MD-CIWPU>D>"?#4WAG1[B&ZFAEO+R[DO;C[.A6)7?&50'HHP* .DHHHH I:KJ
M^GZ'8F]U.[CM;8,J&60X +' 'YU@W/Q'\,6GB!=&FORD[2"'SO*;R!(1D(9,
M;=WXUS_B[5;/4+S45T:X@U^YMX1!J.@//E6@#9=D7O*.!G/'UKD]$\/ZAKWA
MV;PSH$MK=^#M28SQWUTN;C3W# O$RYYD!Z$T >[T5';PBWMXH0S,(T"!F.2<
M#&34E !7.>,?$LOAK3K5K6U2YOKZZ2TM8Y9-D?F-T+MV Q4^L>)+&POH]&CN
MXO[:O(9&L[<\EF521GT''?K7B,.K76L^#=7CO+._UB&W6.76VO;W9/:3@G<;
M>/& %QGGKC% 'L/A?QQI7B"0:<;^S;68X]T]O;LQ3(.#Y;,!O /<5U->8>$O
M ^KB[\.7VH:I8W.F:/"S::]O;M'<2I(F%$I/  !Z#J>M>GT %%%% !1110 4
M444 %%%% !1110 4444 %%%-DECAB>65U2- 69V. H'4D]J $FFBMH))YY%C
MBC4L[L<!0.22:\@\=:U)XI\.1:S8PSRZ):K<-):M<FVDN  !'<ICED4Y.#UZ
MUN>)/%FM1:O,D>D177AN.:&UN$\AY9KM)4)+Q;?E*@?GS7*:=X0L=1@TI_#%
MG=7JR72SIKES($-G"C[6M2A.X@*"NW&#F@#MOA[XCU'4);K1-1GLKY].MK=D
MU&RD+I,KJ>&)_C^7)^M=W5/3=)T[1[8V^FV-O:0EBQ2",("3U/%7* "L[7-<
MT_PYI$^IZE.(K>(?5F/95'<D\ 5HY QSUKR6Z\8W7]K6>H^+M C_ +%5I[FT
MV6DLD]BT3^6))>V&!)![<4 27EEJ/C"WB\:V6J_8$_T9]/2ZN&C2T"L1.)5'
M#;CQ79>"/$-UXE\/M>7L,$=Q%<RVSM;L6BE*-C>A/53_ (UF^'=#99=:TFZM
M(+[PQ?/]NLI7(=2)3N>,J>P;Y@?1J[&VM;>RMH[:UACA@C7:D<:A54>@ H E
MHHJ*:9(D;+J&VE@">3@>E &/XE\7:7X5BA:_^T223EO+@MHC+(P499MH[ <D
MUYI<.GAZ_P!"\;7VM;SJ6I2F:[69S$]DR,T:[#P, +@ =:V?"/B&#QC>6\FN
MZ=]@\4P64IM0242XMY/XT!/(X&0>147P^\-:IJWAZP@\4Z?#%I>G;18V,J9=
MI48GSG)Z#D@+TQS0!Z+HVJ+K6CVVI);7%LEPF]8KA-KA>Q([9'/XU?HHH *Q
M-3U>UN?[0T/3]7M(==^S-Y,32#?&[*=C%>O7!JGXB\8'1]3@TK3](O-7U.6/
MSVM[4J/+BSC>S,<#G@>M>>_$SPNL_C'3[J*TM5;7U2Q>YF8AK*X7E)5*\[BN
M5QG!(% $UG<VWPO\8Q6<TES.;[1HY)K:)WF:[OO-"90,>I!8GIQ7L*,716*E
M20#M/4>U<IX<\#1Z-=QWFH:E<:S=VRF.SN;U5,EO&0,J&'7GN>G2NMH ****
M "BBB@ HHHH **** "BBB@ ILDB0QM)(ZI&@+,S'  '4DTI(4$DX Y)KROQY
M\08AX?NVMX([WPSJ-C<6G]I6S%C#=%64*Z]E/ S[T =QXBL=/\4>#+VVDO?*
ML+RU+"Z1]H52,A\^G0^A%>0V\NHZ/%H8M?$TEYXBDDA$.E6 +V,EF6VC"A=H
M^4%BV<@FM72=6U;4_ ND>'==\#:C<Z7<VMO%'<V%R&5TPNUFY!4< G/O7KUI
M96ME;PPVUM%#'"@CC1% "*.P]J ,G1/"&F:%J=YJ5N;F:]N^'FNIS*RIG.Q<
M_=7)Z"MZBB@"&[NHK*SGNIB1%#&TCD#)P!D\5YGJ?CV!K6YOH-9GN?#VHL+?
M[?91A3H[%!@MU+9+9)[8QUK4^(7C*]T&[L])T\623W<$DIEO5=T<+@")%3EG
M8M@"N7\*^&=1=)8_#LEC86DL@MM?T:Z5IX8)0%+>43U)4@$9P">O% #O#OA.
M;4HH]%O8'L-:T=A=:?XDL$!2[B=B=Q;HQ;)RI^M>MV=A:V$;I;6\4/F.9)/+
M0+O<]6..YJ+1](L=!TJ#3-.A\FT@!$:;BV!G/4\]ZO4 %<[XI\5_\(ZUC;6^
MG3:EJ5\[+;VD3JA8*-S,6;@ "DUWQQH?A_4[?3+N>62^GP1!;0M*ZJ3@,P7[
MHSZUS'Q7M;/7/[(T"$7JZ]=2.UE/:J<0+MVR-(?[F#@CK0!E7VD:9)H]SXJ\
M-WBZOX@L;]-1N6^T+-+M7.ZWRO10C, !U(KJG\&^#_&WV7Q*^GEVNXED9E9X
MO.7@@2*"-V/?TK*\%^$=<L_%46KZGIFFZ2MMI_V%X]/DW"\;(P[# "@ <=3S
M7I( 4 *  .@%  JJB*B*%51@ #  I:** "BBB@ HHHH **** "BBB@ HHHH
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M"QTBRAL[8,6\N(8!)ZD^IIVCZ39Z%I-MI>GQ&*TMDV1H6+$#ZGFKU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M3XC\.V'BC1Y-.U!#L8AHY4.'A<?==#V8&M:B@"O8V\EI86]O-<R74D4:HT\F
M-TA QN..,FK%%% !1110!@Z_X5M->N["^\Z:SU&PE#P7=N0) N?F0^JL."#6
M]110 4444 %<@WP\TEO$-S?[$:PO )+G39(@\3S@@B9<_=;L<=>]=?10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img40748725_32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_32.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +* ML# 2(  A$! Q$!_\0
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M !+I$6J:7*\MG,2(Y&C9-V#@\, >HJX+RU-Q]G%S"9A_RS#C=^76@":BBB@
MHHHH **** "BL/1_%^AZ]JNH:9IM\L]YI[;;B,(PVG.."1@\C'%;E !1110
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M@6]S-9"5)%8 G8W;_$5S'P;L;\:AXHU*SL[NR\-7$;BSAGS@G)*[<^@ZD>M
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M:C!$);A(I!&L:G&.QSU';O6)\1?$>D:C\/-'U3Q#X6N9Q->B/[#-<- \$@#
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M+>&K31?MLEXEJ"J2R*%;;DD#CTSBMNBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#%\6^'O^$J\,WFBF]DLTN@%>6-0S;002,'UQBKFBZ3;:%HMGI5FNVWM
M(EB3/4@#J?<]:O44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>"ZDD\K48IQ&UJP4?7(;..F*](KSWXF,ES<:/I-KX>T_6-9O6D%L+\?NX44
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MHH ANWECLYW@3?,L;&-?[S8X'YUXD_Q*B_X5W:B+Q-=MXP2X$AM/*^=YBYS
MRXQY?./P'->C_$#Q'J/A[1+5='ABEU74;R.QM!-]Q9'R<M] IKC?%VJZUHVI
M7&NZ9I&AR6VBF$:K</ /.FD8*S[&QP &7WR?:@#UN%G>"-I%VN5!9?0XY%/I
MD,@F@CE7[KJ&'XBGT %%%% '"P_\EUN_^Q<C_P#2AJ[JN%A_Y+K=_P#8N1_^
ME#5W5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$*1C''2I* "BBB@#A8?^2ZW?_8N1_P#I0U=U7"P_\EUN_P#L7(__ $H:NZH
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M^7ZEFBBBN(]L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXO+7<2S YYK?KSGX;?\ ']>_]<A_.O1J "BBB@ HHHH **** "BBB@ HHHH
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M^@BG_9+;_GWB_P"^!4P  P.!6-:M[2VAVX/!O#MN][A1116!W!1110 4444
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MNM2L;%E6[O;>W9AE1+*%S],FJ_\ PD.B_P#07L?_  (3_&O/OBO_ ,A+3_\
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MTO\ ?;\Z\K_65?\ /O\ '_@%^S\SU7<OJ/SHR#T(KRKSI?[[?G70>$)'?59
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M6M:]8_A/_D3M#_[!\'_HM:V* /*_BO\ \A+3_P#KBW\Z\]KT+XK_ /(2T_\
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M[!=S_P"BVH M>$_^1.T/_L'P?^BUK8K'\)_\B=H?_8/@_P#1:UL4 >5_%?\
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MMG_WX7_"C^Q]+_Z!MG_WX7_"KM% %+^Q]+_Z!MG_ -^%_P */['TO_H&V?\
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M_P 57<44 >9:M\,_$NN2QR:EX\,SQC:A&D1+@?@U9W_"EM3_ .AT;_P6)_\
M%UZ]15JI-*R9E*A2D[RBF_0\$\3_  XU7PZND%?%9G_M#4X+ YT]%V"0D;OO
M'.,=*W?^%+:G_P!#HW_@L3_XNO0_$GAU/$2Z4'N6@_L_48;\;5#;S&3\I] <
M]:VZ/:S[LGZM1_D7W'D/_"E]3_Z'1O\ P6)_\771Q^%/',421I\1<(BA5']B
M0=!_P*N[HI2E*6[+A2A#X$D</_PB_CS_ **,/_!)!_\ %50U+X>^*]8$8O\
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MUKU[1M-71]$L=-65I1:0)")&ZMM &?TH O4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6LUPVYV Z9/MTHTO0M+T62\DTVRBMFO)C//Y8P'<]\=OPK1H **** "BBB@
MHHHH 9Y4?F^;Y:^9MV[\<X],^E/HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KD_&'@H>(IK/4].O&TW7K%LVM\BY^7
M/*./XE//'_UZZRB@!J*RHH=@S@ ,V,9-.HHH **** "HKJU@O;66UNH4F@E4
MI)&XRK ]014M% 'DTVE^,?!$L_A_P[:+JVB:EN2P:X;(TUFZJ_K& 21],?7T
M'PKH,?ACPOIVBQRF5;2((9",;CU)_,FMBB@ HHHH **** "N,\<>!_\ A(7M
M=9TF5+/Q'IQ\RSNBHPV/X']5/Z9^M=G10!4LX)##;W%]#;_VB(0DLD2]#P6"
MD\[<U;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** ..^(_A;4_%'A]5T;5;FPU&T?S
MX/*E*+*P'W6Q^A[&O,=/\-^(O&8M-0TWQ<4UW1I0)+?5+<+<VK_Q*TB\LAYP
M",'\Z]_JM%I]G#?3WT5K"EU.JK+,J .X7H">^,T /M8GB@3SO+-P5'FO&NT.
MV.34U%% !1110 5S/COPU=^*O#4MC8:G<:=>*PEAEB<J"XZ*V.=I_P#KUTU%
M 'SU9>&O$GC&U73SXLD@\1Z/('DM-3A'G02#H\4R_-Y;<=C[U[QI5O=PZ=;?
MVC)!-J/E*MQ/#'M61P.2!Z5(-.LQJ1U$6L/VTQ>29]@W[,YVYZXS5F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**XSQA\1+3PG?16"Z==ZC=M&)I$MQ\L$1;;O=NPS_*M_2]=MM5U'5;&)76?3
M)U@F#=]R*X(]L-^E &I1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445Q<GQ&M#XWB\-VNFWEP/M'V6:^ Q#%+M+;,]VP.E ':45E^'==M?$N@VNK
MV8989PV%;JI5BK _0@UJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >6^/?#^G^)?%_]G6WB&YT36I-/'FML
MS%=6^\X7DC+!LGBNK\%>&8?#EE=YU635;^[E$UY>RL"TCX ' )P !P*X/XJ:
M7I&K>*[:W@\,WNO^(/L@=HX;MH(X8 Q +$=R2WY5T'PDM]&M=)U&'3=+O-+O
M8K@1W]E=3&1HI O&">Q!R* /0Z0$$9!!![BL?Q58Z;J?A^XL-6OGL[.X*HTB
M7 A).X87=[GC'?->-2O<:+X2\4^'M\MG*FL6L<MK#.SQPVT[* (W)S\P!SGG
M- 'OP((R#D45YQX)7^P/$_C?0]-BFFTW3FMYK2U$A8J[Q%F12Q[D=S4FJ?$K
M5-%TV;4=1\"ZO;V< !DE::$A02!V;U(H ]#HI%.Y0?49I: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KQN^\)VOB+Q;JTOA_QE>:)):ZB9;RS9!@7&S:98\L/O*>M>
MR5\_>+=#T?5/&6KRZ-X(U+77@N"-2NX[]HE$I +(@[D#M0![7X8T2R\.^'++
M2=.D,EM;H0LC,"7))+,2.Y8D_C6J2%&20!ZFN;^'YT<^!M+;0$F3361FB29B
MSH2QW*Q/<-N'X57\=Z%8>(;*WLYY$EO4\R2SL)+PP)=2!3PP'S,!UXZ4 =:2
M ,DX%%>%:6$\16/P[\.ZA<7=Q8227T5]%)*5+RP(<*64Y*J>G/(Q77^ M:U&
MU^&8GBLKK6);2[FM88HY%\QXEE*K\S$#@>I[4 >C45P\'Q OEUG3-/U/PCJ>
MFC4)_L\4\TL3+NVEOX6)Z UW% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!YWXTT-M0\8V,F@^)GT7Q--:,FU8O-6:W5L_.
M.@P2<$^M7OAK8:?:Z1?7%OK3ZQ?W-VQU"[D0HYF4;=I4\J !P/2L[Q78ZY!X
MLE\2>$M0TE[J&S%IJ-M?285$#%U;(^Z>3UQ6C\.-)O;:QU'6=2U.RO[_ %BX
M%Q*UBVZ!,*%"J>_ YH Z?6=%T_Q!I4VF:G;K/:S ;D)QR#D$$="#R#6/:^ /
M#MKH-YH_V)IK:];?<O/*SR2N.C%R<Y&!@]JZ>B@#'\.^&-,\+VLT&FQR SR>
M;-+-(9))6QC+,>3Q7/\ Q@_Y)1K_ /UR3_T8E=Q7#_&#_DE&O_\ 7)/_ $8E
M ';1_P"K3Z"G4V/_ %:?04Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\BUW0YH_$
M'B*Z\,>-YM(AC(N=9MH[8S"-V7ED('#%1D@<]*]=)P,FO(M2@\5>'+[6=2\+
M:QX>;1-6NVN&GOYL>1.0$<!NA&5Z<].E 'H'@RPTO3/!^F6FC7/VG3UA!BGS
MGS<DDL?<DDGZT_Q%X5TKQ1!!'J44F^W8O#-#*8Y(R1@[6'(R.#4/@G0?^$9\
M':=I/VI;IH4+-.OW79V+DK[98X]JZ"@#F+KX?^'+K0K+1Q9-!;6))M6MY6CD
MB)X)#@YR>_K6UI&DV.A:5;Z;IT"P6D"[8T!SC\3U-7:* .(\=?\ (R^!_P#L
M,'_T2]=O7$>.O^1E\#_]A@_^B7KMZ "BBJ;ZMIR.4>_ME8'!!E (/YT6N)M+
M<N451_MG3/\ H(6O_?Y?\:/[9TS_ *"%K_W^7_&G9BYX]R]15'^V=,_Z"%K_
M -_E_P :DAU*QN)!'!>02.>BI(":+,.:/<M4444B@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#P'PC)IFH077A>]AN&UBYU2:Z\1>8K8:")F8 GT/RC ]
M3ZUV7P<2W-GX@N=)@F@\/SZB7TU)01\NT!B ><9Z5U=UXF\,:9XE;2+R\M+3
M5)XEDQ, GFJ<@?,>#]T\9K>B2..)5B55C ^4(, #VH ?1110 5P_Q@_Y)1K_
M /UR3_T8E=Q7#_&#_DE&O_\ 7)/_ $8E ';1_P"K3Z"G4V/_ %:?04Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH P/'"WK>!=<73M_VPV4OE;/O9VGI[UY+IUUX(U?
MP;")K6:3PQH&G9N$9''^FS$#CU8?-ST&\5[S7-Z=XD\*W^I7FAVMS9+>6\[1
MS6;*$)<'DA3][IU&: *?PLM[VV^&FB17ZNDPA)5'&&6,NQ0'_@!6NPHHH **
M** .(\=?\C+X'_[#!_\ 1+UV]<1XZ_Y&7P/_ -A@_P#HEZ[>@ KY[\0?\C%J
M/_7P_P#,U]"5\]^(/^1BU'_KX?\ F:Z\)NSR<V^"/J9M%%%=QX05UGPY_P"1
MPM_^N;_^@FN3KK/AQ_R.%O\ ]<W_ /036=7X&=&%_CP]4>U4445Y1]6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >9?$B?^U-3C\/P^#+;6+EH%D^VWKB
M*&!6)'#\-D8S@'O6)X6\)>,_!DFERV/B!-3MY;V..]TJ%M\4$#'YG4L<C;[>
MW6H?BA9>%3\2;6Y\:6][%I;Z:$AN8-Q5Y1(Q*MMY& >W7-<QX7TO2['6=*U7
MPS:ZC$\_B%+>PFE9@;BSV@S;EZ87GGN#ZB@#Z5HHHH *X?XP?\DHU_\ ZY)_
MZ,2NXKA_C!_R2C7_ /KDG_HQ* .VC_U:?04ZFQ_ZM/H*=0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>*>-[&;QQKE]IFG^$+"VDMI3"^NZA+Y+ @CE-N&;OC.17M=
M?.7B"Q\ P^-/%/\ PFL&J6E_)>,]HL&XK)&5!#H0,;B=QP>!D4 >A^"-%\6^
M&-<M-.NM=;7M$EM7,DS\_9I5(PH8DD@Y/!]*]*KPOX4Z:-&\4:-%96EY9R7F
MCR7.J6\A)3_68@?GH6 )QVS7NE !1110!Q'CK_D9? __ &&#_P"B7KMZXCQU
M_P C+X'_ .PP?_1+UV] !7SWX@_Y&+4?^OA_YFOH2OGOQ!_R,6H_]?#_ ,S7
M7A-V>3FWP1]3-HHHKN/""NL^''_(X6__ %S?_P!!-<G76?#C_D<+?_KF_P#Z
M":SJ_ SHPO\ 'AZH]JHHHKRCZL**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \U\8^(_$>C>-EB@\,7NO:$]DI>&*$%4FWM\P;:><8!!]172>$->N?$5M+-
M>^&;O16M6"0I=*,L".2O P.U>=?&:XNX-;B:^EU:+24LP]D;'/EM="3YA+CM
MMQBNT^'FI7FMS>(-7>*[BTN\O5DL$NE*MM$:JQ /0%EXH [>BLGQ*VMKH-S_
M ,([' ^J'"P^><(N2 6/K@9.*\X_X3GQ)IF@^(XI+ZVU2>RO[>PL]56W$<;O
M*0'!0<$QD]N#F@#UVN'^,'_)*-?_ .N2?^C$I?"7B'4H=0\2:+XDOX;J;0S'
M(U^L(A$D+Q[\LHX!7!Z5S/Q-^(/A/6?ASK&GZ=KMI<W<\:".)"=S'S%/''H#
M0!ZW'_JT^@IU-C_U:?04Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'?\ (U67^\?Y&O8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;7_ZXI_*N/KL/B5_R-K_ /7%/Y5Q]>K2^!'RN+_CS]0HHHK0YB]HW_(;L?\
MKNG_ *$*^B*^=]&_Y#=C_P!=T_\ 0A7T17#B]T>YE/P2"O,?B+_R'(/^N _F
M:].KS'XC?\AR#_K@/YFN0]<XZBBB@ J6V_X^8O\ ?'\ZBJ6V_P"/F+_?'\Z
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MAZK\Q/8]+HHHK],.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9_G7+UU'C3_C[M?^N9_G7+U^?YQ_OU3Y?DCHA\(4445YA0Z/_6I_O"O5(/\
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M/\X_WZI\OR1T0^$****\PH='_K4_WA7JD'_'O%_N#^5>5Q_ZU/\ >%>J0?\
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M\C:__7%/Y5Q]=A\2O^1M?_KBG\JX^O5I? CY7%_QY^H4445H<Q>T;_D-V/\
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MVEJ1F*TEB<@QH#_$JLI)[G- '5>$_&=IXFAFBEC6PU6WFD@GT^696E1D."0
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M7.I1G=]B"2$NJXX\S!  [=:]4AC,,$<1D>0HH4NYRS8'4^] #Z*** "BBB@
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MAC2XMW#17@//G*>IW9Y)[UVU !1110 4452U>\FL-'O;NVMVN9X('DCA7J[
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MCJ3ZTS3[)=.TZVLTEEE6")8Q),^YWP,98]S5F@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img40748725_33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_33.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %@ M # 2(  A$! Q$!_\0
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M_=2?_$T =Q169H/B'2O$VG&_T>\6ZM0YC\Q5(^88R,$ ]Q6G0 4444 %%%%
M!15=K^S2^CL7NX%NY%+I 9 )&4=2%ZD>]9=KXMTJ\\77OAB)Y?[2LX1-*IC(
M7:=O1N_WA^= &Y116'-XMTJ#QA!X6=Y?[3GMS<(OEG9L&?XO7Y30!N45@>$?
M%VG>,]*EU'34G2&*=H&$Z!3N7![$\<BM^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#\3Q0!U]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>/\ Q.LK6/XC_#U$M8%62_;>%C #?-'U
M]:]@KDO%/@H^)/$WAO6!??9_[&N#,8O+W>;DJ<9SQ]WWZT <CXUU#Q+'\3](
M\*>&-3BTNWU#3V9R(5*QG<Y:0#'WMJX%-\67EWHTMAIFI?$N>QN(K- 8;.P\
MZ>>3G,KA<D X''UKL=0\&&^^).E>+?MVP6%J]N;;R\[\[^=V>/O^G:LS6_A]
MJ=QXWF\3Z#XC.E7%W;BVN@UJLV4&!E,GY3A1^(H X8?$/Q'<_ 6ZUW^T"NJV
MFH+:BZ6,!I%#(<D8QDAL=*=JNI_$?1O$?AR/_A*+:>;Q(A00M:@0VC';RHZG
M 88/<CG-=,OP@*?#:_\ ""ZT6^U7_P!K6Z>#) RORD9Y/R]?>M[6? AU76_"
M>H#4/+&@-DIY6?.X4=<_+]WWZT <IX:\1^(?#?C'Q3X?U_5FUJ#3=-.HQ3O&
M$?@!BO'J&]^G%<3'\2O$<VCQ^(8/$=[-J[3[CHJ:8QM?*W8VA]O7'.<Y[=:]
MC3P+&?'^K^)+B[$L&I6 LGM/+QA<*"=V>X7T[U@Z9\./%7A^W_LG1/'4EKHB
MR%HX7L4DEB4G)57)]2?SZ4 <IXATC6=4^.FC_9_$-S8SWVG-<6\GD*6M$P^8
M@#UZ'D^M=$WB/6H?B;XPTO\ M!FMK#0_/@7RU&V41H=_3/4DXZ<UM^,?A_?Z
M]XDTSQ#HVOOI.J641@\WR!*&0Y[$]?F;UZU)_P *^<^+]>UY]4W'5=,^P&,P
M\H=BJ7SGG[N<8[T >6GQ'\05^&%IX[;Q2H2WE6,60MU(F7S-A:1NY)[>@[&N
M['BC5+GXSZ'IRW!33;O1!=/;!5QO(<YSC/8=^U6'^%K-\)5\#_VL-P??]K\C
MC_6[\;<_AUK2@\ &'QYI/B7^T<BPTP6'D>5]_ 8;LYX^]TQVH \=\%6?BY/A
MMK>M:+XD&FVNFW4\Z6J0JQG954OO8]L8 '->[^!]=F\3>"=)UBY15GN8 TH4
M8&X$J2/8D$UYY#\%-7LM%GTBQ\:W$%A?2,U]!]F!60$\;><J<8!YYKU31-'M
M= T2STFR!%M:1+$FXY) [GW/7\: +]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNLM+7,%AY7'F<G>6SZ[3T_A%6_'?@J'QMI,%N;R2RO+2<7%I=1KN,;CV[C_
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M$-M#'#$$OV"1J%&2J$G ]22?QK*D\4:Z?"MO=6<UL+^;Q$^GJ98OW?E_:7C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+*"
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M'>(O^QAOO_1E=S7#?##_ )!WB+_L8;[_ -&4 =S1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%(S!5+,0% R23P!6'9^-?#&HWZ6%EK^FW%
MW(Q5(8KA69B.2  >>AH W:*** "BBB@ KA?AO_Q\^,_^QDNO_08Z[JN%^&__
M !\^,_\ L9+K_P!!CH [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAKEC_ &GH&HV
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M/RIZMQT]QZTXWN)FC^S7/RP";=Y?RGK\H/\ >XZ>XJU10 @.5!P1GL:6BB@
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M=TZ:Y\(^(;*Y1&\V\NM6\Z)6V$$E-YSD\#CJ17K% !1110 4444 %<-\,/\
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M_8R77_H,= '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %4M7@N[G1;^#3YA!>RV\B6\
MI_@D*D*WX'!J[5+6;.?4-#O[*VN#;W%Q;211S#K&S*0&_ G- 'E?@/P]K5IX
MK@?^Q+G2K2WFDFFDFU 3"97MTC* !B7S*ADW'IT[XKV&O+?"^B:N?$?AU[C1
M['1XM$M)+5Y8+\3->*5P$"CD+N^?YN<UZE0 4444 %%%% !7#?##_D'>(O\
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M 4444 %<-\,/^0=XB_[&&^_]&5W-<-\,/^0=XB_[&&^_]&4 =S1110 4444
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M;&%AQ$I\EN<L,_>SD<'CBI4AG6[:5KHM"8E40[  &!.6SUYR!CIQ0!/1110
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M&%M(%$4C2Q@1@;'.<L/0G<W/N:0:?9@ "T@PLQG \L<2')+_ .]R>>O-6:*
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M!%Q9VYB/V>\N-;%T+6-ER D9)QG@<=,UZI0 4444 %%%% !7#?##_D'>(O\
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M **** "N%^&__'SXS_[&2Z_]!CKNJX7X;_\ 'SXS_P"QDNO_ $&.@#NJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "J6L1"?1;Z%K1KP/;R*;97V&;*GY V1C/3/O5VL_
M79+.+P_J4FHEULDM96N#&Q#",*=V".0<9Z4 >9^%M.TW1O&.DQ-\/[W0YYS*
MMO<RZF)44B-B1M#D$XSQCW[5ZY7D7@RTTS3_ !5I,]YX2O--EOXI&TJZN=4:
M[_@W,"I/[MBF3W[BO7: "BBB@ HHHH *X;X8?\@[Q%_V,-]_Z,KN:X;X8?\
M(.\1?]C#??\ HR@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"O?H9-.ND$$<Y:%QY4C863@_*3V!Z5Y5H=I'H_B[15N? /A_2VNIFCBO+
M6^61XV$;-PH4') (KU+59+:'1[Z6\0R6J6\C3(!G<@4[A^6:\H\&VMEI'B#0
MM0E\&:/IUOK2L-.N+2X:6>$F,N X;CE >5Z=#UH ]BHHHH **** "N%^&_\
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M/^0=XB_[&&^_]&4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5PWPP_Y!WB+_L8;[_T97<U
MYY:>"/%VD7&H_P!C>,+6UM+R^FO/)DTL2%&D;)&XOSVH ]#HKAO^$?\ B'_T
M/-C_ ."9?_BZ/^$?^(?_ $/-C_X)E_\ BZ .YHKAO^$?^(?_ $/-C_X)E_\
MBZ/^$?\ B'_T/-C_ ."9?_BZ .YHKAO^$?\ B'_T/-C_ ."9?_BZ/^$?^(?_
M $/-C_X)E_\ BZ .YHKAO^$?^(?_ $/-C_X)E_\ BZ/^$?\ B'_T/-C_ ."9
M?_BZ .YHKAO^$?\ B'_T/-C_ ."9?_BZ/^$?^(?_ $/-C_X)E_\ BZ .YHKA
MO^$?^(?_ $/-C_X)E_\ BZ/^$?\ B'_T/-C_ ."9?_BZ .YHKAO^$?\ B'_T
M/-C_ ."9?_BZ/^$?^(?_ $/-C_X)E_\ BZ .YHKAO^$?^(?_ $/-C_X)E_\
MBZ/^$?\ B'_T/-C_ ."9?_BZ .YHKAO^$?\ B'_T/-C_ ."9?_BZ/^$?^(?_
M $/-C_X)E_\ BZ .YHKAO^$?^(?_ $/-C_X)E_\ BZ/^$?\ B'_T/-C_ ."9
M?_BZ .YHKAO^$?\ B'_T/-C_ ."9?_BZ/^$?^(?_ $/-C_X)E_\ BZ .YHKA
MO^$?^(?_ $/-C_X)E_\ BZ/^$?\ B'_T/-C_ ."9?_BZ .YHKAO^$?\ B'_T
M/-C_ ."9?_BZ/^$?^(?_ $/-C_X)E_\ BZ .YHKAO^$?^(?_ $/-C_X)E_\
MBZ/^$?\ B'_T/-C_ ."9?_BZ .YHKAO^$?\ B'_T/-C_ ."9?_BZ/^$?^(?_
M $/-C_X)E_\ BZ .YHJMI\5W!I]O%?7*W-VD8$LZQ^6)&[D+SC/I5F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *X7X;_\?'C/_L9+K_T&.NZKAIOA
ME;G4;^\L_$_B33OMUR]U-#97BQQ^8W4@;/8#\* .YHKAO^%;2_\ 0\^,?_!B
MO_Q%'_"MI?\ H>?&/_@Q7_XB@#N:*X;_ (5M+_T//C'_ ,&*_P#Q%'_"MI?^
MAY\8_P#@Q7_XB@#N:*X;_A6TO_0\^,?_  8K_P#$4?\ "MI?^AY\8_\ @Q7_
M .(H [FBN&_X5M+_ -#SXQ_\&*__ !%'_"MI?^AY\8_^#%?_ (B@#N:*X;_A
M6TO_ $//C'_P8K_\11_PK:7_ *'GQC_X,5_^(H [FBN&_P"%;2_]#SXQ_P#!
MBO\ \11_PK:7_H>?&/\ X,5_^(H [FBN&_X5M+_T//C'_P &*_\ Q%'_  K:
M7_H>?&/_ (,5_P#B* .YHKAO^%;2_P#0\^,?_!BO_P 11_PK:7_H>?&/_@Q7
M_P"(H [FBN&_X5M+_P!#SXQ_\&*__$4?\*VE_P"AY\8_^#%?_B* .YHKAO\
MA6TO_0\^,?\ P8K_ /$4?\*VE_Z'GQC_ .#%?_B* .YHKAO^%;2_]#SXQ_\
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MM2DEA,B)<?9W@$ZLN<^6Y+*0<@_@>]=70 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img40748725_34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_34.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6J!K\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD#XV_\
M)7M=_P"W?_TGCKZ_KY ^-O\ R5[7?^W?_P!)XZ ._P#V9?\ F:?^W3_VM7T!
M7S_^S+_S-/\ VZ?^UJ^@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *>K:E#HVC7VJ7"R-!96\EQ(L8!8JBEB!D@9P/45X?X1^/^I:UX
MUM-,U/2+2/3[^X%O!]FW>;$SL!&69FPX&0#@+UR.FT^^5R>@?#3P?X7U1=3T
M?18X+Q4*+*TTDI0'KMWL0#CC(YP2.A- '64444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\@?&W_DKVN_\ ;O\ ^D\=?7]?('QM_P"2O:[_ -N__I/'0!W_ .S+
M_P S3_VZ?^UJ^@*^?_V9?^9I_P"W3_VM7T!0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5GVNNZ/?:C/IUGJMC<7T&[SK:&X1Y(]IVMN
M4'(P2 <]#1KMK>7WA[4[/3KC[/?3VDL5O-O*>7(R$*VX<C!(.1R*^;/A=\.O
M&EC\2+&\FTV[TR#3K@_:;F:)=I7:X94W'$@< IN3=MWAO2@#ZCHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KY ^-O_)7M=_[=_P#TGCKZ_KY ^-O_ "5[7?\
MMW_])XZ ._\ V9?^9I_[=/\ VM7T!7S_ /LR_P#,T_\ ;I_[6KZ H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KW]];Z9IUS?WDGEV
MMK$\TS[2=J*"6.!R< 'I7C?@OX^KXA\8KI6JZ7'86EZZ0V+Q.TK)*<#;(<#<
M&8\$*-O (()8 'ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX3^!WA_PKXH;6?M,^H+%M-C#=*I\AP.78C =L\KP-OH2 P /4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^0/C;_ ,E>UW_MW_\ 2>.OK^OD#XV_\E>UW_MW
M_P#2>.@#O_V9?^9I_P"W3_VM7T!7S_\ LR_\S3_VZ?\ M:OH"@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/UW^T?^$>U/^R/^0G]D
ME^Q_=_UVP[/O?+]['7CUKY@^%5_XPG^+EO$+N^DNFE/]JI>R3$&.-2C><.NY
M02J;N Y44 ?5]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R!\;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !1110 5X/XLOTU/Q3J%U%M\LR[%*MN#!0%#
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MO'D:WN'"VYZB)R>F.N&)'L#VY)K7%T.9<\=T.2OJ>K4445Y9F%%%% !1110
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ML%_T1BN3@ DH3Z #(^A&>@KT:O'JTW3ERLR:LPHHHK,04444 %%%% !1110
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MM%N8+N:2_OKF%UD1I9O+56!R" F#U'<F@#U&BBB@ HHHH **** "OD#XV_\
M)7M=_P"W?_TGCKZ_KY ^-O\ R5[7?^W?_P!)XZ .]_9ID2&+Q7+*ZI&BVK,[
M' 4#SLDGL*JW%Q+=W,MS.V^65S([8 RQ.2<#WJK\#KB*V\*^/9)FVJ;:WC!P
M3\S"95''J2!4M>E@8Z-FD#J?AY;RS>,K62-<K"DDDAR/E7:5S^; ?C7M%>9?
M"FWB:YU2Y*YEC2.-6R>%8L2,?55_*O3:Y\9*]6W8F>X4445RDA1110 4444
M<EXZ\+_VYIXO+;B]M$8JH3)F7KLX&<^GN2.^1XW7TC7B_CKP\NAZT)(!BTN]
MTD8P $;/S( .PR,<#@XYQ7HX*M_R[?R-(/H6?A[XA;3-7&FS'-K>N%&2?DDZ
M*0!ZG /X'/%>OU\W5[-X&\2C6]*%M<2+]OM5"L"Q+2(  'YZGL>3SSQD"EC*
M/_+Q?,4UU.KHHHKSR HHHH **** "L^UT+1['49]1L]*L;>^GW>=<PVZ)))N
M.YMS 9.2 3GJ:T*Y?1_B+X1U_7'T72];@N;]=^(U5P'V_>V,0%?N?E)R 2.!
MF@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\P^
M*MTCWVFV@#>9%$\K'MAB ,>_R']*]/KQ?XAW$LWC*ZCD;*PI''&,#Y5VAL?F
MQ/XUU8.-ZM^Q4-SEJ]V\'VGV+PCID6_?NA$N<8^^2^/PW8_"O"XXWFE2*)&>
M1V"JBC)8GH .YKZ/KHQTM%$J84445YIF%%%% !1110!%<6\5W;2VTZ[XI4,;
MKDC*D8(R/:O"O$FAR^']:ELWYB/[R!MP):,DX)Z<\$'CJ/3%>]5S'CCP^-<T
M-Y(D9KVT5I( I/S=-RX .20./<#GK73A:WLYV>S*B[,\:M[B6TN8KF!MDL3B
M1&P#A@<@X/O7O'A_7;?Q#I27MNK(=VR2-NJ. "1GN.0<^_8\5X%72>"_$G_"
M/:O^_;%C<86XPFXC&=K#OP3S[$\$XKOQ5'VD;K=%R5T>VT445XYD%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME!=6KB2WFC62)U'#(1D$?@:FJEH^GKI&B6&FK(9%M+>. .1@L$4+G';.*NT
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M+VWCN(UD #!74, <$C.#ZFL?Q]XEF\(>"-3UVWMX[B>V1!''(2%W.ZH"<<D
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M065O)<2+& 6*HI8@9(&<#U%>'^$?C_J6M>-;33-3TBTCT^_N!;P?9MWFQ,[
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M,2I5AT*LI!4]1D$<$CH31H'AS2/"VEKINBV,=I:!R^Q26+,>I9F)+'H,DG@
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MO;:G'/WTO()[G@?A'X_ZEK7C6TTS4](M(]/O[@6\'V;=YL3.P$99F;#@9 .
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M#,V<[P<@C&#USQZIJNE6.N:7<:9J=M'<V=PFR6)^C#^8(."".00",$5C^&O
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M%%% !1110 4444 %%%% !1110 5S_CJVGO/ /B"VMH9)YY=/F2.*)2S.Q0X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAF(ZJ/RKJJXGP?\ %/P]XXU>73-)6]%Q% ;AO/B"KM#*IY#'G+"NVH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KY ^-O_)7M=_[=_P#TGCKZ_KY ^-O_ "5[7?\ MW_])XZ -;PK
M#)!X9LDD7:Q4N!G/#,6'Z$5U7AW_ )&;2O\ K\A_]#%<_HW_ " M/_Z]H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(1DGYF&YCSZDDUKUF^'?^19TK_KSA_\ 0!6E7CS^)F3"BBBI$%%%% !1110
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MWF%S&[2 'F("-R?G!*G.!M+=?NGZ7HKE)"BBB@ HHHH **** "BBB@ HHHH
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MQ#N(H?!MU'(V&F>..,8/S-N#8_)2?PKQ>O4P*_=M^9I#8])^$_\ S%_^V/\
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M2T9::%7?RS\H;'S ?0Y'X5\^5V-MXJU;2?A)X@ETA6DU'3 KPGR0XCCD8;F
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M 'L%%%?+'BCXG>-8OBU>?V=?3M]BU![*UTV$,89E1V0*T0/SLW<_>R?E(PN
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M ^GZ**\/^/WC#Q+X?ETK3])N9]/L;N)WDNH)55YG5E^0$#>FT;3D$;O,QV-
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MU>1A8_L]C)Y048 ;:0H'IR16?\,O#">$_ 6FV!CVW4B"XNCCDRN 2#]!A?\
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MR6=_:07=K)C?#/&)$;!!&5/!P0#^%2000VMO%;V\4<,$2!(XXU"JB@8  '
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M94Y4'(]!Z5<HHH *S],T+1]$\W^R=*L;#SL>9]DMTBWXSC.T#.,GKZFM"B@
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M+Z!7#K'=0K*H;!&0&!&<$C/N:N44 1P00VMO%;V\4<,$2!(XXU"JB@8  '
M'&*DHHH IQZ3IL.J3:I%I]HFH3)LENUA42NO'#/C)'RKP3V'I5RBB@"O?6%G
MJ=G)9W]I!=VLF-\,\8D1L$$94\'! /X5)!!#:V\5O;Q1PP1($CCC4*J*!@
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ML[^T@N[63&^&>,2(V"",J>#@@'\*L44 1P00VMO%;V\4<,$2!(XXU"JB@8
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M/*I!EDMU9LXQDDC)KRKP=\!5\,^*;/5[O68-1@@#[K5[+ ?<C*.K$<$YZ=J
M/ O^$R\4?]#)K'_@=+_\54-UXGU^^MWM[O7-3N('&&CENY'5A[@G!K[7_P"$
M<T/_ * NG?\ @*G^%*OA[14.5T?3U/J+9!_2@#YY_9Z\-7UQXLE\0/ Z6%K
M\:2LN!)(V!@>N!N)]./6OIBD5510JJ%4#  & *6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD_Q-_Q5G[0KVDOSPMJT
M5HR]@D95&'Y*U?6%<G!\,_"%KXD_X2&'2-NJ_:&N?/\ M,I_>,22VTOMZD\8
MQ0!UE<;\4+OQ)IW@BYU#PO<&&^M7663;$LA:$9# !@1QD-]%-=E10!\_?#?X
MZQ06MU:>-KZ>28R>9!>"'<-I !0J@XP1D''<],5PWQ \0R_%7XBVT>@VDSIL
M6SM$889^2Q<CL,L?H!D]Z]]UGX-^!]:O'NYM)^SS.=SFUE:(,?\ ='RC\!6S
MX8\!>&O!^]M%TR."9QAYV8O(1Z;F)('L,"@#4T/3$T30-.TI&W+9VT=N&_O;
M5"Y_'%>#^*O^2O>+O^W/_P!)UKZ(KY^\6V^WXH>*;G?GS);:/;CIMMHSG/\
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M@;?%*@D1L$94C(.#[4L="TE()HEHHHKA("BBB@ HHHH **** "BBB@ HHHH
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MG:W! 7L 1GZO^?;C87IW[%S6AW]%%%>49!1110 4444 %%%% !1110 4444
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M!]'\#:4UCI4;EI"&GN)2#)*PZ9/H.P' _$UTE !1110 4444 %%%% !1110
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M3<?\A2V:;_GG(D1;_>#,!_WR"?I[5Z6,C>E?L:3V/2****\@R"BBB@ HHHH
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M>MI(?Z4 ?95AXT\,:I LUGX@TV56&0/M*!A]5)R/Q%7_ .VM*/\ S$[+_O\
MK_C7Q+_PBOB+_H :I_X!R?X4?\(KXB_Z &J?^ <G^% 'V_;ZA97<ACMKRWF<
M#)6.56('K@&K-?-W[/NBZKIOCV^FOM,O;6)M,D4// R*3YL1QDCKP?RKZ1H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'W_(DZA_VS_\
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M%]WIVLW$$EM'8/.HC@5#O$D:CD>S&O<* "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% '@'B+_D9M5_Z_)O\ T,T>'?\
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M-=3T:BBBO,,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C
MN(S+;2QK@,Z%1GW%?,?_  SCXP_Z".A_]_Y?_C5?4%>6?$?XSV'@R[?2=-MU
MU#5E'[P,V(H,] Q')/L,?44 >9?\,X^,/^@CH?\ W_E_^-4?\,X^,/\ H(Z'
M_P!_Y?\ XU61>_';Q]=2EHM3M[13_!!:1D#_ +[#']:]B\?_ !*U/P9X2\+:
MA;)!<W=^$>=9UXD41@OC&,'++R/RH H?";X3:]X$\576J:I=Z=-!+9/;JMK(
M[-N+HV3N11C"'OZ5[)7,>!?'&F^/-"&HV ,4L9V7-LYRT+^GN#V/?V(('3T
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MRJU/V<W$R:LPHHHK(04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3\4?^19MO\ K\7_
M - >NVKB?BC_ ,BS;?\ 7XO_ * ];8?^+$<=SR2O6_A=_P BS<_]?C?^@)7D
ME>M_"[_D6;G_ *_&_P#0$KT<9_"-)[';4445Y!D%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ' ?$CPY]IMEUFS@S-%Q<[%Y9,<.>
M?X<8Z9P>>%KRVOH^2-)HGBE17C=2K(PR&!Z@CN*\ UK2+C0]5FL;A6RC'RW*
MX$B9X8=>#]>.1U%>G@JO-'D?0T@^AW?POUAW6YT:4LRHOGPGJ%&0&7KP,D$
M#NU>C5\[Z??3Z9J$%[;-B6%PZ\G!]CCL1P?8U[_I]]!J>GP7MLV8ID#KR,CV
M..X/!]Q6&,I<LN=;,4UK<LT445QD!1110 4444 %%%% !1110 4444 %%%%
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M0O$?_7S#_P"DL%=6#_BE0W(O#O\ R,VE?]?D/_H8KW^O /#O_(S:5_U^0_\
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#P#Q%_P C-JO_ %^3?^AFM+P#_P C
MMI__ &T_]%M6;XB_Y&;5?^OR;_T,UI> ?^1VT_\ [:?^BVKVY_P7Z?H;/8]M
MHHHKQ#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&4[)[>3[\+^A]1Z'O^8'1T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_K\;_T!*\DKUOX7?\BS<_\ 7XW_ * E>CC/X1I/8[:BBBO(,@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //?BAI DM+;5
MXU8R1-Y$N%)&PY*D]@ <CISO'M7F%?1&H6,&IZ?/97*YBF0HW R/<9[@\CW%
M> :A8SZ9J$]E<KB6%RC<'!]QGL1R/8UZF"J<T>1]#2#TL>G_  TUA+K1GTIR
MJS6C%D'0M&Q)SUR2&)SQCE:[FO!?#.K-HOB"TN_,V1;PD^<D&,\-D#K@<CW
MKWJN7%T^2I==29*S"BBBN4D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /$7_(S:K_U
M^3?^AFM+P#_R.VG_ /;3_P!%M6;XB_Y&;5?^OR;_ -#-:7@'_D=M/_[:?^BV
MKVY_P7Z?H;/8]MHHHKQ#$**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH H:Y?-IF@:EJ" %K6UEF&?54+?TKX_\
MAWX3/C_QO'IUY<R)"RO<W4JG+LHZXSW)(&??-?8NIV2ZGI-Y8.VU;F!X2?0,
MI']:^-?"^O:C\-?'?VJ2UW3V<CV]U;,<;UZ,N>W3(/J!0!]BZ+H]GX?T:UTJ
MP5UM;5-D8=RQ SGDGZUYS\5OA5H_B#3-5\16ZR6^MQ0&=I1(2LWEI]UE/ ^5
M< C';.:?:?'_ ,$7$"O-+?6KD<QR6Q8@_5217(?$'X\Z;J?A^\T?PW;7+27<
M;0R74ZA%1&&&VC)))&1SC&: .=_9XU2:T\?SV 8^1>VCAD[;D(93^ W#\:^H
MZ^9?V==#GNO&%YK)0BVLK8QA^QD<C _[Y#?IZU]-4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@
M?&W_ )*]KO\ V[_^D\=?7]?('QM_Y*]KO_;O_P"D\= '?_LR_P#,T_\ ;I_[
M6KZ KY__ &9?^9I_[=/_ &M7T!0 4444 %%%% !1110 4444 %%%% !1110
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MLQ8EU Y)/4D8;\:TQU/::'-=3=HHHKSC,**** "BBB@ HHHH **** "BBB@
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M%%%>(8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@K6KP_X-_$SQ+XS\7W>G:S<026T=@\ZB.!4.\21J.1[,:]PH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KY ^-O\ R5[7?^W?_P!)XZ^OZ^0/C;_R5[7?^W?_ -)XZ .__9E_YFG_
M +=/_:U?0%?/_P"S+_S-/_;I_P"UJ^@* "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q1_Y%FV_P"OQ?\
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M_P"OR;_T,UI> ?\ D=M/_P"VG_HMJ]N?\%^GZ&SV/;:***\0Q"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ
M*TZ>%=8:VS]H6RF,6WKNV'&/QKY&^&/@N+QUXP32[F=X;6.%KB=H\;RBD#"Y
MX!)8<_6OLN1E2)W?[BJ2W':OD1O$ND^!OB0-?\%7JWVFN6)M9(GB*HWWHCN
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MVLOQII*Z/XGN88H_+MY<30CC&UNH '0!MP ]!6);W$MI<Q7,#;)8G$B-@'#
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MQ4,&%Q&,')SA6R>F!A/S/7MZ-7EUJ?LYN)FU9A11160@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M/$7_ ",VJ_\ 7Y-_Z&:TO /_ ".VG_\ ;3_T6U9OB+_D9M5_Z_)O_0S6EX!_
MY';3_P#MI_Z+:O;G_!?I^AL]CVVBBBO$,0HHHH **** "BBB@ HHHH ****
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7$_%'_D6;;_K\7_T!Z[:N)^*/_(LVW_7XO_H#UMA_XL1QW/)*
M]M\ _P#(DZ?_ -M/_1C5XE7MO@'_ )$G3_\ MI_Z,:N_'?PUZESV.DHHHKRC
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ0))HD*-%G@%D).!VR"??%7?@I\0+KP[XFM]"NYV;2-1D$01CD0RMPK+Z9.
M?KGM7U#J%A;ZIIMSI]VF^WN8FAE7U5A@_P ZY31?A-X)T)TDMM"@EF0@B6Z)
MF.1T.&) /T H [2BBB@ HHHH **** "OD#XV_P#)7M=_[=__ $GCKZ_KY ^-
MO_)7M=_[=_\ TGCH [_]F7_F:?\ MT_]K5] 5\__ +,O_,T_]NG_ +6KZ H
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M?P'H!T!7N?ER>M=;7C3@X2<69-6"BBBH$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'B+_ )&;5?\ K\F_
M]#-:7@'_ )';3_\ MI_Z+:L34;O[?J=W>;/+^T3/+LSG;N8G&>_6MOP#_P C
MMI__ &T_]%M7MU%:BUY?H;/8]MHHHKQ#$**** "BBB@ HHHH **** "BBB@
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M8;A[>"XD4AIXE"X8D_?(8LN[OMYR<D^B5'!!#:V\5O;Q1PP1($CCC4*J*!@
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M7;J\L?#VIWFG6_VB^@M)9;>'87\R14)5=HY.2 ,#DUH44 ?-GP9\>>+]7^)
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M9M4AU273[1]0A39%=M"IE1>>%?&0/F;@'N?6@"Y1110 4444 %%%% !1110
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M>\%^$+#P3X<ATBPR^#OFG88::0]6/Y  =@!70T %%%% !1110 4444 %%%%
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M1110 4444 %%%% !7$_%'_D6;;_K\7_T!Z[:N)^*/_(LVW_7XO\ Z ];8?\
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MI()(?#&DJXY#&T1B/ID5T*1I%&L<:*B*,!5& !]*=10 4444 %%%% !1110
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M/4AJ^AV=^"I::(%]H( <<,!GG 8$5H5YI\+]81&N=&E*JSMY\)Z%C@!EZ\G
M!  [-7I=>76I^SFXF;5F%%%%9""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *XGXH_\BS;?]?B_^@/7;5Q/Q1_Y%FV_Z_%_
M] >ML/\ Q8CCN>25[;X!_P"1)T__ +:?^C&KQ*O;? /_ ").G_\ ;3_T8U=^
M._AKU+GL=)1117E&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!RWC_25U+PQ-,L>ZXL_WT9&
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M(H8VD<^@ R?Y5\3>(M?UGQ[XIEO)EN+JYN)"MO:Q OY:]D11Z#TZ]: /L?\
MX2KP[G']OZ7G_K\C_P :5O%/AY5W-KVE@>IO(_\ &OB2YT;4[/55TNZT^YAU
M!F5!;21%9"6QM&T\\Y&/K5C5/"^OZ)")M4T74+*)C@27%LZ*3Z9(QF@#[+TS
MQIX<UO6GTC2M6M[V\CA:=UMVWJJ!E4G>/EZL.,UO5\[_ +.OAG4HM7N_$KK#
M_9LMI):(PE5G,GF1M@J#E>%/7'4=C7T10 4444 %%%% !1110 4444 %%%%
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M!UY&1[''<'@^XJS7BM6=F8A1112 **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\@?&W_DKVN_]N__ *3QU]?U\@?&W_DKVN_]N_\ Z3QT =_^S+_S-/\ VZ?^
MUJ^@*^?_ -F7_F:?^W3_ -K5] 4 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4=:CGGCMK>6XF<)%$A=V/90,DU\B>,_BYXE\3Z
MK,]KJ5UIVFAB(+:VE,?R]BY7EB>^>/2@#Z_K+NO#.@WUY]KN]$TVXN<Y\Z6T
MC=\_[Q&:^)SXCUPG)UG4?_ I_P#&D_X2+6_^@SJ'_@4_^- 'W8JJBA5 50,
M 8 %+7S7^SWJNHWWCZ^BN[^ZN(QI<C!)IF< ^;%S@GKR:^E* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^0/C;_R5[7?^W?_ -)XZ^OZ^0/C;_R5[7?^W?\ ])XZ .__ &9?^9I_
M[=/_ &M7T!7S_P#LR_\ ,T_]NG_M:OH"@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 5Q/Q1_Y%FV_P"OQ?\ T!Z[:N)^*/\ R+-M_P!?B_\
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M $KU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1117E&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XAXUT4Z-XBG$<#1V<
M[>9 <#:<X+ 8X !)&.PQZY//QR/#*DL3LDB,&5U."I'0@]C7M'CO1TU7PU/+
MA1/9J9XW/H!\RYP3@CMZA:\5KV<-4]I3UW1K%W1[[X=UA-=T.WOE*B1EVS(O
M\$@^\,9.!W&><$5J5Y7\,-7%OJ5QI4K-MNEWQ#<<!U!R .F2O.>/N >E>J5Y
ME>G[.HT9R5F%%%%8B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(R+6WA-M$Q'#2,03CZ*.?]X5](4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@?&W_DKVN_]N_\
MZ3QU]?U\@?&W_DKVN_\ ;O\ ^D\= '?_ +,O_,T_]NG_ +6KZ KY_P#V9?\
MF:?^W3_VM7T!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!3U;38=9T:^TNX:18+VWDMY&C(#!74J2,@C.#Z&O$_!?P$O]!\<VNJZMJ%C
M=:;8RF:!83())74_NRPP F#ACAFY7;R"37O%% !1110 4444 %%%% !1110
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ML+\[],Z*0HW0DDG=QRPR3D<GTZ8/9BZ+J1O'=%R5SU^BBBO),@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YNKI/ /_([:?\ ]M/_ $6U
M<W72> ?^1VT__MI_Z+:O=K?PY>C-GL>VT445X1B%%%% !1110 4444 %%%%
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MH@  =R 0?IE1[5W->-4@X2<69-684445 @HHHH **** "BBB@ HHHH ****
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M=Q=?$IKI0QCM[25Y7[?-A0#[DG/X&OJB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD#XV_\E>UW
M_MW_ /2>.OK^OD#XV_\ )7M=_P"W?_TGCH [_P#9E_YFG_MT_P#:U?0%?/\
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MW%BP42,NZ%V_@D'W3G!P.QQS@FMJ%3V<TQQ=F>!5[1X U9=2\,0PM)NN+/\
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MK^&OAGQC=17FI6;)>QE<7,#;'8#^%N"&'U&?0BOG7_A>GC__ *"T/_@'%_\
M$T?\+T\?_P#06A_\ XO_ (F@#ZMU/3+/6=-N-.U"W2XM+A"DL3]&']/KVKQ>
M\_9JTV2^:2S\17,%J3D0R6PD8#TW[A_*O.O^%Z>/_P#H+0_^ <7_ ,31_P +
MT\?_ /06A_\  .+_ .)H ^E/!G@?1_ VE-8Z5&Y:0AI[B4@R2L.F3Z#L!P/Q
M-=)7AGP8^)/B?QCXPN]/UJ^CGMH[!YU58$3#B2-0<J >C&O<Z "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\2>$
M]#\76D-KKMB+N&%_,C7S73#8QG*D'H:VJS/$.NV7AG0;O6-1<K;6J;FQU8]
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M1117A&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ K$\6:+_ &]X?GM4&;A/WL'/\8S@=0.02O/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>'>--)71_$]S#%'Y=O+B:$<8VMU  Z -N 'H*]QKC_ (B:*^IZ"MU
MBM-9,TI);!\K'SX[$\*?P./0].%J<E379E1=F>01R/#*DL3LDB,&5U."I'0@
M]C7O^AZD-7T.SOP5+31 OM! #CA@,\X# BOGZN_^&.M>1>S:-*?DN,RP\='
M^8=.ZC/)P-OO7;C*?-#F70N:NCU*BBBO),@HHHH **** "BBB@ HHHH ****
M "BBB@#YNKI/ /\ R.VG_P#;3_T6U<W75_#JU>X\802H5"V\4DKYZD%=G'OE
MQ^M>Y6=J<O0V>Q[-1117AF(4444 %%%% !1110 4444 %%%% !1110 4444
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MHU:_72M&OM19=RVEO).5]0JEL?I7S!\(K>'QK\6Y+_Q"5NYO*EO=LO*R2@J
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MW_MW_P#2>.OK^OD#XV_\E>UW_MW_ /2>.@#O_P!F7_F:?^W3_P!K5] 5\_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*21R*&5U(P00>"".,5Y_H'P5\(>'?$JZY:Q7<TL;E[>WN95>*!B<@J-N25Z
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M,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@".>3R;>27&=BEL>N!7QAK_C07_C%?%&A6#:'J&_S7,,_F*9.[ %
M1C/.1R#D^IS]H2QB6%XVR%=2IQ[UY%_PSAX0_P"@EKG_ '_B_P#C5 ' VO[1
MGBN&%4N-/TFX8#'F&-U+>YP^/R J?_AI+Q%_T!=+_P#(G_Q5=O\ \,X>$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#G?&VCOK7AJ:*$,9X&$\2+_&5!RN "22"< =\5XA7TC7B_CKP\
MNAZT)(!BTN]TD8P $;/S( .PR,<#@XYQ7H8*K_R[9<'T+?P[\0#3-5;3KAV^
MSWC*L?!(67.!WX!S@G'9>PKUVOFZO>O#>N1>(-%BO$XE'[N==I 60 9 Z\<@
MCGH?7-+&TK/G0374UZ***X" HHHH **** /FZNV^%W_(S7/_ %YM_P"AI7$U
MVWPN_P"1FN?^O-O_ $-*]O$?PI&TMCUNBBBO$,0HHHH **** "BBB@ HHHH
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M 'CJYU>SN/#&I3-+-91"6TD<Y8PY *$_[)*X]CCM7MM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?('QM_Y*]KO_ &[_ /I/'7U_7R!\;?\ DKVN_P#;O_Z3QT =_P#LR_\ ,T_]
MNG_M:OH"OG_]F7_F:?\ MT_]K5] 4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 4]6DOH=&OI=+ACGU!+>1K6*0X5Y0IV*>1P6P.H^HKY
MH^'/B[XAWOQ2M[5[W4KUWN&74K.[9C'#%O'FL4) B*]L8P<* <[3]1T4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7C/Q!T@:9XE>:)6$-XOG@[3@.3\X!/4Y^;VW"
MO9JYOQOH7]M^'Y/*CW7=MF6' R6Q]Y1P3R.PZD+71AJG)45]F5%V9XE7O7AG
M6?[>T&WOF6-)6RLJ1MD*P./PR,'![$=>M>"UVWPWUW[!J[:9/)BWO/N;CPLH
MZ=3@;AQTR3M%=^+I\\+K=%R5T>MT445Y!D%%%% !7F_Q8_YA'_;;_P!DKTBO
M-_BQ_P PC_MM_P"R5T83^,OZZ%1W/-J]M\ _\B3I_P#VT_\ 1C5XE7MO@'_D
M2=/_ .VG_HQJ[<=_#7J5/8Z2BBBO*,PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCQWHZ:KX:GEPHG
MLU,\;GT ^9<X)P1V]0M=/150DX24D"=CYNKN?AIK#VNLOI3EFANU+(.H6103
MGK@ J#GC/"UC>--)71_$]S#%'Y=O+B:$<8VMU  Z -N 'H*Q+>XEM+F*Y@;9
M+$XD1L X8'(.#[U[4DJU/U-MT?1E%4='U.+6-(MM0A&%F3)7GY6Z,N2!G!!&
M>^*O5XC33LS$****0!1110!\W5VWPN_Y&:Y_Z\V_]#2N)KMOA=_R,US_ ->;
M?^AI7MXC^%(VEL>MT445XAB%%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%8B"O-_BQ_S"/\ MM_[)7I%>;_%C_F$?]MO_9*Z,)_&7]="H[GFU>V^ ?\
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M>(_A2-I;'K=%%%>(8A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA->_^'?^19TK_KSA_P#0!77CG[J14]C2HHHKS#,**** "BBB@ HHHH ****
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M#O\ ]F7_ )FG_MT_]K5] 5\__LR_\S3_ -NG_M:OH"@ HHHH **** "BBB@
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M7?\ (S7/_7FW_H:5Q-=M\+O^1FN?^O-O_0TKV\1_"D;2V/6Z***\0Q"BBB@
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M^W3_ -K5] 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWRQP/^ DD_W17FU>W2FJM.[-D[H^CXY$FB26)U>-U#*ZG(8'H0>XKSGXL?\
M,(_[;?\ LE:GPXUH7VAG3YIU:YM&(1"3N,7&#SU )(XZ +[9R_BQ_P PC_MM
M_P"R5Y]"#AB%%^?Y&:5I'FU>_P#AW_D6=*_Z\X?_ $ 5X!7O_AW_ )%G2O\
MKSA_] %;X[X45,TJ***\TS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S+XHZ2L<
M]IJT4>/-S#,PP 6 RAQU)(W#/HHZ5YW7T-JE@FJ:5=6,FT+/$R!F7<%)'#8]
M0<'\*^?KBWEM+F6VG79+$YC=<@X8'!&1[UZN#J<T.5]#6#T/6/AKJCWN@RVL
MUPTLMI*%56'*1$#:,]QD-],>F*[2O"?"6K1:+XDM;NXDD2V^9)=F3E2".1W
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M;BZ-D[D48PA[^E>R4R*6.:))8G62-U#*Z'(8'H0>XI] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?('QM_Y*]KO_ &[_ /I/'7U_7R!\;?\ DKVN_P#;O_Z3QT =_P#LR_\ ,T_]
MNG_M:OH"OG_]F7_F:?\ MT_]K5] 4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<OH_Q%\(Z_KCZ+I>MP7-^N_$:JX#[?O;&("OW/RDY
M )' S6QKNF?VWX>U/2?.\G[=:2VWF[=VS>A7=C(SC.<9%>$>!/@3KNF>.8+[
M7IH(K'3)8KF&2UD#_:I%(957(!501\Q8 G&!G.X 'T/1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!1UC3(M8TBYT^8X69,!N?E;JK8!&<$ X[XKP&
MXMY;2YEMIUV2Q.8W7(.&!P1D>]?1E>5_$K0$L[N+5[:-4BN6*3A1@>;R0W7J
MPST'\.3R:[<%5M+D?4N#Z'.^$]:_L'Q!!=.<6[_NI^/X#C)Z$\$!N.3C'>NK
M^*<B31:++$ZO&ZRLKJ<A@?+P0>XKSFM?4=9_M#0=)L760RV'FJ79MP96*E<>
MF ",>@'T';.E>K&HBVM;F17O_AW_ )%G2O\ KSA_] %> 5[_ .'?^19TK_KS
MA_\ 0!7/COA1,S2HHHKS3,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*?B9HWV
M75(M6C:1EO/ED!7Y495 '/N!T_V3^'JU9?B+1TUW0[BQ8*)&7="[?P2#[IS@
MX'8XYP36U"I[.:8XNS/ J]H\!ZY%JWA^*VZ7-BBPR*%(&WD(0>^0.?<'C&*\
M<N+>6TN9;:==DL3F-UR#A@<$9'O6MX3UK^P?$$%TYQ;O^ZGX_@.,GH3P0&XY
M.,=Z]/$4O:4]-S22NC$KMOA=_P C-<_]>;?^AI7$UVWPN_Y&:Y_Z\V_]#2JQ
M'\*0Y;'K=%%%>(8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>>_%OP)J?CW0["RTNXM(9+>Y\YC=,R@C:1QM4\\UZ
M%10!\P_\,X>+O^@GHG_?Z7_XW1_PSAXN_P"@GHG_ '^E_P#C=?3U% 'S ?V<
M?%X'&I:(?;SI?_C=<=XP^&?B7P1%'<:K;1O:2-L%S;OOCW>AX!!^HYK[0KC_
M (JPP3?"_P 0K< %!:EQG^\""O\ X\!0!YG^SMXON+C[;X5NY6DCAC^TV>X_
M<7(#H/;+ @?[U>^5\F_ 1F'Q3M O0VTP;Z;?\<5]94 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\
M@?&W_DKVN_\ ;O\ ^D\=?7]?('QM_P"2O:[_ -N__I/'0!W_ .S+_P S3_VZ
M?^UJ^@*^?_V9?^9I_P"W3_VM7T!0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 453U;4H=&T:^U2X61H+*WDN)%C +%44L0,D#.!ZBO!/
M GQVUW4_',%CKT,$MCJ<L5M#':QA/LLC$*K+DDLI)^8,21G(QC:0#Z'HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZQID6L:1<Z?,<+,F W/RMU
M5L C." <=\5>HIIM.Z ^<[BWEM+F6VG79+$YC=<@X8'!&1[U%7=_$[26M]7A
MU2./$5R@21AD_O%]>PRN,>NTUPE>Y2GSP4C9.Z"O?_#O_(LZ5_UYP_\ H KP
M"O?_  [_ ,BSI7_7G#_Z *Y,=\*)F:5%%%>:9A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 >2?$C0OL&KKJ<$>+>\^_M'"RCKT&!N'/7).XUQ->^^(M'37=
M#N+%@HD9=T+M_!(/NG.#@=CCG!->"21O#*\4J,DB,59&&"I'4$=C7KX2KSPL
M]T:Q=T-KMOA=_P C-<_]>;?^AI7$UVWPN_Y&:Y_Z\V_]#2M,1_"D.6QZW111
M7B&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7*^.O'FG^ =-MK[4;6ZN([B;R56W"D@X)R=Q''%=57GOQ;\":GX]T
M.PLM+N+2&2WN?.8W3,H(VD<;5//- '-_\-(^&/\ H$:O_P!\Q_\ Q='_  TC
MX8_Z!&K_ /?,?_Q=</\ \,X>+O\ H)Z)_P!_I?\ XW1_PSAXN_Z">B?]_I?_
M (W0!VY_:1\-8^71]6)]UC'_ +/7G?Q)^,]SXVTS^Q]/L6L--9@TV]]TDV#D
M XX S@XYY YJ^O[.'BLGYM4T4#VEE/\ [3K;T;]FQQ<(^MZ^IA!RT5G$<M[;
MVZ?]\F@"A^SEX>GGU_4?$,D9%K;0&VC8CAI&()Q]%'/^\*^D*H:-HVG^']*@
MTS2[9+:T@7"1K^I)ZDGJ2>M7Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0/C;_ ,E>UW_MW_\
M2>.OK^OD#XV_\E>UW_MW_P#2>.@#O_V9?^9I_P"W3_VM7T!7S_\ LR_\S3_V
MZ?\ M:OH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
ME]'^'7A'0-<?6M+T2"VOVWXD5G(3=][8I)5.X^4# ) X.*ZBL^UUW1[[49].
ML]5L;B^@W>=;0W"/)'M.UMR@Y&"0#GH: -"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH R_$6CIKNAW%BP42,NZ%V_@D'W3G!P.QQS@FO J^
MD:\;^(6B_P!E^(#=1C%O?9E'/1_XQU)ZD-V'S8'2N_!5+-P9<'T.2KW_ ,._
M\BSI7_7G#_Z *\ KW_P[_P BSI7_ %YP_P#H J\=\*',TJ***\TS"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\;^(6B_V7X@-U&,6]]F4<]'_ (QU)ZD-
MV'S8'2O9*YWQIH2:YH,N%;[3;*TT!1-S,0#E/7#>W<#KC%=&&J>SJ*^S*B[,
M\0KMOA=_R,US_P!>;?\ H:5Q-=M\+O\ D9KG_KS;_P!#2O3Q'\*1I+8];HHH
MKQ#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY ^-O_)7M=_[=_\
MTGCKZ_KY ^-O_)7M=_[=_P#TGCH [_\ 9E_YFG_MT_\ :U?0%?/_ .S+_P S
M3_VZ?^UJ^@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_&N\(M%SV-*BBBO-,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y^
MUS33I&N7E@0P6&4A-Q!)0\J3CC)4@UTWPN_Y&:Y_Z\V_]#2I_BE8)#JME?)M
M#7,3(ZA<$E"/F)[G# ?\!%0?"[_D9KG_ *\V_P#0TKUI3Y\/S>1JW>)ZW111
M7DF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R!\;?^2O:[_V[_\
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M_P 4-.EGTN^TR.PE=[BZFMLQE "K(K'Y6WYV J3@-N&0,T ?4]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %065JEC8V]I$6,<$2Q*
M6ZD*,#/OQ4]%%P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKEH;'[-\3;BY59-MUIN\LP^7<KHI /L I_'WKJ::8T,JRE%,BJ55\<@'&0#Z
M' _(549<M_,:8ZBBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 'R!17U__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!\@45]?\
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M $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!\@45]?_\ "DOAY_T+W_D[<?\
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ME 'R!17U_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'R!17U_\
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M7P\_Z%[_ ,G;C_XY0!\@45]?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
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M4 ?(%%?7_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 ?(%%?7_\
MPI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE 'R!17U__P *2^'G_0O?
M^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!\@45]?\ _"DOAY_T+W_D[<?_ !RC
M_A27P\_Z%[_R=N/_ (Y0!\@45]?_ /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_
M ,G;C_XY0!\@45]?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4
M?(%%?7__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE 'R!17U_P#\
M*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'R!17U_\ \*2^'G_0O?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y9N/V@
M/&L5S+&HTS:KE1FV/8_[U1_\-!^-O33/_ 8__%5[VWPM\#NY9O#5B6)R3M/)
M_.O&_CYX3T'PS;:"VBZ7!9&=YQ*8@1OP$QG\S^= &1_PT'XV]-,_\!C_ /%4
M?\-!^-O33/\ P&/_ ,55KX"^&-$\2ZCK<>LZ=!>I#%$T8E!.TDMG'Y"O</\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!?VF/
M^/3PW_UTN/Y1U[U7@O[3'_'IX;_ZZ7'\HZ ,_P#9I_Y"OB'_ *X0_P#H35]%
M5\Z_LT_\A7Q#_P!<(?\ T)J^BJ .!^-?_)(M=^D'_H^.O!?@5_R5C3?^N4__
M **:O>OC7_R2+7?I!_Z/CKP7X%?\E8TW_KE/_P"BFH ]'_:5_P"0!H7_ %]2
M?^@BO(OA[X1U+Q[K']@P7K6VGI_I5R_)5<?*#M[MS@?4^]>N_M*_\@#0O^OJ
M3_T$5D_LT(IU'Q$^/F$4 !]B7_P% &?\2_@I8>#_  D^N:5J-W.+9T%Q'<[3
ME68*"I4#')'!SUZUYAX=BUC5;Y?#NE7$B?VM*D,D0<JDF#D%\=EY-?57QG&?
MA)KW^[#_ .CDKY]^"**_Q;T;<,[1.P^ODO0!Z!K'[.UC8^%;JYM=9NYM5MX&
ME^=%$4A49VA<9&<8SDUY'\/]8N-#\>Z)>V\C(?M<<<@!^]&[!6!^H)K[1U$9
MTR['_3%__037PWX>_P"1ETK_ *_(?_0Q0!]C?$'Q3_PAW@J_UA K7"*([=6&
M096.%S[#J?8&OE#PKX=U3XD>-!9&[8W%R6GNKN7+%5'WG/J<D #U(Z5[I^T>
M[CP%IRC.QM33=_WZDQ7A?@2Y\7VFKW$O@Q+AK_R"LOD0K(?+W+GA@>,A: /6
M_$'[.5G!H4LVA:K>2ZC$A<17(4I,0/NC !4GMG/]:\_^#OC2Y\*^-;6S>9O[
M,U&5;>XB)^4,QPK^Q!(R?3-=)_;7QX_YY:K_ . $/_Q%<0/AUX\%T+G_ (1K
M4O.W^9N$./FSG/YT ?9U%(IRH)&"1TI: /.OCAJ;:;\+=15&VO=O'; ^Q;+?
MFJD?C7D?[.M@MSX_NKMQD6E@Y4^C,RK_ "+5Z%^T:6_X5Y8XZ'5(\_\ ?J6N
M1_9JV_VYKW][[-%CZ;C_ /6H ^C:^(/'G_)0_$O_ &%;K_T:U?;]?$'CS_DH
M?B7_ +"MU_Z-:@#T_P !?!(^+]#@U_Q)JMW$+M 8(H<>9Y8X5F9@>,#@ =,<
M]JXKXH?#W_A7VNV]M#=M=65W&9()'4!Q@X96QP2..?>OJOP>BQ^"=!11A5TZ
MW '_ &S6O%?VF0/M'AH]]ES_ #CH Z?]GG6KC4? USI]Q(7_ +/NBD1)Z1L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+<PJZJMQ+&R'<I4Y 0'H?6@#D_VE?^0!H7_7U)_Z"*ROV9_^/WQ)_P!<[?\
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M\5:/>65D9S>3BZA9!)S\L2[AR.@_W0?:OIJBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img40748725_35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_35.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" @T!T(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Q:UOP7XJM])T:.R=/LJS3&XC+$,S, !AAV /XUP7_#0_C3_ )X:3_X#O_\
M%T ?4U%?+/\ PT/XT_YX:3_X#O\ _%T?\-#^-/\ GAI/_@.__P 70!]345!9
M3-<6%O.^-\D2NV.F2 :GH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KYM_:3_ .1FT7_KS;_T,U])5\V_M)_\C-HO_7FW
M_H9H \S\!?\ )1/#7_84MO\ T:M?;U?$/@+_ )*)X:_["EM_Z-6OMZ@#X^^-
M?_)7==^L'_HB.M/X ?\ )3XO^O.;^0K,^-?_ "5W7?K!_P"B(ZT_@!_R4^+_
M *\YOY"@#ZNKYP^,_P 6?[3>?POX?N/]"4E+VZC/^O/>-3_<]3WZ=.NK\:/B
MSY N/"OAZX_>G*7]W&?N^L2GU_O'MTZYQ\^1QR32I%$C/([!511DL3T '<T
M.@@EN;B."")Y9I&")&BY9F/   ZFOJ?X2_"B+P?:IJ^KQI+KLR<#J+53_"O^
MT>Y_ <9)@^$7PFC\*V\>N:W$KZW*N8XCR+13V_WSW/;H.^?6Z "BBB@ HHHH
M *^%_%.I?VQXMU?4@V5N;R653_LEB1^F*^S_ !=J7]C^#M9U$-M:WLI9$/\
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M!^'RV]_//-J%S=27$EO:Q;F4<(,DD*.$!QGO0!D_\,X^,/\ H):'_P!_YO\
MXU1_PSCXP_Z"6A_]_P";_P"-5Z-8_M#^#;J<1SP:I9J3_K)H%91]=C$_I7I>
MDZSINNZ>E_I5[#=VK])(FR,^A]#['F@">RA:VL;>!R"T<2H2.F0,5/110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S;
M^TG_ ,C-HO\ UYM_Z&:^DJ^;?VD_^1FT7_KS;_T,T >9^ O^2B>&O^PI;?\
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MR6CC*37#K$''JH8Y(]P,5]2S_#GP9<7"3OX9TL2(P<&.W5!D'/(7 /XUTX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7S;^TG_ ,C-HO\ UYM_Z&:^DJ^;?VD_^1FT7_KS;_T,T >9^ O^
M2B>&O^PI;?\ HU:^WJ^(? 7_ "43PU_V%+;_ -&K7V]0!\??&O\ Y*[KOU@_
M]$1U=^!%I;W?Q/M?M$*2^3;RRQ[USM< 88>XS5+XU_\ )7==^L'_ *(CK3^
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MJLC*>H+DO@_]]5\X?"7X=7'C3Q!'=W<+#1+.0-<2,.)6'(B'KGOZ#ZBOKH
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M$,EM$8D%K(B@@G/.Y&YKMZ* /+-(^ ?A;1=9L=4MK_66GL[A+B-9)HBI9&#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSW44$UQ()!;7,D!8"%R 6C8'&0#C- '0T5A_\(GIW_/SK/\ X.KS_P".T?\
M")Z=_P _.L_^#J\_^.T ;E%8$WA73UAD87.L@A21_P 3J\]/^NM6O#$TMQX3
MT:::1Y)9+&!W=V)9F* DDGJ30!JT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#Q[R_[A_E67X3_ .1-T/\ [!]O_P"BUK4G_P"/>7_</\JR_"?_ ")NA_\
M8/M__1:T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XH_X]-/
M_P"PG:?^C5K<K,US3)]4L8XK:YCMIXKB*=))83*N4<-@J&4D'&.HJM]E\5?]
M!G1O_!3+_P#)- &Y16']E\5?]!G1O_!3+_\ )-'V7Q5_T&=&_P#!3+_\DT '
MA+_D!-_U^WG_ *4RUN5G:'ILNDZ4EI-<)<2^;+*\B1F-2TDC.<*6; &['4]*
MT: ,/PC_ ,B\G_7S<_\ H^2MRN;LM&\0Z; UM::SI?V?S9)$$NF2,P#NSX)$
MX!QNQG JQ]E\5?\ 09T;_P %,O\ \DT ;E8<_P#R/>G_ /8,N?\ T;!1]E\5
M?]!G1O\ P4R__)-%EI.J#7(]3U/4;.X,5M);QQVUDT/WV1B26E?/W!Z=: -R
ML/6/^1A\._\ 7S-_Z(DK<K)UG2[R_GT^YL+V"UN+.5I 9[<S*P9&0C =#_%G
M.>U &M16']E\5?\ 09T;_P %,O\ \DT?9?%7_09T;_P4R_\ R30!L3_\>\O^
MX?Y5E^$_^1-T/_L'V_\ Z+6H7LO%+HR'6=&PPQ_R"9?_ ))K2TFP_LO1K'3_
M #/-^RV\<'F;=N[:H7..<9Q0!<HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"O?7]GIEG)>7]W!:6L>-\T\@C1<D 98\#)('XUC_P#"=^#_
M /H:]#_\&,/_ ,57/_&W_DD.N_\ ;O\ ^E$=?)%C87FIWD=G86D]W=29V0P1
MF1VP"3A1R< $_A0!]K_\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\
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M\)WX/_Z&O0__  8P_P#Q5?('_"">,/\ H5-<_P#!=-_\31_P@GC#_H5-<_\
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M ?7_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5?('_"">,/\
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M@GC#_H5-<_\ !=-_\30!]?\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%5\@?\()XP_P"A4US_ ,%TW_Q-'_"">,/^A4US_P %TW_Q- 'U_P#\
M)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \57R!_P@GC#_ *%37/\
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M5?('_"">,/\ H5-<_P#!=-_\31_P@GC#_H5-<_\ !=-_\30!]?\ _"=^#_\
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MGC#_ *%37/\ P73?_$T?\()XP_Z%37/_  73?_$T ?7_ /PG?@__ *&O0_\
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M  8P_P#Q5?('_"">,/\ H5-<_P#!=-_\31_P@GC#_H5-<_\ !=-_\30!]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P"-O_)(==_[=_\ THCK
MP#X)?\E>T+_MX_\ 2>2O?_C;_P DAUW_ +=__2B.O /@E_R5[0O^WC_TGDH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_\ C;_R2'7?^W?_
M -*(Z\ ^"7_)7M"_[>/_ $GDKW_XV_\ )(==_P"W?_THCKP#X)?\E>T+_MX_
M])Y* /K^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .?\=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_^C5KZ_\ '?\ R3SQ
M+_V"KK_T4U?('@3_ )*'X:_["MK_ .C5H ^WZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_ (V_\DAU
MW_MW_P#2B.O /@E_R5[0O^WC_P!)Y*]_^-O_ "2'7?\ MW_]*(Z\ ^"7_)7M
M"_[>/_2>2@#Z_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#G_'?_)//$O_ &"KK_T4U?('@3_DH?AK_L*VO_HU:^O_ !W_
M ,D\\2_]@JZ_]%-7R!X$_P"2A^&O^PK:_P#HU: /M^BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P"-
MO_)(==_[=_\ THCKP#X)?\E>T+_MX_\ 2>2O?_C;_P DAUW_ +=__2B.O /@
ME_R5[0O^WC_TGDH ^OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y_QW_R3SQ+_P!@JZ_]%-7R!X$_Y*'X:_["MK_Z-6OK
M_P =_P#)//$O_8*NO_135\@>!/\ DH?AK_L*VO\ Z-6@#[?HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** //_ (V_\DAUW_MW_P#2B.O /@E_R5[0O^WC_P!)Y*]_^-O_ "2'7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#G_'?_ "3SQ+_V"KK_ -%-7R!X$_Y*'X:_
M["MK_P"C5KZ_\=_\D\\2_P#8*NO_ $4U?('@3_DH?AK_ +"MK_Z-6@#[?HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \_^-O_ "2'7?\ MW_]*(Z\ ^"7_)7M"_[>/_2>2O?_ (V_\DAU
MW_MW_P#2B.O /@E_R5[0O^WC_P!)Y* /K^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,/6/^1A\._]?,W_ *(DK<K#
MUC_D8?#O_7S-_P"B)*W* "HY_P#CWE_W#_*I*CG_ ./>7_</\J ,OPG_ ,B;
MH?\ V#[?_P!%K6Q6/X3_ .1-T/\ [!]O_P"BUK8H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y_QW_R3SQ+_ -@JZ_\ 135\@>!/^2A^&O\ L*VO
M_HU:^O\ QW_R3SQ+_P!@JZ_]%-7R!X$_Y*'X:_["MK_Z-6@#[?HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \_P#C;_R2'7?^W?\ ]*(Z\ ^"7_)7M"_[>/\ TGDKZ_HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P]8_P"1
MA\._]?,W_HB2MRJ&IZ-9:N(/M8G#0.7B>"YD@9205/S1LIZ$C&:I?\(GIW_/
MSK/_ (.KS_X[0!N5'/\ \>\O^X?Y5C_\(GIW_/SK/_@ZO/\ X[2'PEII!!N-
M9(/4?VU>?_': )?"?_(FZ'_V#[?_ -%K6Q4-I:PV-E!:6R;(((UBC3).U5&
M,GD\"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\ '?\ R3SQ
M+_V"KK_T4U?('@3_ )*'X:_["MK_ .C5KZ_\=_\ )//$O_8*NO\ T4U?('@3
M_DH?AK_L*VO_ *-6@#[?HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U
M?('@3_DH?AK_ +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_
M^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#G_ !W_ ,D\\2_]@JZ_]%-7R!X$_P"2A^&O
M^PK:_P#HU:^O_'?_ "3SQ+_V"KK_ -%-7R!X$_Y*'X:_["MK_P"C5H ^WZ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JH_X9E_ZF[_RF_P#VVC_AF7_J;O\
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M[_RF_P#VVC_AF7_J;O\ RF__ &V@ _X::_ZE'_RI?_:J/^&FO^I1_P#*E_\
M:J/^&9?^IN_\IO\ ]MH_X9E_ZF[_ ,IO_P!MH /^&FO^I1_\J7_VJC_AIK_J
M4?\ RI?_ &JC_AF7_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: #_AIK_J4?_*E_
M]JH_X::_ZE'_ ,J7_P!JH_X9E_ZF[_RF_P#VVC_AF7_J;O\ RF__ &V@ _X:
M:_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J/^&9?^IN_\IO\ ]MH_X9E_ZF[_ ,IO
M_P!MH /^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &JC_AF7_J;O_*;_ /;:/^&9
M?^IN_P#*;_\ ;: #_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JH_X9E_ZF[_RF
M_P#VVC_AF7_J;O\ RF__ &V@ _X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J/^
M&9?^IN_\IO\ ]MH_X9E_ZF[_ ,IO_P!MH /^&FO^I1_\J7_VJOH"O@"OO^@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U?('@3_DH
M?AK_ +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_^C5H ^WZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** //\ XV_\DAUW_MW_ /2B.O /@E_R5[0O^WC_ -)Y*]_^-O\
MR2'7?^W?_P!*(Z\ ^"7_ "5[0O\ MX_])Y* /K^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /@"OO^O@"OO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8
M*NO_ $4U?('@3_DH?AK_ +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A
M^&O^PK:_^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** //\ XV_\DAUW_MW_ /2B.O /@E_R5[0O
M^WC_ -)Y*]_^-O\ R2'7?^W?_P!*(Z\ ^"7_ "5[0O\ MX_])Y* /K^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /@"OO^O@"OO^@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .?\=_\D\\2_P#8*NO_ $4U?('@3_DH?AK_ +"MK_Z-6OK_ ,=_\D\\2_\
M8*NO_135\@>!/^2A^&O^PK:_^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //\ XV_\DAUW_MW_
M /2B.O /@E_R5[0O^WC_ -)Y*^OZ* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@"OO^
MO@"OO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U
M?('@3_DH?AK_ +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_
M^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X K[_KX K[
M_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#G_ !W_ ,D\\2_]@JZ_]%-7R!X$
M_P"2A^&O^PK:_P#HU:^O_'?_ "3SQ+_V"KK_ -%-7R!X$_Y*'X:_["MK_P"C
M5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X K[_KX K[_H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#G_'?_)//$O\ V"KK_P!%-7R!X$_Y
M*'X:_P"PK:_^C5KZ_P#'?_)//$O_ &"KK_T4U?('@3_DH?AK_L*VO_HU: /M
M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K,US4Y]+L8Y;:VCN9Y;B*!(Y9C$N7<
M+DL%8@#/H:TZP_%'_'II_P#V$[3_ -&K0 ?:O%7_ $!M&_\ !M+_ /(U'VKQ
M5_T!M&_\&TO_ ,C5N44 8?VKQ5_T!M&_\&TO_P C5;T/4I-6TI+N:W2WE\V6
M)XTD,BAHY&0X8A<@E<]!UK1K#\)?\@)O^OV\_P#2F6@#<KGEUC7+N^OXM/TG
M3I(+2X\CS+C47C9SL5B=HA8 ?-Z]JZ&L/P]_Q]Z__P!A-O\ T5%0 ?:O%7_0
M&T;_ ,&TO_R-1]J\5?\ 0&T;_P &TO\ \C5N44 8":OK-OJNGVFI:78117LK
MQ+);7[RLK"-GY5H4XPA'7O6_6'K?_(=\-_\ 7[+_ .DTU;E &3K.J7EA/I]M
M86<%S<7DK1@3W!A50J,Y.0CG^'&,5#]J\5?] ;1O_!M+_P#(U&L?\C#X=_Z^
M9O\ T1)6Y0!A_:O%7_0&T;_P;2__ "-37O?%*(SG1M'PHS_R%I?_ )&K>J.?
M_CWE_P!P_P J *^DWW]J:-8ZAY?E?:K>.?R]V[;N4-C/&<9JY6/X3_Y$W0_^
MP?;_ /HM:V* .;LM9\0ZE US::-I?V?S9(T,VIR*Q".R9($! SMSC)JQ]J\5
M?] ;1O\ P;2__(U'A'_D7D_Z^;G_ -'R5N4 8?VKQ5_T!M&_\&TO_P C4MEJ
MVJ'7(],U/3K.W,MM)<1R6UZTWW&12"&B3'WQZ]*VZPY_^1[T_P#[!ES_ .C8
M* -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ^ *^_Z^ *^_P"@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .?\=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_^C5KZ_\ '?\ R3SQ+_V"
MKK_T4U?('@3_ )*'X:_["MK_ .C5H ^WZ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWE_W#_*I*CG_ ./>7_</\J ,OPG_ ,B;H?\ V#[?_P!%K6Q6/X3_ .1-T/\
M[!]O_P"BUK8H P_"/_(O)_U\W/\ Z/DK<K#\(_\ (O)_U\W/_H^2MR@ K#G_
M .1[T_\ [!ES_P"C8*W*PY_^1[T__L&7/_HV"@#<HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@"OO^
MO@"OO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U
M?('@3_DH?AK_ +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_
M^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X K[_KX K[
M_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#G_ !W_ ,D\\2_]@JZ_]%-7R!X$
M_P"2A^&O^PK:_P#HU:^O_'?_ "3SQ+_V"KK_ -%-7R!X$_Y*'X:_["MK_P"C
M5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBH;N[MK"UDNKRXBM[>,9>69PB*/4D\"@
M":BLFP\4>'M4NA:Z=KNF7EPP)$5O=QR.0.IPI)K6H ***B^U6_\ SWB_[[%
M$M%1?:K?_GO%_P!]B@7,#, LT9)X ##F@"6BBD9@BEF("@9))X H 6BL8^+_
M  R)_(/B+21-G'EF]CW9^F[-:Z.LB*Z,&5AD,IR"* '4444 %%9VH>(-&TEP
MFI:O86;GD+<W*1G_ ,>(J:PU33]4B,NGWUM=QCJ]O,L@'X@F@"W1110 456O
MM2L=,A\Z_O;>TB_OSRK&OYDU6L/$6B:K+Y6G:QI]Y)_=M[I)#^2DT :5%%%
M!12,P12S$!0,DD\ 5CGQ?X9$_D'Q%I(FSCRS>Q[L_3=F@#9HIJ.LB*Z,&5AD
M,IR"*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\ 5]_P!? %??] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <_X[_Y)YXE_[!5U_P"BFKY \"?\E#\-?]A6U_\ 1JU]?^._^2>>)?\
ML%77_HIJ^0/ G_)0_#7_ &%;7_T:M 'V_1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?WFF?"W6;RPNY[2ZC\C9-!(8W7,\8.&'(R"1^-?+'_"=^,/^AKUS_P8S?\
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MUS_P8S?_ !5'_"=^,/\ H:]<_P#!C-_\57T__P *2^'G_0O?^3MQ_P#'*/\
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MOI^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@"OO^O@"OO\
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#G_'?_)//$O_ &"KK_T4U?('@3_D
MH?AK_L*VO_HU:^O_ !W_ ,D\\2_]@JZ_]%-7R!X$_P"2A^&O^PK:_P#HU: /
MM^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>0?M&_\D\L?^PK'_P"BI:]?KD/B
M/X&_X6!X=@TG^T?L'E72W/F^1YN<*Z[<;E_OYSGM0!\]_ ;_ )*I9_\ 7O-_
MZ :^LZ\E\!?!/_A"/%4.M_\ "0_;?+C=/)^Q>7G<,9W>8?Y5ZU0!X#^T;H-\
M3IOB"W:5K,)]DN55CM0Y+(Q'OEAGV [BN'^$?Q*B\!:E=0:A%)+I5[M,AB&6
MB=<X8#N,'!'T],'ZNOK&UU*QFLKV".>VG0I)%(,JRGL:\1\0_LX6EQ<O/X?U
M@VD;'(MKI#(J^P<'./J"?>@"UXY^/&@GPY<V?AJ2>ZO[J(Q+*T31I ",%OFP
M2P!X &,_KX7X+\+77C'Q39Z/:JVV1PT\@'$40^\Q_#IZD@=Z]3L?V:]4:<?;
M_$%G%#GDP1-(Q'X[17L_@SP)HG@;3FMM)A8RR8,]S*<R2D>I[#T XH TM9T.
MWU;PO>Z'@1P7%JULO'W 5P#^'!_"OB*ZMK_P_K<EO.C6]_8SX([HZGJ/Q&:^
M\:X'Q_\ "?1/';"[=VL=45=HNXE!W@= Z\;L?4'WQQ0!S,/[1/AS_A'1<36=
MY_:PC^:T5!L,F.SY^[GOUQVKYT;[?XD\0,51I]0U&Y+;5'+R.V>/Q->NG]FS
M7//PNO:<8<_?*.&Q_NXQ^M>F_#_X0:-X&G%^\S:CJNTJ+F1 JQ ]=B\X)Z9)
M)^F30!U_AC14\.>%],T>,AA9VZ1,P_B8#YF_$Y/XU\W?'WPQ-I/CDZRD9^QZ
MHBOO X650%9?J0 WXGTKZGK,\0>'M,\3Z/-I>K6RW%K+S@\%6[,I[$>M 'SS
M\(/BWIOA#1Y]#UY;@6OFF:WGB3?LS]Y2.N,C(QGJ:YKXM?$*'Q]K]L]C%+'I
MME&R0"4 ,[,06<@=,X48]O?%=QJW[-=T+EFT;7X6MR?E2\C*LH]"RY!^N!5_
MPW^SC;6UY'<>(M6%W$AR;6U0HK^Q<\X]@ ?>@"S^SKX8EL=%U#Q%<QE3?,(;
M;(Y,:$[F'L6X_P" 5/\ M$>&)M2\-V.NVT9=]-=DG"CGRGQ\WT# ?]]&O8K:
MV@L[:*VMHDA@B0)'&@PJJ!@ #L*=+%'<0O#-&LD4BE71QD,#P01W% 'Q[\*_
M'B> O$[W=U%)+I]U%Y-PD6"PYRK 'J0>WH37:?%OXPZ7XJ\.#0= 6X:*:17N
M9YDV JIR$ ZGY@"3[=\\=!XI_9UL;Z\DNO#FI_8%<Y-I<(7C4_[+ Y ]B#]:
MQ],_9KOVN5.JZ_;) #\PM8F=F'H"V /K@T <U\"/#$NM>/8M3>,FSTI3,[$<
M&0@A%^N<M_P&OIW7])CU[P]J.DRG"7EN\);^Z6! /X'G\*@\,^&-*\):-'I>
MD6_E6Z'<Q)R\C=V8]R?_ *PXK8H ^#KJVO\ P_K<EO.C6]_8SX([HZGJ/Q&:
M^C8?VB?#G_".BXFL[S^UA'\UHJ#89,=GS]W/?KCM73>/_A/HGCMA=N[6.J*N
MT7<2@[P.@=>-V/J#[XXKRL_LV:YY^%U[3C#G[Y1PV/\ =QC]: /(F^W^)/$#
M%4:?4-1N2VU1R\CMGC\37VSX8T5/#GA?3-'C(86=ND3,/XF ^9OQ.3^-<A\/
M_A!HW@:<7[S-J.J[2HN9$"K$#UV+S@GIDDGZ9->BT %%%% !1110!\__ +37
M_,K?]O?_ +1H_9E_YFG_ +=/_:U'[37_ #*W_;W_ .T:/V9?^9I_[=/_ &M0
M!] 4444 %%%% !1110 4444 %%%% 'G_ ,;?^20Z[_V[_P#I1'7@'P2_Y*]H
M7_;Q_P"D\E>__&W_ ))#KO\ V[_^E$=> ?!+_DKVA?\ ;Q_Z3R4 ?7]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5X_^T=_R3S3_P#L*Q_^BI:]@KQ_]H[_ ))Y
MI_\ V%8__14M ' ?LX_\E#U#_L%2?^C8J^GZ^8/V<?\ DH>H?]@J3_T;%7T_
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P!7W_7P!7W_ $ %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!S_ ([_ .2>>)?^P5=?^BFKY \"?\E#
M\-?]A6U_]&K7U_X[_P"2>>)?^P5=?^BFKY \"?\ )0_#7_85M?\ T:M 'V_1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!\_\ [37_ #*W_;W_ .T:
M/V9?^9I_[=/_ &M1^TU_S*W_ &]_^T:/V9?^9I_[=/\ VM0!] 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^)= M=.\,:I>VMYK$=Q;VLDD;G6+MMK!20<&0@_C785A^,_^1)UO_KRE_\
M036Y0!B^+I98?".JR0RR12+;L5DB<HRG'4$<@^XIO_")Z=_S\ZS_ .#J\_\
MCM'C+_D3M6_Z]FK<H P_^$3T[_GYUG_P=7G_ ,=H_P"$3T[_ )^=9_\ !U>?
M_':W** ,#PQ&;>76[03W,L5OJ&R+[1</,RJ88FQN<EL98GKWK?K#T#_D(^(O
M^PG_ .V\-;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/\
M[1W_ "3S3_\ L*Q_^BI:]@KQ_P#:._Y)YI__ &%8_P#T5+0!P'[./_)0]0_[
M!4G_ *-BKZ?KY@_9Q_Y*'J'_ &"I/_1L5?3] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ? %??]? %??] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <_X[_P"2>>)?^P5=?^BFKY \"?\ )0_#7_85M?\ T:M?7_CO_DGGB7_L
M%77_ **:OD#P)_R4/PU_V%;7_P!&K0!]OT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?/_P"TU_S*W_;W_P"T:/V9?^9I_P"W3_VM1^TU_P RM_V]
M_P#M&C]F7_F:?^W3_P!K4 ?0%%%% !1110 4444 %%%% &'K'_(P^'?^OF;_
M -$25N5AZQ_R,/AW_KYF_P#1$E;E !4<_P#Q[R_[A_E4E1S_ /'O+_N'^5 &
M7X3_ .1-T/\ [!]O_P"BUK1OO^0?<_\ 7)OY&L[PG_R)NA_]@^W_ /1:UHWW
M_(/N?^N3?R- %+PS_P BIH__ %XP_P#H K4K+\,_\BIH_P#UXP_^@"M2@ K#
MLO\ D=M8_P"O*S_]"GK<K#LO^1VUC_KRL_\ T*>@#<K#E_Y'NU_[!DW_ *-B
MK<K#E_Y'NU_[!DW_ *-BH W**** ,/QG_P B3K?_ %Y2_P#H)K<K#\9_\B3K
M?_7E+_Z":W* ,/QE_P B=JW_ %[-6Y6'XR_Y$[5O^O9JW* "BBB@##T#_D(^
M(O\ L)_^V\-;E8>@?\A'Q%_V$_\ VWAK<H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KQ_P#:._Y)YI__ &%8_P#T5+7L%>/_ +1W_)/-/_["
ML?\ Z*EH X#]G'_DH>H?]@J3_P!&Q5]/U\P?LX_\E#U#_L%2?^C8J^GZ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ *^_P"O@"OO^@ HHHH
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MCT0'KWK5HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJ, 4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ *^_Z^ *^_Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Y_P =_P#)//$O_8*NO_135\@>!/\
MDH?AK_L*VO\ Z-6OK_QW_P D\\2_]@JZ_P#135\@>!/^2A^&O^PK:_\ HU:
M/M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%M;VVFMKA//WQ3(4=<SR$9!Y'!!_&@#N:*** "BBB@ HHHH **** "BBB@
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M *&O0_\ P8P__%4 =!15>QO[/4[..\L+N"[M9,[)H)!(C8)!PPX.""/PJQ0
M4444 %%%% !1110 4444 %%%% !1110 4444 %>/_M'?\D\T_P#["L?_ **E
MKV"O'_VCO^2>:?\ ]A6/_P!%2T <!^SC_P E#U#_ +!4G_HV*OI^OF#]G'_D
MH>H?]@J3_P!&Q5]/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\ 5]_U\ 5]_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_CO_DGGB7_ +!5
MU_Z*:OD#P)_R4/PU_P!A6U_]&K7U_P"._P#DGGB7_L%77_HIJ^0/ G_)0_#7
M_85M?_1JT ?;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF1VP"3A1R< $_A7UO\;?^20Z[_V[_P#I1'7@'P2_Y*]H7_;Q_P"D\E '/_\
M"">,/^A4US_P73?_ !-'_"">,/\ H5-<_P#!=-_\37V_10!\0?\ "">,/^A4
MUS_P73?_ !-'_"">,/\ H5-<_P#!=-_\37V_10!\0?\ "">,/^A4US_P73?_
M !-'_"">,/\ H5-<_P#!=-_\37V_10!\0?\ "">,/^A4US_P73?_ !-'_"">
M,/\ H5-<_P#!=-_\37V_10!\0?\ "">,/^A4US_P73?_ !-'_"">,/\ H5-<
M_P#!=-_\37V_10!\0?\ "">,/^A4US_P73?_ !-'_"">,/\ H5-<_P#!=-_\
M37V_10!\0?\ "">,/^A4US_P73?_ !-'_"">,/\ H5-<_P#!=-_\37V_10!\
M0?\ "">,/^A4US_P73?_ !-'_"">,/\ H5-<_P#!=-_\37V_10!\0?\ "">,
M/^A4US_P73?_ !-8<\$UK<2V]Q%)#/$Y22.12K(P.""#R"#QBOONOB#QW_R4
M/Q+_ -A6Z_\ 1K4 ?3_P2_Y)#H7_ &\?^E$E>@5Y_P#!+_DD.A?]O'_I1)7H
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5X_^T=_R3S3_ /L*Q_\
MHJ6O8*\?_:._Y)YI_P#V%8__ $5+0!P'[./_ "4/4/\ L%2?^C8J^GZ^8/V<
M?^2AZA_V"I/_ $;%7T_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'P!7W_7P!7W_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/^._^2>>)?\
ML%77_HIJ^0/ G_)0_#7_ &%;7_T:M?7_ ([_ .2>>)?^P5=?^BFKY \"?\E#
M\-?]A6U_]&K0!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:-'[,O_ #-/_;I_[6H_::_YE;_M[_\ :-'[,O\ S-/_ &Z?^UJ /H"BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_\
M8*NO_135\@>!/^2A^&O^PK:_^C5KZ_\ '?\ R3SQ+_V"KK_T4U?('@3_ )*'
MX:_["MK_ .C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"MJ-A;ZIIMUI]VF^WNHFAE
M7U5A@_H:^*?&7A'4/!?B*XTJ_1L*2T$V,+-'GAA_4=CD5]OUD>(O"^C>*].-
MCK5C'=0]4+<-&?56'*GZ4 ?*6@_&'QKX>LTL[?5!<6T8VI'=QB7:/0,?FQ[9
MJ;6?C5XXUFU>V;4TM(G&&%G$(V(_WN6'X$5Z1JG[-=E+,SZ3XAGMXR>(KFW$
MI'_ @5_E4>G_ +--LLH;4?$LLL>>4M[4(3_P)F;^5 'AWA[0-1\4Z[;Z5IL3
M2W-PV,]D'=F/8#J37VSX?T6W\.^'[#1[3_4VD*Q*2,%B!RQ]R<G\:H>%/!.@
M>#+-K?1;)8F<#S9W.Z67_>8_R&![5T- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?/_[37_,K?]O?_M&C]F7_ )FG
M_MT_]K4?M-?\RM_V]_\ M&C]F7_F:?\ MT_]K4 ?0%%%% !1110 4444 %%%
M% !1110!Y_\ &W_DD.N_]N__ *41UX!\$O\ DKVA?]O'_I/)7O\ \;?^20Z[
M_P!N_P#Z41UX!\$O^2O:%_V\?^D\E 'U_1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?$'CO_DH?B7_ +"MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\
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M%% !1110 4444 %%%% !1110 4444 %%%% '/^._^2>>)?\ L%77_HIJ^0/
MG_)0_#7_ &%;7_T:M?7_ ([_ .2>>)?^P5=?^BFKY \"?\E#\-?]A6U_]&K0
M!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>3:W\?=!T/7;_29])U*26SG>!W39M8J2"1ENG%>
MLU\L>,OA-XXU3QMKE_9:$TMK<WTTL4GVF$;E9R0<%\CCUH ]]MO'5C<_#MO&
M:VMP+,0//Y!V^9A6*D=<9X]:X'_AI'PY_P! ;5?_ "'_ /%5M:?X5UJ#X /X
M:DL2NKFRFB%MYB9W-(Q W9V]".]>%_\ "E_B#_T+K_\ @5!_\70!ZU_PTCX<
M_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \57DO_"E_B#_ -"Z_P#X%0?_
M !='_"E_B#_T+K_^!4'_ ,70!ZU_PTCX<_Z VJ_^0_\ XJO3O"?B2V\7^&;/
M7;2&6&"ZW[8Y<;AM=D.<$CJIKY7_ .%+_$'_ *%U_P#P*@_^+KZ1^%FBZAX>
M^&^DZ5JMN;>]@\[S(BZMMW3.PY4D="#UH [&BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_P!IK_F5O^WO_P!HT?LR
M_P#,T_\ ;I_[6H_::_YE;_M[_P#:-'[,O_,T_P#;I_[6H ^@**** "BBB@ H
MHHH **** "BBB@#S_P"-O_)(==_[=_\ THCKP#X)?\E>T+_MX_\ 2>2O?_C;
M_P DAUW_ +=__2B.O /@E_R5[0O^WC_TGDH ^OZ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KX@\=_\E#\2_P#85NO_ $:U?;]?$'CO_DH?B7_L
M*W7_ *-:@#Z?^"7_ "2'0O\ MX_]*)*] KS_ ."7_)(="_[>/_2B2O0* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_\ :._Y)YI__85C_P#14M>P
M5X_^T=_R3S3_ /L*Q_\ HJ6@#@/V<?\ DH>H?]@J3_T;%7T_7S!^SC_R4/4/
M^P5)_P"C8J^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ *
M^_Z^ *^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZMIL.LZ-?:7<-(L%[;
MR6\C1D!@KJ5)&01G!]#7F^D_ +PKHVLV.J6^H:RT]E<1W$:R31%2R,& .(P<
M9'J*]4HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% 'S_\ M-?\RM_V]_\ M&C]F7_F:?\ MT_]K4?M-?\ ,K?]O?\
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M444 %%%% !1110 4444 %%%% !1110!\ 5]_U\P?\,X^,/\ H):'_P!_YO\
MXU7T_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?/\ ^TU_S*W_ &]_^T:/V9?^9I_[
M=/\ VM1^TU_S*W_;W_[1H_9E_P"9I_[=/_:U 'T!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !17-^(_$;Z;(+2T"&<KEW;G9GIQZ]^?;KFN:'B;6 Y?[:<D ?
M<7'&>V,=Z=@/2:*Q]!UU-8A8.J1W,?WHPV<CCYA[9[<XX]:V*0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[S(BZMMW3.PY4D="#UKK+>Y@O+=+BVGCGA<922)PRL/8C@U+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7@?QR^)MK)8R^$=%N%FD=@+^>,Y
M5 #GRP>YR!GTQCN<9/QH^)7B2W\5ZGX6LKL66GP"-6:W!664-&K$,^<@?,1@
M8XZYKRZX\):Q:>$X_$MU:M!ITUPMO"TGRM*65FW*.ZX4\^_&>< '8? 8D_%2
MSY/_ ![S?^@&OK.ODSX#?\E4L_\ KWF_] -?6= &#XQ\56?@WPS=:S>#>(AM
MBB!P99#]U1_G@ GM7R/XD\>>)_&6H,U]J%PR2-B.SMV*Q+GH%0=3[G)->H_M
M*:PYO-$T16(18WNY%]23L4_AA_SJA^SCH<%[XCU76)HU=["%(X=PSM>0M\P]
M\(1_P(T >6PWGB/PG?HT<VI:5=##@$O"Q'T.,C]*^EO@_P#$Y_&]C-IVJ[%U
MFT0.S*,"XCZ;P.Q!P".G((ZX$WQST*#5OAM>7C1J;G3F2XA?'(&X*XSZ%23]
M0*^>OA;K#Z)\2M#N%8JDMRMM)Z%9/D.?IN!_"@#[/KYE^*GQCU/4=7N=&\.7
MLEGIENQB>X@;;)<,."0PY"YX&.O4]<#W7XA:P^@_#_7-1B8I+':LL;#^%W^1
M3^!85\;:!IO]L^(M,TS)'VR[B@)';>X7/ZT 'V?6GMSJ_DZ@T ;F\VN5!S_?
MZ9S[UZ7\,?C)JNB:K;Z9XAO9;W1YF$?FSL6DMB> P8\E?4'H.GH?IJ/3K.+3
M5TU+:(62Q>2(-HV;,8VX],<5\1>+=(70?%^KZ5'GRK6[DCCSUV!CM_3% 'W,
M"",@Y%>;_%SXE'P)I,-MIX1]9O0?)WC(A0<&0COSP!T)SZ8.Q\+=8?7/AIH=
MY*Q:58/(<GJ3&2F3[G:#^-?-7QAUA]9^*&L,6)CM9!:1C^Z(Q@C_ +ZW'\:
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MY>-&IN=.9+B%\<@;@KC/H5)/U H A^#_ ,3G\;V,VG:KL76;1 [,HP+B/IO
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MB@#Y_P#VFO\ F5O^WO\ ]HT?LR_\S3_VZ?\ M:C]IK_F5O\ M[_]HT?LR_\
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M*7-G<+OCE3H1_,$'((/(((/(JW7"TT[,H****0!1110 4444 %%%% !1110
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M([R98L_W>#_Z$6H ]2HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P">F\[NF.O7IQ7GGQ$;Q1IENVM:5XFUR.WWYN8?[3E"Q[B I1<],DY&>,C
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MRP4444 %%%% !1110 4444 %%%5[^^M],TZYO[R3R[6UB>:9]I.U%!+' Y.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&TOP)HG]GZ?NDED(>XN7&'F;U/H!V';ZDD@%_P 5:,/$/A35=(X#7=L\:$]
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MUX-X?^&*Z+XDTO57UDRI97D5RT:VN"P1PV =_?%(#Z>K/O-<TVPN#!<W024
M$J%9L9]<#BJE_KL?_".R:A8RIO.$0/C*L2,C'J!D_AGD5YW3L!ZE8ZO8:D[I
M:7 D=!DKM*G'KR.:NUY"CM&ZNC%74Y5E."#ZBO5=/N3>:=;W+##21JS#:1SC
MG /:@"S1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O#_$7[/DFO>)-3U<>)5@%[<R7'E?8=VS<Q.,^8,XSUQ7N%
M% '%VG@)K7X5-X)_M(,QMI(/M?DX'S,6SLW=L^M>8?\ #,TG_0V)_P""\_\
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M1M'_ &<-=NE5]7U>SL0?X(5,[CZ_='Y$T 8-]\>?'EVQ,-]:V8/\-O:H0/\
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MF$#O%D++\H.['8\__JZ4 >@4444 %%%% !1110 4444 %%%% !1110 4444
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MZ\&?\(-X573'NOM%S+*;BX=?N"1E4$)QG: H&3R>3QG ^;/C;_R5[7?^W?\
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M]/NGB _V&PX/YLWY4 >KU'/<0VT1EN)HXHP0"\C!1DG &3ZD@5)7B/[1VO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .BI: . _9Q_Y*'J'_8*D_\ 1L5?3]?,'[./_)0]0_[!4G_HV*OI^@ HHHH
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MG)/&(M+N%1FA=L;CE?K_ )Q7TC)^SKX2ED+OJ>N%CU/G0_\ QJF?\,X^#_\
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M@>#O^AJT7_P.C_QK:L-0L]4LH[W3[J&ZM9,[)H'#HV"0<$<'!!'X5\$U]?\
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M_P"2AZA_V"I/_1L5?3]?,'[./_)0]0_[!4G_ *-BKZ?H 1W6-&=V"JHR6)P
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MH)E<H#M^4@8)Y&2>W7\*P*Z+P3,EOK-TC22$W<2*B%LHIC+G@8X)#G)S_ *
M.]HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&S;A#'D[4' X /H,G)/)-8]=+XX\'WG@W7Y;.:-S92,S6<Y.X2QYXR<#Y@"
MPP.?8@GFJ\V5[ZGVM)P<$Z>W0^@?@1JFHWGAV^L+A,V%C*HM9/+QR^YG3=T.
M#@^HW^F,4?CSXA>&UT[P]!-M\_-S=(-P)0'$8)Z%2P<XYY13QQG8^"_A._\
M#^B7M_J*O!-J+(!:R1,CQ+&7&6#8Y)8G&.@!SS@5?CAX6GU/1[37+*W\R6PW
M+<B.,%S">=Q.<[4(/&#C>QX -=34O8G@QE2_M&_2_P"-O\_Q/GZNL^&E_?V'
MQ"T@Z>KNT\X@FC4,0T3<.2 >0HR_/ *@GI7)UW7PM\)W^O\ BVQO8U>&QL)U
MN9+EHF*,T;*WE@]-QR.,\#)YQ@\T+\RL>WB7%49<VUCZ?HHHKT3XT^(/'?\
MR4/Q+_V%;K_T:U?7_@3_ ))YX:_[!5K_ .BEKY \=_\ )0_$O_85NO\ T:U?
M7_@3_DGGAK_L%6O_ **6@#H**** "BBB@ KR'5+ZP7QCJ^BPR@75FZNT6T+\
MCJK@J.ZC>%]B.@R,^O5\@?&W_DKVN_\ ;O\ ^D\= 'KTLL<,3RRNL<:*6=W.
M H'))/85R>E>)KG7/'4]MIUY<)I-A;OO>VE8174C87$G9E&7VC_9)!(-=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\
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M/JI.?]T5W?[0ZQ'X;PF3&\:A%Y>?7:_],UY#\"BW_"U]-QT\J?/T\MO_ *U
M'UO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_P#M-?\ ,K?]O?\ [1H_
M9E_YFG_MT_\ :U'[37_,K?\ ;W_[1H_9E_YFG_MT_P#:U 'T!1110 4444 %
M%%% !1110 4444 >?_&W_DD.N_\ ;O\ ^E$=> ?!+_DKVA?]O'_I/)7O_P ;
M?^20Z[_V[_\ I1'7@'P2_P"2O:%_V\?^D\E 'U_1110 4444 %%%% !1110
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M[>/_ $HDKT"O/_@E_P DAT+_ +>/_2B2O0* "BBB@ HHHH ^8/VCO^2AZ?\
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M!X$_Y*'X:_["MK_Z-6OK_P =_P#)//$O_8*NO_135\@>!/\ DH?AK_L*VO\
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MJU_]%+0!T%%%% !1110 5\@?&W_DKVN_]N__ *3QU]?U\@?&W_DKVN_]N_\
MZ3QT >__  2_Y)#H7_;Q_P"E$E>@5Y_\$O\ DD.A?]O'_I1)7H% %.ZTJPO=
MYN+2)V?&Y]N&./\ :'/:K$%O!;(4@ACB0G)6-0HSZ\5)10!Y?K<KS:W>M(V2
M)F4''8' _0"J%=IXF\/3W=PU_9@,VS]Y'SN8CC(]>.W'3N37,)H^INZH+"Y!
M8X&Z(@?B3P*8&IX1B2ZOKJUF7?!);G?&3P<,N#]1DX/:FWGA'4H+@I;(+F+
M(D#*GX$$UTGAS0SI,#2SX-U*!N P=@_N@_S[<#TS6Y1<#A-.\'WL\Q^W?Z-$
MN#P0S-[#!X^I]N#7=(BQHJ(H5%&%51@ >@I:*0'S_P#M-?\ ,K?]O?\ [1H_
M9E_YFG_MT_\ :U'[37_,K?\ ;W_[1H_9E_YFG_MT_P#:U 'T!1110 4444 %
M%%% !1110 45S_C;Q/\ \(=X0OM?^Q_;/LOE_N/-\O=ND5/O8.,;L].U>/\
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MH_X9Q\8?]!+0_P#O_-_\:H [_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P!
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M *1D5OO*#]12T4 ,\F/_ )YI_P!\BCR8_P#GFG_?(I]% #/*C_YYI_WR*>
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M .T:/V9?^9I_[=/_ &M0!] 4444 %%%% !1110 4444 ,E1I(719&B9E($B
M;E/J,@C(]P17RM+%)!,\,T;1RQL5='&&4C@@@]#7U97%^+/AQI_B:Z^W17#6
M5\[#S90ID60!0H!4L,$8'(QWR#VWH55!M,QK0<EH>"4R&0W.KP:5;133WLZ,
M\<449<L "3P/8,?P-=GXT^'MYX1\&:IKSZE!,]I(@BA6$D2(TB("QR-I^8G
MSTZFN"^#,\MS\9=%FF<O(YN"S'_KWDK>IB4OAU,H4&_B.HMO!WB2[N%@CT._
M5VS@RPM&O SRS8 _$U[AX+\*1^%-&^SEUENYF\RXE5< G& H.,E1VSW)/&<#
MI**YZE:4U8VA247<****Q-0HHHH **** "BBB@ KP+]I662"7PG+$[1R(UTR
M.AP5(\D@@]C7OM?/_P"TU_S*W_;W_P"T:-P*GP3\0:CXM\6WVFZ[*MY;I8M<
M)E!&599$7@IC@ASUST%=DY#.S!0H)R%&<#VYKSG]G'_DH>H?]@J3_P!&Q5ZY
MKNC2:7=%U7-K(Q\MA_#_ +)]Q^OYX^6S[ QA3C4HP22O>R]+&M.7<R*U--T&
MZU2-G@DMU"XX>3GOV&2.G?%9B(TCJB*69C@*!DD^E:^D:VNCP3"* RS3 99V
MPJD9QQWZYZCT[9/@8.-!U5]8^#4T=[:%J;PE/;V,L\UY;JZ=%SA3T_B.,'\/
M3FN=K8UC7Y=7MH(6B$00[GPV0S8QGIQW[]ZQZO'/"^T2PJ]U+?77[_N%&_4G
MCM@]L\[7$,84X",QW.<9X !_,X'/6H***XVTTK(H]"\.:=;V6G++#,)FG 9Y
M%/!QV ]N??\ D-BN.\%SR_:;F#</)*!\%N0V<<#/IU..PKL:_0,JJPJ82#A'
ME6UCGFM3S_XV_P#)(==_[=__ $HCKP#X)?\ )7M"_P"WC_TGDKW_ .-O_)(=
M=_[=_P#THCKP#X)?\E>T+_MX_P#2>2O1)/K^BBB@ HHHH **** "BBB@ JIJ
MNHPZ1I%[J=PKM#9P/<2+& 6*HI8@9(&<#UJW7/>/-.FU7P%KEG;M="9[.0QK
M:D^9(RC<$& 20Q&TCN&([U=**E-*6UQ/8^7/&OCW6/&VIR3WLSQ6(8&"P20F
M*(#(!QT9\$Y8C)R>@P!RK*KC##(I:*_0(T:<8>S45R]CEN[W&11^6N,DU>TO
M4&TO4[>^2WM;DPMN\F[A66*0=U93P01^(Z@@@&JE%$*4(05.*TV"^MS[/\'>
M*;3QEX:MM9M%\KS,I+ 7#-#(#@J2/P(S@D$' SBMZO+O@$CK\.Y"]IY"M?RE
M),,//&U!OY.#R"ORX'R>N2?4:^$Q=.-*O.$=DSJB[JX4445SC"BBB@ HHHH
M**** /F#]H[_ )*'I_\ V"H__1LM=_\ LX_\D\U#_L*R?^BHJX#]H[_DH>G_
M /8*C_\ 1LM=_P#LX_\ )/-0_P"PK)_Z*BH ]@HHHH **** "BBB@ HHHH *
M\?\ VCO^2>:?_P!A6/\ ]%2U[!7C_P"T=_R3S3_^PK'_ .BI: . _9Q_Y*'J
M'_8*D_\ 1L5?3]?,'[./_)0]0_[!4G_HV*OI^@ HHHH **** .?\=_\ )//$
MO_8*NO\ T4U?('@3_DH?AK_L*VO_ *-6OK_QW_R3SQ+_ -@JZ_\ 135\@>!/
M^2A^&O\ L*VO_HU: /M^BBB@ K+\2:Y!X;\.WVL7 W):Q%@F2-[GA5R <98@
M9QQG-:E<A\4K.>^^&NM16Z;W6))2,@?(DBNQY]%4G\*F3:3:-*,5*I&,MFT?
M-OB+Q/JWBG47O-5NWE)8M'""?*A!QPBY^48 ]SC))/-/\,^+=8\)7S76DW7E
M^9M$T3KNCE .<,#^(R,$ G!&:Q**\_F=[GV7LH<G);3L?9^F7\6JZ59ZC KK
M#=P).BN &"LH8 X)YP:M5S7P^TB70_ 6CV$^_P Y8/-=7C*,C2,9"A!Z%2VW
M\.W2NEKT8NZU/C*B49M1VN%%%%,@^(/'?_)0_$O_ &%;K_T:U?7_ ($_Y)YX
M:_[!5K_Z*6OD#QW_ ,E#\2_]A6Z_]&M7U_X$_P"2>>&O^P5:_P#HI: .@HHH
MH **** "OD#XV_\ )7M=_P"W?_TGCKZ_KY ^-O\ R5[7?^W?_P!)XZ /?_@E
M_P DAT+_ +>/_2B2O0*\_P#@E_R2'0O^WC_THDKT"@ HHHH Y3Q-X>GN[AK^
MS 9MG[R/G<Q'&1Z\=N.G<FN831]3=U06%R"QP-T1 _$G@5ZE13N!A^'-#.DP
M-+/@W4H&X#!V#^Z#_/MP/3-;E%%( HHHH ^?_P!IK_F5O^WO_P!HT?LR_P#,
MT_\ ;I_[6H_::_YE;_M[_P#:-'[,O_,T_P#;I_[6H ^@**** "BBB@ HHKE_
MB)XDO/"/@34M<L(X)+JU\K8DZDH=TJ(<@$'HQ[T =117S!_PT=XP_P"@;H?_
M 'XF_P#CM'_#1WC#_H&Z'_WXF_\ CM 'T_17S!_PT=XP_P"@;H?_ 'XF_P#C
MM'_#1WC#_H&Z'_WXF_\ CM 'T9K^M0>']'FU"==^S"I&& ,C'H!G\SUX!.#B
MO!/$EX/%>L?VGJMI:RSB)85'E95$4D@ '/=F/X^@&*$?Q7UWQY)_9NJ6UC##
M"//7[(C+EA\O.YF[,>A'?.>,35]9DF$HNA[:23DV_D?,YOBJJK>RB[)?B=/\
M//$5MX/DET\P!-+NIC-)L!)BD( +@>F  5'3''H?<*^:*J0_M$>+;:&.W2ST
MB9(E"++-#+O< 8W-^]ZGJ?>N+/<+2I2C.FK7O?Y6.O)L34JQE";O:Q]145\P
M?\-'>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.UX![9]/T5\P?\-'>,/^
M@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.T ?3]%%% !1110 4444 %%%% !1
M110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_ &[_ /I1'0!X!\$O^2O:
M%_V\?^D\E?7]?('P2_Y*]H7_ &\?^D\E?7] !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117A_Q_\)7+V4/BS37F5H (;U(V(RF?E? ]"<'V(]* /3O'
MFI7>C^!-:U&PF,-W;VK212!0=K#O@@BO#?A?\3O&/B#XCZ3I>J:T]Q93F7S(
MC!$N[$3L.0H/4"O&WO;J1"CW,S*>"#(2#422/$X>-V1AT93@B@#[]HKX(^WW
MO_/W/_W\/^-'V^\_Y^Y_^_A_QH ]N^-OCCQ)H'C@:=H_B">"U:TCE:&$J/*<
ME@1D#/( ;K_%7I7P:\07GB/X<VMSJ%Q)<7<,TD$DTC;F?#9!)^C ?A7R S,S
M%F))/4GO7U_\&= N?#WPVL8KR-HKFZ=[IXV&"@;[H/OM"G\: ._HHHH *BN;
MF"SMWN+J>."%!EY)7"JH]23P*EKP7]IAV%GX;0,0IDN"5SP2!'C^9H Z?Q/\
M>?"FA[X=-,FL72\8M_EB!]Y#U^JAJ\9\3_&SQAXBWQ0W8TJT;CRK+*L1[R?>
M_(@>U><CK7L?@#X*Z;XHMTO+SQ59SQ8#/:Z8X>11Z,6'RGVVF@#QYW>60N[,
M[L<EB<DFG302VTIBGB>*1<91U*D9&1P:^T_#GP[\*^%0K:7I$"W"_P#+S*/,
MESZ[FR1^&!7R[\7/^2J^(/\ KNO_ * M 'I/PJ^#?AW7O"UAXCUE[F[:YWD6
MH;RXUVNR\D?,?NYZCK7N>EZ-IFB6@M=+L+:S@'\$$80'W..I]S7(?!?_ ))'
MH/\ NS?^CI*[V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#VFO\
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MZYI-OJ5F6,$ZY7>N&!!(((]001Z<<9JITI0W)C4C+8O4445F6%%%% !1110
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M .JM*D(# @@$'@@UP^T7-?E/J7A:GLN3VC_#_*_XD7_"=^,/^AKUS_P8S?\
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M_P#2B2O0* "BBB@ HHHH **** "BBB@#Y_\ VFO^96_[>_\ VC1^S+_S-/\
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M1'0!X!\$O^2O:%_V\?\ I/)7U_7R!\$O^2O:%_V\?^D\E?7] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4-W:6]_9S6EU$LUO.ACEC<9#*1@@_A4U%
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MS>M$8\SL& PGUNNJ5[+J=)+\8/#D<SHMOJ,JJQ D2)-K#U&7!P?< UQ/QO\
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MYXE_[!5U_P"BFKY \"?\E#\-?]A6U_\ 1JU]?^._^2>>)?\ L%77_HIJ^0/
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M (:8NO\ H5X?_ T__$5@?\,[>,_^?G2/_ A__B*/^&=O&?\ S\Z1_P"!#_\
MQ% &_P#\-,77_0K0_P#@:?\ XBO9? WB9O&/@VPUY[46K77F9A5]X7;(R=<#
M/W<].]?/?_#.WC/_ )^=(_\  A__ (BO?/ASX=O?"?@+3-$U!H6NK;S=YA8L
MGS2NXP2!V8=J .IHHHH **** .>\3>!_#OB^'9K.F13R 82=?DE3Z..<>W3V
MKQ_7OV;7WM)X>UQ2IZ0WZ8Q_P-!S_P!\U] T4 ?(E]\#_'UFQV:1'=(/XX+F
M,@_@2#^E4!\(_'A;:/#=UGW= /SW5]E44 ?)VG? 3QU>L!<6MG8*?XKBY4_H
MFZO0O#_[..EVS++K^K37K#DP6R^4GT+'+$?3;7M]% &9HGA[1_#EG]DT?3K>
MRA[B),%O=CU8^Y)K3HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\ VFO^
M96_[>_\ VC1^S+_S-/\ VZ?^UJ/VFO\ F5O^WO\ ]HT?LR_\S3_VZ?\ M:@#
MZ HHHH **** "OB#QW_R4/Q+_P!A6Z_]&M7V_7Q!X[_Y*'XE_P"PK=?^C6H
M[32?@%XJUG1K'5+?4-&6"]MX[B-9)I0P5U# '$9&<'U--U+X$Z]H\/FZCX@\
M-VRE691)=2AG"]=H\K+'D<#)Y%?1'@ZYALOACH%U</L@@T:WDD;!.U5A4DX'
M/05X+K>MWWB#5)-0U"7?*_ 4<+&O95'8#_$G))-;4:7M'Y&52IR&'I'P@U#7
M;@V^G>)/#TLXZ1M+/&S<$_*&A!;@'.,X[U2T_P -6^GM*+EH+R3<5#JI,>T'
M@J& //7D ^PYK9HKJAAXQ=S"5:4E8I2:3I\L91K*  _W4"G\QS5/3]#N-+OE
M>*_62S=2QA&[<#G # @#/ .1GC'N!LT5HZ<6TR%-VL17,<LL#)!-Y,AQB3:&
MQSZ&I='^!WB3Q'IR:E9:QHDJ2$[]T\N]'[JP\OAN?ZC((-%6X]3OHM+FTV.Z
ME6RFD622 -\K,.AQ^7UP/08BK2]H53J<@Y/V=O%DC2*FJZ S1MM<+<2DJ< X
M/[K@X(/T(I__  SCXP_Z"6A_]_YO_C54HI9()DFAD:.6-@R.APRD<@@CH:]U
M^&WBN\\2Z7=Q:B_F7EI(-TH0*'1\[>G&058< <8ZG-<U2@X*]S>%92=CY;\:
M^"M2\!ZS#I>J3VDT\MNMPK6KLRA2S+@[E4YRA[>E>]_LX_\ )/-0_P"PK)_Z
M*BK@/VCO^2AZ?_V"H_\ T;+7?_LX_P#)/-0_["LG_HJ*N<V/8**** "BBB@
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M7]G(D_$/4"22?[*DZ_\ 76&OI^M,PS.6+2@E:*"$.4****\LL**** "BBB@
MHHHH **** /F#]H[_DH>G_\ 8*C_ /1LM=_^SC_R3S4/^PK)_P"BHJX#]H[_
M )*'I_\ V"H__1LM=_\ LX_\D\U#_L*R?^BHJ /8**** "BBB@!ABC,RS&-3
M*JE5<CY@#@D ^AVC\AZ4^BB@ HHHH *\?_:._P"2>:?_ -A6/_T5+7L%>/\
M[1W_ "3S3_\ L*Q_^BI: . _9Q_Y*'J'_8*D_P#1L5?3]?,'[./_ "4/4/\
ML%2?^C8J^GZ "BBB@ HHHH Y_P =_P#)//$O_8*NO_135\@>!/\ DH?AK_L*
MVO\ Z-6OK_QW_P D\\2_]@JZ_P#135\@>!/^2A^&O^PK:_\ HU: /M^BBB@
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M% !1110 4444 %>?_&W_ ))#KO\ V[_^E$=>@5Y_\;?^20Z[_P!N_P#Z41T
M> ?!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O'_I/)7U_0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'S_ /M-?\RM_P!O?_M&C]F7_F:?^W3_ -K4?M-?\RM_V]_^T:/V9?\
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MN2>2>:*U>,H\L14J33NSYH_:._Y*'I__ &"H_P#T;+7?_LX_\D\U#_L*R?\
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M8W-T]:Z"BD 4444 %%%% !7G_P ;?^20Z[_V[_\ I1'7H%>?_&W_ ))#KO\
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MUYID-E:6SEX+:&)B,%DC"G'IQ4]%=CIP<N9K4D****L HHHH **** "BBB@
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M'_8*D_\ 1L5?3] !1110 4444 <_X[_Y)YXE_P"P5=?^BFKY \"?\E#\-?\
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M[@$?0U\BZ#J$ND^(=-U"%BLEM<QRJ1_LL#0!]$?M(S%?!>EP@\/J 8_A&_\
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M]NG_ +6H ^@**** "BBB@ KX@\=_\E#\2_\ 85NO_1K5]OU\0>._^2A^)?\
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M65<CG R&YXYVKZ5S5J$5&\3>G5DY69[%1117&=(4444 %%%% !1110 4444
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MBBB@#Y@_:._Y*'I__8*C_P#1LM=_^SC_ ,D\U#_L*R?^BHJX#]H[_DH>G_\
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MOC%=3P=11N5R,]4KS_XSXN/AIJ6FQ,IO+QHE@BW %]LJ,V,]@ >?IW(KH/\
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M_:6/Q.MUNV53<V\D$+-T\PX('U(!'XXH ^A?AKX9U'P?X)M=%U.>":>%W8&
MDJH9BV,D#N3VJG\4_ M[X^\.V^G65_#:O!<?:,3(2LA"E0"1T^\>QKNJ* /A
M37="U/PKKDVF:E$UO>V[ _*W![AE(Z@]0:^OOAGXDE\5?#_2]3N6W7>PPW#=
MRZ$J6/UP&_&O OV@=2L[_P"(R16KJ[V=DD$[+VDW.V/P##^7:O5OV?8Y$^&>
MYP=KWTK)],*/Y@T >J4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_[!5U_Z*:OD#P)_R4/PU_V%;7_T:M 'V_1110 4444 %%%% !1110 4444
M%>?_ !M_Y)#KO_;O_P"E$=>@5Y_\;?\ DD.N_P#;O_Z41T > ?!+_DKVA?\
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M(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH ^(/'?_)0_$O\ V%;K_P!&M7U_X$_Y)YX:_P"P5:_^BEKY \=_\E#\2_\
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M**^*])^)?C/0[=+>P\0W:0H,)'(1*JCT <' ]JV%^.'Q! YUQ&]S9P?_ !%
M'UY17R)_PO+X@_\ 0:C_ / .'_XFOHSX7ZYJ'B3X=:5JVJS":]N/.\R0($SM
MF=1P  .%% '7T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'S_P#M-?\ ,K?]O?\ [1H_9E_YFG_MT_\ :U'[37_,K?\
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M:W/?VRX/V>*#R-Q!!PS;F.TC((&#SP1BO9(((;6WCM[>)(H8E"1QQJ%5% P
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MQLL5!\ZU04445Y)Z84444 %? %??]? % 'W_ $444 %%%% !1110!\0>._\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_^TU_S*W_;
MW_[1H_9E_P"9I_[=/_:U'[37_,K?]O?_ +1H_9E_YFG_ +=/_:U 'T!1110
M4444 %?$'CO_ )*'XE_["MU_Z-:OM^OB#QW_ ,E#\2_]A6Z_]&M0!]:>&++^
MTOA+HUAYGE_:="@AW[<[=T &<=^M?/TL4D$SPS1M'+&Q5T<892.""#T-?1G@
M3_DGGAK_ +!5K_Z*6J/BSX?:;XHF^U^:UG?[0IFC4,K@8^^O&2!D @@],Y
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M6/A_2X]/T^+9$G)8\M(W=F/<G_ #  %:%%<<ZDI[LZ8PC'8^8/VCO^2AZ?\
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M'G_0P_\ DE<?_&Z^4-$T34?$>L0:3I-O]HOI]WEQ;U3=M4L>6( X!/)KL/\
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M VD[NQ[5[9\%9+F'X*>)I+*&2:Z6YNC#%$I9G?[/'M  ZG.*W?VAO^2:Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'!^-?A-H/CS68=4U2[U*&>*W6W5;61%4J&9LG<C'.7/?TKF_^&<?!_\ T$M<
M_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\
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M\6O:!8:K#L"W<"RE$D#A&(^9,CJ5.5/3D'I6C72G<\62<79A1110(^(/'?\
MR4/Q+_V%;K_T:U?7_@3_ ))YX:_[!5K_ .BEKY \=_\ )0_$O_85NO\ T:U?
M7_@3_DGGAK_L%6O_ **6@#H**** "BBB@ HHHH **** "BBB@#B/&.I+-=+8
M+",P$,TA'.2,X'M@C/J?ISR]:&NP-;Z[>HY!)E+\>C?,/T-9]4!W7A'4XKBV
M:R\J.*:(;L1I@.H &XGNV>OX5TM</X)!_M.X/EY AP9,'Y>1QZ<_T^M=Q4L
MHHHH **** "BBB@ HHHH *\_^-O_ "2'7?\ MW_]*(Z] KS_ .-O_)(==_[=
M_P#THCH \ ^"7_)7M"_[>/\ TGDKZ_KY ^"7_)7M"_[>/_2>2OK^@ HHHH *
M*** &R1QS1/%*BO&ZE61AD,#U!'<5Y_?_"FSFNFDL=1DM83SY3Q>;M.3T.1Q
MC YR>.IKT*BNG#XNMAVW2E:YA7PM&NDJL;V.0\._#[3M$G%U<2?;KI'#12,F
MQ8\#LN3DYYR?08QC-=?1145\15KRYZKNRJ-"G1CRTU9!7P!7W_7P!6)J??\
M1110 4444 %%%% 'Q!X[_P"2A^)?^PK=?^C6KZ_\"?\ )//#7_8*M?\ T4M?
M('CO_DH?B7_L*W7_ *-:OK_P)_R3SPU_V"K7_P!%+0!T%%%% !1110 4444
M%%%% !7S!^T=_P E#T__ +!4?_HV6OI^OF#]H[_DH>G_ /8*C_\ 1LM '?\
M[./_ "3S4/\ L*R?^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_145>P4 %%%% !1110
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M &Z?^UJ/VFO^96_[>_\ VC1^S+_S-/\ VZ?^UJ /H"BBB@ HHHH *^(/'?\
MR4/Q+_V%;K_T:U?;]?$'CO\ Y*'XE_["MU_Z-:@#Z_\  G_)//#7_8*M?_12
MUT%<_P"!/^2>>&O^P5:_^BEKH* "N+\6?#C3_$UU]NBN&LKYV'FRA3(L@"A0
M"I88(P.1COD'MVE%5&3B[H4HJ2LSR(?"?3]-V7&N^(XH+8R,F JQ;NNW#N<
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MUJ[_ 'A11161\\%%%% !1110 4444 %%%% '/^._^2>>)?\ L%77_HIJ^0/
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M<G)SDY/J%%%%,D^(/'?_ "4/Q+_V%;K_ -&M7U_X$_Y)YX:_[!5K_P"BEKY
M\=_\E#\2_P#85NO_ $:U?7_@3_DGGAK_ +!5K_Z*6@#H**** "BBB@ HHHH
M**** "BBB@#G/&MM:IX;U'5I82\VGV<UPFUMI?8A;:3@\$C\*\(T7XF0:UK6
MCZ7'IDD<U_=QVTK-*"L6]PH9>,OP<D';Z>]>]>._^2>>)?\ L%77_HIJ^0/
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MBHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X K[_KX
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M +"MK_Z-6OK_ ,=_\D\\2_\ 8*NO_135\@>!/^2A^&O^PK:_^C5H ^WZ***
M"BBB@ HHHH **** "BBB@ KS_P"-O_)(==_[=_\ THCKT"O/_C;_ ,DAUW_M
MW_\ 2B.@#P#X)?\ )7M"_P"WC_TGDKZ_KY ^"7_)7M"_[>/_ $GDKZ_H ***
M* "BBB@ HHHH **** "O@"OO^O@"@#[_ **** "BBB@ HHHH ^(/'?\ R4/Q
M+_V%;K_T:U?7_@3_ ))YX:_[!5K_ .BEKY \=_\ )0_$O_85NO\ T:U?7_@3
M_DGGAK_L%6O_ **6@#H**** "O-/%OC^]M]2ET_2"L(MI2LEQM#%R!@J PP
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_P#M-?\
M,K?]O?\ [1H_9E_YFG_MT_\ :U'[37_,K?\ ;W_[1H_9E_YFG_MT_P#:U 'T
M!1110 4444 %?$'CO_DH?B7_ +"MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\ 1K4
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MSNH;B,-M+PR!P#Z9'?D5/2::=F---704444AA7P!7W_7P!0!]_T444 %%%%
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M",(BY))PHX&22?QH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-W&[M@9. #D\ G\*^7_''C"\\9:_+>32.+*-F6S@(VB*//&1D_,0 6.3S[
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M>,=6S7L5%8O$SO<T]A&Q\XZ=X'\2:E=K;II-U!G!:2YC:)%&0,DL.>O09/7
M->M^'OAOH>G:-%;ZOING:K=[C))+<VJ2!20 50LN=HP/J<GC.!V=%*I6E-6'
M"DHZG/\ _"">#_\ H5-#_P#!=#_\36IINDZ;HUNUOI>GVEC SEVCM85B4M@#
M)"@#. !GV%7**Q-0HHHH **** "BBB@ HHHH \?_ &CO^2>:?_V%8_\ T5+7
MS!7W_10!\N_!_P"R?V3J6S_C\\]?-Z_ZO;\GMU\SISZ]J](KTG6-)CU>U6)G
M\MT;<D@7./4?0_T%<<_A?5U=E%L& . PD7!]^37QF<9?B'B95(1<E+MJ;0DK
M6.5\0F,>&=5,JL\8LYMZHVTD;#D X.#[X/TKYLK[8T#PT]K,MY?!/,7.R'KM
M/9L@XSUX^AZUT]>QD6$JX>BW55G)[$3:;T/D#X)?\E>T+_MX_P#2>2OK^BBO
M;("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#X K[_KX K[_H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /CKQ)H<_AOQ%?:/<'<]K*5#X WH>5; )QE2#C/&<5E
MU]=>)?!F@^+("FJV*/,%VI<I\LT?!QAAU +$[3E<]0:YK2O@MX2TR^6ZD6\O
M]F"L5Y*K1@@@@D*JYZ8P<@@G(-<<L/*^FQ]%3S>ER>^G<^:/$6B7EEHFD:M.
MJ+;:BTZV^&RS",J&)'89; [_ "GC&"?6/V:X8KF#Q;!/$DL,BVJ/&ZAE=2)@
M00>H([4?M*0Q6T'A*"")(H8UND2-%"JB@0@  = !VI_[,O\ S-/_ &Z?^UJZ
MH1Y8V/#Q%9UJKJ;7/0]0^#O@Z_OH[I;*:TQ*9)(K:8K'-D@[2#G:O483;@$^
MV.IT/PWH_ANU-OH^GPVB-]\H,N_)(W,<LV-QQDG&<"M2BA0BG=(4Z]6<>64F
MT8GC+_D1O$'_ &#;G_T4U?(-?:TT,5S!)!/$DL,BE'C=0RNI&""#U!':O!?&
M'P3U.WU&2Y\+HEU8RL"MJ\P66'.<C+D!E&!@YW<@8."QQKP<K-'IY5B:=/FA
M-VN>1U])?!&6\D^'H6Z#B&.[E6UW)M!C^4G!Q\PWF3GGG([8'FFB?!7Q3?ZB
M(=4A32[3:6:X:2.8Y[ *C\DGU(&,\YP#]":/I5KH>CVFEV2;;>UB$:9 !;'5
MC@ %B<DG'))-30A).[-<TQ5*=-4X.[+U%%%=1X04444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7."0>" >H-$Z<H;H49QEL6Z***@L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@"OO\ KX K[_H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#VFO\ F5O^WO\ ]HT?
MLR_\S3_VZ?\ M:C]IK_F5O\ M[_]HT?LR_\ ,T_]NG_M:@#Z HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_\ 8*NO_135\@>!/^2A
M^&O^PK:_^C5KZ_\ '?\ R3SQ+_V"KK_T4U?('@3_ )*'X:_["MK_ .C5H ^W
MZ*** "BBB@ HHHH **** "BBB@ KS_XV_P#)(==_[=__ $HCKT"O/_C;_P D
MAUW_ +=__2B.@#P#X)?\E>T+_MX_])Y*^OZ^0/@E_P E>T+_ +>/_2>2OK^@
M HHHH **** "BBB@ HHHH *^ *^_Z^ * /O^BBB@ HHHH **** /B#QW_P E
M#\2_]A6Z_P#1K5]1^"_!?A6Z\"^'KBX\-:--/+IEL\DDEA$S.QB4DDE<DD\Y
MKY<\=_\ )0_$O_85NO\ T:U?7_@3_DGGAK_L%6O_ **6@ _X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH*R-<\2:;X?@WWDV93C;!'@R,">H7(XX/)XX]>*<
M8N3L@*W_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\36;;_$S0
M9IUCD2\@4YS))$"J\=]K$_I781R)-$DL3J\;J&5U.0P/0@]Q53IRA\2L-IHP
M?^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH**@1S_ /P@G@__
M *%30_\ P70__$U\Z?'W2=-T;QU8V^EZ?:6,#:9&[1VL*Q*6\V49(4 9P ,^
MPKZKKY@_:._Y*'I__8*C_P#1LM '?_LX_P#)/-0_["LG_HJ*O8*\?_9Q_P"2
M>:A_V%9/_145>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?/\ ^TU_S*W_ &]_^T:/V9?^9I_[=/\ VM1^TU_S*W_;W_[1H_9E_P"9I_[=
M/_:U 'T!1110 4444 %%%% !7$>*/B9I?A^X-I:Q_P!H7B2%)HT?8L6!SEL$
M$YXP,XP<X(P>LU2]_LW2+V_\OS/LT#S;-V-VU2<9[=*^7I99)YGFFD:261BS
MNYRS$\DDGJ:Z*%)3NV8UJCCHCUVQ^,MK/?0Q7ND-:VSMAYEN/,*#UV[!D>N.
M<>O2O+=8U:ZUS5KC4KPJ9YVRVQ<*    !Z  #UXYS5&BNR%*,'>*.:4Y25F%
M(JJ@PJA1DG &.2<FEJKIE]%K&JG3=/26XNN=B1(6,N!D[0.3@ GZ#/2J<DMR
M4F]BU7KOP79C::PIN-R"2(B#+?(2&RV,8YP!P<_)SVSYAINC:EK$WE:=8SW+
M!E5C&A*H6Z;CT4<'DX'!KW#P5X>M_!?AM[C4I8K:ZGVO=R23#8G)"+DX QN_
M$D\D8K#$27)R]36BGS7.QHK,B\1Z%/,D,.M:=)+(P5$2Z0LQ/   /)K3KA::
MW.R]PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ? %??]? %??] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?/_P"TU_S*W_;W_P"T:/V9?^9I_P"W3_VM1^TU_P RM_V]
M_P#M&C]F7_F:?^W3_P!K4 ?0%%%% !1110 4444 %%%% !1110 4444 %%%%
M '+^)/B)X5\(ZC'8:YJOV2ZDB$RI]GEDRA) .44CJI_*L?\ X7;\//\ H8?_
M "2N/_C=</\ &OX=^*O%WC*SO]#TK[7:QZ>D+/\ :(H\.))"1AV!Z,/SKSC_
M (4E\0_^A>_\G;?_ ..4 >^:KXSL/$^D;-'E%QI=TC+)*T943+DJR[6 .W@@
MY'/TZ\Z+2V"VRBWB"VKJ]N-@Q"R_=*?W2.Q'2H=)T^]TG1K'3]1M6MKRVMXX
MI8F=6*E5 ZJ2"#U'/0]CQ5RF!U ^(^D:-I8N/$MZ+3]X(DD6!W#DJ3T0'GY6
M[ =*K?\ "[?AY_T,/_DE<?\ QNO._&WA'7?%^D06VA6LEU+!.))(A)&B[=K#
M<6<CD'@ 'N>#CCA/^%)?$/\ Z%[_ ,G;?_XY28'T_P"&/&WAWQC]J_L#4/MG
MV79YW[F2/;NSM^^HSG:W3TKH*\?^!?@GQ%X._M[^W]/^Q_:OL_D_OHY-VWS-
MWW&.,;EZ^M>P4 %%%% !1110 4444 %>?_&W_DD.N_\ ;O\ ^E$=>@5Y_P#&
MW_DD.N_]N_\ Z41T > ?!+_DKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U
M_0 4444 %%%% !1110 4444 %? %??\ 7P!0!]_T444 %%%% !1110!\0>._
M^2A^)?\ L*W7_HUJ^O\ P)_R3SPU_P!@JU_]%+7R!X[_ .2A^)?^PK=?^C6K
MZ_\  G_)//#7_8*M?_12T =!1110 5\^:QJ<NL:O<ZA,,-,^0O'RKT5<@#.
M ,]\5]!UX=XL\.3Z#J\X2"06#OF"7:=N#DA,Y/(P1R<G&>]=V!<5)I[EP.?K
MU+X67T\VGW]E(VZ*W='CR22N_=D?3*Y^I/K7EM>P_#[P_<:+I4UQ>(T=Q>,K
M>43RB ';D8X;YCD?3H<UTXQI4K,J>QV%%%%>09!7S!^T=_R4/3_^P5'_ .C9
M:^GZ^8/VCO\ DH>G_P#8*C_]&RT =_\ LX_\D\U#_L*R?^BHJ]@KQ_\ 9Q_Y
M)YJ'_85D_P#145>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?/_P"TU_S*W_;W_P"T:/V9?^9I_P"W3_VM1^TU_P RM_V]_P#M&C]F7_F:
M?^W3_P!K4 ?0%%%% !1110 4444 %?./C'PTOAC7'LXKR*Y@;YH\2*9$'!VR
M*.0<$<XP0<CN!]#7]Y'IVG75],K-%;1/,X098A02<9[\5\P7U]=:G?37M[,T
MUS,VYY&ZD_T'8 < <5U85.[?0Y\0U9(BBC::9(E*AG8*"[A5R?4G  ]SQ7T'
MH'@G3].\)1Z+J,$%X79I9R5)4R,,97/*D+A01@\9X)KYYKV+P#XPL],\$H^O
M:GL2.[>VMMZEVV*B-M 4$D#=U[9 ]!6N(4G%<IG1<4]2E\5/"6A:!\*M>N=,
MTZ.&<B "4LSLH,R [2Q)7(8@XQD'FO&O@E_R5[0O^WC_ -)Y*]>^*7C;0O$/
MPRU?3M-N99;V9HA'!Y#[F"SH21QC!52W7..N#Q7D/P2_Y*]H7_;Q_P"D\E<4
MN:_O'5'E^R?7]?/WQ"\27FL^);NT=FBM+.5H$@60E6*,PWD=-QR><<# YQD_
M0-?-?B[1&T#Q/>V/E>7!YADMP-Q!B8Y7!/)P.">>0>36^%2YG<RKWY3$KVWX
M6>*;C6=/N--OYO-N;3#I+)*6DE1B<YSR=IP,^C*.._B5>N_!O3+B*WU+4I89
M4@GV1P.6(63:6W?+G!P<#./4 _>K?$)<FIC1;Y]#U*BBBO/.T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ *
M^_Z^ *^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_ -IK
M_F5O^WO_ -HT?LR_\S3_ -NG_M:C]IK_ )E;_M[_ /:-'[,O_,T_]NG_ +6H
M ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,U?0[76$4RYCF0
M$)*O7Z'U&>?\,U@+X'D,CAK]!&,;&$9)/KD9X_,UV5% %73].M],MO(ME(3.
MYBS9+' &3^7:K5%% !1110 4444 %%%% !1110 5Y_\ &W_DD.N_]N__ *41
MUZ!7G_QM_P"20Z[_ -N__I1'0!X!\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA
M?]O'_I/)7U_0 4444 %%%% !1110 4444 %? %??]? % 'W_ $444 %%%% !
M1110!\0>._\ DH?B7_L*W7_HUJ^O_ G_ "3SPU_V"K7_ -%+7R!X[_Y*'XE_
M["MU_P"C6KZ_\"?\D\\-?]@JU_\ 12T =!1110 5%<6\%W T%S#'-$V-T<BA
ME.#GD'WJI)KNCPRO%+JMBDB,59&N$!4CJ",\&M"G9K4"C;Z-I=I.L]MIMG#*
MN=LD<"JPR,<$#TJ]110VWN 4444@,;7?%&E^'E47LK&9UW)!$NYV&<9] /J1
MG!QG%?/GQ-@E\?ZY#J\&RSDAM%MA [%PV'=MVX 8^_TP>GOQTWB^^GO_ !5J
M#SMGRIF@0 G"JA*C&>G3)]R:Q*]2EA*?(N;5FBBK'=?L_6%UIO@74+>[A:*4
M:I(<'!R#%%R".#7J]>6_"RXNO[3O+83?Z)Y/F&(L/O[@ P'7ID$CCIGM7J5<
M%:G[.;BB&K,****R$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_\
M[37_ #*W_;W_ .T:/V9?^9I_[=/_ &M1^TU_S*W_ &]_^T:/V9?^9I_[=/\
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M[G#6?PF\,VLQ>87EVI7'ESS84'U^0*<_CCFNVBBC@A2&&-8XHU"HB#"J!P
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MY6)4E5?,9RW"BBBL"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=I7;+2  ,">.N& [DXR3S5U:/LUS19-.KSZ,Y/XJ>$M"T#X5:]<Z9IT<,Y$
M$I9G909D!VEB2N0Q!QC(/->-?!+_ )*]H7_;Q_Z3R5[_ /&W_DD.N_\ ;O\
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M_"KOB)_S]>%O^_EQ_P#$5Q'CKX2^+-%TB]\3:SJ&E30V^P-';RR%@&<( H9
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M*ZMRQ ZC(&,YZ9XR:X^NVCS>S7-N6MCTGX8:-.CSZU(VV)T:WC0J<ORI+9]
M1COSGICGTBN"^'7B6XU%9M*O9)IYXE,T<\C;B4R 5)/.03D=>N.,"N]KR\3S
M>U?,9RW"BBBN<D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***R/%.LCP]X5U35R 3:6SRH#T9@/E'XG
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MT_\ ;I_[6H_::_YE;_M[_P#:-'[,O_,T_P#;I_[6H ^@**** "BBB@ HHHH
MBNK:&]M)K6X3?!/&T<BY(W*PP1D<]#7S!J>G7&D:I<Z?=+MGMY"C<$ XZ$9
M.",$'N"*^I*R=8\,Z-K^PZGI\4[IC;)RK@#/&Y2#CD\9Q6U&K[-Z[&56GS['
MS-7NWP^#>'? \$NMWL%M#<RF6V\^<!51U!5<DX!.&; ]?7->=KXZ^&7@W7YK
M-]$UNYU'2[J2$W+K&X,B,5W >8%X(X.T'@'K6-XE\27GB;5I;RY9DB+?N;?S
M"R0C &!GN=HR1C)YQ70Y*O[JV,4O9:O<]&^,FO:->_"G6K>UU:PGG?R-L<5R
MC,V)XR< '/0&O%[&RBL+-+>(#Y1\S 8W-W-6:3<H<(6&X@D#/) Z_P Q^=73
MHJF[DSJ.:L+77>#_  >OB_3M12*=;:[LV1HY&!*R!PWRMSP 4&"!D9;(;C'(
MUT7@;XL^%_!L6H1WD&J7-S/(H+VL<;1;%!QC<ZG.6;/;IBG6GR1NMQ4H\TM3
MI;;X-ZR]PJW6HV$4!SN>+?(PXXPI50><=Q7K&B:)8^']+CT_3XMD2<ECRTC=
MV8]R?\ ,  5E^"O&NF^/-&FU32X+N&"*X:W9;I%5BP56R-K,,8<=_6NDKAG5
ME/<ZXTXQV"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *IZMJ4.C:-?:I<+(T%E;R7$BQ@%BJ*6(&2!G ]15RLOQ+ILVL^%=7TNW:-9
M[VRFMXVD)"AG0J"< G&3Z&@#S/\ X:.\'_\ 0-US_OQ#_P#':9-^T3X;GMIH
M]/T[51>F)_(^T01^7YFT[=V)<[<XSCFN#_X9Q\8?]!+0_P#O_-_\:J.?X!^,
M-'MI;_S=,O1"A8V]I)(TKCOM#( 3WQG)Q@9/!F5U%V-:"C*K%2VNCE]5UC4=
M<OFO=4O9KNX;/SRMG:,D[5'15R3@# &>!4WA[Q#J/A?6(M3TR;RYX^&4\I(A
MZHP[J<?R(P0#6717G7=[GV3A%QY;:'O"_M&>%D15N=*UF.< >8D<<3*&QR 3
M("1Z' SZ"E_X:.\'_P#0-US_ +\0_P#QVN!;]GKQE>$7#WFC0M( QBDGDW)Q
MT.V,C([X)'H:3_AG'QA_T$M#_P"_\W_QJO2C>VI\7445-J.U]#Z?HHHID!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5>^L+/4[.2SO[2"[M9,;X9XQ(C8((RIX." ?PJQ10!S_\ P@G@_P#Z%30_
M_!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_
M ,31_P ()X/_ .A4T/\ \%T/_P 37044 ><^.O!NEV7A\7>AZ%9VLL,H:=K*
MW6(^5@Y+!0-P!QZXYZ#->75]':C?P:7IUQ?7+8A@0NW(R?0#..2> /4BO M;
MO+*^U:>?3K%;.U9CLC!.3SU(R0"?0<#@>Y^LR&O.5)TG'1=?T/F<ZHPC451/
M5]/U*MG9W.H7D5I:0M-/*VU$7J3_ $'OVKVV'P#X2CACC?PWI$[JH#336,3/
M(0/O,=O)/4GUK@OASJVD:??FVO;4M?7,ZBWNBH;R\KM"#NN3GD9SOYP *]@K
MASZO.554W&R7XG9DM&$:;J)W;_ Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"BO!/:.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH **** "BBB@ HHK/UV1X?#VIRQ.R2):2LKJ<%2$."#V--*[L!Y
MWXT\5Z1?W?V:WTRUOFA8 W<I8 XSE5*$$KD]<X//!X-8FB^(['3-5AN9-!L?
M+5AN*>8SKSG<N]V 8$ ]/;(SFN=HKVXT8QCRFUM+'T59WEOJ%I%=VDJRP2KN
M1UZ'_ ^W:IZXWX9OO\*NOFR/LN77:XX3A3A>3QSGMR3QW/S=XT\:>*K7QUXA
MM[?Q+K,,$6IW*1QQW\JJBB5@  &P !QBO&J0Y)N/8R:LS[#KS_XV_P#)(==_
M[=__ $HCKY@_X3OQA_T->N?^#&;_ .*JO?>+/$FIV<EG?^(-5N[63&^&>]DD
M1L$$94G!P0#^%0(UOAEJG]B_$'3M0";VB2?8,9!8P2*N>1QDC/M7H]Y>7&H7
M<MW=RM+/*VYW;J?\![=J\B\+WD5EXAMI9Y$CB.Y6=P"!D''/;G'/U[9KU:O3
MP*CRM]32&Q>TG5KS1=0CO;*39*O!!Y5U[JP[@_\ U^HKWC2[]-4TJUOH]H6>
M)7*JVX*2.5SZ@Y'X5\\UZ+\$-5EU?PGJL[S-)"FK2QVX).%C$<1  /0')8CU
M8GO4XY1LGU"9R_C'3;C3?%%Z+@+BXE:XC*G(*,Q(^AZC\/3FL*OH'5]%L-<M
M&M[Z!7&TA) !OCSCE3V/ ^N.<BN;C^&&AI*CM/?2*K E&D7#>QPH./H154L9
M!1M+<%-6U,3X6Z;<&^N]4PHMA$;<'/)<E6X'H /U'7G'I]16]O!:0+!;0QPQ
M+G;'&H51DYX ]ZEKAK5/:3<B&[L****R$%%%% !1110 4444 %%%% !1110
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MN_\ *;_]MH P/^&CO&'_ $#=#_[\3?\ QVC_ (:.\8?] W0_^_$W_P =K?\
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MNA_]^)O_ ([1_P -'>,/^@;H?_?B;_X[6_\ \,R_]3=_Y3?_ +;1_P ,R_\
M4W?^4W_[;0!@?\-'>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.UO_ /#,
MO_4W?^4W_P"VT?\ #,O_ %-W_E-_^VT 8'_#1WC#_H&Z'_WXF_\ CM'_  T=
MXP_Z!NA_]^)O_CM;_P#PS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM &!_PT=X
MP_Z!NA_]^)O_ ([1_P -'>,/^@;H?_?B;_X[6_\ \,R_]3=_Y3?_ +;1_P ,
MR_\ 4W?^4W_[;0!@?\-'>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.UO_
M /#,O_4W?^4W_P"VT?\ #,O_ %-W_E-_^VT 8'_#1WC#_H&Z'_WXF_\ CM'_
M  T=XP_Z!NA_]^)O_CM;_P#PS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM &!_
MPT=XP_Z!NA_]^)O_ ([1_P -'>,/^@;H?_?B;_X[6_\ \,R_]3=_Y3?_ +;7
MB&NZ9_8GB'4])\[SOL-W+;>;MV[]CE=V,G&<9QDT >H?\-'>,/\ H&Z'_P!^
M)O\ X[1_PT=XP_Z!NA_]^)O_ ([1X)^!?_"8^$+'7_\ A(_L?VKS/W'V'S-N
MV1D^]Y@SG;GIWK?_ .&9?^IN_P#*;_\ ;: ,#_AH[QA_T#=#_P"_$W_QVC_A
MH[QA_P! W0_^_$W_ ,=K?_X9E_ZF[_RF_P#VVC_AF7_J;O\ RF__ &V@# _X
M:.\8?] W0_\ OQ-_\=H_X:.\8?\ 0-T/_OQ-_P#':W_^&9?^IN_\IO\ ]MH_
MX9E_ZF[_ ,IO_P!MH P/^&CO&'_0-T/_ +\3?_':/^&CO&'_ $#=#_[\3?\
MQVM__AF7_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: ,#_AH[QA_T#=#_P"_$W_Q
MVC_AH[QA_P! W0_^_$W_ ,=K?_X9E_ZF[_RF_P#VVC_AF7_J;O\ RF__ &V@
M# _X:.\8?] W0_\ OQ-_\=H_X:.\8?\ 0-T/_OQ-_P#':W_^&9?^IN_\IO\
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MM &!_P -'>,/^@;H?_?B;_X[1_PT=XP_Z!NA_P#?B;_X[6__ ,,R_P#4W?\
ME-_^VT?\,R_]3=_Y3?\ [;0!@?\ #1WC#_H&Z'_WXF_^.T?\-'>,/^@;H?\
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M;_X[1_PT=XP_Z!NA_P#?B;_X[6__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\
M[;0!@?\ #1WC#_H&Z'_WXF_^.T?\-'>,/^@;H?\ WXF_^.UO_P##,O\ U-W_
M )3?_MM'_#,O_4W?^4W_ .VT 8'_  T=XP_Z!NA_]^)O_CM'_#1WC#_H&Z'_
M -^)O_CM;_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM &!_P -'>,/^@;H
M?_?B;_X[1_PT=XP_Z!NA_P#?B;_X[6__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y
M3?\ [;0!@?\ #1WC#_H&Z'_WXF_^.T?\-'>,/^@;H?\ WXF_^.UO_P##,O\
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M3?\ [;0!@?\ #1WC#_H&Z'_WXF_^.T?\-'>,/^@;H?\ WXF_^.UO_P##,O\
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M^(OC"QU&VO/^$CU6X\B5)?)N+Z9XY-I!VNN[E3C!'<5W'_#1WC#_ *!NA_\
M?B;_ ..UO_\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;7SY[A@?\ #1WC#_H&
MZ'_WXF_^.T?\-'>,/^@;H?\ WXF_^.UO_P##,O\ U-W_ )3?_MM'_#,O_4W?
M^4W_ .VT 8'_  T=XP_Z!NA_]^)O_CM'_#1WC#_H&Z'_ -^)O_CM;_\ PS+_
M -3=_P"4W_[;1_PS+_U-W_E-_P#MM &!_P -'>,/^@;H?_?B;_X[1_PT=XP_
MZ!NA_P#?B;_X[6__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;0!@?\ #1WC
M#_H&Z'_WXF_^.T?\-'>,/^@;H?\ WXF_^.UO_P##,O\ U-W_ )3?_MM'_#,O
M_4W?^4W_ .VT </I7C>SOMPU 164[2?*J!O+P3Q@DD@#I\Q]\]<7;[Q7H]B#
MFZ6=\ A(/GSSCKT_,UU?_#,O_4W?^4W_ .VT?\,R_P#4W?\ E-_^VUUK&U%&
MQ7.SE-,^//B'1;);/3M(T2.!22-\4K.Q]6;S!D^^![ # K/G^+<UU<2W%QX(
M\%33RN7DDDTDLSL3DDDODDGG-=W_ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\
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MN0?<;L?A7B'PQ^"^JZKJMOJOB2RDLM+@82"WG7;)<$<A2IY5?7/7H.N1].T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#&W_DD.N_]N_\
MZ41UX!\$O^2O:%_V\?\ I/)7O_QM_P"20Z[_ -N__I1'7@'P2_Y*]H7_ &\?
M^D\E 'U_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$'CO_DH?
MB7_L*W7_ *-:OM^OB#QW_P E#\2_]A6Z_P#1K4 ?3_P2_P"20Z%_V\?^E$E>
M@5Y_\$O^20Z%_P!O'_I1)7H% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5X_\ M'?\D\T__L*Q_P#HJ6O8*\?_ &CO^2>:?_V%8_\ T5+0!P'[./\
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M._\ DGGB7_L%77_HIJ^0/ G_ "4/PU_V%;7_ -&K0!]OT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\
MDH>G_P#8*C_]&RT =_\ LX_\D\U#_L*R?^BHJ]@KQ_\ 9Q_Y)YJ'_85D_P#1
M45>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM_Y)#KO_ &[_
M /I1'7H%>?\ QM_Y)#KO_;O_ .E$= '@'P2_Y*]H7_;Q_P"D\E?7]?('P2_Y
M*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^WC_ -*)*] K/T31-.\.:/!I.DV_V>Q@W>7%O9]NYBQY8DGDD\FM"@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\?_ &CO^2>:?_V%8_\ T5+7L%8_
MB3PMHWB[3H[#7+/[7:QRB94\UX\. 0#E"#T8_G0!\\?LX_\ )0]0_P"P5)_Z
M-BKZ?KE_#?P[\*^$=1DO]#TK[)=21&%G^T2R90D$C#L1U4?E744 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\ 5]_UY__ ,*2^'G_ $+W_D[<
M?_'*] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#VFO\
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M5M)T;[/?0;O+E^U3/MW*5/#.0>"1R*["@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MES.L]LY!AF&UW3.!(H[J?S'?MD ZZBBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^E;IZ1R'T]&_ T ?05%%% !1110 4444 %%%% !1110 4444 %%%% !7S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKR'QW\=],\-W\NEZ+:#4[V$
ME992^V&-AU&1RQ'?&![UQ-G^TEKR7 -[H>FS09Y2%I(VQ]26'Z4 <_\ 'A9A
M\5;XRYV&"$Q9_N[!_7=7I?PZ^)?AWP_\&K>6\N$6XTTO ]HA'F2NS,R[1_M
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M1KB*4\"[ _D_J._4=P/3=8T73O$&F2Z=JMI'=6DH^:.0?D0>H(]1S0!\6?\
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M)]6]/88'M0!T$"/';QQR2F615 :0@ N0.3@<#/M4E%% !1110 4444 %%%%
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M_P!D?B17!Z/^TEJ(OU&MZ):M9LV&:S+*Z#UPQ(;Z<4 9O[0)\4_\)+$-2_Y
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M_#>LQWMC--9W]JYPP&&4C@J0?R(/XUZ9JO[0?B;4=">PAL[.SN94V27D.[<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=_:N#C."I'(92.W<$5]'_"/XN1^)XHM!UZ94UE%Q#,W NP/Y/[=^HKJ?B/\
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MX_B+=5'H!CW]  =U^T=K4]GX8TO287*)?SN\N#]Y8PIVGVRZG_@(KC?!_P
M[OQ'X6AUB^U<6$EW'YMM (/,^0\JSG<,9'.!V(^E>5:CKFKZPD2:GJE[>K"6
M,8N9VDV9QG&XG&<#\J^M_A/XML_%/@:P$+J+RPA2UNH<\JRK@-CT8#(_$=J
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M%'<0O#-&LD4BE71QE6!X(([BO,-(^!OAW2O&TNN9,UDI$EKI\BY2*3/))_B
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MN>.1FOK2@#G_  ?X/TOP5H<>F:9'_M33L/GF?NS'^0[5T%%% !1110 4444
M%%%% !1110!QGQ4O-=T_X>:G=^'Y/+NHE#2N!\ZP_P 93T8#G/8 ]\5\I^"_
M$\_A/QA8:VA9A#+^_4'F2-N''UP3^.*^W98DFB>*5%>-U*LK#(8'J#7Q7\0_
M";^#/&E]I6UOLV[S;5C_ !0M]WZXY4^ZF@#[1MKB&[M8;FWD62"9!)&Z]&4C
M((_"OD[XR^ Y?"7BJ2^MHC_9&HNTL+ <1N>6C/ISR/8^QKUCX >+O[8\)R:%
M<R9N]*($>3RT#?=_[Y.1[#;7I?B#P_IWB?1;C2=4@$MK.,'LRGLRGL1V- 'Q
M%+K-_/HEOH\L[/96TKS0QMSY;,!NQ[' ./7ZFOKOX2"P_P"%7Z'_ &<$V&#]
M[MZ^;D^9GWW9_2OF7Q_\/-5\!:J8;E6GT^5C]FO%7Y9!Z'^ZWJ/RR*G^'OQ-
MU;P!=.L*"[TR9MTUF[;1G^\I_A;\"#W'3 !]*?$CX?V/CKP_+$T2)JD"%K.Y
MQ@ANNPG^Z>A].M?)?AC4Y]$\5Z7J,!99;:ZC; [C<,C\1D?C7MVN_M'6<NC2
MQ:)I%W'J$B%5EN679$2/O#!)8C\*\M^%_A2Y\6^.K"!8V:TMI5N;N3'"QJ<X
M)]6(P/K[4 ?9E%%% !1110 4444 %%%% !1110 5\G?'2^UZ7X@W%EJTO^AP
M*&L(T!">4W\0'=L@@GU'H!7UC7DWQZ\'?V[X1&M6L>Z]TG+M@<O ?OC\.&^@
M;UH I_L^>+O[4\-S^'+F3-SIIWP9/+0,?_96R/HRUQWQ\\!RZ;K1\5V,1-C>
ML%NPH_U4W3<?9OYY]17G7@+Q1)X/\9:?JZEO)1]ERH_BB;AA[\<CW K[/NK6
MQUS29+>XCBN[&[BPRGE9$8?YYH ^&XM9OX=$N-'2=OL%Q*D[PGD>8H(##T.#
M@^O'H*^F_P!GX6'_  K<&U"?:OM<GVO'WM_\.?;9M_6O&OB=\*[_ ,#7SWEH
MLESH4K?NI\9,)/1)/0^AZ'Z\5@^"/'6K>!-7-[IK*\4@"W%K)]R91Z^A'8]O
MH2" ?7'C#P?I?C30I=,U*(9()AG ^>!^S*?YCN*^+[ZTN_#VOW%HS^7>:?<M
M&70_==&QD'ZC(KWZX_:4TO\ LQFMM!O/[0*_+')(OE!O=AR1^ S[5XGHVEZI
MX_\ &JVR9DO=1N6EGE"\(&;<[GT R3^E 'VCHUZVI:'I]^PVM<VT<Q [%E!_
MK5VHK6VCL[2&UA7;%#&L:#T4# _E4M !1110 4444 %%%% !1110 4444 ?+
MG[06LS7'Q$@LT,D:Z=:H$(R/G8[RP/T*C_@-:>D?M"7UGX)EL[VU-UK\0$=O
M=-C8ZX^_(/[P]OO>W-=7^T1'HJ^%K2:\L)I-4>7R[2ZB7 C'5@[8Q@C.%ZYY
M'0U\RT ?4'P8^)>H>,8;C1=:@DN+NVCW_;5C^21"<;9,<!O3U /<<\5\7_A
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M0VR*WY@9K2M)VNK*"X:"6!I8U<PR@!XR1G:V,\CH:FH **** "BBB@ HHHH
M**** "BLS7_$&F>&-(FU35KI+>UB[GJQ[*H[D^@KYW\2?M#>(;V]=?#\$&G6
M:GY&EC$LK#U;/RCZ <>IH ^FZ@O;VVTZRFO+R>."VA0O)+(<*JCJ2:^=/"O[
M1&KVUY'#XFM8;NS8X:>W39*GOC[K?3CZU[-XGT'2_B9X'^S0W[?9;I5GMKF!
MCC</NDC^(>JG]",@ \A^(?QBTGQ?X(UK1]/2:VE^TQ+$9/\ EYA# EA_=.0/
ME/;'N!J_!WX5^']0\'PZ]KEDE_<7Q?RHY2=D488KT'5B03GZ=.:\,\3>&=3\
M):W-I6JP&*>/E6'*R+V93W!_^L>17LGP)^)-O:01^#]7E6)3(3I\S'"Y8Y,1
M/;))(]22/2@#&^*_P;;PTDFN^'8Y)=(',]ODL]M[@]2GZCOD<CB? 7CW4_ >
MMB\M"9;24A;JT9L+*O\ 1AV/],BOM)E5T9'4,K#!!&017S1\7OA"V@O-XA\/
M0%M*8[KFU09-L?[R_P"Q_P"@_3H ?07ASQ'IGBO18-5TJX$MO*.0>&C;NK#L
M1_GBL#XB?#C3?'^F*DI%MJ4 _P!'O N2O^RP[J?3L>1WSX!\$KWQ1!XVCM]
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M1]IM<Y!!XWIGJI_3H>Q/E7Q@^#YTDS^)/#=N38'+W=G&/]1ZN@_N>H_A^G0
M]W\+>*=+\7Z'#JNE3;X7X=#P\3]U8=B/_KCBGZOX7T37KRQN]4TZ"ZGL9/,M
MWD'W3_4=\'C(!KRKX$> -8T**7Q#J5Q/:)>Q!8K#IO7J'D!Z'T'7D^N*]LH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\Y>OV*[8!OHLG0_1@/K5OX3_  6EM+I==\6VH66)_P#1K!\-A@?OOV/L/QH
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MM;*?GF?T'H!W/;ZX!^1O$'B#6_'OB;[7=^9<WEPXC@MX@2$!/RHB_C^/4\T
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MUG7(=+\-:U?P(N&E=I6:"!/[S*<K]!CFOJC4_"GA[6LG4M$T^Z8]7EMU9O\
MOK&13M!\,Z+X7M)+71=/BLX97\QQ'DEF]R23_A0!?LH)K>RABN+EKJ=$"R7#
MHJF0CJ2%  ^@J>BB@ HHHH **** "BBB@ HZ4=*^=?C!\8/MQG\->&KC_1>4
MO+V,_P"M]40_W?4]^@XZ@'O;/:Z]HTPLM0S!<QO&MU9R@E>JDHPR,@Y_$5\<
M^/? VJ^!M=:TOP9K>4EK:[ ^6=?Z,.X[>X()]*_9W_X2G^T;K[/_ ,BUS]H\
M[.WS<<>5_M=,]L=><5[GXF\,Z9XMT2;2M5@$D$G*L.&C;LRGL1_]8\&@#X8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#TT>G#;K_6^\['F,N?E*?],^GX]>U>S4 %%%% !1110 4444 %%%% !1110
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MW[DX-A'*#YR18Z,?3IM'4#VP  >C4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3(IHIU+0RI(H8J2C @,#@
MCCN""*\W^-7BG7_#/A-6T2UD5;EC%<:@AR;8'I@=06Z!NWU(KPCX:_$V_P#
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M]A"!H,),?V%\!ID)Y=CV?CC' Z<\Y]B\2>%]%^*O@RUFDCD@::(3V5R\6V6
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M?%=L+S495#BT<GRH >Q ^\WKGCVXS7C7PGL[>^^*6@0W(!C%P9,'H61&=?\
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M_N^I[=.O%?6O@W0)_#'A2PT>YU"6_EMX]K32?^@KWVCH,]J -VBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?"6NQ:EILSVUY;L596'##NCKW![C^M>W:1^TI VU-:\/R)_>ELY@W_CC8_\
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M+X:M\7HR]W9QC_7>KH/[_J/XOKU^=H;BXM)&:":2%V5HV*,5)4C#*<=B."*
M/:/C%\7?[9,_AKP[/_Q+@2EW=H?^/@]T4_W/4_Q?3KX[I>I76CZG;ZC9.B75
MNV^)VC5PK=CA@1D=1QUKM_A-\/;7QYKDRW]ZD-E9J))8$<":;)Z*.R^K>X'?
M(^B3\)/ 9MA;GPW:[ ,9#.&_[ZW9_6@#YI3XN>/$F\T>)+HMZ,B$?D5Q73:5
M^T-XNLBJW\%AJ*=R\1C<_BI _P#':],U/]GOP;>9-F^H6#=A%/O4?@X)_6N/
MO_V:KU9 =.\1V\D9/(N+<H5'U4G)_*@#2/C*U^.6C3^%1H-W97WRSQW:LLT-
MLRG[SGY2 1E> 3\U>K>#_!^E^"M#CTS3(_\ :FG8?/,_=F/\AVH\'^#]+\%:
M''IFF1_[4T[#YYG[LQ_D.U=!0 4444 %%%% !1110 4444 %>+?&3XM/H!F\
M,Z#(RZHR@75T./LZL,A5_P!L@@Y[ ^O3VFOGO]HSPILGL/%-O'\LG^B79 _B
M&2C'\-PS[+0!Y[X7^+?B[PJ4C@U%KVT7_EVO<R+CV.=R_@<>U>V>%OC]X:UG
M9!K"2:/='C=(=\)/^^!D?B />OG_ ,#^&K7Q?KXT2;4/L-S<1L;25DW(T@YV
M,.",@'D=QT.:L^*_AIXI\',[ZEIS26BGB\MOWD1^I'*_\" H ^R[6ZM[VV2Y
MM)XIX)!E)8G#*P]01P:E90RE6 ((P0>]?#7A_P 6:]X6N?/T75+BT).61&RC
M_P"\ARI_$5[1X6_:-!V6_BG3,=C=V7\VC)_4'\* ,GXO_" Z,T_B/PY;DZ:2
M7NK1!_Q[^K*/[GJ/X?IT\\\"^.M4\":VM]8MYEO)A;FU9L),O]&'8]OH2#]?
MZ%XHT'Q5:&;1]2MKV/'SHC?,H/\ >0\C\17@OQ<^#DFES2:_X8M6DL9&S<64
M2Y: G^) .J>W\/TZ 'O7ACQ/I?B[1(=5TJ?S().&4\/$W=6'8C_ZXX-;%>5?
M!?X<7O@W3IM3U6>5+^_0!K(/\D2]1N'0O_+)'<UZK0 4444 %%%% !1110 4
M444 %9/B3Q)IGA31)M5U6<16\0P .6D;LJCN3_GBM:O'_CC\/M6\46,&LZ5/
M/<26$9#Z=G(9>I>,?W_4=P!CI@@'AGCOQWJGC[7/M5UF.UC)6TLT.5B4_P V
M/<]_I@5[/\(/A -'6#Q'XCMP=1(#VMHX_P"/?T=A_?\ 0?P_7I\[Z9J-UHVJ
MVVHVC!+JUE66,LH8!@<C(-?6'@_XO:!X@\*7&JZA<Q:?<V,>Z]@=ON]MR=V!
M/ '7)QZ9 .WU?5[#0M*N-3U.Y2WM(%W22/\ R'J3T '6OEGQ;\9_$&L^+;?4
M])N);"RL9";2W!X8="T@Z,2.,= #@=R<WXE?$J_\?:K@;[?2(&/V:USU_P!M
M_5C^G0=R?0_@]\'O,^S^)O$UM\G$EE8R+][TD<>GHOXF@#V/PWJ,GBSP;:7F
MK:0;4WL'[ZSN%#!@>.A_A(Y /.#7DGC3]GE)YI+WPE=)#N)8V-RQVCV1^2/H
MWYU[U7%Z[\4O#'A[Q5:>'[Z[Q<3<2RK@QVQ/W1(>V?TZG H ^:+KX2^.[28Q
M/X;NW(.-T1613^*DBM[P]\!?&&K3H=1BATFU)^9YW#OCV12>?8D5]6 A@"""
M#R".]+0!RW@GP!HG@73S!ID1>XD \^[EYDE/]![#CZGFNIHHH **** "BBB@
M HHHH **** /GCXS?%N6::Z\*:!(\<4;&*^NAE6<C@QKZ+V)[].G7S?X:^#(
M?''BR+3+F^CM;=%,LHW 22J.JQCN?Y#)YQBO>?BS\)H?%]N^L:/&D6NQ+\R]
M%NE'\)]&]#^![$?,$<E]HNJ!T::SO[27@\H\3J?S!!H ^Z=+TNQT73(-.TVV
M2VM(%VQQ(. /ZGN2>37F_P"T!<6$?PV:&Z*&ZENH_LBG[VX'+$?\!W#/N/6L
M_P (?'G2+KPG<3^(Y!!JUE&-T<:_\??8&,?WB>HZ#KTZ>%>,_&6J^/?$1O[S
M.,^7:VL>2L2D\*/4GN>Y_   E^&5C/J'Q,\.Q6X)9+Z.9L=EC.]OT4U]J5Y/
M\&?ABWA&P.M:O'C6;N/:L9_Y=HSSM_WCQGTZ>N?6* "BBB@!I1#()"J[P" V
M.0#U&?P'Y4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\E^-OQ U;PKID6F:3:W$,MZI#ZEL(2,?W4;^_\
MR'3GIZU5>^L;34[.6SOK:*YMI1M>*5 RL/<&@#X]\$?%#Q#X(N MM.;O3V;=
M)97#$H<]2IZJ?<?B#7TWX)^)/A_QS;C[!<>3?*N9+*8@2+ZD?WA[C\<5Y=X\
M_9](\W4/!SYZLVG3/_Z+<_R;\^U>&2Q:CH6J%)$N;#4+9^AW1R1L/R(- 'O?
M[0?@?S[:+Q?8Q?O(0L-\%'5.B2?@?E/L5]*XOX'^./\ A&?%0TJ\EVZ9JC",
MECQ'-T1O8'[I^H/:M[P=\<TNK%]!\=P?:K*>,PM>HF3L(P1(HZC'=>?8]:\I
M\5Z&GA[Q!/:6UTEW8M^]L[J-@RS0G[K COU!]""* /L/Q5X(T#QG9^1K-BLC
MJ,1W"?++%_NM_0Y'M7SGXX^!^O\ ACS+S2@VK:8N26B3]]&/]I!U'NN?<"O:
M_@_XX_X3+P?&EU+NU33\0763RXQ\DG_ @.?<&O0J /@#H:^LO@;IGB'2O BQ
M:VOEV\DGFV,+Y\R.-N3N] 3R!UY/K71W_P .?"FI>([?7KC1X#?POO+*,+(W
M8NHX8@\Y-=50 4444 %%%% !1110 4444 %%%% !7EOQ8^$\'C*U?5M)1(==
MB7Z+=*/X6]&]&_ \8(]2HH ^"O\ 3M&U/_EO9WUI+[I)$ZG\P016WXT\97?C
M:]T^_P!0B5;VWLEM9I$X$I5W8/CL2&&1ZC\*^B/BQ\)X/&5J^K:2B0Z[$OT6
MZ4?PMZ-Z-^!XP1\KW-M/9W4MM<PO#/$Q22.1<,K#@@CL: /7_A5\*]"\>^"[
MR]OY[RWO8;YX4E@<8VB.,@%2"#RQ]*L:S^S?K5ON?1M8M+U1R$N$,+_08W _
MF*VOV<_$>FQ:7?\ AV6X$>HR73744;\"5-B@[3W(VY(].?7'O- 'Q5K/PV\8
MZ#N-_P"'[P1KUEA3SD ]2R9 _&K'P]^'>I>/-9\B(-;Z? P^UW97A!_='JQ]
M/Q-?9M-5%0L54+N.3@8R?6@#/T'0M.\-:/;Z5I=NL%K ,*HZL>[,>Y/<UI44
M4 %%%% !1110 4444 %%%% !7"?$KX:V/CW2]R[+?6(%/V:ZQU_V']5/Y@\C
MN#W=% 'P;JVDWVA:I<:;J5L]O=P-MDC<=/<>H/4$<$5Z%\/_  AX-\?VW]F2
MWMWI'B&-?E57#PW*C^)589W#NN[W'&<>Z_$KX:V/CW2]R[+?6(%/V:ZQU_V'
M]5/Y@\CN#\FWUCJOA;7GMKE)K'4K*4'@[61AR&4C\""* /4]7_9R\1VNYM+U
M.POT'19-T+G\#D?^/5P>K_#?QCH>XWWAZ^"+UDAC\Y!]63(%?0GPG^+$'C*V
M32=6=(==B7Z+=*/XE]&]5_$<9 ]2H ^ 64JQ5@0P."".179_"VP\3WOC:T;P
MO(8;F([IIV!,219Y\SU4^G4GIZCZWU7PUH>N*1JND65YD8W3P*S#Z$C(_"FZ
M!X8T7PM:26NB:?%9PR.9'"9)9O<DD_X4 :HS@9()[X%+110 4444 %%%% !1
M110 445XI\7_ (OC1EG\.>'+@'42"EU=H?\ CW]54_W_ %/\/UZ "_%WXPC1
M/.\.^&YP=2.4NKM#D6_JJ_[?J?X?KT\)\-^$/$/C6^FCT>RENY%^::9F"JI/
M=G8XR>?<U?\  7@+5/'^N?9[?=%9QD-=WC#(C!_FQ[#^E?7GAWPYIGA718=*
MTFW$-M$.>[.W=F/<GU_I0!\6^(_"VL^$]2^P:U8O:SE=R9(977U5AP17TE\!
M/$MUKO@:2RO9&EFTR;R$=CDF(@% 3[?,/H!7)_M(:WITPTC18V2348':>7;R
M848 !3Z;NN/]D>HKRSPS\1/$'@_2+G3]"FAM3<S>;+<>4'D.  %&[( Z]L\T
M ?:9 (((!!Z@U\X?&#X/G2C/XD\-VY-@<O=V<8_U'JZ#^YZC^'Z=,'P_\>O&
M.EWJ-J=Q%JMIGYXI8E1L?[+*!@_7(]J^F/#GB'3O%>@6VKZ;)YEK<+]UA\R'
MH58=B#Q_]:@#XR\*>*]4\':Y%JNE3;9%^62-ON3)W5AW'\NHKZ_\$^-M+\<Z
M&FHZ<^V1<+<6S'YX']#ZCT/?\P/$_C!\'SI1G\2>&[<FP.7N[.,?ZCU=!_<]
M1_#].G._!+1_$U[XSBOM#F-K9VY OIW4F-HSUC(_B)[#MUXQ0!]94444 %%%
M% !1110 4444 %%%9/B3Q)IGA31)M5U6<16\0P .6D;LJCN3_GB@ \2>)-,\
M*:)-JNJSB*WB& !RTC=E4=R?\\5\B>//'VK>/]9\^Z+1V:,1:V2'*QC_ -F8
M]S_(<4WQWX[U7Q_KOVFYW);(2EI9H<K$#_-CQD]_I@5[7\(?A NAI#XB\10!
MM4(#VUJXR+8=F8?W_P#T'Z] #QVX^$WC:UT$ZQ+H<JVRIYC)O4RJOJ8\[A],
M9'I57X<>);KPMXYTR]@D989)E@N4!X>)B P(]NH]P*^R=4U.ST;3+C4=0G2"
MTMT+R2,> !_,]@.YKX<DU*-/$C:I;6R"(79N([=_N@;]P4X[=N* /NZO#OC!
M\'QJ0G\2^&K?%Z,O=V<8_P!=ZN@_O^H_B^O7S.X^-WC^>[,ZZTL*YR(H[6+8
M/;E23^)->M_"SXT?\)5?)H>OQQ0:FX_T>>(;4G(_A(_A;'X'VX! /G'1]8U#
MP]J\&IZ9</;7ENV4=?U!'<'H0:^N?AO\2-/\?:3D;+?5H%'VJTST_P!M/53^
MG0]B>%^,'P?&I"?Q+X:M\7HR]W9QC_7>KH/[_J/XOKU\@^&VC^)=5\9V@\,R
M/;7ENP>2Z(^2!.A+^H/3;WZ4 ?:%%-0,$4.P9\#<0, GZ=J=0 4444 %%%%
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M_P!0]*^E- ^!O@[2])6WU"Q_M2[9?WMS,[+D_P"RJD!1^OO5_P"$FE>&-/\
M!-M-X:E%RMP ;JY< 2O*!RKC^'&>%Z <\YR>NUG6;#0-)N-3U.Y2WM(%W.[?
MH .Y/0#O0!\D_%?P+#X$\5+:V4K26%W%Y]N'.609(*$]\$=?0BO1/V:M3G/]
MO:4S$VZ^5<(.RL<JWY@+_P!\UY9\1/&T_CSQ3)J;QF&VC7R;6$]4C!)&?]HD
MDGZX[5] ? WP1<^%?"\VH:C$8K_5"KF)AAHXE!V CL3N)(]QW% 'J1 (((!!
MZ@U4TS2M/T:S%IIMG#:6X9G\J% J[B<DX%7** "BBB@ HHHH **** "BBB@
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MNT/_ ![^JJ?[_J?X?KT\6\">!-4\?:[]EM<QVR$-=WCC*Q*?YL><#O\ 3)H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMS]"".V:[6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:2WW_=!('4=QD X]0*VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445%<7$%I;O<7,T<,,8W/)(P55'J2>!0!+7S-^T$OBG_A(H6U$YT#_
M )</)SY8;'S;_P#IIU_#IWKUV\^,W@&RG,+Z^DC X)A@ED7_ +Z52#^!J_#K
M?@OXDZ3<Z5#?V>IV\R?O+<DK(!_>"MA@1V..* /E'PAXD_L?QSHVM:D\D\5I
M-&)"QW,(P-G'KM7H/8"OM:UNH+VUBNK65)K>9 \<B'*LI&00:^//B/\ #C4/
M .K;6WW&E3L?LMWCK_L/Z,/UZCN!O_"7XLR^$+A-&UB1Y="E;Y6ZM:,?XAZJ
M>X_$=P0#W;XB?#O3O'VC^5+M@U*!2;6[ Y4_W6]5/IVZBOD;6M%U/POK<NG:
MC"]K>VS]C^3*>X/4$5]T03PW5O'<6\J2PRJ'21&RK*>001U%<IX\^'>D>/K"
M**^W6]W"?W-W$H+H,\K[@^G8\T <W\%?B!J?C'1Y[+5;::2YL%53?A?DF!Z!
MC_?_ )CGZ^IUFZ#H.G>&M'@TK2K=8+6$8"CJQ[LQ[D]S6E0 4444 %%%% !1
M110 4444 %%%% 'E/Q[\*?VYX)&K01[KO26,IP.3"V X_# ;Z*:^;?"\6DW/
MB2RMM<,BZ=<2>5-+$^UHMW <'D<$@G(/&:^Y+B"*ZMI;>>-9(94*.C=&4C!!
M_"OB+QGX<E\)^+M1T63<5MY3Y3'^.,\H?^^2/QS0!WWBSX ^(M&WW&B2+K%H
M.=B#9.H_W3PWX')]*\K9;W2K[#">SO(&Z',<D;#\B#7UM\(O&*>)?A]!+=SJ
M+O35^SW;NV.%'RN2>Q7&3Z@UXG\9?B)I_C'54L=)M;=K.S8C[>8AYLYZ?*V,
MA/;OU]* %\+?'CQ3H6R#4RFLVB\8N#MF ]I!U_X$#7MOA;XQ>$?%&R$7W]GW
MK<?9[W$>3_LM]T_GGVKYT\+?"OQ3XOT2XU72[6/[/&=L?GR>6;@]PF>#CU)
M]^#7,ZOHFJ:#>FSU:PN+.X'\$R%<CU'J/<<4 ?0'Q?\ A -56?Q+X:MQ]NP7
MN[.,?Z_U=!_?]1_%]>M?X)_"N[T^X@\6:UYUM-M)L[0$HV",;Y/J#POXFMGX
M'>&/%&E:1_:.M:G>16,\?^B:7(VX*I_C(/*>P&/4UZ_0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5-3
MLY-0TNZLXKN:TDGB:-;B @/&2,;ESW% '$ZU\8?#&A^,X/#MQ,6R2ES=H08[
M9^RMZ^Y_AXSWQM^/?#O_  F'@34M)@93+/$'MVSP9%(9.?0D 9]#7R1XS\'Z
MMX+UZ73M40L6)>&X&=DZY^\#_,=0:]%^$/Q>;07A\.^(IRVE,0MM=.<FV/\
M=;_8_P#0?IT +WP?^$_B&UUVS\3:G)+I,5LQ:* K^^G&""&!^ZI!(YY/;'!K
MUGXI6VNWGP]U2#P^1]J>/$J $N\/\:I_M$?F,@<D5V"LKHKHP96&00<@BEH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%'2@ JA=ZYI%A.(+S5;&VF/2.:X1&/X$YKP[XJ?&V199M"\)7.T+E
M+C4HSR3W6(_^S?EZUX%)))-*TLKL\CDLS,<EB>Y- 'WVCI(BO&RNC#(93D$4
MZOC/P#\2-8\"ZG&T,TD^ELW^D6+ME&'<K_=;W'XYK["TW4+;5M,M=1LY!);7
M,2RQ..ZL,B@#P#]HOPIY&H6/BFWC^2X M;H@?Q@91C]5!'_ 163\ ?&*:)XC
MN=#O9UCLM00NC2-A8Y4!.<G@ KD?4+7T#XS\.1>+/".HZ++M#7$1\IC_  2#
ME&_!@/PS7Q%<02VMS+;SQM'-$Y21&ZJP."#^- 'KGQ=^+K^)I9=!T&9DT9#B
M:=>#=D?R3V[]369\+_A)<^.&;4=2::ST1,J)4P'G;IA,@C /4X]O7#_A/\*9
MO&ET-5U16BT*!\'!PURPZHOHOJ?P'/(^JK6U@LK6*UM84A@B4)''&N%51P !
MV% 'S'XK_9_\0Z1ON-#F35[4<^6!Y<ZC_=)PWX')]*Z3X0_!MX98?$?BFT9)
M$.ZTL)EP5(Z/(#^BGZFO?:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#D$ CK[U9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-;>+->22&5?GL;4DJPR/]8_X'A?Q->]T %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (0"
M"" 0>H-?.'Q@^#YTHS^)/#=N38'+W=G&/]1ZN@_N>H_A^G3Z0I" 000"#U!H
M ^&_"_BK5O!^LIJFD7'ES ;71AE)5_NL.X_R*LZ?IWB+XC^+62(R7VIW;F26
M:0X5!W9CT51P/R '05Z9\8/@^=*,_B3PW;DV!R]W9QC_ %'JZ#^YZC^'Z=/+
M/"GBO5/!VN1:KI4VV1?EDC;[DR=U8=Q_+J* /;;?]FJQ^Q*+GQ'<&Z(^9HK=
M=@/L"<G\Q6)J?[-NM0Y.F:[8W0'07$;0D_ENKVWP3XVTOQSH::CIS[9%PMQ;
M,?G@?T/J/0]_S Z2@#X[U/X-^.]+W,VA27,8_CM9%ES_ ,!!W?I7L7PB^$2>
M&XXM?U^%7UAQN@@;D6H/<_[?\OK7L5% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?/?QA^,%TE[/X:\-7$UM]GDV7=[&2CEP>40]
M0 >I[]!QU^A*\L^+'PG@\96SZMI*)#KL2\CHMTH_A;T;T;\#Q@@ \5TCXV>.
MM)VJ=56^B7^"]B$F?JPPWZUWND?M*?=36O#W^]+93?R1O_BJ\%N;:>SN9;:Y
MB>&>)BDD<BX96'!!!Z&NM\)?#R[\;V4S:)J=BVH0<RV%RQCDV]F0X(8?E@]>
MV0#Z*TCXV^!=6VJVJ/8RM_!>Q%,?5AE?UKS;XI?#+3]2AG\6>");:[@YDO+2
MSD611W,B;?U7\17G.K_#'QIHFXWGAZ\*+UDMU\Y<>N4SC\:YF*:ZT^ZWPR36
MUPAQN1BCJ?PY% &YX+\::IX'UQ-1TY]R-A;BW8_).GH??T/;\P?K_P )>+=+
M\9Z'%JFER[D;Y98F^_"_=6'K_/K7P\[L[L[L69CDL3DDUTG@?QAJ_@SQ#%>Z
M26E\PB.:TY*W"Y^Z0._H>H/X@@'VN\4<N/,C5\=-PSBGU7L;B2[T^WN9;:6U
MDEC5V@EQOC)&=IQQD=*L4 %%%% !1110 4444 %%%% $<\\5M;R3SR)%#&I=
MY';"JH&22>PKYZ\>?M 7DMS+8>#PL-NA*G4)4#/)[HIX4>Y!)]!5G]H3QO,D
ML/A"QE*(46>^*G[V?N1GVXW'ZK7%?"KX5R^/+B6^OY9+;1K=]CO'C?,_78N>
MF 1D^X_  YB7X@>,9I_.?Q3K ?.?EO9%'Y XKW/X&>+/&?BB2]_M>Z6[TBU4
M(+B:/]Z93T4,,9XR3G)Z>M=1)\$O $EE]F&BE#C F6YEW@^N2V/TQ[5U/A?P
MUI_A+0+;1M,5A;P@_,Y!>1B<EF(ZDT )XH\+Z7XNT.;2M5@\R%^4<</$_9E/
M8C_ZQXKY!\<^!M4\":XUC?+YEN^6MKI1A)D_H1W';Z8)^UZQO%'A?2_%VAS:
M5JL'F0ORCCAXG[,I[$?_ %CQ0!\P_!WQUIO@KQ'+_:EI&;:] B:]"YDM^?\
MT ]P.> ><8KZTAFBN((YH9$DBD4.CH<JRGD$$=17Q7XY\#:IX$UQK&^7S+=\
MM;72C"3)_0CN.WTP3V7PD^+<OA2>/1-;E>31)&Q'(>6M&/<>J>H[=1W! /J6
MJEYI>GZ@5-[8VUR4(*^="K[2.A&15E'61%=&#(P!5@<@CUIU !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>img40748725_36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_36.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7_"6\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEC[K%,\9_,[OY4 ?1]%<CX'^(VA^/+5VTZ1X;R(9FLY\"1!ZC'#+[C\<5UU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/\ ^T=XGG273?#$
M$K+$\?VRZ"G[_)5 ?8;6./\ =/:OH"HWMX96W20QNW3+*#0!XS\$/AQI47AB
M#Q)JME#=7]Z2]N)T#"",' (!XW'!.?0CISGU;5/#>BZU9-9ZEI=I<P,"-KQ#
MCW!Z@^XYK35510JJ%4= !@"FRRQP0O--(D<2*6=W8!5 ZDD]!0!\9^)].NOA
MK\3;B#3+B19-.N%FM96ZE" Z@^O!VGL>?I7V+IE]'JFDV>H0_P"JNH$G3G/#
M*&'\Z^0?'FHOX^^*=[)HR/<BZG2VM%4??"@("/8D%N>QYQ7UWHVG)I&AZ?ID
M9REG;1VZGU"*%'\J /,OCYXOET'PE#H]G*8[K5F9'9>JP*!O^F25'T+5R/P*
M^&NGZK9OXIUNT2YC$ACLH)5W1G;PTA'1N<@ ]""?0C _:%U!KKXC1VNX[+2R
MC0+VRQ9B?R8?E7OOPTLH[#X:>'(8U"JUA',0/60;S^K&@#4U;PQH>N::^GZC
MI=K/;,NW:8P"ONI'*GW&#7RAXATW4/A-\3_]!E<_9)5N+21CCS86_A;'MN0^
MN#7V+7SM^TM91QZIX>OPJ^9-#-"Q[D(RD?\ HP_G0![YI&IV^M:-9:I:DF"[
M@2://7# '!]^:\I_:!\7S:/X;MM LY"D^J;O/93R(%QD?\") ^@8=ZW/@7?M
M??"S3T=BS6LLL&3Z!RP'X!@*\7^/NHF\^*$]N2<65K# !]5\S_VI0!U_P*^&
MVG7VE?\ "5:U:1W1DD9+*&50R*%."Y!X)W @9Z;<_3VC6/"NA:_ISV&I:7:S
MP,NT Q@%/=6'*GW%5O EB--\ :!:@ %+"$MCIN* M^I-=#0!\<ZI;:C\(_B@
M1:2R,;&99(6)Q]H@;G:WU7*GWSCI7U[IU_!JFF6NH6K;[>ZA6:-O56 (_0U\
M\?M)V*1^(M$OP,//:O"Q]=C9'_HPUZC\%=0?4/A5I!D.7@\R GV5V"_^.XH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ) >G_\ 7M'_ .@BKU9?AJX6\\*Z1<IC;-90R#'H4!K4H \ _::Z>%_^WO\
M]HUU7[/A)^&9R>E]+C\EKD/VF)@USX:@XRB7+G\3&/\ V6NV^ =L8/A=;R'.
M)[J:09]FV_\ LM 'IU8<_@OPK=7$MQ<>&M&FGE<O)))81,SL3DDDKDDGO6Y1
M0!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@
MG@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!\X?M#Z#H^B?\(Y
M_9.E6-AYWVGS/LEND6_'E8SM SC)_,UY?X$_Y*%X:_["MK_Z-6O8/VFNGA?_
M +>__:->/^!/^2A>&O\ L*VO_HU: /M^BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP3XM?$
MGQGX,\;R6&GW<,>GS01S6X>V1N"-K<D<_,K?G7O=</\ $WX=6WQ T2.)95MM
M2M27M;@C(YZHW^R<#IR" ?4$ VO!?B!/$_@[2]765)))[=?/V_PR@8<>V&!K
M>KY)L+WXB?!V^N(A9S16K-ND2:(RVLIZ;@PX!P!R"#TS6Q<?M#^+[VW%M9Z=
MIL%RXV^9%$[MGU52Q&?J#0!T7[26NVYM]'T"-E:X$C7<H!Y1<%5S]<M^5=!^
MSQI,UCX!N+Z92HO[QGB]T4!<_P#?0;\J\V\(_";Q1X[UUM8\4"[M+.63S+B>
MZ&V>?V13R/J0 !TSTKZ=L+&VTS3[>QLH5AMK>,1Q1KT50, 4 > ?M):$R7VC
M^((T^22-K.5AV*DNGY@O_P!\UWWP.\01:U\-[2U\P&ZTUC;2KW"Y)0_3:0/J
M#78>*_#5CXN\.7>BZ@#Y4Z_+(OWHW'*N/<'\^1T-?,,FD^._@UXAEO+6*00<
MJ;E(S);7"=MWI]#@CM0!];U\K_'_ ,01:OX]33[>17BTR 0N1_SU8[F_(;1]
M0:FOOV@/&6K6@L;"RL;6YE&PRVT3O(3_ + +$#OV-:GPK^#^J7VM0^(_%=O+
M!;PR>?%;7&1+<29R&<'D+GG!Y)[8Z@'L_P .]!;PUX T;2Y$*3QVX>93U$CD
MNP/T+$?A7C'[2&A-#KFE:]&A\JY@-K(1T#H2PS[D,?\ OFOHZL+QAX5L?&7A
MJYT:^&U9!NBE R89!]UQ]/U!([T <W\%_$$6N_#73HPZFXT]?LDR \KM^Y^:
M;?UKT&OD867CSX,Z_-<PP2)"1M:8(9+6Y3/&XCH?KAAGWYU=0^/?C36[0:=I
M]I9VEQ,-ADLXG:4G_8!8X[]B?>@"G\==?CU[XCO:6K^;%IL2V@V'(:3)9\>X
M+;3[K7TAX&T,^&_ ^CZ2Z!);>V7SE'02-\S_ /CQ->+_  E^#^I/K$'B7Q3;
M26\4#B6WM)Q^\EDZAW!Y4 \X/)(YXZ_1% !1110 4444 %%%% '@'[373PO_
M -O?_M&O'_ G_)0O#7_85M?_ $:M>P?M-=/"_P#V]_\ M&O'_ G_ "4+PU_V
M%;7_ -&K0!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4<<$,3;HXHT.,950*DHH
M**** "BBB@"-((HF+1Q(A/4JH%2444 %%%% !4<<$41)CB1">NU0*DHH ***
M* "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_:
M:Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M/VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/^!/^
M2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/
M^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_:
M:Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HJ.:X@MUW3S1Q+ZNP4?K1%/#<+NAECD7U1@1^E%A<RO8DHHH
MH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"__ &]_^T:\?\"?
M\E"\-?\ 85M?_1JU[!^TUT\+_P#;W_[1KQ_P)_R4+PU_V%;7_P!&K0!]OT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5P/C+QN]C,^FZ4X\]>)9QSL/]T>_OVKK]:O
M3IVB7EVIP\43%3_M8X_7%>".[2.SNQ9F.22>2:Z\+24WS2Z'AYSCIT(JE3=F
M^OD.GGFN96EGE>61CDL[$D_B:6WN9[699;>:2*1>C(Q!%145Z5NA\GS.][ZG
MJ?@WQLVIRKINID?:B/W4W02>Q]_Y_P ^YKYVBE>"9)HF*R(P96'4$=#7O^FW
M?V[2[6[Q@S1+(1Z9&:\W%4E!\T>I];DV-G7@Z=1W<>OD6J***Y#VPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** / /VFNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU
M:]@_::Z>%_\ M[_]HUX_X$_Y*%X:_P"PK:_^C5H ^WZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *KWM]:Z=:/=7DR0P)C=(YX&3@?J15BO(?B[XA\VZ@T&!_EAQ-<8_O$?*OX
M Y_$>E73ASRL1.7*KGKU%<=\-_$/]N>&8XI7W7=EB&3)Y*_PM^(X^H-=C2E%
MQ=F5%W5T%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO$UJU[X:U"!1EC"6 '<CG^E>$=*^C*\E\:>$)M,NI-0LHB]C(=S!1
M_J2>W^[Z'\/KVX2HE>#/GL\PDYI5H*]M&<;1117H'RX=3BO?=$MGL]#L;>08
MDC@16'O@9_6O.O!'A"6\NHM4OXBEK&0\2-P9#V./3^=>J5YV+J*345T/JLCP
MDZ<76FK7V] HHHKC/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ _::Z>%_\
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M_$/]N>&8XI7W7=EB&3)Y*_PM^(X^H-1B8?:15"?V3L:***XSI"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CJ,&BB@#"O/!N@7LAD
MDTZ-7/>)BGZ XI;+P?H-C*)8M.C:0=&D)?\ 0G%;E%7[2=K7.?ZK0YN;D5_1
M!1114'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"__;W_ .T:
M\?\  G_)0O#7_85M?_1JU[!^TUT\+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!
M]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5'6=4AT71[K4;C_ %<"%L9^\>P_$X'XU>K!\97]CIGA
MB[NK^W@N548BAG0.KR'[O!Z\\_0&G%7:0I.RN?.U]>S:C?SWMRVZ:=S(Y]R:
MKTK'<Q; &3G@8%6-/NELM0M[EX(IUB<,T4JAE<9Y!![&O6V6AYY6KI_ 7B'_
M (1[Q-!+*^VTG_<SY/ 4]&_ X/TS7JVI?\(CI_A7^WQH6F2P-&KQ)]EC!<MT
M7IP?7TP?2M/3M%\+ZIIUO?6VB:6T,Z!U/V2/H>QXZURRKIQU6AO&DT]&;]%(
MJJBA5 "@8  X I:XCJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/
M^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 > ?M-=/"__;W_ .T:\?\  G_)0O#7_85M?_1JU[!^TUT\
M+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!]OT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11574M0@TK3
M;B_N6VPP1EV]\=A[GI1N!YG\7?$6%@T&W?DXFN<'_OE3_/\ *O)JN:KJ4^KZ
MK<ZA<MF6>0N?;T ]@.*IUZE.')&QP3ES2N%%%*JL[!5!9B<  9)-60>M?"+Q
M#NBGT&=^4S-;9/;^)?SY_$UZI7SGI.D^)]'U:VU"VT/5!+ X<#[))R.X/'0C
M(_&OHBWF^T6T4WEO'YB!MDBX9<C.".QK@Q$4I774[*,FXV9)1117.;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"_\ V]_^T:\?\"?\E"\-
M?]A6U_\ 1JU[!^TUT\+_ /;W_P"T:\?\"?\ )0O#7_85M?\ T:M 'V_1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5-2TRSU>R>SOX?.MW(+(6(S@Y'0BK=%%[ <O\ \*Z\)_\ 0'3_
M +^R?_%4?\*Z\)_] =/^_LG_ ,57445?M)]R>2/8Y?\ X5UX3_Z Z?\ ?V3_
M .*H_P"%=^$_^@.G_?V3_P"*KJ**/:3[AR1["*H50HZ 8%+114%!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '@'[373PO_P!O?_M&O'_ G_)0
MO#7_ &%;7_T:M>P?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JT ?;]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 > ?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JU[!^TUT\+
M_P#;W_[1KQ_P)_R4+PU_V%;7_P!&K0!]OT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F1G&>?
M2H[FXBM+:6YG<)#$A=V/90,DUXWX8\=2R?$2>[NG*VFIN(2I/$8'$?Y=/Q)K
M2%-R3:Z$2FHM)GM-%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4U71Q,BWL:^:CRE@&&<CZ@Y&:RQ-N74TH7YCKJ***X3K"BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>+)7A\*ZDZ9
MW>25X]#P?T->&5]!ZA9K?Z=<VC' FC9,^F1UKP.\M)K&[EM;A"DL3%6!]17H
M8)JS1\OQ!"7/"?2UB"BBBNT^>"O>O#TC2^'--=R2QMDR3W^4<UX=I]C-J5_#
M9VZ[I96"CV]S[5[[:6R6=G!;1_<AC6-?H!BN'&M62/H^'X2YISZ;$U%%%<!]
M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?+)964AC2-!WDDXS]6.,XP.@H ^KZ*^6;WX4?$[P_9MJ=K>2S21KO9;"^<S
M=3@<$GV7)KIOA3\:+^ZU>#P]XJF$WVAO+MKY@%=9#P$?'4'H#USUSG( /H"B
MBLCQ/XCL?"?AZ[UG46(@MUSM7[TC'A57W)XH UZ*^3[CQA\0_BKK[66D2W,4
M1.Y;6SD,44*>KOD9^K'D]!T%6;_X5_$[PU9MJ5K>32M&-S#3KYS*H'H."?\
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MG/?C\JZBF12I/"DL3AXW4,K*<@@]#3Z\N4G)W9WI)*R"BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?%/@ZW\0+]HB807RK@28^5
MQV#?X_SKIJ*J,W!WB95J-.M!PJ*Z/#[WP?KUE(5?39I1V:!?,!_[YS2V/@[7
MKZ0*NG2PKGEYQY8'OSS^5>WT5U?7)VV/'_L"AS7YG;Y'.^%_"5MX=B,A837K
MC#RXX ]%]OYUT5%%<LI.3NSV:-&%&"A35D@HHHJ30**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *BENK>!@LL\4;'H'< FI:^?=2MO^$N_:=CL[SY[730A"8XQ&F\
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M;6VMZ)JL4:K/>0RQ2D?Q>64VD^^'QGV'I7HOP*U&6_\ A=9),Q8VDTMNI/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_;O_ .B(Z^J?"_\ R*.B_P#7C!_Z+6OFO]H*Q:U^)7V@J0MW9Q2!NQ(RA_\
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M-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]4\9>&]$O39ZIK=
MC9W(4,8II@K8/0X-;E>?>,/@]X?\:Z\VL:E>:G%<&-8MMM+&J87IPR$YY]:
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M .*^#O\ P@NC2'7_ !-J]LNI1R$6EK(CL(0/^6APN"V>GIUZ]/;?^%N^ O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** / /VFNGA?_M[_P#:->/^!/\ DH7AK_L*VO\ Z-6O8/VF
MNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU: /M^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Q\>^$O$
MOBC7%DMHX/L,"!( TV"2>68CUSQ] *].HJX3<'=$RBI*S/G/7?!.K^'+%;O4
M1;I&SA%"R[B3UZ?A7.5Z5\2H]>UWQ#Y%KH^HR65F-D;):N5=C]Y@<?0?A7%_
M\(OXA_Z 6I_^ DG^%>A3G>-Y,XYQL[(R:U_#&MR>'O$%KJ"9*(V)5'\2'AA^
M7ZXI/^$7\0_] +4__ 23_"C_ (1?Q#_T M3_ / 23_"J;BU9LE)IW/I:&:.X
M@CGA</%(H=&7HP(R#3ZXGX9W&J#0'T[5;"\MGM& B>XA9-Z') !;K@Y_ BNV
MKS)1Y6T=\7=7"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/?B*
MR7Q]^T9'HFH,SZ;IZ -%DX*J@=A_P)B ?:OH2O /%MR/A_\ M V?B.[5ETS4
MHP)) . "OEO^1"L?8T >^0PQ6\$<$$:1Q1J%1$&%4#@ #L*\+^''_)P?C#_=
MG_\ 1J5[I#-%<01SP2))%(H9'0Y5@>00>XKPOX<?\G!^,/\ =G_]&I0![O7@
M_B9%\/\ [3&B7EMA?[22/SAZE@T1_0 _6O=V944LS!549))P *^=AJ:?$+]H
MVQGT[][I^F, )5Z,D626SZ%S@>N10!]%4444 %%%% !1110 5ROQ"UO7/#_A
M.6_\/6'V[4%E15A\AY<J3R=JD&NJHH ^0Y;KX@KXE;7]+\,:AHU_)S*=.TZ9
M$E/7+(VY3[C&#U(S77P?%/XO10K&_A:29E&#))I$X9O<[2!^0KZ-J*6ZMX"!
M-/%&3T#N!_.@#Y[_ .%K_%O_ *%#_P I-Q_\51_PM?XM_P#0H?\ E)N/_BJ^
MAHIHIUW12)(OJC BGT 9^A75W?>'].N[^'R+R:VCDGBV%=CE06&#R,'L:T**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#P#]IKIX7_P"WO_VC7C_@3_DH7AK_ +"MK_Z-6O8/VFNGA?\
M[>__ &C7C_@3_DH7AK_L*VO_ *-6@#[?HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:#;3 K)]E$C ]1O);'_CU=;2 !5"J  !@ =J6@ HHHH **** "BBB@ HHHH
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MO,::=F=Z=U=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"MK_ .C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHF5&69;AH2%!^8;EYH ZJBOD"*X^(]]XCDT+2/%&KZO=Q\.UCJ<SQ+ZY<D#
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M!P0A!+8^H&/QKTNO)_VA-+DOOAY'=Q(S?8KM)7QV4@J3^9% '2_"[PI:>%?
M^GQ10JMW=0I<74N/F=V&<'V . *[.N2^&OB.V\3^ ]+NX)%,L4*V]P@.2DB
M @_7&1[$5UM !7CWQQ\/FTT^T\;Z2?LNKZ9,F^>/@NA.!GUP2/P)%>PUY7\?
M->M=-^'LFF.P-UJ4B)$F>=JL&9OH, ?B* .^\,:TGB+POINKH !=VZR$#LV/
MF'X'(KQWX^^$H;%++QIIB?9[V.X2.Y:/C<>J2?[P(QGW'I7I'PKLIM/^&.@P
M3J5D-MYA![!B6'Z$5C?':2)/A5?K)U>:%4]VW@_R!H [/POJ_P#;WA;2]5XS
M=VR2MCLQ'/ZYK6KCOA4CQ_"[P\)"2?LH//H22/T(KL: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFNGA?_M[
M_P#:->/^!/\ DH7AK_L*VO\ Z-6O8/VFNGA?_M[_ /:->/\ @3_DH7AK_L*V
MO_HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH @N[.VO[5[:[@CG@?&Z.1<@X.1Q]17*>*-(\,:
M%X=N]0ET6Q)C7$:^4!N<\*/SZ^V:[*O'OB[XA\^]@T*!_P!W!B6?'=R/E'X
MY_'VK6BG*22,ZC2C<\R)R2?7TI***](X0H!P<T44 ?2GA'6XO$'ANTO4VB3;
MY<R+_"Z\$8[>H]B*VZ\0^%7B+^S==;2YWQ;7V F3PLHZ?GT^N*]OKS:L.25C
MNIRYHW"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\B^(GP[\
M;^)?%3:CH'B&&QL3"B"%KV:([AG)VHI% 'KM%?.W_"F_BE_T.%O_ .#.Y_\
MB*/^%-_%+_H<+?\ \&=S_P#$4 >_ZAJ5EI-E)>:A=PVMM&,O+,X51^)KYYM-
M9_X69^T)I]]IT;MINGD%)"I'[N/)WGTW.>/J.]2P?L\>)=2NO-U[Q-:^\D?F
M7#G_ +[V_P Z]C\%> M$\":>]MI43--+@SW4IS)*1TR>P'8#C\>: .HHHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X!^TUT\+_]O?\
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M/AF":1]UU!^YGSU+#HWXC!^N:C$P^TBJ$_LG34445R'2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\=1_\%MO_P#$4?V]\>_^>.H_^"VW_P#B* /I.BOFS^WOCW_SQU'_ ,%MO_\
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M?^ <W_Q- 'HE%5["^M]2T^WOK1_,M[B-98GP1N5AD'!Y'%6* "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ _::Z>%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXE>.F\ >'8=2CLEO));A81&TA0<@DG.#Z4 =G169X<U*XUCPYI^IW4"6\UW
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MHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** / /VFNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU:]@_::Z>%_\
MM[_]HUX_X$_Y*%X:_P"PK:_^C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK*\2:U'X?T"[U
M*3!:),1J?XG/"C\_TS32N[(3=E<\K^+/B'[=J\>C0/F"S^:7!X:4C^@_4FO.
M:DGGENKB2XF<O+*Q=V/4DG)-1UZD(\L4C@E+F=PKHO!/B ^'?$UO=.V+:3]U
M<#_8/?\  X/X5SM%.24E9B3L[H^K@0P!!R#R"*6N)^&7B'^V?#:VDSYNK'$3
M9ZE/X3^0Q^'O7;5Y<HN+LST(RYE=!1114C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,;VX>VN9"8HU;#SX..O\*#& !Z<8[^RV/PR\$:?"L4/AC375>AGA$S?F^2:
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MVUMN*B9AU9B.=H/&.Y!SP.?8-8^$?@G5].>T_L.VLW*X2>S41R(?7(X/XY%
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M%4J.I*[/H<)A*>%I\D/^'"BBBLSI"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO)OC-\1+WPW!
M;>'M!9AK.H#F2,$O$A.T;1_>8Y [C'KB@#N/$'COPOX78IK&M6UM*.3""7D'
M_ %!;]*YC_A>O@'=C^U)\9Z_9),?RKCO"O[/<5S;KJ'C#4;J2\F_>/:V[@;2
M>2'<@ECZXQSW-=K_ ,*.^'VS;_8LF?[WVR;/_H>* .B\/^//"_BEMFC:U;7$
MO_/$DQR'Z(X#$>^*Z*O#?$_[/5HL+7OA'4;FVOHSOC@N),J2.@5P 5/N<_AU
MK7^#_P 0M1UF:Z\*>)0ZZWIX.UY1AY54X(8?WE]>XY[$D ];HHHH **** "B
MBB@ HHHH \5\=_ S[?J;:WX/NDTZ^+&1K9F*(7SG=&PY0^W3Z5RZWOQW\/JM
MLT6H7*+P"88KLGW+@,Q_$U[WK'BG0/#^!J^L65DY7<(YIE5V'J%ZG\!7/'XP
M^  2/^$C@X_Z8R__ !- 'D<EK\<O&$9M+DWUK:N<.7\NS !ZYV[68>W->A?#
M;X-67@RX35M3G6_UD [&4?NH,]=N>2?]H_D*VO\ A<7@#_H8X?\ OS+_ /$T
M?\+B\ ?]#'#_ -^9?_B: .XHJ"RO+?4;&"]M)!);SQK)$X!&Y2,@X//2IZ "
MBBB@ HHHH *J:GIUMJ^EW6G7J&2UNHFBE0,5RK#!&1R*MT4 <+8_!SP#82"2
M/P_%*X[W$TDH_P"^68C]*\4_:$M+:Q\<Z7:VEO%;V\>D1JD4*!$4>;+P .!7
MU+7S!^T=_P E"T__ +!4?_HV6@#VGX1?\DJT#_K@W_H;5VU<3\(O^25:!_UP
M;_T-J[:@#Y>_:)U-KKQ]:V(;]W9V2C;Z.[%B?RV_E7N?PMTY-,^&/AZ"-<"2
MS6X/N9/WA_\ 0J^</C>[/\7=:5F)""!5'H/(C/\ ,FOJ;PHJIX/T1$4*JV$
M  P /+6@#7KYQ_:4TY(M=T+4@N'N+:2!CZB-@1_Z,-?1U>$_M+JITSP\Y4;A
M-. <<@$)G^0_*@#M/@GJ3:E\*]+$C;I+8R6Y.>RN=H_[Y*BO%_V@M3-[\2/L
M88E+&TCBVYX#-ER?R9?RKTS]G-V?X=WJLQ(35) H]!Y41_F37C/QE8O\6M>+
M')WQ#\!$@H ^GOAWIRZ5\.O#]HJ!"+&.1U']]QO;_P >8UTU4=$ 70=.50 !
M;1@ =OE%7J /FK]I'3E@\5Z3J*C!N;,Q-[E&)S^3C\J];^#NI-JGPLT61SEX
M(VMSST",57_QT+7G/[30&?"YP,G[4,_]^:ZS]GUV;X9X)R%O90OL,*?ZF@#U
M2OB#QW_R4/Q+_P!A6Z_]&M7V_7#W_P (/ FIZC<W]YH7F75U*TTS_:YQN=B2
MQP'P,DGI0!\<45]?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4
M?(%%?7__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE 'R!70>!/\
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M_+K]0*^DHY$EC62-@R. RL#D$'O6?_PCVB?] ?3_ /P&3_"M!$2*-8XU5$4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%KN/!E_::GX+T:[L64V[6<84 YVD* 5^H((_"MV@#RS_ (9^\$?W=1_\"?\
MZU'_  S]X(_NZC_X$_\ UJ]3HH JZ;I\&E:7:Z?;;O(M8EACW')VJ,#)_"K5
M%% !1110 4444 %%%% !7S!^T=_R4+3_ /L%1_\ HV6OI^OF#]H[_DH6G_\
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M:[F<<=LA?_937E/[06MQZE\0(["%PR:;;+$^/^>C$N?T*#Z@U[]\.-%;P_\
M#S1-.D0I,EL))4/57<EV!^A8C\* .IHHHH **** "BBB@#P#]IKIX7_[>_\
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MHHKRC[0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-/$NO12C2TF^TO)<*=U[)G=QGJN>2W0]/7'U'1THH **** "BBB@ HHHH \
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M.SN+^[CMK6)I9I#A545[?X<T5-!T:*S4AI/ORN/XG/7^@_"G:/X?TW0XBME
M%<C#2L<NWU/]!Q6I7)7Q'M-%L>WEN6?5??F[R?X!1117,>N%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TUT\+_]O?\ [1KQ_P "?\E"\-?]A6U_]&K0!]OT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G7Q9\
M0_8=(CT>!\3WGS2X/*Q _P!2/T->@SSQ6UO)<3.$BB4N['HJ@9)KYJ\2ZW+X
M@U^ZU&3(61L1J?X4'"C\OUK?#PYI7[&-:=HV[F31117H'&%=[\+/$/\ 9?B
MZ;.^+:_P@R>%D'W?SY'XCTK@J<CM'(LB,5=3D$'!!J9Q4HM,J,N5W/JVBL/P
MCKR^(_#EM?9'G8\N<#M(.OY\'Z&MRO+::=F=Z=U=!1112&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4457O;ZUTZU:YO)TAA7JS?R'J?:
MA*^PFU%7>Q8HK@[SXH644A6ST^:X4?Q2.(\_3@TME\3[&:0+>6,UN"<;D<2
M?7@&MOJ]6U['!_:F#YN7G_/\]CNZ*@M+RWO[9+FUF26%QE74Y%3UCL=Z::N@
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445!=WMI81"6\NH;>,G:'FD" GTR: )Z
MI:OI%AKVESZ;J=LEQ:3KMDC?O[CT(Z@CD58M[F"[@6>VFCFB;[LD;!E/T(J6
M@#YXU;X+>+_">IR:CX"UB62,GB$3^3,!G[I)PC@>Y'TJL^O_ !YM\VS6M^SY
MP)!I\+X_X$%(KZ0KF_$_CSPUX/"#6M3C@F<92!5+R,/7:H) ]S@4 >()\,?B
M?X]O$D\6:C):6@(;_2IE?'J4AC.T'Z[:]T\(>#]*\%:(FF:7$0,[IIGY>9_[
MS'^G05RVG_'3P+?W*P-J$]H6("M<V[*I/U&0/J<"O1()X;F".>WE26&10R21
ML&5@>A!'44 24444 %%%% !1110 445ROQ#U?7]$\)RWOAJQ>]U)94585MVF
M)4GD[5YH ZJBOG;_ (65\9?^A1N/_!-/1_PLKXR_]"C<?^":>@#Z)HKYMOOB
MW\5],MVGO_#OV2%>LD^ES1J/Q)Q46F_&3XH:U&\FE:)'?)&=KM:Z;+*%/H2I
M.* /I>BL[0;F\O/#^G7.HPF&]FMHWGC*%"CE06&T\C!SP:T: "BBB@ HHHH
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M-"\/V&E6ZA8K6!8A@8R0.3]2<G\:T:BMIX[JUBN(F#1RH'0@]01D5*2 ,DX
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MWZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAU"C:2$7]1V ZU]$T4 ,BBC@A2&%%CBC4*B*,!0.  /2GT44 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!%<NT=K*ZG#*A(/OBO+_@EXPU[Q?8:U)KM_]K>VG1(CY*1[00<_
M<49Z=Z]/N_\ CRG_ .N;?RKQ3]F[_D%^(O\ KYB_]!:@#W&BBB@ HHHH ***
M* "LOQ+_ ,BKK'_7E-_Z :U*R_$O_(JZQ_UY3?\ H!H \E_9K_Y%K6_^OQ/_
M $"O;J^/O 'Q4U#X?V%W:6>G6MTMS*)6:9F!! Q@8KKO^&D]=_Z 6G?]]O\
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M>ZF>_D$DJLU?H;5%%%><?5!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'.AE
MMY8UQED*C/N*\\^$G@#5? 5GJL.J7%E,UW,DD9M79@  0<[E7UKT>B@ HHHH
M **** "BBB@ K+\2_P#(JZQ_UY3?^@&M2J&N6\MYX?U*V@3?--:RQQKD#+%"
M .?>@#R#]FO_ )%K6_\ K\3_ - KVZO*_@=X3USPGH>JV^N6#6<LURKQJ9$?
M<H7&?E)KU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
MWXJZKXTTNRTUO!EO//,\CBX$-J)L* ,9R#CG->A44 ?-W_"7?'/_ *!E_P#^
M"I?_ (FC_A+OCG_T#+__ ,%2_P#Q-?2-% 'RU<?%/XL6FL1Z1<&6+492H2U;
M3D$C9Z87;DYK4_X2[XY_] R__P#!4O\ \35_QE_R<YH/^];?UKZ"H ^;O^$N
M^.?_ $#+_P#\%2__ !-=)X"\1_%:_P#&5C;>);&\BTE]_G/)IZQJ,(2,L%&.
M<5[;10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &C7C_@3_DH7AK_L*VO_ *-6O8/VFNGA?_M[_P#:->/^!/\ DH7AK_L*VO\
MZ-6@#[?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,,?'"4[VO)[([._^)>FI)MMM/DN@IX:1@@_#@FGV/Q.T^:0)>6<UL"0-ZL)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** / /VFNGA?_M[_P#:->/^!/\ DH7AK_L*VO\ Z-6O8/VF
MNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU: /M^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN
M!T'X@+JWCJ]THNOV%_DLV ZLG4Y[[N2,^@'>JC%R3:Z$N25KG?4445)04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBOG_Q=XN\:^&?$MWIKZS*41MT3F)/F0\J?N^E9U*BIJ[,JU94E=H^@**^8
M_P#A9WC'_H-2?]^T_P */^%G>,?^@U)_W[3_  K'ZW#L<_UZGV9].45\Q_\
M"SO&/_09D_[]I_A7N_@4ZS)X6MKG7+IY[RX_>_,H78I^Z. .W//K6E.NJCLD
M:TL3&J[11TM%%%;'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_E6'7D--.S/!DG%V9U?P]\-'Q-XKMX)$S:0'SK@D<%1_#^)P/IFOIX *H4#
M P!7"_"KPS_8/A5+F=-MY?XEDR.57^%?RY^I-=W7IX>GR0UW9[&%I<D-=V%%
M%%;G2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRW^%'_"P/#O_ #]R?]^6_P *\:HH^IT_,/[>Q/9?<_\ ,]E_X6!X=_Y^Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X!^TUT\+_ /;W_P"T:\?\"?\ )0O#7_85M?\ T:M>P?M-=/"__;W_
M .T:\?\  G_)0O#7_85M?_1JT ?;]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^+=>3PYX<N;_ "/.
MQY<"GO(>GY<GZ UX#H6N7&B^(;?559G=)-T@)Y=3]X?B":ZGXJ>(?[4U\:;
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M/\B^Y&3_ ,(QH7_0)L_^_0H_X1C0O^@39_\ ?H5K44<\NX?5Z/\ (ON1D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5/*/CD$?6O/QE.SYT?4Y%BE*#H/=:HTZ***XCZ **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '@'[373PO_V]_P#M&O'_  )_
MR4+PU_V%;7_T:M>P?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JT ?;]%%%
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MC_SRTO\ \!V_^*KY^OE^*K5'.5M?,U4HI6/IZBOF'_A?WC'_ )Y:7_X#M_\
M%4?\+^\8_P#/+2__  ';_P"*K+^R<1Y?>/G1]/45\P_\+^\8_P#/+2__  ';
M_P"*H_X7]XQ_YY:7_P" [?\ Q5']DXCR^\.='T]17S#_ ,+^\8_\\M+_ / =
MO_BJ/^%_>,?^>6E_^ [?_%4?V3B/+[PYT?3U%?,/_"_O&/\ SRTO_P !V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5/4M6TW1K=;C5-0M+&!G"+)=3+$I8@G +$#
M. >/8U<KR#]H[_DGEA_V%8__ $5+0!W_ /PG?@__ *&O0_\ P8P__%4?\)WX
M/_Z&O0__  8P_P#Q5?$%% 'N'[0^O:/K?_".?V3JMC?^3]I\S[)<)+LSY6,[
M2<9P?R->5^#)X;7QUX>N+B6.&"+4K9Y))&"JBB5222>  .<UAT4 ?;__  G?
M@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57Q!10!]SV/BSPWJ=Y'9
MV'B#2KNZDSLA@O8Y'; ).%!R< $_A6Q7Q_\ !/\ Y*]H7_;?_P!$25]@4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 1SSQ6UO)<3.$BB4N['HJ@9)KYJ\2ZW+X@U^ZU&3(61L1J?X4'"C\OUKU3X
ML^(?L.D1Z/ ^)[SYI<'E8@?ZD?H:\5KMPT++F9RUYW?*%%%%=1SA1110 5[+
MX.\*>#_$GANWO6TH?:%'EW %Q+Q(.O\ %WX/XUXU7LOP@@M!I5W<07,QN"P2
MXMV(V@C)5QW&02/P-88BZA=,UHV<K,[31?#.D>'C,=*M#;^=CS/WKONQG'WB
M?4UK445P-MZL[$DM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMQ)SZ,2P_0UP8_%2P\%*%KM]2HQNSYY_X4QX_P#^@!_Y.0?_ !='_"F/'_\
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MJ_F'+B?,S/\ A;OC'_H(0_\ @-'_ (4?\+=\8_\ 00A_\!H_\*T_^%'>)O\
MG^TG_O[)_P#&Z/\ A1WB;_G^TG_O[)_\;HM7\PY<3YF9_P +=\8_]!"'_P !
MH_\ "C_A;OC'_H(0_P#@-'_A6G_PH[Q-_P _VD_]_9/_ (W1_P *.\3?\_VD
M_P#?V3_XW1:OYARXGS,S_A;OC'_H(0_^ T?^%'_"W?&/_00A_P# :/\ PK3_
M .%'>)O^?[2?^_LG_P ;H_X4=XF_Y_M)_P"_LG_QNBU?S#EQ/F9G_"W?&/\
MT$(?_ :/_"O1?A1XPUKQ5-JJZM<),+=8C'MB5,;BV>@]A7&_\*.\3?\ /]I/
M_?V3_P"-UWGPT\":IX-FU)]1GLY1=+&$^SNS8V[LYW*/45I25;G7->QM05?V
MBY[V/0J***[CT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-!JI5=Y?@@HHHKE/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY9I))W*JJ!'&> 2>6'%9G@KX&>'_  S)%>ZFW]KZ@AW*94Q#&?54YR?=B?7
MH ^:]1\+ZMI.A6&L7]JUO:W[,ML).'<* 2V.R\C![_2L>OH?]I?_ )!WAW_K
MK/\ R2OGB@#[_P"U%':B@ HHHH ***X_XC^.O^%?^'K?5O[.^W^;=K;>5Y_E
M8RCMNSM;^YC&.] '845\_P#_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 '
MT!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\ _P --?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6TM8_/WS3V4D:+F&0#+$8&20/QKZHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *;+(D,3RRN$C12S,QP !U)I
MU>?_ !5\1?V;H2Z7 ^+F^X?!Y6(=?S/'YU4(N4DD3*7*KGE7BO77\1>(KJ_)
M/E%MD*G^&,=/\?J36+117J))*R.!N[N%>B_"?Q#]@UB31YWQ!>?-%D\+*!_4
M<?4"O.JD@FDMKB.>%RDL;!T8=00<@TIQYHM#C+E=SZKHK)\,ZW'XAT"UU%,!
MI%Q*H_A<<,/S_3%:U>6U9V9WIW5PHHHI#"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >$?M+_\@[P[_P!=9_Y)7SO7T1^TO_R#O#O_ %UG_DE?.] 'W_VHH[44 %%%
M% !1110 4444 > ?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JU[!^TUT\+_
M /;W_P"T:\?\"?\ )0O#7_85M?\ T:M 'V_1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XC^'%OXD
MUF34;G5+E"P55C"@A !T'ZG\:[>BJC)Q=T*45)69Y<WP8M2QVZU,!V!@!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#,UCP]HWB!(DU?3+6^6$DQBXC#[">N,_05E?\*W\%?]"OI7_@,O\ A744
M4 %%%% !1110 4444 %%%% '@'[373PO_P!O?_M&O'_ G_)0O#7_ &%;7_T:
MM>P?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JT ?;]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 > ?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JU[!^TUT\+_P#;W_[1KQ_P
M)_R4+PU_V%;7_P!&K0!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445SWBGQQX>\&VZR:UJ"0NXS' H+RO]%'./<X'O0!T-%>*W'[27
MA])2+?1-2E3/WG9$)_#)K?\ #WQT\&Z[<);33SZ7.[;5^VH%0G_?4D#_ (%B
M@#TNBD5E=0RL&4C((.012T %%%% !1110 4444 > ?M-=/"__;W_ .T:\?\
M G_)0O#7_85M?_1JU[!^TUT\+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!]OT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JT ?;]%%% !1110 4444 %%%%
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M>V=4OKI?)11U27^(X]N2/JOK5'4/B*?^%=V]];S*NK3G[.< 91UQO;'TP?\
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MJ-3D(/\ >12?S(J(^+O$!.?[5N/S%'U.?=#_ +?H?RO\/\SW*BO#?^$NU_\
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ML8H_L>K_ #+\0]HCZ_HKX\F^)_C:>3>_B2]!]$8(/R4 4^3XJ>.)8A&WB*Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"C6H ]_P#^&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KY@HH
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MP44 ?3__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[7S!10!]/_\
M#1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM?,%% 'T__P -'>#_ /H&
MZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.U\P44 ?3__  T=X/\ ^@;KG_?B'_X[
M1_PT=X/_ .@;KG_?B'_X[7S!10!]/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\
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M_P".T?\ #1W@_P#Z!NN?]^(?_CM?,%% 'T__ ,-'>#_^@;KG_?B'_P".T?\
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M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':^8** /I__AH[P?\
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MT=X/_P"@;KG_ 'XA_P#CM?,%% 'T_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\
MH&ZY_P!^(?\ X[7S!10!]/\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\
M?B'_ ..U\P44 ?5.F_M >%-4U2TT^#3]:66ZF2!"\,04,S!1G$AXR:]6KX9\
M(?\ (ZZ#_P!A&W_]&+7W-0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?(_QUMF@^+&I2,.+B*"1
M?H(E7^:FLOX33_9_BGX??.,W!3_OI&7^M=_^TEHKQ:WH^N*/W<\!M7([,C%A
MGZAS_P!\UXYHFIR:+KVGZI$,O9W,<X7/7:P./QQ0!]X5Y+^T1.(OAQ!'GF74
M8EQ]$<_TKU'3[^UU33[>_LIEFMKB,21R*<AE->!?M'^(8)KG2O#T$BO)!NN;
M@ YV$C" ^AQN/T(]: /!J^U/AG:M9_#3P[$XP38QR?\ ?8W?UKXVTK3I]7U:
MSTVV&9[J9(8Q[L0!_.ONVQM(["PMK.+_ %=O$L2?10 /Y4 3T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5]3@T;2;K4;
M@_NH(RY&<;CV'U)P/QJ[7+^-_#5_XHT^"QM+V*VA5R\H=2=Y'W>G;K^GI512
M;U%)M+0\!U"^GU/4;B^N6W33R%V/N3V]JK5Z4_P:U4$>7J=FWKN##^AJ-O@Y
MK?\ #J&GGZLX_P#9:]!5J?<XO9S['G-%>B'X.Z]VOM-_[[?_ .(I/^%.Z_\
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M.$K[QD?UIO\ PJV\_P"@E!_W[-'UFEW%_96,_D_%?YG T5WW_"K;S_H)0?\
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M,+9M!Y"@#[H X(^A /X41PKUY@A@I:\Q\E45]$6WPETF%]#9W$AT\'[1E/\
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MH;'JI6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M9/VD/^1XTS_L&K_Z-DKEO@U_R5K0?]^7_P!$O74_M(?\CQIG_8-7_P!&R5RW
MP:_Y*UH/^_+_ .B7H ^Q**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OD/XX?\E;UC_=@_]$I7UY7G/BKX+>'/%_B*YUO4+W58KFX"!TMY8U0;5"C
M*$] .] 'D7[.G_)1KO\ [!DO_HR.OJ.N"\%_"30? NM2:KIEWJ4T\D#0%;F2
M-EVDJ2<*BG/RCO7>T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!\R?M(?\CQIG_8-7_P!&R5RWP:_Y*UH/^_+_ .B7
MKZ*\;?"G0O'FJP:CJEWJ,,T, @5;61%4J&+9.Y&YRQK/\,_!+PUX5\16FMV-
M]JTES:EBBSRQE#E2IR!&#T)[T >E4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFZ:V\KS_ #<X1&W9VK_?QC':NPH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_%5CHG_  C7V?[5+Y7G?;]^W@\[?+&>GK7L] !1110 4444 %%%% !1110
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M110 4444 %>6?M ?\DS/_7[%_)J]3KRS]H#_ ))F?^OV+^34 ?,?]D3GP_\
MVRO-NMU]E?C[K;=R_F-WY5]9?!WQ!_PD'PWTYW?=<68-I-SDY3@9]RNT_C7C
MOP\\/_\ "2?!OQA9*FZ>.9;B# R=Z)NP/<@$?C6A^SEX@-MKNIZ!*Y"740N(
M@>@=.&'U((_[YH ^CZBNKF*RM)KJ=PD,,;22,?X5 R3^0J6O.?C=KYT3X;7<
M4;[9]0=;1,=<'EO_ !T$?C0!\R7SWGC#Q+K&I $L_GWLI8YV(,G'TY"CZBN_
M_9T_Y*+>?]@R3_T9%3/AUX>V?"WQMXBE3E[5K2!BO.!AGP?0DK_WS3_V=/\
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M8(HP OWF&Q1G)..?[M2_%+XJP^ H8K.SMTN]7N$+HCGY(EZ!GQR<]@/0\CN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%IC7OQ)2ZV92RMI)=V. QPH_'#']: /H+XD>'!XH\!ZIIRINN!$9K?'7S$Y
M'N>5_&O O@'KYTCQ^^F2MMBU*(Q8/_/1,LOZ;A^-?5%?(/Q"TV;P%\6IKBS0
MI&ERE]:XX!4G=M'L#E?PH ^OJ^1/B[K$OBKXHW5O: S"!UL+=5_B8'! ^KD_
MG7TOK'BNVL/A]<>)XI%:$67GPL3PS,/D'XDBOG/X):"_B3XD+J%RK20V :ZD
M9N09"<(#[Y)/_ : /ICPKH<7AOPOIVD0XVVT"HQQ]YL?,?Q.37G/C?X(2^-/
M%5UK<GB<VPF"A8/L/F",*H& ?,'IGH.M>O5Y/\4_C"G@V<Z/H\45SJ^T-(\G
M,< /0$ Y+8YQTY'7I0!Z9I.FV^CZ3::=:HJP6T2Q(%&!@#'2KE?*>GP_%KXE
M W<%[J)LV./,,_V: _11@-^ -7F_9Y\;71\V?4]'+G_GK<RLWY^6: .7^+%M
M'I?Q5U@68\G$RS+LXVLRAB1^)KZ[TRX^U:5:7'_/6%'_ #%?$7B?PY>>$_$%
MSHM_)!)<V^W>T#$H<@'@D ]_2OM;P]_R+FF_]>T?_H(H ^8?CY_R4^Y_Z]XO
M_017O?PHT2PT;X=:.]E;K')>6L=S.^/FD=E!))_' ]!7@GQ\_P"2GW/_ %[Q
M?^@BOHOX>?\ )./#?_8-@_\ 0!0!TM?(OQR_Y*UJW^Y!_P"B4KZZKY%^.7_)
M6M6_W(/_ $2E 'T_X._Y$O1/^O*+_P! %>:^*?@/)XI\5WNMW/B@Q_:IM_DB
MQW;$Z!=WF<X  SC\*]*\'?\ (EZ)_P!>47_H KS?XH_&K_A%K^30] BBGU*/
MBXN)1E(3_= _B;U[#WYP >NVEK#8V<-K;QK'#"@1%48  &!@5-7RKI^E_%KX
MC1B]%[J/V*0?++-<_9X6'^R@QD>X4U<;]G?QK<-YLVIZ,9&ZF2YE+?GY9H X
M_P 9+%X?^+&I/:*(H[74S+&JCA,/NP,>E?9<+;X(V]5!_2OA77]%N?#NNWFD
M7;Q/<6DAC=H22A(]"0#^E?=%M_QZ0_[B_P J /B[QW%Y_P 4-?AW;?,U69<X
MSC,A%?7/A+PMI7A+0H-/TJW6--H:23'SROCEF/<U\E>,_P#DK.M?]AB7_P!&
MFOL^'_41_P"Z/Y4 $L4<\+PRH'CD4JZL,A@>"#7QIX=WZ#\7=/BMG/[G5E@#
M=,J9-A_0FOLZOC*'_DLUO_V'H_\ T>* /LVBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?<  #W%?1G@SP9I?@?0UTW35+$G?-.X&^9_4_T':@#HJ*** "BBB@ HHHH
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MJ^-_$'PS\3:3KMW86>AZQ?V\$A1+J+3Y"LH'<8!&/QK[)MP5MH@000@!!^E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>img40748725_37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2K>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *L*^$)1CA"24T$!       9AP!6@ #&R5'' %:  ,;)4<< @   J@ '
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M]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M  0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&
M)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M   P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M  0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M!";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <)
M    IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U
M!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M           %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G
M1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296
M-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F
M]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $)     0 ! 0D    !
M$X0DE-!"8       X             /X   #A"24T#\@      "@  ______
M__   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M  "0           0 X0DE-)Q        H  0         ".$))30/U
M!( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %
MH    &       ! #4    ! "T    &       !.$))30/X      !P  #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@  #A"24T$"       $     $   )    "0
M X0DE-!!X       0     .$))300:      ,U    !@             #'@
M   TD          0                         !              -)
M #'@                     !                         !     !
M      ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M    !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M #'@    !29VAT;&]N9P   TD    &<VQI8V5S5FQ,<P    %/8FIC     0
M      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&
MQO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&
M]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M       $QE9G1L;VYG          !"=&]M;&]N9P   QX     4F=H=&QO;F
M<   -)     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37
M-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$
MES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9V
MYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&
MEG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;V
MQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&
M]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='
M1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))30
M0H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M0    ).$))300,     " G     0   *    "8   !X  !'0   " + !@  ?
M_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\
MX  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /
M;6  $     TRU(4" @
M                     18W!R=    5     S9&5S8P   80   !L=W1P=
M   ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48E
MA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M"&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M    !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;G
MD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U
M)'0B!)14,V,3DV-BTR+C$
M                           %A96B        #S40 !     1;,6%E:(
M                    !865H@        ;Z(  #CU   #D%A96B
M!BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14
M,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=R
MYI96,N8V@
M          9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B
M!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2
M!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=V
MEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M            !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M%865H@      !,"58 4    %<?YVUE87,          0
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MR8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .06
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!(0$Q P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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MZ-!RC&Z5$I*-\(QG.F32MC"7Z,Y5M\\8R\).*4O!LN;(<A@# & , 8 P!@#
M& , 8 P!@# & , 8!^%/^;4_^PW_ .HYQE^B^F_GO^KO^HL>]>]?$\M?!C3'
ME =F5#E8;C+RVUAH_7;[E#O2)<5:S:.+>;.696D01?RS.XA8XM1AWZ:J7F)2
ML5S1ZJ/?D[PW1,6GU]I\GW!->4IY->1PWEQQJZ+/0YUTO5-3KG2\F"G+FLOC
M.<;U!3JC;M'=P3,?.L4>.N-YXD8T6T\08TLJ=\7E5VW+3,"55D,>7)&,*Z>S
MKE3SN-LJ^9\O/)/]T6V)Q/DC?*1\9)[6T=KO:O&&%VC3MK.8:=D;)%[#M$]&
MN9@VR4I:53)(G<6HA#NW+9R8WFO9320!)MW*1,GB&[&U/1N"=:TV"QM)EKFE
M:'A:7LHQT>>@Z[A8^5I]3BWVE-5]TG&V7KWW.VR>[DV9'#M-NF\7:_H^7:\W
M4/1OGW+U;:4)ZJM>TG)OIR\BJ72G(E7CJ,Z:VZJH*NNKI!LSKNFQ<96W";R>
M50W=I"Z<I=BVZBU:/TAQJJDL[9QNS+*O2&2+_P"K1F9RC7U*Y$L_\J&1LJ#R
M.BW94G)404 RA-IK\+,CY0-5QL#$AF:@\7*NR)7RJ6-I>E564ROU.3O;KIOC
M9%48UT(JYSG.J,X*S=Z#0K*L;@K#R,[+EAZ?9J%6-#L5:\C4-1ED9LL;3:X4
M[6756+>W)I;Y'5#M)PLC6XF%N![&5U/Y4E:FUSAS-<!ZC=^+%GL\_HM*\URV
MUBXS%9LL4UC+VS85!RM"1;Y!%RYC5NT /G)A,=0W8,3.>';&SASCJ5FI?.4L
M'-X>NQJ)UV.>EN['SI6PIE8ME#,:[:5=+Y7)-S7-L=^93&.?PG='3O09WY.J
M8%N7"RO;.H>.LATVP@]Y68UD(.%UD=E&?+!+:6^2.!7#S0'/NJ<D.3W*>HDV
MQM^[[_V95H*TV!_($GM0UJEOC1E6A=<N$W*;BG.(9,_GJ#ED*3D' -ECB8Z?
M;4T]<987!/"%N*WBYVJ\.RUW4=3Q9M9.7J65E9=<[HY6[DZ80QX1JK6\(1E9
M%/EEL;#(N67Q;Q5C9-=>5@:%K,="P--R(*>%'#Q<3&O<K<?:,99.3/*EZ3=+
M>5O9PDFGN17U+<[?QV\CSS8:ZZMU@C9]'F'M+4L??5':BUGCHVPW^'J3VQN)
M5,R9BRQ8Q595>4,8![]4ZQA[0]K,G592UC ^1O&RE"-7$%'">)J==*]'A=CY
MNIY,\VFM0V5+R$G"$*TDW+LHK9['=5".D:I\I.5CQ=\^'].S]2T^.5)WJ-V!
MHU-F&KW--VPQ]XIRDMVH*4WNC+7E&O)F<1]#^34F]HZAHGU"[+J%1UZ\F+]7
M9-ZWGMH^F):OIS".S7)USDN#64=.SRW1^0ZJ$@1)RW4*(&[>99GY%''?#=6-
MR8N%/C7#TYZ;7",,*&/"Z^%3C0XR5=]#QX.O(BU9!RM2;5LT\70\:O,T/(NR
MW/)S;.'LC4(ZG;8[,ZO)GBNZUQR.CE3=&VRBRF6]4Z^S37-56RO>43M-\V%R
M-X/<:2<?[=REU8CHM3;UAX^5:\Q- 9[+G&4>UBF*ENE+ NVB9>N5A%,SM>OK
M',5\J\^R$, $ZX6+"O(XKXVOR,:O*6CZ?2L/MMITZ=;J>K75VZE9CRDHY%LU
M57C8DU!RQ+T[ZVWO!8]DYXW"7!E5&3+&GK.;9CYD:U..1FT:;I./D5X-.4EM
MBU2E=.S+4GME5)52:<8[W]P/TMR U?S8>6JB\"K9P:XN7745@B-E4!WL^BV^
MANK_ !!BNJI:*Y7:I*F"#EWJ1EH^55(P6*\*5(ZJJ?9ZCSLLA#AOC&C4-668
MK:,/,T'&LJLE=B9<(W4:E"K(G%[8U^+.%D<9NNNJV$Y0YG/EAU6T3EK'#F7A
MZ;Z).B>;B:Q?7.M0S,*<(V8"NJC)-W8V2I[7*,I2A9"$DN1RG0O([<(./VTZ
M1L+D+MRGM=H7N Y5[I2UF6X=N1B-3!4MD2YT75"C>\(VB).4DRC*RLD1(73E
MP"29C]RD4HY_;6:5HO!EV'+L\_*X0TBZ_4XK;,EC78,\:C3H6/=UX6)C2G5"
MB"4)RMMNFNTGNNW4,2K/XCXLJREVN'5K')7@2ZXJO=>-F7YLZUM&S,OO<'*^
M6\X0JA5%]FFGLU\K6I,I>3IY5F@R/#N1UF^(\*R*8R_H0[QD2=$ ( F[DL09
MX*YNR8"H@<3 8 Z9X;67M#2FVHU_YR<,NUR]6*J^?L!VN;;V4%!-SW6W+OX=
MWJ-(YNTS^R_QUH>N^B[/U_2_FC,]&5>_5VNUP56S4G-K9KO,\\*#U97B'QI/
M2S-U*N.C]9A$&:BF9$6Y:C%%,7M)D3**H+ J"X]@H]^!^T &ZAGNN+>;_.?7
MG+9J6J9DJFOT7CRNG+&E7MT[%X[K=/+ZG9N*AZNQXOA;_J]I"DDKEA4QRDN7
M>.;%<N<I\O3M%F1N5O>^TYMVWNR$WE3;%QB(715,W+HJX\K]GVZSS[#2'&BK
M2[AI#;%FU(U%.8<7=HLZ2K8P$*R(+M*2LC=XRC'J0+)IIJ=I9/S.#"=^NO&P
M<196>M*NR<NRYU+&TK2JLB,K-3E*]]G1D=LGC8UU:[>4ISHC*$;/6]#F6UXV
MD._.R98N!;J>+BT1JC9*_4=2=5LJ-.A"O:5],H2[;)IDW5&$(W2C/LW%:_O)
M[Q\KK#RIDU0*_P 0IK@73;OQ=D+1.:$"\UZVUBRS4':HZ-CK\P:5)RK!13KS
M<ZT:N4H%>KG2455$R9RE#TF#+MN'>,';J2U&6)J^@/&JLKFIZ4K\/-[2BJ=J
M]:O*:>1*%3=:<ESI21ILZM5Y_"^3#3WA3M>KXEN5"ROESZ8U>D1A;5"3YK<>
MVM<EMJ4E"3C!;*3=7X'\!>-G*;8O/RZ<A:;[K+:+Y>;GJM6HUM=N'E#J*KAV
M@ZDK9!UQ-1)JG<I,QTD%K L"KQNT;)MFIDTSK IJ*-Z. >$[:%V>9DZ1E*.?
MS2>9BX^+E9,<7$P[-ML:BNVRW)G&M*5M\U*R4E"O;;:Q)W<;:O7:^?'Q,'A>
M:QDW"F^R_1Z'9+*C%KTC904*HV\RJAOR=9MF&Z1MS:NK_) \@==U.^62--2N
M7=PXKTZZ$D'2]EIFK)7:3>J)E:2SA15PFI"0;M9FS=J*E%LB< (9,"$$G=J<
MWKR^22>=MS<33X;P]=E7+L):E&.3D5WN<X[.-^;V,%.2<G+;EDVI/>5T5\.Z
MA\J4<*N#AP[@ZAKNDU6I648F1F:5B:A&J-4O56+B694NQKBDJVN:"321N'U)
MY*W@UI]KJ?8]$TM#P6S]8-XJSQ^SHB0DF%YM<VWAU <N+C.MW0.+.A-K.%'4
MHQD!6;/7/=**)F[H@9V9VIY6'G:ED8:AB5PJU/%C@404,%8]M=E3H>+UKEV<
M(J5<FFZ[?SL-IK<UF%IV-G8&!7G.S+MLEI^7/-OL<LWTB%E>0K8Y/2<&YMUR
M46HRHDZ6N233T&:=@;9RT4Y [HVSY+*[\ZK3?-O;#@HS<+_<M KC#7L/7WJL
M+#T_6]>MSQ&2J!JNF1-91ZT23.\?@B[$QCH@(86%C=GPEPXJ+?FS.U31OG3(
MU:J<I9FH9F=D7SEGUY-3=M.-5:G7BXG-&&.X72ATODEGYV1)\4\0U3Y-2Q-'
MU=Z1CZ?*"AAX>+AT8^^-;1-]G?E9$9NW*RH[NZ-E:<HRK:,V<B=?\E(/R0.F
M=4<DXNXZTV'%\PM84JKGL%EBK3?*]0'^QDF='D7EFBW\DSD)Z&BI'ND9 KA-
M0RS!%44T>A0S=M8^I\;_ "<16=&[-R-,R:=?R\*N6'VVHTZ)FTZAV4>5.B67
MCUQC.54IJOMI34Y3-;@UVX'#W'Z6)V&#37G9.BXF3*&1"C ])Q,K$ID]I=I7
MCWJ4=K(IRY'ZJBXI>AGC!PUX]<4(AY[C&O(BM6&TQD.G?;L!57-OV'(1R)U
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MT?\ )5A]D8 ]]7H#UC1_R58?9& /?5Z ]8T?\E6'V1@#WU>@/6-'_)5A]D8
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MU*V.:38+!%*,H^Q-16*=HH*B:AT%5&ITWB+5^D0[)VNQ52?(MEU%&BI%RD'
M([\0^.NR=(/KQ(76:KC.*L:4.VAZ%3YJYV2 BW,:"P/;$>7OC^1FRR4R"B9%
MV+9<L>D5(% 3%8PFP//\?/N[NY%R<WV#$>-^P70LVIG/G-,Z+F;HF6#I=ZX
M""HD%0! /@'M=0^(0R/P^E_<W\>H)5P_VIB_ZN9?W9+*#L/1= T<BQ!$SP$%
M?-2N3&*@9QV#=R"QB?7E2%3L@H)/K@)VNS]=TSC+FV?)MS<LN7??;FV]7?;P
MW[_';N\3LI5+NJ60[%1VD.V=2B[55S+M'6I/E<U!OD4O5YMM^AKSIVJY?=E4
MY4:.W]2:):]87"U6^)GZTP7ET#2Z=EBF#@S-NJ^,8C1JH!^TC))=AT@[ZN$Q
M**9>GG]#>;&_5*LF&-"N.?=*/9.SFYK%"?3F23CMNWU;WW?B?:/E7APC9I'
M&;H5^MV9N1PCI]$XZBL)U.C!ORL=NR>.E8LA-;*/6$8<JW\#2[Y$8-+\&>3_
M "?X"+-ZQ6;6&R)27US*FVF$\6>I,QWLM6-;Q<8:)8IV&V4I%.20L,VD9("D
M B'14Q/#T1\3/5O@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , C5H#[J.0_Z9Y+Z/063Q?N7QD7P7O?PB25RD& , 8 P")W-_P"]GV!^
M<TWZ;UW(^^/O^Y@E!#_:F+_JYE_=DLH*C@$>*?/Q<%N79M3D)-@F_L+F%L<,
MR[X@+';DAD$) %NUT$BB:O<B4@]14*8!( AVNFJQ[85:AFT3LASVRKMJANN;
M95+GWZ[KKW)I]$]NB/H^MZ=EZAP-PEK.-B9$L73*]0TO.R'!NN%LL^RS%Y6M
M^:,X<ZW_ -62?/MND>;W_E!W'2A:.G].^44U\I.5/:FM+O574\RJ<7)(M;/
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MWV]/H?3N?X]QO5P48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M, '(H0Q>H&*(@7 4Y# 4Q3 8#  E$!Z@("'4!#I\0AX]?P8!^L 8 P!@# &
M, 8 P!@# & , 8!&K0'W4<A_TSR7T>@LGB_<OC(O@O>_A$DKE(:LO*C4B@S=
M"UI8KE$MW(L[VU@_23:62K5G;LI1F[,9G6;;(I.X2LNW+E),SI_),S%6:)J-
MDEDC'$1$?]O#QZ>/3[28/$B%=5SCAJ"#>*5Q52.IS!!(]3.BK ^:%.J9F5FN
MV*FW<J%:F1*\=MTR(NGQ7+A( (H  *2,P!@$3N;_ -[/L#\YIOTWKN1]\??]
MS!*"'^U,7_5S+^[)905' & , ZSQHV?M7+)XD1=J[14;N$% ZIJHK%$BB9R]
M?KBG*(E$/C 1#X\XRC&<90DN:,DU)>#3Z-?V.RFVRBVJ^F<J[J;(6U61Z2KL
MKDI0G%^$HR2:?@T:M-A>2ST_*;*/N&G$)&V%K/-)]M3CHI,JF[.G)-';MDX.
MU+YXBDZ1053%1,?$ZHB<H@)A'P&=\G^E69[U7&CR9$;8VQQFE#&D^TC*<).+
MYU&>SYFFMV]WOW/]=<-?Y7O'.'PHN"-<E++TR[3;M-NUR-D[]:IC+$OHHR*X
M7;43G3.R$E&7<H>JTU';8/K.W#9(^;CUXEI!O*?/.ZHZCF+XCUHB,:FCW!VZ
M@%34(BH@H3L)JIE.4"_&7H.>TPK^VA9!PC5+&ME0X0FI17(ERM;=4N7;9/W]
M>\_-7%6C+2\G R:\V[4,?7-.HUFG*R*)8]TUE2F[(V1;E&4XV1ES2A)Q>_AW
M&3<S3RPP!@# & <= _Q\7P#X?TB'4?PC\. 8VVYK_P!U#7MJHXSDS7RV*&D8
MPTA!/2L7I0>LG#44C+G;N0!LIWH X*5/M'3Z@42CXB!!J!X#V6%CN.T>ER)W
M01MIY@FQDT$[7&]R"*%5+!((U\#5L3(HD6(0@BZ%4PL0$HF[P1, 'TVOP-ME
M[=;(7CN2&ZVI;CJ\*4P([M<68$Y+TBLZ 7X$K7V2($AR=I%,2K"J*@]YT$O0
M#%FM?)J7VF:5MFNG_)G;JTO/-:VBW%C9XY*#(>'BHI@X!T@I6Q742!5BIYL!
M3@((=P53M& PB!,[54+8M?;EE]=.=B7>\P)=91,^F6[2#&5=M)8LT,>JLT=M
M(V..1)9O]8=$Y#EZE*8O9$,FW]NK]GGV^WO!+#*!@# & , 8 P!@# & , 8
MP!@$:M ?=1R'_3/)?1Z"R>+]R^,B^"][^$22N4AK1YJ<>.16V-I:KO>GPITU
M%T!FBY;P-SN$W7HIA8DK T?/I!:%8,)"*LR<W7TUX%1.70.1@105T"@<1,(&
MP.D)S253@$['"0M;G"1J 2D%7' NH.*>=!%5E&.1;M._:(CT!)3S9'J ]03
M!P"F[/0V*YH=G1U*_K,9L8T4N-1>W)F]?U=*7)T.W"::QRR#X[%3LBFJ9LJ5
M4G;!0H'['9P",'#FT\IY[W4&?*QS2V-HC[45*HU:JPX1IV%61:I(#+F=%D7X
M2D1,R)'*D.Y7*W>D03,1TF4_0H =#G/LW7[/1M^IKNWP+:T'?4= D$J_2+)'
M6<W:NF;I%;"/;%18H"*9>GUWQ#D[VOH?7['^*)NOX;[>.WN[R;<0 A$Q@"'0
M0CF0"'X!!LD A_KRE*A@# & , 8!%%.UUG6/)*:KLL[AHSW88"+F8@P/4FBR
MTY7P=,7Y'S-50I.\=M2I*(OB% 5C)@@8#& HCH?2:,+69T6.JMZC7"V#<XIN
MRE2C)2B]MG);---[[[-=$?7WH^K<5_);@:IAT9V6N"-2S,#,_P"CRNKAI^I.
MC(QI8]\(RDH4W.<+*)/:'/VBVBR5A3%.!3%$#%, &*8H@(" AU 0$/#H(>(#
M\ _ZNN^/D#33::::Z-/HT_8UX,_6 , 8 P!@# & , 8!#_:$_=-:;?F=B16K
MKG?H9SJ1:+;+U-.,< VF(N7/)"T?I/7[-1(JK?[(15/O"F*4Q #M] $"[.+>
M_%^0>MT;5)4^P4F?CW/HJP0T^T;M3$E")@LH:.[ATZ*NR[I1/L+"8AA,)BB0
M! < DI@# & , 8 P!@# & , 8 P!@$:M ?=1R'_3/)?1Z"R>+]R^,B^"][^$
M22N4@P!@&)=YTRY;"U5<J?0+<M1K;.12C2(LJ KIG9+ H10Z)EVATWC1-\D1
M1DH]9'*\9IKF<-A%4A0$"/7$;1&VM02=ZD=@2T8Q@I]O!M8"AQ-RM>Q&L4]C
M4E2RMB-:KFBWETUIU0Y5#PR"7F302B<%%53";!/;W;?1OOW==]O'NVVZE>YP
M1,4?CEL!^>,CCOO.J8(/#LFQG0&+=ZX!3 X,D*H&*'@4W;ZE#_-$,C\/I?W-
M_<4EA#_:F+_JYE_=DLH*C@# & , 8!%SDCH&O[5BXRS-*I7)C8-.DX^:KSN8
M230,Y)'N 76BG$F1!9TBT72[P2)D*)1< F)@[/:'-%K.D4:A"N_T:B[,Q;(6
MTSL24O4?,X.>SFH/OY4^O=XGUGY+OE'U+@[,R]*NUG5<'AK7,3*P-3HP9RLC
M5+)J<*\RO$E;739=7/D4I2?-V3G&+WVV[W&3:-BV10&+FZ1T? VEJF<CR'0D
MBO'J*"4A(1Z*[Q$K5L1IWQH]4$$BE,/<D*<Y@$W3.S1<^[-Q(2R:HT7Q]65*
MGSS24IQ4I+:/*GR-I;=VW1=QC?*MPCIG"O$N33H.5DZCH]THRHSK,5T43LGC
MXV3.JB;MN=RK63#M)MQ7:2<8II;DE $!\0S<GR\YP!@# & , 8 P!@'X4*4Y
M#D.4#D.0Q3%, "4Q3%$#%, ]>H"'4! 0Z" ]!ZX!'30R"#2Q;[;MTDV[=#;T
MDD@@D0J:**00L.($33( $3(!C"/9*!2@(B/3X1P"1O4.H!U\1Z^']'P_]X?Z
MPP#G & , 8 P!@' F* @ B'41Z '7Q$?P=, YP!@#J'CXAX?#_H_IP#@1 /$
M<  (#\'C_I^+^P?@'^S (UZ ^ZCD/^F>2^CT%D\7[E\9%\%[W\(DE<I!@# &
M , B=S?^]GV!^<TWZ;UW(^^/O^Y@E!#_ &IB_P"KF7]V2R@J. , 8 P!@'Y,
M4# )1#J @(#_ $"'0>@_%_3@$([MQ^KNK[&YW)KFIV*4L)K/7)63@ZW*R@N3
MQC5R_6GQ:QSF4"/?!("],JNT41*4O010 #FZYYO)TJC!NGJ6)CWVW=K59*FF
MRQR<5*3LY(2LY)J3ENXM;+=[;(^\Z%\I.J\6Z55P+Q3K6EX>F+2-4P\34=4P
ML150R[JL>&F]ME58GI..\7L(QKOA8Y2:B[&TD8LXG\X+IN_9]MUY=-76.MBS
M=N K[\L*=HR;LV(JB]].N7#LX)N"@"0)%0(8IC&,'0 $!S6Z!Q3DZIGY&#DZ
M=DX[A.2JL=+C!1@Y*2MES-*71;)=^ZVW/8_+)\@&@_)]PCHO$^A<7Z7JROIK
M^<\9YT;;[;\CLU1\W55T1YZ]U9SNR46MNO<]MF " AU_QUSVQ^53G & , 8
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MD:E_V"K]J_\ :/)_,W!'_?+,_P!W,C^L'U7;E]4\7\^F?LG'I&I?]@J_:O\
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MZATP#ZFVUK--K(NW%[JC1&&"/],^>ST8U4AS2B2:T>E*)KN2'8KNTU"F11<
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M-?)22\PE3J_'P",FY3*BL\1CD2H)*G2*=0J7V,I2@F4YBD H%*/9 ,%+_P
M8 P!@# & , 8!1+*DHM79Y!%,RJJT-*)))D*)C'449+E(0H!\)C&$ *'QF$
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M@]GX^<\7VW?L]_\ (/R>\2_JM._>^F?U(]W37_X^?^:U@]GX^<\7VW?L]_\
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MEB[L#.LU=C*/V\DX;HL8Y,Z45&O95X)E$42!V&3!%=RH!1_SS%3$$R@(G$
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MFLOGC"?SF /?.<=_79K+YXPG\Y@#WSG'?UV:R^>,)_.8!P/)WCL "([MUB
M F$PW*#  * =1,(B\Z  !XB(^ !XC@%92WWI1=--9':E#616(51)9*RQ:B2J
M9PZD434(X$AR'+XE.4PE,'B B& ?0-[:9'P#:%'^<<;_ #& 8PXTS$5/RV_)
MB#D&LK$OMR2:C.18JE<,G1"0,(F<S9PGU26*0Y3)F,F8Q0.4Q>O4! )MU;]J
M2^QO\0^JV]_\=OP)390, 8 P!@&*]U4!;:&N)ZCH&CBC-GBBJA+-P=QRK=G+
ML7[A!VU,4Y%TG"+4Z/=G(8@F.7M%$O7 /JVTQJ9)NBDIK'7AU$TDR',%,KP
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MXXN&B(-J#&%BX^(9 <R@-(QFW8-@4/T$ZG<-4TDNV<0#M&[/:-\8CE!4L 8
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M260,J@J4JB2@D[29PZE$!ZX!6T446R*3=NDF@@@F1)%%(A4TD4DR@1---,@
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9 8 P!@# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>img40748725_38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_38.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +G!3@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA #TJUX5_P"12TG_ *](_P#T$424>7FB-7O9FQ1116104444 %%%% !1110
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MC9_G7&&SQS@_A7K&B_\ ("T__KVC_P#017*_%_\ Y);K7^['_P"C%KJM%_Y
M6G_]>T?_ *"*;=XB2LR]1116904444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>C1?A;K1"*#LCZ#_ *:+76:+_P @+3_^O:/_ -!%#MRZ M]2]1116904444
M%%%% !1110 4444 %%%5=1O[?2].N+ZZ<)!!&9'8^@%&X'+>-[V>_FM/">G.
M5NM2/^D2+_RRMQ]\_CTKJ["R@TVP@LK9 D,"!$4#& *Y7P+87-U]K\4:G&1?
M:F0T:,.88!]Q1^')KLJTGI[J)CKJ%%%%9E!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\.E:0]U<Q+U=CI$18T5$ "J, #L*=116904444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!A^,_\ D3-8_P"O5_Y5+X5_Y%+2?^O2/_T$
M5%XS_P"1,UC_ *]7_E4OA7_D4M)_Z](__016G_+OYD_:->BBBLR@HHHH ***
M* "BBB@ HHHH **** "HKJ1XK2:2-=SI&S*OJ0.!4M17,CQ6LTD:;Y$1F5?[
MQ X%" \-L/&FN7N@VFLVNM7$_B&351;2Z-M&P)N(*;.HPHSNKM[O6-0\1?$.
M3PO:WL]C:Z?:K/=RV_$CR.,JN>P%>81O<0V>G>/=/NTC\3SZFUO>V"@ R*SX
MV;.V .M>AZ>O]@_&C5[O4&6&WUFPBD@ED.U=T8 9<GC/&<5TOR,D;7@#Q'=Z
MO%JNF:G)YFHZ1=M;2R[=OF+_  MCL2*[$LJ]2!]37G7POM9YM2\5:^RXMM4U
M%FMS@C>BY&X>Q.:ZGQ!X0T7Q/) ^JP32M""$\NYDBP#U^XPS^-8SMS%K8P_B
M\RGX6ZUA@?DC[_\ 31*ZO1?^0%I__7M'_P"@BO+/B3\//#>A_#_5=1L+6Y2Y
MA5-C/>S.!EU!^5F(/!/:O4]%_P"0%I__ %[1_P#H(H=N70.I>HHHJ"@HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\9_\B9K'_7J_\JE\*_\
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M)Z"O5+&W-II]M;%MQBB5"WK@8JJB2%%EBBBBL2PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]R/\3R:4(\S&W9$_@:QGOI+OQ9J496]U(_N4;_EE /NK_6NTI$18T5$ "J,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6ZU_NQ_^C%KJM%_Y 6G_ /7M'_Z"*Y7XO_\ )+=:_P!V/_T8M=5HO_("T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8?C/_ )$S6/\ KU?^52^%?^12TG_KTC_]!%1>,_\ D3-8_P"O
M5_Y5+X5_Y%+2?^O2/_T$5I_R[^9/VC7HHHK,H*I:Q>R:;HE_?11>;);6\DRQ
M_P!XJI('XXJ[2$ @@C(/4&@#S;5/&=]:?#[1(]/U.&_\3:XL4-K( F!))@L^
MU1@*@)['H,YYJ?3H-=\(>+]$TZ\\17>MVNL+,DJW:KNAE1-^]".B'!&WMD5T
M6D^!/"^A:K)JFEZ):VMZX(,L:GY<]=HSA?P K2ET:PGUNWUB6$O?6T30PNSM
MB-6^]A<X!. ,XSCB@"_1110 4444 %%%% !115;4+Z'3-.N;ZY;;!;QM*Y]
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M6_$G4O&,_P /]5CU3P_8VMF53S)H[T.R_O%QA<<\XKU+1?\ D!:?_P!>T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@##\9_\ (F:Q_P!>K_RJ7PK_ ,BEI/\ UZ1_^@BH
MO&?_ ")FL?\ 7J_\JE\*_P#(I:3_ ->D?_H(K3_EW\R?M&O1116904444 4=
M5UK2]#MA<:KJ-K8PL=JO<2J@8^@R>3["GP:II]TUNL%];2-<P^? JR@F2/CY
MU&<E>1R..17 ^.O[.TOQ;%K?B*P>ZTC^S'MH9S;&>.TG+DDLH!*[EV@-C^''
M>LCP1J\?B:Y\"1Z-%<20Z)I[+J-V8&2)6,*Q^2&8#<=P!../E!Y[ 'L%%%%
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M^U91C=<SV*;Z(2RTW4/'5]'JNM1R6VAQL)+/3F.#-Z/(/Y"N]5510J@!0,
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MNAJ5SJ:***R*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>*%LY2-CE1[<5%3X2H[G:T445S&@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_J_XT<DNP<R+U%4?[:TO_H(VO_?U?\:/[:TO_H(VO_?U?\:.278.9%ZBJ/\
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MZBJ/]M:7_P!!&U_[^K_C1_;6E_\ 01M?^_J_XT<DNP<R+U%4?[:TO_H(VO\
MW]7_ !H_MK2_^@C:_P#?U?\ &CDEV#F1>HJC_;6E_P#01M?^_J_XT?VUI?\
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M^VM+_P"@C:_]_5_QH_MK2_\ H(VO_?U?\:.278.9%ZBJ/]M:7_T$;7_OZO\
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M 'TW^-'_  A?AW_H%Q?]]-_C6]11[2?=ARKL8/\ PA?AW_H%Q?\ ?3?XT?\
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MX=_Z!<7_ 'TW^-'_  A?AW_H%Q?]]-_C6]11[2?=ARKL8/\ PA?AW_H%Q?\
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MW8<J[&#_ ,(7X=_Z!<7_ 'TW^-'_  A?AW_H%Q?]]-_C6]11[2?=ARKL8/\
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M 'TW^-'_  A?AW_H%Q?]]-_C6]11[2?=ARKL8/\ PA?AW_H%Q?\ ?3?XT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO>"B(==635-''"ZC"G[R$?\ 311V]Q79V.H6>IVJ75C<QW$#]'C;(JP0&!!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-Z]#_O6G_P!>G[*0<R.SHKC8_B3HY4F:TU.$C^_9O3A\3?#'\5U-'_OP,O\
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MBN(_X5EI_P#T&-:_\"__ *U'_"LM/_Z#&M?^!?\ ]:CEA_-^ 7EV.WHKB/\
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M-?M3*J8FNK$QQKAU/+9XZ5ZIHO\ R M/_P"O:/\ ]!%<K\7_ /DEFM?[D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCVSFNKU_PK9^(I(7N;O4(#$" +6Y,0.?7'6LII<W8I;&)\7_ /DEFM?[D?\
MZ-2NJT7_ ) 6G_\ 7M'_ .@BO+?B3X$T[1_A_JM_#J&K2R1*FU)[QG0Y=1RI
MZ]:]2T7_ ) 6G_\ 7M'_ .@BAVY= ZEZBBBH*"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /PMKP)_T,5M_P!\O_A1_P +;\"?]#':_P#?+_X5T'_"-:%_T!=._P# 5/\
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M_P!#%;?]\O\ X5GOH6D#XP+;_P!E67D'0P_E_9TV[O.89QC&:[#_ (1K0O\
MH"Z=_P" J?X4VHH6IS__  MKP)_T,5M_WR_^%'_"VO G_0Q6W_?+_P"%=!_P
MC6A?] 73O_ 5/\*/^$:T+_H"Z=_X"I_A2]T>IS__  MKP)_T,5M_WR_^%'_"
MVO G_0Q6W_?+_P"%=!_PC6A?] 73O_ 5/\*/^$:T+_H"Z=_X"I_A1[H:G/\
M_"VO G_0Q6W_ 'R_^%'_  MKP)_T,5M_WR_^%=!_PC6A?] 73O\ P%3_  H_
MX1K0O^@+IW_@*G^%'NAJ<_\ \+:\"?\ 0QVW_?+_ .%'_"VO G_0QVW_ 'R_
M^%6/%OA[18O!FNR1Z18)(FGW#*RVR @B-L$'%+X4\/Z+-X1T>232+!W:SB+,
MULA).T=3BG:-KBU*W_"VO G_ $,5M_WR_P#A1_PMKP)_T,5M_P!\O_A70?\
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M5)!D&1P.E=LOAO0BH_XDNG=/^?5/\*IJ*28KLP/^%M>!/^ABMO\ OE_\*/\
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M8QA1'@Y(/!S7IP 50!T'%%1Z!$6BBBLBPHHHH 0@,I4]",&O)_#UA:Z=\?\
M68;2%8HSIB,5!)Y)&3S7K#'"DX)P.@[UY=80:Q%\7[WQ"_A[45T^YM%M5<A-
MP8$?,1N^[6D-F3(C^.VGVC^$(;]H%-TEY"BR$G(!;IZ5ZA9_\>4'_7-?Y5P'
MQ=T_5->\.QZ1I6DW5W.9XY_,3:(U"G)!).<_A7;:/<R76EP22V=Q:.%"F*<
M,,#V)%$OA0+<OT445F4%%%% !7->/M.M-0\%:K]KA$OE6LCIDGAMIYXKI:Y_
MQHUT_A:^M+/3[F]GNH7A1( ORDC )R1@54/B0I;'/?#;3TU3X.Z392221QS6
MY5FB;:V-QSS6-\0_"6FQ7OAFU\.V,-IK37JF)[9=C")>79B.H]S6]\/O[3T#
MX>V^GWNAWRWNGQ%?*^3]\<DC8<_SQ6/I^H^*X;RZU.;P5=S:Q<G8LTMPGEV\
M>>$4#G:.I[FM5>Y#V/4T!"*#UQS2U'!YOV>/S]OF[1OV]-V.<5)6#- HHHH
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MLL;1K%  6R01GDCBJA\2$]C@O@_>Q:7\'UO9!^[MVGD8#T#$UAZ#XALWL?\
MA-_%^E7MVEY,5AG:,/;V46<* I/'NV*Z#X:Z%J-MX G\+:UI=U9R,LH:5]I1
M@Y/0@YSSZ507P]XCC^',W@%M)9Y23!%J <>1Y6_.\]]P';%:JQ#/5[::"XM8
MIK9E:%U#(R]".V*EJCHNFKH^BV>G(Y=;:%8@Q[X&*O5B[7T-$%%%%( HHHH
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MK:?8/Y]OYHE0HZ$HZ. -P.#V!!'(J[;RZ:/%7@N&?2Q-J#:5*]O>^>R^0H1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>img40748725_39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_39.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'R Q0# 2(  A$! Q$!_\0
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M0>TB=I17%_\ "T_"G_00_P#'#_A1_P +3\*?]!#_ ,</^%')(/:1.THKB_\
MA:?A3_H(?^.'_"C_ (6GX4_Z"'_CA_PHY)![2)VE%<7_ ,+3\*?]!#_QP_X4
M?\+3\*?]!#_QP_X4<D@]I$[2BN+_ .%I^%/^@A_XX?\ "C_A:?A3_H(?^.'_
M  HY)![2)VE%<7_PM/PI_P!!#_QP_P"%'_"T_"G_ $$/_'#_ (4<D@]I$[2B
MN+_X6GX4_P"@A_XX?\*/^%I^%/\ H(?^.'_"CDD'M(G:45Q?_"T_"G_00_\
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M_A:?A3_H(?\ CA_PHY)![2)VE%<7_P +3\*?]!#_ ,</^%'_  M/PI_T$/\
MQP_X4<D@]I$[2BN+_P"%I^%/^@A_XX?\*/\ A:?A3_H(?^.'_"CDD'M(G:45
MQ?\ PM/PI_T$/_'#_A1_PM/PI_T$/_'#_A1R2#VD3M**XO\ X6GX4_Z"'_CA
M_P */^%I^%/^@A_XX?\ "CDD'M(G:45Q?_"T_"G_ $$/_'#_ (4?\+3\*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:7F/M/S/*%.0&8DG]2:W:1'5T#J0589!'>EH;N[A%65D%%%%(84444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYKF_ 4T]UX82[N)GE:XGEE4N<D*7)4?3&*$M+@Y>\D=/1114E!1110 4444
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MJ^*[9M+\0>(=*L=*E^6Y^PH3+(O=?NC@]^1U[]* ._\ !&LS^(/!&CZK=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUU.:L["IMM7"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS>"]+EN)'DFE@61V<Y.2,FNAI25G8J+NKA1112&%%%% !1110 4444 %%%%
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M#DBMK=$M#"]]7N>K4445S'6%%%% !1110 4444 %%%% !1110 4444 %%%%
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M4<+^@%=7533S816ZV6GM (K51$(H6!$8 P%P.G%6Z "F3?ZB3_=/\J?3)O\
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MNJG#, 3V)I6944LQ"J.I->5VMCID5Y#<W'BO6KCRW5]C3A5.#G!"@9%=7?\
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M /A,](_Y[']*/^$STC_GL?TH]E/L'MH=SH**Y_\ X3/2/^>Q_2C_ (3/2/\
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M2,&[NZ/IZBBBO*.L***YO2?%9U/QQX@\-FS$8TA+=A/YF?-\U-WW<<8SCJ:
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M5-NRL,_LVS_YX+^M']FV?_/!?UHGU&SM9/+GN8XWQG#'%%MJ5E>2&.WNHI7
MR0K9-%Y[ZA:G>VAC^*M!&H^%M2L[&%!<S6[I'DG&2"!^M<;<)XPN-,DM#X5L
M@S0F,2?:CQD8S]RO2+_5;'3 AO+F.'?G;O8#-5K;Q)H]Y<I;6^H6\DS\*BR
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ML:*YSPUXWT7Q7/<0Z7<-));A6D5HV0@'./O >AKHZ336Y2:>P4444AA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!\T_%7_DI6K_]L?\ T2E%'Q5_Y*5J_P#VQ_\ 1*45ZM/X%Z'++=GTM111
M7E'4%>9^+/AUXEU[QJGB+3?%D>FM;H([14LE+Q+M 92X(+@MN.&R!N->F5Y/
MJND7/Q(^(^N:)?ZM>VFA:%';K]DM'\MIY)4W[F// Y'3TQCG(!8_X0CXE?\
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MBBB@ HHHH **** "BBB@ HHHH ^:?BK_ ,E*U?\ [8_^B4HH^*O_ "4K5_\
MMC_Z)2BO5I_ O0Y9;L^EJ***\HZ@K@O%7@G6Y?$)\3>#M8BTW6)(EAN8KE=T
M%THZ%N#@@<9P?PKO:\PT22&X^/OB3^U)@+RULX(]+B=N/)90TA0'OG&<>IH
MYW2OAE\1GT(>&;_Q!IMAH+R.UPMF"\T@9BS#)4<$D]Q[@]*]FTS3K;2-+M=-
MLH_+MK6)8HESG"J,"N?^)<&F7'PZUQ-6=$MQ:NZ,QP1*!F/;_M;@,#OTJ7X>
M7EYJ'P\T&ZOV9KF2S0L[');C 8^Y !_&@#IJI:MI-AKNESZ;J=NMQ9S@"2)B
M0&P01TP>H%7:* /,K+X'^%(/$6IWMS8PSZ=<+$+2R^<?9BJX<[MV6W'GVK9A
M^$G@."594\-VI93D!V=Q^(+$'\:[2B@!L<:0Q)%$BI&@"JBC 4#H .PIU%%
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M8>+-*6[M6VRKQ-"Q&Z-O\.X/<5OUYMJ_A:T\#VNO>*-*<QR"U=HH>=D;8)/
M(X)P<=N<8R:XEO'7BY;:203:H62+S2#I)P!C()_><#CK6GLT]4S+VCCHT=/J
MDD=CXF\16VJ>&K[4[2]>)E,4 D0@(/4]0:=X!T+3V\9WVIVOA^[TV".VC2+[
M0I3+Y8L0,D=-M=]X7O7U;POIFH3A6EN+9)&..I(K0FN[2USYLL<>.N3TIN;^
M&PE32]YO0H>(="&OV4=O]MN[0I('$EK*8VZ$8XZCFL*Q\#WUA?V\\?BC598H
MW#-%.Z,&'I]W/ZUTMCK6FZG-+#97D,\D6-ZQN"5_+Z5F^(?%MMX?GC@DLKZZ
MFD4LJVML\OYX&!^)J8N:]U%R4'[S-+68+ZYTN:+3;E;>[8#9*R;@O/ID?SKD
MFM?B-;E0E]I%RO?,$D9_1S6IH7BN]UK45A;P_J%G;E"WGW(1>>W 8G]*O>(Q
MK[6T(T VBS%_WC7(8@+CL!C/YTU>+LQ2M)<RN:<CSI9,ZQJ]P(\A < MCIGZ
MUQ$GC#Q;;'_2?![A?^F5U&Q_(D5<TW1/&']IPW.I>(83 C[GMX+;:KCTR68U
MT6M:1#KFFO8W$DT<;D$M#(T;<>ZD&A<L7J#YI*ZT(K37K:73H+F\_P!"DE4%
MH96&Y#Z'!(S^-8%Q\2]&M+J6&ZM[^$1N4,CVDNTX.,@A<$5):_#'PM;2I,=.
M6>5#D-.QDY]?F)KJC:VYZP1GMRHI-P0)5'U/G_7=7\/ZO=>+M233+F_G\L&U
MN19N5A(CZL2/E ///ZU5TC2%T.\OD@\7R:;(=/@N60^4I9V#':0>,@8]_FKT
M'Q?X*\02+XBN-'OXA;ZA 0UJT )8B/;@-N&,].E<3I]EXD4W<NK^#'O[B:U2
MWC;]RHC"@@'[QR>>OL*W33,'=:,ZOPHWBGQAHEI(/%UI$%MX_,2TA5I!D?QE
MB0&^BBNXAU/3/"EE;Z=JNN*]P%+>9=RH'<9Z]OY5#X T%-#\(Z=&]E';7IMH
MQ<;5 )8+W(ZUK:CX?TG5IEFO["WN)%&T-)&&('XUC*2;L]C:,&ES+<P](B\%
M7VKRRZ:--FOY<R.T10NWJ21S6[?:II6@P1F\N;>TC<X7S'"@G'O3-/\ #FCZ
M7<?:+'3K>"7;MWQQA3C\!4^HZ/I^KQHE_:0W"H<J)$#8/XTG)-^148R2V5RC
M:^+M O;J.VMM6M)9I#A$6922?IFM*_U&TTNT:ZO;B."!2 7D8*.?<UGVOA30
MK*Y2XM]+M8YHSE76)00?RK0OK"TU*U:VO;>.>%B"4D4,./K2?+?0I<]G?<R5
M\;>&W=576;(LQP )UY/YUM37$-O;/<2R*D*+N9R< #US6.O@SPZCAET>S#*<
M@B%>#^5;,UO%/;O;RQJ\3KM9",@CTQ2?+T"//U,+_A./#/\ T&K'_O\ I_C6
MY;W,-U:I<P2J\+KN5U.01ZYK&_X0KPW_ - :R_[\K_A6S!;0VULEO#&J0HNU
M448 'I1+EZ!'G^T8K^-?#<<C(^LV092009UX(_&M6PU&SU2U%S8W$<\)) >-
M@PX]Q68_@WP[([.^D699B2285Y)_"M2QT^TTRU%M96\<$()(2-0HY^E-\MM!
M1Y[^\9UWXMT"QNI+:YU6TBFC.'1YE!!^A-6++7-.U:VGDTV]@N/*!W&)PV#C
MVJ&Z\*Z%?74ES<Z7:RS2'+.T2DG]*GL]%T_2[:>/3K.&W\T'(C0+DX]J/<%^
M\OJ>4074UQ;2WNH^.6TUWGFVP/Y*A461E&,KD]*Z3X9>*4U1;W37U";4)8)Y
M-ER8MJM&#\O( 7./3TK"L(M0TQ6AN?!1OIH;B9H[DR1'*M(S#&6R.O2NP^'M
ME>6VG7\]]8FSDN+R258F96*J3P,CBMZGPF%+XC1\2W7B*$V\6@65M,TF[S);
MB4JL?3' 4D]_2J.C:7XO_M2*\UC6;;R #NM+:WPIX_O,Q/\ *NNHK!3LK6.A
MPN[MF9KGA_3O$5FEIJ< F@5P^TDCD4S3?#&BZ0 +#3;:WQC_ %<87D=^*UJ*
MGF:T*<8MW:"BBBD4->-)!AT5AUPPS3!;6X((@B!'0A!4M%.[%9!1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\T_%7_DI6K_\ ;'_T2E%'Q5_Y*5J__;'_ -$I17JT_@7H<LMV
M?2U%%%>4=05YOXB\1^+M:\8W?A;P9]CM#IT4<E_J-VNX(SC<B*,'J/8]^F.?
M2*\QUV+Q%X(\;ZEXGT;1)=;TO6(X1>VML?W\,L8VJRJ 2P(/.!]<=: +/A/Q
M'XAU7X/7.L2W4,VN0QW6R9H0%=HV;&57 _AQ75^$-;;Q)X0TK6'54DN[99)%
M7H'QA@/;(->)^&M<\9?\(*_@[1_!FI)>73SH]_=QM%%"LC,2<D 9 ;N?P/2O
M;_"^B+X;\+Z;HRR"3[' L3.!C<P')Q[G- &O1110 4444 %%%% !3)O]1)_N
MG^5/IDW^HD_W3_*FMQ/8?116/XF;74T=SX=2T;4-R[1=%@F,\_=YZ4)78-V5
MR'Q)XD30TMK>&$W.I7C^7;6RG!8@9))[*!R3_,X!S;WQ+JUK/9:2+:WDUBXC
MDN'17/EQQ)CJ<9R2P X[^U<>+'5=0\=VR>+)5MKJ31I1&UE*R()!)\VQC@YV
M^757P5>WK>)M)U/6)"QGT>XMX[AQCS?+F.&^K)M;\*W4$EW.:4VWO8]5\.ZW
M#XAT.VU*%2@E!W(>J,#@J?<$$59U;_D$W7_7,UROPMMY8_!*2.&47-S/<1YZ
M['D9E/Y$'\:JW_@K6([*XE;QGJY4(3MVP8^G^JS^M0DN8TE)\AJ_#3_DG&@_
M]><?_H(KJZY3X:_\DYT'_KSC_P#0175U$MV:0^%!1114E!1110 4444 %%%%
M '*?$O\ Y)SKO_7I)_Z":\6\0Q1:I'+?PG6;9C:C/^AY(PG17##"'N"#W(ZU
M]%:CI]MJNGSV-Y&)+>="DB'N",&N/_X5!X+_ .@2O_?;?XUM":4;,QG!N5T)
M\+M(O[#PQ8W$^K375K<6<3102JO[D[>0" #CMSGI5#QQH^FQZZFH7?A:[U6*
M1/WLD+[]I'0>66Y_ 5Z%8V4&G6,%G:QB."! B*.P%3D C!&1[U//:5QNG>-C
MB?!>K^$'NI;'0[-+"\*[I+8VIA< <<@@'J:[1HXRP9E4MT!(IBVL"3><D*+)
M@C<!S@UD^(_#SZ]# (M4O;"6%]ZO:R;<GW!!!^A!I-IL:3C'N;8  P!@>U+7
M':/IGC'2]3ACN]7M=1TXD[VD@V2C@XQM.#S["MW7=<MO#]B+R[2=HMX4^3"T
MA7W(4$X]Z3CK9#4]+M6-2BL'1_&?A_76":?J=O+(?^68<;A]1U'XUO4FFMRE
M)/8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:?BK_ ,E*U?\ [8_^B4HH
M^*O_ "4K5_\ MC_Z)2BO5I_ O0Y9;L^EJ***\HZCB?B;XIU+PWH5G!HB*^LZ
MK=I96>X A&;^+!X..!SW(KB[_1OBEX*TN3Q(?%D>L+:*9[S3YD.PQ@9;:3Z#
MGC;T_ ]/\4M$\1:DWAS4/#>G17]WI=_]I,,DJH#@<9W,O&1V.:Y_5=4^,>K:
M/>Z;+X(TQ([NWD@=DO(\@.I4D?ONO- 'JNC:I#K>AV&JVX*PWENDZ*W50R@X
M/N,U>KQ;P_=_&'P]H%CH]OX*TV2&SB$2/)>1[F [G$N*]:T6;4;C1;.;5[6.
MUU%X@;B"-@RQOW ()S^9H OT444 %%%% !1110 4R;_42?[I_E3Z9-_J)/\
M=/\ *FMQ/8?1112&4-3T;3]81$O[:.<1G<N\9P:2\T/3;^SAM+FSBD@AQY:%
M1A<<<5H44^9]R7&+Z#(HHX(EBB0(B#"J!P!5;5O^03=?]<S5RJ>K?\@FZ_ZY
MFG'XD$_A9@?#3_DG&@_]><?_ *"*ZNN4^&G_ "3C0?\ KSC_ /0175T2W80^
M%!1114E!1110 4444 %%%% !1110 4444 %%%% !3719%*NH93V(S3J* ,:Z
M\*:%>7D5W/IENUQ$X=)2@W CN#U%6=:M+V]TJ6#3KP6ETV-DQ0.%P0>AZUH4
M57,R>16LC@DOO'^D2*EWI]EJT.X#?;2&*0#U*MD'_OJNVFNX[6Q>[N2(HXTW
MR%C]T=\U/39(TEC:.10R,"&!Z$4.2?048N.S/+Y?&OBC6O$.HVWA?^QY[&U,
M866:8_-N0-P5!%;7@_Q#XBO/$>HZ-XAALDFMX(IT:U9B"'+#N!_=KSR_B\&Z
M7XX\1PZQYNGOYD1M7M!)&0-@S@Q^_7-=3X"U'3]7\=ZM/I<\L]FFG6T ED5@
M209.[ '."*V:5C"+ES'IOVF#_GM'_P!]"I%977<K!AZ@YKAV^&5DSEO[7U<9
M.<"]E _]"KJ-%TB/1--CLHIYYE3/SS2%V.3GDDDUE)12T9M&4V]473/"I(:5
M 1U!84Y)$D!*.K8]#FN1U+X?6FI:C/>/JFIQM*Q8I'=R*H^@#8%:WA[PY#X=
M@EBAN[JX$C;B;B9I"/H6)]*&HVT8*4[ZHUVFB0X>1%/H6 H26.0X216/H#FN
M<U[P7;:]J NY=0U"!@@39!<NB_7 8"G>'_!UOX?O'N8K^^N&==NVXN'D _!B
M:+1MN'-.]K:'1/)''C>ZKGIN.*:L\3L%65"3V# UC>(O"\'B/[/YUY>6_D[L
M?9YWCSG'7:1GI6?I/@*UTG4XKV/4]2F:/.$FNI'4Y&.06(H2C;<'*=]$=6SJ
M@R[!1ZDXIHN(2<":,G_>%9^O:)%K^GBSEN+B!0X??!*R-Q[@@USUM\-[.VNH
M9UU;56,3APKWDA!P<X(+8(HBHM:L)2FGHCM&8*"6( '4FH_M,'_/:/\ [Z%0
MZA8)J&FS632RQK(FPO&Y5A[@CG-<A_PK"R_Z#&L?^!TO_P 51%1>["3DGHCN
M<@C.>/6HGNH4C9A+&2 3C<.:2"U6"R2U#N55-NXGG\ZXN7X9V85Y/[7U<G!;
M O9>?_'J(J+>K"4I):(HV.O>.M9BEN]/M]+%KY\D4?FR/N(1BO.%QVS72>"M
M;U#6M.NCJ<<*75M<O _DDE3M.,C.*X7PGXJ\/^'M&ATR_O+F.XLKR<[2DA)^
M=@,G'/'-=3\-;B.[T[5;J$L89M0E>-BI7<I/7!K6:7*]#&FWS+4[:BBBN<Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YI^*O_)2M7_[8_\ HE**/BK_
M ,E*U?\ [8_^B4HKU:?P+T.66[/I:BBBO*.H**** "BBB@ HHHH **** "BB
MB@ IDW^HD_W3_*GTR;_42?[I_E36XGL/HHK'\2Z/<ZYH[V5IJ<^G2LP(G@QN
M&#TY!H6X-V1RWCSQ#>:;XATO3OMK:=8W,,[_ &I5!W2JH*ISQSR?4XP*HV'B
M77]>;1-&F)T[4)=.:^O'106&,*HP<XR22<^F*R_%F@WEK!I6AZW?WE_I0M[A
MVO2F9!<Y!B.5'! W8]P*ET8:SI%_H/B+Q!%*7GT9K.X8*6*2 AEW ="<D?7Z
MUT):*QR2>KN=[X*UV3Q#X9@O;A56Y5GAF"]-Z,5;'MD&KVJ7MLVEW2K/&28S
M_%[5C?#O2;C2_!T,=Y&8YKF66Y>-NJ>8Y?!^F[%4-1^&'@^*QN9UT6W\Q4+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[*UP2TL[+T,CL6;'MDFKNJ6MNNEW3+!&"(SR%'I6::YS5J7(8WPUX^'.@_\
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MR=HB13G\5-;].4[/1"C3NM6><?V-\3?^AATW_P !&_\ CE']C?$W_H8=-_\
M 1O_ (Y7H]%+VGD/V2[GG']C?$W_ *&'3?\ P$;_ ..4?V-\3?\ H8=-_P#
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MVJV,LMY,%#NMRZ@A0%' .!P!7EGPL^&7A;Q19Z[)JME+*UIJ<EO"5G=-J #
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M150F1US@BL74?C-X.TYT7[5<W.8TDE-K 9%@##(WGH#[<D&L?Q+_ ,FRP?\
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M; #$'H>37-?$F1Y?V=UDD8L[V=BS,>I):+->B^&O^15TC_KRA_\ 0!0!XO\
M"GQUH7@_P;J<>IW$C74^M3F&TMXS)-(/+CY"CH.#R<#BO7/"GC31/&EE+<Z-
M<F3R6"S12(4DB)Z;E/K@\].#Z5Y[^S]IMF-"US5!;Q_;GU26W,^/F\M51@N>
MPRQ/O^ JWX6A2S_:%\906ZB.&6QAF9%X!<B(D_7+,?Q- '0:M\5/#NE:M<Z8
MB:AJ%Q:'%U]@M&F6 ]]QZ<=\9K=WZ9XV\(2>1)YVG:G;.@<H0=K KG!P00?Y
M5YO%!XJ^%&IZW=V^C+KOAR^NWO7DMY,7-ONZ[@>6 'X<9R,FO3?#>OZ?XHT"
MUUC2V8VEP"5#+M92"001V((- '(?!;69M4^'T-I<G-SI,[V#GU"8*_DK ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>img40748725_40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_40.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,R!X4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKAM*\"1^'=1CU>;5]\5JK2./(V_+M.>=Q_E70/XLT-+#[:=0C\C>8PP5B2P
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M5ISCS1DFN]R:BL&#QGX>N;A8(]23S&.!N1U!/U( K:GGBMH7FGD6.)!EG<X
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MU:3A)I;(PP>,C6I1<VE)]/\ @&E1116)W!1110 4444 %%%% !1110 4444
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M-:-G>6]_:QW5K*LL,@RKKT/:LG&2W1W0K4YNT9)_,GHK.CUW3)=4.F1WB->
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M1[LO]R'_ -#-7/B7I=G!%!J,<.V[GEVR2;C\P"\<9QV%4_'(/_"=V7'5(?\
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M!! (.0>AKFQ#E=)K0]C*HTK3E%IMN[LK6\M=3SKXJ_\ ,)_[;?\ LE=OH?\
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MA-+%( #M94)!YXZUYQKAU_Q+\!;75SX@DMY%TV6:^7[.K_;%P?E)XV=.H]:
M/5]*U2TUK2K74["0R6MU&)(G*E25/L>165X>UW5=6U;6[74- GTVWL;CRK6X
MD?(NTRPWKP/0'C(^;':N/^$F@^(;?P_HFIW'BN2XTI[,%-+-DBB,$<#S,Y./
MIS6A\//$&JZSXJ\;VFH7;3P:?J?DVJ%5'E)N<8&!S]T=?2@#T&BO)+34O%OQ
M+U[6?[%U_P#L#P_IMPUI'+#;B26YD7J221@=^".& P>2.Y\(V7B;3K2ZM/$F
MIV^IM'*/LMW''Y;R1X_C4< @^F?K0!T5<1X'\6:CXB\1^+K"]6 0Z3J'V:W,
M2$$IEQ\W)R?E'I7;UX'X4M_%>I>/O'FG>'KV#2[:35G>[U)XQ+)'AW 1$/!)
MR>3TQU!Q0![Y17E/AO5?%.C^/[WP)KVM'41<V!NK#4?)5)4ZCD=#T;KGE1V-
M:GPF\3ZGK>D:GIFOSF76](O7MKEB "PR=IX '4,/^ T >A45YWX)\0ZMXH\?
M>*KK[8Q\/V$@L;2 *NUI!C>X;&3]TGKT<5R7@6^^(GQ#T*3_ (J-=+L;>X>-
M[]8%DGN'Z[ . JJ".>OU[ 'N-%>9^!?$GB&S\;ZIX&\4WB7]U;0BYL[Y8PAE
MCXX('&?F'XAAD\51M=7\5_$OQ!JT>@ZX-!\/:;.;47$5N))KJ0=?O?='?C'!
M'![ 'K59!\3:4/%*^&C<-_:K6_VD1>6V/+SC.[&/PS7":-K_ (G\)_$*S\(^
M)]136+/4XF>PU'R!$X=0248#CL?4\KSV'(7'AOQ0_P <AIZ>-)5U%M,,RZC]
M@0E8MQ_=;-V#]<T >E?%'Q9J/@[PY97^F+ TTVH16S"="PV,&)Q@CGY17;UX
MW\:+:_TWX6Z-;WM\VIWT.J0A[DQB,S-MD_A&0.PJ;Q#9?$ZQ\/77BR7Q1!:W
M5K&;EM&AM5:&.,<LA<\L0 <G!]C0!Z]17!ZA\1DL/A)#XS:W0SSVR&.WYVF9
MOEV^NT')]<#UK(D\.?$K^PVUL^-2FKB'S_[-%E']G!QN\KZ]MV/\: /4Z*\I
MU+XHW\GP23Q?I]O''J,A6!P5W)#)OV,V.XXR ?49S6QX<\/>)XKG3M67Q^VL
M64H#7,3VT9BF4@\QLOW><=/_ *U &[=Z[JL'CBPT6+0)YM+N+=I9M4#X2%QN
MPA&/]D=\_./2NAKS[5?$&JV_QQT/08KMETNXTR2:6WVKAG'F8.<9_A'?M6?X
MGUS6M6^*4/@RSUX>'[060N?/2-6ENG)QL0MT[].?E;KV /4:*P?"^E:WH]K<
M6VLZZ=8'F V\SP".14QRK8X;GO6]0 5Q/Q*\6ZCX1T_1I].6!GO-3BM9/.0L
M-C!B<8(YX%97C+Q'XAU+QW9>!_"MY'I\[V_VJ^U!HA(8H^P4'C/3\6'(YKA_
MB3IOB_1$\/V.M:Q'K>E/JT,D%X\(BFBD&1Y; 'D$$D'GH>G% 'T'17!^/_%&
MK6.J:+X7\.-#'K6LNP6XE3<MM$HRSXZ$]<9S]T\=*YWQ))XT^&EG!XBE\4R:
M_IJ3HE_:7-JD9VL<;D(Y'/&,XY'6@#UZBO-=5\4:IHOQ>T*WFO6D\.:]:^7!
M&RJ!'/V(.,\G9W_C-3?$WQ#J]IJ7AOPYX?O&M=3U:] >5%5C' OWC@@COG_@
M)H ]$HKSOQ9XAUW4O'%IX(\,7D=A<&V-Y?Z@T0D:"+. $4\$G(_[Z'(YK+O=
M0\5?#?Q#H8U7Q VO:%JER+.0W$"I+;R-T8$=1WY[ \=#0!T.H^+-1M/B_H_A
M:-8/[/N]/>YD)0^9O'F8P<XQ\@[>M=O7E>M_\G)>&_\ L#R_^UJN>,/$^OW_
M (WM/ _A2XBLKQX/M-]J$D0D^SQ^BJ>">G_?0Z<D 'I%%>/>(+KQM\+DM=;N
M_$;>(]$,ZQ7L$]JL<D08_>1@3[CKC)'![:7Q.\6:_HFK^#T\-NLK:E-*GV=L
M!+@D1A Q(R!EL\$?6@#T^BO'?$MI\2?!^BR>*V\71:D]N5DO---FJP[,@$(>
MN!GKA3C)SFM'XB^.;^S^&^@^)= E>%KZ[MV*  ED=&8QG(/< 9]J /4:*\:\
M31?$W1?#4WC&X\3P17-MMFET:*U4P1QD@%-^<L1GG\<'I5F&/XB^.="_X26S
MUZ/0(I(?-T_38(A+YHQD&1S_ 'NPP0 1QUH ]<HKSWP?\1#J7PG?Q9JR#SK*
M.47(C&!(Z=,#MN^7VR?2LK1M+^(/C#0X/$<GC$Z/+>1^?:6%M9HT4:$93<3R
MV1@\YQG\* /5Z*\U\.>.-4UOX:>([J\"6^O:+'=6\[Q*-OFQQDAP.G7MTR#V
MK#\)K\1_'_A6SU%O$Z:);"/;"\=LLLMVZG!D<\;1D$8'IR#U(![-61H?B;2O
M$;7ZZ9<-,;"X:VN,QLNV0=1R!GZBN)\"Z[XC\8>$=;T>\U-;#Q#IEVUD^H10
MJ_*G[VS@$\,.WK7&?"[PWXGO;[Q$]CXSDL$MM8=+I18))]J<'ESEOESZ#.*
M/H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *RO$NN1^&_#M[J\D+3I;(&,:M@MD@ 9[=:U:Y#XI?\
M)-=:_P"N2?\ HQ: ,8?%#4XM.BU2Z\$ZHFF.BRFYCD$F$(R&Q@<8]2*[?0];
ML/$6D0:GITOF6TP."1@J1P01V(->9:?\5]"T[P1IVE);W=QJ*:?%;+ 8=J._
MEA?O$XVY[UM>$K.?X;?"VYN=77,\6^Z>%6SM9L!4SZD@?B: /1**\WT[2O'7
MB'1X=<?Q9_9US<QB>WLH;13%&K#*AB>3QCKG'O5*?Q?X@UOX57NK64WV+6])
MN#'=B)%(<)C=@'/&U@WU4]J /5:*YW_A*[?_ (0#_A*/E\O[%]IV_P"WM^Y_
MWU\M<O:>+=7\/?"2'Q!K$IOM4NSNMTD0 $N?W8PH'&T;OTH ]*HKSBZT/Q]:
M:/+K)\7;]2BB,S6/V1/(.!DQ@_3(SC\NM)KGC:]O?@R?$^FR?8[UQ&"4 .Q_
M-".!G/'7&>QH ](HK@?#-EXRU>[LO$6IZV+.TE.\:0D (\HK\NYO[QX)X_+H
M,?P[=>(O'TFIWL?BQ](>VNFABT^W@1O*48P7SRV>GX'Z  ] \2:G?:/H4][I
MVER:G=1E=MM&2&;) )X!/ YX%9/C/Q)J&@_#^;7+:W2&^5(6\F<;A&790RG&
M,D9(JKX[U+6?#WPRGNTOQ_:L"0J]U'& &8NH8A2,#.3^=4?B;*\_P<GFE;=)
M)%;,S>I+H2: .[T^=[K3;6XDQOEA1VQTR0":J>)-0FTGPQJFHVX0SVMK)-&'
M&5W*I(S[<5PMGHGC_5= M]2B\1QZ7.L"FTTZ*!73:%^42.>K'C/! _E+:>*9
MO%GP:UR\NXUCO8+2YMKE5&!O6/.0.V00?KF@#KO"&K7&N>$M-U.[$8N+F$.X
MC&%SD]!6W7">&-9A\/\ P;L=6G4LEK8[]H_B.2 /Q) _&J6G:5XZ\0Z/#KC^
M+/[.N;F,3V]E#:*8HU894,3R>,=<X]Z /2**Y7X?^)[CQ1X=:>^B2+4+2=[6
MZ5/NEUQR/J"/QS754 %%%>7V%]XG^(FHZG<:5KIT31+2<VT!BMP\D[#DL22,
M=0>#WQCJ: /4**Y*&_UGPEX2U2]\3WD.HM9;F@GB3RVF3 VA@!@,6.*P-*TO
MQWXHTJ'7)_%G]DM=+YUM96]HK)&AY7<2<G(]<]?PH ],HKS31_$OB+7?"_B3
M2)9!;^*-'RGG0(,2D9*D C&6V$=,<@C&:Z+P-XF&N^!+/5[R8>;'$RW;D8PR
M<,QQZ@;OQH ZFBO/_ VJ^)?$7A;5]9-S'Y]Y<2_V7'<)B.%!D#.T9(SD=_NU
M5UC0/&^EZ+=ZR/'$DUW:PM<-!]C186"C<5 ^@]/RH [;Q)J$VD^&-4U&W"&>
MUM9)HPXRNY5)&?;BH/"&K7&N>$M-U.[$8N+F$.XC&%SD]!6!<:X_B3X+WVK2
M(J2W&E3F15Z;@K*V/;(-)X8UF'P_\&['5IU+):V._:/XCD@#\20/QH [NBO-
M].TKQUXAT>'7'\6?V=<W,8GM[*&T4Q1JPRH8GD\8ZYQ[U-I7C/4-8^%^MZG(
M%MM8TV*XAE,8&!*B9# '/J/QS0!Z%17E>@1>/?&7ARUU%O$2:/%Y*B!8X%D>
MX8<&20\;02#P.W;UT_!^LZYXQ\%ZA9S:B-/URSN3:27L<*ORI4[MG R1E>WK
M0!UVB^(--\0Q7,NFSF9+:=K>4E&7#KC(Y'/45IUXI\,-"\07<6HSV?BF2RMX
M-5=9X!9J_P!H8;2S9)^7(XQSBO:Z "BBN7U_1_%&K:F$T_Q#'I.EK&,^3 ))
MG?G.2>%'3&#ZT =17(S^)KZ/XJ6OAM5A^PR:>;EB5._?N8=<XQP.U8VB:IK_
M (>^(L/A36-6_M:UO;4W%M.\021"-W!QU^XWKV/'(HN_^3@+'_L#'_T)Z -F
M?Q-?1_%2U\-JL/V&33S<L2IW[]S#KG&.!VKKJ\XN_P#DX"Q_[ Q_]">K'B37
M]=U/QG'X/\-7,=E*D N+V_>,2&%#V53P3RO_ 'T.1@F@#OZ*\LUF]\5_#B6S
MU._UUM=T6680W236X22'/\2D$D]#WQT&.<C2\::_J7_"6Z)X:L-532+>_B:6
M2_*!F.,X1=W )Q_X\/H0#T&LS3_$&FZGJNHZ9:3E[K3V5;E"C *6SCDC!Z'I
M6;I6A>(+"UU&UN?$\EZLT6VTGEME$ELY!&XXX?JIP?2O-/"OA[Q)=>-O%=M:
M>+Y+2ZMY8A<W0LD<W).[!*EL+C!Z9ZT >X45Q'BW7]7MM4T?PKH<\:ZMJ"EI
M+R6,,(8U'+[>F3AN.G'N*QM<N/%/P\2UUFY\0OK6EM.L5[!/;JC*&_B0C\>.
MG(Z]@#U"FR,5C9E4NP!(4'J?2O._B)XFUW1?$'AJWT$^:U]YR?9R!ME;"A"3
MC. 6SP16[X:T;Q'I'VN?7/$9U0S1AA'Y 187Y)VGN/P'TH O>%M8U'6](-WJ
M>C2Z3<>:R?9Y6))48PW('7Z=JVZX3X;^([S4OAZ^LZU=M/)$\S22E0#L7GH
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M=_)-<*.=F%RP_#FK6B+XN\>:?_;R^(FT2RF=OL=K;VZN=JDC<Y/)R0>.GTH
M],HKB? _B75-0.M:-K;1OJVCR^7)/&H59E(.UL=,_*>PZCBN/\'W7CWQ[H:2
MKKYTRWMBRF[$"O)=29SC QA5! ^OKV /9J*9$KI"BR/O<* SXQN/<XI] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y'\9/^1J^'G_8
M87_T.*O7*I7VD:;J<UK-?6%M<R6DGFV[S1!C$_\ >4GH>!^0]*NT >5_ #_D
MGUS_ -A.;^24>&?^3B/&W_7E;?\ HN*O2--TG3M&MFMM,L;>S@9S(8X(PBEC
MU.!WHATG3K?5+C4X;&WCO[E56:Y6,"20   %NIP /R% 'S]X1\*^!(=?\0:#
MX\MX(=7@OF>WENKR2!98&QMVD.JGU]3N]N/2_!N@_#/3?$TG_")_8I-6BMV+
MFWO)+C9&2 >2S*.2!ZUU^K>'-$U[9_:^DV5\4&$:X@5RH]B1D?A2Z3X?T;0D
M9-)TJSL0_P![[/ J%OJ0.?QH \]^%/\ R.OQ'_[#!_\ 0I:A^*6L2KXU\-:!
MJ&K7.C^'+U9'O+J"7RO,89PA?LN=H/;Y\GH*].LM)T[3KB[N+*QM[>:[D\VX
M>*,*97_O,1U/)_,TW5-&TS7+7[+JMA;7L .X1W$8< ^HST- '@GB:Q\%:=X_
M\$VWA:<7-TNL6YNY8[R2Y4 RKM!8L5#$AN!SQS74?&G4XM%\4> M3FCDDBM+
MV69TB&6*J8B<#N<5Z3!X4\/6L%O!;Z'I\45O.MS"B6R )*.CC ^\/7K7'?$?
M2M0U#QQX N+2QN+B"UU!WN)(HBRQ*3'RY ^4<'D^E %'XD?$?PS??#F^M=)U
M6VU"]U.(6UO;0-OD)<@'*=5P,]0.<"N>^(7A273/AGX(?4K1[BTT62$:I C'
M(C8+Y@R"#C(*Y!'45Z]:>$/#=AJ/]H6F@Z;!>;BPGCM45P3U(..#]*V719$9
M'4,C##*PR"/0T >.+X4^!;:>M]YNE"!ER,ZM*&Z9QM\S=GVQFG?%[3;*/X/:
M1+H,&=*L+JVNH1'D@0E653SSCYUZ\\\UZ O@'P>ER+A?"^D"0'((LX\ ^N,8
MK>>WAEMVMY(8W@9=C1LH*E<8P1TQCM0!YEX[^)7A>\^'NH0:=J<5_=ZE9210
MVMJ0\J[D.2ZCE HR3G'0TW2X);G]FLPPH7D;1)=JCDG"L<#WKN;+P?X:TX7
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M3Z].M ' >)M0U#5?V>UOM5!^V3)"7)&"P\]0K8]U /XUJ?$?_DBLG_7"U_\
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MQCVKI[SPCX<U"Z:YN]"TZ:=SEY'ME+,?4G'/XUH+IM@FGMIZ65NEDR%&MUC
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M:78:1;?9M.LH+2'.=D,80$^O'>J^I>'-$UB=)]2TFRNY4&%>:%6('IDCI[4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!?L5^]O%Y2D?(.F<DY-=A0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYXQ\T*,[ L/0]!GMFLGQKIGPYM/A_/<V6M2:QK=Q"#;ROJ,DTSMG+,T8;
M;.X<8]: /2?&OBF]C^#,WB?2I6L[N:SMKF)E 8Q^8T>1R,=&(K-\(67CWQ%-
MIGBC4_$(T^QDV.ND);AA)!C@NV1AFZ]#C/;H*7BS_DV*W_[ ]A_.&O1/"?\
MR)NA_P#8/M__ $6M 'G&I^(/&^H?%W7/"OA^^AAMU@A<3SQJRV2;$+.JX^9B
M6  .1S^(H7FM_$'P1XU@\,+J<7B-]8@+6,MW&(?)DR<LV,Y"@$D9Y&,8Z5M>
M'_\ DXWQ;_V#(/\ T&&H_&G_ "7GP)_URG_]!:@"CK5YXW^&^K:)JFJ>)_[<
MTS4+Q;6]@>U6,1LW.4Q[!B.G3D<\>A>*]-\4:J;.V\/ZU;Z1;G>;NX:#S9NV
MT1@_+_>R20>F*X_X\?\ (JZ#_P!AVW_] EJ'XI:Q*OC7PUH&H:M<Z/X<O5D>
M\NH)?*\QAG"%^RYV@]OGR>@H 9<W?BSX>^,_#=IJ'B5]>TG6KG[&ZW$"H\3D
M@ @C)ZL/R/'0UN_$3Q5K-CJ>B^%O#)BCUK678"XE7<MO$H^9\=">IZ'A3QTK
MS;Q-8^"M.\?^";;PM.+FZ76+<W<L=Y)<J 95V@L6*AB0W YXYKK/B1<CPQ\5
MO!_BZ\5AI4:26<\H!(B+!ADX]I">.NTT ;^D>&O'>B:Y9SR^,4UK3I'Q>V]W
M:B)E7!^:,J3SG'' ^M9FJ>(/$WC#Q[?^%?"VI)I%CI2*;_4?($LC.>B*#P._
MI]T\]CU0^(7A274K#3K36K2^N[Z01PQ6<@F(.,Y;:2%''>N \/ZO9^ _C#XN
ML=?N([*#6G2\M+J=ML;8+'&X\#[Y'/ *X],@%N;5_%OPX\4Z-::[K?\ ;V@:
MM.+43RVXCEMI#P.1U'(/)/ ;@8YGUO\ Y.2\-_\ 8'E_]K5G?$+6+#Q[XF\,
M>%O#UU%J,L5^M[=S6SAXX(TX.7'&<%N_4 =2*T=;_P"3DO#?_8'E_P#:U %S
MQAXGU^_\;VG@?PI<165X\'VF^U"2(2?9X_15/!/3_OH=.2,;Q!=>-OA<EKK=
MWXC;Q'HAG6*]@GM5CDB#'[R,"?<=<9(X/9-7OX?!'Q].MZPWD:5K6G"V2[<'
M9&Z[.">W^K'M\P/KAWQ;\4Z5XE\.0>$O#M];:KJNJW,2)'9RK*$4,&W,RY '
M _ D] : -SQSXEUF7Q#X<\*^&[R.RN-:#RO?M&',42+N.U3P20#^0]<URGB&
MT\<^'?&7A_0T\?WCVNM/(B3O9QN\3J!G*GJIW#G(QSQQS'\5!!I7BCP=;ZE?
M76DZ=96CB+6+2$O(LP  4XYVC:I([[C5KP=?^"]3\9VNJ7_CZ7Q!K42F&Q6\
MMVM4CW<?*K* 6.<=>_0G% '0ZUXAUCPW\7]"L[N^:30-9@-ND;(H$=P.,@@9
MY.SO_&?2I/B7XAU:UU/PUX;\/WC6NI:M>C?,BJS1P+]XX(([Y_X":D^,FA2Z
MMX"GO;3(O](D6_MW7J-GWO\ QW)^JBN;^'6H-\0_B1?>-)8BEMI]A#96J,/N
MRNNZ3'T)<?1Q0![)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<A\4O^2:ZU_UR3_T8M=?7(?%+_DFN
MM?\ 7)/_ $8M &3I7C_PMI/P\TQ+K5;66:#3(8WM$??(SB( IM'?/'/3O5'P
M%I-WI7P8U3[9&\;74-S<)&_!5#'@<=L[<_C71>"O"^@1^%=#OET6P^UR6-O*
MTYMU+ES&I+;B,YSS6[XF_P"14UC_ *\9O_0#0!Y3X&^)^@>%_A_I^GWRWC74
M E^6.'(8F1V #$@="*ZGX5Z%?:?9ZKK%_"MLVL7/VF.V5@WEIR1R..=WY 4?
M#33K35_@[IUA?0K+;3I.CHP[&:3IZ'T/:J_PIO[BP?5_!M_(6N-'G;R"W5H2
M>WMG!^CB@"O\'T74Y/$?B.?]Y>7>H-%YC=0@ ; ]!\P_(>E=[XDT^'5?#6I6
M-P@:.:V=>>QP<'Z@X/X5YKX5U>W^'/BS6_#VO,;6RN[DW5C=NA$; ]03]-H]
MB"*W?&/Q&T6'0[BQT6]CU/5;R,P6T-F?-.YQC)QQQGIUSVH D^#EY)=_#FS6
M5F8P2R0@M_=#9 _ ''X51T7_ )+_ .)/^P;'_*&NE\ >'Y/#/@O3].N/^/D*
M99A_==CN(_#./PKFM%_Y+_XD_P"P;'_*&@#1^*VI30>%8]'LSF^UFX2RB4=<
M,?F_#&%_X%6!XAL(? /C7PCJ]L-E@T*Z5=-C P!A6;WP<_\  *76;2X\=?%I
M[*TU":RM] M@?M$*ABL[$$XSQGG'_ #4GC'X=ZM>^%[TS>*=1U$V\9N([:=$
MVLR@GMSG&0/K0!I_&?4I=/\ A[,D3LANYTMV*]U.6(_$+BNRT32X-%T2STVV
M0)%;Q*@ [D#D_4G)_&O.KV.X^)'P2@>V/FZC"BL4ZEY8N&'U89(_WA6OX4^)
MN@7^B0)JFH0Z=J4"".YANF\L[U&"1GL?3KVH [P*H8L%&X@ G')'^2:21BL3
ML.H4D5BZ#XNTCQ-=WL&DRO<)9[!).$(C8MGA2>I&.>W(ZULS?ZB3_=/\J /(
MO!EUX[\=^'DD;7AIEI"[(;Q(5>:Y?.<8X"JH(''7W[=#X(U_6X_%&K>$?$=P
MEW>V2">"[5 OFQ''4#C^)??D]<5S?P?\9Z'IWA<Z1J5['8SQRO*CW+!$D4_W
M6/&001BM3PC<)XF^+>N^(['+Z7;VJV4<^,"5\KDCU'RM^:^M &?I.I>-O%^N
M:]H]GK'V"SL]1F#W_DJ[J@8A(D''H23G/OV.YXAUWQ!I3:#X1TN[BN?$-]&?
M-OYHQB-%ZR;>1GAO7[IXYJ/X6_\ (5\:?]AF7_T)JK^-K@>'/BCX<\3WJL-+
M-NUE-, 2(F._!/\ WWGZ T -UZW\;^"--.OIXF.MV]NRF[M+BU5 R$X)4@DC
M&1TQCKSTK/\ BX;K6/ ]GK]IJKII,\<#?V>81\S,2P<OG((! QCM6U\1/&>B
M7/@Z[TW2]0M]1O\ 45$$$%I()6)8C)(7..,_C5#Q_HT^F? ^UT]QF6R2V$VW
MD C ;\,F@#K=!T[5_#UK=WNN^)WU6V6#>%:T6+R0H))X)SQ_*N<T1?%WCS3_
M .WE\1-HEE,[?8[6WMU<[5)&YR>3D@\=/I72KJNE^,/"M[8:5J-K//<Z>RF.
M.8,T6]"HW <J<GO7F7@;0?AW?:$MMXB@M[;7+5WCNX[J]D@8D,<$#> >, X]
M* .^\#^)=4U ZUHVMM&^K:/+Y<D\:A5F4@[6QTS\I[#J.*3X8:YJ6N^!5U#4
M[IKBZ\V5?,90.!TX  J?PCIO@RQCU,^$OL['"I<O#.\HS@E1N8D=STK(^#7_
M "31?^N\U &-X,N_'?CKP\DAUY=,M8F=&O%@62:Y?.>G 55! XP3[]NE^'^O
MZQ<ZEK?AW7YTN;[2I5"W*J%\U&S@D#Z#\_:JWP4_Y)W#_P!?,O\ ,4SPE_R6
M#QK_ +L'_H(H ]'KS[Q/KFO:KXVA\'^'+Q+!DM_M-]?&(.T:]@ ?JO\ WT.1
M@UZ#7E=U?P>$_CC=7VK2+;V.KV"I#<2'"*RA!@GM]P_]]#UH PO'-CXGTJ_\
M.V6L:E'JM@=2C>WO#$(Y5;(!1@.O'(/UKO?&7B'58=:TKPQX?DBAU/4@SM<R
MIN%O$H)+ '@GANOI[BN0^)7B?2]:U/P[9:7<+>BWU*)YKB#YX4+'Y5WC@L<$
MX'H:G^)NEZ8OC[0-6\16[2Z#+"UI<,&<"-P6*DE2".6!^@- %S7+CQ3\/$M=
M9N?$+ZUI;3K%>P3VZHRAOXD(_'CIR.O;6\7ZWJ\WBC1O"VA7B6,NH1O/->F,
M.4C4$X4'@D[3^G2L:7PO\'[=(Y&?36WL @CU.20L2<<*LA)JI\39H+7QUH+7
MU[<:/906CM;ZE:PEV6;.-IQR5  X_P!H^M ":K;^,-&\::-H*^-KIK;4PYCG
M:UC=T91D@J>H/'.>_3BMKXC>)->T/Q%X;M=#_>27IG0VQ VROA0FXXS@%L\$
M5F^$;OPE?>+(=2N?&4FMZT%\FU^U0FW5,\812 "QR1^)XS6AX[_Y*7X#_P"N
M\_\ [)0!KZ/H?C#3++4)+OQ)#J=]<0#R$G@V103<YY7DKR.PZ=*Q=8T#QOI>
MBW>LCQQ)-=VL+7#0?8T6%@HW%0/H/3\JZCQYJ=]H_@?5;_30?M<,0*,!DH"P
M!;\ 2?PKS&>U\$R?#]M4O]9FU/6[FR.T2ZA(\WVAD^[Y:MV8C@@C'6@#T.P\
M:+)\,D\6742AEM3(\:=&D!*X'H"P_#-<YI%E\0]:T>'Q(OB6&WN;A?/@TQK5
M?),9Y56;J,C'/) /7TJ:;IMQJW[.(M+5"\QMY)%5>K;)V<@>I(4\5M^%OB)X
M9A\":=-=ZI;PSVMJD4ML7'F[D4+A4ZG..,#O0!D_""\-OH_BB]OU$!COY)KA
M1SLPN6'X<U:T1?%WCS3_ .WE\1-HEE,[?8[6WMU<[5)&YR>3D@\=/I6;\-K:
M76?"_C:U$;P2WMU/&(Y1M9&=",-Z$$\UD^!M!^'=]H2VWB*"WMM<M7>.[CNK
MV2!B0QP0-X!XP#CTH [[P/XEU34#K6C:VT;ZMH\OER3QJ%692#M;'3/RGL.H
MXKC_  ?=>/?'NAI*NOG3+>V+*;L0*\EU)G.,#&%4$#Z^O;MO".F^#+&/4SX2
M^SL<*ER\,[RC."5&YB1W/2LOX*?\D[A_Z^9?YB@#T&)72%%D?>X4!GQC<>YQ
M3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB++$I,?+D#Y1P>3Z5U]IX0\-V&H_P!H6F@Z;!>;BPGCM45P3U(..#]*VJ*
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M!AX9HPZ,/<'@U/10!CZ5X4\/Z'.T^E:+86<S#!D@MU5L>F0,X]JLZKH>E:Y
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M,8.<8^0=O6LVU\*_$?39[6_7QQ%J4V]#=65S9JD++D;@K#D8&<8 S[54UO\
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M4>)R0 01D]6'Y'CH: /7:*\Q^*WBKQ!X;UGPI%H!,DM]/-$UK@;9VP@0$D9
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M^>P/'0T =#J/BS4;3XOZ/X6C6#^S[O3WN9"4/F;QYF,'.,?(.WK7;UY7K?\
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M]E;:7"DVK:G<"VM%<?*">K'Z9'YUA:EHGC_1=)FUF'QA]ON[>/SI;)[-1%(
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M=.EU6'59+&W;4(8S%'<F,&1$.<J&Z@<G\S0!YOK?_)R7AO\ [ \O_M:C6_\
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MJMA;7L .X1W$8< ^HST-58/"GAZU@MX+?0]/BBMYUN842V0!)1T<8'WAZ]:
M.#^*/_)0?AM_V$W_ )Q5ZI5.\TG3M0N;2YO+&WN)[-S);22QAFB;CE2>AX'Y
M"KE 'S/X-\(WU[\/AXM\-YC\2Z/J4[Q;1G[1$ I:,COP6P.^2._'7^.-83XG
M_!";4M(C8W-I*DUW: Y>)DR'&.X ;</4#UXKUW3=)T[1K9K;3+&WLX&<R&."
M,(I8]3@=Z;8:+I>ESW4^GZ?;6LMV_F7#PQ!#*W/+8ZGD_F: /(M)\-? _5-%
MAU'&FVX>,-)%/JTL;Q$]593+D'.1[]LUH^-+3P[:?L^ZJOA58QI#A&B,;,P8
M_:%#'+$D\@]?2NYG\!^$;JZ-S/X9TEYF.YF-FGS'.<GCD_6M2XTC3;O2VTNX
ML+:33V4*;9HAY> <@;>G! - %3PG_P B;H?_ &#[?_T6M;%,AABMX(X((UCB
MC4(B(,!5 P !V&*?0!XWXOU&+5?C GAOQ)K5SI7AZ.Q6:!$N?LZ74I(X=^,C
M[P'/5>.36)IEOX4M?C]X8@\).);:.&X6>5+B2=&E\F0X5V8@X!&=IQS7MFK^
M'=&U]8UU?2[.^$1RGVB%7*_0GI1;^'=%M);.2VTFQ@>R#BU,5NJ^3O&&V8'R
MY[XZT <GXP@^'?BK4)]&\17UC%J=@ -TD_V>:'<H8;6.-PP0<<CUYK#^%>OS
M6D/BZ&ZUF;4_#>B2;K34ILR'RPKLX# '> JJ>/7@8(KT/5?"?A[7;A;C5=$L
M+R=1M$L\"LV/3)&<5>LM,L--L%L;*RM[:T4$""*,*F#UX'% 'B7CJS\"6FCW
M/B_PCXC@TS6QB2(:=> ?:')&5:('(SW  ]QUK6^(7B;7+?P1X--W=W&DKJTD
M":O>6X*/ "JE@#_">6./]DCUKT&#P)X3MKU;R#PWI4=PK;U=;5 5;U''%:]_
MI]GJEG)9W]K#=6T@P\4R!U;Z@T ?.7Q5TSP!IGA6)/#]]]OU>25',J:A)<D1
M=V?YBBY)7' Z\5ZM\9-"EU;P%/>VF1?Z1(M_;NO4;/O?^.Y/U45T</@OPO;V
M$UC%X>TQ+6<J98A:IMDP<C=QS@],TOC*]N]/\':K<6%C-?7@MV2&WAB,K.[?
M*/E .0"<GV!H \W^'6H-\0_B1?>-)8BEMI]A#96J,/NRNNZ3'T)<?1Q7LE<7
M\*_"[^$_A_I]C<1&*]F!N;I3U$C]C[A0J_A7:4 >.ZQJ-OX,_:"75]8<6^FZ
MOIGV>.Z?[D;@KP3V^X/^^P?6L_XO>,=%UU_#^EZ/=IJ#0:K!//<6I$D,>=P5
M2XXW').!_=->RZGI&FZU:_9=4L+:]@SN$=Q$LB@^H!'!]ZIQ>$O#L&GQV$6A
MZ>EI',+A85MU"B0='QC[WO0!Y?\ &+2=-'CGPMK?B*U>?PWA[.]*LX$9.2A)
M0A@,MGC^Z?H9KCPE\#+2W6XDETHQM]WR]7ED+?15D)/Y5Z]<VMO>VTEM=013
MP2#:\4J!E8>A!X(K$M? OA.RNQ=6WAO2HIU.5=;1 5/J../PH Y;XR: UU\/
MA?:<GEW>A2)>6Q0<HJ<,![!?F_X"*Q_A_J'_  L/XF7WC-HRMGIUA%9VBL/N
MRNNZ3'N"7'T85Z]+%'/"\,T:212*5='7*L#P00>HJII6C:9H5H;32K"WLK<L
M7,=O&$!8]20._ _*@#Q?QSH?A^'XV17?C2VWZ#JMD(X)WE>...=<#YF4@C@=
M^/G!]QNVWA+X,6>JZ?\ 93IDE]+/&+5(M3EF+.2-ORB0\9QU&*]0O].L=5M&
MM=1L[>\MV()BN(ED0D=.""*S--\&^&='N1<Z=H&FVUP.DL5L@=?H<9% '#ZW
M_P G)>&_^P/+_P"UJHZO?P^"/CZ=;UAO(TK6M.%LEVX.R-UV<$]O]6/;Y@?7
M'JTFDZ=+JL.JR6-NVH0QF*.Y,8,B(<Y4-U Y/YFG:AIEAJUH;34K*WO+=B"8
MKB)9%)'0X(QF@#RGXM^*=*\2^'(/"7AV^MM5U75;F)$CLY5E"*&#;F9<@#@?
M@2>@-5OBU<Q>&-7^'%Q,DLT.G7#EQ$,LRH(<X'<X%>IZ3X7T'09&DTG1K"RD
M<;6D@MU1B/0D#./:N,^(^E:AJ'CCP!<6EC<7$%KJ#O<211%EB4F/ER!\HX/)
M]* */Q(^(_AF^^'-]:Z3JMMJ%[J<0MK>V@;?(2Y .4ZK@9Z@<X%8OQ'TJ;0_
M@GX2TRY&+BWO+1)5SG#^6Y8?@<UZO:>$/#=AJ/\ :%IH.FP7FXL)X[5%<$]2
M#C@_2KVI:3IVLVZ6^IV-O>0I()52>,. XZ, >_)_.@#F_BI_R2[Q#_UZ'^8J
MQ\-_^2:^'/\ L'P_^@BNAO+.VU"SEL[RWCN+:92DD4JAE8>A!I;6UM[&TBM;
M2&."WA4)'%&H544=  .@H \+\ Z1<Z[^SCK6G6:%[F66<QH.KLNQ@H]SC'XT
MSP1X=^#^L^$[*;5([&WU2*$)?1W6I2P.)%&&;:9!P3SQQSCCI7N.F:3IVBVG
MV33+&WL[?<7\J",(N3U.!6=J'@KPOJMVUW?^'M,N+ESEY9+9"['W.,G\: .5
MMM/\'6/PP\5_\(6(#9-:W2S/#*\H:00G^)R<\$=#CFK_ ,'_ /DE&@?]<G_]
M&/760Z3IUOIK:;!86L5BR%&MHX56,J1@C:!C!%26-A::79165A;16UK$,1PQ
M*%51G/ 'N: /,_A)_P C5\1?^P[+_P"AR5F_##7]*\/^(/&VEZQJ%K871UJ2
M2-+F98S*&9@-H.-W0=/45ZU9:3IVFS74UC8V]M)=RF:X>*,*97/5F(ZGD_G5
M.]\)^'M2U)=2O=$T^XO5((GEMU9\CIR1SB@#8HHHH ***ANKNVLH&GNYXH(5
MZO*X51^)HW FHK@=:^+&B:>6CT^.34)1W7Y(_P#OH\G\!7 ZM\3_ !'J6Y(9
MTL8C_#;+AL?[QR?RQ773P56?2WJ:QHSD>Z7E_9Z?%YMY=0V\?]Z60*/UKD]1
M^*/AFP)6*>:\<=K>/C\VP/RS7A$]Q/=3&6XFDFD;J\C%B?Q-1UV0RZ"^)W-X
MX9=6>I7_ ,9KALKIVDQ1^CW$A?\ 08_G7-WGQ+\4W>0-06!3_##$H_4@G]:Y
M&BNJ.%HQVB:JE!=#0N=>UB\S]IU6]FSV>=B/RS5 DL2222>23245LDEL6E8*
M***8'T3\/?\ D0]*_P"N;?\ H;5P'QE_Y#NG?]>Q_P#0C7?_  ]_Y$/2O^N;
M?^AM7 ?&7_D.Z=_U['_T(UX^'_WM^K..G_%?S/-:***]@["2*>:W;=#+)&WJ
MC$']*UK3Q?XBLC^XUF] ]'E+C\FR*Q:*EQC+= TGN=U9?%GQ);$?:#:W:]_,
MBVG_ ,=Q_*NFL/C+9/A=1TJ>$]V@<./R./ZUX_16$L)1E]DS=&#Z'T9IGCSP
MUJN%AU2*.0_P7'[HY]/FX/X&NB5E=0RL&4\@@Y!KY1K0TW7=5T=]VGW]Q;\Y
M*HYVGZKT/XBN6>7+[#^\REAET9]/T5XOI/Q@U2W*IJEI#>)W>/\ =O\ X'\A
M7H6B^/O#VM[4BO1;SM_RQN?D;/H#T/X&N*IA:M/=&$J4X[HZ:BBBN<S"N0^*
M7_)-=:_ZY)_Z,6NOJ"\L[;4+22TO+>.XMY1AXI5#*P]P: .5\%>%] C\*Z'?
M+HMA]KDL;>5IS;J7+F-26W$9SGFM/QO_ ,B'K_\ V#Y__0#6W##%;01P01I%
M#$H1(T7"JH&  !T %)<6\-W;RV]Q$DL,JE)(W&592,$$=Q0!S7PW_P"2=:'_
M ->P_F:Y+PWJMGX.^)'BK3M<G2R74[@7EK<3-MC<$L<;CP/O?H17J%I:6]C:
MQVMI!'!;Q+M2.-=JJ/0"J^I:-IFLQ+'J>GVMXB'*">)7VGVR./PH \X\7ZG9
M^-/&7AG0]$N([X6MV+R\F@;='$BD?Q#C. ?QP.]3^.KN'2/BGX.U2]D6*S"S
M1-*YPJDC&2>@'SBO0--T;3-'B:/3-/M;-&Y801*F[ZX'-/U'2M/U>V^S:C96
M]W#G<$GC#@'U&>] ' _%6.'Q-\.FO-(FBOX+.Z6X<V\@=650RM@KUQNR?I6?
M9>'O@[?::E\IL(HV4,R3:G(CI[%3)D'_ "*]0L=/L],LTM+"UAMK=,[8H4"J
M,\G@5ER>"_"\MP9Y/#VEM(3N+&U3D^IXYH XOQS;:+:_!"Z3P\JC2RT30[69
M@<SKDY;D\YZU:^(__)%9/^N%K_Z''7>76EV%[IQT^YLH);(@ V[Q@I@'(^7I
MP0*6[TRQO]/-A=VD$UF0 8)$!3 P1QTXP/RH JV7_(J6_P#UXK_Z!7!_#'1-
M.\0?"6#3M4M_M%H]Q(S1[V7)#Y'*D'K7IJQ1K"(E11&%VA . .F,>E0V&G66
ME6BVFGVL-K;J21%"@503R>!0!B:'X!\,^&]0^WZ3IGV>YV&/?Y\C_*>HPS$=
MJX#P%XLTG0_%OBO3]4N%M/M.J3/%/,=L1(=@5+'@'D'FO8Z\W\$^&A/<^+H=
M=T??;3ZO)+"MY;_+(,MAUW#D<]10!4%_;^+_ (TZ9<:3(MS8:-:.9[F,Y0LP
M8 !NAY9?R;TJYX8_Y+5XQ_ZX0?\ H"5WFG:7I^D6_P!GTZRM[2$G)2",("?4
MXZFEBTRQ@U">_AM(([RX $TZH \@' R>IH X#XK)+87GA?Q)Y+RVFDWVZY"#
M)5&*'./^ 8^I%:GB'XA^&8/"UW<VVKVEU++ RP00RAI'=A@ J.1R1G(XKLY(
MTFB:.5%>-P596&0P/4$5D6OA'PY8W:W5KH6FPSJ=RR);("I]1QQ^% '#6>@7
MFE_ "ZL9XF6Z>SEN'C(.5RQ?&.QVXR/7-;_P[\1:1?\ A'1+"#4+9KZ.S1'M
MA*IE4H-IRO4=*[(@$$$9!Z@UF6'AO1-+O'N[#2;*UN7!#2PPJK$'DC('2@#Q
MGP?X9\$PW6J:)XPAAAU>TNV"/<W<D*RQ'&W:0P![GUP17HGA+1_ &GZY.?"_
MV5]02'$C073S;4)'<L5Z@>]=+J?A_1]996U/2[.\9!A6GA5V4>@)&13]-T;2
M]'C:/3=.M;-6^\((E3=]<#F@#AOA;_R%?&G_ &&9?_0FH^%O_(5\:?\ 89E_
M]":N]L],L=/>X>SM(+=[F0RS&) ID<]6..IHL],L=/>X>SM(+=[F0RS&) ID
M<]6..IH X*3_ ). B_[ W_LQKT>JITRQ.IC4C9P?;A'Y0N-@W[,YV[NN*M4
M><?&'_D%>'_^PS#_ .@M1\8?^05X?_[#,/\ Z"U=[?:98ZFD27]I!<I%()8Q
M*@8*XZ,,]^31?:98ZFD27]I!<I%()8Q*@8*XZ,,]^30!C^/?^1 U[_KQE_\
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MK $=C@C(]<UZI9?\BI;_ /7BO_H%7+ZPM-3LWL[ZVBN;:3&^*50RM@Y&0?<
MU*L4:PB)441A=H0#@#IC'I0!P7P8_P"2<6O_ %WE_P#0J['7;*34O#^I6,)
MEN;66%"3CED('/XU-8:=9:5:+::?:PVMNI)$4*!5!/)X%6: /+OAGXST/3?
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MD,CH0593*F"".HK/UW7KWQ-HMSI-K\/]5-W<1&%7O[=8XHB1@,')[=1TKJM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBJ][?VFFVKW5[<1V\"=7D; __7[4)7T0%BJ&JZUIVB6WVC4;
MR*WC[;CRWT'4_A7FGB7XN,VZV\/1;1T-W,O/_ 5/\S^5>97M]=ZE=-<WMQ)<
M3-U>1LFO0HX"<M9Z+\3HAAV]9:'I>O?%^5]\.A6@C7I]HN!EOJ%Z#\<_2O.-
M1U;4-7N#/J%Y-<R=C(V0/H.@_"J=%>G2H4Z7PHZHTXQV04445J4%%%% !111
M0 4444 %%%% 'T3\/?\ D0]*_P"N;?\ H;5P'QE_Y#NG?]>Q_P#0C7?_  ]_
MY$/2O^N;?^AM7 ?&7_D.Z=_U['_T(UX^'_WM^K..G_%?S/-:***]@[ HHHH
M**** "BBB@ HHHH Z'0O&VN^'RJVEXTEN/\ EWG^=/P'4?@17I_A_P"*VDZD
M5AU-#I]P>-['=$3_ +W;\>/>O#Z*YZN%IU-UJ9SI1EN?5L<D<T:R1.KQL,JR
MG((]C3J^:M"\5ZQX<E#:?=L(LY:!_FC;_@/;ZC!KUWPS\3=)UK9;WQ&GWIXQ
M(W[MS[-V^A_6O+K8*I3U6J.6=&4=5J=Q1117&8A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKX>5%V>QPU*;@]2>BBBN<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY)7U1UU%<MHGCS3-8O$M#'+;3OP@DQM8^@([U9\0>+K+P[<PP7,$\C2KO!C
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M,CJ<A@>A!KGQ&'E1E9[&=2FX/4?1116!F%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_A7$^!3/<^'O$5BC[08<HS'"JS*P.3VZ#GVJ6ZU?QIJ>G-IC:/(AD3RY)A
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MZY?5/C%I\2,NF6,T\G9YL(H_ 9)_2L7P?XHUSQ+X]MFNM3\F,*S&!1A&4?P
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MGZM.5.3C(\^47%V84445F2%%%% !1110 4444 %0W5W;V-L]S=2K%"@RSL<
M5-7!_% S_P!E6(7/D><=^.F['R_^S5=.'/-1.;%UW0H2JI7L7V^(V@"78&N2
MN<;Q%Q_//Z5TUG>V^H6<=W:RB6"095QQGMWKB_"<7A75-$@LVM;1KT)B595
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M+V7,N\@1(A^^3SU],=ZRE1G%I-;G73QU"I"4U+2._D:]%>>3?$'5[:".ZGT
MQVTO^K=F8!O3G&#5U/'%\WAZ?56T8JL<J*-TA"LK9^8';SS@?C5/#U%T,HYG
MAFVKO17V>WW';45D^'-;37](2]6/RWW%'CW9VL/?Z8/XUE:?XQ;4?%DNCPV0
M,,;.IG$G9>^,=">/QJ/9RNU;8Z'BZ*4'?X]O,ZNBBBH.@**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLT=$HW.W_P"%7:S_ ,_^D_\ @2?_ (FC_A5VL_\ /_I/_@2?_B:XBBIY*O\
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M[E?0=F^H_EGUKDQ=#VL+K=&5:GSK3<^B**1661%=&#*PR"#D$4M>$< 4444
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MCTN34&U!-*=DMKTGYI(6#;,GO]T\^_M0!Z=17B7P_P#!+^,O"-K>:[JM\;6
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MU634M&MU22SE:7S"JL.5#>G./J* .SM?%,%UXVO?#"VTBSVELMPTQ(VL#MX
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M'2_]V3_T8U<!\9/^1BL/^O3_ -G:N^^')_XH'2_]V3_T8U<!\8S_ ,5%8?\
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MNO$%\7<^59Q_+;6J<)"@X  '&<=36-4I5'JW85I/J=9_P@W_ %-7AC_P8?\
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M*@!V@22-\</%D9=BBVEOA2>!\D?:N^N[ZTT^ SWMU!;1#CS)I B_F:\_\/\
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MGCWQ#;:Y?_V!?_9M/TEXK>9EC5O,G?)(R0>@4C'L?6NB\)^-UMOA+-J-Z?\
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M]QQU%*+VM<\G^,6H"2_T[35(/E1M,^/5C@?^@G\ZY[P-8:+>:Z=-U^S=FN5
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MD6(MRRCN0<<>F>G4'B+7$^*5]H^AZ#:73V$=TMS>W<L)18U7(QSU.&;\<8H
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M?7!.?PKD+2U\#7VCQW6K>,IV\031;Y+S[6X,,C#)"J., \8]NU=8WA^X\1?
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M==VZ06&CZG=:RX _L]82I5_]IN@7/?'X5!XTCO/#7Q!TOQG%937>G"W-I?+
MFYHQDX;_ ,>'_?/N* -S1?A[9^&]:@O](U+4(8 &%Q9R2F2.?(."<]""<YYZ
M=LUP]YKFB>*O&&M0^*]<:STG3YC:VEBDQC68@D,[%>3R./K[<]OHGQ$L?$NM
M6]CHNGWUQ P8W-X\1CC@ 4D YZDG QQUSSBN2@>S^'_B_7E\0:2\VDZE<&[M
M;Y;7S5CR260]2,9Q^&<<T +X0UJQTKXDQZ!H.LR:EH6H6[2)&\AD^S2J"2 3
MSC"_J/2JB)HVN>/-?LO'6H7%O<QW.W3H9;AH81#D[2A&!DC:>>N?7-=OX9\5
M>'->U81:%I4Q58V<WRV7EQ+T&W<<')ST]JP/$?C3P7JT-QIGB31[P7L1=$MY
M;0^:2,\QN.F>QR* -SQ-;:CX;^%][;Z#=7ES=6\7[J>1_,F"%\L01U*H3@]@
M!Z5@^"-!\'ZJFGZGH^M7K:M#Y<UQ_IK>:Y&"RR(>JDY!P,>AJWX-O-3\'?"Z
MUN=:L;^<QRDB"--TL,+'C*GL.N.P/M7,:Y=Z%XL\1:/<>![&==;2]5[B[AMV
MA1(Q]XR= 3R.?3([@4 >W4444 %%%% !1110!Y[\7=6^R>'(-.1L/>R_,/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH4GRU&ZCV1YG:V=U?3>5:6\L\G]R)"Q_(5]%>%%OE\)Z='J,;0W:0A&5A\P
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M/67_ (]#J8\W\TQ^FZO4*YCQ[X37QAX:DL4=8[R-A-:RMP%D'KCL02/QSVH
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M]OMEAGCS\I;/W<C&1S65H?AV_P##7P<\16^HHL,]Q;7ES]G5MP@#1$!,_P#
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MW]N,(,L(U1UW'\QD^]=%X_LKK4O FKVEG \]Q+#A(T&68[@>!^% '+Z#\/\
M1M;\$QZCJZ2:AJNIV@N)+VX<F1&9<@+Z!>/R_"L_POXEO=.^ MQJ0E+7%FLD
M$#MR5RX5?RW#'T%>@>%[2XL_!&DVEQ$T=Q%811O&W56" $'\:X_P5X1N[GX1
MW7A[58);*>Y:4 2+@J<@JV/3(!H YOP_<^ H_#$$&JZ%?W]]<1![J[DL'D=Y
M&&6*R=0.>""/6MGP-8KK7PZU+3=;LY;FSL+F7[";R,JVP)E3SZ9/TSBKFA^(
MO%'AG1[?1=4\'ZA>2V48@CN;$AXY44 *?;C^7Y=GI%UJ.M:)*^JZ6VERS%T6
M!I1(P0C 8D="<GB@#A?A!X9T6;PAIVLRZ= ^I)+*5N"/F&'('Z50/ARV\3?&
M_P 16NH.[6$,5O/+;*Q"SL(HPH;'89)K0^'4OB/PQ%%X5U#PU=M&ER^-01AY
M(0G.<XYY]^_:M;1-)OX/C!XFU.6TE2QN+6!89RORN0D8(![X*G\J */Q$\(6
MEEX ,FA6JVDFDW OX1'GC!^?&?;YO^ BD\<>*O[0^%MG+I_-UKXBMHHU/.7^
M^OZ%?J:]&GACN()()D#Q2*4=3T((P17AW@70[Z3XB+H-X_FZ=X7FGFA[C<[#
M9GWS\WX&@#V70M*BT/0;'2X<%+6%8\C^(@<G\3D_C6A110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5^(_B?J&D>
M.6L[>W@?0;.XAMKZ<H2RO("3@YXP >W53ZUZ-K.IPZ+HM[J<_P#JK6%I2,]<
M#./J>GXUYGH7A"76?@]J;W2[]3UII-1W$<F3.Z/\\9_X&: /6@<C(Z45R'PW
M\0#7/ -C=329FMD-O<$]F3C)^J[3^-<CX6T'_A9UO>>(_$=Y>M#)<M'9V<,Q
M1(47H>.IR?TSSF@#UVBN#U8W/PW^'.JRPZG<Z@\3_P"AM=G<\0<JBKG^(*26
M[>F*SM*^%UMJ.BVNI:EK&K'7)XEF:\2Y(:)V&["CT''Y=J /3:*\T^(>NW>A
M:;X>\/-K#6[WY$5[JA&UUC0*'<>A8MG\"*Y37I?".@:6=6\'>*)EUJV=7"FY
M>3[3R P<'@\<_A0![M17E?Q!UN:[TGPG=7$UW9^'M1*RZE):DAE5E5E4D<XY
M;ZX]0*Z7P=X=\.:?*^I^&M2FGM)8S&T*79FAW9!W8.2'&,=>YXH Z^BO%T31
MM<\>:_9>.M0N+>YCN=NG0RW#0PB')VE",#)&T\]<^N:]9T73$T?2(+".ZN+J
M.(';+<R;W()) +=\9P/8"@"_6!X1\4P>+M+GOK>VDMUAN7MRLA!)*@'/'^]5
M[6]%M?$&E2Z=>F402%2WE2%&X.1R/I7D_P )O!>E:EITFKW#70NK/4V$6R<J
MN$V,,@=>3S0![317F.K?;/''Q'O/#1U"YL]%TJ!'N%MGV-<2, 0"?3YL8_V3
MZ\9_B;1C\+9--U_0;Z\%@;I8+VRFF+HZ-DY&>AX//J1[T >O44=:\N^(7]IS
M_$7PM9:5?M93W,4\7G#G8I'S$#UVYQ[XZ4 >HT5Y!XQ\%_\ "$Z(WBCP_JNH
MKJ%G(C3M/<>8)U+!3N'<Y(]L9JW\3-4O;O1?!VH:7)Y-S=7T,T&6^4,R@KN]
M1DB@#U2BN#L?"MEX!LM1\3/?W]_J$=C(URT\V5G;AR<8X.5P.>A[UB^&?! \
M:Z%#XA\4ZGJ%S>7V98XXIS'' N2%VJ.G'/X_C0!ZM17G'@6\U#1O&FM>"KV]
MFOH+2);FRFG;+B,[<J3W^^OY'UKGO!?ARY\82:[#J>K7:Z/;ZG.!:02%#+(3
MR7;^Z!C ]<].X![117EOAV*Y\%?% >%([VXN=(U"T-Q;1SON,+#/0_\  &].
MH]*S(-#O?%7Q-\6:5+J5Q;Z.LL4MW'"^'EPI"(#V7EB?H/J #TSQ.->;17'A
MMK9=1WK@W'W=N>?QK5@\W[/'Y^WSMHW[>F['./;->9_$72HO#'PA?3=/N+DQ
M03IL>23+X:0MC(QP,X'L!6K\1/$UUX;\#6TME,(KR\>.VCF;_EEN4EG_  "G
M\\T =W65XDUR+PWX?O-7FA>:.V4,8T(!;+ =_K7D>HVO@:ST6>\TKQC<'Q!#
M%YD=X;MRTTBC(!'3!/'XUH>*5A\8_!JV\47QE%_;VW&QRJ,_F!&)4<')4GVS
M0!ZOIE\NIZ39Z@B%$NH$F56ZJ&4'!_.K5<1\/O!VEZ-I>G:S:M=&ZNM/B\P2
M3ED^958X7H.161J_A#P=!<S2>*/%,\M_*Q<-<ZB(VCSTV)G@ ?44 >G45YW\
M)-6N;W2]6L)K][^'3[YH;:Y=MQ>+^'GN.,CZURO@[PM<>,[G78=4U.[71K75
M)BMM#)M:29B,ECZ  8'J3[Y /;J*\K\76[>"/$OA'7(+BX;3X%72[HRR$YCQ
MA6;L3@L?JHK0^*5S/?G0_"EE*T=QJUVOF,AY6%.6/Z@_\!- 'HE%-CC6*)(T
M&%10H&<\"N ^)NIZ@9M"\,Z9=/:S:U<F.6XC/S)$,!L?7=GC^Z1WH W/B!>W
M.G> ]7N[.=X+B.'*2(<,IW <&K_A:XFO/"&BW-Q(TD\UA!)([=68QJ23]2:\
MT\;_  \B\.>#-1OM%U;4(PL0%W!<3>9'<(6&<C'#9P<^U=AI^E-K/POT*S_M
M.YTZ,Z?:M+-;.$<H(URN[L#ZT =C65XDUR+PWX?O-7FA>:.V4,8T(!;+ =_K
M7D'BVS\*>&-+.J>$_$Q&MVTB-MBU#SC,"P#!ADY]2/0<BNJ^*.E6NM?#QM<N
M/-6YMK9)(E20A,NR9R.] 'H&F7RZGI-GJ"(42Z@295;JH90<'\ZM5Q'P^\':
M7HVEZ=K-JUT;JZT^+S!).63YE5CA>@Y%9&K^$/!T%S-)XH\4SRW\K%PUSJ(C
M://38F> !]10!Z=7!_#+5;_5(?$!OKN:X,.JRQ1>8V=B#&%'H/:J_P )-6N;
MW2]6L)K][^'3[YH;:Y=MQ>+^'GN.,CZURO@;PD_BFX\1)?:E<Q:/'JDV;2V?
M8993U+GT Q@>N>G< ]NHKRWPY%<^"OB@/"D=]<7.D:A:&XMHYWW&%AGH?^ -
M^8]*T?$?A7PQ)JD]]XK\1S'SV+06UQ?B&.)1T"+D$XH ]!HKR_X8ZB(O$_B#
M0++57U+1[41RV4KR^9M!ZJ&].<?45CHFC:YX\U^R\=:A<6]S'<[=.AEN&AA$
M.3M*$8&2-IYZY]<T >T45Q^OWA\ _#>ZFM+F>[>TCVV\MT_F.6=\+D]PN[\E
MKS^TM? U]H\=UJWC*=O$$T6^2\^UN##(PR0JCC /&/;M0![A17DNF^*]?UCX
M):C?6DLDNKV;-;&XCY=E!4EQCN$;K[9ZU8\$:#X/U5-/U/1]:O6U:'RYKC_3
M6\UR,%ED0]5)R#@8]#0!ZE1110 4444 %<)\6KS[/X-$ /-S<HF/89;^:BN[
MKRKXT7&(=(M@>K2R$?3:!_,UT82/-6BC2DKS1Y+1117T!Z 5L>%]970M?M[V
M5#);\QSQ_P!Z-AAOYY_"L>BE**DFF#5U8Z+Q%X5N=)D-W9@WFD3?/;WD0W*5
M]&(Z$=.?2L6[OKJ_E62ZF:5T01J6[*. *N:3XCUC0F)TV_FMP3DH""A/J5.1
M^E=/:>+?B+>P":S-]/"3@/#IR,I_$)BL6ZD=[/SO;]&1[RWL<*&((()!'((I
MTLLD\K2RR-)(QRS.<D_4UW__  D7Q/\ ^>&I_P#@K7_XW6WXOUKQW:>*+R#1
MHK]M/79Y1BL!(O**3AMAS\V>]3[:7,E9??\ \ 7.[VT^_P#X!Y%17H7_  D7
MQ/\ ^>&I_P#@K7_XW1_PD7Q/_P">&I_^"M?_ (W5>UEY??\ \ ?,_+[_ /@'
MGM%>N^$-:\=W?BBS@UF*_73VW^:9; 1KPC$9;8,?-CO6)_PD7Q/_ .>&I_\
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M*@23[->"%?-&=V1N&3TR:\MHK*I3<K-=/*Y,HW/0O^$=^)__ #WU/_P:+_\
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M/.J?&PHHHK$@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME'A[_H.Z9_X%Q_XT?\)1X>_Z#NF?^!<?^-+ZWB?Z0>VJ'EP^#>L9&=1L<?\
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M?5?"UWIKZ@Y2*26=6Z=\8^GYUB^'_&.I> =/30/%^DWOEV:[+>_MD\V-X\\
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MD4CO9W]M'O783G!].<GKD$].] 'L%>8?#1%NO'/CK4)AFY%_Y W?>1 [\?\
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M ,!G_P :/^$4\._]#K9_^ S_ .-'MX>?W/\ R'SHY"BNO_X13P[_ -#K9_\
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MYG:261B[NQR68G))]ZF05[%&"A%)'9"-E8G05JZ'9IJ&NZ=92<)<7,<3?1F
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT4X6U)(UJT@J)%JP@KO@CH2)%%;?A7_D;M%_Z_X/_1BUC**VO"O_ "-VB_\
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MIQ3;_P *Z;J.LQ:I/YWVB,J0%?"G:<C(Q6W15>TE?FOJ1]6H\BI\JLNAYO\
M%3_6Z5_NR_\ LM:X\ :)?Q6]TRSPL\2LZ0N K' YP0<?ABNFO=+L-2V?;;2&
MXV9V>8@;;GKC\A5I55%"J JJ,  < 5I[9J"C'2QR_P!GPE7J5:J34K6\K(K:
M?I]KI=FEI9Q"*%.@'<^I/<UAZEX$T74[Y[N19HI';<XA< ,>Y((/Z5TU%9*<
MHNZ9UU,/2J14)Q32.<?P/HA^R;(9(OLQW+L?[QR#EB>3TK8U+3;75K%[.\C\
MR%^V<$'L0?6K=%#G)ZMA'#THIJ,4D]SG=&\%Z7H>H?;;9[AY=I5?-<$*#Z8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&A:)=:_J:V5J8T.TN\DC86-!U8GTKO-)TS3O!>F75UJ&NHT>JQFWM9]/4LP
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M9-$WRVS-CY<[3O(!R>E 'HM%%8WB/7QX?LHIETZ\U">>410V]I'N9FP3SZ#
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M3:3%X8_X2)KH'3/)$PE Z@\ 8ZYSQCUXKC#\49I=/-]>>%=4M-$G0A-0;Y@
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MG*7R/ PU">(P].%.G9IWYM.[^?\ PQ8USQK)I^JR:7I^ES7EU&!OQG R >
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MN1?XGJ-.5TL!]L9R#&9"551CDG'?GCVJQI.DZAHWP^UFWU",12,DSJF\-@;
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M_P#%'A+4[^:]N_"]P\\S;G87K#)^@K&TN;:5O7_@D6=^I7^U_#__ *!NM_\
M?U/\:TM#L/ VO:@;.WL=7C<1/+F29<849/2LS^VO!7_0J7'_ ('M5W3/%WA7
M2+LW-EX9N(Y2C1DF]+?*PP>M$E+E?*I7]5_F#3MI<I_:_A__ - W6_\ OZG^
M-'VOX?\ _0,UO_OZG^-3V5SX)U:^AT_^P;RR:Y<1+<)=ERC'@'!Z\URNKZ<^
MDZQ=Z>[AVMY6CW#^+!ZUI&*D[.Z?J4E=VU-O5O%<#Z4VCZ%IXTW3I"#,2^Z6
M<CIN;T]JY>BBMX0459%I);!1174_#_0O[=\5VR2)NMK;]_-D<$*>!^)Q^&:)
MS4(N3Z!)V5V>R>!]%.@^$[.UD3;.X\Z8=][<X/N!@?A71445\W.3E)R?4\UN
M[NPHHHJ1!1110 5YA\8T>TC\-ZYL9H=.U%6EVC. 2IY'_ ,?C[UZ?534],L]
M8TZ?3]0@6>UG7;)&W0CK^!SSF@">WGBNK>.X@D62&50Z.IR&4C((KD_B?(__
M  K?7!;L#(L2JP!Y +KNS_P$FL>'X67VG V^C>-=8L+#)Q; [MH)S\I!&/KB
MNHT'P?IN@Z+<Z8IGNTO"S7<ET^]YRPVG=^'% #_!7V?_ (0?0_LNWR?L,6-O
MKM&?QSG/OFN1\!A3\3O'+V@'V3SHPQ7IYF6S^.=]6(?AG>Z:DEKHGC#4]/TQ
MV)^RA0^P'J%8D%?KUKJO#/AC3O"FE"PT]7(9O,EED;<\KGJS&@#C_@?&B^ "
MZHH9[N3<P')P%QFH_A_#&/B9X[D\M=ZW" -CD LY//N0/RKK/!GA6/P=H TJ
M*[:Z7S6E\QDVGG'&,GTI-"\)QZ'XBUS5TNWE;5I%D:,H (\;N <\_>H YFY4
M)^T#9E1@OHY+8[_,_P#@*9H7D_\ "^O%._R_-^QP>7NQN_U<6<5U4OA6.7QY
M!XI^UL)(K,VOV?9P1DG=G/\ M=,5Y[-X:B\2?&?Q1&;RYLKJW@MY;:ZMGVO$
M_EQC\002"* -?XJ;6U_P2D6/MIU1?*]0NY,_AG;2ZCB/]H+22QQYFDL%]SF7
M_"M?0_A\+#7TUW6=9N]:U*%-D$DZA5B'.<*">>3^9/6K7BWP1!XGN;*_BO[C
M3M3LB?(NX!D@'L1W'X]SZT 8'Q=D0)X7C+KYAU>)@N>2!U./3D?G2_%DA9?"
M;,<*-8B))[5+/\*H[Z6VO=2UZ^OM4AN8IOM<X!^1,GRU3.%!)SWZ5T?C#PG:
M^,-%%A<326[QRB:&>/EHW&1GWX)H I_$TS#X;ZV8,[_( ./[NY=WZ9KGO"VG
M^.)/"FDOINO:1'9&TB,*&T+%5VC@G/)'?WS76:!X<N].TJZL=9UF?6Q<95C<
MI@!",%<9/7OS6#!\.=2TE6M_#_C'4-.T\L66U>)9@F>H4DC'/^>] %>U\)W?
MA/X;^+X;R\AN9+N"ZN3Y*%54F$@@ _2M?X70Q0_#?1O*C5-\;.V!C<Q8Y)]Z
MT+?PN8O"=_H<^K7MX][%*DEW=-O<&1=IP.P'85<\-Z*OAWP]9:0DYG6U38)"
MNTMR3T_&@#)U6P\;3:G/)I>M:9;V1(\J*:U+,HP,Y.>><U7\1>*=1\*Z3I%G
M)%#J6OZC*+>(+^ZB9\C+'T'S#\^U=E7.>+_!]KXNL[9);F:TN[27SK:ZA^]&
MWT[C@>G0<T ><_%"+Q>/"EO+K]SHY@^VQ8BL8I 5;#8.YCTZUT7QF_Y%S1O^
MPS!_Z!)3]2^%T^NV@77/%-_?W,; P2-&J1Q<\XC!P20,9)KH_%_A6/Q;I]G:
M27;6PMKQ+H,J;MQ4,-O4?WNM '*_%4K_ &WX*6XQ]B.JKYV[[OWDQGVQNKI?
MB'Y/_"OM=\_R]OV1\;\8W?P]>^<8]\5<\4^&+#Q;HKZ9J <)N#QR(<-&XSAA
M^9_.N6?X83:A9R6FN^*-1U2W6)DMHI!M6)BI =L'YV7.1F@#EO%9E'[/V@B/
M[A-N)?\ =PW]=M=>VC>/KJQ,/_"0Z*UM+'LPMD<%",<<],5OVWA2Q7P9#X8O
M<W=FEN('+#:6QT/'0YY'TKGK?X?:W80K9:?XZU.#3D&U(6A1W1>P#YXP/04
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD4II2K92FF.H<";%392;:M&.F^74\HK'H/AF$GP[:''9O_0C7.^-H]NIV_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\TA^'OB7PWJFHS>#_$UO:V-_.US)97MH) D
MAZE6'/MVX ZXKTNB@#A_#W@.\M?%)\4^)-;;5]86$P6^R$0Q6Z'.0JCJ>3S[
MGOS7<444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ:;;@FS:+O%,****L9]"_#G_ )$'2_\ =D_]&-7 _&/_ )&*P_Z]/_9VKO\
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M2Q,29/3(Z9]^M8D\\MS/)//(TDLC%G=CDL3W-1TZ.&A22:W"G1C#U.A\"_\
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M+5()K^.*.-R,(Y5B'Y!Z '\ZN^,/%D'@_3K.]N8#+%<7B6S$/M\L,&)8\'(
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M5S=Y\/5OO!VC>'I]5E8:9<),MQY0RX3<%7&>  V.O:@#LT18T5$4*B@!548
M'H*\Y\&$#XK^.%)^8M 0/;!_QKTBN&UOX=RWWB>;7]'\07>CW=P@2Y\E PD
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M2TOQ'XZFOK*>WBO-9DFMWD0@2H7<AE]1@C\ZU?"'@9_#^J:AKFJ:K+JVNZ@
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MH$^WV@Y\R!?F4?[2=?RR*]:CC*=31Z,ZX5HR\CC**.AP:*ZS4**** "BBB@
MHHHH **** "BBB@#Z)^'O_(AZ5_US;_T-JX#XR_\AW3O^O8_^A&N_P#A[_R(
M>E?]<V_]#:N ^,O_ "'=._Z]C_Z$:\?#_P"]OU9QT_XK^9YK1117L'8%%%%
M!1110 4444 %%%% !115BRL;O4;E;:RMY;B9NB1J6-#=M6!7J[I>D:AK5V+7
M3K62XE/4(.%'J3T ]S7HGAWX132[;C7Y_)7K]F@(+'_>;H/PS]:]2TW2K'1[
M1;73[6.WA'\*#K[D]2?<UP5L="&D-7^!A.NEI'4X?PI\++/3=EWK12\NARL(
M_P!4A]_[Q^O'M7H8 4    < "EHKRJE6=1WDSDE-R=V%%%%9DA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '.Z[X(T+Q!N>ZM!%<-_R\0?(^?4]C^(->9:W\)M9L2TFF21ZA".
MBCY)!^!X/X'\*]OHKHI8JK3T3T-(591V/E:ZL[FQG:"[MY8)5ZI*A4C\#4-?
M4M_IECJD'D7]I#<Q]EE0-CZ>E</JWPCT6\W/IT\]A(>BY\Q/R//ZUZ%/,(/X
MU8Z(XB+W/$J*[;4_A7XDL=S6\<-]&.\$F&Q_NMC],UR5YI][ITOE7MI/;/\
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M 4444 %%%% !1110 4R6*.>,QRQI(AZJZ@@_A3Z* .<O_ ?AC4<F728(V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1LVH[M+1'H]8_B77U\.:8MXUN9RTHC5 VWD@GK@^AJ]IM_%JFFV]]#D1S(&
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M_+4]1HHHKG/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7L=+17ENF_\ "6>,'GO(=4:T@1MHV2-&N?0!>N/>NBB;7]-\&:K_ &I.?M<
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M1CFCU5O(1PVWROF(!SC.<?CC\*A3@XRBW:[N=$Z%>G5I581YK1LU=(S?&O\
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MU!*9+.S\EV/4G]/RHJU(N.KN_0G"86M"LVH\D+:J]]?(X;X6.HN-30GYBD9
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MR::UW77T."\7>'ET;2XI9=;GN[B1P!%*WWA@Y8#)/''YUT&G?\DE?_KUF_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHI,C)&1D=10 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1534M3LM(L)+[4+E+>UCQOE<\#)P/U(IM[J^GZ
M;IAU*\NXX;(!6,S'Y<,0!^>10!=HIL<B31)+&P9'4,K#H0>AJIJ6KZ?I$<,F
MH7<=LDTHAC,AQN<] /R- %VBF22QQ &214!. 6.,GTI] !1110 4444 %%%%
M !137=(T9W9511DLQP *JVNKZ9?2F*SU&TN) ,E(9U<C\ : +E%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP01V=ZY:SU@1A=X_N2-V _\ '2?0@@ ]@HKAOAOK&H^(%U[4[FXDEL)-1=;
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M12SLS\!8R[,"?;!S7E9DE7Q.OQ-_LI/[!;5"OE;3NVXV^=CUSDY_O\4 >Q^
M?"Y\*^&(K:=B]_<,;B\D)R3*W49]N![X)[UTY(52S$  9)/:F03Q7-O'/!(L
MD4JAT=3D,I&017*_%"[GLOAOK,ULS+(8UC)7J%=U5OT8T 5KOXL>%+6YEB6Z
MN+E(6VR36UNSQK_P+H1[C-=1I6LZ?K>F)J.G727%JXR'3MCJ".H/L:H>#-.M
M-.\%Z3;VL2+$UI&[8'WV9068^N2:XWX>Q+IWC#QUI5H-NGPW"R1QK]V-FWY
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MFWVQMGN>>!WXR<<XJI\0X8)_B+X$BN$1XFN)<JXR#S'C]<5N?%-('^&VL?:
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MF'&X#L/SJ#3_ /DW]_\ L#3?^@M6U\,K>&W^'6C>3$D?F0^8^T8W,2<D^IH
MUO#OB73O$^AIJVGR'[.V0XD&UHV'4-Z$5R\OQ2@>*XN]-\/:OJ.F6[,LE]#$
M!&<=2N3D@>O%8W@!;>'P_P"/(9I?L]G'?709U'^K3:02 /0#]*J^#?$>OZ;\
M/K72K?PA?W4K0O\ 9+B,+Y,BN20S'^'KR.^.V: /0/"7BQ/%MG)>0Z7?6=N
MICEN54+,#D'803G!7GZBNBKF?A_X>N?#'@RQTR\93<IN>4*<A2S%MH/MG'US
M734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8M=0\0>+;C45M"6AMH8%@C+8(R^W[W4]OQH R[4X_: O<\9T88]_F2E^,/\
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M HHHH **** "BBB@ HHHH **** "BBF1313!C%*DFUBK;&!P1U!]Z 'T444
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MS@M%0K&4'[O?NR1@XY'/<5T^NZ-9>'_A;J^F:?%Y=M!ILX4$Y).PDDGN2>:
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MS$EWJ$9++Y>,#8V.#RN/^!CIR* /6ZYOQ+XUTOPIJ&G6VIF2-+T2L)P!LC"
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M:Z@>*--F\)S>)+21KFPCMWGS&,,0@.1@XP>".:U8H8$M4@C1!;A BH!\NW&
M/IBO&_!XV_"?QRD)S9)+=K;\Y&WRAT]L8H ZG_A:UE=6\<NCZ)JVJD1++<"U
MAW"WR,[6(X+#T'Y\5TOAKQ5IGBO1O[3TYW\M25DCD&'C8<X(^F#U[UF?#"&"
M'X=:.;>.-/,B+N4 ^9R3DGU/'Z5SWP^"1^-?B!';8^R"Z4@+T#YDSC\<_D*
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MB33GT35[[0H-.E*B>YMDD,TB@YX!^7/ ]*T?%?@6?4K+06T*[CM;_0BOV,W
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MTB17#SHS1MAE^YR#ZBO5*SK[0M-U+4K#4;NV$EW8,S6TF]AY9;&> <'H.N:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>img40748725_41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img40748725_41.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '' _X# 2(  A$! Q$!_\0
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MT(]* )J*BM[B"[MTN+::.:&0922-@RL/4$=:EH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=\[)6!4$MGD=R3BCV3#G1Z+17%Q>*M3O_$45C9I;K'YL8DC:)G81F(.S[]P
M()"XQGG-=I4RBX[E*2>P4445(PHHHH **** "BBB@ HHHH **\_M$U:^\47K
MV;W8^SZMB6=[@^2MN$4M'LW<DD]E[]:C\.^(;S2]%L([N6V^RRV5Q/'*ZN6C
M,;_Q\_,#NZ  UI[-]".?N>B45PR^*]8>SO=ELK26ERB2R?9F#+"4WE_)+Y)'
MH&Z<T^3QAJ,^HO'IMH+N"!+=F*0L1,) &+!BPV  \9!S@T>SD'.CMJ*YGQV)
MH_"\]U!>7-N\!1AY+[-V74<GKCD]ZZ:HMI<J^M@HHHI#"BBB@ HHHH ****
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MC:';IC@YYS7=)96L<D\B6T*O/_KF" &3_>]?QJ*'2=-MXQ'#I]K&@<2!4A4
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M<F<9[XZ&D\Z,@'=U]C[?XBI** (_.C_O?H?\]J7SDSC/Z'_/:GT4 ,$R'O\
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MOLO/6DHJVX79T]UJ-I8NJW,RQEHWDRV<!4 +$GL!D?G4L=Q'+(Z+NR@!)*D
MYZ8/0_A7(3^&=3NK"87*6TLTD3;HPYVLSW'F. 2.FQ54&HM0T6]FU06J64$R
M,9IQ&[E84!1(HLX&#@!CM_&GRKN%V=FEW ]U-;+(#-"JM(N/NALXY_ U-7%7
M7A2_=$C+^?!Y@61/-"M(BPK&C$LK#J'.,=6!ZBNPMH$MK6*WCW;(D"+N8L<
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M]\YIM*Q<95.=)OKY;&E11169U!7.ZDXC\4VDC9VK%N. 2<#=T ZUT5<_??\
M(VV7_7,?^S4 '_"9:7_SRU'_ , )O_B:/^$QTO\ YY:C_P" $W_Q-=!13T%J
M<^?&6ECK%J/_ ( 3?_$TG_"9Z5_SSU#_ , )O_B:Z&BC0-3G3XTTH?\ +/4/
M_ &7_P")H_X372?^>>H?^ ,O_P 37144:!J<Y_PFVD_\\]0_\ I?_B:/^$VT
MG_GGJ'_@%)_A71T4:!9G-_\ ";Z3_P \M0_\ I/\*/\ A.-)_P">6H?^ <G^
M%=)11H%F<U_PG.D_\\M0_P# .3_"D_X3K2?^>.H?^ C_ .%=-11H*S[G,?\
M">:1_P \K_\ \!'_ ,*3_A/='_YYW_\ X"O7444:!9]SEO\ A/\ 1?[E]_X"
MM2?\+!T7^Y??^ K5U5%&@6?<Y3_A86B?W+[_ ,!FI#\1-$'_ "SOC_V[-764
M4:!:7<Y(_$710/\ 57__ (#&FGXCZ(!GRK__ ,!S_C77T4:!:7<XX_$K1!_R
MQU#_ ,!__KTG_"S-#'_+'4/^_'_UZ[' ]*-H]!1H%I=SC?\ A9NA?\\;_P#[
M\?\ UZ3_ (6=H7_/'4/^_ _QKL]J_P!T?E1L7^Z/RHN@M+N<9_PL_0O^>&H?
M]^!_\533\4M!'_+#4/\ OR/_ (JNTV+_ '1^5'EQ_P!Q?RHN@M+N<2?BIH0/
M_'OJ'_?I?_BJ;_PM;0O^?;4/^_2__%5V_DQ'K$G_ 'R*3[/!_P \8_\ OD4[
MH5I=SB?^%K:'_P ^FH_]^E_^*I/^%K:+VLM1/_;-?_BJ[;[-;_\ /"/_ +X%
M)]EM_P#GA%_WP*+KL%I=SB?^%KZ/_P ^&H_]^U_^*II^*^D]M-U$_P# $_\
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M &O^^S_C[T 245'Y"9_B_P"^C_GO1Y"#^]_WT?;_  % $E%1>1'C^+T^^?\
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MC_:/M_@*3R(\8^;T^^?3'K0!+7/WW_(VV7_7/_XJMSR$.?O<_P"T??\ Q/\
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M\E"<_-_WT??_ !H DHJ,0H/[WK]X^W^ I/L\>,?-C&/OG_&@"6BHS A_O?\
M?1]_\31Y*9S\W_?1^M $E%1^1&/[W_?9]O?V%)Y$>,?-Z??/O[^] $M%1^2A
M.?FZY^\:/(08^]_WT?;_  % $E%1^1'C'S?]]G_&CR$.?O<_[1]_?W- $E%1
M^2G^UZ_>/^>U'D1_[7I]\_X^U $E%1^0A_O?]]GW]_<T>2F<_-US]XT 245'
MY$8 'S<?[9]O?V%'D1_[7_?9_P : )**C\E,Y^;_ +Z/O_B:!"@.?F_[Z/M_
M@* )**B^SQXQ\V,8^^?\:4P(?[W_ 'T??_$T 245'Y*9S\W_ 'T:!"B]-W_?
M1]A_04 2445R'C'Q+>^'KFV-E-9SR2(2-.DBD::<YZH4!QZ<C'O3C%R=D)NV
MIU]96G?\AK6?^NL7_HI:9X?UJZUFU=[S1KS2YDVYCN0,-G^Z1U]\@$4_3O\
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MOS7<$$\$,L@62X8I$I_B(!8C\@35!/\ D;9O^O%/_1CU6\06%U?ZAHOV:6>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^O%/_1CUJUC()?\ A*YN4S]@3L>N]ZUL2]BGY'_/I39$>H^BF8ESU3\C[?\
MUZ3$V/O)^1_QI%DE%,Q+ZI^1]_\ ZU&)<]4Q]#0 ^BF8E]4_(^W_ ->DQ+ZI
M^1_Q^E $E%,Q+GJF/H:,2]RGY'V_^O0 ^BH\3?WD_(_XTN)?5/R/O_\ 6H ?
M13,2YZICZ'_/K28FQ]Y,_0_X_6@"2BF8E[%/R/O_ /6HQ+GJF/H: 'T4P"7N
M4_(^W_U_TI,38^\F?H?\: )*9-_J9/\ =/\ *@B7/!3\C[__ %J9*)?)?)3&
MT]C_ )]:!%/P[_R+6E_]>D7_ *"*TJRO#WF?\(WIFTKC[)%C(_V!6EB7U3\C
M[_\ UOUIO<4/A0^BF8ESU3'T-)B7U3\C[?\ UZ11)14>)O[R?D??W^E+B7/5
M,?0T /HIF)?5/R/M_P#7_2DQ-C[R9^A_QH DHIF)<]4_(^__ -:@"7/)3'T/
M^?6@!]<_??\ (VV7_7,?^S5N8FQ]Y,_0_P"-8-]YG_"667*Y\OT_WO\ ZU '
M144S$N>J8^AI )>Y3\C[>_UH DHJ/$V/O)GZ'_'Z4N)<]4_(_P"?2@!]%,Q+
MZI^1]O\ Z_Z4F)L?>3\C_C0!)13,2\X*?D??_P"M1B7/5/R- #Z*CQ+_ 'D_
M(_X_6C$OJGY'W_\ K4 244S$N>J8SZ&C$O<I^1]O_KT /HJ/$WJGY'_&EQ+G
MJGY'W_\ K4 /HIF)<]4_(_Y]:3$V/O)GZ'_&@"2BF$2]BGY'W_\ K48ESU3'
MT- #Z*CQ+ZI^1]O_ *]&)L?>3/T/^/TH DHIF)<]4Q]#_GTHQ+GJGY'V_P#K
MT /HJ/$V/O)GZ'_&EQ+ZI^1]_P#ZWZT /HIF)<]4_(TF)?5/R/\ C]: )**C
MQ+SRGY'W]_I2XESU3'T- #Z*CQ+ZI^1]O_K_ *48FQ]Y/R/^- $E%,Q+GJF/
MH??_ .M0!+W*?D?;_P"O0 ^BH\38^\F?H?\ &E(E[%/R/O\ _6_6@!]%,Q+G
MJF/H:3$O<I^1]O\ Z] $E%1XFQ]Y,_0^_O\ 2EQ+GJF/H: 'T4S$OJGY'V_^
MO^E)B;'WDS]#_C0!)13,2\\I^1]__K48E]4_(_Y]: 'T5'B;U3\C_C2XE]4_
M(^__ -;]: 'T4S$N>J8SZ&DQ+CJGY'V]_K0!)14>)?[R?D?\?I2XESU3'T/^
M?2@!]%, E[E/R/M_]>DQ-C[R9QZ'_&@"2BF$2]BGY'W_ /K48ESU3'T- #Z*
MCQ+ZI^1]O?ZT8EQU3/T/O[_2@"2BF8ESU3'T-&)?5/R/M_\ 7_2@!]%1XF_O
M)^1_QI<2^J?D??\ ^M0 ^BF8E]4_(_Y]:3$WJGY'_&@"2BH\2]BGY'W_ /K?
MK2XESU3&?0T /HJ/$N.J?D?;W^OZ48E]4_(_X_2@"2BF8ESU3'T/^?2@"7N4
M_(^W_P!?]* 'T5'B;'WH\_0_XTI$O8I^1]__ *WZT /HIF)<]4Q]#_GUI,3?
MWD_(_P"/UH DHJ/$N.J9^A]_?Z?K3EWY^8KCV% #J\[\8:5IUEK]C<6UOX=^
MU7@: 6NHVI(E=F'[P%%)W9(!)XYZBO1*\U\:ZOH,OB46<FOW.DZA;1(9)8[;
MS48!Q(JD%3R&"L"..H.:TI7YM"9['9>%+9+/POI]O'<Q7"1QX$D*[4/)X4=@
M.G//'-/T[_D-:S_UUB_]%+4?A,6X\+V'V5;D0E"RFZ&)'RQ)9AZL?F_&I-._
MY#6L_P#76+_T4M2]V+M_70U:***DL**** "BBB@ HHHH *R]6_X_-(_Z_/\
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MY!8G@ GTYKHYO]3)_NG^52U9V'>Z*'AW_D6M+_Z](O\ T$5I5F^'?^1:TO\
MZ](O_016E0]Q0^%!44LZ1ND9.9),[%_O8Y-2U@2W;1ZE$YC>0K<3(B1C);Y!
MC_/2G&/,15J<B1=^V7GVS9]E/3_5[AT_O;NGMBM%22H)&#W'I7./=7=Q]F4>
M=*+GS)6C@E$;)C ";B0>.<XYS[4Z,WDTUM:2S7$"&=U($RM(4" [69<\Y/UQ
MBIA1E&_-*YG]93VC_3_X<Z*BL)GECO#I@N9A$TJ 2E\NJE&;;N//5>O7FK-D
MC6^L7%L+J66(0(ZI(^XH26!Y//..]6XEQK7=K=;?,U****@V"N?OO^1MLO\
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MLA0@FKRW(H;:"V7;!#'$OHBA1^E2T45!J%%%% !1110 4444 %%%% !1110
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M%SFRA6)3%<H$RX+XR'!R<9' '7FM"3P[IDUK>02V_F"\9GF=CEV)&.&ZC
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M<$GA4)R<#U) S]!2:=I=II5G';6L*JB(L>XCYF"C W'OQ5CSO]B3_OFCS?\
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MT 245'YW^Q)_WS1YO^Q)_P!\T 245'YW_3.3_OFCS?\ 8?\ [YH DHJ/SO\
M8D_[YH\W_8D_[YH DHJ/SO\ 8D_[YH\W_8D_[YH DHJ/SO\ 8D_[YH\[_8D_
M[YH DHJ/S?\ 8D_[YH\W_8D_[YH DHJ/S?\ 8D_[YH\W_8D_[YH DHJ/SO\
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M:"Q]"P'IGVQ6O96=OI]E#9VL8BMX$"1H.P'2E)QMH"OU)ZR]6_X_-(_Z_/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-#)&)YHH(8XMI4)(R@LV>2<#TK"T:ZTVV\.0Z_<:F5U22!GN)997?]YSN0Q
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M!)V5X(I-6N8OM@N6;S<*V(&C^ZH/4'G[O8FO1:F4>4:=QGE1_P!Q?RH\J/\
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M0 4444 %9>K?\?FD?]?G_M*2M2LO5O\ C\TC_K\_]I24T3+8U****104444
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M **** "N=U)=_BFT3<R[HL;EZC[W(]ZZ*N?OO^1MLO\ KF/_ &:@!P\-S?\
M0Q:S_P!_D_\ B*/^$;F_Z&'6?^_R?_$5O44^9CN8/_"-S?\ 0PZS_P!_D_\
MB*3_ (1J?_H8]9_[^I_\16_11S,+F ?#4^/^1CUG_OZG_P 13?\ A&+C_H9-
M:_[^I_\ $5T-%/F87.>/ABY_Z&76O^_J?_$4W_A%KG_H9M;_ ._R?_$UT=%'
M,PN<Y_PBUS_T,VM?]_4_^)I/^$4N?^AGUO\ [_+_ /$UTE%',PN<T?"ER?\
MF9];_P"_R_\ Q-'_  B=S_T,^M_]_P!?_B:Z6BCF87.9_P"$2N?^AGUO_O\
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M** "BBB@ HHHH **** "BBB@ HHHH *\Z\?7>G0>(;$:G:.\"6VXSQZDULZ
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MF4QA%9U&6(C);;A2Q'&<<],U%%X:\J6.?^T+AYUGEF>1@IWF1=IXQQ@ 8QT
MID/A2&"6/9>3_9U\EF@(7#O$H",3C./E4XZ9'UI>X&I?LM8TS4KMH[2=99HU
M;G81\H;:V"1R PP<=ZT:R]-T.#3)(GCD=S':I;+N Z DEOJ2>?I6I4NU]!KS
M"BBBD,**** "BBB@ HHHH *9-_J9/]T_RI],F_U,G^Z?Y4 4/#O_ "+6E_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@:1X<32]=U&]4KY4[
MPJ/X,\M^O3VK?HIJ36P[A1112$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<UJ.BZ=INJC7;*PMSJ\TT<>Z20@$,
MRK(RJ6 W;,\CDX[UTM><?$@PV^K:9>"[LOM<8#1074$LI79(K^8GEJQ7)7:2
M1R#UJZ:;E8F6USOM/L[:PL8K:T7$" [?F+9R<DY/7))-4]._Y#6L_P#76+_T
M4M1>$DCC\+6"Q7!G783YGE-&"2Q)PK<@ D@ ]@*ET[_D-:S_ -=8O_12TGNQ
M/I_70U:@N[RVL+9[F[GC@@3[TDC8 J>L'Q4L$MC!'+]N2591-;S6ELTQCE3E
M25 (Q['@^HI)7=BGL:=KJ=C>^5]FNHYO.C,L90Y#*" 3^9Q5NN!GGUZ:V>>\
MM[RV+)9P72VBME Q9YF0+DD_,JDKDCGTJ/2H+C4DMT1]4CTV6_N9F_?R%UAB
M7RUC+Y) 9LG&<]?2KY/,7,>A54FU.RMYY(9KA4DC5'<$'@.Q5?S((KSZZ75U
MT:""XAUF29=+5K1;=I01<.S9,CCNB[.&/KP36NEI>IJY*K=A#?0Q-)M;+000
M[LD]PTA(]\T<B74.8[6BO/([;7+.R6]@.HR:A)ID]Q*'=V42.ZE$"'Y04!?
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MV&K1O)87D-RJ':QC;.T^_I5RN>\,V=S!<:M-?^9)>M=>6UPR;!+$JCRRH'
M#$<=\UT-9R23T*6P4444AF1AF\5R[6VG["G.,_QO6F$DR/WO'^Z/;_Z_YUG)
M_P C;-_UXI_Z,>M6FR(]2+RY<?Z[_P ='I1Y<N#^^_\ '1[_ .(_*I:*15B/
M9)G_ %O&>FT4GER\?OO_ !T>W^!_.I:*!V(O+EP?WW_CH]__ *WY4NR3)_?=
M_P"Z/\__ *JDHH"Q%LEX_??^.CV_P/YT>7+C_7=O[H]*EHH%8C*2Y/[[_P =
M'O\ XC\J DF?];W_ +H]O_K_ )U)10.Q%Y<N,>=SCKM'M_\ 7_.@I+_SV_\
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MO'IM'K4E% 6(PDO>;/\ P$>W^!_.D\N7;CS^<==HJ6B@5B,I)VFQ_P !'O\
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M+/Q#JM[>65H-*2"65)9)C<.R;4215W*I7<=P;(R![UH^)M4_L?P_=78D6.7
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C,%4LQ
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M&C3O^0UK/_76+_T4M2:"7.AVAD>]=]G+7R!9CR?O@< U'IW_ "&M9_ZZQ?\
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M!<YOS_&7_/EH_P#W^D_PI//\9_\ /EH__?Z3_"NEHHYO(+G,_:/&G_/CH_\
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M]?G_ +2DK4K+U;_C\TC_ *_/_:4E-$RV-2BBBD4%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>49
<FILENAME>ikna-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-14T06:00:35.9350+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="ikna-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="ikna-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="ikna-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" xlink:href="ikna-20221231.xsd#DisclosureNatureOfBusinessAndOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ikna-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="ikna-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecurities1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="ikna-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="ikna-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1" xlink:href="ikna-20221231.xsd#DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="ikna-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock" xlink:href="ikna-20221231.xsd#DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="ikna-20221231.xsd#DisclosureEmployeeBenefitPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" xlink:href="ikna-20221231.xsd#Role_DisclosureResearchLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligation1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="ikna-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="ikna-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="ikna-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ikna-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="ikna-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ikna-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="ikna-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" xlink:href="ikna-20221231.xsd#DisclosureRedeemableConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="ikna-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:href="ikna-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="ikna-20221231.xsd#DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" xlink:href="ikna-20221231.xsd#DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ikna_ResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmortizationOfMarketableSecurities" xlink:label="ikna_AmortizationOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties" xlink:label="us-gaap_GainLossOnSaleOfProperties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ikna_AmortizationOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfProperties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ikna_RedeemableConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LiquidityPolicyTextBlock" xlink:label="ikna_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeasesPolicyPolicyTextBlock" xlink:label="ikna_LeasesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" xlink:label="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_LiquidityPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_LeasesPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_OfferingCostsRecognized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_FairValueLevel3TransfersOutAmount" xlink:label="ikna_FairValueLevel3TransfersOutAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ikna_FairValueLevel3TransfersOutAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" xlink:label="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_BristolMyersSquibbMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesA1PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKOneSevenFiveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKFourOneTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_MilestonePaymentsEligibleToReceive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_StockOptionContractualTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="ikna_DeferredTaxAssetsLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ikna_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_NotSubjectToExpirationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="ikna_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_LicenseMaintenanceFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ikna_AskAtLicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialDevelopmentMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_RoyaltiesTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialSalesEventMilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ikna_BostonMassachusettsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_AreaOfLeasedProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_VertexPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseCommencementDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseRentFreePeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseMonthlyBaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_PercentageEscalationInAnnualBaseRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LetterOfCreditToSecureLease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_Supplementalcashflowinformationleasesabstract" xlink:label="ikna_Supplementalcashflowinformationleasesabstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_Supplementalcashflowinformationleasesabstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ikna_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>50
<FILENAME>ikna-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-14T06:00:38.5730+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="ikna-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementOfCashFlows2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ikna_AmortizationOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfProperties" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="13" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmortizationOfMarketableSecurities" xlink:label="ikna_AmortizationOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties" xlink:label="us-gaap_GainLossOnSaleOfProperties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ikna_DeferredTaxAssetsLeaseLiability" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>51
<FILENAME>ikna-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-14T06:00:36.2510+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ikenaoncology.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:ikna="http://www.ikenaoncology.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2" id="DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" id="DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2">
        <link:definition>100030 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2" id="StatementConsolidatedStatementOfCashFlows2">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100090 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" id="StatementConsolidatedStatementOfCashFlows">
        <link:definition>100100 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" id="DisclosureNatureOfBusinessAndOrganization">
        <link:definition>100110 - Disclosure - Nature of Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100120 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1" id="DisclosureMarketableSecurities1">
        <link:definition>100140 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100150 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100160 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100170 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1" id="DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1">
        <link:definition>100180 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100190 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>100200 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100210 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>100220 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100230 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" id="Role_DisclosureResearchLicenseAgreements">
        <link:definition>100240 - Disclosure - Research License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1" id="DisclosureLeaseObligation1">
        <link:definition>100250 - Disclosure - Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100260 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100270 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100280 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100310 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100320 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100330 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" id="DisclosureRedeemableConvertiblePreferredStockTables">
        <link:definition>100350 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100360 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100370 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables" id="DisclosureLeaseObligationTables">
        <link:definition>100380 - Disclosure - Lease Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100390 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" id="DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Nature of Business and Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>100450 - Disclosure - Marketable Securities - Summary Of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails" id="DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails">
        <link:definition>100470 - Disclosure - Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100480 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100490 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" id="DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" id="DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
        <link:definition>100540 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails">
        <link:definition>100570 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" id="DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Research License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" id="DisclosureLeaseObligationAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Lease Obligation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" id="DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails">
        <link:definition>100660 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" id="DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails">
        <link:definition>100670 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" id="DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails">
        <link:definition>100680 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" id="DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails">
        <link:definition>100690 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100710 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" name="AccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_CollaborationAndStockPurchaseAgreementAbstract" name="CollaborationAndStockPurchaseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_Supplementalcashflowinformationleasesabstract" name="Supplementalcashflowinformationleasesabstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_AmortizationOfMarketableSecurities" name="AmortizationOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" name="AmountEligibleToReceiveInCaseOfExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_AreaOfLeasedProperty" name="AreaOfLeasedProperty" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" name="AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" name="ClinicalManufacturingAndScientificDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" name="ConcentrationOfCreditRiskNumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" name="DeferredTaxAssetsCapitalizedResearchAndExperimental" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" name="Deferredtransactioncostsinaccountspayableandaccruedexpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" name="DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_FairValueLevel3TransfersOutAmount" name="FairValueLevel3TransfersOutAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" name="IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeaseRentFreePeriod" name="LeaseRentFreePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_LesseeOperatingLeaseMaturityMonthAndYear" name="LesseeOperatingLeaseMaturityMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LetterOfCreditToSecureLease" name="LetterOfCreditToSecureLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_LicenseMaintenanceFees" name="LicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_MilestonePaymentsEligibleToReceive" name="MilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OfferingCostsRecognized" name="OfferingCostsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OperatingLeaseMonthlyBaseRent" name="OperatingLeaseMonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OperatingLeaseTermExtendedExpirationPeriod" name="OperatingLeaseTermExtendedExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" name="OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_PercentageEscalationInAnnualBaseRent" name="PercentageEscalationInAnnualBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" name="PercentageOfHoldersOfOutstandingSharesOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PotentialDevelopmentMilestonePayments" name="PotentialDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_PotentialSalesEventMilestonePayments" name="PotentialSalesEventMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" name="ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" name="RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" name="RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RoyaltiesTerms" name="RoyaltiesTerms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_StockOptionContractualTerm" name="StockOptionContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" name="TaxCreditCarryforwardExpirationBeginMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" name="TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TemporaryEquityDividendDeclaredOrPaid" name="TemporaryEquityDividendDeclaredOrPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_TemporaryEquityNonCumulativeDividend" name="TemporaryEquityNonCumulativeDividend" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_UpfrontAmountAllocatedToEquityArrangements" name="UpfrontAmountAllocatedToEquityArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_AskAtLicenseMember" name="AskAtLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BeginToExpireInTwoThousandThirtySevenMember" name="BeginToExpireInTwoThousandThirtySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" name="BMSCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BMSCollaborationAgreementMember" name="BMSCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BostonMassachusettsMember" name="BostonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" name="BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BristolMyersSquibbCollaborationAgreementMember" name="BristolMyersSquibbCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BristolMyersSquibbMember" name="BristolMyersSquibbMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_ElectronicEquipmentAndSoftwareMember" name="ElectronicEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IKFourOneTwoMember" name="IKFourOneTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IKOneSevenFiveMember" name="IKOneSevenFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_NotSubjectToExpirationMember" name="NotSubjectToExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" name="SeriesAOneRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" name="SeriesATwoRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_StockPurchaseAgreementWithBMSMember" name="StockPurchaseAgreementWithBMSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" name="StockPurchaseAgreementWithBristolMyersSquibbMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_UniversityOfTexasAtAustinMember" name="UniversityOfTexasAtAustinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_VertexPharmaceuticalsMember" name="VertexPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" name="AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeasesPolicyPolicyTextBlock" name="LeasesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_RedeemableConvertiblePreferredStockTextBlock" name="RedeemableConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>52
<FILENAME>ikna-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-14T06:00:35.9511+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="ikna-20221231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:href="ikna-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="ikna-20221231.xsd#DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="ikna-20221231.xsd#DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" xlink:href="ikna-20221231.xsd#DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureLeaseObligationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ikna-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="ikna-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ikna_ResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_OfferingCostsRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_BristolMyersSquibbMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesA1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKOneSevenFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKFourOneTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_MilestonePaymentsEligibleToReceive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_StockOptionContractualTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_NotSubjectToExpirationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_LicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ikna_AskAtLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialDevelopmentMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_RoyaltiesTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialSalesEventMilestonePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ikna_BostonMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_AreaOfLeasedProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_VertexPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseRentFreePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseMonthlyBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_PercentageEscalationInAnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LetterOfCreditToSecureLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ikna_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>53
<FILENAME>ikna-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-14T06:00:38.4025+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties" xlink:label="us-gaap_GainLossOnSaleOfProperties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" xlink:label="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_FairValueLevel3TransfersOutAmount" xlink:label="ikna_FairValueLevel3TransfersOutAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeasesPolicyPolicyTextBlock" xlink:label="ikna_LeasesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LiquidityPolicyTextBlock" xlink:label="ikna_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AmortizationOfMarketableSecurities" xlink:label="ikna_AmortizationOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_Supplementalcashflowinformationleasesabstract" xlink:label="ikna_Supplementalcashflowinformationleasesabstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BristolMyersSquibbCollaborationAgreementMember" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" xlink:label="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20221231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UT Austin License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Stock Purchase Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity instruments issued in connection with asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amounts representing interest or imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Leasing Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront amount allocated to equity arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Amount Allocated To Equity Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront amount allocated to equity arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Cash Flow Information Relating to the Company's Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, ASU, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value On Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized start-up costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased by employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Purchased By Employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston, Massachusetts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposits and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits and Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, non-cumulative dividend.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Non-Cumulative Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of non-cumulative dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average fair value of the stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series a-1 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfProperties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfProperties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Sale of Properties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Subject to Expiration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred issuance costs capitalized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2022 and 2021; No shares issued and outstanding as of December 31, 2022 or December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical, manufacturing and scientific development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Manufacturing And Scientific Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical, manufacturing and scientific development current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of remaining lease term and discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Remaining Lease Term And Discount Rate [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Remaining Lease Terms and Discount Rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bristol Myers Squibb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol-Myers Squibb.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of components of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Option exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Texas At Austin [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Texas at Austin.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and of Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University license fees and certain-patent related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, plan effective date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit to secure lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit To Secure Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit to secure lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol Myers Squibb collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payment for Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from payment for issuance of preferred stock and preference stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation balance for unvested options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B M S Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BMS collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets obtained in asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Loss Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated other comprehensive loss policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquired in-process R&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets recognized upon adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use Assets Recognized Upon Adoption of New Accounting Standard Codification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets recognized upon adoption of new accounting standard codification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax returns years open and subject to examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to revenue arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones payable contingent on sales in calendar year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Sales Event Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential sales event milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, ASU, Adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards begin to expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Begin Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration begin month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized which were previously included in deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $0.001 par value. No shares authorized, issued and outstanding as of December 31, 2021; 169,396,576 shares, authorized, issued and outstanding as of December 31, 2020 (liquidation preference $0 as of December 31, 2021 and $202.2 million as of December 31, 2020)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards, expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of credit risk, number of financial institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Number Of Financial Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk number of financial institutions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration allocated to technology recognized as research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash research and development expense for in-process research and development acquired in acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net realized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable convertible preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 150,000,000 shares authorized, 36,257,493 issued and outstanding as of December 31, 2022; 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deposit Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deposit Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposits and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A One Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A one redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through five years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount eligible to receive in case of exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Eligible To Receive In Case Of Exercise Of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount eligible to receive in case of exercise of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected option term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Monthly Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease monthly base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;E</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research and Experimental</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and experimental.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility range maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement with BMS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement With B M S [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement with BMS.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Leased Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased property.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_FairValueLevel3TransfersOutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, level 3 transfers out, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_FairValueLevel3TransfersOutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Level 3 Transfers out, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_FairValueLevel3TransfersOutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, level 3 transfers out, amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company issued and sold shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties terms.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of marketable securities in an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IK-412</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I K Four One Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IK-four one two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of holders of outstanding shares of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Holders Of Outstanding Shares Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of holders of outstanding shares of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease rent payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease maturity month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliated to Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets Current Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development revenue under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one year or less</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Begin to expire in two thousand thirty seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Begin to Expire in Two Thousand Thirty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Begin to Expire in 2037</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments eligible to receive.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage escalation in annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Escalation In Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage escalation in annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Number Of Shares Reserved And Available For Issuance As Percentage On Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments payable upon meeting certain development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmortizationOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmortizationOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmortizationOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation balance for unvested options expected to be recognized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Pharmaceuticals Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex pharmaceuticals.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extended term period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Extended Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term extended expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets and lease liabilities recognized upon lease inception.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets And Lease Liabilities Recognized Upon Lease Inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and lease liabilities recognized upon lease inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-allotment Option to Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to exercise additional consideration if clinical trial not completed within research term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Exercise Additional Consideration If Clinical Trial Not Completed Within Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to exercise additional consideration if clinical trial not completed within research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 15)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Supplementalcashflowinformationleasesabstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplementalcashflowinformationleases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Supplementalcashflowinformationleasesabstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SupplementalCashFlowInformationLeasesAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one stock incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' deficit:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for issuance percentage of annual increase in number of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Issuance Percentage Of Annual Increase In Number Of Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for issuance percentage of annual increase in number of common stock outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IK-175</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I K One Seven Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IK-one seven five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash included in other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance increased amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AskAt License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ask At License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AskAt license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol Myers Squibb Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront consideration payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Dividend Declared or Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividend Declared or Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity dividend declared or paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses for available for sale debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Including Accelerated Depreciation on Disposal of Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation including accelerated depreciation on disposal of property, plant and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds received after deducting underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from initial public offering, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Two Redeemable Convertible Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax effected at statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves for uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value On Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease rent free period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Rent Free Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease rent free period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Purchase Agreement with Bristol Myers Squibb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement With Bristol Myers Squibb [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement with Bristol Myers Squibb.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B M S Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BMS collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax cut jobs act research and experimental expenditures to be capitalized and amortized period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cut Jobs Act Research and Experimental Expenditures To be Capitalized and Amortized Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cut jobs act research and experimental rxpenditures to be capitalized and amortized period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties accrued on uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities assumed in asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset and liability before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax asset and liability before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility range minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredTransactionCostsInAccountsPayableAndAccruedExpenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred transaction costs in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred transaction costs in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends payable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions to defined contribution savings plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Liabilities Current Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Incurred interest and penalties related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recognized on uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges related to available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities Fair Value By Contractual Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Electronic Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Electronic Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Electronic equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BostonMassachusettsMember" xlink:to="ikna_BostonMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DepositsAndOtherAssetsNoncurrent" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityNonCumulativeDividend" xlink:to="ikna_TemporaryEquityNonCumulativeDividend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesA1PreferredStockMember" xlink:to="ikna_SeriesA1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfProperties" xlink:to="us-gaap_GainLossOnSaleOfProperties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_NotSubjectToExpirationMember" xlink:to="ikna_NotSubjectToExpirationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ResearchAndDevelopmentMember" xlink:to="ikna_ResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OptionsToPurchaseCommonStockMember" xlink:to="ikna_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BristolMyersSquibbMember" xlink:to="ikna_BristolMyersSquibbMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UniversityOfTexasAtAustinMember" xlink:to="ikna_UniversityOfTexasAtAustinMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LabEquipmentMember" xlink:to="ikna_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LetterOfCreditToSecureLease" xlink:to="ikna_LetterOfCreditToSecureLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncomeTaxesTable" xlink:to="ikna_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock" xlink:to="ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:to="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OfferingCostsRecognized" xlink:to="ikna_OfferingCostsRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PotentialSalesEventMilestonePayments" xlink:to="ikna_PotentialSalesEventMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DeferredTaxAssetsLeaseLiability" xlink:to="ikna_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLossCarryforwardsExpirationYear" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LicenseMaintenanceFees" xlink:to="ikna_LicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLeaseMonthlyBaseRent" xlink:to="ikna_OperatingLeaseMonthlyBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental" xlink:to="ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:to="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_StockPurchaseAgreementWithBMSMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AreaOfLeasedProperty" xlink:to="ikna_AreaOfLeasedProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_FairValueLevel3TransfersOutAmount" xlink:to="ikna_FairValueLevel3TransfersOutAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RoyaltiesTerms" xlink:to="ikna_RoyaltiesTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeasesPolicyPolicyTextBlock" xlink:to="ikna_LeasesPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IKFourOneTwoMember" xlink:to="ikna_IKFourOneTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LiquidityPolicyTextBlock" xlink:to="ikna_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_MilestonePaymentsEligibleToReceive" xlink:to="ikna_MilestonePaymentsEligibleToReceive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PercentageEscalationInAnnualBaseRent" xlink:to="ikna_PercentageEscalationInAnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PotentialDevelopmentMilestonePayments" xlink:to="ikna_PotentialDevelopmentMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AmortizationOfMarketableSecurities" xlink:to="ikna_AmortizationOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_VertexPharmaceuticalsMember" xlink:to="ikna_VertexPharmaceuticalsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:to="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_Supplementalcashflowinformationleasesabstract" xlink:to="ikna_Supplementalcashflowinformationleasesabstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IKOneSevenFiveMember" xlink:to="ikna_IKOneSevenFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AskAtLicenseMember" xlink:to="ikna_AskAtLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BristolMyersSquibbCollaborationAgreementMember" xlink:to="ikna_BristolMyersSquibbCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UpfrontPayment" xlink:to="ikna_UpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment" xlink:to="ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeaseRentFreePeriod" xlink:to="ikna_LeaseRentFreePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_StockOptionContractualTerm" xlink:to="ikna_StockOptionContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember" xlink:to="ikna_StockPurchaseAgreementWithBristolMyersSquibbMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BMSCollaborationAgreementMember" xlink:to="ikna_BMSCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod" xlink:to="ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeaseCommencementDate" xlink:to="ikna_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:to="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:to="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ElectronicEquipmentAndSoftwareMember" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514710592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IKENA ONCOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001835579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1697316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">645 Summer Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">273-8343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IKNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,257,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#8217;s proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#8217;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550517555584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,919<span></span>
</td>
<td class="nump">$ 232,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">97,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">4,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">160,010<span></span>
</td>
<td class="nump">236,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">5,255<span></span>
</td>
<td class="nump">6,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">172,259<span></span>
</td>
<td class="nump">247,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,343<span></span>
</td>
<td class="nump">5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">9,160<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,503<span></span>
</td>
<td class="nump">27,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liability</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,290<span></span>
</td>
<td class="nump">40,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2022 and 2021; No shares issued and outstanding as of December 31, 2022 or December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 150,000,000 shares authorized, 36,257,493 issued and outstanding as of December 31, 2022; 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">361,915<span></span>
</td>
<td class="nump">353,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(214,219)<span></span>
</td>
<td class="num">(145,454)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">146,969<span></span>
</td>
<td class="nump">207,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 172,259<span></span>
</td>
<td class="nump">$ 247,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514686576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,257,493<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,257,493<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515465872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue under collaboration agreement</a></td>
<td class="nump">$ 15,618<span></span>
</td>
<td class="nump">$ 30,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:InProcessResearchAndDevelopmentMember<span></span>
</td>
<td class="text">us-gaap:InProcessResearchAndDevelopmentMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 64,321<span></span>
</td>
<td class="nump">$ 47,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,201<span></span>
</td>
<td class="nump">18,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">86,522<span></span>
</td>
<td class="nump">65,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(70,904)<span></span>
</td>
<td class="num">(34,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,149<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,765)<span></span>
</td>
<td class="num">(34,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (69,528)<span></span>
</td>
<td class="num">$ (34,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders basic</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders diluted</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">36,188,420<span></span>
</td>
<td class="nump">27,983,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">36,188,420<span></span>
</td>
<td class="nump">27,983,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513660384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (101,048)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 10,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (111,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of issuance costs</a></td>
<td class="nump">131,302<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">131,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,984,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (205,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,396,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">205,979<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">205,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,678,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(34,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">207,877<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">353,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">282,459<span></span>
</td>
<td class="nump">282,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(68,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,257,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 146,969<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 361,915<span></span>
</td>
<td class="num">$ (763)<span></span>
</td>
<td class="num">$ (214,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513802960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515677648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (68,765)<span></span>
</td>
<td class="num">$ (34,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AmortizationOfMarketableSecurities', window );">Amortization of marketable securities</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Net realized loss on marketable securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(291)<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,230<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLeasingReceivables', window );">Lease liability</a></td>
<td class="num">(1,292)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(15,618)<span></span>
</td>
<td class="num">(30,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(1,403)<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(74,109)<span></span>
</td>
<td class="num">(60,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,431)<span></span>
</td>
<td class="num">(1,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(216,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">118,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(99,284)<span></span>
</td>
<td class="num">(1,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">131,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(172,298)<span></span>
</td>
<td class="nump">69,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">233,089<span></span>
</td>
<td class="nump">163,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">60,791<span></span>
</td>
<td class="nump">233,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">59,919<span></span>
</td>
<td class="nump">232,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">60,791<span></span>
</td>
<td class="nump">233,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception', window );">Right-of-use assets and lease liabilities recognized upon lease inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AmortizationOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AmortizationOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from payment for issuance of preferred stock and preference stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets and lease liabilities recognized upon lease inception.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLeasingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLeasingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518269472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Organization</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. NATURE OF BUSINESS AND ORGANIZATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ikena Oncology Inc. is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With a robust biomarker and translational approach, the Company aims to develop targeted treatments and define patient populations who are most likely to respond to treatment. Ikena&#8217;s current programs are across the Hippo pathway, RAS pathway, and key immune signaling pathways in the tumor-microenvironment (TME). The Company&#8217;s approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. Since the Company commenced operations in 2016, it has  advanced multiple product candidates into clinical development. In addition, the Company has a robust pipeline of discovery-stage targeted oncology programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 30, 2021 the Company completed an initial public offering ("IPO") in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,984,375</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including full exercise of the underwriters&#8217; over-allotment option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,171,875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514758912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#8220;Arrys&#8221;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#8220;Amplify&#8221;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses research and development revenue under a collaboration agreement.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of preferred stock, payments from a collaboration arrangement and related party revenue. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, the Company&#8217;s revenue has primarily been from a collaboration agreement. The Company has devoted substantially all of its financial resources and efforts to identifying potential product candidates and conducting preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company&#8217;s cash, cash equivalents, marketable securities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company believes the cash, cash equivalents, marketable securities as of December 31, 2022 will enable it to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements, though it may realize additional cash resources upon the achievement of certain collaboration agreement option exercises, or it may pursue additional cash resources through public or private equity or by establishing collaborations with other companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#8217;s expectations with respect to its ability to fund current and long term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any collaboration exercise options will be achieved or that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations. As of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of December 31, 2022, the Company has not experienced any credit related losses on accounts that hold the Company&#8217;s cash, cash equivalents and marketable securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers and CROs to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company&#8217;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments consist mainly of cash equivalents, restricted cash, accounts payable, and marketable securities. The carrying amounts of cash equivalents, restricted cash, and accounts payable approximate their estimated fair value due to their short-term maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in the Company&#8217;s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. The Company&#8217;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash equivalents are generally composed of commercial paper, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company invests its excess cash balances in marketable securities and classifies its investments as available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its investments in marketable securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. The Company reports available-for-sale securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the marketable securities, the Company considers all available evidence to evaluate if an impairment loss exists, and if so, adjusts the investment to market value through a charge to its consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, held in the form of a money market account as collateral for the Company&#8217;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of their useful life or lease term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had one collaborative agreement with Bristol-Myers Squibb, which the Company entered into in January 2019  For a complete discussion of the accounting related to Bristol Myers Squibb Collaboration Agreement, see Note 8, Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#8217;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_03b4de73-343f-4ac2-8c26-c4a271fedc1c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC) 842 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i) all components of net loss and (ii) all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597735984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.432%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.588000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152,889</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.534%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.418000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers into or out of Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597785344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. MARKETABLE SECURITIES</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.064%;"/>
        <td style="width:1.211%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.211%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.142000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.442%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">739</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did not hold any marketable securities as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> marketable securities in an unrealized loss position. These investments were in loss for less than 12 months and the Company considers the loss to be temporary in nature. The Company considered the decline in market value for these investments to be primarily attributable to economic and market conditions. In accordance with the Company&#8217;s investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any impairment charges related to its available-for-sale securities during years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any credit-related allowance to available-for-sale securities as of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The Company does not intend to sell its marketable securities and it is not more likely than not that the Company will be required to sell the investments before the recovery of their amortized cost bases, which may be maturity.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities fair value by contractual maturity were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.057%;"/>
        <td style="width:1.942%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597696560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.986%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">727</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,063</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,299</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597700080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. PROPERTY AND EQUIPMENT, NET</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.200000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.189%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">475</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,513</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,205</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597735984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.986%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,489</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514751344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_CollaborationAndStockPurchaseAgreementAbstract', window );"><strong>Collaboration And Stock Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BRISTOL MYERS SQUIBB</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, the Company entered into the Bristol Myers Squibb Collaboration Agreement with Celgene Corporation, which was acquired by Bristol Myers Squibb in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the Bristol Myers Squibb Collaboration Agreement, the Company entered into a stock purchase agreement with Bristol Myers Squibb, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,545,450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A-1 Preferred Stock (the &#8220;Stock Purchase Agreement&#8221;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#8217;s IPO, the series A-1 preferred stock converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement Structure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Bristol Myers Squibb Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#8220;AHR&#8221;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program ("the research term"). Bristol Myers Squibb has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, Bristol Myers Squibb is responsible for the worldwide development, manufacturing and commercialization of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb paid the Company a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate upfront consideration related to the Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in case of an exercise of its option with respect to IK-175, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to Bristol Myers Squibb to support the decision to exercise the option for an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Considerations of the Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bristol Myers Squibb Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the upfront from the Bristol Myers Squibb Collaboration Agreement was allocated to the equity arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the Bristol Myers Squibb Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the distinct performance obligations identified above, the Company allocated the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for research and development services for IK-175; and </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for research and development services for IK-412. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the Bristol Myers Squibb partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb research term outside of the committed manufacturing efforts, which were completed in 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company recognized revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, from the Bristol Myers Squibb Collaboration Agreement. The consolidated balance sheet as of December 31, 2022 includes current deferred revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to this agreement. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for the partnered programs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_CollaborationAndStockPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_CollaborationAndStockPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597785344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. COMMON STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock authorized, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,257,493</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,975,034</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518986512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2016, the Company&#8217;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#8220;2016 Plan&#8221;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company&#8217;s stockholders approved the 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), which became effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 30, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The shares of the Company&#8217;s common stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares initially reserved under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,263,664</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock. The 2021 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of common stock availab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">le for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan. On January 1, 2022, the number of shares of common stock available for issuance under the 2021 Plan increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,439,001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares as a result of the automatic increase provision of the 2021 Plan. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,639,915</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock remain available for future issuance under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vesting periods for equity awards, which generally is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are determined by the Board of Directors. The contractual term for stock option awards is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.571%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.983%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,750</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,525</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average fair value of the stock options granted during the year ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.52</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. As of December 31, 2022, the total unrecognized stock-based compensation balance for unvested options was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which is expected to be recognized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.133%;"/>
        <td style="width:0.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.190999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.88%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.056%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.17%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,927,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282,459</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.88</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">878,084</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">362,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">362,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,009,095</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,798</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intrinsic value of options exercised for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is estimated on the date of grant using the Black-Scholes option pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.725%;"/>
        <td style="width:1.158%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.169%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.347999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.59</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.68</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.15 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.58</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 20, 2021, the Company&#8217;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 30, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">346,613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been purchased by employees under the ESPP.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597700080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. EMPLOYEE BENEFIT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). Contributions to the plan by the Company totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t make any employer contributions for the year ended December 31, 2021. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2022 and 2021, were immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597721840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. INCOME TAXES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.7%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.073%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.062%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.200000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.189%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">823</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">629</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;E</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">761</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,434</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset and liability before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,033</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2022, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million primarily due to the increase in the Company&#8217;s book loss reported in the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) amended Section 174 and now requires U.S.-based and non-U.S-based research and experimental (&#8220;R&amp;E&#8221;) expenditures to be capitalized and amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_73fc101d-7745-47d5-b271-65058a5425c1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five </span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;E expenditures in the year paid or incurred. The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of Federal &amp; State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, to offset future income taxes, which will begin to expire beginning in</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2031</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows the provisions of ASC 740-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; and specifies how reserves for uncertain tax positions should be classified on the balance sheet; among other provisions. As of December 31, 2022, and 2021, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recorded tax reserves associated with any unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incurred interest and penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s federal and Massachusetts income tax returns for the years ended December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597696560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. RESEARCH LICENSE AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2015, the Company entered into an exclusive patent license agreement (the &#8220;UT Austin License&#8221;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#8220;University&#8221;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon meeting certain development milestones during the term of the UT Austin License. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company acquired IPR&amp;D on an Arrys&#8217; immune-oncology candidate based on the intellectual property associated with Arrys&#8217; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, as well as certain sales event milestones ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million contingent on sales in a calendar year, during the term of the AskAt License.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597696560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. LEASE OBLIGATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 21, 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,752</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#8217;s corporate headquarters. The commencement date of the lease was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 19, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the lease term is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The base rent at commencement is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per month and escalates by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% annually for total lease payments during the term of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an operating lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the commencement of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with the Company's operating leases.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information relating to the Company&#8217;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,774</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining lease terms and discount rates related to the Company's leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future minimum lease payments for the Company&#8217;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"/>
        <td style="width:1.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.994%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,882</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">817</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,464</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,694</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550519071936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. COMMITMENTS AND CONTINGENCIES</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2022 or royalties on future sales of specified products that have not yet occurred as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597735984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into several agreements with a director and an entity affiliated with a director:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 11 above, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Certain entities affiliated with directors purchased shares in the IPO.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550597393648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.467%;"/>
        <td style="width:1.178%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.972%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.166%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.216999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550517506752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#8220;Arrys&#8221;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#8220;Amplify&#8221;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses research and development revenue under a collaboration agreement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of preferred stock, payments from a collaboration arrangement and related party revenue. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, the Company&#8217;s revenue has primarily been from a collaboration agreement. The Company has devoted substantially all of its financial resources and efforts to identifying potential product candidates and conducting preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company&#8217;s cash, cash equivalents, marketable securities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company believes the cash, cash equivalents, marketable securities as of December 31, 2022 will enable it to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements, though it may realize additional cash resources upon the achievement of certain collaboration agreement option exercises, or it may pursue additional cash resources through public or private equity or by establishing collaborations with other companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#8217;s expectations with respect to its ability to fund current and long term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any collaboration exercise options will be achieved or that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations. As of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Suppliers</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of December 31, 2022, the Company has not experienced any credit related losses on accounts that hold the Company&#8217;s cash, cash equivalents and marketable securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers and CROs to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company&#8217;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments consist mainly of cash equivalents, restricted cash, accounts payable, and marketable securities. The carrying amounts of cash equivalents, restricted cash, and accounts payable approximate their estimated fair value due to their short-term maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in the Company&#8217;s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. The Company&#8217;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash equivalents are generally composed of commercial paper, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company invests its excess cash balances in marketable securities and classifies its investments as available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its investments in marketable securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. The Company reports available-for-sale securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the marketable securities, the Company considers all available evidence to evaluate if an impairment loss exists, and if so, adjusts the investment to market value through a charge to its consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, held in the form of a money market account as collateral for the Company&#8217;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of their useful life or lease term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had one collaborative agreement with Bristol-Myers Squibb, which the Company entered into in January 2019  For a complete discussion of the accounting related to Bristol Myers Squibb Collaboration Agreement, see Note 8, Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#8217;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_LeasesPolicyPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_03b4de73-343f-4ac2-8c26-c4a271fedc1c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC) 842 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Loss: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i) all components of net loss and (ii) all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated other comprehensive loss policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LeasesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LeasesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518363392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value On Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.432%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.588000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.384%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152,889</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.534%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.418000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.204%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.407%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518263616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary Of Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.064%;"/>
        <td style="width:1.211%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.211%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.142000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.442%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,606</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">739</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Marketable Securities Fair Value By Contractual Maturity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities fair value by contractual maturity were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.057%;"/>
        <td style="width:1.942%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518234864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.986%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">727</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,063</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,299</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518260592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.200000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.189%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">475</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,513</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,205</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518233632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.567%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.986%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,489</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513932544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.571%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.983%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.61%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,750</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,525</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.133%;"/>
        <td style="width:0.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.190999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.88%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.056%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.17%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,927,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282,459</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.88</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">878,084</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">362,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.73</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">362,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,009,095</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,798</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is estimated on the date of grant using the Black-Scholes option pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.725%;"/>
        <td style="width:1.158%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.169%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.347999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.59</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.68</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.15 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.58</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518252672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.7%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.073%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.062%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Total Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.399%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.200000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.189%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">823</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">629</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;E</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">761</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,434</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset and liability before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,033</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514641744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of components of Lease Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Cash Flow Information Relating to the Company's Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information relating to the Company&#8217;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,774</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Summary of Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining lease terms and discount rates related to the Company's leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Lease</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future minimum lease payments for the Company&#8217;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"/>
        <td style="width:1.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.994%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,882</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">817</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,464</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,694</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518272608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.467%;"/>
        <td style="width:1.178%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.972%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.166%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.216999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822,373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514557616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Organization - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds received after deducting underwriting discounts and commissions</a></td>
<td class="nump">$ 131,300<span></span>
</td>
<td class="nump">$ 131,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Company issued and sold shares of common stock</a></td>
<td class="nump">8,984,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment Option to Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Company issued and sold shares of common stock</a></td>
<td class="nump">1,171,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513635104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, marketable securities</a></td>
<td class="nump">$ 156,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 214,219<span></span>
</td>
<td class="nump">$ 145,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, ASU, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, ASU, Adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember', window );">Electronic Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful life</a></td>
<td class="text">the shorter of their useful life or lease term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518203040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)1 - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation', window );">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</a></td>
<td class="text">Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of when remaining performance obligation is expected to be recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513789456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details) - Fair Value On Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 152,889<span></span>
</td>
<td class="nump">$ 232,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">55,861<span></span>
</td>
<td class="nump">232,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">97,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">55,861<span></span>
</td>
<td class="nump">232,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">55,861<span></span>
</td>
<td class="nump">$ 232,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Marketable Securities</a></td>
<td class="nump">22,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Marketable Securities</a></td>
<td class="nump">22,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Marketable Securities</a></td>
<td class="nump">74,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Marketable Securities</a></td>
<td class="nump">$ 74,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550519197456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_FairValueLevel3TransfersOutAmount', window );">Fair value, level 3 transfers out, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_FairValueLevel3TransfersOutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, level 3 transfers out, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_FairValueLevel3TransfersOutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515761408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary Of Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 97,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">97,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">75,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 74,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550517508624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of marketable securities in an unrealized loss position | Position</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment charges related to available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses for available for sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550514633008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 79,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">17,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 97,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515760384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ClinicalManufacturingAndScientificDevelopmentCurrent', window );">Clinical, manufacturing and scientific development</a></td>
<td class="nump">$ 1,372<span></span>
</td>
<td class="nump">$ 2,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid Insurance</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 3,063<span></span>
</td>
<td class="nump">$ 4,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ClinicalManufacturingAndScientificDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical, manufacturing and scientific development current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ClinicalManufacturingAndScientificDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515442896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 5,030<span></span>
</td>
<td class="nump">$ 3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember', window );">Electronic Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513930368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation including accelerated depreciation on disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513807456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="nump">$ 2,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,343<span></span>
</td>
<td class="nump">$ 5,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512098512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,160<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBristolMyersSquibbMember', window );">Stock Purchase Agreement with Bristol Myers Squibb | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">14,545,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | Bristol Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_UpfrontPayment', window );">Upfront consideration payment</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm', window );">Option to exercise additional consideration if clinical trial not completed within research term</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_MilestonePaymentsEligibleToReceive', window );">Milestone payments eligible to receive</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | Bristol Myers Squibb | IK-175</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions', window );">Amount eligible to receive in case of exercise of options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | Bristol Myers Squibb | IK-412</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions', window );">Amount eligible to receive in case of exercise of options</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_UpfrontAmountAllocatedToEquityArrangements', window );">Upfront amount allocated to equity arrangements</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">78,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized which were previously included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | IK-175</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | IK-412</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount eligible to receive in case of exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_MilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_MilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to exercise additional consideration if clinical trial not completed within research term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_UpfrontAmountAllocatedToEquityArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront amount allocated to equity arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_UpfrontAmountAllocatedToEquityArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ikna_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ikna_IKOneSevenFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ikna_IKOneSevenFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ikna_IKFourOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ikna_IKFourOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550517503600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details) - Redeemable Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="num">(169,396,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515772976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,257,493<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,257,493<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512171056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Mar. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of the stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,927,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation balance for unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized stock-based compensation balance for unvested options expected to be recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate', window );">Plan effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of stock granted</a></td>
<td class="nump">3,263,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding', window );">Available for issuance percentage of annual increase in number of common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,639,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_StockOptionContractualTerm', window );">Stock option contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate', window );">Plan effective date</a></td>
<td class="text">Mar. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding', window );">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees', window );">Number of shares purchased by employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for issuance percentage of annual increase in number of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, plan effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_StockOptionContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_StockOptionContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550516014368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Total Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 7,525<span></span>
</td>
<td class="nump">$ 5,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512154880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">5,822,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,927,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(282,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled or forfeited</a></td>
<td class="num">(878,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">6,589,479<span></span>
</td>
<td class="nump">5,822,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested or expected to vest</a></td>
<td class="nump">6,589,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">3,009,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
<td class="nump">7.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
<td class="nump">3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Cancelled or forfeited</a></td>
<td class="nump">8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding</a></td>
<td class="nump">7.29<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested or expected to vest</a></td>
<td class="nump">7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested or expected to vest</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Option exercisable</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 362,112<span></span>
</td>
<td class="nump">$ 33,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest</a></td>
<td class="nump">362,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</a></td>
<td class="nump">$ 358,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513843632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility range minimum</a></td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">68.58%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility range maximum</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">5 years 1 month 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513909888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions to defined contribution savings plan</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550516015184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax effected at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.00%)<span></span>
</td>
<td class="num">(32.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512175360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Total Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 22,875<span></span>
</td>
<td class="nump">$ 18,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="nump">5,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">10,667<span></span>
</td>
<td class="nump">6,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capitalized start-up costs</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">6,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">1,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental', window );">Capitalized R&amp;E</a></td>
<td class="nump">14,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">62,230<span></span>
</td>
<td class="nump">40,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(761)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(1,436)<span></span>
</td>
<td class="num">(1,786)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(2,197)<span></span>
</td>
<td class="num">(2,434)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset and liability before valuation allowance</a></td>
<td class="nump">60,033<span></span>
</td>
<td class="nump">38,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">$ (60,033)<span></span>
</td>
<td class="num">$ (38,027)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and experimental.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513740896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased amount</a></td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Reserves for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Incurred interest and penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod', window );">Tax cut jobs act research and experimental expenditures to be capitalized and amortized period.</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod', window );">Tax cut jobs act research and experimental expenditures to be capitalized and amortized period.</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax returns years open and subject to examination</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax returns years open and subject to examination</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear', window );">Tax credit carryforwards begin to expire</a></td>
<td class="text">2031-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Not Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 108,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear', window );">Tax credit carryforwards begin to expire</a></td>
<td class="text">2031-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Begin to Expire in 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 105,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration begin month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cut jobs act research and experimental rxpenditures to be capitalized and amortized period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ikna_NotSubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ikna_NotSubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ikna_BeginToExpireInTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ikna_BeginToExpireInTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550515431008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research License Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">UT Austin License | University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PotentialDevelopmentMilestonePayments', window );">Additional milestone payments payable upon meeting certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_RoyaltiesTerms', window );">Royalties terms</a></td>
<td class="text">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PotentialDevelopmentMilestonePayments', window );">Additional milestone payments payable upon meeting certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_RoyaltiesTerms', window );">Royalties terms</a></td>
<td class="text"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Total consideration allocated to technology recognized as research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PotentialSalesEventMilestonePayments', window );">Milestones payable contingent on sales in calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PotentialSalesEventMilestonePayments', window );">Milestones payable contingent on sales in calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PotentialDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PotentialDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PotentialSalesEventMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential sales event milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PotentialSalesEventMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RoyaltiesTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RoyaltiesTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512038544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total lease rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,255<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember', window );">Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_AreaOfLeasedProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="nump">20,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Feb. 19,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_OperatingLeaseMonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_PercentageEscalationInAnnualBaseRent', window );">Percentage escalation in annual base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total lease rent payments</a></td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_LetterOfCreditToSecureLease', window );">Letter of credit to secure lease</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AreaOfLeasedProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AreaOfLeasedProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LetterOfCreditToSecureLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Letter of credit to secure lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LetterOfCreditToSecureLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PercentageEscalationInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage escalation in annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PercentageEscalationInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550513810800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Summary of components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550511915792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ikna_Supplementalcashflowinformationleasesabstract', window );"><strong>SupplementalCashFlowInformationLeasesAbstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)</a></td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_Supplementalcashflowinformationleasesabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplementalcashflowinformationleases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_Supplementalcashflowinformationleasesabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550518178032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount Rate</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550509659088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">6,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550512146176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">UT Austin License | University | Affiliated to Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">University license fees and certain-patent related costs</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140550509725472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">6,589,479<span></span>
</td>
<td class="nump">5,822,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">6,589,479<span></span>
</td>
<td class="nump">5,822,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>ikna-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ikna="http://www.ikenaoncology.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ikna-20221231.xsd" xlink:type="simple"/>
    <context id="C_5380a635-35e8-4659-a29b-6c6c312f0478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_686297fa-085a-4a4a-a878-5b20c1fcf30f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_3a0f4009-cad0-4026-8941-85d87debcc2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3d9274dc-5a91-43f3-a6de-fddb2971143b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f720352-5344-47c4-bf64-7ee0c53bfc69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_201175b1-5ec1-482c-82bd-42e11405e926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6011e744-0468-4b9d-a6aa-2ad82bb602fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_527c0073-0dca-4b32-809c-4a7e62aec6ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_094353c9-0180-4db6-835f-7fd1043e467d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d13cc7f8-a86c-42e2-8850-115bf15cdd7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7197b178-a4ef-4f27-bbbb-2a2195a83543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f708ee60-4251-4c02-b611-2b02ced0c594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_32847360-0e0a-4bc8-8675-0ec3449433c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d7496043-4245-45bf-886a-e65de0a22afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_51a2a164-bf0e-4c35-b339-4d0fabaee032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1178e06-1abe-41ec-b7dd-8ac5bb40a35b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94b787e9-7a65-4675-ae1c-15ef31484f3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbbd90fc-7f8c-4e81-9033-43797f48a0e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_622ece3c-9861-4130-adc3-64fee0afb1e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_82efe98b-6310-4367-b03b-b818789abe68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7251b328-1b51-45ee-a489-0591be444c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c06f1a61-16c4-4100-89a4-3b2b77f6fab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18a1ea8b-e577-4c5b-9f0d-b1c3d8bddc84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:NotSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-31</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_d2d96cc4-4b37-4a61-9a19-85166d8d9462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_243e768c-5a7d-4e4d-92c7-d1c089eaaf89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4de011a1-1fee-47df-a29f-9beca448f979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_0f2e0b59-0865-42b0-91fa-b28782511684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aaa08537-cb74-4d4d-a39a-8997e07e77df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a216833a-bcc3-4948-b7e6-e2ffb74f7b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_172039bc-db4e-4260-9a5f-1630d4a4a0ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-31</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_01480c2c-876c-40b4-a15a-bc9c124601af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="C_84324036-af2c-40fe-9fa2-a3dbfb992c04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_5422dba2-f132-4a6c-8c0d-9f0758d86563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25c317f9-19e2-409c-9f55-9c90713949a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_56a2b03d-825c-40b9-ae08-f05fa29edc0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-21</startDate>
            <endDate>2020-07-21</endDate>
        </period>
    </context>
    <context id="C_1b8449eb-5f80-4e42-a3a7-9af92acd3f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0328cea2-41fd-451c-a98a-8066850c22de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_72b4e02a-df1a-4585-b5ad-11bbc8dc7393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ac9d39c1-132d-4ba8-be7b-fc7b585405ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_af45af9b-bf8b-48ad-9b86-a379550ecc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_629dc6f2-dce8-43e8-9319-86cbd98602c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e2ab031b-2c82-4ab6-b6af-8f43dbaf9ec4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f069e2a6-5458-4e6d-b129-855b9f38dccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5e250053-4619-45f1-9e2b-a7efc1571f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_01fa273c-adc6-48a9-9be3-a48fc56e1ffa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ac826982-7dbc-4cee-848b-c0246e9b311d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1bdd79a-55db-4f3d-b9dc-b5eea09238fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55096704-6551-4982-b2dd-3b2dd0624c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2afa1f5-af40-4100-93ce-80c9cdaa0874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32986907-9238-453d-9ab9-8a0f5484f461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_72e7b2cf-5188-421c-b31a-cb8c26070efc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f3e63dc-8be1-44b1-bd62-8504096da2d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f74818aa-b473-442b-83e4-0dd0c0bedd47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_006dc649-dc41-474f-8ec9-76fa6ad1fab7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a06410af-63e3-4326-a071-99bd20e03747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_25d90a8b-c846-4756-bd61-dd59c2bafa2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bbac1559-abd3-46e6-b271-d81b0a7eaae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_14d9fef1-667e-4963-8142-cdd235c7f806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="C_aede6e61-a0c9-4e55-bbf8-f41b83685d83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f72bf92b-b49c-4e3d-b668-ab6a03cec96d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_30df2e55-bbb5-427e-82b4-f114563688e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="C_db24a009-c7dc-477b-81ab-fa7a1a7149cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79681f83-bcfa-43cd-b9a8-9202b8e8dd42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0b5743c1-f77e-4a80-9bb0-c3531c20806d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f11f597d-a8dd-465c-abcf-5256cc5c240e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb286aec-68e2-4e6f-b537-31fc48bc69b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_dfe38f01-f9ca-4eaf-a331-878b48fafd55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_039e47d5-8439-4779-9f97-da794a71c14e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_846b01fb-e362-4321-8448-6f496f45b801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_addbb181-d517-444c-af21-20959683d0dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d9ce082a-af1a-4ce0-b0b5-24c0aa1bc3a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b633a850-2bce-4c3c-abbd-d9eeb2480f83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_33bcb973-7966-4f4c-bc9c-e3aa82ff7119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_c5743e53-9eec-4995-bd5a-136752b9e092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a1c560c7-417e-4680-8016-5472ee398972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-20</startDate>
            <endDate>2021-03-20</endDate>
        </period>
    </context>
    <context id="C_84d516bd-f241-4424-bbd6-e29e016466cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_73e45bb4-192d-4764-86f0-84eb2db89c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_61e02eba-c186-44f9-b40a-69c6eda8c2f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_5b851c3a-24e1-41dc-a872-7efb1cd60872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_81be7afb-a84c-4259-b0db-774799b8967e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_35a41072-255d-4437-a4a9-cad64e6da60a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_ffa36058-10c5-475b-85fe-d2a62ed6bfd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_5a48902d-ac69-43f6-b35e-bc502c7e3265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9117ee30-cb2e-437f-bbc2-c141841cb4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_23fc5900-4ca2-478b-99d4-086caa8e243f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_68d0106c-cdc4-4aae-a92c-8c34b9586d82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f9e73fef-5f12-49d2-b304-fdc0a8211ca9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_49f118e2-3aad-42e9-9966-9b49f9d34542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3be42be-7b3d-40ba-ad4b-e05df3584a06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesA1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:StockPurchaseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4e1254ff-dea8-4f2d-8b51-985639cee2f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d8d5e815-4402-469f-92c1-05e99f28eae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="C_30eb871a-b095-47c3-a919-45cc40650449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_76b4cb83-83c9-4fda-8ec2-4663fab1916f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_998a15cc-e896-4027-85f6-00d38c4c670f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f09330b3-63fd-4523-8016-448dd3b3e3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b6fbf11-0f77-40b2-8c0f-e122abf4d570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>ikna:Segment</measure>
    </unit>
    <unit id="U_Position">
        <measure>ikna:Position</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod
      contextRef="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496"
      id="F_73fc101d-7745-47d5-b271-65058a5425c1">P5Y</ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      id="F_6405c329-beba-47dc-a7ce-628745e34612"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      id="F_2bfa3cd5-7671-450c-9646-fc3da919b9cd">http://fasb.org/us-gaap/2022#InProcessResearchAndDevelopmentMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_ea7b51ae-9485-4d01-9e50-58f15f5b438a">http://fasb.org/us-gaap/2022#InProcessResearchAndDevelopmentMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:AmendmentFlag
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_1c0b9497-2641-40d2-943a-f38d1b6ede6c">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      id="F_11ef3329-dcf3-4ec2-8622-e99fe0bb4b61"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_03b4de73-343f-4ac2-8c26-c4a271fedc1c">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_178f4674-c445-42ef-af4b-4fce1a943cc3">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      id="F_839b234b-d83d-4063-a99d-0257ea516d6b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      id="F_158d126e-6bca-4219-b170-503c05bf52e5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f7ac34a0-df59-4770-a2ef-cea6de0ce0ef">0001835579</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_4308152c-2ede-4e02-ac55-8254dbed51f3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0032ec5b-9a77-407b-9d3f-82fccf01f445">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_d611cddb-3307-4b2a-8d09-933885144442">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_d72db59b-5e4d-4a9e-9b19-23e844d6cdb5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0f337402-6974-4b3a-9887-c6afe294e678">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_12b79b0e-fbe8-4f73-b3bf-b7675d1d5923">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_7b8a1603-cece-4205-b09a-5f61b48419d2">001-40287</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_fd503cab-f71d-4cd6-b820-76b9be962440">IKENA ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_c75d021d-bdef-4dbc-9359-af4bffd1e2bb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_308a2150-54a2-42b8-95d6-c3ab6e216c73">81-1697316</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_7ce0fa41-69e6-44ab-b7ab-55406c2de232">645 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_fb0b89d9-a651-4879-83e5-ab464ff37003">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_147c458e-4299-4967-94b8-1b38ecfa4581">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_2d11bde9-ccd3-4440-9b07-ca69c10576fa">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_8ce0bdcc-dcac-43e6-b98a-8bc606dfd3b2">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_6ebf18cf-472f-474a-8be0-137a91c578a9">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_ee8e4baf-fad1-4e37-8cb4-ee914eeba2cc">273-8343</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_e35c4446-120e-49b9-8da6-d273036b60d9">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_1788f8c6-3a9a-4ac0-9be2-19572c5b7afd">IKNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_fbba9783-823d-4cf5-b97e-eb2ed28201b4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_d4be225d-fd8b-4994-8538-bd737f5392e4">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_b262263e-1088-42e4-968d-05c031914194">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_4a6702a0-6d90-4907-ab66-cb497e5c4a0c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_9cc279de-012f-4806-9c34-4bb3c6a885aa">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0dc3c24c-30b2-47f4-96c6-2940d4ea23cb">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f802e109-b619-43bd-b8ad-f63409bf0ee2">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_1ccbaa2e-e5c5-4625-b7a2-88c5426faec6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_5d8f1ffc-6a0e-4eb3-bd65-7b8e6f7c6dc2">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f23f4b1c-b009-4f74-8676-f840f72a1623">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_9ea148d2-cf21-4987-9063-4425f19ce2f7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-5"
      id="F_59544cca-f1e9-4e04-9fdb-b7dbe2e47f50"
      unitRef="U_USD">58000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_30df2e55-bbb5-427e-82b4-f114563688e7"
      decimals="INF"
      id="F_40af6117-b814-4e49-aca7-cdf2f1b642e5"
      unitRef="U_shares">36257493</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_60295a05-483f-4d69-a025-0b7ad68040cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f65e68ad-980d-4f3f-8d83-a33d8a0443cc">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_8d416e17-80fd-4977-b3d2-b8c551bec17e">Boston, Massachusetts</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_5ff6c7dc-a384-4888-8eea-f6623c70ee93">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_170b3a3d-f27c-41bb-9b40-1add33c6fcd3">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_9dd7689a-f511-4f8d-8137-0a7cec907b68">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_6906936c-1987-4587-8944-770049dde6d7"
      unitRef="U_USD">59919000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_fdeb5616-ab12-4dec-8dd8-325f99b1daaa"
      unitRef="U_USD">232217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_6dc49f8e-4c84-4229-8919-b34109975cbd"
      unitRef="U_USD">97028000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_505ecfd7-c469-41a3-a33b-6b6a0d1a9814"
      unitRef="U_USD">3063000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_c2e55227-365b-4ce9-8ca5-ea89781da7af"
      unitRef="U_USD">4299000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_e9f1b7e8-8bf9-4159-bdac-1c72c56e7cac"
      unitRef="U_USD">160010000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_e11e1fa6-83a2-4b40-a460-16d090fd5d94"
      unitRef="U_USD">236516000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_2ab66a8d-8c62-40a8-9148-0be0759827c1"
      unitRef="U_USD">3205000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_8cb77f24-a743-467a-9cd3-985334c59316"
      unitRef="U_USD">2439000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_3355153a-547d-4ed2-8fb0-61c64a00aecf"
      unitRef="U_USD">5255000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_27727eab-40aa-47c1-9663-ebbab41406a4"
      unitRef="U_USD">6538000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ikna:DepositsAndOtherAssetsNoncurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_762d0f28-bf69-4679-88cb-df7060d97be1"
      unitRef="U_USD">3789000</ikna:DepositsAndOtherAssetsNoncurrent>
    <ikna:DepositsAndOtherAssetsNoncurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_3eb79fb5-fcb7-48ef-ad82-09a943a723ea"
      unitRef="U_USD">2386000</ikna:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_e04d8d54-011e-402a-a1ab-f390fd9f9726"
      unitRef="U_USD">172259000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_2503982b-d851-42d6-9207-848089446bfb"
      unitRef="U_USD">247879000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_ffe4e1fc-1669-43ec-9eea-960153aefa88"
      unitRef="U_USD">2093000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_0e3d8e2e-6089-4ec6-87f4-6fdf5d4750ac"
      unitRef="U_USD">2384000</us-gaap:AccountsPayableCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_ea6b7d1b-39ae-4a88-9232-79f0a7abe232"
      unitRef="U_USD">8343000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_a700a5c7-896e-45a6-ab0c-ec3e68577d97"
      unitRef="U_USD">5854000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_7c51ad5c-7aa8-42cf-b76e-f0c7ff2c6aee"
      unitRef="U_USD">1907000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_94511d2a-95d8-4aec-9ee8-7b3dac5382ff"
      unitRef="U_USD">1851000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_cd2442f1-25cc-4b5b-b153-1db8346e8830"
      unitRef="U_USD">9160000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_4e4fb984-aeb0-44f5-b4a8-e56781810264"
      unitRef="U_USD">17100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_ed7780b5-31ec-4cac-bfd4-0d882ef50ca6"
      unitRef="U_USD">21503000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_ffcaf436-3c8f-4455-ad7d-80431ede34dd"
      unitRef="U_USD">27189000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_0965abe3-2d9f-466a-af41-75296f9fd461"
      unitRef="U_USD">3787000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_1fe9443c-ddde-4bb4-9b28-7c5b4e85db84"
      unitRef="U_USD">5135000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_2826f143-17e0-4dce-b4e2-fad153d1b713"
      unitRef="U_USD">7678000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_5d9c36b0-2b72-4381-be2c-c633ce3322a5"
      unitRef="U_USD">25290000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b626f817-f96c-4193-a04b-26913e995196"
      unitRef="U_USD">40002000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_63ba0316-9ac2-4b24-85ea-9e625f777f9c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_4f9e7571-3061-4b65-a3fd-2dca1186364a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_b7b6080c-eb1b-4dad-9bc1-1ce60f1e7be8"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_8382c052-3888-40d5-94ee-ae80584bfda9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_cb546de8-7d6e-41da-a590-399308ef1787"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_b5b934f3-62f6-4b05-9301-be6d14916088"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_cba1f416-89ea-404e-a248-4695448a6d2a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_81b5787e-5e44-44ee-938f-8d5eebb35a8f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_4dfc1e60-36ff-41d9-a392-5bd947fc5c26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_7f7c21a5-4d50-4330-b85b-b06f9eb20465"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_f979d14a-12f6-41d5-a8ee-8e49855dba85"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_5d2286ff-ddc2-40ac-93fd-b5689b320a23"
      unitRef="U_shares">36257493</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_afd7c150-0120-4cc6-ac92-310df9e9d7ff"
      unitRef="U_shares">36257493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_3d3a6919-7b83-4d4c-b25f-ab8267816086"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_ae2cfe2d-b366-4784-846a-1b0923c25052"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_6a380edf-4450-4487-9d16-8d82d58ab93c"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_8330eb24-5a82-4eb2-bd6f-39c0cec753fd"
      unitRef="U_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_c2c7f283-f252-4d21-b5d2-9fd098280842"
      unitRef="U_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_798ac250-01c8-43f9-93bd-3dfdd41fd521"
      unitRef="U_USD">361915000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b2bb159a-2430-4cca-a65a-d1e3da0d5e80"
      unitRef="U_USD">353295000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_538bfb45-7cc3-4f9b-92f3-67612809e5f9"
      unitRef="U_USD">-763000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_3403b16b-73cd-4cf7-9427-ddd9dc4b2023"
      unitRef="U_USD">-214219000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_6c7d4f89-8cb6-4aac-903e-6995dfc627b6"
      unitRef="U_USD">-145454000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_f1090bb7-d9b5-45e1-86d1-b74169881396"
      unitRef="U_USD">146969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_39cc023d-66be-4622-835a-be667a2b1719"
      unitRef="U_USD">207877000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_0807440d-8bab-4ccc-a36c-9015cf4727a1"
      unitRef="U_USD">172259000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_2ee20b53-a17f-4870-b353-e680f8fc7cd6"
      unitRef="U_USD">247879000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_2d51b80c-09e1-4a0b-aae5-8764fbd3fa66"
      unitRef="U_USD">15618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_b45d859f-9186-4604-9fea-903bc4721429"
      unitRef="U_USD">30985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_74e2475a-8a1c-41dc-a2cb-2bc2097121c7"
      unitRef="U_USD">64321000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_b8ee5a4f-5d5d-452a-b8d9-e36e87547e57"
      unitRef="U_USD">47108000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_fa457c4a-fe1d-4003-baa0-63ad682290fe"
      unitRef="U_USD">22201000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_1fb4475b-3daf-4e5d-b109-e69226641e62"
      unitRef="U_USD">18015000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_73e01067-2d38-4f76-9e60-3cc3d6dcf1e1"
      unitRef="U_USD">86522000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_bdc5ce4c-dd8a-4970-8554-5f7571e279a5"
      unitRef="U_USD">65123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_5afd65f7-42b3-4de2-afd3-60042a71b2a6"
      unitRef="U_USD">-70904000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_f9a1aa4b-e7d1-4555-9976-f32c9a8d02a9"
      unitRef="U_USD">-34138000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_92965262-1f3d-4a3f-9e09-913a705c5190"
      unitRef="U_USD">2149000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_9b242fbe-338f-4c72-9bbc-147d7ad3cc7b"
      unitRef="U_USD">23000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_dcedffd0-eeda-4306-8a50-9189a50026c5"
      unitRef="U_USD">10000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_293611bc-abc3-4c07-9f7d-489ae035583a"
      unitRef="U_USD">2139000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_bc768058-2bca-4cb3-8593-76215c21a31e"
      unitRef="U_USD">23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_bd331fa3-5a3e-4280-90d7-7c7e7bffa59e"
      unitRef="U_USD">-68765000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_b9261545-f4f6-48ad-8e34-eddacaf2ed86"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_9aef705a-1379-40bd-9dfb-002ebfc52239"
      unitRef="U_USD">-763000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_cf9e4441-d1f4-4eba-b4af-f84b73dc3c42"
      unitRef="U_USD">-69528000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_a63838c9-6aa1-46a0-965a-f4436c411609"
      unitRef="U_USD">-34115000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_97bb4655-567b-4003-a7ea-edcbbb3396fb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_de35bffb-33b4-4a5c-8b2a-7a9fc9c69815"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="2"
      id="F_9c10c767-c823-4a33-a235-355bb7df1b5b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="2"
      id="F_95079362-398b-41d3-90ed-e85b498b47c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="0"
      id="F_a148df8b-b39e-4152-a8c9-77c7191485d5"
      unitRef="U_shares">36188420</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="0"
      id="F_ce714607-da36-41f6-a69c-91f6dddd8065"
      unitRef="U_shares">36188420</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="0"
      id="F_e1b0a880-ed3a-4978-9539-1340b262990c"
      unitRef="U_shares">27983359</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="0"
      id="F_cdf04b2b-26e7-4798-b351-b8dc48d3bff7"
      unitRef="U_shares">27983359</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5"
      decimals="INF"
      id="F_a4f40769-238b-414a-81a4-703f4f73f4d4"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5"
      decimals="-3"
      id="F_8a3ef001-21c1-401a-bdb6-76e1b7d94064"
      unitRef="U_USD">205979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54"
      decimals="INF"
      id="F_63f038b1-a484-41b4-9f06-189eb6a83874"
      unitRef="U_shares">3096903</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d044216b-e87d-4b40-94e7-da2d4e1f9b54"
      decimals="-3"
      id="F_b99a5668-2a99-4f10-b948-21f3bf598914"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_243e768c-5a7d-4e4d-92c7-d1c089eaaf89"
      decimals="-3"
      id="F_144ba852-fc42-4e9e-807c-6c98fe718d2c"
      unitRef="U_USD">10288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a06410af-63e3-4326-a071-99bd20e03747"
      decimals="-3"
      id="F_5f7acc27-5903-4c8f-aaa9-611e4b78f692"
      unitRef="U_USD">-111339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5743e53-9eec-4995-bd5a-136752b9e092"
      decimals="-3"
      id="F_3bfbf4b9-bf3f-4f1e-9bb7-b774cff231a4"
      unitRef="U_USD">-101048000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_9117ee30-cb2e-437f-bbc2-c141841cb4a7"
      decimals="-5"
      id="F_b57c3536-0a10-4797-bf23-8071358dbbf9"
      unitRef="U_USD">2400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"
      decimals="INF"
      id="F_0d9204f2-3ace-416a-ab87-52c24d0ca62e"
      unitRef="U_shares">8984375</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"
      decimals="-3"
      id="F_3f8021ac-4c59-4d5c-90b2-5e7379ae5e40"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8"
      decimals="-3"
      id="F_cff30641-a34d-4504-8664-0905669edde8"
      unitRef="U_USD">131293000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_8b9ee2af-c4a4-4609-b256-b5d14103c069"
      unitRef="U_USD">131302000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_81be7afb-a84c-4259-b0db-774799b8967e"
      decimals="INF"
      id="F_93edb919-0dae-45ac-a30a-1434d0a45e54"
      unitRef="U_shares">-169396576</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_81be7afb-a84c-4259-b0db-774799b8967e"
      decimals="-3"
      id="F_db02fd6d-6cd9-492c-94f6-b5e693e276d3"
      unitRef="U_USD">-205979000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"
      decimals="INF"
      id="F_2d52fe46-076f-4f60-8747-80f1aea469bb"
      unitRef="U_shares">23678568</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"
      decimals="-3"
      id="F_b4e1a0d5-3d9c-4010-b98d-15a3b37b87ec"
      unitRef="U_USD">24000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8"
      decimals="-3"
      id="F_a78d74c3-3d70-43f6-a6d3-1ddf7e8e6b6e"
      unitRef="U_USD">205955000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_192049fb-6dcb-483f-8b10-64ba9156c82a"
      unitRef="U_USD">205979000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7ec849ce-256f-4ca6-8cc9-5980aed7ca0d"
      decimals="INF"
      id="F_646288b1-dfe9-49ec-9141-a4705a9ce0ff"
      unitRef="U_shares">215188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8"
      decimals="-3"
      id="F_913ae434-f558-4513-8fb1-4f380782de01"
      unitRef="U_USD">582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_292f65c3-fed3-4a07-998d-c3c138bb098c"
      unitRef="U_USD">582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0bf1a8df-0b58-43c0-98d4-2b6e3426b1f8"
      decimals="-3"
      id="F_b907d153-a7e4-4a14-adcd-0c780cc2f550"
      unitRef="U_USD">5177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_5026b851-cfeb-43f6-a3a4-c7076cfdd25c"
      unitRef="U_USD">5177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_72b4e02a-df1a-4585-b5ad-11bbc8dc7393"
      decimals="-3"
      id="F_99f7ab2c-666a-429c-98ee-295d11e79998"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_762b688d-1a27-4ecf-83ee-6ecd9b976b81"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_629dc6f2-dce8-43e8-9319-86cbd98602c8"
      decimals="INF"
      id="F_1bdb3e3e-830c-46ad-b44e-e29d24d5bc1a"
      unitRef="U_shares">35975034</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_629dc6f2-dce8-43e8-9319-86cbd98602c8"
      decimals="-3"
      id="F_09478e82-9c50-4030-9cbe-d03303306c00"
      unitRef="U_USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f11f597d-a8dd-465c-abcf-5256cc5c240e"
      decimals="-3"
      id="F_ad3b26a8-5cce-45aa-a2e9-a5018ec05d3f"
      unitRef="U_USD">353295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7251b328-1b51-45ee-a489-0591be444c4a"
      decimals="-3"
      id="F_0b3b310e-7c65-43c5-a04b-e24764366c64"
      unitRef="U_USD">-145454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_832c28ea-ce05-42e2-be5b-ead0d358c343"
      unitRef="U_USD">207877000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f708ee60-4251-4c02-b611-2b02ced0c594"
      decimals="INF"
      id="F_f55f5716-b306-48d1-9df4-96da43c7ff6a"
      unitRef="U_shares">282459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951"
      decimals="-3"
      id="F_983abdf0-9fbf-4e38-b701-f6d7539bf3fd"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_41591396-776a-4c5a-8fbf-7085898720c2"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2b602a91-759b-4bb7-a65c-f3e4ad9e3951"
      decimals="-3"
      id="F_154b1b83-7870-42c8-a1d4-064e5e1ed8f8"
      unitRef="U_USD">7525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_faef7fa9-22c6-4a4e-b8be-bda05550f4ba"
      unitRef="U_USD">7525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_82efe98b-6310-4367-b03b-b818789abe68"
      decimals="-3"
      id="F_ed4fe579-a5e7-46db-a5f4-82d2d38d2cc2"
      unitRef="U_USD">763000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_8087d33c-422a-43ac-a69a-8a7d2b6ecaae"
      unitRef="U_USD">763000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_23fc5900-4ca2-478b-99d4-086caa8e243f"
      decimals="-3"
      id="F_d4fb24b5-ca70-4c39-806d-31263dbd9079"
      unitRef="U_USD">-68765000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_2897b050-4cd3-42f6-a766-898f95b751ef"
      unitRef="U_USD">-68765000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_51a2a164-bf0e-4c35-b339-4d0fabaee032"
      decimals="INF"
      id="F_1d1276b5-6dc1-4346-84e2-46b896426225"
      unitRef="U_shares">36257493</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_51a2a164-bf0e-4c35-b339-4d0fabaee032"
      decimals="-3"
      id="F_55cd04c6-3182-45d8-9a76-759f7b4aca73"
      unitRef="U_USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_32847360-0e0a-4bc8-8675-0ec3449433c4"
      decimals="-3"
      id="F_d82c01ad-5ec8-4543-a8c9-847fbce5f981"
      unitRef="U_USD">361915000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d9ce082a-af1a-4ce0-b0b5-24c0aa1bc3a3"
      decimals="-3"
      id="F_4b918c4f-2e34-43c2-ab41-0f673ffc2953"
      unitRef="U_USD">-763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b851c3a-24e1-41dc-a872-7efb1cd60872"
      decimals="-3"
      id="F_c915d94a-1fc0-40ef-98d0-4e2b2c5202a6"
      unitRef="U_USD">-214219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_c4efb2f3-18b7-40be-9730-396cb7965c23"
      unitRef="U_USD">146969000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_966e34e9-4de1-419b-a98d-64f3fee7e1e2"
      unitRef="U_USD">-68765000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_aa6b480f-7c99-40a8-8c5d-ba355d96006c"
      unitRef="U_USD">-34115000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_90a81e2e-1c54-4c0e-8d88-71a03d9c7586"
      unitRef="U_USD">751000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_354dab70-a1cc-4eff-864a-c9428863de75"
      unitRef="U_USD">544000</us-gaap:Depreciation>
    <ikna:AmortizationOfMarketableSecurities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_05967816-18ee-4067-b1a6-011d79eaae0c"
      unitRef="U_USD">50000</ikna:AmortizationOfMarketableSecurities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_4ad4b036-ae3c-4894-ba81-9c05034475c1"
      unitRef="U_USD">7525000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_e6694228-7916-4a5c-bc2c-2f8f6a0875bf"
      unitRef="U_USD">5177000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_4c7e8dc3-b63b-4ea2-8020-992cf8e84a0a"
      unitRef="U_USD">1283000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_b3b856b2-6c8c-44e4-b11d-60787e1793fe"
      unitRef="U_USD">1174000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_313f0f4b-c8a6-4077-b77b-5fe1b6ff579a"
      unitRef="U_USD">-173000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_bb3b7463-040a-4d00-b1f8-7bb179bee35c"
      unitRef="U_USD">-12000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_71ebce16-f8d9-4f95-92ea-d19cd7aeafe8"
      unitRef="U_USD">-1236000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_f1ad4b54-e800-4e7b-b8e5-190f1e55d1e9"
      unitRef="U_USD">1452000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_44270916-16bd-4bc2-b06f-65c2a44ed9b3"
      unitRef="U_USD">-291000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_f928e8cc-a70b-4579-bd3f-adf2616a5ce2"
      unitRef="U_USD">361000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_f1a657d5-7ccd-407a-b320-cc607248d4e7"
      unitRef="U_USD">2230000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_44dec041-6744-43ac-abd0-e72c6b8ab3d4"
      unitRef="U_USD">1298000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInLeasingReceivables
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_d3c4a89a-0d6a-49b5-a722-05303b5e42fe"
      unitRef="U_USD">1292000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_7b194d1e-a41d-475c-9032-42a86b73ea56"
      unitRef="U_USD">740000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_ba9fff82-edb9-46fb-a0b8-a512162f6c3a"
      unitRef="U_USD">-15618000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_f5e4e90e-428e-49f5-a3d8-c25f720a19bb"
      unitRef="U_USD">-30985000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_b07ce2cb-1678-40e6-9feb-6230cf93a473"
      unitRef="U_USD">1403000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_5bed47e8-8e15-412b-aa7b-12c4037a3b8c"
      unitRef="U_USD">1514000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_858c39c2-12e7-4256-ba91-15185f0c5c9e"
      unitRef="U_USD">-74109000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_7f040d17-4937-422d-9e35-4fe27656786d"
      unitRef="U_USD">-60252000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_3b3d0c2d-127c-4b4a-b567-be43c2b618eb"
      unitRef="U_USD">1431000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_b0cb7eac-b06d-4012-b389-9c09777234e5"
      unitRef="U_USD">1760000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_14cd1890-ecde-4043-826c-b91db803c63e"
      unitRef="U_USD">216338000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_0399dc49-01d7-4778-9ff9-236059b6190c"
      unitRef="U_USD">118485000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_5cb14d9d-aea3-41a2-b388-e90d2d25f51a"
      unitRef="U_USD">-99284000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_6c1b410f-89b7-477c-ac9a-05f1a598ba2a"
      unitRef="U_USD">-1760000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_416ae11c-b04c-45ec-9939-d8058b3e6829"
      unitRef="U_USD">131302000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_905d117d-f480-40d0-8857-e54af698162c"
      unitRef="U_USD">1095000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_23ef1675-a9dd-4e1f-80ff-9fb644e80cf2"
      unitRef="U_USD">582000</us-gaap:ProceedsFromStockOptionsExercised>
    <ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_622807e6-e9a7-4937-a27c-697b9a1d4271"
      unitRef="U_USD">-146000</ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_f04819b5-b508-46dc-80b1-60bf182c009b"
      unitRef="U_USD">1095000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_4c55cc71-d18a-47b8-a798-f1872b922b51"
      unitRef="U_USD">131738000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_5065572b-3e32-4028-b367-982e89a25a19"
      unitRef="U_USD">-172298000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_c51744b0-27a4-4eff-8a04-01b62dc3f0c0"
      unitRef="U_USD">69726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_461e1578-fb61-4e8d-a8ee-f1f2d019cfde"
      unitRef="U_USD">233089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c5743e53-9eec-4995-bd5a-136752b9e092"
      decimals="-3"
      id="F_04d8a3d2-c68f-4260-bc24-2250d5085c9a"
      unitRef="U_USD">163363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_881ed603-9b03-442a-a0e9-965a7ea05beb"
      unitRef="U_USD">60791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_dc48dc2b-5bfb-4bb9-a88a-6b60aa9dfea2"
      unitRef="U_USD">233089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_fcb76cba-0c3a-402b-b866-448e89dcc7b3"
      unitRef="U_USD">59919000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_acaa84d7-f477-4f15-a74b-7f113cec9ec8"
      unitRef="U_USD">232217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_6a669014-ae2d-4fec-b785-2b45670b803d"
      unitRef="U_USD">872000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_e3d3b2ac-c7db-4eff-a5f4-1b3008cd136c"
      unitRef="U_USD">872000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_d5548c22-c97c-409a-887e-89dc1f033c2a"
      unitRef="U_USD">60791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_07091b86-42c6-4073-a381-87fc55d915ad"
      unitRef="U_USD">233089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_d5c70d6a-1b26-4867-bccc-7eee67f0f378"
      unitRef="U_USD">259000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_49f2cbac-e34b-4178-a18d-c05b4d15f6a1"
      unitRef="U_USD">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_c5d4d06d-530e-47bb-a694-1d70e94184ff"
      unitRef="U_USD">7541000</ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception>
    <us-gaap:NatureOfOperations
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_75cb478e-4246-4865-8eb9-8f415df0c6b5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. NATURE OF BUSINESS AND ORGANIZATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ikena Oncology Inc. is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With a robust biomarker and translational approach, the Company aims to develop targeted treatments and define patient populations who are most likely to respond to treatment. Ikena&#x2019;s current programs are across the Hippo pathway, RAS pathway, and key immune signaling pathways in the tumor-microenvironment (TME). The Company&#x2019;s approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. Since the Company commenced operations in 2016, it has  advanced multiple product candidates into clinical development. In addition, the Company has a robust pipeline of discovery-stage targeted oncology programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 30, 2021 the Company completed an initial public offering ("IPO") in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,984,375&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, including full exercise of the underwriters&#x2019; over-allotment option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,171,875&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ffa36058-10c5-475b-85fe-d2a62ed6bfd4"
      decimals="0"
      id="F_0b65d532-b23f-4c5d-a75c-656ad72cf4d9"
      unitRef="U_shares">8984375</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_14d9fef1-667e-4963-8142-cdd235c7f806"
      decimals="0"
      id="F_cab69bfc-14c3-4585-a7d4-e63aca8d6022"
      unitRef="U_shares">1171875</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_01480c2c-876c-40b4-a15a-bc9c124601af"
      decimals="2"
      id="F_f926a8b4-fb52-470c-a906-6719b9f7fac9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_35a41072-255d-4437-a4a9-cad64e6da60a"
      decimals="-5"
      id="F_e3a53b39-b9eb-42bc-8d95-f59d40c4344f"
      unitRef="U_USD">131300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_afaff87a-7fb8-422e-93d4-317f2df572cf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Use of Estimates: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses research and development revenue under a collaboration agreement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liquidity: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of preferred stock, payments from a collaboration arrangement and related party revenue. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, the Company&#x2019;s revenue has primarily been from a collaboration agreement. The Company has devoted substantially all of its financial resources and efforts to identifying potential product candidates and conducting preclinical studies and clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company&#x2019;s cash, cash equivalents, marketable securities were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;156.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company believes the cash, cash equivalents, marketable securities as of December 31, 2022 will enable it to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements, though it may realize additional cash resources upon the achievement of certain collaboration agreement option exercises, or it may pursue additional cash resources through public or private equity or by establishing collaborations with other companies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management&#x2019;s expectations with respect to its ability to fund current and long term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any collaboration exercise options will be achieved or that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations. As of December 31, 2022, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Segments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concentration of Credit Risk and of Significant Suppliers: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of December 31, 2022, the Company has not experienced any credit related losses on accounts that hold the Company&#x2019;s cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers and CROs to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company&#x2019;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value of Financial Instruments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist mainly of cash equivalents, restricted cash, accounts payable, and marketable securities. The carrying amounts of cash equivalents, restricted cash, and accounts payable approximate their estimated fair value due to their short-term maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in the Company&#x2019;s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and Cash Equivalents: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. The Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;cash equivalents are generally composed of commercial paper, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company invests its excess cash balances in marketable securities and classifies its investments as available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its investments in marketable securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. The Company reports available-for-sale securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the marketable securities, the Company considers all available evidence to evaluate if an impairment loss exists, and if so, adjusts the investment to market value through a charge to its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Cash: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company maintained restricted cash totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Electronic equipment and software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the shorter of their useful life or lease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived Assets: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue Recognition: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts expected to be recognized as revenue within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had one collaborative agreement with Bristol-Myers Squibb, which the Company entered into in January 2019  For a complete discussion of the accounting related to Bristol Myers Squibb Collaboration Agreement, see Note 8, Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Expense: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based Compensation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividend yield was assumed as the Company does not intend to pay dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_03b4de73-343f-4ac2-8c26-c4a271fedc1c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting Standards Codification&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ASC) 842 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i) all components of net loss and (ii) all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Emerging Growth Company Status: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent Accounting Pronouncements: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_886f55de-9a08-4232-a685-d4107951029d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;</ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0c84eeae-0c35-48a4-b4ce-79d94b196c54">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Use of Estimates: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses research and development revenue under a collaboration agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <ikna:LiquidityPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_2174d29e-9ecc-465f-b7a6-eaef58a0dfdd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liquidity: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of preferred stock, payments from a collaboration arrangement and related party revenue. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, the Company&#x2019;s revenue has primarily been from a collaboration agreement. The Company has devoted substantially all of its financial resources and efforts to identifying potential product candidates and conducting preclinical studies and clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company&#x2019;s cash, cash equivalents, marketable securities were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;156.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company believes the cash, cash equivalents, marketable securities as of December 31, 2022 will enable it to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements, though it may realize additional cash resources upon the achievement of certain collaboration agreement option exercises, or it may pursue additional cash resources through public or private equity or by establishing collaborations with other companies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management&#x2019;s expectations with respect to its ability to fund current and long term planned operations are based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any collaboration exercise options will be achieved or that any of these strategic or financing opportunities will be executed on favorable terms, and some could be dilutive to existing stockholders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations. As of December 31, 2022, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research and development of its product candidates and its administrative organization.&lt;/span&gt;&lt;/p&gt;</ikna:LiquidityPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-5"
      id="F_451969b1-9677-44e5-a017-29e7d56adbcb"
      unitRef="U_USD">156900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-5"
      id="F_3206be85-93bf-4366-a49e-731ebb57191b"
      unitRef="U_USD">-214200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_7c029763-5428-46c9-8982-f4fea7c478fe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Segments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_23db9a92-053e-49ec-8bb2-cf5c5b528fcf"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_96c26712-9a08-4b85-a184-d68e1c39ce2c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concentration of Credit Risk and of Significant Suppliers: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of December 31, 2022, the Company has not experienced any credit related losses on accounts that hold the Company&#x2019;s cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers and CROs to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company&#x2019;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_8c0600f1-7dfb-4fa9-a6a8-1c3ec942e411">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value of Financial Instruments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist mainly of cash equivalents, restricted cash, accounts payable, and marketable securities. The carrying amounts of cash equivalents, restricted cash, and accounts payable approximate their estimated fair value due to their short-term maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in the Company&#x2019;s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_c21b7658-6cf3-4473-9ff9-9efa8305b59d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and Cash Equivalents: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. The Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;cash equivalents are generally composed of commercial paper, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_2255814b-e102-4341-91a8-af300e5e4d72">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company invests its excess cash balances in marketable securities and classifies its investments as available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its investments in marketable securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. The Company reports available-for-sale securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the marketable securities, the Company considers all available evidence to evaluate if an impairment loss exists, and if so, adjusts the investment to market value through a charge to its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_c2fb8bf7-94ae-432e-a057-a84d8bfe4dd4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Cash: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company maintained restricted cash totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-5"
      id="F_5213e007-9f53-4878-8c18-f41412febbd9"
      unitRef="U_USD">900000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-5"
      id="F_d84616f0-7fb1-4276-a20f-bd852a0c1e40"
      unitRef="U_USD">900000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a91d44af-71fa-4321-baeb-e313253f58fa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Electronic equipment and software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the shorter of their useful life or lease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_94b787e9-7a65-4675-ae1c-15ef31484f3e"
      id="F_9d241210-3de6-46f3-88b6-068ec462c80a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f9e73fef-5f12-49d2-b304-fdc0a8211ca9"
      id="F_7e88bdc8-e0c4-4936-b782-a8ed23c6f269">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_e2ab031b-2c82-4ab6-b6af-8f43dbaf9ec4"
      id="F_6201a87f-10c1-43ab-9353-77a4327e304d">the shorter of their useful life or lease term.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_3fe9ced6-616e-4aee-9904-4149004740dc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived Assets: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_163146a6-6a57-44fb-bbe7-bef3d1d260e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_b75d043f-244e-4808-836b-7afd22a862fc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue Recognition: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts expected to be recognized as revenue within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had one collaborative agreement with Bristol-Myers Squibb, which the Company entered into in January 2019  For a complete discussion of the accounting related to Bristol Myers Squibb Collaboration Agreement, see Note 8, Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
      contextRef="C_72e7b2cf-5188-421c-b31a-cb8c26070efc"
      id="F_8c9ddc28-e61a-463f-ac73-5048b604abd7">Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_c2afa1f5-af40-4100-93ce-80c9cdaa0874"
      id="F_52ef560c-fa32-4f8f-9aec-c451f602eece">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_ec93bd26-6654-42c6-9997-ddcddcdffb49">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Expense: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_14a2851c-a6b8-4120-8025-18ef500b48e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based Compensation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividend yield was assumed as the Company does not intend to pay dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_d38467be-27f0-4784-8720-a63024177fd7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ikna:LeasesPolicyPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_3dbc20b8-0179-440d-bacf-888e894b32f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_03b4de73-343f-4ac2-8c26-c4a271fedc1c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting Standards Codification&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ASC) 842 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;</ikna:LeasesPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      id="F_dfcf4282-f7d8-46a6-82a4-0701b95c3c82">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      id="F_df6c8dbf-1a5f-446d-a7df-488a6e95fa13">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_e9aee768-3fbd-490f-ba97-3fcf74f7a59b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <ikna:AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_b8f402ca-7793-4ef6-b76d-ebf1777b0936">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in the equity of a business entity during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss consists of: (i) all components of net loss and (ii) all components of comprehensive loss other than net loss, referred to as other comprehensive loss. Other comprehensive loss is comprised of unrealized gains and losses on debt securities.&lt;/span&gt;&lt;/p&gt;</ikna:AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock>
    <ikna:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_af6a1034-8dfd-4227-be8d-2f92298f819d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Emerging Growth Company Status: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ikna:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a973f224-34c3-453b-a0b3-25f27e95719b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent Accounting Pronouncements: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_380cc449-cc31-4c7d-a214-cc4d057d7c6c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.432%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.588000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.534%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.418000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers into or out of Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_c04ead81-bded-4415-9018-060028e07d0c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.432%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.588000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.384%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.534%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.418000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.204%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_aede6e61-a0c9-4e55-bbf8-f41b83685d83"
      decimals="-3"
      id="F_ae669dc4-8c70-454e-b9d8-a436494dddc9"
      unitRef="U_USD">55861000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_006dc649-dc41-474f-8ec9-76fa6ad1fab7"
      decimals="-3"
      id="F_ebfe8a74-70e0-45d0-81b7-b747f0d3cbf4"
      unitRef="U_USD">55861000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_dfe38f01-f9ca-4eaf-a331-878b48fafd55"
      decimals="-3"
      id="F_76db2d08-4fc5-4541-9986-fc01eb1c838c"
      unitRef="U_USD">22606000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_846b01fb-e362-4321-8448-6f496f45b801"
      decimals="-3"
      id="F_ce69b128-98f6-4af7-9201-5e9d0947d622"
      unitRef="U_USD">22606000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_aaa08537-cb74-4d4d-a39a-8997e07e77df"
      decimals="-3"
      id="F_22987c04-23b2-4600-b79f-221ffab59cf6"
      unitRef="U_USD">74422000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_55096704-6551-4982-b2dd-3b2dd0624c46"
      decimals="-3"
      id="F_8874886e-3036-4be5-be03-06e8e4454b7d"
      unitRef="U_USD">74422000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56a2b03d-825c-40b9-ae08-f05fa29edc0d"
      decimals="-3"
      id="F_d958f067-3138-41aa-a717-d05f4b19cb3c"
      unitRef="U_USD">152889000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_998a15cc-e896-4027-85f6-00d38c4c670f"
      decimals="-3"
      id="F_5765ebcb-00a6-4cef-a7f4-6db14276fbcb"
      unitRef="U_USD">55861000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_49f118e2-3aad-42e9-9966-9b49f9d34542"
      decimals="-3"
      id="F_2a3f743e-8bff-4112-a61b-566e136d81ef"
      unitRef="U_USD">97028000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_094353c9-0180-4db6-835f-7fd1043e467d"
      decimals="-3"
      id="F_9b2e45c3-d6db-45fd-ae9a-1c25a181871c"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_25d90a8b-c846-4756-bd61-dd59c2bafa2c"
      decimals="-3"
      id="F_a555cffc-04c5-4399-9495-ac0b9b39fbe5"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_73e45bb4-192d-4764-86f0-84eb2db89c0e"
      decimals="-3"
      id="F_fe5e7537-2340-429d-a8ae-d42c729ce48b"
      unitRef="U_USD">232017000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d9274dc-5a91-43f3-a6de-fddb2971143b"
      decimals="-3"
      id="F_0bde9137-114c-4197-9210-d7e50de15afc"
      unitRef="U_USD">232017000</us-gaap:AssetsFairValueDisclosure>
    <ikna:FairValueLevel3TransfersOutAmount
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_60b2954a-70ef-4abe-85e4-2d42e83e4860"
      unitRef="U_USD">0</ikna:FairValueLevel3TransfersOutAmount>
    <ikna:FairValueLevel3TransfersOutAmount
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_f7caed54-b7a3-4827-b98f-33a3951a262b"
      unitRef="U_USD">0</ikna:FairValueLevel3TransfersOutAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_09907a05-91cd-4b82-b5f1-a4c3e2f67da0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. MARKETABLE SECURITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.064%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.142000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.2%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.2%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.442%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company did not hold any marketable securities as of December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; marketable securities in an unrealized loss position. These investments were in loss for less than 12 months and the Company considers the loss to be temporary in nature. The Company considered the decline in market value for these investments to be primarily attributable to economic and market conditions. In accordance with the Company&#x2019;s investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record any impairment charges related to its available-for-sale securities during years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize any credit-related allowance to available-for-sale securities as of the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. The Company does not intend to sell its marketable securities and it is not more likely than not that the Company will be required to sell the investments before the recovery of their amortized cost bases, which may be maturity.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities fair value by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.057%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_de19ee7c-dd2d-48a6-afdb-3e26c16416d4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.064%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.142000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.2%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.2%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.442%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7"
      decimals="-3"
      id="F_25a7719d-3d42-4458-ba63-44a404e36147"
      unitRef="U_USD">22630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7"
      decimals="-3"
      id="F_1500d7d7-a1f3-4ca6-a76e-05fcac56fbf6"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_622ece3c-9861-4130-adc3-64fee0afb1e7"
      decimals="-3"
      id="F_c5c08f63-b01e-4920-b448-d3e19de3c123"
      unitRef="U_USD">22606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0"
      decimals="-3"
      id="F_e3d561d2-c8b1-4d39-94ba-2a13a5e9d072"
      unitRef="U_USD">75161000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0"
      decimals="-3"
      id="F_89ed79b0-ecde-4717-905b-42a51a05176d"
      unitRef="U_USD">739000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4accab07-8ae6-4c5f-a1dc-e8d653e414c0"
      decimals="-3"
      id="F_f62fd8b2-5cb6-4d9b-aed9-b229f02182f8"
      unitRef="U_USD">74422000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_b41b1a1b-ec31-4a7a-b5f5-3af3bb5952f1"
      unitRef="U_USD">97791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_45d54a49-a755-4d56-9e1a-d9a5c14de86d"
      unitRef="U_USD">763000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_987cfceb-345a-4de1-8f40-9686f5a06749"
      unitRef="U_USD">97028000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_99cc0846-d302-447b-a480-b06d76d91875"
      unitRef="U_Position">43</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_9b22c0f8-fca2-4254-9a28-518d5580275a"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_cb7ed4ca-cb74-450c-9945-a2da4f942391"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_d653cdea-c4de-41a6-81dd-89b37968771a"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_012209b5-1788-4bd7-945f-f332242e345a"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_4532111c-ef43-487b-8db8-3e84b128cee6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities fair value by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.057%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_538e24e4-fd41-4207-bca3-d73a7a909b0c"
      unitRef="U_USD">79652000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_924a9dde-711b-4dae-8ad3-811755af0091"
      unitRef="U_USD">17376000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_9bfc3a39-610a-4b34-a139-aee2821db47c"
      unitRef="U_USD">97028000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_2c0e6120-b6d9-4d55-b924-2926e5adc5c8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.567%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.986%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical, manufacturing and scientific development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_789dd700-37e2-498c-9392-234be7550095">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.567%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.986%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical, manufacturing and scientific development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock>
    <ikna:ClinicalManufacturingAndScientificDevelopmentCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_3d9b7bcd-8ce7-467c-90a3-348a63c6e98f"
      unitRef="U_USD">1372000</ikna:ClinicalManufacturingAndScientificDevelopmentCurrent>
    <ikna:ClinicalManufacturingAndScientificDevelopmentCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_ab7137cd-db26-451d-a748-af467c8927fe"
      unitRef="U_USD">2820000</ikna:ClinicalManufacturingAndScientificDevelopmentCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_3486ee17-684f-4669-a3cd-8c3b2de60e7a"
      unitRef="U_USD">727000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b5099475-2b92-480e-9830-68ceb8f398e0"
      unitRef="U_USD">850000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_8ed7ee72-179f-43d6-ba2c-e778742ca8c5"
      unitRef="U_USD">964000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_0854250c-2368-4208-b914-ed41fc1dab00"
      unitRef="U_USD">629000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_dd38ec81-a312-48cc-b0fa-35daafe2fe6d"
      unitRef="U_USD">3063000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_e53ef7d7-3880-4f86-b04e-847d49bc2a83"
      unitRef="U_USD">4299000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_376e0b13-99f6-41e3-bb18-6bc1f22a5304">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.399%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.200000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.189%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Electronic equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_1c894ecd-a61f-418f-b60a-b0e613e6755a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.399%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.200000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.189%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Electronic equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_201175b1-5ec1-482c-82bd-42e11405e926"
      decimals="-3"
      id="F_a09767a2-f9c6-46da-940b-602e6d5fe228"
      unitRef="U_USD">2858000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f09330b3-63fd-4523-8016-448dd3b3e3e7"
      decimals="-3"
      id="F_fdc14f18-4697-4cd2-80f1-34aea49e1442"
      unitRef="U_USD">1776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5422dba2-f132-4a6c-8c0d-9f0758d86563"
      decimals="-3"
      id="F_d355764b-841a-4e53-8076-48e0ecac3bb8"
      unitRef="U_USD">1216000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5a48902d-ac69-43f6-b35e-bc502c7e3265"
      decimals="-3"
      id="F_1f8f80e0-0226-43a1-b2d9-e6e055679dca"
      unitRef="U_USD">923000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f3e63dc-8be1-44b1-bd62-8504096da2d5"
      decimals="-3"
      id="F_1cf4cd28-0a5a-427b-8c89-e742d67e9788"
      unitRef="U_USD">481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d7496043-4245-45bf-886a-e65de0a22afc"
      decimals="-3"
      id="F_44e0fc5c-6a3b-4a3f-bdda-756bd53e2b32"
      unitRef="U_USD">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_527c0073-0dca-4b32-809c-4a7e62aec6ae"
      decimals="-3"
      id="F_462b3c43-9560-41ce-815f-40376c02030d"
      unitRef="U_USD">475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b1bdd79a-55db-4f3d-b9dc-b5eea09238fe"
      decimals="-3"
      id="F_bb5867d3-e501-49af-bc65-b6cf37be6269"
      unitRef="U_USD">384000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_222b9062-af93-4c34-8990-2c2e3c1c78aa"
      unitRef="U_USD">5030000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_39f04601-389d-4126-98f2-0d8fa6c41558"
      unitRef="U_USD">3513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_2322e57f-21f0-4533-9c87-b8504b5bfcb5"
      unitRef="U_USD">1825000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_7592c94e-d5e2-4333-a946-31a9b7b7905d"
      unitRef="U_USD">1074000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_c27ac342-d3e3-42e1-bd67-69696d0d6b3e"
      unitRef="U_USD">3205000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_5766bab7-6d70-4c20-8fbf-5171025834d1"
      unitRef="U_USD">2439000</us-gaap:PropertyPlantAndEquipmentNet>
    <ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-5"
      id="F_6e97927f-bcf9-4136-93c6-609e2afc147e"
      unitRef="U_USD">900000</ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment>
    <ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-5"
      id="F_d0cc2288-da61-40c7-946e-c59ca6822aa2"
      unitRef="U_USD">500000</ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_99ba23a3-5f0e-4987-8e51-b96e4b73c098"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="INF"
      id="F_6b20ed8c-eb2a-4631-924e-77b7a7eab586"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_e6e7880b-0d8c-49c8-aa7e-65c3c9b595ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.567%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.986%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_7b01192c-c885-4dfa-8645-b2508661809e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.567%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.986%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_1d7c2c63-f9b9-487d-a75f-93aec31b16f2"
      unitRef="U_USD">3236000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_38a6f76a-a054-402a-ab13-1e59225cdad8"
      unitRef="U_USD">2809000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ikna:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_a3bfa276-7415-42c7-b1c8-2e875acc35f3"
      unitRef="U_USD">4462000</ikna:AccruedResearchAndDevelopmentExpensesCurrent>
    <ikna:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_5f9da631-f7a6-4c24-82b6-79c5444e003a"
      unitRef="U_USD">2489000</ikna:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_43f429b4-ba2e-4e05-a8c9-860a4ec5edab"
      unitRef="U_USD">526000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_4543d311-e774-4804-8666-647710118a2c"
      unitRef="U_USD">530000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_e509454f-49df-4632-866d-e52c2d0dbff3"
      unitRef="U_USD">119000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_aa9fbce8-7e0b-40a1-81d0-a76839260c02"
      unitRef="U_USD">26000</us-gaap:OtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_7ebb440f-a310-422e-9300-d92c72c6258a"
      unitRef="U_USD">8343000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_3d387648-83bf-4ca5-a07d-626f1655c661"
      unitRef="U_USD">5854000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_faea375e-fed5-4887-9f21-56eb969ee6bc">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BRISTOL MYERS SQUIBB&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2019, the Company entered into the Bristol Myers Squibb Collaboration Agreement with Celgene Corporation, which was acquired by Bristol Myers Squibb in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the Bristol Myers Squibb Collaboration Agreement, the Company entered into a stock purchase agreement with Bristol Myers Squibb, which resulted in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,545,450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series A-1 Preferred Stock (the &#x201c;Stock Purchase Agreement&#x201d;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the Company&#x2019;s IPO, the series A-1 preferred stock converted into common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Agreement Structure&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Bristol Myers Squibb Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#x201c;AHR&#x201d;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program ("the research term"). Bristol Myers Squibb has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, Bristol Myers Squibb is responsible for the worldwide development, manufacturing and commercialization of these product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Bristol Myers Squibb paid the Company a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate upfront consideration related to the Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, in case of an exercise of its option with respect to IK-175, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to Bristol Myers Squibb to support the decision to exercise the option for an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting Considerations of the Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Bristol Myers Squibb Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the upfront from the Bristol Myers Squibb Collaboration Agreement was allocated to the equity arrangement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the Bristol Myers Squibb Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company identified $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the distinct performance obligations identified above, the Company allocated the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for research and development services for IK-175; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for research and development services for IK-412. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the Bristol Myers Squibb partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb research term outside of the committed manufacturing efforts, which were completed in 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 and 2021, the Company recognized revenue of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, from the Bristol Myers Squibb Collaboration Agreement. The consolidated balance sheet as of December 31, 2022 includes current deferred revenue of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to this agreement. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for the partnered programs.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c3be42be-7b3d-40ba-ad4b-e05df3584a06"
      decimals="INF"
      id="F_3fb0e564-b160-4c9f-9ea9-685e6a834e4b"
      unitRef="U_shares">14545450</us-gaap:PreferredStockSharesIssued>
    <ikna:UpfrontPayment
      contextRef="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285"
      decimals="-5"
      id="F_9ebc268a-1f49-4344-a8d2-6c8ba6998a9f"
      unitRef="U_USD">95000000.0</ikna:UpfrontPayment>
    <ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions
      contextRef="C_25c317f9-19e2-409c-9f55-9c90713949a5"
      decimals="-5"
      id="F_75b84419-33fd-4ff9-a88d-078ea4258545"
      unitRef="U_USD">50000000.0</ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions>
    <ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions
      contextRef="C_4de011a1-1fee-47df-a29f-9beca448f979"
      decimals="-5"
      id="F_e34c73b9-5e9c-4e03-baec-c4dc62db7b46"
      unitRef="U_USD">40000000.0</ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions>
    <ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm
      contextRef="C_ed42db69-a2f6-4c3d-bb1b-d5165260f285"
      decimals="-4"
      id="F_d42ddda7-6cab-44e2-a586-d8f073b57a5d"
      unitRef="U_USD">250000</ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm>
    <ikna:MilestonePaymentsEligibleToReceive
      contextRef="C_bb286aec-68e2-4e6f-b537-31fc48bc69b9"
      decimals="-6"
      id="F_ade6f97a-126d-4aaa-931a-caf7a5f747f6"
      unitRef="U_USD">450000000</ikna:MilestonePaymentsEligibleToReceive>
    <ikna:UpfrontAmountAllocatedToEquityArrangements
      contextRef="C_172039bc-db4e-4260-9a5f-1630d4a4a0ab"
      decimals="-5"
      id="F_09477ecc-c670-4657-b9d3-ec93862b64f9"
      unitRef="U_USD">1800000</ikna:UpfrontAmountAllocatedToEquityArrangements>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_5380a635-35e8-4659-a29b-6c6c312f0478"
      decimals="-5"
      id="F_2ed3697a-f2a0-4e6e-8784-5db8eb8a039d"
      unitRef="U_USD">78700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_5380a635-35e8-4659-a29b-6c6c312f0478"
      decimals="-5"
      id="F_ae6a45b2-7639-4cfd-a7ef-290b5e3dca5f"
      unitRef="U_USD">78700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0b6fbf11-0f77-40b2-8c0f-e122abf4d570"
      decimals="-5"
      id="F_06a8214c-99cc-41de-894c-6af44d885590"
      unitRef="U_USD">41200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_61e02eba-c186-44f9-b40a-69c6eda8c2f4"
      decimals="-5"
      id="F_c34231a0-6e68-4051-a4bd-ac21dfc64514"
      unitRef="U_USD">37500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_79681f83-bcfa-43cd-b9a8-9202b8e8dd42"
      decimals="-5"
      id="F_2edbcdd3-768a-48bc-beea-e4ddd80eb19b"
      unitRef="U_USD">15600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_f069e2a6-5458-4e6d-b129-855b9f38dccf"
      decimals="-5"
      id="F_e7c4aca1-8656-4410-a408-1d66b4014422"
      unitRef="U_USD">31000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_6011e744-0468-4b9d-a6aa-2ad82bb602fe"
      decimals="-5"
      id="F_56d4efc7-0203-40ff-83e7-5588c8787d32"
      unitRef="U_USD">9200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_eb603fe4-4d44-48e2-89ab-c07d05f92802">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. COMMON STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock authorized, respectively, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,257,493&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,975,034&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Voting: &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividends: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liquidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_7f6b318f-6132-4fcd-92bd-39f4e2efc5f6"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_e511544c-9404-4ca0-8244-8937366a692a"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_91bf82a9-7aa7-40c6-b2fe-936f8bffa663"
      unitRef="U_shares">36257493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_33ee195b-b6b6-4266-9473-7f9f7b16bd73"
      unitRef="U_shares">36257493</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_eba61a5f-8ba9-40f4-90d7-eff4489dd5de"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_09a8954a-9f25-4039-bebb-ce47c47fb092"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_ab02681a-178b-4788-822a-a76f6bf226c9">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</us-gaap:CommonStockVotingRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_37870834-f7f4-478f-8748-ba04109effc4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. STOCK BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2016, the Company&#x2019;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#x201c;2016 Plan&#x201d;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;       &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, the Company&#x2019;s stockholders approved the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The shares of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The number of shares initially reserved under the 2021 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,263,664&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. The 2021 Plan contains an &#x201c;evergreen&#x201d; provision, which allows for an annual increase in the number of shares of common stock availab&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;le for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan. On January 1, 2022, the number of shares of common stock available for issuance under the 2021 Plan increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,439,001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares as a result of the automatic increase provision of the 2021 Plan. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,639,915&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock remain available for future issuance under the 2021 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The vesting periods for equity awards, which generally is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, are determined by the Board of Directors. The contractual term for stock option awards is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.571%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.983%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average fair value of the stock options granted during the year ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.52&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively. As of December 31, 2022, the total unrecognized stock-based compensation balance for unvested options was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity under the Plan for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.133%;"/&gt;
        &lt;td style="width:0.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.190999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.056%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.17%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,927,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;878,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;362,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;362,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,009,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The intrinsic value of options exercised for the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each option award granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is estimated on the date of grant using the Black-Scholes option pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.725%;"/&gt;
        &lt;td style="width:1.158%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.347999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.59&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.68&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.15 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.58&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;346,613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares have been purchased by employees under the ESPP.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate
      contextRef="C_a1c560c7-417e-4680-8016-5472ee398972"
      id="F_32c29d49-4ef0-4cd5-b211-76aaba9cebb4">2021-03-30</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d8d5e815-4402-469f-92c1-05e99f28eae6"
      decimals="INF"
      id="F_352b5f5d-3c92-486b-90af-ae3c6f5f4b5d"
      unitRef="U_shares">3263664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding
      contextRef="C_f74818aa-b473-442b-83e4-0dd0c0bedd47"
      decimals="INF"
      id="F_a1bcf823-27dd-4b56-b2c3-da8990aadd32"
      unitRef="U_pure">0.04</ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ac826982-7dbc-4cee-848b-c0246e9b311d"
      decimals="INF"
      id="F_66387948-6a2c-4adf-98e1-8f3586df5c59"
      unitRef="U_shares">1439001</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d13cc7f8-a86c-42e2-8850-115bf15cdd7b"
      decimals="0"
      id="F_3587a7db-063d-4492-b591-1aec1b234f73"
      unitRef="U_shares">2639915</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_32986907-9238-453d-9ab9-8a0f5484f461"
      id="F_0a73056e-01aa-4bf6-bc81-ffd32c57ef46">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ikna:StockOptionContractualTerm
      contextRef="C_32986907-9238-453d-9ab9-8a0f5484f461"
      id="F_13751916-16ff-4146-a7f7-f79fb5f8484e">P10Y</ikna:StockOptionContractualTerm>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_47d976b9-3bb0-4d85-8456-45cae7a49599">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.571%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.983%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_db24a009-c7dc-477b-81ab-fa7a1a7149cd"
      decimals="-3"
      id="F_dc955cd0-6e07-4d9d-a94d-da4f2a2141fa"
      unitRef="U_USD">3974000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9f720352-5344-47c4-bf64-7ee0c53bfc69"
      decimals="-3"
      id="F_9d3dcf6d-34fe-4494-adc4-02fcb577a4ca"
      unitRef="U_USD">2427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0328cea2-41fd-451c-a98a-8066850c22de"
      decimals="-3"
      id="F_5cf72d2f-c44a-4b74-856a-91a0e5d0ff06"
      unitRef="U_USD">3551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0b5743c1-f77e-4a80-9bb0-c3531c20806d"
      decimals="-3"
      id="F_a55370a9-bfe1-4532-8b13-12b37b75a3ce"
      unitRef="U_USD">2750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_17944a17-6608-42dc-a676-e0fa61c58a4f"
      unitRef="U_USD">7525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_c81d2247-17fa-4a5c-9d4b-9785e0275125"
      unitRef="U_USD">5177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_71dfbd72-e298-4809-bc7e-dd873d0ba54e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="2"
      id="F_d14b83d1-c20d-47ec-8e1b-f79c14541fcf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-5"
      id="F_de1b62c4-0e68-4b69-a201-256a6ff7dfcf"
      unitRef="U_USD">17700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_d37131c9-42b5-4e3c-85fa-446223832994">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0cd825b4-2cbc-41d3-9c62-ac287a9fa75c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity under the Plan for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.133%;"/&gt;
        &lt;td style="width:0.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.190999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.056%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.17%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,927,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;878,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;362,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;362,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,009,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_8ef16a02-07e5-4469-9b7b-ba0dc7316684"
      unitRef="U_shares">5822373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="2"
      id="F_ed9d2f8c-712c-4484-8541-a420b4a2ac09"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      id="F_3ae16d8a-4fae-4381-b9b5-b080759f10d6">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_973651d4-7c45-4c27-94c4-c00df15ff551"
      unitRef="U_USD">33275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_3b52a9c1-9918-44d4-b395-ba1d26ccab2b"
      unitRef="U_shares">1927649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_87e249b4-ca09-4536-b030-bc3224e028a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_120bfeb3-c378-4055-bf17-f77b2787a009"
      unitRef="U_shares">282459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_cf59e4d6-f547-48c1-8ca7-26f1fa9ca696"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_bff3ad8f-8bc9-4066-996d-c2cd4a1899b2"
      unitRef="U_shares">878084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_ca2d43d0-573a-4959-b21b-3baf293a9d52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_9c5e3b7d-b2f2-4953-a44f-d39a2b08c4a7"
      unitRef="U_shares">6589479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="2"
      id="F_033782ab-02f2-45f3-856e-e43b343c4306"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a66f0ee7-4d93-41f3-b8cd-94576db9e80f">P7Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_5874241b-7300-40d7-a340-a8db8dcd376a"
      unitRef="U_USD">362112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_fb41aa6a-8b27-4e19-99ea-38a95ea23619"
      unitRef="U_shares">6589479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="2"
      id="F_c2c69e6c-d0e2-4eee-aea8-83fbbae5630e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_4a07bfe6-4734-41aa-ba12-80db4e6e118d">P7Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_22535096-3c34-4a5a-b542-7a84b7f09de7"
      unitRef="U_USD">362112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_bf655db0-a0f7-4db4-aa8c-4a254786bfaf"
      unitRef="U_shares">3009095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="2"
      id="F_ac8ab3c5-eb88-484d-a1f2-cd0ec18a22a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_4df8d6f5-3d80-40f9-997c-ed856e7405c0">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_eccb3115-b870-41aa-b4d3-db75a74c8f4b"
      unitRef="U_USD">358798000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-5"
      id="F_9769da9b-fd94-43eb-a6a3-544f2dcd908a"
      unitRef="U_USD">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-5"
      id="F_9f4c6026-9939-42f6-9918-9ff50a329128"
      unitRef="U_USD">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_5997ee8a-0998-46b5-a708-3957fccef2a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each option award granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is estimated on the date of grant using the Black-Scholes option pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.725%;"/&gt;
        &lt;td style="width:1.158%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.347999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.59&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.68&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.15 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.58&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="4"
      id="F_7867a0a9-84c8-45a1-92a5-8140b6e9155c"
      unitRef="U_pure">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="4"
      id="F_49bbf2a8-1c18-4e4e-b59b-ec1ed55ddabf"
      unitRef="U_pure">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="4"
      id="F_f98bc386-8aa6-42d3-827c-298ce83f7b03"
      unitRef="U_pure">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="4"
      id="F_ac470747-528c-45e7-a678-e4810e0ec0f3"
      unitRef="U_pure">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="2"
      id="F_d98b09c3-dee2-4841-9dd2-b6ba1e62642f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="2"
      id="F_06e72b35-a124-4d7d-8f4e-374d9f867c08"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b0a1ec4d-05a9-421d-bb72-ea7c25d2b496"
      id="F_e2656b1f-1d44-47d7-9d75-c4f35e79488a">P5Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9"
      id="F_b527a175-58bd-41e3-ba41-b87bac0e441e">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_af45af9b-bf8b-48ad-9b86-a379550ecc14"
      id="F_2aa4becd-7326-459f-97d5-eb6fca558d8b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_30eb871a-b095-47c3-a919-45cc40650449"
      id="F_345aa1f2-2b07-4bdd-a99b-11a9366157eb">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="4"
      id="F_788e9515-6bec-45bf-8b1b-826cc41bf226"
      unitRef="U_pure">0.8360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="4"
      id="F_a6970675-5fd8-4fbd-ae46-6f058da7646d"
      unitRef="U_pure">0.8600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="4"
      id="F_bee4b7a6-d6e4-41c4-99f5-9a07a68566af"
      unitRef="U_pure">0.6858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="4"
      id="F_49261f67-4bd7-41e8-b631-cded3cc64b3a"
      unitRef="U_pure">0.7330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate
      contextRef="C_686297fa-085a-4a4a-a878-5b20c1fcf30f"
      id="F_0283e1dd-61fb-4920-9d5d-16cc42fe1d9e">2021-03-30</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_cbbd90fc-7f8c-4e81-9033-43797f48a0e8"
      decimals="INF"
      id="F_f74b417e-48ad-40d3-8ed3-f1d0a4fba5ec"
      unitRef="U_shares">346613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding
      contextRef="C_d2d96cc4-4b37-4a61-9a19-85166d8d9462"
      decimals="INF"
      id="F_26956665-623d-4b1c-8f89-92f249f2ff53"
      unitRef="U_pure">0.01</ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees
      contextRef="C_b1178e06-1abe-41ec-b7dd-8ac5bb40a35b"
      decimals="INF"
      id="F_22406af0-9576-46f3-ac3f-7133f002b9c5"
      unitRef="U_shares">0</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_bc5d1289-e084-4f5d-87f8-e0b09640fcbd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. EMPLOYEE BENEFIT PLAN&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). Contributions to the plan by the Company totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t make any employer contributions for the year ended December 31, 2021. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2022 and 2021, were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-5"
      id="F_ff82a124-6530-47cf-bfc8-95d0cd0dc921"
      unitRef="U_USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="INF"
      id="F_c1e9570d-2987-4d7c-97ab-4c849d88949c"
      unitRef="U_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a2b8585f-986b-4117-88f8-4507e9ae1a02">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.7%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.073%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s total deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.399%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.200000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.189%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized R&amp;amp;E&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset and liability before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2022, the valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million primarily due to the increase in the Company&#x2019;s book loss reported in the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning in 2022, Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) amended Section 174 and now requires U.S.-based and non-U.S-based research and experimental (&#x201c;R&amp;amp;E&#x201d;) expenditures to be capitalized and amortized over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_73fc101d-7745-47d5-b271-65058a5425c1;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;amp;E expenditures in the year paid or incurred. The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of Federal &amp;amp; State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million respectively, to offset future income taxes, which will begin to expire beginning in&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 2031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company follows the provisions of ASC 740-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; and specifies how reserves for uncertain tax positions should be classified on the balance sheet; among other provisions. As of December 31, 2022, and 2021, the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recorded tax reserves associated with any unrecognized tax benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more-likely-than-not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t incurred interest and penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s federal and Massachusetts income tax returns for the years ended December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_66912e43-5cc2-438e-9d75-6966d3f6822e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.7%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.073%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_64cf790a-7164-4942-ac41-97c903ac760d"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="INF"
      id="F_273fa240-692e-482a-9737-9d05ce3dd40c"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_2ef42c9f-5d6f-49be-97dd-e79f305bea7c"
      unitRef="U_pure">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="3"
      id="F_add49d61-d6f4-43a4-9828-efa1c3d92957"
      unitRef="U_pure">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_8e6ae90a-e2ff-4dff-b01e-91c305d7a06a"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="3"
      id="F_e735e373-77b2-4d03-82a3-cd9f824633e9"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_3b4c3017-2eb2-4643-9c82-385537364f51"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="3"
      id="F_3d7f27ff-a135-478d-9a16-91977d72442c"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_9eba934c-88b7-45ee-9372-356069ccb285"
      unitRef="U_pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="3"
      id="F_6c493b5a-fea5-4e56-a0a6-bcc8578b11d4"
      unitRef="U_pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="3"
      id="F_ee263551-cabe-4466-9a48-b617a55d5604"
      unitRef="U_pure">-0.320</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="3"
      id="F_acac9ec9-9701-4203-b3c3-936cd1fc6cd1"
      unitRef="U_pure">-0.322</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0ba6e7ec-843b-4ee7-b887-5baf516ccc13">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s total deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.399%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.200000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.189%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized R&amp;amp;E&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset and liability before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_1c584b7e-2601-4cef-86d2-933e9daa5466"
      unitRef="U_USD">22875000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_7a0f060a-a179-483e-bc14-11a182697a5b"
      unitRef="U_USD">18233000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_04254c7b-e3a6-48e0-ad45-f09e0e162cb4"
      unitRef="U_USD">6693000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_d19add1c-3e2e-41bf-ab93-87fe8d4627e3"
      unitRef="U_USD">5269000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_07a04a24-0101-47c2-8d50-55e1b2ed7f57"
      unitRef="U_USD">10667000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_36c157fa-32ec-4dc8-9436-7ebb5357013f"
      unitRef="U_USD">6385000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_73e9422f-2eb9-4ae8-be03-a7f1a378c24f"
      unitRef="U_USD">219000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_d1509a84-921b-4a67-b141-a94dc96a3c13"
      unitRef="U_USD">242000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_be0fbf35-09ee-4b72-b610-162b2ffb8797"
      unitRef="U_USD">823000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_ff9cacd6-a64c-4cb0-ae37-0d1d70483a5a"
      unitRef="U_USD">629000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_5e47563f-e84a-47ea-9b58-e4df170659fb"
      unitRef="U_USD">2502000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_51767fe8-f8f4-447c-9f69-d75e13136203"
      unitRef="U_USD">6769000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_831bf862-416c-4d36-98bb-24442557e621"
      unitRef="U_USD">1900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b33df7dd-9c8c-430b-87a1-f7d5f675b2fb"
      unitRef="U_USD">1026000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ikna:DeferredTaxAssetsLeaseLiability
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_9254a752-34ec-46dd-972b-c61d786e66b7"
      unitRef="U_USD">1556000</ikna:DeferredTaxAssetsLeaseLiability>
    <ikna:DeferredTaxAssetsLeaseLiability
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b8ee59f5-ac9b-47a5-9616-94a1188e24ae"
      unitRef="U_USD">1908000</ikna:DeferredTaxAssetsLeaseLiability>
    <ikna:DeferredTaxAssetsCapitalizedResearchAndExperimental
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_5e19e5f3-a42d-4e81-84cf-20edc1d397d1"
      unitRef="U_USD">14995000</ikna:DeferredTaxAssetsCapitalizedResearchAndExperimental>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_c0054a55-af50-4550-b053-aa684ca480ad"
      unitRef="U_USD">62230000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_40c9feb6-86e7-427d-85d1-058a363af00d"
      unitRef="U_USD">40461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_72dc9a5f-2ede-453c-b8d9-da05f07042ea"
      unitRef="U_USD">761000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_acb61428-2851-46db-9c76-782c320f504b"
      unitRef="U_USD">648000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_ba8eb8a7-f74a-4cbe-8ce1-bf3979e590ed"
      unitRef="U_USD">1436000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_622a5bf7-f1b5-4c84-9b1b-58897ee144de"
      unitRef="U_USD">1786000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_f820e76f-2f27-444e-9bab-c1311e38d52a"
      unitRef="U_USD">2197000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_909b91f9-32ba-4294-b0db-1912cdeb23c0"
      unitRef="U_USD">2434000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_655265dd-b658-4b02-ba2e-17f4fd1399f2"
      unitRef="U_USD">60033000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_b1b3ad92-d8b3-452c-8dd7-4b3b459cf219"
      unitRef="U_USD">38027000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_86dd508b-9bff-4e30-bbff-548f82f8ef60"
      unitRef="U_USD">60033000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="-3"
      id="F_de6a32d1-e5b8-4bba-8837-2c455955cb62"
      unitRef="U_USD">38027000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_11a2e086-c508-4134-b6a4-7b423dcfac63"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-5"
      id="F_5cde55db-f574-4241-b9ec-29ec30d98422"
      unitRef="U_USD">22000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod
      contextRef="C_69554bd0-d92f-4a0f-8e61-de6c917dd3e9"
      id="F_0ed879b2-085c-4385-81f8-de3088e3ce96">P15Y</ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_18a1ea8b-e577-4c5b-9f0d-b1c3d8bddc84"
      decimals="-5"
      id="F_4e6d80b8-a2c5-4a8d-8de0-13961a606f0f"
      unitRef="U_USD">108900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0f2e0b59-0865-42b0-91fa-b28782511684"
      decimals="-5"
      id="F_149b57d8-65c7-4b1e-b04d-17c1011d4388"
      unitRef="U_USD">105900000</us-gaap:OperatingLossCarryforwards>
    <ikna:OperatingLossCarryforwardsExpirationYear
      contextRef="C_039e47d5-8439-4779-9f97-da794a71c14e"
      id="F_568c2e47-627b-4fde-b40e-643464deedcd">2037</ikna:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1b8449eb-5f80-4e42-a3a7-9af92acd3f91"
      decimals="-5"
      id="F_06ff01a2-5a08-440e-94f9-f102149282a9"
      unitRef="U_USD">8400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ac9d39c1-132d-4ba8-be7b-fc7b585405ba"
      decimals="-5"
      id="F_1c199fe2-8d0a-4fc3-982f-3aaa331ac9f3"
      unitRef="U_USD">2800000</us-gaap:TaxCreditCarryforwardAmount>
    <ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear
      contextRef="C_84d516bd-f241-4424-bbd6-e29e016466cc"
      id="F_bf1f778a-8543-4a3e-828d-2cc9e1cfbf0c">2031-12</ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear>
    <ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear
      contextRef="C_7197b178-a4ef-4f27-bbbb-2a2195a83543"
      id="F_96e1cfbd-e7ff-46c8-9e39-dbeddf34dc99">2031-12</ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="INF"
      id="F_91de8126-fd05-4882-8084-66a3ced1e90a"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="INF"
      id="F_620e9e6e-b8f1-43b9-a72d-2e426acb4d45"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="INF"
      id="F_c89f67d1-5777-47ad-92eb-3ca5212d4424"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:OpenTaxYear
      contextRef="C_3a0f4009-cad0-4026-8941-85d87debcc2e"
      id="F_fa54746f-7ef1-4436-8a32-0ca7aa001308">2018</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_a216833a-bcc3-4948-b7e6-e2ffb74f7b17"
      id="F_ce43b1bf-0a5d-4b6a-aeb2-9f7b006ee794">2022</us-gaap:OpenTaxYear>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f7c56653-c5ac-4cbc-aba7-1ecc9ebb4f85">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. RESEARCH LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During 2015, the Company entered into an exclusive patent license agreement (the &#x201c;UT Austin License&#x201d;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#x201c;University&#x201d;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon meeting certain development milestones during the term of the UT Austin License. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2018, the Company acquired IPR&amp;amp;D on an Arrys&#x2019; immune-oncology candidate based on the intellectual property associated with Arrys&#x2019; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, as well as certain sales event milestones ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million contingent on sales in a calendar year, during the term of the AskAt License.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <ikna:LicenseMaintenanceFees
      contextRef="C_84324036-af2c-40fe-9fa2-a3dbfb992c04"
      decimals="-3"
      id="F_86b66387-6854-4784-bea2-c996f5f7556f"
      unitRef="U_USD">40000</ikna:LicenseMaintenanceFees>
    <ikna:PotentialDevelopmentMilestonePayments
      contextRef="C_33bcb973-7966-4f4c-bc9c-e3aa82ff7119"
      decimals="-5"
      id="F_e1d90754-f033-4a32-a704-6bf51dc93a9b"
      unitRef="U_USD">4700000</ikna:PotentialDevelopmentMilestonePayments>
    <ikna:RoyaltiesTerms
      contextRef="C_f72bf92b-b49c-4e3d-b668-ab6a03cec96d"
      id="F_0ae565a9-80bc-4dac-be79-92378c45ae52">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</ikna:RoyaltiesTerms>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_76b4cb83-83c9-4fda-8ec2-4663fab1916f"
      decimals="-5"
      id="F_b8d5d490-2aea-46d0-87aa-24c8d8666270"
      unitRef="U_USD">28500000</us-gaap:ResearchAndDevelopmentInProcess>
    <ikna:PotentialDevelopmentMilestonePayments
      contextRef="C_4e1254ff-dea8-4f2d-8b51-985639cee2f0"
      decimals="-6"
      id="F_7c5652e7-2414-4b30-a8b8-4d20dd6756ef"
      unitRef="U_USD">4000000</ikna:PotentialDevelopmentMilestonePayments>
    <ikna:PotentialSalesEventMilestonePayments
      contextRef="C_5e250053-4619-45f1-9e2b-a7efc1571f50"
      decimals="-6"
      id="F_30dc8754-773c-447d-b6df-ba4ff05bca0b"
      unitRef="U_USD">50000000</ikna:PotentialSalesEventMilestonePayments>
    <ikna:PotentialSalesEventMilestonePayments
      contextRef="C_bbac1559-abd3-46e6-b271-d81b0a7eaae4"
      decimals="-6"
      id="F_43f534b9-6c9c-4248-b59c-5a39cbae03b8"
      unitRef="U_USD">250000000</ikna:PotentialSalesEventMilestonePayments>
    <ikna:RoyaltiesTerms
      contextRef="C_addbb181-d517-444c-af21-20959683d0dd"
      id="F_fd2119dc-b238-45f4-8652-dd1cea4a4711"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</ikna:RoyaltiesTerms>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a123a5b5-363a-4382-b128-aff0832de03d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. LEASE OBLIGATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 21, 2020, the Company entered into an operating lease agreement for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,752&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#x2019;s corporate headquarters. The commencement date of the lease was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 19, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and the lease term is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The base rent at commencement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per month and escalates by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% annually for total lease payments during the term of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the commencement of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with the Company's operating leases.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities (operating cash flows)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The remaining lease terms and discount rates related to the Company's leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.0%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The future minimum lease payments for the Company&#x2019;s operating lease as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.062%;"/&gt;
        &lt;td style="width:1.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ikna:AreaOfLeasedProperty
      contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"
      decimals="INF"
      id="F_374dda2e-30ec-425f-ac23-2b63e522a359"
      unitRef="U_sqft">20752</ikna:AreaOfLeasedProperty>
    <ikna:LeaseCommencementDate
      contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee"
      id="F_bc31fe7d-2f87-4266-af2d-74dffe3cb100">2021-02-19</ikna:LeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"
      id="F_b50b1196-7ae8-47bf-8082-f8bb2cb89a6d">P63M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ikna:OperatingLeaseMonthlyBaseRent
      contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee"
      decimals="-5"
      id="F_215ff3c7-11ce-4101-9d37-cd56bed2320e"
      unitRef="U_USD">100000</ikna:OperatingLeaseMonthlyBaseRent>
    <ikna:PercentageEscalationInAnnualBaseRent
      contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee"
      decimals="2"
      id="F_44a124a6-e3d2-4972-80d5-d701cd6b3af3"
      unitRef="U_pure">0.03</ikna:PercentageEscalationInAnnualBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_c3412efb-b4b3-447e-97c2-2c5d977b61ee"
      decimals="-5"
      id="F_ed847182-e939-42b6-9266-f1d31823e010"
      unitRef="U_USD">9300000</us-gaap:OperatingLeaseExpense>
    <ikna:LetterOfCreditToSecureLease
      contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"
      decimals="-5"
      id="F_4adca1fb-fc92-4fd7-8bd9-d27cd2722817"
      unitRef="U_USD">900000</ikna:LetterOfCreditToSecureLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"
      decimals="-5"
      id="F_26e86c24-879f-483b-bf16-636dd323877b"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_18f76e5e-f630-4d3e-aa72-98f091bf97e6"
      decimals="-5"
      id="F_ac13c0b7-4bc2-4f72-a3ab-509cfc1d33f8"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_d9ad33f8-0954-4972-b8aa-c7a6953679a3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_f17c2f0e-2fdc-4ebd-a50d-58290d71a01d"
      unitRef="U_USD">1764000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_50dc3210-c324-4538-82e3-e7405be104e1"
      unitRef="U_USD">1693000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_d02d9ae8-663b-440b-861a-19fbfefd108b"
      unitRef="U_USD">466000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_d383baa2-0fea-429b-bd13-08aa4e9df356"
      unitRef="U_USD">479000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_611fd979-109d-4119-a054-72c58214fa19"
      unitRef="U_USD">2230000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_bced8ae7-4dee-4652-bcc3-0ba08cc1ac1d"
      unitRef="U_USD">2172000</us-gaap:LeaseCost>
    <ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_0ad8a936-20d5-4b05-b88d-b53329a1144c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities (operating cash flows)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="-3"
      id="F_3d9f405c-1b63-418e-95ff-8346ea25e9db"
      unitRef="U_USD">1774000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="-3"
      id="F_d0ed6f04-2788-4c50-8521-5474d102c1d0"
      unitRef="U_USD">1259000</us-gaap:OperatingLeasePayments>
    <ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_6d4f5334-f50f-47fb-b3ac-a53d609b8bd5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The remaining lease terms and discount rates related to the Company's leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.0%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      id="F_babddb6e-a2c5-49ed-ac8f-f65a9ab748bc">P3Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      id="F_2f8152b3-ea8b-4df1-b7ce-44b743948c64">P4Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="3"
      id="F_295f648e-6336-463c-81e1-8f07349a8d13"
      unitRef="U_pure">0.077</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c"
      decimals="3"
      id="F_2336bc72-a4a6-4345-834b-2cc7ebb0bd92"
      unitRef="U_pure">0.077</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_269f4e50-40ea-4c98-a5ef-c8f76f8ed04a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The future minimum lease payments for the Company&#x2019;s operating lease as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.062%;"/&gt;
        &lt;td style="width:1.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_282a9a65-b272-45d7-8e84-1432f9a4769d"
      unitRef="U_USD">1827000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_39f8f05d-101a-424b-8040-28bf1d35aa56"
      unitRef="U_USD">1882000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_91a8e2a1-0d7f-434b-8c1d-5309e5683184"
      unitRef="U_USD">1938000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_d68da348-dc28-46d7-8dfa-ef90d4612538"
      unitRef="U_USD">817000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_9df8486a-6982-4d70-a6ed-a5f4cc513889"
      unitRef="U_USD">6464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_f507fb81-5e11-46e1-bc23-19f5f5f50c03"
      unitRef="U_USD">770000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c"
      decimals="-3"
      id="F_6eeb961c-14d2-4aa4-b763-739b447ad445"
      unitRef="U_USD">5694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_90dc5dfd-56c2-424b-a3d4-4016e6d1928d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2022 or royalties on future sales of specified products that have not yet occurred as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_6ab52a0f-4cd4-4ec3-8b6b-20a2cd9cc730">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company entered into several agreements with a director and an entity affiliated with a director:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As discussed in Note 11 above, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Certain entities affiliated with directors purchased shares in the IPO.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_b633a850-2bce-4c3c-abbd-d9eeb2480f83"
      decimals="-5"
      id="F_31b2df6d-e368-4f15-9624-926fc7535016"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_c06f1a61-16c4-4100-89a4-3b2b77f6fab2"
      decimals="-5"
      id="F_0dc52d62-89d2-4bd9-b994-832a19c0d6e5"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_f1f938dd-2613-46a0-a163-482acba4b75d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.467%;"/&gt;
        &lt;td style="width:1.178%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.972%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.166%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.216999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      id="F_a8508d5c-99be-4d8a-9312-e3da46e3ac79">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.467%;"/&gt;
        &lt;td style="width:1.178%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.972%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.166%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.216999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_01fa273c-adc6-48a9-9be3-a48fc56e1ffa"
      decimals="0"
      id="F_335ad33e-20fc-4973-be86-1ed8dbb1f39b"
      unitRef="U_shares">6589479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_68d0106c-cdc4-4aae-a92c-8c34b9586d82"
      decimals="0"
      id="F_9e0303dd-8604-48d0-b574-64c211b05545"
      unitRef="U_shares">5822373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0"
      decimals="0"
      id="F_a9862c6f-c9c0-433e-88d5-92e23a699725"
      unitRef="U_shares">6589479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_270dcb5c-f47a-45c2-a15a-7a061ad9a7bd"
      decimals="0"
      id="F_5f8bccbb-dd8f-466c-8d50-0f3745e556b7"
      unitRef="U_shares">5822373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@JT%U/<KIAJ0YD7?7[?_KYC^#U!+ P04    " "",&Y63;/G)^D"  #A"0
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M'S'L;_)D6YZA?TCR/-F4EVOF+UE:%."?KY(D?[DICN4??DHR^A=02P,$%
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M%MJB>3RP.T+I836G&NX@'+1RMJD]RB<4Y&N@+'5&C:G0V QS[OOT3984.;M
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MP9F@$,EIOI)DX[$M)65I8Y-+1Z,SEF+WW#XCYF5S([> G][3;7@\H2,7FOV
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MG0+=;Y2RAX-S<'P>Y_\"4$L#!!0    ( ((P;E8.!2TFV@(  $4&   9
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MSP)9FU:]T**LC&(M--E.-4W)YU&: #I/A-"'A4G0_'-,?@-02P,$%     @
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MJ[LGN$(XYE994CF J\*C]B[!B$F"H@!F)&$ABT*>/A$'_Q.!2'P0\+3CYMP
M3Z7Q*7?4CK2)E5=!I5C*.AG3)<J%7%'T[P@_4B#T$C'./F-*(6TV1@2_N[I"
MK^ CA&%63+'&R%;F$4YAO\QS3<]0\(D8]$>'R5%]\:DR@2S;/KJ?'4P$38*T
M39@H.$5M#G)=T1,B<]@!)OY4,(Q)>46(<42)2TQ,]#\PK;F 6[.2A<?Q92O+
MG"R(_:U9L!9S#$/"(<?"P1C]X&55HLC,$&94N"PS->H(DO"B#7Z7C%Q#^O9'
M<H!$;.]K84;L;!010&IYBE (-5=YKP"IAA#8SP92;<BB=L^QH[V@5C$V=20\
M&(VW''TOIE);<2>+6@6I33=4682TX;)O')#8(U#&1)%D&<HY3@LQ69_45$](
M,I82?MA_T: @>C\14Q//[VN@"2U%@:+<HC$PO 9HT.O*<K:!CW)%:8B.@)23
M_OM/M8KG)O:OY C2)!:H1,916EFVWLU-7>3LJDY(B)SQ@\TYM+QS?',AG@^>
MW^/.T -I%8#FET94RO(-"6,B= L$YW;OL[5?H&$/\0[-4^!.7I-8[[:A#=?.
MXHTE;G>5=@VF2.?8GS4)\[ IZ);+1L_8Q4UK[@LXG=KA,\S)#7\RG^(M3S9T
M2>(2)CI!(1>M81E8_1ZPMS@Y>*B%+*#/&88 VE#7]*.YIAL4O4#ITTAO1\4H
M*^J<6UEIO<YT%3.^%'\8-.:"&F)'.K-/M0>)N:U8>"*.7O2/.KG$70" 6#H9
MAH:0V6F0B8AUG:3K=@,/$LDBV&6MNIDT7M>1[O;H.&Y03*= U%1?VK5%ANAT
MF\+4W@$VE?%D*HY8%PH*7*H'ZZ+!]$J>I;Q*%/+0"Z$77<6&AUOK!66C"PR
MM@N!*%8A3^<:=B-U'S2+'1/*)E$2I#!7DSL2LZ41F\%!S050BZX.I)N+6&_!
MG"A,>+<%;NV0@XCN[A7>5L#FZCXF'CIADHYF+Y#3X5J]8 '.PPI9D*,=JG 8
MN3@#FY(4VJ9MFDI*>.BS=*_"E/O\F,K^L#]J-")"^!YF.N9%:V'/COJ'/R:L
MX;:-)> Q?FC8[-MG-F[6= U!>9+$-RU'9ER@INC--,*S@#978))!7QI&]R@+
MOS"]TOG-0YR=M<T#O9 4F?\!T@O9'"12EEDE'9*7VC30YE1[,*:=:72!-WI6
M FK(!;H>J@!F4;NPO7%72"^FFGCV@Q9WQXB:M*#UA2IGGE$%W]#V>,N5*D19
M\X56J#'.T\([:;6I'6($YZB8NGS1L";LH&_3I//H7E6@%K:XK1=:KO+!G (V
M,O#"G^3[Q'ZM(>F1B? XG!!EM+2.XWMW8&VKEW13;I-JWSYO?5;MPD@:PBP6
MRL\-WR]BALEJX@:\#AC5H6/-J=,+5P&HKEA,PTU#(T2/C(FPIP%MJ A)!%]J
MO0;=QYO*T;#+9E8]E0Y@=C$I0]ZFNX?6;$\]*KR>W^L9,*S(E0OSPV=P/8$
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M--Z ]K>:ZN0P\0[Z_Q'+_P!02P,$%     @ @C!N5BG<X_Q7"0  7AD  !D
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MC<-WYP'H9J VAE65'V(K96DD^F5!_T&HG0.=KY6RG>$2]/]JD[]02P,$%
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M!AT;T/?<VM N>(/N)]'D;U!+ P04    " "",&Y6P&O":UH%  "/#   &0
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M/T81<(7?MP/AU]1M]]"C6O.X0>"B;H"6+A,:5!Q-5]2G[_"QK(5&'H*'QB-
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MN@&7,T=1SR6G4]^5SA]^P:JZODNTY *I(13=D](.)(TL9D'O@-X(RBV:YIV
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MWT9 K1JWAC--4,"5<:RG85CQ X;D'7B]--Q^G>$3]$_BY']02P,$%     @
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MKV@TZWIXUQNK2C\P$V5I_/IE3N\=:N= YSM%=]1L7(+V!9W^ %!+ P04
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M/'=;U15JO2;/RTO1XL9">-0N*C:]KSL9VM1J53>B=OB[JEW9&-=;W@G)+8X
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M-&?]SZ^<#2%1Y,QIJDX\9!WDTT=K24;T$P>G7K!#K$I:#N;<,7,$P?LWW);
MSQG'V?1B).UU>KUVV30QZ(;L6ZW/Z'6;3TZPS<)PLB,G%XT2'M(@DK'<]T0N
MY_V]ESPZBC33CJQ)[TU:J(9BM5@]OBI^@4H4EXL<79L5Q$'R0K(>J?X63W[O
M.4]'1)4>((I]E-,1LRF).%@IP7S/_1K+P1I^XA#\$/[]W-PQ,Z%K'E21L2X1
M=6+--OT5B7_.1RR+?S58O&^/MT@+BAHW==<U'*BV)J3.*:Y2$E^/+#@M:DC9
M_PT4CP+U&LQ=Z>X>:= &2T?,.WG"/GV55^*05NVP?+E%JK@85ZN$$:5B&<"
ML/"LK;F\2/TM%_.8.4 Z_L>KI$.332Q?.->P0,-VHF*D06X[Z=,B +*&"SO$
MBCO2([$MDD*S]::&74Z*!S9^?T$</;#S:<AC<=F@I!D<FW'AMOB3L9V8=JF3
MX#85_CD:9:5><\T 62+DGM4>*2:NNV\,N> 6E)^Y/?H1@%(UFAU(WEUNT_R
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MOC8RY^O8P^+6$GMP[;^^*-G,8#J,R*]@68XN'K)3N= *?)T^$R)0!2H@WR_
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M:D4V'2_0\[4Q7?@#"\3/>[_X#U!+ P04    " "",&Y6[23K;5 #   0"
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M2EE:1^VUI/V/VAG0>Z&4?15<@/X?9?$74$L#!!0    ( ((P;E9S;1+ N0(
M "<&   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)55VV[30!!]SU>L
M3(6H%-77A#0DEM(+ HFJ45O@ ?&PL<?QJGLQN^NF_7MFUXD)4AK!2_8V<\Z9
MF<QXME'ZT=0 ECP++LT\J*UMIF%HBAH$-6>J 8DOE=*"6CSJ=6@:#;3T3H*'
M212-0T&9#/*9OUOJ?*9:RYF$I2:F%8+JEPO@:C,/XF!W<<?6M74783YKZ!KN
MP7YMEAI/88]2,@'2,"6)AFH>+.+I1>;LO<$W!ANSMR<NDI52C^[PN9P'D1,$
M' KK$"@N3W )G#L@E/%KBQGTE,YQ?[]#_^ACQUA6U,"EXM]9:>MY, E("15M
MN;U3FT^PC6?D\ K%C?\EF\YVA,9%:ZP26V=4()CL5OJ\S<.>PR1ZQ2'9.B1>
M=T?D55Y12_.95ANBG36BN8T/U7NC."9=4>ZMQE>&?C9?%(5NH237SUAF X90
M69);6X,FEZW6("WYPNB*<689OKY[H"L.YG066B1W$&&Q);KHB))7B.*$W"AI
M:T.N90GEWP AJNZE)SOI%\E1Q"LHSD@:#TD2)<D1O+1/1>KQTG]-Q>)H*GXL
M5L9J_%?]/)2,CBH[3.4Z;6H:6L \P%8RH)\@R-^^B<?1AR.!9'T@V3'T_+YK
M,*(J\G_E/13(4:K#@>Q(89]4>=)B2\KW$EDH;'%CG5RT(97B."F87)-W3.*-
M:@WZF]/I8&&<#98=Q JQL/0#5WI7_WAP+1JN7@ 03CA:ZIO^A*3#)!WCF@PG
MT?G@#C527=1>4@E/.)0:X03U6K-A-D;(838Y'RRUJL"X^4,YJ0!?1\F8C-)H
M</MJ-'%\3I+QX$%9]#DADV&:I;B.AI-11@X5-]QK7@%Z[4>4RTHK;=?'_6T_
M!1==\_\Q[T;H#=5K)@WA4*%K=/9^%!#=C:7N8%7C1\%*61PL?EOC) ?M#/"]
M4LKN#HZ@_S;DOP%02P,$%     @ @C!N5KCA_R0T!0  @@P  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULG5?;;N,V$'WW5Q#NIM@ BJR+=7&:&'"R
MZ;8/VPURV451](&6QK802G1)RH[[]9TA9<=I'>^B+Q9)#<_,<,X<T1=KJ9[T
M L"PYUHT^K*_,&9Y/ACH8@$UU[Y<0H-O9E+5W.!4S0=ZJ8"7=E,M!E$0I(.:
M5TU_?&'7;M7X0K9&5 W<*J;;NN9J<P5"KB_[87^[<%?-%X86!N.+)9_#/9C'
MY:W"V6"'4E8U-+J2#5,PN^Q/PO.KE.RMP9<*UGIOS"B3J91/-/FUO.P'%! (
M* PA<'RLX!J$(" ,XZ\.L[]S21OWQUOTGVWNF,N4:[B6XFM5FL5E/^^S$F:\
M%>9.KG^!+I^$\ HIM/UEZ\XVZ+.BU4;6W6:,H*X:]^3/W3E\SX:HVQ#9N)TC
M&^4';OCX0LDU4V2-:#2PJ=K=&%S54%'NC<*W%>XSXWLCBZ>S*\RK9->RQEIK
M;H_K_0.?"M"G%P.#;LAX4'205PXR>@,RC-@GV9B%9C=-">5K@ '&MPLRV@9Y
M%1U%_ "%S^+08U$014?PXEW2L<6+WTIZP15T2=_R#7+,L(E2O)F#'?\QF6JC
MD#!_'LK>80\/8U,3G>LE+^"RCUVB0:V@/_[QAS -?CH2^7 7^? 8^O@>F[)L
M!3 Y8P_2</&Z:#?/-(9#41_%/1SUPP*8L4Z*?2?@G&!+%G+>5'_C(58-,VBL
M#3?V!#7%A\*A[ [-N-:RJ/!EB?0V"\:%Z#80^Z:V$*]\\#57I69SK EMFFZL
M.>7*FPVK")'-I$!)T>R]]2Y;S9M2GY[W?@>N'/48$@?J*2@B3X_(0PP*>W>8
M(5<%QM&4V,(KE*:E+?P[%GNC;(C/R!M&6>\C-)B#L':\Q/:KB!>D(VB8)"&:
M94G0<Y70EE4'DMD>V#N6>4F4X#/QPBQC1_B0[/B0'.>#TU(Z;MO)[//2NIR0
MV%5F<X@)1Q'?9H([[JJ9,T/*T,DXEE^[,F*]7W067;,62Z!LW6X%;W"_FVRH
M//"?\MC>/N_]UMH%S.>K%50HS_9&D_E<P1QYU/O<&F1;4U(\W-+MWV AGG(>
M15Z<Q73R?IBQW(\RJG'L15G2^]B1*_1&4>:EPQ$:96'OYAE445$1W[,H1QXD
M(W;*8C_/>]>\*?#[@:\P%\QG!I6Q=GF6>T$^1+O<1SY\.[B(I5Z2C[QA-K+!
M1=8Y!1JGD1>&4>\+:.,<$7T*&AO)5KCZOR$=-S0"V@QM%=_"BKT@&'G!R++5
MSU*68F*$E>1>-LJ/<3?=<3?]7NY.-+*IB^Y1NU2_<-'"*U9KMBW9HZ:CO1(<
MU0,E4>*'JK,YNU55@2\/$?]H.$>(SRO%5C8:#!4XZL:6ZJ12.Y$J6V6[H^.X
M?HOD5DTL05''L)Y5;851.@TM<4)^+"IK]1;R=;)= $N7+*ME"<)G#PM$M&-4
MY$*JI42Q0NL5]BGJ(\GP]I@]LA!MN87?D6PE!:J6P ;V]I@'JO9LW!6FJHB$
M%IE<@FMTL7%L?REDVQ72'=V^1KP(.[Y><F4P"Q1VH[^1[]DVWS7&L/<)^"[-
MK_33V4P!O$Z!A7Z:L1,*)/:QTT]8X*>Y6PC].&8GO9OM*92H:R46E6TJ$"4+
MR'C_?5<4.BS[4;(L.,7V"1."2_T@IY]@.WG9Z0Z'LH.] C![(V%Y[*>!BRBW
MVT]8BC+3!9G%?DQ+AQIRL'<OK$'-[>U7X\>I;8R[(NY6=Q?LB;M7OIB[V_DG
MKN85%D[ #+<&?H9?$>5NO&YBY-+>,J?2X)W5#A?X)P$4&>#[F91F.R$'N[\=
MXW\ 4$L#!!0    ( ((P;E8.1EN4D@0  *X*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;(U6;6_B.!#^GE\Q8KNK5J*0."2\%)!HZ>I6NEU5;6]/
MI]-],,D 49,X9SNEW*^_L1,"[5)V/Q F]LPSSXP?.QYOA'Q2:T0-+UF:JTEK
MK74QZG95M,:,JXXH,*>9I9 9U_0J5UU52.2Q#<K2+G/=L)OQ)&]-QW;L3D['
MHM1IDN.=!%5F&9?;:TS%9M+R6KN!^V2UUF:@.QT7?(4/J/\H[B2]=1N4.,DP
M5XG(0>)RTIIYH^O ^%N'[PENU($-II*%$$_FY4L\:;F&$*88:8/ Z>\9;S!-
M#1#1^+?&;#4I3>"AO4/_;&NG6A9<X8U(_TQBO9ZT!BV(<<G+5-^+S6]8UV,)
M1B)5]@F;VM=M050J+;(ZF!AD25[]\Y>Z#[\2P.H 9GE7B2S+.==\.I9B ])X
M$YHQ;*DVFL@EN5F4!RUI-J$X/?V21R)#>.0OJ.#\D2]25!?CKB9HX]"-:ICK
M"H:] ^,Q^"IRO59PF\<8OP;H$J>&&-L1NV8G$><8=<#WVL!<QD[@^4VAOL7S
M?UHHS!,5I4*5$N'OV4)I2=+XYUC-%6+O.*+9+B-5\ @G+=H/"N4SMJ:?/GBA
M>W6";Z_AVSN%/GV@[1>7*8)8PNURB5:]<%#%/==(I="4Q!B64F0PRT29:[@1
M65%J&EQL8584Z3;)5_ 98Y0\A0?-=:F%W%J 8U6?Y'6\ZL<U C8DDXJD)I+2
MD(Q?D=3DRRNBT0%1OB-JYI<U6=60M4!:V%E3'\^WGSX,F->_4D!KJ6"!=$(=
MYB8]<P5+D=*YHT;.7\AE)4X@:6&V0&GDY1AY&8UYCFEJ503Y</TV.?,Z+GRL
M_QS3QEV:?H?11+_3L^,B>K*%T<'%[<%S#FXG@(N/UNB3X7P3^241*:E=M-\
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M/AT>Y]CW=!BWPL:JVH\X*V5Q8/)BA1,J:'<!OZ^5LON-4]#.O(OO4$L#!!0
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MM!M1Z)]\4-KO2<RMHO 1TC!HI&%@5VT_G/9OX*M$O^PF7*CJ14S?4K$)"5Q
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MN5]F-&I1.P/Z/E?*;C8N0#V\X]]02P,$%     @ @C!N5M$4]:!Y @  C@4
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M$W SW ')@.L =7_#F'R<Z&-P_[='\C]02P,$%     @ @C!N5M= L<V$ @
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M6NAR&'P(4 %+LF%Z)G9WT/AQ G/!E'NB71,;!BC?*"VJ!FP45)3[-WEH\G
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M:7Y'(&V V5\*H?<3>T#[@\O^ E!+ P04    " "",&Y6.637\C(#   >"0
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M)2I%'\WN'VSC23U?9I2K_V'7V*:3 ++*D2E;,"LHI6Z>XD>;AP/ 670$$+>
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M"1]'VW3C9D)F4S>TI2%NC_6PX \8M-Z WZ\,[W,[\0ZZ3Z+Y3U!+ P04
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MW>U#MYFD21]V]D&8 WAB6ZPD(/GV*U]B@S$"T_("LBP=G=\YNORM_H;Q9[$
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MA;+8UGY9X> %[0SP?JF4W6V<@VZ4YW\ 4$L#!!0    ( ((P;E86@;EV10,
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M0F47T/M,2K,;V ^T?5O\$U!+ P04    " "",&Y66"X!ERD$  "*#P  &0
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MNK35K]L.U$Z,:GP1+Y2Q+<$/*]NT4;L N[]4RNPGKB_T?P/Y'U!+ P04
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M$57=W%7'R,+=EC-I\.YUS14^=J#L IQ?2&E>._8";I[/]#]02P,$%     @
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M/SSSUM3=(9\-__^:O0%02P$"% ,4    " "",&Y6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ((P
M;E;4])/([@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( ((P;E:97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ @C!N5G3)AQRW
M!P  'BD  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( ((P;E;RA7[\W 4  +L8   8              "
M@?H/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "",&Y6
M3;/G)^D"  #A"0  &               @($,%@  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ @C!N5FQR ;9#!0   !4  !@
M     ("!*QD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M ((P;E;[4$33O08  %8R   8              " @:0>  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "",&Y6L.Q@HV<"  #M!   &
M            @(&7)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ @C!N5KV-,-TW!P  <2$  !@              ("!-"@  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ((P;E:UUNKWS00   0*
M   8              " @:$O  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "",&Y6K]C!@ T;  "M4   &               @(&D-
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ @C!N5A$*5I5]
M P  50@  !D              ("!YT\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "",&Y6-P#EWP\%  # "P  &0
M@(&;4P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ((P
M;E8&I!GOR@(   H&   9              " @>%8  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ @C!N5A#.TO$\ P  *@<  !D
M         ("!XEL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "",&Y6#@4M)MH"  !%!@  &0              @(%57P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ((P;E9K9>K7X0H  #8?
M   9              " @69B  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ @C!N5DH;V_B0 P  4P@  !D              ("!?FT
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "",&Y6*=SC
M_%<)  !>&0  &0              @(%%<0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( ((P;E:,^S^O)0,  .$&   9
M  " @=-Z  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M@C!N5B#1RYY/"@  YQH  !D              ("!+WX  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "",&Y63=][P2P%   >#0  &0
M            @(&UB   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( ((P;E; :\)K6@4  (\,   9              " @1B.  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ @C!N5L$R2O:V @
M]P4  !D              ("!J9,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "",&Y6=!Y@F"4#   >!P  &0              @(&6
ME@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ((P;E:O
MM69J3P,  $T'   9              " @?*9  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ @C!N5CXX:&E>'   ZEL  !D
M     ("!>)T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ((P;E9S;1+ N0(  "<&   9              "
M@13'  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ @C!N
M5KCA_R0T!0  @@P  !D              ("!!,H  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "",&Y6#D9;E)($  "N"@  &0
M        @(%OSP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( ((P;E9=*3JK&P0  /\*   9              " @3C4  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ @C!N5ME%NA7I @  7@8
M !D              ("!BM@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "",&Y6W^-##($#  ",#   &0              @(&JVP
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ((P;E85(N!$
MQP0  !45   9              " @6+?  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ @C!N5C6U+ 8$ P  "0@  !D
M ("!8.0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ""
M,&Y6\X\#26($   U'0  &0              @(&;YP  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ((P;E:)]<&6.@(  "X%   9
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M970T,RYX;6Q02P$"% ,4    " "",&Y6K=S)WXP#   "$0  &0
M    @(&"^@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M ((P;E;70+'-A (  &\&   9              " @47^  !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ @C!N5KNZ5V[& @  \0<  !D
M             ("!  $! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " "",&Y6-S! B#T&  #"+   &0              @('] P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ((P;E;=],;TB@(
M .P&   9              " @7$* 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ @C!N5CEDU_(R P  '@D  !D              ("!
M,@T! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "",&Y6
M:\Y"^80&  #N+@  &0              @(&;$ $ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( ((P;E;89@\Q)@,  ,$+   9
M      " @587 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ @C!N5G#?ON#>!   7A<  !D              ("!LQH! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "",&Y6(C#8S[4#  #Z#@
M&0              @('('P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( ((P;E9;6&?.;P(  -8%   9              " @;0C 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ @C!N5A:!N79%
M P  PPD  !D              ("!6B8! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " "",&Y66"X!ERD$  "*#P  &0
M@('6*0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( ((P
M;E;Z_MUDB04  (4B   9              " @38N 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ @C!N5B&?-!+N!   "AL  !D
M         ("!]C,! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M    " "",&Y6\_B4/6L$  #;%0  &0              @($;.0$ >&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ((P;E9(' DTG@(  /D&
M   9              " @;T] 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL
M4$L! A0#%     @ @C!N5H@GT,.O @  2@8  !D              ("!DD !
M 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "",&Y6]S.I
M"UP"   2!@  &0              @(%X0P$ >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;%!+ 0(4 Q0    ( ((P;E:H6.6:Q (  $H'   9
M  " @0M& 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
M@C!N5A!YLV6F @   0<  !D              ("!!DD! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " "",&Y6*&]\%1$#  "K"0  &0
M            @('C2P$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( ((P;E9)(VQC.P,  .P3   -              "  2M/ 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ @C!N5I>*NQS     $P(   L
M     ( !D5(! %]R96QS+RYR96QS4$L! A0#%     @ @C!N5O0Y9ZY#!0
M<"L   \              ( !>E,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( ((P;E:U<6!\%@(  *HF   :              "  >I8 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ((P;E;2-&04[ $   <F
M   3              "  3A; 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !) $D ]A,  %5= 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>111</ContextCount>
  <ElementCount>320</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100090 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100100 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Nature of Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization</Role>
      <ShortName>Nature of Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1</Role>
      <ShortName>Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Research License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements</Role>
      <ShortName>Research License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1</Role>
      <ShortName>Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Lease Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables</Role>
      <ShortName>Lease Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Nature of Business and Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)1</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Marketable Securities - Summary Of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary Of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Total Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Research License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Lease Obligation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails</Role>
      <ShortName>Lease Obligation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails</Role>
      <ShortName>Lease Obligation - Summary of components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails</Role>
      <ShortName>Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails</Role>
      <ShortName>Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails</Role>
      <ShortName>Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ikna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: ikna:TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod -  ikna-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ikna-20221231.htm">ikna-20221231.htm</File>
    <File>ikna-20221231.xsd</File>
    <File>ikna-20221231_cal.xml</File>
    <File>ikna-20221231_def.xml</File>
    <File>ikna-20221231_lab.xml</File>
    <File>ikna-20221231_pre.xml</File>
    <File>ikna-ex10_4.htm</File>
    <File>ikna-ex23_1.htm</File>
    <File>ikna-ex31_1.htm</File>
    <File>ikna-ex31_2.htm</File>
    <File>ikna-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img40748725_0.jpg</File>
    <File>img40748725_1.jpg</File>
    <File>img40748725_10.jpg</File>
    <File>img40748725_11.jpg</File>
    <File>img40748725_12.jpg</File>
    <File>img40748725_13.jpg</File>
    <File>img40748725_14.jpg</File>
    <File>img40748725_15.jpg</File>
    <File>img40748725_16.jpg</File>
    <File>img40748725_17.jpg</File>
    <File>img40748725_18.jpg</File>
    <File>img40748725_19.jpg</File>
    <File>img40748725_2.jpg</File>
    <File>img40748725_20.jpg</File>
    <File>img40748725_21.jpg</File>
    <File>img40748725_22.jpg</File>
    <File>img40748725_23.jpg</File>
    <File>img40748725_24.jpg</File>
    <File>img40748725_25.jpg</File>
    <File>img40748725_26.jpg</File>
    <File>img40748725_27.jpg</File>
    <File>img40748725_28.jpg</File>
    <File>img40748725_29.jpg</File>
    <File>img40748725_3.jpg</File>
    <File>img40748725_30.jpg</File>
    <File>img40748725_31.jpg</File>
    <File>img40748725_32.jpg</File>
    <File>img40748725_33.jpg</File>
    <File>img40748725_34.jpg</File>
    <File>img40748725_35.jpg</File>
    <File>img40748725_36.jpg</File>
    <File>img40748725_37.jpg</File>
    <File>img40748725_38.jpg</File>
    <File>img40748725_39.jpg</File>
    <File>img40748725_4.jpg</File>
    <File>img40748725_40.jpg</File>
    <File>img40748725_41.jpg</File>
    <File>img40748725_5.jpg</File>
    <File>img40748725_6.jpg</File>
    <File>img40748725_7.jpg</File>
    <File>img40748725_8.jpg</File>
    <File>img40748725_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="448">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ikna-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 448,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 111,
   "dts": {
    "calculationLink": {
     "local": [
      "ikna-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ikna-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ikna-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ikna-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ikna-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ikna-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 522,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://www.ikenaoncology.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 11
   },
   "keyCustom": 44,
   "keyStandard": 276,
   "memberCustom": 17,
   "memberStandard": 27,
   "nsprefix": "ikna",
   "nsuri": "http://www.ikenaoncology.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1",
     "shortName": "Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Research License Agreements",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements",
     "shortName": "Research License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Lease Obligation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1",
     "shortName": "Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Lease Obligation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables",
     "shortName": "Lease Obligation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_01480c2c-876c-40b4-a15a-bc9c124601af",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Nature of Business and Organization - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
     "shortName": "Nature of Business and Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_01480c2c-876c-40b4-a15a-bc9c124601af",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ikna:LiquidityPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ikna:LiquidityPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_72e7b2cf-5188-421c-b31a-cb8c26070efc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)1",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_72e7b2cf-5188-421c-b31a-cb8c26070efc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_56a2b03d-825c-40b9-ae08-f05fa29edc0d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_56a2b03d-825c-40b9-ae08-f05fa29edc0d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ikna:FairValueLevel3TransfersOutAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:FairValueLevel3TransfersOutAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ikna:FairValueLevel3TransfersOutAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:FairValueLevel3TransfersOutAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Marketable Securities - Summary Of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary Of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Marketable Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Position",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails",
     "shortName": "Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:ClinicalManufacturingAndScientificDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:ClinicalManufacturingAndScientificDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ikna:DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
     "shortName": "Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c3be42be-7b3d-40ba-ad4b-e05df3584a06",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_a1408ad1-33e4-4724-aaad-b0d4bd9658c5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Total Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_2aa48149-fbc5-4fb9-a4e4-66baef9e5d2c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Total Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_84324036-af2c-40fe-9fa2-a3dbfb992c04",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:LicenseMaintenanceFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Research License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_84324036-af2c-40fe-9fa2-a3dbfb992c04",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:LicenseMaintenanceFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Lease Obligation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
     "shortName": "Lease Obligation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_18f76e5e-f630-4d3e-aa72-98f091bf97e6",
      "decimals": "INF",
      "lang": null,
      "name": "ikna:AreaOfLeasedProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_9117ee30-cb2e-437f-bbc2-c141841cb4a7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_9117ee30-cb2e-437f-bbc2-c141841cb4a7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails",
     "shortName": "Lease Obligation - Summary of components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails",
     "shortName": "Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails",
     "shortName": "Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails",
     "shortName": "Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_3a1bdcd9-4bcf-49b2-806a-96cd896fb52c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_b633a850-2bce-4c3c-abbd-d9eeb2480f83",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_b633a850-2bce-4c3c-abbd-d9eeb2480f83",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100100 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Nature of Business and Organization",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization",
     "shortName": "Nature of Business and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20221231.htm",
      "contextRef": "C_c9f01d81-5fd1-4e6e-a9d4-256e2d8aafa0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "verboseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other liabilities current.",
        "label": "Accrued Liabilities And Other Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive loss policy",
        "label": "Accumulated Other Comprehensive Loss Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveLossPolicyPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_AmortizationOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of marketable securities.",
        "label": "Amortization of Marketable Securities",
        "terseLabel": "Amortization of marketable securities"
       }
      }
     },
     "localname": "AmortizationOfMarketableSecurities",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive in case of exercise of options.",
        "label": "Amount Eligible To Receive In Case Of Exercise Of Options",
        "terseLabel": "Amount eligible to receive in case of exercise of options"
       }
      }
     },
     "localname": "AmountEligibleToReceiveInCaseOfExerciseOfOptions",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AreaOfLeasedProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased property.",
        "label": "Area Of Leased Property",
        "terseLabel": "Area of leased property"
       }
      }
     },
     "localname": "AreaOfLeasedProperty",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ikna_AskAtLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AskAt license.",
        "label": "Ask At License [Member]",
        "terseLabel": "AskAt License"
       }
      }
     },
     "localname": "AskAtLicenseMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for issuance percentage of annual increase in number of common stock outstanding.",
        "label": "Available For Issuance Percentage Of Annual Increase In Number Of Common Stock Outstanding",
        "terseLabel": "Available for issuance percentage of annual increase in number of common stock outstanding"
       }
      }
     },
     "localname": "AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement and stock purchase agreement.",
        "label": "B M S Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement",
        "verboseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and principles of consolidation.",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_BeginToExpireInTwoThousandThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Begin to expire in two thousand thirty seven.",
        "label": "Begin to Expire in Two Thousand Thirty Seven [Member]",
        "terseLabel": "Begin to Expire in 2037"
       }
      }
     },
     "localname": "BeginToExpireInTwoThousandThirtySevenMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BostonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston, Massachusetts.",
        "label": "Boston Massachusetts [Member]",
        "terseLabel": "Boston, Massachusetts"
       }
      }
     },
     "localname": "BostonMassachusettsMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement and stock purchase agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement And Stock Purchase Agreement [Member]",
        "verboseLabel": "Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb Collaboration Agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "verboseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb.",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "BMS",
        "verboseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_ClinicalManufacturingAndScientificDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical, manufacturing and scientific development current.",
        "label": "Clinical Manufacturing And Scientific Development Current",
        "terseLabel": "Clinical, manufacturing and scientific development"
       }
      }
     },
     "localname": "ClinicalManufacturingAndScientificDevelopmentCurrent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_CollaborationAndStockPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and stock purchase agreement.",
        "label": "Collaboration And Stock Purchase Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndStockPurchaseAgreementAbstract",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk number of financial institutions.",
        "label": "Concentration Of Credit Risk Number Of Financial Institutions",
        "terseLabel": "Concentration of credit risk, number of financial institutions"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskNumberOfFinancialInstitutions",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ikna_DeferredTaxAssetsCapitalizedResearchAndExperimental": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and experimental.",
        "label": "Deferred Tax Assets Capitalized Research and Experimental",
        "terseLabel": "Capitalized R&amp;E"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndExperimental",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred transaction costs in accounts payable and accrued expenses.",
        "label": "DeferredTransactionCostsInAccountsPayableAndAccruedExpenses",
        "terseLabel": "Deferred transaction costs in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "Deferredtransactioncostsinaccountspayableandaccruedexpenses",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits and other assets noncurrent.",
        "label": "Deposits and Other Assets Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation including accelerated depreciation on disposal of property, plant and equipment.",
        "label": "Depreciation Including Accelerated Depreciation on Disposal of Property, Plant and Equipment",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationIncludingAcceleratedDepreciationOnDisposalOfPropertyPlantAndEquipment",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_ElectronicEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electronic equipment and software.",
        "label": "Electronic Equipment And Software [Member]",
        "terseLabel": "Electronic Equipment and Software"
       }
      }
     },
     "localname": "ElectronicEquipmentAndSoftwareMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_FairValueLevel3TransfersOutAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, level 3 transfers out, amount.",
        "label": "Fair Value, Level 3 Transfers out, Amount",
        "terseLabel": "Fair value, level 3 transfers out, amount"
       }
      }
     },
     "localname": "FairValueLevel3TransfersOutAmount",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_IKFourOneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IK-four one two.",
        "label": "I K Four One Two [Member]",
        "terseLabel": "IK-412"
       }
      }
     },
     "localname": "IKFourOneTwoMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_IKOneSevenFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IK-one seven five.",
        "label": "I K One Seven Five [Member]",
        "terseLabel": "IK-175"
       }
      }
     },
     "localname": "IKOneSevenFiveMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.",
        "label": "Increase In Number Of Shares Reserved And Available For Issuance As Percentage On Common Stock Outstanding",
        "terseLabel": "Increase in number of shares reserved and available for issuance as percentage on common stock outstanding"
       }
      }
     },
     "localname": "IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ikna_LeaseRentFreePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease rent free period.",
        "label": "Lease Rent Free Period",
        "terseLabel": "Lease rent free period"
       }
      }
     },
     "localname": "LeaseRentFreePeriod",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ikna_LeasesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases policy.",
        "label": "Leases Policy [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesPolicyPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThereafter",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LesseeOperatingLeaseMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease maturity month and year.",
        "label": "Lease maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMaturityMonthAndYear",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_LetterOfCreditToSecureLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit to secure lease.",
        "label": "Letter Of Credit To Secure Lease",
        "terseLabel": "Letter of credit to secure lease"
       }
      }
     },
     "localname": "LetterOfCreditToSecureLease",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fees.",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_MilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments eligible to receive.",
        "label": "Milestone Payments Eligible To Receive",
        "terseLabel": "Milestone payments eligible to receive"
       }
      }
     },
     "localname": "MilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_NotSubjectToExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not subject to expiration.",
        "label": "Not Subject to Expiration [Member]",
        "terseLabel": "Not Subject to Expiration"
       }
      }
     },
     "localname": "NotSubjectToExpirationMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_OfferingCostsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs recognized.",
        "label": "Offering Costs Recognized",
        "terseLabel": "Offering costs recognized"
       }
      }
     },
     "localname": "OfferingCostsRecognized",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OperatingLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease monthly base rent.",
        "label": "Operating Lease Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyBaseRent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OperatingLeaseTermExtendedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term extended expiration period.",
        "label": "Operating Lease Term Extended Expiration Period",
        "terseLabel": "Lease extended term period"
       }
      }
     },
     "localname": "OperatingLeaseTermExtendedExpirationPeriod",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards, expiration year.",
        "label": "Operating Loss Carryforwards, Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to exercise additional consideration if clinical trial not completed within research term.",
        "label": "Option To Exercise Additional Consideration If Clinical Trial Not Completed Within Research Term",
        "terseLabel": "Option to exercise additional consideration if clinical trial not completed within research term"
       }
      }
     },
     "localname": "OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_PercentageEscalationInAnnualBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage escalation in annual base rent.",
        "label": "Percentage Escalation In Annual Base Rent",
        "terseLabel": "Percentage escalation in annual base rent"
       }
      }
     },
     "localname": "PercentageEscalationInAnnualBaseRent",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of holders of outstanding shares of preferred stock.",
        "label": "Percentage Of Holders Of Outstanding Shares Of Preferred Stock",
        "terseLabel": "Percentage of holders of outstanding shares of preferred stock"
       }
      }
     },
     "localname": "PercentageOfHoldersOfOutstandingSharesOfPreferredStock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_PotentialDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestone payments.",
        "label": "Potential Development Milestone Payments",
        "terseLabel": "Additional milestone payments payable upon meeting certain development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestonePayments",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_PotentialSalesEventMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential sales event milestone payments.",
        "label": "Potential Sales Event Milestone Payments",
        "terseLabel": "Milestones payable contingent on sales in calendar year"
       }
      }
     },
     "localname": "PotentialSalesEventMilestonePayments",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets current.",
        "label": "Prepaid Expenses And Other Current Assets Current Table [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from payment for issuance of preferred stock and preference stock.",
        "label": "Proceeds From Payment for Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development [Member]",
        "terseLabel": "Research And Development Member"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets and lease liabilities recognized upon lease inception.",
        "label": "Right Of Use Assets And Lease Liabilities Recognized Upon Lease Inception",
        "terseLabel": "Right-of-use assets and lease liabilities recognized upon lease inception"
       }
      }
     },
     "localname": "RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets recognized upon adoption of new accounting standard codification.",
        "label": "Right-of-use Assets Recognized Upon Adoption of New Accounting Standard Codification",
        "terseLabel": "Right-of-use assets recognized upon adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RoyaltiesTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties terms.",
        "label": "Royalties Terms",
        "terseLabel": "Royalties terms"
       }
      }
     },
     "localname": "RoyaltiesTerms",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities and other liabilities current.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Current Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of remaining lease term and discount rate.",
        "label": "Schedule Of Remaining Lease Term And Discount Rate [Table Text Block]",
        "terseLabel": "Summary of Remaining Lease Terms and Discount Rates"
       }
      }
     },
     "localname": "ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Cash Flow Information Relating to the Company's Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series a-1 preferred stock.",
        "label": "Series A1 Preferred Stock [Member]",
        "terseLabel": "Series A-1",
        "verboseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesAOneRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A one redeemable convertible preferred stock.",
        "label": "Series A One Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1"
       }
      }
     },
     "localname": "SeriesAOneRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesATwoRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Two Redeemable Convertible Preferred Stock.",
        "label": "Series A Two Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2"
       }
      }
     },
     "localname": "SeriesATwoRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Purchased By Employees",
        "terseLabel": "Number of shares purchased by employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, plan effective date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Effective Date",
        "terseLabel": "Plan effective date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ikna_StockOptionContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option contractual term.",
        "label": "Stock Option Contractual Term",
        "terseLabel": "Stock option contractual term"
       }
      }
     },
     "localname": "StockOptionContractualTerm",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ikna_StockPurchaseAgreementWithBMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement with BMS.",
        "label": "Stock Purchase Agreement With B M S [Member]",
        "terseLabel": "Stock Purchase Agreement with BMS"
       }
      }
     },
     "localname": "StockPurchaseAgreementWithBMSMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_StockPurchaseAgreementWithBristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement with Bristol Myers Squibb.",
        "label": "Stock Purchase Agreement With Bristol Myers Squibb [Member]",
        "verboseLabel": "Stock Purchase Agreement with Bristol Myers Squibb"
       }
      }
     },
     "localname": "StockPurchaseAgreementWithBristolMyersSquibbMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_Supplementalcashflowinformationleasesabstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementalcashflowinformationleases.",
        "label": "SupplementalCashFlowInformationLeasesAbstract"
       }
      }
     },
     "localname": "Supplementalcashflowinformationleasesabstract",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration begin month and year.",
        "label": "Tax Credit Carryforward Expiration Begin Month And Year",
        "terseLabel": "Tax credit carryforwards begin to expire"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationBeginMonthAndYear",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cut jobs act research and experimental rxpenditures to be capitalized and amortized period.",
        "label": "Tax Cut Jobs Act Research and Experimental Expenditures To be Capitalized and Amortized Period",
        "terseLabel": "Tax cut jobs act research and experimental expenditures to be capitalized and amortized period."
       }
      }
     },
     "localname": "TaxCutJobsActResearchAndExperimentalExpendituresToBeCapitalizedAndAmortizedPeriod",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ikna_TemporaryEquityDividendDeclaredOrPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Dividend Declared or Paid",
        "label": "Temporary Equity Dividend Declared or Paid",
        "terseLabel": "Temporary equity dividend declared or paid"
       }
      }
     },
     "localname": "TemporaryEquityDividendDeclaredOrPaid",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_TemporaryEquityNonCumulativeDividend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, non-cumulative dividend.",
        "label": "Temporary Equity, Non-Cumulative Dividend",
        "terseLabel": "Percentage of non-cumulative dividend"
       }
      }
     },
     "localname": "TemporaryEquityNonCumulativeDividend",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one employee stock purchase plan.",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one stock incentive plan.",
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "terseLabel": "2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_UniversityOfTexasAtAustinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Texas at Austin.",
        "label": "University Of Texas At Austin [Member]",
        "terseLabel": "University"
       }
      }
     },
     "localname": "UniversityOfTexasAtAustinMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_UpfrontAmountAllocatedToEquityArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront amount allocated to equity arrangements.",
        "label": "Upfront Amount Allocated To Equity Arrangements",
        "terseLabel": "Upfront amount allocated to equity arrangements"
       }
      }
     },
     "localname": "UpfrontAmountAllocatedToEquityArrangements",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront consideration payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_VertexPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex pharmaceuticals.",
        "label": "Vertex Pharmaceuticals [Member]",
        "terseLabel": "Vertex Pharmaceuticals Inc."
       }
      }
     },
     "localname": "VertexPharmaceuticalsMember",
     "nsuri": "http://www.ikenaoncology.com/20221231",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r571",
      "r657",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated to Director"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r291",
      "r298",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r332",
      "r511",
      "r543",
      "r572",
      "r573",
      "r591",
      "r597",
      "r606",
      "r653",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r332",
      "r511",
      "r543",
      "r572",
      "r573",
      "r591",
      "r597",
      "r606",
      "r653",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r233",
      "r513",
      "r592",
      "r604",
      "r648",
      "r649",
      "r655",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r233",
      "r513",
      "r592",
      "r604",
      "r648",
      "r649",
      "r655",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r322",
      "r332",
      "r359",
      "r360",
      "r361",
      "r487",
      "r511",
      "r543",
      "r572",
      "r573",
      "r591",
      "r597",
      "r606",
      "r647",
      "r653",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r322",
      "r332",
      "r359",
      "r360",
      "r361",
      "r487",
      "r511",
      "r543",
      "r572",
      "r573",
      "r591",
      "r597",
      "r606",
      "r647",
      "r653",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r291",
      "r298",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r593",
      "r605",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r556",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r593",
      "r605",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r180",
      "r181",
      "r182",
      "r237",
      "r238",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r368",
      "r369",
      "r370",
      "r391",
      "r392",
      "r401",
      "r402",
      "r403",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r144"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r150",
      "r538",
      "r551",
      "r555"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r104",
      "r474",
      "r546",
      "r547",
      "r623",
      "r624",
      "r625",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r631",
      "r632",
      "r633",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r93",
      "r94",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r690",
      "r691",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Fair value of equity instruments issued in connection with asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r125",
      "r146",
      "r171",
      "r218",
      "r227",
      "r231",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r408",
      "r412",
      "r436",
      "r603",
      "r651",
      "r652",
      "r704"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r140",
      "r152",
      "r171",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r408",
      "r412",
      "r436",
      "r603",
      "r651",
      "r652",
      "r704"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r241",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "verboseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r54",
      "r244",
      "r536"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r54",
      "r243",
      "r535"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r51",
      "r239",
      "r263",
      "r530"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesFairValueByContractualMaturityDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r142",
      "r576"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r39",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r33",
      "r38",
      "r43"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r33",
      "r109"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r134",
      "r135",
      "r179",
      "r237",
      "r238",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r390",
      "r401",
      "r402",
      "r414",
      "r417",
      "r418",
      "r428",
      "r437",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r470",
      "r515",
      "r516",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in accounting principle, ASU, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r134",
      "r135",
      "r237",
      "r238",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r390",
      "r401",
      "r402",
      "r403",
      "r414",
      "r417",
      "r418",
      "r419",
      "r422",
      "r428",
      "r437",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r470",
      "r515",
      "r516",
      "r544",
      "r545",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in accounting principle, ASU, Adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r171",
      "r193",
      "r194",
      "r196",
      "r198",
      "r205",
      "r206",
      "r248",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r295",
      "r296",
      "r300",
      "r304",
      "r311",
      "r436",
      "r574",
      "r618",
      "r629",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibb1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r118",
      "r129"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 15)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r276",
      "r277",
      "r558",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r631",
      "r632",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value, 150,000,000 shares authorized, 36,257,493 issued and outstanding as of December 31, 2022; 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r157",
      "r159",
      "r165",
      "r532",
      "r540"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r123",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and of Significant Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r313",
      "r314",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r313",
      "r314",
      "r320"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r313",
      "r314",
      "r320"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Deferred revenue non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized which were previously included in deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock, Shares",
        "verboseLabel": "Shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r594",
      "r596",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r242",
      "r263",
      "r267",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for credit losses for available for sale debt securities",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "negatedLabel": "Net realized loss on marketable securities",
        "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r247",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of marketable securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Issuance Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r116",
      "r124",
      "r383"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred issuance costs capitalized",
        "verboseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax asset and liability before valuation allowance",
        "totalLabel": "Net deferred tax asset and liability before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r101",
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liability:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r103",
      "r688"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions to defined contribution savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r36",
      "r61"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r336",
      "r364",
      "r365",
      "r367",
      "r371",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r80",
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends payable to common stockholders",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r191",
      "r193",
      "r196",
      "r197",
      "r198",
      "r202",
      "r426",
      "r427",
      "r533",
      "r541",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r193",
      "r196",
      "r197",
      "r198",
      "r202",
      "r426",
      "r427",
      "r533",
      "r541",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r172",
      "r376",
      "r395"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax effected at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "negatedLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Acquired in-process R&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total unrecognized stock-based compensation balance for unvested options expected to be recognized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation balance for unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r136",
      "r161",
      "r162",
      "r163",
      "r176",
      "r177",
      "r178",
      "r181",
      "r188",
      "r190",
      "r204",
      "r255",
      "r312",
      "r368",
      "r369",
      "r370",
      "r391",
      "r392",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r474",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r429",
      "r430",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r292",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r430",
      "r484",
      "r485",
      "r486",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r292",
      "r323",
      "r328",
      "r430",
      "r484",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r292",
      "r323",
      "r328",
      "r430",
      "r485",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r292",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r430",
      "r486",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r292",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r484",
      "r485",
      "r486",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r269",
      "r294",
      "r309",
      "r415",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r587",
      "r639",
      "r640",
      "r641",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r514",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfProperties": {
     "auth_ref": [
      "r627",
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.",
        "label": "Gain (Loss) on Sale of Properties",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfProperties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "verboseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r36",
      "r60",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of property and equipment",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r377",
      "r381",
      "r388",
      "r393",
      "r396",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r173",
      "r189",
      "r190",
      "r217",
      "r375",
      "r394",
      "r397",
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r373",
      "r374",
      "r381",
      "r382",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r512",
      "r626"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposits and other assets",
        "totalLabel": "Increase (Decrease) in Deposit Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLeasingReceivables": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.",
        "label": "Increase (Decrease) in Leasing Receivables",
        "negatedLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeasingReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r28",
      "r216"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities Fair Value By Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Marketable Securities",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r113",
      "r121",
      "r131",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecurities1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r466",
      "r602"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Summary of components of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less amounts representing interest or imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligation1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r171",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r409",
      "r412",
      "r413",
      "r436",
      "r585",
      "r651",
      "r704",
      "r705"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r117",
      "r127",
      "r603",
      "r630",
      "r642",
      "r695"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r141",
      "r171",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r409",
      "r412",
      "r413",
      "r436",
      "r603",
      "r651",
      "r704",
      "r705"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "UT Austin License"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary Of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r207",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business and Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r37",
      "r119",
      "r130",
      "r139",
      "r155",
      "r158",
      "r163",
      "r171",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r195",
      "r218",
      "r226",
      "r230",
      "r232",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r427",
      "r436",
      "r586",
      "r651"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Assets obtained in asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "terseLabel": "Liabilities assumed in asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Income tax returns years open and subject to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r218",
      "r226",
      "r230",
      "r232",
      "r586"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r463",
      "r602"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense",
        "verboseLabel": "Total lease rent payments"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Fiscal Year",
        "verboseLabel": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r461",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r151",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r73",
      "r156",
      "r159",
      "r164",
      "r446",
      "r451",
      "r452",
      "r531",
      "r539",
      "r623",
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "negatedLabel": "Other comprehensive loss",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale",
        "terseLabel": "Impairment charges related to available-for-sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment Option to Purchase"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2022 and 2021; No shares issued and outstanding as of December 31, 2022 or December 31, 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r4",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r577",
      "r588",
      "r643"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds received after deducting underwriting discounts and commissions",
        "verboseLabel": "Proceeds from initial public offering, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r92"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r139",
      "r155",
      "r158",
      "r167",
      "r171",
      "r180",
      "r189",
      "r190",
      "r218",
      "r226",
      "r230",
      "r232",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r407",
      "r410",
      "r411",
      "r427",
      "r436",
      "r534",
      "r586",
      "r599",
      "r600",
      "r625",
      "r651"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r143"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r64",
      "r128",
      "r537",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "Property and equipment:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r329",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "University license fees and certain-patent related costs"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r329",
      "r477",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r475",
      "r476",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r95",
      "r132",
      "r712"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Total consideration allocated to technology recognized as research and development expense",
        "verboseLabel": "Non-cash research and development expense for in-process research and development acquired in acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research License Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Tax Credit Carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r619",
      "r628",
      "r713",
      "r715"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r38",
      "r43",
      "r557"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows2": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in other assets",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r80",
      "r126",
      "r550",
      "r555",
      "r603"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r136",
      "r176",
      "r177",
      "r178",
      "r181",
      "r188",
      "r190",
      "r255",
      "r368",
      "r369",
      "r370",
      "r391",
      "r392",
      "r425",
      "r546",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r225",
      "r228",
      "r229",
      "r233",
      "r234",
      "r236",
      "r318",
      "r319",
      "r513"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Research and development revenue under collaboration agreement",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price allocated to revenue arrangement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, explanation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Company issued and sold shares of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Total Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r333",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r147",
      "r148",
      "r149",
      "r205",
      "r295",
      "r296",
      "r298",
      "r300",
      "r304",
      "r309",
      "r311",
      "r591",
      "r618",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r620",
      "r621",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility range maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility range minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of stock granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average fair value of the stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding",
        "periodStartLabel": "Number of Options, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued for purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToValueStockOptionsGrantedUsingBlackscholesOptionpricingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Option exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r171",
      "r193",
      "r194",
      "r196",
      "r198",
      "r205",
      "r206",
      "r248",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r295",
      "r296",
      "r300",
      "r304",
      "r311",
      "r436",
      "r574",
      "r618",
      "r629",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r73",
      "r136",
      "r161",
      "r162",
      "r163",
      "r176",
      "r177",
      "r178",
      "r181",
      "r188",
      "r190",
      "r204",
      "r255",
      "r312",
      "r368",
      "r369",
      "r370",
      "r391",
      "r392",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r474",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r204",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r73",
      "r74",
      "r80",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r73",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, net of issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r73",
      "r80",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r18",
      "r73",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r73",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r73",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r49",
      "r603",
      "r630",
      "r642",
      "r695"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r170",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r312",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $0.001 par value. No shares authorized, issued and outstanding as of December 31, 2021; 169,396,576 shares, authorized, issued and outstanding as of December 31, 2020 (liquidation preference $0 as of December 31, 2021 and $202.2 million as of December 31, 2020)",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Redeemable convertible preferred stock, liquidation preference",
        "terseLabel": "Aggregate Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r0",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Redeemable convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Redeemable convertible preferred stock, shares authorized",
        "terseLabel": "Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Shares Issued",
        "verboseLabel": "Redeemable convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Shares Outstanding",
        "verboseLabel": "Redeemable convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r0",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r245",
      "r246",
      "r294",
      "r309",
      "r415",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r639",
      "r640",
      "r641",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBristolMyersSquibbAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r583",
      "r594",
      "r596",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r372",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Reserves for uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued on uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties recognized on uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "verboseLabel": "Incurred interest and penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r208",
      "r209",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increased amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r464",
      "r602"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r192",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r191",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ikenaoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r614": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r615": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r616": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r617": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0000950170-23-007681-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-007681-xbrl.zip
M4$L#!!0    ( (,P;E:>H+TY%TX$ #RB,0 1    :6MN82TR,#(R,3(S,2YH
M=&WLO6EWV\:6*/J]?P6NNT^O9#V5C'F0D]RER/(YZL26KR5W^O07K9H@(@8!
M!@ E\?SZMW<5 (*#!EN4!-*X[_6)18*%JMKS_-/_O1FGQI4LRB3/?GYE[9NO
M#)GQ7"39Y<^O#L^.3DY>_=]??OH_A!AOWYU\,#[(:^.05\F5?)N4/,W+:2&-
M'\[>_VB<9&F22>-_?OWTN_$VY].QS"J#&*.JFAR\?GU]?;TOXB0K\W1:P:O*
M?9Z/7QN$Z+6/"DGQ8^,MK:1Q8)NV0TR'6.ZYZ1^8YH$3[-NV[?U_\$_3G/\J
MG\R*Y')4&3_P'PW\$;PYRV2:SHQW248SGM#4.&M>N0=[Y/O&89H:G_!7I?%)
MEK*XDF(?E_RWGT85W 7<1U;^_*JS[VMG/R\N7UM1%+V^P6=>Z8<.;EB1BJ1]
M%O]43]JFZ;_67RX\6JU]U-./5MU'DX4-=)]V7L,E5G TV3P/U_[ECL?Q:T;+
M]O&;E><7SH??-H\F-[>M:^$V$-X([N;Q+,\^ -B+A*__F:B*U]5L(E_#@R33
M3\Y?5:W_T?PUKZN"9F6<%V.%*K@+CY@VL?W.(J24BV^'O_<O\ZM[UPF)8[57
M5";K+@BNTWK]/^]_/^,C.:9D&0Y"+J%"\VKX GYKV\V#TY)<4CII'XYIR=0+
MZB\6'D[*W+6MX"Y\T$\T/Y!PL_8Z1+/-U_*FDEF9L%02J0"@;J D-I)]?8JJ
M( BD\AX8XGK$M(C=WEI95*M'@@\7C_,EHPLK)U]D1G/@.&E^.5-, 1^W[#DT
MIE5QZ^FCU_#MJU_^S?AI)*F _QH_54F5RE\LD_SVTVO];_QT+"NJ>!&1?TV3
MJY]?'>49W$5%SN$PKPRN__KY5057]%K3^&M<]G6][D\L%S.CK&:I_/G5F!:7
M279@T&F5_Y]D/,D+0(3JS80*9)L'1CBY>?-*O58D5\V/1%).4CI#*I'P[4_)
MS0&N+0O]ST0(F:E_SLG(2,3/K]Y=!$[,+=,2) A<C[B!\ BS XOXGNF%U'-M
MC\-E970,;\'[/3BG-T?3ZK]R5@*K1AY'"SXZS,3QS0261<9,4_QW)I(*^'=Y
MGO\JC^@D@8^3?TD!3QZ.X4SX[X_P@US4%W0#B\5P=1?,I);DKB"F1R,"V"<(
M8X%-) VX[0F;N9'_ZI>/WC]_>KUPH.9\[PK*%;O7!_1=T^..'1$F&<4#<@(+
M2>+;(9Q8.JYOV<T!:QHY.,K'XZ3"LY2P7X0F7#U(KD26R[NU*75#RXU(S#C<
M7\PB0EWI$M]G5,:1A T#'YIFB?[!YXO/9V\!^<KD($M20(EB*@%>KQ>WOAY4
M-HNIPP% @0\ <CV3D\AW?1)S1]#(BEC$Q?))/LDK($;YKLC'> Q<_X^D&AU-
MRRJ'M3\6N9CR"@YY!K(JX?*X)>+?D[):.6Q@"LX\3F(W@+OTN$VHY5$24-.W
MJ(AHP,2K7^[B//]^DL$[N2S+#NJ\A4VF^03O^[T<,UG< MG%ZP!\8)Y%)8G<
M$&Y> +^ ZS:)%\:6%WO,=4+ZM-?!HQ@H)[2(%PL B/0EH9%PB>WYTA8AI3$U
MG^TZ+&ZRR(T"$%DN;,84-ER,0TGLA,)BOA32Y\UU@- X.(3U!;[C74HOO^ED
MAA9SP!=NJ@.6YZFD64Q3T 9^4?]Y&'U:EHP=I$_!8P=>!3@5^C:0>Q3%TF3,
M9;ZU#,:/A8QE44AQ5N7\RW_3="J73^!0BPDN@($P'A,W8K"LZ5.@&"["R(^9
MMS&Z-!WF"ADXQ'$=>!7%$W#;)]REP$EC*;C%ET]PR'D^56SE#-B[H(4H/T\$
MZ*=/CG&WOAE4%=^TOP;C@C!V_<"%@Z+HL&5,:.PR8()<6A20CW.GBW&-XOX.
ME'N::N;_#CY;X:D/.^6[!PJ T '@.[ O$3H"",-W8+4(Q(OM!9)ZEB]\]@T(
M]J2,?YE&/*!A&Z[!9YRB2 1I9@7 ZDR'FQZ+/5MZCY!AST@K<4"YXU*3B-B#
M]P5P"(J(PR7UA32Y-&7<Q9ECV'8U.Y+(J].33,B;W^3LV_#%! T[=#POB%;P
MYO6BDJ2 #U<ERU]^0I/EH%1*.;S-4";, 2JI/[\J03M+44-7GXT*W RJ2*11
M,O=O2H$7L[B&?EWW'>K/,I\6ZB]EHAW4)U37=G3A.:%)?<<CCB=#XOIP=]2.
M&/&YSQW+CDTW"%\U/Y7JSIJ_$H%_QXDL#+4%N=:".3KY;?&&EG_<+%?*2\0I
M_:> E]U,TH0GM:0R!&J VMQO$!&5X-/XL ##Z%+B;P]ODO+5+TJ9_+4 )I>G
M[V>R*,] =V;L*$]3RG)M/!Q>%E)VY>#:E_[2[+;=V^MU%S%1#*>]%F5@5;\
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M'WU4/H<M(I^CLLH<$-ZHNT847A ">ODB%)'K]U9C[:7SM0<&HNTZ,O!#++)
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M7.S\('W,P+8QD\MC$<X;X+RW@=G^1VQ>B'MZTO9,TW.(ZP//=+T8QVG8C-!
MQMSR BOVS+X!]9L%W(/194/A$(5>A^67PZH.B#RI8S#<H(UJQ=0.'(ZUECZJ
M/1%FCCE8!A9SSY=6'/=6#3Z$%42"\]FNY#R]XOB&IU,AA9X!,YY,*T7<IW%C
MS@ <ST:TD+_.UB_0@>CI1-4M >QKQ^^N%^':V)$4^VD''JC"+F,!H3[. W*D
M2T4DG<CKK>.J;_F>/0 G!97,CT M"P3CQ.52DM %\X:;MNO+B#F6U5NW?X];
M["V \E'=@<&T=)DPB8ALG"QD@MHL?8O@+*?("H1P9"^3=Y=E,KW9V2Z5S&)"
M!!$EGB=P]!$6S8 92I@G)34CVPG[V\"YWXV!-]F-R3,C/S!=XGM8QXX<C]E"
M8+&T$*9ON]SM7;?73<Z"L#>E#@]IK2\2[K5I3,'^PO%JIJ[UCQP.LMKD$1>8
M)1V\D L%!V&)NZPG-6[QDQS3!'7KVD3"P;:G+$TNE>:-T2!>27&>C.&1T_@,
M/BUCW1+@K&'B&JP_/<W"^R+'=1:$R-.^J<6YS@7V".$<.PK]R P(RB_B>B#4
M(LHB$H(&XF'_+=?OK9K?+[VP!QI*8,N V3PFGA6&V.H<E!/'HH0SG%)I!J9\
MJ;:1 _=X8>[1 ^Q\T.S))\;.%^.S8>Q(WP%K(602]%*7680)'V[ ,UW06+&C
M1>^R0K>JH^L&814';FB%E!+F!IAS9S,2.M(E)E@0W&12"+>WM44]EHDO,]/1
M-'W!?1>'3N.P[,!%QPJ/2.#'U*?"BBGK+3![,BEF&$SX$EDHI@_F'XV)[TAL
MI&K[A)J!1:*("=N4IA/TEPGU)KOL:1HMV)Z(3.Q-QD/7!Y;B^2C++2*$%W&;
M@07_](K,P%*^$Y:RR4E8C'++PX'B3&#P7P+>VL!21&@QDP:24MF[_)QOCC$\
M&!&^][B_Y8HHEK%%?#^08);Y#@DMUR9<"-OQ<"R7V5N/^=F4E8E(:#$[ T8&
M]C3JM(ND>WHEB\,TS2M<6D?Q=U+/M<(X\*4G2>P[.!'1D832P"91&)N1Q>(H
MD+T#8V\*A1;TA(7:GT>I<%)('X.XU 2#PY6>1QB+0Q*[%@L='Z?*][9 H"=Z
M0J]%\T9=#C:0J(UE?CAJ5F)LV?=#D-0^-1T.!JO?V_2,H8_ MCEB31';FALQ
M[,4%8C^TF4MBRW(]'QA3^/3S%;Z.TAR4D]9&.G8(9KO4-"/" P&4%@0,U!W*
M2$P#:M'  OKK+:4]J!1O/3GN="%>Y(=6'#J$\9CB>$),S*$AB> U+)2A$&YO
MVXUN09+Z2\V<] ( I47B ,T2&IHD8LPDW/$<B]LF6"7;3:<O6S+[,I4'(&%B
M+PH$H4"4Q,5\8HK!0,_V?,X];KMF;U/H^I94_%0^(COTJ>3$#[%[C?1CPK Q
MHV/%W T9]R/6RSS4H;/KUV#,)AO*B%@Z80S+Q1$'Z2MI3*CC6"0,0N:&,8V%
MU]O(]D.LW&\8V#58NG>UPHBD&PB/A"X.20V"B$1QA#,]@L@%_9M;;F]%P- (
MN%<J8NCZS+1B1J3CVQ@B!:;CNB'Q8S>"__-8:/8V=W'K<KT'-KC9\+X0C%FA
MA2-7 H+S];"%J$5L,_+ G'6$*7IKWFQ/Q*P'3$I$7)JA30&\V"4(_B ,;%MB
MN]RDU&+<H;T- CS4Y'F)F9E/-#;<=QP:>B:Q&5?#W-% 98*(2$IFNZ$9]S=D
M,\Q:'.(!WQ8/<!AG4>"0(/)]XL8@B[!Y-ZA5E(9V' >6U3N;?T"V1WH O T6
MK:&G5GH. 2;)B1M%'F'"H\1R_,"S623-Z,G][U\;Y-^<(F=QSS<YZ' 6^JG]
MT"1@=F##G,"6THG"*.AM\*'OR>+VPY-H[(TDT80N3D $>1_;F"SNVBX!Z8]3
M10")+=_U?=[;S,[OL5MK#X2G'9B",VR,X@;8!93;>OQ%0$W?HB*B 7MR0VX[
M@C^!(UV/,9=8$?;9#'R7A'X,[-(%U5JP,.+]#?YLBX=B@Y$@:KEF2(5%'*Q]
M FGF$DJI .M5N$Q$OA?RWOKU6\/U**5EN38O]),4H.)1EDK0$$'_JA+XY\="
MQK( =K95 YE]2YJV9)1P*P3]W8TCPER3$C_BOA0TY';<R[SN9QK\V.]4BR>:
M\L!"S^(.);:+Y::6X(2&@4T"&3.+"]\,^ZN5]K%Z:).5P!:3 8T9  0,;=?V
M(F2IC 2!&T01B$$_Z*T8["M?[8%VXWC4M4P@,=OS0+MQG8!0ET:$4^%CWU3J
MFT_>/O&;C*QGKU2(8^KXIA<2R^0>EL\Q$GJQ),*FOBV%SV+1.W'U%04G)Q]/
M=[+ !/ [C$S0W"GW(^(ZL4^8XTG"N&?:/)".[?=6'^QC=^>GT=HCRPJD=$S"
MF2T!2D%,& .;E%NN%;H69R[M;]EP3XCK!:2'[<3<BTR3N!RGQ 0A(U$D7)R6
MS2D-I0WTUENP]45?ZX$WR ^%:9D^)UQP,)HIE81&.!N5.RZ+O- 786_U[IUN
MHOQ"^<Z1#)Q8QL2+84TW$C;(3-,EL> F#6W+XK2WD;7^=OWI 9V[46Q9F"'M
MH$O,M64$_-KW2<3@FT@XKM??DI->I9YMBV-UHR,=F71M)DG '($3."FAPF5$
MFIZ('2]T:8\+[F]W "A6< ;W "S?^BJ#_\%OO\N#MSZ)_H^D&GUU_G]OO'@\
MBDU+A!:(#V%A,09J$Z 5VIXO;1%2&M,G']2Q)?Q86K;GQC$1DH;$C<%,#9EG
MD2CT?"?B4MIQ[T::;%\ZY=,T('$IYY29 0FI],$ \F)"T6$M0^%[CG0ME_<6
M=N^2C&8\H>D)7$ QG?.DQ[7([HVL$J'P9&AYQ'5-4&#]*"9@S@"!>S**8CN4
MM']=1?J9W;+@[EEPRCVJ?;,I61A8E# S0E\J=T!"J*%.G+NF[YFNVSL#X\7&
M1KQ0VH//7,Y"AX0.=H&)!<4&E$A,OA-39D66WUO7SO:(IBZ@03@]%-#+<NPQ
M@(ZBD%I =R"X(I!CIAU@7,,GIBF<D+O<#\S> GIHS?>R<C8V(\<QF4. )^"
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MVO\*UU3_9'6?<7_;E,4?CF\HKQ0%&'ELS#'?H*513B3'N@IA))F15*7!1[2
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M?H.S>=L\*P.0!B -0!J - !I -( I %( Y!V"4B['C=['N_$UDT7&8 T &D
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M]IJ! O:-P[G_];8KP#54WP3E9?F2Y==94Z"IVASHY>9/""G'^(!R;;17C9*
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MM*XFOP]Y'WV'YD!!+T%!';=#QQW1MB5?;$M45]+)*^R@@2.9 /FPQT]6%<E
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M1>X;?^ 4KBO93/00J," C%9YAO7$JGHU3J>J[KF8=1>:_^X!PYY4C1B?IK2
MH]7+KF,Z+<\I=1G9GE9']"6MFYO5N4E0$>ZXQCNNI!DTJ._E]$Y(&B)7>%#(
M.%7S91<*8.<Z8,=<HORO::)'4P$<QQ(;-L,_4 KE[<>+9:Y[QI]@[E4&'@RU
M.37%*[N29;6\XYG:M?X>+D!K9?4WRI6[H9&% P?2'.B?<W:@YZ;>,R^GZ16^
M.HP4, @'N '[ .$MZTZ*BB)Q3*D>W):ULX_5]+;Y3R@.Y1LE#(NM\>>=5J=I
MT]NXKK]4TAX;C]<: -7#,&LR:D>E:6K2*21W#)J[KG>O^8_B(C5%T+*<8N8)
MNBU8VK@Y<)SG1.AZ@;NG;%V/9.W9,&AC>P A90"?SF2[=KA;3?2-0^0ZP5[G
M\@;+#W")NIF#NK:47O>%"G8GO'+UW&.>AZ&I^N8_'GXZ-TYZ,HA6<W4C$3^_
M0O/WPKIH7!G;?LWM#6_U*<YWXA3'[PUKW_CU\]G)A^.SLXV@OK\M^LR37NSI
ME2RN$GF]#DOZMUOC^X+\T]O2J@^=H2>JHL:9X3XO9TJ51'6M]N"BIH:A(C6I
M&0P8@=U7,?>8)G L'4YB2:X<L@41,E8S@">@KZ':B-<RJ8L ,&BELBRGV5A6
MNK<6Z)#XE7(?YR ]JOE:6GLNP/[5+G#05U5?$##Y]U0?O42-@V^F5K4'J4#Y
MJ"TE[8C&';4;FN23)F<-E,Y<3ZK&\7MI\@6U9U@1U,])GJF#M6MIR["9N#<?
MQ:<LO"(OM4?['\EDDN.K1J#S[!F?#L_F?^!>,-LT&8^G&;9SN(03J<O53[0&
M=S4=YP49)["LS*Z2(L^4$_V'QF(^?W_<&4R-VVJN!5>0^-]Y]:W>9J+L8WU#
M!F#V" LT.(*K2*Z48:"^JNNC)$[ 3LJQBB_"921Z<)&*&^IYT.U5-YGH>A_J
M'E6I!\<O5S"KWL^><?(;B1QS#_=%T3M X6M2RE1/8(9C*.,&M?MF$"!@ 2^2
M28T',AOI=X#9D?,$#0R18_?$SBT='[Y=G-]MX$>+2[6^#GDC^;32;B0P/53S
M.*!N.6F HB&[ C0 J_$ERZ\S#355:8;S';$41C]1Y^BG)6!JH<9++][H&%\W
MP6Z0S76I2,](CO/EZXT3L.2:2VPVUL&Q4EVL%WGJ8H7$W<H:C>G$>'^L#=)/
MA^\,97#"_U)]X=IZO-D#"!:R:TO6D, 3XXOT^4L]$%S>P#%TD*H&%^SS)&L[
MY>TUS2X[C 3V9P4>$@-\,TN-T4P4.<=Q\)F*0DT0Z"T,#__QJ06AH>J'<L#+
M2O<:ZK854^SEUP)GDJ?&^QG6]9V!!<A8X]#A4Q5MJYF 0GN9+8X#2=/\NC2F
M9<T!="1+T8H&,%Y=EL,/&F+9JTN;C')$D0]>3A.AF258[@JDZ G20S0Q@"4$
M8D9ME;<,$!^ZG7UVN-6^<98@SES73944_G<FG\"EP$WYZM:5(Z$EQ!;%UE1G
M*;]1&_'O7,@J*/6B#9MN)@>BH^D2&:Q*$S#0!Q+G:9+CN:1R^)58]W4[-U#N
MT9:#HBNMD-6L96')1 74]M#O E!@L+_K+ON?5DG;,E\ _HSTP%+ S&I:<PN$
M7RK%I=XCVJ9"/U;E>5JNC$1LY FV.D!1K.>W3<MF+JK^<)P+JF*3V&YG_G$-
MN,UX')Y$6;E=\W@"-6.#49!'7\;< Y",+XVRX&"UCB]=,W##P/8NS/T_)Y>O
M<-S[VL^;VU.']*UH<O-FI#4U._#A#_1O-*<=?*V;L$X>IE L,K1%U2(S0$"D
M>ZL:!KP;MI["^O#!-%W2.%!/0,&^3E6X1Q_0BL:"&H@[N9295/D?Z)Y- 0MU
MX$3I;3=*V8 O+/-O^/;1%*ZHUL^T0I:@_BR4:U<U6%%Z#_+:0E[1%,6$DF=J
M[_IWZMTYOK5,Z@0NI;G3^H237/4(J[!:L!X\J?F6EN!JIE:=T::4#L!>HO?U
M<41+:5A+26*MJ%>25J6JH78!ID(MG)02A#W]X!RKTS.;(!XJ.ZKG7QX3^/\!
M%_"X>SK_!([\X9VMU'G%JN% ):JC*0I/W:H>Y([0BEAM<?SS\*.%3N+SP_]5
M,##B:;F<'2<GB5X%?@M:%P5I!GJWF"_=JB/'_^@JWH<+P',U\!;VU-RINIDN
M"LS/T B/%>T1CXIGLDR],+Q[OIZ2Q$@$L"B84[>=4L'R%+"6 4;8IFWIGJLG
M*I14N^@! $B7;U'$'6*7! VQ^:%//LS5:+5=36#&-<"#IY+67O;5WB7O\ESK
MLGIM 72>J,:N"\N_>WO85?$$(A*.2I5_3;4XKF>/(\X_#!>5/,?4(EKK\R6-
M0:'8@\]34)9T1A'P!$Q;HAPC$0B7<OZ)F&7 O'@= 9Y@G!?V3E6?6-0J$%+U
M?$>EIM07HDARG&>YUMI5H+.%V+P('AG9*J+"DOA?($D-0<4DYHK=BFVI^4QM
M$-2Z(D)$-''@_Z+9%+>,63#[S191PTZN5'1I@AJ\4FRTG:#!TJ)C8_:NX'0;
M407 X7O>*S6Y?@N\%DU;_&NOBR>@YF4(P9C"=K$$\\OB6[MKKMW"-$.-G%>J
M;3Z0!EG/!?:-KM*J#!_LB]B!R8(# 6/KBOV4)2KF]8:5<3%F2=8Q+6XS>QO;
MOP3N56 $N,/RU ]7K;N.3?<K+94PT^ICCD\AFUP!-FY4NP<>9HRKPX&B7"=&
MP)+UT518^&;23C!>XQ+I!-SK?LXM>.HCHY_$./[[NT\=NV_/^ W-P^X'^!*T
M.!<^ U!<ZFV7\Q0$-"6;,0BRDWZ\QL0[1 ;RO[ O3EM$J6F]&6-2@JY1@%F:
ML(VY-9\Z56B(3F[V0JWG#DX.*GL=%E[#.FO6T]4Q]1?(0LAXJE*.TBGV?&E4
M7A2D/!]A-D63@]3PA-IG@+)&5U2"TM\12EU67[]X^:>H3>OTA7G"5(EIT9A^
MD<;(0T!^.7U)&=@1S !>CWGG6:W(K9V!W>3D=3R:76?GA_Q*CFM-UM;Z3_=)
M "L.M4+Q6QM7@%82%0X%5E#-<-PW8"6FE-16$AA$EQEH3*7VFL] F[VE#U^:
M9SIIKO8ZU:[T6HJJ#6!PI)'V*9YOP<J8J($CREVJW8D=4=YQN'>,(2'E1)LU
MTQ*S>:6H Q/EG?Y@!>-;'<'-XMJ1V7AWM>@$:4W0-XS:/*"'\M<^B\^XWJRV
M Z(W9<<X7)R0B>\SCF O>UJY;K(*]YKK1<Z!%08$--W\,@,\%AT;G<TF%(>;
M-===*SL:%SC\#/  WI&KURF3NE9[Y!1>M%;Y0@VZ;',@>0KK+SE.VZL\NOT.
MY]M'"()%@G8-\IB)5(Q&&1Z$@IY6Y;B3>*IK.G YO.(&0C4WK1GIGC+ZE\^*
MR5I,-MYH6:>*:51"TZ-6MQ95-]7:BV9$'V$.N3_6.?@!E(J':^]+?86SUEN.
MY$C2))8+B"DSI=O39;L,T1LSXMK$N4:OA:/@.5I4256;/V!"J!8VX&F90T<)
M;5/C+O-Z/O&D @/O7XU[MPOR:P!"?KWD(/EC;CF I3I.$#P&F,F-O=%8,?55
M/$#&]%Y#[8N*NB/2$&07$'AUG;<QD-9<1E)N>'=9R?$8S>9Y&PG06=%ELQQ\
MV6L+LE#$3#&NHP8!U&&OYO%F:FJ'7KL1K?7!&90T.I#31L7B7 ?+5(!FE*1Y
MF4]&RA>B25J1TCP*C\2@7:_K(UM&@OB3Q(DR8@&4ES6!:I>9RG$FTTD=#$Z*
MQG.RD.BZX%"\T\AM6>&2A;MR!^U> ,.4 %F,C*^7#?K"FK"5#OS6R?+ZPG3\
MGW1<Q[4 UQO 3P[_\:GV.^ (LJZHSHN].H:J-:#&2UN[PNAKBRV[PU#?K4WD
M-@"[ZJQ2?N8UZGN67.7I=$S9'>XL;)HE*XKIO%A9V'%N=36@::']-&C9 Q8E
MH ]2> "1HT;>.KE"92MCGC"Z@%&\M ZU$B[# %7L$EB[+I9&(8I.>1W(5/Z]
M5,ZM@WE@<\%,:&X<?5/H<)59K3,NZ)A&[8LYRWDBZT#?"0*OO31 @B.M/=0Y
MX.^E J""C1+A'2.EK9B@RED,-"D19JIK;9[.NZK;Z/!5[J2T5?CTM[#!=9?8
M <LHG_OX:DC?"=2.-!S3/_.B]FAV?] NKL9AP3_5[.5"8MRE5D%JHM0J<2IK
MWS.B)]:**[C5>+K7N'A; 8JA\SI'O%P%D(II;Y.@[%5B[K:G)P+S.].3X&9#
MBF(/H?\\*8I"BMJHQT1#U&&4W@+'[=HKZZ1WVR4U[X1%.U'.0A7"YIT:0@S5
MYG4X\SI)TU:ATDE!Z:PI]E/&^6)M3=VB%<TYEN 6T'AI$[.4:X"T22,Z\M)H
M<:CJ%5/5D9Q@%E&3! ;+34'C(U1]U(G6[,VYL18:Y9<$S==$QW0NYYI='<*Z
M2O)IJ6QSU0%3CQ]NTIA4*[^EY,LF16HQ_[+5 '5-CNK4O#9W:"%9LM&%X#)1
M2RKK'FDZ-9&I((A.^]'WVVBYJOQ(WY#4EX'HV^FJ5N^YW53=9D"+'DRU5+_)
M=*50W66@U3$T7]$)G&6CT1YLC: Q5FRR#;4[L(9^!T._@QYK!4<=CEQ;((WM
MW-AKZU@2$KE*YGR8V;,46J676FH\5SW-<TG6KMM.94W=GC+U@(RI;N(%^A\6
M3'(EN1=LYL;ZKO+USK56]FHP-_ZYQN3M@O&63)!Y<D:2-4Z#$28;J[VT[H5I
MM2[38DUNEY)JZY"K%2>WN-N[0:B%W"9\Y7)F$/Y6I<#4HY07DD6PW%=M#0LI
MT-FK4XE560:LCRG%VLE>3S;)52RB4!FX"UX2M&8Q'P.8/JG[">43S-Z=HM&J
MYS34:2*=K(;5K. &6@LI-UUZF@/A[E2*Q13I-9Z5KC-A*?^@IN/VS]7<^&["
MC/;=E'KOF=8MFNVJ6@G,PX*;T)E->1?H:I+,[+[4A$5_B\*_NC5 UDU0Z$84
M8,?J3 H9<4O:A[]O/'%SM4'<#^*^S^+^<"[B,9@"3 (C+8US5]/ESLCE-N49
MG7B8UKLN3+X0VZ6&4'['.G3;&*!SX?Q-54#(?R6POD='=CO2G"X"4J7ZJG([
M; E1=J!YAQK!I$[_5'%6;%^EP\--X\JV644RSV;L6/QU. [T0(G[K"^W3J;^
MEF#E0T.5H[K?W8(^E*K^(;EZ,P8@VY??&GFL>_1>=<+/6B]=BC\/ J,O%#T(
MC)>U#Y632?7%[7:G!&I1EN!JGJWFB_.<HH8Y-?%)WFJTC0J,*GU+U6O9M69-
M\;1 @E5^0M@+$C]H=Z.DK2]5U[4S@NR/.ZH%E9.NM>*6KGBF;FC!#E%YOJOQ
MZ<:I"#=S78VZMD$'-M=Y\46Q\@7+;@G,RF&(-3;P<!-(UQV(=%!P.3NI-HFQ
M)VMY6R[;7N-I5%*SCO[. [QMHEB6"[G>7#GMHFPE=>*B+B/N.L0;%_CBN57
M$;ZMT4[AW+P*LGY=2P1-"E%M]R+6J"S,?%W%>]<C+J_R]$IV*F.;]'K9J3=O
M[/:VS%VJ)FBWB:DA^_F1M&>_]."+04,8-(2MT!#F?L4Z5P),GO7\=#&/Y)8\
MC)V1WDWF2&,I-=:83JN^S=GZ;2E%ZR_R9"D51WL:.YDZZ])[[DW7P0W5^3J
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M3NA!2Y 1.$D4ECM'E=*)XH*L569_AIO*KDOR.Y^&L(''IC8HFXOQ::J'<%?
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M-;9%<9B@6-ORB0]O07+.69YSN!I.TBC)LBBXP\.K6[)QD8^%)J*S@+H3[?4
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M&-5IG +NJ4JG%/XRP0/X!J4#^(:SQHE+U#Y?0LD824_;W;]F'[CJ<VK\1:X
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MJD2'>)/E:!^9!U*36 . [X8'W4G#0?/<^KS 0S5O%\X<1H2ID@R;+Q+#%'K
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M$OS/__%Y_^3@-74/J6:X0\[C<*;@$XO@(S95QZ<'.TV%YJ^UB'5K]*B?N*E
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MR5T87/5.X:Y?%ME]&+P+;V^SX)<8?)?@+(-?_UI&\-\KC-G<_)[EMT7C*\]
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M#L)5KQ NZ%"L,M8YB%&E5&.,K7CIG]KO8 9>W&(8ABA(]NW$NU+7/%*$WLU
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MEI0/:2N.RN">FREW_/9%(N0U#HGYA>3#--.$U5\X=8NYT-IGJ>J"2C;LJ\K
MI&@7>@1G/&-&;3*Q/P(5F'_S+DON\$T,0R(>PP)?-H(O2LV!<SA=S3-3_^#.
M$S&@EL;SZ,WF-6#74;&:G?L:1=O2[(EMA2<A _M$(%I$_49GT\J,YONU44E_
MB)9.^4@MLA3[&=1/NOX0=Z/T@H\I+T[M> NE*G\T-Z9SEM7;G8[Y@Y-*82Y\
MJ&>9UXE(O$>BQ."P,#V0P\(Q'T[O+SY_=6RL3YX*E)%^K;W#>F*<&&^XP0P$
M#AU^7/"2CAA,<F[I4.KY9RT6TH#(6T@*GIH%,&'Q IX,.V.>6+?(:3OAGM,"
M>P.0C<;3YGP.<\T::"9[A)9J6S^EX-WF"6$-#R','\8A0<G?!A\G$_0.V-@4
MIX/7HFB<*\<KJNU%'AEZ-:$=&SX"=I=1"SI8&J\T1S4]CID0D=_P%"YC_JRI
MB7%H3!C:."!3XECS')Q]A[O1NJBL[WU\$"DF/;M&_!0E:%@A:Z1DKFM^LH..
M>Q*[I1)"5FDC.\T01UKEY.O1UOB.KBAYW30YC%OE9TF17ZK 5N+;5B]YAM^)
M_0:):]2H:E-=2V5"FI'RKSI]GF_%(#<=B-#> ?L";#48M7,7YJ;ZT(&;Z"72
MJ#+\,HTV*;.NQR?K67XS'+PL9]V\ F7FV'@=WV>,]68+D?^)ON NC!,=BH$K
MK,+M:E?+;M_F6]AH)"" &(<AK^@8GI1[8#>3%8A+C7Z3Q(!YFA5?/2T>7+L,
M3)P(# %I N+F@ES_R@2$LM0]U(7M/2'/"&<X.GIOW!;9/WU\$":6.1_ZB"(?
M['.@BW9@8HQU3*J!2QYGNIEHP78KDK8O@IWAWJZ^<B(X0EKL/&85[,G2CA%=
MO_6N>K3'+L^N X0"Y$R\U>@DZ'#@:K$G4068N#3X U1[@3$GJCXGO>9EM1KN
MIOB-F!DN^0/M7&Z9W1BU]!+1]:XU-%2N4*CA=^5-$1C,8XV<S4I._M4CH758
M_=:EW-JTSXI@Q-O3<S@YTNJWCN5M<T ;L6>^AXP'>PI;'B9L4I4J79+?#GR;
M=IG34)JE$;+?*+1NJ*:'M;F0+623)8P.Q\)!0')@GD0_6H(BK[T(/9N7VN$L
M5'UL'2=!PZ8NBE2#>5!>E1#U&T'*^PZ%)-@3X.^2L#2]:+!WL(>_@_^'Z4&_
MV!IM=5O6C2\UVKCD<185:!<*AF#JRC% L= BGJ#>4;;J[.KRS+;50WVU_-G2
M8U%#CA$>FM%O2K#V-AR!',5W>KAR*O'TO3KH#0?'/[Q>.O=17,R3</%JDJC/
MRV<>5R>>+/3KZ"KL5I^7K^ED=^';9\4KK-_#EE.-<L .',:P?_3#BQ,,WIR:
M"8U3G)$NS>N#[ZW+T@?FW)W*H^&@?W1\>' RV#\Z.!H,?X!YI'T_&+S66\+9
M"_ZP-G[."8Y)=B:&7TBLNF=\X5F#H:DDHG2ZQ(YJLOAO2-\F=0!.?M$T'J'B
M+6B\8L:3Z-8&- 7I5,VB=V.CKLW^1<9Z1_HY%,';"M$#G> _PSF6FB(?'/@D
M_S][[]K<MI6M#?X5UCO5IYPJ6.U+NM.)ITZ58CL=G[1CCYT^73/?0&)31!L$
MV+A(9G[]K&==]@4 92>Q8SG"E\222&!C8Z_[LYY5YAD&2>1%CM;A C^^;H9^
MM_J!KD8_/'=ORTU#'V\OX$S7>18UK$HD,/,@/JR)MA/[M,][-'NIL^YJ1DAT
M'-4\^^'NUP_O"8SRQ-;D[V?I1ED8S;K,O9 /;/EX_MR7]SZ,O2,+=A;4.@FQ
M_G=1[XMZ7]3[C'KOW*:IBQNOW_,;H=U/*)8%POM;(;Q__=40WE^@U!>-_MO?
M%0 4DH3_9E<6M*\W2,??!MW^?O[EX@T&;_#S2T8L7NOBM2Y>Z[5>J^ !?C>G
M]1I_U1Q/5 \3-.$O2S#_?JKU_A)H+RIK45F_?QZU&=I^M^BL16<M.FO169^'
MSII15E9R#R2:B]+ZZ$IKT5DW1'X6G77#=1:IHC6(SAHF+)O0\XS\K=NBBAXL
MJFA118LJ^GU544]"W%6&)8]4D9*Y"WZ\9.7 O5RMR_LPU&!158NJ6E35HJI^
M%Z])6==3G0.]L!^JN/%E/IY;5-.BFCY3,5E4TTU73>V1]J\2RJ^\ZEDI=?&H
MB$^40Y\T[VD?,IJ0A4TS9YH/=.!S&^ND'9U9RJ[K-L2:_ZR=Z[(G*__ICFF!
M9ENKF7,#;=3%",8!OU)_ P8+4"I,J8YD>D1"GR)[,?,@-U=7?Z#VF457WR"]
ML>CJFZZKY]U(R\F)CL34M91$\=<ZD )M>P>ITRW64 LMP6\Z^"^BEOO*Y<7H
M6&?:>Y.!]X;),H3-@RE ?5?K"(')F9UKNWOT2/X^C3+O_8COZU+!H<K"2*[K
MMF7"OY *YXAUX4K9%M\%7_T\NG(_3USJ0I[P$6@&GC_]8>%.6+@3?B-WPC9B
MEIXC3\ I^TTA\@UE2WB@>OG+C^!,+=Q.'^#L?@>>N;?Y_E Y)2__A:WFO^WD
M^H"!68]F6*9.YZ'?W^>81!"3X.&6V?JEL=$W-G[U>\\F612/[/QG4/RY)=I@
M\?SGM_?5^>O5:WJ^G'/MY/GO2/XQ/(>.[GZ)!)9(X/TC ?>6M!(&=F@X@"F#
MU[.IC8C4A/EW3P'%9L $])ZVT_FI%CBIG3^I!SFIO]05BPEH.UG>O..E5,Z<
MD0*5?\PS_!XIW^[F1BOW;W$6:3$F'U7/GG__BHY]GU\T&"/1+>9C,1^_*I'$
MZ[C.<."@Y>&@_?)44E0.46W,Y46EJQ!XPASMI')7;-%%2;;J!NKWAW_[\/I=
M2*.'=55VNS R92'C7/ 5"[[BCX&O&"G448)4*-&2/.EOUL"GP1;7K\6#+_I=
MZURBR#.O?T]QKGG*M=>D$/-#@U$J0E>4@84M[TKE,'J\*RMW/:D;#\4:EXW?
MC^&-K@ZRI/>D\<3UA6K)V)!/5*M_H7WBJ2?!1KWS"'P, ,K#ORU-]8L.7W3X
MQ]?A_55S W4X+>I7:O!G79N[ZD:J:'K^.<*[#Z^4:?L6I;PHY44IW]0]?Z=2
M9A_VQJGEWX?G6%4LN]NL6W]9SOP]=O:C*,>O%^6X*,=%.7Y\Y<@UMY%NM$:\
M2?_=IU>:\[SQ']M!C;7G!U2?V/N;SJF\:,^;(LF+]KR!VK.\G'B6\\KRO1D6
M%K]2MG51C(MB7!3C3=WS=RG&KGP[UHOOIL4::4S/DK4H1=W2FTY>NNC$FR*?
MBTZ\@3J1H;"GM:+PEHZN\4%UWV_BWWJ/A[OI^FEA3_C=L(93$H (/3''9<0$
M GB]"4O!R"5X]L/=^U_])6-Z*+E4FJOR*:A?PF)@PU@M%S;.+I&]I\BM+P_5
M>/ L78Y$ZG.%W2TM?[^UY>]O2\O?I]GY=]&I?624VIS^HON\>\1H%"!('\Z)
M^ )VDQ04;3/6F"!_\S4I2FE8_GRPS;=,12ZM*_/;2^;[R_L/ED:/#\O9AF8.
M2'_<&DAO@430O=/KBMH]X/S("T+;'3I3=;HH1>MR-7\)TI;]MJG*)OZ^4D=*
M3ZN?;R_@BW$S@\06ZG:]MV<8K7!=,J/<9E6TPP7N6@R;7F@XYSFW1JZ?Q%IP
M +M\#^U>H;+8X&D3$CMF\1)5+7QV;NCIKCEFL7;2LB%/.+/Y\ST<_H_6L[+Z
M9TU?:SL0;F+TCGN+Q^C9?)3U0E+R\6,5X4$%(<G,6=?X=G2@-4J(G RK,F>1
MU:9S^>]Y?,N7?"#I'Q3,\-&9-;#>D$H;DTK%NG)R\MZU9B9F\PN?+MG\E>\;
MNO</])_K?!:#@BHR4WT<A6;B+?Q_+J_HH<2[$>#F^;:E]<IOV-WRHGX=]N?+
M7[DE_S+.6])#[]B:[!VNG"@FTA:=2]_MMVW^<UE--F?D^8UW8!'BWT>(.T<?
M*MY+BAFH_=MD^->++AW0=R[U7<(K\LA'+3IUOZ^4O>LALEGQXEU5\4LVW83*
MI,D_VR(_OX_\R*SE]Q"?$P%P>)71M/K(I,QH3X36JD0?TU:1YY7[^+NVWO87
M[45>ES]KO2XR5W92KC5.TC,P,E)QU+_+2_FEQ?\3_:T+.=5S/#W>)Y7&U]>)
M70BHNQ6SJ9V2PD4>?H]F>5;!4<?\KPB@X*8A(*$W?3?.@[]'"$7KZ[C00FN+
MQA!XZ#4=1$V5QY(9V+(GBWV?%-8[ZMV1++^K]'V3PS:39@@R+NA#L=E790;Y
M.KD&LNC&R/62?IJ7\Z<OOUR84Y:$VJ\S!DQ=0D_F$ST^QT:J '"G<;(GKO+C
MY*7 ^=]6MC2PZ$]ST/:/S+@R:I[\'5E7'GPIE8F'7RV5B<7E^S@N'YW5\^[-
M>4^AQ.9L]>^F9/<*WM]\)ONTE"?"G,4"O,_?,-!!@>(CY<!K$!E_;\SX#6/!
M^^ ]?(N4+E(ZSV(&_W_DJ%\CDB=P0Q/92N.,7S'[;)0&6Z3K!DG7$A[-;^]/
M;5ZXU6NW:5T/<N)>J/F7L.BS."P?6?:>U:10"DG/D"KRR$C2QBWKXGHUU/);
M*"L^2AT?)?K0F[JYNKMKKD3S-D@,<]XEC(;;D"HNZ[JYS.T.A;MT57,0S0S]
M"%<)J22X5:ZGE6 .BOI79ZOOFROZ0INEM[8;;DN\[9)N$I8"5%6YW9:;H>KY
MD>3$GY'G1X_7]OA#WJI72#^5>#J;_-GOZ+$[J&;)V[G5>B@KUL-(U^DR\88I
M3%RW>7L42.QT=7Y!/$X4.;-53R\(@ST+LBINCYP6;6DTT9/.+O)PS+_0#!<[
M_,(AL0<=K_O&T^4YX0=&R0T]';E]M(D26BJ<S(R<6#Z\B./9ZE]8GWL3;8E,
M\V!KY7IZ%+H?S*:FXTO9K@RCO]Q;MQFXL2?>=!XE>D'>LV3 )#G'6U15^;II
M<T].W6W0#51ND:LK+LO.?E\W]5W_WG%3_(*\ 'HKO2YC<D,N3%WB%TA]=F"U
MEDV968G;'ZKFZ)P_,!T=BIQSA384D9/!\GRPXN$BK?O/4'*B,[H)'0)_<[V/
M-#VYY/+9R2=.]L;RR*>WE!P%0"(Q9[8QP""M1?R&]WB-%G3$%VUX4AT%&-$S
MWC)78<$Z>ZSSU[\SUGDQO++Q)Y4*"?;0362=PPS\ 26,MMN5!\X51#-8Q83)
M]]A4X(MJ2* AN!Z%.^"[K+F@%]3:P>AN:/_H-4/IB[G8Y#5"D8LAYQC'C*03
MD\;:TRM.J22-5+#&0UH%F6ICLIH;F0G5M')QK;O&U\$UMJ30"MZ6@C06[/7!
M^[%FF!%J\=BI =!Q%+%:-1>G=&.+]]RQ8V ^T EK_F>>@3OG;B!KNG9DPQS_
MKL:3K%ULN1&Y^A>"651:CN=]QL?W93=T^K?ZF%@(O/FK'06?5^PU;"H EWBK
MH^<P8M-HU[ J-FRT%$CP9N<4P'7E^(]XKY;Y]GO:TK>+HXXV/\I]Y-MGJR=T
M3DA@^ ][EW=#RS,FWKAZ;(EFWT-&7F0^D#?2DB3)L^/(\CK[G@X&^UN;YD _
M\X'L[+5J,9'-%HJQ:W$86^WP"6_3#F?K+G+:WKR+WSN%^A7=';) '\&Z276X
M0_?>WE!X9[;NV5?L<PM885>2DLA/VV:\>[H0US.O2GJ<"SQ:OMFXKK/"\XGO
M<OM@#NDECR.SMTIOF[89HL8=B'E-EGT[5+2\^!FGONK)FV#V&_.1)V+#&VP^
M9EMV;R;E\A-GX(!Y(.R&KKA]]/[FT2OZ^NH[40/RNR_Y=]WJU:@"'U_RI5[R
M3+Y2/%HR"!\]@T"/_F9)'RQ>S.QH^6U9N4(M1Z%*FG[Q8T,!MF-=?EY5S95D
M0AO507RB(D/NG1).R;X,!+#A_+U 8*^7H \^^^'IC^?\$?G7BQ\?O_C'B[__
MOZLK^ OXAC!07#1( ',DZMI++&E)CM[0 _M!U,&IS7S<[/>NW2#0%M3AS=)B
MB\[Z/23J];#^MR;X6K=QY25<&>@*&9?&!9Q+\IYU+ILE S<X.]!?F_$A(I>-
M JB2/4-RXGW&,"?=LV'7OLLKC7K"?9H(_.I!MG4)E^=U3[J/7<#.(7D8N<$<
MF*U=59*_*2ZO1%YU>CT.F\@=-&>0XIN6O4H!P^V'6MN2FGK#\2,*U!1I</R(
M#[UQ% #0H^,I.T71@[?'W#XE^%D=FH-5LEG3"L ^6C&BR*(L^(%P\;7#)7Q$
M)"DP1*& 1:[+2K91N_A/[-95,U2%;^?0:^%3CNYHW<,E/6*9([+M)HE=><>N
M"-$%-]IU?<YC>G"I.%P.%W"H6;K6W&:\>'P(ORGA&5?N$G'ZMG258@)<46[(
M%J+GKN_*PDW?\^B<10D_"OGZMEP//I.G0_["66TI,K^(0^XT3K%0+HVEXE?"
M1TB#JJD,+%;RAJK(CVINGN?UL*6C/7S0S/!B(3\;"TDFIFCB'-&1=$-T)E;T
M+]74DBCT>'74##/M6@Z&DPN#3@PN_L[9FK&>$GUO=W'7Z"S:2M=>- QW)PM>
MD:9'G9'^!.7%<^*O8#=SN?#X YI]-".>W+0\>5-Q%=RB)!<4DZ&8A,P#YX7;
M'D:.3K='^CL,Y&6 4)N<<8;N=L>:CG[/M=P&J3_( P!'^27ZE^# ,2.;>*GD
M&]"9M<KASNU+KAC36237A&Y"KH#Y?!V=>7=WD%)[T=!E(=&QK*+XAY3AT"&I
MAA^EOJS>:"KSNCH6^'GAMASH*3>#?H9/*G_F@FG7WW7;K=0?T(K1^ZK :86S
M2-NME+9GVU7M<  9<Y%XS 94>2^;(JU <*B+,K^HZ0B6&_EP'&;%G<(YW?,H
M]0>'4 BSM[D.M#UR^20"_$VC(E1.K#>K$;'R1;LC (^#0@D@S4V#(=N:S+>G
M\AQEZ>,APQ\]F>2V8/16P#CBX[38VR8LB_^.U?\=:",N+9-6?^4N]"@NGOP-
M/ @?6:[@)7SWY#Q*'K1R'AHX#5*0975"IG?KR*W.JPSN1B\:I6K@-U>PZUWB
M5T<MI0P;:+G90"'(;,OU/FCFW*.QV[HV23EUF4$/.)V2Q=BV++CQD7K+5O\9
M!!S%_D%#BRSW:+7%/>7_7;YUJ#%Z?Z(F6Y&MR($"7? %L-*;-_D%_[.CQ\\O
MZ*IQ@B6#B]^TQ1OG#A)&J'^? <'E2.MV<AWRS1KY@H\%,B 6Z>CH-\CKJTNZ
MAP4;Z1];AQ4KI!">(_M4TO1Z$;!K] 0%8R.\2V0;EB3#!#SQ^-4+?-(B'<!)
M:!<O @+OA%\U<Z7G+SJ?/E07D8NP=7Z)"TH"ZS)ORV;HXO@KW#X;W604;T4;
MP5=75)ID_"Y8=TD"+AS4"U=OHK2@/W(XAV*H&972[=0E9?>SZX>"O]0*\-'?
M]V1DJ;.ZQ='ECW%B;+P:2Q#[]R<!;]W)XW;#NJ,G@Q\ 9Z,JN>HE@)C(5TC%
M+5-9BQO^\(>AU]"A]7K<8'M.TKGP@^@!S+_!W8%!Q$XSX)2O6*()H>0][^C9
M;V$!;/&C/>![+@.-GE2&1#/8 YGSBB<9;:1EQ@>YJ:I6ZV*ZODOZ_S51(Y^2
MP[[ZKFF*;/6$/J6< DVWY]CW?-.S^OGNR7_E^\.CQ_*+7"+:PM!+)2H1)%*L
M,R*QA%2<\64E]A:&AU#G45+.4P;NE*"=K2CJH$W94B"N): #[8J)LN':L 6(
M']2^1DH-@+SZ*'(XKD&8^DEV=":9Y;66IO+'5CRYH50M4*,)-TCLJ"HWOO2.
M'K=*#>+$S)I9C4S=*6L8&=A@=<T\F[E.+2Y4<UZY",#$2+KHS>4%'61\ARLY
M^,*_!U14\-9(I8D^])M?N0OZ X#8K( WJM*!.8H_''\ QB04DTY[*_22!6ST
M]2-L\W;H\BHJ)<U.FLBX?XS5/R)/>[>[!L4A#CEK26.JJ0(A!YT/[N*B=2X:
M^I:"LK^\MQ!0?YJ=AY(NVOQ*O$1?)DZ%^BH7#Q4@5#)#/:!/E0.O39=YK1NN
MQ"J'_&2RJ-'?.U?^#!!MQCI;U*5\,-*C?=.+YN>L#W2>UP_:<9XZ\R/U6M;_
M'FKC^B$?$'?;E)=DS.@B>=6K=[QI2W0C,5*SXT:?IE[<P]LI "_FJU_[H>L9
M3V(2H=E53\%$&^WYIM9'[QFN'8(9_'@TA+)X$IZV)/5$!7*<L$@E-3CQ,XO8
MLTP<1MR3UVIF.><-@&>X.H^'0]%=?GQRG@9\%&7"/V3:K<NFNM0 :]L ND@"
M]LWG*A/+G*9E3M-MF-/$\9FSIB"?C4Q0 I85DDZ+IBV2[(R%=%$0F$5<#/9E
M33&)$AM?!F#CE6_A.2I,;.-8Z?S]'R^S)&1[M Q7NRD':!':3R^THXIMII;>
MAD?]';*5X--6+U6\)'V]^?OSEYPR+XR@22_*/H4F1S>2_$G<#&L_7#$2M9$>
MIKK0?DQF9]D-M+(H1<-(C#AM[]/E.7G3Q[ZTA"YPI27G532MLPC]C3F B]!_
M"J$G0=R77:><(!8M(.2NH^*5 +EKNC2+:CYRX)_]^,1P&AJ?</;05P M^AA+
MK 0B%Z5@JBVT&0Y%+D1.]<!! +?+[ESM"=TV.X"M.T5Q%6Z1XAMSHA8I_B0<
M!E:;X-9U$ES:M7Y0L6W=94F76S?HQKYC_;[/7GUK/;M?",%SH+AQ_0Y8+)2*
MRQY\ V21T7T^$N!5AT9TE6W^N_Q:\PO:]^&*13QOS%%9Q/-3B.?!M=RUK_4G
MS_,@/!!5=5>K?,A?CVWD]>$Q6=XT1.:8UU\CC7@?CR+>"(R4WO6NL0C$6 =T
M1%E?EK(KH"(ID MT ^>;H_GX8\_!?'LD*UE1 'W1=!RV6[IRT1(WYL0N6N*3
M: E4G-K %G:=:_[CD_-%7F[,NUODY9,XO:O"@7#79I)$U2[E<OSKO57!'0-;
M!BQQY]BA#R($N0)AAA#S18-<MES_A=N\2-F->>.+E'V2!!%)1+=E7JCC*DT1
MZV@@YJ6"U&%Y/A*E&/3@#.DU3B='G63,O!:ZRA0 Z1/%!H#VO6I >J$UKYM@
M>I%Q3OU;^>S0NI!4#G<*$P,\++NI%+5H#CJ#]QRH:J(EJ3,;0&C2A 1P7M>W
MKK[H=P&_)PRQ+?UST20WYE0OFN2&:1+NC!F*LO>-!=-$D_:N"C:$^>@@D'F?
M<^_N< "LU;Z^N,<WZ=4OXO9)PLG\:*2V0\>@>^W%E48!S@G'X@)+M8C,#7E]
MB\A\"I&))(-)(J(^-163"(-DO3HA&YO)2%'TML0H"ERODZ#S*)9.>.B/H< "
M-'(IO+K"/!QQH@3B+6[12& 4\\C-$U*\M')_4/[2ES-8-HXD1@G\K>)HNZ6?
M^@.*ZK>*9_9,0D<O$8P.TF:A"7994 9*7 3B\:8=M<_:-<]6<V_8N.XB6*$C
M%3'D/M+UMS1.F"P>,Y?"D.)6[CE,\PU^,>\O*'@GER5%UY_9$YY\'IGF6>ZC
M8Q&R$E%5#'$)<#";O',S];-6JV-N@N'WHT>M@YJ/U<QA[.(./>VJM!/6Q^!9
M;:@,N9$83/OW?XSR)ENV-7B./_<-9KL+1XK<U1-%#E7H%I]9'9IF+AQ7%SD]
MDV9_QJ-1(J >8KK,HX&X"M+[^=W*HM!Q(XYF<I_]^&3IDKF=9N"<WSX$(><C
M3!(F7)LZXD#3^39^_#O)^5LO*\\_/UFLI@^**8G1:;\0V*9B[,#Y4$D7=SBT
M<86O[(R52)M?ILNJ\C!%"&3=#;V0.]T7*;5>(J2X!W=@^^GU?2JZJL7BT.\S
M.1#O;W[,^GQN3W@RC6:^)ML;HP$.>IIBB5U.*]@T;R@J ZE6^(W\G7/2^IOB
M6-.*-H!4 BM"=Q8>+J_7618>Q=Y,HLBS-'L>J?5'?NIUX,\3X#8G[>C0D@>$
M4(GS\XU/X>&VP'E?#R4Y6[V&) +R?9>G;LYX<"R&GA>/NW2%K%XTAK<LD; ,
MI"QS-D.5-<%WD;@_U(*B7,OJB:'P")1\9?3._',T5>[AO;OT9>$@.-!&@X"A
MS<M.VE@VKI6>>%9B[$R2BSGTRK/B_8!I=C0VY?Y",IN<M]NSU:BO$%AEP G0
MB64=ZM;E72.<A3N75T#18_R'\CU@TC(.W0IC3.)&V*29_BST_=4-\[+%0'YC
MEF%Y"[QP^*(_*TKH5M*J"K<M,;R-"6?,'0!M2H6^Q]#0.$X6"[LA*]_70<$&
MK2N<;M"!%C]CT:!DS+6_<*+/8]9Q6O7[?]:(YC"$GNS1!;I[*R7TYH?4%<"%
M69VGF\D/8L.#Y 44H E'+Z4\Z0ZT'!6]N(+-S<#C<5SKZ$#NT%5LNH$_C [I
M2E('\<;:(,9>!A^Q=P6+UK0RY'?QK&ZG9_53+%@43ERP1HZ'7R:]N3$]2$A]
M3<-O.%6L78XK^C;FG(&RG?4),S;&7#5D$3 DQ,272ZHJ-!&K5L9T^:%E&*?W
ML#MVX":IA6I5YYWQ 6>N +N#5I=$/X6";N VFX(O__[XY2B0DL8'2PR(AQ47
MH7D:7%7-Z&&D%Y6)OFS5=NK\2FRP*LA2E2T/2-49!9PE3!3/V>KQN!^J=5%_
MI#RT^8V84-J3518+?H)II>%E,F^_O,]%%=Q6'I3["P_*)VK*'+EZ1=-Y#NA"
M:$LL!23S;RVAXMZ2/F+5N6E+)JL.P2.Y^GM YS1A;7_OV=,8!)8=4R?&2&]-
M=F+&1TSP>+9ZJKANUB^9=^@B$CYF$//(G#B,??]TCW>6OAM:*"R C[+9YI3@
M,:( XXJHI&,S'E?/7GT;,.E1UPP:7D2MS_B7YCT'W<K#0E*<D4SC T,Q63Y2
M\@,T<J3&:U^\F;2QHJF-?K7G 8U&5AYYYTR<W(8="L.SX177Y-SU%O_3X[$#
MJ8_=:40UM3-[6;GMF1HF>;*YQA\]<K1UNY+-=R#]:ET8A7WI0NY$S]/<CHIK
MJI 0B\<X?.KE*70N:0@EX,,+!4^A;#LASAM?/>9^HU=KC)D:AL314PYN'AVH
M:$W(9JO#R)PH:LHQE!US(@_].'#BAS &/'F#D5,0V#7%7XB(2(V*;'(NA+Q3
MMF@NZM!!Y*V[8.XAQP-5HRPK1Y.C[\5/;WFA=%2#7-Z< WK@ESN,CKR?!N;=
MG 1K[*O!SH;?P!:J1^XAZU5_L5Y=75V=F0OSDW#KTRYED_?9<?X \  _ME[D
MF4NTEB9XIL(LOLOW_%Z64.9VVM!SKS80*8"=UG4Q/^U$8S0Z(4KM33H,C%1/
MMEJ3*-6.?DGA169CFP3%%B>>HYO,JKU",M!LT)YM>4Z9<CFGGRQU9,3(FY>O
M9@IYK]"A#4;(G>,<E.BE<<J7E5H_%,<1;$X1\67\B:O\'0PKTV#(? PL"5EY
M'8%!7H/&?P;:LXG8&)A6<R-I0 QC%05&*!=AU, BO+=3>,=1+3P2\4'=2=ZS
M*)M,9UJLS71<D(S8.QXTVYL<=#J=#O.1V7&%!!Y@]7RPS].B2=2J_/#9GLL%
MU+> ^OY(H+Y?@-P2#_8/4@^T8>WFET\;R#E-:V3BH%.2K&R4ISU5 H?)7U44
MBD(MAEDZ^)IE<:7&="*7ZP=)TZF\<#WB-!X\+]3/P@SEB:&MKIEHY<)U)/\:
M[**Z'SK/.1F"O'3?5&0':K2YYVMR\PXZ%,)1F-!49;<7DJEXAN>[G]M09.[M
MII4^!;XSW$))?' %MMDPPX4\*(52"--YK&K#UH+NF\&9H8"Q*QDA2H]Q 5_1
MY6T%Z!CJ7<(*,$JG+%#L&R)AB]:^25K[P1]2:S^8YG.\!C3]/5]ANP:\%&GN
MR30T)1*)"M%SJGGL;#/$-I3)#DVOWK'Q?V0R?5"ZLN4K#6EC8(Q$5W<Z Y&5
M9+?9N6*H)$<8#W,S=2D3#KJQV@6^43+2G&5==.6-.=>+KKQ)NO+A'U)7/OPH
MNK)&6C_'@)LY;0ETM=2;@CX4A9;I@!>NXP-US?@Y ?F06"/OC3GTL:/GE^]9
MDU3_V2UZ0[&:GQN!&_HPAO+"-1?T)G;F*=.QAK(<UP:D>=:\[+EJDQ"L:K4G
M@:@CQ\'0!=*S?];:DN#6W[6G^DBV,T R65,]J<A2*P#V89^1862B8C?\\)JS
MU=]M VB[KYKK";3LE$0/Z.E@(XH01@E'#5Z2_SS[L+U32Q+/V:RK\^$"!2(2
MY+_%\ZHJ.!T%>2)%FV_[U<502GK9V3P/XRM\"O'D>O;C9M>T???-ZI_"!OQ=
MV7;]W6?UW>\Y%/4)PY]\PI"^ZPJDF)]$\"5ZYR]J;6UXXH?'?5OB-P#-&CNB
MIOR:H8>YZ%:[YBJ9P(68%T@]"BPKVCDYZOF!BY\B@!+#,BJPJ7DBX]:UK7%9
MP MS^5Y@H_'G?93(Z"L9@V<+'H\ 6]TIS]R9;.R6]X/>Q!Q-\A<V/JLUF"HI
M2?'V\!%.>TJNDR7<4@@8W54[ ].B?&I82Y8Y4Y^"-^#W8ZBDN 0Y0OGJ<X*=
MQQ?))]<Q%<7H*L[-,E WF@,C-7)&0WL,X]GJZ>QZY%5YQQ4@WU:Q# *)/+('
M.]Y=Z9X! 4GR:\S-EMNCM/G99H(7Y?:;MO-E,E34ZNKH_.KY<B-Q%_OTY;3$
MWLIXTE"H\(U42J@:*A2"/[>,WK2T8=8^LH&#0A8X^Y077N0QM;(MV3?Q;3)]
MZ_+>E*1/YBE>)7@+L]47CUCQZBYV+XR](UZ!QG)<%6S=1=XR&B%J 4BRD0&3
MZGIITWP6B*$!X8'Y"*/B>._H5?KBXXB+\]3;8+T< F'Z)*JC?G\_&U%?9/W#
MRGI+/C<LIT!V(ACM7)U] K:)D;91J\P<>(8\??A&?:!!#X"XL]6_6GQ*N\@T
M%Z(KNAY)I^7Y="[QMB1]XNJXMV6"C@YIG1A%)B)OR.Q.B?,,S<0QC!.X%>X\
MU- VK,$8O"6Z3',\9%<90: 0K$[4D>Q5-$%86];FAS+>X!-UB_NEK1V+077=
M<'&!^#9/XF,$F'Q<)N4DPY&:+,&@\ C3G%L0N.+BS#:Q:4$PYX_=])S1%[3V
M=2F0-A(T](+Z7AP#I0HK>I 3<A6;S6YHM3?;0Q%YRAE0?E'+DV=J/<:'?IOK
M%$&2%G<7SC:MMY91U2>729:H:^3_/B\*^!&MMFZXMWR%[AU%YW40([CE9'+S
M=BS1DTX'<R$B:LR1<'\^IFZQ=!\4=T.QIL[Z$7;%L2UC&'(-K3QT@R)H!)T:
M.W<CG@2/!F:!T5@J_GPY0:RR(;7NTRA#A.CSVJ;5J.O(1J]+@.[G# HN**8E
M&),\0LHB-AXR=,A+G!A;-B&@%$61WL'N;69ZDQ\8)(?$((!P'?:_.NH"\ VC
MDESG_6;GWO&4T<BF5F^BNSS?YV,<F-QKY/6T"YR6B_C?UIZ?!TO/SZ?J\#_-
M(FO2S]HL455GJW.O1I$HYUCUT *?$B;"A^B FX6TP02"[XIL-"+-=+;75'&_
M2^%(F7"!)6IZF:JDHG$"73;&I:1=@D.*LK$J#?PQ\'1W.U=MV4>Z;<['PK4V
MO[W_/'M]-H?@7;C5/DJ_1-<->XE*-O!5MH-OSHJJJ;ZH-J;=R.92(7/T53-L
M>6/2*$FO<&P6_$*>3L..2A.KG:A_>XZL1.@9E>0;^M1&T%B9<=Y!0BKS/3BH
MD!T4+>N,B"@YJ?1%.;^)HL3YC5G4(Q [J7/MR)AP&TVOF8?9?.-+QE0315(R
M8;V.+4'FE"Z)^E+@E@R[.3?GQ[@[=%WIU<WMC<35-WJ573@XO2<F6I%$[>@9
M+D+/8+Y?EQ=<:8I.TGN?HD"KAZ"YY*M:8NDCGC$^17;*LO<_9F>K)\A^"U_-
M7C/Q$F =[VK0/CL;*F361^#8R5BF?/H(@\"]^&9T@H;]VC%)2UZ16:[E573-
MT'(^?3I[V<]W0\TM22C2 0B5OJG:SD(74)"LD+;44AS'7K$#I,'7\3=-HF(9
MT7?J"<DCK<;9U>GP>A%%Y9S)Y2I:E9'G"^FCE(SUECDPBPL?V%,"FW#'_!_A
MK'-34MPT[HYJ9^SLQ]D4P&B0>>]M:C(+IDUUE"-)?Q2_FI/S>];/6ZE+2%;@
MZ$W(B60+.>&^Q5<N9:D G'RZW+?_.(\NZWNTM;D[?\-R0;:FTW[><!&5GFA-
MT_D\FH#4&&38[,*U-LU0%=Y2P!9NAT[,'P_O":">,R ZG/5M1]1ZLA9D8/T:
M0H60N:(Z80*\6]#G=G,;'3B@PZ/[M^NG"?DBR;PS<;5S^G-4U10+:]I+F<;,
MP,9&NT/#9&_C</V%_" 5VE'EHN&K1JY/D5G>B?\I?DHA??NTMWOG$';U*).V
M1>>;+A)FL7%R*TMZ,W3.BEB\:&+*U&X*A 3Z\KW&IIR10C6ZGHO&&N$/385)
MXZO\HG6R@ C:%?A]7M)2-FW)#2$,\@%FJ%U]Y]SJ?-,SJ\#+)__\[CP<!FE4
M(2ERS(#1[U"1LKJXGEY$MEG8;074L*R6?9Q3MX,C[MF^H9![J/)6P$U'J2@S
ML@0F/O YB+M4FS"4;W4ELPMYQ_4%9D<Q=LDE0JPHG%\?G4O^AL\!/P)O"F\W
MWT,98?5\K.)+LBJSJJ(^L:4XP0RQQ4:2>A<_10G&5!7)94_H(R8AR%LN$"UU
MB-MK297G)5.I5G$%/&//9TK)7WXT2T0>&?+R4IL0GI>@SM%TK[,P@A3D!7#F
M4M66@Q_F93">14OP EP]8^UQE9>7VNS&N#"-JJ !/=EE&0TL+]O-L/?8E)AQ
M1*YDYB490N>"&6!,7_I7#EGD\?9P+]9#5TKK6)H'K)OH>7B%!I5KZM >K7K:
M=+\,8,?S'> 0<(XE(;?TT-V$7I8445/?U2\%T[7([NV472]A."3F@Y9MXIVQ
M^7J%\O]3SZ//!N5Y:6$;Q5+(,X.ZED[JJZ?/7W-390EAKTIW::.A<H$1N/0Z
M^W"=3J_#?!I&+#''WF0T2LFPC6;H>=MDEJ1T'IWS<AA4:@ZJ M?>;RF(HZN2
M?.>]\P Z8* =D_8:$!X5R*&VOX,(FE,<$&-&Z=EOZN+/(+.J)N/OV,&DA67B
M6N><5.G;DK/Y26.LU@,SWP41Z(0RR24!<!BHP9!M8D\4SWM7>:L,[=M42P!\
MRT5?I'XK9#7C$:LP%Y<N)&48.C^>C<.)T.FO)2]*F^0J19 [L('AR#*D-1UQ
M()FSTLC<%57&H3934_FOB$NO@5WFNWU\RAC=+)*0%9+?(C>0#JT_CLKB9^UV
M',*N7>"?$S@</)HK*!V/-.V"7Z*D/VN\=PMOTML:E_S<0"&&"/5^(E$GDC_^
M_B9'- WP!JV]1AC/<86&WHOTWE+IU>DZ<EJC%(Z/DGW''=-.*7-3FHTX-=8U
MRGO$&8IP[H7)JDFRK[$TJ1=:]BDD54WW+-I&Y3=:CS25O,<,68.SQS-AU:H&
MO(X]U SUL::Z?-'#V/!\E2=QUM?OV'BH4]OMN,HS/R\S6FGZF.#M"GIP\KP&
M\[^($0?^%J/$?01+7K3%K=06YXPOC9AA+6O,LL/,U\(OGT#>@W%F<SDU\*FM
M8I<_KW5\1<059[CWT#HR50.QX$_*A2(M:<<(!2>#*1XIME:.%M4B LG2P4Y@
MJ'QL^;]7G,JC". ?_'$$"*?^9O%QK+PT@;8Y;L*@OU'U-( L55!'?X?BE(D
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M"K]K&J'W8(SEBWU=KDDCOD)B; _()20&HZE9[+Y[\N)5Q#[(N,(KS>VK<ZG
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MR(R,,>T:Q_"<U=1Y !<ICY<!"*<Y<!["EL&)1%*KM+8CA7KTST39K6F3*Q?
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MY_-[ICSX9^>B41/?/W\97B!3]#''D:<?52H6/4Y"!UY%)!-XOJN=DZ81_YR
M!'<* --._/\,/( IFTW23"?P3*^Y8^XDD"+SH5%"OC]SL9PA!<8Y==H_$]%Z
MRS/' 5)@;BTONH[\TB%Z::?>:"Q3@5CS/!($\X&?GV-+']R_MRK(4"ML67 +
M5;-Y ^#%@76*JV.']ZK%JY3Q/2V?8-!1YW[6" /<U$4O[&9!,S#PD-\B%Q<8
M_<SU@[Q[$SZ/-W^V>AS6P>4%I0QB3>8W"-#$=&]()9R?>S+7?%T=C6#('O9L
M]2_NAK5;K2[ (1^_P.90"E5,V8=X0W09_X'6?B%G0*ORGNZZ:#9#8!4<*ZL0
M<&!GE:B+82@L$3;0B[F7.*HY^::]MN^,@E4U]5^_XF<4!B5/IC012L 7]QA
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MU1,AH7(CUGS+XHZ/M"3K?'/>79L&M,XK&7NXG>-D)B^FY&M&I:D-W0D-="8
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M7I<YK=J-&YQF\Y6]4,A+-*>6*X!ZM[/5BU-]HO\_>V_;X[:1;0O_%>'@#I
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MY YX"(7VMC-(#-47"L$(X"A%[,#=,-$Q/Y9RQP,+=]L("?60(+GW<@(D(*Z
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M<JY7]I*%\UM,I__LW^+:KRD210\4^6!OH/0@!1,[J>50[#,=S_?*MI2J\^$
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M^O7(#"TD34X/$/),Y#["F>2*#N=<#5<K&RCR+'6UD'?%%S\<]WC(\DC#>7.
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MR*8NB_I\RGS,8-$_R8[)B&-EXZ!7YM:G(]$L36?%<')3KSHB+A[&G1/Y*@X
M]:Z@5_-18,(W];0EZ6,$DC%Y53?NH@YD=1SR%QSC)XO?M.^/K_^ 74U<3SKG
M5)>(2N5R8NK&M:JL8;?0H^@WZ$0LMG6]%D%O9K64H%P$"4OMX?#/L2I:4?E0
M%#@C136B7N5[RBVA#E1IMBY5AQ7=R8:)&'DS2WMO,BWW+3L];W;)1JN"E10E
M;])40<PTIKG@@Q\^[W;D</EGT%<>H:!"1H?!"+C)O[RKP[;70+[XCUH8LF1=
M$W@=&.NK9W,]1CZ7/IV8'?LMR5%B?DW2+I@8T@TT*;Q[MDWG(M*$FG&0>*$2
MK&Q$IH(8<L)*OQ#*GTH6$9H/UF/5SE.[-$MTM(P92,0IF3M%6K B?6Q?Z&"*
M-$PYI1,?D2%K!T=TG>@TT^N;W0UX-YYJK@9]&OOF YNA7R9HP 51G7-K)C43
MC#+']ELU!D5_B\W1GZ#/)5/:.:MK[W<%MW=GH>4[(VQBLW[M'-=BRQR$.OBO
MUF_)_ )LXZ&[ELZN0]'2YZC1U *HR4N'T EM,\M.QK6C?DJ)HN@_FQ3%6N_\
M*]E**XA8@1Z@*@]:=B.=5:,P4^Z[O2F.A'I=A8Z?6TQ[&K<GFZTB]?X)?;;%
M,ZUY9T1A>T+-D\GA0_]R*NLW4:\*[;&!N9!Q)&AG4>P(^FJ$4N=D[QC!@R9P
M^](#W /U$+$7\@"LL#>M$I!P-D7U@J0?5?1[G'MMW;!^7RI9?G(!3TWZ?WK!
MHVFZ ]5946J]5?I^E?H_D>V);;BP_I,"/2JIP,NZ@?]$N.6B69^!XOJX>/;R
MEU \,)<@6%&)HBL+#_EI;$G#AYZY:*/RP"NWXEZD,6B0G*2M]EGMBK:5IKAQ
M<HBD<4F8(I*9*"J@FG.+\H@<7*/+ ^<U*SP8QSO&KP0Q:>%.%^TVX9 *"R!"
M$4<X[J^9 6H$.S$-]GGRI0*I=0B]_C>><Y*MX][$"*_<]+[K_TL;RI='U=<M
MW65>'<8FZLC!]D37IK@S(56=*1J\KD# 7Y,6%A973&83X]:QEQ"P%%O4XA:0
M_)9P*U,^VL)=EUT7@2GF_R*-@Y,4_*9K,Y#-FJ0 D:$G<,P3G4)H;/2S#/!<
M)%L8?5U(G,2WH<WRW$H9]B$.9CR?/1.;&&'1,B)E5DV94+Y3678MU9_?H>DX
M9G+1&:&?(/2?S%S?MS/SO[%I9ZNPN49E*6/IHDE/,E\V=;[.AJ)$K"^,TDEK
M=(DLSIF3KS?%,YO3BU-=TEJ4HA-OH*'>1H==#Q")?ZDW@:<#WB&K]A$&GPD#
M)"N\]:/F'#;.?&)C",@PUOWSO^[VI 5(WV#&@A'9$H+ 4Q.[J$^IAD6/Z&#(
M %I4E^ +67OO>90^(#SAOBX+B@6,?),-FN#UU>M$T 2>2N4'JQ"\A.\@/W22
M*XL!"7.;CO,8**6"#B/X02Q#B=7T+[\4?GU!RP'OF*G/DRXWS%&;F31[3)A$
MUDL5FOC=&2:(5)?R-Q,UW;PC5R33(_H/ 4CC>I!RF6[95WG0T=M@O$PP#!A^
MSK(>L8&//134$M8F0 A=>MZ[BATE5'FQ1 ^*31S? ]G"!D=UP!504#?A: 7\
MKLD)!>!]QEX$%S<DC,I&E]V&GJLZCE'2<F-(6=97,U9PQD#,&(B[/.>,%7QK
MO2-A%B$IY8&2,K+? R'E$0[P&3-X9Y;!O/5N8^N-4\6QZA9T>:-C$-'X@39?
M>NGZ_O"\J>[,"YXWU2UN*JK;ZY9*A(%51_10M)M(*O=.QR K_8R%;^V4&#"8
M^M&:3B(,)C],L;)26-((*L(@%?E%5;>43&XC(B,!?9A6]Y%6]-D@W)G%.1N$
M6VR&4>W1/AV0GL!!'+A$]H1208:_P6K^1N1&PGSQ%G;#QOGS_KPS:V7>GW?R
MP)XX9$>H6R):0L02B0N-'H,.7BFLDLC1O._NS!J8]]TGG/AA@EQ+7TRRYX%M
MYV8UFWDWWIF5,>_&V]J-M&E6D%PGM,4H>^5IXO/0UATR1T;980@+\C/V+RMR
M:#]M(J#YQA275.(K6T<$8/.6OC/+:][2G]0!2Z"OM>,MO(H]<[$V:^EB1^%@
M;@ (2X%@"?Z++R\4<"Z"Q!**F!1]34:EI'PS/IAW^AU9=?-.OZV=/D3DI!B:
M=TXR$R8\*G>41T'B"&&\(DIZ>.93T)*Y<?O#+ /5$$9_EFO<:0?J).Q7[?LU
M[0HP\22WHLK6BO;O-4X390&REJX]1"J *F\:PNC0NAQOGY[ I]T<P'S1Y%:]
MAD7*+@AYQ@ZDP/R4.UZ81TF>AGLV,, !PD]@56&>1FHP=*CEW,_#VR10IC)6
MB8]/[??Q]\B+G>UYJ!NC-;<1JE;#F#2JPB.*TX/YBL++TBE/9,(K5Z&M8$I]
MN?]>M"7V1'?@#+B^G[:'&U)-E\]HSRDWIAH.4.U8M:ID4PU,[[ :-;/+#*%W
MIZ?TTUC;<_/U-,#]V2___?R'LP??+L!/XW;%*N,2NM*@QS^[?1&_4'<':CR0
M[$=146T>?5U""YJ)TEBD*ZC6XY0%@1)75W7"%Q2DJ]BR,ZPYMZ*BXSJ5']JJ
MS]W4G["1_[5;^LE>;%U>>M]F!=G2J!6I*YX"#]T&NMYOI,/& 'IJF:3$(6<$
MPDY3@5DFO(H_%\DVT0[T[E\;A),IY;#@E /^O[?U"51\2EEN4" P-Y$6V+7;
M@^O(;R3A#C$;*9"/( S:^C=#HG>J&D2[DK5TET[E=+7MW#_D!M":E>M#VM==
MDUNTD$XM'XS.'XL73IQ8=(504RL%>CQKZR /2$J3-!(^49NZRB^+IN/I0^,=
M%2MYAOW1O*LQ4_#:_1L*;\.\Y/CF3[SDJ5;J_O2&Q.[YJ_/^JS+GMK]: WHG
M*[>HT$2F;_$_+?8#,2!JM(5J1WOPMO1\\1-I0N; "V?A@>"8<!EW($$JT"CM
M/?>V>M3G8?XKBAV>_^N',X?*,GG<O,"H>?]0^SV.95/HPF+HI3[M6-"QKEOZ
M^ 004S4O6I)QQ/]BS0$!QN,!-35/.N9!%!,KY^<'&#%Y8^$U0T<2!-H"[.(1
M[J2WE!9+^ ?M7;?JKA$$M0>21%LR;UB9Z;*(_ PIG<_H@6A6QXFZ 0LWK0>$
M):?ZYJ/.:I2'C%+IQ(9&@M?AW.[19\)*C)[0]\VCG*,EI\IZ \UT;V:A\4K[
M2.WF)FY$Q692XIMR<# S;8OSD#ZC<Z*6'O@V.'/Q<.T)$/EQHY<];FB84"&_
M[QN3HI7S#M^CUL/>1B53DMS;;E>@RWL[EM%K%V6]]+\6A\+OG@,=T .7@CK$
M4_T*Y>JWRLEO(;?I'_;"@7QKOZ4"1SBNXQV6CC@JS'#IV*TX=S(( ,X7K^J=
MTS9,D?H9BQ06(M![&9O@_">S);BOC>K?S(WJMS/SU.]K+##M1G*S:'.2"W@%
M%8P1XY7:37*D;XJ4R*QOED3R09-3'5\WMZ_.I=>Y]'IGYYQ+K[%>)>35'/^P
M5[."4Q%)0O,K "S4-U#'9:0O #2_2IT</ ?__95KJO:[&?!P1U; O.MN8]=1
MG5ES?I 0S2^UR,H1!R&"D>E>O'9'32: F# DS2/SHXU4F'>%=+YZ.:QDNS;,
MW*L,-WS,,TW9Y< 3F(&(=V;ES+OU]L_(D&K,0VZ,XFJ3Q3?)^S&\X+RA[LS+
MG3?4K>C&Z.DF%%&21FNWQ7X?<U:! :S)JY80^ ,W,R2LDZ0;I_I;*HI0 EP+
M*,P M6ZZBQ#6<HFYXLPB[HA/6],)IT!=UGZ+"LSS:7GG%]J\N6]C<P<7-6(U
M6BZ740XZ'J17=?/:/SHJQ66^K!LI=!$WXJ9886?5K3\PVWE#W9&7.V^HV]A0
M%KI!57\JQ&_]@9A?$*Z0H\<DI@2\%QS4.#J+@]V*F8*BQ^O1(["6'D"%0\P(
M\Z7#G+$9T@D#!:@R%J\!#/"^,,$K=L1IZ>P!RSS_A')67GXYE*F+II[]Y3NT
M&F<+<!L6($G+ L%35P2="40JXI:.,YM3&YI@MV*VAW6;UEPY&E3I+_/5JJB$
M\!YHDX"4$>VH.8-[5Y;'O"5O8TL:-N>-@[)"28?S@3G+DA.0E;]; G 2;AKE
M%+^%VT"F-HG)4-084R4SES%+*$H/&WY])9@]_NHHEJX)N5^P>-MK L:%'W=5
M4"D J(W1>J@I0TQ&2LP480^N71[J"X>3?&YEO5-K=+8+MY[:4F\Y@(+3)+%I
M9QUJ5,4^0+MAQ3T7UGCJK0@B30#$P6&?VU,_S*O];>M:9P(71<KE#0F:<54\
MF'!Z-]4Q8MDYTKKROW 5*PEV/L*)-)B@J2^]F[4FE$YI,/46LR[H8X/Z:??X
M$;$:1);[<'';.=FZ*+(P? QU_7 A_Q,R]C:%$T;900S)7\Q5F0SG9NCA0<./
M814,&Z.G'!Y2L^>+G[H&X\UB)P+$(&@)R<,QEIZ?0I"E/+XR3) =5ZNE&^?O
M4N]"?^E0Q(,GBK\VP'*;B-GB^W, KW"Y&"F+W+'_BUOS1*M&65^:SZ5>^KC0
M]/G<)?<A6Z]$TPDOBQLVT&8-\SP%M4]6Q8CR1%57-V#RHI?-.99!>ULSVA&@
MJBL?:H7,W6.\(/!UHCZ4)IRHA380WSS=S:L"C5 $XU ]K@$6W9R4'R&%L5[7
M#F3QV.ZPT>.F(#:)QK40G9&KMUW6YXM76%WQB[#2(P&)8$O>?L%#);HIUA>.
M_27+7.D"SP<_H*0O=O6ZV!1NQ"@2 7S>E(5_9,F9],RU(&2Z<35,AN13^E2Y
M$Y+.F]$I.E^\C).#7XR,*\C#Q9!+59+(%Z#SG'^<S@\U%=Y$U1S]>*.]7#J-
MI0NZ/X/VM<9\<8??6\58\TNC-2YO3S)(?-+=V%2R7N2R!:<&-2M@3W1M9&H2
M]1SU@X4@XI3 *#=5LFR&K'X3I/<67;^;I+G1"^2F+U[O9JKSD(W'G:3!!0N=
MOLZSVAY8137 0,9GAIY"&K;8=4OWW75M::G45FC]TC%$K=&J95(K6?O3"H3F
M/&*7L*<H/-PH]ZTI['XY4%.3^9).QI<QB'C6IW>Y6SWX<\?]+3G5I(]JY>)P
MPG@+PE1(8[E)[MT.;A,QL5B[U22QDY0^8,9:?V*2-+?R.T7VH?(8B)W6]4P/
M\6DLUH\@_-D_WD9)JM""'I:8.$[#5OLD'>&=XY:S/46KE IAX5\Z:A#E?SN]
M8NLNB(PAL(@EE\]PQX-;;2L_DQ='F]'1F_+1K)F;]9KPWGX4'1P0/T!_ ?ST
M[*(KD(]8;=VN\!\?SUBBDW!RHDEF<A4LT"V2[L3'5;ARS=H0\$JY/1VM8%!=
M$5J85MU8))!$*EJ9"+A/A'8R!%&;"X?!^]B!1O?VM^;+QQNC]1:>MTXO60*2
M945#W*JIVU:(0$GBGLJEH$^+PC/\)HO=LFM:8C.3NX6J:"O-LR'/9EYM7"DY
M9ZKD$3 3/-'^L5MB&01%(;M1N7\9)N7&BCO^!GG"3@*F@*X)OS!KH'=Y7)MT
MY:% [1JGE')T&WHU,F9^(<KOMBXNBU:SU27>S&**3H*[$^R*-)\)I0=H@K!M
M^9W0.6!L/[O^*(TA9RB/)MW,XUV(U9HCGVNOA'SFB&>KX1,Q1#KWVBZUNKEG
M7NS<T!P:FK_]R W-\_DK-?4D ZXFGK(-&8?^N_QW]"Y-4MI@Q_N?@RWI7>S4
M5=V4:S\R?QS_&F"J:EBHU(-S1*UCOLJYJ[&H6O]Y)_"Z"_BH%3L0%M#&Q]*>
M*:B$XN>2F?O\2=6@=-]<^''\3V[J+9I5T^]D;*CV^4&LXD'4G"FN1R:P+-HM
MD> SI):.KZ9!'H2=B0TE5_1JQMW)>O"A4>_GOL7V<^V3I_/IZ1,TB:NFBUK"
M&<-N&-.%13X4IJ)-/"0HO8/M*?R%[L=9]!7\K?PR]XX0/++$6K"Q>"O_>=I]
M/E_\[.+#;[S'!TRZ/#JC9T<YG(+[&#Q]57RAN_!#T6"BPT752(#?\Y7WZ$5N
M2="PEZXJE"#-I.K8F0('KR-?4VG#K >J)5YQJD(A5FZ;<*2A;:VZ /XG?9R@
ME^BGC6:&JLCQ\S2T9MPQ#%.P;J&:6526*"NQ0(,"JI1,,_6=O:.<EZ8:0._5
MOR[D2+/%OM@3!")+>F5GFW4_;=:+/')&QS->399NR?PBQ_F-L"HH.#"Q2OIY
M:F (\9"RRE\@&'0]DC1E39"L>W/ HB[,KN#L^M0AG"6T@V0(>I7"+-(3CQ6'
MV]$<?:R<M38+MG@!#D8A&<Q7?W0%[^$0;E]O0:W>:DQYI.D\$!5S$!XGB+FJ
MB!ZBHN+?6FQ2OFC]&BG]O$8-9PH,HU?F8V_Y"K@0\Z8\ I=V85]ZJ+Z)[$=-
M*C_Q]=G+9034+%9^*AO*$OI5?W'2I>*F!PJ/$S<L*M&F07;B329'0]?RXB!N
M2'7"F!X2__JC\QN4"I\V7T ON,IY-."#;^NJ<F4ZEB$+O'">D2<J+9-^ 154
M>Z5:V[!4FPU8&5$!ICY-708%E:*"?'T#6TY8T@B#\1?.$GS+^>*YYDU"O7KI
M9[AP?&9A27BWHJ829^-VQ!Q'9&_H'>MGDZ3(KE*(M-#6A9_3 U?E)L_E;CXI
M[NE)\4MG2PB+FO2^N@H^1B  ;)RWE\BF0:*KV*$Y GG=@34ZX?Y:F\MY/7AX
M?C/0&@WK,N/3)2A3E)2V=0",)*B3C"Y!OPWN(9UC^#/]B N]!0D=Y95-@\5S
M4$ -T;SA&4BFD)^#H2@#LX5O"$OI)(35 B?\AT7T61=M75?D:_+A8Z[6AUOT
MX!NF*M0;5F+J<N2Y<7Y(4G=?BSLJ!:&I!R<4IE@.RF>9S##3.X./9<RW3GO6
MQ1LFL$5Y4A7 KR ]E/F%EL5KF"8^HWC:^B%!9N,!^ @%-=&J\#+1L!';4DR)
MTI'.T5)PGC6ES0<'Q4PV>1$"(DMDL<^/.'+OF:&\7R7^F]<?^=S631;MIHIT
MWP#%RG90'#BU!_!M=P0?(L&-G' P0\,2;!B;CJ*-%8]<Y'E0"7(;HK..U./J
M[^SKO0!K,@$DLX8&;988BN:KK037M7]\_4"%-H;DBAG,35LL2RN$,->8/XT=
M]!%JS$C1K!DY1EO"^;5,_Z2#D@J@(TNT'31O3FPH\AZ8G=\'6C8:(3<7$255
M]?ADWP&:YM<P*IKKD?+KX ;9XOG/9]\^^C+#?B.P)$)!@#3]]\_\1E OAC:U
MO[[_0T<9NFVQ)(9H_QR__?CT!W_<<:)HU13<+\-GJ4:;_RR\/:$H+2=.>3\E
MVZO\R,<P?RA_PDBDX,R:(^7!25LLV8HW9$S\!P^^_)L>R5S"#459'WMHR9I^
MK6U[C8NLI@.8[[ZV,5+='9"4;$<&2%5_\IOZE]@Y@!2+=M?RB=P6P,6L&%.I
M+R/)%491E,;MD4? 6<WA9V.6B^78C_337$X@#RGB=$,R(IEXG5N;^[,L6&\.
M*CZ$N\58+@567O5YK['8.U$6^/GLP9/'#(7]=0N<XH-^C&IE$6B^VKHL_(1T
M.Q5#2#_N&K@L)=5M_",5E=^9J1 %U#58VHPE!?ST/OWGRW/\OP48@R@CP"^?
M-A)MHK7#(EV.+:G'?\,,/7Q("VM9^FE%-,KX@,'\2\0?7L*8M@).+S\SC[]]
MS(<2[Z_>9GKQX\]G+Y_^)*'VF[BY,C(B0@=>X096E5B NO#8_8)4MO2@S88.
M%W3SE!L\S,,O'SZBD7-[3UPO-L<2C)%YKSOOH1=^6-X(K2-6X^735V$[G"]^
MQC]WG1)6F.\,-ORB7JU()+TW\P^_[F_F )O_W:V"R?0'RI;AR2&!M'<UAG>U
MK?G9>/\K8B3)<K SOVS=P?ZPX$N:'R47,_N$W/C*>R#B8,=&>MLH<,J>9RF4
M []0]VAN\'CO9_.A/E #&X&E*!(<.+?B^F&1RTH4+1T("XS74JB3AU.C?M]Y
M4T)>H=9?UA'.A.U%BHK\&ZM#&??U%%"[<3&_BV^W.41A<A^)[OE,$0F '11[
MN$2TXP>R2<"<(M<LW '194Q%FHB1SSFSJQ)+3%EW<\8FAOO:9]$DGCX.=F+8
M.?CPT#78"P>)DTOR]"E\T#[V+ [(2+L;4O0=65X^:4=W):4J)'EYE5Y-ZH\"
ML/?3(]@JI(T/R9'I?WU!>0U."" ;*AD!*3=,"\*,]4?&[LDHC*&=:BI>'Q0V
M)4LBE!W)L(PY'VOY^8&[.O!KU41-JQGA<6*)#GF<KJ4%0ST9_S,09U,6DC$C
M%X&_-D=/_ :4R%EMZT(\9LKFGY*4NV_IB1F[I1/ZY,N/+48QIX8F4T.G 9R4
MJ:Z.6E$=^8)4?#3]0I!=/8[CJ9:); ^G;C0E%'11E:N^X/,P'"UBU@1&JDV1
MER@]L6W7;$_IYM3-I['"/[SH%:=6:)4DI9WU:,O@1E9X].+.%ZIQ?LW>4/:(
MZ<V1>'OBV-&__?'+J,+1+LE-VML*QXR\1/_S8_ B@L,B?B.[M/OML?6N8%ZU
MT;7*1HH#"0Q=/-N!RTDUWPE<]L9B,4Y(X8E]X-%"3]W]T>'10R%DQ%9<15\I
MF @+!+ IX.A4]0R"RJ<O^Q@0U<.BZ8/5DF:DF#8^7[SH#RI &O[,<IAR[8T7
MS)FN_MOJJX'FQJ,/;"&M-#=$F;&E.];BB!)38UWVM"CC:N&>#W_DXBV6?MPY
MRZ.VWM=>;;4R&!94DM2161[YG2""W9NBU:J;@ 0)7W*U]?^O$HZ<$(XC(Y_4
M6JF; D58T\LQ4OCS:U6 N]X/QWLCXFJL[DW9.<J<^A>P*O-B)Y55_+IC(5=)
M!A5X([5I86D7785[P_=U"?)0/.]0H0Q%3F)2>O#M=S8Z,;&*#0-X?47;(%E,
M?0Y)^8SLRY]XC06NE$LG*IV#W'#&S^3.0K)8KCKLA1(PD-;3>YWP"IV*U<>$
M/0W,:@WX<!J.C1GK1.0#N["R8\K%F(JT"5X@4^1X!'S4]9K1,\;B?9R>SZL)
M<AWM4M-&S\A=9&Q7S,%3&Q,1]PPL&5$/2(*"@^PFD.Z9#OA>!I[M3]C^2&#+
M.4+=IOF%&Z8^^L7RH %):DF:T(N<]"]HFS5\)?Y'(:ZGP9W(8TB&B+/@M6TV
M-(<&ISJG\+<W489-##_EV9L@9M'7L$YF(IRSO2D)I"-)PUNP:=&^ALII0&_W
ML0<BJ)FO_6J*B+2$$TV[)^2K1=62MH:!+23M%-'S"L^"#+@W NA]_/_9>]?F
MQHUL2_2O,.;.W+ C4#HNN_UJWYB(NK:[CV/&70[;/?T9)),27"# 1@)2\?SZ
MR?W,G4""HNHEEH6(T\<EB002B<R=^['V6D5TGV[=^%T'[V?@K!/;5NC?#*<$
MX@*A/ES7[9W00F@/!OH(5<,)#\JA^0%21!7/;9@1?#^E_7WG*+5%J1O2+J!U
M^7>#S3 >7?Y8-WH()R9*A4N!MJXA9\3.&C2(0*U2LC,NIB/18<0W>2B/JDH<
M'S^=0W3)%I/Z;DWJCS&O!^ TH<S)IW<S]I(W.]<G_#OQ0RTQ4.I7V^QA-EV)
M;M;;Y@S2L&CHQTF$!\0)"OT[8%  1@SM%#;@/M3KI][RX.BX[ VQD-4<W\DK
M.,>AUXKH(M"Y$,HNA+(7.^<D/B;XSW=B'DIHPF^N:X?MJ>RE(0?9?BV4[P1-
M02-%Q!";5X>V0JU@ ?&,PMDBAH=T64M(82]-?UTD'2YFB2W;^K&VM0G]#%X<
M_W+?CCN23MD#=QWMZTGA7=-LF_:9A%R GULVZ<4LF&63/IKP9X3G8K4$BC_<
M/S%*D>9(8-_JI,:$2FL3*F;_:L%FV;<7O(:6??MHAZL B=\<0R>< _H+6^#A
M0N*^?.440"O[=-F %[,8E@WXZ/KV8<N5'?2O>RP5EU43$:^\8Z2NZ0&:_DSW
MFU;[]"1D_3-@!*]QWSE@)YS338FX_U@=G!N:M*N]U8EM^&F4X0!+E]J#&[O5
MQ_2 B]&XF 6\&(U'EE3#KHL^[*NRVQ*$HHNGK(:\XY/];;?ON-,<&OX-# 3L
MB(B]4+9^Y _0]]@C@)H@? -Z;:)41T0>(&#D :9LQTBHQ;V_H$6[&(K'<N\1
M5@#'IV5&PPIT26[""#OP3C+G_(G9<)Q:+)=8_#(7SK)9'R_1[0F$I6U6=/(9
M"):HJVU2EC/IG<0^S["A&MKT!DS4"I5B.":7S78Q+W[9;(^UV<8L/^4$SH@,
MP!:=A1#AJMNN4@19#)\GT+P$YW@:YF@J4O:[>(]EPU[,XEDV[.-5F"K4+VB@
M HS!+ /HMKHQ)SAG[HJ1+;WLHXMYI\L^>JQ]!+C'<%@UC*/0WH&^18AR._3/
MVMVS0[L!Z"4GF<JU%T[MZ3DY@?U_M^RR"WGCRRY[-"PBM88@%B*$8<TU(!U8
MEC7I*]U"\J5:#^\J_3)[QBVD"6]+FO#\C4D3%LNW6+ZG8OF$>S>R\1I9'ZTO
M(Y4B4*,%)^06R)TSS+O%7#*KK,._MT?H'-Y29HOKR37VQQI&I,7COYC5L>S(
MQ]B1B7L!>PRZ[15N@9R"^T/K8P,\TY2?77-]H![AF7C.-C);E-@-!AV:W*-<
MKG[]\>??X&.W;3V0>D)7^5>)O$,=ELBR]R]E'2Y[_[%.XQXT&*Y-,V4%+"1(
MK/INXHV$!G0!;%WTDEBVX6-LPY%"7 O2PF]_2@ISZ:KL1]NNVBPEW@M: ,NF
MNY!,=P1%9F0#B-[V.!+2Q,AU9TFZ($O>,<TY\[@LN(K+6P#+IKO Q+>MT4;]
M1D>4.'XX'.HJ_ #_:,/$+IOI4E[LLID>#:04]1E&TJQ"C3.#LWTG!$5+R^P%
M+Y!E4S[:IM0VE1V7-0SWX.($7L[K6K;(8VP1H7L@!EWDU5N# LF[J L\M*T$
M54EVY6U+E8SQD/+I2AC)@_>P[I]E#_\Y]O!7GW_UU=>?/W_^Q3>???'4MG L
MT\LVK"O)8%(SY]6EH8S^%(L=M;4ZI-RUI*!#PXI _=%RGY/RE1\Z9,8\P<(<
M_)3@H=3'R- AQNYJE>.;+IAS  0X#R @P$J8GLWFI"OB.D^YNVM3UP@M='\\
ML/SDOMRBUM;W/_]6 -=>>(CP3Z;2]<KVCO0B4 \.48\D%Q*V9^%)QAE@/A(=
MXC;,'D@-2L_%U>H7)OH]E$?@]^T=79]:D7$$P%6,:G9 I5_A!$ -^FKUG^V=
M0[!*V_#W(R/#UH439R]$8I@F1-+D^&*0_%='O6W#,R+EJ@>F88KJ&"5#(\/G
M0@KX[*50+*T;KN6*0$G?P?=!,'0R.'J#)\9E+Q4'5^T/(+(M5/V(K&<Z8[Y,
MGN;Z:O5K2@Y][<)BBEWK/PY=>W!AJX:%%X9EN2#"9@A[Y+:,9!#AG82'8P%Q
M!O?#IRIXL56C4T^$]\EMK22@+"A#J!%VVE]'H+[%37\R1_S3=M/57DKS*!E*
M8+AFOG,$T2S1[(6\LF6;/,8V(>69*(2#M.S$'%]#M1":T<KNN&R32WEERS9Y
ME-/$2*JI3O8A>)T[$(.B:ONR1R[E?2U[Y%&(NUK?/].3!/.,RXZXD+>S[(C'
MV!&-JS B!RWRKF*%L*85/:?JNB3M[:LEV?@^IO^%BIO7QR+XLCV#1_$$1^+\
M*"P))'_8([('ND%2#:P\:M!Y8DI98Y'&<C+<0X<"LG,Q%]>RUM;Z:,M D.Y\
MK=1D=7G'\ ? X#E4%9)>%NQCZ4B>B<:.*D2JD@?I'TRS13YPWX+&8K^JVSO7
MR;-CQJG*9$4A5QIE['.*KIANH@D@J<UP;4RK1>R&9,W"U?=4P I/(ODKMS5S
MBJ.O*Z\O!0MDD!^[">_+-=>LYBE_#K_NKD%["0356-HJIGG_Y:"2IEI2DF],
MLV49P;FTYF9$>R.9HY70"W]&#L;TNI6/EZ3<LDI*C9*&/X'L%"W* E9:N',J
MD&EA8V%U!C,;QE1O ,0IF6]8!2M.F#-I"/T2)FSO8+%X29_'%1J%X$I.BY(,
M-EW@$TJE;KY[\=LO],_M=Y_2<G7RAJY6O[BPE3#S#0LLN,0UB!J3*NPF'*^>
MY%;Q1C(0>*/P6ORPWE<]*E1L-@/H[=8L2!9V=GTTR5T1#_QP.W71HWNG9C=9
MY+(^I,G.J'IRGIJZ\T0:T23K<?6OK8Z;@ZNL*N56#O:2A"Y%HX@$UA)16'KU
M<&FN -!];J&K+HP>EJ$QI-C!P/\<*1EGTOIL[<*R.T3Z64@P_NQ0:HWE35'C
MD:TXDE8"P2VV+($=JQICR0PU/0F2-NPB)+J-6!#S1P^.K9K<466 JCXLRFP-
MZ?Q];X;PCJ&!,DQC&Q6WDU);IS,H,*$H"TT[-YY(5@20A6["3,IAI^1^X<.@
MP(L6EPD!5:<U9J8$Y5YBGV0%)C%#W8_/3" ,L"]JZ!7#?K5ZD;P=,66PPJ J
MIC$]VD4)]2<3ML(7C5\.;Z1W)>BAAE4 E\#W@L=T>'#^:,/_YO>AHHN)/& 4
MJ(7C] CYZ8V<@ID1-(DV-556PT3 QFA:*KOA0L&)19YB6>+PBYM2C'\<TY@0
MSI*DPU2,#BN#5,%*'M07(QAENAYUY72X VA_RA$\+\"\^L_@);0=I22+>->Z
M')K-3221'VU.5GSDNB<]:MB$ QZNVC#QSZO?KG!P45I8'"4NG$[4W=&=NI0S
MX\_#/O+Y&[./O.'<?_.QG-?KX,>_MWG_M?*O_.K7"+L 0>GP8T5ZI$TP+$ )
M^0L87>??R:K_ZDE-/'T?!OG78$SK:C/[*O[E4EES.NG(@0B?(JL?WLXO-T!N
M_7QR@@:3]M/_>O;M%Y^A00O_?/[UET2&_5K("^Z]_OB:0JA/R WEW&\;F-#K
MHQ$YCS2AX<Y??OMETC@=$QYM%V8\'"AMY[:Y)Y@[!'X2_R(=.EOY5/8\'#!(
M],8^%!YP$%0!U&4@(GWT18Y"[J#$#XGKB)&FZWGZ('H-YSRDIGPANC\<<9*/
M87RFR"0A8&J<R.X\279LRPM_6@^^0K]'-8@-:B>,'H[CX/2^,^W>#[S>QUJ^
M?W)K\IX/T& ]>#/<E+>.:0VU*QMF$Z2@R3&>V>V81^DD,H]6 VY2-8.S%D1R
M,.#^5OW .O%&;BMN>-QNM 5!RR?XA^#.R3IGS)+9U#%7\?VO+R%0-.:/+=%=
MY9UTTLW:K!R90[12%J_]$(N:V#7T7$G+9Q;ZG3.- -N^7SXHV*$. &PH-SZ<
M,K^7XH[^>?;2.=L@Q.2WE1RHF+7B4VF'B0.W&>:"W?DE2L3W'+:W#6Q6SO65
M2$$DD4LXUZ![[A:AJ%?A 6\=)-#J<%S@Z42Y6CQJ*TEU.D@>:.K6E1MM71V/
MK_*RY430?M-V6W0)E:H?$H#A.]AXT+5]&UYDL:K=-;"?8:8R?ZIB,^P&"N88
M:(N^CVC6#A"$1N\3+ #%EV#9X"_A05>#N@K)7?AIP>CAI/R-8\O;JJU+[33$
M++L9(?Y^*Q/CHJW)3DT1)7[H//Z#5P=+B(49Z'M(WN)\AUG?< !,C#2ZM\DF
MA$N%5QA":4VM#@?$YZ(8MUB-30<L-Q1Q>UY5RXY_QSN^X TIJ/#D!-.UB>LQ
MUD$<9]DFSB0=A_$5_OW[7\+/._0 <7F%7Q:K?=N IC/^NW.PQ80V-:;T2>;&
M#S5M_4G:K*5M[2**.=B1DB]"7X/QQBV'KN,F#!WM I9=."5?L-8E7P?O$ F4
MD=&?T="8^0]/LW=;R:3$IHH.0TKD7H9,7057 -&L9C)XEM8,MJR#ETSW &."
M_C8FM9#.+>Y3^ !O*TOI1NG9[['?"7;;"P/3Y_&E.5G^Y8\_OF"#>RX=W*AD
MY)/'VD+=ISU0L>=W9IOCX7I8 \FS]#=ACUS?K* XW 9O"GPI,/':$IW,UHK#
M)E^<7*3\V4J"IKM[%C8?1+BN=V4P1:/U;*P\K>%$5167&J7.^*3(G2:<KM\Z
MM\>&!33PLOC>B)3/II8'8BUQ':Q'+3V$NX^'P?4#"LG$!31LQ?2D./VVHF@:
M&(I@GMO&O*="AX]GE%8Z8]*53Q'V]L9#PF_9Z88Y'M4)LS/*M9%X2'.Q=>).
MT*\@UO[[S\GRN\),#[QR&!@GNO7'W7V+!A?,:*WTD^TZ?4_!L+ERXK.+YMX=
M'JQ;5Y='-GS32#K\9X->3IJ6K:AZ34$U.&UA"BC52QL<+HS=)G)F#VP\QV<T
MOGO\Y-C.A]%@XV5P3*Y;/)@S]NP 98NQT:;*1R[C$=ZT*4^:W AL+0 M%:OO
M^3N_4Y 6/EW@?(/E8=\0JJB[$ B@U\/O, PX!(3A,: H0(.!#;JC!$:FC16F
M";T1_)?X'#ZX8K1@WEF>X3V?Y>\FK["X1@*CJ8/=A7/J#DPX;#JW3:+GN=TP
MFX^L&BFNT/7(].0MY'G!O,35G"+DW=A9 PF=>.B\A3O?.0GK8GPA;G]PCTX;
M[:O5BW 5WE$,XR!P#C0SFB@-+F$\@FRN5#.4=&\"1* _"*-OAQZZP/1B21&1
M#+@-EF:SNC-SBT9.S%0P#1 \CFZ"[-5<:%3V6:AMPL'/#P?&D5V93%&W8:.^
MYJHNF.@*_)+P?X2 .L)$@.^(036>L)AROH-=4^YV5^#8[8<&#^?P43QK9&KD
M:<'(X?.L$PA1$?U2*-VYDF:]7>V#)2]?P>D0LSG;"CB]!PK$4%<'/7*ZJXVV
M7XYN'HZYOWZLUG'I^7\R8-RGW/./27$T)X@%,CO]#1AMEIVQ[(P_S<[(1?VV
M9-J& (&0ZLM6N9SWMFR51]@JU,B!4G$F,X$;AYSPROMA.5$NZ)TMV^01M@DR
M+5RW$(<UUQ1*';I*\_&@8+1!4'B(K9H-A68HY!+B3R#A#)]8-M"%O,UE SV&
M2P:5#*3" J_KICHP&R!!32"=P3@91MY3\IS++)B:8^:_MENHS-[3.Z+:Y(YI
MFV#N]Z#.1M:,L^OP+VQ@6$WX^J-F!I8B3\ ]<T4&N%U:QQ@:A2EBXX240QA.
MA$Q1[MAR&5M3B#_M1F1H^4(/(\NDR#:!BT 5PX?5ZFD^L#FK@6XN@&UK,XN)
M)'#(GN@KI^''#':$JFTFI5ID"T1<T%6<I?97SB!NM#P9; AP:CX8VSF^X2RP
MDW/9F:2P4H29-029\JX#8 ] >!3N255=?*-#(Z,36%Y:F0W[IG:2_3ZCH)>"
M6]+2%Y3M"F*HHZ+M%C #-+,%-;EP 0[),7 6=M1W,BYZNC3A?5,)PC6MZ%$9
M</HF"=I 1<7T&]>@H>C2\M]2MGJ:]OFGG:V_9PY3 R>7-N?[RMW,@.CF; 0V
MXT!YJTV;G A)8<0^X7*XD<\TO&?CVZV)/85?KW;4*MXX)UU.88O7Y8841^G/
MJW^'2^(1U3%&:!.;U!)#@]=B"UF13EK7[BOH[-PB8'+9A$^UK^N+#]W7M1A
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M.P!KENFY2UM&E!-A=VU*1$%SZ[1IGC)H_W3;85Y,3G;H*0*:S$JTJ=,4N*$
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MC5N[6[UR[H I.LOG46Y!;[Z\=FAEA(6'&^BP=BY4MV+9C0 I&S,P?BR',/H
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MZ[QE-IYK#&A9[IX]$J9@CVN72\()F8$\ %_Z>BBA7\&Y],HX;9BAD';)<1,
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MJOX&],;PWL^_@6Q/?Q,^"[!TW@GAZ>NP<?JH3;$CI82MJH)1Q)L.R0@?AU,
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M5K^1YE5]%.G9G!/QIDN@I'RRME<GT4LLW>[&4<BX,VU$-+IF9B/L'RL/1W8
MB7S6U4Q5QY>X[S6?]9:%^83"P[=\X[EWRJ^4MKY_X[<9W M7$>=/"=.&=XAW
M?DN751)@L-Z&1B9,TV"QV&*P-&5N/=UWRR)QDT]MN(<R#D#+ OK^6!2LRR,8
M2"LC!B[7T#66#;L^3BE9$ST+G0$--BI=5L&--P BK'>NL8=4(RQ3XRN)NHWC
M<T00):X=7W]+.*,E*_<T/8M?-&!XA0:1<D7"Y\+@->_<*\+.T>*LFC^&!HN_
M,32!.+CGO'4(J';I3K#5XJQ1W)%BU GC>'XNZ0<6>]8DODBSIXU/TK:,[4^R
M85%C/BFZF^0Y,]F3U(F$=VF)'MNA/*<5A>W'D*IJ%U3<_#]18(:TS7BF&#4_
MCM%&+>%GM7R8EW@O7I(;(U+2I4G+1+XQ D]<;L(8C9*7BV4N4FQECD\;AJ70
M3?B*(+E8 5&X'@W@,F8AR" ;*%4.1H75&&KKG^*I+#E:V(O@@8"B#>%%Y:"7
MXRB^?SW\Z)!!\C+^5M7G/G>_<FFBGT92C[1(RK67TKY5/>/7VS@ZC-)2&K^%
M$S./9^LV1 V;$3<ZG)QUW=XE6S$1>3QO1_XK#5;DC%-P@C<+ Z,2,R50D,/E
MW62.=G SQ9W@Y"2K4MXY2Y0J_L6[,S-CP=#1F9Z>^4_M=%VHT^^C3I^XO.<Q
M,!GV; &?GYU!',8?\!*F%0C="*8K+57T-RC>!84VL#UW;5<S8_)=5M<MJF2H
M<)<HU\Y"Z*UQ2^].RJ]WCKR/^. +,?C'L;4>15J0I?H$EP2)@_+Z0:5(V0JJ
MX!5.8RRT89(!4)Y$F@]"74A^:)F>X61_DWMDMUH\O[3G#OUGA=APK>L>3FG/
M:O%\IW +7VU=K%=RM1N]XK!*&+V#D$[BH+3%S;'&$JDRBV*X5#SCW;C&$@DQ
M3XS51JHXD!X5G8,+V+$T5'#C>KZE'=3WP5P 6@U.VF+&-K%:]<COF4B)3[3#
MT]<TGKS89JBMC1UZH:2LH"1)>R PC9V(HUO02VSC ^DA,*)2_GX$X16:]%')
M9LZ0:KU6\TB\3\RI8O)3%!]!]5.?@YC;T84BQ@@ &76] ;MFG'1\L:[K8-Q1
MTEO&,QF"5.G@0WR,[#E#3:S%P*+8PA;DTJ)="@I*DWD_IMU1#^(XGI])7M8$
MH0U>[*CB>:*V? :]HEF]&C9C]VR4M4H6M-NSK@JMCN;Z:O7S$%5/9(+#>]JU
M==5B097,#.HM.Q1=#UOKF@(@(EYV0M0)A  F"MI&3K:1LQ"-;^JCX(V812Q=
M^#@Z'1:6Y]&-B*GKK2NWT)VPI*>>Z"G_,^PN9<6F#0?T; .45 $]970&P[H+
M:X9PR+(&)R?U?:?E#(D]($-)"\0?/70X8<6",3%Z/A1,KS=@$43_;E@+S4?9
MAB#>DQ) QMA%+KQB1']]']6/-:3): RA-'/YC/@/QTD5BFQ%GW=;@?4!A$>4
MY_4]'1,3OL*S]'HQ4:'L +MHOZ+]#I,7\UD9N2!^;]>N 1\!U/E^,2#=D8 P
M?]BFPL0(Y6WU64\QMV9X^B(JQJ:A"&1,8J]*GQ2,?=OUFFISEC:)K&]: 8NM
M&72KPW">?#98?V1'#-=9.]H46 -"/%_+?4]AM\./3=EU[5U-A)ES<V4NB,7A
M<!K*SN.A=>UM^\IELDX$ 9VDG1-11SCJ('/$*2,5X(I,>JS6([PN1HQ,8-=
ML S'^EW9H>Z/!+[FL$UR<GM70O_H;JBO5B\VF[:#)07NI7U39H'=&^B6'<&
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M;HGD[D(0\G>^+G0TE]$ 1>%;M8IE0P\6K"?@@N&]"?:>*;2]NT623"#('!!
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MBR(CV<S$(JBWY.S>D:#>*=KK;;M*[6FT+ I[.5/>*\)4XQI7PL^KU3^D5QB
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MK;L0&_\8JU.*2(N[PUYGQPP7>2B<5?.E;<,2%?824J;7XJ61Z..]QO6[&>2
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M,L8:[=E)M1T[A^+O]NB-6,Y=U*,H&$KG'T"KV,^#7+*< T;3$"TYD<'1OM/
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MW'@: 4X[[,Z\[FF'?8(=EFZ9V45=+J=3Y^Z\H&E/? KF&VXUE%AF5CK0P,=
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MRVM:B/[ I.4=JKZ2GVK87-FC<,Q0?8R<P'2N?4[GVO/*8 >R&%";A%,^@W9
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MUL1M(:<KV\]50LF2U@98QY9%N"*9?]HRLX?%;$)0?!8[X2,;EA/8;NZK.7K
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MFV_HIL1QH<OF$@(*P:N0-* B1G&73:,DRA(V".,EK;(8W^! 23-HG&0E?8>
MSHO.=%X-5=K$Z:&SUX]>B43 29@HM 7464N4?[LW%"I-_,5/3)B/0SHNX]-)
MRIN >,S4^1?9+;Q'5#X1R(<!_ZS,@TSGD'A^YMWX:N<A]RDB&3%$\7.239A"
M_42HR?^!#GCQ$A0<N?.Z=J;FP^S8R6*''@IA<==0:O]615K!+\;LFDW)'J^N
M6OE>E!E(-"!R6;BY#]$9,Z7[(7GAF=9J_.+P@5J_-A&^+!?$[;1:?+#FIT>#
MM2QN(Y.M2,V/;BP?"?VMH!X2U@\6-F*):NVJ'#<0M'Z-&5*.9)X617 -$5MB
M); [!7>5 %(QM>D^W3$,,L4:Y M[\0K17.4X?X^]3%D#YO86"FO_'*N^DIZ5
MO(M6S;\B90 -9)OY9=WH&$5CUK]'8A;>1\-TCMG485-<!;CJ1%MV7TW-22FR
MJ'Z)B5]&,6#34%Y#B-H9BHC2$)T)VRP<2'YS4?-C2S4C/1K,IAX*P \H^=)Z
MF']ZO^G)#LD'4I$M:($OW9PZ43 NUO4U%(KF(H%A.=Y16[:,;Q&R!>"_ 7Z
MB+6<]ST9MW?A*D /_>$<L9YB:5;"(IR>?RFY%\\8KHZA)Q,PJ'BR:9MWJ3ST
M@AA_%<?.S(*6^AO9 ^0_ ZN_2#/0;-LR)XO6BY)614!_DJ)8+)I>LB1]M<D+
MT<=UFERDU(.?@'7A#3M0!V_]TO27I!.#D@4T/_Y7HX\]KQOO5,",!3]K="J"
MV82P<ULLB[R1XGA)*?,F_#R9+LK@#:^4S!U+<Q$O>LYR\^G$68A_ZRHSA:=#
MMJ-]V6P[7!$\&8^'TA=C'L.;E8MK[VD>#HT67<L/S;YT\O2?C^V>C/<']A-Y
MSX(GF['7Y?9 C-IPB\A6DN]4B F6LEG)U9(EG,A;Q41?[#M)OD#! N4 @]92
M"+I"7=6HG[.QT^-"J0[-&#5A (4+--@3";ELH*Z^'BAR.Y]P1Y6]'%?LHC3)
MV06^C!)*.!NO @R#(?DMEX<HOJR;MY@K<:_(TVN%@YKCO-))S\-%,2_$!$5N
M]"LZ=LSEBTY+6T;T=8<?_?82N3MT^J/RN*HUQ JY4RKFHZ9B3DVACM)L1HGN
M%AFV06M=>(43AN'S6&R_ Z:XZ2F87U+;#-FNH"8BU:Y,*GJTD,IZ 6TEI'ZH
M.A28&1 GYI"( DJ!LD6%'PN!9='2V&HL$'I?PTIFK:J%KM;Y=APU<49<10MF
M1GC^^BQJ]V&T;QH(V6]G3QUE_,BI.YSIWB'GC?8.B9ZH8HG\*43/C>N:.F<D
MIY&!^W+?+NM11;WFN('GR\)97$'+1*JN-[?'K>$LK_,E3[+^B:85BDH[N<=Z
ML8 XO:G<^YMUVKHTI_DD4FB@@B\(/]UD.#H 9+PB5Y=:Z3"3>-_X*(H;+EGA
M#23#.FUR5 =1+R02@G0,0Y?[$EZ"?)4:X?KRG*FM&PVD>'7$#K0FN<V^6G@>
MJPU:\948RR)5 J@W+9ACJ!(*IJ@'_SZ\V\Z3 A==.4CX+@VJP/6,W(PUZNE&
M*AV=W,EQRIC>@;G.KV9U>%>(H#9$XRB-;-XWJU>?CW,^G?0?\V@[\3O\@!0Q
M@6,R.%C%./BE#G*->M&+M&NE&^JI\RL-%L,O.-6[?>N&)#I^@?:)A,E<>TWA
M'D@RP68'!.D<^CT#;$+[+@E'O=[XP7B[O=-DP"#D,N<FSL:ME0E ZPVQ)WWR
M2#Z/3?&1;0SA>%?%RA]*[]\5@R!M[%?S+1\N=!MHOL>]94K5.RW%N6(,T:L!
M.)LYZ '!3S4<X7G7I"/MO[;T!P[KM^$>.WMCC1P4.4X$XH^I>A]4"K".@^7$
M$(!'?^+,GU@A)U;(NSKE__4_^9@1@ *?EE !4>9&3G]Y96'U$WE^CCJK@3"C
MJI=QU !# G:"LIRM@;X+!0*^I:B5SYSH>Y+AJ1SZ'B>ZXSNS1*9=^4EV9<BJ
MDB=<V=-8]$Q#N4G[09%7)2HN]I@EC-0B>UF.7 /IW Y*1_0=OTV9^62D!W?:
MD7=F>4P[\I/L2"/WSGN*2@H4B<JN":=;ZCE+=[_?@)1;(E2[) U'SEW:E81'
M-&VKZ$2H2V8K8UX\%_*.U%$/5=U+83:@9A-_RW_7C2#P4(XWSKV#<GU- ;+C
MK.384^P\@:3JY"G0/K+5'B*D3!&*</)TDOBX,\MVDOCX)*9B>8F"L/!L&+O1
M FYCSV&_GS=UFY>MM. SQ3J=S/1->,9"BS >K^_=;%.#QV]M\'C\JQL\)D,W
M&;I[8>AV?:*JEE@_,*ON>CGB$G&&?2ERR?!(1O/R[MW";5 %]/X']3TSKW!$
MZBD-$_LC\(,"LXB_(-HAT2H*ETFHA9GZIF-&$_1M=U?U >@WV]D7QW]Y" 8/
MT.?T'96+@?%,28:$<H2;C>%;668H#$2*:<&0W\IV3R'5O;$?4TBEYD/[Y$?W
M9AK4O,^NK+G* @/!I16R"2/I%/:_/J1!T%LCPO+F;4 7A-+,-26B2;/J3JW7
MR41\ A.!$[OO+I)\QEC5LA9,_J#M@E*GW&JT=/2_8);9GW\A@)'?W:EY"%H$
MG%<=WH&\&:EU*K1W?R_#H%DBA6#=L4CN#[%K!PI.<\<NI'"11WO+4#]%IF3Z
MA7."MY@U,T[X=OP@\"<%;,O?N.%W=AI8_'XD/S2B633!'RAY @S6KXIY2 ,
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M:0U;C>)O!2R#$+PEK:?60;FW;H(/Q11("5B>[!O6\C;\LG+G3 BNK;@B7A-
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M ^R(1ZZUZH7WM?^[H":!]E*,'P[B$H5(H=SWF)( +?AP+.9/?#%-!;ZC_S(
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M@ZXV:GOG235UF#9,'A]TBO-.)O"&'3_/%?POG#.6EMX'[&N=12H)X"HX9^7
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MT6U41+H\&@:?EW$1)3<XM]LH@.\':>85,)73= 3[,?E?_]^77J=[_#JO32&
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MJ ]K[=?\AW^@>9H'P,9:+'%5GK=T8$VS,C*@@#':P'FK%@MT9';+T[&V-)N
M4J =Y&ZLL#)LO12M.6^<XC@B#B-.F9R&G>DWD!$+7.9U1:JP,?I?(5DAV6TB
M6:+*EE>@*LTTEI8%Z,>*(^DW9<Q4B+%T>/I"MXX04V,V5HAI):8XZLG]*,;(
M)^C3(+1 88YTD>D(+&VRMFMI)#GJNP/_%CZ2K<S6+PJGPO/C6$BJ,=LK)+4J
M^>0'PPC4-O+D8)Y!% -E@<5)[IPT8',S(&G%BJ"C1FH[%W3%FQM4$?T)?PMK
MH#A*L2"KBS5&G");U/"0O R&*"654&5C3HA0Y4JU1I)L6G$$\EOH6W4#G-:?
M\\T!O-;#(4:Z I8)*/9.F:R$.<%*(>7&'"LAY94)V!$,N7#RIHU[I%7E\U#1
M1$783+/WA?CS(<5O[J=2(<PU."1"F*N5L4 ^,("QGY%H'(!]J64B4 J&G(AN
MQGY!91?C<1P%;%JV='Q72U0V/\V]*L&PJJEK@M]4C/E\)7M/QRH#&Y8*HG,=
M31TH$PV><^F.2<L)8C\:B2>H.0=)B'=5Q(N'.PI4DA.1@;X:_+>,\LB4*/EY
MKBAXZ^&<J[0*4'.!DFXD--&<_10:6I4W=:C\,"#E% 9_5[ GU4G -!F9.HG3
MUYD4ID#824SRS&^/J%A\3;\)^37D* CYK5S_?"#)< &I2$;:=^W 'TD1Q977
MF8QRX%>8Q\]E 3"[&Y7@SJA:#J<QM*TU7TMQYU(?SNJBE+:$*G>*(:S.#;!%
MW-8^)E5J1043M0JJOE9H@8!9$:I^454,P1?UD%;+Z#!P1/PXCO!MS'\K?<C/
M,C^Y84\[I:V%J9>DQM=.;OG1*"J0Q\.^J@SS43G=C/V,28@UXEP'CQ<D.FT/
MG7V4;.JF[>N4,S-#2E/Q8^5.CM)9"<0(PW TP2J;K^5-*#_O#M8Z'T9CLH%
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M8224>4[E,^1U\.,)*$T4_^9P"LLUCL#HS@.,M5!E;&#F$]S#>#!:W*'RA<V
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MR;X>5@_'LUPYDTIVOMB3R:^TQY<+EFR$L$AW*#1(U>D1YUX;C3S4^2E\"T6
M1^-8N4*16.Y]1,8CU:,PX2,[^2AG'D1=OO %M>7BMQL"5'Z6(.U7X#B4QUF.
MRMCT+RV"X4XY!E:)!6S2>+#!%/G,:O])$&0E'+%+M[+UC9,5?Z:]EF+7K,7Q
M>6J&SCU5+6?#UEUY'67DT6$"XWNMXML5W#P%UOED+JRY-OYTW>_5C$77H^4:
M<E:WF$B<W!9*B#&9*VF&3I@6Q>?+A.!/X Z+J% %YY&-Y]C*(J;^/L;.L@8
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M;#"=34VO)M(FG;HJ'84'T#0-+*9-."=QI;X@-@?AL9(U@.."I5(5S&*=<&=
M)_TZB*-95*'0[:30ZT>)!\Y(KM?_4')R_NH19ZYEW1I4WWN;HIB)G6RM>RY&
MGY!-ZIH2R$A04?YY9Y I9='J/<(>I/H.0WQL^F++O2_&Z'_4*RRXB[W4X+%[
MDTC%80W2!=>0#%S3-T)#(QM\Q3H18OVZO45WF-BQ6/).'3G%1T;C.*HO'-"N
MW[+I<UJ-X+? KE1=#>:M.;-4YQWU#?'1>8#F>5*P<P)/])@<+FY#C,AD5>01
MG$&?BN_1X09+#IPOR#E[S-6L0#>Z,8GSTYC6"$(PP'HF*IF'F\(2^/$$5B_
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MG"G3RI:P[C3GTA$/;#"RTU<)T$*AP=I@P8815T.G>4XQW@53WC8GF@17*]^
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MDF[;82"G%^\_GGVX6IZI*[Q">,4V\8K>)XW@/OF4WB6@< RC\6;PB5X;<2S
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MW1#+7J\N*W?-\)E\BP-IUF.X; =203A6<V2N7Q;IZSX"<F8T0-!H@1?0Y3M
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MPOL(*6RHX&#-!'NS<-S1P+H'OL_0 IM@R8K,_7SS= P .%  H !  93D(*
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M')!VUG5#'3RR3'9)3R)\XHHJV\LLI=>?&65O%K85?%(T[_8A5'[=X#V@10O
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M:-@B",X?&FDH\'AQ$N=5O0*1ZH=-O=>/#YU^"OG?Q]);3W;P=OF:JB0S@6G
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M?./-/*8XG\=0O>W&>)3AT=]\^&;IVZ8@" !H+M,N ,T[!LW[ZWX0@-V=<&^
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MY$ F)5AA% L.9 )D CX%9 )D AL?R 0BAN?GUCD3([4)>6XYXA(;Y*B0R(E
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M\JOC_/-*B;-%U3;3.E1?;NG"K#4*P]SC(%]KFO+UXP AM*09/_=LA,L?EM<
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MLTW*+Y4NR4Q@&C -(!D@&;@+F*9PB?[E,]GE-=Z\4W^J?;/@'3*=OWD!H#C
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MD")E21'EB.&!9#'!24!<"8\,9A1Q:K5TBD4KY';"7EN2(HKWEG8:,YP.4(A
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MU;PY[:AA;Q9^6?/"I^.TM7 %(7K""STE8^C-J;L >(4M.2@"4 1E.<AX%,$
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M3X9HI$K#@RR/!NFZ_.;-\CAT /QO8%ON,8;'&!YC>(PQ?(PA!:%28(X2KCF
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MB)6J)^78+K ;ZS"P.^F\ ?GK.FAJ1)IX>] ;;AI%0E1E7=MI_JV83$KSUFO
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MO;XT$0Q79_K"WE''>N"S$:C YL?].3 K[ FML7K.=1J!;'C.$QZ,!"N=I*&
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M;,DC232JRRX8PWJ2M#:^]M)ULVN&K$SM4NOW[8+O[Q^3IE,>?#03!MZTWS6
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M<QG+'&=$"I2P/$(DUC%BJ51(2\EQGL%(,?> P@.*00HQ#RB&0PL/*#R@V!-
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MK'>/6*^GC6?&GAE_!S-^#[\KSXU?S(WWW'BXM/'<^(5Q8Q/#&-@@QN'<6<^
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M[VX*%T\JV$4@XPTXIZRHNXU-(Y8F84"3IGC=*BQB"S<!Y.N _O-9@K^)QL'
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MV$'IWZ#5MG7S&L#V]=70O"XMU4O>E].4B), QNL)T*DO+4JE9I==N4O;_#$
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ME[4/D]/BW06LV/X,IHNK9U?U+.4_P!Z Y%\TA;DY_2?IBLG"#\LO^Q"^KR?
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M^J\7+XJ?7_S^XI>7[XK7OY[]GKU[^R+QNQN;!W@?H &(P_:(M]<,9[QHS'N
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MKS;!:WCT_FW36STQ<)R&>>/IP>'$/<%/V\O1Q%S7BSG<XV/P3[O[J9;8_?5
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M.-_VOQS%\2[2-@$"AVV^2J+\/4#;DQ9@=[@:L+BI.CT,ZJ&]&-[6S%KSR43
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M3U(*M\>8NASWFN4F+!^:DP*>&I1 &YN^C:U6O2_?$&392**4RB X(B68P&5
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M9L[7$1;W<(!8,YZ%-&/4?#'M$3Z(<-YEX40Y(T3Q[923(>2,* 1 4!A $1)
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M>>JK0#7UWOJVMA+P@WM5O5%^&3T<C.Q6F]Z,C'\/I'AU<$9>&]/E@ Y&841
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M)I()4>#-P^P/.,;S_.QN+]F@A%;=1ZO(ACV%ZU@L<3"#GL+UH83KW'&EM5+
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M9(8]1WXY\]Q_>=BA,TILZ&2'J-Y)$,2*P2JNN+4E;\GUBHA$RZ]3[IPS/K^
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M==KC;Z@W&/Y]W S<_8TJAK/ ,4(I1.<=MH1^6JBTT3,9,%',U 6X& #PJ1@
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MO4WQ3FD&)] I1:[85P>D?#]FZJ']N+U[=_EWE I09XF__C]02P,$%     @
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M5$O6@9:KN^DM BF 3!,="M(@JR]7(/4..BO@<7BR. .EFSZ[*XFFD.DM\J]
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MF?>4H33;XAY[(QRFES:L*,^1"PT>XX@4J*_:+^A]A@&+1@<#LEV#OO&-UQL
M:5L)/.7?2FM#]AK2  0/<806#Q[YBMAM$@5RY@2-38KUY6+]\>\8$5ACIHM[
MT.^A9)^BV-DD6WGEO$NCM$2PWAC? Y,F#T$OG^]K2C?KLH!1]?[6,">9>9(.
M1_5O4DQS*C$WHVX)^D^"(G^AIDR%/2U1,FNB:JN6[9Z'QI 5HG<7S1-&T_7W
M0CK)9#TL>3-T;?"J<2+K:H"EE\&0I!0M-M?@21F1=#!Q^L@FV5Y]I:WH9,G,
M^%![9GPP]QZN8L)O*6?H&HV8HB3)^Y@H;TPWMNIR)&YOB0A]K"U"'\O0=R/L
MT(J3*.],U.A@L=,OKN2NW=^0SF,J<DI8"I!2W50]CT6IA*GMEZT'259$U1%*
M!U!1U;IBJ^&YL!-$Y8">=A]Y-8Q65TDKZ;-JWX^X9J#N"F$]3C*5UAU0UFNU
MN@MEE2NJ2O_O^$>LQT5Q;=0,C/6"4V,YK!-4*(6IS UU4+ (O(:5QM2.2\OA
M]!*]^Q69N\Q9D%HW,*N\='8B9X=5J;06V F@*67^H9T9V6$IBVZU5>&>=1:G
MUC67Q"5L)VC6*2VI<\=.#$WIK8^J\]&&9-/-5,C<MUP4-IIEG69:]J.Y1-(R
M:G;F_W8JG+2/B42^$H)DB9OB]B9B;*_PZOG#;V/"RS2+"U)O%A/&ZU!Y)6:J
M8D2AM[K#&& U/25OC$AZ.APBK]A/T\L+QXJ0)-4<_+@66OZ3-.%#ZR..V0>U
M8ZZ[8,KRIP2MCZ)9]0B324L5FF9SS-@7$E/Z A:2%W+5\P7HOD3CF*"A]]9,
MBRF.?4SWZ/;-WL-?;;W9XM@6@)*WVO(L*/(M[.Y@@HF2\5A(;A ;:LZZF6N#
M4-_@<Q:;-E95,\[GS@/SE7N:PMY99';9"8)B,%1N2^;YURMGUH,FC92:0:VM
M,&J'GG?=BES5$'86L+:U^Z'ZZ#L3M"V[W-ES;/<&3&RSN^!8WCK%8'7P:/[,
MT4?$U@[FLM_-.9B%QZ16>9D5.IJX2<V?HB#AA^F)3YJ6W3.MVMVFF_! N)9G
MZ(] :WN^Z#JK&@/8Q%ZJ-.NRE'6RB8WC#<=Z;C@^@(N "U<]S D"BRL[W'(>
MHG19CX*EFR']7HBCR*6E:_CO\,;;5K5T [U\O-A9&,I*"%AV8&\!-;?XC7^2
M"XJD@X.^776[K7#TN[)Y9*F398\;1H1FDM*M 4LKY/!@D<I+'3#MA$;]_JN:
M.P?#=UL=;]:S=TI)+KERY^*XUE6M/BOX\ "TYC:L#MVN+2W<J=U]>*!(=(R)
MB_0Z]#8WG#2R_8(+7N:-@_DJ#F%K$V?WP/4F!*'5*^;WASPEQ)^"?EC_\ MF
MTTN"*8O#AP4B= !XC4:RZS4,N*%S/+VBW%54-,OB]P4_Y^YUKDR+UOH(HZYM
M#9RH.<&U/4@77)2P'%3PUP8F^(.KAB#Q69]DX<XR;ZNP6;<D;F*RJ#PK5=[6
M)6)-YL+R):$_SHFFQ/]>WM:$>WAGHGGE<TOJ[JH[RO?"J'9QK)A#SVB^O2)?
M\:NN$)E[8,4\>K/R*$J]OMK<Q+N6@M@U+&QK(L$[]"A=7J$FC4J5--0&'B@^
MGO!Q\426][2E3Q$#*&UO)'B1IR.]!)3>49IL[->=T(6P@SY0Q5;MPT""K4(W
M$U8<\U@VD7-R*%F5Q.T[TE_;"D=@4Y4V.R05N\>Z(1#LN__K1VC +WRY!?M9
M+,FE[;11\3*'[77$EO?\ECU_JT47$[O&(M1@%(UO\#9."+R=X;=8]OYV6FFC
MH#?CPGH3X@F_$G88/R,?@9#<15> 1G]\\X:(C_FG?G9=<QE]M<=HT=BHZ=NH
M8YLT&UH;KQEXPW@%Y\8!<P68X@!EA-V-KV L['OAD& O?(P9OZ0[1 P%7*9Q
M](PHXJ7Z0T1F98RW\AQ];_QAH.\5-QU+&S</.$0@91%:ZD:Z,XG*Z%;HU?D,
MVW\BM;0N9<JI%Z9=40!R#32P17[3)UFS5'JW+]L-1-B<@:IT YW 6%7K:Z3\
M-THC1URU724@SS-$5J?'+-94;^X4%SB0:PUB&YM-N+*.B:L$=IO"S$>EKK:Q
MQ!WIS;G*]78PBZV-L$]YOIN^F(FE^2K2/)ZJX C'K,+A;SW;9567>_-M_?&S
M2NE;TC!((2>GKD?>>E1DM;AMP6*]T(B3+!JYT]:9)V*_C7- 5,<5UES+O?[N
M<M[RVBP+-M@)6H-<8MVI&H7S <K5EYW8*0A<PW#P9AZJ!(HL14=I&:^,'16J
M\TL4EXO,5\6@5B9<C57+>AA$IJQ6'!RW4BISD]9ZH3S.YFS2>%OK<FDTT$Z4
M+%N()7K93OS,+L8=;1(Z *NN'MJ-%CM;F-"J%JH?U;831TOTE-ATL!.V#M23
MMLP#9\MH6IW [20[V(FU19.\W-5M)VQ=3/+&R29Z(?OC@<QJE7079Y'K:D5I
M1\1^.! 1JY/UXRR"K>FU=F3K1_=EJV9RDU[\_G0X^-7-H](+Y)^_$R!UX_;3
M=X+;.CE,LR/I@(*NRIEH+AR)L'7P[C,*8!GD^R+@\A41QDW38I39ME,/<O[B
MG=<FJ5N\M^,<@I26RT5*F=J! KL]3##@K4GAGK#^.#=[I*6C"AT-L'/WU)?6
M1V]^-X%U,J(XP!Y9Y,"3E3L*VQ]\3;&&S/U*_2<5%/7^Q[K9FL=0H!F_*8$L
MLFULENO43QAE7A3 -D3 0V4W6UB1UHC+>MC"0"]A4S!WQ+4?5;W,%!7 ).7N
MYJ5T9T0MYRX*+D3*JK*?\9,'?HX9B/<SGDQWJKL4.A@@_QJ_X@"L6D!Q-HNC
ME"8!X:5-M=6@;<DI6/17V2&+L%]8/7F+,/5^;5&Y>L U\D./7^)-GCRL0J:@
MHW'YS:V?F]GVS#<;2M(LZ:[M%3PAXL/JZ$W R/I[',)&%Q;)W-JR7&S&1<K*
MWDG#D5RL5I)MU\K+CDJV2,YEV]7?-^6QR&U/+.5<+?>V:B-3>/\*2%D*QKX5
M$0TV(W8BT2"L+_2'&$D6/.:F=S\?I*M"]2[0S@3(UF:"6*7:"43KPM!.^5.7
M6:%[L9_?A3N;M*0,@<+^W=ED&F409/M^9_,[E+DO=QNXF[U1Q7<-%X6[*1A-
M0!!Y0-S-GVBF &2.$W=S(I0DHJE#QH5 ?:T8_<:*5&A\C-U_7[%[FXYY;AIO
M;3;&,>;J9IQ/+D/]2$4E5HI1K6%L>1D=1HWE+V'X+=;Q$FH-8\M+<#,+(4/\
MLD9RBZR'^7=QY1&R "R7=0^,$3Q*F)>6UCQYDK,!ZX]CGME[#/\+EI?Z\=>!
M(E]D?BAU=3!Z?@QX.N;9EY_]=8QV':-=QVB720^_H1B/7"W4L^X/ I#Z,G%0
M02^Y/-3;:!P$(/7EH<6(N*$PH#A+1KJ/.0C>Z[Q_E5W0X8=$U79+AQL<U1@D
MM"'VL56DF%G-'F#,C[H!4S.KX+>K+C%5Q+M$;NI-+Q>;)LO#0'K?/!+LO-!M
M+\S^ YN-FE313T4,*,98]AS?1.9[Z$7"&_8$C?0Y;+[%PVF<4# 7>E$P_ 9H
M+/AAGWR2W44\G@KZ@C]<[+RM.X3).,QRF031B*.T*%PA%E/:QP 36W1(Q:6\
MK9$:JW5>CM2[O-M.7XRBJ<KD,GLS'B,_73-!&DI#%_I&-ZA[)/.@T,0-]:C_
MIE&!CKN9S<-X@5#A++1&VK)J)!-*LZED/R:<Y.5:3'NO8(/QM?4V)E^@KR@0
MT]KC]%T5FAN:^USXH4?YI*->%"7<_O0) AKOHA5A.=TF#A:V\02S^O[*FV/F
MA=EKX>=0DE<4 &.W"0,S?L5>]7J@.(Y+,R3]YV=$67:"%HZ%M<9:'Z'WXN'L
MB-+5>3@@EZ(+526M77IIRZ.24Z5"[Z(,U%\0S[5&0>\5$9BBZ8]\,;_U,/G9
M"Q/ACJ5C*IP'^@N)J?9-L>1))@S\E0V0G3U;SM4C=WI3_JXY W08,WXD\.;W
MJYBRQYC]"['-,7*Y"2B"L)MG'Q*HF;# .K3\BK<3:?&.B7!PLJ_.N5[/PI3]
M.U@M<$2QWZ8J57JT2Y#FHX(KGG1C5_H,;?;%KH5;M/Y@YU1F*O=HSEB.U,WN
M-A]GWHU1Y&FUMPPN%RNM5'K_=YN/<S"12Y]#7Y#UM:]?W-E\F'+_SB:.5==!
M;2D0];*B9'[JO  )?,*68E M#%(?=['V=\>O["S3>G6+=I^WG;@VR;?4$WLL
M%%\6_.=V(J6F>LHB 66<6JYBU.ZMKL=L6_<\=IA@V&R1K0QO.(M'2^9<:Q$3
M.X&V0P=7&$W.)H&V8!;HCF YFV#9SOQO$/QR-AO3,@U:&E%S-L6SC1V!)&3G
M['DYE@EATPBALT?UN(#_,G#H[$% [6#<4:S1V2.''$-=$(QT]QHG.S6+6I12
M,^K?[[:X/)"I&5ZW=W2M1DHU(^WL_J[]^.O!U&%M/#T[Z];-&_^(CD59QZ(L
M^XNR0*_&,[1V+=[SAW":Q742LA[V,""MHI#W.00F]J@,V9N9]67<Y=-AJ1X%
M7"EV-G)I'D6P,D][_/#=5Q3&\]07GQ%4<5U>=4\##'U!$2)>R"VG8 ;+*F79
M;;$J+*GU/>8_?3?Y3TJQ=X7%IG AD%PK6H^$+#*O$XJVXO;.NT%45R)G85.R
M&XJ7+2DL8G;"84<07CIO[<Q>:$..%&T'%[;[6SO]T<Y./YG-/++HCWN4)K/,
M/_H";89QZ@;-QP'2@ P*7BB.)I>AYW^E_A0>0;.? 0P??CCZ!8Y^ 4-^ 4I8
M#ACX:P,*_/'K,R>G9.=?_*U+8DKW(-N_VD:0]KUW!6$/WAN>)3,A:<7?72KP
M6J<.Y%3O,Z9?;PE"=Z!I":+L&=:L!U@E@$/=VJGNX[MZW]GCQ.^[\/M!ON],
MHHV][^7C78>6&VL^V"NK8_*>=X_^Z>ZYIL#<L?=VF1K588IGFDD/N6CG@8<B
MBS_'_.C&$/8,'2MV.0$'"F]W>E1.P-%1?'04<W!+=R$<GQT#W'KNRIR_JNPY
M[- 5[)163&[M59QCS]($LMH;)3N!-^OBW9J=SCESJZ9><=OH''NN3[V5K76L
MTVL/^/(=[;%Z;Q?QEK:]QS*_]H5;L$4^%@%V#KVJ2K<KS)D%>X?>&Z)Z;Y,0
M'W*V>IXHD"ANI_.HM=7H94&[\C;&4D&!AN4-:&RAD 5:TMP Z?!D7ICL7_%+
M><A"FD!8WM;$E:/>6U9P(TEY+K8Q2:14%K9;N4*HR61EKNFSE2$,XV^\9.AZ
M><,6GU.4(G8UY2O&793=-27@J/8PQY!^*3G=AO2MCZ3N:O?*PHR=QMI6T$LT
MP=$P!EL(<R,B=Y;2<(H)6PS0*Y)<"%&GNQG-=073%;/T;CDPAM+3-J1K@J"]
M+<177B92U>M0&#&YOJP2;I4*1&Q2-(VL3I-(I]FKO2C@R:OA/Q*":8!]OB1+
MH:_J9?)=+)-I+U$$&T21Y2%J?2#)9X*UZ#%F@V3T;]B4+U<43_BFJ]L;>,?]
M.>(D1)/[F-*\UA(M-Y(.)BX;\$B(8?\&8O<OT%S2&5;>5ILDB('9O&?^W#*I
M4.YK .)[T$MJ )>UM&7IEFZ:9#WTW6A6]I#-ZTVMTH<X8KPD1B0GM<?02GW"
M_A&/:,]GN>(=KNP)CY$R+TP5/Q"7$$2'\25:'LG'C\OA]1FSF+#-T3DB]O0^
MQ(#XO41D?4H0,+1<!D7J5-3:'L+7Z_H3BKR0\4OAHV 54.SY/DF0Z+*+?49T
M! !Y$?D^(YHQ!J*E^A:O_NL6#N7*5;K_\\?[;'GG[<Q04:ZE$V^E\D$J@<?<
M4MZ5:KQ+_>F%6^NW7<36<RNKXZ[+KL.I?4JSN;E?W5(\#CM?U<YLLL[R":61
MX=VR[UU'O)U\*ZQ2@D#=>D&NY>RW% 75]4KN]]]2YG+WM/5(5*QEVJ!P>)VK
M&8LH.U[C$":&//8H5XX',1WV!^  +M2ILYNIC, XAT(MDU<8MW&.;9-%/)W=
MV:-L^VUM\>QD5X/))X^I.5>V4&ONRN)Q=G*^OWRW6N_485V*1*XKXI7.%8:H
M.U35PZ)V@J!5?8MV-7:RKD?D2^/'SI7GU%+BT@BT<^4QZG.]?HC;N8NPZH&A
M.6+NW+55M6:-,'#NW$U2.MA6"[L[=]U3Z]"T=)9N%U<QU=TH;&+U+M3];=UF
MLM*(]]CG[ZLW(2@[)D%O*6!+I^WGRC=7ESL.8U#3G.#;F/39%!%AD:'6H8V>
M5[H'!VH'EN[]@&-Y4RDY'9]8BN;+2YC6TSQ--$%D[A&V$)95U.NK+=?Q)<*O
M($"@3_OC(7KS:(_U$G[1K3BMNZK+L8YL;Y4W!+*DM2!ZQC:18;VU!/(C+*@\
MTUK2PZVW>KG@V$O*V_2,K4TW+)%_ %$!PXBG$]VF]\GMJ@1!RXXTP;:.%*Q-
MI<W<DJ!N],*AG:4M$.\>_=IC*\D5KG8EK;11\!3#;&'8"W/OZ@&'L+.+([0\
M'J5TOJEUU$;G<[S(]IZI[BTC:*N%-;/J+GHBL8]H/8V[Z:7_50\\>$TWK[7?
MM*R?0]GI;6PUR\]RW7^_9GTBS7>8'%MW=[5V45=N=-S$P_%D886PFU9SJ1"L
MDVU%[(2KP5FMNMQ6U1>:U=X#V8EQNR)9NGA)=UN6HE2Y"LEV9>L%25V=NPA#
M*SX#31,QKQNMQU:6,6PWN YG(Q]"0JH)^T+H7+ 3(L,VA7BIL!,N4^:!HJ_(
MSH12"V3L$))N6Q&L;>>>L_F9;;F4*CV+SB5X=J.HI)Y.%[)X-@D\]PBV*/U1
MB"=9>;U=:3OW((4HH_$:49_@^1(8:49.52\3P>%2DF39,[(>)H[C@K'[X]P$
MDIUE6MK6 -'Y>WM $SR"7&^^&<(GZJ4%A?(P?=U1.HHM#K+ Q1<43X@WGV(?
M#"A1^HVXK;[C?&.N!Q\\"FA,0>TQ5HYJ16-],5""O/XXG3\!K&=@I;%%:12T
MK)TV*GZ&X=#;T]0#5>JCA''D);C(FG<E5KSJ=EM8!'D'XK8NS8$]D@)$Z26I
M[M[43''A>O!8PLV"JL,!E?MJI!8><17/ !T_?9O7NQ?W2AH:6TV+&'$;OS]>
MF772157:42^LSX 2O[I+?%IB6;,63C--Q8B+3[BX7#ZPC!IY!WTY [!GYJ4S
M$W1#81ZF5N9=U(NBQ MEY"GU,WK^+H=-?II@>5N-8L<8(B#0:0G7,!X@?V7F
MEXN?N+EQ()_Q9,KZXQ>*TB.^E #=[F.<B7OLC=([GI3(W[1N20EP=7>SW$AN
MBOK$^JE&;P>3=10WF(7@NFPK9WV\279TE6R+ET>@]K;*4E3D :)*VW)SN)EX
MZ^,<YPTFAF2[Y2S[#3T':SBD^SX[45&.9"CXLE:A"<EFTDX0JI,_*O?':][%
M^L-ZWD6WS>_/O,-9 TU5H[HWP$Y(="N&"GO#V1AF?;DH];LX&Z5L;$O+'3G.
MQB ;R<.VP\BY<V::<E_AJG+NB)FF.*BYQIP[0V8/)2%PKCEWGDQSO2#QZ#EW
M=(PV0=AQ#KIW5(PV+'(^1LTH6&Q7U_%KNI64\XQ [Z/@B6>-YIT-EF7G",C<
M>6,[E:D5W0P?AE.._>6B\(OBN3?J8QDI+%8A3WJJ@_( AMFK.%I@IZ%;Y'9]
MK,'Q)"!KC@&PZ'"-XZ$[BM.G-QZ#L<;G\$W$N!-0=#R(H.'Q\)GOY?BBMI;X
MY2::WH(!GE^X?\%LFN]2;]U7'M7!1 %56U=T8D<-H]+ZZ)"T'KBN25FL1]DU
M@:Q'0U[!JQ<.AZ_!.IYQ(A*1XR$@M> 2[9)6H6>1=64IR\?3)HZG35@UJU2M
MF[U-2SO1:E307=ME:/V90T;/8&@$9U?'+1@].6!/05.W1ET(F&S=1?"(&+^=
M"N;(8.H1U&.,X%'".!K#F.?9Q-& Q?[7:1S"BZ2#9#;S"-B3_811YD4!CB;K
M"N]P<8W#A('1F49;,3]%X.;-#Q,@_"ZZ\D(_R4+S_7':$ 5;3S<7E>D! X&0
M>*Z6 8LYX)*1?^.1"#A?$UX5O=$VO-$HSYY<J(5_M#S$ $Q7H4=I?YQ.%JG;
MN*2A$1]7 "8O!PL62M@E,@P?GV!L1 @*4N*D'F'U_B9*V/>3H<M%^0 27V>;
M3[0&0&&(2KG;X;"B/7I81R.O$LKSJD0BG.+VUKP/Y9FRNDJPC5FX'%MC#6%J
M*<(.9.EGR-E3XBBJ0B\'0P&Z#:SRD($>"\7./;:"1T)L@Q1W-,I+OZ5(*/F]
M.C ""O6=E>N,]6#*@C*6H6E]3$=)1"L7\CPD99/;4N852D5;7 XT61@'AJTD
M3JABI]B)1@-WH$XGAD:IDRO(@W%3MX6^1),:<LKN[(U2R! *9N=IQCWE5M=-
ME,Q0EG1_CRDSX?E<%I0&&2A2GT]I4Q-;2-_G*AH$8\!=T!X)Z,L\  'X\/[B
MQ_<?Y.<2*O7M*%GPB<1!XJ>')0P0><4^HL(48'%; V]@?=IM>1A.^@;4^MJY
MQ"J]M+Q>4@2JH8Y:?LW_&<&R_=?_!U!+ P04    " "#,&Y6GJ^)%$:J  #I
MP0< %0   &EK;F$M,C R,C$R,S%?;&%B+GAM;.R]?7/C.)(G_/]]"ES?QFUU
M/')W5?7,[/7LSE[(;S7>=ED.V]5S<QT7$[0(V9R&2"U)V59_^B<S 9 @15*4
M")!4S49,3\D2F<@$02!??_EO__MM*=@+CY,@"O_TS8?OWG_#>#B/_"!\^M,W
M7^Y/IO=G5U??_.]__V__]M]/3MCYY=4-N^&O;#I/@Q=^'B1S$27KF+-W]Y^_
M9?_G].Z:70?AKX]>PMEY-%\O>9BR$_:<IJL_?O_]Z^OK=_XB")-(K%,8,/EN
M'BV_9R<GBOQ9S#W\GIU[*6=__/C^XP\G[W\X^?"[A_=_^./[]W_\X7]]][OW
M'W___\'']^^-VZ+5)@Z>GE/V;OXMP[M@[##D0FS891!ZX3SP!+O7@T[853C_
MCDV%8'=X5\+N>,+C%^Y_)VD*D."/0HOQE@1_3.;/?.E=1W-B[T_?&/*\/<;B
MNRA^^O[C^_<_?)_=57L%_G6B+SO!KTX^?#SYX<-W;XG_#8.G$28T=HM!].5O
M6]>__D!7?_CQQQ^_IU^S2Y.@ZD(@^^'[__/Y^I[D/($GE,*L\6_^_;\Q)J<C
MC@2_XPN&_WZYNZKE[L?O\8KO0_X$C]"_]AZY@+&)Q'/,%]7WB3@NW(;3\B-.
MRX<_X+3\CRIJZ6;%__1-$BQ7@G_S?5=&'Z+4$W:YW299Q[+ B_"U4=<A\8;'
M3V.KARKI!BG>D)$ICL??4A[ZW*>'F0T9S0L7"5S:4;PM? (LT/ )GW_W%+U\
M[_, V/CX$3^<X >2&?[XVT4(C&RFOA_S)#F#C[/X(7H--4UB[T_?-%WY?3<6
M%U[R2-.T3DZ>/&\E^>0B3?0W.</JB[_ABO?7@L\6%XL%IUT-=H=HR1^\MSMX
MC'=\'L'^(0)Z\Q^\1\$?8$9/@9M?2Y)9(=EQ"MH^I8NWA]@+DP YN.5Q$/FU
MCZGBT@&>TZ47Q#][8FV<.<GT,4EC;Y[6/(?&6P80X3:.5CQ.-[?""]-IZ%_\
MYSI8X0%YP]/3S0.,O$.@/0@,(-Z%%X>@-22P1NZ?O7B7,+67#[FXKL+5.DVN
M^0L7'S[SY2./=ZVMBCL&$. <=I<D#>9GT3I,XTTCZ]77#K'UIK#A727)FOOG
MZQC6@MQ=:%I!QZ1?DKH]MM6] PB%JJ07SY_A]3S'11'1"WKQMN)APF\C$<PW
M-2*UN7, @6!O.?.29]A[7@+0(DXW7Q+N7X5*KPZ?R!* PV'G=GP H0'$11;Q
M/]Q;7SP!3R"!!Y/&P1Q4.OP!'D_Q"^-*N0CAL <[)N'G7/Y[\387:S2HX,.S
M%SYQ5 *D:E S53TS,<2[CUO^*?#EGT5+7.&D"TWC&%G#=7^ZR2^Y]3;XU?35
MB_ULXYW"*[Y<D4&'[PA.Q'F *PNF!D2KVS><CSO 9%Z#%LWY#'0#D"9\NJ;G
M#CH/;O -<['SMB%$">:XW4V?8DZ/XX''RZ3Q.&NZ8W\!@E]#C[CZ\%&:Y/\#
MO_G;621@V"B6JR7TZ?BY7<-N[1E#UVR AU!P;@9,83@?A[P4WE.%[E_\?8"5
M .\93Z=SV->DZ7$&+QR\97("R2)9\#CFI 2GFZLPY:#>IU(E@/G%#VA9U:P:
M6]0'.:%60>H)4@S\($6K!C;[-7)[NDYOHO2O/+WU@K)!M_?MHU&>=N@5.VX:
M1(P7'J[!SE]Z02AUTT44+]&C-GL4P1,M,GUX/ 1+N&2VN(=ODP5P#+]=!R&_
M2OFR3ONU.,  TU,\<<@%.UN ,DCO9(W$S?<,87%QN4$\>&_$0Y)S&"7)F1?'
M&W@DJ#DD]RD<IK ZT7TLZHRR0\D-(/IG+_Z5I[C]W7/8.$AEW[5BF^\9B<YT
M'7B/@8#]_@OLC%(/@A/@;0Z73I?XUQZ*U&Y:P^RO12.B9#I4?]NH?G4B.< 4
ME.VBJQ ?%SRU.S[GP!ZLT+HUW.I6:RKGE]4BCN <H\4R%70K!A6D1F)8+&5V
M][U[$,\/<$/*>H.*5KIH\(,J>Z-O(JDOU>X'N^\;7!AEVM8M]9J+AW _K7&G
MF"TRCN[Y4Q/G]=</XO%7QSI9>^182&;K%(.KZ(JI=?,WWS6$S1$MEU%(_"C[
M0;*E ^>747RY1EN"#".,'-<8'WO3&6)WXC%H)Z?%Q]!X"#;=X=Z27X,9!_,6
MQ,NKJBA>\?<!YO.!+U=1[,4;>?C<>O$LILU=NNMU *AF;MO>/<3>Y.%2S?::
M**S=E+8O'$;UD4'HZ3I]CD 'WYQ':$#6JSO5E]MB/8E3@VWX*V<9_L!HI[^>
MI_"T86L(YGSZ%I3GM_8R:UI8'LN_7Z]6@O013Z V>RFBUZN0S&Y\HG=<2 V+
M3LRD,5' )N4A KW+E8@VG"O&M'X#.^!9HUJT^[Z1V(')K@R/'3<-XC?/)E,[
MEY\CX?,XD=MFK?-\QVU#'!?>FPQA5;SPU=<,Z_XQYE#9@PW&V?[W#Z&V"B^\
M\9:\\7@H732$19,^\[CU[E-W]7#^X<LX6IZ!D8YNZK\$Z?/9.DGAQ(W5B88O
MI#S2+C"#+PE@W[\.DGHW>">B0Q@5%(>^"J=S<H^A'SL.PGD AV'^U3U:/>CV
M_++RT>_I1RLX.^K,BPX4>TJ\0ZTJ7JDX(.FQ*@_G+/++*G#;NP;3)3,7S8X0
M3=W50R4=%<XX?''BA$MC>P6;0U/*T8X[AQ!H_9@$?@ &TBR6;'WFH*_[5^$+
M3U+.[SW2,9''T\WVQ?JR1D^<S2&&F**</SRQ9@L*\,I(6.,9U^+&876]YB-O
M'*==?21KI_-QZX:1& B92U=[1L_7_*_<BQ]@S'VR;9KI#)D(^QG86\=2!;W#
MB!WF6+;+B&VZU9I=GCDGZD./]=<-Z7N1B9R[#,S:RT<1,:O2+[.EW#IXUDQE
M)-YZY?OZK5;EW'&3M05_"I9A,EO < DZBE066:;>PD^8P@2KQ:??FI>9#8IC
MR+E0,82V!TO[^WLR!NZ7GA"G:[#YX7"H5?Z+5QU;3K2+%.=!W%) >[8P7#--
M[JG*:X>)VV5)SLKM>A8E:=+N%&I[MSUO^Z'9V3KJ*_=?G5;KGVZTS[E2.7 Y
MW% 9LSM,@N(U8RJ"JU/C]KC1WF$+JSP*/WL)V'K/:YBQFB2H'1=;X^><KZ(D
M2-%'3VY,^11K\U#:W3/ P_\+Q\1-[D]?P IZXL77R$AQ0-5D7K,.]J/A_" _
MHW0J[M6X[PH_'U.=S4R6N!@3>@7J>A#"I)*59[N^9N=X0YC^<.(E*6B+:),W
M%Z%47'F$3_LRBA=<UP14EH6['&D(BR*K#$=KIUK;(3D>#3EV%3IV)&KMU"AE
MSL#6?[9>KH$'0FZ1)6M5)T>K^X;U>^YV>+K?^36\C5R]%Z%_OEUJ5W_=$*J7
M6FG*HZU3[&@]UBE=3;>,P0, '_1WJE*ZL!^%_BD/^2)0+]S6AH6"M'46V!CJ
M",^$3W!AFFW2)>V+?L3UG'E_'9T7^W(QA/GUX@4"0UQPMF'@Z)P_IGFQRW09
MQ2FZ!'$=D.NMSD+;EXP]ZYNR6*<?6B2^[KY^$&='@T-Y9])^V[M[RGZ\PQ>C
M)N4Q_VTDU5^['$G-]PR5.M3&7U)QX0#L?O*"$)W4LU!&I)4OI%X1:KAAD'PG
M4GQOO3C=&!'TY'1C_M+@3]V#P.!QHY\C#.]*8,%6,:/"#8.Y#1O]A2-"!Y)^
M'MBL%68E1:E><&T7=I>F')[#B0Y5*J>K??\#&$G\@!9_<T'*CKM&  ]V'HAU
M?29?W=6#(@1.PS3PD1$PA/-5(9%UN"\S+Y>KM8RESA9E&=KC!EH;J*<XID)R
MO 6=U!/_-U@UYC)67FQ-B;V)TOOUX]_Y/'V(P$P+9,IDO1+;>'UO/H3+(($7
M56Y&E_!=53"X_EIKDU<-I5$_>8W7#U[?7JM,%"X:QHL1A&C"H8?[D4"),:JU
M:W_8>=N #IG9 OZ%/:C)F51][1B\2.@SD X)(:+7AOK5-G<.8_EFFHN1AZ24
M&.Y_J+=Y=]PWO#K=X%2JNG((!=K_^SI)R4_Z$,'I1H!2L$-[@7\5FF7.CV7_
MUQV7 %1<U63(31WQ@9]"HM(DO?-A1U-6M2O>TGR3M=-1N2(?(IWP852SUY^1
M+>X:)*D3<_)Q\<A44XUP5IN]67-Y7]XPOBI#Y5$!#(]7:/G7%JOM=^_@J!R[
MDFCKKAXU+&R-+'L0&,U&5)N#M-?.5$_%'EXE7!* E?#9"]<(^4:^#JS]FP<P
M3K (YH:^7NT!/9S.D(!"LT76\.,VDM"..TZ/5K<.CYHA-3/INJK+.FVXHR='
MP&4@5$96K?EO7.( I2&#1*0=$K%@T38U0&WW 6;8E]BP"U]#1^Q2EQIOZ>D\
M5Z!,GWCT%'NK9]QB:L_O^FO[#,55*GCE7^TEH,9!DD;B\P:LLWMXFQ\?&_)/
MZZX==CENE\NV7Y<-]PY:86O4@S9$J^JO[PL+"MW^>'Y5;,+E*X;P5@@OT1E%
MC>6W%1<.4@!*1EN2MFK^4W?U*$K=;Z)T5UN6'3<-69-JM/'9]12:[QDJ"VO+
M$;.=__18D_]T\<;C>9#@FBHE/V5*BDY@67L"594ZG]\0G Q39S+GW$\P6$9K
MNLA^0SWGKON&2E?!QQ7S9P1MT0W%,,4#7='-KW3;N\?@B8</9_!WD!;J,76<
M:8]4S28J]C!ZPX#\Y^EFMH#MQ4NFZ72=I$%#O''7+=9XN_8>,\="/3L55XVI
M*&S7/M_BQN%-]U9Z0_,]P\24YASW<8H8!,FO\HW"3_71I-H[A@C+U"$^M8+3
M:GOW$()URPXYW503:+!H7(XXGGQ$E=5/1[^998@9P>8M^R4IMJ8Z>*AU3V#>
MEC>/+1&\.=^WU:WC*RZ8SV6%%O<_Q:#5?0EC[@DL$\!$X%,.&A""R1Q6<="2
M]F#03+)O&4_F<;!JTSQGUUWC -C (,MS%%,[LSSZN@>:1AV!X<$:4%G+.B-7
M%,W9IFY/I>9IBK7F4J]YB.@ED2NI4K=NN-RAI[C8:2[K+%?7<FX?Q_)AI <Y
M 3)&7[@)IPN\8BU/S<_F^;QK&[$ZQ'BP&%2B==M>%?M2&<)_&(1!"LKZ"Z87
M !]/J+M+/\%G[^]13%[FG7#'^U(9#E;X\*YP31B@EHB[  "L8KOZFD%V(HG;
M6]*J&JLWFN^Q-H6FJU.=H* !ZAIO0H8S%'S"AL,O./Q(WU1->6>:0U37\1 V
M+P',3'U8MT&2REU;66Z-CZK=O<.DPE=UQ<P/(FWI/$3J58;G1)[B!-'+&O="
M.[0'[%RA\EZK=<R;2.(5^Z1.)@\1MN4H%?++-JDJ8_8WM9I5I*!FTOH9VSW>
MD;2!91$*HMW4 U_47FI/^?U\;T_;/936(&&35<SG056,O_*2(7S@JH=RDG4<
M((T@2[&["F&K7,OL=6 CJ?ZI<1NR.L00*;1@)8#-/HO1_Z?^,%I2DQMMMI Z
M)GT?UU=R'$:KW_) ]0]:/64QFJ_MK0QO&H9K3]QQT+[*#L+:R\9ET9QN<FND
MP:&_#X5!,JX:.V+M2F%I>?=84LEV>1IVW#1H]4AR%:*1 CMPCO&ATH]S#W+H
MG_$XA5T6=FST LB%EJ?F[$9#=S2<-47$<))O9UM@GH6$S&V!RGT@I2$A[96M
MH^"O:I]A]=5#6 ':.YSQA+G<J%"#;B "K8C['!LFX<:H6*XV>^K4?;N#V"OQ
M1G_=;/$E4=M];D=\6<'>B,V0*(9[PU^W0^!GD8\U'U5ZIV7BPY1BA0K!L[[\
M*KMBR!=NGYVSX9;! \XM:EH:;K!7UVG6H^=+MFJ!UUTZ()KC0Z3T^7V+T_8@
M<$2;]-XXCPX&&JOOOXMK?R0;7JM&<]5WV/.;1RD6/WH"U?'DX@5=00%\2J.0
MZY>JTC?>YKXA0A2'=DW$+FC;KC]K9"W"YY?R@QN+K5O=,C9 --"HZ*>#@,_R
MF^UA3U=E8.?X2J?\*0@_1V&*>FZ%QG48C9$DL)=0@E&CCU_(+H5U'Z\]T;H_
M43MBPX"YB: E-G[UM4,6$IUNLH]_#GB,YM;F&HVM)H]9NYO' /XS7>+FNC_X
MS]9]?94K8MI$A;O5_'50W+\N\<ZFMJKV!AA;DFVF4M884P<2&3".;CZ7T)?I
M[CR^CQ;I*\%3MK7(#Z<W1NSX9/\V'Z6,,5U7![IA+>I:[VP,"024U^;5>Z&V
MKASCVJA[)J83QU67F<HQ!JXTV9%2LW7A\(5KI'=C (44@VDJ82>I,BT"3NM=
M2_O3L9C4QE=>H-7EK/N9RD51:G53 &8_ H/J)192D-OI)]8&LHC%5]<C/#<0
MZ^S*UO?:@^,R*R-U00#61>I\Z4)B"AQ458ED72B-)@$1-F/,$*T]W';=-4P=
M:0S'"'"P  X(8_.2\UU]-IMO&D1?SV G6[0HJ+NZ1QRQ^ Q.Q*<H+OOGZJX:
M0PRFJM%)V_!+Y;U#(V=X@E.R!2+_(63!/@+N36=(M5N?][N4[NRZGMX$M6/(
M9#/I,$\KX>$;+W?.[-5\$2M_#>AW/)&EX)?"*Q<.[;CXN*%YBBU+>T#@*0\X
M&I2I]@Z1]O>/0KC64@P3C2A4;I?JNN^,NNT&_\*>1(;1R.ISY*17I#$BT?[^
MX6UPZ<F8KM/G*&YPI.ZZJ[<4Z@3G3Y6O^=B?2U5WU6T#^]W;TZ'[X+U=^0K@
M6": -&/:UET_6,Y$AJ5YK7 >&R);37<,;*<T=#_8NFP0$Q>SC+FO\6Z,?05[
MM<QKDV%;W#@D>*ORVL&N&(7DY6G .FV\9YCU'TMH#_DO)HRO$,[;Z.18_R+L
MOM4>?(;LGCH+X4CU.5_B&6MTG=NS">M>9 9".,$X5Q&CI#D??K][AT*&W06W
M7;IH;)':0P*SPV<.&RL\3V.XPW.K51YQP^T]:1@7,)]/L/5_BJ-7F&'8-KVP
MWM%5??48W"6[H$=KKQ\*1?4F"J-B %6QU@9$=??-(X &RVTWM.24RPW/B 6B
M$87\X3F.UD_/EV#K8)0CV=6ZW1Y]>^56%$B\$ '5+3Y$=WS.R72#,X+/%CJ8
M/UM4E^0?1L->;N1K]/ <K1,O].%8>WB%TVP#\Y8!!)C%YIB+7W_X'TAIR/ST
MK,=8N[-_]WWVT+V".4%V@&:><@RB<8S85$U[S96#QH+I69]NJ&RW75!W^XYC
M<KYFNPKHY>NE=HPJ^"$7\.>[!W00W$;=D5*<Q09S7.ZV XXM;AA23RBDS6/O
M*Q7U.E_O/'#W(>&N5$ U4D0GFA&;Q@<?![+$O%7Y0 LR]DH\=QN"C1DP>]W?
MD[[\<R3@M/9B&?.MCW^5KSNFQ+BF'0;D C*4%>NE</*\!<OUTG;6W/X,V/.&
M5"+LH/5Y^OF^P?O1XC9[6F?,O=F"MB-?UTI6:I95UPV8@=,8"RE=-(S#-U^D
M(6R/:1#38VQ=];</!6NK(7M9J/CCAPR,:+9.I6E1M31VW]1;H(;&#F0[X!UX
M-UN7#K&KYM G.M6MF.1K)!O6[8O[D!C"D"=-H:)U49UA7GO]$'[WY0H8D>W;
MKB/0VA!;2'+X9R[\RRC^LH62O-^]]O2C:.,)U"11;:\T\$I7#+O<J21A!Q9_
M[>4CPEYNGQ*R#X6!(I1!JO.?T5,.5@H/Y^@1VT/&O8B,48_=576C76B#EO[L
MQ\0XDUDPS^:&P^;8T,-A3RI#)+9X;_()-(,ZEJX:@-&JW%3I=:SAN>&&OK)$
M\VR(7<CM+6\:3<5 JRK8ZQT0>E9(#Q6R.FQ'&.LV &/O+'$L7F,3I0^+,JH7
M@XY05M=U['__Z-(_\\8]$D906G3:$M)_'Y85VI;V:%S1.]I [;C)8D<93 YI
M#0[9=/D0JHOOTW/UQ*T7^!@Y)2=W<^YMXSU#"+%5SNA55S VB[4G%7M],'ZZ
MC-84=G^-ZOVD%5?UI)G<\2=JBA"F-2@?E9>-)D-MFNKBY<9DU%;W#H/34^C$
MN,LJK;]^V.!V=9&_T?@ 9UB:AGGHHE7?5<N##)FV2Y%\C>73(F5WZ_I!4BBK
MFO$U)3 TW3$:+\E>WHR!BCRKL3Y!]:Y-H6RXY9A21_3;+!NMR"@\97%$^)5A
M!+?N;]_PM,?!X)#;TB[;O.)">V@@/$:X!)B;V>+/LCIOMC F4/D]2FVIJC2H
M RD-;O HL[25G:.OM9A2!WL$Z/NM;)NZ:T>SJ;?(H#CTS;7B"G?+E'-[07D7
M-A\^/CX$Z=;Y7WF)14,<M8I2'IU"*]B%4]KZWE&40RGL74RC:]"R=M]G2Y@D
M3@U!X*]<"/CC;]/%@E"XN2\-Q4H;M^'"82L8=[1Y+%_7*PJ6^J/12NI(;#1F
M_!UL=+"+P>)H*B;;R[IO27(8#SOR OKZ2^!C(?67!+-;L@UJBG#WTHW;G%=U
M *$A?!S%RM/&Z&+UM</50R V3E6IW<7;7*QU[R+XGU\?YSF$4D^^/]7$C13\
M64S+*-Q2;W9>/IA7HB8(8.2?XZF.CM5&5\4>9'HZ4S.+ZQ./GF)O]1S,O2KL
MZ^9K1USJAB] $,Y".;.6ZMMJB%H[LPG/_B$B#$+0MXS:KH?G(,8.9_"B-_0O
MW>/V_I),@6)38BG^/ ;4_GI(2#@BX* /YK5AT?TI65LQ6]U#MJH9JQ9*B[MZ
M.A_NG[D0NVJ?"Q<-L><(HLO]:ON[V;_2\N8AFR%4=\5M5(C;W>O B7>!G:1I
MYL >I2:L355QK>X;<NI5.][0-ZK;/H.2L(8-91;>X3F$K5ID/#G6?P+KP<Z$
M)[MCV(M6A]J=4,S 5VU-T#ME'L>8F(_EM=/$<+^&AMU<G^;F?#A[RUNWA3*2
MB?;K)]5XHS4^*T$H)+YD"_?N'G<?Z2O9%+2T1]\FAD*<!K\I(.D6N*YM[^K-
M40RF+;48JTDLJ;QL"(^4$6;?M6U77SN$U@,;BQ^(-59@Y,]6.A.X+YT-V+)$
M+81RWL@N.:V1'TEZ>-.[7W_]$)&MX"DDE,(P-?KRX09,U4X[<F7:W3QJEV=G
M5^<@+DX-Z ):2S"O:3UZ$U&;=-!JR-Q\B%)/E%N3WD3I7WF:=U22I1:@^A@
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M:QB;.D'A(5+:%RQ\LC^3!Z#?'1A ,R!1J Q,R4(WCBQ- ALC2#YH_4M.P (
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MQF(9(!"ZH7KU]3H0N]";,TCFGG#<8M2E,%J%XTG""7BA\! +H<<T8H]@^B'
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MY B^3=D&5G3.U(1)MN@I&(R-%Q5V?_C7C_W![#H-L1S1#%8LTZZX6>/#R,5
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M5M%>1)<^5=T ^I;RB\Z\50"O3Z=2W+RG--)$V$9%U7U!K25I"D[>3!I4]DY
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M*U;1F*FT=B W0[^9CG"S>U6YNJ("U/<L 3+X;1 #[FN<QJ^[HX$-ACO4M)M
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MD9?_O=QL> 4-%@GUN6L,L+>B5JYKAXJKN':KT=PQ&N4_['KE,$K4W\QHUWB
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MCI9/:!=\"(0[=]2@0R[WUH/);UZ8@P?@X7\3BE-<'7>,@8[D@Y=\!QEF$L_
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MH0WJ9+O]H_U1&8%COV 0"#U'H.O()D^ OP)!'@+Z!NW.].46F_X2S\]R+WS
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MB9.KT$O3R3MDY810&<'  HLHU!W0 A<JJ[6)5$N<@-JY]RY8B&QOBQ;V-4J
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MI>.0L6V?S6/5-CDZ#@O+QDH!1<VXZ3AN8BF7=N#<#<$_0F[CFI)[R6QI3_H
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MUN$XY*H,0.7ATJG4 AU$7MU7 M);%]0>ZY\JGM)<>(A2H,.G#[^&J1_&:9Z
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M1A)@GB)>!V)H S09B<]QU+0*B73&IH-Q.KX+1FZ9&FTX[GGI=M5P5 77\=+
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M>?97(,AQ7G':7VM!>U=Q1.#.O?#!R_#?MV=QR"9QB"_/EWN&_O4WF*U@-(W
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M+9#N,>SMPF#(TK-EW"$=!S' 4&_6FS#> C #1(NNS8H?ZB?NI^UV+'&<H1.
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MK)M=E'4R]S)O26EO^YR ;,7*4>>GHF*V]^A1-27G0:*I6XW )9ZFXS@Z'2U
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MZ^M*IK6Z_ /^GQ?$(__C_P-02P,$%     @ @S!N5IWFX;_L"P  '9\   \
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M-,G9R[GRO;*:X[LQP8-;"H@2L[,I*FE.ZX-F68*5.*5(;%W0V>*69:'/'E<
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M)9-I*=XYGF-=9([M1Q89\7K@252C#ETB[WA*2W[UD#^[M<19$?<"0O7DG3A
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M-)S_B&E@7,0X>K&)^),@*$@H(,61FA!$F<\%K*]84<[0:(X$"8D@S$^;M,2
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M2-&[2(54^XK"8ZV8!;LHE+)6:7.;Y=T-4)8DPEK.-\;_H8(* I\P 3:YYOM
M80BW!L,Y?&(I/9]K_%,NP&0WN_(T<IL.!^6BZPD675T)Q1F,20#5<,6+:^=(
M<"!&D:%O%S]33J\QY?IBS25=5V:Z_=#Y5M%7T:U8I_C]A@UQC3)H:/AM6-M
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M8:^=]X!R#2@P;&+GYP-0\42,5S'R!QTO/;5FNIU PQ&_=CSM9'CV]5O,DS6
MG,-) ?ZG\0<7*O@;Z]FG/Y!\/)B^5^B"+6O>R7 ]%")H$Y?/6K U=-V==QSF
MM7-<L8U";9IAU%1%P3V(&H*B5_ PZXU_7QV4')- -7=B+!(>WN$%<[S8*XRP
M!4^9'K67J+!:_9+NDR%&"1U^YD!L*T09LN!.5\U?(62WY3IRPD$\_46($ 6P
M$)DY\[,G3#V]=E%JI&P,.ES.M1$[X5T>R1,U,XZAR)5#:_?X/DZ6^M[V20@O
M!\K49K]-P,[ZO-4V&!5KB \K:KHXF?%8I=(Y.2S/)B:>+X4.>E2O6>L^-<9
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M(N5,WPB=:Y6*D?2S0?F&3 ;M!K:*G:D+Q<R&%K-]UJN_O*8C=(YW_9)M(_X
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M6W B"J'\ K;A7F_7FI0:(,D(YK3@DFVMZEC]>&53LQZA(_ZIB V*%93D>[[
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M_*1)VU/2F Q5-%>Z&ZD 0-YQ1(WILB<Y_C'?A%O Y;T\W<;BV;(ELFQEBI,
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M*Z9.VTA[2N [V)ZLWI-15K]W-81ER=O:O5WXB?6$7L;R,//LV;TJ""H?I\I
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MT7BTF2TUCL5MOE'7O%6H?Q9]L2_T]@7Y4HE,I)^X!I9[&,5&?(#P]@8"<=2
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M<NA;P&:_N R")FZWG)M-&?L6PV$"7@Y"(M^NHH-P"XHVX.\1ITV?^5)X>@@
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M>+6BT%8B4+8VM":_4VUY''Q88B \(1QQ#Q>CGAJ=GMP>MH 6-AEWD1JW8)?
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MXZSH7P)["_R@#F2BN53V*UV+ R+SZ%:4;+KMG_1^S!_9I3T=RXOG-Z"0WT=
MK#(XBMRR"M2YX5&82@J #YEV3OC+3_ 1[AH*7HL#&$0401X*LQ</=+?@3WL
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M'=8>M0.>78*.#5^"*<G5W8A7F-H=I/:3+MBB%$I]-3/7#GP%XWKY72PJ#$Q
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M[&6HW%65BM=6X![(\J[*\<N")QH5R(ZI11.J!3-[<^AA*O(UF*[MKA!<8 U
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M"G?/RFTWAM +WFBA25PLS)&+RV3.UWR/5+=+3'FODT->V#--4V>Y6'[*T,<
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M2:%R9 D/<\.;)=ADLCDZ%#]HS?F^$IVAC!?-3KV, 3\B<%4U@HOAG7UALF!
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MC0BDB.ZLR KQ=/]X0]J!K7>T!VF8K)QDJ&:5V]*3(>7FI$-Y;*>K'VWN1'&
M)W-O<%&+A+^,'R_;BHZ.&N,LB[@7J! @ER[5O36#*K\'VWM[S85\;=GR67QM
MRP@KF\8<.8A5R)<>>Z1M5;V+>G61F5M<MVZ8UY._L5A;3_NCD?&=LB]4-[K8
M!H]>/SNM=9E+RK00RI]P8_/+F) TH^E/JTQV-=RYTGKU+3'--%VIS2F%]=(
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MK;]XF^EY^4I/?Z3Y&J^=..D*>%2,N#KNZ:.L*,S;3@(H$^L86]V@JTLUM]C
MF?H64Q3OJ@/<GY;KY-I3O*PJ&+TLZ_F!^I#0T:W.#_>](Z3-[B2E)*K3JMV[
MN R3_/URI'I!#:,16[Y1]MA;K:YGQ;>NR;REE26Y571(1L.0/?H:XIZ(DU7I
M ,:L^\2#(YUV@D8_]@+(3'$Z[2YPRJRH?YW2Z).84YBC,;PG]HQ0F00<+MA
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MRT#_-+3J"L+.5>KK)3AL?-=U/8MM^P4$ER9V"09T1IQHM_?K>-AQE!;JV I
MCIB4,F[@#YIAATZ"5IM/JN_>"Z]X[KGLF&3Z<-NZ@,U:9H":19G]'C5,KW(K
M=UF?O+2&P0/6V7"2LEO0KJQ<'*OZ*-?:3=1GPGF(8Z+9KB#E#,]6@[FSQ.9&
M1UJ17K)C+D4Q6JM86C4Y._'GV ^7ZN02]^3K[HH+?<HGE3RZSL#3U<X8WD70
M4<5X_>-&'HY8T<V_)18 =2-QY$B3*8_FOI.M9Z;'?I4 'K6@NOA4?D!FCCF9
M5Y'U.PN-YY-W\VMHLTG05H^A&G5IILF3%D(EL?8B5 Q;:9^Z%3""B+"2N3QM
M]?:]=^33M$N;FO(;,[W,K61HK$&^-?$[[9'*UY<?X^VZYF<EF['&*Z5F<IHZ
M4U;9ZB?,C+_9%+D#T96VO)0FXGI-\H!F?HO9XBT"?;ZW\92G_E.OV_Y;1[,+
M[ X^:NMMI-MZ0%<XNIY_S#@170MGOL:9R-@BJ4=I"'EM];C)9G8;^Y-C8.>.
M'/F5F>AN^T0*:"C_W:2J6-;=!!V=HTTCS9VEU[?#X]K:LYS@(LD6^86^#AW2
MT"&21!S1R?6=6\**2TZ>;E#Q6<3XFQ '5<#$M28K>A'@:A[T5+[;OO5T]>ZT
MVKOJ"+GUS9O1<R<K$:B:JU*+DBG-_<_&-3R5TEGM]L\!)H8/U%H2891"0UX)
M,V?4\M7\1.'=-1QRP0TEMJ^&+?!?:CN-9?K,3RF5SN/+EWNUSJ.O[[5D7E^I
M\BB_H=/B;KUS[XK+D(26Q&JX],([+0+8UE0"5:!Y1I[-OJ*FYFN/AC#U<NQD
M2+SO.>"3D'YJMNCJV5O2#(#BOGNLOV)(@G=X_,M3TR=TT8[N9AHV[R<"/>L,
MCEY[IA9S?YR'$Y83I3\5?3_1Y(SUX2??<%U"7<<VR&:^=#K7'C6FV7%F(WX/
M=BZMLO][[!ZJPY8M/KQ.T6"S93>]K&##,B?.(Z>5SO:X;BX[V_7(NQ95'C'U
M%HKC3J^<ICGD^):@8B5#0R4E<DE[6.I:OI_;H@"P 96:^'>[$[72J@D:T/Q>
MGN&A[9R''VI>&%/Y?;:P*=595%YJ>1/% ^8XDIS'_RS D]>L)/W44JA_.?X9
M_\-F-NVY>P&$N(1:":FL(^[]9F0=JWP'>+18^!^%[]ZWJ:4(61DA);"KUM4<
M:BXE#+:?4U1\C*]C9B?+GF1+M1"%4@044/%\  W-%%A-MM#UC %TX<R4G*V]
M1$L,;@)ZV+=X($\F#Z>EZ(QK!C!JS-%0=)7QX7(L)6,42AVI/;=P(E9M0R<.
M4^0!>=Z04#B3)C)B[=/29JO$+7R*/<_"*AC60.KQ/JV,'\_:;SN7_>WR]KWB
MVO6JYO& HC" [3"U LOF$]U*:;5 M7?Q+C,!^Y,+X?QI+"]B'C\49217APY]
M'BM=KZA 1[L>9MVV'L#28K= &&HZ1ZZ8K[#1-A_ >*N"0R;_YB0C /_E'F*$
M;.@;/\&&<*8W_ZX]THO.R?[RKKJ*TEO+_7 =:<CGNU^F6^_>.;D+$9@WZ+_H
M[$/2FV[[$_LF\"XS._Q2/O5X,LLY(%4+M,5JF9>6&^>$E0C>7PH4_ZSQ^!1+
M6ZK@L 3OB##V'( :4S7&L*CGO41S5CLW?4R( ;_$?MCW[6]9Y-_#>LAP.;KS
MN/5S" _%E05:7P8U1\)OX!&#>A'CJDAF..^(LBS7&K' .>!03@0QWKH+AM\O
M/.P'?9*:VYC"/P>T19\#R-;,TI$TV)S2BK$CZ *> ^B(3\T0'7E@T_0NXSE@
M_M,Y(-A)3;FS^E(WQZ%?TUD-(C$2"\X#W@IW:8#[ $]#Q)NK%1AWV#Z": *1
MY9JI=YE \[9PGNE#N1HC1+/9YX#ZAE/+LK20IR-LMH\1Y5K@/LKG )#?(13O
MM<C39!$6\4V$$L@V&+[2(GY*F\R%H.41:'H:7LMS&-NL5X/(L>#\C8IKAPG-
M4H4^?F<'R$!/XD'UGS41HX=@YRCDKZ<AF(?IS1+G@-9"Q)R&3&H.3&H$EP8-
M#'LBI?6X=49\EG$[]@R+.B?E$-(L!7\:NJ1W1F#/]M%Q9 <A)X4:A$N_V[*3
M(<:T#;;!]O*MO1P@&/MDTDED!WZCD PQZ'A_S'MK^W&PNXLE]191X;VT$,<1
MMFHJ1P0EIL&@SSK4!PVJY$UU?!APZ8^(SF&L]G: Q^H[/2>1D</JYO1"/]FS
M$PO@H>*I%:*9+81<@/K1TA1?,T#A^'C(!NK$-Z$('3V% 8^)6\Z.W';;&99"
M#:K67&-/Z?1Y$+,I *(8N^1V;+#X9U3QS8[AK#Y9$?=+PT:=H%FN;<@9(!9^
M6DM_2N>%S(NH<#JV$)@6XK*/5= 2"R9S@<)?!(BO!X*">0Z'FUW. 6%<>"<&
M@RMJRCW4"X@L"$A\LH2)'Z-#S@XM3$_IZI"U&()FA#5S^X#)XNW$>J'T8KR(
M9M BSP$H8V&(2L [,^!#W,%5 0(#-V0MN$]'OJC"'I.!>@)"3YQY_)JGN%M.
M75/. >7V^N4OE^5?+LN6A'[QXUIS)=VN#ZI?&L0XJXXWWVY!_.F-=^+,NSI"
MY1V<BXP[M4YSFMI9327B80MC >5*G@.L=\%;"8<=?>);9+6!AN< !R^U!/R3
M]"\01,[T1;U0A'G_--ZLGRV^/J%"3>[2@5QZ?0$[91XY+8'/P=5<S<^:3K/W
MP^ /$7G)O^85WQD4WZ($?8KWL()1'VV\@H^P'VH6'R'0V</S]:;E]R!5LB5^
M2))=*K?!07BGM2_/ <\T3QDA37!V\2]PV?X[YX"K^^#W#>< $2-DL5MEY:(&
MH?!#@K,\\2C!6*,F8*"(+FB1]AQP@+ G'YY#2!,$;A@1FE9XJ%E*SJPZ-$9]
MLL\( 1:+6MU$J-<07/JMN=1MXD#R@GS[0P.00K[H@7\!8@9M41Z\&Q6ZH#_O
MT'%Y]>DST#IB9NPC2>^W&^>U]Q/-V>#X:<[;DA.\>-%0#"'UK@;K>"U:^AP3
MNKR&%.S@3[6^-AC+=J#<&_<\$\2[BVT\R&VO$I=$F[1L4>'87"V)LU FG:7&
M6KZ.7K43L>B(4F:$@@>M=?HB$]'<UYH:[GLU^2?-2-*"DI-WV]P-MM>7H3OY
MYP!\EWXYD3O80X]9]X:,$-XFQN6DY52L--I-95%).%*@.BZ9%KJ;='L^/_^8
ME+2RM'NN/M2FN?(H[W:EW@>-!Z_2+<AJ-V[)WXD.T7I])E^H JW!-GSM->S8
MXQ@$TAY5"Z(Q+QZ(T$ZV/4MR?-8XKMMU?4^6YDAMVR+YSOMS@&JNGE$?V'FG
M4,OO4Y4NR(TN##$V6CI6;RVQXJ.N- *(9:+ ':-R53PQ[5\O/'3I:>HSN*+R
M7+P6DWXW/Q!([E+4.IEZQ>_D^KM"6;E;04]N!\L6OU0Q(@S,(2Z1L],+L;\W
MS)M_=]FH;NNT+/R:/6>8@1=&_.?/:<76\\CS0__.L@'>K2$;5EZYC3R>>JS5
M<K[>:7FFJ=%6U1OS?B//GW,G,_=YT%_5.=3_1+)&_TXMU*P\<0$*GA.#%,)T
MU7VRTGGWOI@E"Q7[T%;$J%J4K;[IAE7[SML/E[NMGC+F:UN,F483O<?-<7SF
MI*M$MM9A_RIT%1HP!6EX>AS78O=7AT;RW'#^*PY'#:-Y/LEM8;8DXGMP@,C5
MLY!>(.Z@VH$-&IWA=1YHHPNXAEU\&^T#RP>3Q*>&\94?=%TLE<M"-8@"><JO
M0%@8Q64KPB=J,JA57X@SZ220!U9F#I0D4;F3/-MMLS)X/?ME/EZ>\P5Q 3$E
MT%[_E;1FB>&" *D'M^-3'J(QZ?=WGSEH&08\)9D67J<HM_\2>0@MR1?2J:XE
M7><QS[O5OP[NM'SS2:2XV&I$^%VWO'62T+"+'"#B^2792XW\'+1;"A'W8$R?
M[3#W+H>:K5%DSSBLTUE.X[J E"K[ET+/V+OJ;S25/)42[,EFD: JL=!6/RJM
M<EFW-BJ/U=JY$X*)5AX16/KHUNS+6T IO?7:3N+G+/M0VB+^28=GKPX'2MQE
MGR\(**=D3N\;BQO51&#E[CB[#2LSF1I>JXYZGI)H8%2J-O2,;;1TE627$1*_
M+S?G_>3:E_17@.?N!C$"% >%]UC>2K"@T*/1YW,)^YM$/()%4\Y9%3.5*22:
M8D #"&4H(,EZC>]7M7<?FD&GE/8=H'GSUWT#1-@[K\ IK#'$)E0W>:K?E(Z(
M"%MTT6JZ&7-,=N)QMES_2#_Y\J:FNY6IC8D)WS8ZM]S32/33;K=XN6=6^1L%
M;(8^&N[>V(4#99<Q%I:!8UA1L-.GD"Y/1QN(KO;C.G_6-]GOE!H?8(Y6X#['
M>#"ZJBE"PILXB6/2MW[G7O!M'P(688 XEP_M9?IL2H&"XH!DD'.41]7$W)XH
MT_YVZ?CG=?"Z+1 [QB"(^(NOU^,<$^I@Z4SSL9^*7!RM\^F"D^<\97;L8!UV
M5]1M/.J!%AMFZ4EC']M=BP]!.A7O!VX_HO5QF"YE2ZY!XXG@O#7<>TF :GXP
MM*C'EH5_S"30U@@W :)(84XK3!NO^1#59T6B65ZTRPV'X"P=5[7')_,<X+=A
M)5T7Z>BP?\Q05F86:_?:/G;"W8%:.Q*XM=NK:YZUTI:EQRQWAS"6Z8"]P\!9
MA+J[>HQA/TCP 9K<UGJ3MXL)YII(Y1-?R]R<,A@^P0<5KSR77>W<]!'][BFJ
MDLK>#9J(,>>J 7;ZH*=9@%W1!XJFH@*$RSS*ZR1VR3:9YN6:?3HZ'6F3.OH=
M.>0G'3FPJX12,0_)*VG,/BQW6_8SI&6I+))I(*:E&4_^IC46\W"TGUA20V_9
MM^6=F>J]Z[6"Q1_?#:19T\N-4+(EJVT0;V+E38\.>N:OB1%$-A6-(>JD 7H)
ME<)A*K>1-H'#^LT*'C=X,47J#CDRTY<_&AI)"L*5!\#B5Y@%H='\'31,)9D*
MNL43R+/&'&E_[_W>__D/@Q)6R^[H/WCS\93D2S9A2.&L+GT4>Y_$T>O/S&/T
MWL()KC>CG65O1QNXO]*WG07A 6WFJG.%?<34(ZW;/G\X&UM-U>BST,-YPLSZ
MH*-!FU:;+II"(;W;MDKC8/>4V22 .4:IW,EX$N%7,_X6BN]'F,V-+\KEU)85
MP(+ DL \:D(^,$YPYN!>NAX/?SAOC<4X,%['(A'.TU_]+FYQ#.Q7JJB8X,]S
M0DDY)IQCJC/K%-YUT[/A25MK\\:IK1Y]PQFQVOM![94=H'<W)L_A6G1*N):U
MEHZ8*=5476GH7" [[KA+7$D7_R<,S0$%\H3\R.(U]*7APE(W>I]YZ.)6UT]5
M:I>QZ/UY;*ER5O J! M>MWUQ.P?H=<[5SHG_19=5X.7#_N.;/)*NSI=\$H>=
MN3!G?+"JJ3YH$/N(*(K5F[J++L2.Q$_I8G88'SV58A3SNYQSF+M^/)5CDV+>
MUZPB6JX9*F##DBW.8DII)P-\EZ>8D*0C5[MM,=ERO:(2"HNG?L],,+DC^S+Y
M-&"(0\DU;"%G8-0E#K*E5G<K^5*P!B/=/9RP]LKQGCJ,)?4-#]FW)"7D[L+"
M1MDKS^.2!3,,PAD> B63,ZXN[H'1M9>G"(I+?9=4N=NW=-[ AVED^*]7SW=S
M!@TE0U+Q;KC,S3'2596]>@ =$GA:'IY^6_Z*J*RR#X6Z-GG %R$\7$M-H>+'
MTNY6%/P:FI>G@(P=,BV !7FTH;+5^*UKX[/DZNZVV)_UZ%#D6&;]6>P'$DVJ
MM-LM^LV)RKXZ@G]U+8JDCF5H?FO)UX;W4:I6\J0D9@M@_N69Y6U8\^*P?M]:
MP2U?9IWQRS7Q3G8B>6QRQVI@?!I7+VJ+'#+N(NE/V6WB' 7,C5Z4-M== AN$
MGB4_4Z0+TNQ\*"$['@YN*;5YP&F)?)9("9+Z69]@>*-&WM(VFS=V-(_LOM9[
M_#HUZD;99_M9A_6-FG444)RNF,@[.^BF3A-$ M&V'52UAVC]136,[ODK^I2>
MA%GPSB&>\D=WPO,;<E/045-F*&#9NP<Y'I9>//5HNLO'F:NZ%L0:7VB5*-_C
M\=8%8.JGY[.I]SR9GN1CY572U-@J .<LEPV!+2N#:<TV:)]*HQO/O !F&IK7
ML0]E;1/E9.H_>@1[4,K=Q5K2V4Y.JC:/:PXGW,;)+&QX9&VT<\=3J$O%K"9+
MA8)]<AY[9_GA(18PHN<3<55S+GK$Y$K>@29#MF)QXJS$*E3$O<^XT('8NFD:
MRW+JUO:E_)A4UJQ8PN!/FP:1E=&R4&ONP^''^K+SYJHN[R6I,$NK7\Z^29@K
M4J10)';TA)&NZE>J*M/N4CSZIQ\E6@UZ5PPM/0-JU0Y%,(?2+><;^MI'^Q"'
MH,P0T0NN]E<+=8 ;XD6[T\]2^<!8D\;XMRCE/LM]!@XEZ@58++&[O[7@.[9.
M=X8\]HS!X0,5C6L=6<#=&;%\66/FMSBDY?-6CL?JRNU-O<)T1MH('DHO,)/>
MN?E4GF8CXH/;\'T/\8PDN16Z9AH''=>P5P?UM2%Q!ZNJ?)$&?:W!%C[&;Q[
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MLL/CXUD\^"NMJJZN0<2TW\&U@#;"_%)#CM/\+HRN=&-]2?S:KL:7QS;AQ,+
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MAG@'6@$AT "(> @@/(0_ P#5DYS("'\GX!\) 1&$A(R"BH:.@?E4H/$9@(@
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ME^4YN>'S%@=L1M#-#_LD?D,.47PFL'GYR)#,N/UA#F?2I,IL0_8+.3\U]>Z
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M!G@IQ BOPRU?.*9.(7\OJ7%U\#RFRGD\!@S)LA]6]59&+4D"P G @8+7]>1
MK+B/_+&:Z-E81FJD6?=X=]*Q,7[(_<XKZC00:@YGU,&#!O;/X9#&"-<SA>U4
MYRIJ-Q9E&"'L\;E1N)JGC_3LM?RQHM[3)&^\:)RY5X5=A(T=A[V=?K83\!;.
M/\?HFWUZE-7:05P\A*N?:6M3#]0+8,&F$%:N*HC6GS6JGTNE;:X:]25_MWYQ
M@1]BP%3K)29KB84*-DOI.5RH%S3R,-OLCOI(-.<F><\3;F,BR"97^YR<DY+]
M(DY8'^']%+=LA]GYIX-HB!-.>@G$7*?A_!,$*S:>$S4!#3O JP>U$W!]&Q_'
M6K1H?Q6/Y?E1P7IK&/%"LU7/T]1L1&& 8OP(E7#,5WUQZ;!'E]P[+M?-^%=J
M,<;DAW[?J++!=%$JSR04(><WS0&^%H5P>87YJW&W:M/%N'+!NF7F^HYFK/&+
M%,#W1W6P0?R] PPU%$KY6C#[[5<[V?FT@"-Q.A]SO-R^ !8(I4!W[F!3#M6"
M(#=/TN*4X(WB(N-+"T49-Y4+<O?1Z@5(87.0[(Y;',-<>SLYLC*';#4ZWK52
M7)*<^AVI< *>(M^EA>\?8(^F29A6=]WPX>TBM&';BZ6HP4)=+-7D0=0[J94
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ML;PTF^90ZM.PS_,Q\#O TM$110KA6/_X#S!(H?>(=P_U7NY[$=Z_PWOA,'8
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M+.P+]+:]6VY-V$@\X%Q[TEKB(+EH!.P=:O4\8E@4KYM[K$[:21*']$RNCL0
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MK+95$U;,,Y/-^;XIY^?.\.C.E^^5N8;7(RR)#GGPF@'I 4.T]D7-/X"R3;O
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M;8WRPW:G(]?A1T%,#%=@[UTD":Q:P6C15: ;W3.M=RD[+,6K J(K]"E5B:(
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MQ=LX>08C_@.4I%1Y&:Y.?U/+YOGI$/H8+EOI&22$YSI'Y#S&,AJ+SZ+]K!7
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M7Y]&KZ>NR,'SWJWP&+E5R_!DD*Y+2@15V?O?Q(P_3:KLZ^\T]TXV@&K;AB@
M27SF6&TRO0.N7"?VX%\6:K[VX! +M8[>JHIB]2O=*,^!N2],+31[B.I"R&"H
M">5PRJ%;)>34:<#^5>)PCL'"T+,<6(4';ZWZW/]2+%$>RCAC1'D&3-*ME&*,
M2[.F!EL315@88;I%B'H6I^$311YE[T4%OTY21#YS;3-F\W(<UD7!EJ8R>S)G
M*7-44M;FHUJO"M,6UW&Z2[V&N? YY%(NV@UMDIEY_S*@[W\&_T(V3&*6C9=:
M3$ RM72"KEC)TV,?M:(''5ZH1)G?KH@U8;R6MRBIT>9.5K>4?"=V3PDJ2J(Q
M)^=FZE0<&+B+\.\@[P_3]J/LAB5-QU[5VM"LH9%E#C_[U#U\Z<8*!O*[/2++
M@;HL^WA_V=.(0Z^,D98WZ^O YF!Z>C(SX^AZ[LI^\GJP5(IJ96=(]P._'7>:
M2O,9B>Z,=@*-GX&%"XIF*JY[O>*]*NDY3YCZ7%*D@HQ$WLQ2Y%?6(]%Q^M++
MB\U^2"DXFF0%LJO/?*NJ(!]RZ&HY5735S$A96LS_%IAXKIV+3N&8$[3S03SZ
MSL(=KTL1M(8^\PRH4Q5G0V)(DRH1B7LCQQPU]X,@''>PD6_$,\Q-3IP3QD^C
M*3' ,9Q0:#;A<S&W17CTC(@QY%@I.L/<\X6T7PTS?5_1WCM,&! P02JM2!^"
M(O5BN4NTV4RT#'5CB*A]0ID2<;OXSM7)N=SPZ$K@[U8>T$9FIK$FY9ZJMLP(
M( T_YWP&&+5GE;_)KDZC[%M.H ;SU8M-K_G@*LS&/K*<#=6#SDBGME9XA&\^
M5&Y-.?'E@JBO#+_LPY5QBG3/I0]35Q;BFT;\$7V$,?#I5?R>B8"@:-]DX22?
MT36Y1_BR0-_^5Z7 F"VZGYTA E!QQR0H0A[(YM)NA$"I%F3""W^N)_A.;5@3
MS$58N)L) U\\IC#^&V6'J.PES1KE,T#>1JB/O^D)VHL7>4VUB"8(?7M97#<G
MS&1R.=O6TJSIE09U:]@P;S;S,Z $2XS@"-KO/J12&3TW5N"EEH__\3/Z-0U.
ME91:6:'M^./Y MY)5X>E3Q=J';>#EW1U22N^4A/#.W/@;CX#PJT#Z_G*NB=O
MZRL;S0@31MZ^.D+&KON'QPHN?*'UATRH5X!,7&_&@^5?%7Z5O^?A_R(@8;7P
M6BT38Y?CTGNT@ ANVAEFZDQ+]A7\I>R+YU:V,2KD1= R_TJ+BG9B9&J)-XGC
M\P]+LOPB5^\[YBA4 ]*PFT+J)N2LU[G6V.*X7Y*T \<JB?,++',O4$;&&J)G
M(_5%S<W)W)O]?J?V^:-$P.LA.I4[Y6'I@9F6T"7@Q_OJZDF"=4!5\8Q"UI.Y
MUQG\X[R<T18'_PX7DCE+I_.5;J#$XPCX(*';<,O37B.R_0PH7FY^!BR-\H/=
M^(-+Z<J]B(4MB^:U1_4<*GKS>5O:-(BCF,1@>:[1MFLKC=9;0=*UFIJ\&MN4
M&,>97X2>F)#XX<G0KX3S6=',\+JXG)+R=W58)D_(F[7Y</JB^K[%:-E&M&"/
M!SKHHES2* DXW++THL=:+1J'9?53S,ZWE!Q@1]<UU[-7LZB&X:^I[0SKC<6X
M%F:=H5=;S80CY3"Q)C-I1H?UY!?@.A1>6\SI$Y?F7[FG&=W5MM]:LE]_9F=3
MN=:(T,%*&6+FMHVW0!)U@Y)?RK@5?D2VS=5J]-15HZ$=V^$WB:P[N8Z\V]/J
MO@EF+95> R[)N XAX7_L I1PX4*%38=&8KE$'"]KNH?KN!+%2W)]U/V&GP/&
M+4E4X6JKJPP409VU"5&;R6<D3W(EBV@'VK_M[&7*.'NBV2O%/ABMQ^+L1;M
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ML'O!G%KWZZTS1'MJ!"SQ7=EM4VC17W68%'41CIWPZX[/@$ -E8(C&DV8N&?
MH'B;XNTUZ_)XV*1T:7 <"9D933ILP2--L\^W>>TM=]I@O[N0CI3O]X\( N&X
M2 >$D(9RL [<2I&?<L;G>J\"&A$-\:V$-Z%S:G<UM\(Z)];/@&C51[.S6PJ-
M^(H];&256/Y!UA/&N6[Z5EM#>8^"-57=Q-14YU*T\=+$V]>?&&6R+1TL/3L@
MH[G-Z1@FI_LF7ZRL)/!F6"!YS8@$WQ.NP[!QY @>3B[8GP$:K70LMR2[OB6T
MXFFHBO:Q2RF*G1/Y)?)^^;=.E!]'F(!.' ED4*+4DM2(';^%1M^> :Y\-??
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M.9YE^EH""1#RTRYYC:?H5Y\]POPJHF,XUO.2YW%6@MC99E&"B3PYG4D<^/F
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M+DPHJ/1^MS&I'HZ^'K]'#3VM$&K5'8DE66WNV&TT%6<[-\.@/;KZ2M<O_@E
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M,^XFPO9SJZ3#,21 RJ!ZWJ1PQ"^))LIUFDULW=K\M2)\9P0\T8?&,#WRT6R
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MPO(OAR^PKH?L:PY&?LX=L3QKPG*43KNAHW.]\$NJ)P"JMJRXD!YR.[V!Y:;
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MZAW@]CS2/P'D8[[\=A4_A'  $'"^W/$_ =Z8;WG>O[T%ZB$'97=PIP@(SE#
MD8H'0M],5(S1W]=\Q8KXYE?=7@^+VBCY\^>D_*/GL<0NE2>K_<>QAKH$I4QX
MR!8K37P!,6ALTSSNDJIOW-S#.,D3YS!@'&_GHRIBI*NR_.":NJGF\6$U46EV
MJTV2<W!43G[*VC%'M;;E\DY#<,$TF5"=QLP'J#'<)P#!5$9>KZ_F!6D&9R2K
MF@,6F#KW7UI@P"0WI9-O$(/\[2I6C-H:N3'>%"4AD4/G>\'*[8LSQ]##S/J3
MXN)3%@I&]??[V!O$:46Y'3+J24ZSQ1C[=?'/7'5(H5947\0;\:R^V&:_C.A
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M(?;!4:GU<C:"* 47 TQRSK-YRU.26*W@VOL*A@J7)#O,>2>^R!&U)T!9);&
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M<%?A&[H3K>L=#EGV).GVL73Y2']W]/JM\?E+/G-XB!X[]@@#B%JZ'%649"-
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M?%)+GH8,H<,&)QV]]@<1%XJG#.!HNYA+Z=H7*\9LI2M5IBYJ34-N9+9%M#M
MYYM>\R<^Y M!W[4O!W0'VFVJHQLC1^RYHR:C)E'BI_%HQ#8GPP1AXU 3(YH.
MT6OFHNIUE9"AWY"@$<9,>*ST4XE:Y9%^L4/XHYT!U0D/<O>PQ3/%7\.'EN<:
M6/JUXUBKW-&T5K^9NUCU(KN4F-F$"1<PN_8\A*I'2\[-\,U9CS[531S,FAGK
MMEB\BL A2A@B3T+$8VPP\<1<J(HS7ZD/+K(^\)BR_EJM2%T5SN<<D9P9/8P
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MZ]/:?L/_5E,^I!.2J)92A[A!?>7<L_OL##2;!&ESSNGY=\C,=T:]@-=9A/\
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M[]%>Y.L8IY+795X,1P/ P"E]I:C'82%MK-!01APO.L;0^%HS<%E(CEIZ,LV
M."0XL[.YW*>S22X"!U>W3A#D  JUV8;FQ<DX[2D ;C_#5CN-&0L"77/ <V7Z
MU*I#DMSU^YZ$KZQ'-S2+);)(Z)LP9<]\:8+!;3ZIEXNSL6!<P88_/(FJ^-\
MI]<UFKJFFA$:M1O\#,S$RI9/\@MMDU^IN=K*'()YS@;2I2 ZIO+,G@4:?MSC
M#G=2^2MSAG-+8(?Z:MA+R"9Q.YOR-0ENNC==<?D-_^O3QQ>>LU<POPKALVZ,
M"8C@^R&R1@#H0P?(7^,G-(5::[1&[MB\<G6QBIV<S\A&FF!5$S!<#>R/V?7
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MMF7"PLQ$^#%N)R/>GCKCP;U>/(N[_<P8KME%66Z;:VAXX'D;TR+E<#)('T%
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M^EQ5R2@L:=8_%='L;@-.E5\.,1-#_5=6(&;'H@VV?"@OT?'B#@^" 2 &\#Q
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M*;@O:YE&B<W24LBYM.:&,[W,T7W_@ 3#Z^PA@K/JP2"T.[;#M2?K0)(!?1)
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MN;-L5.^Y;ON?@>MS8#[#LFG7IRV.\/5X-2];LR)E^ED]T1TGI3W8^ZZ^N!+
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MOZRT6 GCN6U<M[Z0A:@A1W>:&H)PY75G)>C #(2'T \#.M;$3I1%*0.6HF%
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MN%+,">XB7=[/N\"*VB--0E:6[&QF[PTW6 K3BS*?%(327/00[7K1U)'7ZLU
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M%:IHS,J(Y/$07,([DPPSV1\96)?F#U#70>/<6VP>]IL&(XA_2!P:Y)0#C8E
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M\R%YWSTZ-O7'2TXN,,"X\X.53*(IILAV9#2Z+QF$# );/.*P!H>15ZI-J0-
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M#CH)IMS3SVA-#K2)FAY!2^@&B1E=[OX!4QP&!EI2L,H&H<JSJX<%M'=+=L_
M$!#LSITGIHUCH3ATQK?ZI>[2:=V?W'?)TSLXFG#G#C\>R":)IM<ZN 8[[#I@
M>3ZTH8B%PW5J\2Z_DW445PYLL @/N/&!2\#&0?>20??0(!BZ*!(Z#;-3#2C[
M_0[RJYHR1*4>=N$@(&K8Q0PG:8';SU?[W?E"<6"5(I]\ /-P^:,WA6<9%GEB
M&(_>CPC2&)R;=;DLUSM>WOJ=VW]W%?1R4CRP@\6( V?0NR9&(; [AIR]/'B
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M#P0?"&%"8+UJ; 2M96VE8@%=GK?=JV+R63H<(_;:7\,9AH+\SQ++;>=(* 5
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M1M=0,-RM%(*2:]F0(.'-.Z(":U/JVZ$$D^UFEJO>LW-:*/Z:^U+\F#I/>*9
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M,,*>=>,H\$!2B54?U!>$G_K%(!(!I<A:CP[0O%B1RWR=@5^GV?YR1Q7K2R!
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MIOC\,)+7+E[<,<S5=70S%XT&6TZ*??@9QA$U[06[F[K$>B)!RRW_GUCNO89
M%<>4@4NJ3FU*]W9SC7P9SO<;5#]-?3P0\A;'D5\T17PYUC'S(7P,/J,#IYW2
MWM&+3Z'X!D4?+SB9?GXP(&UA'P+58FQ^ERT!#YM7!TV)6<=A!NW:H;?-4#/%
M ^IX8#46^+Z.P 1&P]>AV&,YAA_%_A8))%(.!:U9IX^T0\9#KIFBG^L[YCJ/
M#ZWKCUG2.CSN-K%.(_9%/ZIL-<-)EB%V&A!1]H6PQCXX'GA0EOH]9'X]Y_7D
M@?Y^L=*./RI4K,?+XW ?;3!='P\T@@B;D+V6,8)>$H5G=;W8M>HHG/O\<Q<M
M5@P%G6N%KA5IS&?-/G[_ZI]+4C3F,UKJPAC$4 +0CN[,QA9+O<&D S7:CUD3
ML!/9QFM\?>D_?#RE1WMDME#RXB)G/"T&S8?=-M^:!#$JN/3:8*WDC/CXL2]D
MH1*0_1VE@_G.N3IP&- '>3(5R+"T2!3<*_SKC;28"-CA;4([*:D%.4':AR1W
M5UVDI>,T.)M9M7MAQ2 TD @DU-3[&?1GJSJ+E7>&I(4>%KTF%$ET4F#0G-AM
MRQJZBD'#KV3_6,1W6&3_8??J9==U6'LR"-YE*_/(.K<C>4Y+5:_36 7_EM>'
MK]_7Q$GPA4PE11DXRV8UIG&R1:H8RA6'H?Q+WM@MR(%/<L5OW"W\(:,I%PZ*
M"0\UN:_RM4GU,\5ZK9M! -HXI\F+Z.4C>*LL7G4WE2S>.VB:$<16BY>##0@\
MH3>MZ6I2_5?819^!6)%_O[,"-O<6LU"LMAM.:W%N&(2NH6VYNE&B'Q*]A#4)
M,D\O;\G6I1OMLIV*!,?3-^R2BULQ87%3:4RC4UEA9QMZV)C& G,*X +;6_-_
M0HK0@VY/&M%54UH;RAYA%X]!J"VZN-U7 6^4P?AU5"*(*YNI+[/R6H3XUFU3
M$T#NN(B Z/'LBI5PR7;+/!8O=IZ#X1HNP8+UH::#="0NUFO=$?)YX$"9O(&^
MQ6*H-*](M;JGP&'#-$/Q\K/<:S:YBP$T$U]5*0S?BG,WY(Y=J"T)P EFZ+$G
MF>A=2G)ZFD%QC.LIR0G<Y\_(]R;>MIW:)PVM&+W.UG[X6%%8YM?'!1?4K<YM
MV#,+.X]D]N1Q,2-A/S5.[,T V@0:A4;$QB0HG 9*F[EK1""&U9S#E<.6OQ1[
M@.$#&P-\IP<,_5K7(1A?&]B2/ZZ%9]8*]FT,RO<-M2R'"4W9Q(1\L=8465M>
M20F0CYYYYS&_;GR+2(13_/Y-2H1&C%)QZ/?-Q)!SIV)D@IV\ZX_?I^CIC44;
M+Q^:I+@?(7UWUB]S;.IBA)-I5D)!<'Z]!3IL?T-B'62L/Q45C&[_TM3\0!T0
MLUY9P]K!9O2;$GC<XT5:SW]EOO<T+43 0@#$UI]78<A-Y ]LK> 35]&>Z[_?
MX[CU<12>W8EC^F6>'S&B8A:YK=90&%@B3H-V P1A_3]!6!8VXB[DJZ'OH7GN
M/#26K,%T3D)'E_5^HJ_LAKDQ'UP%98'6E?;SXN#2LOX]LF;Y/X*LZ9S16J7]
MKVGPP-W=(?23P$EX\XY$F;_7F1_2.";QIGF#YMW%@N16"ZILI<CPB["JFM,"
M<\/<1&D?>H29L\)X'71R>WA-PG60IJ/S<:>CT6^JO30R9 #[ODKVHH5*;/#4
MVY0>7C.N[U*BK)+'&I&?<X,5Y&M[A<R+E]9H&J^EG63G7Y3\TLE[9/_SXY-<
MGZ;)EKK%K<J3O6]T3P[KC=-9,@Y%QUC84S40#S>)R9\C<[;Y^DQ.Q8#^9U#'
M@1Q'K8,8.S]C7]/9&P3</(2$)W3WH:Z$.&BVJ)30B[ H,Q=:W*TRZ YHTQ[3
M;PDCIFTA,=,>3A=P<IW[7G*>("SMACPZ=$"#AWFA>,4?(-^<A.?O+OW;GR[#
MFVL)NDE6 X[-A\E^Z:199GCF>?X59%1*&0=5)H?+BM8.?)\8C+_[&7$:ANTX
M&0<\4&",R1)(VK@P&Q@6V/1I81:4K$4P:CL\#W"(\0=MVGNS/(Z ,B!+X-TY
MV&NOY/3?01L>.(F54?P%!."#0DD8TWE-(67S3/'C()=/JPQTRAE+)C3\D^M_
M-K)Y@2"K,H?.^B^1>O.'5<6=DK@0BIA6Q:ID@00)\CKYTR/SOP%#YARC/(T<
MK4,,8%7BP;6=LB[708@J"77H073?ZU9HT;N0N*H-BLS+S2\!7*D$[A"''$K5
MQKGQ!<-A(\4PC."^5T;?^EH=] ?(;^PB^[D-\.LZC3O;R:Q7YL?Q7F:FXDE4
MFTOV&&2]>S[F65N_ I?+[H.+_-\D:GL[.O4_?E:)LK7IKQE7"]#Q8M/V?6VW
MUZ^':#9^5].OO;A[?'@\K>IN/3//JUMBWBP,'*^XQ:_>R(]-"N\;T]'4N3+E
MRICRD5@.J::E)5UVF/K_C0H<+P1_:U[DESPC\3<3TL^?(3=U1:#A<M_7+HV@
M4DC[5ZE'GN*+_4,8>3P@V:QT 'XR_DM^YPAJ5FTP[@JOK@CTLRDXP(<7=)U
MN_-25WP$\G$K= ^T-)42%I4@BYM#T?/C;<DY,9<L=INVA-YM,:,\%\5+85MC
M2@=3M5XJSE"-U/$B70>>3LUK@Z!G<H6N!?R^T<_M6BLBE.C\*OEU<T,[_T"
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M./>7Y>'SP\]GH]B1YF?Y]+WH,PKF.U ^MZJZ9JT#G\9)/X\/[KDF.N%M=3<
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M8H+-J-L:A.S^=0]?5N(S@ C.O"%JL6M?.T%KN^'57[@8>QNU11T@^"/B_!F
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M,(S3.KH/@'CJ/W55Z:_ZH2?EH@O>?R^- ?6)J?F1:Y*TW(/Z"]B&-FQ9D:1
M*0EV*6%)QO?R>U8F'[IW9F]-DSZKU9.!G6\VC;E34A];_(EZM>N2*-K,CZY3
M4 JG9@0-9,I.F([ J.VS.0@S<!PZ@$$G\DCQ5;\%5S'32D-*+/-B?A2/X\#;
M)'7\+L'6Q)//AF&[YUQ?X89"/TDP3C*XOJ4301<42Z$\%RS[%EO8[CV\ELY?
MKC4% QTYG"VDC60DL])QEF_9N3*3A>"7OD1D)X9!O2MXB,\>UZN-[VIF)*IZ
MBL@!E5Y!P5R=+X^IWL9-S2KR*XLB2E\1##R*E!SG-C:?F3JMT7."%P<3/[("
M@^--?'M-]-("_"0IY7#7F3/K90TN3#-U>JGB8S@%SDK;,/T(S0*O]GW9"G\,
MB>E+1RRE$%2;IY"[Q-\W.;>39CA! I@LIQ29/W^@FG 0K-QB=SAJLQSS.[S^
M!^*GZAP_[V[\?__D?HJRKN48=$ 99;![1V!RHIV&6^C@@UK;H\4W=*H>BDXP
MB'!=937[R>E5L'?#,R"6X,Y9DA=Q /KW?&%YJ7YC:+*'9^U7'40#I>"[B%*>
M1X:XJ6LF*]!,3'ZUJ(!#8>$5>R\TR+WW]G%Z;)TK1I>W:NCBD(&(*+)E\%47
MD>SVBX9A]WQ@&%85Q].T*=-]8(R>$Z..^E815H%!_N7;_M:=4P1P58E^:O,(
MH]#6@I_E8[D=9T+&IJ2(\S&W/L'*-B=A=^UXNL%Z2KQ=.&5AQP,=G<^\Z)^F
M85Z8B9< 7:X<I?1O_19SJO!^%1L51..F0/(0'(IHL;*2=2@59?G!CL4,.M7@
M=N/4@9=!D@SUF_MZ\[6JX++IU\UW\[[EDYUO]NV/IUDS\5;FD"?^<I]@?%JL
M3:86[1K6ROF=#_T"VXZBG922$4#0"?,JL;8B+/NV[[28J9ZW$?OES[1"TFQ_
M!QC.CBLRVS1%]DVKRLCR\RCZST0B@$GBSP07G20E^#<3Q6Q(O<<FJGAD5O<B
MP;=F-[:4YL<GBWW<%M^L;[)-J$JS;,)[;C71":74%MH!0'VP$_#.DN%TCP!*
M;,'61[Y3%J;PH/=^RS6,+EEWRM/@#HT9UT=QI<O*T>MVC=?,_=%VZ:,027PD
M[O771^#8N4;:'.3YIJ"?\LWU:#OAN9;!)OS.B&/\TSK#;H^5\U^?\FAB[=<Z
MVAQX3V[]=< 2@(MFT]QOCMJ53/.A'SNK?M6>^<.N'I?(6][;,:RBUUM3@LAC
MNS<F/DP_1JT=0"W:T,F7,3T29@:#W?&#^\4TE6X<2G#\H\Q+2LFD.W(AX9N+
M&=#XI4*_B"01*7'B_6'Y?"=KOLTE;/_ W&ULN!P9*CA!?_<^)RK+4^"V*B8"
M&#X[*6CB(VE_30GZZD$[VI+J4@\H*$B/"UR7F)[=T\8S<D:+*P8."DDTA^4E
MSE3=+51/O$(P8K". +K!$WM^R%-]5D^]@A7I"3981"!3^\=#,",2B/A"D:92
MKVY*XF7!6&5=[/[>II-(V2Y25E0JBRA[&Y@8E8&:Q2#V]W-,AI097]FXPX':
MK@ZFQ>1P6WM!=(9B#ZTM"W?D,G:9$[W&\<\I/U5BS.-^@!G'3)82\JOUKH4+
MO;3+>RXD>>Q.J\%^W)=/8([/3(];Q4&F+> 8RZ?M"'R+U8(B<63=SK@^UK!<
M-1]D/V_'W1V]I:\AV,IJ_W!:1NN)<OJTNI+)K$ZZH*6N1:YDX\L&%4.<6I:C
MHPP"\2L&XQ9_TK#O&Z22;1G]Q50CYK]@VU!K+@A$!VA*>(@S7O'FH-HQ*)PS
MYPR:E>S76C4%J_)%)39"WH_>=Y-'J_OL ;6";Z^J1:L9IKYOJ/K;+/I;^/?_
MS,JV> 9BJZ_30]<Z^O7<-CM4_EHRMO5$L:\C>!OL]BAY*5O;_"U8MOG"WAPL
ME2!8V\8\1TD)F\ V,?_!P/#<INMW7W6QM<Y*=J1#PQ&1(+TA__M/PJDN-?Q-
MQ](((XBJR0+HC[0PXG\]%/6B@_ZJ<?Y+ZD*@"S^O9#^U?;\L=U/I/AU_!O37
M?LVV#GT^FUC=D,#6R/O+"/PX3PIE03QD)(]P6 EL4A%#C>/&0B1G61T0, ;;
MT/0,6K%\KIJZ5VR;8?I"ZZ,K8<*8S;H/A5 MZ TC@N_DZ=-'#:+L#TRU[")4
MDX^_'A?6.0X5(> 5:MQ*U/$D7%3?.T,(SQ4;"MR)4"<*[R1@OZ7!.9;[$86*
MZOI'8.P_5DS_ST8Z*!S;;-NHC"]16=X9\Z%D?N1+U">$XA;!$)![3W/*QJ>$
MV+;^H6S11^\Y>[MO6@YW+$?@;7Y,&:)#S#KI(GYS?'I/#])G8(6L>JK<4L>N
M(XF]732RH2KDR_:&7H"P[%Q9FL>#C_"C1_HS(,EIM"^^U.>LF:!HV.SA_D>@
M;4[ZWSG1"*6J[H(;ZT,.QH,S<GY#*60Q]%'/YZKJK>1$NZ90I!EG=;1QZ,J&
M1@QMP]VN]$P,-C_7+DR1HH"F56E8NFS[ZRZF'FH\#%3RU'CWC++UX,0)%P-Y
MP>S DQROO3N_3<_<:#F!!''ZLA?UPP(=(.@^Q;M1'\20'MN@$%\VR-6990(U
M;$>,FN6DJLY$8C<O48N;<J&[A/AZ*-2P@_ $7W5P&\-%\U\BRU5R[]MGM^["
M_0H-K1G<;%OUN)7S1"C5S%,D! <%R _]Z8]LLB-EVPS#/'2Z).Z)T]2XRNY#
M?7M3-"A)O/DN18C'PJO2(TO-9QM'[1>^53K!TL_EVKF'+QK'CES4#H60^20X
M99RKKAYZ[UP71[BEDRC(.>7+,VJXRQ&;\[9_Z19.T_8@&='V_!  1;R=3MB7
MO>GPRO(DQW!1)R=EYSTDRCF0+*[N,YP)K\-;Z\#@3H'3(D-+G9-&<#A')M<J
MG=$\=8*6_:I2WL101(*#064002K!F*/37  H6'G&5[O20+SXL/X@)26%:ZIW
M6XJ((_%]Q?JW:UYUI0Q4"Z:L!;/YV)WICUA26PR1<,W-TL9O=2J^:;$3X-)
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M/ID#W3G,E7Y;H27V87ZLT5H1M?&S:@)RU\'MZQL"F8UG@&M) =R&*4/2SIP
M**Y2R2;SK >UC,,2&U=*%3[6=1][;W.E1?0] VU6QACMZ%%#DC 7HOTD=V,
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M ^<EAUB?U<<<X@R[RX<1UZ/8N6@Y*3LQN<>I"J?EQ0+D%5GV^HSX@TOTQVB
MC\G#[;JRX+?==;D^[JOVH71=9*T]&ZQV]$\PX_.O#99'6(XK*I<9!OJT%:"6
ML*Z/#F6K-_T8F+4;>7U%\WM]<#)T#;2Y=$>F4J"Y]/OIVT08$3YJN1P5%DN
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MB$VF]#-^F1%D76;&V"1^N])X=U>OT,N\3V9AK()"/&M+J'.2>'#/@Q&#$G1
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M1GCI[=)MW3Y]@T6PC#CF;/^2'?A$<N=F8K5:8VG(A7T(>GFPCV)PGN^#!@
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M%<)]MCL$HG@;F/V &^2OIH1)^YFNJN,U,)&,]Q5<ZN6(% $S>PV3X^##:,A
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M!L^B1S+.9!A,.]%0,8:(XAN<CE'F&$<(!^BCW):'GJ.6^7^@B8R6.5 SL$)
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M)YU#=D)$@D(:1-,),DDIH]%<\B>]5/+<@D<?AMN4@L)/"F?EOI168= &VGO
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M')NA$!HF7[EL=W,W6JXBM%F#<["@)+'Q7RS+LR79@K+%1X %*59V;&.\A:2
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M<1VV,287O3'SUS6/K&]:?#YD%A3WPWJ636$J(I4G'+%Y1N)27WEOM#.7O=O
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M$5:I8VDE^H/<WN(IZR%OSX8)(JKZ%*F,8W6GU5#TBT_1XYJ(QR)J5SC2KWW
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M)N )<ABJHL;.%..$?NOX!?J*)A6IN?V&%C\Y107Z[$D/B<A(G#*G=2R<_Z/
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M?9KUF9C 7C7%.VR"$U^,/6V+_SG%TO_2O_0O_4O_TO\VPG]<^"]02P,$%
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M=BR_A5A(Q.[N5+R1['E,#C[7OQ-GASWWS'(T"NV$@(>(S*%T@FIRK"[8\W\
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M5T;@[E.IL:AJ Q)2B3@O(HQ<N.TIW63G&D>Q% V-24\A1>/F;"NVX QRIRF
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M@1=C/%*P^G[L5PPC[4%'DZK/G3YLZ0_I3[H^8)>F[SCGR#*\W)NU1VKE-N8
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MEP*%JWSE%=YK_) -10II-WS9)U#<P *EY%T=?<<<>]T9F5]%IAQ-T+LPR6,
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M9?&O2&C8ZF>@#^L]2P[O8B1C&*3C6N?FC(I5$!@5(^H?%?F#S&X1;UF0H0L
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M0D?3GKH,5\A"]992XP\IG7>%T_91-!_=BK!=&&\G]8DZBQCU]#)9M$^K2'\
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M;6YM[^SN[1\<'L$O_EQ>7=_<WMW_@Q<"  GAO[=_EQ?!7UZ(R,A(R&C_X(6
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M_Z4J(,DK$BT70*(8(#JNL-U]QPIB?@'4ZR\^QSD><.;#UQ_3)PE? +\XCE\
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M29%L8AOC/#DDP0\WT*NG9AU;\P6 T?D<B1?#J';LWR&&LY-BQN:P!U+!I*!
M[\-_M2TEDON^;?D,RY)&7K=E1BBU?*@J\N&]4'-V[P_D=8(51#ZM@IW7=W*#
M7JF/#-?L@B./,O[9P?<A6;_P-1% 8O1WRKB%7](P=_#[*B>\9$DD\8*M9J /
M0/6^98=[\#B$T4GU6372O0K5N)[. 8DU3*RJ2Q!NE^>U88G?DPD;#A <^Z++
M$N\?AQ$;S34-*%Y)00L\?)0I8HDH%VII2=L+*$O;VMJ215+C;#*N%T6J1RH
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MS7"&^KD5G8#OZ7 ?U=B].7?'7#]1,1;3#$6L1\C2R'P^*YWKX+4.$+I9+LG
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MT6C?U85UBF[?DZ,'P&K+JD/+7YZ$\B\E9Q7%/</;T < _0/@[3GG R ]\@%
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M=8I="/0);DGS]1$SVE9*0A>XQ8H%-5&F/Q<QXE9B=9N\P$M85^1.E#<O$ ^
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M 2E"X4Q'H]W8XIY2%B7UICJLR0C&7JC065I:TGM:T[5YNF0U;DVJI   &*T
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M=[ \P@+.*4FYI"*5L)'!2'X>LV'YZ3(^]W3-HPBO_"$#[T]K._B+N@_#;%6
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MJXXB<CH=Q4K>M3!ZT.%[H>86ODD4LC?C AVH&?P)?.\'+=& ^2-B4RA7&K(
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MV-%>-0N]A5/"!T8,YRSGN&^'4K1K530R[#\2$^2=E3^$\8>1;\=Z%+!]-#P
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M1X[<3-EYM0&(ZIQ=6MC>@])LE82,H^W30G4GCF6-R.0'5^,!68"K)($;>)+
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M"]?YY?+%23<1S1L:=H)?B90\!6^Q])R(K2)'/@"<+D%#K/VKSP"J=G8XT9C
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M<^:L=INPJV/,IQ%P_H:L.Z6W[\\@I#^*HWTB8P[>,"GJILDP_DUD/^GSHCM
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M#M::;QQYX#%;2>BTWZJQ  </9-5ZQ\98,[4P5KGPD[I*:/CILC::SA5]B&%
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MWE0@W?<31C\#NG)<C1Z,R:;S9P6X1-^*-V=D)8U[TF4<_+1#HSX0H;AAI*D
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MZZ0U0P7<(X*1C!TF*H-H>"Q+HIPB<#<.;,=UP0]T=XH/]]:^-X@7OAV^N<^
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M4+,KX@B2?BXZ1"T9',;90K8#76SI'*FX/9.R 5%O\59)7LT56*["A.P=4HD
M\^6^?X\?,TME4_AU,4O:0_$Z0P'2&^()+E04@3L2QO]*^OT?B@Z-T;B=WMO0
MQ=XKMPI1%??%V/>NAIA9@&LZBLOR]$JNK_H@3X6,3D8!?5F./JP(AI?1.^_+
MN-,QF)AW;W#V5"HAX3Z799&]=]4TG5H9_KE*TL3^2_"&0XT?C@W@VQSUQL7A
M2G%V6%AMGGK^'3J;,E#L98)*_(WW&;D7^8Y]-1^!)PJNR;U_@^C[">1: 3%K
M<)=2=KX?[Z$F> :8!CXR?6,]S=K[7G3R<:NU6Y"OF&VO+B[V&?"-"+Q&@[KV
ME@3C]B+BR9I)6S.GP7\] 7<]5K8J7?PUFP0UIH0-O+T842^.-2Z6Y&O_,90H
MEX-;P>Z^QP*1A!_TV6%#8_]= <#_MA;[BS'1&$ 2YZ7T>M(TUC@RURE8249X
M.KF58A+J0/ZKDXYXX*%6,*[?71O9N(N.B;KJ]2O2CJB"_<E];2\&NF,FK$/*
M)WPGS)M\.Q&FUQY:.S)+T64V^=GQ'L;T'\C=D2@_XHI=FO1N)G<(XS>>5]"&
M#XXN\XT(9SQZ[F8&VQS"@CEJ<>A':^T,YJ@;T:R\@"M\V^>$:&>$3ENV M6S
M7&/6KZ5NO H]YI>NWGP?S>_IW0U;BAN9T1+L9UEW>SJGH,U-)CBBB'L3J\^
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M4+ME1$D=ET-DEZ/OZ.Q$DZSI6.XIP89NT?4?LM4KX<LTIZ)G@!E=DO.7LF<
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M"V)*$Y*E]6KWG2)U#0O\N0;>^;3!=]Q)?X-=22P'NWT,>$,1<?@"[J=F$4V
M6G4LTYT2=1.3Y6FR 5<.-5%;8>L0UE/Q3Z>NE8^_"Z1<JV]M:,TBZ-M[O#*T
M WN? =BP$Y;+M)IDT-)C/@>%V4_:11*3K'+DS89Z/:-;<H&94<6A5G?HM<
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M,],S[U6_GGXSK_KWQZ_WK:_J5IU]][GKG+W7M[Z]UGY=>-T ,.2D9*4 *&@
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MGY)JUD!M U1^@BG/A PI#I8757:IU3&US9%S&13\4F,E]D-ACPCY!4]N.:I
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MG-F=3L:$M/[^\H,_S.Y%PH/)B4TT\7N@N9X];@I_M67T )Z4,W-AKRWT#^6
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M-'3&;!%$8Z%P)4!24S_U+N\>+K]E]N24J]@-FR[#@4S*N#L)M.P>Y;':/Q?
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M$K;V.%V$T"(6TV1ISY<!K1.'VPY:#E&/F(5>P'LWRA8M"X25^R-/+H>:WQQ
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M&81P1,;C_%%Z]/G<VTUC^JGR9-F04B.)C89'II]F'@;V65+[/X6[@L0(A9"
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MG-#7E[9V^/DNTU0R@/4EEB"6^+/W*L,3.72;)MXI$WW/">.>4,%ZD63,;%R
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MGH8_FC"=WY3NTT]55R_&SQB=/P("7Q*K43__;K\B7Z/;)&J;?^W\N\1.TUD
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M74M74]^BZCY-S=0W](M('JZ\>P0LDZ7]ZX]E4XGO+T!WVUI&][2S. _([(^
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M+R T9#YTK)'C8JKVT8&NN6E&C3?RF=[E! "HFK9F\T8Y<JM&[3GR52J[2;0
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M6Y.]F"I^@N^QP?AZ6K8KE,]Y+B6P%;Y(1.A_^N:SJ<;FZZGVNXO3<ISSNY/
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MGAA8?6.O.Z8Y<R;G\0H;3;J+)Z+Z05'+;[1)2&UNMIK]I)^RY4D9O/7?0:7
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M_;P$3MML-%U=(K)UOA%A#'>T^$[=7 \6B/4CQI# USH2IY3T*V18/]472W$
M5P7142^@0 XX#E9K@HR#!=ZK!A"8E">(3N;<0,)8#<Z 8I&TK=>2)7LB/>-N
M',[$7M,"'2]Z/OD18+.-5A^A7?LH8-CSATK_1+KK"N-+]TU)FL^JU%A.'6,E
M,"9VA4#S=("S"\UQ51_S%Q([<[M'U@1LLODZ*W^$%= #"<I[[UD5<J:D]'68
MB[A*=&3=+BWK53D_RV CG3/EZI^9/@+20F_&PM;83ANGM:6VB^R+ICFF9I(V
M4.N[1"WA0-;>>)Y)Z?L=UI]Q^Y<DMVQ4('SK"@-^+#IC9<Q&?\GK1X!A;-EJ
M*KK(;GSWP]3P:2Y&]9:_/)/# %5RTKDVNZ^3!>=EJ&B,98I? 5(8V,=QL7LE
MW0;V"$!/^SI[,OS0V/\(Z!PE>YJC^S3GNQK/=6KX+EN<^!L8L<3)FL3T&:*U
M!>CNUKUW  )36UDO[K3$'[QGA1<^+>'(2T4;?9WK:"#!EY]5YW2"K.IN%B/W
MTWIF5=JW/]*@60)SO.R$2=&HT;A0: P7(:!2B'[/"]H,ND@R,/]K4E56TXDO
MN(3C=UV"=-@T?J<UTU' /LCN3B/\A':C=?S:W>418,#T\CYVO*N&A:W+^GY$
M$5]9 K]B:=30F!@BI@%+M^%"+=A" $G?:J(ME:TEC5&QG&BD>WR :_@,IC\D
M:G3@?T\K+T@?2(?*EIBU'DPA9'VDO93R<E?+#J13;(2C95YG_^J.EE@& F[)
MMK.;3J32%W=GZ:6FM^ZM(MAP!#S'09O,J_6M&_,)#PU#8Y#3_M>E\E#! \=]
MA/'K+5Z'CSXHW6.U#,>SAF%&GBU>L1>J@J,W#G]8/9N TIZ#$DF,:8S5$P]A
M"="$S:%H^!\RALLL.XX:$K-ZU("O$CR4G[VIVVOV!L6 *W/ZCGAM[0@6NB]7
M[Y%??8Q(5SAO:'#;T?HXGCH%'>2>8%/FF/S.UO)7S>!W2;TC4%6KIGZC5;ZF
ML"KM5\A0XW%:B(>#B2"/5)I4>Z:.OX"CEKVN_<\=W%FQ.X2QZP"Q@ZC]48HV
M%Q2T=C%F(3C9\"F&TMX@Z:WH 29/4D%'8CN43+U5#/^&/-X?;Y1]&?<ER>86
MPZ;* )ALK!I>LH_R4E$G ^>JJ09%H/W:<&T5?^?0 7I OGF#G:5+WSTJ"X*Z
MS4KM#9T^ NPZ\KL2J8QF#*9CED0+^RB:I17BF/6CB6[(:M)N76 _,L?O_TS'
M1SJH4T0/A:??>UQ ,5;$-&:A/R8<Z<[6DWV-9H8)IZ7#5F0ZJ+P8JKJPE]^N
M$:))/F%Y<]4HQW[)(9V,?CU3NC'/3=_A0?@R7CY[TU67Z$0ZEA7,F_&7!RI<
MFAUNH/BYCEW3(R6(_M1I_JK$SV3U##1ESVF/>ZEP&I8[$W. YV5?RT>ZHOUY
M2/:#^Z"03.K868?:W!+(A3'3GC[ARR8G^3I64T3H]QO/[H__7WM?&13']NW;
M! @0/,$]P0D>7 ,$"\'=0X!@&=QM" 1"T  !@KN[#BX!!@ON-KB[V\ \SKU5
M[YYS_K>N?[BOZGW85;.ZNE?O67O);W7O7DL%9<Q=S*N>?4/5*J]I) /#KGY2
M/EHZRLQ[-</ 89#D=+36>9]OSX9?J.;ZBS(KAFV4I+R&-.M\3%BTSL5V2$X!
M:?KQ9&#MR6I?G8+?D=W=8I]?0+6+X(&3FK41+9G/01E*M'YZU5C7O*_I^VBW
M\\V\/B9 &?M'-3[:%_&+@G',+SM8.<?G[5 ;7I%G0BS!AY//12I+CJ3%MXD.
M:064/Y)"?4B_>F:V/&^J/!8=+')Q!%<2]0WM.SAJX7(9?)--1P%\@D6+I#J(
M&\(/0WEURSY^EW*PL'.PL^P.IF5CH@![^/O[UCW$[T2<Z%G1FG'ZD3C]>HO7
M 4B:$9+WA$7_SFL"+=]ZNN];;E72S\.SOJ6Q!$8 O0#.FH,>@4I02LH0MGX4
M!9NCB6LYDS\Y(>2%3C8:XWKW\$8CI.+XS?>L9O@A*7GL/CIVP!A+EZ/U>E+]
M54%1AFFY%=$7=G>T@=2&AO6.]]LFAS:-+:UKU7:-GBU99?2J].3=HXMK'K\3
MWWSJ--Z=3:9O.6KP@^+"T1UN)I+L'FW'OWVG';70/45MG?#U7IC>K:ZGO9"8
MC#W!<6Z]\BO8<*=1_Y2$=[8Y<9;9._Z:HI30:W%C:@<!T"88?_54^ZX4E=TC
M"S^7IW[($YRTGQ^%Y[1R;7FBBY_O1V[9J-^2R7E4C1^^/]-V8+E7PKBSA#;:
MC127$7@&!4;>?WEI; W[E@FR"^$X10 !5WBY\3S&.V?-%."&0/"%7F6 >C!(
M00&5>J^O#;S%,[3_;1D!1#:SG'!<9*IR(X#5//$<A<?UN09BG<W?S+8KI2I:
M&=H+0 B A5DI=7X2+LYY6J.* -A=N[<%$<"*Y:U2'@)XO14Y^I#25!0M^2.A
MX'F%Z*6ZP(N.$< K(^V%>^JU#SMD70=IYO2=-YXO(I!N7XND)ILF9BP/6.^<
M*N-)F3]KHN"CPP^C2F,B'),G<&*?,94UV,1*#_FD=?1:/H1DE;% &IFWL$AA
MIJ[.YO25\XY3WD"&^L!$4DY.)@)H%@9+9PFUWY,_I!6?A<$2>@1:!KO7JGF,
M2:\NK#>++Q3.OD7>#\C.G,OLYDNV'LPA@%"M0 (OV1F?'D%BM\N$E2$5<2\-
M\2,2 G XQX5/[^ULSA0<506\5^,;(EK<U+)&$7KS:>C^M^EE#?D8 @ !]Y+Q
MMPSB*PW-=B7]X'#CS$@;L>6]U>F,N_"/OI>I".#P >.MZB1"OAC=;!O!G(,(
M231!OYWFUQ)W\HOROA4IGDK'"!%L%(_$@C+T<IILA&P3-!Z;1;4Q3I4H/K#@
MJGY7=Y:" *!E(RJ[&K:7YBPJAD^H9S@C&QW<6Q7B$0"9>&6\(#&DXWXN!KYS
M1^"E>XEK0=6%NP>EY"5_R+Q 2/<?(O>VVU8U&N&2U'=Q92.R-?%GW[T$?HAU
MN;^":"0=?\,]*[4S"#4&2>*#-I7BUH3D7@!$<"$$<+-;E5F=$^R\/F!V_T8C
M,X_<L"PA ;5D[TB6KB&\\U,?AC(;DOKV\'C:3"5U<X%16A;3O8+V5O&"KC,\
MRG> 0+PRYJKT4/\>1@)F$:\H'H*=+MYMSR, O59IJDF?CIGNBE0>1>'F<KO+
MGVD;5JNR8QK'IG8(P+?+,#.^)NV4\\)^3UL?D_>V]CMN]H<<G0_*C60<(Z_S
M1M368'O9T4\^!5="1R L;0$!$<SC:J0)-LMWW(/+[&S[M6_37 (@5Y,I!)I*
MCDE-*;UAM(2617]TLU?IP%*<Y!'7).BPL%X 98AK$/(27"<21NEL3[)-#CY,
M;8[^(17U]R%K7W&@C"WLT0@TQ:.A@E8S%6HRU'ZP#]URTF,,LG7VD=K'](P(
M>]+PB=8>?N=@R$:@J5DB5+F1NC:60V83)XS*)S>J,RM(P,W9P4R!KY19R</<
MD;U]<5)</B-!$3H2"[PH597^I]KZ] 2U$BH&>M+.PSSI,5C^&NW=OY&HQ\?/
MU$AE%N6J:]RI")W=I5B^;VYHT7V'93'2BK(HS*&T/*E4%.KV)Q-8M+3WXO?6
M+&1Z%#R:<:NG=/)[EW2!@A4!-$J%/4(;C1Z2JZU,&@C/\4DO5J ]P&?>(7"E
MP.TK&WF-S90ST>??GTSA^.I=?6W0R6/_%=YHOIV\,[%NV!^[+66S=-]4HNJ&
MRC62R:3*Q-@9H+'5X684E#C?ZO.QH>CKA!&QZD#H3N1[!1ECM"S_$[N@U[VE
M> >F0GD,\>UL6??93>I292$^D;0,"_GD^=1<C)0.&F>AB\]V8)CA9T5SM/G2
M'CS4UJWA"0Q!_,[87V@W!(P\[2V1DZ]RO'CT[K*):I\9*5R #EZ@L?!36$#*
M=N67RY[:8)C8\FR##IY1\V970<VD8J(@SS]?;&0=NW2'-HE;X124\85Z,J2^
M?*//&_T"\YF_F\6+-*>CW:ZI5R+A'($8IBE#%B_Y5YQZ2Z6-"0K[V*/MMPX_
M(H"RJ,WQ?N:&B&J&5<;I;5MO+P?SRI<E1):E0@W">%P[ B4Z33:9O4_DZ2H[
M=258ANN[5QZ_3!KU?E8V.T=2@QG.+8-]XO-#B,GX'1_X;8G#,G6PC 51XD$D
M=KEX8UC72T*CML1!@;!WA6_%^GH_'=3PA&.]X[V8.H^\YG$AIN(?^YY?%6'3
M#I?AG24^[>9]Z3XGI8&V_S2.EAZ%5>Y"1)O18FF(+.^G70T;T7;2P?=HAL7A
MC<*RS]ZNI?JWZA+>R?!>!W@ TAL64X.U'/3\LPD$$+\5+IIB8ZAL?+1],G7Z
M::O,VT&XKW5&2V*%VN? ,3OM]:N;\?[5+A;Q%56W1HJ3=.3S 2=N=\;NTAE#
M]8X*H.Z7!-?FU(;IP+L6[.-T31P1TI=(_0JFKV(.'"=4X@0'#?J>B/*#"W%-
M1>^R6@U+3D82I\0X6AM<;.@B9GEW2E$"(UMPD<_3X7+5D6L)("WI9;_Z(7'%
MF@%K:AQO*S!W7SR,O(+&) Z*D:&+=ON:3YRJ)@OWB[<5BCR%U5)Z/D ZML%X
MNJ#^Q!WF(3ANT,Q&V4H]4.Z0WX(-AR& E[Y://K=W$9IW*-RIN%"?D[7:S@L
MS4,1-?)H-S1C&J[<Q /FUE3 <6X6]]M+(Z(O^5":Z@2)F_")+.H@;S<R%N8C
M(X+W%LH_TG[7".E8'R?GL)3D55:.';W/"_84Z-(O@;5^_NI^4]KH:'OHTFL2
M!>!W?VA7Y9I?,TOL;@83&D93=VDU>B*O):\>#^@>^Z:M['-H#*\TB)%Q6[M)
MCHCU@UBM<0W*%\:V!YP'EG%)ZY"RCE0!TWL1AH?(65@PW"GC&%.\=Z$5D>8)
M+U;0^69E62;<[*NG?VB!DHH>JJ;=,.'B87MPP]H;QB#D\I!!:YWG1B[G[Z\:
M*FM-NJ!I MGQYJ9HTSBOX=;K4QUVI/._3QBREG=5VG#981BQ8G5T"$"H+A7E
M^ . VNHOCTQJ0]HKGC0:1-3P(_GXJ=59Y=C9[;<+%Z/D"F.OUKZ=12].6SC7
MLH_DNBV([1T>#7*__'1 Q)ZR(.]8QZK B@2*=FVM/<UL@1WZ$FY!<5%K4 MG
M8X-NUV(0R ^Z!2K9E%O<X0>S:A5>*4,+ 7QW$B0$H%(O#@T1>/LCC]E+Z_!N
M>OLR[TJG[E?FC+1W:FL(!-87K\UW$]MA1+\64P U<R4EN7$NF(+Z4E8B %43
MV]_B$3(P^?.- IBWR''@_NQ\$XPP+,PV@OPA=G07!K67F!\] )>8+S'MUFBY
M*4P(8*9(3K7,PVDJ1MG<K.1*_%=7KZ9U7__: @*@%'\F9$<XMT/\TI>,GLNG
M+9^32[VL\WI^1=@' 1R\43[)+X5CK[[<'6^L$\.STB;MRMXIB3P$KG@K:XV?
M?3=QX7B23Q47 S[6)#CB_)+#J&:+ &#3J092H^H*(QS02SB6E;<;765"3F,T
M3 ,!Q*&^C=H^N1RPE%T%?7P'[BQ2V;RM?0?.89TE[B0/S6Y(M7O<;Y_FJCVV
MSMHJU5#B$[_R]0Y5A T!^,4@@&,-]3:U/&:%Q <4 0/GA+-I;JU?<73?HT9X
M7D('&P+N,@[3&R4?O1[AKCC[=3MY8VW$4J=:)3L^"&ZEXWP(MIOG; HKJ'GA
M/*"G5MYL;!L9!*-23A?,RC]H26GIJX9JG(W-KS(0@(0R)GCI03_@F@0G<%%^
M9G8+'Y>8.S*XK7'+I86H$_^WQ\6@M->-_(YBJO"!WDBUI0^0.>GC=]T;-:/:
M,(6$Y'L_]9;^8ZE[_U0B!- FCP"N"L7^1CN?P.GYYJU*W)H7-W 3#GX+5BL3
MEV9^FE*L9MGOFI6_S5'?4W(_*^F!H_H.-(#QHG;*9UDBQQ/_SN;OM$/;LHFO
MGNI4'P)(V3_!-MK[Z<Z];ZLIMD ^9_91QD A HX;+X8 <FPEEE/8J<J;\B9E
M&>H7*^$J"" ]+[#UZ"GXGB7RK^0/3A(=X[C$J?X;^),-GX'391^1A6L$T(29
M?*U[#8:6(@#3[<733=R[4X.T&5\F\+#ZK\4K#'$$0"C[5U*)A(*'HU_19BT@
MX5+HV7**P,+U+3GI4'Q:/-QZZD+L =:)/=QWD;?O[VO^=UH*-2CPVJK$^^L
M^Z84 D ?3+EH%3<%#7HWP5M7M< 5S@](E-W!5W.C:(4C>']UZBA^%BYX$5MQ
M:Y=VH>L*6H#8\F^*3$E<&(=0GQ$<0>X?*2. +E4*'#+^&MZR:!PK-_[X7Q>8
MKA^%^RS$5$7 X89D?(GBZX,<??7*_Q%)W0:D&@Z&BPCFT4^EK3]]%44JJ%?'
M,X<_.HA[>_'R^RU'%^[-$W=]!(#$^.#G\O]&%VXO'9W=H].?H#'<I A9"CF[
MB;E#4#:%E5G$GU3=I9F!UT?_8!/Y[[ IZ,"4?#+B;TS'_M%YY JL&+$ZB/?(
MZ7M)7^2O$K#%#.ZU<\#]7<CJ_;^C3L\#,U MVSF^"_(Y'V\).6L_-H>@( #G
MDZRC(O&9"]E[0QH$T/JA#@'\FW()-K&4T.-4>%CWJGS(\!Z;;<L(P1L!0=54
MM-%J&[\CBV]-LEZK/N".5!J0D.S8B\!)?:849&+RUN#43FVPYMMPH9=QR6I&
MK^>\ @E4]8)#5E;(=<*J>O"1H(JJ\9UDGQRJ0F,=T194>TM>()'04)=P*[A_
M#,^*YC6S17]1ORO3V%H9;530.G5&!E%GG^IL\/D50_L3?>_N(6=K!N7/&@DJ
M>$S*(-/AOM4'B4T.R/D3&BXHJX&%R@EE7Z,-:[F[KXQKU_[0WS5# ,+W =[-
MJ,5\#6-3G?%<1KH2A)U$NTZ$8WX*4&Z230J0"/5'PGJ=%IJCA=9@U+(DD7(2
MNNLP'_/@NZO(6U;@<2,&T_2N)X]]=W[_^UH(/SYY=$6;T9LO,=^HK>'IGU/!
M.?1YP3SZANIJC]#?ZZQ%NOS&BRXNS0@0SF]#2=V$Y4Z(T(+ 16*900OFT:A!
MTJF+ VH$*=E8851R9[P\+200'WZ-"ODP5>/"4GP '_ALGS46 B0J?H RFWF5
ML?9CMT.^R.3*DX8$T0"ODJE>#Q'^O$P4WH5 (+4A&2":N_5."[??!X]0:&DV
M(>J)$/X@IWQL2=AQ9J-^7IV,90<35DA8MID97OHFS4;F.)PNL2Y.H;]\"N?Y
M\R]2[]T3$I3F3W#V\!.!B8KF\O$ONX_@6V^<I.FD*=V7N,O12$0TAT,HZE3K
MPHBZZ;1<P[.DL^GFGDZ+_,;DP?-X[<?YJI>QU7/L/X"83RM6*+VLW8,7WSA#
M)\7:[U+6L-#?P>0>PI27KZ^=TG1IC.9$DZR5[[$5C$3A]CV2[F!ZE-EJ5'6!
MB KJ7^NL:\?K[5(Q4^.?"\;_DIM2S)DM:K\KH.[+E"^?JSV-ENO^Y#4E?]>\
M2GWSU!0!M#>!X8J 2[4V_5\/4<_!N!! !H,XG+P; 70.H^E+.QK_]=C(WYG4
M$%P,&^3V+D=HGD5)X4[6@_</21# < SU/?;J'P\,[F''D7<8#RR68.+W#)]Y
M4L-FQ*C+U?1FS*M-8;-:RL,4OC_23"8>["[21WM =80] _OA)_N8#O-*&I&\
M!V_F%;/(EBIE]T6U.U(H$EQ\+S'IU@LJ?D;W,)L ]S\JAI:ZC0]-2V5"<M.B
MB$/.![QDQE[\D 4]X\GPWDIR%WD67BRP/94X=!0?QBM\V_BE5?X@RA15"P:\
M33X7Z#)H:CWFR\(+.6TC.H62V^OR6O:@31V,NZI??55R]>+X&E?^*HPK4C/8
M#+S(6UB HZ1-J<1LPH6+5RB3M;Y_9^G<.E>!VVR:GU<*TH_LB[]_BOG\,JM)
M_="" P$\TUG\-T5G[GXA[&&- +AO6Y>2Q(^BK)K7$\ PR'<P;S8"^!(C>^@=
M>G\2!>]Z.-_.O?O^RT\$<&1'_<!7]N(R#+PE'XD 'A\_1 \>(]'6LCK!?^*4
M=ITDU:DG;$$6"Z$J197C;69NL-9*"^N_Y^V56.5X:K0#F37SQ9"IK\"OWIG-
M=J=Z3V_O>MK&:UZC3-#BYOYX>G-*(Q0!!&<M8&H>M&S>6Z@TE"9WHK;6")XE
M@*$Y^OW:T+F?^F(1V [[7BM\MXNXK$-3:E\?+LA/-/1HN>P(148 #B3@JQ#1
MX;O#^!6W%V]$*957=<CRPLY27MPKO(SA3_PYV(GBB'1^6?RTH;<;KJ^/(\K+
M]'#!QKD=IGN1VKA90\"O(SV9JTY:51DH0.F@IZ:1= G[RL[N7M<NA*^X>+/G
M.1%X)A0;QA]WVU0@LS[/:3W@D1,8&<QZ=@4R/^)Q$C%]K#D9R^^UA,/2$VD(
M?%ZBL!@SZC[+MR8>21J+=4,=(/1R>PB[GH2$&WRS<04.14;;Y>Y4QC4SV7:<
M]["V1XIS]EYW8]J25V$4D:B*:;<DX)OQ$JKU4\U[S3\VQ8L^#CF==T^[#\0L
M@S.UWHPW-NFF71.6?2T_?E#Z)VQ4RP/:U]J+"  X(^MO.*:*-'>\N!3ZPO4[
MF9M+D'(WBFWE $;20GW)]8=^Z!*G8AX3%3E?5NIBNGU?ZV);^=W_.<(X[*R$
M63(Y)7O/T92+)%%%*5:X\>9>MG!N7MK%-J9M12Z;//:K),O;TR0;.V*KBY%9
MV?2%ON^E;<>[#M!B-/M&'+%8=@3PAPG6@_]X'OA@(2%?219EG"5SM GF><__
M^ >697!MWHFN2G<O%>ZY_5.DJ:Q5^YY[W+<5K0^&Q6[\8*OWXO<O8K/F6SS3
M^J]2 Z0]+O[.DO^J^SZP_P%14O^AVJJ6ESC_Z5-5AT2TAN5%!I\RC5=5; $[
M-OZ+#_9!_"":(_"#GN.K&DBM[,YYL)D-<]#*_\APFUQU47'O-4R.M+:2N8T1
MBM705X4K01<[$WD7?DD\SL"*KO^5ST@W6>(.C5W>_R!J?0YB:[HM8='0S50(
M#(XSPWE4/W14ODDX9O?@D##C'V8F_F!"P24LOY(-LUXFUXG(,!23%RD-'<"'
M)#*;;@>.\^XP+Q>O1![T.WQDXVKL/O#V$$[9@0"@NR_9-RU$'A+M8]GT$2/P
MIONT\W#9USLH:.@T)%(<B@#.D%L>C+P+@@#(,OOKG(:NP;3#S-']%%PBE0W9
MEIBON-J0QZ=0V$5LA2S=%J_X:\5OWV8V/AC]Y,6@C2Z/?HW\]RRB";9I0$8(
MO5W\M30O 6QML'A<7P7\]3JEF@P6[\3=\3@#1%?V*U,.0SS0N(QJ^(P:;WNV
MIPDRJCA>J[;OKK=,BQJ"'-XM^I,J=A;\5_>AJ8<?4&WXVUX@I&9I78NB]!Y<
MT.A4/*LW.-P#H9\J[;>B\#5Q,# .%@'[F!2)$'%VOG^2[7'44.LPA!*YKH<
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M..L1E=:IJ?'OFQ2VT3']Y_+S@9I4?G^T2NP\E@UBA>OFMIMZT8UT8_]V8_E
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M=B+>IPWLPP,1<I1!UM;_\SWN_ZM?[!)KMHZ;3K)6[POO%8YUL19?/OG]^%<
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M4OEU?D#F\" ,O[=+WJ[$"N(6;H6ZIJ:4GI)^WFU ]97R>+12"RH3WZ7F$XL
M1B?>F.5B9?6H1OHZBM7GR9K0J;@;TM:8$=7A$#JLXSZ/3U.R9T)6OG5Z=S]\
MBSOWX59I/^D5W'AA2!$V,R!S3SNR6L^WGR])KXOU[E5*>+))I+3@:K(VATF.
M0<X7,M[UP=+B&.QMPF1?W>>7'OZ&/]M%-ET/H=498^94Y,>L# -?(.HPH=Q!
M\X64O$61#WZ\+XZQDUN>I\F@-EUE:0U"VQE=9=\Y0$J])AKGXB") T1R>(K\
M<6^R_3ML*!C$0R/N/A?W<P@M=C(.!OE B#@S!<(3I)@=VX.7E7\+K0H6U-0Q
M)%Y*6V:ZZ90%]&A86%^K8:5]^BY.!GR_BI0E?K%X*TG]ZC<7'HYDG<!L=[K@
MZN.B'=_GH;(!ZO7U[F818^]U5N8-GM9W'#FDPB:2$\TZVF?W6Z>G%1U$5XN]
MQ*PPA0D%#J/"? GBXX@K.U92XD;C4@6\2\4G/SQ/:6GR9T)V7517*+H:)5WB
M%*W_P3Q?F<SWRE_L\#P[P'BTU"Q:@,,T:E7J.6:JALO+N^6S@8]]4TZ[ P6Z
M>F_;MM58)2UG.<U@Z#+8_AC=GAE6E.N3K9D&Y>,;>-^\+^O\)*.>D0*HL\+'
MR5$'ELAJ0YW#UHDTK571))')%9!9?E32&-M7GZ.]O**T#UT&7BDE]34V10AR
MU971Y9\+;(D.."U:-,3\>OF>C=UWPLZ+ZLSRIYE/-I_&F0DD.6QBUVI.NF6"
M: =ZH.YD;Q%BXTZFRA(+,-,>1(69E',%) *C#5/5C7QO4F_HW<+D@O.<A*C"
M@%[:B G'V0WR?O<#MG5YD^^VLE+?I1WO*4?967GSS>JJ9R"*T^1 </^[P_6
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M^\@78(EB*.?]IZ>W0<?Q6RJYT-&,_T<,T:G2HK[1=VNE1D@$L_D1@$TO^NX
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M7!$B?*'/+4Z=0IN _,#HO'-4A:CD#SP(:DMO6!_K=_:R(NXD?M+@#U/QE6B
M9\(+4!S_-/%8<CD0--W_O/NL>0\PEB8K!M8FHM5S4%C;R4NDLL2>$7SV)!,Q
M: #+0Y<C!'3U]8:%"N/$*P<Q3^)N"5BZK7-Y[,JE>Q_5+$_H32S9<_?4RMDY
M#:QRYXB>8SS"UV/6R+ #CFY0HVC2VL(T?&SAE%BAW,Q\H7CGUSUAOPC?,][)
MY5Z6OP"88VR-29:ALK&/NQ%;!V'48??$O9,-).V*/=[I'\#JG619TTG,R1'-
MJB[0.<<<;X1WR%KRXE+%Q(=8TIKC1I?828_MM"F)XM\GQZ0'C!0V'+YA*?,I
MBN$T3<HU2QQ?O2D'N:NE*@I1U1B,3PR';N6!7=99'[>YY89=GQ9SWHW4-*7>
MR$^;CC;PXH.EJ&SG^MVI\;0[6;6:6/U6-XART4L-6 QBGSWKN9U5V,!]Z%L'
M]3O%UT4&^@N_.Z@:0AFIC:.PX=1ND=>/BMIG'+_2SCCEI0YUCV+@.-(;C4KX
M]H^ 36&Q0MV/C )SW&Z(E2JFRSXEP29VD"&IJN!""?Q>>P&RN<Z?;98H_!]6
M3/R&9RY].2;Y&OT)@]T.V5D_;K@^4PUT8QC;3GV0<BZQ%_!*['7Y#@^EKVB'
MR3E/DC0$'$R6W78MK4@U-4>?G\\;>+#&@D3DDN0/XG[& L;5$R"/RWJD]F4(
M#K)(HP\MON!>DIP^F*X<VXD-U>HSPJ(J3I.'<_&1'J;AXMQ^OCS8A'\>$=^W
MTNE8+P=5U]22-">MN8^%\[;K2/M*Y@O.(+$<77/4DD6BL62.;P+,-&FE#&"W
M%TCN(/9^Q5#)_AS.2J:A'I-=-W3X,6O816C5<QWLD/J*JS_I1*ROL=<_<.$5
M]J@JGRUR<6R#.B5U&M<27%?P?I8L-J2F^'J$<:!R4(>*!"L!^GG-631'_.F]
M]6P!KIYD6XE-"<H/C0/(YS^7$%Q777NYYXSU?$KEIF5VDCU%Z H^^^B3@@8T
M"$XSX7>R;6%*\FKY0++/\\]]OU0:0_6<4F4Y1 OQH %_:&7WZ.'Z,Z.)AK@;
MU>IH%+LCNN88.?X;$PXBM [2G1B*"L!34YLMHJ1$H8PNY:FP_HV!5Y-<A/D<
MU!<09<C8R+2K;LN/ZO%YQ?(Q5V:[LWTN.<(W+A:R5!EQK1D2P;A0\VJ&F^G;
MI>LRX)IZ'H,.=AL%=G3HQO5H1 36-^=^ 0Y.79O+=I!9&7ZB/#WD'<$!!*)'
M6^C>?R(2:$EOH_F39!$C47BX.@!/OF0+DGVP0^DBE:Z&A'E4!">&'N+SV=&N
MV.#W7R\ S@(DV/W[@CB]6%%"$$)+R<&^SZ&#0Z%)5UO'FS>A"AVD2?8M,&[K
M.K!OT2TT5I[RGQ@I]D Y=Z9%\==CMT'"=:^)O<=[[^X%Z"#OU"H/FA9X\@AZ
M0IP^[L6LEG63"/=+KS"W1!RDQ9:[X+&JB5/V)U8/:H_/?X+YYA3-6/'Q7]5.
MW'[0M_\NG?]MY*"2K]O&QC"OEH*:! T_<HA(2KKQ<TW[ U/@C<MR%\=HO@.(
M,PYE*M3**#=!?BV2-B;ZDT&\9BW.HI)_H;'=UN>G#'692$J88%I2S^,A^YT(
MOE:0@W+BD6/VI" MY^$\/[;(-U+NAVB@:(.E@KH+Q2#+ZF1^<7"K''^XTRA>
M@E.=9R_451<?\HR9:IN*@;@_+EK K-R(W5\GZK2,0>8W:[!NY/UNO'XF30<J
M]VN/ Y'DPIBAZ=F"Z"Q>H8G!2)F^8N&!OE.X]2B,;L6](>]=!\K6CCGY"M.)
M)/EG,^M&_"C'9!5FAB6[%7^HO>3!_G8%5V>X132X8:X1E(#=3=4A_W,T11G
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MLI[XKB5[=2I6#C_3 X6<XW1CC6_GTP=;3U]/77HE83M*6P@]W*^W0K"7#R]
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M+C&VT-,LQF3_'<B/SQB)YV<@RQX!9HKP9</L<86KCBE.%$LHYM=+9RXL;*N
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M]>Q5?:.F><);&["EGLZWV">4FFT?L46[+];]Q8LPF?1?6R+)8NRHX6U81'>
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MMM!"=.H%0+L-><(ZK_V^92NZ@%_I"8OBDGQ(YAN2N,$;+YW93OCP</C4 '!
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M.K=PJ'A"Q]#5,V3L2'!1-+E9%*GZ_DLON< C1&E0I"HEP8W[-%I%;L%)[7I
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MK=>]1FR!BNLQ&6?"+SQ=1\*X5Q9.2V0HEQ@VCI"HP.D6QUQ[9.<S$.AC_1.
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M1)4;G@M)^1!,N&^6@<$O/F[%?(&N2J"[-_^.O^LM]P<. 6K*NM7>R56M"*X
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MI>&0.QH,5W)NG\&6])E@S\8<Q^+ =3H)TCT]NTVV;[JB5+OJ@N;'9^/_5AG
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MZ>QIQN.2@&R:[KI]1.X^P4YJQN2V&W8;VV]AAJUNZ/8#OTL)>:.*M%'-CKS
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MW!G,;TUM(T62C$TFM2XLSU*IDR"+8G\@)9X:.MI!;.(U!;)IC>@R:1 <78>
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M7 ?'OJ$\/+TL! &@.PS4GW8\73U:/EJJ#Z1^D%GT-R\W73DF6W)A>A5-N%K
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M6_<UBJGD!3]<@?8MO%,1_HE#7[F-K]7%L3?G2)X$Q):XCP!0 W>5FI]H80C
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MLMWR?:52-\>^>ND.!7:>]QY)'YJ;U:*P1N]S75V#J#+JXU*Z>!B2]?36H'Y
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M?$'F\J3$:?RM7.MKET%DMKG$@GAN6B9">_$IO!PT%NZZK"#4=U<GQEW)%PC
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M^AO0*!" 74;@0M#ABQK=O^O_E<COW_E#OJM'N0"VVV[H <&CF]F>-/&L/ E
MZQ_!>!DLX5'@K6#[?"'#,]6#LPS;Z;DBI>B+[.T$ZL,N+KMYM20M 0;^03Y'
MQY*6W5#V5N;Q24>,L5.W@GSPCD<N.(=J5M#@^FCCV&#+,8G" K=\?4B9!LQ(
MJ:KT3;DS?@4\-7/3#B0\(K3WQ)UT%O(\-W[%\%F&7LM0(,/N9Q1K/ECZ::$
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M+6@Y//>>"F1>#6N6KX?EDJ4 (QR=G.4'B()L^5D_3I%\&NK/;H\,7!Q^>(8
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MF,9ZC]A:48R08S_\QL6_V[L/9:5Z<6VI^5\6$Y0N;!ZBJ<@?O>40@&_8]3O
MWV2"SO>7F0B M*!1;^XEDZW9S38!/)A]^LEC[>HO=I^,.3\"EAEA\/=FMD\)
M?[@877JU@V^X6/87D-:P$R693(]X\*2GE!C,H* KTJW4-G73JJ,I=LQ"@9E9
M:Y2")2S8!7P0B!XTTE\>M/RW%_&#?MRM;J0Y(:7&$SJ*M VQJPDT;#MM#CI?
M'&PG65Z6Y.UUHW8HN@BO/ !=GGOO))R2K2:L42)]\;,.>3@IA@8-X@'[J1)N
MK3L+,SY]X^T2" "'7Z-N[5Z*H'3Z;/:*T#[8N+W"L-+3:/F3JHEQ]5"!TI]Q
ML]X<5[0$F2M<=!I79@UWXJ1,V-BB2W^TWU/@*WLIC+H[K5@+F[!8T%X=H*)9
M\7>>SBB*EO8ECI!A7 O4G8-M#N=>1*[:W?$>=3N'7GDR&25P<@,88>JN!$>F
MYA!'+V-H45&E-DSV<LG(B[.N4ENTEZ9FG<8=&.'1EA/F4_: V_3I=D/I_->[
M9Y6N;+AY6%MA(X\;WJ4I(BQDBQW5+*0%-M]@?H:1 X9H.17('U3#U]YZ>KX2
M892\D"$=Y1G8RQWNOH@U/'II?IOLY"0_]$IQ0]SSMO=\I;4[PI1=3;S7\-?;
M6I8W>!Y4.<=C@5I/]O[)SI7YD\UM:D+)"JK7]B:POAO?)<DE!3$$G9?G6E-<
MM;K_,(XV/?CV/]>'&RK$:BM7;$X4H5;E'6<\/C:579SK==5_47662A,?@K3P
M-N]=UXC!".#=)@B )\$!LSWL/_'8*1>,T8WG=^^>=""%IJ-A/\W5T;;!HXL7
MEE<$T_[U0Q%E<[,:-Y'QEWXO)>4'.A\:@,/7>MA>3(J:HHQMG@4^K&2<_?Z4
MG?\W>#^0JI\^JNNEX'Y^O@VR46>=6]HTY;W3]+9I)M1-O:G] F]]X7M9SFQ!
M$CEC"O.BTG0+<"PS0D3YK?UI0BI;:8/'_?L2NTJ[6GLROFC'$I.1+<O5$@M\
M>9_&R*%3(3^CT9J&4:X,AJXW6I/[ @,'"6U"$)K<R_>PYRZ<.21=(>,4.QWB
M6(=\%9^!=$%46U+$=D*&S7&RF]+U19WM4U$0C@Z^8*7SN&'H(.M<Z,'^(3-J
M36"D@35TEJE;MW/6OT+A SDX8"ILF5HA2.4&9]T")PAO[<03UAK*H= >^T^Y
M ;[+D&*CS_ P'M^,;49@\?<7ZUPCP2T4G!$46_=;I0_'FQ$'24'!RSGF%MI]
M4)*<+8SAO?F+HG])#>;L!&3(ATY%&^R<BN?6>5YGOFA0OG.FP'!Q++ ]G4$
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M221N+$09/(:!*D?U>V&=<6(L;JI;NK\._E@,IL>U_79CO]43Q;@"!.I&7FC
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MUM6$H39#UA2;EQEZM:+K-8P'9BC>!SH7"9GYBD4QGUI:\?9&6TUHMC4HKE'
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MXHQ_IA8=+I:F?RO][$$=JKN?OHTG!5%J<=!=V%>:W!<%"VG_I M/.-DHFNM
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M%=!O1)@"O(%QSJ9/L4/<\*.K\YY!%\6L0#:*O"H7R5G]Q@3UY)6PT$>?^]A
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M,2VO!^+6O(8G,+:-.Z?[\0PJ=[,E7*J[2DGJ1FRL8[N=O]"$K-;0%^FU+MP
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M,F"%GU87)1P74;DO-:39*V(V8./(LWXUOPS]<ARW;>;Q=_>(^+"F'KGO_R!
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MQ)4Y88Y^[I]-'P0XWQUV50 +&8BJ&[%<#;U64M)+[]&3_"B.W2E?_\9S 0X
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MNM2F,*43EL,\:N-E"5K1Z. ''MP/Q+>]>#3HW>[2DET]NS)\FND7_8P?Q8)
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M+3O_EW!BAB-#\9>4+H$,8MZ5S-;_*SA"#71*-GH$/",KG_Z7GU-_BI^P^G/
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M@)O6*$="<^H@3Q5"@]VO4^:/^QDCTD@%QP+_2=V@=L:-0>[GM3U;1AHQFTU
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MX8Y1"*38/W1K^G?P-H5QLF."YCI)XGQ2N2%-HFJE<)M@N5;%C)1<VRN+Y9N
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M[(G_QQL>@QBF:.]1!J=]9[,Z8<FB^(K!*KU5'76>S(DHWG R>+P-C]X7\4^
M>W<.]4AE2[%TW9G&L2+!ZO:E;WWDWW69,JK-^MTPB1PAX@TTA&)5#W.Q6G]
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M]$3K)R 2')U7$%_GY'H"WZM]\UX?[IZ>H],'R TQR\JJ#!O'XI*/[LZ4OG>
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M@:_')N$K8CJHLO+J@%N _'>4UQ.;!.-AER5RB!#$L_K7_*Q:=*\J <M7>?I
M&45SF-<=I S%"A384$K:-G5PG<PXF/](^R''B:^Z#.ARE&/T00X81B)FS):K
M2<;HI/Y0**G>\R#$W<$I&T-:EIKYH#H5DQ9A-0:S)8^Q;1YV0:2-8_D>>_)E
ML?+#+K< TJVD2] /PHA^TCOJG?QOU%N#&QK?@N%;AE[+'\RIPMY$-^A]3%N-
M1EQE+@,MN@%ND[3!^446#.O!7>Z4HU;F%:+KG\G)@+[R95PK&9&N?"3;GL8M
M":PZYYYY.[,\:P/U/.T[T])6NW,BL]N7/OF)9O>#@YO<SG[S]JY$F7W0UG@(
M<W^-5OIV:5=AF:Q3HF#+&E@BR<_RU4,Z H VC6*DJQ_&/MK8,1&=<*7[81%-
M/K3Q2F^#>?V[$CYL=WPU8JM%XA;0][3V;HY&^EWC3<G_5\;5@[FBA:/JE(*(
MDK\6,K:) -QJ0=S#ZR@+1%A.:Z MMV'E15:=M,^\VV=T3/U*4Z3"GW3$F<$$
MK8OYU<L^8;/6.G--X/"J;+0GZ51[*ZZ)S6'A0 XRK;;IT=]M0GMC?W]04*Q-
M\DJN@"&6=8HY4#B&8U^;7-B(L] " ) $<-PS#35A'K4'T5H?=_KAQ'1JA-!E
MFS*J*5.3T,D(!$W5BG1ZB^ ?=C ]K/X>ES3PKJ$Q?LZA9WT:SG)SB8LJM25
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MH.*4#<MO\.TJ@3:6BAY%*"RC_9(IBGNE9K*D:X62AR1BG5'0,]$,809_>Q\
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M<NAB!I%-?%3/>IWE<9',*2-E[CP^I6;R*'/W\N_B/4RR,V^Y[_',?'_-:/5
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M(HU"3^?70P@!)Z#$#+3A'1:/P4I9%4 J9SNYQ2*EJ@?XC;/T'*LU9/G+CB(
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M,.<?-C=X:,6"+J]6*IC)E8J@J6'8\]@/RB"=>U'Y[0@BR3C,Q"T@)!U_',M
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MD1M>!B*SG -5B@A@IBW <@^8\G63FZCR]+76?CT@R!_,H=Z]%A0P9N^8XX*
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MA1E0[SD,F(B\BE4\Y 2%-YN2;!^9100%Z4^EO*%\(3$8&/>(3G'I+L1%_W$
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M(%"*KJV[5=7M,KO;A40UK %@H%Q/*PY1OF-$,Z3VUWTCAYNYUN$,E5<:R-Q
M][6,($/%WV5S01X_5=6);R/1&/P*:[2/\UFB0!:[U2>(5OR"%>68&,4*_3_,
M#.>F6)'NFXR_=N\4W\-:/UV*<&%VHO9;W-K1[C/JYU1F_N+]VL6PE'**>?DM
M5Z_,2,$+XLV/BJ1,D6OS9=UN3),9ND^:-C[\ IF03%?-%TY2?N0-<6J:_:#M
M-97,>=ZXTI4$G'IWKF.-Y4;UUU^)KA$3VR+FD^[??:NP-WTVIS%=NYNU#NZ]
MGNJ<2V+RT<X-XY%WM[<S<:HV<4E/R:GJOOT]*C_"]'I+,DVXK'.E9;O,;3WN
M.OV2K;OW4]>CAJ0SRS4)CN)<F&ZBB-W;(B:'K=\MG^O3L1ETVMK:&J(4$]=^
MO#YD<>P%38CD'L[HIG:1S"28F'RFU9<V?D6"$Y-I$X/8<T3!BL'5[3 T:KW"
MAIVV0UO'W9FGS1%%]-77X]=:Z*3T_+] AU[. A,57^JG7T@:9 6R.2J' K38
M$+GI^K/L6JWAP\=XU+H91[^/KC//C=&F(;Y%B\9FK7# 08=0D4</F5<4&\_"
M.%6A;HIS\].RB0G?HI)Y\#L(9PA@ZD/%D[Z8^UZKSOZEY\>W2='./X^70I"C
MV"E:&LM@\T[Q*(<5?QS1$8U94E&[&2I3G2)D.9&Z=]ZS7"4>*0#-,[7.W(0O
MOQ2Q'QEOD:?0Q=I*^B,LEAW[5^W]*^DW5T4<A((B'DXORMA@S#4AU=C0WA^\
M+H6%_>0J[ZCDV'9Q=.W'DE540HL$BX2ED@W#%-]\IQ/NZQLQ#IG.GMZWC>8B
MZZ?%:]&B0YU&V&DACG!!V"&)#ZKG['J0[E0LF:WE@*>\4Z=P<N!*&P>;0J\N
MRP\U>2+=_^79(,T@312JR_B@XFL6QC.=-NDM9"C94/+B+W*Z.I>4_H$>OB$U
MXJJT!D%9L&@[H/4:H [+2+6V4;^I8HBE-RO^HIA3I"4O4_F?93ZU>2-,R8U9
M4:AWYU=1FK%YX0 H0MZAO8#3B,!($#P'?JCS1469SG4)@)1$%3"_78VSN75X
MR+2# ^UPX)9<JAZ\TV-QBW"K5>5)^YYPP#-4-R2.YA!O(,[OF:XW>$'J?(W[
M_@H.S([=U\ !=43W/\'WL3X0F_=_.4#]+RV\*S<4A?Z>3_-O[6:4+X7!?YS(
M[L6[PMA0%,/]7_7*]:S*;\XDF!9S>UBY=Z5;#CTA&&J*64&5,2$!7)9_-985
MI;TKT9,W#R?*S%AT8C2HKE95"BLNU=52^L]288"" I[*<'-E)Z^L9,ES'F-^
M'?6N 7:5']TQ4V_[:./J)+K+U]HE*1J+&03\F^(YHKE[F4\0:J*O4HDK+R>D
MOOH?=>^_)>I/B$5'Q7NI].I[RFW>!=3/PSU(-\?24J=)$ !(49"C6/,U_\>T
MMI*25J(GQ\@KG1-_^5&[Q/$?@E\",HD_W$6%//:YJU$Y:#<L;1^\N>N:-ZX9
MW>&5D'_U$_K*^D3OA![3;3^I,DJB*Y0+LF'(O=9!+$8B>K"ID0=()?MP,M.=
MJT[!@41[]5:-TC/Y5VU6)U+=T]CYSME!\;^RGW]]$*>9;LE"68NJ^5"WQ\U*
M^-#^DS-OMRCAMWUA0-#Q5,]#.AQ(NBT7,.:\C&*/R"@SW)T&+<V9*HH38)?F
MV9)W9$ZSJZAL3R)LL>5_-T7$J)7N8JE'0;KGFLSE^G%EW"HN+&+O1()TK%6^
M(:8ZZK]&+F6^,VLN"=%.DCWCUX]]$VH[U+- V7Q[\F&;W40$ &,FTG+3[9+^
MJ4F@!V(;#",#?J;76YZDU-%'RR4\7K-IRB^V67-\<O/_EB'?^4?RG4I*>HSG
M1'7=K[1GUD?%GWH=BZAF)-)&OM<T@=ZA:ZPH_W0\/+_M6DH>$?F=<?+,3673
MC5 ^*Z\V-DH#1&$Y$%R2<"=9U#%1D>R3&R:]9SZ%A9]';7CWTSM*V\O?2IYY
M99<5E3JBGM&8M4^"30A/2YIBF>3$/&]%3=Z=BRH;G6&XGNM422HOB/Q&XWLV
M8^V,SV#P@I&0'.^Z0TGVKJ(USBN(>?0QQ"1Q1K=YW&@D591LE3J1Q33$0.IC
MA1B5#--!7O//(?#7N]CBX9%/-YR44>S965[/N))KAMDW/+/^[420#--&F2*!
M:5?1TM?B'FA1TIM@=/!>3MF2L]-<?\@OD]R\N "$[3!@E[HMPU'63P_*02S(
MYW^S<]I\[-@U:-3YJZ])HLIN8C^!0P^1+CYJ/RNPA@-^IRAPP W-X0"ZO#AX
MA#Q%%#6PQM[YOEBD /8?W'=>8D N'#!B9[G]@<8\/O5&SJ"YZ4W92GVB</JJ
M!^? 7B,W:APOPN]B[3:0X-3H1\HZ(.]B?X8#O^1*X ![DE:PA/;0 7WK^Q&/
M= )* DJO_%#ZIM\>]K2FR'H_Z5](9$CQ0GH%=!>=N7T7T\0H#'C*H;#'WB#:
M-UPOBJT^5OPPC)VC"B#F%)IP.F,JS)_3%[-J[B&^SQCKR+*>WP_[M6C([Y>4
M$!$;8?71M[<DE%*_++TR?0EVQ!]=[T?*4V9N+37V'C5X.KYF]FTSK+^NI<A0
M>P!C#N2;_!,.B*_1A, !I)L$(ZO$RW$UYN<,KWNK\>][**$CY=+%A]A5K8F+
M0"H?D/O<>[U+E#E$0^>WOK-%OFB8+ HF[R-73SQCSW>C*G[V%V57U'0-48(&
M$5-$CU.V;4%3& W0._;E^JAF'Y*^+]JJ'_*PT-&%<*542AT"<5-#>(>_<:CV
MG/U*:-1<?[6M89,-)D_2F3R_MJM[T7R6'V7%G>Q>J.^*\J97O6U79\J/PIC/
MZ^/'G!1:I,GT3HC>)".&K:9AT561!Z_&[4I0*'/-HIPWR\W+)//*]8SW"^1K
M[=UK-*:3Q8(ZB:+"=6:2P14U<H'82=ZG' Y%QDV&06;-/\V8<^D,W>C17%?U
M%CX&/%/L\'!>S.\)0QC!Y_](8%U!^_O4XI9;&45,_')DQH-FNBVT42-:E&+/
M_''FMW=%M5:>KWW%@N)OU]-!B;%*_?L( T7/7$$2GUZJ*#_E49NE(.+Z#!N/
M@=-=-CR9DU<$O:9Y(N&'%T-<<6=$B,Q0<%+4)U/CIJZL>&LWA5UP+(9JBIX@
MR4HV*[9+'5[23&%P^CI3W%8W-<=X+53@?&HU<'@U99.;26805]?AC9'+&I?\
M*_,'IE.WV+TP+&))BZ6%"9&=(_7P'H(Y,XEI2-Z.GQ .44)@_4FC54<I=M76
M>&M4 'MMV1IQZ(MF)R[WVXN=#AT'_JM#GW8A'9@3B?%VI8N<2^BE>@1]6K2?
MC>L3OMXSF)F&07/2:FZ 7\!*T_BS5XW98RO:1+RVE<)]M&>9,Q"YU24S_I8E
MR<V5"JMFS"2_ [H8:!^K\J_IV-XN*@67?H_5B?-!-P6ENYI@(L:!IZ2_:I[@
MBKW1N2"'>GD5)B8:'P3SWVX?;5+N>6=.PL8G]%KK/VP*.P1,WKSNPIH_1K):
M:V/QD&- OW%UG1%69DQ49EQ/6FZ1>I_N,^0?4LH\ZO;E^5?#7_SCV(!D=..#
MWK8-4_^[K(OQ9=C.=0):(,-R*P];L"GY=FGTL7U>\BW3;N!3FQQQC)O@&2=S
M ?)1&+6CU&_J(D>]X)8]%]+6P4@]#*O%>XR@D2F!CAKE2U7^LR.3UWD?.RR.
MRV)Y^P];942=BT92^)?"O)#6XF=V3(5CODT1DV.=NL]L0R"0C_M&S2=H%]VM
MU3N7=I8Q!/9)HT%^#SXI01+#,!>JH<L\/HZ8#Q.OI8IVC&\&WHT>3DD#+SPQ
MG/FEKI'GX4#+O9K5A8,.\?X)H;=I0_W 5?W@1>-1803.<K2#&\QP@;TI3J/]
ML>]=J3H<D)W(G2BW50TI3^!#IFJD#7%*A]S%I'N,P@'CR4DXL$[L#P=,+:[)
MTX5?2AW-T(_MY$XLR7AGC[=*.844R'F.JU'"6CC+Q'BHN@5W?,U(#N<?NTPW
M$B;B,U+_\K^9[HU =('F<>%Q_VA*S?M!+DCJWD?JAF":]]MX4=@[9Y<4_0CH
M@E_2W;>;^(83TC@M]"+WRVHX$!!>"P<@/?5CTR]P8\@T:,,_.HME&#Y;Y3%]
M44VW_[UHO/% X(*"[-EF-;5;+6]R@/((F?A#\IRXFBOE&E;[G=F%JI[[7L7@
M(7&YW[F>A)AVP^1!5V4#PQ'=;B%,K,QQ>)]8US8Q +E-6/>=$EOWDF0NE5%Z
M1)-#41*9#><2JE/_2$>!PPC4;(]0HC[EI?Y>5RI7[\;.W4,R6&7<U8W>R))#
M_/V#";7R39 !2K=NEVHJC@N8;V&]^69?S)\-4^! XY->U=MSEB.:O3MH_XIC
MOM@1-TMCZ+5X:), <YUXE7.ZMB(#>VO'<PRRC: '^_H]44,5 6=U@0HADH8@
MYXI<XU D;_01E;%GYK81S'[OZB6WW#L@5;E7*F-<+V4=T[#+\ 5K?.]VVBGA
M0/R2R4,[WL/;R78F.&!2" =F0/<<D)3XR;:.ZMC[IV>&(3)W7%B"MV)-!S_K
M<15WPF\F'KO<./SHY/Y"!;KJZ+V>D3<T%J^6;"CE$.,MC4$.\IIJ<V4B%Z C
M%PI/JH]7(PQVO=SG2*F]]QN_;VW][+"ST=]YAQ<T439DHEK9\JZPJ>MEWKWG
MK_@*F/W"KE 0?T)G,8WD$!R8,JT0!T-.72Q@NM\'DPCM.]+ !X-%Y9TN^SZU
M.C8)3+&VL>$,V!$8M%$5Q<XD-VY-Z7Z]=EI3\3GEUY-OZ;=8;)L_5!]6??&W
M+$%79@'TJ48^3!6<\L]2'UIHXHX9-N??Q/YN2%\G=6/ZQ/X"%Y.ZZ,ZEJKZV
MH>:#H@=!3_OWBIGIUCYK%QL65JTK>EBI<<NEF238\\#F<_W#]+2'N]LA-T[E
M>Z1QGHNU\'NG&\A[-\Y:Z"%JDC+[FPA[JKYS8@\%.) 0KH_00S"?[ITRYY?#
MW.;F%-(TH@7VCP3J"K]Z)WW+@X39]2KKV/6N\ILN_(,%4R#K;*J?QL9J,XBK
M:II/^7AB+4#6@3W>>A>%0]OUSTOL^3C=I>(AGVE '\&$NJY';JN5]887>TFL
MD=[8H$B_DPDD9\/NQ2O9(\T4C>I.BD?Z =,B5)\M[_+J)5SFOVF^(P>M*SO6
MZS<1) 7QVRYP#:1)CN[.>21Y6!FLMC6]4^GE>!V,[(R^$<?.MGKVQ?&*>&G1
MP'MJU[K6F*"&CX=3F:4I_^NP)]^>5N?3!*S>UG:Q],0WJ;23=A$HCSF]7H##
MY!?9R2Z>1BP-L'>3DK%AH=$4:-6E!/I?'U\'2'&W&>8ELQ1["]:2>4C-KQH]
M$6)\C>-H-,=UOKGT@22A\BE>9F#LS"#U<D>R0LKI?KU27'_YQFD>^!# M+]Y
MC2OQD-P0XE&T<\.[T%8]2+!"__;4;$2C*QMA8"+%6NASR\J'-)%? P N0%2G
M\[(A9>)E0YC_3W9:;._L$*D"DS+SS5++/[*A_]#'S23:1-Y\6WR-W"3ETN>2
MWK]CCV_<L [=#%Y^:,]@<$\4(!-<AP/[[V<:5,Z:;TE.Q]R?G QS]-]I'5>H
MMZ6K1A/,^PYZR3)O&R)LZ!085Z*T/()GPC39UPP.C-P]/&R);U]$KNH:Z(4<
M[W6EV,7X)2S3/G 8R3V\QS@OJUD!/T&)W^=2/:[SON=H%T[GG5(+V7S&Y1Z3
MSA$TTVG.U.K*'.]->C@1SXI7OF\@YW"\P649#'.^>R[3LC_-XBU4Y?WUCL]H
MJF>T,,.KK<7E&D<G:8XR^UW.\N_W6B0IS@ -_X34XKO@&IJ=Y38+]7&KNBD?
M-^JO0K._F!J>=Z;(90TO;]&\AKD]5CVK'0S@=!T?Z(O]1GJ;>6$S%=\$6Y\@
MZ.U*-T3):H(#HZ5??X"T88\T',\4!J=@%A=?IM33XZ$UH"]R@98?0I5'0P^U
M)H-IG(L\H!:M!#M>Q-':&LE4([@2\>52HDVE+E(.( =;\849,=D*,<GV"\H;
MRAEC6^O 08O>,\ZF[:"#D:*VP-_QH;79)'?]P=-SUQ;7+9)9:@9I'LKC#!/6
MG+T_FD+-Y>[>:5<A=EDS''A #.E$X%ER&7]BR'M-"_83X>M&/(0E*S22I_]=
M?CWP7([TNTW\2E$0[SLT&<>"!KV\MKO;#VTP<!_)V4,3N1K>@W1]QR$<T%']
M?S\RLSBC@0/NH5]&\Z!PH*^_\![O J:F\2!C +[H1KR^K$WC04%-:!L,<W8&
MGV*UP(%R[KM8.\57&A4/\^%5.M_!I\@--PT/;YT+$:.D:Z-Y:*:YQW3^^5^X
M-3VI=1.-A\6[5<DB&5,X$ &><09?'(/3RL,0K?%"-RZ$4M>U1!@; -_R,HW;
MJ:</W'VJEI/G3:Y%#Q,3Z'-/T^BI2/W7;G1L>7^G"(M'=NF'WP>AG*&?7U%_
M$OSB7[:+C",PSV$89PNA"=Y1+9[5*#2GTE$SC:OY)OK\$&3N,\DT(JK<K';;
M[WNXMG&W=(,]F3[/H48=8"G]H;(>N"&'KL1?(W4_G,&!;85\,Y6?VF/E3.^:
M3C.\J$L\G:6PP7VXW%<0!"006"#327F6471\*F8R]?@+>AM"]!"&!\1:[0^:
M7+RI /=9*"%FJN.6=_K>"3$5 16['>>?L+?N1.  37/#_2O$'$%?J3XTJ"%J
MK=UH!W@_2/EZW/R6NB'4_IUZ[YX!!\QZS\OQKI,[+.Y;0]1NOHY)K8N5PH%V
MJ7-FV+_[5WYG<;(=U''/%.EJ?$)S]WKKIN+A+;N+6$"YCZJCO?1)+?LC*1G-
MWTD/TCKW!HBA$U7MDMSXO7/A/XA?+)^B,ES+*<[\0FFZI-9$?+3[_4MZK%!$
M!:J[L9J@_K4)- 8!,H;+%IP(S)UQP,4J2:Q2C2]$S-IBF2'$R^7,C9.2)LJI
MKIY^O38(;2PYU@"M#$*JE]P3.T<."_8:[FX,L(GH!MDC;RF6+(I<*C8.0IIC
M,KII_#7@0,6;NU(#G<13+DF#JEC;1L!-_^;L0KBLXTFX-TGF,0H]62=V9HQU
MP][8=SC0I@]>N7M[*7[3H_.LZ!5S:\N9X1FI%8I(_[#TUFGI4Y)I][+"?EYP
MG.PP'$ACKMWG/*CP;3,7*V9(%L*E\H[3T%!QK\FCH)(TB19K(M:A:4Z]"B_>
MUF X@SU/AMX;ZR2.B5BL+UU6$42W1P0[HP],,9R]U.(>^!+PH#O&\OG+=W=L
M/HBQR]<A*^R&2]<J48PSZ9\T#-!>CM_Q/04!+U7>(FU4;Y %H@;CFW]BPB!:
MM9ZL@.KV2RV@6M.M'_2#@S(_HBM_)=*QU>!ED04UJ3SXNBH3$ZB6=FZ^V$-E
M.21H27M?45G$.=')J^BE-S9,H$>Z-1IE5[?HV55_A5TY2#HO1XF.TLBORFX^
M2/F<:K><6AECB72+["+'+CKC75WT#SM.OABL!$IE\D94=++./?7<6$XN=]-;
M634[2@*^;D[N31GQ ":*[:!XK2,-DY:UXEY_$.734H+D2#HP)_1PP01Z,%U=
M+M__(>03\O669+*5MGP,_V=U27N6Q]?C()-/!:/;$UV"%&&F::Z+)_6;O) *
MC>G:O!21C^+:'%^V![QPO/1%W[*QRG&8LBA$D/YHNORZFN_&K=G<&'B>[T9-
M@N(EA2XW(J8@76:JS:_M8"1/I$ORCZ;6B"D_,N9AYTQ^TD27& Y'+:*UG"(3
MEW@6:I2)!_.94M2>G%![X1!A))3T.KS 0=]GIWNXL _W6>_W0@]"9S;&\DX%
M!4/(X?30U?N#@_/H>G;,4SA07#+=G/PC:&AID=SG-+*'V%-!- AEQZ!0]++T
ML:Q;;MV['@K0%LW6?*NQ<-\@GBA(K;_)N/_"?7Y?+SI(U=C04;#ZY0[!V]W0
MPFKW@J897\>"">(U0P./[$6DF;O0NM"1;Z,*^!7,P1'FT9FLEQ>P[36ECXR.
MQ>&YQ5^):ST;8^19)V"'\B;R95FMEQ8<5>;=.-R*X2]?QB^K_PS5WPW-3LZ3
M)][5+L#2U"PL^QA%GIWD >T1[ZS6NTWDUGJ@K\Z=K*C5?^*<4#OJ@.G9^A#:
M,;)GQB0P9BL;]^73L0P9>E.IE4C1@9.DT=7VO8'%#W]6TWZ2TGQ3IDPH6R(O
M.AX8K)*A&J;JQOO(CM37%/_WM.](1.Z9^(&D?VU&_;@*'/A0W/H3W_!X3#X@
MO''O7BK9.]CX4\FM\?G2@4NOGLM/MU&\/\(=VXE0R)HQ(@8**X<#>]%P@,$0
M5AYZ(\+-;Y3B^+"'QD*V%_-&NR%RQ9?C\G$*JF587OHP:2N_F<G(FO_<3JY9
MZWM[X^.?=Z]A#S X\(7<OM1.8AA:J$;@KF3+-!R$#7V(*)$O6R:=YL AD8_Q
M;'D#A$*F,]T$[J6M5S>XZ"7T)3N*?H_K.8W@4(HSL,TIVMD5-+<\>S,YWC'-
M>?[K1;5[4JW3(/BBE-5DEYK6\DJDKFKXA<V1A*/AMJ"^VJ8KG]K,J\RU;0[M
MYO8*$\*'XP.:#8O2O>U:XH,JXKI:P8^<SQ7PG^80<Q$9?"$M+F6R94#1'26;
M._29P^:KI!NEY B?V=%T#,HW?O6XR()A8>#MW3@V6__(BIF 04M5?7N\W0_V
MM2H)Q=&9+'$,)@N/"+]4AYJ.C=WWH9N2C9UU9E2?P@K-'VV'VB'<773\XR&B
ML2$K/\5/"PE,^][9'??.D%M5T[K5M9>$2'=:U!TI+EC"D:.EVH8?!'Y,#Z8Y
M)BZ!/QJ*_^<>1-\]N:0>(K&?-&<:^J#V"VVG7WB+NM9YOFK2?+33#G2;)O31
MH$+CY0S>]/:]W)S%<OLT> C<YS>Y[P(94S+S-F1\C1*3]'"F=0^%+5'5WU@D
MXIVH!(4&%-,>=W>=*0O<+V,7>>>;#7N/>(RWE*ZRF,-$K'YM#"Q,><'2EVXN
MD6XV86@;-4Z7,N4L']_<5GU\+K.W#"G\'7)&U5/\X/,AA_'%AB9NV@4L6D)R
M^IM$RACJA7O^O9H1[,MK7_;;5ZKJ9BF#=P]@SXI9=I%?49LD$;9X%+@R4-8*
MY?RI[&\B];63_)C8*2;EKI&#LH$<YW  WS@]M,ZA&&#XR-BV%HK 0N:U'+P(
MYU;=P30GW@3>RG]%>7LS [EPG@WQ'#YY,+B1S,[ O5JTS["2J*\HUJ!_0_D#
MB_)B/3V\:_Y=J['K=$;THC"J0C@CSO>D;0ZJ<@$3H_*R@SKA);IKH9<#,(C\
M8G"H;LK\1CWDL8GISO8W=5NP4+!2B/*65)9*LJBPOTH^8U-%GAK,HR5>+<15
M+GDY9G'T8"->/6QW=[OZ/DNV1])P[+GH#<3;<(<>;(?V8H$RE4 -&0[X\89:
MY(BGFT">+.PFR!>9?&?4)$#= '79_%80=2"]L<_-UD]7>(5WJ>N)D5.A^IAU
M&+.WJ"_2R#'JK&?\6U^Y9L+5>V>N54=+W4#L&*D/XW.*@>(.0Z_?C\B3K1;X
M."ZX0'6VY?V$W+"GFV-L#4A]]6D.L$<!K7< GC0[9GEKQH>5TZP&./#D0)]-
MP%*-MZTKE8W1^E$X]+;KLA3$DL9>&)2IZ]I)5$,)\*H)+ONDH5;Q<&0&Z6Q3
MJ17OH]U?=-=Z\9.DY"L,T1"HK".'NG^U]2G5#K!0#8CZ8*@\9>_P["L<^%IS
MK1<BN=4_-=5_/YV3>?LR'#+D"<9JOTK/\7M<P,$J3E-;W'=7BA>T.6\8]7B.
M?]K$31[_2::B-_FJX"7#;XT=XU_KMCYE:<_JR!@<-\?D\K");V4_*K;+"RDW
MM#><?>I>-[$-Y%%F/LWR0J)JMM1<\P6Q&<W.YD9Q\$G_R0?CD3$Y8?9>IPNR
M^T$UM,R?I_43>KHY?S%BOV:@G"IA6XKJ6^-B?+<OR"BDO3Q$E[@J[/8!J>69
M.@" #&C'!<A MZ7!+RX^7E=<8W.?E6='E?L]T[7$H1\U*RCH7MJ?:+67]^#/
M??V($NTKE8ODWI R2UVV',=\HVYR^UD>=KF&EP@9K/_]G6X]PJBJC^/=!;IP
M&*FE3Q;5U@_\C*K"0&P-8E4?U;FT.K\E*G-AJS?,K9])M+@7(S%.*H]& +T
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M<6PA\P-N_HT1K5=+*[D+O\J:&5ONET<6[$9NK!4U[:PYW)B;4M8SRJ%T1Z6
M^N2U)IN%K0?.YY#^7>,(QX/>N08GZTH;QS-_VEZC(4 I71D<^;#HT!C8?9A?
M@2X"(\,38&5^<LQ([IORE$0X&)D^YM2\Z]*]DZOS95/5U2$JJ09H:=4JG)A\
MOF,<_&T#)H>2-TO:-3K.]"&ZE>9=X3@]]GCKQ?C:%2/X;2 L "DQV=><%WX"
MQ*R)*.ZNQ25,L'NP2R(-J@\<WT,$"A: RNT2DXL[OAUI>FR)]Q9@8_4>""%*
M36U4L9#:U5#\]-\[N9+H49IL2ZU2UDIU*:V.^S]%-?]_#\_1V'\!4$L#!!0
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MDEO+^"^6^A^C@!OQ;>#>F79T9G*J1.4!\)+W,5(-G NZN&1C76<=4.ZKU3\
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M*_"?-&!LFGF@BM@"^>H#['0V)G)'![;U<A"+8Y,P 4SYLW(SK?(CII:!]<S
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ME7R$<JULB&P#9DQ8T45['#HWI<+)2G_O!B,9/ 94;%Q=0Z1JCT'>Q"ZF@N&
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MP:.--!"HQ/"+H[$\<?,%&A'_<=I1<:*1<1IZVO*CD..>DNR ?51_QT!8H'_
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MD6R[RV4$4A23&C]UJXTJYJI7U>4<T@;Z)K#W7U1:TQQ<_DERJXO2E[D8X<&
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MMGY^ _DM=G.Z47C,#>FJ"OC1:P!9B?8J#6&0BL"Z)<IM$\34_\(ZD+3G\P"
MU2(5O/UOH3$/@-=>EQ-$'DD^S!N,,Q33R\>$V6&2HPFG03'#K3&;5HCHJP?
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M*L";S["AM]( @-$; '5S6=GP(9.M@KCH_"24M+[@LR21]XKX6U6N<7(C =9
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M@/]9V!<4'=]?LEN''@NVQ?QL98(1P%^K@;PY26>5+$73($J4/IE!\_C*E[0
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MN05=C@)I<+5^N$UE.ESIXP%^R\Z<1?;)LU"'.]F6KZ+2K"&F)PHX6N,_ B9
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M?PC_#^'__RO\5X7& Z1SJO0,LXLW_W,> >K+;&O?-Q"Y[F"D!9@ 9'+#"4!
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MYNLL6Q@_F([1&;@UR<9Y:UV!?6T>M9P(.6UZDP]UW'HT(5*:1NZT\"E2'^K
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MC(A)G6FGEM+[Y=>)"@'!+91NTRM,@M$-7#G842UF]B_WE:KW>3.8I_G%SU?
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M]<=;+57DCDP+V6:%7=.]EY?/2,U8(FEP5^$,#<*HSA,BHV5Y.$:^8$=JQ4
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M7I<8VY;5:Q-S=3MI)D9-IR -'R$K<(Z-"[T 0-. $EO6&;= +')\^70O%/'
MJ&]@?<+>V5#8/7&:IL($8MQIYT W&/]ZF9*H@,-?FDK38 1)2B/YDIAH:H?F
M8%E6UMZ>0HE5\FZID_/L_8;$YNR-1G"U*Y01Q+_G4[C\</YH3MX:^#(L:/P
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M(4_^<B#5SV>+6<%XW,4G ^&9DQ"=?"HU\3'6_MR>38# -^S@V\6GC)/H48L
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MR%G)G-7JM"YAW6'GU=8OGB#9R]N[.D1=(.9V*D-CG&"3CY*\1!\/0>W[X_E
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M<RCTN[SSP0UY0C(G>?$9F>4R9FO(4_0.8CYA0!;J4&<<'D.9^>R%^X$T*C5
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M$EE: ?YZH.LG,OTG>D4=Q3T'M2P9T!H7SQ]-Q1KKE]LHMGN]=K4I;LPBPX_
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MA1*Y4Z;CWYE-/76I=?R?S^S$3=]WZ5 05Z(*D.T/4 #J74"\\]H.C+QD25V
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M7B(NE>QJD]V>>*]"*?;X_'T <3;^?P!02P,$%     @ @S!N5H0EI4.&F@
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MXBSWZY2LF=GM([$![*_E C,5=\).-U2G^DX394TAU;WA!C:.86&+/O3I(8S
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MLK^!;T<9)$AAFC"50%)\U^UE./V;C@D9Y9[60?_QU(H1*U9:M^WMHJ*H"^=
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M%&4$;2<%X:VRK(2CP)Z!YD'C=7;-^*LO4UIA#>'YC.F-*&M?_I%=HRH1-CA
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MD9E\FHR]V>",P3,EAO=E6:UU0>$3N[$WTJ1!,VM-9J$/W^BLZH86)-:_67A
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M)S^0X+LU%N#?FZ\\PY,N@\;;=Q\&67^#X?D:IR-A5[[FM#EK6,R./$!%Y><
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M5D\,[RW)'[GE-V&,(L?]TQ0,0)@.R>3?+P'$Y'.!E+M_B?5_V_[Z:;;62LT
MP/P_T,7<\6J_^G[G?Q00Y@FZKEO! \K_PS<#_W%31H<J,^WI5P3/N]7EO*WV
MQJSSQLJ7P9?G_-"S(:1T,B>-J?ACX$&W+VD7M2*&D*5 'K9N%AZ2[5_*K[NL
M'G;A]^/,JNEJM@G-OU+E2/MHS _@U+FN!O/2017G=ABM',^BSE15R]J]I11_
MT.ZU;(7OIM.B H:'(H_ME=W0=SRD.QG[5!<PTADD6\Y1'"D/5?YB>)16-'B.
MB@;0UDAE<%3B/Y$?"-ZU%0>Z-V;?3D[GJL]VF)/5GSLIYMB@D#BAD*E%,:08
M(T<,.J>@GR@+\RKZO*WD?%'Z1(*]!\\'FR0XMVURJT/K+^YML'Y\I:)>DZ\@
MJ[[.\!B#9\DV9]2&J3?%.+A&^),&BX-1N?=<9D7U]9L^<,"P(S'1*=4^F(@T
MHH[\!"E=3'ZT0JV"L/KS2^Z&CKJ[<6A>6+'$J&O4#R5>H.6=_*E-**A':XRT
M>- D-@3-[0Y3ABM8%=__^8O5T*)^B.A@N_ ;*+\6S,8U]W&VL4(Q0PEV"V0'
M#%"I0_FNY.]5X+^4'=<?TUE^@C%Q3K!+8/(,$# TI/@:*DIV_UG1]S]9=> "
M/8N(_PU-DZA*QD])O@BR<[K<+UHO=U,4HPY,%0H+=>D41LNH/<3C.=*Z=%2-
M9ILFU1JZDR,9S"'!A/Z03?8[Y#D=LGY 3[SNIX&CW0)+!U0<IJ$S^9A75K52
MC@H1@T#/2J9.<6/56+Y^?87'02]'1B"%M80^-AZ2_G^@\?]/&Y8'2>_A2:M2
M"$A.% ORQ;QR$;2?8BK$?3WP4J=6%KS>V&XAP#.FK ]:% EIK;3BNF9^P1U\
M-H+^5:E&Q:3-RT/D::8?4<&2I%X0E?^]\5?R^!(IR)E_.?]CV3H]IQI?KO*!
MB=:Z+ZNO0YEZ/=7&KNC70K*1)Q(S)(N=(]K9^Y<,.<3XYCH-CIJ'ON,_+8*T
M\J=:+=Q^R;(:=/*(Y$S6B=0_EAD]Q?6[:IW8_.88NZ0ZDU3=O>S%4?^XX-;;
MJ 5GR$YHV+B6*_#M[?V-PT+OT)]S/JH(O<F?C1CD#X<4,[".?.UY4U[-N7 B
M&MP7BGS*8R$K<U%"2<*H%A-S^8@E-5I[D U)\Z2 K8M"7Q65>>5:-S4N+W(+
M=Q,7CE;[L!RN#(F#A'PS[%YZ_>ANQ?T)P1E)%@79-?5T+*13( #H/)C<Y\9T
MW>*OBKO&*=Z<45#^# <^W $]V#0-;<.OI\=@S["AG,X.N)-] MAG_9D=RJ/2
MX]>/7/1IZ$+I\V/:4/S7F Q+@3:00!52V7>L"KG78X6L#B"LA06!L*?:FAFI
MCOE!U6"]377YY#5MH_7HK&W!YW,&8(<R0:$+Y;.-0@Z^'!8FJ"6T<< .C/'=
MYCJ'"J/>?O%0A*@6LE]OE3=$R"X!1L%JRXI!9Z>0)_)T^#[&,Q$U(<]$$'4H
M^F #I_W#6^,?;\?^;)PB=>I,:V_#Z,;\HK,A1F_ #UX*0N<M7V+V2J^"D4.)
M['I6]5.&"]/-AS#DSIRAX)OX^+=J/>RQ2$0,7>%$5 _E:.=K=P9HWXQIZYS+
ME=<8$:DDX=NBIG3G&)>6UU9<,W?D<VH>""&ZG(#H<@>@OP4'&@\;BX2T.LC*
M'PIB);UC:O<0T;N<?"D_HZ&I+E*LH=F!PI@@@7M7(5E/Z<_""P_OMZS*HPJ;
MPP$J6"8<T'D(V;12+C>/ 7.]L;',4#9WJXM*=D*Y1_,!I$R%7T+XJ5SMF53J
M\,G%VLL:;>90CF1YD<6QT2T-A_$1;2TUC0'KF!FFT#R!Q=5W86$!P"J,@CK.
MG;<RNKW#]FE53'X"#L77%(H4RA"S'P=F56=HT2@2POW'8DF;(^Q*)U3)G156
M7 T@!3JK?&;+ &/3)'R/FIW 8(;O/\T9RTO^+]WF_SM-0A"O*NSK4B0:ZD$*
M&EVA6^LR[%IB]%2P06?/. Z'JM7@H[@4^;#?K=E@\K*@A^0;:IXJ*3"R9.FL
M-+X",1J*QVY2;#>*W1BI%U*)F*'ZA1]Z7;QSW/_5SGD%-1UM:_P/H2@=)4A5
M,$@'A4@3D-Y$>J\BQ23$ *$'1 $!%3"0T*2(2 TE(!U"$:1+E19):%(M@(B"
M-.%ZSMN=N0_GOIPY<^<^?,][9JV9O7[?MV;O\:TYG]3ZNMJRV!<TN=>Z'V/]
M.@1L,*T."!;1E9D%A8SLU2OC^L4J_,'S-U$=, TY -VYX@EZ&%_$4,)R6+26
M6RZ4/@4)$6$MO(G&1CRW-N.D#);8SW7Z!D 78/V->G?DJLGE]  -WJ@'N&]A
M7[6$%*];QDC;B9];<1QDSR 9KHBP@.G6"6HPH<1[Q0UDX:REM?FE^:7WR-"8
MD0Q^3.+Z&KU#G++Z3TV^5%NQ8Y&$O;-7L1F$!*^8(3P&_F!28 68$? 'T1_O
MEU>54:_TQ$BUZ[<//,VCHV=NJEXO,>N.!]KT8 O> X@0<&$P^4*(I02:A<:?
MH/$TW<L<VB<F5N\>^KB;[80G*_R,S[B5/-4XNO1*BZ]YQVJ3LC+]WV(M9P%?
M/U?L-SK!$S_T!3"+^'3*>OWTM!I835!\!'5N3ZAT=1%]NHT4LVININY13:HY
M:=,&-?KSBMD8AS C-\88T7K^\Y!IW\VK/^Z*?KR^G_[U()AA/K:#.JI39S@;
MQE2]).BR*3)!.Y>MREQR&;EK<_/.8"JOF[6/>O_F_ABCCI[M&SLGW87PO8X%
M>5,;+2^UQ,UWKPBTS2WJON9F?',4%Y.WIO@ %.V!&\;RS%3?D(IJE$][*LWT
M!^?T\LH[2=P?*0XCYWI5GVYNZ??<]"#5H@:^U$G^.MF]7]GB/9U5U(%%92%)
MMZ_)]W#)44?5+N[GL=Z2RLWN5C*NG''4*C93J!\N-VN^?3=IMI,7W3$W@OF2
M.-4R%Z9^4]M'NHI[RM.>LE'V=!(/+#9L>$8E%X:/_26 6.YFC%B\;%UM\1!J
M":MXKC0)@G:S/SX%0K#7H&1(D5X),C@9GF["N!?[;;;_"YU_&F9%&+N!UXY4
M64D&>H! :UO54.RT%/-1]E-9MW!.TM+<U(,>.D_.:.MHU<=F#>2[N2>J1C(^
MQ"PXQ?YBH'D-H=>P4T2 PZ_C8I@Y Q$\N.\?P;=N3\HVROH D:/;R<?=3N'H
MDR>MJYO*S^;@P^*__N_]T'^J".N6>SN2B;7"P$/P%2Z:T= [70TDUZ22ND.O
MBANI?K%XFV=J'1\[#_KNC&26P#,,WBE17/HY3/S(0N=TW%3EK/JJ&4BWQ$$9
MXW6/]Q(TZA%V'X:]S_XLF<RU?XR2>D$>NK^N/N7'7@5.(^@0ON2RN8@ZT4(:
MLJXHW;/Y^&5==CQ/D-K,2T=#SLW\[JV2%[<&X?HA4HT_:V?>);3B%]$+!S$9
M(X_8S]UQI=K7SX:,Z4;%$*+%3+K6!T9FKZF8]SWN\>KZ1/U\?9C)"%6,=^(I
MC \/1Q:PQ*@(E,>9H[&Q<5J[/)73\<"JUP<1E*)&#>*G%N2KN?/[E#E,#=C6
MN18JQ_ON%TLHZ"W8P^9#99"@XV] Y *?$^69D8"*![7*%)F?'RGWJ]1WGL(L
M-2>Q:/]I1IHHR>7.<%.S$,_>Y,S4LQV4NFS> OV+-@ZH&U-1(]:*:QK.]^_L
MLP;;""AN4PU6.UG0HL:HY]J)*7@_=1/ 8XXZ[["?=&0[/V+<7]S O6-P/I\$
M=N^,V\G#&JJMEX S@EY_5>*[F+< H]TY/%1-\1%\%%PVT*E^EM*L_'U"X:.%
M)L=<@;&7&EQ^F%_\8F'\FO 'W\W )#8S\-OCVX$_! )Z!;7@3ZF7UY65/Y%V
M';_!\]@<R5V-&<0RESNN<P[MKR%2U&YA]"I-O9;T\RG,XN_2P/JIZYMLS,S#
MHL;=3]6;9Z2]7M*\D[,5XK"K4AGU"?TBGL=RE05A^279-2/2L2? ?T('7G$F
MRA DX'=6*(>-(;1,*0R\L8TD"MSU<?TANV'_IM-3M^^AO#4V EF>'ZDB_DMU
MM_Z#RQ)[L )[PP)'UZHT,?=X63CT5R'IK[D0^L'ZO#+7AZ'PNS0T$V<1TLM5
M[KG5#TFD9=,W7,&2XH'UB^\/R18?JBR'M[B9%1NRE%^"A%%/-*" P7L#AIKZ
M"(C#VP3S.&.GYO7PYV.W&N==FF*N2;;;H].!$-?6]:(0+G,&L9FMS58'A26*
MVC39]D.WY_,QS.V*OC46K5[^AK# BN=*^I-U@R9\&S.9L-HC;9/[-:([>$4M
M2]/91-" P+T627%0\N3UYP:6->2MD_Z[3>T-3J$R6;HRL:/26I2STN&Y<L/W
M76><C:O@9(F+=QO/8XA-#UJ2:?H>1DBY_HO?7/Z__DVJ51 ,ZS)*\VC%0*3E
M2P9%+KT&@R6U<S#%&Y&O+"<A$RC=G3\3E\76.B[U>YZ _5N_]YP(UTT1B<2-
M0IB>_X[7K9^);&^MG!I<KX^W=P'-+Z?1?,\8T_O6^M3+1^.\],BI FEXVY"C
M]ZO!-\(DF57[JXCI2QPG3G_&O]I!R(SU9JZIGH65#2+B95G8TI(OW N(R>^;
M]XF_Z7_ZW+,GB^4-<D"M*UJ=/K7=VI215M,J<G$>>)G<&<[?XN;Y26M@\?QM
MUOA_)F(5D&5!5I^3$;(5S3KF$ERQ)L$7JAI\</2@=>L W?+]05MH'BM%2L-Z
MNN)Z4,(FWJC=W5;<+78M_3;+R^I>9@Y&2T;!+Q37*H\*JMH>E!<LT'>9=-V7
M'UOVN4,^]PD=*)H][!_,XYVU]JK@0 HC=5"+OQS-XXKP[!.I@#-SJ"9?4QW_
M$C85]Z;F#]9(Z9WV(,M8JWP?#D=2HHDS$,*->@-C_WW,])*/[?)#/39. >J%
MM_>.]+]+_38]:EC6"!2(^$2>CJD4';>[-PP>F#F^O1W[9X,[F/(V$XV^W',N
M(LNB^<4B2VK'RF]BFYE]D@E>N7T8'0 M&%C5O."GU[NF^H+%G]'YYWBVB0_3
M+2>H?GS!'Z+WJ#O.-[/JPM!3H<\OZ)I']58>BC!%W^&P[^0ND"[6=3I+9^G)
MT@*FHP=V3!<9VX2SZFS5#D^!E" DG.3UJ]&.@[=;8I4V_@R=' RDAHV9:E.U
M;IS<H*P)?>:DJ%A:Q#V?_)36XADN8$Y/D8+JDE%!WQS$ZHUP'A%%]\R)_2S\
MO&H<6EQ4]:"K*_H-U:WA!O[/0L%J#4*X')^%Q$28CP8;'&3[3[M-)'ASDVP2
M,QIK#FQ_+(=ORB0F,P+G)^.[3H'8J$^/#L^> BNM;X]-+&-R^T>"$)T42^.U
MP#H;%^T3&<7A2B\[-UX+"T!ZHYO>(H<%KUE67N5X"L#,,-)6[]Q2WVW?>"R6
MF4P+%$:;ZE\SL["$>UO8_SX1J9E04+_Y[JO*N--"$U7+_@#$%M GP@8==G:Y
M=6'Z+T4.K/?1CCB!?,8-094!?46 <W[S_K&#S]B?THVK^=7G7[!2G^Y),<ST
ML]FSSL)0+M.[@RX,P[(^> 1X 6YO#?5C/A]M $B(??E'+":C8]TX083DFNQ@
M*JN[!#2YTZCYE7XJOX6L-BKG-^\,U3;7!2I+*#OCOC+52AQ_IIWZ1_ (MD7=
M&I^WC7<()NWR&YVD'H7WR_[&G/.A)F[K0W=+WF^&<Y1IM5M/#7RNR PZ@M=#
MX&Y-G@[I<UM<5]/QU]Z_7@_&"-((8+W'O<T'0H)\^?I/ 2]S+[^;YMVP>^$-
MU]!4R#3.Z[V40E#YO>WO>Q^-'@[O/:I#=2PT\O9"$T\4!$=:DUT=*3H>(4'J
M0Z)!]@^J8WE&C$G8I4@%0IEC<*EOZ4S]D-88I,Z_L("5O[1+*KA_3YD0:!),
M=JW'AUMG<BM1;+V89B,[JU,ZZ3C_5L'6)I>4L0-QLI]7+VC6;67*=>(P'%'R
M[=6'-EYZHE#^+[_>^[?*MOU-PR31D?)53@3U;?*2>3A?[>U,BK)GD/9&F:'%
M9$Y@:59"@J6=9NA:"5(06Q* Y(K3C=>.>MJI3#P%Z.%[86G=$W,/MZEI4F<%
M!-93ODT4^7[./1<WJSY->(8.43268BF#54T>G5C_4>KZ_GH_<AAN_'%66-]J
M&C(98< SVO9@^I)T*=,;HO(1<9-:79Z>?L,UU4(O0B79[E*^-\AH.^YMJ3PO
M?=%>D8HFNN7^N*+&K0VI&Z-Z=;5O2#4TQ=%?$<5I7IT#:9F9H:"D%TE%@-OM
MP[4$U-VR.:1O^/IL)^MPMM:YCGP$6"/01N=Y49P2= 64:ZH3'/K$AD2>9^=H
MPSNX7+=%ZR'/@Y[BJB6\KF2(Y6^JO7KQHU%_XITYU02Y[DU*6RW*9JBO;0X=
M\L.]RRECC"B(:LLFXVFX[FXG_N;#-JI1TDL\6'=GKK*V?JE9NBIS(?E]+[2+
MY;6^^BB3)L/)$T)#51Z"DM*SJCY7%U#W:$XZ;WFWPO="T]32'6;'DYVM(P]G
M\(J34QQ]H:]V<)KK:ELJ;KR3Q7;,@$Z\NN=<C*Y%9!D#<"DVP+:=);=W:0=I
M!D;ZM:VL8;"#!M)]<WEB  ", H XS?:#A?.^#SHT0@HUA096&-)-]H]MH+^X
M$ MBW2@,!#2(Y%<1Z3P%TK.+>6\>:9\ -G_,NGY\5>)NQ"W,.WAS]W\H6JTV
M6>7G3TN;PD4)7;2+EI>S0MRXSG?+U!:QY>-S::B)U"0T /4 J6J:_STSC^;+
M="3T>G+-_G*W_.!PMQ&*!:-6<8793Y5V]:1I#QS0W6B[1S%W>N:;,8IS-ZQ@
M$WV99#B)M5/6N"85E=*,SG(QTTPP;\.>,%/;5,UU=]JGX(/-!0.JO"X./)YX
M^<+$',Z4K/%0&[%:N3GO0V+/6*88=G=52\2T54+7FA-[ENY^%VQM&'#?]][9
M8C_O?6CEY+T77'X7/.GGG9$0<+D9 <YT-A*F:%?1-PDE,V"&)S:K[A^#7N_C
M77QMFJ<4*8;?9:@'EB*)\1[PVC?'E?I+S##6'+)+<:@CJZHU:7)E4H&9^JV)
M^VPQ"6=J8P1A*BMKFM7GHEG@%<E\^XF_]A2(<2=K_H0=7:G1X;OYJ?5I?-I
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M3]1=B:2Q !5D,V2]4HS()< H8K$5PE?3VJJ-D^.GVSC%.4J7 &K1IY$K1P:
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M]_E4[O"$TL2]):%&JQ?10H9F-/DBWZY1$[<N8( ;%>]YN\<,& !M>N8:1^@
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M:>G%;JR0$7';[_D S3:Q707UCW]O_;F Z_""<GR/QP*E[<7GGF8AC]_J2R?
M'E/C]'W'>=:_>!FJ%K0,"/]*:I=4=?Q=YCKHD@"!C<#7CPM;BNT?%0W!A,5C
ML@/YWP:Z/'Q1?RL:EB6N2;T&.-<_1W*Q>\E2_WD33YR"%=^;*+DOZ RM_<R+
M7'_9&AME<.?[YWA%FU[B)H:=^R<#..FZ=5%E  8($/:51NO-+;01QJ\=&4&T
M-'GS,'RCEN"%#U>S2J8OR7^<25M<_(GYMV3UYU.2^%$@-Y3@CA$AX3_.?KA8
ML!*@"*S<DT;]DZKD)_PEHX01VC[Q&@:(MP)>X&LUO4J_L>U<A^K! !K:D+);
MP![P\I !ZF==&P!'[/H5<,3N,S%-!@-XFJSZ)%))&GRXR$*, Q_\PUYI@&9R
M+%4L?1=TYZ%@0A7)A>-:9E/Z7[DBI@[7I!)#X>]?OHYAA.Y <W,R?9\!L@
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M3]/.$[0'5Z1 0M!CD ]<H/OE^\T/T(Y6^'T?CQ_/(/52P$+U\_OEWR;Y/W'
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MG3IY%S)I$87W+3[P41]]KEI)&/FS]*I<7 5<*5/EC$F\F&,M"M$B5D6V1$8
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MOYIE?/16M##OQ>_01!'#68I)&9Y@@*T,%@D*! J-PF$A0/Q?LG1JH#I),Q$
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MN#9E*ZR!T:<C?QPH(Y?;J/0EKDJPB3UO2N2Y ZSSM4*)Q<DH-DJI82,'-V.
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M<D(DR!%+!RUECQ=(NGW9_J2D19R27V(,$!"3X-T9OHGF*GP#?S/W*AQ!NKM
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M>BMPPNKR  C\O9-O/OSZ'U!+ P04    " "#,&Y6E&XZE>4H 0#P8@$ $@
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M4!X& (;']\1 ^1\#^)>!@HJ&CH&)A8WS!/?QAL:G "H*&AHJ.AH&!CKZX]7
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M?I3#E?KQ!MAC/K"DA6!ESZ&<+)_&"-;@'226.XJ4V]M54ORP>&=P 0 JDO3
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MX>IJ#0O24B#;=]WQDPVM4=B_(>ZF8U;@A#!L)+Y_21KLNF^=R'AEC5#U]OE
MTQ1)]_+S-(Y%2A_F,E*4?K T?/4<R0=7;'?^NM_FM>SNQQS6-]=/FL",GZFQ
MQ-;D(5H.IH(+#-,+YJEE]/<+1[]5R>#2@J7F$_N=A8)A+5/K2 X(PO8!8.$8
MSCL9?P *%/QE>H*DR0R#%_T>@ L!64I5N.JP&>M\(]%F'NZOM8,FXD]% 9^5
M/JUF/Y4<&)+=1ZD\333JCKTDC%XVJ=L?M2TQ?21M?J7$O>YI,3 #VN >]3E]
M/NCX:722JZ3"EE2 SL^.UU2?#)7PXNC.1T8HW^8I#3=ZFPEW+#2>+G4-:\U#
M/<%6<2J_\K6T_70]I'JU$3^QWL/B;@<7S6B;(0/4UL757\C26V9M(WO]9EWU
M_ZYD.TM1E%=#AJ6YFV%*D=5"G[<$ZHAH>:-6=B6\J/Z(IP9B6(+9X2Z)-0CY
M=[->1R49IVK?PSA:?KSM,G9>24@)'\N-6' =KBO<BNQQ%,D3X?N@(/J4-B_[
M!O)(#$.? -N-P?$,I VJ@=)'&K"A%$?7<E[R1':QM>RG-"3@4O3 38D;ZA.D
M(9Q"$Y8;7B GG=QLQCYOJ6N,;7QMSPVXR+&$# .HGD?K'='*G8UPZ:I"8U [
M]%V>9_%!'4<OT)S!/V#YY ^<<9^OI9Z^J[4:<A4RLZ!.!/(UZ%+-_!EWE[MK
M;$(NU^W>*T;%_DY@T1EP-4:^@Y=&"W6*SPZO4S74UL]9/QWTM&<<L&6T[O)%
MQTM("$_(=8]KWYZ*,ZJ)D RV_+I\P.= OBA<($?JL!XP-CBOJRPZ].H!P)',
M.C=V)412!2JI1PT/2#-UMN7NBJ:2RK;86&!"?Y8-J8N*7537#_4S-&1&1-_Q
MQC\ KU)#> S .O"@].U "7EX3327($*(32=T\X.A".U+KL[T5D:B7JJIQ@":
MP-F+&A+$] /PG.)Q&>\"'QX97<4*S4E>,0!^7["\=B#N@%CH_^Q594BL\$>.
M)E-Z"9WA.C+@=(B0O #,WZS&MU0"Q\HD:YJLH@$F_E93W&.8*/4Y8X#58+-#
MRW) Y\ OB%01[D>9ZY]DL;!.(1X:T&Q_FTV!J@'"AN(C!Z'26/AI2_[-<\ 5
M3#]-&'4O<$0M(;S7./M$N?\KN,^8?HFU]<@<(?<86IT1W?<D-8BS6Y-[I9O3
MRUS7._Z]$G^XZ49X\,[O#N,'P*P&N56M*C\/9B@&6\ _=O$E31S3[WI'F!I^
MB=S8\T$QQJ+:#9%B4ZN%O3;'!>L&;-KUU.>.;;$&SA)/IHA09J:$;%3YB40@
M77V+P?ST9#"$O:1<I0/QZUS#_E<)9:U7-CMH*^CP4+,12?G-.\>M[KA\F%^C
ML:,CSH]I8\/&M@I!M?"P;S@2 ?[ZR2#;'E=H3;BV0]8'HJJ#S+-1-*5^Y5"-
MCR.G:X'W#2@G&P0=./:;,OC%'P.LNKX0FYD0;H.]&/XDA9\?JBG C0WO>Q$!
MP<%W.>_+G$"9?ZYA?[\WF2K]:*4:UCS5[2(%P25=M[Q%N#&KK&-J2+Y:+K_U
M%Y;A=:@9-O_+<I-YYQW^ "AR =9'#P!1(P,>F!FV$2-X+*&69#S%+MQ$Q-]/
M_=$R0O<]I(UOM#+'$GJ=U+"B+*GP2%6]GH(^V&K2K/*=YZB_4G9-DZJ+",A>
M8!A@^"L2C/D =!/>Q_D?=W$\ *.8#)=#4X]6]@8809R6RU4B.7XV2CC]I?#5
M?!=RB5+@@7*]^\T$J0M?",\_:&N%>1&!',>36%*WIKXPKH0LX9]A#BEJ)/EG
M?86SW:N=]^89!]\17_Y"ZC\ J7@R1XEY]Q$?@3PRL#-&:?\QH7'3]$6G%OXK
MN[5G\\X=.[+3]:@4S/@K,D:[TA+K?KYF6%UV]<U>0Z+#'4J +D-L]YD<F/ !
M<)*YD->=2IR1Y$=@&FSYY:!8QV(:CIPE8;7FXW/I0T^3.@3\K(.A,EARUE_-
MI)DU=B8Q!<)6OM/0'EN;;%[T5@7'FO'%OX,3AF-T00H/-1WXHY.@-RL_0#H=
M(+LDQ=FHR<#H8O=N\BZ6?6EQ6-?G D3 5'M7:[L*-3,:QVLWV7=*G*J6OT<V
MSV>*$7GO63,KP#RSNP^ L4-M'W)O5R^"/J@@1.">8P-4?T^^'F?^KM'0^43'
M;HSVPXY?^&-9EI?0C'4"_[M8YI#WM%$=$RD5;OCHRGC^JS,-+]\[,F)/I#7O
MKB)H%%5&;_2IX$U;@C6QTD_F3_JY/A)S=(381J0;MEP"<;Y# ;_ ^IM5N(-&
M.(['W)-PY# 1_Z857G+/4Q%N?B5W61)3L"8B\ZM!?_51%VX]1#XY#-QDG:[;
M=7*:$_< ]"1[)GVNCA\.)BW^V4'X%?%%+FH=BO_&6ZM9>> ;V0=%LBA*LF$M
MCB^(<'APWSHC(L"[^(!_RKO<X44*KFM]VZ=8QIR!!%I+-'O)[2,#!F)!QVY"
M) XLZ@LXDKN@;8V)OLS0RKETU640\+VQ'7 EQ>?1A0NW;WVL@ZWZV.SV5$"D
MM5O0]?XFB=B*+4OYG>;E@U\ATBLZHRK!#-9LT2Z[NL3&*FW6"4UKJV)LM'L[
M=!+ZWC7F]M2^_>7<WD>VK3.#1?:>Q*S0L17]$J6WX=GPA,6I3/%<R):S[[L6
MA"'4^=VA<45(W8$KWI=W_FBM.KQB*PG$XKLATD4=CA&U+0'*"ZKIB0G*:U3P
ML_"1;=%3<UZ0HPXBG&*PRF?O[;03&YPVI:6S/E66*=&7]4V>( '!]#5$VURK
M^DU" JT'QUZBS("_;5BPG3JI&2C,MJ$Y2^1U\,N\YPDN'2_8DE^@5<&;!YU=
M^W(E&GYR78!X,J 3=,]DUQW?_0XK>U;;S.C#6B_IN<U <B!#Z'0*-MQ2P[BD
M$A)XVM@>8?**^6R4 / \]Z::JB$CC%VSNBOIX#WTJ'*DPEHAGM]85KI_/<%Q
MWX?V "AT JZ(#2C7 Q"M_WK&BXY=XBY +]&(DH9)=)@V&7M*[(07A05N,I0.
MYX":;#SE1'*4@P*4PG[GT$-Y*?E[>VWUSM]D<ZM3'?S<)DN!^Y\8,Q CN'?7
MMV]9H31T!Q7*=(58M*SS>FQT")DC3$4.^2W+@^5N" N<H'';D<MR@/^517,8
M9>ZS9MID.A(V /FM<W0W1*1##LXQZ!O$UP7;"Y64<2X;+X%<M)Y\BIQRD_9"
MPTI28<-"BU./?(Q<8,-M.FTMZH4O)<L'&41U4YSL(_ ?V'W)D^]X&9I=.BLF
MO.\"-'YV<8*JM]\L6L Z:G@555NL/IG@>6QRJB?<;26+!N'[R_3CTRC1HR]6
M7K@2]58ZM(4I+WJ6Z!36D6E&]5N*_8VA&LU_4@Z7&7XD]FUM,)Z(8Y>& 'L\
MFX#A_C$E,;0?[]:B3@H7R=H+P5J! 5M=[37]%AEMU2FTN=Y% W58NB.2%L?2
MV4_EZ.K-"+?42'JD=8]+DQJY;)7FJTI?_AZDUR@;1L=>C<(2F\1Z<S&!I@Y+
MK.E3IU/?HDE\M[NTF?K2NGM9A"PA60,#BS)H6Q"E=',J-E<47G3CU$1/U2#^
MX6VM0V9$.I V]1%W+W(HZ'K+K+;<7*G$WM?W//A;4^1N<$$YVU_]/##68]C4
MM7X 3!\#S,\)?\P*B[:2E(#2UN5,#4F6;5&\HF C ,80E4L4#FWZ6@&J'^)7
M Q<$,W&X<S"A)0Y8*S_3X050)7;;Q[NC_?7#D!+0VPEBPZWZCAE6I3I?[KBQ
M!'G4=_[$8E,+'8]9V#61*XC2[(B>%.X_81D?SJ[V6Z#,R5GR!4L8:K(LXV+!
M!E(!=IH YH-6X!- '3.:I_?2?_/RLS[A'9X(S^L+D83TW##T!TQ%-2]VL;4W
MAALH?53<<+;.?J'94"G7Y>*)9!,ZD*D?=^#:Q+E?F/FB">J;]1/%"6UWO96H
M1^RV$*(C^6:0[V%A#X!6W%)4-^W97:YW2I=SJ/*KUI5)Y4F!">\N D2V_F9&
MA;<G4Z*V0OR?\9_D7&=]O^CWL.YF[-#2X2Z?W>$B@_?"<_DV <ZH4V,-N-.?
M:5@(38X_WC-UNFZ>QD3'=-':_SAS::TSKYTX?.)6"C<MZ6C>V@L/8BN-U'H
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MD&220#>&24CKJ<<I>$3'/>TL>"L1(&'-4BD,Y[3#V=D$, P+0OC-^];I,QZ
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M#E(%&H;</P>%F\%>9]G&@+F$/_&8B56>O!(OC+10_ML&3Y)#BE7Q0#3C>2A
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M@&BX^T)H=X/0:\W_%LH6XR2X0<(=^8WBXXC9FI4 5+Y5UE5^Z@'X]E@@]CP
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M\=J Q/4[P%,!PUSXE&:.BXUT**5RD1G07YJE:.SLS>>'?0/V@X7Q06?;[]9
MB_%%0R-G^C6F.KLK0=+>#Q0H%<B7,6)^"O\9KZ20^>9GW<T3;&)_A(N7!2O!
M5(_WS<?_CS=3U5]"UQF >U^1'TLF_CST9H_XHGQ/9QZ!8Y&O7WF"D+X6YW\>
MFCT\_P<Y,=:?W',G^/)^SN[7&)Y_M)M)Y3:T9"F 31/W,5MJT >N@Y.2<8]8
MIJUM3RF7@/*5 U#;Y0OVE7??6GN_9WH!1YMR3;!>0>A41MXU!H_*1D\$8/SH
MYLUB%O@>=QQ56#"2RI'=L[TFMIJC#:Y[A8",\P[Y7\34RWTTF(DTH4@X*:$
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MGHF\7O<RUM3%;N?'+XKJCJ'#"I#N!H8;KTYNO666MH YO[AWMZ?_OSQ37?=
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M<XL[^2.I4$:G;*QNPF-R#V9@:LFJSYS(:+KIUDBLU*=2W>QCXJON(/JK\-N
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M.U:RHDW3)QV#ICQP.Q+=LPR3W_8HF>(3H7\3?WU^'^!+4Q5C>ZFF\['$+UN
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MQ_.: 73O'"J[;ICY4MTG\Z&"KO,YC9]_0Q@*_A+DBT\W)-BO[V!$4R6BG(I
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M49ZP!Q)QQN5N/]?]O4UKL=.&JFY$,IGAP^^AC0!AFD2W)J+MEMSVW5/7_'H
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M*G-+G>[%_@(3SNA=3% >_0"HSFI6)&.T<2VN)>=->5YAI'K#LV9Z^!$Q$=Q
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MV9._[4IYQPL4L*(L '&@Z"G*P,6.%(IPC&B&]B1&!H7+( ,=BRDFCPQ$^ -
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MF7L!EGYUW=T<>BD/KJJMKHCMKTS7-+@>J5&Y#%7 K>5 _FR"O=BJ'S$0WC3
MOY'.-9);GT92M+CPWC.0!>_3XFW)BP:(;EE7@7:/65<D.][/C$C'2Y)>59.(
M9(]IE;G)DP(F< +8,F\&VI'6KM(^1\Z#S31GX@KQ^2\UN;^+*E+RA>0\"[=>
MBXBN:%%5?I!$5"'N .&2/"7NH&7-DP'&.#&+EOUUYFIO">$AT"=O?#T<_=++
M)&\81?8-:-'72)Q E>3O8=&SZ?:HUMZHGWXQ$C.I*XDT5<O2P' Y-9<+DV]3
M<*V/1>9);0_E"7/,T [0\5JA*MZA@I3_JK?[-X0HK<E"7G> ;T)RX!Z_LW"9
M5;7(@ZI'"HOON3=='T'CH3$"VCIB=L5KDO@2SSC)BQP1&=HA8DF%:5R.N'$T
MV766)=&KC7@-#8<)=3D=>6)4DDO=4M5X<-G4.&5?/^<M7.O,8=!*D4<)JEK[
M#K#QL.ZU-[.L-%W,]#21OOL"LR21"K57*9E"398@LV;Q:EW$-$'-SP<L?42X
MBRZS<_+"6]32A7JG LS&QKPBFE-\4VS3^<#.]>3_C6/24<@4\??!]6=+'3]L
MOXYIB<J*@>3)/^"V6F_S(MQMF]6SJ'4YKNGK82W@Y$5$QZIH;9*8I1&43FZ.
M)Y3VH4H-_12!B <#?"WMR1?)KLI><SKRR321+",NS"V+9$_;KY[,%%D>=FMS
M4QR>XOWLR*:N.;D#D!IG'4HTF"\K?/>* )LLT$3EN="OA;<5JUY'HIJ\]EAM
M68ML8^;A\\P>+_8ZGJ.K[3>38A77\L153KS<SIT*9GO]Y?#)*QOH5AL1_;:T
MLA6/7CAM9-A60:QVOIZ7_AGHURXUZGTEQ>D^!>H;TRHWOK'X1\6\OW0-G!!L
MC9&[I,W<&YP*S=\MPIJJ5+D74R6>QH6O4W)185T^ZU== VQT-WGM:)GAC4$#
M31@!7OLPSCE]5OVZUD4#>)I3'#S=]P49R1Z92+&4KK#"_'W,E]8C4;47.EEV
M3V@>%>P SR=8K\9+L^F<5#OA@8/K3;)<#IF>)E+#KF9\A+&.RT-XVC&TXT5B
MN 7TZM0'CQOMJNMJZF/[:ZH3W%$GQ9HHLTRH.IFK.5?YJ[///@0+]\B0XU\D
M'KT1 0+3W[  L4##GX'79W> &[DON^+ PJX:BFE"0>I-J2^F2WW?T+W&(A3>
M'S]">4 MV';W8GWJ#WL;2ZN-KC1Z*RYR$S#1H[H/JS>ZV_$O_H(3V3_[BA0*
MG1A*TER:*"YB98S*E;R#NV[*:VX7@2$KOH_KPJF1./4!QF-%Y"^&^Q[,-BE#
MHJ_&G3)I7$8[X0E7Y&!Q\\WD\8PBG9 =MN7JR!J)%6]\! 74 BVYRQC*-39\
MC^W_9',6&ACH;(Y'.CM32DT<TP][)2O'A*[%#C^!_<C?Y9HB'W^5L/0[NB!L
M*1*0822;8XG\!%^LP'"F6IVY[O>D/P:/LMG9LR1XI]B7E\>H<SBYG0UE%L;'
M44%H=?H4MH<4JGU%Q0G46__0;\JO\G2U'*F9<40^B9_O #LS!5[?YE5CO,'B
MAB.]A#U"+TH5R">I3_.WC*PMUR^_WCNZ]_]*P^"_4UOI_UZ$:P8OA!S.'E2P
MLBE7L0#A9BK]5I)S&(@(R.];)G8G-PE7J\XXSQR=P\CV&5OBE=_PAWH&V(6]
M\L;WIK?3-?/KEKG+E57]6J/.&OIA2S8D\I!_<P?CO7" 2E:=D9R8<1LT.$VC
MN.7^T032#KR5:1BWA_<I^ ]6.\CD+M8 3(ZD"&'.!]<=+]W*=8? .X$$'((^
M6=0!:#2+/%;KK7> 2W(H:#LUXPHSY] @\$NXF!H"5'FB!823*Y1+NB?5^*8X
M(LRC=[5J1*Q?=R:[7.XZ Q4.>$.X=9Z4V%0L\,PKR@#32%;,R9ZB39>?ZF&H
MCK#%S"B5>WL:[-E1!EZ]XP.F>7U*%MS.P#QAYMNWV=7MQX+-UA%&Z-IB8-"L
M@\T]4$LV+"X4N#)P!7<SPI5J5\IWG0!EK\B#*T1^Y8ZE 'X8?WWBLB-)KE^!
M1=6(EL$T4;&9XDAG4;'F\_>=<.^(N.3&H+P-7OR6?)U@VFC> L_0+OM/:3G(
MPQ+G,:X\X-*;1(.C@-75P'21(3/(VERB8!.Y_^%^Z(&/BDK=.#?C?HG)6R%H
MC#?>>V' IOP+)[H&(O@MEHN2N)4S"8E\5=Z&^P>D0JV'SD4<:>$U_O!$\87L
MLFEN*9.6%5-E8K]#*FI/90-SPR=R*?F0R;IXE=)U"Z_!7,!*XL3Q1<[)3.GI
M-S['*,NQ50J<>G>VK(PI[;BZXF7=+FIR4Z5MU/"M)%(_G_2;.#K)4IRN7M(N
M/)\D>BWXBB$K^M=?U$E<:L=RO&8%9/9CMCZRM7)WATBZ"Y=/0R7=[86.=3H<
MPKGXGC/]9DG:C)[.WY@FJPPG:-01FGA1ZKE'R^^)5W-R5J"^94Y/-\$V)SL\
MTV)G\JXU.LG >T>1ES?_E)N50#59N^4_RW3("3@Z6NV]T704ZH%Y[T8GNB/#
M4-QV6551LOA&3+(A9.X,S42?V4^)6LX)67FKL\ONMV%4Z[^JZ?#O'/SSCZO:
M/CB=^P[PW:U;4[,:-5JM&[B] CEOA%2MJQ'5"%(QJ8;SU4BE=%(\*_K"13(^
MRSH/CCQ]?U-Z78-*\XU?KAULRK_XMKU+$C_:+WJIDD5?5B*J-;A/$TX3UK\C
M;68<([UG"9O!LL((,7@A4*)7=T]GM$E7SMQB%^;%+*TIDH0&GW-U_SGR6JY5
MN%"?9[T#_%) ?>JX W2HX3V^ W2OYX FX""!K7K/I0R81Z(R EAYHNFKN&"6
MO&\S2XFT$TAU/"5,S4$4V<LG.SA97:56QB[N>NM66$,%V@8#=#MU!L0O@Y2.
MWYT67'4%PL+1^@32?C27D3*O<,1NQM.83]?MXTS>4\H;BJ:*:S5829(3R,>5
MKGL".RAV)I<)CS#_8**MC@)7K]=N#P+B-GW_)4?1.<!X(H_H?(A4>?W+..MP
M:!!O_!U@D90N^]>6MAP4/'!:%8^SO.]756A/A,&'CLS;ED?4 PLLSBJK! +R
MOPEFUI(-UOTTI*C%E51"8)UYN C*Z2^TENO%1VEI>?;8IIO:EB(/,"A"R J[
M;E2@!MO)IQT=5Q7R8<::F'< Y0?73<C]CW0K'=IAEH7G,Z?L%EFAB#5632O>
M9#WX[.1L#WK?2!3R0"1[<J+@0F,Y3L,NP6M2UE/^X2PN?N2UP=S5R95&E)*2
M@)5.BE*)@,+<Y%49O[IX-S>MQU!;$TD?^LC&Q-%>V*$M-;GD-<;,Z-%)B5&@
M$=-#'(=!-K;^LXVQ<,WCCPFA#/G<_Y"J8H*>95OFMJSK]9?F.G#VT _CGN(F
MY<OF$U/L<,[,A'DZR7TU.;WT\H.7NQI"=O9+[+>-)KE9S48_3<>\C%FZB'@2
MN&[?"DD?G#[]%;,,V'UA'^E^D&S;F&1NZ\Z-4&1(-YL](E=85!#=5=\R)NY%
MP<<W_(?OC7?R[YV=:-1$GO((8IM5KW0,^H6K!PH%9R,TSO,</=4][\PHY@2?
M&1\!4-R?<P4!_Y-^[+%=4T%NT*_Y+7G.E8]:HGMS!+XT?@:<NKI_9(O;CXCI
MXOOJJM1I5I+/FL)X\3#\C<1I6"9*LZ_#BQ8&Q#U\7)<FZIR[^^EF$=Y_)K)A
M_"5"A%_@J9>-?-&R]\Z36YDI$"C?9?VFZM>,/M9@U]9ZGJ@=F(WQ@W> N8=#
MYPY@+L/1'O/*$3G#W36BC(0.$,I*QA>F598LXW!L+R7$9K<YUZ(P_:5?);19
M7%Y'^Y\'B2E?!+5KJS<MR;V4ME,X&TM!C\>V/7[[P=V8S&][=@+SCT IE!X2
MWX@<Y5Z@T!9%IN 82%7S\H38_-;-D]#KJPDA,N0G1O>>8$5J<0FFN9:X,&=P
M/(U>DZ5(Z%EM\OWEX'6XK[M*P$#[&Z*M(B>2>1\6)_TUW)F7@U@IS<V4:AG%
M.D7?-,:?9 2>NB!L*-/P>I@PB$^HN8]?I]91J.@/'4RO!OJ;Y=P!/$#(M1IK
M*)L7L<L"9\@V8$5)J7TF^W%.L?$X,=>(3BM\@$J2!+N\IAEM=HQ5^77?KF#?
MZ%OEJ17FZ]NZWT'Y!E]<@*C:3->E ,2I9,V8/6U=I7K_2X^9YZ!ZC'F@]MQ'
MS1$E B:&!VH2 /)OA>)F81-<>SE%3<\#([.F-A+2Q0O(^MVEF5/KP[>Z&BQ&
MQ.EFW$T[F9CZ#/^?81C4&%O];"<:\V$2V'D-FVR FM.7F)Y\LI!;N\5.?:YC
MJC_=)<?E.MW89A,U.%TNM_?)]T_Q&]5_B2__3[N)_P^SXN8;J>3/4 _']##1
ML^C)P[8@)W2-[L5% B/EO?UTEW$B]X&&AO3ZG_=,TDA2[R]_R)/BZ7)-&;BD
M+]'"!SARX"\N:8_VD&TG.1W,OP-@ND>O[]Y.G-E PQC(/$Y.2H!9X,Z]M>A\
MBR.8B]N9-BH1HW5.3-P[X^32?#;:T[9[-HB_4P!M/D'AF:47I(T+[OHT)AD<
ME@1[S".(('_\OOE2FC1Z6 /OWG:!MJSU15XO:Y""%M!Z9I%P]S6]S1';-!X.
MOZ-?3$Z/15M(U>TC3G'0=&JJQDZ2NNO2WM=56DS)5/+Q=V+N.'AC(3<R15F#
MF. QEJ?W*%C4_N<YJ9E):D@P]3H]X:.\FFCTX-07R(VVY:P:[ NZ-U$'D)+^
M(_WH@VFWB%[Q(0H+OCM H_KO]K=NZVX/;54=][P%4L/&=&YE1C_Y#]0E&6/L
M111U#>.>%*X-F/5A9_%C+>D6[T(FR+9CCNC@YLEZFL!I$[X?:C/K+%\.CRCJ
M]"68ZO-I>QM]7IVNFZYY,^IN5&S/2:!6^L\^C[?9=]/> ;372[O>,ZN7NEP+
MBZX$;I[> 6 M$U;O0XM%LDJL2!P0^ 1S>CH!-!GE?>7NI:>$JJ8J4W.Y"VFP
MZ^(B/*=5\_EM+[/45;82:FD,50QGO&9G6<CFRRMKJ8/ZO2, ,3BJAN]JK*1L
MYG(-1/66[S36<!9$#K.?KK8T0=T!CG >:^M+^IA5\5Q7\@FZYZNT=,GT1<P8
MU,63[QT]Y8OW]U3OJTF9+$7%UX@_!P\F<GJYP>]A-D_7NC/&=CYT1GZU>Q O
M#Z(D;O,/4E!_#F*>D)LG;YK*Y<4$!"-?)WY.O;[I"%I20;SKCF1M+2PG6L%J
M/E&!R6-4/@&&Y!<85\W_3V??2#4Z]+AA% _U.!Z;5[A4/Y#PP,"Y9&:_86[^
M[+.!YWMZZMK//CO3@YU'SD]0R+@A2D35:'IH$ 0YR BFJS UJ_RL/2]V8SF3
MH31\!SC=SOU>2ZYO)#VG*N%*$-HR07DHJR>9_,>#D5G7V =6J<]3-"#L78FH
MJF'?>\>C_:AQ.=#>45O>; >62!P8W,2""._OFN<.,(SS<49F8_J[,1TB>IU[
MVDJ??+2BZ>$FQ]#SXM)\&6)33Z(GR]O=@^S?:I U)\7N;5<ZUMJW$:F<(:M8
M*ZY/QR)7<.R_2(^IW].VMY:XCRK3OTT!A$Q\]B<B6P/W::)$:3'H-[1&A= @
MUL_E+(V6"[5.G\0Z?TC8_7VVU',9Z/W5.KR^(KGUS%OV^Q07F['K">5RPZOF
M9!?]5W [(8,B3O$7'XUA/RYRT$_1%DB]34[6ZL^5&V-5$'LEX ?ZR^I17SV(
M^3L8*F=V!$I#O^L5+:RH_1GL!\A;\PGV47B8NH?O9)52X]:3,XE38G' G3UM
M6>GP6_";'>49S3H%U#,R\"1PC)O0W.#$(]A<!%)V!T@?VR,G*Q/TQ]>-!P^?
M'%W)Z6<+O@:=BFTJCRJYY1%L-9_\,]Z.5?OE4%='L+VX@#[IB7%LC8FI\4DW
MWUFA&L'32@X>B2;!5,G1?7)?2/[Y@*S<'L/.MW^U?/B_KX3XW8TQA*=PB4Q^
M!(VS@C9:U:3\;3_&\GO"8ST?_3:J1I_#.T @1=O524P;\<M7G_2I!-[LI4_N
M[IYPCP8E3@G-ML9:JDK2_L?HGT?N J_:=* :"J_<M<->>B^]Z'CR4(L83X(2
M_RN(9*EPI/'Y_5Y:*[\#Z/M?(E1M)39F\(AZK3@TA-;JF/6>RE=<V#L76[VS
MKZ])["V]G+1=1U\D)0_S'!+5C8?6)R8ZS'S@E>4LLA"6YB.<_2)3$SIP,H2C
MG3%K.<R&\JHANST<NL$*$586E:,EOM^\<O$ND8\LO<#MZF(=ZOY*\;Q%SYKA
M;S\A?=\/"D1"G;W&HYTSK48W)XR^3,IS-!"1BY*W:Q@=;']XUH]B0N1<BZ1\
M)HZ>B60OC1!^/[3L(&R=>"@"N_=(&,'%IY0!S]4?<@M_\//+^(*E9)\\A\'7
MH:(,2[D)"V7(JOBKML()Z,$,%P][Z:"ITP4UQ'XS>8FK#Y/[-<*/XU5AU;EZ
MPX^V9 \5(K56A@>2OP@'@A-2(>!$N+LK\>P4]OLFF=^]Q6#-ASF&W_BXNE5,
M#%7C>[T";7-_V!I]F> )IV%8W/?3.3>Y0I9>J<<3J'Y(-802FOQ!MJ__#,T(
ME JD!5F\GU:;V=P>5V"CWN.U@O-8ESW6:\UCG7H83(@'1THE@.\4D"J(+L/[
M^\_[5_@&UM_Z/M3^)E&9][#A'^N+DO[Q2/P7IL7_AF@PIQR" HINY, P6.NN
MZV56O.3 :Z_K2*7Y6ID/#XBX1BOSE$-CRB<O#72&810X!BG6W8<9-51',7B*
M((AV;BSSZ>+UQ*CVO)]YX;30*T6:TBHUHZM(L7U]WN6W@:_<Y.&;\F8_4![=
M[XU.A/&0D9VU1EK"Q"L:+3(D;:J."-47XNY&[('+C%2.8S3*>-M25<!Y@]XJ
M9<FGHQ*:Q4==7<EL:;EZEN.-+Z:LW=@%0!8U"YT"\=U(>/V- O%^)%2P7^S&
M^G(8GK#:FI-YD)ZX""FK$+@#_'A3]M+-[?>EVS#QIQ1=O^CJ(R?'.X"/1@9X
M?%?:;@]Y+6%V;"K!=\S?@WXVQ*WB=4\5?%V(GX&>W6PR3%7RJ];*EFZ0-+7C
MO-9[QI:]),;QGJ?=7]E%C;Q%%6L9AKEK9[^:W#NTX]8OT2TT2C<(K/<4.E8-
M.XRXO%*U=;X=N]F0EC22+X(<^DJ5*@EMU>/*J5N2754M*4]/S<[WK,Y\.*JZ
MIH8@SG)7/LC54=&Y.2=P9^985 G4SQB_-L)8CXO &$5,B.5XO)E+D#T;NF4/
MNP-PHBC2O.ABEP[RHG-$J?4?YC43#@GTV+@/-_<J).<&9R_=/A:TR/[VY*RS
ML4'Z5.1T8]KV9U4PMJJ7[\^$#1%]:T7 XT?.=EX]-$4!][A&],],5D7^FZ"W
MAA3X>7ZZ.6M$0(X9]0%-9"MTS!K3CK;*K48N!A.LR!X9)=6"MYRI@%2W;.@)
MKU'[]J_J#?ZW:0Z:;%_1%M?DRIJ[DV_,.D@^4OB,]YE9^QOG![<7TH6<:R7X
M%_K7;>YF_!,^=:22 A&O)Z\H[-<UXT_V(&"=K9?[V",TP4CL(@X<S[?!C20]
M=OL\<5/ZC1^#+GDO4*X36)N;U+TE?G&ND *AH]!2=V-7(_;0+<PW($FBH=&)
M@X+3AK_,K<#:O1%&AC.W55[;?N%."7FC"4G9W;V>=164B:H1.M05)TA5&8G'
M[,4]%'[1PFZ9G/@C9YS5921W<]JV-!YI'1B'L8Y34[,9>P=X4$ROB<@9.TUI
M^* LJ\#XA;SM]\WC1TI9J<;[NG#.-=W*O3L 6F/=A5^.P2;/M.E$@/NTCE\9
M#8*<NYMHD% "1++"[=T@<G0@F[O9-'5@ VA;KVCBY1=,R9 7+@@@B%.>#!F+
M0[WM>42@LAPJG8-)8+/GQ126;&9I8!1OUMF*5,SH]>, A42*DY]603QDEMUP
MW+Z 4<NII3=>>.-U ]1M?<]9'%J?LT^"#+0[7>%P>E=L G#1B00HJ%XDH;1(
M*=],J"ZZC^+@K$0:;O.H7BS",MDN)F$+4]_:5)6AN5ABQMV\A"BOD#5@4YQ
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MZT(#I=8/75L_Q-EMO7>WFI?LZ8FO((8B2QC]UFP;^D/"J8[;O"I;+WKB->\
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M'S/S)74Y??7-0":OGK!Z*U=?%.9O.NF6EH;K*0/>A5014;H)@P1.K(XB<>X
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M,U-9.)MJD&,EY<.A80TT(!!7J]E5YX[9&B/JFG](Q#$KR$JA:,M\955IJ&;
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M+_OJTJN^$J@!9$.B ;A#1L3N16V.T*SMZ%<4"&2E))0XEO] 7<O4X:0B,UI
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M"4FVM?I9PXN0%]GY ,?'(+_X7CH,A7BR*U N)N=AZ]+P]/Z<>&OO2"ELF80
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M4HJD[]%=4N4[OEBC&%*]C9[^;U!+ P04    " "#,&Y6+PXZZ-6;  !UP0
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ME4>IE_!K_9M**CF>J0VO*LVMH*M/H'LTNHH$_R?9?14WC1=6'Z-6,FK 9ZE
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M'^G<Z(Y,84$W WX2'7%@F$1'RG1#7$CUII@A#![1.GXG0X>ZSG9 ]WT/PN_
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MKX$_5659:/I(+PMB&&UYE3M'0RKR]F'-WL&GT'M!LK9KX"QC8 /2HY$A?[(
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M7& MO"C(>UV"!2UK6?J/7-$.%\/Y<[W;K2;>]X+6.OA]BKKW.[)1AS+QW?:
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M60D:.8-4E\,[@]3JYZ,/+EOAC0(K6#<B-ZF*4WPX)5*6; :.>C2WG#ZTC=X
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M%/\-//\S-BKIO)+;D353_C<7WO^1E2H^13>N)Z'2?\[G^7<7O,_<W?._3$0
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M!ET?#QNPD=3FT:AL?ONORH:6&*M3Y5SP?IPN I#\[E[XB>+EY3R5NQ" 1]N
MG^!W6P2Q;E.,U5SZ;*8TW_S42D,0@.(B<\IX?"'#F]:%1^TV!W<4B;\M:='
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M]J-/7\0[6((I*\W,V*3GE,RO*O0>W-9N,OO)%Q8'Q$.6Z<$S1(^V==Z3?Q"
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MB]Z?-C,/^N(8^$,R\FTG;%SK>'57[ ^71,71CXV$-MIM'&I'%E350AN^F2,
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M!:+'#W1 W 61XD$)K@PKQ@#C5(9;313-'+5F!_[CGE1+J#97>X))L:B2V7X
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M,[#5I)IAQ50V=U5CK5%W7 V/N>0'P.29MCHG8\P7)F.SX8TFY_G*"YKK1J_
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M48#30UBBXMH'=>N0FV,H'TN'1%?S:*WX3YTB8--$_9#J"P*"/5DPZYO;;-L
M)6VA9$BV ZPY^(A;-H46^0O%-$1DPVJ8WL"G5WYR]ID6H1N7Y68L,$;^Q:>B
MK,#<C38R +,B*$/^DT]!2_"Z2N<^%7.7QGSQ:&[%$%,<LR02DS8@: I',Z2Z
M"#RF, I' *IOINM<[)LP'&=PT!8M3-G?X>RA&/7%:+<BIVG#I":.^H\KJ!BF
MZ"=O8VR_G5RD@/D32Q?G8(4?_080@.-$?4P7!_)N_?93UM%!F1&D=V,>?&+S
MMJZ&"NH)7*DZ,[RCMZ@VNSZH^WSQMY^OI7X_L+C)S[@_ZF$ #5AJ'S=$N!\E
MMC(:Z_C(T:%P":&CIG8C]:TW#3^O+Q]LEG&7=+U4W"HE,3_F-V=PO%[:)52;
ML_OIV=*K4\(9>["R)%[DZ3Q8"Y 8_I /:^8S[8Y(>J6A [!LJ33N)[',WIH?
M%8H^MG88T0(O.P9=%A&UV*.]JQDS6EZP@288&OZ)^TDT)$R![--84&K@W:0:
M8Q6=/[%JO]"]9"&^\NDA])8UC>_I.XM&JJF<(5Q 67B9.)SQ/GW//>MU'0OW
MU&!^8+W7,?S]1D'^8H;$));4]ZH16M3/F@2-Y<\!R, J,^Z.PXFY>7EA,.JJ
M;W9W^]V>IZ>56XJIO%AQ*^4;(X(L-AG)W,7E#03@LBO+U:U3R7TB.GF4AE@G
MW:_<_/TV?88T?FD?_M ^ G#&:WV# -BV1IA'-IO6E6)Y+XSM_USOK%2;:KA(
MN)\T+NU>W-TMM4M/8N5<5F5<6;*/*+( ^5M?BW=89S W86^&6@^LBF&KRJ*<
M5STL;./E6+[ IWKM3173$-@]=\Y0U16^.RKL5ERJ3"@O,P,=ILV8UH,X-'9T
MNCNP!D]_N_?O!29PK9!^TWI/=!@Q%;-,9(I&9D-F*X#.B>QVC-=)_&T8M[Y5
ML=$\RM7A]Y'X7-5GHFK6WQ'OQQ5"L2 E-)5.&&Q"V9;4@RI971Y7\APM>O1/
MCKV2[;!7R<S<HBE&9H&&?X7O\[:#"OETPU&VE;T/*\0;O';YLNS/-5"T(2OY
ML 5G03'L2-6"6,5LQV;"ND;>]7!;?"[KH>^S/]3)N$B@A;>RVF,66LC$1A%9
M %R!8V]H351TSOZR3)<>C[^F=73IHH#<-\RR^L(&L7(\($6I%,!OOZE=#G^Y
MU<B=V:9JQSQKU$VT/83%#SO>V$+MD%@E8?YI6XP+QS*@J#M-5SUKS_'J80;"
MO0[*/0\%9BU\7%=DA0:9GL_#(G0Z[>VA*G4)>VMA$5PC+U4,L,2*Z]Q5<!$
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M#)#<R++(8+F^JTW!2K8_BCZVME?K4*L-E.2\6I:%*FH?:;>Y;1#"<_@;S#!
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MISMTRG-PLQS.K6'K.*DL1$T7,,A1AQH3$P519+GQ,T3!:U23.OH;PU69./9
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M.>[)X@EA@A;UR3#FLPU2-#]M32:Q,>#=O][7$0'.S-8X%A^%[FC6?+MT'YN
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MQAJK:.TN9>"Y@L-0GF#9*5_LYCJD].HS:X47@O^B ]]0>G%*?C_9(U_J2_1
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ML=W$USFDP=W(VM<AUWJC+7 35(,NBC]HO59@=RFUGX?^[)$IB'6BH&DR"E@
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M&4$N>?NLL>$,L@XW_NG\T1?66P$GBU>YKY9N\-!LF4XE!CPM@SJ>2]D;U#=
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M_W_?>_N>\]Y]9^6;WY>5M>88X_<;<\XQQEP+<)]QR\"%V^I:Z@"(  ! ^ ^
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M;I_52E%X:\ QAF_IXL_0^XC\/NAO;9:]7!>35%QHJ #8TF]R/@LM:[M $7%
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MFVJ1Y-@(W:V%T&KZVCNFC(E3-2-O4H9N*F/*Y+&,_"$X8-.R#@>TY?S:E:/
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M8Z;1>^6ZFB->4M9<L]RQ#X8F12'0;.6#*O/6!"G"(;'6TI=.=-RN!<+>.8'
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M=R2 E-S$L?^]I_Z],7J+X;6%GAI&)4LW=E94(O^R^SE)'61H P=$Y0^BV7"
MRJ[>?B,.6+D*_B*16<);&R[B]O9)2'N+[3+!4Q<3^;*@M06U).SG*N(_0E:_
MMR)M5 _USE;R-'Y>C5^IK-023CRM(7^$C#05, U" :TW5M*YXQLM7Z,WI6/V
MN?[(0+B%68:DD(*=.\NB;&%Z4L1/A8!-)4]KK3_2HM;ZB333 CJ&(;T;ZD\0
MO^08M5HL+-"-^7O[_X&57)H';4WARNYR8G*8RNM)'TT]ZZ']+*-(EZ&6/^AS
M-P'*]F-!(V5JG9'SS$[@D<]7++(WP/^/W+1-S_R929K6EN9'@O/;MC" ;\@X
MJ#70-.L/QFR5BR>]981+5,V;IZB,&J%ICDK>?L^/IHDG__,ND65?^Y2_"$*M
M-1=DRVN;8\@HDALO<30WF7+_ 6M^.,#5U+7KEAFJCW3$=%HD[WU-,N*KO4<C
M.<V65>0?@9KN+;985*U!9KZ@8YY]H/TXC5A33K1#,-!$[X]Z;3)=!%V:YZL.
MC:.\4::R.\0^S.S6[S$24/5'G>8QI#C@!5=4XQA&]^'OY=NZD2N2U3U" @=0
MD"E<%A@I_'IG\J32K*:=W+N9\.G"@Z;M_V<OR97*5587.?KI!)1:=SNY45,F
MUT_DW-Z ()S1;-@(>9&SS7$2.S4I63JS9,W/8G(1AO)ADUG*1 P&_] X#=[B
M@,%A:":V X4#=LD/ _?C:;"ZECU+1R2).,#1M.S_-14$2,T6G=C'"@FWF/'5
M>F3:=/F^IFV >12+PM4KF;G0J9LHH9[Z.=^I\\++"T@]"K5+-O?*0;V #X/I
MM3*,&O(HNFSDW;U!*-RCM#::Z,V'<)+"VR6,U6_1D=HHCNCFR<K)E<NN\2$J
MZ@>V 22?QXFS&,,JT/TWD4=%]XN<_1^Q9:Y3D#]_Q/ZBD8_RZB#X2KWP7EYU
M3<:>GP#E57LO8@]@<"7DRC_$HTIG^$I#^ \+6K>YE.@HTFZ='*<Q7;]5QLE?
M^TH5_[:O! 3\Z!SAUVE"F^:/>!;-Z0BP[.^KEO<?C\HEW1L[8DK,.2'\#%L6
M@X5[08@2E.@<V\UQP$'0J\\Z?M7#M>,$L/N.^'.R:GPDL\<!Y)#WM8]A U>Z
M<0!H"G/=M]&PU8FJ(Y=\X^9$)*;K,03) >EZ[>/*A@V5@J"I<Q"&K0/]%J7'
M 3^4Z37R-D=PP(U,&@R)'K($]MXGR.'LMYP4S'5Y^?BQN-G7:_I$X-S-I0.R
M]W_5-M8Z(1%N+5&&ST_<MK",;2XBAD_+E%DH\K=DQH[NI6'!16CC,/5)V"8+
M?D*$;&$9^-H.+Z7MYY+O;UH8?^Q+?W3CB7([PA 'V#E=@@T(#__%:CVQK/6'
M ;FDU(D%A]CA#WA=/GA=#2YY3H3>[\QPP+(<+%QY$A4S4>TZ=!4$>U\+.R7\
MC/\9SY&*4FQ^*?UYBMUO=8S%ND2&+2\$;Z7,A=RPN3,IS85.-8<MA>.EJ10Z
M<1P,BV!(;)"EXC:AXL!!=*!H\E(X8"/GAB_JE8=%SI#M"*WSS +ZODR\\<$7
M,=?#;(1U65^[OZ1I5;XXKSNI@>E^W/ZC"U_=ZSD4.M%I@J8$$\^;B] F C9%
M$,CMFG?.!G6?E;M"Y.K&#[P@:_2_;!K$,L#':SW$SU_]U4(_%FEU*KZ*< G0
MIZ6M0%6MQ._#W'\AT]QGER_GA/B+'?:C"-J8=3V?_:*,,*C48%MTF>N&/G'5
MD5_*_!T\.>T46$8VIU-3O>_SOVTVSC1,9+^QDN>JRXMY$"+"(7\;C%69M3E&
MP+K>)O=K+X@6F2>>V?ZZ[VX4Y1Y7UJ-%Z#-2Y2O*HC^4.>HS"[;$BD?3[6&[
M7R%==>KA^8DGX7]EW!9J9)1P"@QTP"VSQ969X1E*+Y)$6>^]Z#^7+T*;\E]N
M2ZUY+_<TQ^9DN1UQSZ_&H_[(2YX=$.AW4[!Y,/<\B2QB>6&<Q$/HX,,-B1W(
M+T-UF.9LSL'E.. WA]XWT E?TG@,3B8;HBI"5PP&#G.I<[YGX$,VE\-?Z">K
M..B]B0/HSG[WMD*B.!H)R2(WC*LPYDZ4@A8J'8>Y5,,24^^F"9X^FV+96JM"
MFSI));V3BO?JOO.!4'E#214'^)R9CAU9RU%47NKC=>C;/MZ13_)$E!20R%?@
M!]!J8<AU#"4.2+;$.^<>/HY.Q%LG6GLBQ;%:KHGG_CDX0%TR4!%@,%"Y1*#5
MP0 8&'1Z4DVK6@;DIXIY<$I10D0-\4N4F+E=Q)544[-5E51_&2 PY>[;F8/A
M]%OZSE+) X$\NN5ZRU2 55ZZ8'4GO;9@++NSV.@&0..M18E<Z/G0>5V;S<?'
MM@.?PO#EO?W84E]+[N;&_5QVKE"#XN,IY51A-ALTKF:8W2"A\CL#3<\XX4MC
M*;@?/"D=7^YED;#E>73_9!C.4AT:*&YJ:0AI4!$L;<2, .9YF>S1$BY\NI5Q
M8N5%EQ(KY/YTCU[!YB@4.VH6)"I5)%_7XN]F_T%5)1N2XDGH(]"! T(S-HPL
MT72,L!4=F=46;Z[SC%;M%?>H6BXJQUFX15\24X4G7Z& O&F\50WMJ!@U"1@2
M'C";N3IR1>CVG @=1JQ^\O&>%<\]-EO5E"E9%>P3?9+F+Z\MAH@;F)_W%8IN
M?EP]*"FI_KX/'^[[1/5Q*V'Z?PR3_QRBX"\=8?M>BU=PP'L%V)EJJ_5__E..
M?V-R?H7QY]:B+-)UVL_T8ESR6)30RXON7[-#DHS+)>^7!=G7M+1/[=5J:%]\
M-L<V<#3HU[.V+W8#V'HSBP/B:^,#5WLXN68EY$E%<G2339)9W @O1=S+3Z;9
M+XW-@^;T*EV;J-.[8&;N9))QJT+"0\5S8U @*32U _2T&,R-N0F)Q I \\QJ
MA;2-3>H:1(X83/8[2%('N=XY8P2?+U;6K<3=I SLA;].39(*"LEW8SNO,K"T
M4 ]_ZH BL9F]<HO)_WW'B_>V6@)OUOQVS$V".>$MBB70AC,>9ON::3MIJ>OV
M%!_6XBZH;))UC@#>_H-%Z%$]UL6QI\X)Q8(2/\34#"/HVST&Q\1 )Z:F12[=
M/3FD!=.Q8(&M?<$.SH32F\%Y:=TV5 J0(K3?T/S=\8/Y$14[XO6 BDGU !I!
M;=JQ*Z6;;1>F#[1M+CH>C2MGZ&PY^<QH@.WD7@PF(H!5+B-E%BR >GI@33]>
M3O+<]POO!0VNN5D93!ZD->ND'V$=^O>;7I*FG:</1^.7SP5T6NY:9KH\3%"N
M>,%,8U'WCSMC71@6&;1&/E? [QCK;3P]*S#YKG%$'RV?@S:V4()LM6,3DZN#
MC!O(BNG2^QS!%;'&1!HC>MAIJ_/M%5?[IOV^FW>+)[?F6P%?D9)K1BG&:S,7
MZ%/+E]XOR/S0KT_QY/ZAS':J6UX%O2@[XI?T)E>RTS&0;^)K>56V0$O<A1!]
M\(AWQOEX:,"/>[1;5L=1CW6F93@<P00<NF*B3>54:J0[YJ*;*==^F*2HO_:]
M$B("<ZRJX)K3)+$H.T^2;I5Q_/%#F?KIW8#UAEKY1$5IZE<A$E=2*@,J\S4_
MG/&!/)59J2;?M]ST&'>JT92_)MG6'=,_*Z0V\B8IJ9O@*GA]ISW*J+OT4Z0\
M^$&A7C189K#L%-Y-+U4B.+%&\D"S] 7FQD.(E [ BU$]EK3"J/'+7JF%(2P(
M HA?8L35600&CG(I6;#<=SJ^C]@@_6/=JX)46&_(:Y61(#P<5CT8I]'R':);
MTIV?[3=D)4#?,WS"*_2S"\@SO/=9'Y8'6UW/?U_"QV(!G,!7LJMA13LJ#P09
M,M9L4:W8\>>BB@(+&#N$Y=-'.I/J9!PHJW(;ZEW]Q*^)0R$RW"MG^RV1@\7S
MO7*9!*H-DMMDR]K6)*DM3^X68\B<$AYPO0*@F$6^Z3D>?<@W,^F,U'?09<U)
M&F6!S2@,V-Z4F!%3LH4\ZH=>(5S& 7[X]9^GMCE1W;21*F5*<OOCB:?YJ7HZ
M9\[CI+Y<0)Y\FC<&6,6X);='[CTW7WJ_RKA_J\MQKV#IH];'C=FVF>G=6T>C
MSPE(JWAF@D!VBF=##\">@QVY-*26F>^5S"_WSZ;M2D=B+;1/X$UJRVR76FY!
MK@>BJ7NUB&ESW@%0Y<86#K[4US\\5C?$:']8'^, 4J$HV7W3_2*MY2=,46$$
M88FW >13J4F7$752'E7S-Z8SISHU*@AI]>WZD9RS]8^N-)WUJ7)120]82"H%
MIM:BU-XN%'-<@IT3CA-#.L9.+M=##A=AY\PSFX<;7&#(6BH^XL%_C7,[T_QQ
MD)G25>06BJ/ ;\K9U&_VMK8>4<UC:3"[@+2^4I9+8+6"UHJV'O5<_E?+)9V-
MA\86%BT][/[DU%?!J6B>M\',7XHWA?G!6*QDX.4 F\ZL>ZX827?$3B;5[<43
M^VS#1S5)O'-623^3XI8/*KOO("]&^L3?5E0=FD0(V_&5*1[L4ZO3#(VJ[&PI
M7PBZ@P^_#BLBIZB4$Q.I+.145T;#LP,<@'YI.?=5YR']T\J9H))70S2O;_S(
M#EAI".;IE(1W5P130+/-K8>4D_K>I2?( 7)PV0*,LEF0N%W1UB(77+A.IH(W
M_+[+Q6CI<'":+;'X8H@HW*Q]1HD(G3IO]'(DH(BLO.#U88J=+?V/F FT*:^C
M]'$V_>LDVH98@_>#.VS%BR03[5EB-N3.K%R=.GY#WZCZ*IZP-TB3D0JE<WPP
M!L$9LB6F#EVEE9'],0?:LE=F:E\GL[C.Z&YQ)Q%\>$$,E3FUSP VL/RI*,GU
MJF)W?EWD3\NY#A"BTOX593Q:^"*J,G;ESIV,M B10TN!6'RM.!]YYG.AQ(.]
M^/->_H^K&X>'Q7555/>V<@CCHYZ9'[*L1ZROJ8>G%P2\>KWLW8]GU QEK\3Q
MQ.7)5WZC[$5-QI8S2R.QL('/JC^SQ:=: 0<G<?3-V\C9BA4N4HU'O$S?UBP?
M=3T$72?W,4I^0CGK$-I"6^"2S5P'QVBY,%67.D<?E3QLX;157BC-RV8 );S2
M4$7^A";V8KEG\.5Z/._-]JG@ 3K'3^HK=K-Z(O40ZNQ#]R[LM6;DHS!WQ!*=
M8U/QQ_<V/ *QVB;9LJLDWRY5>O:1*+T$< #U/*R+"V6QTRU%-W@>7VP6^]DU
M:Y@B ,3]S"%79E3QO&Q*8 PC>K_4I4V^!17QSNY*CG-]UYA>_>L'ANG#\M1?
M^%#6H?]#\?J/[:[KK7M94IMF#!>SC0*(]9K;V1WF)4 ;-LP2\89Z:(T6G7?F
MD@=-C/,ZETOCTM3GM#K6EG,Q.]$HC<0ZKAA60ZC1'63%=W&K,:Y,B7R>"^5D
MBC);TW"'$C748[2+AJ5 O(QS9^'9D_M22:_VJY,2,FMB>IEP (?*0.,D/HE]
MW8[. (XL9:CJ7K40KO6ROE7ZR%Q2*N N__W]>3ZG7^]/T2D_V7-G"WS^4A:[
M<U,Z63CW9^#CG\2PZT#U7]XLHYFKP.  WEW:@*6?8]"O)[ZY9,7_G\IU_J&-
MHD@PL8%%YP'XJBZ7=:)\-X@)N5Y<2G9E4A_XL<\*+&.I*#&\$]@:'+!Y(G#3
M^+W6'IFM'#P+(XLN0B120<&Z$X?7]NCVP2*OR\@NN;WZ['W 4[>.[ET^X1MH
M^MA_[B$!FIW?2@KGNGIJ\IS5&>9C2L75IT><R]+T$5\4$5?P]XT175O?WL!B
M6($?DUTWY,B3'MN-?67L3$Q0(L4!.655&!*)_-6T9Y"-O1U\X3D"!/)Y"#X%
M2JJMW?&3<*R3Z^>Q+[Y(6T]$6V?_ZM#\JP-HB[ALH8\C@!%?'B!;%?"%+\3?
M!DWM5(7J[Z2$K/Y5DM^P8]M+E'-^G4?8:N0S_.!/_-VY"']"VC^WUXYD'R<)
M./)50&E\29MLP8K$MY'=6=_?W,!FC6CC=??_37>((DBH@^-Z5S%!RRKVXG^W
M500CHD<(&_L*QX(S@ ,OF=*T:Z]X/HJCQCI)L-:_Y$^+!;DCC2@IFJO.D([@
M_.R).\]?7!=]E/^^4@LK!I7,Y-E;Q1/CCA$6(8&-S?2?HR5 \,Q;V,V",YY3
M\C6:OK_]#.M"(/TQYU:PI3!E#J?:.SX$Y7.6I0/4LI7L&%ND)P1UZ(DOSZCD
M(''6-.IC<WN0'YVY-(:)[T@R?M:AYY>K<8"(/^1X&3]#NG:1IGA!.."7)-\#
ME41)?<LXGTIU6%PVU4N4_V\QJDHWH!!L<"7DQV N]5=;<$:&3(AD9PY>]B^/
M)9[M.ZVN<H6%_"(T\1>P"5ZU@[)KK-DSZX.HG,XAV.IO6%G!4N@;G&Y[L%^V
MW%$#/'5Y)==W\!Y2W*O$<S/5C@B \D-0?Z58?B=\B'6CL/Y3?ZOWAR WI!$!
MT5?X.5HR&P<PM["/:OYE/(7(@]Q$)U]TB&?5]>.Q()!^D-7M7\J<T)T(,!ZE
M*=?QVCC) U=XY;4*TLZ!2@@6OS@\AVQL!\'@]#J0BT&7U)5F(.<G$J 9RRZB
M@=6XV?.55?6F?@P2'Z+AK_M1+EW:,MZ^2I"=Z JVJC@L58KNQW#A2NV6._G'
M)"7,N51CH3G[VH]A.RTXX%2T;&)G5(F80(G)C([TJ\2:O2_G[S"NQIA2"<U4
M0\XTC95OZYOGGR^)-KKGLN=TA4@6EV>1],R)1.]:;ZA-WV^)IH:+IKQ26EZ.
MF<TEB!F$8_3RH=:S\EG.)X*(I"/>INK!G010Y9-?($)@FW8-> X,82@)T/R$
MP?P8XTRMZ049Z#OES>ZFI!?.M_^N-BO=EGN5G50T BNVNMQ:SBMV^YS!)Y?"
MV-COF/;>O)JW.\\@93&GM'5<@3TMVO@E8& L=%@AMW=T-#2W)^M67GT4]1(S
ML6;_J!1MTW,#G:\:>_<9R3-9EI>\+S3G-'</<JDR_B?KC1(4';FRQ'%S]9Q)
M<O)1@^63+\0Y[&Y#(B>ZS."!+1SPE+6N<GN)J>7>@PP-#"^=4[;]P))S= Q#
MY]B]!?(=)>$=4U;U(@3@ECVLDZD/>=R<",HW: #[VZK8X>=;L9(@=$>O%ME;
M@.5""?(;6Q8O,C^N?/6I+/LF$?^W_JI X%# .%E AC>]8:BZM#GPA:RDI(J#
MP(B=NV 8-:KLQ@&?_?0!:"VC*"3(>]6E+&R%BQX'/-HJ_\Y;_7Z4W"%^(7XA
M<+V4ZTM_=[;)1*DSYR.EX^'$8<8M)8EI]X-$8N>YB'2N] !WM[$+?1X:1HGW
M4]"F"6C_+ABM@GGNG$M2D"IT$J70$2W D5WJ]P+$0?K=$5PT$42VFDCD;!*F
MAA(Y*HR[K)8Q="QKM@^Z!B>D[F;<81Q!<ZG-^G  7W::NIT;@KUE/C[0(E?N
M^KD5=@+74J9\I? Y6['7_YI522?+0=6K%J="-.>HY3WI+FG3BA7-*DRCL/"5
MS[G/;M*-A% OWU![JN?-V^TBD:3^,(DVW8[#++0#XX)?(CEWC* _-73H^A'K
M1>X5@V(Y<I8ZA9S![CG@L(4WU >@W9KMV4569*U%1'M@=;\KI;:WEXJMU:X5
MDDS6;FNQ<0EME8.?^9MVL5@,?F'L,5F/S"VWIIBJO>=,*A)4YKB:+3NN&6=*
M\@(J<RG8N!WY'&V$#8^_B , 'ARPX@@>":*OV%KD.<]MN5FR):VZ/GJ/6_4V
M0S$?L\IR2&"8]9BU"L*%0E'Z* [%41%>P%2_5<!MEAO'0WE"N$PM!Z_Z%VQ\
M2WO#/+ ^H8-C ]#C7)()33)%4X9:P$"-X5_6C"Z_NA3^[=4S]1CSUP> EXY2
M38L*#N!9+,$!UEYX[HA#9$G09<AI>>+9Q\,.*4?F-#L?,O%!QA11=$XLB(]B
M='I8GO=86JB+2CO:IN#KDJ/%PYGN] 8=Q0*WW>@WE,EB4,#40X$#H7HC2#P?
MO])9B_Y:!R+_640BVJ*="K(IZH!?,))A*,9'.*![\4*=R5ADK4'"^A W#O@P
M(Z!(WT7/^\%13OZ]0MA#+B[T+J#U9W+<1"B@NFJ&08I_T[V&S E_[XWXRE5E
M9(?W-;TR0SO"&2.!3S-Z<[ $6K\>S?RST HMA TY* *YEY(,%;#CA!RP>D&U
MN]9"\47646(H7,H KTTEEQR&K MFA8T_&,//>;Y?C_AP0'@9<@H;Q@1#D_'C
M %I+6K1\UW-B&VK'3Y"=/A'LE5]_]R72U0,;J,MWP+;\9=318)FJNO5.*<UQ
MP#)?#D:-ZY^D"AAN="XRZ2LCU^.HY<UZ($<6931A+8(C.6B-@V31\2\:6 :0
MZ9_(N'X*E>XF>A\D6V![=$9I@]%10$MWG>$#XW-O31S0P?PK&1WY9^LU,$(V
M$3D'S#6_7D2#H&,FTCJSF9CYNYN422:'\&#R8CN#64UQ0-(3S8?\V*!\R)D0
M8/1G0N;TB*&F7/M"CCT;V* '>-.<-CJ#F3K[(WP,(3M=>*DA-_[4/77V2/=P
M5!*B@ATV'X<'H]Y&CNPJ)NEN4ME0^**&[S%.[/]/:B'_)-,D!BW>+8A68I_
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M9>@[I@,ISXV3NYW+/VC$XJ P[87@XU.&H.!?1>N?V/*VA1%136:0Z]2<Z.W
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MGF7,WTNNOK+C,-<]>=863B!&#_K[AX27H=^N/N :NI/9(O^_NY^F5O#*J[K
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MOD@84.C],C[W,J_%V,O:#5DQRZ/BK==^\-WG>GI<_3[: ;-/;0I'I6R U>Y
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M2@389>.D/AW[7&HN4X0,O>_IO=#TU@M ^!$,-BK4N=!()"JP_7A%N%:V,%/
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MY-8F+&)RPF 0X^?0O!6  SA,.7JQ9=C<QM0":\'83<L^51KO+UM8GY=X<C<
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M7=#+958]W;,)5WQ3'A%U*9VBE&2#.V?#L>63,.FMNF7ZE.PVBRKC]CA>S<O
M/LP/!^R1H<#GP;=PP)!6X^.&\O_(7M(OA/%&HA(K2_6WDMEBT_LLR*<#'C(9
MUB0K:A:F^88!/_.+0%0SZ$^,N?+LS:,"%CRR&5;VJ!BO-6>6B4. 3A<446G[
MD;2UKJKP)8?$U<1!/O.["3VLG68V6(&Q(I==$@V:UF;]^NJ@-2>:"W7^,QX+
M6!>"V6$C&W26Y@3&]CPVG8_T\>@,]E;2%VZS^HHG"]$I8T<E7WTO\PZ2%"\9
M.W1*'T:%>V5-3UO'<RH8&\I&S21)]9@9)J?5PA!@(B.;NB7#.9,9=CY^S:XX
M(4E- LZH3%]I3]Z!2A U>J:][A';C?$DU91'?$&K(T2NB73F4I2/F1G7PL90
M/LTEAIL^H-$&.?YW6C81)XD[MV(5=,@EB3R'2&T5GT-\YCLU![E1Q-@D9VK3
M'^$R[A%!Q[/=-ZK7"1AU@JY=D+N8H:-I]I3@)_>K__DBN@^BA40TCUH2(M58
M/ F2O15=!6.M16?<7RN]]EQXZ2MO@FJ.@K(NDK46OTH\38M=O/A-:P>@4X%-
MMV[M@ W<_1JL%@0OJ]1%[L +;#QG6 <]I OM+"9?<976KC;"[J."4@J@0BE=
M[I[T%;:7O^XZ,'%S<E"W<C3QP&@@</7A)N;2\.T*-6N=$085SLB[[9]98F1>
M^LJD>$RL3G,/7?F2_H;*B#HY,;T\95M<?'^;;+6KM,(-SP$]@36HQ^OC-)()
M_JS1Y3$V0Z=".X8Y)Y4NN6[3MH;@=A\!-!PQ2*6_CD+3+$**.?:6W*I=;RH_
M6FIN=#,1"%BL1R=O-XB)^6^06L7<M"275_R1&KUK7Z3Q!>." ^"1@MA3#60Z
ME2)2J:S$-IF@'D42,VV\F]K#/W7E(7!G=O^;QHKQ3>>TBQJTW>GT*-N6TZ34
MJ3O4U7TMW8]/!EQ<_IIZ_S_QEGEDDU+D5#L_G>0D?.M4*X@<(AI^//U?SY;]
MOXXO_;]]].>NXU-_AZ<XH%0*=D!H(*:G56.H+K"WDD7#=T<VD$J)0+43@,RW
M-8?(TPTUL5A[NN45W[7SH$[I#QW_4ILPY<+VENDG#/$:PH -DC$]6_FU?WC?
M^]:^(8HMA:TX!WH3N=V9T&K!DK-H/&6>Y]]R2%II)&["P^I#B7;'8MM_NRW*
MD:M3XT+=$I9&QN%W <4X@$RD)1VUR/R'Q"5L[R+\E&..%0<T?_YU>16S!IT?
M'*W]]P."*5A;'_(6;-GLUS4BIC@@- M[U=0/MO[7]Q*9GTW<."!3#C%X=H9G
MUPS*WV6UX2<<<RQ_RX"'^A!U@1'7_RR38XI_H U'J]C!=I-PP*)MY!E7&&P]
M&N+\>]M'SN,[P0?*#5(X &;VV]5@=1IA3<1/HM$JV[^7L+Z)SEM0O5**X=3-
M _]LQ@&T1A+?9;5@JW_)&#[2H,,!PVS(M?/SX%\W@5'&H,]:?*QA:!5^#0PQ
M#FC+!EW!7!K$/+W:?-R';Z=8GW?2OVL]$_QGHX9(=>5OH*^ 3J[Q_]:&RYX8
M%23>RQ_\)[$G,.RM6M 7=!XVY#@8MOL3C#$&6:(TSJEW*6'S4S!T';"ET1%]
M@1JOP.^%%VTZFSMV+]R31-'GXP#?WQ0PQ1L.!SSP:H<?'X&P O%XNW*!D'D-
M,G]9H0E/<DH73$^O%?\AI+(;+^21%(JBX"\A4QB=?PA)^FG"\X=SSJE^NPG/
M *.$O(9O== 8K.67+_)@;3U(D/8BF1;LQ^]:0+)A W^9+>NG#_>_!< P?*4$
M^*&LU1:?#/^J\S&^54D+&J?7_O1FU!DHK/DWP^& ^[\LQX=Y^KMG_OA.:H%'
MHF#+VU_3^C;@!4$<T#$>@N5&TY.0AOSA8-O@,X9_"1GQCNXT_<,[&7]9HVS!
M"-;3_6=+--50RBU?8/V=?SXP4OF">K*!_&6-T]^LP<:+5T8&,?^G,OX8=>0-
M'-#?;OT/93[^P\2V$?AV=&.&Y_&.7,<[TO0S&M_I#+#B[8/]'5;=V*ON_PR(
M7W/_\ 63.?:_(D3BSVK_L*'R%%0O @_ CW\+Z< \1K*#]^Y,XX#Y7^88S4)G
M+#R08KOQEQ#!G_+_(:3A3T?_4LU7I@QEVM)\(/2GA#%GJ#:2+T0/2\-K#_N.
M]VR-G]5BUNC"<3!X]P"/3\$I63U\>?<_RTLKH@,6A&XM+9*9-/^ (0M!R"_0
M2]$G?SDU]C^<.A(N2)\&)_V'/XI!-%#25+Q>]_^-#".\F_\"BU$T7OE_U!O]
M&5**#=G]HU& :]ZBJ9\&IE_\CY@DA-Y#,JLP8VG(3,#?8<B2YU/H(E?T7T90
M>8W1H@0C-/X!+6<&?*_7Y0=#W*A<.O\M2$S1AFSX>,^(FODM3FN$S!:K&$&D
M4$G8=L4O0QRYA\/6H_XAXB[RQJL=%PWJ03+2,'4;7276B[??,AUZ+OC0VJ*V
MFE@:OV=\7]^UAA[M&4X#5S[K<*+F4WWHYS4)?JW+Q7!8+AJF,(>'UY_I_PR_
M9OD%_M6LYOE^V#HO80?;E5&,HB/%0&?G>7'_PR<OR^H@(&NI5MXQ35*1+".;
M9-*.>;029:GK)^OR9RDY#*_9#%^27A,<"]@UIDQQ7[HD=GM4>Z0B_W6HS++_
M]H^6[FM:Z3Z5X. &]FR(=5[B5ZD7]37=<'=G[D1KQU'G-%LW7RF-4/C>(XPB
M/OD2AO$L0<WL)WT8T,ZOXV4I^%>RS9]A]VC9)*@<)QK!ST:**W^P[:HU4-J5
M9 FIEGUV2ZL14]IM2[;<;HHD:K-+?E V8!O<W1] 5C_A*P4+2KK_P+:4R+25
MM2GON<%3UVL,L;38"K:U--OTH-TN4KUGJR,5.:,-LXRZV_UI)I[;,Q%+5383
MI0@["8-QEQ]:",NHL\?Q4-J6,V;6L;1-;[D!.TU2D!?R]-N23O,XO^M'*XW:
MQN=[YW&[YE<)@81N<*0YQ%RF- 1$=1C);%QOW:\7]SUG[S:)YGM>+I87H!5#
M]WF* Z^MWAWY[T6&V3LFAEYV]U06G3Q7[G;+;=F *:PU(2[KXA/S+T>/Z"X1
MTG'(+M]9DUH3)5CUD1^5U;-8((L$:Z&((SL;_/C-HGCOE1L)/:=7Y8\N(7:7
MCO;?%IOA9]Y.TINHEG:QZ$O\"N/VXR%88QO[(8C/)W,W-3=IU/)M).[0//=6
MVMZ1C?/*MR<H3+N.#((O2B%J:M*P$ZOTM^._&\L*5J3&/#QD3*>T4H$_11YW
M+",'CSHG"G)GIU+2!:9DJ_HII7RR09X'!JW(XX"#: K9?7UEOB3W:[3&LU\M
MDQ6D+ZPES_WW&T8RZD/SRM/HKXO&?HDXC0U+SJRC$<MN8[LI]/F1)SZM/CF:
M1P1WJH')^Q!]WMJ/C'D4O@Z==,=T<WW\D#<'%4.7Y4/L9.5</VU$Y_)DACSJ
M]LVF7WL)N:['2+P6DCZ6_04%#C]LO+ @Q+S#OPP9E/_T'0=T.^X:[R0@]SL,
MQLCDDU!&QEV>HGP#.*!\B+3V6<O$M'<%523J0?[41@Q02$]?X4!1)*2"M<CD
M*<<!$+_>@E<7WB:OQM-%LB3GQ$G3%!5+^U_\J63=C(QY-7]P]==!]/@!@FDO
M.@1\25;0(LMVCNM%4^(NC='["1.R<JM<Z1=8G6XT#+'6OGT?<6!0?!R:%?[$
MUFDO_LTG]GC&*<W];L)Y5#I5=G')]NZ-?3NK,,A^)$K2#/XH++FA;T%D!MQ^
M6W[P]1!];:SES5 :R2XCJS$+%$FC^-\G+O_G2M7#_V"\_[T[DG' YLRZ]=@D
M#M"=OZ_ ]MJ5>19^4 #;S5(^2MC%G*O].DNLR#/Y(:9SD==T">8E\SK<=%JB
M>?]0\/S@%7:D$<_5?_U;YU7.8=C\-^S15:6N:&]7@6+[.".5KX8QAL7NE6L&
M($R07?-\J6+I9\3&5XB'E,S6*4?:EW)\^QOWK__CAIL+B?\/"S1*Q/Z34GM)
M/1XY8<LUK@@:5J3_R?9>[Q_K78T4W7# I>;E= /8I 16)X@++7SP4C(:H39T
M>@]/MA/D(?_KETXT8#5"V*[73+@:\C.W:FUJ6I>?T,P*Y- ]2+5Z:P;O$R58
MI].3R4"WC9HBLZ>WBVCRXKYX5(U"2YG396*PQK;OJM$YQ1\O@Z^80&AV^"_%
M#]C6B%W,M=38]8"*RWF:^\J)AY5:>COD6R--#578YB =(=A/2K9QR-(.-1@M
M.NI,!3L8-]019*B:IMZV(^84\?6.D#^I\X2OC %O(BHIW+[ASO13<6D1FVK/
MR%;_VXI?VWN,SE>)8#Q)[=.3H:Z\O>83#9S3HF1LR^\WA8P<7D<G7>I9XI(?
M(QAY@A\#(ETW9*40MH5;KA00MW:;MU8N)6[YF '%(D@8C-PZF6O&[,QN?*7C
MJE/=YPC2UQ?0K4M2B[[2!G^M_OWU9F) $AUP1K8-0@F?@:<;(B.QA6X_9LJJ
M"S92AT@"_WV?J,66P?9.Y)(WY83>_6R;\)M-EWV'9ZD^//8*8KQV5!S]CWLD
MTBD%%S+7$&RA?[QLJYC1DQ+K@E(SHA4SO>W!!]"$X:UCTY=^<,F6]$M[ES@X
MZ"9<09U&9)"<_D#H;L^8QJ)%&E?O03K5O7TZRLSX >VNS?VR12D-3$.)3\7H
MHKY."VT$/G?/\@B8#"-*3ZM<L^BD@!\NB9G/=$3R?^5Z?\=[G7#H+JLUYW.9
M<2_]"17Z\M2PL%.8 /_W!4VB14T(*W=G82R,FD>]O*: LIZ=L:=[PE>Z>(%2
M0S3S+@Z8+-$[<WJT%&T KLKMGJ<C&'=@64LF\F7+K!4I_M9@KVE=ND@28C;#
MA1]-7Q3E90Q(GND*Q/I4/WR,.)G(:J(- ^[?(4TVE;3(IQ_89/HRT]/7G)PO
M]O;%JM%+7VD<($G83CZ\=AL,T>.L^V1U;@]C NDIRO;^:L&H]+&9BKVF%;F(
MD>W6FRAH^\F8E4'(WI>(\U>$-=6I*HXQ-KW/18S<@HOXCF7N.V\8WU?; ^4
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MR;%70Z[IC)6*A@\X=(YN,C!9_G07HBHK>I)@4EAFN,LF;Z[Q.'4"'@)E\"B
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M8"19,SN'M9Q-'$'=^D$ /TZ(_F=&,NB5/]<%]COH* GU$-W,V]!_T HZ(H\
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M&]P<PTJTZA/Q=XRHX6B/&G@DO/'FC5C6MWTQ] &)T #FB:X,@#$$S[U=K20
MWD<@1O!&1:' ^SC-D>O$9>&HQL>0@L);ZF7.RY6^M49&DD4]**15?!%TRJ/3
M&N\#)OI[N40L]!A#"0) S4]T*.J.AL3PZXF/73TRRR8N;5_)'B[6 BY:,Q#&
M(VY>>N'Q1ZV.+G<Q;94AUL3\X,_\5J>5V:DQI:RX4UXX&[)DV'%LEKXS-K$P
M$7]P-(X1?F*H#XVP&<O5^EW,=VX&N(\U75%823L5#WWGVJ&CK\1:!#W3FB!
ME/'VS ^5TGK1@+\8<9L $(40"QXCUEB$4,B_TGJZ>)8&K@%\>^X.8FH]"\'>
M3L7TP,1U\#+:$'IL#CJ VSYCY_!K&@&8TUB5DOSBK$HQN;7J=ER0P_.C)$DG
MG!J:<]8)>WM_5['P2&->*[)CC X9'7]GK7"&]3[O[1.YTK?'@AHD29#U83B#
M#$O4Y0J=0X]$HG ,:#.AN5:? \[;UT,N$_LT3VMGB/*EX:HQM&H,+T.[*BR1
MR?8TI5^LTD*B%*OJU8FNVYH&<8"HU"*)3GR6_=3NP)% EK=N@:T_+D8/UW>V
M+\GU4CZ#+'$)%H&_Z7D,[W\BAB^C2>2%B:CJUYZX:R-0 O#V PSC,8(-IJV0
MM\Q])WNM]1B_$U^@6/T,%^:A&LY,P0N^;\]/I#Z+BQ-SMUOQO'T%:*OONYS;
MM#I8HL6RE5:,.*R' Z7GT1M1L6X8>C/0SC"1^EL/W>%G3#VPCPM!!XY$!&?,
M^YROD,JZW4XM&'<\^6!M4)>"-S8*-=9VE/2(WDQ_33*, %@7R-2 4!4%6<G$
M:5RE<<[!*<"9J$ *@CUA"]'C%VYJ^XY80H&!A^_%Y9,7T9(D_(UKA@3 &.MD
MZ94[\<G+;:$CU/:%VR4ZI?:-5J^D?W'GZO_H$UI34(*M7>U^\?*(8. S,6G
M@Y\B4#X6%O>L/4_['/IP;E2J9O)&^6H"XR+K<M!6ER5T!,G%ADE:M?6A?S32
MXO49,*>*3-H7GRG:/FLD]QJ:W,HFVIP'IX*3V>E?7!:77[,7Y6V?BZF9!6?9
M0^60D^?186'"[E%.849K\Z(;O*:VC!T3GW$UJ< ^12.;@NP7-K#P,QYRB9?9
M9)%%>J8: Z/-0J]B7C)%<KV[?G0X[O_[_=T,=<O[1L$6Q#7H$'GHX;1HL3[E
M?BC4) J;Q<_BJ\HW,ZB^?\)14R+&P&':Q!@XF.B[A%@;QA)C*FZZEP0 <IP
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M?9 ?J,*0DV'X.7BG4=W(+YL]=EB=#CH#8/$]"G$TKR.%5CJ_V_E\/"VL76Q
MD:@:K]@V[!]AB63P(&_LU^.#[6L1,:TPKH#\I=A686N\4OG4-E&GXQ'Q<P2
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M.I5I)WV+A;30KZZ4YO[[=IR@1<5L)+ I^G=RM__GO_S]^50<GFXZ8P)I<6*
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MW]]^KS#*UU/BNB&*%R75P7%7\>D<7G;""\:MT4=-P&8X^R16%Z\0 ":+8A7
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M0V7&\\LR9K/.G$B=3B,C"Z:9O:T-#IQ)'TYY1IC/GEU8D1G?E]9R7O5>YC'
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M 'GR=N-P==VXY* /KJ9%FJ_@MO:"R!;[?. R)NE@H&M6($*2Y- 5W"2S/E.
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MW.U$+SGK/:H)]XN>RX4&C>F'GG+#];\$.D/SRP$.#3V6QCYW%JS0OL5X&<U
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MP6V1V;L7F<N*/42OOB)''GD,96U1<\%9)/CUEHOG<,@%M6R]<+WOZGH+-*D
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M4]WNRG+R"FW/7PG*V=@*[Y?;LGNQ98'SVOBF9?+PO/?:^B_ID\0/EN5K[R^
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M]")H2F&$(K<(C;,AQR?5MZIU<"_LW$()O?Y^Q6]+@1N>SK$KB6HK8D9)DQA
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M]3JC9AO SRH.L,2-GM"2AHD<<<>T<N%#:]+\65U5*IM=$F+K!7IXA:?@;<?
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M(V=)/LV@PFM%+2S31AR[$,B=-QK#RO?N,OAUYGT<F'7K FCHN:F1OP.P@!(
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MG7M-DE/6<Y]W(9 9UB.!6+@*S<$"0]>MH:^U%H@J?L5E*K*>8:2!;PB5#I_
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M>(N+YFCN4:#3ZDI?S*G48I5SZ'B0''%[$R5::"FZZ<>L>8_O-\IRH\F"#($
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M\>@RF2J"DZ'BU9$&L62%>6:1>WF+IS;.VVVE+%DC%0Y_\R%AJ(H50H1/<(F
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MNJB:\%OK/&'JB1Y*%NBC3LWYP9?H;^#UPR)0O E^5XA./"O>49'UQZ@JX]?
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M@:+@$$BMYQ1C  )!9E0F> UV=;[&ZM$BCCEN"^ZE1%*[/FS;R97TB=\GT*S
M+@\*V2@.S-'59O6\$,KQ<O%PWCL'/5F0H9S!&K&X?+VEA2F/XY F54.I8*F[
MZW9ESW(Y)L7-FEHN)<"90D'QQ-NZ=.J<7%A??3.,IU[>W8V<<Y]_0\CD0YJ
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M=^E!",,N).#[=CJD0'2?%PF(3;]+=5Y^!DF$OUCYA 0HWFK.NX(&6)-=CY$
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M<#C9Z50![P%)ZB!_[TXM0K^V)++.\.FLC+%C4E7,Z?#:]B=*\MOE;\)X%T-
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M%=\GI! OZ%.>>!\.#7I4VN9S^!?L.,130:7K+1LDP*\0">B:G-0HY.Y<T*E
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M,X-+ ?)AHL6..C6=K,8;>"'<(!R=O3[CO '7*!:9YS&S[/3?2_G4%^VQ=KH
MWH+_''-4_O<D+<\W6G LDH*#+KS%=^1KK&=M3%/9"%W[FF@%94S;/KSFXZ?
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M5A,;(SW&BE:.-V//I,*!80<=-:)FB-;2VJJ%AN&S;ZE+;S:V;=-Y\W3VN9$
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MZ"^UXP"<'5+3B6 ?5\S+UEUH*HW/'(S[+!C$U783-H_*:0\W6J[/?MTRY/S
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ML"KPA!9P"!PL/HT;I5J]B<H'YY\K6'5TZO"4%.8.OJRL4]A=ZLFG+</R%Y8
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M?].-Y\9O3AR3/XGM3]*Z@;]!2<5Y9YV_]&2:9,ESWHZV2Y2W!4T<0(Z@((E
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M%3%2C#UVM-_??[-KTB\.%%R$#1!'MT#_POX@3^AJ?GV*WU(6L=@M#*4QK_/
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M_MY,.']O$06W0/%1(@MU3FV:,Y61TWR;L=9M^-W?\ZY\6$JJ9(Q4<M<#*V
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M&O;D0.URU-95$]R^>E&L\V:KPP!%< RP]KK>_M?877<$X:L[[*X\[S!PP$V
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M@T(8UKA_/>+4^WP7ZFZW8@ 3=$?=F=+XT4E#M?UDC>!9H_%.<G+T2C5]2T-
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MIY1H'K;O]3!<?B;%\:UU#L!34?"X(OPEE\Y$C,2,G$%P7VJ-MVYUKLB/,R#
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M3:QVQOMUQIO^ZW#_ J_A#PU_:/CGU[ A*G#!"'R1"M*N_CQ!NBSJ;(WS+WS
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M6" RT6/ EPVZ6^>+@'W)[_<D0PDHX9CLR3JN/X8YXU3:+QLH#_*+^^:*]0^
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MWG5D^, W^0AG\R,XQ5T469+A#$_@N_EE),*)6H/>^@-Q)G7(8F4CPVRA*Q%
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MG[<[B46BEN=0Z\$L.G_.57#!S,>^Q:\HRE6BG:/@IX3]?K/A8?LIYMH9;%3
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MA'N9&$:? %-WB$F%Z^_J A?%B?*:/;:<]Q\ZYP.52;N'(M/_-DQS-,>-M"F
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M(5M?!,>1 [?=PB.6KM]9XX_8;ZB%D3LSH$^)\M<T6((/:D>/V:V[[D^1J4O
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MF3^N!YORY< -*4?VUA! F;S7R_NP#ZIZ[H)PLVZQ9IX[:B"PJ UQ=DRX9>/
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M,5XF\/I[0\RR.ET4S7V1ZSK0*^YO*E5:+N[W1]\A=&HYN+1)?8DF@XPXJC'
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M%U(80'&DZ;<;=[AMEN7UTY\6^&^5F3YLYQR56V7>B>#YU\E'-X=2?M;M!4/
M\)]5O"ZON^;)#DGR5J)U]P=5&M+G573C.;R(CWA6CLHS;6@:JJ,C&MN?M14\
MPJ)N)(*,YPWFVVD4Z"72N2BQ",);[RXW7P$+\(5Z\-*=0],;P*'Y8,Y/]FQ&
MZ_(J#(TFD)NQQ@!@;0RPT&)B.B/0O8,>*D05+,J164TG16;;D&WKO3#L/K\_
M;F%,(1Z8<F)C[J(DR/6 _-=.56"'7&W1^-FHFW2:&->VQN]322URZYID?RFD
MV^Z] \ZJ3Y-V3JQ;M%8$9?ZYRW5=2&B^F]^RK.ZP7$>I0K'8>H(+ZZ4Y\W.;
M[OD?32/YFZ0V)]M\PD2$TCZE<,V?8PZ:^;DF,O(:Y@D![(Z:"K\VTL-JNYZ9
MJ!C6OS>9(27>?FR/I9^(HRP=H'(>N:1BUL!T(7M>D$E"J8Y<E7H<<,)/:#*\
MH._SDJB?2)TG2*&;G4.P<QE+9Z:*F7F8:\1-UJ%]>)/4=I*\XVYU*J7*!L)*
MTV1@+^]/S9,YJCLNO_8W,TGX=&N:#A^'WY(1DD072X>\V<:Q2<@;G>]F%D?#
M"ARKWW\OOG;CCMBS^N>5ROL(/-M\"E97H>HU65JS/"_<D*7FL*M<9FH#% N.
MA]1-R23A6L\:V]&X&H@_X6L;]:[(WK5,P]C/74GL0MKRM$H&.#%L CEKY4]Q
MJ#%BA*N/BG[C0N+)2GQI?+B5SH,]Y<\L%H9BKQ&TKK<U]"NMSG*Q_]Z^%CAU
MWV1*9G5%; (BM,@DQ_2X=0M'2N,LZ9LUX\S",XYDCM4?KS5=)NJ]_P'VCC'
M/RZ$#-0+#/"%#]W9P'*3WGCG;_;PVB0W3]4K[6& Y'6_%%#JNUW[Z=R56W\G
M EN.I8).*[HY+#8BM>A_,\!MGC[F(PH.$AF:6(@ K^I,-.^TPF_NC7F:HI68
M:- (5@PP##-2253\4KRS<24\_LG!C/L:WK%PPH$!UO0$D#E__Z7L9P1T!-S=
MS'),8C%SVU&1!/3"H<<-/OCR522*Y^_.^4JR8ZU95DUC+\.$]RYON_\; SA<
M-*#?9Z"*.M#4XK'+=LKG[5HY-MXL9[;+0W,/K@W[ZSQ"T.0QN>=[)F+.\&,]
M#+!_%P-4;6>O<$SR&GIA@,^CFE=,%E0Z^G0A_\2E_[?RU[HV5!AOJ@0J_P>Y
MU[T'+*88_L/H\PV*W;(!DCD,@ !_+%<L4WF%/+U9+Y1M5V=)VHM+[K)!'F]3
MP]ZLT.O8+>3GB.6.>*=U4%=A +RR_)ONYH/;A4T]A@'J:&[.31_<?(G" !D.
M^X\W8EU,6Q8.UUPP@ GHJ"S^!T+ZVZQU]2CG+^V!Q>A\V>)W32L/\WD]59_8
M]+.GV!^Y2V10RJ2PQ,I(EH73V1X06M,$<SL,'C_YLRGGJ R?[J"0N=IHOXR?
M-U;(U"<3UERHFB41EMZ+AA^BY\X09ID9E)Y:VB-Q[1X47?7S3U2GA#\.5ZNP
M$X&64@H7;TA?#%<2?AO+JTXP;JY-VM]6/:=%3$AHBP17\BC$VARPKB*H/?(,
M9_]LR7$%'6L=?HC[\JW>BVJ^5I*3$V0;X8S;MU(M4:[94'LOZ<5LXBQ;=&Y7
M&2XL;L)5 ]X!^S:U[9YB%UU5N@MQT;H[VK=K)GE'T,RD3E9-ABB*N:I)YG$.
MQ_$@\U<'QN/BDOAL8,-C?F-!%&LCG67\Q!+9$18NHV-1H,8_I98_7L;VAHAD
M5[S(?%VBA3>S8-I[=35E&V%MM[3'_F0,H>"7:V@\J\(,\7U=.<+(*]"D.:S?
MU3+/5H=\+H=7;P>^%A)7X,I. *=,]/P*8)L*6 5R]W_M##[;E%%;NIZ#0X>P
M9=B5O]<^3A9*DEY+5-D/P([.C.^2"PJ09$CU:<:[>-P*I4^"#4KK-N 7_+:N
M^V9;K,YV'PKA#^GNI)&5BBXX;00I5$_*M>2IY=M,2)DG#UHZIAKJ?Q(B;:-^
M4_OZH[/T1%?$"=_<J\KB&Z%%$T7U!AHASA8VR9?%?%FL%'7$+2TM3'PR%[KG
M)A-5LEI0(Q^+^I$,M8CIB7<)MIK.^P.O_-\Z!> "3)J>0#OR=#[2+F_3.ZG1
MHE#-S_.-60GT:8M&VV( B0N]O81.U0M:ILN3[47P$NTA5\[2#7N;=\:9J[NX
M\"_+QE!+KT<4% 1WHS+Q^EYY4+23.*4=+@S]5W'''1$<W3['3/,,!2CE,I.Z
MVN%-K[&G8MLRX6('I/V%";',_:YY6NFUDU4GZ&X/W;/O=U5;0(V>;\:;*!67
M956>UR$1^'>+,M4F.B&/+E]OOQ0 7K\^D<PD?86T*,NW7$JU$O.SX7][B+_@
M<4_0:\E9:N6;%E?-3N*%C^S7P?<KJ5K#RG'OCGM7C4+XZK _<K0 T;\LJ<?_
MH8.@_^0$$1A@.0/UV_1,[ \&V#W=_+?D0,)R["656_D5,@,#*%4QTV" .!4E
M#%".!SXQ'/YO=!/-1SOKIG_$"K)3U[E3UQQ,11BJ-]*\EW^RNE$;7FM7C/(;
MKE^M\WG2%'?_H3NY&C<1:#>4J]Q-<<^YVU;P6\E6D+E69KDX20,Z33(P*;J3
M@ %2:C" H\!-N8G%W[NR+;_R)SEC.[=^ICO@_Z9DE\MDM*.N*E4S$7#OWRD+
M#MC+VIITWO ?G1@OJ+$JND>VC[>MJ#* _,5DB.<&6D56_>84 PPIP9YE5+K7
M]4:VWT )])KR;^,>*P/XX%SS#8IE1>4L)!EU,_,7 4&+'4=3#Y\JS1XW5RT<
M^8.1I+G9Z70M@CWQ6&,YV+$]N6782UJHP ,,L+,(WV1KN%HK9#:02*\B:)I(
M^5KJF%U[\&':KMA3Q'CL3'B^);]G^'F\\"?>W"!!/QN^AE0M'!0XN5VOVM]\
MV/#I$9]JE_^SX+'K!&T;]S$]L=+)#YRC],LF4@/2A>*5XOV.;;V@@KC6='GT
MILRJSS@A*85I>;C#";'NR-RCTMTD-)U=[CLULX<]"C@6JA9R=5188SI0%YIV
M67-/:<W#EU=$+%/G E1V.!Z2:0?WL1\ISSJP ^DJ'#'!F96')#DT$7:N&M#.
M:9K&*I]4C^HON=/:!:ZV!1M$>&]:-@+EF<2H-WZBU.(J&3+(IV>V1K8$1:A#
MRMUG^RFJ)^(@M*"@)Y3=V!\U'[@QS+UUB)C6W3J>3C6H_)(7SF$YW=LDDX0=
M/27CHPWR_]FYOUF6-\KPB1DB*[*E648 )V_)W0:3"9161EHTC+P)4N,"$;O[
M#S8JIL%)W&-M;N</OGLA3#S8J=#:_>R,OF_'CE8]Z/C)?DC.K%#EZH,!TMYM
M[R&0X:0@ZZ?*X?+$OB^OQ3TV1O)PR/ D<1'EG8^K)^DA[3M6E9NLM=75-09E
M"0>SZV2]#3=#CGQ96I3;T[I6NC;3)HA[]&F'4V6_>S7L]\$>"+MIERA&ED_I
M);?1UL!_9L=UI.2>DVK(@:JSI\.GLEJO4JB3]"N+!:1>?:"@3EMU2EO)V##Q
M<_2>3RCGCBH[-05MISP8XZJ,8-AA4G>Y^^JAV4<ON/#&0TE:"5&L\4WOM; /
M)YYB&N(O.$M^[7$^^_G1\67P4! >6R4L!?DH*44E-*1VK/24(:PN'5:<ZBPN
MVL]. ]QQ"NZ4;7 M2_HW#K0->6%@?6QL-*7A(TP:/T^1E<NQ OP _-2VC&.#
M43Z/&K(N@E],/'P[&AKM)BJ2Z_Q%7G],A''1DA']:L)F.HU>/%DNRSE!1A#H
M^]YI[M+-R+-Z6GX/^3RVQ$I.!KEML-#B4VH,G9WZLI<NT5/_QD.(EG$E M@2
MO>5GA@VS5I"4\M"1P2>3]G<;O_;,A<41,MYWZU+>V06;ZI2#JFK'?-6S+TA;
MM3>]\ZKV8^$.<EF<_<4JC/@ K^9*RRR)RIK)1K0_Y6U+$V_&Q=0;G]$MUQBY
M&1F0ORQX9_NUNTO296$D@/T?,YN>S(W(5 4D<\42\0OUAK%OZ:;D4T8_YU2C
MLM3O=4]'N'QBNH$M_%N>AKN#Y8AGQ_1T"8R.M)$1P !L,;=A()0,OEF5\\]5
MI?"UR;[F[S (H8?,K=.B+9VWUA5%]W1NO 8M.!CN%Z=/(E@R=VJ>7+\,J(SK
MI(2G==\)TI*0V+?*X>EHLB]JP4T8^S6Y6'&HTL[/K9YN43NZ6.63'",I7'+)
M#F)10&LHK3B0;C4QC9:B%')F5"R\+)SH^MBQQM+(5#0QP$"EJ)_(KWK<_+-4
M8N5.Z>]Y@M,!9L&30>-UI5833=P55='[,[L_!BJ^OP_BG$%Q7.FA)^-UGJ$*
MFF!B?Z;*M- V"S>_FL\:W1)OJ6:_$0:HI4%/ECRX];CL_\<>5[D;)P(P?(#K
MU,__-Z+HC '(W!H62#VE=G1'YW37'T<]L" 2U,=N.1-;HV?I,*4VA5VYY9YK
MT]H_RHZ09]5^5@' %:&QAQYHM?'S&]?;X56D7H3^!3DURK>0LPD^>3M)[?7[
MI9K(0/M8FDWNE]-2*AV3_.R_VKI_W:NNZG\T\H\X#358AN/ 4LK#!1SL7D=G
M)@;JC@1H4I%DA'A_?97\XGNH<HS1CM6<=W%/9FR;6)YD#\FA8'E8B.=1WR$&
MN( PL]_R4"OXP=$P!B!8:8<?[Y'>H U/%_:B1=!!XAGG-_#.V+\[K[[J@'9Q
MGYF0[&Z@[F8N;-*[C=$<%LG$AYF4,4295;E54='HG3\SG/?\INWXW)Z!)5'=
M^#CA4]G ]LMQ"1X5\[<7#<]K)Q L)=9)@1K]<[D?.Q"+]A:LYA.6D;[2\!*4
M</T0/P[</FE$XI/T&X\'QL<7]#M6A:*2MQ-N*Z6L.(N_.L[Q[6?CI\>L7[-$
M6DN3HU2;A>\QFNO=BUQ2OS:EAVZOM\YW#OCQ&'11S(D.(E2-'JJN2.[%_3HM
M.[N-GD87]UZB>$9DI#_X+UB=E;(>RYG.]97] <O#X-K#]ON^/MDP\O?7G%_S
M^H37FNP&*^Q!\'I83G: !!-VZW18J&M<ME+6EM1[;=7EB3/K)Y0,0J\Y&/!G
MZ[KH!D#L8H4EUO0IGKWJDR<S5H_,:BI2!O29'7BB=Z-*\JUQ?'/)]X52MF\C
M7Y N,J;0=8&,Z"W+1?I,!U.Z:?W,I:4'H^]X5IFG.P;0_HY,$\0[W_).K.KO
M7._JCJNOEM74AQC2"K&2.3HZ>M,; L=SL);ZTJ,+U)/; "U\59L_W;SK 9YB
M0XPDM?/!D\G3.E%"?DUI"3O7AMH#[KH@78W>=M(D:KQ+!0FSA$Y!_!V3HI_U
M:_J"IR#1RK^OG_Q-(*G-K6"1=IJK?!17TX/(O3>>-4U'LZ]_3)N"G(D7>!?M
M-A)23J0S!'83O 9T^:,; SO'N[AEB]L'VW^?"*8SCOJJYVY_[.THJ_-Q.C9L
MEPH?(YV7V,SUV\_/RB0U0BZ$V:($<E2^&<BV_RBNC.5O3UU-_!/?US\;[\=G
M6+> <_/^PH;K^R3GQ/"J>SP:,FOQ,:U&$P %Y&0"$*6_"]E>R1JJ;[K"MEQK
MS3*TU;WH)QZ04*\1N#]8=33"+KB* );_<RJ:M+R\$TZ. 2QN*EJE=.'OMLEM
MR"X?DT>/J'S-JI#L.7+&)6WT5@ET8V%<N&E&4VK0=VE,K=TD[,8P] WL7;;'
MCN)OC9WN8OWY5S#)XJ!#ZLB+G"Y'3__]=7W7[H=-$X?*,\_[FQVVNE;]8(UE
M#NWSU';VRS/:/YH2M,;Y%?3+R"QYX2%A^:9]I_G*SX0;W(]WR=PM'ZRPW/7T
M>#JZ*\#_\$Y(8SB7(E]-2G0+8UKP2>&I'[D_2S]N0]:@J#NS=]Y>0IVYN5E4
MU G[@JS*T%P54J\&7C@]>Y$*O79KS U2W5O6*.J3H@P ;?I7#7MF*&" ]PFJ
MZ(''RO-<B<Q/*)TL7GQM5);LDAMOKJZ(LN K^Y9V]M/^IC]E%0.LEV* 64(,
M )LT,,Y C3=?!\+WO#?RSAJ)5OX/?6NN0[W_I\KWYN3R!%(Z*C;_!E9A%PT8
M@&/[&EU_.XQ9$4B!VZ:Z9W+@DR<L5T*P+0$F3_^#=C15W4A);JCDFJN%]>>0
M2WW*>"S91KX^5X=@*-MH5;_<&6R./[NF+L82_^'[CR7XG2_*J3N@:7DZHK%@
MRF?.16EZ8;7#2M33WG\+=U@0E56_>YK QVGM\PQ'YTRI*-1*M=].SNAM (T'
MKXRN0W0=^ ]F"$BB&8\O1ZVF\YB5_,UOZ-Y%\.2^_1^E0>HC[H[!2U[#@QLW
MK9M[5:=SO@>'A$NFD0B%E4;(R]'*S=7*6C>A!F/EW( (*<KTS,G\Q)<A4J7]
M,UKCY&*NGHW4FZ;(7(07!I O:$8^$D#SQE[H0F4P0.9+TPN:VTE%#3V?V(1+
M7??5&6R95I2C(J:;;_QC;[!@4WS]3<07Z@;(T)"":9A>+\ZH<3C9PXA+DTPW
M79^(DY3+*-N<AT_S:%SMF&+ RX\R2%'WK^:+XDV4?!S>\"EQ/-;MJBR*)QE_
M+9)A$[&\/=D"Q4YNUVES<N)PCY,I%ILM;^!4  O9N@W>J4:\^3:[PTPTX3HC
M2NKB9OE0Y\%KK'>Z(.X\BXOFMJO0'\CZ@R<5T89H==7EEY: O6X=W=:?R0?*
M>7GH1KFD<]W-B4-C";V:*E@K+?:TWE0(JYFTQSFVQ/JWC&58Q3+#'N'+[T&$
M,SYB3=&E&\(J#Y6^>"?JY@K'1=&G=MXS[$"'?MRL$'4A_)!BH18E\/!^LV<X
MZQIM3'37& 2<[6FF6W/8>%8R[6+PIS\W4B()=NSRP.F^0RK'WLX0A<2 LVHF
MWM)%;&$&_M8\3T9;H&O#MXC'3QMP%VFD%7GMIB%.@$4@ZP9VGH/A1=(9F*(E
M!T;O>L_!P^9<;T3193WJ/M;P47%5@(4D'9/72AKV$K\QBF,8!5[-/XLNGJ8S
M.\8%8BS>;60MTL^/NTHW##);U:=DI_+!^ JX[7Z1F4_58#?/B6)]6B#GHB?T
M3'2=<<GD,Q="=(PJ-C!;1;Z3/=L?D-PY&O. 7&U==!&79E7[B \SOPS?3V,G
ME<1RSE)=& !!275&LI'G[[\-57YP-8K%OT6DI+5X605$9GQ7[9ZU<%[;7J<\
MCKE;Z5=UM3$[!-QBF8%/R,->=$KTDLW@%;VP.83TV!&RQKJ2829/58I0R[<F
MNQA\8<+=(TYSS75DZC+W>ZVK\K@UH9944P3"[ZM4'DMK8.4=DY#_*UDOUI4K
M]'#UUY.BW\'TJT$[@]@LB<[H!R,"H@L$%^/VND(W546M_%0?6[71S^S <[^)
M1&;*WQAZ>]8ASZ-%"TZ+3:N@-G%JUG;> M/N(3K/0\1I1PG<5VM_<Q!=#>'"
M@WSEITG;F@EY9_";*]T*2TA,'9*8O0;VPR1F1N<;U!"JK(<_-RGDBVG.C+:)
MG4WW]^*TRX1&UP=<INL8M.[NZ,UCW9('[:]:*A,,.M?2S\3[FESSK>P#/B6P
M7JV(%9*$E]K R<PGJO@D2F_'PMKU)/H=*6]2' -_C+#CG# N2%("(*]IEQQ]
M&MGN;%W].[-[YYAAX20QY#//IZX:>TF0_6[@()0/42Z+/ ]Y-UP9*<N\TVJH
MM'N6J723[9O%6$!*\JO0\=H[BCQC^0 :\@\)1G(3(2.USV9LXNSLLL7=,N"5
M.0I57R;<'+>E+MBUVL*K=%-.9GSREYD2][5_\+<PKD1!OO=F<)X5N%0N:<%M
M+H_5QUETFJ1<T?@7/GG;\BN[AE]3C7J\5A@2B-/_< 7(6B[-%UUUA965/?^N
M3K$-T?F%9..E3=*E9)#'L>N2O=DI+0'C_YFWGB9RGYRV3\Q_7M:U>Z6[%W#'
MD_6UL\^AT:=_1W^Q.;;HW+B@['_;5M\/2$4<-F@Q7,3J720NS7RVGR8ELCE_
MK&UH^/D377:HT/6(ZMRQ" 6(EH!O4N"@]*1?:AU]I/5H8H([Q7):<TQ;G9%$
M$Y#EN=-!O8$!D W^S/"A-@P0#V%!V=>3$GG.M#4)74/.<+/.!G_N'C>[</AX
M6#HLZ*3MV:=_PAKZE^#LIX27C:819%M!2R$)UDW68=AWS]/]$1"(,?P#@J70
M)IT]UF!4K'SW,OZ/O-.]E:AXK\'F+25FHZI'+82FNLU1YF-N< KK)IH?C3X\
M^>%EC]Y%H6:P6$F'T&[)?KFF*!GQZ<:8<C>/_/ DZ0:CT.[I+H8PVXT9<"@,
M]@096OQF^>F$F(;'M<((;@!NI#60=CI89H,!HDY@@V36@EO53?H11N\?D^Q%
M_PA.B'V1IK>=^W9%0ZQWK(HC)58QYU\;L_SORN$"S?;5UYJ(@Z5@G88(3J<J
M"G=M.9TA;./:$MTV!8WB;:<5I[A6!<UGY^ZR$1%(EKT],W30Y&T408$!5E3.
MSGY@  48!D#APP_+2/<^P_ED!O>NX-V#_MFUY:'G-9!ZDY6YV7[IA[]PDYZT
M$^=,-!B>\KQZ95T46;B[M,-[DOCTK]P0:;@<^R%NB%NVXM+9AUY'>_,D[@_@
ME._M%G^D@Y[$=97:V\P_K*E"\GG&=Q,&BM7+IL&/)]0$V;4ZOBB<K%>)2TGQ
M]9U@  K3W\B5=@\HU_@CME2-YO0!HSEQ,34@>MPY^)O+%?WV*0O-UA6T@3EH
M&&J\[6Q4VNZH0/8N#O]-VBI6=!C'HNL&!P&P:57"MT ]-;4-GMJ"^7EX?B<,
MSZH*]@H2&6J6^-W2&O6CY9=8^*(I>>-!B$.5T9>R\H_;R0_P5:=5A"YS60EP
MY;%9%":IL&9U]*=-P_G%-#0WG@N:&-K<&R[Y:62B3(VHY@#A4)0(XRTB5<2B
M0>T+I(.Y+<4A32:\*OKSEWO=H??, IB:<N\HR\M0D"@!;O0QJ1;%?]3-"J85
MW6 \6$M?L/E>KSKZX>$66:,91D1[?WC86:/C*7L-\N+67#6W2U83F5N+_WB6
MM6* 5V&:1P[\^;4!LT9^1;.=W%%F3L9'>+/")=@N:2\AZ2*C=AQ-,W?W^NB]
MV,[6I^\<SGP45I#5#W!^$MKEJPU24G*\6H@JVY,Q6TJ5E1I9/M8<>UW[9?IN
M- ))3D=P[\VON831@AW#G)=5D1WGF^?):%MZ<P^*J>H%3DH75%L3&D]F!= &
MJ2@Y)V605<)Z3>3.),J36F]&>,J99S^\CQVF/06!'SG5R%B*.4*-,C[PFPL<
M-(W4&_;8HDTK;(4_<FQEB+#&U'8 #L-0ZT53EJ?-I*+]BOI^3Q;9$A%CSY5R
MHB,_/J[1Q556Q2&Y*'_V5Y(+]#]W96']E(C@CJNH4C"+M;G<,+F(M#CDZM]U
M<! 5(-TR_QDND 5K:-;HSG+/][\\$3M1\MKX<&I*]CC*2!Z)DF.IT+>=V/LV
MKE,AIU_&3CCE*.QC[L]*CP%(^"M]P'>GC:P,$5>E[Y_W)(M0QKOT! 8&2).,
M_U7/$R#[O0PF;/%R(<ZE@9K'U4_+O?V8D[C XA=&Q](WJ?5OL/!BO/*/V%?F
MX^?UC_CWESPYCV:(JT))2(?&>WBPNQV:2&XR.IAI$IZ-B7F,/DPQK:RL#YRS
M;X#TDL-=*?!8W3N\QY"*;@[\C>TZ_3@%NJJKVCW;RGBL2 7&M[G9 3(9RUKO
M48_-, !>[!\4.,_H$LU9$>3 U2-ZS&YW'?==\D7@1T^Q+?IW(3F;Z0YGFHEF
M;S;,^JXYZY6:Z3K= ]/,3T_%NOZ+TJ*PK\Y?.:$J# "EQ ";U3FWD^N(9[/Y
M= F$CC24^>^4DV@3W]YKW"HJR(-E$Q\]Y'HQ];&A7[&\5>O@&NF\_"48/(KC
MXS2#>$)BW_VI;#?27V+NMO>:Y362UY);AE+,!Q<J)W.7<V?Z%>EU?WC5934[
M,8"FR9/I;4E^.@^OAN_ 0=I)E^])F?AQQW3&AU/VO(LG@F;1 ;5CN:9SF2?&
MIVC+[P>&G<*?O/AA]CUJ56:-_\3%%MZ&+G=D-7]&\)1\^%_]QU7.>ZQY]8$'
M!C"YA:$G8KM-H%L<>JR) =PPP(EX.?U_J\WH:9[GWL0 HK[5ZNA3L,IE3F9V
M!-\F:2$!TC1FX4C$.N/T%C@KJGS&/06Z'"[I*@>OCC' U/3W=CC1J;/#>=7M
MO6SP@(4CV@GPSASXA!VZ :5#,J 5Z;MN?/+1[V&SF[=X2TR9!F]27[O\CQ)G
M5=TZHTK'PB4W9.%T1."&"!+H:8I6GF- -V=B@.%(Z/5_FYG"Y;XH.#J$=YH*
M]%U-1/"4'8^1W:SEY8*]K*VPUZ)?H)],-I_>OK<3=E.%"VST4PUN=!W+#=[D
M8$H^*J0<OG,;RVTJ-P4C0:@/*5HWSN K\M)M%,_5+@:X&<DH0GT9T5&B#CRZ
M_Q^9+;$58F$T_)X-A:*9"X?M"E&<$&B-Z5>Y17:=D^>K\*!@]XD-YL>X/US'
M&*J^#F8T_S@%7X&@\(70O[9N_?V7*]R(V['[D87:/<( WQ]@ .GK&/:ETM*.
MLD3O&C)U0KJ6.T]Y5:=E8379$:=6NB\+BZQW?21L>$-X1C7/)#  I>&LQB%V
M"V47SD]%HLE0 VI\_9::UX^9@[EC8%^&1(FA8+K\4'O;52WB34C\MIY+8JOZ
M^NLV,EE4M9<6ZJ[W:\OQ@E*-09:QRD8%]#U/])3MHY3E%0-$/.W[AX:O1!X0
MY="QQCCSE:M+8H EYUYON]5K,(K]L)W[C[O#M6)\0[TEK<05Q$P)<*P^4EMJ
M_I#.CFBL0,3/0"(FC SV2J&OGUOI9$MC3;L<$RTR=0U-R$5Z+1.3_H(DWZO7
M:*=QWJF@RXF?^Q8_#4H[^*@<=I[Z<M6.@QD1<<K+@SV D&1:Z^J0_JJP.F:_
M1Q+QD7-N+GFJ3?!S?)%X.>,&A\N@CGYXWC;VF7/%*+K%[6S\2,1NM>:SD'N)
MO[%E@,A)^>OL (D;_XEETW!_XKH8?"C>VV:*GH)GG0;L,[4G="V=WLMU<WSJ
M-2/O)D7WW'SEXS4*C+5(_T2/*KH0E>A3'P5J+X@3I"O0;?5[)U)A;=17O?>^
MU[QHU.O#T#Y\TNN3:HE/E(# 6E:@?9V5>H$W*+/\K;:J+KEKGK5>W1H5C@!3
M**]S8:6Z-O-T7\_&2!V;K%%AK4UZNQW[DB-O/E?4/M:)EO9EXYIOL(BJAM#1
MM@SFN3Z .<H)JWNLJI^9+5TL4]I*$T:&27NX#N!)G)>U1@"'7^EAIQ<<350)
M3\;9)\KLH!.T].-GCS_WAQ-]GL[$3B)2H-WJ'BS7GTG5D)N>2G51HLAR,"9Z
M5_)WNPE<O!<"9/B7917WKIIBB><F?J6;-6!7NC*2[Q@EGXE?I7]U>>/%\@7F
M1MDF;,_N+'@_5(6=-3UQ:9[UPFFIG/BB7LT"R5Q19*4[E3WS+?ZH3]>OS[CV
M&)M$/'!@X:TWX%T6ODA*Z.FB?>T?E]-F[?8]_W-4^YZL"L>DFK%EZQSSAB*2
MORIQ//A/389(%TXNW3WQN B'+H;J%?!*RN[FOS,]\Q\<0PA=HIQ"/;I.A1UY
M*KNJ&_JSFUU^-Q_\@Q?2>\MURG%.D[PD2E:3 =OWR*U9*!'LG.?OV9#?4AW<
MD3.S4PB7U$D.O/80P9>,'K\O8\>\:\+%!JFM4Z(<-_U)T--55L%576=I>C.F
M'%33*]P =@;<!NCZ3Q6+YJC;6VR\8X.S)F68;B)MFCA_NM6B1R,V7-8"- J$
MA?$ES\[_?1<74085O#NG%#[Y'@-<\1<@FU$14@(WG@H8('LB]I^K;J$HV508
MW5)JW/4!!>&*]*TV4VAN5OD@&8]WSLT1G1_K,%'OO>ZKN#SERJ_ _T)Q3"!8
MF>/8;BB1CL,L'PHV?)FX!C-%4E'/3\HT78FEWX1\"UMFD.5U/WY4PO:$_(_K
M3"> (JVIL?CF.2XZ8V5KZTM7-#-3=J?HB:/L(&.&BQYXR6P6/I1? E_(05,5
M'M(OS4'0Y!JOS0,S>#! B/M@NLU(V++]_G@*2G._#GQ9##^_@P&F3R<@W!A
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MJX:)L:R*AVS;QR2\<N^>&X?Q(@&!;)KFX%[]('B^['"W\D+KFHSZG3]>%_5
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M9^R\=5@=3[<FVGB"!G=W"!#<+00+@8V[!8<=W-T"! \0(,%=@KN[0X#@84.
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M8'WW/WL\4P:_&6(D<A7Y$$IE"954Y]TZF$<?IF?+#]KGEZ@AUKI7V=+-,6E
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M]D< _\ZBX22V*;SR'(MMF@@O_=<;?,-1K50)W6U)H>TIG^VH\R-">  7 =Q
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M2L^ ?T8XN6%B\@^\0N]F*P&U(V=U5Y QA7R8BLARKRV<1WS(I+>>)0='\&<
MQ;X 9##4M<HK2OSU9-\)GX_?BR7O-XFY,@HN+J^#K[%]MCUFY$_LLR..8(\
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M!>_\[ Y";QNKV7#N?+WOP2I1PFUHS!Z/0)4,[RUJSR.PL6G5>D',*Q85N,8
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M^.O'[._-Q695EH^6SO7,KA.]KHRBZ%M02/E'&JVIO>Q]?=XYER>D.#B[2N6
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MV ]Z5<A[V*C>DH$D;TN1N4 (@!-H^-/N,X]*USS[LYSP!6[[5V/ZMD$Z\-/
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M;W:[3X[=LI0FW!Y*W<?TW=O#I9.@,QFW<?(*\(MOW@9D+MX)%>0/>;]U19B
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MDRF\E&;5GX1,WT9UIFO)2>$ &CN6^SUAY>.W!E;FC\U]3XH)ZX[X5I,F^&0
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M?UUH1DCPBH$1NYF6*-L;'.(V<V;/ 6LIF-M2U.6K)J]_G00(XW6)^O@N3/2
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MWT4<[RR4,#K!0^(J5AW*&NV)M'4L^]!"SJ+/5]F-Z=5AQ$W*+7WDKJD2;P'
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MXIO#,Z1H@EC/_COW;Y'R]XB$Q,PO5OWY):B1,I..S[-&W2GWW5^:/<>7I1C
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MR@*!!J+Z>NM1X-4/$\I*FF4CN[ #M;HPV#SH^:,NB<#Q:[S,\^</P,.V8V@
M>P,-1.K$(LW'*B>^JM36UQG4,\_59P1TEM5V+=! U(:OJ6%!]R9RT]9JBZC5
M\O@IF$:7CHR^U.*U+<]V.^R;,SL *]AT1BTMOX<P$1 Z7MF)B._:Y 58!B%8
MOT1I?Y6M_J)?354&4;3T*;\TH>ER_5#,^2BT8XR0-$^=3+5I+X=^8>*44YLK
M+%W2BB)=-]'V>^WCUK"GQ:]^_'N*CF3G*_8Z=YU3$TI>3#9HW.I9PFG^\Q*&
MP,*]KB,E3^XY/U(S#K\ORM[VH-<F!$A/P1#SR<I-/H8'1@?]3&_K?W0\.-5M
M_0@QB]I+M<8L0YC!2TA DP:UE>(D-,H"? Q6]:%&VI9#,HOC9LF1L9L3 PA;
M58J$555B/>NJ\P+*!VC JH])8/?T40!@6J?X5W3RZ:BJI%AI98@(I/&RF?I#
MXK=$GZ1%%@MK>(3+G0+GGNYS^$(]#-Y@MLRII#-980^6'N?</?/CZ,X[_]'7
MP2;/K54V1-=4@8'3YN>H-VXZQ=?HL2W:-\"@YL/C$76OOQMXE" 'G&WM3>6U
M39XYDB&".YJ>CIW2N;OYF!#.OD:0YSVKC1VNF3,0,OD>*5'#GVFV!":QD: >
MUU Y(N4!?=48EYCU]+9O@43SAN6(O0-?U0L:';*&@)>?3+H[$NP(>-@4&V11
MC,Q+&>9IP>AY1??$B5S\0,#$<(.S+1H@*!0S*NF-^U:!-\7+_*&WT*2O6PMK
MJ4K<.7$-J7<$_IT(#73OPQ?W[*^K&]M_%"31(S2W1X--]>QCM)S^J>1]Z[<@
MJS8/:LZ&"&8/IY#V<&[#,\[(&>9D[2+ 2_(SZCGBX9M#A^#W7L67GMIU?@TO
M6&=818W,WK8]XG:2WC)@.*SWIP</M]WJ<AT&I$/CG3#@! T@C)J))#??HX$>
M=@A*4 [)M1@,/>5& ZNQ76B ID3J+Z>!HB@<VX:N*,''BO _XKIH +]Z>>.&
M0/*2Q1D-=.X,_Y';@@:"9@]/4%\8D-$U: #N!F[=0]P2YU=$* 5#\%'=Z1\E
MP9<U)M>QDN?[ 43_<X]]BCF$!I8]D+?W2P]& \S%DHCY_]N?XM\ITU&$3@<8
MV[U(?G'!)-"IBY>TJD[ZT06&I''E2,M1TG)E48.3=#'SV\YT-9).)U+" "*N
M1I*P6LWD:'5/^1QA!>:96\WTMW<M0TH?42P_#^-4OZ^C0W)I_F/>GHML3-SI
MI7\*NQG*@0*U9G)37R*5%YYLM++;0254G]F#%/_CBJ ]X_OL.L1>GZGHBKBH
MYB(36"158LO^_NTSU%T\8^IQ%7KF4\%_^G7S3Y_%?9-4G?CO)(3\[2P8?_R+
M^^5/<Y'YM[,PE?9'(=B_?MPMZD$#?SL7DG^:!6]L4HS_<S+MF+6!B<785_9D
ME>X3:5T;C3M3)4@,<8"DI%BYTMS?7TZI&=]>(H@GN7N+R&;S@=-_6@2YAI1Q
MA>L^;SF\^1G,&1!"X7.Y*D<4 ZWC"3<[*\YH:%N!!#:8W#YGD.[)^;2US0-!
M<O4Y,0FWI$A/,HW8SA%(R60 ]WM$)1P?^K MP^9*.[2PW^CU0';#:)92JH)K
M$(.QC(^]%S2X DH'<ABEN?^B;8&XO)Q ,,0JR95P-9IW('(U\?2O!_"S,W1X
M]X%\6KV+2Z,*H_5FQ7(C1GX0?6?XL%+%+FH\^FCJ]/XK^1K3*&.IPU^Y/49M
M-,$U.XBW. F;5T/A%7Z>+:,[(MNV'JDL$0T[VI7RJ-YU[IVR^&)!P'733U:D
M))3^T7B%,NN;RI%L>7XZ$_5@E2_+PT+!7L)^.9]D11CT>X:;&!!?Q$VDH.WZ
M\]GS\<&9YJ5A,'+9;['WJ%^JO@6VML[ZKTH^-KPJ 3GNPJ ACV)T*R:^9/Z<
M+P0X'OFO\(9;%?B;%3_%\*7+0WSJZ_+N^GPVH&F[Y6A'M]8(ERH3TA9B:P'M
MW%KYDH^6:& %#7SD&Y!=;STQ.MXOL@!9JI:K>-1%4YH_(;PGSN:(BU#5&D.^
MR@-!VD4B*A>*?$@,@BI"LMZV-W[Q8D[U*NX-$)-L:R9MH#$[8NA,K!S\5=ZE
M?DTTPW+-T=5_O,R&Q.IN$5HE."]N^[^\O(W!1]4H!<);KG@+.Z_4Z "&__?W
M:!)K)S3XH>Q(3PE[)@%O9?@J\:9<O'&0# #R#$4]1BA7!#HNTSDH<%%U<H23
MA'QSC5-['%&S%22TD>,-MV]P+9!V)ZTFD>-[VI(J()7^W9V*-NS*X:IS2KTL
ML?><+!%F,<ML/QRV5F'R18)Z^$QKW'YO/<[-?@1W=:Z,X2W/N,<@6&3S,_>+
MKZ!$1?7]47#H_"MB%6Y;V]VU6ST/LG[H-GE:(+UM?\!%M+;&>I*)(I\*NEU.
M$$C(?8:2Z5,O)C0P$M5C_$O&8FB&"0(M%TM"D:NV*4C"=SJILX>N%^VDP/=&
MY+;498YHEI!<S 8% M_ ?0I\,REHX.!G>.*9_M/SF'W:XWT0--S7Z#"G8[*T
M !$^,S?[Z7$JIX1K$&LL>ZFY/Q/.46X#V4I)T/]7WI5'0_WW^Z\?F4IF?F1?
M\T.*DF7L2]3/7D:(-"+),L;896@8*6M$IE+2$"'+S A9IR0:9*<(6<:^#3.V
M!M-XW/O/<\^YYWFZ][G/?<ZYYY[S>?_[6=_OU^?U.9_S?KWQO @_X4^0L$C%
M9?5W]^8%@[,4E[6[1:<W2(&YI"5!'8,7&V=&[*>GW\?_\BBDQ;'3:4L-6ZM[
M0#[?8([#<;/_180M:&/D49M[*X.62N1\53X/J*>9U:PM];S.@>A4,3_1NS[S
M\194"/!QICU$K!?/S<L6-?SGH;4"_H_R"J5NMN9^#S*#6-KX'F IFP,Q^H?%
M"?> ZQ7L7G;OKIRTWQHYM7+;O6-MO=YSI3ZX2]>SU#$;87B&(;$'"'K0!TK<
MW1'>(;/DQ#^"Y:+#GSL&T]5,K8$/4YG AM@OD_6)TI/8)'UCZAE>6/'\@*;M
M^=]*8 9?[M%&_\BY;-Q^M%Y'#@!%/>+X%AG3O6NV>WXY+;+^\YIA_TRJ>GL7
M[7D=K5M[(?.-LU82QK7DRE6F/ZSW>@4./OCTE.E2&(Z_F/MAJXNUFG;W7$_G
MA+^ SS#E)7$^8D.HJ'B^WS2]W:O&1-'\T#G.(+# ;+2>[M^=9_'@VJBQFWZ5
M0WMHR.L+-I7X*[>6>:Y/W)Z,/O456^:T!WCOM\AT2'6XB]DPYLUL>/AH1=BU
MVCE)=6?8'3*BV&>+?1+7S#?4O"._7*;UK0G%(Z)7ZX[K6;^S0<3"F"F3F_>;
M=MB$P@4+ZL];/WVIU=&U-=$Z,J)/684KN \+#YY] #87E5HUSB9**>\>KYV\
MJ-ADB05[#\[V4K-:E95_*W,(=5N[\T1D:I"H$NDS'%KW-HZJ7FX/KEV*43?B
M[_UO)(K_1[M\>XG'P+K+2F_77)EVD\+T2C9/B3GX&0\^"**7"#9B+C%<$\@R
MU&T- S%*V\0]F<S)A;9&K\."-J'ZT^E&G%]Z0+=-S+CBX.A7OAX]JBTU1;_R
M/,)KJU#N;/TJS9)_WV;H7[=9:.=CMUU%>A>[CZ?>2?6]Z!2_[/48M<*[,1PL
MQ4_AJW<QH46+8F'WB603P2POH_I,!2&W*EH"__=JA15\@.'CA_DL(P8F&(VT
M'UBN?)F+3EI $2;?KNOO!BOLE#=G:9HI2!=: IN9OW)84J2;5]%0FQ<6<6"T
M].GX$48B7YFQJ%UC(\ 6;$*.J3"D< SQIF&E*]^:7BWBVOE;N_HN'C.QA7-R
M<%\!#-T;NTXP0(FLRZ%33BQUJGBDBH7'3>45H@;OM)#[&N5EQ-'&MDT#U590
M3J\+#,4XZ\20>DR%8R'?ADQ*EV*"9:^M>J,&^,]7">.R)*),ZU(!=)X=@Y=8
M@B# X4W%""V25P#*0M7<S,QY3;U;:FA*&Y#\FYJ'?_=_PA*!USXKE/$)0FV_
M7*G99"V[:VS!%_Z<//:LZVS\)LGAOZ#!,1&EM. BRQ".S>^!&BB+OUX]M]W?
M%O3FJ:7Y Y7"52^$))JXDP2L_71L8BM_"=D##B,#%IX$(.NX5@R;Y,>F,X5L
M"/&<' F7!@M@!>#N:)9>Z<).80+9F)1/%HM[JX_:@H=KE:I2\FV$5L95N[0G
MI)B2[W[AS:AS\!KH4J(OZLDL3?:XR-6+,:8MA^%5D3Z= APSAB#Z>!+A# N&
M(GJ77?V&7/_NW 8-NR][[F9WJT#H;@M>]_)IO48I:%T%O3ON+3+24%+!N,&J
M BLP@Y\PA=\H=I^AE@5OTNXNA]B 4ER8PI1 1.8><,_W6/^XR==-[KIKIA:M
MM]&CCY]=0+?S56^SI1J1?E55:2,OY6^8&,%L@4]6_W@A <&Y;*%*+#_S>5-*
MSGR$O;#*=UJXGUS=E0X39Q4.F//4P#MP$M!.WZC+&I:O1PKQ?1N+OCSQP.T$
M(,%9$]K:2+#\11YDB0__:&.ALY6[;[460E3E8Y\OOZ:V[6C%DH-W#D2.'A]+
MMD]'5\,&H<C;5A"^MF!]7 NZ''K<QO1#'FE,G]&7VX<1G8*/,_^L1 6-6%?U
ML;1",HZO\<2L!MW8 QP$ S_,@P/QY!##QE\O-=PK98,DYH/7[]6XJ-ZT53$T
M']1*UQLO%L]6M=/APM0H1@8[;**$/^VXIA#U8=110PI]\2KFU@_-06%#5YS:
M!F9JUD;[PU)GA(D Q]26*QAC0M6#''3USNVW^;)QL\:J'B&_UN>F*G?OAO:P
MQ?3FQ*ZC*WT/:,HLN,]-PA*>"MM^7<6O74&-!)V#<'"LF!%N0?]GNJU_M;9<
MIXET(3FE(EO[B8GD &^.#<?X4;0RY4QRE8O8-3,G=F>&N99?]K#:RKI^B_-*
M5V"LA"/,S2#N/L.6_5&/X.)83E^KB4,T-<Z\-$Z#'+<&*7Q]Y\W9YTTZ[9JR
M<[V_]*T3^2S![-7W5ADMBJ!J:;S.I2ZXB(YLSYTL1V/J:H+#SGB"5\]*9:25
M^3LK_RK3C/F2]Q)385P3ZSV[.S8@#Y/P3!:R9_AFUL)PS'SWV30-S8.R78'U
M?K01]7'I>)]E%KS8,''BI[M=PIW3A*SRENS56#VLLPUWI9V)[I,X^X?&BI8J
MQ_B^!,)(V?I&%6CW">&[-ROQDZ!LFYA9K]C/E3%_/CD'UMV43B.01- [(]<8
MTC&$$!(-:?>SUG\N?& -7IIPS?1[EM]27[1!01(U%)L8X(3,C,/E>^L2WQIF
MWEG%?]8X"38]-XV' W20^WP E6%FEFU%'\M#'.@8V*$M#IFD";Y,J^HG>[W9
MZ*[RYJS)K7TYI6<WV>FZ3\8\GG?U^\9.IT^C0H])@+=GRS92[VOJ$A/#B9J)
MQ2,(H2<$O3$+L>4PVYSF+%;+Z62Z&B0?"%LS3Z/T62XFY)WJ" !^0(L_STN*
MJ)6U'IOF<_;$D5H8/']^@2Z] -GVTU9/58B/Y@Q!;7_C<+ -ES1?5%,L;$RQ
MOF9%C7M:S;4]X$$3X8OY3?6PZG*]&=5(\N>_NMR0X Q6+$1$AAY5,HD^HW%0
M0X2?*[6M/B294_'D-@<E@/*:67*^#Z- KUWMRIOD@A=4AN-Y)ONFO6*5 T =
MP1M2CSB6[1V/$C&F]\T9%\8DJGLV#6"7K$)KS)=[-&=TVN2R'QT!PX* I2N)
MC ;+#/.++F<A2UX7+(24VO,.WZL*"JQ\,:XZCV:O_=#.@5S*K1D_RC(IHV\5
MH5XUNH<6^=@U;MTY4&MR2"A ]%D"IT+.'K#D!?\8I=3/<L]-@<'X<TL)1WHZ
M<O1ME=4(,:;AH'D3P/=9KM,3H<=<I8?L3VG]KG<'1H+V0+8&6_R/CENL*Z>X
M'TB6_+B=K2=-/ _)#\3R1LG"%_8 \!F4AN: ,BG3XG/7D[4.;GOWN3D)MCW'
MZH;C0Z9LBR9;C*E.;:?9C"T*5U=8^?MSN;[#3Y[7CS[1MM&"-9Y7*NAERX[X
MZ!*V'F+S%G6M2Y ^?NS.6R6[WUI"KIN?G2." 3T?I7O^26(13,Z+C+"MR.XA
MTHI)G7%M6-%8&VY$]!Q6#.?,3!5Z.%FDK^7_TB<"GWO,:4!/P^ZQ3IN.+.!>
MM&*4 QY[BC.1K3-35*<$+)8>LEM=<+9OX*<U4$^0>WTK#1Q^^AY_P-->XOTU
M72@X.O!%,SC(:(J[G):ZI4 [%.8OHL1=_TJ^^6[%17%!T-);&&S5,]I [9\N
M%?^W#:P\UR26W"#B2[;./;,\'W+7<PB;W;$N61?A%J]Q%7MP,1T#^\HRRI4N
M&_6^Z";E.KMN=7+:O1"4N;I_U<A@X\483*V73&<>?YJ2$C7PQ'K4Q?>^J8TM
M"F"E_"]DV4@LXP8O)F$/**<D#?!+,B.75]!23]TZPZ VH-CY/>"0!D'Q0)_G
M/J+'GIFR>#!Z=:Y#3>2^UVQRJ*^7Q$2 6B!N\;U6_\VO+![BE7/U!9F4RREF
M8<.6J1V'Q_>?8&Z55GM @BL7613\P$UMJ-NO;[N[#!7K<KQ%,CAIF15&33%K
MOIH=J_"&S[=? TU2UF\9QKP]EA6!UW6$%2!THU)\!H91KQS*H"DR#^0_KAA8
M*]* <!P:2<&+[A/I4.DCQQ_?1A#J.JNV3,VJ'W'B/FQGR#&RK5^L>S =2Q%1
MW/3.![A01'")=UWZXJD*H2OYJ)&DN\D3$N# A_@72H/S.1!HK[[\Y-TI2:SK
M "4KM6@AV].<)G?C31G5\90:&L M6BNNQNF?)'AC053ZE$E!>W&+0/O,-4[Y
MBI7'SY%3Z8>K( /UBR<XVS$0:J1CHV/=2GU1?@$N+_)1*[3$JC!3SF,;[]PP
M.B$%^I%ZX? [NN5GI&N<@]WWW^3?9\(+6BEA.@!;QIB%)+\OK_I2ZEE.CO6L
M>F9I(;[A86!<.#QB[('@)51:\))/R#Z BMC;J "2T0(<I__%6"=1V)P-&4<7
M4ME%N0NYZF'!,^%12)3K$_M@W(:=4\/O9-EB= :U- *,E]GUV19=E_9A/>W6
M)FXE 9,TLNKK3XRD'\W+?["[GIL+(>.W6=VJXH4% NO.Q2R=P8R)L5HJ!HY%
MN(R+3DKYMU5WIFQK3U!Y(S8%.*:C3C(11:/,#-@@"DJ3=;S<G]ZUV'3IEHUH
MA*Z*=+QA/!%-8_'F?$=CC6\C2WB5*0@_*7?_ J6#:;\#,[6>'Y,S%_8C0(U>
MQFYC3DV=-KQ VGI,>,?28<M?>MO F).EEV!Y6>+%3#CUZVS\ZVUIWR<60Y@B
M+651(XFIX7HGZ M#U%5)!ROSYS8QZ@)A!Z)"SW\-7G#TYFRAL<7028/4?:Y*
MH'F6I[K2-Z<SK"1*KXJ>M^RN+!.==]Q<&*@*:3C(O._(>#&8I _;XM$!9PZ'
MOB7@*I]?3I1_EB"JXTDQN.V>;;8?(^ILP994\0];4OR!>3R2FNLTO@Z<3OK4
MC_SZY!/BWW;HH"(B>V0? 5Q%2!CKCV>6%RKO>-;\&P+P[2, 3&/XDI'4^<EL
M )WMS,".+*,J(W4OUSO],4#S3-=["))6HA@Z8H[<I!MQ/D!:Q&]5TWXGB(X*
MI>1.VNK*E:L>DPXB0J@NS^P)T!1#RL[:UD#7"2+)Z>JLAVNF;1YGX&IR)E#_
MSR%K_Z\-M#?T%U!+ P04    " "#,&Y6^TI\X5A5 0"V=0$ $0   &EM9S0P
M-S0X-S(U7S,N:G!GS+H'5!3-]B_:A ')*(,@$@5A!@1%0'+^R!)F0)&L(,J(
M)(F2!E!$AIPEQQ&0)$J.*DE$TA EYR!)).?7@_J=[]S_?6N]=]>ZZYS1TN[J
MJNJJVGO_]F_OKI/!DPF 5EU931D@( 0  O /<#(,* )G2$A(22!G2$E)R<C.
MD%-"J2@I*"@OG*.C@;(PL;&R,#$SLW,)\+!?NL+)S P3A5^Y)B@L+,S&(RXM
M=EU*0$CX.GX0 C(R,DH*2D8J*L;K',P<U_]__TX^ &?/$,E"RH@(+@&$9PF(
MSA*<- )LX#PA!*<_X/>/@)"(&$)">H:,G )L4$H+$!(0$1$2$T$@Q,3@4R_P
M.4!\%G*.0U">A YQC_22 _2Z;T3Z&4Z%XH_TR.X?7$+F3_S(R,\S,%Y@NLS-
M X/S"HO<$!43EU#\2TE9155-75?OUFW].P:&%O<M'SRT0CUR=')V<75[ZO[L
MN?^+@)>!F,BHZ)C8N%?Q"1F96=C7V3FY;]Z]+RDM*Z^HK/K4T-C4W/*Y]0NN
MI[>O?V#PV]#DU/3,[-S\PN+W]9\;FUO;.[M[^_AU$0!$!']^_]MUG07714A,
M3$1,BE\7 :$KOL%98@B'(,DY>03I/0>Z2]=]ST 5(M*+/Y)Q"B%_T)L_Z28_
MSR4\>7D=O[33E?U_6YC?_]'*_E[8O]8U!% 2$8#"(SH+R *;+G75(VB<Y=+1
MAMKV4OW>7MSQ@0B1U_161E7^RRM>56O'WI8G0%T[SW#A"3 _9W:PW.<.>T?8
M,KSZ^[;[[UZFF"L^Q7_NA+WJP*X/\%WU,X(XSLN,NYX LD+H\0=AY28G0.?7
M^IUO;S81]R'_NLU<V4%O;(@>;3^JA2Z#(QV (R6"(Z7:59\ J?'HM?>W]KN5
MP@OO''B-'QZVGP!>"3*C?T;- Y_0';U;.GUG_8NHE7(S_%B'(F29V//R3]!E
MHS1[3Q./CYD@LP.GG=%4\OW@A%/_-!3V*OO3.3UK"7R-]G9;$7X"QTPRP\Z_
MWM*@@T/<9^ YL/PS!,GVGSYIW#ZP=Q1107_Z4*W\:2.G"6/,OL\7=?1N@6;W
M])EVF0FZ\^OXSH]>%I0[$NP%/D*WX2MP_YI$&G91*=PX=27N]_12;:KPNU"_
M-ID#=]=]1]]Z_,V)]-#S]!4\P[;U\W-V![N/J$O2\#-D^-/KXO#I? Y$"(0)
MP.&23'^_N<ON5X_E7N&QUT$<^/>H')N>OCAYNRW]!+B*W]3T!7A-\7;& #C#
MLH44@5-IBIF:_-Y)'THDG5*X253B[W<(^_U<. %.U]'+CNQ.,VT<?_Q[SN]5
M[014/U9$GP ?VA75(<+AA>H"MK+S-:=2%PK;L^,!I2X0'9_%%)F8%[:W!MZB
ME)I:GL[BWZB<%U8@"5WV?Z)=HGT"2&>!=2%7AWA.@!0<>EPY$XN]6\GS]VW<
M"AVH3BC9M4R$;K&2OXO:=B"HJ"6I.]W8C;D_73*"(*TRW:*'VU''^\)UGN,;
M0]H'"[U.%1F?JKG^;A77F7CLW@IJ&5,8M"+CLX#:/+C7TO=/WYXJ>K@%]A5A
MX>>#M$KMU<_GG0#CRF$R=GO?3X"=[M?FL4'DR^ADL!7Z8 &WAP.GI(_O>!US
MA>%^BE/]1M\)L):IDGSUM$&/H :&$&Q^]7]M+@2MP-XS"=O @E,*P\_$3,)L
M;^'T#<@N!HN:1?1\)O[%<>UQQ^ZR1YNHZ(J,CRZR?^X\O\G^>AZO(5?8\O0=
M.*P*?E@2%6F3L&E-;!.!B\#.\8&W4_7X0?L>SCP."FD:.P'&[#KB/$Z I_42
M-Y%3OL8F:T=SAPMCXV.RR9<%8!3%KN4[8?/*<\?KAXO@O"$.KJ+@O49E?0T:
MWS[<).CT4A1?JPQ+$V@:P?>\F'C0LI&5Q;\H9^RRC>]*&7(TO=<CI$3@(OG5
M;HVM(^HK>DUT7C/#AV5.=B=Q(_/7!&P8TUQ9:D^ FO'DBZ=S1,@9FZR \UD\
MG078O/+*$ZKIKR/Z=60%9U%G@1>>;-MYW"7YW*,7@K=,4]4#QYULE%XOMWJW
M,AR@=[HSER/0I?B-3,&TQ2=+12S+;ZO6#YV*])OYIAVH!+T(%^:(9<7M.[47
M0=WPBF5;3?UG;7T56DCEF_GQXF&[IA+#O3;61EG+H(/Z7.R!L-G(T2-#6#7U
MG>U+IS=6_UXE93:2N;R.?H+-"'H[:_+RN)-A!\+ZE]D(_66H25B,"^?/2\<3
MV)\6QQ/9W4J#3PH;I%Z= !6P?U;DG%9DXBO4)^\+?0D[>/83^S/J(&A/-R=C
M\K[H%^W5J[,JL:DC9E^2E0CNBYJC'="\-WAV&'YF(^0,J 8S=U5F-4K15;*\
MAC *CAM%.RJSRMT+<*LT%SJB+H0O_HH0 _N_4JB!+5E#&S[0K605OL-7R"M!
M=0C^%%4K;HPY.2PC'$*"D6^_!D7T/UM442>&(N0WTX@*^%G@<$!'D\0'[D,@
M+YR%(QCS!5@6N/U02@#TA1]*+@V@1"A!ST@@$>H00@#&_:P)T $@5]4E=-T3
M4$"MIF1:%A%A5.Y4[ 2+EJ2N3Q-P%TF78$[H* <ET%![\5%-"0;%O06@3FGK
MFDO*4UL,N=F\4_[&NL5R)' K;)J\AC+<00["#T72(KNUF@!N^& FM 1 :"@1
MDALC,(8 V*B)\%P<:*E-['3X?_D)Z: ER"X"#8R@AAP$6J)S>H51H$1@C)%3
M/O@V&;X01FR3 (P K/]=!P[ZG#$#H] +E/CG5K9#@0<8=1@C0@EL!'=0@@*(
MTR(P1'H/;H^RAT #[@[K&JG-:F473_0*ZXAD5E8JJ5#LA>>Y8R(K.V96"Z$(
M)2)P2WW^VXK44=WZ/DXW,<"NX$;59[#&E]00M@B*$J$$7.:')J->2B]D8.2@
M"%4K8$D#%^KGNW13#I81AP5XU!&JTJ"*QF&AR9H BR8H8:2S\!E2X:PN% 0
M-00N[*,#D+H;PIB[V']IAAR$%&,:'4WZBMPTVBGK.RJ+T#F;  ,T<8A/($>
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M"/!(D=LS@LC@AWI)ED;9];?X50%RLB;BJ<3>[@K_)2TB* '&'I03:-#LV"8
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M^P);(+HB"=Q!/L]D&MU(BI&3[.[%@=NHJ Z'$(.N%_3VAL27X5.AT=$ N3.
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MPB"9X[\@_?]OGP)(79MF3H"M[OKDO\1R;?=J4X^K1#=R0IPW!<\]TU#K[0'
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MP?\#;E_:?G)=#N0?J!!N01 6S7Y"Z[\YX,^O'_JS]G,LSSQ ]L=M&Z,WND\
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M%RC4X7 E#G(\1<< AH;J]OC/?-@TO#>#97$HX1W7Z7%*/#OGYX!P2.?P0(<
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MH^CRM)6\ (#T<&?:#($XO3J49)9@7F_/;LR/*'EBQ_)3:$NDV1-Z D18Z)X
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M45]?7_.C[J-#^+Q 0@]I@52YHDGQ29G.OV4JN'[96)>^YQM[S\58LKFZ5IM
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MHHI+K)MKZK*>LC2$BU:0E_,UA=D]I7@ANRVS$:5/]*0HH<@ *RPKT\Z9]1X
M6OU9NNYY/45])AE@#ZL+@^-P#M?,VB*)C- 3&$ E]%>Q(C><K[?/D3V"D/UU
M*@]OHC)5>IG?:F@?_;(ZTE@*+<CR\;.95['\7CV/FB] 4]1$A&W+%/^^CMWE
M\1C F2T#E96)L&1-?)GM9S*#,H"9E;?T2O+BHTX,9HR,0?.J#H_KR+JCB9O-
MLA@Z,>TD*A0Q2:APA-I Y_#@!:Y K3GRWJ_/1&>H*OB'.+I)'@'O 6I5$]S
M28WJNJ8Z9R#GYT]106A\NA[9^+90LI."+2$]!34:V)(.EV0?A6"Q/,#\9:@_
M+\1(J95VK,X(C85EC'\='4$K6G:5E5"THY=M-<'%7>ETTC10_UDL="=T<:%"
M4X9P9@8T-2/O8/?X Z@KES&*&;L$4P:P960=ML3YRG/X4@D.DSHUVA%^CESP
M<."9FHOVI*85)9V;X#;5_S$"+SWC5C##*P!0,-%G6 :+T*YJH%<(M$@=J(EY
M=L? :^5?!V2BM&DQ9>O(OR%I*4?@=6&[ DY2T\OS:Q)"?>7IX52/<:.#^7>
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MJ(#Z-NJTG=P)]0,JPM)D6#E$-V:"!9B.(J($,DWEQ>YB+%R*["\8D'R/=T]
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MP#Q3ADLN8Q^0P=?CFMC#R=K1R/SKYIT460+ZY@)50[I677_?[Y\^' 'C//(
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MI_*][4>L59KI!>R%5NAA:=PG"1[,&S_Y>T!0W"6R=:]&^$)47_BL9/&)B6J
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M?&Z\:<)@+*%2N2#')4RVX(O+VYDS)U0GM;3DJRWAMZP2A.?/]GV4N\+:S=,
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M-C[0567(F:JVZMB""Y$ ="$=[/*B&3+E8Q5'A?L^FD>$>KU\BY88L==L<0_
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MXGN#OZ:2A&ROQN$ZX )/U7>3O%Z7F2(J$1@L_CWF!CO*O2@N>(F#%#:/V45
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MIU-K71*T$\0/::TD1 "9P-)O_F.ZFRG_=_<_20/=,0?YKP)YW!>&"#NDG82
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MOQ#E)5)N2SA5;6EJ28&^]UTI86+X?9CA7J4SV1!IYZ&B?RA_\IK0-,= <E*
MZJ@:A>"[#, I'.0LSCOD=>WU>=A7O :MD2+]<4)E984GQDG+E\K"PP%&-4B$
MIZ],CC=J_RE^ZZTY K9[8O=@@T>]&DKTFJ>^YDP[PF:;;GG1W3MXULXM,3&O
MG1/I,,ZPYT%+-P4LHJT(Z$FDV3%MIHS15VOT!];:[>X0L=3\)@3"=?U)U3=[
MH,/H.5IQR#JSQ4Z^>WW7A0>IP*(TO-0Z&LI+FRQ4\&L  [ XG@27F,[DHE(*
MI=YLW/H?!,;S!BMZX_E^@5?';[G300(L)XLM(LY<754?GKOR1IX'7K9IZIE
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M$NM5VKFJR\U9]7&2NGIM--)6?_04$E/Y74%$1(+524G,]%_GYN?N7FTJHT\
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M(.I?U\=<BR79%>>>!4?#^R-5@?4^7:SPYLV^68?I4;3OCY?F8MP1WAC;NCP
M'.\B#ZY$[GOT>Z.@T=UB7*8>D K_MX'1/BYCC@<'1P5C<U/&>39%%/96I&1!
M;E.N7*85.O-=PV"D*9(97%!\:K)K"$C:K='+V!H,</&1"^&S;U?3G;E5\W:X
M*WET+6 )W5XI#JC[[Q>3&3(O>MU2.K';G )7>58OVL:H:M_SR1='T^*HXD6W
MPKJN$[@5KK?: R( ZVT.:UEFNE.\8M92V>-\;/36[C%'7BG,+6O!+ .[:AG=
M+>#+2#^N&E,ERYH2HY$4EQXCC!,J2GHY*DI-ENK'1T3(3P12A6 V=>3')OY9
M++E,8-ZZ?DH@+^(-@+4R;4"0&&6B"$H8)BH#"7PV]VMER;9;*^:>M,R0:O^9
M]KL#X_<*_:[(_A6-^4%"H_B@@'V3EN/;AHFNR.*]VN6A+1R!EQ7PA(#34ZRF
MRBJ][FS:1B@42AE>,JFLIUMFZXUY" VJBMNO=W56,SQ\7-E1>@T)HVZEL H*
MD,<HY=OH-+T3U(01)7[?S9C_V@C G]OU1"W:Y??Q<Q7]9 \O77VGSQR<>*73
M\I\2___?AA V%;A!\P168Y^60RKM)$Y>/*F%A>7BSY''>%(?*#*)3%SDRJA(
MY!;'J+"XYP5Q5&$JHN"%)RH_+KX'"@HH6K%0UD%SR '6]<X!V&3'..9%K-O5
M_><WVPH3G0WLYTNROD*56Y^D40'4\@AQOF<'1I?7'L5E-C.-<9_,'9U]*=5]
M238GUQJB$H]LJS<DW393U,4_!*=/*WCQ1T%FJGMRL''OZ;SJ^D+9-ML\0]6L
MOCT S@/P?T6\GY@A%;$Y.%C7ATB% LG0OC#3'AY:";DI?,'+?USL@X%L3^V'
MGN3SUR31'QT'R0\>'*3,M9I2<.$:1_H'/DC#>4T.7R4M#0*1]F$SO\H%#(WU
M],86^<75VB3:=XT%YW6L\':=/$I4)F_9+HV;>#M>VN/R?+-*S9H@_XY]C-55
M%2&EBC_][ 0H>TG=VAK!9(O$6$%K^"3?]91M6I.7_N-Q ![=E#_H;B%>_0?J
M52U;_4D;(O5_DA](9H:&(AKR7XH*_WPO?/(QGF!=P%/ZX]'IT 24:*(]T7@5
MF0#U3^V1A.,TQZCR(Y"H(XU1>L$6:ZT*@"O- R5*29WP\^K[+WX6!5EN79<-
M"O?UQ;#.%5.Y[:@ /@W/MQX6P\CQJWC:+ER;9.:S[S$53*P3A/FP7Y:]SOM(
M&BMU9!KM KDC5)QU;V)[9]$6KAQ-'0%3W0^2&Y&.P=::TLL85^@5&Z;6Z+88
M7U;!7X-Z9MA7S,F0WWX9?'=2BQK=FVJ),%FBIEB2N^<"T@/.0L)UZA/.,KP:
M;8@^QX4-(E!9Q[3IH0+954-]O7R+JCNC'P _]T2MV!/+5!RJ;!/Z$DS9':M0
M,/':1\2PK_:-V_%TZ*PLA(;2%IDSMA2^"-&N:I\JU#H+I]?F&O!=U*"M,X;[
MWJ$\ $R+50<T(I.2- X#\!D&X5O*M]L$'"T:$"^KPYI&'0[_ .)XFNH83)*Y
M:(:(3QDYQ#^<Z/H_+:+5X53A@[C^@M7PR8]O0HT(+-@NO>31*A29\K#GB,98
MPGTA#N.4*%DW_63,$0LVNC'1 GZ9=,\@E]Y;*P0E[Z+C6W[_D344PW.E(^/&
M?+$Q.W3*=RB*OO:I<AYY_,!"I6DY$IRRXF4X -.A#>].\>R335Z>OY#/=5L2
M% V@O?<(?UQE8F,/^83J W]C<AU.L)U(:M]U'VVMMWM(8)T+>;#!N_"%%D4N
M+(G2DVHS!P6AKC-DYA@6I\<4.R?1:;A6.(WME^9'_-Q#2Z=L"0!CJCV_8N+.
M:[IFS"^<^I>&\G_+MG:.?87Z%(_HW.A$R]Q+ZSW&*=,6)I&/@0E\B"(3)B^U
MMHN\MYV7'7!C*RY4%,UF_RF[K*4 9,P#>!9?]@K.\JT;#:L.R1C4=W(J; 73
MR+9&%&.?]_-"JG\+]J<5>L G-P?"+^^E7/,FV(7)FC.]:(NL_[H:X'=97:A!
M9VVN*%K]_4]>E]900T'7P>%V:W -Q5"EL/H[_5(\B>P)V<O$L[+>I/ZOL655
M^#I M%R &),]BLZ9@+:>ELAOK<"ZJXF[&+.+0.&Q_)3ZN+LD14K+E+N<D93?
M"0^ NJOI/<:+!,+:3TJ_OSY]G;A+5WL<V@RDF)#Z_4;[1C3G][U[IW7BPFF%
MML8!+44?G0Q>",SMK-C2&B5$KUS(W$ /)>173'YZV6*:NLDS),;R01;:88PV
MX?N"F2JTF4NA](8H#24@8V[<W_3UHWUXZO/QM\W'D]!#KJ96.'S<V&-(@L?X
M9-.?K,E_>H!_C;R&_)NG;CM:94ALU+FY&HJ,<#;_-HB/BXK2')>D8(&2=G';
MMH3L$W ] /)_>"E7/ !8?YU+R-SN?XQYO8X2=E93?%AET1*:'X_ @O%<5@I_
M_9X%YD17'^M1"#\XR(D[>3=YQV*CO3-" O,*L"$#XIL,]U:&"158>:Q61+U0
M9-=KB3=:(K,\TS:SB5TY*11@^84+',/5=E4NZ]?:5><]7!*DF!:+2?,JE2=X
MEAISZ(/=EQA'N_"5A7E0-$^;P%,0X%6C?!P>KO*5T>KGB%3<M:^6J- :?J.5
M<['"QRUI87^62=XJ)C8:,K_I8:&55S[Z?A)UET7-/C\6I>!+R9$,<S%<E/ZT
M64]ZC-T$T?X74:6PJ%#]*:33#)9\2CX_!2"&?]UR<WV?G/ %=2A_=$5D4&2)
M=W-4M=*1L<<H4=4\HVJ7BYJL9>_:C8V?FDL-Z]>,3ZOZ!JBD /)^XE$*,':8
MG[B?F)/OBV;<N^*#0[<ZQZ5?ZV6CBHOY6;^:\0_Q-)0T];6A=]_5M7<OD>BU
M!<@?;3WO_^XR^']^*R@"X&EH#+E@8)(,\;JDD;Y!>2T@D'LN/@5'][\Z"Y')
M%CP J$ECKW?L:K1TP917SQ8#.^Q*J\&U([T'\D*\Q:'E.U2.205%O"<NJ@<*
MSV1F4L#\63)8[S4C+#.B5'&/' 2O9R-Z_2$B6=)*@AP<V9L&P5&*<X@>1X:R
M9'U)NV[GORZZ9RKL!'+F6DR&CU*VO+E2YC(=^]_-)MW%]G6DE]S=2JRK+QN"
MFEDW[6M+[U*93@4&% ^.LNT^TRV.FT_?T_IXA;9)^LD5#WHZM(60%7/G75H'
MN65B&RY5TZP%WD;.FIU?!)XA52_GVTW8$DU'1,U+/TEQ@I&EC-1E:8+Q?-ST
MERI<5+5?+.KJ>,I.>;V9M(Q_$UWH%JJN(#B*M_<,\?59)>:<AH<(OY*UP535
M>(\@XE$)>Y[-Y<&;.J9FX.+XZ@;VB7WV!"ND;M9#P);H^VL)U_!"\Y/AV"'\
M#++&B[Y9H^PA.](0EM&MJ-2-;WW+;1@6NR84@P*6HUSK=K),@QZS7OGCG1T7
M)\+-? ?L+'WU"2>\:4:VNHB @*9>U>OH=#.Z1&.&>;/#/B$Q'E@ W[!,\6#%
M\C[_ \!6_X!D5SF"9D@ <.S6OZFY=QV6XP!QX#*TE($+%(G18^;*F4BIB_0T
M6CBCG-EC;!X9-*&[G#L_J-EQW"/))'&*WT:FM_Z5)ZNFG'B&;TJ)8TN(6_C"
M%#G^%W-UWT9.5WY4M$POCC@/_@=?O ? I-Q&SC<7V!2!&UOGQ_.YS#5-P=0[
M^'3%%PVMOYKURD8R#3<=%SQ5CSRF><SYT!4XL@?IM=R(_MX>NS(H5A)[QT_'
M_JS.H87:C@N7F&SP$)#OKNSKC".KI^QD&FW.,(JK4G!TNZQ@_T0]<DW)"BS1
M8WB^4#=V<Z%G[FI#E.!6&*WF34I:1/\/!39<IW)[N5G=MCN#&0T@_HA/L6P3
M!A/2Q+G<_(K, V#VWN/MO!2K5+A/%<0 T8<U:)U]I^)\0&)LO+#6_M5HD8/*
MCJN>83I>?D(FBPP<D+$0;T\:S5RHA")I'O!H(/XF?C1FDH,G(H!43^!?UY.G
M!L334/X3NH?\S01)_FG0U!7!!*0B^$O >_SZ/N(O50_PZ!RR4:'%R"=KA &F
MDM!>NPGW?ZCTX'UI#UH1&]CPQ]8P%GL =!,AX"(H4>:BO&P/2+?0W4/BH__T
M65 )(A?:V9TVE6G"+[&?\NCV?+RG4,C)ALA2#,;NFZXZY(MIJ[.]I.QB.AUJ
MIM0KNBU)_.4GT1@=0D0BD_V5[/[SS.X]@7[7H3K@-S*2QQ :!Q#O&+##;-2Q
M51ME<5R!S^8.JTI!RPW =\;0 %)'_I6^"98,??*)B#2?&(:&3#9,CZ^^_%\X
M#CZ"Z9]EY\F _F,H'P<S_;E.YF\W^173Z<I-1,NT8]M0Y!SR),.LW@\!KVT-
M5\(\OE^Y98L$Z&Q=XU?-AG6P]^?MSD=/+R7*JG0I7O4/J(E]Q1*ZK%Z H$04
M'9>$=TPZ$=RDK?SXF-,2CG@HH>S^^/YN?Q+E*5Z2K5/Q\JBQ<RU7<3[><+3H
M"LE<9TA<KH_PJ]RL7#MX4V-]9WLJ%A&Q725JX.2USK*"656XSU<I+<.%8.%<
MLG\KW4(R7$'NDI#\W8#BY1@-E" SV75IR;!\@';EW8W^ZHO8$KX:(.UO(:""
M039#'DCK1JN?9/D3>UTY6WO03\>ZK.$!LGN/&O8"I[652.=N_S)>74[;,H*K
M#4%:=CCQ;7RG+H1[]I5(B27*:YPIPGG_[!+HMX45PUXWN"\8%I\1V*7/OU<=
M>=58C&C4X\;<KE303+=)V5;XZ1Z/3X"I7=[A5;XGQEK<;*+9C1B>C?Z\W5ME
M.FDX<^A^@_B>/SIA-7=EL__;P5*TS7ZZ3MAGJ%?W"]L9=<.^W>9DHBYXU\5,
M7<>:TIUTO3X5N_4>_GV^#"/9TAKL5($KE]?K.Z3IA"GF*NW>G1F;M8TU\_.V
ME*A\3/4FAGN'Q$4QKYIMARC//Q8BDS=)5+GZ?#)!D!L[5T'O:=3:NT3F8<MM
M/A5B24"+F5M'F6FIP;,79J\[3M3Q1Y9@'T$MB'T=.82V_(;K,3(+?EO+EX7,
M@0'S[0[@'*]J:\Z+(6@%)%"ZQJ:&3#+$]FA0BJ_IF"R+T':*A^>!]HT37QWK
M3 _\,/GY_MEGM9=RZ[&Y@[<L<3"?Z_!P47.WM7;5M<T;G4JO%T=OG&]<OUGO
M=:_8%/01)H!6>K(IQWF]>VS,[\=LEP00!WYL^@?MWH]5/@ (;0-HCD?*"F$E
MFC,T4Y:-66_8R%MZ=(0$17S>"V#W)>EFM@^5"1R(Y<\_VLSWMJ"$P?/1R+A=
M'K.EA7EPG)\4E_)SHCOF0("9F0%LQ?!X;NKME/N^-@?9UXZ3*+0HZWM$*8H*
M;8\EYM&>3B(V!T<2#0?^[*\(N >.47)\.RW88>XYF$:BPB:E'^7=:))91_P'
MB^B3WND(*NJ0I<@^ -9BB8_=#2DJBH8%/HIJ>5M[,C!_NOC:K,PT*KYQKS,+
M UM.MEFO1C*R6W/1/!NTQ3)&UD@^%ZR6^^9S^8$WBP2RTJ.K,>SI:)#47AKW
M8;Z ^&! 5,\$"ACF@=GWSA!,+,[-<Z9+1@[(@(-I&@'30Q"N$B<+#_O=_4[-
M[3ZFK<;C#Y@87V7[#N 8>RA;EI- ZUV#;H4K]NO:4]39Z&+[>%ION'7\61#Z
M*.C!L%"DL-"U?=^*3^D>R;HV$1^3,-RNSG=-0];QYE;%S(4/:N,"U\$D?0-+
M)U-NOA4<4^OW9# ;8QN?P$]OI_E0FJV24@W?6 A:J^9(Y52I'YM]/.0U"Q5N
M*!V95,,?8C6U(.CF5!>^&!SVR,%$%B>V[3P<?0 4F#;5H.S4[:\\XXM$MUH2
M,4Z)5H-R?Q"\=8FH6&J]Y%'HX]Q8ZKV[D"T.666I>6'S9=^G\:,'=:DI1V88
M$^=+E!+*&J*S&N4O[^U-Q.>7(6O5]!%T<FEA&!\P""0,3R4P;Y4GSTR0,6GT
MZCK"M;YJP(6^'/1SYDK@](_VL0H=6MZ]N-24O#CBM=LB%C_!X0DY9&88GMKI
MOA'Q;3T7C=B:F=2#I4#038Q,FB8/\N#R7^[_(.XZYG8Q? !@>J@H[G7W$-29
MJOB:O^UU8-^@3;Y90KU <UG@DYWLGO?Z>,\$*I_4;,3)C<(3HBIX7D!#OG?4
MO7 3^8QO])D9]EFTA*^TRV7<!N6.7)VOSI"]#]G4I ZNO]$#($S([)G1CG!Q
M_+9]-G-;?3OWYQ?^E35#?=@2T4ZW4BTW')_J56@T.]O!8X@(/Y,9A#R)B=\(
MKZ/O3\T0!K?)K"ZQ2'':SV@,^="_Q9AY+TT8Y78UZP]Q(@29&(I)]!#PB!7U
MH(MRMR'%=V/UN!*Y3,YDU@S7\EZ94'YB*#GK_V6KZR/Q'MQ<G_46<C]BKV 9
MFNT >4GCU"*G=@]VY4^OKK(^YC71'^+*7.1U529*B>'>IJ58"F^P]<.U8C5$
MB7(\,&^*!&;/F]56?KO]QG(B!OHV"M.-?7^^$(CMQ_:UM;TN&S*BE$:3VI-Q
M"Z;K>$N11G1K:[CLDYS#US$2>TI_C)689SQL76XK3MV1?"AXZF7/N@+Z3'5H
M)JDJM>&B3R%^W'A+P[5[:F@OG)'1FL/6DYB-8LJE8)=N6@=E4&P]5JD_[L9%
MY<A2+U1LW@Z9I*$AQR8Z,L'N>ZZ2'?H ,.N^TBA/Q]5PIRM>TANP_N0^OFJ&
MO-)M46:V:&*7(.= G&WRLR3SX&Q@=%?A>-EW&+O'I_/#N="R0@&Z*-*OS"B,
M=?&?)<=\E)&03JA<3RLFJ6J+D?4D]8U:.C1<VRT,L6SU 8!B9O@3BE3<^/B1
M<">;;@;\:NI%T0E]NH@+P=3A,U-LI(_7ZF!=W]K!D]%L%OE6;^][*S6BE7W=
M3ARP[X'XWIMTS>]"X3\=6OEEG_47&^645:?T".],>]0@F.F/OC1:&FV.-X[9
M_RRX'Q*O-LFVU@8;@J0R2-'BVD(+RG9^:%(;:PL[W =#"16.;Q>6)Q;4<0V3
MR34&-GS]VFY"5 P6!E\P,"Z=.4&;9^TO#5.BQ*D:0QV<MFHGWZV?LIOBAKL%
MJ=U_0!;V$)U)ZG@1B&8C?#><# YDQ2Q6^TCO=^#\(5SK%W07-L/?S-8?W$$W
M!!'ZO9DAWQE%F]##\R4.9?LSRB+)7 L4'!OA)P%!=V"?@:[%*C59-X,NB@\^
M(%&4W#)[3"R0E* /Y4!F[^'Z81*JQ_<U1?K\!9",7QX&&XP.H6LHGB=X ']9
M">%SH]@7<_.@XJ'N&OS!UM;@[1@I"@NT=M>Y?5.CU1P\&(OB&.O+J=_C8'V3
MU*$+E=]8)]J'%T0U6CD]\QZ=$:QM8M0I!Y=QO- W$HEVYX._065EONGF0MZ\
MX+/[M%KCSACP?C0V4,JZ=WKH2OX!L+A.>^<;P#>E1P-%D6V9=I<O^BI#>_'U
M*@//*LTE)#8@+$)W6X^WI[F<>V.QQGI5*#\"/666(T7#I/H$%=7XDFA/SA&L
MN[H$Z^XC;#%H3U]0F?R.\:5AXF R\7QT4X_UGF;W4KV;<(Y]0=WU^4(_18#C
M[74 .)7=Z/OC;SH>K:;NSC]Z'/F6R R>$MS =\V'5XT[+@KC]?X9ET[5#P"6
M^SP/_-%@/X5B=-_]3V?[6R<;$=8C0H"<;F>)+"M8^;:F&JG=I*')SYS7$4S3
M"%E-\)R@LZLZPY04L^,L6(HRB1_. ^#MK\XTUL-4Q T<">B8!*ZNPP%-!ZP(
M0FHPRZ52\G'1%_^C#H.#53OXYF<)A<>0RDVUXHK;+;L-J* '$2:.^LX@=*08
M1Q">,I5@/W83-B/P 7,:G!/!5M22K->@J_YS8S74/'YWHJZ-SL+7%^+KS__[
ML'&<1):8?,A90CS@/=A/%#6G+PA>P5;P ="Q*UC:VQMH^)GX1Y7\E(]CQV8-
MQ$UWV$:4W@/[8+\4'.KV%:F)MG$X^.1\=[DEAV!Q#V6M-W/V'=14Y)55_P^W
MD%G*</R?MH;AX8%K+WS1*Q!<RAN@Q/*N-Y^NG*<K*@U7#/V8P.'J6'7HH=1F
M1\P;JR3-'-YFS=%" 8>Z]Z99M[=# 8("C<]A;R<F(/*;S;IFGP<6?\42]T_=
MN\^UR?"7'<_\;HM)N8B*^RGS?&Z1,_#%=8CNK33V1?][B?V2!P!)I03EKIM-
M2W3O4O[GKU.SN !Q#2JJ>VMBRFAEUJDW#X J%18AJ:GT!>O3B+J;84HB8\&)
M-O8:+U8N14#:C'0)D7)"(*Y1-N'DF7[-1H[R3$E'O,7\P.D1 $>H?\WX 1"5
M+NC>B3KHG!;,GR9E?-ND'.4/5YW8G7X45E.SO"#;J&_-E>S0<,.=&_, B%:N
M^7UV>CML>W)G?LHWZ7^QH[0^1\&!9(=-^I7SY%C[T0I5&FZ)RKEQ@TB[N:].
M6'A>&5S&J0TNSBI!$>Y?1<O=SST =GJKC7I"Q!&.FVBHZD4#OS%IS/G<A_0V
MCDH<U_P<#SX4M8>XB+H.47PJX<>KP#\MO)48$0<OSV9%+R-!;2@YQ_GHKS_F
M/%YVSL"-WJL.7. ,<L%=12D._6E; <?@K(C+KI8&&]]D7C6%IM[$24=GR8\%
MLJRB,JC#1;-+J9W;=[J*I/=\*79]R,XNN[VV,+L3I^<P+.WVJ2+PC6BQD&/(
M6@2 -%E,4' 4K#%[V$;D@=Z8J)KL8&!<DU"^1YO8("DH))%E8^,,7.- 8)IA
MW4P028LT?E5[=-*-@=D]B<9S:*]@3]G2S\=G%ZL]G;6T\N,NRE^<KPZZ%$5!
M-N7(X6 @U4*OLH.LZNI#(6$XT1ICA@_;.E7,/H20HA-]Q2%<:(X1DLC9U9\8
M-"^#M:H$/C-2>B&+O F1_M1(4WK0Y[8?;UAGVK\F\9'PLB5"/ED/^E9(!Y5X
M=?T4Y;1XLB-C84N9!)S3/5S5 .X<=;T,YF!?;Y_A52I;]OB2\4YUF\%Q"R7G
M&V5? S@09V%G_B*Z:-'H9R#8$I2?Y5)++BO=*#1X<%:I!F^DXN);N?^U9[P_
M4/PU!J?B1N9];@">GPXXZ_8%?Y&-Q"2O=\%4KG@83>(#(.:PVF>%5 R#[BZB
M,V?)'Y-ZW82KS6\9NR?'R<BLWFG=NGJD>:EQZUKW;2VDBD5G7-3<WL46=&$H
M3>18^*F+6'7I9VV<Z[/+7N^MBTA@"*2NY]["/MI]/S;GM[)H=&>NA.*.PV]:
M, RNTM2XFL-#R2A:=N.ZK=G\BGT<IFNM(!!YJU.Z0T(8DM(](] ULF4D2>GW
MSI2[35*)[(B&[.RR$!9>]=40QJ/[Z&578+,816\T)+Y+ ""X/Y.GO0!<EK:]
M56GL-D.R4XZ9F?<?#NT=8D[\RIE9V^\HMZTG:E%I>WW;@3C%.Q3:7)_8\P+Q
ML]3W;Z]];L90I(I FTY^<A3AI3LM88G>+KAJ]A=5'Y1#JM$2P\A[/<#?077W
MBIU!'^\/\W)N+LF]ZO\3E^ZQ,_L' 2N/ )<]  84U^].=4(]JN)'+I]/Q"1E
M[:K!EWV4&GJ;Z:/)H8AMB(A0A8>5I&D4A+9Y'H@ZZ 9!][=0;5$R^D U@&;)
M10X[)R/9 U*7:]KN" [V+L&?V'6467J0,^_]%)3AM4)XD?FVBA&2R?1.T=.+
M\Y9A[4I4J%C)GG:?1X$KT;4:L(H1\+F-L0A/P,L3)S&Q%4]SC!'O$T%]I34.
M<#.G(],?:(UF[_VQ2S[#/B:LV&4+*&U<N9S_-6^6:F2H9E&B[*8$>@";'B\U
M^#+0&D)Y/J;'HT*NJ/!;/[_BKF7T/B#W =#Y/K;1,'!TBO+R6)/X343-Q;[:
MU77(_3V:V;^[U>$<K)%*,C;DZH;=:#(3FV.UAM74_5LF_[_3M;S>*  -<,?5
M_1L>C^7].=8P_WA,XO'4Y(,[Y0E[R<_+;-G7 ($-F*_M3!EMNXUV;>9$O7]S
M76%#BQ,MF^F:*3\> 0\+,#\PN'9Y"5$NG]VBG%8-/6NKL**8#L_?98W>&DKH
MV4A<;K$BE45RPK=TF4KA(?M31%G !62#CY F6;*M+TX(#F6C8P/@:2C68Z(#
M\33_*CXCX=6'X6D .=$8\X.1\+S^,)#QPMB>\IK"<9H3)(\#\H,(_N6G/ Z2
M?)H+*"K\V[@$\)3K,/^WPS$3DRTC+IIS(7QRT)^4LN:$YACOX[F>D*6U/[ 3
M9W[$4P/N".2_.)3&4]=NS7^I0X"*R_"92FW4RUXUA?17CZ. J$&H@L1B*FS_
M=%'^L^&CMC8:@>MY^M@-,")?F+>5"C*0NTCB:AC0F#6(LXN3G13=J-<2+EN3
M\GMG<.UG1LS\PR=AQO5R;+2WL8XR_DI,\++;6]U951@21)\?P0A71B+[[)4.
M2F)PA,>?7_D0A,H \* /@H_0YU+7=Q?<T)S2O>0T62CJK1\?Q@AAHGU'K._[
MXDF+"#_6%B*B-(JW1T$9(Q0Z'<4U3/.%])G?*I9;MA@CPIOTG00,X0J,;0P>
MC<4EHSDC<.\4]#O:NGL"IPYY,WV=J I$R0S=1JW"I)_U"TM?AOEW!E\DE,0C
M25(Q9"1$R]?C0 #?"QHBH [Q"*!7^%]LNMPN/:OZT0+:"50/.CB&;EA)]V#G
M#O*Q5?W4:W!>DNS-2^=+X-8N8Y:50XG_?B2)^R(^9")>1]M<$F'L\=\"%,X+
M('\;6.<%&ZE/L;E7"4/NK\TQJ]K>*EA2Q94+9POEHO/JL9A#:;J$LS8(DN>G
M9+T'7K#6#A*FJDD63<';E^<BSN<U.A"+0:7@@A'AL2V4@  J.$D  ,5<R6">
MO=D<@D[0-FGE365@BC-,2KU8@A(&F(D&X&GK7NI>QGLW3/;SFD<<1H=@A+SG
M%@GYJ^?TSQ^+/SS=GBGN\1/:32!]%/\^*C&(VU^A%Z#TSP@$3_J[&]G#C-KA
MQUL!5QX1\BQ/SA29R4 GC A>[%EI=37!Q(A]"F(A5WT4BB9@^*W-,OWD>2#Z
M/"BH<X[U4%U0@)70T<@&<9O<!N%MQ,@,>%BB^QK4,65E<_ SDL@RNE D==4Y
M-WW\\5%AH>D6IVJ JH4?@#/DBR+0HQ<TU04P*[6W$2_QX*HE:1 M28#JY?B2
M '> YOA_(,!?(*#H 4#-DG.]8]=H5U?ZQTS>MY"4VU>+D!TYF];S,9\5[DU=
M)PBZ%T_&PL=Y%,-/:*8K/D=C*LZ:C_/?0QH#E?QAW#U!Y9+HBDQ,0&HLO/KW
M69+/AQS(NC%R9_Q:\+#<&L"[0&KCK@? !Q]*1:];FB_7NCM%> 9(<X_!V[/?
MXDF=QS'=NT;YF4R/NT+^VR6S:S25'XF>EBKQ]%GU<;8KI>)R4?YW3W..\-<H
M1:8-$Z]#$*F&;2(T%+M:$25# %JA>/EI?RB"7<'H\CZ:DT955#@)$8Q$^7\*
M.03QQF>RY L?+SOW"4<+>WRGE?_E;DG]P9(+R6V?,KU)ZO"/QR/@GM#^?\NO
M<^&3'^W+XQ.-!/AC;1C_!YZK?YP2(HGZAX%H\V@K>AZ-!N(30)V;'Z'."/B3
M@TWZI]SD#T7N'WCO;S'U/QL1[/Y.1>.5$'U1X5#,]R=[]R_LRI(%[?]DU!6
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M[+VI&II.#3<'1[:IM5T6HAX DA@+$B2PT X<NY9;NT;#3$*W5U'4 Z]P');
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M$T #2(?P5SCU:<7^9QF6_,./_J^ZXF_*'W'P\G'Q=\<#TY?^[_(HEI\=M*!
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MYWK*FAH'.6&)G0-GRO23X);T7[0D0QSP_X@H+)(5N#_GB<701;@UZ9D0=%V
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M(%)_V+;@_MBS0/+-/W5O_A#!X7NF&_(_OC*9P+]4'*!0*V%$;T[<%K4N22<
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M4V2@#E>=N2%D6]99?'FLW4DF]LXD /?6V:KD8P-'JRN=B^Y;Z-D4['O@[1U
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M\+N(,?K*SM$#=-6W$Z6Y-*,;2*PM(T1:#M]'V/7;\*A+@,.'^V6.5GWB(A<
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M;S"I:C'1 L5+II$7 _J"L7P9V ->VBFXE;7X/XQZY=R"'X'6O68S/)1NU/1
M2,*2CV2%"GQL>R]?7R+[1B#9J:&?[=/>-JHP9_-H; 54\MEEANS-3JA_Y2G?
M;5DD!!P""<\-SGA!E9!D\KH#WU@12((-?69&@**@*J > 4JEH?R[)O?6M)&:
MK,(!K&%A'-'[N;FH181??Q814M,/9U4A&ZSD6S+$,V5)14$^FL^*N4QM$H]/
MGTX-+3]]Q3\5TBF)8)_S<-%:Y,NP=:COD4@&I0^O?C\UC8OME&:,;<4\?N]1
MN@I>:G>!'^O8/?FS;IZRVQ+U_!OXE>O0]]'7^0&97LZBZAB9>0CL_DP*N%W&
M4%@]%13!?[_=4%_=].W3)QB$J*5:^ !?4\0J5!KF1^+A-Y J$0T#T]"8+BK$
M+.XK>W)3!Z%"0H^</S@-B1]Q1=/B=B($4O(W=77]K#M3'"U2A^4UBL)K6C[$
M/ (LAU-B+@-F'L9]GXF:$:093"GPIGY2HAZ>T1NOM#$T[5M/'$%YGUY,:C-_
M42Z"(V,"T]0'7WS%:?/J>FT+P8OA7VO^+:-?NHU@.) HA''DE0/E'5::?G53
M;6-PGTR)'*^P"<G\Y]T882%)0?.(H<4[\>(-CZ5^\P$CPJ7VMQS]7ZQKP?([
MBR0O&P.W_:6C.URF=]U%'LC@A4U.MV)'J42'2Z1_TJM>Q:SL\%(U4NCB"(C
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MN@'2M,C6*H7#G<G[?N30F1LI6,]VJ@,Z/GZ$;DT]T[<:PE'_7LSQ"X/<A%^
M_CEAP+#GA0=CEP_S%'QB1[L5=I$?ZI)8Q0?KP?2[MC_&3#/+<_@%P(T?X#UP
M_JMR\!T4X!]1VATD'PHP\&(6=+2* LC2EP7\ I\J GE1 ,-B@SOBFGMC_[I&
MJ35.&=;%O'\[;"^I@1.\0S]UB;&TYC4ITQJXF54VY))4N)S;TSH#MFKS*J0W
M'^Q!J\H V=!;B8,T&I][^3Z)I[>I [ZCZ#B2Y.4F('HB:M#A<,'KRD]?6W=:
M^CF21&PN8$L7B1%FV3]\)J]C D<!#*:C'S:.U<KIB1]R?5*PY7I?E"G4VE=P
M56X,;4OEBX<,";'X S=5=#'2B'HJX6;$ _0S.5,VQ\B>_.A7 O2+EWT[#JII
MUWIUR-I2C(]CA0U1_%O(EY%#!3=$6"#FW7)]=;IX?@Y^)J7"UQ+M+&6!WY4E
M'#/^AQP/#0GCW4\G.KL^58UYLZ[1XN\+;IW;.0X[F>!(9^/>,XKADF%LM[WN
M\1SVP.Y]W<+#&_F"=Z#6AWF;?_[()15SL%OF>?9&_"30Z7S@YV,#_+*\2IA-
M;T"Y.[?$.&^'J:UATR3KAD0*-41Z<(=JH]TV $.D6-\!VM>E3UD9=Z ]@9!&
MTDVQT1/*>?!TK/",N-J,; T 8I:@+..[_W'D-8\0S5I6.%LRO_&>%!B2>5G%
MS7G%X*2MIO1 )YU;L=4\9;]WP37\[E/BRR_@CU&OKUPUDJ#7;Q,KEGK2#E,X
M#L"9A;L_<>33B[5]8DLS^19=KU]B_?:TV0MCM6$M,7RBK=-CA[,I182I#'^4
M\B\58/VW6U&28'IZ289:/ ;GIC@9^PL4P*],7NPR4N$ *7RD,DZ J&D22H5*
MB Z'3!0GQ.Q+"+%^&G0O[X5J&["!;>QV:FMV3QNM\09_'=$FXME:T-#%=[N^
MEQ>\]Y@@T>S'Y@<? %4E(N2TC+&'YN%4UM3*\5QXP7$NN<U@!(/3)#8&9@9+
M#=0NQ 1ZF;AG/VAK9G/Z0.!Q'\9*4Y%D6$Z:&[ $"'/JD>4ER;[3_CU?6Q$V
M_SNG9A:78W+0L6]QC.#S5XV"K$;*MIVRK*P2M&_*X?@70<)]RB%IWL<LX2P%
M@76SA#4JO<O49(8!%YBSH?"33@J:Y)*]%6IHTM>:VZ,OIXP-I@V)8E2<KS$8
M=ZC/5NO%4ZZ83VG#WPK:U(?Q6*S#Q.%NW83OD!)#[T9Q*[F-C&+P!3!/<39W
MZ@ OX#JF3;01QS4V9IU\@GPM;R*@NO/]PU1CI/="V+H$^GS[OD;YQ+6L0G:"
MV"8UP3U-?6&&,!+$Y:IQL-<77.6>9@= U,/1GV0[9583?S5]C-%_Z))J1__1
M71%SC)__@J0PL'NTTQ/C#9-('9>"![2RZG_T3M!ZTP3,UCHB*6 F"=-CP1<7
MQ TKVNSGR2\_<74'+@AM8.3S'VF+ "?,9HW\A84IO%*%A^G8.$C\-ACA#50N
M?9 ,@PXDR92M2['5_$]WUM+<E9&-!\D$RQCM]-B[5DUIKV^?;5X @?*Z4K/$
M%GV*\K=W?;F'4^QH5O+4R!;T%8>;X\HV'&Y\&U9O8V%G1B[GGG!/P&BJ\H+A
M5+&Q<+>,D677B_D/7H+6"ZT_Z]:0)LF&%M"E8*4K#VYTR[:HF$A[GCHTA:\>
M2F]9V ]T&MQ8:=;>0$C L!6@[>'GRY3J'(O:*XLM[39QWCCS"O<3^@ H@'L,
M$X;HK_9')=Z41<.E,@5R7L6*E%(,X43B.)C^KKW940'M6_I?M18,PKV%2I=3
M]5AT*EH;<'1[,/</B8T8 >>;OB[5_Z=HJ29]X4"FU@&?1M4JCW&U1[\=P\;6
MM1OUDE-8@U3RW&"I@6EY_O#<04$1-+<UX>?<K:%RLU._EN'54F\1"F#-@-#2
M&78'M9,MTMY=VA- 4C(T+E\/LX<[R?YL;*FKBA#^#>O.62.U-KXA4%47&2[4
M<W)P32P ;:47#/FR=5TSW4Q=+IBDYP1K96)]X3!UU!>_,(J_F:S2"4]1-+E"
M1SD$)_9EY/#H,SXB$M'3F1U.QDW)C6N"4MKY65+@JD'_ 0H +$4!',$_A*+O
M+J(M)[*BK*QIT-#T:?O%G9TCI96<%S^BV9P^5)&![FO\OH^\O 2)4&*<;'__
ME.%T65B.\CS.1OI+E8DV:0U,8YN-7(/:MR:41Q;W^7P-7@[A>FT^JI1039C^
MIE336(9&\S+_5F#33$=(MT]M-M6-.Z_>%U]_F_&4$>SJUW%O!, 08=:^HJH?
MJJ4=$OZ&9_69A2]U0]2:GJ5R<P?;-*&W7UQ.'/Z)(8'R.RJ"+H)@[=$@A)S;
M.IY\S>T+)PRINU3#D?Z<!(&7H;T<[I@7:U$)!\[H_21)+3VX40P^WVZ?88=4
MU^F_[?<PVOWIV#=WW^(Y##_> ;(U.W').Y%""]3M?\0VJD)V7Y3P'86SI@!D
ME<;=J"=>'BNTN,N%AZ5Q8V&\0O^>(=5]*?K8/KK,21$&=U&M&12@\OS.=<%K
M75I-J4,W:G#3QNY7"F#?O$Q' QX-P2/0II#,+=-97#7&BBA^$GB^](O$ $Y(
M,G6?7/PU)F&,E"=@3>3_O/_*2ES'X=R1I_+8:_4;W9&76Y3197!3:J;Y:HR9
MXOIE6[-V8#^PGFAY<&;&IN;U(FLOU].[A N[,;?SO)HJRX]&=:Y18U3 ?7OC
M"S61C-)KI_Y68N4.HAXBS$A)$C7#>XHV_<T9BR0&,I5Q9!!WKMC-Z!\[C(6,
MP/A]BQAS3Y>:,.@BIHE-%_X2U8ZPC]7[,('<)=]!TM8890F2ET%_5L;X+_9O
MUV/1 DR)2K=S@I![RY?K?NA<6'AEK_+<PY0E#1>LT!>KGZNO" LZO^.ZE9G9
M@.FX@W1#&<*PM+25@5*8Q<P!?OCXTO09@1L 0@1K:A<8&J?W*?J!'"2:L,M:
MMX=%R*/B&2"!-6K-]>;IB+!CBR:$+S?O@(:CJ;T-9MV$ GS3_MU'=LO20_4$
MZT%EP[VX'B]\9.V1VI^<$5 SF[;92/@9*#S\:ZT+L*1YMS$.(F(6I5=N00&B
M0WMRI)"?=-(:;QJI0+^D-M2'ED*4;:AECB\>6[TGW+H[(XAC4#E>E:"*U<?S
MH9[2G,Q=[V=S W/(7-6[#7MME2;4QE74!RG5OUG^%%UH-""JW=5F;GNA0YD_
M;FO,46WK5H>Y8=%WH,?O693JJ@E<ZGH$(XSF*;6;"NA8X!>AJ4E5\1L2925+
M2YIKO+;/@;B?WV]J"ENQJWG/<)H3+=I%!PF!J,P"-[=>S>\JY5(X3WU!^Q"Q
M?X^%_JU,([WM:J#+P]MQ*06SY;SDRG&SBA.;2E08<8?DE!D.?2)+FE6S&>YG
M$K /-"\G@3H0%BN=@T4YM]J,D;6OVY)] BK2FTY+-.F>2M@OH#HRT-SZT!/C
M2<AL"6\_J^R045&5TU.NK5G+U_POI/CWA:V6BG^WD.2X=ZG!II#L,)>@O!^P
M.1__A8G[Y,ER(4O=W,Z;CE[GU'=\?@+EWY[5G<$?=Q,-8:K(X">YC@O]?/DP
MZ"NSER_)U@K=&U'3=$P^W]^^@VR>*$#QZJBB3^V![TMH<-#ZK19K[2)M;1=&
M,KT![\;"7*]CA)"Z/ OD*LA9_M6M7,4$O1PEPB>/G,%#XZ/S[:$#7 D[W5MZ
M#NB.'Z5Y) ?1.>$^O,LZ71W:.TGS)9&$:M&&&#QZ$)UPF5W\Z3OAAJO'&0B&
M,%MI->C*P(2.!D8<95EP:K=L6$?I;9H:'!\[2M,L,^,Q0OH">5B-]V]L0^SL
M?.(TWOWN>'A0*\/<[D=\;\L5SW@55^0U7\[G6[/+VK'O[2O+I]?BX,NS:._9
MG+V-'A;H9)<<! 4X'#T2,[%D1,Z<\=F<2IXTCMPM>L)F2BU!>"VT)5:@1<'@
M(#MAV(ODN0I-^N;G0CHPK*:? #(,@!)V"$(%!0B*1@$>;6@@T=XQ4/66^TK$
M;4YD? =4)M_LAFCWLG5:Y-W_\T\9U<G_X^C!P*)!-?B1?2SX<K%^S/A65:;*
MY"7UB,XZ6^6K="L;&SN*AV;+R<EB3-E4;%*8.^76FO00/ 5-M!<]B#.IS?C(
MM?9LE/^Z,H9["D-O]IOW6[YJ:_]-X>'^ 1EZ!PKQ0^(+[#8%]WT6H<X,@E3)
M*97CTZDACG[-,U)K7_AF?/2.WM2. H_VOGO"[A?&"%4#?+";0<OQM#HQLU\1
M%@ #\$B;J0QC^<\K=_I/#88"A%Z9#JVS?14!0\KATKPO3#CB1J2]NT_=<#G6
MC@SG=[ #HM9;_5O ZQ&DV3W:ZG<AD<Y@ D4[R_UPM^>:]L-GA#&.^1@!O1(
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M7##]G)O-RT2WN,5%G;J.30&5OD8&1RNO#NV5RK)Y19N7ORUG>MQT!>U<\=(
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MVP'["BO^'-=[VCN=SBO??O8V@RWGYT^TC"7.QZ\,E*.1C?MNK\&#8E((>HV
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M!FU((BDM%.UG#=VM/D8/SI3FMI^R0D)<"I:WL?8:/<CUG7:MO-DXQ^-M]%$
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M"Q?\-JP[M>#N/BG&XANFV/_J>]$]\]DYJJN=L*\AUOBFU[AP>8!O(FWK=O]
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M/5'I]GWR_D72>(<KTB!$\)!G/3(')F&255UJ5O'"@B_GAW/;N*SUN+0.4/3
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M9O\-#<86U6?"H+<PADH+..A[0]8BVEB\_3 KB^866CM2?-[8_2E!9_XJ=O4
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MU/XL%G!Z:  =**P"RNA,U;N0K:RNK V_J)]MV&.*&_D,?:GS)&PMLQET*]X
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M<XH^^55U>#]B?DT[?$4264IWM94N(%YA4[/5+_S*1DW#N*9#$VRZBJ_R]>.
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M#$7X['\_D(H-ZWA*G6B\O/2*WX _*\<ZY@M@IN.3!*:*-X!R_ -N.3G[<B!
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M(OO?L][MF/7N].1K.\O>ZIWIHSAN9M!O:=P4I\G)*)(L^>L=>[ZTVTCO3R\
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M4?EPM0E:5YLD%;78FE$,24>/<B1&),E(Y8PT0W*QT1H]X?H=<\A>:ZPP$(C
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MBY?R>>3[AH7W+4,.N5X^YY[KLYLE("*\5!KVQE&J5K[:ST0WIVTIH<IJSHW
M!WS??3NB3BU1+G%5$*J^!'A^6]"T$=96(PK(^_;H* '&WG.!+M9(NV5%8[!G
MZ#I?]>DA8<W(D<AJ3UG1P_W'4?TUU5J/L+%RR-M.Q8;6);4")O&LSI4+X\Z2
MBWC&TQ049&OZPDE<!%MV9!N"ED>9WB<)HBI8Y#F%OZPTLM_1IA+B/ML_TC_L
M4XMHLN/;T1U78?G_)2#_(4"%)] L6Q>FZ"QJ_I<%WF]S^AZVCK-FJ9(0IA#U
M]AN=')<>PE:8^[5LK.=D[_ZHD%K->DH!.N3":O?ZD[P?DOYGO6[#(+'_1KWT
M?Q?^O("@"$PD*&9KFSV_B74WSA#6Q%G&>YCE_$SI<IH1&W&QBGH^Y71%*%$#
M_WFPUF7%8&[SQ [;QL6!'(YU'DEXLE.1J=R1RDK 9PQ'E.SJ-1_L%&R3:,@B
M:-,N PO2$,$0+4JQ:\ ;J_8DWU"G)>Y*,9GZZ?P!6\SS:P!+O^=<PRN6YW38
M$[(%7;-1UIN=-^B/JD)^DJ\<@L\6QD45Q:$*<:(Z*A+(6AZ2?80;QZ*,X>J/
MBJ*]QCRE,=;'W]%C0W.L>#JG:Y>H#GUCU?779)-KET<GK*71;H^>RFTN&^\'
MEK076.]]LS#,]ZX.P!J81_-2NBEJ>*6IMNLBG ?]I#$!]E@FOJE,E-Z'=\ZG
M>NIC1.ZQ(*H'%-*E\NN#[MXU $)CU2[QV5;CA59E.3^:*7ZO\C&U_@?YTH=!
M#S/:C*GL[]FP]I#B%G.EAE*<B0NF]J@VS104SZ2U55YS;;VD^#;-^SNR2ZNV
M8#VT\Z8A/-I"I,O[?KIT7_ID19>48E8%3]M;L^!OF:K:OCJ4:AIV")RP3J:)
M71[:17-YM':!JOI8-J^"^$3Y%F?ZCAZJ8M=E&C-GK<L@9RT1QPD!OD+:"Q4L
M2??<$H2PV\&"$-LDJ$8BBM.HL[7N.SDXU26->FH)\2"!;46"JL@JEM.QNJ6Y
MRYJ?^*-[=M"85#.)LE;(7U6BTK"3\I5KNHGWZQF;%U69T7;>PBWCH[9&7/G_
MP&*NOQ>\#I-.TY</0%Z2\):"IY3S@WD.1C4FCS>(;VG->'O87!!M,X^6>M$4
M;R_B"PIDPG;.?,"M%;4UQ$J0NO(9@N[P/6?>7A 4'LE<ZZGKSBB[@)MD<EE!
M<BMQTU.M"NNHIU,IF)9AV.MV@27&>-\[T=>9!#-[?UY1B%U74T[IZP@0V_30
M2 ]J>>!6I POC?&T10AH5P:L]%$8UX3+U9":W*3K;#/"COR0)V;P%4'<X9K&
M!G^2DSDM>]-5TT"C)S5$K$;-,19+B.2T1 G?HM)\@724JS$H(J^B(FA!*CPV
M)^9&+"=6MW1&!N&+:R!0;)7P@IE_XQ?/-0#.0I."PD4VBW?2/R^B?)H#P@!,
M@(54H^7 ^([*4A]57\3%QG$4MEN'&L(WY)@0J0U;,YQ>?'^%/D\>/,IB/_-:
MKB7O44VWO+A1[TW8X9ID%HG2+%5@P(<4747M;H;+0>.)I.9PVWH%C=+;_7A]
M?S^SR/(;MPYTV&#]N0(FA]^99LH@!/]A?:6^W0LXB. /30^]H9AD;G"*7;C_
M%WK5:V1__E'>PE'D\T8A <UATG[4*_C\QJ>FVP7F+O?%:":FXLLWWMVSCJ=>
M\U.2%,K'#O[/H_W_6%SZWT.)S3\,K!M&\;CGNAUT>:R-BDXVM$ZC!T,Z&\Z5
M2:S;PN_&==]&,>?_>[3__?K..U9$@IK>PJ^!CLF+6A1+A,,U,-BH:\L\D,1B
M2E-K-F"[;TQ^H.^+>D9([CNB/27RM!5YY93^P(NTP.VHO:;!(%$H^T671^+=
M*<6^'''^)6L-OO[(A>J%-Z H#%TS$,%7I*F.A\G70-3(-7#G0S?X6,-YJ,\6
M+6+P71+ A Z_F]>!EA ^%2ZHN0(FWA*!5W#W&^X*M%:ZMU@-;: .V7;=LVPO
MFE89H=7>8#VPOR!F!89=!L\GV,VJ8O$MC_5T6=BZ8ES[IKWR@16QX;0@/[[6
M_[Q<2/P]Y#"4G@(AS+[K)$8),D-RMAQA$H*:!78#3KN%:O08NVF<4K>W(TJ]
M^#O<P/!\P;>8B--,#Y5[#:R>[)+\723R6EZZ!O#=.KI\'B*$XZX!/'J]:G1'
MXR5/\OI/M._0H_V>I)?70-$@I\>EIN'OA^LS_FT:-?;]?1**4E^R)7<SNR1&
ML[G4.U[E%7[/O3J/ZSOB\;H&=B+M:_,HAI3U0;]#V)66"Z,[(;]=>79)'<UX
M:E-KG:^P\9PJ*\IEJ0[$^J.-E_9D_+\D)HYH4CA/N*#"5>TU0":@5X/^.6$V
MYH,:6C_W]/$]Z:"8'TLQ+H!F,"?"#8,.!/DP(3#A+(/_-5!5W9@J#GX<.DN=
M[!+T@]R&0/3'608!^'<Z$?5[6IS>8<+NP:#P.XJD(S3]F]XNI^\J(>MAOX9.
MTXIPDL_6E9A_SF.2C5*^[H44,R%)[]\*#P5YW%=$D-(M/0RWKY)+9BV)W7]*
M;:[.U[%A]3MP$(": ;MKX/=R<>S[.VI,E2F+DAPG\U7M47;WK>S+]>[MK8;)
M?7W1\%X=J.]E9 @_$?)(JO^3[9O1;>J'1N3'%&MC17VF9;\=RJZ"B>;;8RT1
M0_ERMV; S;67 OSM^?-J[ D$./SIJOHOFU<OP;C(%W)3)\F>]0^.^L)S*IX:
M'5#X2'"&>^4=9]P5"5D U^G6<_]0:R[[Q,,HLET3U>0[T[8S"^).7@(3^EK/
M2Q3^B.G/85N!1O>_N%N*0TA'O7;<MU+A)8<X:V\8"G3V9EM4FM3PG'U:LFKQ
M,(3)3#PC14:1TQO_O9< <FJY%1=)K#!\L%NMS5;B-7]P4_FS0(XK^1-1#XX]
M?692;J7HH\?QR@F,.V2NS7OKGE 4/>SY)4P]+EW37PO]+4<!+!\>D.2<M)I+
MIQPUVE2)IA3X?@T<XT^)''2*H%RBD.8'H&M@F >3W;3>NP80L(XD_2'%C>*<
MU&+W&>L[&Z,<SXQN^ $ @9]FM&^'M)L(VK]AXPJ),?21&,G$I\%HXP7.3OK9
M"A@MH&HG%% ')?82^:33"MF1B[$63-]13WS6,Q495*_T[SXDLIS5A#$WHO..
M:)0$1HPLEU7>N(:,E2\B==L3T)0!X@Q'^SF7A_$]M'XNX,$&RM_T\F_-8?%:
M4?&0V%7(RZ\M"/@P3AFXNV="[FFN1:B&TY3\-U%/]M^.R-XJ=8!Y9X%5[Z1O
MO4DGV,P&(S]/!WB6-'PX]S<P_B/&TB@NUP_7P"95J>]BB"]R3Y.K,;#/ ^I_
M4H0OMAPPJ)LOY[.O%21&4[GI4[W@IH3Y_$R2+'K88G1?8Z[_UL^8/1I_IHXG
M=7\'9A"/+P6#@L5Y3X84T=WAWOWS8B)[6YB,1/Q)U&Y!S]PD]TW,2(PV9CZ$
M8F+OH$BX[Q6V\] E@O"W.LD_8%ZV89*6>HHOYK-?B7FW-%K*-YIZY-3ZK<]^
MGJ7O3LY7D3ZQOXTJ]="%F&/+%$$K0; '0LE\OZSVN?@FLH?!JR=%,\2UM.>/
MWS1<66P_9_>97*">]!J8#0O)PE6Z;+$1(8B?".[L3K*4J>OK*4!J;.C;WM6J
MG)GM>TD#Y1ZCC^^=/3PW<>KF6WM7XS-1=#:ZA&*[!B[O'-VZRO*B+B1U&K!C
M(@?$"$!HR9P_8EUJH?!R/K1^:]%Z'+-LHFL@CEGZ%)/_7V'9B!P<&Z+4W:/^
M@!(8/K* &9EA@TGF?1YBC$]5?>);VM2K/$PL*<HJ@;[$V-?5Z@^KA/<-ILWO
M<S?'SQ=7U(4HT"E7\@WB&@^18@SC[S5D0E]Z]<S_1/>V5>EQB?URM%'4$SKI
M3'#SCOKM+MF705]#30L7+<Y63F'KK]+Y6!L//,'*!K,6*\S:NTM)6K:/+.@U
MC*S68;<IVJSK1/RAZ;LM=%["M2W$2J"0TH<:?>W6F7J7SX_<KYCKP%6V']H
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M/=V1!G,D4MLG$6/6J\2C]237='JPCK*>UA5&??56.Q7:*<^X$1V=$2N*':O
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MWD7-BL=>6&,4HB*4Y44HWLIQQ2AG2,'"5D-IO%5-V2(LFB8+FTKKGAB-HM
MX)Y6[K@RS[,T%?IVHKO(DO4@D]]I*@[;CLZ";,U,=?#YU.(88*&_I;E AA#Q
MLUF:.M']RAU\*9Q12\;2R_2LF>R;?]V22_L9A5#U8@<S\Q#V@INEM:Y*\EY<
MZ$9S7=S UQ0.&Q16CZB( 41. VY:4^*ZW!C*MBXUG'._D^3N:U'EH&N@Q?,-
M* 5% ]]+H>5!I+;+N1@J3##4?N3:E6#;(F,3"2WC3X/,,L>,H&[99KKU*$_M
M<LM-KXZ;6)1:<;;(_7 \<AK28-R&E/X38[__A?^%/P?"ZYG_ U!+ P04
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M3DD&%K7>KFF<PBO488'D= K4?HJZXQ[PJ>>FQAIK6;3@CS_-&KE+=N+8/6.
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MP68QHCTF?!2L=O6=[;R-AGT:C\/5I[IJ]V)^ZD4TPU$Q N8'Y9E=UW<HR[\
M2X$#LYPL]7A\.5I;<DS0RZ>#IA!O+'!=O'J;N3SI]94J7LZ8.\9$@<DRHT1]
ML8*O]M0[3T_FVE93 [S4FV%.:X<#N=**DGF]E%5@^LG=^+0W<I;@S?J*0J>,
MMS[3)_4E\^;Y% 2Z PKKT+Y*2O%]F?W()S#YF]8B1M%%M1_#-EDK7[R49E\Q
M84]"C'0&<-GT.18E"I]P<$%YD[*L[WUZG %LM(JX44:V<Z**=4;+^V;L)BHJ
MJ0<8.IFBW--7Z G <',0=9 FS'(Y,J"G[2"LLEPHFY?RY>EH8YR'C59I_Q&L
MC:\+0S?6*D0VYDS_E%+ZC59/; W\=2K/)[QO=.'_KRW"" L*)_+<YC@8"*#+
M</0,<T3'.V(:<99 HL4YB.1,SA:YL4VWWTZ"RVNUOLL)])"?<2 X3''5H JG
M/[@:R0R&(?1Q4.Q)RQL=4Z7[%OC][]IUQG#;ZW-R#<Q9:=TL0S+3<P9/3U)-
M7!6V>C5)LXN)/[VX:U-FHUJ HNQAUBTE3/Y>O##K9.O:.$'',W?Z_J>FT<T
M.ZDAP*>#TJUVWH-H3B*E5+O4<N'>,.0E8KRE2E!CURM;H*32\9O,E8U(N5MT
MV?EC++.\J>O>D?O</]9BP%^'!3[__S;YWVPR:AFFB/X N@Z"[.8,M_\ QV-P
M(MROCB2^#.E'[QP_S$15'UWJ:F6RMM$:V-ZW#W9$N&(T0U*.W^-*?_$ER)6_
M'O;".A(535ZI/\954'CAOW_]8>C68W0Y)YC?FJ.5^'SNZKR_9%F^JY%O50]<
M_ R\U@&EI%EVE:DL+7:Y_JW:0MU#SO"^+K.TW0(!Q4\2Q:RG:-.)C/.YH7TQ
MV6"USNN[A^1*%E8/]#BXV1FI/H$#]-Y:%+\]$-NY )&;+\T/T92V7CQ9YI;D
M?'G&^16O5T:?N'#LM\W\&YOM,]6-QJUPLA'XMSAB@;%8)3:U?ZZZ99BK;4CR
MZ:@WYN-"Y0]>J G%F=ZW%?<YE@MJZY"!HZU+_/)_Z<R"G7R:@YL'+](Y6VD8
MY(X9&6'U75B GCMA@_+O6HWQ?A*GW1+Z2Y*1M;%N6B8.U.6G]Z^_^73]A9=-
MDE<P3 S1ZFMR+EZ;,4;:WE_Y+5[7_W)=^MN_P5/JK^'YIN>4N6*Z/'G'Y/K,
MTL=O3ER90_JR;%,C$#>1UQQ\L1BYR_M_JCKX&E@?,5P$VWQ>.Q](23F[X,P3
M>NH11/5-Z!?;Q[V1Z:H>-,GN "A61&7,#'J5+=S_ T9Q*K\Q^4[JJ@#5J>+Y
M\10J41^I4S1)M6E!5YGWO#^]* /Q0'\CEW$CP75 .):E5)M, OZ.XH5KZ&E"
M 8:>'7PY"+J 8P&PD:7?A4GV-G^,9>@^+50>EY*/3E3#=WEI[T6R*$OUYU+Z
ML5VA&_+S-4 ZK!U5[<Q=^9SC4OIQ+>+HH7FU5*\47&[RW.$TF@\"%CIF8YZ#
M:#^\S-Z6S>,>'&%ZZ)DT!'C\>U&!!UMFWFZVC=E[%2S,PANM,"2T"]&+N#LH
M^8'0=2%!4[ZL TR#ZJ=[NW2C]I[5C.UB(?? 6%%MTGJ(WFTD^AOK*SE/)?;T
ME<40$+5?L(=[7HS QXW4)0/2_?@,R=OFE-Y20Z_HAE 4YD6(\'>92IA._FM"
M$2$KQ&]V1FS\*Y/_4OW?P+F]1);$\]7E@2;;<-#APR,]W/XYBZEQ(!9@E^0X
M[N](>=EQ#9=BZ9LYN,&11"ZY[1].I"WQ#YK)Q?_#B0S_P3*A\LV-E#$=AR0X
MVJWL.S,%_969M^#H5K\I>[FD_L% E6Z;0]C'EJQC]3D6:/#%I.RFP$%_CC:>
M=D0%TYNC*=.[_/ZD$I4_/(IMQK..@Q1YO6>R5_YP(A"6/TFF71US29FSVJ/X
M=EL #HK" H<&:&4L8%L-DKG@^AM/,B7J 1N<.):^_?SE$<[I7TTZSOD./N,]
M-YW6NR2#!%HQ_#FR98G!);+Y&%M8#'\YT>_VN[]CSQZ#[K3#1'(PGWE[^P,[
M@EE:,[M54(7(X?%Q16*$#[O@Q-$L#'GKZ_7X_&E9;Z5-Z1_!H<*>"2GAR/R!
M[35!WL;JMK:QY"6H#8N^I4._[:)LR6J)8HI3D)!EZ7Y=O*:0B)#88$H]%>]<
MBNC#JKV4*3VE?[FKBC^_(-NO(C?9?TTC+UY;MJFSA$U3#(_W;SK,V@4[<WI1
M0A8;&I-"!T],9D9(]^>"*8N\;/\\:I38X#^[0^'+/_UYHYX#5<7J*Y<1PP]^
M/G,$^@\)%_\/94=6V?8\,UQ =D3G'(KGG,,Z!AKG=MMO@GY,@W9B<-(#=ZU/
M^Y;XO@>7D2%Y-CLKB6>TST&+BC\AX:;-*&Z,*@O'J=XO\021%?5G1FCS )8#
M3$5[1.O-7QC%9U@@"-*B>%Y_SHS('$%=9E[^LB)N53;!:?\9R>]S5\5X6Y1O
MX9:?J@&7FK'H38)%=65M#9EK%O_>AQ'H5[BUA72QN5%5D_Z*E+CI4<RR88NO
MI,,@5;W80U9\=1[XS3;W5A"LK;S9-DK(>].C5M4_F>2MS*=,)C+1L[P"A<B"
M0'WBP!57N@DTK^,UUVI7IY>#P=S[PE<W*?0(BEYY__0CT)11?UL!=\VTC&Q*
MUJX/U#N^\:,'R7'!+44W,8JG2M>WA'XP(1BD^\JQMM4/GHUSG$EX84R%3 _L
M/JTBA^_<4V+3V?A+&2&!,=[H(-ZM^]%ZJWAAT65TJ$B3(#A[R*V^5=U_^VRC
MP_UXTS3G7YKC\W_?'"^N<%[BJ_\Z53QYO./:)CUY9C(V&S4KVN4QE/U"4>;7
MW+_7(#CA"?=;IRP"Z IR03^^XRR;]<39M ]ED;,3@ 4ZE9_TH1M^%^UIPEDP
M'Z3,8A_84CB.D>;I\^\O[_Y8SK$Y[@_2;9@<@V>[;JY.9(6&3:I$Q(>>10?]
MRC@Z_[-\L1C%<$G?7=X_E,N/N1/,__T(K'_FE8\P;B_V!K\=]X!7-Y*8#?(H
M/.8G66C\L;-C4PPCE^V&I-$/Y>W4SP5I* 8EST;'?CHFYJ;;Z""+1!N#3O:Q
MP'A;0NNN*9(R?U#Q]2\I6P9\<:DNUH8/35*]>N(C$!4X *I[GWAFKYA>"2(>
M[Q ; BW?#LC^Z4-=7SLO__)4,U6>V#A2IY&ZU)^W@8;(BAWXT2>_PT(\WL)!
M1'GDFO-7-0_U$"8'9MXJ[^;F4&DYOUUB.M+JJC1XX_LPC9QCXD"[+K+;5Q^U
M;)YP G473MWJKN%Z3C&[^GI^R];)M!<+4.%8MP#U!M-AC_$^_ZR#R^R08EZ=
M!!L<E/)$%8I0YD0%BM_G-6HO9O8JEW\>WO3SC<)X37F-@(9;/"CG7"4"_&.M
M)J&3[@W)-V.6^_'\OO7J=8@/HIEQ?L*V*-@>MXA#OG7(1C!\9"J+:@:7ZM]^
M=_N),]#:V4RM*M ];O/)C0DY69^;DO=413[PIBC-LB@^F;R8P# N]#:#HXXJ
M1![E&"$NX[[&"D0[_)*HX11A[D "GD>5$(-$M2FA[!%#>M,[-+]4I4V8V/O:
MO-BI6ZE0.]W-;&FS\'%!KCI7,R&X\0/A=/>LETX$394T\.L?T7>F@BKF03X.
M.&C*H7L644];FNVKU,7T:$NJU5;*N,DBB$NX0N4FND0?8 'J5E.^R"N?4N$/
MZTBX;B@]ZW(C!#=8><7HT6S94LL905L6J=?[NEZH^KQFUMA?%VQ\[#<0:)KG
MG*&0F3]?UYYNY^%(>O>9!C?)U6.ILEJ\;W.*W?/:4D)I#Q%=@G?+'V<V52LQ
M8M8<_=YHH1)A F+UC56(A=N)K6*^1C03BP(3F\5,4BVY<NP;T-,$-[=GC<GR
M9(4:PS.-[Z4(%!>_S(F$H9TK-^LM*LHM;L\O=M:H\60K?3>S=R2=;ML^7][+
M"![ZZO;9*4-^9EB49&3G4="]@AQ*E)W../.3NS4-&@]?>[8X]7K.U9\/V:X+
MI&<'0T<HT:J(L4:)DQ"VS.'>H,%2M;M'>@%+%[8X%CZ_XF>+!0AN8@&80&-^
M]8=/66M-LMGR8)0*C#+*6Z1^Q V*LG6R+O6ZQ1ILV"1RW<^V9XG56FY)M?!.
M>VO"L(BPKY2O%.&:.MV1MU>(,*+%+TLLW#+/XX1<C67BPV(KY_!2J^-TA4F&
MR</U5(JWJVO\VR/"6"#<$=ZQOVF+HL+5;C36$>\]D +J$YQ5L;J(G]'7;]RS
M_GEU0W$!K)K_V9B7UUFT],F6H6]855<F.+J;ZC(%&@+:.O3 <#5N!5V%;SGX
MD\D @EZOO41P7V4SH:K<M$*%"NQ]Z9?A1FBYV>$:,^6>'G?X?,:L9,/=*VG+
M N''TH?032Z7P>/_'BHI^BL111Y@9</NU.KI!1.I#:LQ*RI.:O@,$6I13-1:
MS*7@V+/%>>1-.B@(38HCNJBR<_&^A,))N+5+U_V8/N+ .2NM0X*$.TQ*.]8Z
M?W1\/Z$:'DX)MKJWWVA =/HE3+OB.9Z\W&1?[*)?($!&$!(D^('5*HGTV%'Q
MO*]L(P,FOE3AO:U:2;2IQ2M"P+5S-!"OZ!MN7ODP)!9/2$VL[39L.4 (\I6J
MK&Y<CC Q/;&A^^!B(CJSH ?R\ES5CA\ <S[Y%,B\6P* N:;00K"K0=JESB^<
MW81S2G<DYG).HE+N/X@.V^ZJW*TDKG2%..52&)DCZ%(;2G4"):HJOXV',@M8
MJ\+C/!-H7PA(S$,E$AW=4T^:(=$W7A-12]6I&]OFL@FTY8=*:8;0.7NIV65:
M(P63LDO.R]]R=):!.C\BEM%8P#4'=<<# 7Z0'RIGVZ5(+A9L:HX4JAC"5*UM
MS84VO''[15 SJ+8QN1;_JA3AT376^&K2>]);FJPY%I_<UZ0Y..L#Q,C2LH\V
MS="_ICJ.B0.POUC!,W$BB,3EBBW.&XQVP1+1+/WZ"T$\8QZT0M-5L%M3NDII
M1CX$ORK/8PC' ^X-"8>0HIX)F-M;MCGRAT>>>_EP:'4A)#N'2+O922?$+>>'
MK!86U"QTTLJ)?*F^H05FTXU'RP#C"!+Y'F6[)ZZ?S54=[3S8VFI5KM+:72L
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ME&04R:&@R 620Q4Y%%6W['OZM/[];O<YW7W'>V\SYAA[C;UJ[S57^.;WS;7
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M]'>.YF8_6MZK#!T<Y2W% NW*.;C)98I[.3XMVGZP51 7[C6TL$"Y,'IS4#S
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M3-\#JYHZ&T(*0E7J$?$0&[3,DU;[-4=&M40W/K_-DND^S>])\(F4@$*- /L
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M*W%( 5)+!;*/2V[?//)&<29)47TX;_Y_>\/X?R:31?T'.1TW^IVYMII%!+*
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MJW=.&4"5T;8(3SWMS+*6$\'2H+\UE_S-$P,7^9]EU7%J\C]NRA4ZV'.%B@0
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M>SI.^:%SCA51H:P'A6:'=7J?@V^C5_7 3=9TP\EZK(42(!VE)]^O#]7+P"[
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M\<O=S>OY&F[-US;3WW#J)\QCTR/>(>;5\_-&V[*/2TKX ;&C<94Q/IS(P8@
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M/#V^U1I#YD;+@#32;=TU:#NO#&-%I3^->E8=X=?V'9TIUVE4(XZE%=O_OTH
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M1K4-GA-: &.Q_UH+98X49A#8IKLATP5KPG:\XM=K7?_V\%#4//"O70$@MZ\
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MZ!2I>,O5B &X'3,'U@2ZQZS5IQOE.)'H(P#.+OKM6&=@"]]J;^I5W<'AX_-
MHU+<W'&KUX%GY6P^13)<GAN<-OOP;_A0DH$N=,AUKEP1CFRQ(C?5Y:7LG3@
MXRV13EE&&WHI!5KC:X#NZXR901N:(BO%TC%9M.'8CP^6 C9N*:-"F=+/6XZ"
M0 J])Z<$Y\, O*N51+J,T?D?S1!L\I[U!DBNG_E.+/29K9HC4ZD/6Z=^Z.<=
M&_Z0*Q<2OJ).MF68K<D'B# 87GY!+2R2D#*Z^])B2+$Q/DQR8--(DW*-G&'Y
M7A$1?3[&Y'MJ[1EK;E-7$E(PU>*5G0Y2B['&A-VN !QBPNSY0DWUT4RH,% !
M?%/"L+)K45XVLWXM.-45\H><\EA?!=:%*)*>$?4W(K_/M3!$\HVQM[Y:I_R
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MXNKF'O#C9V!0<$AH;%Q\0F)2\J^4G-R\_(+"HN*2FMJZ^@9@8U-S=T]O7__
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M+WD)5=H&84O=0A) OFN^'#&_2TQK_C_I/_]?DL>0Y:OQQOV-^\2;2<D/V\M
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MA-(>T@MB<)(\K)UUQ-D*$$Q,\&&(;K94T0AU7&OESNKC'RKJW^BV7M:%%,J
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MCK%SOQ?CZ>SM9H,>*>(RZ'/*GMV8\LY."A(_&+J":H*1*>'1ZH[!BOACK"F
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MR$8+LLT[[-3)LJ?4$KY\!OIUK"$/D/T+_P48*2-:M!!/B-_4<P??C)N/7:$
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M^^W=LKN-]C#YT9_YRC\F*NRB&R'C\_H1868A.+&-,*4V33)\F/(B(#K@<1.
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MU8^E)K:PSN7';S%"0 R+EQ.-4#_#WSIQ2=7;O>YO84+;T0"S9>TJ[>6IA':
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M$8P"'GT.0P&!R!9D\A$;"K!Z2E9VX'+GQ%X^@=)/I<3U4E67'05D0ZV7%5#
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M&2CBCRE.P@#2IE6* A[<>49]+YZN^"A3F9E/(JJ2=I'"5&80%X.J=4C6D 6
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MC,4U6$FUI!(9H/]=G1WO3LC3V?0T;/[T65_1UM(NA2E,C.W&/!ZFO I3[A,
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MK)\,RT25)'<U%0 97#4I_@'Q$$MG@?L&K-R!,DQ43AZ0@+B)N7I[E=HZ'H!
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M<G!DRYL0WG'90"I0'0@RBS;?&+JTT2WJC96EFFGM*3'!@5DZO.?'N<*\%A=
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M/?S&F43X#?8J.V_[\SL [PKA@057>M$ZD%4/68:$":  O%.=G@I%IDKENN#
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M+%*LPNK@_&+5G8(+VUU-LT/+QK;.?A@H()9%#054I9_S%G4C)3UFVJDD/[C
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MYV2"S"OU2Z+[<8SQ=$_DWA!%+/5-P@0QFGL$B[)_'9R%_S3P@:]_&O@/23!
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M'HAS6L$KZR..W_2U7B7!.'!U:;PU_/:HB="3?$_:V8:$BZ-%[.FS^"Q_Z>7
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MZ.<,5NW',=NX4OZ!M6*.^HPPQ4JG99I<>OLMO5(K9/:Y7+,]WZO%08O\C>J
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M5I8Y'\7(^M5F@$9*]:$\>G Z#Z12/)C'D7]]84/7BXFG!\/NAD@/WUS SG7
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M^*;<;[#G?]<5?A.K>/%WY+#99H^9;#D(Y#A;*^&]>_WA'@]#:SF=3=OK5U1
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M:;U2JN&&_%-4"(E^A!O__)!QA7Q^A@D>!E!AP)L182M$P[9D ]>;E.A!O-A
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M6;<>'=RKV-J*4COX6)B3BB<.4.O&3VMLT )#<6K;S=PE;PK948 #O=!YEI,
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M& I0&ZZQ,'MG[B:3X>9YVE#NNSY6\R7^R\5/?+>H\;ULKQ;**6=-L<7U(6G
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M)$J523.E86052>FM.T%2'Y>\%)[T#-=]BHRY[@*IR%6R&ZV[:T.\(H$%CQ!
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M*&*^/X4V?Y.CQ1U,"XWO6=G(=>!]L1U^\O/#1+^S!2(/P73P"Q,=E+8B[^U
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M(>RCIN1U?;P.$?C1%+7/WK>]#U>;[M@5]#MSL!LW0(BP S:)  A.KRS>.3&
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MA4[JXSAO.G4R< E+C1W$;P_MIY']8P/S^Q^-[#\&]I_CZ@>8:*B@Q:-A!9#
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M0283[9ZQ)+?R?G](19(%]A#GXF5=6D\^1FW))G%Q/NOL[#?7<^O8'AD(5AI
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MONH, LF3V4W3B_F.+'/OI0M2\U*V$ELCSK'-19P$OK7[G1OE=ZB_(];PU<L
M!%3B^4" 5A(B?FV(PG]@ KV?WY-J=.2[/4Z*.I=Z;G]C,NPR:1 HB#S[_>O>
M"&.C]D'!>$C%O%\/V]CK=1H$4"?1LX'B3A_NQQ];H7@K35<3&$V>RADK6Q6=
M%*=3.W-< (ZWDEM2YNTQ1/QX&X@?9BH72?9LIHQ1#&+&D!OL]Y";L $0F"U(
M-VVN.Q8<<+7S?0UBA3X&!"+LM#3?4YH[L^Z!P,G6S:-E=]SC7+[UOW8.O?M*
ME[;I7YX\NH,=[& '?PZ(CZ"^SD4[F:*&JFSL!&5;%?RDKCVCNX*3U$"$F(-
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M$P= 0#C@.@@4H;=$0\MH1F/(44N,E&'D6L)Y@$3Y5V<2_@_ C&Y K^@H:('
MC4S,%L?G%=@#Y.1KHAVENA!+DK9;  $!$&A4P$ML^>5@URX9?1+<(:8=8MHA
MIAUBVB&FORQVB&F'F':(:8>8_GSXWR4F!H_'V6DVK,(ET:_M+/@*/WN^C#[>
MP%-Y1.TB518($+45Q$'@K$P("#S H_&7[1 KQXFNE I+$.AD,YP"S$"@VF8,
M1>+)=R3#GX) 4#*%78<!!#I:D]&C7BBR@<-ER*5K*,-^0TPI,W+D#IZ)/'M
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M@64-I\R(GA2E]>T"-464H"!?V;\E$X# Y.DQ+&D+X@_-U.UL@A]^^*?F&]#
MJY$K$B);7H,0=6R(.[TG"X' @15T7VL[)2RB"!HCU.&D)S0)BSS;]4)N0)=/
MI*B7(RE5,4B2#,/?)F)'<_[_!-7XJ[>Z[2VO6$6980NC>G>;&C%\."PL1MU
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MOW'CNVAG?XA+LM%?L25-\KQZQJ(B,.XK51#//&*(*_\6\("?FRO[=IEWI1%
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MQ);_$D1]QKTAW\G^W] +D6@A98ZRDY#\285,/-/C$,M3%XA+U"!7Q"!F69^
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MPJ3MQM$8Q17\ZG TK[T",L< ?$::>.-TLJ$TR#YLE3"7GQ[7P+L;<M.A^0X
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M[75.48]!G("_"-,2(RT0=NT@@H/LQK+<.4O':5GR$,TY'>K#7K\V)L9"ST
M8K'+N+AIRU_(T4Z285[N6E7-Y*S5\MS;#\M;6RO-B^J@+]$?I69?FQ7$)8*^
M3Q<;R-;K(JS)Y!2I[2-P8IN1,V55Z]T1>(PG7MA*M1K:2?"MT>U 96<W7V].
M_EF0'5-MN6F\_^JI0MHD?.SBX#B=,"K\&B!WIE=IY4I_I[7I+;"<D2;G-TEG
M)64JWLUD+VHAL#Z/A1)_6'? #/?^,&U94Q=?TLQQAC/N@+-!^&X35K8?OL^M
M\<2GXPV1CR5KBIS##J4P^!7'QA-,"*TBXF'H%2QG+U8'U_-C(I7[EY$+C G7
MBUBYVS=,Y5U;.XA\U#D2TV!:[)V*Q(I7#D)(X("5;'8C^:?CSCL[3EM,&P?_
M6!8++$]2(_?Q.)0\DL-R&;]S]-@S9$= ZQK0+7U\F /*H<OW]'7:G/,5N(^<
M7,A!;(RRCK0JK>Y9TX>_)8ZJQA9>#S\^*XX7$)V&D4#\]\XSN9R@CH?GEMV<
M.\HX2PX&FTB\Y1)P N=.SSK#NUJ#IAM.F^<EB+R/$^B"6Y'JNL8QJ_ D&=<$
MIR>PJ2'.OV^S&7-FP9=8"F'XP4M@H8]-]KU[PMA6Z7+.9Y^;5>X,+4[V$4%Z
M&- N"?1M/.=RX=<+^4)GVZS%J'\SR\V!WA;Z^^'UU-F0>2F;9^K/G[JUB'@C
MC4:@:G.^8M"%Q/;9NS*(F33&\>+8[O3XK,H$55?>9P\<14@FQ4YF=_5SX/,,
MFVC>\?>%Y:'A4SYID5C3"J&LCL](B(4P7EML3^6,-EDT44[JEVX.F.>VP&+&
MC!Z7[!4V@Y];2[5!RRIK7-QID4&'<_"?=/7VX"0.8DGXKY/N"U7L]9WYQ4WF
MJM%Z:5X*G1)+6[G+9OI^GZ0),*8Z^A>:(6%98:A>\LX]/5GKF]@K[47.-D$B
M.QKH"8K/GGR7;%#Y)4?BAZX>D]RR8=M%VLK90UBNY6ER$<SAC?<M%6O[(&$3
MA[;'Z<2?&@D@:[TM/H^J#5Y)W4N%DD3*/X];K4W))Q'NY 33[/OPH=0&7<"X
ME7X91MG'XY%![LPX9@YYA.%GK'[-NRECX#"HA8WNW*%\/9_[[=%,N@+*)Z6O
M3_L%J\:CLDW_,S-\A"FZ  O.&O=AU1[X\<7FV3/'2J';/@L7>TQ7&,6Y]1J9
MQ"1(=8TA(4*W]P<9XI@QA[#FA5'B?V*Y*BH2C-B27'.A!9W<\*!#^(+@.-5C
M9D%[V1**$R\PK1@YFIXF*_FS?'U#GVE)>,O!&= I=I"6=I)XP+90F!/^A%'K
MUQ[+CU&C*ZNNG)Z4BQ3'PCV,@1R/0W7$W4X3**?.9'R_V"_G.FCG<3H1OGI#
MS0%."/=^,N_XL[,G3Q)28OO;%WS8*$X3_8]9%HNQ+45$37]65FDDTHNU'8'1
M8DKNZVUV_B00+=6/.N.V)@TC7\_3@YB\<O4N)X4XYU( \7[<T__3S?=?45G
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MXZ?BC34"G>.=)C\JGFJ0L^M4%L_7"BK);1P+\U/330]8,B6KE[PL7,-, 3
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MVH>5.P?!96N9 IT!=CMF>M\4]5I-8R5>2AI(3@2+2Q*T$Z49@SL,10^J;AS
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M_+LRD[O%7--F,6!5: R6L;\0D[^0 -93)?M5IM!5^X)5-462[_@\RS^ 6$]
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M)-PBO@"^E^>AC3M>S65W<H!S,LJO"XS&I2:7N'13FP5S%HZ4JE2^ "1_P"\
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MNQSYN&A\D E[A(DZ)M"U\J\F<RYM/+)IL4J?T-&)VM/3:S8,DRV0Z_ @XSL
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M)J;MTK[7RB"E-2;)E6_O/-!F22V#_=SBAMF< W&!OQ!IHNHQ( Y<H/_!<T_
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M=AECCH6NHEVD=JL+P *>PI)"<,UW1N_([V59=>%0=^8XUY#/0.-S4Y& [O'
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MBK&_3,[J_QKJ5CHU)9,<T&W(?]ZGN.LSAL,?DIC'\$1&@D%(+Z"48H9Z+_C
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M_@FN_YO1/QP3=RDFJ)8GK2E]@W=@<EMO=J7M1$W7<O69B^%M_%@>EUT<"&C
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MRT4G[*FE0%6,P3W2_8/0Q:Z%M9$$U4ID]-F>0_:XV]<4 Q(F*!:W5:_WN8H
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MFST9?_U/VLG-R0$Z+/O8K>XL;WXX9#__\!W7)9S(0'[ZG2.9#S#K7IWN-=Y
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M1F #433WFW9TPO?'F\X=3C\:CZ64^#)=\81?3@PR\1MY%2<XH%H+3IR^1&E
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MT!+P2^?7T:^F3>NHC;\8XV\M_][N<.N/]56FO\S63,%N^%V[9A[/I>FBIF:
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MH]?"T>_D/0'DLI .;343.L=^UP.S+I(3"L;QTAYHR>3FN$WCDP,"H1=1P2\
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MWXGIO]_'6$.I\PEFL+_XM1"K#LVB0;FOJ#3@YSA(7T"[WB1(S# !*$'N#]I
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MO<N#&*\V3MA&'['H>LW%%/5+G/CLR\:$Q*TI-H&)=G::OX-"L<)9#HTHT(;
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ML3OB\O\6_RW0]-O[%2]C%Z_J@UK])AV[I#6!-=XU3G_7,+JNB1B<Y*]K#V\
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MH,8!:_LI93@ZY".9D=O&RF(-(7'47 "X%%F >^#"UQ>D-"-&+_U(EADPAEM
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M&.*[NL8M+8._E-KP[T.30/=".E/97-1\'W[?9%2>/CY*BN&QD2,-990J9?0
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M),DX^2HQXX&HTGQ)-X#;N(29::W<QPS-BL;XG$FUY@'MC I_/:4O")2T"#P
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M3B,W)AW&CWKZ<<OEV=\2Z.%@V:1<J?;A02 :R4>0JC(."#O76F1M]#>4UR@
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MD@6T?0Q]B)0)E&VQDH<P29K"0EF\\M =)I<K*PG"I=2T=I[\;"XS77DO><T
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M9KLA[-'!$J(=GP+8R[4/+8?:2G*QUOZ7/%O1^T!RJ;)1H,?E99_6"X6T?'L
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M"BV>O=")VP2K:'\AOZ8H5?&^:UK&%V19O?G672I>:BMEU&$?WX:ZLRT/:C6
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M"D7UD@>8-N/*WI&^32;VWJ5S[6 CF/*0%(E^N43@XP/Y'NO/;^+MO?)#7OF
M5=G;/,!GR,(:F+=/^MR7WVY;/U,6>^YPEFR[-I'S$91S-6_+=-QPN3='TX5N
MK(/V;?;4YDE*V=+E&-M=]'430Q57>W%7I6MA,>JCHB4I+VB'[I\L^Q/VRZX
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MU:V3Y2-I1M\<4MC@_G(['.DYA]"/Z*8*R?'0X/PV;UO!BJ3=.*O'YPNB9()
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M_V$%7I#RI9D9/GWR K1!;,-0@19_)7#VG5J8:MD83\!91U[9A7C<=$H+Y7B
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MG9R2Z^M3G'@C\NVXUMMVEZKWUI2;R$(R_3%.;E,X77RA)K+[S(,1'-MF07[
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MXX\ DU/J&\V%"!%2?,4[A(^SE?^FL0J?N=EE]_EK,=(TL:ZT%[@1R\4=Z<"
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M-UR?O=ASIC72!!5H*7+;"@I=SG>Z^;KD^OT=8A0]VD<-]'N#E<$R9!0!,)R
M8J-X *0$F29-!(D+0Q]0J$$4%P[3\^_3!1N\9-V((\ IQM(22G1+#%T>P&*Y
M#\@%+<@\H&52ZNN4%4 A:>=6$?[9J\B$_=8ST &GU(:UW&]I/\&@9_[5)->@
MAC,N!=?%J<:%I]'S@&31^Q^>GFK?W0]NI@7$;]RF>S/#?&:C-96[MG_5V[AT
M=-[L-%$ ->IRH(M@1>DA($TP.BE?JMH&\6,__GYIXDFAF)LU6,&K JR[(L#R
M6Y^1HG<!TK+]5_IE^Q[=IGOR^"E 'G#UOS9#G/^4#P_5Z-4I&BI3,)4HK>]
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M%L82EWO]#G7@?LM\DNI0-.4E]_F&OSE*A8"'4)T+%LGC\)=-X+%A&KTPSC'
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M\$ 22:#,^NL!<5)$"#<4%/E8EZC+/$ZDVJZOSD!6#LV!NX<:9*3?5@ G98X
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MHM]\/9+,6$8$1:;*!O4\*+OJ"IXK?WTX(M0Q*1RY9T>B5VI4TI[>:$O&GY]
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M@<.RT6K_E/0[?_Z)_NP7#'I^?QVN:B]^8_<K#8KV^/&TV&$L+O/YN:/GU/<
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M07R"\EQ<6%]8^O!3N5 N4I]AS-6F4\PL^V'>!P91RQ*1 =6Q_-E?7'D37*W
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M-I5?1WR0WS2WL?2EA^*Y,PRJ>@4M,#]CL1TM>V^W&JU.J\=1=_R'O#Q6'FH
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MF["Y341#!\L+F@+E73DKY55^<HR<T\['!CSEAIX8."D0<LL3ERL2<2[X;%B
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MM.?GQ-M2=J?"7N^JHS2_J=N[9P]<3].=,M-QY1^YJ3=ZK5+:9N!Q!XOG!"C
MNSULD3E)LGHNSIQ+)%ZK.;=P/L?E*K01/#A=PHX8+)^&< U+]OWB:7L#\_I\
M#'\%3S[<R @K(L8K&1??)_'#@]QLIPN+<W.ZOX09R=FP^JM.2.&$ !R(@E]D
M;7F<0T8I:PJ33K(U;H:!5IV:_*"M\)\T>$J5([BONNGP\=I,@HR^\M'>$/-A
M\]G289WWCB)M\G7"SEMOJ'H&O7E"3RDX6>7AD.; >=$57KA:?,!0<J?[HD%-
M\1O$W,ENL_M?=CH+CD)/N3U<0":"2M*RQ2=CL5\IFX'E/;-O27(M9TI>>3/C
MCU8L%,"OL2[&+=K^?_6#'1+_:"LEF9Q?%'SNA>&?CC<'7N>X&-@_[*PA-;V9
M'F)OMG/(?J2=&'U36S DVEKEF!KI/",1 E!W#,B\N9<6V>+:[A[N39+C-5S?
M>#BPGV[?%%%$"+>_$!>-1:'Y48R07V8V>P $8P1/51OY7/$/W<Z\+P@%/F 5
MN9%QPUTZXGPG5R+5:+$4&:""!7;LG1S]/.5LN4"P1.8W(:BH,RV(X&-<\4^=
M<M4_U>P>:BKE=G_EQKGZ6CRL1.F)0KOXH00B9E9Y5[R!SD,SZI=IYPZ#W[4O
M,^HV*-R*_7 VW B.9G'>!V*;P*J0WJV*#G?3W-UK; <[B^V3GM_;$-[V9'*?
MMTRUH^S<+R KSSF=_)B5?2;DSB-.$?S8PU&\JC<X-:(]YQ_[B.ZO*"4*;QZ1
M345&(GYL:33';04;<YA.@58MAI>E'2IXA1+/I.[4)EC]&A?]*?_!W?V"J ;;
MU,@F_+OL^N9+%9$4I)1:R,UND6ILG.G[/V0"N\J<%\K_,^3.2/SK0&6I 6$/
MJ*,D2= %R5.52L&'+V5W[ 'XBO3O]#W@#RK7'G?L#UKLZ\& W/A)XI^T&.)?
MM%@/8QV-?:)DOS93(]R&[8QD&%N+"ET3+JFL./>&WP;6H4&R&_N8738%J7<C
M2+OKP7'S^JO:4]\<%_!%\%W'%^7G_L6-_3_MG7DX%'R__\<2H4PD.Z,LE9WL
MRPR5+4DH0J4BC#5;66<L2;),")$,*4(,V;>Q$\J^9&?L^XQEC%DXW/=SKNLY
MUWF>^SG7_?M=YW[.=?7'RQ_SQ_QA/M_O][.^/PGO_FMN+,V6DEZ\0=!,6!>S
M(GP>W;6R$=AS.#0W\RI2ZG"G]VX:<R/&M6E4BFH)?5U54CY[2 '?A TA;2RB
M0RK(NK-H9G_+&AS?+EFP<G]O8](S81<*FJ2)S0?4M5KWE=VU:Y#(*SG2:WCD
M4_DB+T!DWA:2=/[#9U @-1I%\,*NW, R(^9T2@-N>($<J@03(.-66OSOB<@'
MS+U'_[5"+Q2C_<39?KF.<>,?DL)]-E")74JW+I^.VVMF=8V\G#]]:FE^[,MY
M)S:!>;#PI'1+)?.?K1[^82(#AM>9FQ9XCB264\A,,^-F=94;HWF\/UPO4J\/
MC,XEP3.8G\#3SZ&[4X^[Y/U-5_("KO)O\<J>*V:HP;Q:\ FQ,^I(SW%2=L=1
M6QV1XPNJPPO1+$:)-:G8158+BV1\NB%<ELJA;=*H/>JCS?>R:X>7FQ"2GI];
MEZIZM#&)J>/2_(A^:&6Q[6\;DXYZ)/)OS9SGNT#3<]1AJ-+W-%R>T[7;4[^<
M;3^W!+%PKS2>=*U\I+(V[!:Q#0J&X%I )'DGAP- 44+(TTP#D&EUX5,N!MGP
MUW[ 2KC)?;\O9"I<ZKN*U80NDTAW<)=":VLE&G+9GN:G' K!3]?_-'Q#LG@7
MTNCEXH;,<0&]?SIB]4J.SPFX6F/;L(; -C[Y,OEJX1SZXD"U:IZ]L=. 9VZ'
M8 J-FG@@A8$3$NKG6K\10B!!PLD&KDO"\6]"<*Q*^_J$9, N\5\X5O_6B"&J
M"!E3)!!K1]KXBG3C,W::JN!SINNA1&K5A:P;U6:6;#V&C/HGPH5<9/,CCS]<
M/KZBP>!&:V;:._H]"!//J)(:^?$!HATM<QAO!NY(4:_TCHQ=W7@H& =]ADBX
MM7II.' 9DGDRX-/->\,CR^Q=SG[.)[\#&[5DZ4V)(?5IP.!4<Z';9C%)-Q]J
M*C.JYQ9A[1JZ6 F]5V-'^D>@L^2A,H$<:TK,0%<?PEALV<\*0-!NG[UK27"\
MIA?T[:%#&!3_;0;[N03T$LS>0]:NI$O/U73TM0:&,_=?WS9U>>76R:S4^CGM
M!(+!'X3-"G7N+WGC^QX/]LOM!W:11+T/@]WD3?@(L,$7'/H9JI*0Z'@R8Y+!
MV/OAS<_-"M/!T51[!6YK]]>^>,\TJK"G#I41!V*;.$2S9:O:5G,8SF-1<?N"
MWNL+K6AA1[SVB_8SFWD"Y]]<7SA/R>C?IRD!/(,4>?:A(KWLV9!GMRD;2^6Z
MZ7!M!^+]ZMPINV 1;.L+X0'YXY&^+[)+R*6<,@V7"D"7W?6(T9@:T_]5 ^ 1
M@LHY\W[.CY1N;Q1 N/WCSH<<!XM/+Q"V+CMBWYPE0D23;)_D,"C1G)\(O%1M
MCAD7JT_F3<[/O7BG?I07VM%.B==!;:*07I 1L68.CN;M43YP;S\HX2++IT>0
M$2=$-Z-K*\_*8?3F;U2*W4F#PCIC-%T94[GU-![!^=HO[?]PA3?*U^)%-@BZ
M]/C\[VN;$(\J4D7G*KP$T1"HLO'B , MKF;])-DT]X0O+'],^TRMUY, #K7#
MSVT6?J;&+R9OX%'X,QMX4 PE>PY4Y', \( ['0!2[/+\M;[8$Y$OY+,]*=H,
M$E)Y/]U2 KATEU6#Q1:1SR$<B4T7@6%D3>E[YMJC?@E*'!I/(6L'  CJ)C 5
MM;HSKM-\>GA2\QFX0KY>[]'KTV+7#*_#D>WH5((9-G^TGEW_LP,3+W&U;:M\
MSKG_ $#M1RR#A437]'3+Q:%.>O[4I'P^MZDU.(FTRX1?WVGE$],.9+2/8M=^
M?2[L 8TT[VL5F_WS6UG_H,"BPX8=HY-NCSWV*-(HJ)'YN-*Z^J&WH>"O7X/]
MR+*H<DWOY,XLV'K"FEJI3? XO/J)S]J.FO]2AG><!79GJ:I77O6=7EL'Y]CT
M8>#"QX.C"P2O?$![8\O6N#S8.^!LT ]>BRZK=6;$K_S *9W>FJS&U$O8W0B!
M+;E[QDP)-!+,3]N1MY0$5R)OTB<>C9S+&QV-G+M&X'X;<D?M>((F=T#-.RM;
M0;2LQ^OY-%&UN4U@:7\0]^??:HK-A-]&TX>(E< -(@)#W $4D<!MT];32QE]
M+\;A>;OO$3*)D(N&1+L^W,I(33(:^,_>\GPP#UFW (>/([,3BQG! XY(<L#O
M52X-U5=_VOSS!3'S9> @;)]I98E[(FO.:$8TX\:#CX@KQ2E^W?3OR-<(*QZN
M< 7$-)>@$<M%A0^WP/-\5Q_@@B@S*?@=\/5:EFK[1(@]_\6!L@4EQ>MF^WOG
M79?,8&<(IETM_&K%?5ZLL):76^VO?LH> SU3_ZK;5>JX:,7K+X;-_S3-TU34
M*UZ\4F7/K>\789\@RZ4I( /RYGVPH.XQ&"B]#R1;5N"<.^Q5\(TYXH^GRK48
M)0&DNJ"Z!\HSP9?J6L$U:J?&+=M<W5CU3^08S7BU?TT]+K!S!H=L6"'=$\,H
MQ'RVNM<*=73IU1/O5:!&)8SYQ?71Y#LNOD6K>#-:=@F2;G@:/Q'Q,Z>&BR.:
M;M(C_"T(^HK/74#F/1D^GA<MY^_GV;<6[AA>(? W[6D%+)T8@55\"C\;.T%L
M6)95O,BJ(\I_?%NPQ+\9YS@M/L%2'F"G'377_<DUR;<D@[]U0!TXY<=*M0T/
MK=;)).1JE [(506),Z??X>=6I(E_^!.Q7WO%4AYG%DCVR28 +3E*KS\NB6,Z
MRH$>^2&M9=TQ5C9+%L]]2^.@G[78>G0\6-L+.T/Y-+D::;J[CV5IQ3"JO#"I
M/R%[4N7?(*K]L^33S["7Y-M#@/DHSW."<=_O+*0$$!ZY,$FEMQFE#O]X-F!R
MN\^Y)$IDPZ#: +][LU@6:,LY,Q$(/F$KWOPV5J_M?(TKP;5E7Q#[)GW;V=C/
M>RLA\'V/X@ 0A+#(R%M2A/'@3JXG>L17?$UIN>.6PL_IQQ(,+MD@&C9N'">;
M86^G5M$*7AMXKU:5[?1&=&^ET06QOK5;7M_(;$\-9(+U)'BLEN&T4P:[NL>'
M@W&4:Z"WL&/H^%5?Q9=R"!;SB#Q!H[*:L(K0>K'5QARD]:L]D^8# !WY]K1<
MPJ)E_J<L;2:>=QIZ6GSC*B@^0P'?(6#6LMF( >;>TE#<R-WSXPD,C-)D+4#
M0(X$"6JF_ZF8 ?;HH4M?L#4PFLDZQ18MCGL6YF_P886#U3NV<TG2]G75V#=%
MH>\W])B5Y!=3V2GI)3\4']>^=+8>D&BE\\:QU<% 8K K*_>'IY'A_*=QL>(*
MW)&7IUM.ON]FZ=@>\78E,,A1X6JBD7[9X\)YH1]WS8 -S;2/?^Y3HP,)5ECU
M;=);KR[VJR^\O_D%0,X&\_\XNVCX87MG&^7V8H3IL1BM3!/PYDL.2+S^/RZ!
M_Z]RRXSCE(5E3?/WGL83UAYM@L=N\W],/0;0M[H$Z];'( FZZ<Y7%S0. (G
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M!E-&%12/7QXU[9/PXE&F31B2$2]46O\B>X&F#F)?R^C#'8IXY3RS)PDHJ12
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M-*<5]F0+T<@9?&% J3H*RC+>1]$HY8,QMWB@]T3(E;UM_H)/VWS&]U62=0)
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MF$WEW_WN*=,3_C3\GK42QOIZU]Y_6\_X@H=<F?QP/O3Y%WHM-=%)9JM65P*
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M129W 1U R1)8!)M29GK$Y.TVVYQD[QYZP=:D-DF[[<:2"[DGG^[331&R3P3
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M7;QE*P**35N148+K8H00>\<\F L;7J]PG>1T'>Q<P:MB1&F;3=UL6;8GRC1
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MMV9<-46P!(H@UK'CQU*VU>\U\50I,3U#05\"I&!KI<+Z3[4&URO[[EYE?2'
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M <?([NB[X'FQKPN6K63?HXOL]U/J8P:N^7!Z9KFZ< H//#BZ#DJ!M[_%UA
M=3C>N R*38/.WO+_%8=;"(#H* 2G'\#TO[H0+!<MT;'U/ T2M;Y+Y]6)@ UE
M@Q?;CG-D&BIRP4EA8 $>V ]8Y$"SP,IA?XQSXSG!F,GD//N6LP$-#\8T/5\$
MT,]NJ'"7_O7<G(_<!DU^TU+'A[)!O8!(C("_IPF%V\$[Y)VBM+)46,F*J9GC
M>J!MU; ^<]2ZYN7]3%IG .:"?=I:KX2[4*)?H<4+4K#4' %A6+Z:?GK<+(UE
M*+OF.'<$#]\4^')')]*J0P!>G,CE=Q1LV16^P3V;FF5=L^*;5_+](%E6YWH
MIVLB ?"/!/9T?_;'U7]K1J!7]95RC=S>7HOO@;@6M;TZI@1P&O=7B9E<;!3+
M^QA.S>:ZVN7\Y1)M)?R-SN/+AY&+./%9"2:<&<:"1QCS*$&<YRR'K%CY@^NN
M_#&&Z*5BKUWA3%"%O^30PI RQZ-+0Z05 2^U6W<Y>Q_#Y[Z-? 58U-X")$$@
M![-_GF> ?G&./:3P(2\@I;-A-#'19N<H^/E3,?/%LB6OR]1BT=AT%%\N%K;N
M<OE('V]#SA-/ !APKB!4@&C.&:$$H1M&IHH%W6D'&$B$TX5O$37J"RK@!]S@
MN5X<S'PV_#F\'*=]?M'?;!HEG1%,M%OX6ASL>=X-XZ?GVD"\D3MOF.+.M></
MU\45ORWS:S/#8LZ$E6[^>._Z].,;>+4"GA^$*0MK[$[SM//U,E758+[!]OO7
MB9_PCV :8A\OWK-A'.@$?-+^?";P*C5H6=]OTOM,5X-Y"SGNVB NP)8A84KS
M5KH6F6],GLY&W94 .L!O@R5I=IIA)?#<X.SPSNNDC"G5#Z#%F(9B^DY?DU*
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MB:Y70)D]Q![B,0RI0RCIT<=@HR%E#A<EC[2+F(Z$]3683?F^_NZM$4_X(UC
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M_X.\]XQJ<NO:A6]$11!!!*03E2H(BA25DH!NNH 4"1T55) FO1.*B(02BH"
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MM1M>V_5Z;704?40-)3>5>].._IYIJ'O$HN*-\!B 632+"JPF@P19COL--:+
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MXMWPS)<DGT!%T"CX Q*%N>B,9$QB[SE)XSXU:+2Q?7#7KJYXB7F7<:^#_[G
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MV[E?6MV3?99^WMEV]"X>REG^=$,6]*SOD=YT??:HX8S!=^ZR\N#GP:U80>J
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M']55[9.3]+J%5$N2;J9"$ &%#E.-00<YZOQ*I73'T.?O68%Y'SI8FT O9"T
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M0&/L0B>-?I=EI72>%-;/]_J(CT0!W!_)!A,.>UHYKX"O8<6;VR5LTDZZRHG
M$U>\NL:\X:.L'B$7A<<O.^BG=X4,.!SE2P93T2]D2>K4N9(.QP[O0W'@%.=
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M0V#@@#0=1QNBT5V"^[?SP7H3%2&FLGA)+.W^P5LS95/GJ>2K<7Q1D, ZNJ,
M4PCT 9J600UMK*6:H<VM]=MW[,NW=]N1]86X%Y5KVDOAB1\'LSJXLG%E<Z#2
M5_867\!/BP\76Q]<9:?]!AH<2=0INW-I:DK542HN%BJ\[A&EKIR=B^94RGCX
MHW/34Z/![N))F7*<0M*.3%;/90TA%D@O<A":#NVL91O.Q!!JK+);H[B\E-)Q
M$9C&[1.K%2OWN<I2^!P%[<_RE$[/N:Z,T%QC_UJYZJR9-&_;]%Y3_HGU7UU
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MNI7VGW\ :S'==DR@/1Z>&:[U3Z%-K$,+XY9(R*2#9. 9?Z8Q&O/Y5BMB#8A
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M[87BI^B>N(<F(_UZ9A4S/3@8.[3JI*W[^JB,P@](IZRBR_\O=LE3C0?NLKY
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MC7<LYQN+^OM\4JY/C;<:38.9IJF'S,J2H8GR\5CITTL=/=BL5,XD(G#MKH!
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M:)_\R^OWI+[.,S*:DU"'4L-?'4^14EU3.K"1O+AI_I9AM1/6_0KJ'"X1.2K
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M[,SX!<Q^2<S,;JZ@&5C$87<AV17E-""[$84X8F'^\-.Q![UTW95K.3 #C&0
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MR"CL[IW\//_$\RVNHO5IP3Q 'J44%<),7Z 98K6VRQ,+WF9$D !%]6L<)(#
MXPLB >]RR35(32CDH!/V6QR$&%A!OGB4;+I87>P1!HI5<+Y\1>H2#!,.,U\L
ME"1J#GNCOAASEXG-FLFH-CK"N$SU)UNF"K #03F7+X0SG^_-3E+EOI\%OZ"M
MRN,'S$L$*0(^523@^,1S$K!@VTF>"&:@GV;O#R_W5B CHLS0*-I%]XBA08_G
M:F6E43+GGFU+<WP^+G7GB2,%)."Q?A,).$P"9G*MH-L3)."F*O3^OUS,'W9&
M,1:4Q]%+J:1HKS:E9+!<K+3!7BX2"I; 9RO="HC(8T5.*=0BVK9R=7!?T>#/
MW^D6,/(\Y;MI-;,/J?8B]EBQABMUU]O>)!;,N[>28Z4K^]1/NR#:)M>H/2#U
M26Q%%7:\/N^4XQR/U)>K7"4!3+Z@:5,)TS;,LQ,*:2:C"LXBQ9=.H\>"AX^U
MZ',T*G!A) +/+S+=Z@]+_-31HXCIB)B:%NG.IJUZBQ#;R<'G)?J@?6[;:BDZ
M7AG_M*PJ^)OF$;G"N'=62YD&IF8S'J%0>"1LVV9S[]N BY7$V&5UOHY10O.D
M>>K)P()4>=5,L9?"=;)*G#K353=JK#Y>#0C=LR#TNPL4WDNPWI2?'MS*ZEOF
M\='"1+Y\:;U*9C)909%1L*"\R%W$J#I@-N992OA,IWB"F[()IK_K Y8F3L97
MY9RTPW4/RG74K.G7>^.LG><PQ-C"YANW2(!X-\RSJEKOFR?C(E_' CZQB 8S
MZ'K<H8SLG_)D:O_555DEFB&&Y*0S6!YL4VKZA@KI*16JS+EE,AC#O%Y/42VW
M]#$E)W&4^T.I#<VN$)&AB3P]%BA(0-0K&-8%5ON:G-'N Y#U)R#BY<K\E JA
M%?A^W#31_*FX-]DS4YN1#7(3( $MS1!<*63JE@<)(/J!=Z6IR,,.-=12WF[P
M;2-3$-ZV^L>T$7\B_6"Y:QU*X$. 24 G);GZ.$L.] OD0"]"K@CW -C,#)A@
MXF.M"!YAQ LU$>J&4F>J<'<Y(20@F8JHH4".%%T_\K77#8<4"FQ#$;M!7Y5;
M8)@/LC 2< U$2"1/R9>IOV3+=2N- ?98?[D*O %ZA(@D ;^4R5BN_O3P:)N#
MZ$KL1=ZE5XX*-3/Z8S'8^?IOI^U.-.T5E&?<?-+>4^M4QY48ZC4MM??<!$?C
MC:5W>EMY4^W*X$Q&"GQ+Y4^IM4M50))8O\N@! =$F7Y8HVSZE<EU2= [1^5I
M8U>? $QMASHX<)A==-ZIZ+3S0OWG?5I',ZQV78W:F3(?M5![5!+LEXPI_Z"Q
MI24U@5;B8.Z0+V3.^O>LT?\+X[S_Q3?G-S"Y%/Z%F2!^R=A ?[36?A[T"P'6
M+A<OBYIL"I"H.KY@&%!89+%M\*%D@\Z[USNG4RR&ISCW5@I\8TG7]=&\X)"J
MP3W>%'CS@[^U7A4:(F394RZ1:3HB;#!9Y,GUD**&,IS6@XD@.$%.43JO@PE'
M$02!!5J89IPNAO@NO;KYR^@U[+LGUY\I25?+ZH? :L.QD@028 W9V=8D2AH7
M!V@5-#L]C-&_L+SZ"%8[AD7L'SY'3F&MR,(A<$:5Y*PN^04$1PO&Z2$)O&OT
M,-1V% F F9. :9<?:6WGSCU91WNWHW[QW,'/V>Z-D,U30>0$()4\6CWDX>5
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MZ@DGOP!<P)D$VZ*4+%$G]^O1.C%O9K]A'O;FC63?HKI_GXH$/'I/ @*$'$B
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MK%3#-H21:$FIZ#Y!O@=9N$"UCY?@AIVXR+-3^LE&3N\T+., \5EK'F+95X"
MDDNIH*@\,V:_*R&EAF]4WB*/?FUV.3ER1(-WEKNVXDT:]F-"B9H-L#?5728[
M!/X1U-YQ!7),^28G?V;TS/Y<YBFH;G 486'OV^5I8FLCC ==U;ZQ*-!ICC-R
M9-OQ>G^K,IL.W-L#F=(;AW6J@?#;5F3,J;_2-!XOFCXF?OOIG>[W^9'Z7THB
MQ][K 2)* A%;#:Y0VDDP'9L.G?07/"@FK,YW'T]\W8CRS2<KQ=% 0V0?0:9
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MY@G.CH6N9G]E).R ['MA5E-5R(V32AYAC"L1OAU>;UX=+U>PRAQ]3T/F6&<
M\C6L-7>/)^3\J^GWA0%D+B'YCB/.!SS1IE040H;:M*0WO&_8E&,+QQ+VX.L(
MYH7_P]Y[1S7UK>O""U&C D9 D!X5! 0!Z5(#*DW4"*(H'0$1$ $1"34@O49
M0$$)"@B($.D]$>E2I1- 2N@UH80 *5_\G>_><_:Y8Y_OC#ON'N?<\>T_WC]@
MK:PYUYQO>9YWSODN.;):\QE?P:9V#ZEO5QUB3Q56,Y_$;OS/=T_2>6%UB)#<
MBE1<>I%NGE=H'S]1I/PS^Q6S!!ZYB[VQW8YPE"2>?$3D*C6D#E4X0#+PE#S:
MKT8$=%X@EL@G.?:1^K[\Z%5'(E>)LDU*YW?:A3!9J*/&G3;F%9*M6G)8%*54
MCQ3/OT<'+L\Z1AM9+4!7\:HM;-@H.Q_9ML3.O)X!E;SSC*DZ#TN?X=<1K/C>
M1=5AD6U$*/]YO*HD+F)UX8O/6U5J1N?.IOF5?<?]OO8#E64;I&03=ZQL]R*O
M#Z4+@N-Q6Z T)F1<U/'SH+Y'4V*1[&,^50>?1RL65FKW[]HP>LC=@U._Y@+)
M37W6@^J,9HS99,]>A+#Z[6@2FNRH<;>SE?3_MK#3XDM3%*/()^^^!5%$7HZI
MH4J5]*9K]W_]3UU1,"WO8G0A1O0L0[<^J]:QYFX>I@.J_EB&CL;RU.D][1G7
M*!6G[$+F_O7%(P<+U6[7#I8?NW3)QF?=T3VA)2OQEI]&[NK<2WLZ<)-X6OP=
M'4A1:HZ"1/&@[Q(0C?7,#48I_84XPTI+M+<*FS!8>U3O&ZG;A6\TAT=OW-ON
M3H!!W9%I?0K_M)KE)2X7Y$[JR7J^:\,$0= WKGXC'?_Q^06QB\^Z*AC1+OL_
M(G&L2,[%.V1D8V6:?28S@T4B"55SL(7]QQCCVO*TG^LN#WNS>ZOUC%4."_ =
M<%1UZ4UCDK[ 4PY,JX"86COV&)L]>W5>$$:6/%]=\,OKTM""J-C)Y=%6S_EH
MR<486"CN5G'OZ(1]@'JI!0>*N D35B>&[Q.;K],!T'9*7]$:]Z.26W Q@PJ'
MK%C(3B"%LZ?0,^"^(V3@BY"*SS3_@<RQA_!H':AC=7+2,Q4CB@C5??+U3E$@
MIFQ0'>J8#W_LROJI]6GOGCXP?5G36#/TQ%PA[?0BH>>3_H&]I:;HPU]),2GJ
MKWSPB;# QG*+;T6TI6R"<<V<YHNBD*8,#BRA"Y.N.#5#8A+'\_/70#P2]H:+
M'U*$^ER?K2[(EV7HX+L;DJCVB.\12\$[[459S32N"N*S*"I*?N]2B62KN,6;
M5BN-%@3LAM&/CN1)#[TCTJ8!^Q")OB\I-E_D#+X?PL0D36N&[R>O?;_W0*SL
ME!YP^[R_72=H. BA>HG&M72_DH]UK%'S[?'4.3J #.^>@JG;1FF0O^?L/$S:
MD8B(@F?]\/[-E=(E<U2GDT7\[(M'F@[[(53)0YA<(C)42MTZ5]O%G7;WFEQ;
MR9%V%HHA&3EPHADU?3].:AVM>N0ZII)=A^?F,?Y\VY[GITGK:H,P%FDW[T<+
MKU*5:XNWDE_PB86B=R8X[PU*I>[>9P\7AJR C4&]]FDD<T@HGU1AHWJ\@V[Q
M@<K]VXD)(>+M4]O?]X?O3ENSF<.M&WN7C-BEY1Q>%ZFW:!A <OLB;1T0\(M3
M.0B$W1R?I,M,=W3&<>*;^Z22=U+KKKAI.V%^9C5 /L.CS//!)/B<D @Q(_63
M)>?<.&\R2H.2*X%@#B&;!-RW#[B1*5%:I7.X5 !02_M-A(7)^$MZNK"-].#.
M/KQV,BAA2V;JN>38*HU[Z7YJ&E>;N_G-:_-LV)5)%58?/*O!QLC+0B0/7+._
MF:0TM N>4^ \SJTE]Y(.<!S8(\[=_U8RYSU>_BI5$D,%I[ADIO]0)I#EP!QR
MJ-(.%>0S%9913&@X)&@';8<(Y3/HV^'7GQ??5994D%MK#P,1O!9>3>;FO#0-
MA!37$/H7=2]7N()>9X)K@"GD1X!V6N_$SOPQFQRT[.8]KFV=RA^6HF=Z1\?U
M7Q "?[UAS&S2^]BM%AZ4U94\\RG2ZQ?Y:X>;#"\L?G <4;[$0!^F>]X[E"^:
M!?+0?!/-@,(K92Q[=1I*50F<#JP_N)\=1/;,]:,\K':@/PKYS"?,7IR(\GMV
M/OKRVU-0X\:,6>:QJ@WS"BOV;V4$&T(_0%H['C?I=JDUD;S3H\A0RGR/AAL;
M;_?N5U"DIM.Q7,XM/_J94L02WF[S"#@N,R@D:<PM%'?S^,=U]XW<:I^Q#D9G
MWV\R;3-AZCS,,S@)EJFA<P/V%:YKWK(>K>.PZ=MU>+&T<V')PTH-K*>K4Y5:
M.[:N7:C;O":1G,!3<)'G;'0\)F% DV?)++ZZP-DX@88ZVHQT9-?W;=.XK05%
M%5YS(^3JA;MRZ(V=[<=+JKZ9F4.>S8#/)DU^6S-<+JV&&N=[+MSXU5L6M3/Q
MK/]F):2NZK4THD8-]=U^N H5@M/NL^KIUG2J/]!"V8R?[]G'=F +W9Y@CO2_
M@)V>='G9H%VEE=!TYI#,!OO.V8"+K2R2!?%7+DYX/GW!YQKZ5SKJ::WM*UD^
ML(W$X&G3C\7+.3;_#0Y%_6\=I'I'W @]2ZP,+2J+NI$]ZY/2]XVA1N('N4L#
MD$<N>%<7G0%UC0+89^>4'C=O%MN$".NK8'<_=FOO(;$H]7.9Y(I!UYUZ5<D<
M6-6"Q!)MA95]NUN<&1\GW))QH?<IKO_&T(:KU-ND.;V+)XXO:ZT&)B,]/#4F
MFE+/R!LH;"HM).I>Z@PP4$^ROFD1V*W)E6C<Z^Q;)N$S8A\7M.__CK)EGB%$
M/C=5?VA:VFPHX,8+M61T]LDOB''@(D4[\R3S%+0QBC:2(3-8V.EQ'K5*'G\^
M2W!H_7Q%J+K'!M9;%G0$   !X.*3_Z-CA@Z"_8::'>QCF*!PZA/F2>QCZ_H9
M9$XN;0B=*;E !T93-^!92TYTH+Q@\<0_]$@Y.:9U<M-(W9 .V!JBJ'R#*ZA2
MY?T>3JH4@E3H T%B9S_!4VD_4J'[B@7#T,=N.QEB^V9T8,T,V#_ZCRS.@+E&
MGJ8#%]P>T(&78"I'\LZ<?P2QD7;C=S%M%;)_09S9D?2"#B3&>=,!FW;$MKW7
MCJ!_]8$JHEVWE@Y\L\?NRZGNQ_]#"\QJVE.SH;/P?N@J'W9?Z<8<A@W1;M:+
MF$RE ]?KO:!E$10DGR,UQ)0.Z+9;5#:@]R3-_G4WPG]U(8'_VT1RBG,7.82A
MH<]"2Y&AQ^G ZY1J.H!@J C>A*DGL!/KUPPQA%$+K;5,(5/6X?O0QBT$-<DS
M0'G,'RN_=CLN+KTX[@MV4K.^X-L_MJ!(9%T 0VTYF["DTXP._BJTJCZ01WPE
M0ON&Z8#SL&4!A9E045YH[9RJO/\3YN.^RW')\_II^>)'1^W$>#4_UT /491_
MT2#I6SD6D[=(DS*=!R:1(Z.U/+@"*GX%%Z3V#ZV8O ?&1U"2Z^VH(]#M&Z;#
MR0N:$F2IZ9XSY.@%\P$9KP=%SPZ!#'WL3/A-Q+^+P[34>D$,*HC:-"JB ZN\
M,K38>$Q6$4L#XK@"Y-"*L7.-P^\<A4VM7J[J1"7+['RQ$]&>F_$[OWO_D<?0
M0)VH_\#NT)_J7 FY5XGS!4>SOE@N7^YB/73$_"&[2=ZC4;6$Z@Z^'D)/@PP;
MW+3I?MI$'*GP0E?^HQCUXC<JQKEG=<%7_7I!.?\-2B/\4_XI_Y1_RC_EG_)/
M^>\J]Q0-)U<G1$D''5N:7<Q=I2^578T],B8D?]"!Z<_892,Z\)/!$YPSP8A/
M& 0="$^C _EZ=$#"FOKEJQFMCX26EJ;(*#!N\Y7\=8X2+;.5"89_JD(=H]PC
MH&,_FYOSMU1BGJ6D.G/HT@'O1'XLD+1F60Z<O@^+VL&2=2FR>2M0QP.]D6FY
M/3626^O3*?QF$<OT0HLU&>:OOZ]' H^\'"NCN8VICZ])R,;%4->KU[2$<O\7
M0.6IJ4'TIIP3XDXU/P"/^5>SJZ.4.[KQL>LX1+*MOSPYBPZP< ?HRJPB5NE
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M#F^"OML[\O:8D0^FD93D6V :A@%BT"72S\Z5EJ?,SYM$'[O3+A+O_B73/C$
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M9SAP<JVG]2W']P$5T;J[4[!P+ZIPZ^;XLJ]0C@/3MX3#E4J)NK4QHD<?,&6
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M9>N)%4[]5_PBUQ16C\^]%U?3$CS]@M0B64[-V&9SU*D?'KO7)[/*_6"*/;W
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MH'0K("$="@C6?\&X^HU[?[][[_-__O_G8=Q]WW/FS,QG9LZ<\YX7Z^OXUUD
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M0G'H(SLAR,5C(0MT/_ZX82,\$EN.=1)Q^;$2\\M?(\;@^$?$\@=XZ&PNHWW
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M^<TO^]X_'?P?TLG<GA QB.1DSDB=.G[R_DH.]X@)@!6!+GJQ7WA<D8 SWIH
MC+"<GSQ,%?3EPQ7 &:?]7^*Q0=<+;I"B(E;F[H&7%VP)J2^X=)S0GS']*X'_
M ?V2/\P%M#FL'^DAP_ZVPF71AS5FW.-U;,",)X).OS;FX!^*^-]6_!L_.MCU
M;0W8]9? VCCH*D/O[S#T="]!XH_?"W"1\W\SB?^FVA\([UM=HY,K?G460V%W
M%N/LSA6 ]'0K0$:@' #JGD4/4?Z8-^S6. L<]!W'_0OB6]V?T%]8Y]Q&7SC
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MW"OP*"WO1#T=H&81U(F-RQ@<GA/"IT)C(2MW6,&Z^A[PJC=L(!%Y!<_JKY.
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M-#3',]R!4D',1,34="G#6$/;[1Z4*S_W#4V/.FNRJ6EF45RILAX^5__H8*F
M,YO8U6QKJD6*[$GUZIB9K (">-[$M=Z.,6>][A7QC_[V4@SG1.C9CTC''_B#
MXJ]W]ZRAZDFY_$F]Y771-T)FK &*935!BY2=C=@LLQT-W0G.]44:XYA[TSH:
M*H+.[,EO7\)"7>+(HL.V0^W$;09K!>+?]NO5O:#I;=/@4GU:N=0%^W%X^^4<
M=]S$F[MZ6'/YX[FO@%4QU+7,(]?E)ZM;1R&,>UO7R'NOX0IWQN+9ZHH9N@CN
M3AE>_XSX&"LQR-9AW)<5XE.%A-J3*'RJDGA@.#]L^3JWT-Q*N\)T8#7K=4RS
MB'Q'WMCDS4=NZCXJ/J %MU>F[D69+^12X8]U=$KAS0E<O4F];\10>SCB62X#
M,T^%+HAW,(J_\9F'")M<);%6Y?;J6#1P[E5KC=.78S2-"N7)JRK5?5<_Q7WX
MB%\RYO. \\/V0Y:;V3=MTD8')K<<=NY37Q^JK4JPGZ!G-7]6?172D #N5C'6
M$U1*[<B_)U''FY+PRG%"G16#?:9'OGN>OJ)&BOZN9PGX#+TRLB'GNK>Q>0]P
M8#E]K=[PT-A/@W<_=L1OT+W6_/&!A%/:IGKB>0GU1E=JQR-ILS(1S?>NCV![
MSCD$JT7F@S#7/'[F G@>L]Z;_/ZDJ<)\[K6B;'JATI4*][@Z@N8TO7,SV7PI
M.>.UJ[S&EY7<"PLN;:2X/*\L4[()^0HH@MC"POQ4%E0O[V9$5:;OBO-.:,-T
M9:X(WIMTW*YB6<320[6VW[=-WX&5=L7M%EC;^^KIZ_#LB4E,E2:_L=&C&9/E
M7A;KS^\G['L5(%M9[$+XK*N_%\GXR#9#7UB"TK%K&$1K8]M+KUY*L0$=,:RK
M8T<>,FAN<)QA,7D86,^(,M YU-;/'1/U +7ZAKT.H;HA^25$Y9UI[2B?$&7R
M)1W#WBDP)1Z/K$*+##6?M?X&0!IF"1P6L6CO]T:@^L^_*3 JN+EXZ?PKQB:Z
MAV/6:<C-SOZX\EQ]WE@ANHT<,_ZX;A%07\7K1#7K1VU>BAKO:5_'%%J8Q)_A
MF1(/"J]D +<1^QB%V3#->49-0&Z6J]J[1HM2/NO#>-&8QRHFU>/[$(QZW;3U
M.5'_;O7XA2ZR&YJC!:YAM/J!8WSDL.1@CP<V+Y;SQ6RXQ/  $]8/PQ\YJTNY
M(ZFQMP/K2^:7'9HE>+VTAG=L1S7,<^+BXDTWP_4W-1+D&$D+:YHOTAI1'$(K
MRKL:H#NNE-8V8^;ZN('%G;*M0S"FO,#SDJ9JCM,EG9- I(;:;LZ*B*J/R42;
M<EX#Y1YO_^M.5Y878+JU(L^[8#]&RPU>U0M^6I,A1F^RG$0^^,9,T3_4?9X8
M<LFP0U_/1XX&[XGN&LT-N<GGJ?K:HP+2D)W*6!8#$JTV[Z14>)EBX/AA8YK:
M._L2.:AJEW(;20GK=!-G25JGIV9X5.'-[$7KCM?2%X:J]GBEQ;2]\F?N9.G8
MTCWN$W$"'@3#HF?RN=0W0VL6Z79MW2_('8+8]\,S,OUDUQL#%<V;$YX8V+RJ
M2YN43D"6Y0F$]\$\^U4#C!0U7O .'!(5DF$K]WH2,KF\@B8>4KB_/C<2UAT2
M* UZ-I26;,IREM.Z;6U.)XQ(4.^U7&= &3.O$1Z/MK.)\ Y<TN&=L&1(Y?2N
MA]/<>IBL>&JMA%!1=QI/X]CY\'#=&7JGS![H8YVR*G4//1.>5UH2ZN\L82(!
MT_8<%S:F<T8>O*T![P5%Q#D^5\=(ZTV!,HYR!2-75#$W,J%K<?=TA&K6ULYW
MW"QZ44G2BKT6&$*X*UH65M:%*N.Z?N3'0UP["5\97?6M&9DJ,(K@XEPP >EY
MC\=HPMH?2ZPY;^%$V"R'M9G2ZM$*HM*JDFVE;1QUPB'.="XQ$5'FY\24G4-T
M<^#KO=HWH+IQVO8HB=?3Q(/3_B.?QGT<,K>Y)YZ6\IEY4MYE@6HRK!_QMMQ?
M_0H@L6HL-.:)F\PNN$MDM@HQEM;3%C L(]0-+RS8]XV0N'1/U#7T^C (FE"2
M12PD@ZHL8D.PF[)XTL5R=Z68CX_-]U,ITC:N%8YK:"YY+ ;I56L8=Q)!YU9:
M'HIS)#\LOF:ZIOF\+87%%K,QOUL$ 59)&^/LT0Z,O!>] $L]T[711G3961S2
MML WG5<S25U/I+<96Y/HPM! $Z9&R1O%!S?3S+K1!GX0$QO#V=/337H1OMC*
MFA@QG:T=?MO9-BYS&SH.6W^W6R^GU/A9@\>IV]HL0-)!^*WA@>><E;6*I^P#
M-H*>*9>D#8[&C6$@]XMYZ4M%7(AZ3\?S<;.JI=R/Q\(2;SFMF4">]VZYP5I,
M^DD**17V[?.JKO$8QW#YB/OH7Q>4E(@:=7VP71QLS?]6KME&>0# 1- 4W4X[
M6^J"/N#<:6^U($J<JXFO%LZ=#+N]S'&VR?2Q86'+K59$0^V^IJ;Z"\\ZOB\,
MK[*4EC:$/O+OC :5'O&]&'O_)$E(BM;@B8%CS5.]*FT/1]NFY^_: D;BYB_0
M7545\N1^D[67($^;GVNCT.  5 #>4(X2#$XOYSX389'U^L['*[BKM)OU=<F?
MEL=2:AV,<VT*'=^;2Y:F5.28STA0AZ_!=X]2DX.#BBKF/YA\*;,G5.9!4@)[
M5..]ESI@RUR[[S>H;%ST#UJ&DA&OUN^]TIVBIGE@1JDVW<C]IN?S(Y>J%^6#
MYZ\7J=;;GZNP'0Y3$ NB1H2(J]0*D!0_X!N,KA3Q[@&N7JFTS\VSM_G4?Y;C
M5N-.N3N5ON]@:7=OY;(V:K"ZL)*%!R2F<C Q$#7%$1;FZ5@7FR?.P@EY8?)R
MR<0<'+G5WXWDPVE,X^,E+02K?%;4]C3A%GXK^SC'3_!>DU.2S8S6/19XEG1?
MA^/'[JT+/,62!3&ZA.A*S:VG5F_:0<@.B&5@OC.O';U4I8G(?SN^]@XWCH/[
MJ8+X.X\2N@85'-^&02T]^>Z4'&+E +ZI(.^G4P6\$,.D%O^=PLJ&@A653Y*O
M!H/S'/:*>NP75"A%C&&F*\IT3JLC/I_X8\Y)S6F,%<V;Q)WA67R1"_*5MW36
MC%FJ8YP<8ZO-82,0?>J4/7/MSB><-W9<M?R7^5("<S\6UX8L+BT7CN2/CKDP
M:JYRUR,""GAL&-Q!9 ZI/6J=RCC%9S#+Z*N=DFUSU86*"1TX7X5CS$E<-TNS
MU8B*S7K4QY$8$A$2%W/>5$T"/$47O%$YG8BJSG%^IUVIK5GF7%O!X47OL#=Y
MN+,CX&WN2"M"Z%KYF3'(IC*+ZC$+%(<PRU6PD'[7,]F6/MNYKZCH4Z3DG3%/
MB<5HX>%2LVG1,HU&,IG!?6/;XKA)]=6'<=E5@91N29&1+J.V?9/!L2;,;IBT
M A>Q4R=37C6W*'.DUHF07[V_O3=AP-=F'&L=$V6VZ1'>+[*T+Z 3#8--(=4+
MI!;A!L\:@WIBW8H"@HAF5^DV8_0*C"#L$-NXA_F0_!%^/:MYHS@^5'UVD6,2
M@7!4O9_R0LGLZ"/'@GTI<E6YITZ?+5YQO[A0E<G*FF#N[.$\-XS'QR=4,H,5
M(D[N**HUG$6+850U)C48S.[R]DYJXF2:/B,B)^I^QD-3[N$=ZSOR% +Z4C43
M.AGS>Z5F*<PYIDDN3;<ESN76@1*,$6 $+HY/__,F)^2C>,FI=5C?^P=&YK*U
M8E(<N$LS,"T'P4P-9 /KT$O;U#NUL &-*YMA50N53>\*AVY.31$1"KD]F:XF
M?'/N!O$UW^)+4I=-QDI>D$;GTY4FDALIEI"I;5VXR]>.$F>Z&!@8-K$=3\3-
M>U@EH3O0 N\:*4S)2<RWM;.Y)F8W%J.#& K3*Q@+>=A'8UUOQ@EO4;9;ME'>
MN4HR(JVN2JXX\BHJ(J^'D,;;NQYNO17F3.Z7>FA$FES'PRW1E 6U[Q$LR0+#
M.*[M:A-W8^5Z*K+.;XH/67:\.V.H7;A<;F15(M*SA_$%I9S*J+"8Q/LI1HS@
M[?4"QA5:S'IUN4M/*16$?2F$$*/2>:BO  Y2HX$F$1:U[KQKO6VEAGZU61H/
MDS4R)A3CQ-GB(TRMQ?2X"C_:JVOH@.I!4W>>3=]"<E@&J/M,B/.QJV5$$0I(
M<9#SD"5*Y4P:1/C&(BJY>J.."OFX?&G?X)WSWNO #TI[0[?+7&-9C9++\VO"
MT/-P'8>1=J5>26E0K]<R(!?<9!"'KWBY8&M 37DFUF,J-<>@2Q-P1@:!,F+U
M,F8OJY6$"CU+*Q%\'9H!%1-%!^[2!E4OKOP\]H4IB6TWQQR=&&<D=+F7JI%_
M&&:SWML=(=1H5A)1I#&AXGYW4N UDDN!->>6!3WIGP[XWYJW-,P'U*ZU8=+2
MS8 VU/VR_))NH1Z-'[S[Y"5\1V77SL-$7=D)U8C5(^AGHC ^Q3=7.9)/3/]V
M- ;5,\T84M?.NK"^NGN&T 8[FJM5ZVIU F>2<H(\'C)ME"\H\VVBZ83G]03M
M5E0M_\!2Q7KW$_:1FALM/E>9NR$NVK&LHWTHH&J9>$U4\1I=/[=AG:-85%]W
M21U<PGBG$%64/:@,H=#/SLRB[9 :C,WA2&/ZE%!#]X38AQ25D)KLE-BR>PO\
M?-EI*[F2P+ $S%.3<\>HJ:(AA.7!?D>$]=YB:(#"I'VUDU1W*G=^JL?N,-1<
MGSTB=T[G_#E^N6'W=^45Y(A^6)%FD?2:H$MT:&EO+WSL;&@\)5<]5WU=4SPO
M?\VSX<J]E#6IRSK#[F\B$GV#,TO[FR6 G%ET"9OY'2C]\;=923?+8P*2E6%[
M==0QMI"#(N\\ZE*1OB!-U[2+"HH01_6Q,X9AB3*#V $03/?LS^SJL^51H0G7
M(XO>[K'>P"]EHU1;%*#H%!+2;-QDZY^7-.RDZ[M*])E?@N[VH](-?N:>S2H&
M#TX4N&BUM,L\HX^:,>26P?E+4M+!WKZE%WJO\C6KU:]ZBP%=&=?5-0K&5WM*
MGG;O-I:D4@TO#*_%UKJ[J*VZKW5W5X""N*Q\O!K$]%P7V(>E*RH='47'[7<H
M\W&,5+I1DL&$3JP\ Q%Y'8K@")(;%,'$C[E8%WW(&Z]H<.)Q"P'=MCU+)(@)
M#")*5-6[NBNGH BUJO)75YT]XU7XJSLKJ5$II@HT<H1)L<SKZB 75%=/G6I7
M3Z_'$Y6>;J1X89R&^+/:ASIZ*@G=^8M<RA,Q"8M<4-6X>CD;H\$OJJF)!I/T
M^CIA-Y^/I\ ';FQVE52YK 2/B#>)SBE/P+@#2[[4-O:4+!\MCMPIZ)WRHF:<
MZU6\<H8]TS]$5^MIF^=(SIOK2:$<CW)69JJ%&R^"0ES H*J-K !;!?O^:;K-
M&44&3@[Y10-AJ,0EI(M)Y0QDQH[,_=D(S#%3S(>H?D'+K_[E0AF?(=)9IS<:
MECJFWCUAK8-<!09W32IV.Q;4>)$=N)[; -/Z!1:)G.O?L94(RL_O[\ >'$<X
M5*I%%TE%&4-ND0X)OX[VTU)0=/77DY#OLF:5K#$-\51C( SL#8Q_-FS][&IO
M^ST'PT-1L0G:!%J:8<\P8,>&8R[E.^7&-==4%>52;V>+56.DI^D$Y:I#_>)
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M>*:1)4]*!9\Y/26=21\T.CI,;\GW%6 ^SK,OZRO6G!^7I:7PU'J&.Q-?3,+
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M>H-SC:4&O:'[JZ.ZN+54.WM3SQ\;/1MO"*%X9QN6*.O8.UEZ"15LG/<JNV_
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M+-_)9"]K0%#!(H,YP:#)?E(+6%;,_=PK008I6B6_/B8,SXJ"7#H-N4(Z9UM
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M\X! 425JP_5Z:R_!$>LZ?Y/ISYYU66D;/*GW"&1-;Y&1(.9QCL=S;$6.4]/
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ML!SS8PARD:_M1%(C;N:8)3KR<[YC(@PT:UC$,*YJK&*'&,T"F[F$W/6&ESM
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M?^7=VLK51-+*#YY/]!6HUN4<OYGUAM\A("$S!:*I488GF<M3,I0K\UI\0,R
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M@+;\-Y_V!(RMO,()HA7(,>O=^&,1<JU>W(X:> #CF(0=O:QQL4ZA,K()O[5
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MGS4"DUOU2$33-SX[;B^H-JYRUO%:\A>J.)[Y9XV/;"<&Q\"T2^3N7WQ2UOF
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MWF#)SJC5:!?:*?E2&?IR8PS*S#.] NB_AALV<LNC]-T9I#H<S2?FBT@[9%4
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M9S0P-S0X-S(U7S,X+FIP9^Q\!UA4R[;F)@@(2)(<E:PD07)J4,F2<Y-40)*
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MZ<Z7%[*$&)1DZKHO['JS1PP9.KU?G*P:>4JWIBB%\MM,UBGDO*J2?6.8MDX
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MH*9S2Y)E*^&9>=;8W^,X7^)%6QAWG8?U-2'BO<V9/?AG26,1<3HW:0F6'Z&
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MW[CH181H#&CT=9UMTO V"]=R/62+LZ9W)H7(I\B'ZU)ORS7WW#2,,*/5_6
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M<:&RQTAX_O67FUX9X\14E54_C63>VE!(&=-\%WTXTR+LI0SMA1DI,UQ ^5
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M_BPV*_&E!$ ;;]@]U<5S"_+)6R*JS,)-HJ8Z_HQ7'N^!##,*N+^]$<H:NIJ
MT;.C_3X*1YS8<#Z=L)F;RRZK9J24RZS>7YY:SQ2WW4A>&!2I93NNLOD)86]B
M2Z@0W-/*,@+A3M=^/;IC/A%8R7NFK5F40;FN<Q#H=M4$:S),7B>9F[:"<D%D
MI?1)>9EV4_R:[ZV&1Z-%HRM;$,ZT$UTSK.3Q0C\#IING=<NFHS5S'4E(*M@3
M\'<_:Q[3Q&Y.B"U8G>8V)1HM^5I&.UFQ3<,-U<"CEM:6-2XJ@RN27DW)1P0A
M-,Q^^^F_G;>@SA"<X\>@,%'6/*SRBNMIIL/5@7N1)!:T&DE7V];8YKZD,7X
M_KXYP%P4/R)]Z&=D;B'8T/0^,3CJ4A[6!6Y[*Z!$-BQPH7D_C[6Q@K>GWD6\
MUGW;N/"/,W>&9;_?9-SUUX0N&!K\A[F _Q"T9&<7&MNISC,*+;.6-5/EQ^RP
M6,MK8CSX%7US-7UO(EQ5VS*W!^&UJM#2L'L_)%<K14(EZ1"*CY0L73M!"_TH
M@$G[O[7WG6%1ILG:31"4:"!G 04D249RD"221')41$+;Y!PD(QD! <DYTTWL
M!IHH&<FQH<DY26B) L+'.#NS.F?V.WMF=Z^S9Z_Y4;_Z>JN?M^JNN^IYZPG+
MQR;S"H")/%[!"T"J??7Y2_@)RUYWM5U6F%&@+A$(3GX@&'E*&L:2-]_SR)XP
MB"__ K"UZKP'&0LI 8HM+,N%'.=)U.ZNAE6Z3Z;=L&1Y@>+%S>]^P[^M,(=J
M?FOA87&E58S6W0Q5B:Q$I,M=";/-(@]F(/\@>-#KCG\0 ,DQNY/SZ48_IA\^
M99B?-E+<ITX@P]"S1'DH(V2QTC^.=;]+L$A# WJGI<PORX7!(/11I6()J649
M=[-WRPW5ZW.VR4[K6HR[U#T]> UL8U/[*QJ7E/1I+?^PO'Y0/W^A<=Z@X/2<
M82SI?(;K*S,M ;L=+C!QV.T"D%-Z.7[1XM,W] ^PCFVSJUOCD;61TFZCM&>L
MA(1I=2=^7O5.*[5"+.X*1P1/;;/FO0*]0G#C+@!NRY$'!</S5?ZC$D*&%P"G
M5&4OU,;&6L9(S(;84[O97? 9PP5 0EME=.J2-UV.7>?OK&=,OGX@/@:W9+'O
MKM:A.C.\LEO)Q)JAG7:4B7^V83M/2T"02)(LOC4AW@PSSTHT:.[\:(2WQGKD
M $3;KS+:+2"5&$1LKSN9K.-<$J7YH)Q(;4"4OO9$1%PIX>E+EN:Q*8>J(*^F
M*THRK&7CD9UOSEWE+@ >(6\!6( F(C69\2M$:O*_?*&]:@4V;JB,&UOABR9_
M6I3E0(>X<6FMA8T9!I-G"RF/$(],>C.3MZA']?*)9P8UR*L_W8UA-D>*QOGE
M2N>-2S'XWO;9Z*AAJBG:5U.HW6C_NZ]$6>8KP93S*J(V4AR!.*0H>.O<J5HV
MI=WB=-M8*PQ+=KJED-SQQH,<*]R3(\_572RO\",_=+1#@R9$&&=]+?-=]M+V
M!T;8?_N1O=#0PHG"1]W5U-I&:_M+66#'JN9:;I(>H#,SXFH<<Y;VHEK MR.%
M,M_^3T[IN_H1DJ,CS;)QM9/O"4)^^)4I-W)<3Y+!QE P5N%,HNB=>JVD\27Q
M_[-:1;\K+-P\86$G3Z*QU7]NUOSAELJ]ADYX?'YF2%3 O\'YA__.\B^Z->%A
M[M@S-/3GX<NKI^.+!YD;:(X6?+4\]SZ&!;R=\Y;E)@3;4C"UL!KA6[(7:F]2
MU/<./=RD<G867F1[ZA,58MELEK >Z>H%Q(JQBK?UD/1[.NW(%M'T1>?.^^3%
M;J1$FS.8U:5D ;KMEX_!D9"ET]Z+M4"BD W8>>78)$C\@?K>Y\U'0S/,UC$=
MAR=9O$.NH#BI+R]?KJD#3!)WEJIBFL5O[7A(ND1[O=PDL<V.830]J\D"@ 27
MS,(HUISIH+L(C;HXK^OFI#$*#P9+$J_F1)6W\WST=5_,FS=XG0-9%Q*FW]"-
M!6?)7Y/DS< E?(5@VIV5K8?&&""LYZ.O.2:-5<N_T.=N%]2/:(VPW3$(.(S*
MW7@5[I6'-'A'IBYR[_1U I6F>A5_CIQ)_VN6RWPR\IIRXQ#FUAO>UE+L3A_A
M^/*5?)ZW:-$ [_>GK_H?@^>_DG3/0\IL+;*U)878W%^$3!#''X4(TKVL_>%6
M!N4I./8_+^?^!\O_J<MG_I3?$RS:L$LC/AX3WQR] ,0JSAM](:I,.]G_EAQ(
M__9/>6>U7V(.P]V8,RM^Y[Z.FGZ2"9?"SS,3'NR%.N./BA_W.I+L=OMX"PKN
M2*'O!+\8F1NPRAMZZ<OZ/LM"0#DG'DUA37B_F!##)7/E C ?T!ATD. ?'62:
M:*:!<S][GU92<RL=\:H.OX I&(JK5[M#__RE#__=Z3<89,0?CPG:E?0.7U-X
MUF !0RF#WF*</2PESD2VAHMQHC#%KH5VV.D'PEQCEX;KRLK80XV?P7< ?LFG
MFBW'F3NMJ;PJA.NDX::@*XD&4U.96$X<W$$\;[$>,!%WSEA>LST5GK3@ EBO
MR.\?5/7WK[PA)SMLLSB6;5?!.WO:X*?:"O3,UG/EYC$6>.>C;S9BDE=O84UO
MY?CZ"DJTKYX@RR3?_WQH:#L1Z23I<U=LTP0FXSCZT^%N\W&+.JC7U:0D\(CL
M=JQ/&S68D:]6X/5>S;#7]-&D-;4C=%SH &@-%T::OF-Q;KS \[AVIO_O*41U
M50LJ/KQ;M//G15X$&46*C(^2GKBW.SQPI"K8'/OMB;'_]0*9/^5?> G#?RT6
MB/G8.3JTH*<<&2#J'LHJ5SN\RR"+T=@O(;2@($WX&I_WP6+%<_[F',5P9LHX
M>7>Z!4L!+!ON6%IG$B,0)V"&V-QY8JDKFU;4'K5!8JM?2-W)J+\E-NH4PM'<
M:J/7 D27M+XI<Q/O'KUWH:AWP6453"70CDXZ_Q*FHO33^-KR'1I#&K"KAE[-
MQ[3R=S/:T)<BIZZGTXQ.]UOCC^#CMW+UWO)<BI)F.?'3N0#LAIL;[5\9;MPE
M%F\NX -RZ4RM7H8GR.76>:"PT>GR!: Y\EC/$/,"D!$R>?[%:[?XJX#T$.5"
M0ZT5TB JP.'TI78O'(3-WDD&:3F_ <8]]X8[GZ/G':M;,NLF7P#.V$O0O0;:
M0)?SC\9CM<O( #:E[7/I><URGA,/>#7S97@-D"I? )J>7DXZQ.<I!AK7</.\
MYNYY!7 ZN/TCC].L6=I?OANL[MH%0)JXZNOGRW>2^T&;EN0%X.I8P.7,S$#X
M H"F?L9\ ? '2EVF%8Z4"X!WP3F1>T9!_^7K(W>9ON(YS1YU7\ZU:/^BD?IG
MC:IG#P=X@5YOD%.EZ_Q<G;"EHAPX^@/JJ\2UN<?.TIX<@TFRP]UDUZ-!,3&5
M[NJ5(%O+%UX_Z]/\4=]?1FB ?<:@2_H5S6'G[(K*;M;W]GQR)/?7T?R/GU;;
M#LP3_\%\1#\.Q('V>QQ$'LM6<IZ@K\\>XZ3-R\$I?L\3UC^I^FGG\>^X8HEQ
M8-\']9K2-D?'%?LAA\FI$&AZE<8VHG(HE"3G O #GK+.21 ^XFO/81> !J,S
MUO3?>N$WJ@W7#A[\8QI$!T9^13BK]>\@'.+W@^E^"Y,C:?5+I@V SJF<D($;
M=^*_0>_G>/E9&YSP>_/IB+'L'H:2^O,5, Q^NC'6[*2I]P+S!J6Q7\CE0(I^
M\<GD[_A$99Z6<*W"15PVVH#^PW3Q EOO*_^82D=!<-KW^I7R\YZQ_F=$VN2W
M2&O\/6SK[&188"RB3UX 3"\A)4VX_#6%?WOOO1E9.[#TM]J0(21_&.R*TS3_
M[$#Y0X:D_L&0'3]KTX@D.7:7"?V0^"EJG>0:O<417C&L\RH]_P=LH@:BW?-0
M 7\'5\8A-FID'WW/6*>"L)QZB%,XA/W1[#_FG?K!C7\JE_X3V>LO8/G1*=73
MUM)#)L=Y\]JW%,NU7U36<9)5J8*]WW=V".:^T[:T^.,4_#<CG_7W(E_N!TW3
M^,I>/Q 5\V]4K?V AA]AYL#W-TC/Y&^0'K'6T]W#8)(85WKS$S=XT[(\5)E@
M>$N)N<IXI.N7_]WZO5<H\. :J PM"3RA0E!HA)5#&WL^ZV7=ZMJ0AU1];PO5
M+YJ^_Q"-LKAG_:MH^.]VQNQ?#?A;9W2.[H-8Q.Z[.(TZ=-^I\A1;3KQMY:.]
M[,I A;#^S4CN)8;<!/TC@:\"%_U70..?D \C$#_I Z_NSOB7E5%P)%_%C-S_
MZ9'%UR3F<*55/\PJ(8-W0Y[E2U;N#DSHFDU+&G<H];6<RPK^((.J;T?^6T78
M-X! _T:$M1[7R@YEH/K]Z$(?E\OGP-_+AUIYBV_W&SXH# EUN@6B^,=HEUCL
M_UJEHQ33DDC1OF2.M*&[23AQ&>*G&05^OR#AYTKQ-U P/6,?Y$UJQ)1A[XLW
M94NSK*9,G;[6%%LOXY3VO7,",U/\(7U_V+?Q_Q[Q=?PW9U1I06X<L2"!0!)\
MCH^W[U;@-'0[4 92^G4\VFK\?ESJ:@I<!O\A1"/\*QQ?_Y5H?H2CUJW=19DA
MR-;!8?4P6PYK\53A3I5TI=6:X)S&'9(DXNE/P#^:R)^>_N_GGM\XH>I;0O;Z
M'2?8BE^O-+B'W&DNPDHPO=E5+ NY.8TU#ZT6<2@,"4OQGY2M^D_ PS_JA;^8
M[D<OE+^F-(=K3,?!$4*F[XKA;1\+W!T$*>$$@L23OQE* 7/>L[L3?[Q"_7=
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MZK"V+YHF[RTVHR?^Q"W(5"!X .E+/J>+^"!#]/1GF*[+R-FBZT\J6M]U>A1
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M-S0X-S(U7S,Y+FIP9^R\!51=S9(_N@D0".YN"1K<+4B $"Q T!/D0(($=_<
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MJ0OT%'U2X2$)7< =VN?V^*G?&K-6:M9CE;%;2O]F035/,-.%X:VM\./76-M
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M4>I1OZ+(C1_>3[!?Z+W$9S&+>&,J=2CKV"K8=)P^SU$BQF5F4VG"I-2P? ]
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M7DY9#'DO)PZR>-@_IO8Q.QR-R.S+ FZ26-MIZZOY(3D-# ,7#/IQ VJ==Q]
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M%F>X5OV09^&Z)X>'2WN'6U[QFAZ<[WFI..UY??,:(:'52\&?)Y1>9T%8L1]
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M-Q:A2&UA+ W!FE,B3!9V!=9-\-8.C66+Q4+R/H_S6VV<#SSXXS<T!;+GZ@O
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M5LAE1__[C='@BT'P:E4BL%-\!_]4%S!&.49)=D@HYI=$""DU?C,@\5* \H#
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M4DXVB )O#W'F350XY7]\HL7C$ FYV22Z>HUDK)VW$B47E#5)?>F97Y<,?OE
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M\O'\9H*"A86%_1";% >'E.<)Y1.>_^,'T03@8]XC1!U$1:$#[N&CH.*C(-H
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M#I#@B?(@#-48<_B7Z*,\T)+V#&1(P>3F%-11A@"6K&TA)VLV5X)_G IQX*C
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MD85@J%O!;-WZ<$6=3XHH5G]]@%Z/O&B1(-H**MF^5SXG_YWVAGZZ\O#I)H.
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M2YYD>]+2FFL*]K+T@.I$Z4"2Y4T<]VLY;\^SHG-2W)D9L(YFJ[FWPT2HS[!
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MY%3%TI#A_E=O]EPLUG-$HLAY@9VNO^P<6G]WTH.7=)M\(]1M=NSY+[M'V6+
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MHE5\+=UPRZ5T3/3"5'$S>44S+R2F5'WFOK*40.&BX5<U$,+U@=_(L,7 (JA
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M&9E^K94;FDDMSFHG:""P7;2,5[9OA3-QX\98"G]Y@"U"I1XK@NS/ XD-]9D
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M;LY_7H*$@8&!A8E%BHU-ROF*\A7G?W@\_@3PT5$XT4)1D.@ 9'PD%'RDQP&
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M0D+V^&<"/NJS5QS/"234T#XZO:3C#$(GE$S,J^O%H.=2/R/ZY#SU@AC$O<$
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M>[\-+G#PR8)2DZFH,#G :6U*UYC3/;Y/,)J>2%27#&TNL$;DK"5$9\#["SC
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MO#22.1%><^!3J)I=B/7\DX%6N>0JCL6=UK3]^<TB,M:SJN_V)8!@]!&1)_9
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M\51VA7O^ZE=[]@_<WC\"L<?"N!N*$94UU+B-:S8$[T%_A?VC2H*] ]:D2D"
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MN)TBWF J&(W"+ \NI2<R='H("L4TDEB%RN6_K7O#<;Z%F^+H)9J") N5'0C
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M%ZB6%TPBB5,R]IF\W&OI1IWD'G$3DBHM:DF;_V3!A?PU6,&2UM2R1$JOYT7
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M10FW'?17Y*H_B*6N-VJ/!P\K+WV2D,O2!(.=K2#TE04D'<Z/#E77S>YS9UP
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M.;T;P6U&P,59LL\2KHQ?G/<J4:N$^'^>N30P_.#1?RVV.K]HKFKB7B_?*^)
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MH:6N'L^%P^80';:]14>D,,&:8[]0Q;IZ^[T40A,?9=76"$X:T4NB0M,19>(
M7OMY5;D]GY)V7*N$6(P?G!D=.%2<<:; YMA]2,2(JUD0D@_>0>5TB$R^-!]W
M^O:V%'GO_>FD.<\58:KOW!M']))$(;"9 K1ABB,B.Q_1(M8";%^..3K:3 BK
MU1FFKKY)$L_ %)$89"!"N8%2NOTU9D1XB;3&"B:<TA>WIUC"7Y+1]RM:OR/*
M+?+706*6K@YQJ#6.9[VOL=?M1<8$GGE6SR81"LIO!4F5E9;N&33*?G8M6>JW
MJH<_.Q%X^8M18<BGM<T1B:<V6H04;F5_;PJ"9?&ET==<<GVF-EL$H;>9-XC(
MQ16U(?D[?]4UR:A5.*8/CGRO)8X@/<([.>+@#LU6,1W%^F)D =KS#:@[*T^#
M-\3:?(ADY>IB6CD1+R=O]Q<?\QAT9%1M:T1R+X+'C9CCM46C0@3TR&E_)P?W
M:=D7AAU'WC(MVXO1O&UP=R0<7ZW,%9!G (6;VGR0P6(MKI+901\OJ2+M-#GZ
MYKQVJ-))<S-NO@#JY'-T-A (-_J CH]%31NQX7M6Y:PVV>RX=N-F/G9P%O_5
M>'9/"*OM1']1YRG.(T(9' Z)BP-YF<"HC>-39TKMXMU4BFRV\/G!R,K#B]E0
M36[7V#)O]"HM-]-U<^_D#@;!T=H;17-'6\VI#8$WWL_42!%H&+9-_%!S29J_
MZL 1R+;(,SN/+.[.6P;OU2D1WN$9P<>K&(H2KR5)NP+-S_@2<U%=*M.5!3D]
M>.6[XX_XOGR'DS3Z%^._MVT5[Z<ZRR4,EE8H:HO<&*5XYT&U\D=1J?HK*9.M
MY],%?6?2?<G4: B$[_,7S;)F.!Y98O>OIZ7#1@AH5_I)O[_<FABJQ>MU-E^B
M"/G$^]B2@ \XU@MMCX=^'4F,V._[NY7N!U+=T[S\" ,?9T:=\*6M_0%](4Z"
MG+0$H>#Q(!G<J W_@+6,-L+=<X,Y4T[1RM(%/(B2ZTF(;_65=:!'6*E=MMR8
M^^>Z3_Z6YW^:O*]W';*'GK\$! <:SD?D<<YSB=2_-&];(.L6MSOJD;(IS-^:
M7*D&@I9 EWET^'%94%S8?T :3V)%FT1M+0?KU]ZW+X5=X6HA<6*E3(EGO5":
MI>\-<</CD,\9#CKYJMMC\C]R<2#QB(LH_C-M!N]DI0;5AU59FY</R<(WW)*S
M(1FC&7T,DC7)W:*W+&844QN65G:IY2PUI;VFV<TA4O?@&L]#V3XNY.BVH*B'
MD>G:T[XAK5#A;'!-/'#-Z0V2.B:ZW^ARCS*E$KMD\ ^PZZ8"6VRB2_-U5_".
MI+7;X5]/D[OW-"M=I(;7A::@\5Z2(L"%V8VQ@D_D=!:\.@\C\;[2U#J7HY!-
M.)_1Q#<):,9>>AGSNM7'X?2::!3PK2/O1AV_G/:700SXU;8QSGUEX[K0[07>
M\N5%OA002KZ<@N+/>@\:-M4@*8HKHZ74M) %;$#\$]C@][9F;X[XP5S@N*2*
M56'ZC+OMO['WED%QA=V::"<D@:"!X)[@#@EN#2%X<'<(01IW=P($@A,@$-S=
MW5V#!.F&QFF< -T$::P9\ITS=<\W=\ZY=6>F[IFZ-3_6CUV[:G?UVFL]2_9:
MSQMES#1CU695VQ!%'$*0CZ%0*@H3FW@[<'U<:(:@ZVNS:)R5M?+>\<^CS8GD
M%ARE R8#/#5UTKWR31 ?3%[:G^$\UFU:WN\-F41/Q2*Q&_,:I>52F9X7<S@9
M[,:M8N>SEQI@TI]A;,$WEF5HRXWS=!_RQQ5"H\6F?'!KFU7:63<ANX_=&4.7
MLU^] #+VDSZXZ%2R^K,/:4AEX<'4I@G>9/HA1R<XG] CWC]3KB'PFR,Z$"BZ
M#K%.M!%_#J\J+;6%P@YEGK[)IW#_',O]$I!5&>N_AU:1US&E,'/KN1G#2N42
M2!SXJ7'F"@S6OH@:):?6<69BHH.(!6+.PYFB&CD^4ADH@&?XP&[>?J6K/&'?
M7"/0EDOWAZ6&G"6H.HE@XGAMB),X-]YD]S]%!DO$&AZT.HD''W9)2?M*:/W]
M?7TI%?8QV>,Z^X*FHAW$)ID?G>F(;2J)#*1G@*>MH0/D6E6DRQ-;5_4OAQZ'
M]E!Y3_KHO(9DT<-EHQLX@*J0'WJS[M[8I%DO$M_? B3)CL?7(+'A06+B47^F
MOAB_AIPYOO2RF7VW1+>:-KTD_EAA0;4]<@M@((JO9TR?.DR-7M>,H()$OM0,
MLY3NJ+MY,TRJ<=<G=#&%GKO[4)@.FB.K-;.EX47%I=#/;Y<,&A(BR SCU'2S
MQ! 6JY'YNK)Y>:-E-K,<G5F(^/;NKU2"(X>':T1CR&X91%?,^I&,;QR^; 5T
MW$'[8M7 /7H(3R<F^&B8TCE+#"!&TI=><+T6QCNAO$>;M;/R*5Z&NU4\I(DM
M'>E[#Z"_?*A%JM^7H&B1B;M]JX0IUZ/XQUL)M*&!*]KF<W< WD=S$#[87<"?
M?G'LSOD*8CK7Y]&TR8I</P^*:?$7TC=N+:Q@)L^1MC>.J)?RQ_0RTJU??^\1
M.@B.^3]_^/4.[=0!9LXC%.;RL'])4[[S38IM\9?WGYY9T+$*DC[!ZPL2PU+)
M/&Y8,HCDZ=)56Z)Z(\%8 7D.X]"_>8]4NLLM6N;KG',R>)(@06\13YT3^QFB
M030WL?&MG2MMXONW+O35Q0R4VZ-":6](Z*VY6_;S'01CHXB1DN-.X@# ,+RO
M&JVUIP@$U8GMD,KOKP)^!=97.9B_7%J4LBYBG@_7Y!'-XH$(7OX]6J75) +%
MU(*0C=#WW4OD>#?CV=BF>5,(H8PKH4-,N&O^#U&N_,^(3L+?*?SXJ6#@;^[N
M:P*=*BVV.SJE>>K%D]\<55E@278<7LF?#L!(U^EI] P_M8=:(A2^A.ISO-VL
M5(GI/I5S7[OQO ?,?#ELZ)AQ.WJW,[-S.K2ZZ2OPQD">W2R=$9;,E+L>\"ZS
M! 36;XQN$HZI$-!.A/F]I;6P>R$C>49+TQ<D.KYI2#!U ^3Z%M;1KBA@"FS#
M]@:&N9/+-.<CVWN+E6?.%86.BV<N.GB4*^#'<8Z3Z&PASA/NC#/+BW?1O?A-
MB]M7#,\FO@^M=/+$\FCR9F/OZ6,GCA;L$VN_4>"A,^@IT?4A0%>Q <"S(XS)
MD"#O//',S4-;6Q,"/15Z 9!W($.[.&F\Q"KANO/PI8O/UG5Q4$,V '3I$PG7
M6336PDA5<73Y$X2K$//SIPAU1#-?]U^NL+:M37^-][,G3  \?EMWJYX] ?P,
M7ZW.MW*S;K:.]2 ?_\IO8A\\$.RFV>J K;^* SPHSM_U'F FU)VHAI!%*>#U
M.]X\[_X3U4FG]* W\L7*AG$*7T&RG^&"=!B%<1K!JU\GF)3G..TY'=GMCYGJ
M71D:$H?(\AR$U'VHT;>8T;XBEQX\*L+H'M <>,<<VWKR17@;E;3N^!3:&^A<
MM']YY/CT[KP5BI"N=0T_2FBY!_0$-!Y<AV=:E.N.FY= ^]U!G +];YYI]S[Y
M1//NT2T+9T.E^*62L/M\3 =8^IU_EER_;(,;A0JE1PY>ICCK?A9@5I2-P"O@
MYNBZ(S$_34,U<>M+>_WM( E]E2"55_4[Y.4]X+5VVL/_^P(\(V-KCN@-(&FN
M21_BP@-%V@IIL+^;YQ\-36B/=?*Q;'#_]XF@2-C& OB&Q;[ JR,32=*79.8)
M;,.4G3Z73HJ71M\#&MCF2Q,'*>$=;V42WQ]H_8*\"C[ $),&N"3YJ<#M/)IF
MI:OU#1O'\Z2?MD<R6'X$/$5G@R!KHW;<NZ^$N'#N 0O4)G>51H,1H7YO"]>P
MEO#P]E,@=,DI%)K:)KEH<7T-]/\!8]>CG>NUVXS4\+]GV'"AP/G_M+TPOT_P
M'Y#+_<>/O0=0 [>TI@-_BSC> W(490=IKIB!.-V_&>\!DZQG,;+RLXU?/D:H
MUS:WQ[*\_U6 B,"$"?Y#6=([2<4V)/RI BG\ER\76Q.A\N;8OP0H2\7PT$X)
M'VVO$7#*AHNS>0$'(5']"C'T]5FJS_&)L=\X'[T2=8?:-M&\Z&#A+#0KUK?5
M3H5XSF!L1$U*\J"3C=O3,\,ZW4A2M-O"*E*:FZ:7ET:XX1.D;F;'>,_J&ZHQ
MO0*E,HMG&@RPA+Z;CCYM*S>?I;6BGGNT3; *6F5"YF\JO1V"_KX@%G9EU06=
M^-B;)7.[;(4(4)J>3U),:YK@DDBHQ+:-(:V8%(RH4@3^4$M[$ R0E@LQA*_+
MN,8*5AO-^[%MW+ELBL3H2-=TIO.$)6X^]4";I7>[*.>'<J9:>36GM+D7D+
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M'>X/O&+LHKP'U/@!KS&JPD\GEU3K4R9/5T6^@KX5)"CD/ACDLQ0P>'5HALU
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M;F2HN=78]%7! G%X.O\96V-_$1I*%R@ADHUJ]'[V%<&D4X-X KF<X9MO' ]
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M N\SN>43;PCV>-8Z #A4?K JCB!.VE4"AGU2E%LN25L)HA-].4Q6>7-X@P=
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M#<#Y=4[!16IB:+BH1,B>^#0! DA<CR8_4Q@FF,W*C+TM>A-+5<IF,T56,U,
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MW5'OK340X<&F3.81P-L=+:?0_,RWOBT?!6@M#W,S%B(;F,M7Z+I3Q!6:_RS
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MP9'N/0U_.5RE;^!<C*&&1JORA:/W>ZQL#1-M&RNAGG%R</N2T(V3M;=V9VW
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M*4O8H#93B&22(LK3<6"T4*(TK?78L2.9O-(]>_9T"SK43P63D\WZ!PI U\<
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M&5_,LY?XBL+6RANC?M0DM^^4%BVB -$/TW]U5<5[):.H^PG;IB1\1LE6CU"
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M&LP^/[%'1+\J=0JD;;93+B#2;: UU3-V2V2X?:<K??CJYO$I%Z;?UW"FW%
MW+J<TK<. 0/7US#%?@OVSD\ D!+(KQ!]H5P )*E>;QBQ? 2V-LR-5RXL@+.0
MZAVZ4Z?*&TO<+IV^<319T_Z!?H7QR("&3=%L4J)JS\)T*!K(CY[6MOS>Z7HM
MO$PY7L8KYRP!;)G,08P7Q. NC5I:>EDQ&,E,\+-ML[]A*Z@?:O\U]Q44/G<]
M=\O(F3<B1!3,9D*%_M6/5VQB/K'(/3'&Y=G*0%X<\888V@JWIK# G@01$!9Q
MKP''"E[>J9D!S'#T?\EHR;E@1"[.I),"87&/EPC":'9KISNFOXQKQ-X,/*A/
M[J-/V:8AR_,/E$L+#\D3;===5]Y5!EZNR!F5,R,@V39(X5]Z<+5V^U\7H]XP
M:5H4@%>6^JO4,T\DAS_][E>0*K>=9?6=A<>;UK(II/? ,SLZM=.DFS_G1TUO
M\;Y4'=;QU Y@ FZP<1L/ZC-^P\I</L#&DC<ST#S_T+&Q!#^/8$^.9!YF$XJ3
M7DX/#-]KHT&0R+?!TC-*;"?\VJXM=:)VS$.)\(G>HW=0CF])T2<_/2D=J99S
M<,&MDEJV5-S&-9>(Q)+M/#IX>Y-8-R5+>_.FEVFTCCFV*YD@.W#F8JEEI_^>
M(8-&4[W1'"KF5U!!4GXU (Q,8 I$$L=$6;?[#W<G+L<X[;5?;?N_EJ+;05;G
M'1A":MS8Q4 H@,<)28G7K3U#LD^)WI(-=^'O80=&,YZ!J4(%82; 8N<8^]#9
M8T]0@-"4U?5HU^#FRG:+.[S[.J0OSPNLG7YA$!:ZN,]NLTNFIPX*T''F4+!D
ML&)#&;?[5)[K&VS]S5X CKC[@13.!H1F&9$C7=O8TE!9/_/9P[2J_PU>-^&;
MW+T??,9XR,I\&VFUG,(E_>"[?*A;C*1JCVZ:[PO86(30=_Z3S\:B6#-Q^LHK
M1!>X(NB7Q4@F]1!OT] R+H%]:/-LV75BT.0I)0  >('!VC%N"SCCY.9TV"!9
M7.EVPME0POTV@V0,WW#%87*(IN>(;"8U5/%]+4X0)S$;!8,>=OJS( +F98-]
MC%^!Y=+L\B+SYY]B/?-"W_WB!S9]9$7G1O?&*(!)(@IPR\4&</_&% 7O[HW]
M]2G"QB&(Y=NYPE+S4?.1J@0ZZ&2&?!)??# 7NSVY7!*& MS_DJ2 S.>U(R/"
M"P\,[-IC_)D\P_<,U6OUK:>>JQ@JL QC<5"%GOK+7HU79!*H5,X<"PA'UE'4
MS3M%ESJP#6!!\43/D>-J@>-MS0%SM%LCZ5(1?^--#*$GU,,=;6RPW>;,MQPZ
MNW [KI/-@6@MAVO_Y'M''ZVFFVO+\3[/TGN="<CG_@*'"I5L#,Z79JE[D; '
M/ZQ:@#<I/>/$:3I__9SK0;H,&;E8[J>>2W2LE$;FJUQ=H%7<(4:JO.7YDA3-
MQ\.%HQCO<S\*)=C.>I]7>T5)21G_L@]SXN<PLNS@#<FA]]%H!]/K4[GPQ/#T
MEXC9/!L7=0Z=:AO&DR>"G7$"<?*OTSM^\$G19UC^.5CZ20 *S@*[X5H1,)&P
M_\F0D89FUL/)0SS<K@WMK-12ME.]>%89)?S>X(,9;KKH2:9;A" V C4ZU%IY
MELW+?/*E-9$6>P4 I[F6_KY?$ (N7Q;G-OKI\+6W6IT>=E8,;#^Z19PQY7E%
MSJ3H]UQ<GJ;B@6;@G<_,7>,:M*F$M]-%9PU+790J4X3MKU38O2RIHI@;WEK1
M9Y*,.JZ)-2;>;*BLJO7FIX^-*9BO)D.9D)]+K#/P?,4\-CUI-.N$YNLK.*I-
M1GJ&&W])OD82\G70!XIDXO_J/8M!/QJ+&K^VZ]3Y@ *\6X[52T>?X^!' 4)$
MGQ]Z)]16QA&3E5EIK7C0_XX1&$;(W!Z:!B(YINUW;7ZKA)_/"8G?!S!(C5>.
M3WPJN1=#0+)L39Y5S0CXN!2N&+^5XJMD(!U$([3:H;N89YK RE<M7%A>RINY
M280;#D;%M?PI7-S^&!^84FW"LGF";VRUN1<ISD&WBQQI_Z%/OATL^P-KI@@(
M8S3&:X]V@KT["C:]7"B-RA+9&[_[^N!%<)E)\+:VI;8M<M#&!:_'ME?E[68'
M8^' V8=Y/MB=S..*Z]%);1>1O[@D*>KH?09)"KP<  :YSJ#M29*YC?HHVST9
MEFJY$^C+<IW8LTWKWWG&V[%A6>S3(?%:@AW6H_MATPV;LM.+_HV.]#I=U1L(
MSU)C1GC[.:\G#;(K$ 60C<YN1P$B_.#*($5+?DG"#*Z]NTHCJ^#K[3TD!O(G
M6O5&FH?FK*_Y%CO[<G[B6M>A\$D.&R!*Z0?A&Y&[G/(\)Z%T23C7[ZT3-:]R
ME7U1__S$>G*DP::Y<P?MEO@7%I&C&(,#_T?H?E1,<"QD>PX*,)%?HDHBJTYT
MM$Y2\PO=K6>(D05AQ!]$L-'Q'JLJ@$KV-0;1#P5ON&EH.@B.5]<(>?@&N;:3
M5/(LW;6,,AQ).U<<Q,K4Y#GV V?#,J+FEC<YEJ(.'@T^F0/6-_?/EX.^\6_4
MN!IU2F>>M)SRQS88]XB'%-GB^#B?W$2(5E*A %^WX*^^@@B@?:U%GAZ=V1?*
MC8(W>*ZQR4\"9'[T7&%-Z*B5YR/NNE,X;E?;(W4UR2NI\FK3.PEYT1*WB3VI
M+@_F<A$[*  #!N3J 8@,N K< NGVN]^^)4]G(">G)EO&YG+@;TC1T;(?H:H.
M (&0W]%GQ%^7Q9!XFG3K$7G)[XI7605]5*Z@7\2L XO)3)?4I#T;ZE83J0YF
M)A)T:7!;3?\[!J&>_-]W8OR_4MB#X'MA5Z- @PG^*)PO<GU%3*$6S3ILN7;]
MJ_L2YNEX  \MW21;"5YX>2#]\PS2@Q3+N02F;*'&Z<5 >?5J>C\%]".3W[1A
M_$K_G(Z0?4W7>2"%_U]<0AM(IL/Z6XLU*G(A%\.(*!WAO/-EFHFK#X>@0O26
M_^'D4X/D_SQ$["= P^A5?;%I)SRP6]1"USDOJK?DA!^M3?<ETXO8]:<*.\:K
M_Q[A3ZJ#%2K^ 2OD2I6\S]"&V4YG[WA_0 K;.8<%>5N*9VVK(-],+?+=5D+_
M''?=Q:,58)I=N+^E00W*G(U4>'_>OX0KZ=CNJWWX7S-P5(@S0I/$C?/&_1SL
MF)NZG:]W+%[$::&G2ZYEXMW^LX/!_AWQK=CT8.DL,*NZ.1'[M%8KW$V^(_8Y
M*YN?/$[9Z==GK"4$A)[Y! 2'*9R1=5/*2Z7CBY,_OA+NR*L_7$G17/Z'LPG_
MJT*V:4KF5G["3?H0+C1"CK.S57<Q#-R6?':=9O@^1FF*ZPKGC<[:JWCZ7'PL
MJ&=Y$A=+W.&N85A2356CA_E*?!QX<OA@3<TA:SHD:IV'SBW]Z6:+_.J\;-.+
M6[^E[:,2F-#]2,;UDR848!$\50KCRX?@#,YGFQQ(4/GQ*;7[T+V+B-#&T&-+
MP&^A6Z1:41?8<UN[!\V7RRIM[H S7NUQTM:A /ZKS?5W;;7"05PFUI=D*DO[
MOQ0G6_@\_BQUXR>7%U.A$;\CTW :,XQ.&$2DG]*<D1SJDF]@F[@O1B=AH?_5
MA4!'#?5@9R&]J=Y!8YD.O$PS.$^U7!<:]A\7I#\Y^*D98J_2UEL>OX0;==!_
MS;M"9Q4-V35$ 2K(RI&C1FENZ2(H0+(#LD.G_4[ V2T!^(V$X/L\;"_TK(7O
M#^?.;TMUXJ[^G00_@DM0\3X(O4>0GFF:_+KO772<_+JWX"7C_6Z;9:DI@6?P
M7;=!MLFB9$TLR?E 6\B]CXYP"=N?LGJ&4F:0SEZ)YR/_PBF5O\W_19V?G<,K
M+TP2@V1?;_5,#84W,X4/'"I:F@5@'X,/U D\H_M[FCZMZ4LRAGTROY!?>WS5
M/-\6)&02$2[ME__7T5;DB>H*4\[,5A9]ZZWN*QK2@W8K721E7X(NT-TJ3!IC
M_D,N.5R\6M$]FV&[\O))JWE7.TZLIM@X8:65>(3P\C?D'7Z[]-]YLTW)IP=K
M9+7T!F%G29\,\TV3[KAO%.KWC#G5&&EW3J<G/<B43PZ(V<'6'"=3:TN4FT&8
MY,(S;-^.GZK(D>VE;OYG?D*C1R)Z3Y6#2.&UWS@_E>I:Z>V.*;\)J7Q@S\S^
MP_O3&'K,O^2A,);.!I,OVK2)&&KS"Q-6*>P?OC2[9[D/ *>,^AER\*S(_),,
MG22J))J7TIO(1!=*\#W=O9QTB7\0[^?XW?[*WB#=T&V,@ZE]>AF0-CV!WV_L
MC]OTE,+330BN"2+G WE=MP5[(/^V;V7YE41 6^ DOR$WP<&CHI>K8GY4]'OV
MQ_V-A9<@ZGZI:<;*BA@+\##/W=CJ8HR+$4$/,-34ZL+5F-QAW;F>@M5_[T_1
MU3^>;Y%#K70NWQ_+M[.QKY5+2NJ8$$%P7(,P5SOR+RNTI;U#P"O_/P5W:P7U
M\P4QD_]R=O_T^N0F\U^=W9G9!555C3,.C#750;L-/S89I>-\4 "V^A)KZOQO
M'$Z'B0[V4P$?."@%13<"%)S^3NWJUEX]+UX8+2ONO#T+*TE1%>L^V/O[?60B
MJ?OCQI.5RV/16UWS34BP@0#RFPW$#]0SM=)3]4GH65%LJNN14=PAGR\(7GOO
M[41!)/^.V0K))"P>&ZU .\]7^JQE(KS9>,18<0QN4#WA2P=-,]>?=> W);09
M)HW \3=['?LC3X\>6^2!P&"?WP'G( 4SR\TC/RR+@@V]LYTGDG8;O_%HO=5Y
MR:KWA&MG5H#F]?'@1A-0 *NQ ^L<L_7)TB[-L/4IYXZ26:PL8]: F8FEF[#0
MZ7G!#:T;:?9U[3@+HK<0A_OR1$!10LN.;VLV&@L9 !'=:\$SRUX#%ZC.'Z^F
M[$C5?W:/ 5]U=M(IJ!>TROE! ]8)F>93,!JBQ0(T6?8U_#4NA;>!)N#9*V/\
M_KXY YUJ2\>/Z:_TLU*YU%8"M&+>*VQ(7PDLO_:AULB_5'583,.[$V9M;]EL
M\=N@DY2:#BXH,.)W.B.J;2E-C7^8GH>)E%&C (HS_+5!Y:7,WZRDX-7EN 19
MR(331Q8?C\C1F,:=E^;@U$^QEA++9:&31(OIJY)@.DK!@5V-)7# 1_U^? KG
MX GK/%27VV*<Q\Q_5,;''@Z0EYHEEX;IK^5(=7/=TL]@U0;(:5AA=6PU*-!+
M >1.KX4"\*  :&70%HI-]_*'WU#$R6HEWB&EGOOJK/KNXZ4GY=[E6%3J<<7U
MQFK/)G?^^;.)(8M_H7FWKT*@T9Q=28M0SO*[ES-,3Z[_#^;>,JK-[VT3#84V
MQ8M[0H$"+>YNI7AQBDLI4"0%B@>7XD4*%"A0""[%BCNTN+N[2[ $#1!@^/WG
MO#-SUCOSSKO.6>N<^7 G7[*SGF?O_=S[NO9S[>M&</7A24<%^5YOU%,>FPR1
M8G1#Z_[4-A8$DLA-Y!"IOX^\P"/ :8QYXC^_20)WF:_QH2FT2XT-Y;":+LFO
MGM3PU,XMKF[BHOES)N'74 IG!921K($2_'.@](9PW?CY1=]?\B=;QK1.(WLF
M2Z08VX93257_%)#2@F9S$-A_;-^>>J_Y"5/)07YQ%7RI?GOF67A8VJQ2XO-N
M%"U3:.-H;D[7/,:0M#Q6UOWW6PS&AT6<<VI6S$%);EF7/+E<5).:5<REVH].
M_4L%+#_Q3?\_T:XK!-5\F5"P>FV<8D.BY)A31M-* NPSMQ2..B5*V8Q\)%?V
MQ;Q<@:'Q;?;VH^ 49!3>3HP087?C+P!;/W]XLP)B16N*G1YQ.UR1O;18,U2=
M%$P1E<'= 0H@6!+>-RV7 SA%2X77//0P*AQN*%R1L3T-/2B9NNS7Z91>]&_6
M/ULO]Y&J;)AH!N8:FDHCC!4(0$*45F(1FWHJ<H#/_N35/0V(\"G[<)4E!M?F
MD-,@;GF%$RD$D4)[M*0E8O)Z:_<>H#9=9GJBO6++Q'KMQG@+GT7VA!ZA#1[Z
M[. K9*LJQB"NP/UU5X[V3XR,AGE_G.6:VLC^85Q]$DMN^8KNG,K"/^!OF01\
MFDC3&JR9>;?+P/)RB^4]W(7#)*J-D7XC*0]&*MJ)5EJ4Z<UKA$E7:'X0=CES
MDL6CVK5']3@44J'^U(>[F82<*#>N<#0/J2G9I+B ^UC>P(:&/$CQM<O/C0S?
MFXM\(]DR%%]/*WV;(X$)A'R^)$B1TQY@'669'B8!I ?!7$&0*=9,0@%$!FR=
M2I(5[G54E><;*38DC*5C#X?Q/GZ]A+OF[*1WILI\1Q@%8I[<JDYD=^!XKV_-
M=M* 34D/0KWR?W6TFTE \F;<<17U=]U>S4A)JWM]^G&H<QO;M[@@C..@@I.2
MA31\_[\@X2F!4A;%!+UQ-V<0]+WC<A=]W[#8B='I88RO8"3@5+YBIMEWW9[Y
M6'ML:^Q,E=.L^FD9+97#"[@P'>#/_BS,E.>\6&5)?;WU=ZIN<L'^+H>Y46'Y
M1J=[,$:(GL0P7T_1F<"!6Z<9E%&[#OGBJ&FMU/M&U/NPS2X(XL3O_$Q8_$3J
M>F=/FJI1*(+3AZ-TUH:Z+?C@S*;FI:"1>D%O*4W?G[\ ZWHJ\=/Q<K,]H1,?
MNPD!G>K$$L;Q5)9ZW!.VHX0MEIEM<+JJQ6KTZQVSJNEF];)T+6_:FEPBZ>>1
MS%)= 7X6$Q.99=,!PB.1(/"DC]+J3/7XI)(3[9Y0O!'(KLRY^=8%I2>T+J'2
M!7J)L!J.-5\=2 .8@SSKVPN?RLP1Q^C_! B7ZV4'B,_T/%.!("@71F@4^'5U
ME1B$WKU'/B+<>'?61HJ:4$9LE67<D:9I-)'W<CC:SWIRYLF/;] ^XXGK=IIO
M4J="^:F3HI1OY$-=@U2B?\1-?A-LK).Y.V+34ZL1%+7*R_+=?JK%\,="3)KJ
MEA4S9$P<[)N)?CE=/1<&*S9;,!YX)>_Q42^J4,/[#!PAT(*XZ__G#$.<K2?F
M7R=:8>BB^?<CEC@3#E*,=A^Q<<>S(84N9]-YE4?&\$H5[&\6@Z_5*+V=V8+\
M"9;\VR?]@<P$$<R9C1WRHH]QE("C+E4GY= RO8X[XN2WR(\-ZS3[U0V-D_I,
M,AJQS$1C7J=_S&ZV ^B1=9'GA(1VU(]C4AP=G9R*EJY4:3,3?A/%US."O8MZ
MR6:G>1!+N1EL((8,I8^-,815"SD;EKC#ZSE@Z.;I7M>G42 ,+3]V3J=M@O"9
M%G1>5( 41K#8=+^!-!"H9_Z12G0UY4$L/O#CKN5$YC'&,M0#0\7*.8+M^D8\
MY,.'9$6TFT$_?NPCZ[2.*_(^8R^SHU?F5/DJ,$9FIW!GN1Q%HS#I>@^@@XX?
M'0WKVQ\=Q95N.@6R+NZP[4_ZN>V2:@"C(,N J;)6ICY;>[PV1#0\F<?,E/?V
MC[;[%LMD_.P] .JEIXWT4&B;]B&CRTBVYAAL/Q(\R3;^ELD]+"%"MJ(I34O8
M=<BH,=U,GM1HGUNG_;5^L8=X\[ #[RZ[,=I#+M84T;4=)PPPEK; N@?@6FQ)
M?0'XXTQG!PC? T)A\PB4("Z^W3 $4DP!<3N5%^J6W /-BOFO"LS^)QG$_]=!
MMF5&6E90B:P+*K,O!9W8Y*?$+Q%0R_Y /6G1;5[I&5.\!Q U/]VGX2T=;/J!
M%SCH:X.)V6FX7;HQ9#KRMS$F55P([X1]\-+!5*G]'H#GSVI\?CSI=N!%&&&X
M;Z/;2!%VR'4/J*)O2^C/0(!3GY+8"$M$+,TL+)>B]<<^3HJS"H@]Z] <MS*J
MIP,. J0$I?"$T%BZ0E_)CSNII8+1]M;Y FL5CH)'G0I)EI\< : FY;B)5F\-
MH$2YRAH=IHIHW9=F3=Y]W>$RTL5FF.WF$P)"8(P_SEFI;C\A!<KZ;4O35%EU
MBZ2B%MPMR/R9FR46F\CN$PB6CRQ"/&>@=FRGOH7QJW#UX #LK06X5 :I+*+:
M$\IY5,+)@C@@.6JMC<!>N'0_UIS%[Y@H/):FO?C?*.[A=VSW@')$\FWHASNW
M/E2;UIC;K*O+FC]AI:%,X>OQE1[+YVK.6!8!1I,7E&0S/CJ12BP(6%+4[#0#
MB\VP2":A7+D0Z@M[(V&T.-OZN[CI6;5/#@UB[H).<6><_ABF<<8%G=&D^ZV/
MICAR7I_V@.<9 )9'ZFF8BP$*&]*TZMT<*EJ^%NI5X[EN"2JU]EJ^45",*1U8
M/N&.$9BH9F82C9N[8!M/5H_$&U4@F.C5[0#/V$@99B'6ES>Z>CJIIRLPRQ<X
M/DP\695Y58'QG.J<B;H3Y6E;!,_@&J\>4EZ:)L25^RS$^Y,_:I-P@!%\I $T
MVVC:O\%"K 3SJS1P,$_^-*H9AV4(:[ *2SB[_#R_4B_5FO&C6K!IQ%\NS;)K
MS*6N^<DA.CSSHGG\"Q/W)2"R#<GV=M*B==1'.]]08C%5_&!BH9OWF,2"R9=;
M 8TK\2NI!LD[8CI:5EU.L'<=/5WJ352GC]]@QE3_E]T+#Q.FWA[P$OJ_/@M2
M%MLAB74B@*M. I]/WYIN7!UX2;Q.U*(X2P%VDW4Z.UMO6*&"^IE@KIJTQE;W
MB>,3?:,?&1YIJ#A,$H#_-QFA#L;.,NX](+YX(_8R\TZ^RMYU!I6RH>H#3ZZS
MS;'ENXV?G\9V![Y79']X1CPDFV.@I>I/NAC06LBF2FY=&^[.SU"!N )XQUIR
M5+,L09V]<Z-:@=-%DU%O-F>D$E-1S\WL^977^]''4%>:6 (T!#&48.=!,>UO
MG5[J-[Z0&^'3P!O2%'4B67.0N,EC5]?Z'-6SEJZSIR?H91NZ+J:7[M[\B\&G
M =R.;1YUOK_<XA4@GF92/7GN'S6^)^A5,DU^NF=[D<+P2>H[#1-+#DD@[.TM
MOC^)C>Q:R%%"^:[>3/:T2E==2VVJ_?ZK.I&=.?6-+RKK'!_W95#S\R&MZ0)H
MI[VO%S\RJ>(^< RP'LGT@%+V)D$,,R3KB1>Q6;N"R>KF=..+RTL#V'+1>HRT
MY\(?T4Z1@,-FL[5#*3VH@UNI^W;/VT!%*/FF#&F4NI[%3 R/,5GPM51H*Y.-
M;BO1]-!T6B%%Z-&80_/N:.!)1K/;QJXW=<O&*5ER9S2C%I+N^\/<B9G[_H&/
M25/UU++RC.7H'"[A9'"IYR[:UJF.;6KCA9?D9:G'"8/<L(8X4 9 C3$#@-IP
MFT?^$:UD$[G(NM"=C_4KQ7:/V& KM(]I*+;NCH$UKM>7827HEXB>3O)&B\5@
M&Z9DURJ*]UW2JQE?(O.0YISV5HCA)K+JJH4]KX"DU3=-D64Z._^(!WP5BU./
MPP]\C! =G12I6L.($L)GO&_T/'&P_T@H"*/Q 6]:&=(Z8%B?SL.';WZ<H=Y8
M75TMV 7Y?E;SQ]GDX/#!]\WI<2N&]KLCL<8<XT\/'?!XN?MP<J(PNR6:]/27
MP?5(BC_[JLQD71-[B&;E#BK7^3\N$\(]&P:-ZC'HEP5[NK6F]&,9'>]"!4+U
M+2<J32;?)]*[P/S-N@-H\J'QEYU@3+>TM+YYE0'][5K/OW\3;+"$9O" K:R(
MXXX+I%ZPZZVLV73Y5GW\.(_-;Y4*CF^LV#U((6=U[:OIBR;O)Z4(F$%#Q00G
M^X>D>9-OJH"(8>&E:J\-AEJ?IR49F*.)WXMQ62N?_@6S9A*H_\%EB?:C6[*E
M/N\\I5'IKK'5TBJ#IQDX+WEO[+(1K@D%G96JJ"7HU4.RW*R+?G^UW-+#K@B5
MWN_;;@1_B5,BCRB-8'1ET?T>T %N3XQ%G'9J0.7A]X#VU)::1</@^1R:S[^)
MF0AK9$8*J$;>4@,N<$Z6/M+$TJ%5&Q&+,W6"U\P)GRK5Z9H.^7K_@-31N& $
MR;YIGNF[_X3:$]"+E H!MR]S(#[I-J9/=2=REA+%S&]=_J 5M8;XNT8Y':X(
M[)IR(2Y@Q<U"HM--+A;YTKGBN,[TD?(LQ17[/91EA)W+#&E=K2R(D&58OG%9
M])/RIRI].6P[(FXL=N?S +CW[:OCV$%=,V+^:)5.=VT3U$>QCYKA@W%R0D/Q
M Z.PIIG"\RZ YF^8 F*F,QIGIEUTKG'"[1%B:9YC)IWZF:3V3$RS+Z&%%EH5
M49;.$MTL)";0?6ND061\AUIEG6WCNH1*_,(M;J(S6V<)+N>7>*(BP<N6K%YS
M^_UU'9ZT."?&'\RB<X%1M+Y*FH$/7UF7/?O%M6GFBWHBSO7BQ(<^Z'&":;%B
MYE4A?&OCUIJ&P(JM+544[$:'(%M/1B: <L)$H*G+NB,ABDU^[)B3_YBTOY6^
M-CHWTNQ0XE0\DJ\ZP"LC'6.[T9%XOQ(ZL193[K2FZ7[P]&MXI'@D3O)34=CW
MN./>,M4:?YPE*(X)RVM$QTAQ&G/,.W)]B/O<J>+)[\,^H(BX:R:A-L*A0+)B
M]9!%HU&LC*56-Z[B,BU+*H9/&_I5V=Y:T5OJ4"Q=E/=O7NI<NXC,E(<[<+JJ
ME8Z1I6.)R$3Y=RT5UOL8U0_H][63#C[/"6>S,KSUC\:.L[Z(93PC\'(?YD.!
M)A_H>.U(>P;E^'#1FA0)4>F"8G0MA^PPWZ,_W.8),"T)($-3;+@D:]N$.)&%
M8&H[A^R[>#;H3[>HQB,F/WTT)/Q_+STWV6AY<@_00WGF#N6_MFJ;>$NAV4G!
M?J.-A;$_['0W!!"1)#%8Z*#KRF\HEBG)Q((_<NY*:]4Y-VVV1@J HXX<FV4V
MAKC^NL]4&<PI.3@<Y];9E^TG!(\X-MT#8CVZ1*6^-KHM-<J8Y\ ]# <"I*JF
MB?/,;O-W*220*!T0?\QIA]DSUS:J+BN!Y9\<0WDG?])2>1)"'\8W[/;TB!73
M10[E;;W68H=[RZ@U^3S@"06YL[)EC,^7()?1()<,+_>ASY>IVQ'KY900#52Y
M,42"1?W'_+Q^;K? CR!9,;+-$^'K&Y>%71@1NX]*J='L;J/O>2<>Y>*RN+SP
M*H828*>(!9/6;42X3!E8A?)?O_7TD<EMGE?+^^QPZ)@T,Z1_HF0IH=CMA+*F
M'7V$DC6L&&]EZLFT$1U,30HI-*J.H.FUO.'_A4U/,LS=5GCV*SQ5L&%CR&^@
MQS"DJV700\QUUZK>QOS9YB&K_!/%><]]F/&,XQJ,#.IB.A5L2)[(\R[ZYPI'
M<C+Q&8T'+>W/LXL20B+4Q%^O:B%JZPA^[[_>1*XJGO:$J8HC//5[&3T, 4+B
MJO:%*,<UW\/6+VZ>+FZ.%$<%<>B^((J!9PI:A6J$[X%Y[U&,,@B_7ZE^!3G[
M>J7%LEM#3G>IRY"XH $&T"\UF3\]6<5^^,V3:#I$X_2.847;SYZ7#$\G7'^W
M]T05'8AN_):<&H0D>U%\%9?+682"NMVFQ\]-UX]HW$.(>2ZCTC'$8WQYQ0*E
M04O_X[F.#+3)5&O?6B__YB>)@S;N>X YMSI<MUFY"19YG;S@\]X^L3+I<XG?
M0NR@_P]PR.>IX]6U/CE/N!>IA0U]6=6?E5->_UF<_7N 59E:XPBF_V#?/> ]
M6_EM4G4I@K< \3/=BZ/TMN +/XTW\_CRR;%6'8F):*_%JV!TT3>^B5+/*:_%
M9#_6J>IHWLL.#TU<3;L*M2@-3V<NX(LVG!&2,8F63ZIJR;QGCB2VE8'9_NV\
M%Q<4E5C?KD:8VZ&+&+1Z^"5[0[G[0DEXSN\3$R1S:KP<T@ECALZTX*(E1+.=
M?X],+,,/9?I6">U._9_!V8JAH7>WDIL3?)R^8GZ)_))" W6EYV12$;.#V9%L
M)9/_5CM]7]SE'L"[<AM0ZG]AM[E?@AQ!#_A?/*JY!\P5)Y04W@/P20B#7[(6
M+!BI>KN1E5;;,YW\?B,'[SPKI:E0D%L5G+X'K+$&NJI9.9[_/=VZ\KV\\6OH
M%BG/3GP=I2>RVH8CLV9"*WO2<C +25%PO]N] *][SRB9DG-6%HOU6'Y^E_J]
M&H<UN^'M_^1XV?^]7*W".FWJ5%LH<[(<I=0)H@_&PWBD=YW1<0J6_-A:P<CX
MI)EM72'H'O#;L:WZ@+$[S1G]*^:YR\+MQ,+)6;DZAB';Y:>]CB$NUS6,O/SQ
MF5]N7PU;:2LJ)MWVC>R5#SDXJ*J8RA;D <.\4*H]F%=_64Z[*783\GU]/%OX
M8688CJ7;4I)$0&'1"\K:I8@T92&'GL*Z /[0278W>X+5617,)X08I\32PN(D
MBY:6H!WZ<1_5,;-WB)P1G*/4OF8$4.M'!^$ #(7O">>*N*.&YPU^NOBT(L@[
M^E:RK7TE#JS6.I(+UYW?CG7T=^![W&X-(4@/EWK]M)RY7.*E?($0[^X]0#;2
M9]1.KU'\H;-9PGT6#,ZH5G;"^(QV&A-.N5;5_%<5QILONQ_'1KE%=P /G?T,
M-L[*I<&$YQR$/;J&29%D9\?53SX;L[T.7IO)R,':H))L+<!<SPAAAJW+%C&
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M#@^[T_*5GX="_RX.Q3_]H$8H.XJG9R$-TDK2L#.C:Y:Q<&[*K!]K+J*8,O@
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M^14^V[ID<C$\Z=I'U*&"-*%VRK.D/W-#_"=2IY4&ZJ\QOC/CIK+P>()$I\&
M?J(#<S-S:8;VD8?KQ2Y;:R8A39NH==@= \3#3V2<^JC[-N% Z&3A"M$9 $ZF
M73VCQ4,>IQX<EU8;.89XC2(083>"JJ)P170R>PIKYP;3QD_D0I[>I(]>J8S
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MI#4A%KUW#$ 6I(A4M,W_ 3L&_UVHY<>(@A7:@D0@8MY0L$Q5?>C\M7-P97-
MPI<,;HS#*?52+\&JHH[LW;K&G_< >*FYK>*(,=X&W,M/8-N+(OC%M!^AG:-K
MT[F$;>ZD!U%?@E@.&@E#4642&@(9&?/(>GV$D( 9<4P+-_Z4U#G\EK\2*<)]
MUV43J!G&-7O@';E;RTXX6L'3:[3/>6QNKH/G30A%UD91WRW?L WFC$T9H:Z0
M%/X=+;RRHV@13DAR#\BJF5M$ E]%-MS1YR8=[D4.C[=2&-F)<I3E%4&H*V98
M(CY".AN>9[O3_,X9=;IRSR14S6Z>6 <U>639MH(0IQ!\A\M-.>]?1#73_#AT
M/5D?YM!/R[1-D]M%GR2Y.0*AV5;3I>G&+QL\)2=Z\6A!A+1WI!A'DWJ):)GI
M[:9Q'Q8W)X$E6%@-<25<RS">ZEVB@4[<L(ACF81T6?+?93K$-HP-[D<]F9\Q
MKC]HCV.2DK7TS>/]9AAEC^E.)&!_MYSBS5C-" AR82HZR<EQ9-&P4"#+T2'[
M-(S%]C4WK_S$B/'U=HNUW 2)PCC][QCX.EPX<(%C,&TQ2 E0YV.-.8L#:-,'
M$2'?@CC'=UKK:N.7S!N\G2N?*;W"& $?OSMTE*M!/DGD3/>R>J:H4Y?X7'YU
MTUDR<?,>@-U,D6=GZ)K:TF&"6RRA&FS$\JI>-8H7:*K.CW'(K_<#OO()V=/I
M/8)/]WI[1&X\4Z'>R'IVAI@;ZY&OY">+VX3];O^(:@M$K:J0V:AC^>/ 1GVN
M3_D_&D4%U>2]0(22N=ZCP')-!<.3XW"S>1>T'*(F*=%O6GNQ2]ST\\Z'N--G
M$O_XF.])@W+D/(%1/A3W@*=JX<NLB+OBPK(L:P;^0XF>'RQ:?]76%C=C/WTL
M1;^=XG(X,P/:41MGJ Y-G?'))%W)\@8UM<@K9A+J9->+@7'FH$\&-)%\*RLK
M<*+9WAD.\3F#A3 6RM6MSR*[WM-<H3[/Q"%9LNM@4KA7R-#6A56,< %/SZ/-
MD/F< MH[J6B 5PW9#NAQ\R2_(S7$%*>E)?4:5S%IN]]V@9-1S#GW\F;_"FRX
MTTRQ-@"C5"KK*(+/0'(6X"Z!ME@A>)4D?>YWNY1_SD?45D%C<IZ.81\:$'I=
M&&N*QPZ<KM&O1Q>-%,2.N'^/R-X# (YJ.>-5]*/'/N^00EVI.HV)7:TQE5T<
MBY];0<8OGP9<F.K#,J\#"-\BA6?2Y)S6:FM-%+Q6%WV7&G:0I?KB*U4].X>G
MM=$W7@X]PA=#GK!.DU=<>#[/?874ZQMX9$0_>3(-K.5R1$5]Y@L\>&R'?H,4
MF E%X]MS?&]G&^B)F1=)NS-PT#)XN(Z"TR& AUOBNJHS%S[*[U0OE2)5S K/
MXC7&I]]T=S6;7M'E@25G!L?\Y92+X&>R%"ET:TW.$XHY]$036$C4=%BD+I@2
M35V+E$-^-UM8<*KHSY'Z012A^;=/R[=*&E2>;\99D#L'?QI"#,=*>==8: 4$
MGA:_Z_211+@GY]AZN5?9S<C#]]6_#A*K&4A:Z0J;?HDSH&X+%J=[/#C^ ,+Y
M!OS9*/!="L/GQ<]F4U8QSDDQ]B;UTM%,4V6.KBV&[9#+MC#U5AO[,I,ZBJ\H
MSR/AWNL9MM5C7&/H\(Y)F,[DT8Q\S10SFSU>FJ'2CZ@DR8!_',-;I24:(T_:
M*(SJ@L15UNB<<;^&3JR^&S^*JB3Y@0SY>*"&"_X5.8K*<Y&X&D6_M&)3<"HV
M*?_1ZZFOG215*(4@D09%R D*3[/&\U/J:&1:B^.L2C+#O0+37B.&4UPOJB!Z
MS"(.C%*\;[AIP"9S&S>Y'IGX(^$4=:(> >?>32++N.%K_8IA> 6?::G;UB 1
MY>+/LQ<7%<?5!8*)%0^G?G3G)IPS-T\\+&Z$#(B=+P(TAQ2ZDXRXSR@^&ZMN
M*WP."77FZ; &2D[-VEYK0Z1PS]C^)6'A*YBOKC(25F!E-"X[^G,]"K0P,&6:
M84"LA!T+>&9YYM1J=//3DP]@K.R;RJPO2.% +51$"X+1;^7K[!D$9VL(A0=Q
M 7]#U7P5SV@CX:VL>[J-,QW=,YSB4PVUM4H,.M^"!RJM']B<UY,4G\:,!.M"
M!E*50F(K77C6=UKP<*D>$>+F[[QI=-[>_%"Q"4UQJ207MY*(Y56B_IH7@9RE
MW=TSA"L%G])Z+.D(![K$6& XF]'F=.*#=0!P4@-8H =$#+QKFWJ.Q&AM2EWM
M^#5 :FIA_0'/7"'SXH$68PM TI:X='^GWAZO31RGTD"2[;O6[T#>,;R2-?TH
MFG;U];18HA<7>2[DL: B07L.F'F2]F3#&28EJ&%O$7.AL)P#L:DGB8/*%'])
M=]XU'%=H2//59L>WFYQJUW\5_RI6>0P)#O'A82Z2N(Q$*_"<SE:3SU"L4ZYK
MCC)LDD0"SJC9!NXHX0Q<)*@OTI539EICAV^<YY1/KM)DX%DM(CV3NJ+,T670
M4[-*Y'26DZ,+W?"2*)4#->4;$3%EHL!XP0ROG9F'3$JJ!RY?!@/00HVIX]O>
M==6Q]LUUZMLBUCZ<ZI^;VEZ42U77( 0N8NFF2S=>+G22R+6JC-34<_=V,+V*
MX2:DO#C\QPC:DS-MO<5?'_6B<,50A:FQ)4V@HCXVV>JQDE/,&DUYK==4+):-
M).&4MOKDF:_=>8V-3T.9U(31D#.W@:7LE%*O,.49/P9<Y]\6]W8?P^8;J2]O
M *<NSA&QYDEW=FQ-Y:]08T[AKE_?>U57$IW- T\%QH)C!6QRE)5/%>+'Y,C.
M@)ED%6N^5JX<?LL7.KQ&I[3(>X"7(*7C#JR]8C>/M8CYAX";13:2(L3!-05_
MZ8=0ZIL5B99-6>?$LP^B1!,PY:ZFUL:V1,O&E#Q7&>JD@YR 5]L)ZQ(6KS^X
M+ER5_A5A?<JJ7J0==ZVG;KN^$E[W&[MDZ R1$(#8Z^WW?_:CQ*B([@!][#@6
M=\QQ\#DKG#Y(AC;HY?@ TTEU9>^X8@_[L+/ZY(S_PY2AZ+P'7*T5W0-62_U1
M2_:H-D/D4D$D%_U8=IN]A+NG/!L&PTFD&HWYR%#&N>2\<9^![ST \7CXV%[R
M'H "QFF:AOR[/P$CXGS4[P$9U+ [G)E[0/24MX'G/ZV @^C6?QIEC)DVK>%#
M>CS\6*N^&$3>NEZL;*=\PH*T\U#9?P$+BDVSH)G,'D#*3FC!/2"HYAZPX2:Y
M;+Q8:^:/QG!I6E!ON\/8J1F%>K?7>75FKZ_2J#)S9:Q?F"62 8U))F_9/EYV
MFSVK1@4GCYL:R?=@%$R,84BFO#2>+E\WL3;IN4C*XH<3O"8FPSB?YY92;IJ,
M'Q\8OKQ]=LRLLM[R4<+%-&E["<=0OOAQ)7@M6IX"[4_=SOQ]\I/=N&:D8FY)
M2:PYBB_[H*9U>LO42LHZ&'84HW_'@GGW"#(%86R?M[X0"JE>>-1DRDHQ"#[,
M,#IGKMG?V9^\2*2-E<QMR/W'M#8.2%&,5J@8KU$Z4$WL+,6TM\;"R$#E_4:E
M9)L,5[Q-)L^+$>K/S+S^!D47)]6^<_QZ4(+QY.AMD-2<@,=Z=$:Z0RT7ED:7
M^\%"L!V&98]VK/^^B=]P^J1]HWA81'F?Z"_E,?>:6#5=O*SO0;F61,M)];C1
M_AK_U$?WI3XBHE';8KC=91<D^R!VS?J+![K?:5ARL:,R\56&,MK!Y+WUP$^'
MO5%KX>,8R MY]7<5T\CJ#<MC]X2;$=7L!D<*5#/45=8>@K-H-LP;/M<>M4H,
M9&')O! (=%N/I=I5(CLJ+3!*4Z)\E .(_13TV:\ACUHKON$=C^L:"X6'_4'M
MN01#9.\#G8OIA%I"\L)K>!Q[?,X6SD?(.F4WP!3[]AS=<?D*%_H+E-A-"*:X
MA+.'YHD]VF1JY$9U"]H-2%#9/'F(4R$3R$6N&HL%,_Z)>IV 4;LI?4)GJNRR
MRB=ZR^\](2+X 00*.['M559(^:P'?/1XN(KCY^?ESF4C.8;TAF72GR#OC)?+
M8*1. HIWQZ MDN?"VJGR\3P-Y9_-<Z;UXK@3"8$&T))H\?)$TD7=NMM4XKJ$
M234'SH:&HOCV5YNG:D F/)@#)*H"R1)=,VO9.GY@+]E?IL-%&[>P_0DVWDBG
M8CSY"8W-7"J1^WGE%RO44KN:>$V=:D0VH[HE(2K>XGK0[K6:D*&0MY\<#!L:
MI$YL2^C)\3LP7AM$NBD($ %G2.$LEUFW2](GZ" &&Y,RZ8-?'U%V-^F\"G")
M\55U\4?\A,::MB1Q$>R%F\>F#S>E@7+C2:TGKB9<?^8>YH70OC57XU2M1=?X
M,XX7EDN--GOXW]8W2H5S$&,O!=O!\Y0K=BF)O9"]Y\4@#F3B3IB/DI5-7.>T
M/;&*H$8R?=.3'GI74XD];RH7Y\3S?N.?MUP6]=G-M3<]?B\5D[5BWZKXBBP0
MI3S_0.D^8'U.67;9D3H._2(7>JL]\+&_T5I,W^T> .[^OJ?\ZL"U0@<^$"^6
M6JTI]]$USGBARP,B4#W0^/);-]R[B)*AU63J;,_5]\.Q6IK8X9;E2"$=X3JW
M/_5U1K/4!BCEPHQX'HY3K]++W3,U\>4>$)-8=O!8S:#^4JBC?[QB)[L&+6!K
M40B-Z9[0_-YCRYYF^=YI(3!C3A@<;?%%C>S@(:E6P$M\><QS;$%TU7$'[!\"
M-;'=Y09^TY[T)*!2D<=/4']+?*PY[HJ<UY<OG0<[XTD3$H4O&$%_)D59.FEN
MP1W)HC*!#N\ZV'F5GM^.F@?Q+'I@QM3TZM'1\AG#\^O@YFI?C?M-U';6W5L*
M]KU:8!>N^^*?7\LJMF"S"(-W6CY/:IJXKA9UR;D*!NM8]$>7/_WG56^=2N,P
MH%['8K?T!#::>KX2<5W=:!V<*DQ9DAS_E%<TY"_'-9Z?P!K9?BOG=U3!FGU2
M.=42.U[\6^ 'WMB>R9T]X_H?7!#LEMI[ "-UA3$R03RRQD=J'7>%P"YN>:YA
M-9#I#;JRW$UJ8[ZRL*Q/3LD@'9^Y9"3O;,@0_&R7X?+MSY>IO*3?L".08V&%
M4CNI"$=R./7A=-E%ZGEOZO;@C^[1+'G/WGF@Z:NDY#)XZLMO>W7C"YXPG^=K
MK9G(Y<(A_CJ^YHG>$^7-JJ:?29*Y,QQX0I5IOJ(>W 4*\:I1_^@%%U\9V<Y/
M']$$WR!%&V]EAN3D +Y&M%_9E1AHBPO?^T:+5HISN%RTX=CR[;PH95ST;0_P
MUX"8MGY0'LH9M!O^*T>J]>S?WK_J"6W$XB^AJCKN 7/D,P/6M%6,:@<A7^4+
MA#$E7*KOR,8UI9_-+\A963\NP:ZD9-3?T)S3>4_8JS/Y7QT-_EOPZM@^=U7"
M^]0O[09(E,SAOV;%9.G( %4BNK^ENB5=:'0KO?BVM>4R]>-2:I7-\']11_@7
M]7+&?&U@X5XQ?739H56 "!6.B?(..-HL.X 'S9;=%N;#99[;QSMX,79@2_J>
MIT^<L+OVWSG5__O _$GK5J;W5Y(XN1T!YS,U*=W.*5Q,^QHQ)?AE5^22W9\:
M7OA_@*O)?P]",505Q]1M:,+:5_H[APKW(D96)G8[&:9K9YU[P!]5-4E\%!OX
MA.#'/6!A$K9A<DB*L66*_?LAUZNOD[>M<;U2/VCJ#1G*^O3MB8CQ+3;M/<"Y
M"*K>.8;FJVU&S$24EJWK.Y@<<N8$5ZJ%38 VI&((>$R[Y "?J6?F6QG10E/Q
M*V\;*CU\YEZ,SI\&O_I;@1:+V:*%&4_[Q2%-NP?D:B;.Z?BTJ3>)V+DLDSJK
M8W+ 7!4]:QGG>V<:P%34I?JD8RF:9[W^S#W55R2X+M4!*X:H/<D4QJ/U=&]%
MHA#\#$W(>G)8[7G$I;@^S,''NS-!V;-OFB@'<&YE0KHGKDW6?M&?* M-=\->
M8JT[98B]#</,ZG& 1".,R3U@)-93/BQ63K9K$]:U6ZF",2^M6!@_P%#8%W_W
M,GR=(P$G]X#_4 E=YT<^"V_T"#A8G9K627/A=U)-1W:K]Q=(B/UT'V:K>I@N
M#[ Q+(/A2[N0WAWIU&'9^B3S%.5"2$ <O>\O E_A8:_W_WC[@HQ^J;JL<D4D
M+S_/Z%[?>#.U]B;)R.:2DDD#R'CW2!V-&_/CUS+#-+#KI>L2KDQUDZ^ @];Z
M];5^I'PAKV#4N7B&9 ;JO)$54,Z"2O3V+/"11Z1OPRP='<QCK(VLQ'MY3C&.
MZX0OS\OUR\3,$-M9A>C7B.4JAXHT"0DKDB0?[L6GE'2[F-^0CM':/8WTB)'0
ML_T]1T<KN?K3K%F.*7V>12_,;Q(5J>.HL (:-BDL_3^E#(9P7>2CXCEIJHL]
MTW0Y@#7D 3S-A#T,Y&=9#P=$*.-SE9> .^"3YI7V#(DZ1&@(,,Q'T\+7VM_B
MAT[)XVFK/K;J6,<_&R+E!MD!XL=_IO6NVZ($8-1F!JH6^)LJ]E9X'00?* >(
M%L0H3B4JC).#Q"U;29J0&),EG$:*:3K)MZ)8G S)XL4Q?Z*>^;5X>T<[+0,>
M[FMMMB9ODIS;X9R*DV'VIC*,<B0/\![J=.1CBQ1&57PJJ!UGY\"OR1E.,_PH
MTH=Y]V0ES^A_9@?\68J*T=./SH3=9GC9QYBU[V;R.+P5U#+C0_+1%26^OX#]
MH5$19[.73)$M-FM8;(-L^6$ K0@[S; HXSCY/=^WL0W%3;@P'ZTZ?3'R>U6;
M;(8R\ 7!"M0=7W1EQHL)?;7\&D3C,#:*'&]ZQ8H9B/+>8.. R%6.'N;4Q^I4
M_M;YH82-34.OLWGS\YED31=43'O4E<;[1HIL5T](DL4[V9IXCB;"0=3"ECZF
M+7 _(?52E!5S\(Y(5IP7FKFH7_-5,MOL8)-PR9K%IH?6FO;A^<;.CA<65]EF
MY'2+"%_DR7CLQ4&*,0+=D $Q(=QS\G\=I:QS 6]=S5+\>7G.F)MOUC[5M7(@
M^5!A6K+W .*TI]4H(8\$,)^OWX7_2KGV=,C5&)>>,H[C/+F1[V$UD!&PLU"^
MIO_ X-&\=R2(Z-ITR0[WP0GC2MJ@ U_O58 4#F!O?_B.Q?8Z6*@5C)1/A[R8
M&SM24<>R8!^KT%*\![0^1*!UC=<+4HQ-/Q[D@23[PU45H%Q46QJ9Z6:<^[#?
MU,K1?_,UBP)(MA3YF-L6#2$@'2JVCDX"S1J& NAGFV)O&*B M!O"(P7 &J\E
M4HRU#)ZI9KX2%//Z2+L?S4?+I^.+/1\8R/O+>'&)XCN1@1D%J6=@4ML945B[
M=QJ;?H9*Z.^H$CO>01VV]X2FHO\X:'^6(O2QLBJUJ36DJ_8@@B?IXB1@/W_.
M:(GS$^82!)RN+P?:>1%\<?2W7F_!V=[I/'8^6#=B=.+H>6O/1#2#D'!V,=WY
MQ\6^G=4Z5)V4YBMYA?6DRNW/P)N2S4/*C:B-R!TTU7H=PJV[\;HVQ97?.UW+
MOFY,WFC@.]&WCM$@;E^7F;K:APEEMM93CRSHW%COK,Q84/Q=+3A=J9;V=M E
M'E@PO)+W0=]T3Y0P&BU_)S3QHKZUOH'#2KPVWPU:Z5YB@47 $SL0I5<S)@W2
M_@\-[O.1X&AQBF)9IWQH@D(S107%F[JDT:O<J%.:F)0#9[;)AX7CY;@/2RD<
MAID_QI7TINVS54VD'QV9L>CSD;>K,5Y/+G*4D"LA_+>OI@<ZJ?EF[7YW_Q[
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MNL/=PA34\<H[<% ][S-40/+RN]![57$7I,Z@2Y/COAN-NUV>4 \_169L>]S
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M.()C^#D/? 'W%,I?PD'=,"TSA'[%-->S^JKV"(6:&>UGWSDJ.H2%5XT09KZ
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MO+P7)8[-;NZBKI)]L^3-=%X,$G"=VSI8WG >\ZIEJ+"J)0&OIBS=NR/JOEJ
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M+6$=!/D( UB7JP^#+F  _?X[&ZQE[>@G:H08P-@^-MW'T;_KM6RKR]?T#A@
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M>48\CWOQ;5_//O\G5 .\M:77(*M^^5/]E<)9N1X< P@[PP!P;'&[ QEQ:N^
MQ@\;F!_0 4"M>WY_/_D1[:+O3.!_0<GBVN%!<N:=%4F$ !"_J8LRPW5#FN5(
MKF.4^>,I7X<(99?G52'*],V^)*^CXF8:"@0-$;&=]:<GLJ^2)2(M"L?%(+9K
MX4[N9F22!/.FPB=TSD4[N1<2T?O&81&H)X5(L+J5?%YCI4.-WOU@Q,[O';E]
M0P8JN++IBQDGI_531Y3XHU^Z"MY>ZM[J 2[8PL/TD:6I'WXD&=+G4E)0##+R
M/ -#Z?P+Q/&+1NQT5C6GR&_*(M$/0(]@N /%FV4)16;<^RH2>ZL![T.^!WYN
M+=Y7@_<LI3FN#;O)4Q 6M:Y^)4K/_/0M8'W!.M.G3%H=V5I$K>RK$P*KK8)_
MEN'\C;J/NVLH]T0$VA4+&])AY@DA]E9:3<HN,H'UUN(E>;*Z6D"2% (JI^7:
M-_<X47((_NF:@BX*BO*"WV^R]>_.;_,X6"!!4(CB5BV(P3M6)UX@3<,[6)F>
M!&?S8U?V>OEZ*O;US[<<(0+\S3-H9#\SJ.R*<]G:5YR)U?C6_)JO=3CL6II\
M$IB9I@KJ-V2R[%^)!TN0(WIR<@4U8JO4G'GE#QX<R%E,N?-W(?LZ+C/)I@0D
MK*J^09^O _UN$W8Z:]?':R$DWJU\0%*[6+ +^(F^H<SC=OH[9R.^VT4]'@*"
MAS;'*U#:YT-X08YYZ\ D&30PK?),7')E8NM"L\6C#<8S3( JVS_" !A[,DL:
MRII[ PE;X)G9E:=<WW*O**ENE@^@LN0##64Q5D*G<A9*^65?S!M3!X]H2WP>
MN76NR2]XZ.(_G9W.I$#@,;# #_.+<-2ME!4_8@ E7P,V41B LMX@"<$AFL+[
ME[>%V0WY1K/[T!J%5-\7*-+LMZ?$PD49G8J$E4<3;PEMSBX!ZS^VD=A*[_B_
MC!B\P+<2UBF;+S" 8T=JU)XB:]:][^O6A/UY85)RSS/^,9>Y+DD@W$V)X1O)
M[(/@_%^><9G'MP>^/%I(PK.U](RO$\V56Q :?TV>6GDQD/T+\VH)J][)CF\Q
M^"@\X'!LGD_P^QP?RX9,A2W/> .JYF:ZI/>N"I=%7_4J90F>*-!_C4X,'],M
M"_N0&MI<8*#0:6S<1QI _1$T4DVLNQT"VG :A^RCB6ZI:B?.(C_$6M2V?)XW
M0[0U<Y=L2:3]D'P6,_-B_EOLQYPQAII%87_QHIP!_$\;^C,/N'$'(,]+B@,.
M"^@R9426T;)$7X#G^RX80/:,!'0]MF+'L\GKM]<51;+ #>J7]?#3H"C/OG7C
MP5=VX[M.=3O6'V:"3_>62&N=DQGN9[ZP(B0_SL4KHL:/&YLRFT=C"25;& L4
M[\XI8.M,TWS-0](%[.+=GN.E>2=:@W07QSHMS-F&]B3+:H&GM_&]N&)Q\P#+
MA,S(U&E)UE/5_2T,X%<)4SG'[>;Q(09P#S*6CJ467E]0/0I+*%)N&,!*Q][M
M=E=(0U-UFE)[Z$.._@F9&/2;A"RG>;_IWRC15=I6(_6QGJ0<,'<*K1+72L(+
M]>^+B6*/+DJO=MT=4<M7"=X^20YG7-PWJC$G0%Q6DH*41SS%54/LU\6S0AZC
M]\+86(+RI0AI;X5/VL-@#@IKX <F=A<BITI%TFX%O8P1HS;/WS3.G[K3^Y2+
MM379'TJM'7YC5..0UW:_&^-R/:U9P"8X#&G% #)S@HV6,(#PG6O99(;D]47I
MSDK%$UO#Z&HKIFTG+5=HX6[J*<'9+>'(2=_:;2GE[+"?4/U 2K+MTZZ???6*
MIP1-1$N^RS+7B6J0>*P8;U*Y4[9+ 9VCF8[.?+V]P.1]74&NV$P4J@MTPH[>
M)]_JY#+:<3Y=5Q26<.L+>Y)E_/AS?*8AXS^^]0]Y[@PB<\H4?2PQ]?(A9\P!
M?D"6!=:59=<-[>$BELFI3()QCWO'!US00^](KSX9F<_ID(\\&GF51&(G.G\^
M"^=#D5J3%X1P1MGA*N?K2>1"X3]1'%GL#_ ^Q8U=Z^&O0"EVQW<J;2\OV<#\
M;3J&TB$>(W(2.7GN26C6"3"_?LV\$K1&Y7GE(O%@V3T?T&HJ^R14M(F"B%3Z
MMY:BDB5LRT70-[]RG>?)4+YMO8JC%;63=B*MW-TTNO3,H(4 N\>:1,3>#'MS
MJ_QRC9^E9*DJI>34!Q50Z%K@Y[+5,3$##\?"_J<+T?>N" 'O?I[X6>-#\VS]
MY6<XR[E*#QR=&#-EOO9OO7A$9@&P]!*^Y2C7T=!26A13ZO4V6+,6*&99=O2L
M].N]KJGVEE-MKTJUN=M=N,R8*,3:AQ=[VF.1G[%63KP#G>,IY%.7HSPR/Z56
M_B1G*IKN(:Y6JX]PS$T"$=48V6J7AC\':TV11,G?VI? 1U'ANF;G!Q"8]?#!
M;@'#MEF5=[IVMD[M48'E85''CF%L.$K:\3;:UG>(QO_$N)E^,.-;O7%@>XA2
M_I(=F@(116.UN#[\*)[)*6^(D>/,/#/8^JP$]!"R?J.! 939HH:EUY:OV"@@
MQQW8448P7;.GF%%3V7>7.:0@?,M_86:YP$)M3>=V\=N<05UC*MU5\)<-CG3'
M7A=M'G<S<KLFA]3%GBO9WU9*VIZ:1;,?A?#IFZY/M5#:&(!1'J29!SUD9+MV
M"T0_><W:'*5<=R,QTD=".1]EL;^<9TW).AD4(5+<FZ%L8C.3$:\ <YP\X_"F
M[*8TS$_P<?3B4! OWK0"MPQ*]JJYWM\_*P8^!I=S'_/CN'F(_90-?L#$%92P
MK^'_JCIN5JNAXWY_18DG2SR$&R22#;_4JIVHM>\OWU)R87IW[]LASK<SIK,]
M"+O;Y]NUB ,9@E,,X$.&'&H9_IB(UHZR#OVZ(O1AX]J7OB>L\>1XR<(KVD 2
MOOD&I]ZLRZB+R0;]PP&AJ."-]0(A4(8Z0A5F6X(<F;$7/'T>U4>!<NY^R13K
M9)^'S K>J0/'?C-^AV:'=*:#J;7>ZF["U$@Y%E^D$N'9&$8W_=ESM7.XB'_C
M.>_D\.AL76@MPV?5C'A?)/I7?>J?NKI3HX&8YT8/,R74W^S&^D[! TO,06%G
M^_)'J_:)8;;!0DOW]_L,U_@&K!!)[2)[<Z5UE>S)\HD7GT8$"L4>$?56&Q^Y
M)DPLR2DGWE?/4V'A=DJ?T:MJ7=XQF@3SFSU"SM SK*&52GR8Y/L]F8AO[^,+
M"3^/#:=Q7!"T4/?K];-=X/3<2)>5<G693 >.5$GT%>RBQ2OJ)IT,UQ:Y5Q@L
M>,%ISOW] )K]0-9G(EQIZYN45* (*!SF67*O*2>.VY_>9LBFE;^U+4#=FU%J
MRG%F5"M!R[HF'K=NWNV==0%U'[E<EV_(P?(3<%;2D5>PPK\CO7LFT;0#RQC?
MWW8*<A!.$B):GLS&U YX&Z$5K2YOW1NP,C3:VHM%PJE/*XJM#TM#M'JS Q0M
M"F5[37WA[:L,$RPVQ*"D7\%%'W Y%>A"Z.#BCS6GSR#$WK+W:ZGX4SY$">EU
M">"(O\K]*@<<S(EP'PMD5>-'L)$:RRO56WTE(9J,,T*#9OEV_<4O1/T:K%.]
M-/%4:0D(L8[(9Y]>9^WED#7G-JS9URUY44!Q"(,YUC!-U_ZIY0D=+>H\QCNL
M-.[MD7^W(G#_ !)7^IAALD>"=2+.8BKUH1".C'7<I\0J-297EZ_"*Y['NDLC
M2J!@;F9-&$=I@T2H9.RO=VC^9O@^6D8( ]C'BG*1T&DA08:M\:A*H527XKD6
M4D_/MGS@)_YH12[?];?MF0HZTA^9''OHU9Z2SI>35\*\_?Z>6 ="J:#[\J-_
M,$7%J^$*:T2=9N8W'F.U^X!6&W9P7X*&BY(ODR48$35S.D>Y%YX:@XCB$D<@
MM\MA0DQ^L4;@9*J(K9N(CMZTCDAR<MN$7NVMV7O1[6D44;G1LVGFIGIGNE 6
M>VYG24U5HE9W$"D&L&%6BP&49V, 6?PN#!R3?,,LFDH! HBC0.5?)EV.#F?]
M=YHAX1C "<\<!C [AGUX-&E*F>G-<0_XI4G5+&%6?O-;3D@YM(RX(+HA=LL^
M#9GCCOAM>Y']Q<#2ZYWH(2[PFMP]\PD&$*>F@JT_XU5J#S(A7\'GA[0/\8(C
M73+PH X'])T\1" QP"\SB?U5DI'-\6"[$OH>]+/#6@T\+R[ZC>VWP>VI!#05
M,,3]KN33KZ]$@(HK*-*U11%Q"BX)]";75OU@B;QS66/_]I1[6?QR#XW*5@E%
MAJW;1?B&YI\H*]E_O% B:K9'CJ(KO%,9.E,UC9C!KW]EF6BJT2[WY/(J-3J]
M>+.-)*L<&'5B[RW,? 9W*G 4:TI/N&I\Y]]KY6_A6B'N&SM2AOR//=@(68(!
M\$)O'#& *CUKP6-MKARYX,+Y!UK$N5,Y7/RGLI>1_LK7<F$K#34_&YO[OLF/
M=$0E'&-=6.;+\] ^681J>MFTB3*:,KT2[/2]G[;>V>5087W>%MAE2#[XV2*"
M-TKNC0$E\/I!_@Z:%%Y7D-?A[F$4_#7K5'V4YL#!E5=OIOJS>G[J\=RVB8]J
M&[MZ?)."@9OK4?VIH/_C-=H,>X7&F,/+A;FO8B,'N736RT'&UF%.+4JE8M>.
MH=F\).:;F0KZWW^.2@]0CSJIWO5JHY[@,WGU<#UGB7_FA$+O%<?*1^=[8_B^
MFX&4D'Y%# #=4'Z:+90G+./YH+,TDR%1P>ZJ;/(VX-$?'C')52)B\:QF^W"J
M1QRO110:G)W]MJ]THMV4$!*QM@S57L7R5EXXW6X"%BQ?Q5_.XT94KIM= 0]
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MMNZ]C'5Q(JV4IZ&GEJ.=N<5Z+)/BKY$SMR21D=62JC"1DM3T!%-)&3+MU'_
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M=DG0M#<@F ]6:Z;N*/E94Q/TU=^8=IWNFEJO=-<F]!IJFM[E3>F5=N="/<4
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M'[S[M2!6E2U6M;A,#V92?Z::U)A9E7,+L+J9)+EG.?=JBT7$'5A5<+-09IN
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MLB4^5.6Z_4^5OIY8S!Z+] ._G*4%7.?+LJ'A"W$.7IR1W'F2@T%Q&G_PG6X
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MW016*BL9!29%T;;/QXIW@Q^PD?V./'$*#Y1I:YG24YUVHE99D/FA^A@O*EB
MR*L?87:R1NDN097\4;",V?#-4F$Y A2^'##9QM8T*7*YF3^1HO1]3F*><S30
M_A88MES+0!AZ95^DFJ7)$'1A:GT_DI&S<8=(; +P<R^ W9<F:/Y(7G[WBE>W
M/'22W6@_J?S%R/,ELN#FN/E=94=X,R1WTYSD. )^FK0- AZ"53_=5Q$GB@[*
M8*S/O@(2)7Z^ ?B4@?G":#Z:G5;E.#()];U!WVL+1>WI/!4CB!X4XQBFY4J$
M95@>KS="OE7AJ'9^F/R=8YAG/G:-=FDAS5Z)^<48Q@25[)NHW8.@0!%L#0U?
MOP0QV_\Y?Z(YF(?\'<C16*7:7(->C-Q;12>!2"?LXI\-@!*9[R\ E5@_*;=7
M*?+/2VDL7 RXOPS<J4$V(B +A#68##)L2.?$RPIG*)0H,[O>#3?D&WL=V,3\
M#$-U$"S-4; 5;ZXL^K.6NYD$*T^J)8L%P!I$E+5;QP-9L+('RA,B>AXE\X)2
M*&=Z(?E[#7)\@)6,C>/#B**T=>LT'[.WX!2O#]W7JA7/=3T<A@\HC]MU<PAD
M3E^G(I'&R:NI7C4M9^2,S8VK4[Z<50K<MK%!)$^*0*^6^1\L>)=I'ZX,&[K$
M;\R1=<8I;/<6NFJ;C/_1R*_L]^=>EFJG-#]W"6'*MZ3;8 UE#IF*\3.%Q=GE
M_U&VLGH42]N'WR@S(#,"L9O1@,45*5I8/(A\T ?PX&CD:)2%KT$?^7MS"&U>
M2+<WK3GR:5\?&.AM;?M=2V*/,C!N:[%]#*YEW+S154S8#FL[]PJN-WV#",FL
MUNW2 !DMZ,9Z9;)'2JYEY:9.C/AAGL<]*DL=R^+O'U?87P_H<4;DYACO2$MA
MN+MQ= 9A,Y=[U&6_ZIOOO\;_[9;,_"MR_2V7$#PI&Q:=4NG7&XY95&N<9887
M(2ROUSZ?_[Q660[?,=U/7C$G@8 5P^ VW/4J,QJQT"7>D O0P#V[ADJ?]ZC3
M%^YCIZU4F-;"^K(M["5U28!#+$RCJU".%>Q\I7X[EKM:CTS)<'] <NEW(&)A
M 73,(UF&8V9,N=Z7/6+&,BT3'T-7W[GV/FCL8+V$1Z"ROBSPU;:%/IXV$Q%<
M#0T33$S$C5C0BO'IZCON!M 9[!]4"&/?(.NUP:_E8NWN\*]#5B\1#-C2&X"<
M+>9^KL)VB=33K YG;G*[PL: HR&VJNN-#WTG%2ET)U:E-A/&]3T(@BVU#H_[
M;4G0(2F5H0W<7>?V"I_I9@P2U+Q('?6>)-HFB*=H)'&;@%".U4R3.H.Z+N9!
M;K)PE'%*6?&.F/6.;@MLV^W*M='>#ZBPR_7#V%DM7K=>1UCE8X%FA%J)'I?A
M6(0=$>GFO"EM6<E@=<8CR)\K@A7:$^<TS]S!U*7WC.AG+%>@>M]#*F/8T[&F
M)D&0+N%MJ@!%*@%,&8- L@B[=0!-.=9UJ%O2XNT"1XLKWI'20MZ5%#+,.Z2K
M?H%A,FWT1%RZAY.%)VI;KGC/K& )R/SL!X7Z%).>-C[9H#=%'([['&E5B0WL
MZ_8%_UE4_NJC2K 0T]X"/!]Q'B^3YCGGJ#_Y^9F#2W<MI6\8E5(GK;S<?$#\
MT7H<XUKTC"[)O[JJ^.R$J8RY]=N JJF]9V%:D^2..;61N=T/(^_T-Y"3>M.O
MIB\OGRGBMN2Z96L/X%=RMR#*L?X& -6[@L159!'91J& C\!;AVH?(NJE*R5#
MM57[VJFB2SJ?#^[QZS+J@L1XS7^)>7T%/\NLN)^F&$W!]8[<9<=0Q%OZ8=XV
M4M)]FKYKP/&2+L&R0_:OB)F,5X<AR(Z]/FQ_5:#!=LVO]]X7B;NQ6:&R-X >
M9O+)@_769G1K%^*%HR=-N5!@\,_:QKKD5NA2O$U@ ?2_-DW]U0^T:&LQ@Y0?
MDYD8F71C@E4OI>5Q.6*OZA[T=XG+#2!H#^2.H/$&J32+B9K1-<3JQM ].ZX?
M["*H(-==\R\%G9BODTC9N6;-X%AN:8H8^ ;07H(3#JBZY6#7^"+MEQ=9*WI_
M3; <AFWA6KB.EFI(*AEOIVDJ9]\G9]\CD\JJ(MG$<M.M_>69!<,X9QP/,SS_
M0_[N?E:)JNFLGI,AQ@18(!J78[>B,9'_>%A]/\55TM%)Z^/:9NZMX3.(MV/_
MH:/H(0<\YM];I)IEBVB:F3T[LG1^"2- N6"M(T9>\FEEJ_XUA0TL!5!NRE+4
MP.-%1U=&OWDMS"U=!@5A08J*5$=NB4D967HCCON[G+F1\?^Z)?B$]PK[J5R)
M5=I;AVM.&A3,O/BD!E.^PF>):_4-T)\\'I*QT,S2FGS\=L_&M%II_L$.EO$H
M#0!;\*ZL6&D(5DR@TY>4S C3%7I0J87RC[L!$"Z:4.\21Y&7 7P 3?N(J[MI
M?>'+5J<9)&TQ*Z8?.KLXJ'_MSSQ$#"K07J":8@@Z+AQ#<N>V(FV:U3M'O-@G
M#GR&2(J\EGL <AWF-C> SRRO+OD6.78%+9PJQ[+Z)!!MD'@TK1Y&JH_?EN"O
M]&87U=:Z50UV(\ H?#ES/RW!>!,F,'E\+?@GJSH4^(,YQ^@K:&>ZJ8H8:Z&)
M+DSB$3YQI6L9L(J_E4K?&GK "HZ@-VKISG8DW?[JW"]79QJZ8AQ+%RWV^TJC
M-'RA_@&^Q5<B">G+KW)<.])TRT973-DD7-QU3>8B!4=THC"77J& Y\+\#_MR
ML%$F4^-[:P[&BO%YG( XA@8"Z>MMP+JC/L<>OK7^N[98=8OVX1O TO,TFL0;
M -%.C]15N]BNLX_?S^9KD[<]'KI80PE_'X+(P.E.E?*1JK^GSDJJ\QDW /@$
MU4:-]T=^<G\;S&OKP_7![04B'X?*BBQ(-\[$ G.7_$$V"30R'6R.5E.,J\O4
M\:_2;DZ4"_,<WQ:/.PT>5V?T25._=R:1>L5M_@KKSR-RC/3(M#XPGLS1^*HJ
M&6H4+M$9[+.*LSPI,^-%OV;F:*QNC\2M:$[N1ASR+=$]9N[V8HESVY&G9:&Q
ME(?11#>=AX,B@C<2"/3B-)4WU#&6H:F=]GV$(E\B..#J<IW%!P5UK9/PG9T]
M789OA9<F2RSQ0O[P-\L*'#(7(.45X,,9;)<B-0V%JB-F\%F8][GMG*7-8K#M
MG:SN"0&L4\6W%^W]@)7+YE2OK;2-%MXB+$J+T(Z_<&?FM:?2."LAP\L>D.U2
MQJ$RU!_Y-MO;]4!SO++\]FL"[$VLC.8* 2\%0'0R?D=& OX2D[7)$"@0VZ<]
M47O8DS*%>AML4ZRKTB>WT0H P=&9BY]Q#-@VAJ%^1\OFX.W5<TX#_6\JC_&/
M*Z"AOWN 70$,@S%Z_O9[03'#1JM9OK_KT8U1G5X7C!?PO96%'BY5+_?9.3H:
MNU^[!.]!TF*Y5>'^,E;Y;.L><(W@E\WJKEI:O9^$/,! !HT2Q+/4"KN4T]=Q
M7,\KU(6BB5<W8&X&5XJH3.7.)LUX&S;M;6-<'F?]%_[]7)O^(1:%(R "[FDP
MZMW><=K&5U.GZFA=VUR;.EK7%'Z@M*BY$K3UVTV>V0WSDI\FCA \5#6WN0ZL
MZ_E2_N$KE;THZ;J,)%(1DXY3'&' =0E -\GU3OA#)W;J@CP0E(N+<[V_.EB5
M2AA-CKYT=+ 16Z9M7IG?RC.XZ.^,JN=TYPR&+X3+<4Y?8'82ZE<!<&VGNN4R
M#MCGCH*GK*55F<W[UZN] 3^;FLR_!&I=<>]Y(0Y/K^,Q[;3S5S)^&[1G/288
MK3 >:7!NV_=B@H<-TJY/NI16Q-^?9XTVVF#?B^;8L!<VHV*4]>N-OO/F?G4P
M^E:"-TNP836J9(N?@GF;%(B8>1"W3^'(?@/P(KGV1)K-B,55EK^10W_=K'#@
M\1.H4[[WH(_QN,=IUENWQY\.&,;OYF6=@B+@$4WI>]7W"J8\WK@##9^9_\QM
M583=T0O15( _L=69I_D!A G(W .X+HBB]Y"?<82SMH?S1'%<YV^JZ+^*OI!Z
MA[^OZ#ORYQ_GG4"7RZR? <EMIZ(^?@'87JX,&$UU(SH'?7*%%)L>8>Y+09F.
M-X[N];0JK ;<<Z.&$K/'TM9>O^JA3SX-IQ;=&CGDQAM[&S1@EN$B3XH5O &P
MH9"XYJ$;0 XHVQ#X6?H%RV=_&>IXJB&3<L>#=:$]#A>$VD(V4!B-9XA-7JF1
ME9TZ_=9I4Y6:NK47DU7 +'0(77;$<CNE;N#. @6;'65-SOH6^E; ]#> KI/)
M%H7K]OSM,V/1TH'JM]G:.YRT^*X)+WXQSQ%6V: '9V;-QD\:/2#-%6KCH!04
M:F4=DE$,\#A_N?+IQ?2G%R>V'])//XU)_YDZM;N'=!ZE%6Z0,]YI^5AP1515
M&IVU>WX#.'Y;O"_-S=07NR>MZ_C7LKY&-'?1AOBA1;/$#0!2*&5X_+O/Y>[7
MX2!4O)IDO=+==R'RC$5=!""L0V[UC\<O?V4Y[Y*XM@/7:QTH^A)--*)8 UP/
MU>D0^Z<)1KZ8$3NP/Y>?^-K$GK]!:5?.X%I:IQ!>QW;S-?!5GXBEMRLP'$>*
M>7WA_^'P^=5L$CQ!+IZR4I39=9# 7)L3/PVM5+-"(O;+TS<P:_F%'T->NE2'
M:V3ZVXA[2.EWB;W*+)E>;7?0<VV4Z%!8JLO3 >?F_*2B>>(^<19-@F4SMUOT
M[JVVTFGH=82M6Y_QBAO.4"@N)\*'J>W)/-A"F%@W04,E87D!3A4*,E<7*>EV
M7FM&YEH)XT42JR<K=K?00)O !H7/A772%[ 9I4Y(ZCNK8PR$#_FS',HMO]UJ
MTQ1S2A_I,UVP\+@2Q=%6;D9',R=OE*';-&3W-R[QNR]BXXOF)7SLE_$^(4RC
MM08#T!H 0[1Y@BR?-[+_\#1P1]9,L)E%3/-\-.#(Y*P+8DYM:C?3O$5?EVD+
MK2VX?.-%O:Y*_,TDXP(:5"6/;O^T*\U1ODTSXW](6XF*E6/O]:1BK-M=39'@
MF$LK*_&7Y0 W34O+5<YOIJ;ZSSW05J6LN$:%,YY<78\ E+.]Y4SAF!88^[0'
M6"K"[/>L$%A>S[G_<<:U7+*5B3>T^P8 G-6>E.:7:<5%'\I,SECU=_7U&N61
MM@!_.VMXP%C0(_O)'C(+>2C>5P8PHZN6-R]?AT@,9B^Q^'9"PWV[P+(9;1)3
MT.H,2HA7C)E&>.EY_@;M2@% #U/72A"!NV\&H<;4NLR5<PQ9))3SD1G9M#\^
MTO%_K5* 52SX-=J)TK--*14,3RI>VJ@38^ELJM#J$!6#W7%Z:*QVFI).1OW&
MZ3V\:_5X@,WMI-("5=IGL31"\_J;\JGJ?DY=RJD^XN^4DEC0GR66KJ>?Z%!
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MSY7,%G9 !<>0@E$GLY_3>WOE!&&KK\$&G+\%:3TZ0W?Z:&4S(>G-Z(/(%KT
M>X_\X.D'KD+E18 5<4!&8A REGN<L]SB;8]M\N6)#.$?0H^L5@X;!_Y"V"L+
MQ4B1F/M4\MHRH9*1W!0-_]D88H"1"\RX$23(($C0*6!HR;DZMOW;QD[:T<4%
MN$>2.) 5?3V:@247F"?*6OKJ+O?[DL)<=$Z!MV*X[B@GUC8C+\_#D. NJ#&X
M J&5O!^[3;$>TTPVIDCUQYYJ$T:'"0L7"U,.E]9QW(.0#>MQ<N!+T,WVLW+<
M];SVWX\<+1"?-+0<Y%(;/MF49<7:O(0X\*M,%#CPV(PF$3/"EIC!<QD&+BO
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MY2P6=.8\D]4!13,ESPR8^$#<;+X<QR.09O7:,7\%RY_V\"0Z=]ZT]I_SV<>
M@1C/Q9]'!. *+N=\L6@=VUX4P8;2A,%0E;7!C_8P37I"P4Q_J9]D-AQ5/,2
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MI5NJ$2-B(C^]8D@Y/78RA8_I_NG&M./_8C)E\.(U5N@URWW)R[)?S;BV_;,
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MG^@R+WF)*?\7C_XL:4=)Q5Q_?,>A:-A]V M?0_0;LDR"S5I6H[.:-?J2I7.
M.<\:CF?\W,:(HU-KGY/J/YYU+)S&\7/4KLC1&#K61=84>AN&O%%K9M>$;.GA
M;):+X$8GS./X +!VY>>6EDDN'O>8F#>^U$=$'S$U _*@%7"#R[W;!*#Y$&I6
M:U_C C(S_ I%WATSGC4\L7H?=Y,V3GHK:J$.W9[:.;[INXN;[1QIT!#K<I30
M5 9D;8C9IJ^W=>TZ=])73> \BSL*.6<_U_#M1<^0C3!QA 0)P]61_? ': 8"
MH)JYY6S.H+P8I7 &T_DI>EP. D'[*5/Q+0($X.B-WNAV*XV&;GL5Q.J8O\!
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M.J1,W_W$_0_VWC,JRN_K$BQ% 8DB.8N ("4@.0=%LH#D6""2*8N<4ZE$R4%
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M%P?85&HZ" ?7_3)YBP-8CF!E)WY=V^  \?N9MP'HQ0%>B:!NM<C"8JGX%@Y
M?3TBDAL)_"OU3Q4SV<;R5*CP(F5MO@BKU V3<M5@8)N_EWOO3X3::,"=W$W)
M#+_0U)D 3.>=UC>Q2N1TYX@[8>O^@0MOQI2;RGO8Y9)5;_("<0"Y.M;ST[:>
M!J#EMEY2]2Y,@>AKP=,]7O*B4B'0GP_-BH510!Q J)^,XV86(D'_SW9T7BE=
M8:%.<@<[T!C6&;'%XZO;# $UO09GVAQ%-28D=E3O?]_QV^C4(M^ZQ,_S!S0>
M0_;RD\74$QKT$K)D2GNV.RT6)*G\&Z95VO%?O:0V;[(?SZ#431Y.<_UJV+Q/
MI:WXP>C?GJ-X+E!BH,4^R6,K\I-I7FYVGFN]N62WVP(;R'6/IA7.#'W&75H%
M&_.(VG.Z>5Z-87!('\^-T_$G.I<C\"'K[:3@[6IR\GS**KSJDI5#X(S0W1NK
M/=' TS@\C:\9AW>!KYU\?<E+64X+S66YZ'E:=SV4F=6&37@_WP:,_7]X>5&1
MT^X>8B]KYF@!&,%DN9*,!PQ\65R43>8W^ZN5NJJ!]J$]#3&W5##=RYE >6FB
M3?O<CP]+4DCDYR29/ K^ T^3>!B;I,!7=K7-=9$K!'0^!?(#BV\=';GQLFH/
M^4,_["MV,=S_/$"VU//0"_:6_&XCPW]1(/__4R/RRTJV*INN^9$#8>[BO7XN
MR?K6+W@?V">M>UA^I<GOF9O:4K-M*;?SS\W,M<09 IQ;EQ>1R;6_ZT"4&-8[
MP!?#6"F9;"/.HT0HG'SB''%-G>>33#S_<@UDM=80?@<'8/DMVU;@RQ\1Q+#C
M]_0B6ZMNABR@CW9=&SOF>5T)G,R++M15SI-<-A$\$A_@WG2Q+Z_Z=Y-&_K/A
M;<+"VX[8MBQ.A]I.1,OQ_OU]( ZP?' =X6=XX^Y\0UKZ$3.( [#-2V%;XK A
MX-Y.'*"ES>#?GH*#%:D,?WK]ETT [E/I1P$96Y36(&7PM?KOC1R.1G_F:]X9
MEC::)Q2!#=]/:=8DKN@B'R\K%\L SD4VLY@QBL)-3B(7U\D[9_:$SZ$+3L&'
M(Y,MZAIC91[^BC7C>U9U(5 BLM;54ZZYJ?L?/-CR1:"?0G8*\CW%H40!SZO&
MO4 [BOQ\X4!"'$ O?/&J=Z>WQH_NCCP 0  @,@$.%!MX,J\.JVKTSX=2:1LG
M_K].&_G?]K_<W!L//@OS/W3R+WU)W0D=[&)EWT">R46(K)LL=D!LNZK3K!.V
M'\9&RJH2+/G(?;H&SFZ61QJ55)]H*:CH?_62-6BL:JC(S&[ZA]:6J(6J7),J
M6.@L;J5(YK,HWN2+"9P9OQ65S4KNW%XD/#$=&BG4D@D)S]WXK=5W?#F5H_4B
M&#,1&['RY%Q:+7*O1BXTB*-B;A+=&4AW<._;!VCCWQLAL^1UF'^A^IKYC-8'
M'& ^3;#PM+Q//P1+Z^XS+#B=7)0;^<?R_WH]/BI'#EU5&&O;28=N0LP(>BPN
MR+863W>A)^R@6\&U>/'P!'&YOGC):'@'G8I5:/2^\6>](9R*"\<!_(/*4(77
MAL?2DY'<B'>[_[DO)]#TS>%P7=F[OPZI0FQ;3X>*<8! )O+))E[@$K;81?]4
MZB\O9:/R5>^E%]ZQR->=\?"N_F257B_?%L<M%H9)D2D\S9]I-L,DWV:"MWLC
MS^;9E]O"3N!E'X96.S'[MY3MVGL?FSR1^]R>@HJGZ-?;%X!RAN^1)B\#UQ]U
M(2KCGO]I)>=)3C5KF5_LJUT*>@[-O@:/G@RQ:H["KV,DAX'V5[OFIMM^L!Z$
MMADU&%F*%LK2Y^3]JZU(_>5_V7^0_VW_<7N3PKT1W?O<X0E+R3:A7*AL)&"#
M_YI@.4;Y*>@IX2WUI**/P %0]:R9[MXP N$O;A 1XKX'>X^- 3=W;L"CF_"\
MB%+F?)-BD2IIIXVER1\A-ZEZU5^]CO7SL*:E3U#+%I&6.( AY'[OC7NF,C8T
M\KP1Z!E75H<<??\T8(/_8X N^<)H.?E5J.D%0PF6 LUDQ:6 U+JJW87&(PJ*
MX#16LL7D.X*[[@OW:[/&V_VL:5_TD_1%,TB\+>4?GG^Y:DB!ME)!GC+;=J@S
M2^YOT<R%V3^V ^Q+/[KOUTT]J-D4:N%@)8ZL;HA+IVS/XHS_**R^##MXK7Q<
M^O-: FW]MR=QFTS"U\HL"&*AH WB%R@>9=<J&ZQ8KETDO%86):DT^B5U\#4)
M!X@--J6!X7-P, [94'D;O>.2^\)^80C7-AYD-CZMX&N>[C .X#Q<J\!?FI_/
M6E'U"L8! CY"3;;*I(5RMKZ)^NGGOY&4^TH,751.F\C]F>R8A,G_/;=Z?HL@
M!J]#_RM==OZ_:DRV+:CEW!U=A](?C&%13A;#LXEZ+/CC.WIYF!R& 9H=Y10J
MF4E([Q&/7*8-F/7(( \'0)1";^X#QVJ81:?T*_U-ZU-4YJP2!F#:F^!RM:]4
MSLQ3[ET%TC:^$ZO%3L;"R:GK8NH3NS7I+]VMQ!.$PIB)8*^D]&>.H'<U^+ZC
M)#S&5LNRK/FD:-[$0Q4N)FZ<>_Q:4U<&9XV^J=\-2)"W8O4I:N^CE\[Z7IS"
M?'S4BQQ+ 9.7EM0D9UZ FK*2%-UD&=*[ME./=CYU1(3$'^C12>, WH=+$\X
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MI.Z/^8*Q,[&NE65:'D.'HCK/<>R#/S[N!DU(X3N!Q>UGOGJUNVQO];S;-W"
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M70K.?DV(.W^U!!MH;EM>3^.75G-2><KXFN\!:Y>/&;;PL#1'N+@6.]Q#'_-
MG9JN$VMN+)=D<M-;:CS3:V-SOTSAW*6G O&'Q% "C7^Y,MA)>F9K(Z16(<7_
M-O\15/H.9DI?OX:8&*+98RI5?][YN)-\5;G%[96JAFK6PI.DS >ZP56.?<<(
M,HR"QE0SBXVJZ/;SO:NAZ:,^+B+E'#K9YDFFQE9XCL,YEK'QK7:K/-W&X"IE
M]?D]J.2VQ7)^_/"095D_D9BM0A/+*@5L /XW0&2<+08[[RJ"+"><DY4O1)+Y
M7F+U9_>*YQNDRB=EH=MTJ70]F;*JG+;[95.%W_V7;[Y5'^8_9S8N]$JNS4")
MTUTN$6T#OQV.A)AVIIX+\5YID1376#VK8PI.&A;J 1:62\(E:C-'O._3=X18
MBA_5%$*W-^*-MLX:"[O2!Z7ZKOLX&AOFFB)/YI39Y_0:SV!<GZ[5(?X_4JZD
M@]T(-@H77@5*!@5-_#7R$?C0;,C7<'9TM9JHQ3700[R!J9J53<Y;L2!77)&1
M@)@[<XYVYC>)6570]>V ^)I])UOW:J0CUI)E0A9Y2]S%: LN/<47(\Z!T,+-
MU)^B.[[Z?X/85$;:3.H*,6#3MC'(6GBWX$V6O=)#_,=W90\6]L;J(,UL3M(O
MA-5WPAJ_F#6[W?^K6]_+A<1ZAL#($/!CYL((VT@:Z9(\_DU&_*^."JG)4J9]
M)=_4AJO@/$YF_:!G)D/\(&W$,H)(>?E*XQ4PO;HA=NU5G^B>_ELR]Q&7B2''
M!3)D@&B58R-?[@I=V!EHUHS_R!+K"O)*7581WL,_5@=_MZ7U;YY6 :Q&N\C=
M>'Y<)$.DR57>YD8%@:J1R]R8:&A3$U6.MKOH&L8)%,"12?>*RE-U9FR2?ZI8
M)*7%%1$@,V';1+S129505?0+FOH85;&>@_F0H+Y\HRG1\<U<HQ)?G%'M&-;1
MJ"(M!+9;+CXQ-;1630A6ZW2GL8SI<MV[T <Q=E!LF3"??>=$::9^)]EAZ<@N
M%U\=\V0;Y*AN$HYE?%BJFS&Q1P,K'OQ7BV$-JYF%/?31.3(MP%]YC!;B_C\<
MF4H;= XW'&*=ABZS?9O>N-%6ZI&;GX_<J8;0C"N,&PP@'WU_OGN=:H6$C1_E
MPE7JM_=O'G18@E]5.4K'UY:<3_4MM])(1L5H/+B(5)(_NU]UW>WH,]5->^F4
M REP"+7*LB$9^TE SP$0^K4U63(?(*#4XLLK(OJ9AF-7P+KHA(!=I&J%%=\4
M_'.6PN70;+;GB;'7/DE>-GL<=+A$-W_[N,[C]];;GD[\3251L)UG>9W7KILY
MWYA(*3.#Q*F&RSQ^LF'?!GW[JA]J:Z'.X^"" X$#F%=!-S7>.(=K>7ZX37*F
M]?7U1#2TGISO5^T^SQT*(#WA5\[DQ- 'F<1[G)^^H(YKK0X>N=?)8JLURWQU
M6D=^;EH"><;30Y.B3)J:;FDC.PP#P@$>IQ]<[LN=4!B+*;#2IF);*7$ Q<@]
M:?[EBN4FB3WLQ%GP\_1S7W^!'H'HM&+^X)!6?H;SV8C.T@L6P]S0J^FSDX(]
MRSU.X.:H%H'I=K7#T0[]T[-9W<3)-5.+R"\RX_<CM(B=I %-AK#.2\/"$4_G
M#T7C0TR.NQ3$+QB_G=RMD%9?9I2CV$U8M>?+ Y7RQ$RSA'C? !G?8-QXG??V
M^4[%,GGGA%U+()MN$AQ+_D0ZR1+=H.E\$(]/AHA#D<)WU87S&L3<1H V4^&*
M%'>C*)PC@7 #!\CRU:>_WLEI.I2M";P3=M!5J4'C7OGZO1 .$&BP\46:RVY%
M1#E1Z?.Z0,U3[2P9PGTYGHW>SJ9S[7L+3[[#PQGOB@J<\'XR*%7L]I\$#VQ(
M'XJP&Q1L-11+;0&=1TLSG8)_D#*^KOU)>8%]*]?<(V83Y7$-SL1DX@!/)NIN
M@OBQ'T\GC8Q_P IGIWM^]]][+\*+_"@P9(N!=:*Z_*R];#=VKS@?A4^W9;/3
M]9V6^VCP- ^=RCS7>*!.N*5K,M,/;9>(RA2[4E[6*.7^G3)ZL8.A;#IYVH!7
M#-HQ\4K*+N+H?J8OM_#<I2U%PY\LN>!'>F[[CZJ+?B8;8NJ>)?<L.88-#SG
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MB,A.@D]2"WP!X$#MC=_[)CHV\%A7*3?*>QO\S=+.)(.)>@ZTYV^Q;FWA0VZ
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MX"(?6X^VTD\;,9(:R)5B/.G*B?V,5O]M#,D#P#:"8?53:Y>:NU!ZF+MOE<O
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M<QO1X&FYX /@2N01H7\*;ESCZRX.<G@YW--_7G^KPIA!_.-&482/C>4Z$["
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MI//RU$$2!1-%%:T:+AN.OZB9%6.*5$+D ^Z-W4 ^\X%$MG604,@Q$R'P[P/
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M1^R+&EIO6..Z6^#W;]48_EJ*4OUY[<..,7S+4;CBU3G$\')NT:AWJLQ^-];
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M.M:/.^;$M+L'[7R[VVY39?1PHX[P3B.?^76L&;7><6EPQ,FI59+G\?V=J2C
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M=5_E@_WF%=^VRDPV4+JHO5.14_W2^K;*B?V:1\@U@&SHQSE#W>F;].]R)]>
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MHW3](U&%1%?\Z<.? VEJUI4I\.9NGZ"MCA-[R_7(*B^8S.+=5Q4IBHW6P R
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M71F6=W(CFI<3)-ZEGS+%+';/F5'EQ!!YLS%6:<:4D[JYJ:S^0()0F41)@A
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M"_W6X/JR-IHUST"[A(!G)E61K\AA!/T*[$6S!J]8TYAQ?)0#[V:4I9VMU="
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M);^D#P6J4G@)>:^-52I<7TYI/"4D<XI;$KKEPC!>YE9%;(#Q(M1V0[,2XN>
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M7#8+6R7\UP;Z?SK^;,5+LC6UG,[?ER2<KMV"^VN]BK(*U&)*#GD@H39H/3/
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M\5*&H1GFGI5E@MUB-G4)9L]$Q="VR9KASHZVCP(B M7\0E3Q]43H";/<N;$
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M;APSW;< -TAY!TP?VGD("0_/GH/O04 M@WIXW=6#TFI?#]8^?+BN[_T#:Y:
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MQHXP%6#-.CW'^ #U3]@+-7X 0+L8/&T=[UO3+(2=<4:QV+I"GH5EI4J7'?<
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M7KQ/MH]TRE/J#CE-K?HZS34Y_&+>Q^B>H7ZP?XO*F2T YRHEA?6YS:'5Z%R
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M&A/4_?0Z"X&'G"12J139BYDI;G_+O/QS<*I?/)'DK_FSU0S'+^F].3^%J'X
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MSD#N7A*J7/Q-9QOG:D4=+4GW C<Q$#]^LH^XIS=$XDLG]X;N_I@_<QW+X<9
MG12]0S/B?$+="?M>0GFJN3E&?IW=OE!Q,^I[ 6FW) M ^C/R/'>*D1 ?RJR_
M*&[_6\XZG-GFMX#W&</=\+J'#5+MT+PLC#OJ&+]L3=Z[F*6Y!232$MX"[D&F
MO,5G[_8P0?T)@;< =]1O)\*<%X_6>-<<*L'ORD#7#^_.@Y/Z%W?'.'C!,)VW
M@)9Q?@C&_3[G_@/0]?GZ+> <C>(6@ 9<.V\&O[,!7<-!,GPJ\/%YOHS%WLSK
MQZETAX)RAR*<N$1X<3!X"]B[_O;TN[7C_3[S_H/(ZPN#6\#9I>1^VM&U_BV
M1X7W!AQZ39V>$F!.5-USD]J6>+24>@N86TN[DO3G76N&Z,2-_>K<W_*KS3B,
M@]TO)6_ 3I+E#E-@]TG)FQOS@[NCVSJ/-2JS.O,IB2'0WA;(_VG-01_;<%GB
MU?G<DKKZM\P",^=[%?&0,3-G>@MHE16?"W0VG%2\.06=YVQ3IL9VT%EF[+7/
M'2,-->Y!M/Y6&9?"1=@;Z++&JRT('0OZ?-[-\EO[LH(>@];QTR&%:-S$,\V^
M>[63:9AX-GX+T%<O1[>^(*INBNW_V'C\:+@10OW68?&]%HB9W,$I><-[7K-'
MF9K8>?\Z ':G$:5QG5#K AE,%V,.)@F\^/ 5#-]XK>YT'_UB7)?S@L ! H68
MHEY%E\2W@ .Y89<#0K +$>%I+ZBM'M.'.V7;,[;CR-/E !O47:;QGEJ,]1:
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MX0CM7G8,R,GZ8B&],5,A&++-.E,2O(C<1H#QDXG?J8];*>3=Z9C+!* #.D
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M*0W4CVUB1/#$+03@4R<9C@GTQ,?R E&S.S#LD5<$X'D*G@%&B^A80J$I>0D
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MHP+K$5>W[O3^^MWV@JM\V<AIA NMHH^]?:V42?'N4P?K=:J[(L=.J6.SP12
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M7#VH-0"<JF.7(BO,8MT01UZTB@7 Y?UZ< #^TK(L&-'1HG]4<?]'Y"XC](>
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MQ#66!FRPR>%/>>./VF ?*J-W]5%>E=\<9HK+C"8*:9C4(G5$:4>'C3:7F]2
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M%\LJ\$-I/W4RZHYH>NA_5J34H=56I 3^Q8/7Y^B?5FQ;P!9)53>D-W@C"AS
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M3$(LJ26<6U0>8B:Z#HHG7X,/U0]$\,A704W0H^\,Z9@]W)%+5#\"J&Z@V!%
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M/V &88&T4]KU&Y"MV(5C<,WWV#HD_F/D->DG.[*><Z)KYB98P&N,:<&9K,V
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MM_[_4WN"B=SH3[\\U!H(I];G?=4MKH,A-)M]Z)^9I_]R_ ;! 0>9O?'(N6P
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M&<6J,%GW5(WZP!!#]GXPXOF3184N=AWMG54]"$U+ZQ*1,M#;IMZI'3L(GZ:
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M?L#A&3B-LB"Y9-)]\48T_8D1;B#'3TD:K4U"#ML=3" ]4\H*:KLC(6('BV?
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M$*@N$<W](A%@Q[X8M:XP];WP3DT^].U'?"H4!-AKN.F:-L&"CDRC:>V&PY'
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M]DTVQP 9</MA(]!;#KC,JF42.:A[B1'1K$"Y198&7J"UBI&!T T\QGAV[9E
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M&L3$,WEUM1YAX02'!1<4@LN4.4^P#:)N]0<7(T-7^TI;$7ZAFF@.X$"SO)Q
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MF"H,"D;U%+[Z.,[8S2$,F*.0V\CIK;_5?9M<$ 35:6P1?9>4<LPBT=&ZM9L
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M8==,EVAL^EP*)Q>FZBXY--WRP?9B0M/"^O.((DB]?C%7 3\M+N(YHP[T?C;
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M.S1J[%W;/;R:27>8,&Z[.T:J,=3TL;_=H1#<0N84VS6G5 LDF]LR[*EREY]
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M^WN=L%#_U@#_9X/Z  T#"P>/@(B$_+<#Y"/@ Q0T] <8:%A8&)B_1_W_'@?
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M@,7&.87!I"7&V)+RM]#9)"HY'0X?K(R$0=26#'K^U1])$/Q,\_.X.%U?A9>
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M(2U.@IEK@TY\^6IWR-8YST4)YUZ5NQ$C7KUM>"9(;,="Q[L,C;4!Y>H@%'C
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M*27"7: $C29\0?OC$ZN*%$#I-=?,47B0A>EMCN_:;_[W.\#O@,NB/5P _4-
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MC9N"D'^=.@%PS.+A%+WA6ER=KW0'F;8RA:4-4:P3X.:J5 NNT< A:V8!AO(
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MTQ#J@/V2TGP'B3)4FJ^J2N!JCF82PG9(NISH]UA]M?WD*Z3ZI?G9[8_S),G
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M#VF'Y-8X\.'.RH8\@] 5!/X^%T"R[%-[)O0O6[;TR"JPVE??@, -V/# Q\<
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MRJY!U%>VL'<_+Z)'HQJ$^&$?>W?PPEY-759D(\1-ID]7$8G/#MB?7FFF;V6
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MFZ#\.0D3#J]GS%Z71EJO8=[%5LKD7!'B01WW&C"[ 9#A;(@3@=VPE%<_JBB
MIX>N% ><^(L%:MF/9,-O]<>[7_6)&7FR1#R@6"JDF^ H\U*_RJ\+WI=+@%Z7
M#6X4XL>"&EN-C:@]49?FYG7?N5.=3E).]]4KL\C5C0UBH@17Y'1#T"&Z3M+(
MX[>7,&7$!OFH(C=#MW6DG.*([I7IY:[+? @N-\-L[WY;2S18^PQ*A(O$")9L
MLM1I QR#!?W\;HD/KXK-WI&NDB)='D:R<-KFM/>K; EW-*)WI^P' 6I2YA\
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M9X]S11M!K$8D"Z8-[?$38Y>50@$>@6HHPI:HX7-Y804WLC!#9 Z<9UJ2)"H
M$HQ;..K,@503A^TQ/&W\@ JW5ZJ2>GKCD3Q3)!6AT\^VX\IS/,,NR3^54(<
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M]7S_JJ149Y]2RWV5^/BMZ=+I5?5S4EK_/9#?CB;(+:HM_T"#P??8J;A5L73
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M!V-D.#ESP(/ZNB3\=$XE$RNFFRQ0<B:<8KZ=&5\W3'B[<?T1PX?6@#[*^D<
M/Z%1K(%=XL;P)FQ,\7,VCV1_7?>.8 [)QXELES+\^8XX=#-^_<BFXP^^\FW-
MR]H].=C6_"JZS8A?BG,+](CX6&#QT7EFJ9P^"$KXF_>>7-J+QE27+LU^U1?.
MP3S&''I2[WWZD15,LU2US]Q0)L&6&\88\D^[7N*3.VRY+XZFV]LJY],&4LT,
MH<U*,D_4\]5;X^!=-O8'&XS=F694>%C2\$PR/V>RO8Z*D'I:I2MANA?5W.!,
MI%/I ;&W4>);&#&Q:("QK BR->ZWE_9V*\T+[QK+]<R?L@K%MJ0M)R&5_A%
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M@!\!<=YECX#9IXT^-A/ 4)/ALOZ>T-63Y3UTR(IF0SI5*4SRB<MB;039<6+
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MM#2_= *#^/0I,A(R%@H*%@TA+B'-/TP/7P&,IS#+3R1@8<B )Q@PL!@P#UT
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MYDMNWC^]&;)HDCB>LUR9?'1>+1VE.=NHLEHND>ZI@'AGUC9-*=$F44?$@3K
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M1:Y<,C/*O<] 4VL?TSU>-Z";5<?.#EW>B*;I'E[/SPE35&5GC(HI/"*1H88
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MO ]U,0>+]96^7R\H(31[!B*4R ]B*LP"T(5HI*B+AYY4N$G>Y\D]^E1HVWV
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MF7'25]-(JF?A+HNYCP F@('C7Z?%,O<AOQ[!S6A/<EV-Y2OE=X=UG;(?5!X
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MM^G5%X4MWTD8ISDK1#)2$32,D(<\"P+.I&A#IO-:O.:W.?"G6QSRYSLW!NC
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M:%+*]W'U0"J:XYKK=&E#J=:EJW"\2DN0HX3/_0HE*FW5<VPL$_C/I ZWH(0
MJ>9) 0I(Y.[9GH@T1K<Q'CUYG1Y5WYW;]^3[=RII&$.%'R!%LA/5TEJT)WD%
M;0W2@[5U"KUOT+]52$;?5U14NX_:06&J\B^C!N4/DRX_4=2IZL.GP-<K'=,:
M$-@*]?=!194^X :6?@S0&F/GQ["DP!!EW_);,:%"SEF.$OJ4BK!K>,A-UD#0
MVUQY:;(BBZCB/S>W(V]]) SFCL59TH#M@67)('7KOQ!?*,U;>38FNUQ@#]'F
MR"BH%#$!!'D%#IV\9Y!"NTYA3&&+,QL$\2UB3WD)-FGS=,UIL;]3H9 >+T9Q
M<-\4+PN3=%^XKC24O)V;Z'09"8INGS[2U-:".!M*@T3G(OH;E9#3ER5__D1S
M64T5XA<+.KJRI]T!(]70"TJ-L@UJL U&V]D9%$K:<.3@U5E8#34ZAS:!K(PI
M[* @Q\&W$]5V/^_$9:N#4';BPU"2LG'CUO%G^S$%U?!4R!VMA;H!%R+LU<%<
M$/ZMR]"MIJ[?70E"EG4DZ&5B<N2B>DQ$X%=ARWDL4N5R 5S"M&;0S ROV*YE
M+]=9.N+_[BL-[S)(F=SAU'ZL5>'G&',GA"7N2&&)>;S!Y-M""-YF%&M8C>.%
MFD^OXD3Q1IA8O&+L2F ZP?M"UI2%TX[4A(WR9@TCJ_S+JDY5M0JZZ1F$8VX#
MFX@!<!]9>?>W<P'NPS;_,TF*N(V!#9/:ANAH!_"Y\Y,*_D7Y@:5+JQ4LF/&M
M5H8DG:@W=+?L190QE3STI^'F9%?J!>!,N]<LV>[?;I3CN_,38W NY@3R#*P<
M."/![M:1@3EV*475W)&LOJ%;S4>3(:MN7+XZ'] U91GR\HAHAQO(OJMS?4'G
MD;\";X)W1JY;DUVG8Y 80Q@LV+E9$8+!3(U5(0] <9/U4TF"FX+A==T\'YL+
M4]BBS 9TXGE**,1E";RDG3@)TU&!1T#1U[?KHJI2YL?&W:Q8MC6^K5J6HZ4U
M/P+O'>C\7)(TVNTSB:A!A3-N+\7'Z CT=X7Q+\^GZSC*Y5_W6V8S=S1)+K5+
M8_3*8:6ZT_H<$NT,%6_'OSPQ!I6AS)4[$[Q6BA(XB9X,W4F[\#.>->-!# P/
M8#BHGD<5DB^!2D5ISV<G33@, BBPD1&X: D;7OSF0<=M1)2M!28KTELE;*Z2
M]D]EI/-UM:XN)*EBB-R26;YX'/M][(J>]TY*E//.N8SO2B6+[L)A@E(-5M+4
M41,IAI933A)CM\T1AO5X\<X'WX"TDM2IH@WKE'"7=;(//N8$KN8ARPO$6C9W
MVZ?0?B@_A!]NRYN%JF$RQHTO?8WF\]*2^$[I3179M#-D=7D\35M_RP^F%E#>
M4:"E26D@H%@-Z\T!'$[54N8NE462NO'O0QEBS:]5:EJ:#]5Q R+AHI X^R)/
M57E?1H;8BB%Q;U:/[*&_&,J:@^++Q9;U\ F"^52OATZZ0G;5)6G*HJDC>R;A
MPY WPYM-86=-RZCC1=*DQU>FFU7,<B!A\[*U>O1%(YLUGT"TE?VP?;ZNNS1Y
MUF("ZIV.I4'7G7)'+\.SRX^(JCFG([<KY V,G' AVO%Z=*E:UM_:FO#(:0A"
M++D!:"GC7HDE^&.J;-2BA(&?8W2+3QQY6/(;OFL565X-SKG]DMPKX@_GH'>M
MQK=72:OH$X0&7%#0\/+H*;V\]H1>TX2% ZH JN7&=/M^AD9 1.VW'@HZ-$6C
M)0 /UA)1CN/GX5)T&62F.[C$[/!#)GM^&*\?6D4:J=L .O*//31Q R&B.\,/
M($&#([2$G"N"!Z :Q_'$:77P>$I>QBYE*0M[PY$92DS6-%YL==K"VL64ZV=%
MQP12&\*LBM.CR'C'@D0(%E+_60JYZ:FK+I+>(;)KGYXK/ARTP3>GP5]R3,$6
MT/F\P5( +O+K!XZ$B*;\)I;4>VTHD\_!I!2=UE@\=C_,R'^4:)6].5QO*<W+
MO124FB'7J&[88_BB)<.*.M11/Q>6%]"!A_L&SB:UD ET[EBKR1C,5H+EGB;A
MO?M6Q-*Q%\PKQ=<5@O8BG#XHS*_*^S'6:0:=7/$Q9O8>/:%_PS:HE[MD5KF@
MH_ZEW7_C?22V820ZVG?'M;54I'Y87'QMCL2]EFD_AK3,9A>"A4;M'2;W O#R
MC4P_;AC+8$?@49/M3P"Q'+%L3'NF\R;!RH/8U(F3M::K4D-,4VWX0U@>1=JW
MQ&W3_V,B+(R/MP(]MZ])_1D=&N%'X7HLCFT9[2N4,C>Z>7 K; /*T]8.)3[%
MS30AN&UI?N+<&1UTO,>Y@AZ(T(0UH=WRS58"NZ0VM!AI*ZOBE'T?7AB7W1OT
M<PBA5^E^M&YBS!+64KD^5@2*E8R^/==H]CX/:S+3&??;:YKJ91H'NK@[0?I!
M<LVT>Z^Y@+L3D@?@I2;'<?4A73A61!R)K8SEAU(D;.J<:S5>4 54C$6K*5@E
MI];'62\.0NY,:GO$FOZ:@]3G?6H 7$A8UU3BT"3[(I5DZE-V6:6! 9#_/)P3
M)Q*!E(N>R'/UNS?XV#6"B)<@S29.E]X ^Y*W:_G*[(LQMJV(P@TQR:I^)7XY
M2:R:FITP1N\,L/1L"YFRPKY:(YJ+319'T28D'B_J5U-:$@YDZ)$^$4F^K8<C
M=L7/$0QJ%C2QPVY9:LIM9ZO$S0K3JI]*:6]70.HGC6">]J)?W.9QN$S;NW:O
MZ:L/%&%*Q/;D8))\.DM8*LG%9Z>PK8L_>HICE['5Z)%H>+,Q//5J\6P.P6SF
M>C\ZATE'7KFRRN+-DY5E<BJ;CKL5GDAOJ)GQC'T26)6>856U,ECABS$M9[UH
MHO#NI[7[)U[D,R66I:>?Z7=WJV].7J%0YF9*=;(X*;VM%3R((YZ*7;9"E<S6
MD7>U,<HS&Z)X T;U3XB&;S;_MD!4T!#,3;&KZ[N0XC=SZC2M):&CVE]#J3-D
MR/#\&P)K&B-O1;AY\3WUN(F.&!&CR@0C8_5ERD:MUB0"6?K1*SSFD!!,<2S@
MQA-EBT/MI?+LE@NXN2YHT(Y"-;)(#EUA#?T+8?)&61*O\7/TJA[5!=^GWYDQ
M "^U"1]QHE"EQIG314;)NK89!UI4#KQ8B2C7:O5@C&3:6EA7XCL;)?DR,X[I
MR,4%:*V-EBQ>'/=:O:BX$ P=;O)S&$1^[G2$A4LKD>8I@\D#-A!*Z%LZ9R?;
MN2RI+]L!Y.0G)5(%>@4:YM.*2V9.<1=QE2:&Y\?%@9=<RS$1SD7V_R&QHW;E
MHCA%ZD7I%T420A:6.BF>W;/'W[79/ !"J%KWE\$/0)CJM&D&&_D&JD%/ZVL=
MVTOQ$G,FTGKW"O<,__;Z(R]KYCW=P9]E&#^T(9QR<0<R4U8YIF$[D>OET1M\
M:_541]C\(QUE2(L+@S;LG_PEDYLBK>\D^P]T&&)SYK;FM/$]4OUY(2\MS-5K
M$>PF[T"Y)5*V08IB6-O#+$WZWW](NH485C16S=D$1Z3738#PFT2QO]ECK]74
MQ4%,HIXNJ2,Q2_2AB$?Z5I_WK09)6NR9-/ILN)IFIRY4^*N&X 1;=X*I(B/;
M>S6#;E3*)UXZ9KF#C9&K?&U8>CC*Z)SY$<3D+28='WW..2=%;N)]96HGK\<,
M=@>;QC!S,Z$#J<..$ ZXA+X$+-I2TVS=P1J8)5343W'(M1;EB=]7>TCUJ=AR
MM;'RL#;8RNX%8IAI]:7B6,!;7 ;ABX*<(ZL THG0VWO2\=4JS"^H@TL]Y)AH
M!?7)EL0IYD0FNAR16U5FX59V"#F>V TQ1-"QQHJ%;$+/I^UK"@A=YW$7K\EM
MGME>L2"1+WG7<FUU\J-3I;F0UW@S&"4+8P[1% Z2*C9\'8;AE\#C&BDH5>[2
MY0IX.Y:;N'$A7E[O+K*K6F+C5D;R0X6%ZTKN/>8WKZ,P=1/RCY>^LA-LO-*+
M3CKCJV'V.G6MYNUP:R'KG+S6+MX-K;E>KQL/-X)=S<!FSEG;%SC3GP@@1C7B
M$A);BA(=JW-I#NG;G-,('3=250U5+'BRS=-;1P<4%>!L VZ*S5)9RLU -G=^
MY1L1U8H:-.SXD89W"[C+$OUK+[Z>I5\&B.H8FM$7J:/*^HM&-LASA;79\;9)
M =)MZ*8S,X.NSMGJ"SK9QI3U<;/X0I\^YNNS^B#A;@]I^0_,S6E0U-7Z4\50
M.TITQ,\Q-9"7(L*.JG&E"HZQP^1W9YB[@!<WTJA#E^,5P]CU8N O4+NH&4-6
MXPA )N^/T((SOOC7%'TWZS$(]%L<$&U^ *KJ0^ZQ@#I-XEC/W-=)[CFSVM][
MWN<4/ZK"P*/W]&NO)<WD=.W)E]8Q.-LK!HI 'MCU\I],(V]9G(EK4/?+\LPJ
M B8?T<#S+"ZSC??P:O!)%*=X>/Q5\N63Q34@Z@.VID'700W62E=GU7=NA-8#
M$GRCL*O_R9P5<K;BC=;0"Z"@BHA.[._N'?VO/;E]/JM?)B;Y:9"!Q9>U61K,
M2O$\&>;B9=O-I=3FZAZ=P9UO?,OM/(-,0X];N-Q5N]6+,J/>;KK]NBIUWF*N
M;4_[/MU5#:AU2'#+=NIB.+?KPI?5;PU-;M_5._7LF.UNW;3M[IUE?^\H2DB\
M/2Z:9NU=D38M8D&ORFRY[%4,EQ(2\FP_6$BN%@E@"WW?]D4WV+_M=/#%DM^G
MH^N_FGT76ZE2^+%_JH="X<NP8/_-O6_/E$U0W!HT[7=RX).5$HH5/QT92KZL
MGA+ 5O)+;G+ITO\,:3$ORXHCZL\OF?;B8NGY.\JRM2L3+Y;LSM7)W/8K=TD8
M9^^V3J8USNS*'&Q6GR^OS0AT$/UWFG%/]+8VXX(5R9%=O0\]65;D[5!A[D\,
M6?;A6:?-!>_"Q1&^JGO6FNA]6W%,4^)=>I [C[]*G^?:* TFZ>J*7-U+W!%!
M'(LE/!X'K%I\@?' RA4DKN/_M#:L<LV>^$?>M>%'I-CZ9LUVFZ"W>?F6M:7L
M4U:)F7]^S,,L_I-!1<CS]Z&]85T,GPI9PF:M7=)6MO?BEAMO=;?>7LX:]J@D
M\*E'P)/>F4X_;;F>S&U;=MDTGR?RQH]]QR,JQ![]9PC=TW/KU/X]^]@;-FH^
MB]MQZ#G[I;U>FTI\)5Y<O+]B_KG?J5^NUQ?GG3=XGA\\I^K?%,93%?D^TVX?
MVQ64U95R1=?&D"7O7;G1_AG.GU\?,XYY=KHSZ5J-_<H?BYTNZ>=OU7QBMKTJ
M>^N7F1-F+.W==V%?(I=PMI: 6>,?M;V3NA@^WU4.V7)ICT])K'KXIFNYZ]:M
M4]FUK:.Y<KG'P;OWG)9,FKUI<=%JWE/FYDR;=4VC*VK,5U=4NU_5,;VK=]MM
MI\'=FQ-2-G/-$/0+F:IS4T5^RMQV[8.FK[8$L,]]^:MM]H+7WZ*F=^;EOLE=
M<N'MHHU[]TQ,[N10.2U1=B#,LN>Q9<+>;W/27X9M^VYG<?%=TO;X-R_7OW^W
MY4'RH;>&KC-%Y!KVSSCP(-U2UG%]R*(&R_U\2JZ/Y(6/2W L#^@]P2QO''W$
M\T_V$@(#G _WI!<OC_SQ^%"YU4&/MP]^)_^\U'_WD$MV>_)%AW\?'\B$VS_B
MWYAMY=^]U59WVF./_6:"E1?FWXTYM:E1>3%SVT^?K(B"LL?JHB_*=YG?MG%>
MEK6OTO_-U[DU:V=^MCD:>-TF.7_AN>RH!HO9M^_J']YG-^GW$>';F==ZEQUE
MFU]>\EK&\.'MLSW6"=HR1PKGS] X?O>Q:&B4K=VS<_;Z?KL^)ODGF;WEE>S<
M;M5WZIQLN\]SV\]Q"UT9*O?$?V+9_Y]AXX'ZET&!C[IWSU5^I'W_;G:577>V
MVEP9L^U19V=["^:^2^V5/]<9V/_N),ND SRUE^,F K4N;R[IR+')SEI?SK?D
MPHLU%V*.,G8RG2Q53A38G.B@Z*[>>%UT[B/;@E?3I@O>R5:Z]>U^1 NOV"6-
M(QV=)5V;3N_TF:' =F\WNQ:C[=\B8#)^+W#_EMKLQ[R&[Q*C/Z^\?8<[Z(%7
MDMH-3J:OVO/,2\Z+KI=;N[BB^FB=4KY([*T;YZMUXM.F?;W*>G9'I]-QR?R]
M[9^-FM5UY]0<MKTJPOC,RF[^YI /+N%E^Z*._EVLN\9834KB))OBEB^*7!]O
M+Y=8M_IPQ\2*]B,?CS%I7E$N8CA^YMI'H7JIEW18UCP",?__FP!02P$"% ,4
M    " "#,&Y6GJ"].1=.!  \HC$ $0              @ $     :6MN82TR
M,#(R,3(S,2YH=&U02P$"% ,4    " "#,&Y6UZ$7H\T5  !F]@  $0
M        @ %&3@0 :6MN82TR,#(R,3(S,2YX<V102P$"% ,4    " "#,&Y6
M,(Z;>=X/   FW@  %0              @ %"9 0 :6MN82TR,#(R,3(S,5]C
M86PN>&UL4$L! A0#%     @ @S!N5F'4^SA)*   .\," !4
M ( !4W0$ &EK;F$M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (,P;E:>
MKXD41JH  .G!!P 5              "  <^<! !I:VYA+3(P,C(Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "#,&Y66$6Y$0U+  !PE@4 %0
M@ %(1P4 :6MN82TR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ @S!N5IWF
MX;_L"P  '9\   \              ( !B)(% &EK;F$M97@Q,%\T+FAT;5!+
M 0(4 Q0    ( (,P;E;LL2XDCP0  "\B   /              "  :&>!0!I
M:VYA+65X,C-?,2YH=&U02P$"% ,4    " "#,&Y6,!TC I((   '10  #P
M            @ %=HP4 :6MN82UE>#,Q7S$N:'1M4$L! A0#%     @ @S!N
M5O!3EHB9"   <$0   \              ( !'*P% &EK;F$M97@S,5\R+FAT
M;5!+ 0(4 Q0    ( (,P;E:6_U#EVP4  (Q0   /              "  >*T
M!0!I:VYA+65X,S)?,2YH=&U02P$"% ,4    " "#,&Y6<E+/XVSJ  ".-0$
M$0              @ 'JN@4 :6UG-# W-#@W,C5?,"YJ<&=02P$"% ,4
M" "#,&Y6HG\('>\( 0#((P$ $0              @ &%I08 :6UG-# W-#@W
M,C5?,2YJ<&=02P$"% ,4    " "#,&Y6$;0KZ5\[  #08P  $@
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M-S0X-S(U7S$T+FIP9U!+ 0(4 Q0    ( (,P;E:*>@B-])0  .^J   2
M          "  3Y5"@!I;6<T,#<T.#<R-5\Q-2YJ<&=02P$"% ,4    " "#
M,&Y6(<GSA/^K  !CQP  $@              @ %BZ@H :6UG-# W-#@W,C5?
M,38N:G!G4$L! A0#%     @ @S!N5OI<@6[A>@  +(P  !(
M ( !D98+ &EM9S0P-S0X-S(U7S$W+FIP9U!+ 0(4 Q0    ( (,P;E8 R%GI
M"54  "IE   2              "  :(1# !I;6<T,#<T.#<R-5\Q."YJ<&=0
M2P$"% ,4    " "#,&Y6^RN4I4X( 0"96 $ $@              @ ';9@P
M:6UG-# W-#@W,C5?,3DN:G!G4$L! A0#%     @ @S!N5F'97,P/3P  BE\
M !$              ( !66\- &EM9S0P-S0X-S(U7S(N:G!G4$L! A0#%
M  @ @S!N5AS]'347Y   FS ! !(              ( !E[X- &EM9S0P-S0X
M-S(U7S(P+FIP9U!+ 0(4 Q0    ( (,P;E:$):5#AIH  -O/   2
M      "  =ZB#@!I;6<T,#<T.#<R-5\R,2YJ<&=02P$"% ,4    " "#,&Y6
MQ5/5R!!V  !+CP  $@              @ &4/0\ :6UG-# W-#@W,C5?,C(N
M:G!G4$L! A0#%     @ @S!N5I1N.I7E* $ \&(! !(              ( !
MU+,/ &EM9S0P-S0X-S(U7S(S+FIP9U!+ 0(4 Q0    ( (,P;E8O#CKHU9L
M '7!   2              "  >G<$ !I;6<T,#<T.#<R-5\R-"YJ<&=02P$"
M% ,4    " "#,&Y63ABZMZ@[  #^5P  $@              @ 'N>!$ :6UG
M-# W-#@W,C5?,C4N:G!G4$L! A0#%     @ @S!N5D7>(I?5T0  ( L! !(
M             ( !QK01 &EM9S0P-S0X-S(U7S(V+FIP9U!+ 0(4 Q0    (
M (,P;E8RG]XJ3X$! *<K @ 2              "  <N&$@!I;6<T,#<T.#<R
M-5\R-RYJ<&=02P$"% ,4    " "#,&Y6 6Y04HYO   LA   $@
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M-#@W,C5?,S$N:G!G4$L! A0#%     @ @S!N5A<-:9$]E@  B+<  !(
M         ( !^Q<8 &EM9S0P-S0X-S(U7S,R+FIP9U!+ 0(4 Q0    ( (,P
M;E;(!VOR-$H  *=9   2              "  6BN& !I;6<T,#<T.#<R-5\S
M,RYJ<&=02P$"% ,4    " "#,&Y6R2G+SWPC 0#VX $ $@
M@ ',^!@ :6UG-# W-#@W,C5?,S0N:G!G4$L! A0#%     @ @S!N5C9>V-,T
M/0( >8$# !(              ( !>!P: &EM9S0P-S0X-S(U7S,U+FIP9U!+
M 0(4 Q0    ( (,P;E;45MPP6A(! )/] 0 2              "  =Q9' !I
M;6<T,#<T.#<R-5\S-BYJ<&=02P$"% ,4    " "#,&Y69HO:7="%  ":YP
M$@              @ %F;!T :6UG-# W-#@W,C5?,S<N:G!G4$L! A0#%
M  @ @S!N5K4=YG#&;P  4=@  !(              ( !9O(= &EM9S0P-S0X
M-S(U7S,X+FIP9U!+ 0(4 Q0    ( (,P;E9GUQ=/A7<  %R;   2
M      "  5QB'@!I;6<T,#<T.#<R-5\S.2YJ<&=02P$"% ,4    " "#,&Y6
M71I!JBB*  #RI0  $0              @ $1VAX :6UG-# W-#@W,C5?-"YJ
M<&=02P$"% ,4    " "#,&Y6ZY-F5]BK @!#\@( $@              @ %H
M9!\ :6UG-# W-#@W,C5?-# N:G!G4$L! A0#%     @ @S!N5GQI[%<(BP
M'ZT  !(              ( !<! B &EM9S0P-S0X-S(U7S0Q+FIP9U!+ 0(4
M Q0    ( (,P;E9BRCC^4$8  "!5   1              "  :B;(@!I;6<T
M,#<T.#<R-5\U+FIP9U!+ 0(4 Q0    ( (,P;E9\@3P]E%(  +QA   1
M          "  2?B(@!I;6<T,#<T.#<R-5\V+FIP9U!+ 0(4 Q0    ( (,P
M;E:,.^K.EW(  +U\   1              "  >HT(P!I;6<T,#<T.#<R-5\W
M+FIP9U!+ 0(4 Q0    ( (,P;E8Q"&F'5Z   (2M   1              "
M ;"G(P!I;6<T,#<T.#<R-5\X+FIP9U!+ 0(4 Q0    ( (,P;E9=OXN=#4<
M %1Q   1              "  39() !I;6<T,#<T.#<R-5\Y+FIP9U!+!08
1    -0 U #$-  !RCR0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
